0001493152-24-002363.txt : 20240116 0001493152-24-002363.hdr.sgml : 20240116 20240116091127 ACCESSION NUMBER: 0001493152-24-002363 CONFORMED SUBMISSION TYPE: S-4/A PUBLIC DOCUMENT COUNT: 123 FILED AS OF DATE: 20240116 DATE AS OF CHANGE: 20240116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AgeX Therapeutics, Inc. CENTRAL INDEX KEY: 0001708599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821436829 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-4/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-275536 FILM NUMBER: 24533858 BUSINESS ADDRESS: STREET 1: 1101 MARINA VILLAGE PARKWAY STREET 2: SUITE 201 CITY: ALAMEDA STATE: CA ZIP: 94501 BUSINESS PHONE: 510-671-8370 MAIL ADDRESS: STREET 1: 1101 MARINA VILLAGE PARKWAY STREET 2: SUITE 201 CITY: ALAMEDA STATE: CA ZIP: 94501 S-4/A 1 forms-4a.htm
true 0001708599 S-4/A 0001708599 0001708599 2023-01-01 2023-09-30 0001708599 dei:BusinessContactMember 2023-01-01 2023-09-30 0001708599 2022-12-31 0001708599 2021-12-31 0001708599 us-gaap:RelatedPartyMember 2022-12-31 0001708599 us-gaap:RelatedPartyMember 2021-12-31 0001708599 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001708599 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001708599 2023-09-30 0001708599 us-gaap:RelatedPartyMember 2023-09-30 0001708599 us-gaap:SeriesAPreferredStockMember 2023-09-30 0001708599 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001708599 us-gaap:SeriesBPreferredStockMember 2023-09-30 0001708599 2022-01-01 2022-12-31 0001708599 2021-01-01 2021-12-31 0001708599 AGE:GrantRevenuesMember 2022-01-01 2022-12-31 0001708599 AGE:GrantRevenuesMember 2021-01-01 2021-12-31 0001708599 AGE:OtherRevenuesMember 2022-01-01 2022-12-31 0001708599 AGE:OtherRevenuesMember 2021-01-01 2021-12-31 0001708599 2023-07-01 2023-09-30 0001708599 2022-07-01 2022-09-30 0001708599 2022-01-01 2022-09-30 0001708599 AGE:GrantRevenuesMember 2023-07-01 2023-09-30 0001708599 AGE:GrantRevenuesMember 2022-07-01 2022-09-30 0001708599 AGE:GrantRevenuesMember 2023-01-01 2023-09-30 0001708599 AGE:GrantRevenuesMember 2022-01-01 2022-09-30 0001708599 AGE:OtherRevenuesMember 2023-07-01 2023-09-30 0001708599 AGE:OtherRevenuesMember 2022-07-01 2022-09-30 0001708599 AGE:OtherRevenuesMember 2023-01-01 2023-09-30 0001708599 AGE:OtherRevenuesMember 2022-01-01 2022-09-30 0001708599 us-gaap:CommonStockMember 2020-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001708599 us-gaap:RetainedEarningsMember 2020-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2020-12-31 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001708599 2020-12-31 0001708599 us-gaap:CommonStockMember 2021-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001708599 us-gaap:RetainedEarningsMember 2021-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2021-12-31 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-06-30 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001708599 us-gaap:CommonStockMember 2023-06-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001708599 us-gaap:RetainedEarningsMember 2023-06-30 0001708599 us-gaap:NoncontrollingInterestMember 2023-06-30 0001708599 2023-06-30 0001708599 us-gaap:CommonStockMember 2022-06-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001708599 us-gaap:RetainedEarningsMember 2022-06-30 0001708599 us-gaap:NoncontrollingInterestMember 2022-06-30 0001708599 2022-06-30 0001708599 us-gaap:CommonStockMember 2022-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001708599 us-gaap:RetainedEarningsMember 2022-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2022-12-31 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001708599 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001708599 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-12-31 0001708599 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001708599 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-12-31 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-07-01 2023-09-30 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-07-01 2023-09-30 0001708599 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001708599 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001708599 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001708599 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001708599 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001708599 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-09-30 0001708599 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001708599 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001708599 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001708599 us-gaap:CommonStockMember 2023-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001708599 us-gaap:RetainedEarningsMember 2023-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2023-09-30 0001708599 us-gaap:CommonStockMember 2022-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001708599 us-gaap:RetainedEarningsMember 2022-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2022-09-30 0001708599 2022-09-30 0001708599 AGE:JuvenescenceLimitedMember 2018-08-29 2018-08-30 0001708599 2018-08-29 2018-08-30 0001708599 srt:ParentCompanyMember us-gaap:CommonStockMember 2018-11-27 2018-11-28 0001708599 us-gaap:CommonStockMember AGE:AgeXMember 2018-11-28 0001708599 AGE:LifeMapSciencesIncMember AGE:MergerAgreementMember 2021-03-14 2021-03-15 0001708599 AGE:MergerAgreementMember 2021-03-14 2021-03-15 0001708599 AGE:JuvenescenceMember AGE:LoanFacilityAgreementMember 2022-12-31 0001708599 AGE:MergerAgreementMember AGE:ReCyteTherapeuticsIncMember AGE:AgeXMember 2022-12-31 0001708599 AGE:MergerAgreementMember AGE:NeuroAirmidMember AGE:AgeXMember 2022-12-31 0001708599 AGE:ConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-31 0001708599 AGE:ConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-01 2023-03-31 0001708599 AGE:JuvenescenceMember AGE:LoanFacilityAgreementMember 2023-09-30 0001708599 AGE:JuvenescenceMember AGE:LoanFacilityAgreementMember us-gaap:SubsequentEventMember 2023-11-09 0001708599 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001708599 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001708599 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001708599 2020-11-03 0001708599 2020-11-03 2020-11-03 0001708599 2022-01-01 2022-01-01 0001708599 2022-10-01 2022-10-31 0001708599 2018-01-01 2018-12-31 0001708599 AGE:SubscriptionAndAdvertisementRevenuesMember 2021-01-01 2021-12-31 0001708599 AGE:NationalInstitutesOfHealthMember 2020-04-07 2020-04-08 0001708599 AGE:NationalInstitutesOfHealthMember 2021-01-01 2021-12-31 0001708599 AGE:ReCyteTherapeuticsIncMember 2023-09-30 0001708599 AGE:MergerAgreementMember 2023-09-30 0001708599 AGE:MergerAgreementMember AGE:ReCyteTherapeuticsIncMember 2023-09-30 0001708599 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001708599 AGE:LeaseAgreementMember 2022-01-01 2022-09-30 0001708599 AGE:LeaseAgreementMember 2023-01-01 2023-09-30 0001708599 AGE:NationalInstitutesOfHealthMember 2023-08-01 2023-08-31 0001708599 AGE:NationalInstitutesOfHealthMember 2023-07-01 2023-09-30 0001708599 AGE:NationalInstitutesOfHealthMember 2023-01-01 2023-09-30 0001708599 country:US 2022-01-01 2022-12-31 0001708599 country:US 2021-01-01 2021-12-31 0001708599 AGE:ForeignMember 2022-01-01 2022-12-31 0001708599 AGE:ForeignMember 2021-01-01 2021-12-31 0001708599 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001708599 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001708599 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001708599 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001708599 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001708599 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001708599 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001708599 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001708599 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001708599 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001708599 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001708599 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001708599 AGE:LoanAgreementsMember 2022-12-31 0001708599 AGE:LoanAgreementsMember 2021-12-31 0001708599 AGE:LoanAgreementsMember 2023-09-30 0001708599 AGE:LoanAgreementsMember 2022-09-30 0001708599 AGE:AssetPurchaseAgreementMember 2018-08-12 2018-08-13 0001708599 AGE:ResearchAndDevelopmentMember 2021-08-01 2021-08-31 0001708599 AGE:JuvenescenceMember AGE:TwoThousandNineteenLoanAgreementMember 2019-08-12 2019-08-13 0001708599 AGE:JuvenescenceMember AGE:TwoThousandNineteenLoanAgreementMember 2021-02-09 2021-02-10 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2021-11-07 2021-11-08 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2021-11-08 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2022-02-14 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2020-03-30 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2020-03-29 2020-03-30 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2022-12-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember us-gaap:WarrantMember 2022-12-31 0001708599 us-gaap:WarrantMember AGE:TwoThousandAndTwentyLoanAgreementMember 2022-01-01 2022-12-31 0001708599 AGE:TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember 2022-02-14 0001708599 AGE:TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember 2022-02-14 2022-02-14 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2022-01-01 2022-12-31 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-01-01 2023-01-31 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-02-28 0001708599 AGE:TwoThousandTwentyTwoWarrantsMember 2022-01-01 2022-12-31 0001708599 AGE:TwoThousandTwentyTwoWarrantsMember 2022-12-31 0001708599 AGE:TwoThousandTwentyTwoWarrantsMember 2022-01-01 2022-12-31 0001708599 AGE:SecurityAgreementMember 2022-01-01 2022-12-31 0001708599 AGE:ReverseRatioMember 2022-12-31 0001708599 AGE:RegistrationRightsAgreementsMember 2022-01-01 2022-12-31 0001708599 AGE:JuvenescenceMember 2022-01-01 2022-12-31 0001708599 AGE:JuvenescenceMember 2022-12-31 0001708599 AGE:JuvenescenceMember 2021-12-31 0001708599 AGE:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 AGE:JuvenescenceLimitedMember 2023-07-31 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2021-12-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2023-09-30 0001708599 AGE:TwentyTwentyLoanAgreementMember 2023-07-01 2023-07-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember us-gaap:WarrantMember 2023-09-30 0001708599 AGE:TwentyTwentyWarrantMember AGE:TwoThousandAndTwentyLoanAgreementMember 2023-01-01 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-02-08 2023-02-09 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-05-09 2023-05-09 0001708599 AGE:FourthAmendmentMember 2023-07-31 2023-07-31 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-01-01 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-07-01 2023-07-31 0001708599 us-gaap:LineOfCreditMember 2023-07-31 2023-07-31 0001708599 AGE:JuvenescenceMember 2023-09-30 0001708599 AGE:TwoThousandTwentyTwoWarrantsMember 2023-01-01 2023-09-30 0001708599 AGE:SecurityAgreementMember 2023-01-01 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-03-13 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-13 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-07-31 0001708599 AGE:JuvenescenceMember 2023-07-31 0001708599 AGE:JuvenescenceMember AGE:SecuredConvertiblePromissoryNoteMember 2023-07-31 2023-07-31 0001708599 2023-07-31 0001708599 srt:MinimumMember AGE:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 srt:MaximumMember AGE:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 2023-07-31 2023-07-31 0001708599 AGE:JuvenescenceLimitedMember AGE:DerivativesAndHedgingMember 2023-07-31 2023-07-31 0001708599 2023-02-14 0001708599 AGE:RegistrationRightsAgreementsMember 2023-01-01 2023-09-30 0001708599 AGE:JuvenescenceMember 2023-01-01 2023-09-30 0001708599 AGE:TwoThousandNineteenLoanAgreementMember 2022-12-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2022-12-31 0001708599 AGE:TwoThousandAndTwentyTwoSecuredNoteMember 2022-12-31 0001708599 AGE:TwoThousandNineteenLoanAgreementMember 2021-12-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2021-12-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2023-09-30 0001708599 AGE:SecuredNoteMember 2023-09-30 0001708599 us-gaap:DebtMember 2023-09-30 0001708599 AGE:TenThousandMillionSecuredNoteMember 2023-09-30 0001708599 AGE:TotalDebtNetMember 2023-09-30 0001708599 AGE:InceptionDateMember 2022-02-14 0001708599 AGE:InceptionDateMember 2022-02-14 2022-02-14 0001708599 AGE:IssuanceDateMember 2022-02-14 0001708599 AGE:IssuanceDateMember 2022-02-14 2022-02-14 0001708599 AGE:IssuanceDateMember 2022-02-15 0001708599 AGE:IssuanceDateMember 2022-02-15 2022-02-15 0001708599 AGE:PeriodEndingMember 2022-03-31 0001708599 AGE:PeriodEndingMember 2022-02-14 2022-03-31 0001708599 AGE:IssuanceDateMember 2022-04-04 0001708599 AGE:IssuanceDateMember 2022-04-04 2022-04-04 0001708599 AGE:IssuanceDateMember 2022-06-06 0001708599 AGE:IssuanceDateMember 2022-06-06 2022-06-06 0001708599 AGE:PeriodEndingMember 2022-06-30 0001708599 AGE:PeriodEndingMember 2022-06-30 2022-06-30 0001708599 AGE:IssuanceDateMember 2022-08-16 0001708599 AGE:IssuanceDateMember 2022-08-15 2022-08-16 0001708599 AGE:PeriodEndingMember 2022-09-30 0001708599 AGE:PeriodEndingMember 2022-09-29 2022-09-30 0001708599 AGE:PeriodEndingMember 2022-10-21 0001708599 AGE:PeriodEndingMember 2022-10-20 2022-10-21 0001708599 AGE:PeriodEndingMember 2022-12-14 0001708599 AGE:PeriodEndingMember 2022-12-13 2022-12-14 0001708599 AGE:PeriodEndingMember 2022-12-31 0001708599 AGE:PeriodEndingMember 2022-12-30 2022-12-31 0001708599 AGE:IssuanceDateMember 2022-10-21 0001708599 AGE:IssuanceDateMember 2022-10-20 2022-10-21 0001708599 AGE:IssuanceDateMember 2022-12-14 0001708599 AGE:IssuanceDateMember 2022-12-13 2022-12-14 0001708599 AGE:IssuanceDateMember 2023-01-25 0001708599 AGE:IssuanceDateMember 2023-01-24 2023-01-25 0001708599 AGE:InceptionDateMember 2023-02-09 0001708599 AGE:InceptionDateMember 2023-02-08 2023-02-09 0001708599 AGE:IssuanceDateMember 2023-02-15 0001708599 AGE:IssuanceDateMember 2023-02-14 2023-02-15 0001708599 AGE:PeriodEndingMember 2023-03-31 0001708599 AGE:PeriodEndingMember 2023-03-30 2023-03-31 0001708599 AGE:IssuanceDateMember 2023-04-04 0001708599 AGE:IssuanceDateMember 2023-04-03 2023-04-04 0001708599 AGE:InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:FourteenFebruaryTwoThousandAndTwentyTwoOneMember 2022-01-01 2022-12-31 0001708599 AGE:FifteenFebruaryTwentyThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:FourAprilTwentyThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:SixJuneTwentyThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:SixteenAugustTwentyThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:TwentyFirstOctoberTwoThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:FourteenDecemberTwoThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:TwentyFiveJanuaryTwoThousandAndTwentyThreeMember 2023-01-01 2023-09-30 0001708599 AGE:TwoSeptemberTwoThousandAndTwentyThreeMember 2023-01-01 2023-09-30 0001708599 AGE:FifteenFebruaryTwentyThousandAndTwentyThreeMember 2023-01-01 2023-09-30 0001708599 AGE:FourthAprilTwentyThousandAndTwentyThreeMember 2023-01-01 2023-09-30 0001708599 us-gaap:WarrantMember 2023-09-30 0001708599 AGE:ChardanCapitalMarketsLLCMember 2021-01-07 2021-01-08 0001708599 AGE:ChardanCapitalMarketsLLCMember 2022-01-01 2022-12-31 0001708599 AGE:ChardanCapitalMarketsLLCMember 2021-01-01 2021-12-31 0001708599 AGE:TwoThousandSeventeenEquityIncentivePlanMember 2022-01-01 2022-12-31 0001708599 AGE:TwoThousandSeventeenEquityIncentivePlanMember srt:MaximumMember 2022-01-01 2022-12-31 0001708599 AGE:TwoThousandSeventeenEquityIncentivePlanMember us-gaap:RestrictedStockMember srt:MaximumMember 2022-01-01 2022-12-31 0001708599 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001708599 AGE:StockOptionsMember srt:MinimumMember 2022-12-31 0001708599 AGE:RestrictedStockAndRestrictedStockUnitsMember srt:MaximumMember 2022-01-01 2022-12-31 0001708599 us-gaap:StockAppreciationRightsSARSMember 2022-01-01 2022-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2020-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2021-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2022-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2023-09-30 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentDiscontinuedOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:SegmentDiscontinuedOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001708599 AGE:CaliforniaPurposesMember 2022-12-31 0001708599 AGE:CaliforniaPurposesMember 2022-01-01 2022-12-31 0001708599 us-gaap:DomesticCountryMember 2022-12-31 0001708599 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001708599 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0001708599 us-gaap:NonUsMember 2022-01-01 2022-12-31 0001708599 AGE:GILTIMember 2022-01-01 2022-12-31 0001708599 AGE:OtherIncomeTaxMattersMember 2022-01-01 2022-12-31 0001708599 AGE:LeaseAgreementMember 2021-01-01 0001708599 AGE:LeaseAgreementMember 2021-01-01 2021-01-01 0001708599 AGE:LeaseAgreementMember 2022-01-01 2022-12-31 0001708599 AGE:LeaseAgreementMember 2022-10-31 0001708599 AGE:LeaseAgreementMember 2022-10-01 2022-10-31 0001708599 AGE:PaycheckProtectionProgramMember 2020-04-13 0001708599 AGE:PaycheckProtectionProgramMember 2020-04-12 2020-04-13 0001708599 2020-06-01 2020-06-01 0001708599 srt:MinimumMember 2021-11-16 2021-11-17 0001708599 srt:MaximumMember 2021-11-16 2021-11-17 0001708599 us-gaap:SegmentContinuingOperationsMember 2023-04-19 2023-04-20 0001708599 AGE:SegmentContinuingOperationsOneMember 2023-04-19 2023-04-20 0001708599 AGE:SegmentContinuingOperationsTwoMember 2023-04-19 2023-04-20 0001708599 us-gaap:SegmentContinuingOperationsMember 2023-05-16 2023-05-17 0001708599 AGE:SegmentContinuingOperationsOneMember 2023-05-16 2023-05-17 0001708599 AGE:SegmentContinuingOperationsTwoMember 2023-05-16 2023-05-17 0001708599 AGE:JuvenescenceLimitedMember 2023-07-24 2023-07-24 0001708599 us-gaap:SubsequentEventMember 2023-01-01 2023-01-25 0001708599 AGE:JuvenescenceMember us-gaap:SubsequentEventMember 2023-01-25 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-02-09 0001708599 us-gaap:SubsequentEventMember AGE:JuvenescenceMember 2023-02-15 0001708599 us-gaap:SubsequentEventMember AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-03-13 0001708599 us-gaap:SubsequentEventMember AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-13 0001708599 AGE:JuvenescenceMember AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-02-13 2023-02-13 0001708599 srt:MinimumMember us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 srt:MaximumMember us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 us-gaap:SubsequentEventMember 2023-03-13 2023-03-13 0001708599 us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember AGE:OriginationFeeMember 2023-03-13 2023-03-13 0001708599 us-gaap:SubsequentEventMember AGE:OriginationFeeMember 2023-03-13 2023-03-13 0001708599 us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember AGE:OriginationFeeMember 2023-02-13 2023-02-13 0001708599 us-gaap:SubsequentEventMember AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-03-15 0001708599 us-gaap:SubsequentEventMember AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-03-13 2023-03-15 0001708599 us-gaap:SubsequentEventMember AGE:SecuredConvertiblePromissoryNoteMember 2023-03-15 0001708599 us-gaap:SubsequentEventMember AGE:SecuredConvertiblePromissoryNoteMember 2023-03-13 2023-03-15 0001708599 us-gaap:SubsequentEventMember 2023-03-15 0001708599 us-gaap:SubsequentEventMember AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-15 0001708599 us-gaap:SubsequentEventMember AGE:SecuredConvertiblePromissoryNoteMember 2023-02-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-10-03 2023-10-03 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-10-31 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-11-09 2023-11-09 0001708599 AGE:JuvenescenceLimitedMember 2023-07-24 0001708599 AGE:JuvenescenceMember AGE:ConvertibleNotePurchaseAgreementMember 2023-03-15 0001708599 AGE:JuvenescenceMember AGE:ConvertibleNotePurchaseAgreementMember 2023-03-15 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-03-15 2023-03-15 0001708599 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:SubordinationAgreementMember 2023-03-15 0001708599 AGE:JuvenescenceLimitedMember us-gaap:SeriesAPreferredStockMember 2023-07-24 0001708599 AGE:JuvenescenceLimitedMember us-gaap:SeriesBPreferredStockMember 2023-07-24 0001708599 AGE:JuvenescenceLimitedMember 2023-07-23 2023-07-24 0001708599 AGE:JuvenescenceLimitedMember AGE:TwoThousandAndTwentyLoanAgreementMember 2023-07-24 0001708599 AGE:JuvenescenceLimitedMember AGE:OriginationFeeMember 2023-07-24 0001708599 us-gaap:SeriesBPreferredStockMember 2023-07-24 0001708599 2023-07-23 2023-07-24 0001708599 us-gaap:SeriesBPreferredStockMember 2023-07-23 2023-07-24 0001708599 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-07-23 2023-07-24 0001708599 AGE:JuvenescenceMember AGE:IssuanceAndSaleOfWarrantsMember 2023-09-30 0001708599 AGE:ChardanCapitalMarketsLLCMember 2021-01-08 0001708599 AGE:ChardanCapitalMarketsLLCMember 2023-01-01 2023-09-30 0001708599 AGE:ChardanCapitalMarketsLLCMember 2022-01-01 2022-09-30 0001708599 srt:RestatementAdjustmentMember 2023-09-30 0001708599 us-gaap:SubsequentEventMember 2023-11-14 0001708599 srt:RestatementAdjustmentMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001708599 us-gaap:SubsequentEventMember us-gaap:SeriesAPreferredStockMember 2023-11-14 0001708599 srt:RestatementAdjustmentMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001708599 us-gaap:SubsequentEventMember us-gaap:SeriesBPreferredStockMember 2023-11-14 0001708599 srt:RestatementAdjustmentMember us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001708599 us-gaap:SubsequentEventMember us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-11-14 0001708599 srt:RestatementAdjustmentMember us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001708599 us-gaap:SubsequentEventMember us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure AGE:Integer utr:sqft

 

As filed with the Securities and Exchange Commission on January 16, 2024

 

Registration No. 333-275536

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

AMENDMENT NO. 1

to

FORM S-4
REGISTRATION STATEMENT

 

Under
The Securities Act of 1933

 

AMENDMENT NO. 1

to

FORM S-1
REGISTRATION STATEMENT

 

Under
The Securities Act of 1933

 

AgeX Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)

 

Delaware   2834   82-1436829
(State or Other Jurisdiction of
Incorporation or Organization)
  (Primary Standard Industrial
Classification Code Number)
 

(I.R.S. Employer

Identification Number)

 

1101 Marina Village Parkway, Suite 201
Alameda, California 94501
(510) 671-8370
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

Andrea E. Park

Chief Financial Officer
AgeX Therapeutics, Inc.
1101 Marina Village Parkway, Suite 201
Alameda, California 94501
(510) 671-8370
(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Please send copies of all communications to:

 

Robert Phillips
Harrison Tucker

Chris W. Trester
Gibson, Dunn & Crutcher LLP
555 Mission Street
San Francisco, CA 94105-0921
(415) 393 8200

  Scott Ludwig
Stephen Hinton
Bradley Arant Boult Cummings LLP
200 Clinton Avenue Huntsville Alabama 35801
(256) 517-5100

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effectiveness of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein. 

 

If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, please check the following box.  ☐

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  

 

If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:

 

Exchange Act Rule 13(e)-4(i) (Cross-Border Issuer Tender Offer)  ☐

 

Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)  ☐

 

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

 
 

 

The information in this proxy statement/prospectus/information statement is not complete and may be changed. AgeX may not sell its securities pursuant to the proposed transactions until the registration statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus/information statement is not an offer to sell these securities, and is not soliciting an offer to buy these securities, in any state where the offer or sale is not permitted.

 

PRELIMINARY-SUBJECT TO COMPLETION-DATED JANUARY 16, 2024

 

 

PRELIMINARY PROSPECTUS

 

Common Stock of AgeX Therapeutics, Inc.

 

Warrants of AgeX Therapeutics, Inc.

 

PROPOSED MERGER
YOUR VOTE IS VERY IMPORTANT

 

To the Stockholders of AgeX Therapeutics, Inc. and Serina Therapeutics, Inc.:

 

AgeX Therapeutics, Inc., a Delaware corporation (AgeX), and Serina Therapeutics, Inc., an Alabama corporation (Serina), entered into an Agreement and Plan of Merger and Reorganization, dated as of August 29, 2023, as may be amended from time to time (the Merger Agreement), pursuant to which, among other matters and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (Merger Sub), will merge with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the Merger). AgeX following the Merger is referred to herein as the “combined company.”

 

The Merger will become effective on the date and at the time the Statement of Merger has been duly filed with the Secretary of State of the State of Alabama or at such later time as may be specified in the Statement of Merger with the consent of AgeX and Serina in accordance with the Alabama Business Corporation Law of the State of Alabama (ABCL) (such date, the Closing Date, and such time, the Effective Time).

 

At the Effective Time, each outstanding share of common stock, $0.01 par value per share, of Serina (Serina common stock) (after giving effect to the conversion of each share of preferred stock of Serina into common stock of Serina (the Serina preferred stock conversion) and including all such shares that are so converted, other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares) will be automatically converted solely into the right to receive a number of shares of common stock of AgeX, $0.0001 par value per share (AgeX common stock), equal to the exchange ratio (the exchange ratio) determined in accordance with the Merger Agreement as described in more detail in the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio” beginning on page 171 of the accompanying proxy statement/prospectus/information statement. The exchange ratio is currently estimated to be equal to approximately 0.83217216 shares of AgeX common stock for each share of Serina common stock, which estimated exchange ratio assumes (i) the Actual Closing Price (as defined in the accompanying proxy statement/prospectus/information statement) of a share of AgeX common stock is equal to $12.00 per share (on a post-reverse stock split basis), (ii) the number of Company Outstanding Shares (as defined in the accompanying proxy statement/prospectus/information statement) is equal to 9,012,558, (iii) the number of Company Merger Shares (as defined in the accompanying proxy statement/prospectus/information statement) is equal to 7,500,000 and (iv) the implementation of the reverse stock split (as defined below) and the AgeX preferred stock conversion (as defined below) prior to the consummation of the Merger, as described in the accompanying proxy statement/prospectus/information statement. There can be no assurance that any of these assumptions will be accurate when the final exchange ratio is determined.

 

 
 

 

At the Effective Time, (i) each outstanding and unexercised option to purchase shares of Serina common stock (Serina option) immediately prior to the Effective Time under the Serina Therapeutics, Inc. 2017 Stock Option Plan, as amended (the Serina Plan), will be converted into and become an option to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the option and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume the Serina Plan and each Serina option in accordance with the terms of the Serina Plan and the terms of the Serina option, and (ii) each outstanding and unexercised warrant to purchase shares of Serina common stock (Serina warrant) immediately prior to the Effective Time, if any, will be converted into and become a warrant to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the warrant and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume each Serina warrant in accordance with its terms.

 

Following the AgeX preferred stock conversion and prior to the closing of the Merger, AgeX will conduct a reverse stock split of AgeX common stock (the reverse stock split) at a ratio in the range from 1-for-35 to 1-for-36 with such specific ratio resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the Effective Time, unless otherwise mutually agreed upon by the respective AgeX and Serina boards of directors. Prior to the reverse stock split, all outstanding shares of preferred stock of AgeX will be converted into AgeX common stock (the AgeX preferred stock conversion) pursuant to the Side Letter (as defined below). The AgeX preferred stock conversion is expected to occur on February 1, 2024 in accordance with the Certificates of Designation of such AgeX preferred stock.

 

Immediately prior to the reverse stock split, each outstanding and unexercised AgeX option with an exercise price equal to or greater than $0.7751 (which, on a pre-reverse stock split basis, is referred to herein as the AgeX closing price) (each, an out of the money AgeX option) as of immediately prior to the reverse stock split, if any, will be canceled without payment. In accordance with the terms and conditions set forth in AgeX’s 2017 Equity Incentive Plan (the Incentive Plan), AgeX will notify each holder of an out of the money AgeX option that each such option will become exercisable at least 10 days prior to the reverse stock split and will thereafter be canceled if not exercised. All other outstanding and unexercised options to purchase shares of AgeX common stock will remain outstanding and exercisable in accordance with their terms immediately following the Effective Time.

 

Following the reverse stock split and the AgeX preferred stock conversion and prior to the closing of the Merger, AgeX will issue to each holder of AgeX common stock as of the close of business on a business day following the reverse stock split and the AgeX preferred stock conversion and prior to the closing of the Merger (the Warrant Dividend Record Date) three warrants (each, a post-merger warrant) for each five shares of AgeX common stock issued and outstanding held by such holder as of the Warrant Dividend Record Date (the Warrant Dividend). Each post-merger warrant will be exercisable at an exercise price equal to $13.20 per warrant (such exercise price reflecting the planned reverse stock split) for (i) one share of AgeX common stock and (ii) one warrant (each, an incentive warrant). Each incentive warrant will be exercisable at an exercise price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split) for one share of AgeX common stock. Each post-merger warrant will expire on July 31, 2025, and each incentive warrant will expire on the four-year anniversary of the Closing Date. Each post-merger warrant and incentive warrant will be issued pursuant to the terms of a warrant agreement to be entered into by AgeX and a warrant agent in connection with the closing of the Merger. The terms of the warrant agreement remain subject to agreement between AgeX and Serina. For additional information, see the section titled “Agreements Related to the Merger—Warrant Agreement” beginning on page 197 of the accompanying proxy statement/prospectus/information statement.

 

 
 

 

Concurrently with the execution of the Merger Agreement, AgeX, Serina and Juvenescence Limited (Juvenescence) entered into a letter agreement in substantially the form attached to the Merger Agreement (the Side Letter), which will become effective immediately prior to the closing of the Merger. The Side Letter provides that:

 

(i)immediately prior to the Effective Time, Juvenescence will cancel all outstanding and unexercised AgeX warrants with an exercise price equal to or greater than the AgeX closing price (each, an out of the money AgeX warrant) held by Juvenescence;
   
(ii)Juvenescence will exercise all of the post-merger warrants it holds to provide the combined company approximately an additional $15 million in capital according to the following schedule: (x) at least one-third on or before May 31, 2024, (y) at least one-third on or before November 30, 2024, and (z) at least one-third on or before June 30, 2025;
   
(iii)AgeX and Serina shall use reasonable best efforts to appoint certain directors, including Steve Ledger and Dr. J. Milton Harris, who are each affiliated with Serina, and Dr. Gregory Bailey and Dr. Richard Marshall, who are each affiliated with Juvenescence, to the board of the combined company effective as of the Effective Time;
   
(iv)Juvenescence will not sell any shares of AgeX Series A preferred stock or AgeX Series B preferred stock and will take all actions necessary to effect the AgeX preferred stock conversion, whereby all of such preferred stock will be converted into AgeX common stock prior to the reverse stock split;
   
(v)Juvenescence will release all security interests, guarantees, pledges, assignments and other forms of collateral that it may have in AgeX’s assets pursuant to the terms of certain loans to AgeX; and
   
(vi)Juvenescence will consent to a newly formed subsidiary of AgeX assuming AgeX’s obligations with respect to loans agreements and promissory notes governing loans payable to Juvenescence, including obligations for amounts currently owed and future advances of loan funds, and Juvenescence shall release AgeX from those loan obligations.

 

Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price of AgeX common stock being equal to or greater than $12.00 per share (on a post-reverse stock split basis), giving effect to the reverse stock split and the AgeX preferred stock conversion and excluding the impact of any post-merger warrant, incentive warrant or the issuance of any share of AgeX common stock upon exercise of any post-merger warrant or incentive warrant. For a more complete description of the exchange ratio, please see the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio of the accompanying proxy statement/prospectus/information statement.

 

 
 

 

The accompanying proxy statement/prospectus/information statement also constitutes the prospectus of AgeX with respect to (i) the issuance by AgeX of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and (ii) the issuance by AgeX of the shares of AgeX common stock upon the exercise of the incentive warrants.

 

The shares of AgeX common stock are currently listed on the NYSE American under the symbol “AGE.” AgeX intends to file an initial listing application for the combined company with the NYSE American. It is a condition of the closing of the Merger that the initial listing application with NYSE American shall have been approved. If such condition is not satisfied, the Merger may not be consummated. Each of AgeX and Serina may waive this condition as set forth in the Merger Agreement; however, neither AgeX nor Serina is expected to waive this condition. Substantially concurrently with the completion of the Merger, the combined company will be renamed “Serina Therapeutics, Inc.” and expects to trade on the NYSE American under the symbol “SER.” On          , 2024, the last trading day before the date of the accompanying proxy statement/prospectus/information statement, the closing sale price of AgeX common stock was $              per share.

 

AgeX stockholders are cordially invited to attend the special meeting of AgeX stockholders (the AgeX special meeting). AgeX is holding the AgeX special meeting on     at    , unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Merger and related matters. The AgeX special meeting will be held entirely online. AgeX stockholders will be able to attend and participate in the AgeX special meeting online by visiting www.virtualshareholdermeeting.com/   , where they will be able to listen to the meeting live, submit questions and vote. At the AgeX special meeting, AgeX will ask its stockholders:

 

1.To approve (i) the issuance of shares of AgeX common stock, which will represent more than 20% of the shares of AgeX common stock outstanding immediately prior to the Merger, to stockholders of Serina, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex A to the accompanying proxy statement/prospectus/information statement, and (ii) the change of control of AgeX resulting from the Merger, pursuant to Sections 712(b) and 713(b) of the NYSE American Company Guide, referred to herein as the Stock Issuance Proposal;

 

2.To approve an amendment to the certificate of incorporation of AgeX (the AgeX Charter) to effect a reverse stock split of AgeX common stock at a ratio within the range between 1-for-35 to 1-for-36 with such ratio resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the Effective Time, unless otherwise mutually agreed upon by the respective AgeX and Serina boards of directors prior to the effectiveness of the Merger or, if the Stock Issuance Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal is not approved, by AgeX stockholders, determined solely by the AgeX board of directors (the AgeX Board), referred to herein as the Reverse Stock Split Proposal;

 

3.To approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants, which will represent securities convertible into or exercisable for AgeX common stock of more than 20% of the shares of AgeX common stock outstanding at the time of issuance, referred to herein as the Warrant Issuance Proposal;

 

 
 

 

4.To approve an amendment and restatement of the AgeX Charter (the Combined Company Charter), in the form attached as Annex B to the accompanying proxy statement/prospectus/information statement, referred to herein as the A&R Charter Proposal;
  
5.To approve, on a non-binding, advisory basis, nine separately presented governance provisions in the Combined Company Charter (collectively, referred to herein as the Non-Binding Governance Proposals), which are being separately presented in accordance with SEC guidance and which will each be voted upon on a non-binding, advisory basis;

 

6.To approve the Serina Therapeutics, Inc. 2024 Equity Incentive Plan, in the form attached as Annex C to the accompanying proxy statement/prospectus/information statement, referred to herein as the 2024 Equity Incentive Plan Proposal; and

 

7.To approve a postponement or adjournment of the AgeX special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal, referred to as the Adjournment Proposal.

 

Concurrently with the execution of the Merger Agreement, Juvenescence entered into a support agreement (the AgeX Support Agreement) in favor of Serina, providing, among other things, that Juvenescence will vote all of their shares of AgeX capital stock: (i) in favor of adopting the Merger Agreement and approving the Merger, the AgeX Stockholder Matters (as defined in the accompanying proxy statement/prospectus/information statement), and the other transactions and actions contemplated by the Merger Agreement, (ii) against any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii) against any acquisition proposal involving a third party other than Serina. As of January 3, 2024, Juvenescence is a stockholder of AgeX holding approximately 43.3% of the outstanding shares of AgeX common stock, 100% of the outstanding shares of AgeX Series A preferred stock and 100% of the outstanding shares of AgeX Series B preferred stock.

 

In connection with the execution of the Merger Agreement, stockholders of Serina holding 100% of the outstanding shares of Serina common stock, 100% of the outstanding shares of Series A preferred stock of Serina, 100% of the outstanding shares of Series A-1 preferred stock of Serina, 100% of the outstanding shares of Series A-2 preferred stock of Serina, 100% of the outstanding shares of Series A-3 preferred stock of Serina, 100% of the outstanding shares of Series A-4 preferred stock of Serina, and 100% of the outstanding shares of Series A-5 preferred stock of Serina, in each case effective as of August 29, 2023, entered into support agreements (the Serina Support Agreements) in favor of AgeX, providing, among other things, that such stockholders will vote all of their shares of Serina capital stock (or execute a written consent): (i) in favor of adopting the Merger Agreement and approving the Merger, the Company Stockholder Matters (as defined in the Merger Agreement), and the other transactions and actions contemplated by the Merger Agreement, (ii) against any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii) against any acquisition proposal involving a third party other than AgeX.

 

After careful consideration, the AgeX Board has: (i) determined that the Merger and the transactions and actions contemplated by the Merger Agreement are fair to, advisable and in the best interests of AgeX and its stockholders; (ii) authorized, approved and declared advisable the Merger Agreement and the transactions contemplated therein, including the Merger; and (iii) determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement, that the stockholders of AgeX vote “FOR” each of the proposals set forth in the accompanying proxy statement/prospectus/information statement.

 

 
 

 

After careful consideration, Serina’s board of directors (the Serina Board) has (i) determined that the Merger and the transactions and actions contemplated by the Merger Agreement are fair to, advisable and in the best interests of Serina and its stockholders, (ii) authorized, and declared advisable the Merger Agreement and the transactions contemplated therein, including the Merger, and (iii) determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement, that each Serina stockholder sign and return the written consent indicating its (a) adoption of the Merger Agreement and approval of the transactions contemplated therein, including the Merger, (b) acknowledgement that the approval given is irrevocable, (c) agreement that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Article 13 of the ABCL, (d) agreement that such stockholder has received and read a copy of Article 13 of the ABCL, (e) acknowledgement that by its approval of the Merger such stockholder is not entitled to appraisal rights or Appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the ABCL, (f) election that the consummation of the Merger is not a deemed liquidation event as defined in Serina’s certificate of incorporation and (g) election of an automatic conversion of Serina’s preferred stock to Serina common stock immediately prior to the closing of the Merger in accordance with the relevant provisions of Serina’s certificate of incorporation.

 

More information about AgeX, Serina, the Merger Agreement and the transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus/information statement. AgeX and Serina urge you to read the accompanying proxy statement/prospectus/information statement carefully and in its entirety. In particular, you should carefully consider the matters discussed under “Risk Factors” beginning on page 24 of the accompanying proxy statement/prospectus/information statement.

 

AgeX and Serina are excited about the opportunities the Merger brings to AgeX’s and Serina’s stockholders, and thank you for your consideration and continued support.

 

Andrea E. Park
Chief Financial Officer
AgeX Therapeutics, Inc.
Steve Ledger
Chief Financial Officer
Serina Therapeutics, Inc.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/prospectus/information statement. Any representation to the contrary is a criminal offense. 

 

The accompanying proxy statement/prospectus/information statement is dated                 , 2024, and is first being mailed to AgeX’s and Serina’s stockholders on or about                , 2024.

 

 
 

 

AGEX THERAPEUTICS, INC.

1101 Marina Village Parkway, Suite 201
Alameda, California 94501

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON
   

 

To the stockholders of AgeX Therapeutics, Inc.:

 

NOTICE IS HEREBY GIVEN that a virtual special meeting of stockholders (the AgeX special meeting) will be held on     at    , unless postponed or adjourned to a later date. The AgeX special meeting will be held entirely online. You will be able to attend and participate in the AgeX special meeting online by visiting www.virtualshareholdermeeting.com/   , where you will be able to listen to the meeting live, submit questions and vote.

 

AgeX is holding the AgeX special meeting to consider the following purposes:

 

1.To approve (i) the issuance of shares of AgeX common stock, which will represent more than 20% of the shares of AgeX common stock outstanding immediately prior to the Merger, to stockholders of Serina, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex A to the accompanying proxy statement/prospectus/information statement, and (ii) the change of control of AgeX resulting from the Merger, pursuant to Sections 712(b) and 713(b) of the NYSE American Company Guide, referred to herein as the Stock Issuance Proposal;

 

2.To approve an amendment to the certificate of incorporation of AgeX (the AgeX Charter) to effect a reverse stock split of AgeX common stock at a ratio within the range between 1-for-35 to 1-for-36 with such ratio resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the Effective Time, unless otherwise mutually agreed upon by the respective AgeX and Serina boards of directors prior to the effectiveness of the Merger or, if the Stock Issuance Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal is not approved, by AgeX stockholders, determined solely by the AgeX board of directors (the AgeX Board), referred to herein as the Reverse Stock Split Proposal;

 

3.To approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants, which will represent securities convertible into or exercisable for AgeX common stock of more than 20% of the shares of AgeX common stock outstanding at the time of issuance, referred to herein as the Warrant Issuance Proposal;

 

4.To approve an amendment and restatement of the AgeX Charter (the Combined Company Charter), in the form attached as Annex B to the accompanying proxy statement/prospectus/information statement, referred to herein as the A&R Charter Proposal;

 

  5. To approve, on a non-binding, advisory basis, nine separately presented governance provisions in the Combined Company Charter (collectively, referred to herein as the Non-Binding Governance Proposals), which are being separately presented in accordance with SEC guidance and which will each be voted upon on a non-binding, advisory basis;

 

 
 

 

6.To approve the Serina Therapeutics, Inc. 2024 Equity Incentive Plan, in the form attached as Annex C to the accompanying proxy statement/prospectus/information statement, referred to herein as the 2024 Equity Incentive Plan Proposal; and

 

7.To approve a postponement or adjournment of the AgeX special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal, the Reverse Stock Split Proposal, Warrant Issuance Proposal, A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal, referred to as the Adjournment Proposal.

 

These proposals are referred to collectively as the AgeX Proposals.

 

Please read the accompanying proxy statement/prospectus/information statement for further information with respect to the business to be transacted at the AgeX special meeting. The AgeX Board has fixed                 as the record date for the determination of stockholders entitled to notice of, and to vote at, the AgeX special meeting and any adjournment or postponement thereof. Only holders of record of shares of AgeX common stock at the close of business on the record date are entitled to notice of, and to vote at, the AgeX special meeting. At the close of business on the record date, AgeX had                 shares of common stock outstanding and entitled to vote. A complete list of such stockholders entitled to vote at the AgeX special meeting will be available for examination in the Corporate Secretary’s Office at AgeX Therapeutics, Inc., 1101 Marina Village Parkway, Suite 201, Alameda, California 94501, for purposes pertaining to the AgeX special meeting, during ordinary business hours for a period of 10 days before the AgeX special meeting, and at the AgeX special meeting.

 

Your vote is important. Assuming a quorum is present (i) the affirmative vote of the holders of a majority of AgeX common stock outstanding and entitled to vote at the AgeX special meeting is required for the approval of the A&R Charter Proposal, and (ii) the affirmative vote of a majority of the voting power of the shares of AgeX common stock present or represented by proxy at the AgeX special meeting and entitled to vote on the matter is required for the approval each of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Non-Binding Governance Proposals, the Warrant Issuance Proposal, the 2024 Equity Incentive Plan Proposal and the Adjournment Proposal. No AgeX Proposal is conditioned upon any other AgeX Proposal. However, each of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal is a condition to the consummation of the Merger. Therefore, the Merger cannot be consummated without the approval of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal. 

 

Even if you plan to virtually attend the AgeX special meeting, AgeX requests that you sign and return the enclosed proxy or vote by mail or online to ensure that your shares will be represented at the AgeX special meeting if you are unable to virtually attend. You may change or revoke your proxy at any time before it is voted at the AgeX special meeting.

 

THE AGEX BOARD HAS DETERMINED AND BELIEVES THAT EACH OF THE AGEX PROPOSALS OUTLINED ABOVE IS FAIR TO, ADVISABLE AND IN THE BEST INTERESTS OF AGEX AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE AGEX BOARD RECOMMENDS THAT AGEX STOCKHOLDERS VOTE “FOR” EACH OF THE AGEX PROPOSALS.

 

Important Notice Regarding the Availability of Proxy Materials for the Stockholders’ Meeting to Be Held on         at              via the internet

 

The proxy statement/prospectus/information statement is available at
www.virtualshareholdermeeting.com/   

 

By Order of the AgeX Board of Directors,

 

Andrea E. Park
Chief Financial Officer
Alameda, California

 

 
 

 

ABOUT THIS PROXY STATEMENT/PROSPECTUS/INFORMATION STATEMENT

 

This proxy statement/prospectus/information statement, which forms a part of a registration statement on Form S-4/S-1 filed with the Securities and Exchange Commission (SEC) by AgeX, constitutes a prospectus of AgeX under the Securities Act of 1933, as amended (the Securities Act), with respect to (i) the issuance of the shares of AgeX common stock in exchange for each share of Serina common stock (after giving effect to the Serina preferred stock conversion (as defined below) and including all such shares that are so converted, other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares), (ii) the issuance by AgeX of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants (as defined below) and (iii) the issuance by AgeX of the shares of AgeX common stock upon the exercise of the incentive warrants (as defined below), in each case pursuant to the Agreement and Plan of Merger and Reorganization, dated August 29, 2023, as may be amended from time to time (the Merger Agreement), by and among AgeX, Merger Sub and Serina.

 

A prospectus supplement may also add, update or change information included in this proxy statement/prospectus/information statement. Any statement contained herein will be deemed to be modified or superseded for purposes of this proxy statement/prospectus/information statement to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this proxy statement/prospectus/information statement only as so modified, and any statement so superseded will be deemed not to constitute a part of this document.

 

This proxy statement/prospectus/information statement also constitutes a notice of a meeting and a proxy statement of AgeX under Section 14(a) of the Securities Exchange Act of 1934, as amended (Exchange Act), with respect to the special meeting of AgeX stockholders (the AgeX special meeting).

 

No one has been authorized to provide you with information that is different from that contained in this proxy statement/prospectus/information statement. This proxy statement/prospectus/information statement is dated                , and you should not assume that the information contained in this proxy statement/prospectus/information statement is accurate as of any date other than that date, unless otherwise specifically provided herein. Neither the mailing of this proxy statement/prospectus/information statement to AgeX stockholders nor the issuance by AgeX of AgeX common stock pursuant to the Merger Agreement will create any implication to the contrary.

 

i

 

 

This proxy statement/prospectus/information statement does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction.

 

Information contained in this proxy statement/prospectus/information statement regarding Serina and its business, operations, management and other matters has been provided by Serina and information contained in this proxy statement/prospectus/information statement regarding AgeX and its business, operations, management and other matters has been provided by AgeX.

 

This document contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this proxy statement/prospectus/information statement may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. Neither of AgeX or Serina intend for the use or display of other companies’ trade names, trademarks or service marks contained in this document to imply a relationship with, or endorsement or sponsorship of AgeX or Serina by, any other companies.

 

Web links are provided throughout this proxy statement/prospectus/information statement for convenience and are inactive textual references only. The content on the referenced websites does not constitute a part of, and is not incorporated by reference into, this proxy statement/prospectus/information statement.

 

If you would like additional copies of this proxy statement/prospectus/information statement or if you have questions about the Merger or the proposals to be presented at the AgeX special meeting, please contact AgeX’s proxy solicitor listed below. You will not be charged for any of the documents that you request.

 

You may also request additional copies from AgeX using the following contact information:

 

AgeX Therapeutics, Inc.
1101 Marina Village Parkway, Suite 201
Alameda, California 94501
Attention: Andrea Park
Phone Number: (510) 671-8370
Email: information@agexinc.com
Subject Line: Request for Proxy Materials

 

To ensure timely delivery of these documents, any request should be made no later than                to receive them before the AgeX special meeting.

 

This proxy statement/prospectus/information statement is first being mailed on or about           to all AgeX’s stockholders of record entitled to vote at the AgeX special meeting.

 

ii

 

 

TABLE OF CONTENTS

 

QUESTIONS AND ANSWERS ABOUT THE MERGER 1
PROSPECTUS SUMMARY 13
RISK FACTORS 24
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 124
THE SPECIAL MEETING OF AGEX’S STOCKHOLDERS 125
THE MERGER 133
THE MERGER AGREEMENT 170
AGREEMENTS RELATED TO THE MERGER 196
MATTERS BEING SUBMITTED TO A VOTE OF AGEX’S STOCKHOLDERS 197
PROPOSAL NO. 1 (THE STOCK ISSUANCE PROPOSAL): APPROVAL OF THE ISSUANCE OF SHARES OF AGEX COMMON STOCK PURSUANT TO THE MERGER AGREEMENT 198
PROPOSAL NO. 2 (THE REVERSE STOCK SPLIT PROPOSAL): APPROVAL OF AN AMENDMENT TO THE AGEX CERTIFICATE OF INCORPORATION EFFECTING THE REVERSE STOCK SPLIT AT A RATIO IN THE RANGE FROM 1-FOR-35 TO 1-FOR-36 199
PROPOSAL NO. 3 (THE WARRANT ISSUANCE PROPOSAL): APPROVAL OF THE ISSUANCE OF POST-MERGER WARRANTS AND INCENTIVE WARRANTS PURSUANT TO THE MERGER AGREEMENT 207
PROPOSAL NO. 4 (THE A&R CHARTER PROPOSAL): APPROVAL OF THE ADOPTION OF THE COMBINED COMPANY CHARTER 212
PROPOSAL NO. 5 (THE NON-BINDING GOVERNANCE PROPOSALS): APPROVE, ON A NON-BINDING, ADVISORY BASIS, CERTAIN GOVERNANCE PROVISIONS IN THE COMBINED COMPANY CHARTER 217
PROPOSAL NO. 6 (THE 2024 EQUITY INCENTIVE PLAN PROPOSAL): APPROVAL OF THE SERINA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN 218
PROPOSAL NO. 7 (THE ADJOURNMENT PROPOSAL): APPROVAL OF POSSIBLE ADJOURNMENT OF THE AGEX SPECIAL MEETING 224
DESCRIPTION OF AGEX’S BUSINESS 225
DESCRIPTION OF SERINA’S BUSINESS 253
AGEX MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 315
SERINA MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 333
MANAGEMENT FOLLOWING THE MERGER 351
AGEX EXECUTIVE AND DIRECTOR COMPENSATION 358
SERINA EXECUTIVE AND DIRECTOR COMPENSATION 363
RELATED PERSON TRANSACTIONS OF THE COMBINED COMPANY 367
DESCRIPTION OF COMBINED COMPANY CAPITAL STOCK 376
COMPARISON OF RIGHTS OF STOCKHOLDERS OF AGEX, SERINA AND THE COMBINED COMPANY 380
PRINCIPAL STOCKHOLDERS OF AGEX 387
PRINCIPAL STOCKHOLDERS OF SERINA 389
PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY 392
USE OF PROCEEDS 394
DETERMINATION OF OFFERING PRICE 395
LEGAL MATTERS 396
EXPERTS 397
WHERE YOU CAN FIND MORE INFORMATION 398
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 400
INDEX TO FINANCIAL STATEMENTS F-1
ANNEX A - AGREEMENT AND PLAN OF MERGER AND REORGANIZATION A-1
ANNEX B - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMBINED COMPANY B-1
ANNEX C - SERINA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN C-1
ANNEX D - APPRAISAL RIGHTS D-1
ANNEX E - CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION, AS AMENDED, OF AGEX THERAPEUTICS, INC. E-1
ANNEX F - AMENDED AND RESTATED BYLAWS OF THE COMBINED COMPANY F-1
SIGNATURES  

 

iii

 

 

QUESTIONS AND ANSWERS ABOUT THE MERGER

 

Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus/information statement does not give effect to the proposed reverse stock split of common stock of AgeX, as described in Proposal No. 2 beginning on page 199 of this proxy statement/prospectus/information statement.

 

The following section provides answers to frequently asked questions about the Merger and the special meeting of AgeX stockholders (the AgeX special meeting). This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections.

 

Q:What is the Merger?

 

A:On August 29, 2023, AgeX Therapeutics, Inc., a Delaware corporation (AgeX), Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (Merger Sub), and Serina Therapeutics, Inc., an Alabama corporation (Serina), entered into an Agreement and Plan of Merger and Reorganization, dated as of August 29, 2023, as may be amended from time to time (the Merger Agreement), a copy of which is attached hereto as Annex A. Pursuant to the Merger Agreement, Merger Sub will merge with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the Merger). The Merger Agreement contains the terms and conditions of the Merger. Substantially concurrently with the completion of the Merger, AgeX will be renamed “Serina Therapeutics, Inc.” AgeX following the Merger is referred to herein as the “combined company.”

 

The Merger will become effective on the date and at the time the Statement of Merger has been duly filed with the Secretary of State of the State of Alabama or at such later time as may be specified in the Statement of Merger with the consent of AgeX and Serina in accordance with the Alabama Business Corporation Law of the State of Alabama (ABCL) (such date, the Closing Date, and such time, the Effective Time).

 

At the Effective Time, each outstanding share of common stock, $0.01 par value per share, of Serina (Serina common stock) (after giving effect to the conversion of each share of preferred stock of Serina into common stock of Serina (the Serina preferred stock conversion) and including all such shares that are so converted, other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares) will be automatically converted solely into the right to receive a number of shares of common stock of AgeX, $0.0001 par value per share (AgeX common stock) equal to the exchange ratio (the exchange ratio) determined in accordance with the Merger Agreement as described in more detail in the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio” beginning on page 171 of this proxy statement/prospectus/information statement.

 

At the Effective Time, (i) each outstanding and unexercised option to purchase shares of Serina common stock (Serina option) immediately prior to the Effective Time under the Serina Therapeutics, Inc. 2017 Stock Option Plan, as amended (the Serina Plan), will be converted into and become an option to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the option and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume the Serina Plan and each Serina option in accordance with the terms of the Serina Plan and the terms of the Serina option, and (ii) each outstanding and unexercised warrant to purchase shares of Serina common stock (Serina warrant) immediately prior to the Effective Time, if any, will be converted into and become a warrant to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the warrant and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume each Serina warrant in accordance with its terms.

 

1

 

 

Immediately prior to the reverse stock split, each outstanding and unexercised AgeX option with an exercise price equal to or greater than $0.7751 (the AgeX closing price) (each, an out of the money AgeX option) as of immediately prior to the reverse stock split, if any, will be canceled without payment. In accordance with the terms and conditions set forth in AgeX’s 2017 Equity Incentive Plan (the Incentive Plan), AgeX will notify each holder of an out of the money AgeX option that each such option will become exercisable at least 10 days prior to the reverse stock split and will thereafter be canceled if not exercised. All other outstanding and unexercised options to purchase shares of AgeX common stock will remain outstanding and exercisable in accordance with their terms immediately following the Effective Time.

 

Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price of AgeX common stock being equal to or greater than $12.00 per share (on a post-reverse stock split basis), giving effect to the reverse stock split and the AgeX preferred stock conversion and excluding the impact of any post-merger warrant (as defined below), incentive warrant (as defined below) or the issuance of any share of AgeX common stock upon exercise of any post-merger warrant or incentive warrant. Each post-merger warrant and incentive warrant will be issued pursuant to the terms of a warrant agreement to be entered into by AgeX and a warrant agent in connection with the closing of the Merger. The terms of the warrant agreement remain subject to agreement between AgeX and Serina. For a more complete description of the exchange ratio, please see the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio.”

 

Q:Why are the two companies proposing to merge?

 

A:AgeX and Serina believe that combining the two companies will result in a company with a promising pipeline, a strong leadership team and greater access to capital resources, focused primarily on developing Serina’s product candidates to treat neurological diseases and pain.

 

If the Merger is completed, the combined company will primarily focus on developing Serina’s product candidates, which are described on page 253 under the section titled “Description of Serina’s Business,” and it is anticipated that the combined company will not continue to develop AgeX’s product candidates, other than potentially the development program of AgeX’s subsidiary, NeuroAirmid Therapeutics, Inc. (NeuroAirmid), which is described on page 234 under the section titled “Description of AgeX’s Business—Products and Product Candidates.”

 

For a more complete description of the reasons for the Merger, please see the sections titled “The Merger—AgeX Reasons for the Merger” and “The Merger—Serina Reasons for the Merger” beginning on pages 150 and 156, respectively, of this proxy statement/prospectus/information statement.

 

Q:What will happen to AgeX if, for any reason, the Merger does not close?

 

A:If, for any reason, the Merger does not close, AgeX expects to continue to execute on its current business strategies described in the section titled “Description of AgeX’s Business—Business Strategy” beginning on page 231 of this proxy statement/prospectus/information statement while seeking out and evaluating potential strategic alternatives with respect to our assets and development programs, which may include a merger, business combination, investment into AgeX, sale or other disposition of assets or other strategic transaction. In such case, AgeX may not be successful in executing such strategies or identifying or implementing any such strategic alternatives, and there is a risk that Juvenescence may decide to stop funding AgeX’s operations, which would likely result in its delisting and dissolution.

 

Under certain circumstances, AgeX may be obligated to pay Serina a termination fee of $1,000,000 or reimburse certain expenses of Serina up to $1,000,000, but not both, as more fully described in the section titled “The Merger Agreement—Termination and Termination Fees” beginning on page 190 of this proxy statement/prospectus/information statement.

 

2

 

 

Q:Why am I receiving this proxy statement/prospectus/information statement?

 

A:You are receiving this proxy statement/prospectus/information statement because you have been identified as a holder of AgeX common stock as of the record date and you are entitled to vote to approve the matters set forth herein, or you have been identified as a stockholder of Serina eligible to execute the Serina written consent. This document serves as:

 

a proxy statement of AgeX used to solicit proxies for the AgeX special meeting to vote on the matters set forth herein;
   
a prospectus of AgeX used to offer shares of AgeX common stock in exchange for shares of Serina common stock in the Merger (other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares); and
   
an information statement of Serina used to solicit the written consent of its stockholders for the adoption of the Merger Agreement and the approval of the Merger and related transactions after the declaration of the effectiveness of this registration statement on Form S-4/S-1, of which this proxy statement/prospectus/information statement is a part.

 

Information about the AgeX special meeting, the Merger, the Merger Agreement and the other business to be considered by AgeX stockholders at the AgeX special meeting, and for Serina stockholders to consider in determining whether to sign and return the Serina written consent, is contained in this proxy statement/prospectus/information statement. AgeX stockholders and Serina stockholders should read this information carefully and in its entirety. The enclosed voting materials allow AgeX stockholders to vote their shares by proxy without attending the AgeX special meeting.

 

If you are a stockholder of Serina, you are requested to sign and return the Serina written consent to (i) adopt the Merger Agreement and approve the transactions and actions contemplated by the Merger Agreement, including the Merger, (ii) acknowledge that your approval will be irrevocable, (iii) agree that you are aware of your rights to demand appraisal for your shares pursuant to Article 13 of the Alabama Business Corporation Law of the State of Alabama (ABCL), (iv) agree that you have received and read a copy of Article 13 of the ABCL, (v) acknowledge that by your approval of the Merger you are not entitled to appraisal rights with respect to your shares of Serina capital stock in connection with the Merger and thereby waive any rights to receive payment of the fair value of your capital stock under the ABCL, (vi) elect that the consummation of the Merger is not a deemed liquidation event and (vii) consent to conversion of Serina preferred stock to Serina common stock immediately prior to the closing of the Merger in accordance with the relevant provisions of Serina’s organization documents (items (i) through (vii), collectively, the Serina Stockholder Matters).

 

Q:What are the post-merger warrants and the incentive warrants?

 

A:Following the reverse stock split and the AgeX preferred stock conversion and prior to the closing of the Merger, AgeX will issue to each holder of AgeX common stock as of the close of business on a business day following the reverse stock split and the AgeX preferred stock conversion and prior to the closing of the Merger (the Warrant Dividend Record Date) three warrants (each, a post-merger warrant) for each five shares of AgeX common stock issued and outstanding held by such holder as of the Warrant Dividend Record Date (the Warrant Dividend). Each post-merger warrant will be exercisable at an exercise price equal to $13.20 per warrant (such exercise price reflecting the planned reverse stock split) for (i) one share of AgeX common stock and (ii) one warrant (each, an incentive warrant) and will expire on July 31, 2025. Each incentive warrant will be exercisable at an exercise price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split) for one share of AgeX common stock and will expire on the four-year anniversary of the Closing Date. For additional information, see the section titled “Agreements Related to the Merger—Warrant Agreement” beginning on page 197 of this proxy statement/prospectus/information statement.

 

3

 

 

Q:What is the Side Letter?

 

A:Concurrently with the execution of the Merger Agreement, AgeX, Serina and Juvenescence Limited (Juvenescence) entered into a letter agreement in substantially the form attached to the Merger Agreement (the Side Letter), which will become effective immediately prior to the closing of the Merger. The Side Letter provides that:

 

(i)immediately prior to the Effective Time, Juvenescence will cancel all outstanding and unexercised AgeX warrants with an exercise price equal to or greater than the AgeX closing price (each, an out of the money AgeX warrant) held by Juvenescence;

 

(ii)Juvenescence will exercise all of the post-merger warrants it holds to provide the combined company approximately an additional $15 million in capital according to the following schedule: (x) at least one-third on or before May 31, 2024, (y) at least one-third on or before November 30, 2024, and (z) at least one-third on or before June 30, 2025;

 

(iii)AgeX and Serina shall use reasonable best efforts to appoint certain directors, including Steve Ledger and Dr. J. Milton Harris, who are each affiliated with Serina, and Dr. Gregory Bailey and Dr. Richard Marshall, who are each affiliated with Juvenescence, to the board of the combined company effective as of the Effective Time;

 

(iv)Juvenescence will not sell any shares of AgeX Series A preferred stock or AgeX Series B preferred stock and will take all actions necessary to effect the AgeX preferred stock conversion, whereby all of such preferred stock will be converted into AgeX common stock prior to the reverse stock split;

 

(v)Juvenescence will release all security interests, guarantees, pledges, assignments and other forms of collateral that it may have in AgeX’s assets pursuant to the terms of certain loans to AgeX; and

 

(vi)Juvenescence will consent to a newly formed subsidiary of AgeX assuming AgeX’s obligations with respect to loans agreements and promissory notes governing loans payable to Juvenescence, including obligations for amounts currently owed and future advances of loan funds, and Juvenescence shall release AgeX from those loan obligations.

 

Q: Did the AgeX Board undertake a strategic review process in connection with the Merger?

 

A: The AgeX board of directors (the AgeX Board) undertook a process of reviewing and analyzing potential strategic options, including remaining a standalone company pursuing AgeX’s pipeline of product candidates and technology platforms by exploring potential partnerships and seeking to develop more mature assets, seeking to raise independent financing for certain product candidates and disposing of certain assets, pursuing strategic mergers and acquisitions, including through a reverse merger, to identify the opportunity that would, in the AgeX Board’s opinion, create the most value for AgeX stockholders (given (i) AgeX’s amount of indebtedness, (ii) that reverse mergers typically require the public company to have cash to obtain a higher relative equity split, (iii) the risk that AgeX may fail to execute on its business strategy or identify any potential strategic alternatives with respect to its assets and development programs if the Merger were not to occur and (iv) the risk that Juvenescence may decide to stop funding AgeX’s operations if the Merger were not to occur, which would likely result in its delisting and dissolution). The AgeX Board believed, after such review of strategic alternatives (including reverse mergers, third-party collaborations and licensing agreements for its core technologies UniverCyte™ and PureStem®, and its cell therapy programs, including AGEX-VASC1 and AGEX-BAT1, financing alternatives for its iTR™ technology and a potential spinout of Reverse Bio) and discussions with its advisors that the Merger is more favorable to AgeX stockholders than the potential value that might have resulted from other strategic options available to AgeX. For additional information on the AgeX Board’s strategic review process, see the section titled “The Merger—Background of the Merger” and “—AgeX Reasons for the Merger” beginning on pages 133 and 150 of this proxy statement/prospectus/information statement.

 

Q: Was Juvenescence involved in AgeX’s strategic review process in connection with the Merger?

 

A: Juvenescence was involved in AgeX’s strategic review process. For additional information regarding  Juvenescence’s role in AgeX’s strategic review process, including in identifying the potential transaction between AgeX and Serina, negotiating the Merger Agreement and funding Serina, see the section titled “The Merger—Background of the Merger” beginning on page 133 of this proxy statement/prospectus/information statement.

 

Q: Did the AgeX Board engage an independent financial advisor to shop AgeX or deliver a fairness opinion in connection with the Merger?

 

A:

The AgeX Board determined that it did not need to engage an independent financial advisor to assess its strategic options and to shop AgeX at any point from 2020 onwards based on the relevant experience of its board members, management and other advisors. As more fully described in the section titled “The MergerBackground of the Merger”, prior to negotiations with Serina, the AgeX Board was unsuccessful in identifying any other strategic alternatives. In the absence of any other strategic alternatives, and given (i) AgeX’s amount of indebtedness, (ii) the risk that AgeX may fail to execute on its business strategy or identify any potential strategic alternatives with respect to its assets and development programs and (iii) the risk that Juvenescence may decide to stop funding AgeX’s operations, which would likely result in its delisting and dissolution, the AgeX Board believes that the relative 75:25 ownership of the combined company alongside the creation of a set of out-of-money warrants that if fully exercised would result in a 58:42 relative value creates the most value for AgeX stockholders.

 

Additionally, after publicly announcing that it was pursuing a transaction with Serina in March 2023, no offers or proposals were received. As a result of years of exploring a potential strategic transaction, including six months where other potential bidders were aware of its pending transaction with Serina prior to AgeX entering into the Merger Agreement, the AgeX Board concluded that the cost of a fairness opinion, which would have required additional indebtedness to obtain, outweighed its benefit.

 

4

 

 

Q: What is Juvenescence’s relationship with AgeX?

 

A:

As of January 3, 2024, Juvenescence owned approximately 43.3% of the outstanding shares of AgeX common stock, 100% of the outstanding shares of AgeX Series A preferred stock and 100% of the outstanding shares of AgeX Series B preferred stock. Juvenescence also indicated that it beneficially owned approximately 80.2% of AgeX common stock in its amendment of the Schedule 13D filed with the SEC on January 9, 2024. As of January 3, 2024, AgeX is indebted to Juvenescence for approximately $5.0 million for funds borrowed and loan original fees accrued pursuant to the 2022 Secured Note (as defined below) and the 2023 Secured Note (as defined below). Juvenescence’s Executive Chairman and Co-Founder, Dr. Gregory Bailey, is a member of the AgeX Board. Accordingly, Juvenescence is a significant stockholder and creditor of AgeX and has an affiliate on the AgeX Board and, therefore, is able to substantially influence AgeX and exert control over the AgeX Proposals (as defined below).

 

The AgeX preferred stock conversion is expected to occur on February 1, 2024 in accordance with the Certificates of Designation of the AgeX Series A preferred stock and the AgeX Series B preferred stock. The AgeX preferred stock conversion will increase Juvenescence’s ownership and voting power to more than 50% of the outstanding shares of AgeX common stock, enabling Juvenescence to approve or disapprove the Merger and other AgeX Proposals without regard to the vote of other AgeX stockholders.

 

Juvenescence’s interests may not always coincide with AgeX’s corporate interests or the interests of other stockholders, and it may exercise its voting and other rights, including rights as a creditor, in a manner with which other stockholders may not agree or that may not be in the best interests of AgeX or stockholders other than Juvenescence. So long as Juvenescence continues to own a significant amount of AgeX’s equity and remains a significant creditor, it will continue to be able to strongly influence and effectively control AgeX’s decisions. While the directors elected by Juvenescence will be obligated to act in accordance with their fiduciary duty, they may have equity or other interests in Juvenescence and, accordingly, their interests may be aligned with Juvenescence’s interests, which may not always coincide with AgeX’s corporate interests or the interests of AgeX’s other stockholders.

 

For additional information regarding Juvenescence’s relationship with AgeX, please see the sections titled “Risk Factors—Risks Related to the Merger—Juvenescence owns a significant majority of AgeX capital stock and will be able to substantially influence AgeX and exert control over the AgeX Proposals,” “Risk Factors—Risks Related to AgeX—We are highly leveraged, carrying a significant amount of indebtedness, including indebtedness secured by our assets, that will become due and payable over the next three years and there is no assurance that we will be able to refinance those obligations as they become due,” “Risk Factors—Risks Related to AgeX—The terms of our loans from Juvenescence and the Security Agreement could make it more difficult for us to raise additional capital from other sources,” “Risk Factors—Risks Related to AgeX—Risks Related to Our Relationship with Juvenescence—Conflicts of interest may arise from our relationship with Juvenescence, which owns a significant percentage of AgeX common stock as well as shares of AgeX preferred stock and is a significant creditor and will be able to substantially influence AgeX and exert control over matters subject to stockholder approval, including the Merger and other AgeX Proposals,” “Risk Factors—Risks Related to AgeX—Risks Related to AgeX Common Stock—You may experience dilution of your ownership interests if we issue additional shares of common stock or preferred stock,” “The Merger—Background of the Merger,” “The Merger—Interests of the AgeX Directors and Executive Officers in the Merger” and “Principal Stockholders of AgeX.

 

Q: What is Juvenescence’s relationship with Serina?

 

A: Juvenescence does not own any capital stock of Serina. Juvenescence’s Executive Chairman and Co-Founder, Dr. Bailey, is currently a member of Serina’s board of directors (the Serina Board), but does not hold any capital stock of Serina nor does he hold any options, warrants or other equity or debt interests in Serina. Serina appointed Dr. Bailey to the Serina Board in accordance with the AgeX-Serina Note (as defined below), which note is in the principal amount of $10 million and will be converted into Serina capital stock immediately prior to completion of the Merger. For additional information regarding Juvenescence’s relationship with Serina, see the sections titled “The Merger—Background of the Merger,” “The Merger—Interests of the Serina Directors and Executive Officers in the Merger” and “Principal Stockholders of Serina” beginning on pages 133, 161 and 389 of this proxy statement/prospectus/information statement.
   
Q: What is Juvenescence’s expected relationship with the combined company?

 

A:

Juvenescence is expected to beneficially own approximately 27.14% of the combined company’s common stock upon consummation of the Merger, assuming the closing of the Merger occurred on January 3, 2024. For additional information, see “Principal Stockholders of the Combined Company” beginning on page 392 of this proxy statement/prospectus/information statement.

 

In addition, Dr. Bailey and Dr. Richard Marshall, who are each affiliated with Juvenescence, are expected to be appointed to the Combined Company Board (as defined below) at the Effective Time. For additional information, see “Management Following the Merger” beginning on page 351 of this proxy statement/prospectus/information statement.

 

Juvenescence’s interests may not always coincide with the combined company’s corporate interests or the interests of other stockholders of the combined company, and it may exercise its voting and other rights in a manner with which other stockholders may not agree or that may not be in the best interests of the combined company or stockholders other than Juvenescence. So long as Juvenescence owns a significant amount of the combined company’s equity, it will be able to strongly influence the combined company’s decisions. While the directors affiliated with Juvenescence will be obligated to act in accordance with their fiduciary duty, they may have equity or other interests in Juvenescence and, accordingly, their interests may be aligned with Juvenescence’s interests, which may not always coincide with the combined company’s corporate interests or the interests of the combined company’s other stockholders. For additional information, see “Risk Factors—Risks Related to the Combined Company—Conflicts of interest may arise from the combined company’s relationship with Juvenescence, which will own a significant percentage of the combined company’s common stock as well as warrants to purchase additional shares of the combined company’s common stock and will be able to substantially influence the combined company and exert control over matters subject to stockholder approval” beginning on page 123 of this proxy statement/prospectus/information statement.

 

Q: What proposals will be voted on at the AgeX special meeting?

 

A:

AgeX stockholders are being asked to vote on the following proposals:

 

  Proposal No. 1—the Stock Issuance Proposal to approve (i) the issuance of shares of AgeX common stock, which will represent more than 20% of the shares of AgeX common stock outstanding immediately prior to the Merger, to stockholders of Serina, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex A to this proxy statement/prospectus/information statement, and (ii) the change of control of AgeX resulting from the Merger, pursuant to Sections 712(b) and 713(b) of the NYSE American Company Guide;
     
  Proposal No. 2—the Reverse Stock Split Proposal to approve an amendment to the certificate of incorporation of AgeX (the AgeX Charter) to effect a reverse stock split of AgeX common stock at a ratio within the range between 1-for-35 to 1-for-36 with such ratio resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the Effective Time, unless otherwise mutually agreed upon by the AgeX Board and the Serina Board prior to the effectiveness of the Merger or, if the Stock Issuance Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal is not approved, by AgeX stockholders, determined solely by the AgeX Board;
     
  Proposal No. 3—the Warrant Issuance Proposal to approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants, which will represent securities convertible into or exercisable for AgeX common stock of more than 20% of the shares of AgeX common stock outstanding at the time of issuance;
     
  Proposal No. 4—the A&R Charter Proposal to approve an amendment and restatement of the AgeX Charter (the Combined Company Charter), in the form attached as Annex B to this proxy statement/prospectus/information statement;
     
 

Proposal No. 5—the Non-Binding Governance Proposals to approve, on a non-binding, advisory basis, nine separately presented governance provisions in the Combined Company Charter, which are being separately presented in accordance with SEC guidance and which will each be voted upon on a non-binding, advisory basis:

     
  Proposal No. 6—the 2024 Equity Incentive Plan Proposal to approve the Serina Therapeutics, Inc. 2024 Equity Incentive Plan, in the form attached as Annex C to this proxy statement/prospectus/information statement; and
     
  Proposal No. 7—the Adjournment Proposal to approve a postponement or adjournment of the AgeX special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal.

 

   

These proposals are referred to collectively as the AgeX Proposals.

 

The approval of each of Proposal Nos. 1, 2, 3, 4 and 6 is a condition to completion of the Merger and are required in order to effect the Merger. The approval of Proposals Nos. 5 and 7 are not a condition to the Merger or required in order to effect the Merger. AgeX does not expect that any matters other than the AgeX Proposals will be brought before the AgeX special meeting.

 

The presence, by accessing online or being represented by proxy, at the AgeX special meeting of the holders of a majority of the shares of AgeX common stock outstanding and entitled to vote at the AgeX special meeting is necessary to constitute a quorum at the meeting for the purpose of approving the AgeX Proposals.

  

Q: What is required to consummate the Merger?

 

A: To consummate the Merger, AgeX’s common stockholders must approve the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal and Serina’s stockholders must approve the Serina Stockholder Matters.

 

Concurrently with the execution of the Merger Agreement, Juvenescence entered into a support agreement (the AgeX Support Agreement) in favor of Serina, providing, among other things, that Juvenescence will vote all of their shares of AgeX capital stock in favor of the AgeX Stockholder Matters (as defined in the section titled “The Merger Agreement—AgeX Stockholder Meeting” beginning on page 182 of this proxy statement/prospectus/information statement). As of January 3, 2024, Juvenescence is a stockholder of AgeX holding approximately 43.3% of the outstanding shares of AgeX common stock, 100% of the outstanding shares of AgeX Series A preferred stock and 100% of the outstanding shares of AgeX Series B preferred stock.

 

In connection with the execution of the Merger Agreement, stockholders of Serina holding 100% of the outstanding shares of Serina common stock, 100% of the outstanding shares of Series A preferred stock of Serina, 100% of the outstanding shares of Series A-1 preferred stock of Serina, 100% of the outstanding shares of Series A-2 preferred stock of Serina, 100% of the outstanding shares of Series A-3 preferred stock of Serina, 100% of the outstanding shares of Series A-4 preferred stock of Serina, and 100% of the outstanding shares of Series A-5 preferred stock of Serina, in each case effective as of August 29, 2023, entered into support agreements (the Serina Support Agreements and, together with the AgeX Support Agreement, the Support Agreements) in favor of AgeX, providing, among other things, that such stockholders will vote all of their shares of Serina capital stock (or execute a written consent) in favor of Serina Stockholder Matters.

 

In addition to the requirement of obtaining stockholder approval of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal and the Serina Stockholder Matters, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived. For a more complete description of the closing conditions under the Merger Agreement, refer to the section titled “The Merger Agreement—Conditions to the Completion of the Merger” beginning on page 174 of this proxy statement/prospectus/information statement.

 

Q: Why are AgeX stockholders not receiving a proxy to vote at the AgeX special meeting on whether to approve the Merger Agreement?

 

A: To consummate the Merger, AgeX stockholders are not required to approve the Merger Agreement under Delaware General Corporation Law (DGCL) or the Merger Agreement. As a result, AgeX stockholders are not receiving a proxy to vote at the AgeX special meeting on whether to approve the Merger Agreement.

 

Q: What will Serina’s stockholders, option holders and warrant holders receive in the Merger?

 

A: At the Effective Time, each outstanding share of Serina common stock (after giving effect to the Serina preferred stock conversion and including all such shares that are so converted, other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares) will be automatically converted solely into the right to receive a number of shares of AgeX common stock equal to the exchange ratio determined in accordance with the Merger Agreement as described in more detail in the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio” beginning on page 171 of the proxy statement/prospectus/information statement.

 

At the Effective Time, (i) each outstanding and unexercised Serina option immediately prior to the Effective Time under the Serina Plan will be converted into and become an option to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the option and the exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume the Serina Plan and each Serina option in accordance with the terms of the Serina Plan and the terms of the Serina option, and (ii) each outstanding and unexercised option to purchase shares of Serina common stock immediately prior to the Effective Time, if any, will be converted into and become a warrant to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the warrant and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume each Serina warrant in accordance with its terms.

 

5

 

 

For a more complete description of what Serina’s stockholders and option holders will receive in the Merger, please see the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio” beginning on page 171 of this proxy statement/prospectus/information statement.

 

Q:What will AgeX’s stockholders, option holders and warrant holders receive in the Merger?

 

A:At the Effective Time, AgeX’s stockholders will continue to own and hold their existing shares, options and warrants to purchase shares of AgeX common stock. However, immediately prior to the reverse stock split, each out of the money AgeX option as of immediately prior to the reverse stock split, if any, will be canceled without payment. In accordance with the terms and conditions set forth in the Incentive Plan, AgeX will notify each holder of an out of the money AgeX option that each such option will become exercisable at least 10 days prior to the reverse stock split and will thereafter be canceled if not exercised.

 

Q:Will the common stock of the combined company trade on an exchange?

 

A:Shares of AgeX common stock are currently listed on the NYSE American under the symbol “AGE.” AgeX intends to file an initial listing application for the combined company with the NYSE American. It is a condition of the closing of the Merger that the initial listing application with NYSE American shall have been approved. If such condition is not satisfied, the Merger may not be consummated. Each of AgeX and Serina may waive this condition as set forth in the Merger Agreement; however, neither AgeX nor Serina is expected to waive this condition. NYSE American’s determination is not expected to be known at the time that you are asked to vote on the AgeX Proposals at the AgeX special meeting. Substantially concurrently with the completion of the Merger, AgeX will be renamed “Serina Therapeutics, Inc.,” and the combined company expects to trade on the NYSE American under the symbol “SER.” On                    , 2023, the last trading day before the date of this proxy statement/prospectus/information statement, the closing sale price of AgeX common stock was $             per share.

 

Q:Who will be the directors of AgeX following the Merger?

 

A: At the Effective Time, the combined company is expected to initially have a seven-member board of directors (the Combined Company Board), comprising (a) Remy Gross, designated by both AgeX and Serina, (b) J. Milton Harris and Steven Ledger, each as a Serina designee, (c) Gregory Bailey and Richard Marshall, each as an AgeX designee, and (d)        and                 , each as an independent director, until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal. The Combined Company Board will have an audit committee, a compensation committee and a nominating and corporate governance committee, in accordance with the rules of the NYSE American. All of AgeX’s current directors other than Gregory Bailey are expected to resign from their positions as directors of AgeX, effective upon the Effective Time.

 

6

 

 

Q:Who will be the executive officers of AgeX following the Merger?

 

A:Immediately following the Merger, the executive management team of the combined company is expected to comprise the following individuals with such additional officers as may be added by Serina or the combined company:

 

Name   Position with the Combined Company   Current Position at AgeX / Serina
Steve Ledger   Interim Chief Executive Officer   Chief Financial Officer at Serina
Andrea Park   Interim Chief Financial Officer and Chief Accounting Officer   Chief Financial Officer at AgeX
Randall Moreadith, M.D., Ph.D.   Chief Scientific Officer   President and Chief Executive Officer at Serina
Tacey Viegas   Chief Operating Officer and Secretary   Chief Operating Officer at Serina

 

Q:As a stockholder of AgeX, how does the AgeX Board recommend that I vote?

 

A:

After careful consideration, the AgeX Board recommends that the holders of AgeX common stock vote:

 

  FOR” Proposal No. 1—the Stock Issuance Proposal;

 

  FOR” Proposal No. 2—the Reverse Stock Split Proposal;

 

  FOR” Proposal No. 3—the Warrant Issuance Proposal;

 

  FOR” Proposal No. 4—the A&R Charter Proposal;
     
  FOR” Proposal No. 5—The Non-Binding Governance Proposals;

 

  FOR” Proposal No. 6—the 2024 Equity Incentive Plan Proposal; and

 

  FOR” Proposal No. 7—the Adjournment Proposal.

  

For more information on each proposal and the AgeX Board’s recommendations, please see the section titled “Matters Being Submitted to a Vote of AgeX’s Stockholders” beginning on page 198 of this proxy statement/prospectus/information statement.

 

Q: How many votes are needed to approve each proposal?

 

A: Assuming a quorum is present, the affirmative vote of the holders of a majority of AgeX common stock outstanding and entitled to vote at the AgeX special meeting is required for the approval of the A&R Charter Proposal.

 

Assuming a quorum is present, the affirmative vote of a majority of the voting power of the shares of AgeX common stock present or represented by proxy at the AgeX special meeting and entitled to vote on the matter is required for the approval of each of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the Non-Binding Governance Proposals, the 2024 Equity Incentive Plan Proposal and the Adjournment Proposal.

 

7

 

 

Votes will be counted by the inspector of election appointed for the AgeX special meeting, who will separately count “FOR” and “AGAINST” votes, abstentions and broker non-votes, if any, as applicable to each proposal. Abstentions and broker non-votes, if any, will also be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the AgeX special meeting. Abstentions and broker non-votes, if any, will be counted as “shares entitled to vote” for the A&R Charter Proposal and therefore will have the same effect as a vote “AGAINST” the A&R Charter Proposal. Abstentions and broker non-votes, if any, will not be counted as “votes cast” and will therefore have no effect on the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the Non-Binding Governance Proposals, the 2024 Equity Incentive Plan Proposal and the Adjournment Proposal.

 

Q:As a stockholder of Serina, how does the board of directors of Serina recommend that I vote?

 

A:After careful consideration, the Serina Board recommends that the Serina stockholders execute the written consent stating their vote in favor of the Serina Stockholder Matters.

 

Q:What risks should I consider in deciding whether to vote in favor of the AgeX Proposals or to execute and return the written consent, as applicable?

 

A:You should carefully review the section titled “Risk Factors” beginning on page 24 of this proxy statement/prospectus/information statement, which sets forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company’s business will be subject, and risks and uncertainties to which each of AgeX and Serina, as independent companies, are subject.

 

Q:When do you expect the Merger to be consummated?

 

A:We anticipate that the Merger will be consummated during the first quarter of 2024, soon after the AgeX special meeting to be held on    , but we cannot predict the exact timing. For more information, please see the section titled “The Merger Agreement—Conditions to the Completion of the Merger” beginning on page 174 of this proxy statement/prospectus/information statement.

 

Q:What are the material U.S. federal income tax consequences of the Merger to U.S. holders of Serina shares?

 

A:AgeX and Serina intend the Merger to qualify as a reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (Code), as described in the section titled “The Merger—Material U.S. Federal Income Tax Consequences of the Merger” beginning on page 165 of this proxy statement/prospectus/information statement. Assuming the Merger so qualifies, Serina stockholders who are U.S. holders (as defined in the section titled “The Merger—Material U.S. Federal Income Tax Consequences of the Merger” beginning on page 165 of this proxy statement/prospectus/information statement) generally will not recognize gain or loss for U.S. federal income tax purposes on the receipt of shares of AgeX common stock issued in connection with the Merger.

 

8

 

 

If the Merger does not qualify as a reorganization within the meaning of Section 368(a) of the Code, then each Serina stockholder who is a U.S. holder will generally recognize capital gain or loss for U.S. federal income tax purposes on the receipt of shares of AgeX common stock issued in connection with the Merger. The tax consequences to each Serina stockholder will depend on that stockholder’s particular circumstances. Each Serina stockholder should consult with his, her or its tax advisor for a full understanding of the tax consequences of the Merger to that Serina stockholder.

 

Q:What are the material U.S. federal income tax consequences of the reverse stock split to U.S. holders of AgeX shares?

 

A:AgeX intends to treat the reverse stock split as a “recapitalization” within the meaning of Section 368(a)(1)(E) of the Code for U.S. federal income tax purposes. Assuming it so qualifies, an AgeX stockholder who is a U.S. holder (as defined in the section titled “Matters Being Submitted to a Vote of AgeX’s Stockholders—Proposal No. 2: Approval of an Amendment to the Certificate of Incorporation of AgeX Effecting the Reverse Stock Split—Material U.S. Federal Income Tax Consequences of the Reverse Stock Split” beginning on page 204 of this proxy statement/prospectus/information statement) should not recognize gain or loss upon the reverse stock split, except with respect to cash received in lieu of a fractional share of AgeX common stock.

 

Please review the information in the section titled “Matters Being Submitted to a Vote of AgeX’s Stockholders—Proposal No. 2: Approval of an Amendment to the Certificate of Incorporation of AgeX Effecting the Reverse Stock Split—Material U.S. Federal Income Tax Consequences of the Reverse Stock Split” beginning on page 204 of this proxy statement/prospectus/information statement for a more complete description of the material U.S. federal income tax consequences of the reverse stock split to AgeX U.S. holders.

 

Q:What do I need to do now?

 

A:AgeX and Serina urge you to read this proxy statement/prospectus/information statement carefully, including its annexes, and to consider how the Merger affects you.

 

If you are a holder of AgeX common stock, please vote your shares as soon as possible so that your shares will be represented at the AgeX special meeting. Please follow the instructions set forth on the enclosed AgeX proxy card or on the voting instruction form provided by the record holder of your shares if your shares are held in the name of your bank, broker or other nominee.

 

If you are a stockholder of Serina, you may execute and return your written consent to Serina in accordance with the instructions provided by Serina once this Registration Statement is declared effective by the SEC.

 

9

 

 

Q:When and where is the AgeX special meeting? What must I do to attend the AgeX special meeting?

 

A:The AgeX special meeting will be held exclusively online via live audio-only webcast on    , 2024 at    . AgeX encourages you to allow ample time for the online check-in procedures. Please note that you will not be able to attend the AgeX special meeting in person.

 

You or your authorized proxy may attend the AgeX special meeting if you were a registered or beneficial stockholder of AgeX common stock as of the record date.

 

You will be able to vote your shares and submit questions during the AgeX special meeting webcast by logging in to the website listed above using the 16-digit control number included in your proxy card. If your shares are held in “street name,” you should contact your bank, broker or other nominee if you did not receive a 16 digit control number. If you wish to submit a question during the AgeX special meeting, log into the AgeX special meeting platform at www.virtualshareholdermeeting.com/   , type your question into the “Ask a Question” field, and click “Submit.” AgeX will respond to as many properly submitted questions during the relevant portion of the AgeX special meeting agenda as time allows.

 

If AgeX experiences technical difficulties during the AgeX special meeting (e.g., a temporary or prolonged power outage), AgeX will determine whether the AgeX special meeting can be promptly reconvened (if the technical difficulty is temporary) or whether the AgeX special meeting will need to be reconvened on a later day (if the technical difficulty is more prolonged). In any situation, AgeX will promptly notify stockholders of the decision via    .

 

If you own shares in street name through an account with a bank, broker or other nominee, please refer to the instructions provided by your bank, brokerage firm or other nominee to see which of the above choices are available to you. Please note that if you hold shares in street name and wish to vote virtually at the AgeX special meeting, you must obtain a legal proxy from your bank, brokerage firm or other nominee.

 

If your shares are registered in your name with AgeX’s stock registrar and transfer agent, Equiniti Trust Company, LLC (Equiniti), no proof of ownership is necessary for you to vote virtually at the AgeX special meeting because AgeX can verify your ownership.

 

Q:How are votes counted?

 

A:Votes will be counted by the inspector of elections appointed for the AgeX special meeting, who will separately count votes “FOR” and “AGAINST,” abstentions and, if applicable, broker non-votes.

 

Q:What are “broker non-votes”?

 

A:The term “broker non-votes” refers to shares held by a broker, bank or other nominee (for the benefit of its client) that are represented at the AgeX special meeting, but with respect to which such broker, bank or nominee is not instructed to vote on a particular proposal and does not have discretionary authority to vote on that proposal. Broker non-votes, if any, will be treated as shares that are present at the AgeX special meeting for purposes of determining whether a quorum exists but will not have any effect for the purpose of voting on Proposal No. 1 (the Stock Issuance Proposal), Proposal No. 2 (the Reverse Stock Split Proposal), Proposal No. 3 (the Warrant Issuance Proposal), Proposal No. 5 (the Non-Binding Governance Proposals), Proposal No. 6 (the 2024 Equity Incentive Plan Proposal) and Proposal No. 7 (the Adjournment Proposal). Broker non-votes, if any, will have the same effect as “AGAINST” votes for the Proposal No. 4 (the A&R Charter Proposal).

 

10

 

 

Q:What will happen if I return my proxy form without indicating how to vote?

 

A:If you submit your proxy form without indicating how to vote your shares on any particular proposal, the common stock represented by your proxy will be voted as recommended by the AgeX Board with respect to that proposal.

 

Q:May I change my vote after I have submitted a proxy or voting instruction form?

 

A:AgeX’s common stockholders as of the record date, other than the AgeX stockholder that executed the AgeX Support Agreement, may change their vote at any time before their proxy is voted at the AgeX special meeting in one of following ways:

 

By sending a written notice to the Secretary of AgeX stating that it would like to revoke its proxy;

 

By duly executing a subsequently dated proxy relating to the same shares of AgeX common stock and returning it in the postage-paid envelope provided or similar means, which subsequent proxy is received before the prior proxy is exercised at the AgeX special meeting;

 

Duly submitting a subsequently dated proxy relating to the same shares of common stock by telephone or via the internet (i.e., your most recent duly submitted voting instructions will be followed) before 11:59 p.m. Eastern time on    ; and

 

By attending the AgeX special meeting and voting such shares during the AgeX special meeting.

 

If a stockholder who owns AgeX shares in “street name” has instructed a broker to vote its shares of AgeX common stock, the stockholder must follow directions received from its broker to change those instructions.

 

Q:Who is paying for this proxy solicitation?

 

A:AgeX will pay for the cost of printing and filing of this proxy statement/prospectus/information statement and the proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of AgeX common stock for the forwarding of solicitation materials to the beneficial owners of AgeX common stock. AgeX will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials. Fees paid to the SEC in connection with filing the statement/prospectus/information statement, and any amendments and supplements thereto, with the SEC will be paid by AgeX.

 

Q:What is the quorum requirement?

 

A:A quorum of stockholders is necessary to hold a valid meeting. The presence at the AgeX special meeting, present in person or represented by proxy, of the holders of a majority of the voting power of the stock issued, outstanding and entitled to vote thereat, as of the record date, will constitute a quorum for the transaction of business at the AgeX special meeting.

 

Your shares will be counted towards the quorum if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you attend the AgeX special meeting and vote your shares during the AgeX special meeting. Abstentions and broker non-votes, if applicable, will also be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present at the AgeX special meeting or represented by proxy may adjourn the meeting to another date.

 

11

 

 

Q:Should AgeX’s stockholders send in their stock certificates now, to the extent they have any?

 

A:AgeX stockholders should not send in their stock certificates, if any. For more information on the procedures for exchanging stock certificates, please see the section titled “The Merger—Procedures for Exchanging Stock Certificates” beginning on page 164 of this proxy statement/prospectus/information statement.

 

Q:Who can help answer my questions?

 

A:If you are a stockholder of AgeX and would like additional copies, without charge, of this proxy statement/prospectus/information statement or if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact:

 

AgeX Therapeutics, Inc.
1101 Marina Village Parkway, Suite 201
Alameda, California 94501
Attention: Andrea Park
Phone Number: (510) 671-8370
Email: information@agexinc.com
Subject Line: Request for Proxy Materials

 

If you are a stockholder of Serina, and would like additional copies, without charge, of this proxy statement/prospectus/information statement or if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact:

 

601 Genome Way, Suite 2001,
Huntsville, Alabama 35806
(256) 327-9630
investor.relations@serinatherapeutics.com
Attention: Chief Financial Officer

 

12

 

 

PROSPECTUS SUMMARY

 

This summary highlights selected information from this proxy statement/prospectus/information statement and may not contain all of the information that is important to you. To better understand the Merger, the proposals being considered at the AgeX special meeting and Serina’s stockholder actions that are the subject of the written consent, you should read this entire proxy statement/prospectus/information statement carefully, including the Merger Agreement attached as Annex A and the other annexes to which you are referred herein. For more information, please see the section titled “Where You Can Find More Information” beginning on page 398 of this proxy statement/prospectus/information statement.

 

The Companies

 

AgeX Therapeutics, Inc.
1101 Marina Village Parkway, Suite 201
Alameda, California 94501
(510) 671-8370

 

AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions. AgeX believes that demand for therapeutics addressing such conditions is on the rise, commensurate with the demographic shift of aging in the United States and many other industrialized countries.

 

AgeX’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows it to utilize telomerase-expressing regenerative pluripotent stem cell (PSCs) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX owns or has licenses to a number of patents and patent applications used in the generation of these product candidates, including intellectual property related to PSC-derived clonal embryonic progenitor cell lines (PureStem® technology). AgeX’s technology platform also includes UniverCyte™ which uses the Human Leukocyte Antigen-G (HLA-G) gene to potentially confer low immune observability to cells, so as to suppress rejection of transplanted cells and tissues. AgeX plans to use or license the use of this patented technology to produce genetically-modified master cell banks of pluripotent stem cells that can then be differentiated into any young cell type of the human body that now express the immune tolerogenic molecule.

 

AgeX’s product candidates in the discovery stage include two cell-based therapies derived from telomerase-positive PSCs and two product candidates derived from its proprietary induced tissue regeneration (iTRTM) technology. AgeX has also sponsored a research program to derive neural stem cells from PSCs to treat degenerative diseases such as Huntington’s Disease. AgeX will need to conduct or sponsor research and development work, or license our technology to other biotechnology or pharmaceutical companies interested in furthering research and development in order to develop these cell- and drug-based therapies, each targeting large unmet needs in age-related medicine.

 

On August 29, 2023, AgeX entered into the Merger Agreement with Serina and Merger Sub, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Serina, with Serina surviving as our wholly owned subsidiary. For additional information, see the sections titled “The Merger” and “The Merger Agreement” beginning on pages 133 and 170 of this proxy statement/prospectus/information statement, respectively.

 

13

 

 

If the Merger is completed, the combined company will primarily focus on developing Serina’s product candidates, which are described on page 253 under the section titled “Description of Serina’s Business,” and it is anticipated that the combined company will not continue to develop AgeX’s product candidates, other than potentially the development program of NeuroAirmid, which is described on page 234 under the section titled “Description of AgeX’s Business—Products and Product Candidates.” If the Merger is not completed, AgeX expects to continue to execute on its current business strategies described in the section titled “Description of AgeX’s Business—Business Strategy” beginning on page 231 of this proxy statement/prospectus/information statement while seeking out and evaluating potential strategic alternatives with respect to our assets and development programs, which may include a merger, business combination, investment into AgeX, sale or other disposition of assets or other strategic transaction. In such case, AgeX may not be successful in executing such strategies or identifying or implementing any such strategic alternatives, and there is a risk that Juvenescence may decide to stop funding AgeX’s operations, which would likely result in its delisting and dissolution.

 

Serina Therapeutics, Inc.
601 Genome Way, Suite 2001,
Huntsville, Alabama 35806
(256) 327-9630

 

Serina is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina’s POZ PlatformTM (POZ) drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an increase in efficacy and safety of the resulting polymeric drug conjugate. Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection.

 

The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. Serina believes that POZ technology can be applied to small molecules, proteins, antibody drug conjugates, and other classes of molecules.

 

Serina’s business is largely focused on the development of a wholly-owned pipeline of POZ-enabled drug candidates for central nervous system (CNS) indications, including Parkinson’s disease, epilepsy, and pain. Serina’s lead product candidate, SER 252 (POZ-apomorphine), is a POZ conjugate of the potent dopamine agonist apomorphine being developed for the treatment of Parkinson’s disease and is in preclinical development. SER 252 is designed to provide continuous dopaminergic stimulation (CDS) via a subcutaneous injection delivered one to two times per week. CDS is a long-sought clinical strategy for Parkinson’s disease that currently approved therapies fall short of delivering. Other POZ-conjugate candidates, including SER 227 (POZ-buprenorphine) for long-acting pain relief and SER 228 (POZ-cannabidiol) for epilepsy, are in preclinical development. Serina intends to develop other potential applications of the POZ technology, such as therapeutics delivered through antibody drug conjugates (ADCs) and lipid-nanoparticle (LNP), through partnerships. Serina’s SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, was Serina’s first product candidate advanced into human study and has completed a Phase Ia study in 19 subjects. Serina has not internally advanced SER 214 beyond the Phase Ia study and will seek to partner on any further development of this product candidate. Serina has not received FDA approval for any of its product candidates and its lead product candidate remains in pre-clinical development.

 

Canaria Transaction Corporation
1101 Marina Village Parkway, Suite 201
Alameda, California 94501
(510) 671-8370

 

Merger Sub is a wholly owned subsidiary of AgeX and was formed solely for the purposes of carrying out the Merger.

 

14

 

 

The Merger (see page 133)

 

If the Merger is completed, Merger Sub will merge with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX. The surviving corporation following the Merger is referred to herein as the “combined company.” Substantially concurrently with the completion of the Merger, the combined company will be renamed “Serina Therapeutics, Inc.”

 

Following the reverse stock split and the AgeX preferred stock conversion and prior to the closing of the Merger, AgeX will issue to each holder of AgeX common stock as of the Warrant Dividend Record Date three post-merger warrants for each five shares of AgeX common stock issued and outstanding held by such holder as of the Warrant Dividend Record Date. Each post-merger warrant will be exercisable at an exercise price equal to $13.20 per warrant (such exercise price reflecting the planned reverse stock split) for (i) one share of AgeX common stock and (ii) one incentive warrant and will expire on July 31, 2025. Each incentive warrant will be exercisable at an exercise price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split) for one share of AgeX common stock and will expire on the four-year anniversary of the Closing Date. Each post-merger warrant and incentive warrant will be issued pursuant to the terms of a warrant agreement to be entered into by AgeX and a warrant agent in connection with the closing of the Merger. The terms of the warrant agreement remain subject to agreement between AgeX and Serina. For additional information, see the section titled “Agreements Related to the Merger—Warrant Agreement” beginning on page 197 of this proxy statement/prospectus/information statement.

 

AgeX and Serina expect the Merger to be consummated during the    , subject to satisfaction or waiver of certain conditions to the closing of the Merger, including, among other things, the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal.

 

Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price of AgeX common stock being equal to or greater than $12.00 per share (on a post-reverse stock split basis), giving effect to the reverse stock split and the AgeX preferred stock conversion and excluding the impact of any post-merger warrant, incentive warrant or the issuance of any share of AgeX common stock upon exercise of any post-merger warrant or incentive warrant. For a more complete description of the exchange ratio, please see the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio.”

 

Reasons for the Merger (see pages 150 and 156)

 

The AgeX Board considered various reasons for the Merger, as described later in this proxy statement under the section titled “The Merger—AgeX Reasons for the Merger.”

 

The Serina Board considered various reasons for the Merger, as described later in this proxy statement under the section titled “The Merger—Serina Reasons for the Merger.”

 

15

 

 

Merger Consideration and Exchange Ratio (see page 171)

 

Pursuant to the Merger Agreement, at the Effective Time, each outstanding share of Serina common stock (after giving effect to the Serina preferred stock conversion and including all such shares that are so converted, other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares) will be automatically converted solely into the right to receive a number of shares of AgeX common stock equal to the exchange ratio.

 

No fractional shares of AgeX common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any holder of Serina capital stock who would otherwise be entitled to receive a fraction of a share of AgeX common stock (after aggregating all fractional shares of AgeX common stock issuable to such holder) will receive from AgeX, in lieu of such fraction of a share and upon such holder’s surrender of a letter of transmittal in accordance with the Merger Agreement and any accompanying documentation required therein, (i) one share of AgeX common stock if the aggregate amount of fractional shares of AgeX common stock such holder of Serina capital stock would otherwise be entitled to is equal to or exceeds 0.50 or (ii) no shares of AgeX common stock if the aggregate amount of fractional shares of AgeX common stock such holder of Serina capital stock would otherwise be entitled to is less than 0.50.

 

The exchange ratio formula is based upon a fixed percentage of the post-Merger outstanding shares of AgeX common stock, expressed on a fully-diluted and as-converted basis, subject to certain adjustments and exclusions. For a more complete description of the Merger, the potential adjustments in the exchange ratio, please see the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio.

 

Treatment of Serina Stock Options (see page 173)

 

Under the terms of the Merger Agreement, at the Effective Time, each outstanding and unexercised Serina option immediately prior to the Effective Time under the Serina Plan will be converted into and become an option to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the option and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume the Serina Plan and each Serina option in accordance with the terms of the Serina Plan and the terms of the Serina option.

 

Treatment of Serina Warrants (see page 173)

 

Under the terms of the Merger Agreement, at the Effective Time, each outstanding and unexercised Serina warrant immediately prior to the Effective Time, if any, will be converted into and become a warrant to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the warrant and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume each Serina warrant in accordance with its terms.

 

Treatment of AgeX Stock Options (see page 174)

 

Immediately prior to the reverse stock split, each outstanding and unexercised out of the money AgeX option as of immediately prior to the reverse stock split, if any, will be canceled without payment. In accordance with the terms and conditions set forth in the Incentive Plan, AgeX will notify each holder of an out of the money AgeX option that each such option will become exercisable at least 10 days prior to the reverse stock split and will thereafter be canceled if not exercised. All other outstanding and unexercised options to purchase shares of AgeX common stock will remain outstanding and exercisable in accordance with their terms immediately following the Effective Time.

 

Conditions to the Completion of the Merger (see page 174)

 

The obligations to consummate the Merger and the other transactions and actions contemplated by the Merger Agreement (collectively, the Contemplated Transactions) are subject to the satisfaction or waiver, on or prior to the Effective Time, of the conditions set forth in the section titled “The Merger Agreement—Conditions to the Completion of the Merger” below.

 

16

 

 

Non-Solicitation (see page 180)

 

AgeX and Serina and their respective subsidiaries are prohibited by the terms of the Merger Agreement, other than, in the case of AgeX, with respect to any Asset Disposition (as defined below), from, directly or indirectly, (i) soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any Acquisition Proposal (as defined below) or Acquisition Inquiry (as defined below) or taking any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) furnishing any non-public information regarding itself or its respective subsidiaries to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii) engaging in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv) approving, endorsing or recommending any Acquisition Proposal (subject to, in the case of AgeX, AgeX’s special meeting and the AgeX Proposals); (v) executing or entering into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction (as defined below) (other than, in the case of AgeX, a confidentiality agreement permitted as described below); or (vi) publicly proposing to do any of the foregoing.

 

Subject to certain restrictions and prior to obtaining the approval of the AgeX Stockholder Matters by the Required AgeX Stockholder Vote (as defined below), AgeX and its subsidiaries may furnish non-public information regarding AgeX or any of its subsidiaries to, and enter into discussions or negotiations with, any person in response to a bona fide Acquisition Proposal by such person, which the AgeX Board determines in good faith, after consultation with its outside financial advisor and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (as defined below) (and is not withdrawn) if: (A) none of AgeX, any of its subsidiaries or any of their respective representatives have breached the non-solicitation restrictions in the Merger Agreement in any material respect, (B) the AgeX Board concludes in good faith, based on the advice of outside legal counsel, that the failure to take such action is reasonably likely to be inconsistent with the fiduciary duties of the AgeX Board under applicable law; (C) substantially contemporaneously with furnishing any such non-public information to such person, AgeX gives Serina notice of AgeX’s intention to furnish non-public information to, or enter into discussions with, such person and furnishes such nonpublic information to Serina (to the extent such information has not been previously furnished to Serina), and (D) AgeX receives from such person an executed confidentiality agreement containing provisions (including nondisclosure provisions, use restrictions, non-solicitation provisions, no hire and “standstill” provisions), in the aggregate, at least as favorable to AgeX as those contained in the confidentiality agreement entered into between AgeX and Serina in connection with the Merger.

 

For a more complete description of the non-solicitation provisions, please see the section titled “The Merger Agreement—Non-Solicitation.”

 

Termination and Termination Fees (see page 190)

 

The Merger Agreement contains certain customary termination rights, including the right of AgeX to terminate the Merger Agreement if the Serina Stockholder Written Consent (as defined below) has not been obtained within three business days of the date of the registration statement becoming effective, the right of AgeX or Serina to terminate the Merger Agreement if AgeX’s stockholders fail to adopt and approve the AgeX Stockholder Matters, the right of Serina to terminate the Merger Agreement if the AgeX Board changes or withdraws its recommendation in favor of the AgeX Stockholder Matters or approves or enters into an agreement relating to an Acquisition Proposal, the right of AgeX to terminate the Merger Agreement under certain circumstances to enter into an agreement relating to a Superior Offer and the right of Serina to terminate if certain closing conditions are not satisfied or waived prior to the Effective Time.

 

17

 

 

Upon termination of the Merger Agreement by Serina or AgeX in certain circumstances, a nonrefundable termination fee of $1,000,000 may be payable by Serina to AgeX or by AgeX to Serina. AgeX has agreed to reimburse Serina for up to $1,000,000 in expenses if the Merger Agreement is terminated due to the failure to obtain the approval of the AgeX Stockholder Matters from AgeX’s stockholders or in the event of the failure of Serina to consummate the Contemplated Transactions solely as a result of an AgeX Material Adverse Effect (as defined below). Serina has agreed to reimburse AgeX for up to $1,000,000 in expenses if the Merger Agreement is terminated due to a breach or inaccuracy of any representation, warranty, covenant or agreement by Serina or in the event of the failure of AgeX to consummate the Contemplated Transactions solely as a result of a Serina Material Adverse Effect. AgeX or Serina may receive either the termination fee or the expense reimbursement, but not both.

 

For a more complete description of the termination provisions and termination fees, please see the section titled “The Merger Agreement—Termination and Termination Fees.”

 

Support Agreements (see page 196)

 

Concurrently with the execution of the Merger Agreement, Juvenescence entered into the AgeX Support Agreement in favor of Serina, providing, among other things, that Juvenescence will vote all of its shares of AgeX capital stock in favor of the AgeX Stockholder Matters. As of January 3, 2024, Juvenescence is a stockholder of AgeX holding approximately 43.3% of the outstanding shares of AgeX common stock, 100% of the outstanding shares of AgeX Series A preferred stock and 100% of the outstanding shares of AgeX Series B preferred stock.

 

In connection with the execution of the Merger Agreement, stockholders of Serina holding 100% of the outstanding shares of Serina common stock, 100% of the outstanding shares of Series A preferred stock of Serina, 100% of the outstanding shares of Series A-1 preferred stock of Serina, 100% of the outstanding shares of Series A-2 preferred stock of Serina, 100% of the outstanding shares of Series A-3 preferred stock of Serina, 100% of the outstanding shares of Series A-4 preferred stock of Serina, and 100% of the outstanding shares of Series A-5 preferred stock of Serina, in each case effective as of August 29, 2023, entered into Serina Support Agreements in favor of AgeX, providing, among other things, that such stockholders will vote all of their shares of Serina capital stock (or execute a written consent) in favor of Serina Stockholder Matters.

 

Lock-Up Agreements (see page 196)

 

Concurrently with the execution of the Merger Agreement, (i) certain executive officers, directors, and stockholders of Serina and (ii) certain stockholders of AgeX, entered into lock-up agreements (Lock-Up Agreements), pursuant to which such persons accepted certain restrictions on transfers of the shares of AgeX common stock held by such persons for the 180-day period following the Effective Time.

 

18

 

 

Appraisal Rights (see page 168)

 

AgeX stockholders are not entitled to appraisal rights in connection with the Merger. Unless consented to by the Serina stockholder, holders of Serina capital stock are entitled to appraisal rights in connection with the Merger under Article 13 of the ABCL. For more information about such rights, please see the provisions of Article 13 of the ABCL attached as Annex D and the section titled “The Merger—Appraisal Rights” beginning on page 168 of this proxy statement/prospectus/information statement.

 

Management Following the Merger (see page 160)

 

Immediately following the Merger, the executive management team of the combined company is expected to comprise the following individuals with such additional officers as may be added by Serina or the combined company:

 

Name   Position with the Combined Company   Current Position at AgeX / Serina
Steve Ledger   Interim Chief Executive Officer   Chief Financial Officer at Serina
Andrea Park   Interim Chief Financial Officer and Chief Accounting Officer   Chief Financial Officer at AgeX
Randall Moreadith, M.D., Ph.D.   Chief Scientific Officer   President and Chief Executive Officer at Serina
Tacey Viegas   Chief Operating Officer and Secretary   Chief Operating Officer at Serina

 

Directors of the Combined Company Following the Merger

 

At the Effective Time, the combined company is expected to initially have a seven-member board of directors, comprised of (a) Remy Gross, designated by both AgeX and Serina, (b) J. Milton Harris and Steve Ledger, each as a Serina designee, (c) Gregory Bailey and Richard Marshall, each as an AgeX designee, and (d)        and        , each as an independent director, until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal.

 

The Combined Company Board will have an audit committee, a compensation committee and a nominating and corporate governance committee, in accordance with NYSE American rules. All of AgeX’s current directors, other than Gregory Bailey, are expected to resign from their positions as directors of AgeX, effective as of the Effective Time.

 

Interests of the AgeX Directors and Executive Officers in the Merger (see page 158)

 

In considering the recommendation of the AgeX Board with respect to the issuance of AgeX common stock pursuant to the Merger Agreement and the other matters to be acted upon by AgeX’s stockholders at the AgeX special meeting, AgeX’s stockholders should be aware that certain members of the AgeX Board and current and former executive officers of AgeX have interests in the Merger that may be different from, or in addition to, interests they have as AgeX’s stockholders. These interests may present them with actual or potential conflicts of interest. These interests include the following:

 

19

 

 

Dr. Bailey will continue as a director of the combined company after the Effective Time, and, following the closing of the Merger, will be eligible to be compensated as a non-employee director of the combined company pursuant to the non-employee director compensation policy in place following the Effective Time;
Ms. Park will serve as the Interim Chief Financial Officer and Chief Accounting Officer of the combined company following the Effective Time;
under the Merger Agreement, AgeX’s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage; and
Juvenescence, an affiliated stockholder of AgeX, entered into the AgeX Support Agreement in favor of Serina, providing, among other things, that Juvenescence will vote all of its shares of AgeX capital stock in favor of the AgeX Stockholder Matters. The Support Agreements are discussed in greater detail in the section titled “Agreements Related to the Merger” beginning on page 196 of this proxy statement/prospectus/information statement.

 

The interests of AgeX’s officers and directors in the Merger are discussed in greater detail in the section titled “The Merger—Interests of the AgeX Directors and Executive Officers in the Merger” beginning on page 158 of this proxy statement/prospectus/information statement.

 

Interests of the Serina Directors and Executive Officers in the Merger (see page 161)

 

In considering the recommendation of the Serina Board with respect to adopting the Merger Agreement, Serina’s stockholders should be aware that members of the Serina Board and the executive officers of Serina may have interests in the Merger that may be different from, or in addition to, the interests of Serina’s stockholders. The Serina Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement, the Merger, and the Contemplated Transactions. These interests may present them with actual or potential conflicts of interest. These interests include the following:

 

as described elsewhere in this proxy statement/prospectus/information statement, including in the section titled “The Merger—Management Following the Merger,” certain of Serina’s directors and executive officers are expected to become the directors and executive officers of the combined company upon the closing of the Merger;
in connection with the Merger, each outstanding and unexercised Serina option immediately prior to the Effective Time under the Serina Plan held by Serina’s executive officers and directors will be converted into and become an option to purchase AgeX common stock;
each of Serina’s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement; and
Serina’s executive officers, directors and certain affiliated stockholders have entered into the Support Agreements, pursuant to which such directors, officers and certain stockholders, respectively, have agreed, solely in their capacity as stockholders of Serina, to vote all of their shares of Serina capital stock in favor of, among other things, the adoption or approval, respectively, of the Merger Agreement and the transactions contemplated therein in connection with the Merger. The Support Agreements are discussed in greater detail in the section titled “Agreements Related to the Merger” beginning on page 196 of this proxy statement/prospectus/information statement.

 

20

 

 

Risk Factors and Risk Factor Summary (see page 24)

 

Both AgeX and Serina are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective stockholders. You should carefully read this proxy statement/prospectus/information statement, including the annexes, and especially consider the material risks discussed below and these and other risks discussed in greater detail under the section titled “Risk Factors” beginning on page 24 of this proxy statement/prospectus/information statement. AgeX and Serina encourage you to read and consider all of these risks carefully.

 

Risks Related to the Merger

 

The relative proportion of the combined company that AgeX stockholders will own immediately following the closing of the Merger is not adjustable based on the market price of AgeX common stock unless the Actual Closing Price of AgeX common stock is less than $12.00 per share (on a post-reverse stock split basis). If the Actual Closing Price of AgeX common stock is less than $12.00 per share (on a post-reverse stock split basis), AgeX has the option to issue additional AgeX common stock to Serina stockholders in the amount necessary to equal the Target Merger Consideration Minimum, which, in such circumstances, could proportionally decrease the amount of the combined company that AgeX stockholders would own immediately following the closing of the Merger. Accordingly, the Merger consideration at the closing of the Merger may have a greater or lesser value than at the time the Merger Agreement was signed;
Failure to complete the Merger may result in AgeX or Serina paying a termination fee or reimbursement of expenses to the other party and could harm the common stock price of AgeX and future business and operations of each company;
The issuance of AgeX common stock to Serina stockholders pursuant to the Merger Agreement and the resulting change in control of AgeX from the Merger must be approved by AgeX stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Serina stockholders. Failure to obtain these approvals would prevent the closing of the Merger;
If the conditions to the closing of the Merger are not satisfied or waived, the Merger may not occur or the closing of the Merger could be delayed;
The Merger may be completed even though material adverse changes may result from the announcement of the Merger, industry-wide changes and/or other causes;
Some executive officers and directors of AgeX and Serina have interests in the Merger that are different from the respective stockholders of AgeX and Serina and that may influence them to support or approve the Merger without regard to the interests of the respective stockholders of AgeX and Serina;
Juvenescence owns a significant majority of AgeX capital stock and will be able to substantially influence AgeX and exert control over the AgeX Proposals;
AgeX stockholders and Serina stockholders may not realize a benefit from the Merger commensurate with the ownership interest dilution they will experience in connection with the Merger;
If the Merger is not completed, the market price of AgeX common stock may decline significantly;
The market price of the combined company’s common stock following the Merger may decline as a result of the Merger;
AgeX and Serina securityholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing of the Merger as compared to their current ownership and voting interest in the respective companies;
During the pendency of the Merger Agreement, each of AgeX and Serina may be limited in its ability to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects;
Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement;
Because the lack of a public market for Serina’s capital stock makes it difficult to evaluate the fair market value of Serina’s capital stock, the value of the AgeX common stock to be issued to Serina stockholders may be more or less than the fair market value of Serina common stock;
The Merger may fail to qualify as a reorganization for U.S. federal income tax purposes, resulting in recognition of taxable gain or loss by Serina stockholders in respect of their Serina capital stock; and
Litigation has been filed and additional litigation could in the future arise in connection with the Merger, against AgeX, the AgeX Board, Serina or the Serina Board, which could be costly, prevent the consummation of the Merger, divert management’s attention and otherwise materially harm AgeX’s, Serina’s or the combined company’s business.

 

Risks Related to the Reverse Stock Split

 

The reverse stock split may not increase the combined company’s stock price over the long term;
   
The reverse stock split may decrease the liquidity of AgeX common stock or the combined company’s common stock; and
   
The reverse stock split may lead to a decrease in the combined company’s overall market capitalization.

 

21

 

 

Risks Related to AgeX

 

AgeX needs additional financing to execute its operating plan and continue to operate;
   
As a discovery-stage development company with incurred operating losses and limited capital resources, AgeX anticipates that it will incur continued losses for the foreseeable future and will need to continue to raise capital to finance our operations and is unable to predict whether it will achieve or sustain profitability;
   
AgeX is highly leveraged, carrying a significant amount of indebtedness, including indebtedness secured by its assets, that will become due and payable over the next three years and there is no assurance that AgeX will be able to refinance those obligations as they become due;
   
 The terms of our loans from Juvenescence and the Security Agreement could make it more difficult for us to raise additional capital from other sources;
   
 Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates;
   
Unless AgeX common stock continues to be listed on a national securities exchange, it will become subject to “penny stock” rules that impose restrictive sales practice requirements;
   
Delays in, or failing to complete the Merger could materially and adversely affect AgeX’s results of operations, business, financial condition or stock price;
   
 If the Merger is not approved or does not occur, AgeX may not be successful in the execution of its current business strategies or identifying and implementing any strategic alternatives with respect to its assets and development programs, and any future strategic alternatives could have negative consequences;
   
As a major stockholder and creditor of AgeX, Juvenescence, will be able to substantially influence AgeX and exert control over matters subject to stockholder approval; and
   
Conflicts of interest may arise from AgeX’s relationship with Juvenescence, which owns a significant percentage of AgeX common stock as well as shares of AgeX preferred stock and is a significant creditor and will be able to substantially influence AgeX and exert control over matters subject to stockholder approval, including the Merger and other AgeX Proposals.

 

Risks Related to Serina

 

Serina has a history of operating losses that are expected to continue for the foreseeable future, and it is unable to predict the extent of future losses, or whether it will generate significant revenues or achieve or sustain profitability;
   
Serina will need additional financing to execute its operating plan and continue to operate as a going concern.
   
Serina has never generated revenue from product sales and may never become profitable;
   
Serina’s product candidates are at an early stage of development and may not be successfully developed or commercialized;
   
Failure of Serina’s technology would significantly harm its business, results of operations, and prospects;
   
The FDA regulatory approval process is lengthy, time-consuming, and inherently unpredictable, and Serina may experience significant delays in the clinical development and regulatory approval, if any, of its product candidates;
   
If any product candidate that Serina successfully develops does not achieve broad market acceptance among physicians, patients, health care payors and the medical community, the revenues that it generates from their sales will be limited; and
   
Serina success will depend upon intellectual property and proprietary technologies, and it may be unable to protect its intellectual property.

 

Risks Related to the Combined Company

 

The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all;
   
The market price of the combined company’s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger;
   
The combined company will incur costs and demands upon management as a result of complying with the laws, rules and regulations affecting public companies;
   
Anti-takeover provisions in the combined company’s governance documents and under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by the combined company stockholders to replace or remove the combined company management; and
   
If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.

 

22

 

 

 

Regulatory Approvals (see page 164)

 

In the United States, AgeX must comply with applicable federal and state securities laws and the rules and regulations of the NYSE American in connection with the issuance of shares of AgeX common stock to Serina’s stockholders in connection with the Contemplated Transactions and the filing of this proxy statement/prospectus/information statement with the SEC. Neither AgeX nor Serina intend to seek any regulatory approval from antitrust authorities to consummate the Contemplated Transactions.

 

NYSE American Listing (see page 167)

 

Shares of AgeX common stock are currently listed on the NYSE American market under the symbol “AGE.” AgeX intends to file an initial listing application for the combined company with the NYSE American. If such application is accepted, AgeX anticipates that the common stock of the combined company will be listed on NYSE American following the closing of the Merger under the trading symbol “SER.”

 

Anticipated Accounting Treatment (see page 168)

 

The Merger will be treated by AgeX as a reverse recapitalization under U.S. generally accepted accounting principles (GAAP). For accounting purposes, Serina is considered to be the accounting acquirer in the Merger.

 

Comparison of Rights of Stockholders of AgeX, Serina and the combined company (see page 380)

 

AgeX is incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of AgeX currently, and will continue to be, governed by the DGCL. Serina is incorporated under the laws of the State of Alabama and, accordingly, the rights of the stockholders of Serina are currently governed by the ABCL.

 

If the Merger is completed, the AgeX stockholders and Serina stockholders will become the stockholders of the combined company. After giving effect to the Merger, the rights of stockholders of the combined company and the relative powers of the Combined Company Board will be governed by an amendment and restatement of the AgeX Charter (the Combined Company Charter), the bylaws of the combined company (the Combined Company Bylaws) and by the DGCL. Each share of the common stock of the combined company will be issued pursuant to, and will carry with it the rights and obligations set forth in, the Combined Company Charter. As a result of differences between the respective organizational documents of AgeX, Serina and the combined company, and applicable governing law, there will be material differences between the rights of AgeX stockholders and Serina stockholders before consummation of the Merger and the rights of the combined company stockholders after consummation of the Merger. For a full description of these differences, see the section titled “Comparison of Rights of Stockholders of AgeX, Serina and the Combined Company” beginning on page 380 of this proxy statement/prospectus/information statement.

 

AgeX Stockholder Meeting (see page 182)

 

The AgeX special meeting will be held exclusively online via audio-only webcast on      , 2024 at    , unless postponed or adjourned to a later date. The AgeX special meeting can be accessed by visiting www.virtualshareholdermeeting.com/   , where you will be able to vote your shares and submit questions during the AgeX special meeting webcast by logging in to the website listed above using the 16-digit control number included in your proxy card. AgeX encourages you to allow ample time for the online check-in procedures. Please note that you will not be able to attend the AgeX special meeting in person. For more information on the AgeX special meeting, see the section titled “The Special Meeting of AgeX’s Stockholders” beginning on page 125 of this proxy statement/prospectus/information statement.

 

Market Price and Dividend Information

 

AgeX common stock is currently listed on the NYSE American under the symbol “AGE.” Serina is a private company and its common stock and preferred stock are not publicly traded.

 

AgeX Common Stock

 

The closing price of AgeX common stock on August 28, 2023, the last trading day prior to the public announcement of the Merger on August 29, 2023, as reported on the NYSE American, was $0.75 per share. The closing price of AgeX common stock on    , 2024, the last practicable date before the date of this proxy statement/prospectus/information statement, as reported on the NYSE American, was $    per share.

 

Because the market price of AgeX common stock is subject to fluctuation, the market value of the shares of AgeX common stock that Serina stockholders will be entitled to receive in the Merger may increase or decrease.

 

Assuming successful application for initial listing with the NYSE American, following the consummation of the Merger, AgeX anticipates that the common stock of the combined company will trade under the new name “Serina Therapeutics, Inc.” and the new trading symbol “SER” on the NYSE American.

 

As of           , 2024, the record date for the AgeX special meeting, there were approximately     holders of record of the AgeX common stock.

 

Dividends

 

AgeX has never declared or paid any cash dividends on the AgeX common stock and does not anticipate paying cash dividends on AgeX common stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined organization’s then-current board of directors and will depend upon a number of factors, including the combined organization’s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant.

 

Serina has $10,826,718 of accrued and unpaid dividends on its Series A ($2,050,373), Series A-1 ($1,868,125), and Series A-2 ($6,908,220), preferred stock, which is part of the liquidation preference of those series of Serina’s preferred stock. The stockholders of Serina voted on June 27, 2019 to amend Serina’s certificate of incorporation to cease the accrual of dividends on those series of Serina’s preferred stock effective as of June 30, 2019. The certificate of amendment was recorded on June 28, 2019. Serina’s Series A-3, Series A-4, and Series A-5 preferred stock do not have any accrued dividends. Serina has never declared or paid cash dividends on any of Serina’s capital stock. Any future determination to declare cash dividends on shares of the combined company’s common stock will be made at the discretion of the combined company’s board of directors, subject to applicable law and contractual restrictions, and will depend on its financial condition, results of operations, capital requirements, general business conditions and other factors that its board of directors may deem relevant.

 

 

23

 

 

RISK FACTORS

 

The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained in this proxy statement/prospectus/ information statement, you should carefully consider the material risks described below before deciding how to vote your shares of AgeX common stock. You should also read and consider the other information in this proxy statement/prospectus/information statement. Realization of any of the risks described below or any of the uncertainties described under “Cautionary Note Regarding Forward-Looking Statements” could have a material adverse effect on AgeX’s, Serina’s or the combined company’s businesses, financial condition, cash flows and results of operations. Please see the section titled “Where You Can Find More Information” beginning on page 398 of this proxy statement/prospectus/information statement for further information.

 

Risks Related to the Merger

 

The relative proportion of the combined company that AgeX stockholders will own immediately following the closing of the Merger is not adjustable based on the market price of AgeX common stock unless the Actual Closing Price of AgeX common stock is less than $12.00 per share (on a post-reverse stock split basis). If the Actual Closing Price of AgeX common stock is less than $12.00 per share (on a post-reverse stock split basis), AgeX has the option to issue additional AgeX common stock to Serina stockholders in the amount necessary to equal the Target Merger Consideration Minimum, which, in such circumstances, could proportionally decrease the amount of the combined company that AgeX stockholders would own immediately following the closing of the Merger. Accordingly, the Merger consideration at the closing of the Merger may have a greater or lesser value than at the time the Merger Agreement was signed.

 

The relative proportion of the combined company that AgeX stockholders will own immediately following the closing of the Merger is based on the relative valuations of AgeX and Serina as negotiated by the parties and as specified in the Merger Agreement. At the Effective Time, outstanding shares of Serina common stock will be converted into shares of AgeX common stock. Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of the common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions. It is a closing condition of the Merger that the Actual Closing Price of a share of AgeX common stock is not less than $12.00 per share (on a post-reverse stock split basis). However, if the Actual Closing Price of a share of AgeX common stock is less than $12.00 per share (on a post-reverse stock split basis), AgeX has the option to satisfy such closing condition by issuing additional AgeX common stock to Serina stockholders in the amount necessary to equal the Target Merger Consideration Minimum (as defined below), which is equal to $12.00 multiplied by the anticipated aggregate number of shares of AgeX common stock to be issued (approximately 7,500,000 on a post-reverse stock split basis prior to any such adjustment), and, in such circumstances, AgeX stockholders immediately prior to the closing of the Merger could own a smaller percentage, and Serina stockholders immediately prior to the closing of the Merger could own a larger percentage, of the combined company following the closing of the Merger. The exercise of this option would also affect the exchange ratio.

 

24

 

 

In addition, changes in the market price of AgeX common stock before the completion of the Merger may not affect the number of shares Serina stockholders will be entitled to receive pursuant to the Merger Agreement so long as the Actual Closing Price of AgeX common stock is equal to or greater than $12.00 per share (on a post-reverse stock split basis). If before the completion of the Merger, the market price of AgeX common stock increases to be greater than $12.00 per share (on a post-reverse stock split basis), then Serina stockholders could receive merger consideration with substantially more value for their shares of Serina capital stock than the parties had negotiated when they established the relative ownership proportions of the combined company immediately following the closing of the Merger and the exchange ratio.

 

For a more complete description of the potential adjustments to and exclusions from the exchange ratio, please see the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio” beginning on page 171 of this proxy statement/prospectus/information statement.

 

Failure to complete the Merger may result in AgeX or Serina paying a termination fee or reimbursement of expenses to the other party and could harm the common stock price of AgeX and future business and operations of each company.

 

If the Merger is not completed, each of AgeX and Serina is subject to the following risks:

 

upon termination of the Merger Agreement, AgeX may be required to pay Serina a termination fee of $1,000,000 or up to $1,000,000 in expense reimbursements; or Serina may be required to pay AgeX a termination fee of $1,000,000 or up to $1,000,000 in expense reimbursements; provided that neither party will be responsible for payment of more than $1,000,000 in the aggregate;
the parties will have incurred significant expenses related to the Merger, such as legal and accounting fees, which must be paid even if the Merger is not completed;
the price of AgeX’s common stock may decline and remain volatile; and
the reputation of AgeX or Serina may be adversely impacted.

 

In addition, if the Merger Agreement is terminated and the AgeX Board or Serina Board determines to seek another business combination, there can be no assurance that either AgeX or Serina will be able to find a partner willing to provide equivalent or more attractive consideration than the consideration to be provided by each party in the Merger or any partner at all.

 

The issuance of AgeX common stock to Serina stockholders pursuant to the Merger Agreement and the resulting change in control of AgeX from the Merger must be approved by AgeX stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Serina stockholders. Failure to obtain these approvals would prevent the closing of the Merger.

 

Before the Merger can be completed, AgeX stockholders must approve, among other things, the issuance of AgeX common stock to Serina stockholders pursuant to the Merger Agreement and the resulting change in control of AgeX from the Merger, and Serina stockholders must adopt the Merger Agreement and approve the Merger and the related transactions contemplated thereby. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger or the ability of AgeX or Serina to complete the Merger in accordance with the Merger Agreement.

 

25

 

 

If the conditions to the closing of the Merger are not satisfied or waived, the Merger may not occur or the closing of the Merger could be delayed.

 

Even if each of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal is approved by the stockholders of AgeX, specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and described in the section titled “The Merger Agreement—Conditions to the Completion of the Merger” beginning on page 174 of this proxy statement/prospectus/information statement. AgeX and Serina cannot assure you that all of the conditions will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or could be delayed, and AgeX and Serina each may lose some or all of the intended benefits of the Merger.

 

The Merger may be completed even though material adverse changes may result from the announcement of the Merger, industry-wide changes and/or other causes.

 

In general, either AgeX or Serina can refuse to complete the Merger if there is a material adverse effect affecting the other party between August 29, 2023, the date of the Merger Agreement, and the closing of the Merger. However, certain types of effects are excluded from the concept of a “material adverse effect” and do not permit the parties to refuse to complete the Merger, even if such change could be said to have a material adverse effect on AgeX or Serina. Such exclusions included, but are not limited to:

 

general business, political or economic conditions generally affecting the industry in which Serina or AgeX operate;
acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics (including COVID-19 and any evolutions or mutations thereof) and related or associated epidemics, disease outbreaks or quarantine restrictions;
changes in financial, banking or securities markets;
any change in the stock price or trading volume of AgeX common stock;
any failure by AgeX to meet internal or analysts’ expectations or projections or the results of operations of AgeX;
any change in or affecting clinical trial programs or studies conducted by or on behalf of AgeX or its subsidiaries;
any change from continued losses from operations or decreases in cash balances of Serina or any of its subsidiaries or on a consolidated basis among Serina and its subsidiaries;
any change in, or any compliance with or action taken for the purpose of complying with, any law or GAAP (or interpretations of any law or GAAP); or
any change resulting from the announcement of the Merger Agreement or the pendency of the Contemplated Transactions;
any change resulting from the Asset Dispositions (as defined below);
the taking of any action required to be taken by the Merger Agreement; or
any reduction in the amount of AgeX’s cash and cash equivalents as a result of winding down its activities associated with the termination of its research and development activities.

 

If adverse changes occur and AgeX and Serina still complete the Merger, the stock price of the combined company following the closing of the Merger may suffer. This in turn may reduce the value of the Merger to the stockholders of AgeX, Serina or both.

 

26

 

 

Some executive officers and directors of AgeX and Serina have interests in the Merger that are different from the respective stockholders of AgeX and Serina and that may influence them to support or approve the Merger without regard to the interests of the respective stockholders of AgeX and Serina.

 

Directors and executive officers of AgeX and Serina may have interests in the Merger that are different from, or in addition to, the interests of other stockholders of AgeX and Serina, respectively. These interests with respect to AgeX’s directors and executive officers include, but are not limited to, the expected continued service of one of the directors of AgeX as a director of the combined company following the closing of the Merger, the expected continued employment of one of the executive officers of AgeX as an executive officer of the combined company following the closing of the Merger, severance benefits if employment is terminated in a qualifying termination in connection with the Merger and rights to continued indemnification, expense advancement and insurance coverage. These interests with respect to Serina’s directors and executive officers include, but are not limited to, the expected continued service of two of the directors of Serina as directors of the combined company following the closing of the Merger, the expected continued employment of three of the executive officers of Serina as executive officers of the combined company following the closing of the Merger and rights to continued indemnification and expense advancement.

 

The AgeX Board and Serina Board were aware of and considered such interests, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the Merger and recommend the approval of the Merger Agreement to AgeX and Serina stockholders. These interests, among other factors, may have influenced the directors and executive officers of AgeX and Serina to support or approve the Merger.

 

For more information regarding the interests of the AgeX and Serina directors and executive officers in the Merger, see the sections titled “The Merger—Interests of the AgeX Directors and Executive Officers in the Merger” and “The Merger—Interests of the Serina Directors and Executive Officers in the Merger” of this proxy statement/prospectus/information statement.

 

Juvenescence owns a significant majority of AgeX capital stock and will be able to substantially influence AgeX and exert control over the AgeX Proposals.

 

As of January 3, 2024, Juvenescence owned approximately 43% of the outstanding shares of AgeX common stock. In addition, Juvenescence indicated that it beneficially owned approximately 80.2% of AgeX common stock in its amendment of the Schedule 13D filed with the SEC on January 9, 2024. See “Principal Stockholders of AgeX” for additional information. A member of the AgeX Board is also the Executive Chairman and Co-Founder of Juvenescence. Accordingly, Juvenescence is able to substantially influence AgeX and exert control over the AgeX Proposals. The AgeX preferred stock conversion is expected to occur on February 1, 2024 in accordance with the Certificates of Designation of the AgeX Series A preferred stock and the AgeX Series B preferred stock. The AgeX preferred stock conversion will increase Juvenescence’s ownership and voting power to more than 50% of the outstanding shares of AgeX common stock, enabling Juvenescence to approve or disapprove the Merger and other AgeX Proposals without regard to the vote of other AgeX stockholders. This may prevent or discourage unsolicited acquisition proposals or offers for AgeX common stock that an AgeX stockholder may feel is in their best interest. The interests of Juvenescence may not always coincide with the interests of other AgeX stockholders, and Juvenescence may act in a manner that advances their best interests and not necessarily those of other stockholders. As a result, the market price of AgeX common stock could decline or stockholders might not receive a premium over the then-current market price of AgeX common stock upon a change in control.

 

For more information on the risks related to AgeX’s relationship with Juvenescence, see the section titled “—Risks Related to AgeX—Risks Related to Our Relationship with Juvenescence” below.

 

AgeX stockholders and Serina stockholders may not realize a benefit from the Merger commensurate with the ownership interest dilution they will experience in connection with the Merger.

 

If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, AgeX stockholders and Serina stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.

 

27

 

 

If the Merger is not completed, the market price of AgeX common stock may decline significantly.

 

The market price of AgeX common stock is subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of AgeX common stock will likely be volatile based on whether stockholders and other investors believe that AgeX can complete the Merger. The volatility of the market price of AgeX common stock has been and may be exacerbated by low trading volume. Additional factors that may cause the market price of AgeX common stock to fluctuate include, but are not limited to:

 

the entry into, or termination of, key agreements, including commercial partner agreements;
announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;
the loss of key employees;
future sales of its common stock;
general and industry-specific economic conditions that may affect its research and development expenditures;
the failure to meet industry analyst expectations; and
period-to-period fluctuations in financial results.

 

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of AgeX common stock. In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against such companies.

 

The market price of the combined company’s common stock following the Merger may decline as a result of the Merger.

 

The market price of the combined company’s common stock may decline as a result of the Merger for a number of reasons, including if:

 

investors react negatively to the prospects of the combined company’s product candidates, business and financial condition following the closing of the Merger;
the effect of the Merger on the combined company’s business and prospects following the closing of the Merger is not consistent with the expectations of financial or industry analysts; or
the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by stockholders or financial or industry analysts.

 

For additional information relating to the risks and uncertainties regarding the market price of the combined company’s common stock following the Merger, see “—Risks Related to the Combined CompanyThe market price of the combined company’s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.”

 

28

 

 

AgeX and Serina securityholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing of the Merger as compared to their current ownership and voting interest in the respective companies.

 

Immediately following the closing of the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own, excluding the impact of the exercise of any post-merger warrant or incentive warrant, approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions, including giving effect to the reverse stock split and the AgeX preferred stock conversion. The exchange ratio formula is based upon a fixed percentage of the post-Merger outstanding shares of the combined company common stock, expressed on a fully-diluted and as-converted basis, subject to certain adjustments and exclusions. For a more complete description of the exchange ratio, please see the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio” beginning on page 171 of this proxy statement/prospectus/information statement.

 

In addition, the seven-member board of directors of the combined company will initially consist of two individuals selected by Serina, two individuals selected by AgeX and two of such members designated by mutual agreement of Serina and AgeX. The Chief Financial Officer, the Chief Executive Officer and the Chief Operating Officer of Serina will serve as the Interim Chief Executive Officer, Chief Scientific Officer and Chief Operating Officer and Secretary of the combined company, respectively, following the closing of the Merger. The Chief Financial Officer of AgeX will serve as the Interim Chief Financial Officer and Chief Accounting Officer of the combined company, respectively, following the closing of the Merger.

 

Consequently, following the closing of the Merger, the pre-Merger equity holders of AgeX and Serina will own a smaller percentage of the combined company than their ownership of their respective companies prior to the Merger and will be able to exercise less influence over the management and policies of the combined company than they currently exercise over the management and policies of their respective companies.

 

During the pendency of the Merger Agreement, each of AgeX and Serina may be limited in its ability to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects.

 

Covenants in the Merger Agreement impede the ability of AgeX and Serina to make acquisitions during the pendency of the Merger, subject to specified exceptions. As a result, if the Merger is not completed, the parties may be at a disadvantage to their competitors during that period. In addition, while the Merger Agreement is in effect, each party is generally prohibited from soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry or taking any action that could reasonably be expected to lead to an acquisition proposal or acquisition inquiry regarding transactions involving a third party, including a merger, sale of assets or other business combination, subject to specified exceptions. Any such transactions could be favorable to such party’s stockholders, but the parties may be unable to pursue them. For more information, see the section titled “The Merger AgreementNon-Solicitation” beginning on page 180 of this proxy statement/prospectus/information statement.

 

29

 

 

Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.

 

The terms of the Merger Agreement prohibit each of AgeX and Serina from soliciting competing proposals or cooperating with persons making unsolicited takeover proposals, except in limited circumstances as described in further detail in the section titled “The Merger Agreement—Non-Solicitation” beginning on page 180 of this proxy statement/prospectus/information statement. In addition, if AgeX or Serina terminate the Merger Agreement under specified circumstances, AgeX may be required to pay Serina a termination fee of $1,000,000 or up to $1,000,000 in expense reimbursements or Serina may be required to pay AgeX a termination fee of $1,000,000 or up to $1,000,000 in expense reimbursements; provided that neither party will be responsible for payment of more than $1,000,000 in the aggregate. The termination fee or expense reimbursements may discourage third parties from submitting competing proposals to AgeX, Serina or their respective stockholders and may cause the AgeX Board or Serina Board to be less inclined to recommend a competing proposal. For a more complete description of the termination provisions, please see the section titled “The Merger Agreement—Termination and Termination Fees” beginning on page 190 of this proxy statement/prospectus/information statement.

 

Because the lack of a public market for Serina’s capital stock makes it difficult to evaluate the fair market value of Serina’s capital stock, the value of the AgeX common stock to be issued to Serina stockholders may be more or less than the fair market value of Serina common stock.

 

The outstanding capital stock of Serina is privately held and is not traded in any public market. The lack of a public market makes it difficult to determine the fair market value of Serina’s capital stock. Because the percentage of AgeX equity to be issued to Serina stockholders was determined based on negotiations between the parties, it is possible that the value of the AgeX common stock to be received by Serina stockholders will be more or less than the fair market value of Serina’s capital stock.

 

The Merger may fail to qualify as a reorganization for U.S. federal income tax purposes, resulting in recognition of taxable gain or loss by Serina stockholders in respect of their Serina capital stock.

 

AgeX and Serina intend for the Merger to qualify as a reorganization within the meaning of Section 368(a) of the Code, as described in the section titled “The Merger-Material U.S. Federal Income Tax Consequences of the Merger” in this proxy statement/prospectus/information statement. In the event that the Merger does not qualify as a reorganization, the Merger would result in taxable gain or loss for each Serina stockholder, with the amount of such gain or loss determined by the amount that each Serina stockholder’s adjusted tax basis in the Serina capital stock surrendered is less or more than the fair market value of the AgeX common stock received in exchange therefor. Each holder of Serina capital stock is urged to consult with his, her or its own tax advisor with respect to the tax consequences of the Merger.

 

Litigation has been filed and additional litigation could in the future arise in connection with the Merger, against AgeX, the AgeX Board, Serina or the Serina Board, which could be costly, prevent the consummation of the Merger, divert management’s attention and otherwise materially harm AgeX’s, Serina’s or the combined company’s business.

 

In the past, securities class action or shareholder derivative litigation has often followed certain significant business transactions, such as the sale of a company or announcement of a merger or any other strategic transaction. AgeX and the AgeX Board has been, and Serina, the Serina Board or the combined company may be exposed to such litigation in connection with the Merger (as further described in the section “Description of AgeX’s Business—Legal Proceedings”) and may in the future be exposed to additional litigation even if no wrongdoing occurred. Litigation is usually expensive and diverts management’s attention and resources, which could adversely affect the business and cash resources or either party and the ability of either party to consummate the Contemplated Transactions or the ultimate value the AgeX or Serina stockholders receive in any such transaction.

 

30

 

 

If the Merger is not consummated for any reason, litigation could be filed in connection with the failure to consummate the Merger. Any litigation related to the Merger may result in negative publicity or an unfavorable impression of AgeX, Serina or the combined company, which could adversely affect the price of AgeX common stock, Serina common stock or the combined company’s common stock, impair the ability of AgeX, Serina or the combined company to recruit or retain employees, damage relationships with customers, suppliers, and other business partners, or otherwise materially harm of AgeX’s, Serina’s or the combined company’s operations and financial performance.

 

Risks Related to the Reverse Stock Split

 

The reverse stock split may not increase the combined company’s stock price over the long-term.

 

While it is expected that the reduction in the number of outstanding shares of common stock as a result of the reverse stock split will proportionally increase the market price of AgeX common stock, it cannot be assured that the reverse stock split will increase the market price of AgeX common stock by a multiple of the reverse stock split ratio or result in any permanent or sustained increase in the market price of the combined company’s common stock, which is dependent upon many factors, including the combined company’s business and financial performance, general market conditions and prospects for future success. Thus, it cannot be assured that the reverse stock split will accomplish any increase in the per-share market price of the combined company’s common stock for any meaningful period of time.

 

The reverse stock split may decrease the liquidity of AgeX common stock or the combined company’s common stock.

 

Although the AgeX Board believes that the anticipated increase in the market price of the combined company’s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading in and a smaller number of market makers for the combined company’s common stock.

 

The reverse stock split may lead to a decrease in the combined company’s overall market capitalization.

 

Should the market price of the combined company’s common stock decline after the reverse stock split, the percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the combined company’s overall market capitalization. If the per-share market price does not increase in proportion to the reverse stock split ratio, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some cases, the per-share stock price of companies that have effected reverse stock splits subsequently declined back to pre-reverse split levels, and accordingly, it cannot be assured that the total market value of the combined company’s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the combined company’s stock price due to the reduced number of shares outstanding after the reverse stock split.

 

31

 

 

Risks Related to AgeX

 

If the Merger is not completed, we expect to continue to execute on our current business strategies while seeking out and evaluating potential strategic alternatives with respect to our assets and development programs, and, accordingly, our business will be subject to the risks described in this subsection titled “—Risks Related to AgeX.” References to “we,” “us” or “our” in this subsection generally refer to AgeX.

 

Risks Related to Our Current Business, Financial Condition and Capital Resources

 

We need additional financing to execute our operating plan and continue to operate as a going concern.

 

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future financial obligations as they become due within one year after the date the financial statements are issued. Based on our most recent projected cash flows, we believe that our cash and cash equivalents, the amount of credit remaining available from Juvenescence under an Amended and Restated Secured Convertible Promissory Note, dated February 14, 2022, as amended on February 9, 2023 (the 2022 Secured Note), and the proceeds we may receive from the sale of additional shares of AgeX common stock in “at-the-market” transactions through a Sales Agreement with Capital Markets, LLC (Chardan) as a sales agent, would not be sufficient to satisfy our anticipated operating and other funding requirements for the next twelve months from the date of filing of this proxy statement/prospectus/information statement. These factors raise substantial doubt regarding our ability to continue as a going concern and the report of our independent registered public accountants accompanying our audited consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement contains a qualification to such effect.

 

We have incurred operating losses and negative cash flows since inception and had an accumulated deficit of $127.6 million as of September 30, 2023. We expect to continue to incur operating losses and negative cash flows. Because we will continue to experience operating losses, our ability to continue as a going concern is subject to our ability to obtain necessary capital from outside sources, including obtaining additional capital from the sale of AgeX common stock or other equity securities or assets, obtaining additional loans from financial institutions or investors, and entering into collaborative research and development arrangements or licensing some or all of our patents and know-how to third parties while retaining a royalty and other contingent payment rights related to the development and commercialization of products covered by the licenses. Our continued operating losses, the amount of our debt obligations to Juvenescence and the provisions of our indebtedness agreements with them, including restrictions on the use of loan funds and the security interest they hold in our assets and assets of certain of our subsidiaries, Juvenescence’s ownership of shares of AgeX Preferred Stock, the risks associated with the development of our product candidates and technologies, and our deferral of in-house development of our product candidates and technologies in connection with our reductions in staffing and the closing of our research laboratory facilities, will increase the difficulty in obtaining such capital, and there can be no assurances that we will be able to obtain such capital on favorable terms or at all. If we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate our research and development activities, or ultimately not be able to continue as a going concern.

 

32

 

 

We are a discovery-stage development company with limited capital resources and have incurred operating losses since our inception. We anticipate that we will incur continued losses for the foreseeable future and will need to continue to raise capital to finance our operations, and we do not know if we will ever attain profitability.

 

We are a discovery-stage therapeutics company with a limited operating history and limited capital resources. Since our inception in August 2017, we have incurred operating losses and negative cash flows and we expect to continue to incur losses and negative cash flow in the future. Our net loss from continuing operations were $10.5 million and $8.6 million for the years ended December 31, 2022 and 2021, respectively, and we had an accumulated deficit of approximately $116.2 million as of December 31, 2022. Our loss from operations were $6.4 million and $5.2 million for the nine months ended September 30, 2023 and 2022, respectively, and we had an accumulated deficit of approximately $127.6 million as of September 30, 2023.

 

These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital. We expect to continue to incur significant additional operating losses for the foreseeable future and will need to continuously raise additional capital to fund our operations. The amount of our expenses and anticipated losses will depend on our capital resources and whether we license out product development to third parties or participate ourselves directly or financially with collaborators in research, development and commercialization efforts. Although we do not expect to advance our product candidates through clinical trials, seek regulatory approval, or commercialize our product candidates ourselves, our capital needs would increase greatly if we were to change plans and determine to do so.

 

The amount of our future net losses will depend, in part, on the rate of future growth of our expenses, our ability to raise the capital needed to continue our operations, and our ability to generate revenues. If we or any licensees or collaborators are unable to develop and commercialize one or more of our product candidates, or if revenues from any product candidates that receive marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability. If we are unable to achieve and then maintain profitability, the value of our equity securities will be materially and adversely affected.

 

We are highly leveraged, carrying a significant amount of indebtedness, including indebtedness secured by our assets, that will become due and payable over the next three years and there is no assurance that we will be able to refinance those obligations as they become due.

 

As of January 3, 2024, our borrowings from Juvenescence under various loans and accrued origination fees outstanding totaled approximately $5 million. The outstanding balances of those loans will become due and payable as follows: approximately $4.3 million on February 14, 2024 under the 2022 Secured Note and $692,800 on March 13, 2026 under a $10 million principal amount Secured Convertible Promissory Note, dated March 13, 2023 (the 2023 Secured Note). During November 2023, we entered into an amendment of the 2022 Secured Note pursuant to which we may borrow up to an additional $4,400,000 from Juvenescence, of which $1.5 million has already been drawn as of January 3, 2024. Our obligations under the 2022 Secured Note and the 2023 Secured Note are collateralized by all of our assets, including the shares of common stock we hold in subsidiaries ReCyte Therapeutics, and Reverse Bioengineering Inc. (Reverse Bio), and UniverXome Bioengineering, Inc., under the terms of an Amended and Restated Security Agreement (the Security Agreement), and those subsidiaries have guaranteed our obligations under the Secured Note, as amended, and have granted a security interest in their respective assets to Juvenescence pursuant to the Security Agreement to secure those obligations. If an Event of Default, as defined in the 2022 Secured Note or the 2023 Secured Note, were to occur Juvenescence could foreclose on its security interest and sell our assets and the assets of those subsidiaries to satisfy the unpaid principal balances of those loans plus certain loan origination fees and costs incurred in connection with the Event of Default and the foreclosure and sale of the assets. As a result, we and those subsidiaries could lose some or all of our respective assets, leaving few if any assets available for the operation of our business or the businesses of our subsidiaries, or for sale for the benefit of our stockholders through a winding up of our affairs and liquidation of our assets.

 

33

 

 

The terms of our loans from Juvenescence and the Security Agreement could make it more difficult for us to raise additional capital from other sources.

 

The terms of our loans from Juvenescence include certain covenants that among other matters such as financial reporting: (i) impose financial restrictions on AgeX while the loans remain unpaid, including restrictions on the incurrence of additional indebtedness by AgeX and its subsidiaries, except that Reverse Bio will be permitted to incur debt convertible into equity not guaranteed or secured by the assets of AgeX or any other AgeX subsidiary; (ii) require that AgeX use loan proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, for general working capital, and for repayment of all or a portion of AgeX’s indebtedness to Juvenescence; and (iii) prohibit AgeX from making additional investments in subsidiaries, unless AgeX obtains the written consent of Juvenescence to a transaction that otherwise would be prohibited or restricted. Further, our obligations under the 2022 Secured Note and 2023 Secured Note are collateralized by all of our assets under the terms of the Security Agreement. Accordingly, the terms of our loans from Juvenescence, and the grant of a security interest in our assets pursuant to the Security Agreement to secure our obligations for the repayment of the 2022 Secured Note and 2023 Secured Note with applicable loan fees that become due, could make AgeX less attractive to new equity investors and could impair our ability to finance our operations or the operations of our subsidiaries from sources other than Juvenescence.

 

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

 

Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, strategic alliances and licensing arrangements. We do not currently have any committed external source of funds. We will need to seek additional capital regardless of market conditions and the terms of any financings that may be available to us.

 

To the extent that we raise additional capital through the sale of shares of AgeX common stock or other equity securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Similarly, if Reverse Bio or NeuroAirmid raise capital through the sale of equity securities or convertible debt securities AgeX’s interest in those subsidiaries will be diluted and the terms of equity securities issued by those subsidiaries may include liquidation or other preferences that adversely affect our rights as a common stockholder of the subsidiary.

 

34

 

 

Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we or any of our subsidiaries raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we or our subsidiaries may be required to relinquish valuable rights to key technologies, future revenue streams, or product candidates, and any such licenses may be granted on terms that may not be favorable to us. If we or our subsidiaries are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

 

Unless AgeX common stock continues to be listed on a national securities exchange, AgeX will become subject to the so-called “penny stock” rules that impose restrictive sales practice requirements.

 

On November 17, 2021, we received a letter (the Deficiency Letter) from the staff of the NYSE American indicating that AgeX did not meet certain of the NYSE American continued listing standards as set forth in Section 1003(a)(i) of the NYSE American Company Guide in that we had stockholders’ equity of less than $2,000,000 and had incurred losses from continuing operations and/or net losses during our two most recent fiscal years. Pursuant to Section 1009 of the NYSE American Company Guide and as provided in the Deficiency Letter provided, we provided the NYSE American staff with a plan (the Compliance Plan) advising the NYSE American staff of action we had taken and will take that would bring AgeX into compliance with the NYSE American continued listing standards. The NYSE American staff accepted our Compliance Plan but later required us to revise the Compliance Plan as we remained out of listing compliance. On November 22, 2022, we received a notification from the staff of the NYSE American indicating that the NYSE American accepted our revised listing Compliance Plan and granted us an extension of time to regain compliance with the NYSE American continued listing standards as set forth in Section 1003(a)(i) and (ii) of the NYSE American Company Guide by increasing our stockholders equity to not less than $4,000,000. On May 17, 2023, we received a notice from the staff of the NYSE American indicating that they intend to commence proceedings to delist AgeX common stock from the NYSE American based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX did not meet the continued listing standards because it had stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and had incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6,000,000 or more and had reported losses from continuing operations and/or net losses in its five most recent fiscal years. On May 24, 2023, AgeX filed a request for a review of the delisting determination by a committee of the board of directors of the NYSE American. On May 31, 2023, AgeX received a notice from the staff of the NYSE American which scheduled a hearing for July 25, 2023. On July 24, 2023, AgeX issued shares of AgeX Series A preferred stock and AgeX Series B preferred stock to Juvenescence in exchange for the extinguishment of $36 million of indebtedness owed to Juvenescence with the intent of adding $36 million to stockholders equity and returning AgeX to compliance with the NYSE American continued listing standards. However, upon subsequent consideration in consultation with our registered independent public accountants it was determined that, in accordance with applicable guidance to GAAP, the deemed liquidation preference provisions of the Preferred Stock could be considered contingent redemption provisions that are not solely within AgeX’s control, requiring that the Preferred Stock be presented outside of permanent equity in the mezzanine section of our condensed consolidated balance sheets for the three and nine months ended September 30, 2023 included in this Report. To address this issue, the applicable deemed liquidation provision of the Preferred Stock has been amended so that the Preferred Stock will now qualify as permanent equity. We have informed the NYSE American of the accounting issue and the remedy that we have implemented and the NYSE American confirmed that we are now in compliance with their continued listing standards.

 

35

 

 

If we are unable to maintain the listing of AgeX common stock on the NYSE American or another national securities exchange, AgeX common stock could become subject to the so-called “penny stock” rules if the shares have a market value of less than $5.00 per share. The SEC has adopted regulations that define a penny stock to include any stock that has a market price of less than $5.00 per share, subject to certain exceptions, including an exception for stock traded on a national securities exchange. The SEC regulations impose restrictive sales practice requirements on broker-dealers who sell penny stocks to persons other than established customers and accredited investors. An accredited investor generally is a person whose individual annual income exceeded $200,000, or whose joint annual income with a spouse exceeded $300,000 during the past two years and who expects their annual income to exceed the applicable level during the current year, or a person with net worth in excess of $1.0 million, not including the value of the investor’s principal residence and excluding mortgage debt secured by the investor’s principal residence up to the estimated fair market value of the home, except that any mortgage debt incurred by the investor within 60 days prior to the date of the transaction shall not be excluded from the determination of the investor’s net worth unless the mortgage debt was incurred to acquire the residence. For transactions covered by this rule, the broker-dealer must make a special suitability determination for the purchaser and must have received the purchaser’s written consent to the transaction prior to sale. This means that if we are unable maintain the listing of AgeX common stock on a national securities exchange, the ability of stockholders to sell their AgeX common stock in the secondary market could be adversely affected.

 

If a transaction involving a penny stock is not exempt from the SEC’s rule, a broker-dealer must deliver a disclosure schedule relating to the penny stock market to each investor prior to a transaction. The broker-dealer also must disclose the commissions payable to both the broker-dealer and its registered representative, current quotations for the penny stock, and, if the broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealer’s presumed control over the market. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the customer’s account and information on the limited market in penny stocks.

 

Risks Related to Our Planned Restructuring

 

As part of our corporate restructuring plans, we are pursuing the Merger with Serina through which AgeX would be able to enter the field of drug delivery polymer technology, but there is no assurance that the Merger will be consummated. Failure to complete, or delays in completing, the Merger with Serina could materially and adversely affect our results of operations, business, financial condition or stock price.

 

We have been formulating corporate restructuring plans that include the Merger through which AgeX would be able to enter the field of drug delivery polymer technology. If the Merger is completed, the combined company will primarily focus on developing Serina’s product candidates, which are described on page 253 under the section titled “Description of Serina’s Business,” and it is anticipated that the combined company will not continue to develop our product candidates, other than potentially the development program of NeuroAirmid, which is described on page 234 under the section titled “Description of AgeX’s Business—Products and Product Candidates.” Any failure to satisfy a required condition to closing may prevent, delay or otherwise materially and adversely affect the completion of the Merger, which could materially and adversely affect AgeX’s ability to enter the field of drug delivery polymer technology and could materially and adversely affect AgeX’s results of operations, business, financial condition or stock price. AgeX cannot predict with certainty whether or when any of the required closing conditions will be satisfied and whether AgeX will be able to successfully consummate the Merger as currently contemplated under the Merger Agreement or at all. Accordingly, there is no assurance that the Merger will be consummated.

 

36

 

 

AgeX’s efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, AgeX’s business, which may materially adversely affect AgeX’s results of operations and business. Uncertainty as to whether the Merger will be completed may affect AgeX’s ability to retain and motivate existing employees or recruit prospective employees if vacancies in staffing need to be filled. Employee retention may be particularly challenging while the Merger is pending because employees may experience uncertainty about their roles following the transaction. A substantial amount of AgeX’s management’s and employees’ attention is being directed toward the completion of the transaction and thus is being diverted from AgeX’s day-to-day operations.

 

Risks related to the failure to consummate, or delay in consummating, the Merger include, but are not limited to, the following:

 

AgeX would not realize any or all of the potential benefits of the Merger, which could have a negative effect on AgeX’s results of operations, business, financial condition or stock price;
under some circumstances, AgeX may be required to pay a termination fee to Serina of $1,000,000 or expense reimbursement of up to $1,000,000, but not both;
AgeX would remain liable for significant transaction costs, including legal, accounting and other costs relating to the merger regardless of whether the Merger is consummated;
the trading price of AgeX’s common stock may decline to the extent that the current market price for AgeX’s stock reflects a market assumption that the Merger will be completed;
the attention of AgeX’s management and employees may have been diverted to the Merger rather than to AgeX’s operations and the pursuit of other opportunities that could have been beneficial to AgeX;
AgeX could be subject to litigation related to any failure to complete the Merger;
AgeX could potentially lose key personnel during the pendency of the Merger as employees may experience uncertainty about their future roles with AgeX following completion of the Merger and seek employment opportunities elsewhere; and
under the Merger Agreement, AgeX is subject to certain customary restrictions on the conduct of AgeX’s business prior to completing the Merger, which restrictions could adversely affect AgeX’s ability to conduct AgeX’s business as AgeX otherwise would have done if AgeX was not subject to these restrictions.

 

The occurrence of any of these events individually or in combination could materially and adversely affect AgeX’s results of operations, business, financial condition and stock price.

 

37

 

 

If the Merger is not approved or does not occur, we may not be successful in the execution of our current business strategies or identifying and implementing any strategic alternatives with respect to our assets and development programs, and any future strategic alternatives could have negative consequences.

 

If the Merger is not approved or does not occur, we expect to continue to execute on our current business strategies while seeking out and evaluating potential strategic alternatives with respect to our assets and development programs, which may include a merger, business combination, investment into AgeX, sale or other disposition of assets or other strategic transaction. In such case, we may not be successful in executing such strategies or identifying or implementing any such strategic alternatives, and there is a risk that Juvenescence may decide to stop funding our operations, which would likely result in our delisting and dissolution.

 

In addition, the process of seeking out and evaluating a potential strategic alternative with respect to our assets and development programs is costly, time-consuming and complex, and we have incurred, and may in the future incur, significant costs related to the Merger and our other ongoing restructuring plans, such as legal and accounting fees and expenses and other related charges. We may also incur additional unanticipated expenses in connection with this process. A considerable portion of these costs will be incurred regardless of whether any such course of action is implemented or transaction is completed, decreasing the remaining cash available for use in our business.

 

The development and any potential commercialization of our product candidates will require substantial additional cash to fund the costs associated with conducting the necessary preclinical and clinical testing and obtaining regulatory approval. Consequently, any potential counterparty in a strategic transaction involving AgeX may be reluctant to spend additional resources required to pursue development of AgeX’s product candidates and may attribute little or no value to AgeX product assets in such a transaction.

 

There can be no assurance that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated, lead to increased stockholder value, or achieve the anticipated results.

 

Our goal of spinning off Reverse Bio to our stockholders is subject to uncertainties and risks, including risks that could result in the spinoff not being consummated, income tax risks, liquidity and valuation risks pertaining to Reverse Bio stock, and Reverse Bio business risks.

 

The definitive terms of a spinoff of Reverse Bio have not been determined. Before a spinoff can be completed, Reverse Bio will need to raise equity capital through a financing from private investors, and there is no certainty that it will be able to raise sufficient capital to initiate operations as a separate company, independent of AgeX. There is a possibility that AgeX and Reverse Bio and any investors that may contemplate providing financing to Reverse Bio will not reach agreement as to the terms of the spinoff. Accordingly, the contemplated spinoff could be abandoned or a condition to consummating the Reverse Bio spinoff may not be satisfied. Reverse Bio might not be able to satisfy the listing qualifications to list its shares of common stock on the NYSE American or any other national stock exchange and if Reverse Bio shares are not listed on a national securities exchange the liquidity and market value of Reveres Bio common stock could be adversely affected. The Reverse Bio spinoff might not achieve the desired tax treatment, resulting in unanticipated taxes to AgeX and AgeX stockholders. The number of shares of Reverse Bio common stock that AgeX may distribute to its stockholders may be limited, or a distribution of such shares may be prohibited, by provisions of the DGCL that generally limit Delaware corporations, including AgeX, from distributing assets to their stockholders in an amount that exceeds the excess of their assets over liabilities. The other risks pertaining to AgeX’s business, operations, and future capital needs, other than financial obligations to Juvenescence, discussed in this Risk Factors section will also be applicable to the business, operations, and future capital needs of Reverse Bio.

 

38

 

 

Risks Related to Our Relationship with Juvenescence

 

Conflicts of interest may arise from our relationship with Juvenescence, which owns a significant percentage of AgeX common stock as well as shares of AgeX preferred stock and is a significant creditor and will be able to substantially influence us and exert control over matters subject to stockholder approval, including the Merger and other AgeX Proposals.

 

As of January 3, 2024, Juvenescence owned approximately 43% of the outstanding shares of AgeX common stock. In addition, Juvenescence indicated that it beneficially owned approximately 80.2% of AgeX common stock in its amendment of the Schedule 13D filed with the SEC on January 9, 2024. See “Principal Stockholders of AgeX” for additional information. The AgeX preferred stock conversion is expected to occur on February 1, 2024 in accordance with the Certificates of Designation of the AgeX Series A preferred stock and the AgeX Series B preferred stock. The AgeX preferred stock conversion will increase Juvenescence’s ownership and voting power to more than 50% of the outstanding shares of AgeX common stock, enabling Juvenescence to approve or disapprove the Merger and other AgeX Proposals without regard to the vote of other AgeX stockholders.

 

A member of the AgeX Board is also the Executive Chairman and Co-Founder of Juvenescence, and based on Juvenescence’s ownership of shares of AgeX common stock and preferred stock, if the Merger is not consummated, Juvenescence will continue to substantially influence us and exert control over matters subject to stockholder approval, the elections of directors, approval of our equity incentive plans, amendments to our organizational documents, or approval of any merger, amalgamation, sale of assets or other major corporate transaction. Furthermore, upon Juvenescence holding more than 50% outstanding AgeX common stock, AgeX would qualify as a “controlled company” as defined by the NYSE American Company Guide. Being a “controlled company” would entitle AgeX to exempt itself from the requirement that a majority of its directors be “independent” directors as defined in the NYSE American Company Guide, and that the Compensation Committee and the Nominating & Corporate Governance Committee be comprised entirely of independent directors.

 

On November 9, 2023, we entered into an amendment of the 2022 Secured Note to increase the amount of the line of credit available to AgeX from Juvenescence by $4,400,000, of which $1,500,000 has already been drawn as of January 3, 2024, subject to the terms of the 2022 Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. As of January 3, 2024, in the outstanding principal balance of the 2022 Secured Note was approximately $4,000,000. Juvenescence also has controlling stakes and minority investments in several other companies engaged in various aspects of the aging industry, which companies may propose collaborations with AgeX.

 

Juvenescence’s interests may not always coincide with our corporate interests or the interests of other stockholders, and it may exercise its voting and other rights, including rights as a creditor, in a manner with which other stockholders may not agree or that may not be in the best interests of AgeX or stockholders other than Juvenescence. So long as Juvenescence continues to own a significant amount of our equity and remains a significant creditor, it will continue to be able to strongly influence and effectively control our decisions. While the directors elected by Juvenescence will be obligated to act in accordance with their fiduciary duty, they may have equity or other interests in Juvenescence and, accordingly, their interests may be aligned with Juvenescence’s interests, which may not always coincide with our corporate interests or the interests of our other stockholders.

 

39

 

 

Risks Related to Our Business Operations

 

Due to our limited financial resources, we have reduced our staffing, eliminated our research laboratory facilities, and eliminated in-house research and product development work. We will seek opportunities to outsource or license product development and commercialization but there is no assurance that we will be able to do so successfully.

 

During April 2020, we implemented a plan to reduce spending on employee salaries and consulting fees that resulted in large staff reductions, including the elimination of most of our research personnel and certain management and administrative personnel. We then subleased most of our former laboratory facility space and we did not renew the laboratory facility lease, or lease other laboratory facility space, after our lease expired at the end of 2020. As a result, we do not have a research laboratory facility or a research staff, and we have curtailed development of our product candidates and technologies except for certain research and development work that is being conducted under sponsored research agreements with certain universities and a limited amount of work contracted out to third-party service providers. We also may license technologies or product development to, or enter into collaborative arrangements with, other companies in the cell therapy or biopharma industry to conduct research and development, manufacturing, and marketing for AgeX for particular product candidates, but there is no assurance that we will be able to enter into any such agreements on terms acceptable to us.

 

We may expend our limited resources to pursue one or more particular product candidates or indications and fail to pursue product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

 

Because we have limited financial and managerial resources, we may focus on research programs and product candidates that we identify for specific indications and we may seek to develop those product candidates through out-sourcing or out-licensing to third parties if we are able to make such arrangements. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

 

40

 

 

We have not tested any of our product candidates in clinical trials. Success in early development and preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials.

 

Our product candidates have never been evaluated in human clinical trials, and we may experience unexpected or adverse results in the future if any human clinical trials of any of our product candidates are conducted. Typically, it takes about six to ten years to develop a new drug from the time it enters Phase 1 clinical trials to when it is approved for treating patients, but in many cases it may take longer, and the costs of advancing product candidates through clinical trials will be substantial and will tend to increase significantly with each successive clinical trial phase.

 

Adequate and well-controlled clinical trials will need to demonstrate that our product candidates are safe and effective, with a favorable benefit-risk profile, for use in their target indications before regulatory approvals can be sought for their commercial sale. Any positive results that may be observed for product candidates in preclinical animal models may not be predictive of future clinical trials in humans. Our product candidates may also fail to show the desired safety and efficacy in later stages of clinical development even if they successfully advance through initial clinical trials. Further, some or all of our cell-based therapies under development may require the genetic modification of the pluripotent master cell banks such that the resulting cells can escape immune rejection by the intended patient. There is no certainty that a genetic modification will provide a long-term solution to transplant rejection, or that the modified cells will not cause unanticipated health risks to the patient that could delay or even halt the development of the products.

 

Many companies in the biotechnology industry have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and there is a high failure rate for product candidates proceeding through clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. Even if a clinical trial demonstrates statistical significance, regulatory agencies may not accept the use of the historical control. Regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development. We cannot be certain that any clinical trials and applications for marketing approval will not face similar setbacks.

 

The development and commercialization of new drugs to address obesity and type 2 diabetes may substantially limit or eliminate the prospects for AgeX’s prospective AGEX-BAT1 product.

 

A number of new GLP-1 receptor agonist drugs, including Mounjaro, Ozempic, Rybelsus, and Trulicity for treating type 2 diabetes, and Wegovy and Zepbound for weight management, have entered the market. Ozempic is also being used off label for weight loss. The attention and acceptance that these new drugs have attained in the medical field for the treatment of type 2 diabetes and chronic weight management may substantially limit or eliminate the prospects for developing and commercializing any product based on AGEX-BAT1, brown adipose tissue, for those uses. Although the GLP-1 receptor agonist drugs may in certain patients be contraindicated, carry unacceptable medical risks, lead to intolerable side effects, or may not be satisfactorily effective, it is not clear whether those patients would constitute a large enough market for an alternative therapy to warrant the time and expense of developing AGEX-BAT1 for the uses addressed by the products currently on the market. Further, it is likely that the administration of a AGEX-BAT1 cell therapy product would entail a surgical implant procedure which would be expensive and would pose risks to the patient related to the surgical procedure that are not faced by users of the injectable or pill GLP-1 receptor agonist drugs currently on the market.

 

Our choice of product candidates and our development plans for our product candidates are subject to change based on a variety of factors, and if we abandon development of a product candidate we may not be able to develop or acquire a replacement product candidate.

 

We may determine to abandon the development of one or more of our product candidates, or we may change the prioritization of the development of certain product candidates, or we may select or acquire and prioritize the development of new product candidates. Our choice and prioritization of product candidates for development will be influenced by a variety of factors, including but not limited to:

 

the amount of capital that we will have for our development programs and our projected costs for those programs;

 

41

 

 

ability to enter into licensing or collaborative arrangements with other biotechnology or biopharma companies or universities with their own laboratory facilities and research staffs to conduct research and development of one or more product candidates;
competitors may develop alternatives that render our potential product candidates obsolete or less attractive;
potential product candidates we develop may nevertheless be covered by third parties’ patents or other exclusive rights;
potential product candidates may not be effective in treating their targeted diseases;
potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;
our analysis of market demand and market prices for the products we plan to develop could lead us to conclude that market conditions are not favorable for receiving an adequate return on our investment in product development and commercialization;
a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or
the regulatory pathway for a potential product candidate is too complex and difficult to navigate successfully or economically.

 

We may determine to expand our organization and obtain laboratory facilities if we are able to raise sufficient capital to do so, and we may experience difficulties in managing this growth, which could disrupt our operations.

 

As of September 30, 2023, we had nine employees. If we are able to obtain sufficient capital and determine to reinstitute our internal research and development efforts, we may have difficulty locating, leasing, and equipping a new laboratory facility and identifying, hiring and integrating new scientific and laboratory personnel. Many of the biotechnology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do and are better positioned to attract and retain personnel and consultants. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product candidates and operate our business will be limited.

 

Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Any growth of administrative resources could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.

 

42

 

 

The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.

 

Even with approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products will depend in part on the health care providers, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and other health care providers. The clinical development, commercialization, and marketing of cell therapies are at an early-stage, substantially research-oriented, and financially speculative. To date, very few companies have been successful in their efforts to develop and commercialize cell therapies. In general, cell therapies may be susceptible to various risks, including undesirable and unintended side effects, unintended immune system responses, inadequate therapeutic efficacy, potentially prohibitive costs or other characteristics that may prevent or limit their approval or commercial use. Furthermore, the number of people who may use cell- or tissue-based therapies is difficult to forecast with accuracy. Our future success is dependent on the establishment of a large global market for cell therapies and our ability to capture a share of this market with our product candidates.

 

Even if we, a collaborator, or a licensee of our technology successfully develop and obtain regulatory approval for our product candidates, the market may not understand or accept them. Our product candidates represent novel treatments and are expected to compete with a number of more conventional products and therapies manufactured and marketed by others, including major pharmaceutical and biotechnology companies. The degree of market acceptance of any of our products will depend on a number of factors, including without limitation:

 

the efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments;
the prevalence and severity of the disease and any side effects;
the clinical indications for which approval is granted, including any limitations or warnings contained in a product’s approved labeling;
the convenience and ease of administration;
the cost of treatment, particular as additive to existing treatments;
the willingness of the patients and physicians to accept and use these therapies and the perception of efficacy and safety of our approved products by such parties;
the marketing, sales and distribution support for the products;
the publicity and ethical, social and legal concerns regarding the use of embryonic stem cells for our products or competing products and treatments;
government regulations restricting or prohibiting our research or manufacturing processes for stem cells due to ethical, social and legal concerns regarding their use in medical research and treatment; and
the pricing and availability of third-party insurance coverage and reimbursement.

 

Even if a product displays a favorable efficacy and safety profile upon approval, market acceptance of the product will initially remain uncertain. Efforts to educate the medical community and third-party payors on the benefits of the products may require significant investment and resources and may never be successful. If our products fail to achieve an adequate level of acceptance by physicians, patients, third-party payors, and other health care providers, we will not be able to generate sufficient revenue to become or remain profitable.

 

43

 

 

If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations and, even assuming approval of a product candidate, our business may suffer.

 

Our projections of the number of potential users of our product candidates in the markets we are attempting to address are based on our beliefs and estimates and include several key assumptions based on our industry knowledge, industry publications, third-party research reports and other surveys. You should bear in mind the following:

 

Our estimates have been derived from a variety of sources, including publications and scientific literature or market research estimating the total number of patients and currently approved or used therapies, as well as certain assumptions regarding the potential size of the market assuming broad regulatory approval or potential usage by physicians beyond the approved label, any of which may prove to be incorrect.
The scope of approval and potential use may be significantly narrower, and the number of patients may turn out to be lower than expected.
Competitive products or approaches may be approved or come into use by medical providers and the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, any which could adversely affect our results of operations and our business.

 

If the actual market for any of our product candidates is smaller than we expect, our revenue may be limited and it may be more difficult for us to achieve or maintain profitability.

 

We will face risks related to the manufacture of medical products for any product candidates that we develop.

 

The manufacture of medical products, and in particular biologics, is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls, none of which we presently have. Unless we are able to raise the capital required to construct our own manufacturing facilities and are able to develop the expertise to manage and operate a manufacturing facility of our own, which we do not expect to undertake, we would need to rely on third-party manufacturers to manufacture any products that we develop. There is no assurance that we will be able to identify manufacturers on acceptable terms or at all. Regardless of whether we do our own manufacturing or rely on third parties to manufacture products for us, we will face all risks related to the manufacture of therapeutic products for use in medicine including the following risks:

 

We or any third-party manufacturers might be unable to timely formulate and manufacture our products or produce the quantity and quality required to meet our clinical and commercial needs, if any.
We or any third-party manufacturers may not be able to execute our manufacturing procedures appropriately.
Any third-party manufacturers we engage may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products on a commercial scale.
We or any third-party manufacturers will be subject to ongoing periodic unannounced inspection by the FDA, and corresponding state agencies to ensure strict compliance with current good manufacturing practices (cGMP) and other government regulations and corresponding foreign standards. We will not have control over third-party manufacturers’ compliance with applicable regulations and standards.

 

44

 

 

We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates.
Third-party manufacturers could breach or terminate their agreements with us.
We or third-party manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments.

 

In addition, we may rely on third parties to perform release testing on our product candidates prior to delivery to patients. If these tests are not appropriately conducted and test data are not reliable, patients could be put at risk of serious harm which could result in product liability suits.

 

If we or any third-party manufacturers that we may engage were to encounter any of these difficulties, our ability to provide our product candidates to patients in clinical trials or to the medical marketplace would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, could require us to either commence new clinical trials at additional expense or terminate clinical trials completely.

 

The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.

 

Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.

 

Further, our product candidates are manufactured by starting with established master cell banks of human embryonic cells and other cells that are cryopreserved. We will be required to expand the numbers of the pluripotent stem cell master cell banks for future use, as well as produce working cell banks from which the product will be manufactured for clinical trials, produce the relevant product under cGMP conditions, expand the number of relevant cells and cryopreserve them under cGMP conditions. We may not be able to expand the numbers of the pluripotent stem cell master cell banks to provide sufficient cells for clinical trial or for commercial scale production. We may not be able to manufacture product that meets release criteria due to sterility, identity or potency issues. We may not have access or be able to make the reagents necessary to manufacture the cells and we may not have access to adequate supply channels to transport and distribute the products. There are also risks that the cells may be destroyed by interruption in their cryopreservation by means of natural disasters such as earthquakes, power outages, or other unexpected events, or the cells may be determined to be unacceptable as a source of human cellular therapies for reasons we cannot envision. We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. If any of our master cell banks are lost or destroyed, including due to systems failure in the cryopreservation processes, our planned clinical trials would be severely delayed, and we would incur significant costs associated with obtaining new supply of cell banks. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products and could have an adverse effect on our business, prospects, financial condition and results of operations.

 

Any therapies that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing cell-based products for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval.

 

Each of these risks could delay our clinical trials, any approval of our product candidates by the FDA, or the commercialization of our product candidates, and could result in higher costs or deprive us of potential product revenue.

 

Any cell-based products that receive regulatory approval may be difficult and expensive to manufacture on a commercial scale.

 

Pluripotent stem cell and progenitor cell derived therapeutic cells have only been produced on a small scale and not in quantities and at levels of purity and viability that will be needed for wide scale commercialization. If we are successful in developing products that consist of cells or compounds derived from pluripotent stem cells or progenitor cells, we will need to develop facilities, processes, and technology for the commercial production of those products. Pluripotent stem cell or progenitor cell based products are likely to be more expensive to manufacture on a commercial scale than most other drugs on the market today. The higher cost of manufacturing a product will require that we charge our customers a higher price for the product in order to cover our costs and earn a profit. If the price of our products is too high, hospitals and physicians may be reluctant to purchase our products and we may not be able to sell our products in sufficient volumes to recover our costs or to earn a profit.

 

If we fail to meet our obligations under license agreements, we may lose our rights to key technologies on which our business depends.

 

Our business will depend on several critical technologies that we have licensed or sublicensed from Lineage Cell Therapeutics, Inc. (Lineage) or certain Lineage subsidiaries. The license and sublicense agreements impose obligations on us, including payment obligations and obligations to pursue development and commercialization of products and technologies under the licensed patents or technology. If the licensor or sublicensor believes that we have failed to meet our obligations under a license or sublicense agreement, they could seek to limit or terminate our license rights, which could lead to costly and time-consuming litigation and, potentially, our loss of the licensed rights. During the period of any such litigation our ability to carry out the development and commercialization of potential new products or technologies, and our ability to raise any capital that we might then need, could be significantly and negatively affected. If our license rights were restricted or ultimately lost, we would not be able to continue to use the licensed or sublicensed technology in our business.

 

45

 

 

Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.

 

Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on our executive officers, including our Interim Chief Executive Officer and our Chief Financial Officer. Although we have a consulting agreement with our Interim Chief Executive Officer and an employment agreement with our Chief Financial Officer, these agreements do not prevent them from terminating their consulting arrangement or employment with us at any time. In addition, because we will rely on Juvenescence to provide the services of certain administrative and management personnel, we will not have the benefit of the full time and effort of those Juvenescence employees in the management and development of our business.

 

If we lose one or more of our executive officers or key employees, our ability to implement the Merger and the other Contemplated Transactions or, if the Merger is not completed, our current business strategies successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult, in particular during the pendency of the Merger, and may take an extended period of time because of the uncertainty about such persons roles following the Merger and the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also will experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we will rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to implement the Merger and the other Contemplated Transactions or, if the Merger is not completed, to continue to execute on our current business strategies while seeking out and evaluating potential strategic alternatives with respect to our assets and development programs will be limited.

 

Our business and operations could suffer in the event of system failures.

 

Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters including earthquakes and tsunamis, terrorism, war, and telecommunication and electrical failures. A loss of or damage to our data, a disruption in access to our data, or inappropriate disclosure of confidential or proprietary information, could disrupt our operations, delay or otherwise adversely affect the development of our product candidates, significantly increase our costs, or result in delays in any future regulatory filings we may make.

 

In addition, our product candidates are manufactured using cells that are stored in a cryopreserved master cell bank. While we believe we have adequate backup should any cell bank be lost in a catastrophic event, it is possible that we or our third-party suppliers and manufacturers could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks. We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of our product candidates or products. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products and could have an adverse effect on our business, prospects, financial condition and results of operations.

 

46

 

 

Security breaches and other disruptions could compromise our information and expose us to liability, and could cause our business and reputation to suffer.

 

In the ordinary course of business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of the licensors and licensees of the patents and other intellectual property we use, and personally identifiable information of employees and consultants. The secure processing, maintenance, and transmission of this information is critical to our operations and business strategy. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance, or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure, theft, or other loss of information could result in legal claims or proceedings or liability under laws that protect the privacy of personal information, and could disrupt our operations and damage our reputation. Even if we do not incur an interruption of or our operations, fines, penalties, or financial liability to third parties from a security breach, we could suffer a loss of confidence in our services, which could adversely affect our business and competitive position.

 

Failure of our internal control over financial reporting could harm our business and financial results.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting for external purposes in accordance with U.S. GAAP. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our consolidated financial statements; providing reasonable assurance that receipts and expenditures of our assets are made in accordance with management authorization; and providing reasonable assurance that unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our consolidated financial statements would be prevented or detected. Because we are an emerging growth company and a smaller reporting issuer, we are exempt from the requirement of having our internal controls over financial reporting audited by our independent registered public accountants, which means that material weaknesses or significant deficiencies in our internal controls that might be detected by an audit may not be detected and remedied. If we are successful in developing new medical products and technologies, the commercialization of those products and technologies will place significant additional pressure on our system of internal control over financial reporting. Any failure to maintain an effective system of internal control over financial reporting could limit our ability to report our financial results accurately and timely or to detect and prevent fraud. Our accounting and other management systems and resources may not be adequately prepared to meet the financial reporting and other requirements to which we will be subject, and failure to achieve and maintain effective internal controls could have a material adverse effect on our business.

 

We are subject to laws and regulations governing corruption, which will require us to develop, maintain, and implement costly compliance programs.

 

We must comply with a wide range of laws and regulations to prevent corruption, bribery, and other unethical business practices, including the Foreign Corrupt Practices Act (FCPA), anti-bribery and anti-corruption laws in other countries. The creation and implementation of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.

 

Anti-bribery laws prohibit us, our employees, and some of our agents or representatives from offering or providing any personal benefit to covered government officials to influence their performance of their duties or induce them to serve interests other than the missions of the public organizations in which they serve. Certain commercial bribery rules also prohibit offering or providing any personal benefit to employees and representatives of commercial companies to influence their performance of their duties or induce them to serve interests other than their employers. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the United States Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.

 

Compliance with these anti-bribery laws is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the anti-bribery laws present particular challenges in the medical industry because in many countries including China, hospitals are state-owned or operated by the government, and doctors and other hospital employees are considered foreign government officials. Furthermore, in certain countries (China in particular), hospitals and clinics are permitted to sell pharmaceuticals to their patients and are primary or significant distributors of pharmaceuticals. Certain payments to hospitals in connection with clinical studies, procurement of pharmaceuticals and other work have been deemed to be improper payments to government officials that have led to vigorous anti-bribery law enforcement actions and heavy fines in multiple jurisdictions, particularly in the U.S. and China.

 

It is not always possible to identify and deter violations, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.

 

In the medical industry, corrupt practices include, among others, acceptance of kickbacks, bribes or other illegal gains or benefits by the hospitals and medical practitioners from manufacturers of pharmaceutical or other products, distributors or their third party agents in connection with the prescription of certain pharmaceuticals or sale of products. If our employees, affiliates, distributors or third party marketing firms violate these laws or otherwise engage in illegal practices with respect to their sales or marketing of our products or other activities involving our products, we could be required to pay damages or heavy fines by multiple jurisdictions where we operate, which could materially and adversely affect our financial condition and results of operations. There have been recent occurrences in which certain hospitals have denied access to sales representatives from pharmaceutical companies because the hospitals wanted to avoid the perception of corruption. If this attitude becomes widespread among our potential customers, our ability to promote our products to hospitals may be adversely affected.

 

47

 

 

If we and our subsidiaries expand operations internationally, we will need to increase the scope of our compliance programs to address the risks relating to the potential for violations of the FCPA and other anti-bribery and anti-corruption laws. Our compliance programs will need to include policies addressing not only the FCPA, but also the provisions of a variety of anti-bribery and anti-corruption laws in multiple foreign jurisdictions, provisions relating to books and records that apply to us as a public company, and include effective training for our personnel throughout our organization. The creation and implementation of anti-corruption compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. Violation of the FCPA and other anti-corruption laws can result in significant administrative and criminal penalties for us and our employees, including substantial fines, suspension or debarment from government contracting, prison sentences, or even the death penalty in extremely serious cases in certain countries. The SEC also may suspend or bar us from trading securities on U.S. exchanges for violation of the FCPA’s accounting provisions. Even if we are not ultimately punished by government authorities, the costs of investigation and review, distraction of our personnel, legal defense costs, and harm to our reputation could be substantial and could limit our profitability or our ability to develop or commercialize our product candidates. In addition, if any of our competitors are not subject to the FCPA, they may engage in practices that will lead to their receipt of preferential treatment from foreign hospitals and enable them to secure business from foreign hospitals in ways that are unavailable to us.

 

Risks Related to Our Industry

 

We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may harm our business and financial condition, and our ability to successfully market or commercialize our product candidates.

 

The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, competition and a strong emphasis on intellectual property. We may face competition from other companies focused on therapeutics for age-related disease, which is a highly competitive environment. There are numerous biotechnology companies developing therapeutics for human aging, with each company often focusing on a specific molecular pathway within cells. For example, ResTORbio, Inc. is developing modulators of the mechanistic target of rapamycin (mTOR) pathway to treat immunological and cardiovascular disorders. Calico Life Sciences LLC is a Google-founded research and development company aimed at identifying molecular pathways that control animal lifespan and translating these insights into novel therapeutics designed to increase human healthspan. Unity Biotechnology, Inc. focuses on cellular senescence, in particular, the use of agents that can target senescent cells for selective ablation (senolysis). Unity’s stated targeted age-related diseases include osteoarthritis as well as other ophthalmological and pulmonary diseases. Our therapeutic products in development are likely to face competition from a large number of companies and technological strategies including therapeutics intended to address our lead indications. See “Description of AgeX’s Business—Competition.”

 

We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or non-competitive. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In particular, the Ministry of Labor Health and Welfare in Japan may grant SAKIGAKE designation to a competing product candidate, which is designed to provide for faster review and approval for any such product candidate as compared to the conventional process. If any competing product candidate receives SAKIGAKE designation in Japan, it may be commercialized more quickly in Japan than any of our product candidates. Additionally, technologies developed by our competitors may render our potential product candidates uneconomic or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.

 

Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.

 

The Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA) includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full a biologics license application (BLA) for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.

 

There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

 

48

 

 

The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

 

The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that any other product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator or licensee is permitted to market any of our product candidates in the United States until we receive regulatory approval of a BLA from the FDA. It is possible that the FDA may refuse to accept for substantive review any BLAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates.

 

Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators or licensees will need to demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that the product candidate is safe and effective for the intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other FDA-required studies, approval of any BLA or application that we submit may be delayed by several years or may require us to expend significantly more resources than we have available.

 

Any therapeutic products that we and our subsidiaries may develop cannot be sold until the FDA and corresponding foreign regulatory authorities approve the products for medical use. The need to obtain regulatory approval to market a new product means that:

 

Expensive and time-consuming clinical trials of new products will need to be conducted. The full cost of conducting and completing clinical trials necessary to obtain FDA and foreign regulatory approval of a new product cannot be presently determined but could exceed our financial resources or could discourage any future licensees or collaborators from pursuing FDA approval of our product candidates.
Clinical trials and the regulatory approval process for a pharmaceutical or cell-based product can take several years to complete. As a result, we will face expenses and delays inherent in seeking FDA and foreign regulatory approval of new products, even if the results of clinical trials are favorable.
Data obtained from preclinical and clinical studies is susceptible to varying interpretations and regulatory changes that could delay, limit, or prevent regulatory agency approvals.
Because the therapeutic products we plan to develop with pluripotent stem cell technology or progenitor cell technology involve the application of new technologies and approaches to medicine, the FDA or foreign regulatory agencies may subject those products to additional or more stringent review than drugs or biologicals derived from other technologies.

 

49

 

 

A product that is approved may be subject to restrictions on use.
The FDA can recall or withdraw approval of a product, if it deems necessary.
We will face similar regulatory issues in foreign countries.

 

Approval of our product candidates may be delayed or refused for many reasons, including the following:

 

The FDA or comparable foreign regulatory authorities may disagree with the design or implementation of the applicable clinical trial;
A clinical trial might not demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;
The results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
A clinical trial fail to demonstrate that our product candidates’ clinical and other benefits outweigh their safety risks;
The FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical programs or clinical trials;
The data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;
The facilities of the any third-party manufacturers with which we may contract may not be adequate to support approval of our product candidates (for example, regulatory approval of cell- and tissue-based products require high standards of quality control); and
The approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

 

Of the large number of potential products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.

 

Ethical, social and legal concerns about research regarding stem cells, could result in regulations restricting or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed interest in further regulating biotechnology. More restrictive regulations or claims that our products are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.

 

Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. The FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise the CBER in its review. Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the National Institute of Health (NIH) also are potentially subject to review by the NIH Office of Science Policy’s Recombinant DNA Advisory Committee, or the RAC, in limited circumstances. Although the FDA decides whether individual gene therapy protocols may proceed, the RAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and authorized its initiation. Conversely, the FDA can put an investigational new drug application, or IND, on clinical hold even if the RAC has provided a favorable review or an exemption from in-depth, public review. If we were to engage an NIH-funded institution to conduct a clinical trial, that institution’s institutional biosafety committee, or IBC, as well as its institutional review board, or IRB, would need to review the proposed clinical trial to assess the safety of the trial and may determine that RAC review is needed. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. Similarly, foreign regulatory authorities may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines.

 

50

 

 

Some of our future products may be viewed by the FDA as combination products and the review of combination products is often more complex and more time consuming than the review of other types of products.

 

Our future products may be regulated by the FDA as combination products. For a combination product, the FDA must determine which center or centers within the FDA will review the product candidate and under what legal authority the product candidate will be reviewed. The process of obtaining FDA marketing clearance or approval is lengthy, expensive, and uncertain, and we cannot be sure that any of our combination products, or any other products, will be cleared or approved in a timely fashion, or at all. In addition, the review of combination products is often more complex and more time consuming than the review of a product candidate under the jurisdiction of only one center within the FDA. We cannot be sure that the FDA will not select to have our combination products reviewed and regulated by only one FDA center and/or different legal authority, in which case the path to regulatory approval would be different and could be more lengthy and costly. If the FDA does not approve or clear our products in a timely fashion, or at all, our business and financial condition will be adversely affected.

 

If we encounter difficulties enrolling patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

 

The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of clinical trials of our product candidates, and even once enrolled we may be unable to retain a sufficient number of patients to complete the trials. The enrollment of patients depends on many factors, including:

 

the patient eligibility criteria defined in the protocol;
the size of the patient population required for analysis of the trial’s primary endpoints;
the proximity of patients to study sites;
the design of the trial;
our ability to recruit clinical trial investigators with the appropriate competencies and experience;
clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;
our ability to obtain and maintain patient consents; and
the risk that patients enrolled in clinical trials will drop out of the trials before completion.

 

In addition, clinical trials of our product candidates will compete with other clinical trials for product candidates of other companies that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in trials of our product candidates may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect that clinical trials or our product candidates may be conducted at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.

 

Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible.

 

Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize its full market potential.

 

In order to market any products in any particular jurisdiction, we or a licensee or collaborator will need to establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.

 

Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.

 

51

 

 

Clinical studies are costly, time consuming and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.

 

Clinical development is expensive, time consuming and involves significant risk. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of development. Events that may prevent successful or timely completion of clinical development include but are not limited to:

 

inability to generate satisfactory preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical studies necessary for product approval;
delays in reaching agreement on acceptable terms with clinical research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;
delays in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;
failure to permit the conduct of a study by regulatory authorities, after review of an investigational new drug, or IND, or equivalent foreign application or amendment;
delays in recruiting qualified patients in our clinical studies;
failure by clinical sites or our CROs or other third parties to adhere to clinical study requirements or report complete findings;
failure to perform the clinical studies in accordance with the FDA’s good clinical practices requirements, or applicable foreign regulatory guidelines;
patients dropping out of our clinical studies;
occurrence of adverse events associated with our product candidates;
inability to use clinical trial results from foreign jurisdictions in support of U.S. regulatory approval;
changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
the cost of clinical studies of our product candidates;
negative or inconclusive results from our clinical trials which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon development programs for a product candidate; and
delays in reaching agreement on acceptable terms with third-party manufacturers, or delays in the manufacture of sufficient quantities of our product candidates for use in clinical studies.

 

Any inability to successfully complete clinical development and obtain regulatory approval could result in additional costs to us or impair our ability to generate revenue. Clinical study delays could also shorten any periods during which our products have patent protection and may allow competitors to develop and bring products to market before we do and may harm our business and results of operations.

 

Even if a product candidate receives regulatory approval, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.

 

Any product candidate that receives marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice (GCP) requirements for any clinical trials that we conduct post-approval.

 

52

 

 

The FDA closely regulates the post-approval marketing and promotion of genetic medicines to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the U.S. federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.

 

In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:

 

restrictions on manufacturing such products;
restrictions on the labeling or marketing of a product;
restrictions on product distribution or use;
requirements to conduct post-marketing studies or clinical trials;
warning letters or holds on clinical trials;
withdrawal of the products from the market;
refusal to approve pending applications or supplements to approved applications that we submit;
recall of products;
fines, restitution or disgorgement of profits or revenues;
suspension or withdrawal of marketing approvals;
refusal to permit the import or export of our products;
product seizure or detention; or
injunctions or the imposition of civil or criminal penalties.

 

The FDA’s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of any of our product candidates. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects and ability to achieve or sustain profitability. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.

 

Our product candidates may cause serious adverse events or undesirable side effects or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label, or, result in significant negative consequences following marketing approval, if any.

 

Serious adverse events or undesirable side effects caused by our product candidates could cause an interruption, delay or halt of clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects, toxicities or unexpected characteristics, including death.

 

For example, there have been significant adverse side effects in cell therapy treatments in the past, including reported cases of certain cancers. In addition to side effects that may be caused by our product candidates, the conditioning, administration process or related procedures also can cause adverse side effects, including compromise of a patient’s immune system. If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.

 

If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including:

 

regulatory authorities may withdraw approvals of such product;
we may be required to recall a product or change the way such product is administered to patients;
additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product;
regulatory authorities may require additional warnings on the label, such as a “black box” warning or contraindication;
we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;
the product could become less competitive;
we could be sued and held liable for harm caused to patients; and
our reputation may suffer.

 

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.

 

53

 

 

We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our product candidates harm patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or could otherwise be negatively impacted, and we could be subject to costly and damaging product liability claims.

 

The use or misuse of any product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies, or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:

 

impairment of our business reputation;
initiation of investigations by regulators;
withdrawal of clinical trial participants;
costs due to related litigation;
distraction of management’s attention from our primary business;
substantial monetary awards to patients or other claimants;
the inability to commercialize our product candidates;
product recalls, withdrawals or labeling, and marketing or promotional restrictions;
loss of revenue; and
decreased demand for our product candidates, if approved for commercial sale.

 

We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we commence clinical trials or obtain marketing approval for any product candidates, we intend to increase our insurance coverage to include clinical use or the sale of commercial products, as applicable; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

 

Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.

 

We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, property, auto, workers’ compensation, umbrella, and directors’ and officers’ insurance.

 

Any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any of our product candidates, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the commercialization of any product candidates we develop.

 

As a public company, it can be difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on the AgeX Board, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.

 

54

 

 

Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.

 

Misconduct by our employees and independent contractors, including principal investigators, contract research organizations, or CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA, European Medical Agency (EMA) rules and regulations and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) data privacy, security, fraud and abuse and other healthcare laws and regulations; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.

 

Government-imposed bans or restrictions and religious, moral, and ethical concerns about the use of human embryonic stem cells could prevent us from developing and successfully marketing stem cell products.

 

Government-imposed bans or restrictions on the use of embryos or human embryonic stem cells (hES cells), in research and development in the United States and abroad could generally constrain stem cell research, thereby limiting the market and demand for our products.

 

California law requires that stem cell research be conducted under the oversight of a Stem Cell Research Oversight (SCRO) Committee. Many kinds of stem cell research, including the derivation of new hES cell lines, may only be conducted in California with the prior written approval of the SCRO Committee. A SCRO Committee could prohibit or impose restrictions on the research that we plan to do. An adverse decision by a SCRO Committee, or their imposition of restrictions on a research program could adversely affect our ability to enter into co-development or licensing arrangements for the development of a product candidate.

 

55

 

 

The use of hES cells may give rise to religious, moral, and ethical issues. These considerations could lead to more restrictive government regulations or could generally constrain stem cell research, thereby limiting the market and demand for our products.

 

Adverse publicity regarding cell-based therapies could impact our business.

 

Adverse publicity due to the ethical and social controversies surrounding the use of embryonic stem cells or any adverse reported side effects from any stem cell or other cell therapy clinical trials or to the failure of such trials to demonstrate that these therapies are efficacious could materially and adversely affect our ability to raise capital, conduct and complete clinical trials and achieve market acceptance of such products, if approved. For example, research institutions, including those who may be our collaborators, may from time to time publish findings or studies regarding the human genome (such as the Human Genome Project) that adversely implicate our product candidates, including findings of cancer dependencies in cell lines used in our cell-based therapies.

 

The price and sale of any product candidates that we may develop may be limited by health insurance coverage and government regulation.

 

Success in selling any pharmaceutical and cell-based products and medical devices that we may develop may depend in part on the extent to which health insurance companies, health maintenance organizations (HMOs), and government health administration authorities such as Medicare and Medicaid will pay for the cost of the products and related treatment. Until a new product is introduced into the medical marketplace, we will not know with certainty whether adequate health insurance, HMO, and government coverage will be available to permit the product to be sold at a price high enough for us to generate a profit. In some foreign countries, pricing or profitability of health care products is subject to government control, which may result in low prices for our products. Provisions of the Inflation Reduction Act of 2022 may impact the prices of drug products that are sold in the United States, particularly through Medicare programs. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the product’s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. There have been a number of other federal and state proposals to implement similar government controls, and new proposals are likely to be made in the future. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.

 

Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.

 

56

 

 

There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.

 

No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.

 

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits.

 

Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. While it is not possible to predict or model the insurance landscape at the time any of our product candidates may receive regulatory approval, we expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.

 

Enacted and future healthcare legislation, including the ACA, may increase the difficulty and cost of obtaining marketing approval and commercializing our product candidates and may affect the prices we may set.

 

In the United States, the EU and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. As a result of the adoption of the ACA in the United States, substantial changes have been made to the system for paying for healthcare in the United States. Certain provisions related to cost-savings and reimbursement measures could adversely affect our future financial performance. For example, among the provisions of the ACA, those of greatest importance to the biopharmaceutical industry includes the following:

 

an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;
new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting “transfers of value” made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members;
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;
expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate liability;
a licensure framework for follow on biologic products;
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and
establishment of a Center for Medicare Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

 

The ACA has been subject to revision and to judicial, congressional, and executive challenges. As a result of tax reform legislation passed in December 2017, the requirement that all individuals maintain health insurance coverage or pay a penalty, referred to as the “individual mandate” was eliminated effective January 1, 2019. According to the Congressional Budget Office, the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise.

 

57

 

 

The costs of prescription pharmaceuticals in the United States have also been the subject of considerable debate, and new legislative and administrative measures could be implemented to address such costs. To date, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, improve transparency in drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare, and reform government program reimbursement methodologies for drug products. Under recent legislation, starting in 2023 a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the product’s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In these other countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.

 

Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for approved products. In addition, there have been several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare and reform government program reimbursement methodologies for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent labeling and post-marketing testing and other requirements.

 

Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

 

Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.

 

58

 

 

In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.

 

In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.

 

We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.

 

If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.

 

Our activities, and the activities of any collaborators, distributors and other third-party providers that we may engage in the future, will be subject to extensive government regulation and oversight both in the U.S. and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions will directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, and product risk management. Our interactions in the United States or abroad with physicians and other health care providers that prescribe or purchase our products will also be subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place greater restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations, and violations related to environmental matters. Risks relating to compliance with laws and regulations may be heightened if we operate globally.

 

59

 

 

Regulations governing the health care industry are subject to change, with possibly retroactive effect, including:

 

new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements;
changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;
requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA’s clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception, or legal action which could harm our business; and
changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products.

 

Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as sanctions against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention, and adversely affect our business.

 

We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws, and if we are unable to comply with such laws, we could face substantial penalties.

 

If the FDA grants marketing approval for any of our product candidates or technologies and commercializing those products or technologies begins in the United States, our operations may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things, product sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:

 

the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;

 

60

 

 

federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;
the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;
HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and implementing regulations, which impose certain requirements relating to the privacy, security, and transmission of individually identifiable health information;
the Physician Payments Sunshine Act which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;
the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;
the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product; and
state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payors, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or that otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances.

 

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. Further, state laws differ from each other and from federal law in significant ways, thus complicating compliance efforts.

 

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

 

Risks Related to our Dependence on Third Parties

 

We may become dependent on future collaborations to develop and commercialize our product candidates and to provide the regulatory compliance, sales, marketing, and distribution capabilities required for the success of our business.

 

We may enter into various kinds of collaborative research and development and product marketing agreements to develop and commercialize our products. The expected future milestone payments and cost reimbursements from collaboration agreements could provide an important source of financing for our research and development programs, thereby facilitating the application of our technology to the development and commercialization of our products, but there are risks associated with entering into collaboration arrangements.

 

61

 

 

The process of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, such as:

 

a collaboration partner may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale or downsizing;
a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;
a collaboration partner may cease development in therapeutic areas which are the subject of our strategic collaboration;
a collaboration partner may not devote sufficient capital or resources towards our product candidates;
a collaboration partner may change the success criteria for a product candidate thereby delaying or ceasing development of such candidate;
a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;
a collaboration partner could develop a product that competes, either directly or indirectly, with our product candidate;
a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;
a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;
a collaboration partner may terminate a strategic alliance;
a dispute may arise between us and a partner concerning the research, development or commercialization of a product candidate resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and
a partner may use our products or technology in such a way as to invite litigation from a third party.

 

There is a risk that a collaboration partner might fail to perform its obligations under the collaborative arrangements or may be slow in performing its obligations. In addition, a collaboration partner may experience financial difficulties at any time that could prevent it from having available funds to contribute to the collaboration. If a collaboration partner fails to conduct its product development, commercialization, regulatory compliance, sales and marketing or distribution activities successfully and in a timely manner, or if it terminates or materially modifies its agreements with us, the development and commercialization of one or more product candidates could be delayed, curtailed, or terminated because we may not have sufficient financial resources or capabilities to continue such development and commercialization on our own.

 

We have no marketing, sales, or distribution resources for the commercialization of any products or technologies that we might successfully develop.

 

We do not have any infrastructure for the sales, marketing or distribution of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could delay any product launch, which would adversely impact the commercialization of any approved product candidate.

 

62

 

 

If we market products through arrangements with third parties, we may pay sales commissions to sales representatives or we may sell or consign products to distributors at wholesale prices. As a result, our gross profit from product sales may be lower than it would be if we were to sell our products directly to end users at retail prices through our own sales force. There can be no assurance we will be able to negotiate distribution or sales agreements with third parties on favorable terms to justify our investment in our products or achieve sufficient revenues to support our operations.

 

If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of our product candidates, we may be forced to delay the potential commercialization of such candidates or reduce the scope of our sales or marketing activities for them. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to our product candidates or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects.

 

If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

 

We do not have the ability to independently conduct clinical trials required to obtain regulatory approvals for our product candidates and intend to rely on third parties to conduct, supervise and monitor our clinical trials.

 

We will need to rely on third parties, such as contract research organizations, data management companies, contract clinical research associates, medical institutions, clinical investigators and contract laboratories to conduct any clinical trials that we may undertake for our product candidates. We may also rely on third parties to assist with our preclinical development of product candidates.

 

If we outsource clinical trials, we may be unable to directly control the timing, conduct and expense of our clinical trials. However, we will remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.

 

We and our third-party contractors will be required to comply with the good laboratory practices (GLPs) and GCPs, which are regulations and guidelines enforced by the FDA and are also required by the competent authorities of the member states of the European Economic Area (EEA) and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our third-party contractors fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Accordingly, if our third-party contractors fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.

 

63

 

 

Our third-party contractors will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and nonclinical programs. These third-party contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other product development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by third-party contractors, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our third-party contractors do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.

 

If our relationship with any third-party contractors terminates, we may not be able to enter into arrangements with alternative third-party contractors or do so on commercially reasonable terms. Switching or adding additional third-party contractors involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our third-party contractors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.

 

Risks Related to Intellectual Property

 

If we are unable to obtain and enforce patents and to protect our trade secrets, others could use our technology to compete with us, which could limit opportunities for us to generate revenues by licensing our technology and selling our products.

 

Our success will depend in part on our ability to obtain and enforce patents and maintain trade secrets in the United States and in other countries. If we are unsuccessful in obtaining and enforcing patents, our competitors could use our technology and create products or technologies that compete with our products and technologies, without paying license fees or royalties to us.
The preparation, filing, and prosecution of patent applications can be costly and time consuming. Our limited financial resources may not permit us to pursue patent protection of all of our technology and products throughout the world.
Even if we are able to obtain issued patents covering our technology or products, we may have to incur substantial legal fees and other expenses to enforce our patent rights in order to protect our technology and products from infringing uses. We may not have the financial resources to finance the litigation required to preserve our patent and trade secret rights.

 

64

 

 

There is no certainty that our pending or future patent applications will result in the issuance of patents.

 

We acquired rights to patent applications for technology that Lineage has developed, and we may file additional new patent applications in the future seeking patent protection for new technology or products that we develop ourselves or jointly with others. However, there is no assurance that any of our licensed patent applications, or any patent applications that we may file in the future in the United States or abroad, will result in the issuance of patents.

 

The process of applying for and obtaining patents can be expensive and slow.

 

The preparation and filing of patent applications, and the maintenance of patents that are issued, may require substantial time and money.
A patent interference proceeding may be instituted with the U.S. Patent and Trademark Office (the USPTO) when more than one person files a patent application covering the same technology, or if someone wishes to challenge the validity of an issued patent. At the completion of the interference proceeding, the USPTO will determine which competing applicant is entitled to the patent, or whether an issued patent is valid. Patent interference proceedings are complex, highly contested legal proceedings, and the USPTO’s decision is subject to appeal. This means that if an interference proceeding arises with respect to any of our patent applications, we may experience significant expenses and delay in obtaining a patent, and if the outcome of the proceeding is unfavorable to us, the patent could be issued to a competitor rather than to us.
A derivation proceeding may be instituted by the USPTO or an inventor alleging that a patent or application was derived from the work of another inventor.
Post Grant Review under the new Leahy Smith America Invents Act (America Invents Act) will make available opposition-like proceedings in the United States. As with the USPTO interference proceedings, Post Grant Review proceedings will be very expensive to contest and can result in significant delays in obtaining patent protection or can result in a denial of a patent application.
Oppositions to the issuance of patents may be filed under European patent law and the patent laws of certain other countries. As with USPTO interference proceedings, these foreign proceedings can be very expensive to contest and can result in significant delays in obtaining a patent or can result in a denial of a patent application.

 

Intellectual property we may develop using grants received from the federal government are subject to rights maintained by the government.

 

Research and development we perform that is funded by grants from the federal government, and any intellectual property that we create using those grants, is subject to the rights maintained by the federal government.

 

65

 

 

Our patents may not protect our technologies or products from competition.

 

We might not be able to obtain any patents beyond those we already own or have licensed or sublicensed, and any patents that we do obtain might not be comprehensive enough to provide us with meaningful patent protection.
There will always be a risk that our competitors might be able to successfully challenge the validity or enforceability of any patent issued to us.
In addition to interference proceedings, the USPTO can reexamine issued patents at the request of a third party. Our patents may be subject to inter partes review (replacing the reexamination proceeding), a proceeding in which a third party can challenge the validity of one of our patents to have the patent invalidated. This means that patents owned or licensed by us may be subject to reexamination and may be lost if the outcome of the reexamination is unfavorable to us.
The patents to which we have licenses to in overlapping fields of use. AgeX, through our subsidiary ReCyte Therapeutics, is a sublicensee under a cross-license between Lineage and Asterias, which creates another potential risk of Asterias and AgeX creating competing products.

 

We may not be able to enforce our intellectual property rights throughout the world.

 

Filing, prosecuting and defending patents, if issued, on our technology and product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. The products offered by foreign competitors may compete with our products in jurisdictions where we do not have any issued or licensed patents or where any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing with us.

 

Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws of some countries outside of the United States and the EU do not afford intellectual property protection to the same extent as the laws of the United States and the EU. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including India, China and certain developing countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and the EU. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents, if issued, or other intellectual property rights may not be effective or sufficient to prevent them from competing.

 

Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in major markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market products or license our patented technologies. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.

 

66

 

 

We may be subject to patent infringement claims that could be costly to defend, which may limit our ability to use disputed technologies, and which could prevent us from pursuing research and development or commercialization of some of our technologies or products, require us to pay licensing fees to have freedom to operate and/or result in monetary damages or other liability for us.

 

The success of our business depends significantly on our ability to operate without infringing patents and other proprietary rights of others. If the technology that we use infringes a patent held by others, we could be sued for monetary damages by the patent holder or its licensee, or we could be prevented from continuing research, development, and commercialization of technologies and products that rely on that technology, unless we are able to obtain a license to use the patent. The cost and availability of a license to a patent cannot be predicted, and the likelihood of obtaining a license at an acceptable cost would be lower if the patent holder or any of its licensees is using the patent to develop or market a technology or product with which our technologies or products would compete. If we could not obtain a necessary license, we would need to develop or obtain rights to alternative technologies, which could prove costly and could cause delays in developing our technologies or products, or we could be forced to discontinue the development or marketing of any technologies and products that were developed using the technology covered by the patent.

 

Risks Related to AgeX Common Stock

 

There is a limited history to the public trading of AgeX common stock and there is no assurance that a market for AgeX common stock will be sustained.

 

Public trading of AgeX common stock on the NYSE American began on November 29, 2018. Accordingly, there is only a limited history of the public trading of AgeX common stock and there can be no assurance that an active market for AgeX common stock will be sustained.

 

We cannot predict the prices at which AgeX common stock may trade. The market price of AgeX common stock may fluctuate significantly, depending upon many factors, some of which may be beyond our control, including, but not limited to:

 

a shift in our investor base;
our quarterly or annual earnings, or those of comparable companies;
actual or anticipated fluctuations in our operating results;
our ability to obtain financing as needed;
changes in laws and regulations affecting our business;
changes in accounting standards, policies, guidance, interpretations or principles;
announcements by us or our competitors of significant investments, acquisitions or dispositions;
the failure of securities analysts to cover AgeX common stock;
changes in earnings estimates by securities analysts or our ability to meet those estimates;
the operating performance and stock price of comparable companies;
overall market fluctuations; and
general economic conditions and other external factors.

 

67

 

 

Because we are engaged in the development of pharmaceutical and cell therapy products, the price of shares of AgeX common stock may rise and fall rapidly.

 

The price of AgeX common stock may rise rapidly in response to certain events, such as the commencement of clinical trials of an experimental new therapy, even though the outcome of those trials and the likelihood of ultimate FDA approval of a therapeutic product remain uncertain. Similarly, prices of AgeX common stock may fall rapidly in response to certain events such as unfavorable results of clinical trials or a delay or failure to obtain FDA approval. Further, the failure of our earnings to meet analysts’ expectations could result in a significant rapid decline in the market price of AgeX common stock.

 

Because we do not pay dividends, AgeX common stock may not be a suitable investment for anyone who needs to earn dividend income.

 

We do not have current plans to pay any cash dividends on AgeX common stock. The declaration, amount and payment of any future dividends on shares of common stock will be at the sole discretion of the AgeX Board. The AgeX Board may take into account general and economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax and regulatory restrictions and implications on the payment of dividends by us to our stockholders or by our subsidiaries to us and such other factors as the AgeX Board may deem relevant. For the foreseeable future we anticipate that any earnings generated in our business will be used to finance the growth of our business and will not be paid out as dividends to our stockholders. This means that our stock may not be a suitable investment for anyone who needs to earn income from their investments.

 

Securities analysts may not initiate coverage or continue to cover AgeX common stock, and this may have a negative impact on the market price of our shares.

 

The market price and liquidity of AgeX common stock will depend, in part, on the research and reports that securities analysts publish about our business and AgeX common stock. We do not have any control over these analysts. There is no guarantee that securities analysts will cover AgeX common stock. If securities analysts do not cover AgeX common stock, the lack of research coverage may adversely affect the market price of those shares. If securities analysts do cover our shares, they could issue reports or recommendations that are unfavorable to the price of our shares, and they could downgrade a previously favorable report or recommendation, and in either case our share price could decline as a result of the report. If one or more of these analysts ceases to cover our shares or fails to publish regular reports on our business, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

 

You may experience dilution of your ownership interests if we issue additional shares of common stock or preferred stock.

 

In the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of our present stockholders. We are currently authorized to issue an aggregate of 205,000,000 shares of capital stock consisting of 200,000,000 shares of common stock and 5,000,000 “blank check” shares of preferred stock. As of January 3, 2024, there were 37,951,261 shares of AgeX common stock issued and outstanding, 211,600 shares of AgeX Series A preferred stock issued and outstanding and 148,400 shares of AgeX Series B preferred stock issued and outstanding, and 2,895,341 shares of AgeX common stock reserved for issuance upon the exercise of outstanding stock options or other stock-based awards under our 2017 Equity Incentive Plan, 10,929,503 shares of AgeX common stock reserved for issuance upon the exercise of outstanding warrants held by Juvenescence, 29,388,888 shares of AgeX common stock reserved for issuance upon the conversion of 211,600 shares of AgeX Series A preferred stock held by Juvenescence and 20,611,111 shares of AgeX common stock reserved for issuance upon the conversion of 148,400 shares of AgeX Series B preferred stock held by Juvenescence.

 

68

 

 

We may issue additional AgeX common stock or other securities that are convertible into or exercisable for AgeX common stock in order to raise additional capital, or in connection with hiring or retaining employees or consultants, or in connection with future acquisitions of licenses to technology or medical products or for other business purposes. The future issuance of any additional shares of AgeX common stock or other securities may create downward pressure on the trading price of AgeX common stock.

 

We may also issue additional preferred stock, and such preferred stock may have rights, preferences, and privileges senior to the rights of AgeX common stock with respect to dividends, rights to share in distributions of our assets if we liquidate our company, or voting rights. Any preferred stock may also be convertible into common stock on terms that would be dilutive to holders of common stock.

 

Our subsidiaries may finance a portion of their operations by selling shares of their capital stock or debt securities convertible into shares of their capital stock to private investors. Sales of subsidiary shares would reduce our ownership interest in the subsidiaries, and correspondingly dilute our shareholder’s ownership interests in our consolidated enterprise. Reverse Bio has, and other AgeX subsidiaries could also have, their own stock option plans and the exercise of subsidiary stock options or the sale of restricted stock under those plans would also reduce our ownership interest in the subsidiaries, with a resulting dilutive effect on the ownership interest of our shareholders in our consolidated enterprise. Subsidiaries might also issue preferred stock having rights, preferences, and privileges senior to the rights of the subsidiary common stock we hold with respect to dividends, rights to share in distributions of our assets if the subsidiary is liquidated, or voting rights. Any subsidiary preferred stock may also be convertible into common stock on terms that would be dilutive to us as a holder of subsidiary common stock.

 

We are an “emerging growth company,” and may elect to comply with reduced public company reporting requirements applicable to emerging growth companies, which could make AgeX common stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find AgeX common stock less attractive because we may rely on these exemptions. If some investors find AgeX common stock less attractive as a result, there may be a less active trading market for AgeX common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an “emerging growth company.” We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the Securities Act); (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a “large accelerated filer” under the Securities Exchange Act of 1934, as amended (the Exchange Act).

 

We could be subject to securities class action litigation.

 

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

 

Provisions in the AgeX Charter and the AgeX Bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

 

Provisions in the AgeX Charter and our bylaws (the AgeX Bylaws) may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of AgeX common stock, thereby depressing the market price of AgeX common stock. In addition, because the AgeX Board is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of the AgeX Board. Among other things, these provisions include those establishing:

 

no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;
the ability of the AgeX Board to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; and
the ability of the AgeX Board to alter our bylaws without obtaining stockholder approval.

 

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

 

69

 

 

Risks Related to Serina

 

Risks Related to Serina’s Operating History, Financial Position and Capital Requirements

 

Serina has a history of operating losses that are expected to continue for the foreseeable future, and it is unable to predict the extent of future losses, or whether it will generate significant revenues or achieve or sustain profitability.

 

Serina has focused on research and product development and has not generated any revenues to date from product sales. Additionally, it expects to continue to incur operating losses for the foreseeable future. These operating losses have adversely affected and are likely to continue to adversely affect Serina’s working capital, total assets, and stockholders’ deficit.

 

Because Serina is an early stage-company, its prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations.

 

Serina expects to make substantial expenditures and incur increasing operating costs in the future and its accumulated deficit will increase significantly as it expands development and clinical trial activities for its product candidates. Because of the risks and uncertainties associated with product development, Serina is unable to predict the extent of any future losses, whether it will ever generate significant revenues or if it will ever achieve or sustain profitability.

 

Serina is dependent on obtaining, and will continue to pursue, necessary funding from outside sources, including obtaining additional funding from the issuance of securities in order to continue its operations. Without adequate funding, it may not be able to meet its financial obligations.

 

Serina has not demonstrated an ability to perform the functions necessary for the successful commercialization of any products. The successful commercialization of any of its products will require it to perform a variety of functions, including:

 

continuing to undertake preclinical and clinical development;
engaging in the development of product candidate formulations and manufacturing processes;
interacting with the applicable regulatory authorities and pursuing other required steps for regulatory approval;
engaging with payors and other pricing and reimbursement authorities;
submitting marketing applications to and receiving approval from the applicable regulatory authorities; and
manufacturing the applicable products and product candidates in accordance with regulatory requirements and, if ultimately approved, conducting sales and marketing activities in accordance with health care, FDA and similar foreign regulatory authority laws and regulations.

 

Serina has a limited operating history and it expects a number of factors to cause its operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict its future performance.

 

Serina’s operations to date have been primarily limited to organizing and staffing its company, developing and securing its proprietary technology and preclinical and clinical development of its product candidates. It has not yet successfully completed all clinical trial phases for any of its product candidates, manufactured its product candidates at commercial scale or conducted sales and marketing activities that will be necessary to successfully commercialize its product candidates, if approved.

 

70

 

 

Serina’s financial condition has varied significantly in the past and will continue to fluctuate from quarter to quarter or year to year due to a variety of factors, many of which are beyond its control. Factors relating to its business that may contribute to these fluctuations include other factors described elsewhere in this proxy statement/prospectus/information statement and also include, among other things:

 

Serina’s ability to obtain additional funding to develop its product candidates;
Serina’s ability to conduct and complete nonclinical studies and clinical trials,
delays in the commencement, enrollment, and timing of clinical trials;
the success of Serina’s nonclinical studies and clinical trials through all phases of development;
any delays in regulatory review and approval of product candidates in clinical development;
Serina’s ability to obtain and maintain regulatory approval for its product candidates in the United States and foreign jurisdictions;
potential toxicity and/or side effects of Serina’s product candidates that could delay or prevent commercialization, limit the indications for any approved products, require the establishment of risk evaluation and mitigation strategies, or cause an approved drug to be taken off the market;
Serina’s ability to establish or maintain partnerships, collaborations, licensing or other arrangements;
market acceptance of Serina’s product candidates, if approved;
competition from existing products, new products or new therapeutic approaches that may emerge;
the ability of patients or health care providers to obtain coverage of or sufficient reimbursement for
Serina’s products;
Serina’s ability to leverage its proprietary POZ technology platform to discover and develop additional product candidates;
Serina’s ability and its licensors’ abilities to successfully obtain, maintain, defend and enforce intellectual property rights important to its business; and
potential product liability claims.

 

Accordingly, the results of any quarterly or annual periods should not be relied upon as indications of future operating performance.

 

We need additional financing to execute our operating plan and continue to operate as a going concern.

 

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future financial obligations as they become due within one year after the date the financial statements are issued. Based on our most recent projected cash flows, we believe that our cash and cash equivalents would not be sufficient to satisfy our anticipated operating and other funding requirements for the next twelve months from September 30, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern. In addition, the report of our independent registered public accountants accompanying our audited consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement contains a qualification to such effect.

 

We have incurred operating losses and negative cash flows since inception and had an accumulated deficit of approximately $34.2 million as of September 30, 2023. We expect to continue to incur operating losses and negative cash flows. Serina’s operations have consumed substantial amounts of cash. Serina will require substantial additional funds to support its continued research and development activities, including the anticipated costs of nonclinical studies and clinical trials, regulatory approvals, and potential commercialization. Additionally, its estimates on future financial needs may be based on assumptions that prove to be wrong, and it may spend its available financial resources much faster than it expects. Because we expect to continue to experience operating losses, our ability to continue as a going concern is subject to our ability to obtain necessary capital from outside sources, including obtaining additional capital from the sale of Serina capital stock or other equity securities or assets, obtaining additional loans from financial institutions or investors, and entering into collaborative research and development arrangements or licensing some or all of our patents and know-how to third parties while retaining a royalty and other contingent payment rights related to the development and commercialization of products covered by the licenses. Our continued operating losses and the risks associated with the development of our product candidates and technologies, has increased the difficulty in obtaining such capital, and there can be no assurances that we will be able to obtain such capital on favorable terms or at all. Furthermore, geopolitical instability, including the ongoing military conflicts between Russia and Ukraine and Israel and Hamas, as well as the impact of inflationary pressures and resulting rise in interest rates, on global financial markets could make the terms of any available financing less attractive to Serina and more dilutive to its existing stockholders. If it is unable to raise additional capital, it will have to delay, curtail, or eliminate one or more of its research and development programs or ultimately not be able to continue as a going concern. Additionally, raising additional capital may cause dilution to its stockholders.

 

71

 

 

Serina has never generated revenue from product sales and may never become profitable.

 

Serina’s ability to generate product sales and achieve profitability depends on its ability, alone or with collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, its current and future product candidates. It does not anticipate generating product sales for the next several years, if ever.

 

Serina’s product candidates will require additional clinical, manufacturing, and non-clinical development, regulatory approval, commercial manufacturing arrangements, establishment of a commercial organization, significant marketing efforts, and further investment before it generates any product sales. It cannot guarantee that it will meet its timelines for its development programs, which may be delayed or not completed for a number of reasons. Serina’s ability to generate future revenues from product sales depends heavily on its, or its collaborators’, ability to successfully:

 

complete research and obtain favorable results from nonclinical and clinical development of Serina’s current and future product candidates, including addressing any clinical holds that may be placed on its development activities by regulatory authorities;
seek and obtain regulatory and marketing approvals for any of Serina’s product candidates for which it completes clinical trials, as well as their manufacturing facilities;
launch and commercialize any of Serina’s product candidates for which it obtains regulatory and marketing approval by establishing a sales force, marketing, and distribution infrastructure or, alternatively, collaborating with a commercialization partner;
qualify for coverage and establish adequate reimbursement by government and third-party payors for any of Serina’s product candidates for which it obtains regulatory and marketing approval;
develop, maintain, and enhance a sustainable, scalable, reproducible, and transferable manufacturing process for the product candidates Serina may develop;
establish and maintain supply and manufacturing capabilities internally or with third parties that can provide adequate, in both amount and quality, products, and services to support clinical development and the market demand for any of Serina’s product candidates for which it obtains regulatory and marketing approval;
obtain market acceptance of current or any future product candidates as viable treatment options and effectively compete with other therapies to establish market share;
maintain a continued acceptable safety and efficacy profile of Serina’s product candidates following launch;
address competing technological and market developments;
implement internal systems and infrastructure, as needed;
negotiate favorable terms in any collaboration, licensing, or other arrangements into which Serina may enter and perform its obligations in such collaborations;
maintain, protect, enforce, defend, and expand Serina’s portfolio of intellectual property rights, including patents, trade secrets, and know how;
avoid and defend against third party interference, infringement, and other intellectual property claims; and
attract, hire, and retain qualified personnel.

 

Even if one or more of Serina’s current and future product candidates are approved for commercial sale, it anticipates incurring significant costs associated with commercializing any approved product candidate. Its expenses could increase beyond its expectations if it is required by the FDA or other regulatory authorities to perform clinical and other studies in addition to those that it currently anticipates. If it is required to conduct additional clinical trials or other testing of its product candidates that it develops beyond those that it currently expects, if it is unable to successfully complete clinical trials of its product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, or if there are safety concerns, Serina may be delayed in obtaining marketing approval for its product candidates, not obtain marketing approval at all, or obtain more limited approvals. Even if it is able to generate revenues from the sale of any approved product candidates, it may not become profitable and may need to obtain additional funding to continue operations.

 

Risks Related to the Development of Serina’s Products

 

Serina’s product candidates are at an early stage of development and may not be successfully developed or commercialized.

 

All of Serina’s current product candidates are in preclinical development and will require substantial further capital expenditures, development, testing, and regulatory approval prior to commercialization. Serina has limited experience designing clinical trials and has not yet filed or supported a marketing application. It may be unable to design and execute a clinical trial that ultimately supports marketing approval.

 

The time required to obtain approval from the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. The outcome of studies is also inherently uncertain. Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval process and are commercialized. The results of nonclinical studies, interim or top line studies, and early clinical trials of Serina’s product candidates may not be predictive of the results of later stage clinical trials. Failure can occur at any time during the clinical trial process. Product candidates in later stages of clinical trials may fail to show the desired safety, purity, and potency traits despite having progressed through nonclinical studies and initial clinical trials. Nonclinical and early clinical studies may also reveal unfavorable product candidate characteristics, including safety concerns. A number of companies have suffered significant setbacks in advanced clinical trials, notwithstanding promising results in earlier trials. In some instances, there can be significant variability in results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols, and the rate of dropout among clinical trial participants.

 

72

 

 

Accordingly, even if Serina is able to obtain the requisite financing to fund its development programs, it cannot assure you that its product candidates will be successfully developed or commercialized. Its failure to develop, manufacture or receive regulatory approval for or successfully commercialize any of its product candidates could result in the failure of its business and a loss of all of its stockholders’ investment.

 

Serina’s product candidates may fail at any stage of preclinical or clinical development, and may also reveal unfavorable product candidate characteristics, including safety concerns or the failure to demonstrate efficacy in initial clinical trials. Further, its product candidates may not receive regulatory approval even if they are successful in clinical trials. Although Serina anticipates completing the preclinical development, including toxicology testing and clinical supply manufacturing development, necessary to file an IND for SER 252 and additional INDs for other product candidates in the future, it may experience numerous unforeseen events before, during, or as a result of clinical trials that could delay or prevent its ability to commence or complete development, commence or complete clinical trials, receive marketing approval or commercialize its product candidates, including:

 

Serina may be unable to generate sufficient nonclinical, toxicology, or other in vivo or in vitro data to support the initiation of clinical trials;
regulators or IRBs or Independent Ethics Committees (IECs) may not authorize Serina or its investigators to commence or continue a clinical trial, conduct a clinical trial at a prospective trial site, or amend trial protocols, or may require that it modifies or amends its clinical trial protocols;
Serina, regulators, independent data safety monitoring committees, IRBs or IECs, or its data monitoring committee(s) may recommend or require the suspension or termination of clinical research for various reasons, including non-compliance with regulatory requirements or a finding that participants are being exposed to unacceptable health risks, undesirable side effects, or a failure of the product candidate to demonstrate any benefit to subjects, or other unexpected characteristics (alone or in combination with other products) of the product candidate, or due to findings of undesirable effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;
new information may emerge regarding Serina’s product candidates or technology platform that result in continued development of some or all of its product candidates being deemed undesirable;
Serina may have delays identifying, recruiting, and training suitable clinical investigators or investigators may withdraw from its studies;
Serina may experience delays in reaching, or failing to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or CROs. Contractual terms can be subject to extensive negotiation, may be subject to modification from time to time and may vary significantly among different CROs and trial sites;
Serina may have delays in adding new investigators or clinical trial sites, or it may experience a withdrawal of clinical trial sites;
the number of patients required for clinical trials of Serina’s product candidates may be larger than it anticipates, enrollment in these clinical trials may be slower than it anticipates, or participants may drop out of these clinical trials or be lost to follow up at a higher rate than it anticipates for a number of reasons, such as adverse events, an inadequate treatment response, fatigue with the clinical trial process or personal issues;
patients who enroll in Serina’s studies may misrepresent their eligibility or may otherwise not comply with clinical trial protocols, resulting in the need to drop those patients from those studies, increase the needed enrollment size for those studies, or extend the duration of those studies;
there may be flaws in Serina’s study design, which may not become apparent until a study is well advanced;

 

73

 

 

Serina’s contractors may fail to comply with regulatory requirements or clinical trial protocols, or meet their contractual obligations to it in a timely manner, or at all, or it may be required to engage in additional clinical trial site monitoring;
regulatory authorities or IRBs/IECs may disagree with the design, including endpoints, scope, or implementation of Serina’s clinical trials, or regulatory authorities may disagree with its intended indications;
regulatory authorities may disagree with the formulation for Serina’s product candidates, or its product candidate dose or dosing schedule;
Serina may be unable to demonstrate to the satisfaction of regulatory authorities that a product candidate is safe, pure, and potent for any indication;
regulatory authorities may not accept, or Serina or its clinical trials may not meet the criteria required to submit, clinical data from trials which are conducted outside of their jurisdictions;
the results of clinical trials may be negative or inconclusive, may not meet the level of statistical significance required for, or may not otherwise be sufficient to support marketing approval, and Serina may decide, or regulatory authorities may require it, to conduct additional clinical trials, analyses, reports, data, or nonclinical studies, or abandon product development programs;
Serina’s product candidates may have undesirable or unintended side effects, toxicities, or other characteristics that preclude marketing approval or prevent or limit commercial use;
Serina may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks or otherwise provide an advantage over current standard of care or current or future competitive therapies in development;
the standard of care for the indications Serina is investigating may change, which changes could impact the meaningfulness of its resulting study data, or which may necessitate changes to its studies;
regulatory authorities may disagree with Serina’s scope, design, including endpoints, implementation, or its interpretation of data from nonclinical studies or clinical trials;
regulatory authorities may require Serina to amend its studies, perform additional or unanticipated clinical trials or nonclinical studies or manufacturing development work to obtain approval or initiate clinical trials, or it may decide to do so or abandon product development programs;
regulatory authorities may find that Serina or its third-party manufacturers do not satisfy regulatory requirements and standards for the facilities and operations used in the manufacture of its product candidates;
the cost of clinical trials of Serina’s product candidates may be greater than it anticipates, or it may have insufficient funds for a clinical trial or to pay the substantial user fees required by the FDA or other regulatory authorities upon the filing of a marketing application;
the supply or quality of Serina’s product candidates or other materials necessary to conduct clinical trials of its product candidates may be insufficient or inadequate;
regulatory authorities may take longer than Serina anticipates to make a decision on its product candidates; or
changes in or the enactment of the approval policies, statutes, or regulations of the applicable regulatory authorities may significantly change in a manner rendering Serina’s nonclinical or clinical data insufficient for approval.

 

Furthermore, Serina expects to rely on CROs and clinical trial sites to ensure the proper and timely conduct of its clinical trials and, while it expects to enter into agreements governing their committed activities, it has limited influence over their actual performance.

 

74

 

 

A clinical trial may be suspended or terminated by Serina, its partners, the IRBs of the institutions in which such trials are being conducted, the DSMB for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or Serina’s clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If Serina experiences delays in the completion of, or termination of, any clinical trial of any of its potential future product candidates, the commercial prospects of such product candidate will be harmed, and its ability to generate product revenue from such product candidates will be delayed. In addition, any delays in completing its clinical trials will increase its costs, slow its product development and approval process, and jeopardize its ability to commence product sales and generate revenue, and it may not have the financial resources to continue development of the product candidate that is affected or any of its other product candidates. It may also lose, or be unable to enter into, collaborative arrangements for the affected product candidate and for other product candidates that it is developing. Any of these occurrences may materially and adversely affect Serina’s business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of its potential future product candidates.

 

Preliminary results from Serina’s nonclinical studies and clinical trials that it announces or publishes from time to time may change as more patient data becomes available and as the data undergoes audit and verification procedures.

 

From time to time, Serina may publish interim, topline, or preliminary results from its nonclinical studies and clinical trials. Preliminary and interim results from its clinical trials are not necessarily predictive of final results and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, interim, and topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data it previously published. As a result, preliminary, interim, and topline data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the preliminary, interim, or topline data could significantly harm Serina’s business prospects.

 

Further, others, including regulatory agencies, may not accept or agree with Serina’s assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or therapeutic product, if any, and Serina in general. In addition, the information it chooses to publicly disclose regarding a particular nonclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what it determines is the material or otherwise appropriate information to include in its disclosure, and any information it determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular therapeutic product, if any, product candidate or its business. If the preliminary, interim, and topline data that it reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, its ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm its business, operating results, prospects, or financial condition.

 

75

 

 

The FDA or comparable foreign regulatory authorities may disagree with Serina’s regulatory plans, and it may fail to obtain regulatory approval of its product candidates.

 

The FDA standard for approval of a drug or biologic generally requires two adequate, well-controlled clinical trials, each convincingly demonstrating the product candidate’s safety and effectiveness, or one large and robust, well-controlled trial providing substantial evidence that the product candidate is safe and effective for its proposed indication. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. Product candidates studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA usually requires a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals.

 

Serina’s clinical trial results may not support either accelerated or regular approval. The results of nonclinical studies and clinical trials may not be predictive of the results of later-stage clinical trials, and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and initial clinical trials. In addition, Serina’s product candidates could fail to receive regulatory approval for many reasons, including the following:

 

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Serina’s clinical trials;
the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which Serina seeks approval;
Serina may be unable to demonstrate that its product candidates’ risk-benefit ratios for their proposed indications are acceptable;
the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
Serina may be unable to demonstrate that the clinical and other benefits of its product candidates outweigh their safety risks;
the FDA or comparable foreign regulatory authorities may disagree with Serina’s interpretation of data from nonclinical studies or clinical trials;
the data collected from clinical trials of Serina’s product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a NDA or BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, Serina’s own manufacturing facilities, or a third-party manufacturer’s facilities with which it contracts for clinical and commercial supplies; and
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Serina’s clinical data insufficient for approval.

 

Failure to obtain regulatory approval to market any of Serina’s product candidates would significantly harm its business, results of operations, and prospects.

 

76

 

 

Failure of Serina’s technology would significantly harm its business, results of operations, and prospects.

 

Serina may not be successful in its efforts to use and expand its discovery engine to build a pipeline of product candidates.

 

A key element of Serina’s strategy is to use and expand its POZ Platform drug delivery technology to build a pipeline of product candidates and progress these product candidates through preclinical and clinical development for the treatment of various diseases. Although its research efforts to date suggest that the POZ Platform technology can deliver payloads including small molecules, proteins, and nucleic acids, this hypothesis may prove incorrect, or Serina may not be able to identify a product candidate that is safe or effective as a treatment for various diseases. Further, the scientific evidence to support the feasibility of developing viable product candidates based on its platform has not been established.

 

Even if Serina is successful in building its pipeline of product candidates, the potential product candidates that it identifies may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. Investment in biopharmaceutical product development involves significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. Serina cannot provide any assurance that it will be able to successfully advance any of these additional product candidates through the development process. Its research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development or commercialization for many reasons, including the following:

 

Serina’s platform may not be successful in identifying additional product candidates;
Serina may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;
Serina’s product candidates may not succeed in nonclinical or clinical testing;
a product candidate may upon further study demonstrate harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
competitors may develop alternatives that render Serina’s product candidates obsolete or less attractive;
product candidates Serina develops may nevertheless be covered by third parties’ patents or other exclusive rights;
the market for a product candidate may change during Serina’s program so that the continued development of that product candidate is no longer reasonable;
a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors, if applicable.

 

If any of these events occur, Serina may be forced to abandon its development efforts for a program or programs, or it may not be able to identify, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on its business and could potentially cause it to cease operations. Even if it receives FDA approval to market additional product candidates, it cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives.

 

77

 

 

Serina may seek designations under FDA programs designed to facilitate and potentially expedite product candidate development, such as fast track or breakthrough therapy designation. Its product candidates may not receive any such designations or if they do receive such designations they may not lead to faster development or regulatory review, or approval and it does not increase the likelihood that its product candidates will receive marketing approval.

 

Serina may seek designations under the FDA’s expedited programs for serious conditions, such as fast track or breakthrough therapy designation, which are intended to facilitate and expedite the development or regulatory review or approval process for product candidates.

 

The granting of fast track or breakthrough therapy designation to an investigational product is entirely within the FDA’s discretion. Accordingly, even if Serina believes one of its product candidates meets the criteria for a designation, the FDA may disagree and instead determine not to grant such designation. In any event, the receipt of a fast track or breakthrough therapy designation for a product candidate may not result in a faster development process, review, or approval compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the product candidate no longer meets the designation conditions, in which case any granted designations may be revoked, or the agency may decide that the time period for review or approval of the product candidate will not be shortened.

 

If Serina is unable to obtain approval via the accelerated approval pathway, it may be required to conduct additional nonclinical studies or clinical trials. Even if it receives accelerated approval from the FDA, the FDA may seek to withdraw accelerated approval.

 

Serina may seek an accelerated approval development pathway for its product candidates.

 

If Serina chooses to pursue accelerated approval, it intends to seek feedback from the FDA or will otherwise evaluate its ability to seek and receive such accelerated approval. After Serina’s evaluation of the feedback from the FDA or other factors, it may decide not to pursue or submit a NDA for accelerated approval or any other form of expedited development, review, or approval. Furthermore, if it submits an application for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could require Serina to conduct further studies or trials prior to considering its application or granting approval of any type and may require it to have a confirmatory trial to verify the clinical benefit of the product underway and partially or fully enrolled before granting approval. Serina might not be able to fulfill the FDA’s requirements in a timely manner, which would cause delays, or approval might not be granted because its submission is deemed incomplete by the FDA.

 

Even if Serina receives accelerated approval from the FDA, it will be subject to rigorous post marketing requirements, including the completion of confirmatory post market clinical trials, submission to the FDA of periodic progress reports on confirmatory trials, and submission to the FDA of all promotional materials prior to their dissemination. The FDA could seek to withdraw accelerated approval for multiple reasons, including if Serina fails to conduct any required post market study with due diligence; a post market study does not confirm the predicted clinical benefit; other evidence shows that the product is not safe or effective under the conditions of use; or Serina disseminates promotional materials that are found by the FDA to be false and misleading. Under the Consolidated Appropriations Act for 2023, the FDA may use expedited procedures to withdraw any product for which Serina receives accelerated approval if its confirmatory trials fail to verify the purported clinical benefits.

 

78

 

 

A failure to obtain accelerated approval or any other form of expedited development, review, or approval for a product candidate that Serina may choose to develop would delay its commercialization of such product candidate, could increase the cost of development of such product candidate and could harm its competitive position in the marketplace.

 

If Serina applies for orphan drug designation from the FDA, there is no guarantee that it will be able to obtain or maintain this designation, receive this designation for any of its other product candidates, or receive or maintain any corresponding benefits, including periods of exclusivity.

 

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a NDA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

 

If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a NDA, to market the same drug for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of Serina’s drug candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if Serina is unable to manufacture sufficient supply of its product.

 

Serina may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

 

Because Serina has limited financial and managerial resources, it focuses on research programs and product candidates that it identifies for specific indications. As a result, it may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. its resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Its spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If Serina does not accurately evaluate the commercial potential or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for it to retain sole development and commercialization rights to such product candidate.

 

79

 

 

If Serina encounters difficulties enrolling patients in its clinical trials, its clinical development activities could be delayed or otherwise adversely affected.

 

Serina may experience difficulties in patient enrollment in its clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on Serina’s ability to enroll a sufficient number of subjects who remain in the trial until its conclusion. Serina may not be able to initiate or continue conducting clinical trials for its product candidates if it is unable to locate and enroll a sufficient number of eligible subjects to participate in these trials. The enrollment of patients depends on many factors, including:

 

the number of clinical trials for other product candidates in the same therapeutic area that are currently in clinical development, and Serina’s ability to compete with such trials for subjects and clinical trial sites;
the severity of the disease under investigation and the existence of current treatments;
the perceived risks and benefits of the product candidate, including the potential advantages or disadvantages of the product candidate being studied in relation to other available therapies;
the subject eligibility criteria defined in the protocol, as well as Serina’s ability to compensate subjects for their time and effort;
the size and nature of the patient population;
the proximity and availability of clinical trial sites for prospective subjects;
the design of the trial, including factors such as frequency of required assessments, length of the study and ongoing monitoring requirements;
subjects’ and investigators’ ability to comply with the specific instructions related to the trial protocol, proper documentation, and use of the product candidate;
Serina’s ability to recruit clinical trial investigators with the appropriate competencies and experience;
patient referral practices of physicians and the effectiveness of publicity created by clinical trials sites regarding the trial;
the ability to adequately monitor subjects during and after treatment and compensate them for their time and effort;
the ability of Serina’s clinical study sites, CROs, and other applicable third parties to facilitate timely enrollment;
the ability of clinical trial sites to enroll subjects that meet all inclusion criteria and any patient exclusion due to erroneous enrollment;
Serina’s ability to obtain and maintain subject informed consents; and
the risk that subjects enrolled in clinical trials will drop out of the trials before completion of the study or not return for post study follow up, especially subjects in control groups.

 

In addition, Serina’s clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as its product candidates, and this competition will reduce the number and types of patients available to it, because some patients who might have opted to enroll in Serina’s trials may instead opt to enroll in a trial being conducted by one of its competitors. Because the number of qualified clinical investigators is limited, Serina may conduct some of its clinical trials at the same clinical trial sites that some of its competitors use, which will reduce the number of patients who are available for its clinical trials at such clinical trial sites. Moreover, because its product candidates represent a departure from more commonly used methods for disease treatment, potential patients and their doctors may be inclined to use conventional therapies, rather than enroll patients in any future clinical trial.

 

80

 

 

Serina’s inability to enroll a sufficient number of subjects for its clinical trials would result in significant delays and could require it to abandon one or more clinical trials altogether. Moreover, a significant number of withdrawn subjects would compromise the quality of its data. Enrollment delays in its clinical trials may result in increased development costs for its product candidates, or the inability to complete development of its product candidates, which could cause the value of its company to decline, limit its ability to obtain additional financing, and materially impair its ability to generate revenues.

 

Any product candidate Serina advances into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent its regulatory approval or commercialization or limit its commercial potential.

 

As with most new drugs, use of Serina’s product candidates could be associated with side effects or adverse events, which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. Undesirable side effects caused by any potential future product candidate could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. Serina has not yet completed all clinical trial phases for any of its current product candidates, and it is possible that there will be side effects associated with their use. Results of its clinical trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, its trials could be suspended or terminated, and the FDA or other regulatory authorities could order it to cease further development of or deny approval of a product candidate for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect Serina’s business and financial condition and impair its ability to generate revenues.

 

Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of a product candidate may only be uncovered when a significantly larger number of patients are exposed to the product candidate or when patients are exposed for a longer period of time.

 

If one or more of Serina’s product candidates receives marketing approval, and Serina or others later identify undesirable side effects caused by such products, including during any long term follow up observation period recommended or required for patients who receive treatment using Serina’s products, a number of potentially significant negative consequences could result, including:

 

regulatory authorities may withdraw or limit their approvals of such products;
regulatory authorities may require the addition of labeling statements, specific warnings or contraindications;
Serina may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for health care providers, and/or other elements to assure safe use;
Serina may be required to change the way such products are distributed or administered, or change the labeling of the products;

 

81

 

 

the FDA or a comparable foreign regulatory authority may require Serina to conduct additional clinical trials or costly post marketing testing and surveillance to monitor the safety and efficacy of the products;
Serina may decide to recall such products from the marketplace after they are approved;
Serina could be sued and held liable for harm caused to individuals exposed to or taking its products; and
Serina’s reputation may suffer.

 

In addition, adverse side effects caused by any therapeutics that may be similar in nature to Serina’s product candidates could delay or prevent regulatory approval of its product candidates, limit the commercial profile of an approved label for its product candidates, or result in significant negative consequences for its product candidates following marketing approval.

 

Any of these events could prevent Serina from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing its product candidates, if approved, and significantly impact its ability to successfully commercialize its product candidates and generate revenues.

 

Serina may form or seek strategic partnerships or enter into additional licensing arrangements in the future, and it may not realize the benefits of such alliances or licensing arrangements.

 

From time to time, Serina may form or seek strategic partnerships or collaborations or enter into additional licensing arrangements with third parties that it believes will complement or augment its development and commercialization efforts with respect to its product candidates and any future product candidates that it may develop. Any such relationships may require it to incur non-recurring and other charges, increase its near and long term expenditures, issue securities that dilute its existing stockholders or disrupt its management and business. These relationships also may result in a delay in the development of its product candidates if it becomes dependent upon the other party and such other party does not prioritize the development of Serina’s product candidates relative to its other development activities. Additionally, any collaborations or licensing arrangements would be subject to the same product candidate development and compliance risks and obligations as Serina would be if it were to develop the product candidate on its own. Should any third party with which it enters into any of these arrangements not comply with the applicable regulatory requirements, it or they may be subject to regulatory enforcement action and it or they may be delayed or prevented from obtaining marketing approval for the applicable product candidate.

 

In addition, Serina faces significant competition in seeking appropriate strategic partners and the negotiation process is time consuming and complex. Moreover, Serina may not be successful in its efforts to establish a strategic partnership or other alternative arrangement for its product candidates because they may be deemed to beat too early of a stage of development for collaborative effort, and third parties may not view its product candidates as having the requisite potential to demonstrate safety and efficacy. If Serina licenses products, it may not be able to realize the benefit of such transactions if it is unable to successfully integrate them with its existing operations and company culture. Any licensed products may also subject Serina to the risk of regulatory enforcement should the product or business not be compliant with applicable regulatory requirements. Serina cannot be certain that, following a strategic transaction or licensing arrangement, it will achieve the revenue or specific net income that justifies such a transaction.

 

82

 

 

Serina relies on contract manufacturing organizations to manufacture its nonclinical and clinical pharmaceutical supplies and expects to continue to rely on CMOs to produce commercial supplies of any approved product candidate, and its dependence on CMOs could adversely impact its business.

 

Serina relies on contract manufacturing organizations (CMOs) for the manufacture of nonclinical and clinical supplies for its product candidates and plans to continue to do so for commercial supplies should it receive marketing approval for any of its product candidates. This reliance also results in its reduced control over the manufacture of its product candidates and the protection of its trade secrets and know-how from misappropriation or inadvertent disclosure, which may adversely affect its future business prospects. Nevertheless, as the developer of the product candidates and sponsor of clinical trials involving such product candidates, it continues to have regulatory obligations to maintain oversight of the CMOs to ensure compliance with, among other things, contractual obligations, specifications, and cGMP.

 

In complying with the manufacturing regulations of the FDA and other comparable foreign regulatory authorities, Serina and its third-party suppliers must spend significant time, money, and effort in the areas of design and development, testing, production, record keeping and quality control to assure that the products meet applicable specifications and other regulatory requirements. Although its agreements with its CMOs require them to perform according to certain cGMP such as those relating to quality control, quality assurance and qualified personnel, Serina cannot control the conduct of its CMOs to implement and maintain these standards. If its CMOs do not successfully carry out their contractual duties, meet expected deadlines or manufacture its product candidates in accordance with regulatory requirements, if there are disagreements between Serina and such parties, or if such parties are unable to support the commercialization of any of its product candidates for which it obtains marketing approval, it may not be able to produce, or may be delayed in producing sufficient product to meet its supply requirements. Any delays in obtaining adequate supplies on adequate terms with respect to Serina’s product candidates and components, due to manufacturing issues, global trade policies, or for other reasons, may delay the development, approval, or commercialization of its product candidates.

 

Serina may not succeed in its efforts to establish manufacturing relationships on commercially reasonable terms. Its product candidates may compete with other products and product candidates for access to manufacturing facilities, of which there are a limited number that operate under cGMP conditions and that are both capable of manufacturing its product candidates and willing to do so. Even if it does establish such collaborations or arrangements, its CMOs may breach, terminate, or not renew these agreements. These facilities may also be affected by the ongoing COVID 19 pandemic, natural disasters such as floods, fires, explosions or such facilities could face manufacturing issues, such as contamination or adverse regulatory findings following a regulatory inspection. Further, Serina’s CMOs may be temporarily unable to manufacture its product candidates due to government restrictions, requirements, or limitations. If its CMOs cease to manufacture its product candidates for any reason, Serina would experience delays in obtaining sufficient quantities of its product for it to meet commercial demand if it receives marketing approval or in advancing its development programs while it identifies and qualifies replacement suppliers. Serina could also incur added costs and delays in identifying and qualifying any such replacements and transferring any necessary technology and processes. The terms of a new arrangement may also be less favorable than any prior arrangements if it is able to negotiate a new arrangement at all. The addition of a new or alternative CMO may also require FDA approval and may have a material adverse effect on its business.

 

83

 

 

Serina or its CMOs may also encounter shortages in the raw materials or substances necessary to produce its product candidates in the quantities and at the quality needed for its nonclinical studies and clinical trials or, if any of its product candidates are approved for commercialization, to produce its products on a commercial scale, meet an increase in demand, or compete effectively. Such shortages may occur for a variety of reasons, including capacity constraints, delays or disruptions in the market, and shortages caused by the purchase of such materials by its competitors or others. Serina’s or its third-party manufacturers’ failure to obtain the raw materials or substances necessary to manufacture sufficient quantities of its product candidates may have a material adverse effect on its business.

 

Moreover, any problems or delays Serina experiences in preparing for commercial scale manufacturing of a product candidate or component, including manufacturing validation, may result in a delay in a future marketing approval, if any, or commercial launch of any of its product candidates, should they receive regulatory approval, or may impair its ability to manufacture commercial quantities or manufacture such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of commercialization of its product candidates, if approved, and could adversely affect its business. Furthermore, if the future manufacturers of the commercial supplies of its products, if approved, fail to deliver the required commercial quantities of its product candidates on a timely basis and at commercially reasonable prices, it would likely be unable to meet demand for its products and it could lose potential revenues. The manufacture of drugs requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of drugs often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, and compliance with strictly enforced federal, state, and foreign regulations. If Serina’s manufacturers were to encounter any of these difficulties and were unable to perform as agreed, its ability to provide its product candidates for use in nonclinical studies or its current and planned clinical trials, or, if any of its product candidates are approved, its ability to produce its product for commercial use, could be jeopardized.

 

In addition, all manufacturers of Serina’s product candidates used in clinical trials and of its products for commercial supply, should any of Serina’s product candidates receive regulatory approval, must comply with cGMP regulations promulgated by the FDA and equivalent foreign regulatory authorities that are applicable to both finished products and their active components used both for clinical and commercial supply. Regulatory authorities enforce these requirements through facility inspections. CMO facilities must be satisfactory to the FDA and equivalent foreign regulatory authorities as determined by inspections that will be conducted after Serina submits its marketing applications to the appropriate agencies and prior to product approval and commercialization. Its CMOs will also be subject to continuing, periodic regulatory authority inspections should its product candidates receive marketing approval. Further, Serina, in cooperation with its CMOs, must supply all necessary chemistry, manufacturing, and control documentation to the FDA and equivalent foreign regulatory authorities in support of a marketing application on a timely basis.

 

The cGMP include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of Serina’s product candidates may be unable to comply with its specifications, cGMP or with other applicable regulatory requirements. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product testing. If its CMOs cannot successfully manufacture material that conforms to its specifications and the applicable regulatory requirements, they may not be able to secure or maintain regulatory acceptance of their manufacturing facilities for the purpose of producing Serina’s product candidates.

 

84

 

 

Deviations from manufacturing requirements may also require reporting and remedial measures that may be costly and/or time consuming for Serina or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales, if any of its product candidates receives regulatory approval, or the temporary or permanent closure of a facility. Any such remedial measure could materially harm its business. Any delay in obtaining products or product candidates that comply with the applicable regulatory requirements may result in delays to nonclinical studies and clinical trials, or potential product approvals or commercialization. Any such delay may also require that Serina conducts additional studies.

 

While Serina is ultimately responsible for the manufacture and regulatory compliance of its products and product candidates, it has little control over its manufacturers’ compliance with these regulations and standards other than through its contractual arrangements. If the FDA or a comparable foreign regulatory authority does not find these facilities satisfactory for the manufacture of its products, if approved, or product candidates or if such authorities find such facilities to be noncompliant in the future, Serina may need to find alternative manufacturing facilities, which would significantly impact its ability to develop, obtain and maintain regulatory approval for or market its product candidates, if approved. Any new manufacturers would need to either obtain or develop the necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take substantial time and investment. Serina must also receive FDA or other relevant comparable regulatory authority approval for the use of any new manufacturers for commercial supply.

 

Serina’s failure, or the failure of its third party manufacturers, to comply with applicable regulatory requirements may result in regulatory enforcement actions against its manufacturers or itself, including fines and civil and criminal penalties, including suspension of or restrictions on production, injunctions, delay, withdrawal or denial of product approval or supplements to approved products, clinical holds or termination of clinical studies, warning or untitled letters, regulatory authority communications warning the public about safety issues with a product, refusal to permit the import or export of a product, product seizure, detention, or recall, operating restrictions, civil penalties, criminal prosecution, corporate integrity agreements, or consent decrees and equivalent foreign sanctions. Depending on the severity of any potential regulatory action, supplies of its product candidates or products, if approved, could be interrupted or limited, which could have a material adverse effect on its business.

 

Serina relies on third parties to conduct some of its nonclinical studies and all of its clinical trials. If these third parties do not meet its deadlines or otherwise conduct the trials as required, its development programs could be delayed or unsuccessful and it may not be able to obtain regulatory approval for or commercialize its product candidates when expected or at all.

 

Serina does not have the ability to conduct all aspects of its clinical trials itself and does not currently plan to independently conduct clinical trials. It uses third parties, such as CROs, to conduct, supervise, and monitor the clinical trials and will rely upon such CROs, as well as medical institutions, investigators, and consultants, to conduct any future clinical trials that it may conduct in accordance with its protocols and applicable laws and regulations. In addition, it occasionally uses third parties to conduct its nonclinical studies. Serina’s CROs, investigators and other service providers play a significant role in the conduct of clinical trials and the subsequent collection and analysis of data from such trials.

 

85

 

 

Serina’s service providers are not its employees and, except for remedies available to it under its agreements with such third parties, as a result it will have less control over the timing, quality and other aspects of such nonclinical studies and clinical trials than it would have if it were to conduct them on its own. If these third parties do not successfully carry out their contractual duties to Serina, meet Serina’s expected timelines or conduct its nonclinical studies or clinical trials in accordance with regulatory requirements or its stated protocols, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to Serina’s protocols or applicable regulatory requirements or for other reasons, Serina’s trials may need to be repeated, extended, delayed, or terminated. Further, Serina may not be able to obtain, or may be delayed in obtaining, marketing approvals for its product candidates, it may fail or be delayed in its efforts to successfully commercialize its product candidates, if approved. Such failures may also subject Serina or its third-party service providers to regulatory enforcement actions. As a result, Serina’s results of operations and the commercial prospects for its product candidates could be harmed, its costs could increase and its ability to generate revenues could be delayed. To the extent it is unable to successfully identify and manage the performance of service providers in the future, its business may be materially and adversely affected. Serina’s third-party service providers may also have relationships with other entities, some of which may be its competitors, for whom they may also be conducting trials or other therapeutic development activities that could harm its competitive position.

 

Agreements with third parties conducting or otherwise assisting with Serina’s nonclinical studies or clinical trials might terminate for a variety of reasons, including a failure to perform by such parties. If any of its relationships with these third parties terminate, it may not be able to enter into arrangements with suitable alternative providers or do so on commercially reasonable terms. Switching or adding third parties involves additional cost and requires management time and focus. There is also a natural transition period when a new third party commences work. As a result, if Serina needs to enter into alternative arrangements, it could delay its product development activities and adversely affect its business. Although it carefully manages its relationships with its third parties, there can be no assurance that it will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on its business, financial condition and prospects, and results of operations.

 

Serina’s reliance on third parties for development activities will reduce its control over these activities. Nevertheless, Serina is responsible for ensuring that each of its studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and its reliance on third parties does not relieve it of its oversight and regulatory responsibilities. For example, it will remain responsible for ensuring that each of its trials is conducted in accordance with the general investigational plan and protocols for that trial. Serina must also ensure that its nonclinical studies are conducted in accordance with GLP requirements, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require it to comply with established GCP standards for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. In addition, Serina’s clinical trials must be conducted with product candidates that were produced under cGMP conditions. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical and nonclinical investigators, manufacturers, and trial sites. If Serina or any of its third-party service providers fails to comply with applicable regulatory requirements, it or they may be subject to enforcement or other legal actions, the data generated in its trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require it to perform additional studies, which may significantly delay its clinical development plans and the regulatory approval process. Serina cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that Serina, its third-party service providers, or clinical trial sites is in substantial compliance with the applicable regulatory requirements.

 

86

 

 

In addition, Serina will be required to report certain financial interests of its third-party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by investigators who may have conflicts of interest. Serina is also required to register certain clinical trials and post the results of certain completed clinical trials on a government sponsored database, clinicaltrials.gov, within specified timeframes. Failure to do so can result in enforcement actions and adverse publicity.

 

Serina relies on other third parties to store and distribute its product candidates for nonclinical studies and clinical trials that it conducts.

 

Serina also relies on other third parties to store and distribute its product candidates for the nonclinical studies and clinical trials that it is conducting or plan to conduct. Any performance failure, or failure to comply with applicable regulations, on the part of its distributors could delay development, the regulatory approval process, or potential commercialization of its product candidates, producing additional losses and depriving it of potential product revenue.

 

Serina may incur substantial product liability or indemnification claims relating to the clinical testing of its product candidates.

 

Serina faces an inherent risk of product liability exposure related to the testing of its product candidates in human clinical trials, and claims could be brought against it if the use or misuse of one of its product candidates causes, or merely appears to have caused, personal injury or death. Serina will face an even greater risk of product liability if it receives marketing approval for and commercialize any of its product candidates. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Claims could also be asserted under state consumer protection acts. Product liability claims might be brought against it by consumers, health care providers or others using, administering, or selling its products.

 

Any claims against Serina, regardless of their merit, could severely harm its financial condition, strain its management and other resources, or destroy the prospects for commercialization of the product which is the subject of any such claim. For instance, product liability claims may result in:

 

loss of revenue from decreased demand for Serina’s products and/or product candidates;
impairment of Serina’s business reputation or financial stability;
incurred costs and time of related litigation;
substantial monetary awards to patients or other claimants, and loss of revenue;
diversion of management attention;
withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;
the inability to commercialize Serina’s product candidates;
significant negative media attention;
decrease in the value of Serina;
initiation of investigations, and enforcement actions by regulators; and/or
product recalls, withdrawals, revocation of approvals, or labeling, marketing or promotional restrictions.

 

87

 

 

If Serina cannot successfully defend itself against these claims, it will incur substantial liabilities or be required to limit development or commercialization of its products or product candidates. Although it maintains product liability and clinical trial insurance coverage, it may be inadequate to cover all liabilities that it may incur. Serina anticipates that it will need to increase its insurance coverage as it continues clinical development of its product candidates and if it successfully commercializes any medicine. Insurance coverage is increasingly expensive. It may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.

 

Risks Related to Serina’s Business, Industry and Future Commercialization

 

If any product candidate that Serina successfully develops does not achieve broad market acceptance among physicians, patients, health care payors and the medical community, the revenues that it generates from their sales will be limited.

 

Even if Serina’s product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, health care payors and the medical community. Market acceptance of its products by the medical community, patients, and third-party payors will depend on a number of factors, some of which are beyond its control, including:

 

the efficacy of Serina’s products and the prevalence and severity of any adverse events;
any potential advantages or disadvantages when compared to alternative treatments;
interactions of Serina’s products with other medicines patients are taking and any restrictions on the use of its products together with other medications;
the clinical indications for which the products are approved and the approved claims that Serina may make for the products;
limitations or warnings contained in the product’s FDA approved labeling, including potential limitations or warnings for such products that may be more restrictive than other competitive products;
changes in the standard of care for the targeted indications for such product candidates, which could reduce the marketing impact of any claims that Serina could make following approval, if obtained;
the safety, efficacy, and other potential advantages over alternative treatments, such as relative convenience and ease of administration of such products, and the availability of alternative treatments already used or that may later be approved;
cost of treatment versus economic and clinical benefit in relation to alternative treatments or therapies;
the availability of formulary coverage and adequate coverage or reimbursement by third parties, such as insurance companies and other health care payors, and by U.S. and international government health care programs, including Medicaid and Medicare;
the price concessions required by third party payors and government health care programs to obtain coverage and payment;
the extent and strength of Serina’s marketing and distribution of such products;
distribution and use restrictions imposed by the FDA and equivalent foreign regulatory authorities with respect to such products or to which Serina agrees, for instance, as part of a REMS or voluntary risk management plan;
the timing of market introduction of such products, as well as competitive products;
Serina’s ability to offer such products for sale at competitive prices;

 

88

 

 

Serina’s ability to offer programs to facilitate market acceptance and insurance coverage from public and private insurance companies, provide patient assistance, and transition patient coverage;
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
the extent and strength of Serina’s third-party manufacturer and supplier support;
the approval of other new products, including biosimilar products that may be priced at a substantially lower price than Serina expects to offer its product candidates for, if approved;
adverse publicity about the product or favorable publicity about competitive products;
the success of any efforts to educate the medical community and third-party payors regarding Serina’s products, which efforts may require significant resources and may not be successful; and
potential product liability claims.

 

If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, health care payors and patients, Serina may not generate sufficient revenue from these products and may not become or remain profitable.

 

If Serina is unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates it may develop, it may not be successful in commercializing those product candidates if and when they are approved.

 

Serina does not have a sales or marketing infrastructure and it has limited experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved medicine for which it retains sales and marketing responsibilities, it must either develop a sales and marketing organization or outsource these functions to third parties. In the future, Serina may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with its collaborators for, some of its current and future product candidates if and when they are approved.

 

There are risks involved with both establishing and managing Serina’s own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which Serina recruits a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, Serina would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and Serina’s investment would be lost if it cannot retain or reposition its commercialization personnel.

 

Factors that may inhibit Serina’s efforts to commercialize product candidates on its own include:

 

Serina’s inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;
the inability of sales personnel to obtain access to physicians to discuss Serina’s products;
the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors, and to secure adequate coverage;
reduced realization on government sales from mandatory discounts, rebates and fees, and from price concessions to private health plans and pharmacy benefit managers necessitated by competition for access to managed formularies;
the clinical indications for which the products are approved and the claims that Serina may make for the products, as well as any limitations on use or warnings;

 

89

 

 

the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions, and any liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements;
restricted or closed distribution channels that make it difficult to distribute Serina’s products to different segments of the patient population;
the lack of complementary medicines to be offered by sales personnel, which may put Serina at a competitive disadvantage relative to companies with more extensive product lines; and
unforeseen costs and expenses associated with creating an independent commercialization organization.

 

If Serina enters into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, its product revenues, or the profitability of these product revenues to it may be lower than if it were to market and sell any product it may develop itself. In addition, Serina may not be successful in entering into arrangements with third parties to commercialize its products or may be unable to do so on terms that are favorable to it. Serina may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market its products effectively. If Serina does not establish commercialization capabilities successfully, either on its own or in collaboration with third parties, it will not be successful in commercializing any products it may develop.

 

Serina faces significant competition in an environment of rapid technological change, and there is a possibility that its competitors may achieve regulatory approval before it or develop therapies that are safer or more advanced or effective than Serina’s, which may harm its financial condition and its ability to successfully market or commercialize any product candidates it may develop.

 

The development and commercialization of new drugs is highly competitive. Moreover, the CNS and drug delivery fields are characterized by rapidly changing technologies, significant competition, and a strong emphasis on intellectual property. Serina will likely face competition with respect to any product candidates that it may seek to develop or commercialize in the future from numerous pharmaceutical and biotechnology organizations, as well as from academic institutions, government agencies and other public and private research organizations for its current and future product candidates. Serina’s commercial success will be reduced or eliminated if its competitors develop products that are safer, more effective, or less costly than Serina’s.

 

A number of well-resourced pharmaceutical and biotechnology are developing products anticipated to be in competition with Serina’s product candidates and its drug delivery platform technology. These products and technologies, as well as marketing campaigns by competitors and clinical trial results with competitive products, could significantly diminish Serina’s ability to market and sell its future products.

 

Many of Serina’s current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than Serina does. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of Serina’s competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Serina in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, Serina’s programs. Serina’s commercial opportunity could be reduced or eliminated if its competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than the product candidates it may develop or that would render any of its product candidates obsolete or non-competitive. Serina’s competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than it may obtain approval for its product candidates, which could result in its competitors establishing a strong market position before Serina is able to enter the market.

 

90

 

 

Serina’s commercial opportunity may also be reduced or limited if it or its partners are unable to scale up the manufacture of its product candidates to meet clinical or commercial requirements. The compositions Serina seeks to develop may exhibit poor pharmaceutical properties, and formulation, purification and stable storage could be challenging.

 

In addition, Serina could face litigation with respect to the validity and/or scope of patents relating to its competitors’ products. The availability of competitive products could limit the demand and the price it is able to charge for its products. Further, intellectual property protection for Serina’s POZ platform technology and Serina’s product candidates is dynamic and rapidly evolving. The scope of intellectual property protection for its POZ platform may be limited, and its commercial opportunity may be reduced or limited if its competitors are able to acquire or develop the same or similar technologies.

 

Corporate and academic collaborators may take actions to delay, prevent, or undermine the success of Serina’s products.

 

Serina’s operating and financial strategy for the development, clinical testing, manufacture, and commercialization of product candidates is heavily dependent on Serina’s entering into collaborations with corporations, academic institutions, licensors, licensees, and other parties and it may not be successful in establishing such collaborations. Some of its existing collaborations are, and future collaborations may be, terminable at the sole discretion of the collaborator. Replacement collaborators might not be available on attractive terms, or at all. The activities of any collaborator will not be within Serina’s control and may not be within its power to influence. Any collaborators may not perform their obligations to Serina’s satisfaction, or at all, it may not derive any revenue or profits from such collaborations, and any collaborators may ultimately compete with it. If any collaboration is not pursued, Serina may require substantially greater capital to undertake development and marketing of its proposed products and may not be able to develop and market such products effectively, if at all. In addition, a lack of development and marketing collaborations may lead to significant delays in introducing proposed products into certain markets and/or reduced sales of proposed products in such markets.

 

Data provided by collaborators and others upon which Serina relies that has not been independently verified could turn out to be false, misleading, or incomplete.

 

Serina relies on third party vendors, scientists, and collaborators to provide it with significant data and other information related to its projects, clinical trials and its business. If such third parties provide inaccurate, misleading, or incomplete data, Serina’s business, prospects, and results of operations could be materially adversely affected.

 

91

 

 

Even if Serina is able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, reimbursement practices, or health care reform initiatives, which would harm its business.

 

The regulations that govern pricing, and reimbursement for new medicines vary widely from country to country, and current and future legislation may change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Outside the United States, some countries require approval of the sale price of a medicine before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, Serina might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay or might even prevent its commercial launch of the product candidate, possibly for lengthy time periods, and negatively impact the revenues it is able to generate from the sale of the product candidate in that country. Adverse pricing limitations may hinder its ability to recoup its investment in one or more product candidates it may develop, even if any such product candidates obtain marketing approval.

 

Serina’s ability to commercialize any product candidates successfully also will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government authorities or health care programs, private health plans, and other organizations. Even if Serina succeeds in bringing one or more products to the market, these products may not be considered medically necessary and/or cost effective, and the amount reimbursed for any products may be insufficient to allow it to sell its products on a competitive basis. At this time, Serina is unable to determine their cost effectiveness or the likely level or method of reimbursement for its product candidates. Government authorities and third-party payors, such as private health plans, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third party payors are challenging the prices charged for medical products and requiring that biopharmaceutical companies provide them with predetermined discounts from list prices. Novel medical products, if covered at all, may be subject to enhanced utilization management controls designed to ensure that the products are used only when medically necessary. Such utilization management controls may discourage the prescription or use of a medical product by increasing the administrative burden associated with its prescription or creating coverage uncertainties for prescribers and patients. Serina cannot be sure that reimbursement will be available for any product candidate that it commercializes and, if reimbursement is available, that the level of reimbursement will be adequate. Reimbursement may impact the demand for, or the price of, any product candidate for which it obtains marketing approval. If reimbursement is not available or is available only to limited levels, it may not be able to successfully commercialize any product candidate for which it obtains marketing approval.

 

Serina currently expects that any drugs it develops may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain therapeutic products that are not usually self-administered (such as most injectable drugs and biologics) may be eligible for coverage under the Medicare Part B program if:

 

they are incident to a physician’s services;
they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; and
they have been approved by the FDA and meet other requirements of the statute.

 

92

 

 

There may be significant delays in obtaining reimbursement for newly approved product candidates, and coverage may be more limited than the purposes for which the product candidate is approved by the FDA or other regulatory authorities. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third party payors to pay all or part of the costs associated with their prescription medications. Patients are unlikely to use Serina’s products unless coverage is provided, and payment is adequate to cover all or a significant portion of the cost of its products. Therefore, coverage and adequate payment is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Moreover, eligibility for reimbursement does not imply that any product candidate will be paid for in all cases or at a rate that covers Serina’s costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new product candidates, if applicable, may also not be sufficient to cover Serina’s costs and may not be made permanent. Reimbursement rates may vary according to the use of the product candidate and reimbursement in the clinical setting in which it is used may be based on reimbursement levels already set for lower cost therapies or medicines and may be incorporated into existing payments for other services. Net prices for product candidates may be reduced by mandatory discounts or rebates required by government health care programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Third party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. However, no uniform policy requirement for coverage and reimbursement for drug products exists among third party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require Serina to provide scientific and clinical support for the use of its products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Serina’s inability to promptly obtain coverage and profitable payment rates from both government funded and private payors for any approved product candidates it may develop could have a material adverse effect on its operating results, its ability to raise capital needed to commercialize medicines, and its overall financial condition.

 

This Merger may limit Serina’s ability to use some or all of its net operating loss carryforwards in the future.

 

The ultimate realization of Serina’s deferred income tax assets is dependent upon generating future taxable income. Serina has recorded a full valuation allowance against its deferred income tax assets. The valuation allowance may fluctuate as conditions change. Serina’s ability to utilize net operating loss carryforwards to offset its future taxable income and/or to recover previously paid taxes would be limited if it were to undergo an “ownership change” within the meaning of Section 382 of the Code. In general, an “ownership change” occurs whenever the percentage of the stock of a corporation owned by “5 percent stockholders” (within the meaning of Section 382 of the Code) increases by more than 50 percentage points over the lowest percentage of the stock of such corporation owned by such “5 percent stockholders” at any time over the testing period. An ownership change under Section 382 of the Code would establish an annual limitation to the amount of NOLs Serina could utilize to offset its taxable income in any single year. The application of these limitations might prevent full utilization of the deferred tax assets attributable to its net operating loss carryforwards.

 

Serina has not yet formally determined the amount of the cumulative change in its ownership resulting from this Merger or other transactions, or any resulting limitations on its ability to utilize its NOL carryforwards and other tax attributes. As a result, if Serina earns net taxable income, its ability to use its pre-Merger net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to it. If an ownership change occurs and Serina’s ability to use its net operating loss carryforwards is materially limited, it could harm Serina’s future operating results by effectively increasing its future tax obligations.

 

93

 

 

Serina’s insurance policies are expensive and protect it only from some business risks, which will leave it exposed to significant uninsured liabilities.

 

Serina carries insurance for most categories of risk that its business may encounter; however, it may not have adequate levels of coverage. Serina currently maintains general liability, property, workers’ compensation, products liability and directors’ and officers’ insurance, along with an umbrella policy. It may not be able to maintain existing insurance at current or adequate levels of coverage. Any significant uninsured liability may require it to pay substantial amounts, which would adversely affect its cash position and results of operations.

 

Risks Related to Serina’s Intellectual Property

 

Serina’s success is largely based upon its intellectual property and proprietary technologies, and it may be unable to protect and/or enforce its intellectual property.

 

Serina’s success will depend, in large part, on obtaining and maintaining patent protection and trade secret protection for its product candidates and their formulations and uses, as well as successfully enforcing its patents against third party infringers and/or defending these patents against third party challenges. If Serina (or its licensees should such licensees be granted the right to prosecute or enforce certain patents within Serina’s portfolio) fails to appropriately prosecute or is unable to obtain and maintain patent protection for its product candidates (or aspects thereof), its ability to develop, license and/or commercialize these product candidates may be adversely affected and it may not be able to prevent competitors from making, using, selling or importing competing products. This failure or inability to properly or adequately protect the intellectual property rights relating to these product candidates could have a material adverse effect on Serina’s financial condition and results of operations.

 

The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that Serina or its partners will be successful in protecting its product candidates by obtaining, enforcing and defending patents. These risks and uncertainties include the following:

 

patent applications may not result in any patent being issued;
patents that may be issued may not include claims that cover broad enough scope to prevent design around solutions by competitors;
patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide adequate barriers to entry or any competitive advantage;
because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before a potential product can be commercialized, any related patent may expire, or remain in existence for only a short period following commercialization, reducing, or eliminating any advantage of the patent;
Serina’s competitors, many of which have substantially greater resources than it or its partners do, and many of which have made significant investments in competing technologies, may seek, or may already have sought or obtained, patents that will limit, interfere with, or eliminate Serina’s ability to make, use, and sell its potential products;

 

94

 

 

there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns;
countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing foreign competitors a better opportunity to create, develop, and market competing products; and
Serina may be involved in lawsuits to protect or enforce its patents or the patents of its licensors, which could be expensive, time consuming and/or unsuccessful.

 

In addition to patents, Serina also relies on trade secrets and proprietary know-how. Although it has taken steps to protect its trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and assignment agreements with employees, consultants, and advisors, there exists the potential that third parties may still somehow obtain this information or arrive at the same or similar information independently, which would reduce or eliminate Serina’s competitive advantage. Moreover, Serina may become subject to claims that it directly or indirectly (through its consultants, advisors, or independent contractors that it may engage to assist it in developing its product candidates) has wrongfully or inadvertently disclosed, acquired or used trade secrets or other proprietary information of third parties.

 

Serina may be forced to litigate to enforce or defend its intellectual property rights, and/or the intellectual property rights of its licensors.

 

Serina may be forced to litigate to enforce or defend its intellectual property rights against infringement by competitors, and to protect its trade secrets against unauthorized use. In so doing, it may place its intellectual property at risk of being invalidated, rendered unenforceable, or limited or narrowed in scope such that it may no longer be used to adequately prevent the manufacture, sale or import of competitive product. Further, an adverse result in any litigation or other proceedings before government agencies such as the USPTO, may place pending applications at risk of non-issuance or limitations in scope. Further, derivation proceedings, entitlement proceedings, ex parte reexamination, inter partes review, post grant review, and opposition proceedings provoked by third parties or brought by the USPTO or any foreign patent authority may be used to challenge the inventorship, ownership, claim scope, or validity of Serina’s patents. Additionally, because of the substantial amount of discovery typically required in connection with intellectual property litigation, there is a risk that some of Serina s confidential and proprietary information or trade secrets could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the value of Serina. Such litigation or proceedings could substantially increase Serina’s operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. Serina may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of Serina’s competitors may be able to sustain the costs of such litigation or proceedings more effectively than it can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on Serina’s ability to compete in the marketplace.

 

95

 

 

If Serina enters into future arrangements involving government funding, and it makes inventions as a result of such funding, its intellectual property rights to such discoveries may be subject to the applicable provisions of the Bayh Dole Act of 1980. To the extent any of its current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh Dole Act may similarly apply. Any exercise by the government of certain of its rights could harm Serina’s competitive position, business, financial condition, results of operations and prospects.

 

If Serina or its partners are sued for infringing on the intellectual property rights of third parties, it could be costly and time consuming, and an unfavorable outcome in any such litigation could have a material adverse effect on its business.

 

Serina’s success also depends upon its ability and the ability of any of its future collaborators to develop, manufacture, market and sell its product candidates without infringing on the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which Serina is developing products, some of which may be directed at claims that overlap with the subject matter of its intellectual property. Because patent applications can take many years to issue, there may be currently pending applications, now unknown to Serina, which may later result in issued patents that its product candidates or proprietary technologies may be alleged to infringe upon. Similarly, there may be issued patents relevant to Serina product candidates of which it is not aware.

 

In addition, third parties may sue Serina alleging that it infringes on their patents. Even if Serina is successful in defending any claims of infringement, the defense of such claims may be costly and present a time consuming distraction. In the event of a successful claim of infringement against Serina, it may be required to:

 

pay substantial damages and/or ongoing royalty;
stop using some or all of its technologies and methods;
stop certain research and development efforts;
develop non infringing products or methods (i.e., develop or design around); and/or
obtain one or more licenses from third parties for an upfront lump sum, an ongoing royalty, or a combination thereof.

 

If required, Serina cannot assure you that it will be able to obtain such licenses on acceptable terms, or at all. If it is sued for infringement, it could encounter substantial delays in the development, manufacture, and commercialization of its product candidates. Any litigation, whether to enforce its patent rights or to defend against allegations that it allegedly infringes on third party rights, could be costly, time consuming, and may distract management from other important tasks.

 

As is commonplace in the biotechnology and pharmaceutical industry, Serina employs individuals who were previously employed at other biotechnology or pharmaceutical companies, including its competitors or potential competitors. To the extent Serina’s employees are involved in research endeavors that are similar to those which they were involved in at their former place of employment, Serina may be subject to claims that such employees and/or it has inadvertently or otherwise used or disclosed the alleged trade secrets or other proprietary information of such former employers. Litigation may be necessary to defend against such claims, which could result in substantial costs, be a distraction to management and ultimately have a material adverse effect on Serina, even if it is successful in defending such claims.

 

96

 

 

The biotechnology and pharmaceutical industries have experienced substantial litigation and other proceedings concerning intellectual property rights, and third parties may initiate legal proceedings alleging that Serina is infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which could be uncertain and may prevent, delay, or otherwise interfere with Serina’s product discovery and development efforts. Serina’s commercial success depends upon its ability and the ability of its collaborators and licensors to develop, manufacture, market, and sell its products. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights as well as administrative proceedings for challenging patents, including derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Serina may be subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation concerning intellectual property rights with respect to its POZ platform and any product candidates it may develop, including interference proceedings, post grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office (EPO). Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which Serina is developing its product candidates and infringement claims may be asserted against it or its partners based on existing patents or patents that may be granted in the future, regardless of their merit.

 

As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that Serina’s POZ platform and product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including Serina, which patents cover various types of therapies, products or their methods of use or manufacture. Moreover, as with many technology-based products, there may be third party patent applications that, if issued, may include the claims that could be or are construed to cover components of Serina’s POZ platform and product candidates. There may also be third party patents of which Serina is currently unaware with claims to its technologies, compositions, methods of manufacture or methods of use.

 

Serina’s ability to commercialize its product candidates in the United States and abroad may be adversely affected if it cannot successfully defend against infringement claims or obtain a license on commercially reasonable terms to relevant third party patents that cover its product candidates. Even if Serina has a strong defense and/or believes that third party intellectual property claims are without merit, there can be no assurance that a court would find in its favor on questions of infringement, validity, enforceability, and/or priority. A court of competent jurisdiction could hold that these third party patents are valid and enforceable and have been infringed upon, which could materially and adversely affect Serina’s ability to commercialize its product candidates or technologies covered by the asserted third party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, Serina would need to overcome a presumption of validity. As this burden is a high one requiring Serina to present clear and convincing evidence as to the invalidity of any such U.S. patent claims, there is no assurance that a court of competent jurisdiction would invalidate the asserted claims of any such U.S. patent. If Serina is found to be infringing on a third party’s intellectual property rights, and it is unsuccessful in demonstrating that any such patents are invalid or unenforceable, it could be required to pay damages and/or an ongoing royalty or obtain a license from such third party to continue developing, manufacturing, and marketing its product candidates and its technologies. However, Serina may not be able to obtain any required license on commercially reasonable terms or at all. Even if Serina were able to obtain such a license, it could be non-exclusive, thereby giving its competitors and other third parties access to the same technologies licensed to it, and it could require Serina to pay substantial licensing fees and/or make ongoing royalty payments. If Serina is unable to obtain a necessary license to a third party patent on commercially reasonable terms, it may be unable to commercialize its POZ platform or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm its business. While less likely given the high bar required for injunction, Serina also could be temporarily or permanently forced, including by court order, to cease developing, manufacturing, and commercializing the infringing technology or product candidates. In addition, Serina could be found liable for significant monetary damages, including treble damages and attorneys’ fees, if it is found to have willfully infringed on a patent or other intellectual property right. Claims that it has misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on its business, financial condition, results of operations, and prospects.

 

97

 

 

The defense of third party claims of alleged infringement, misappropriation, or violation of intellectual property rights often involves substantial litigation expense and could also be a substantial diversion of management and employee time and resources from Serina’s business. Some third parties may be able to sustain the costs of complex patent litigation more effectively than Serina can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Serina’s ability to raise the funds necessary to continue its operations or could otherwise have a material adverse effect on its business, financial condition, results of operations and prospects. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on the price of its common stock.

 

Obtaining and maintaining Serina’s patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and its patent protection could be reduced or eliminated for non-compliance with these requirements.

 

Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications are due to be paid to the USPTO and foreign patent agencies outside of the United States over the lifetime of Serina’s owned or licensed patents and applications. In the case of any in-licensed patent rights, Serina generally relies on its licensors to pay these fees due to U.S. and non U.S. patent agencies. For patent rights owned by Serina, it relies on its outside patent counsel and/or annuity services in the United States and foreign countries to monitor these deadlines and to pay these fees when so instructed by Serina.

 

The USPTO and foreign patent agencies require compliance with procedural, documentary, fee payment, and other similar provisions, such as the requirement to disclose known prior art, during the patent application process. In the case of any in-licensed patent rights, Serina generally depends on its licensors to take the necessary action to comply with these requirements with respect to its licensed intellectual property, and for its owned patent applications, it engages counsel and other professionals to help it comply with these requirements. While certain inadvertent lapses can be cured by payment of a late fee, by petition, or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in a partial or complete loss of patent rights in the relevant jurisdiction. In the unlikely event that a non-compliance event were to occur, Serina s competitors might be able to enter the market with similar or identical products or technology given the partial or complete loss of patent rights by Serina, which could have a material adverse effect on its business, financial condition, results of operations, and prospects.

 

98

 

 

If Serina does not obtain patent term extension for its drug candidates, Serina’s business may be materially harmed.

 

Depending upon the timing, duration, and specifics of FDA regulatory approval of Serina’s drug candidates, one or more patents issued from U.S. patent applications that Serina files or those of Serina’s future licensors may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during the FDA regulatory review process based on the first regulatory approval for a particular drug or biologic. A maximum of one patent may be extended per FDA-approved drug as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of Serina’s drug candidates.

 

However, Serina may not be granted an extension for which it applies in the United States or any other jurisdiction because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time or the scope of patent protection afforded could be less than Serina requests.

 

If Serina are unable to obtain patent term extension or restoration, or the foreign equivalent, or the term of any such extension is less than Serina request, Serina’s competitors or other third parties may obtain approval of competing drugs following Serina’s patent expiration, and Serina’s revenue could be reduced, possibly materially. Further, if this occurs, Serina’s competitors or other third parties may take advantage of Serina’s investment in development and trials by referencing Serina’s clinical and preclinical data and launch their drug earlier than might otherwise be the case. Any of the foregoing could materially harm Serina’s business, financial condition, results of operations and prospects.

 

Changes in patent law in the United States and in non U.S. jurisdictions could diminish the value of patents in general, thereby impairing Serina’s ability to protect its technologies and product candidates.

 

As is the case with other biotech and pharmaceutical companies, Serina’s success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and are therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of Serina’s issued patents. For example, in March 2013, under the America Invents Act the United States transitioned from a “first to invent” to a “first to file” patent system. Under a “first to file” system, assuming that other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on an invention regardless of whether another inventor had made the invention earlier. A third party that filed a patent application in the USPTO after March 2013, but before Serina could therefore be awarded a patent covering an invention of Serina’s even if Serina had made the invention before it was made by such third party. This requires Serina to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, Serina cannot be certain that it or any licensors were the first to either file any patent application related to its technologies or product candidates or invent any of the inventions claimed in its or its licensor’s patents or patent applications. The America Invents Act also includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted, allowing third party submission of prior art, and establishing a new post grant review system, including post grant review, inter partes review, and derivation proceedings. Because of the lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use USPTO proceedings to invalidate Serina’s patent claims even though the claim would not have been invalidated if first challenged by the third party in a district court action.

 

99

 

 

In addition, U.S. Supreme Court rulings over the past decade have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to Serina’s ability to obtain patents in the future, this combination of events has created uncertainty with respect to the validity and enforceability of issued patents. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken Serina’s ability to obtain new patents or to enforce and/or defend its existing patents and patents that it might obtain in the future.

 

Patent terms may be inadequate to protect Serina’s competitive position on its product candidates for an adequate amount of time.

 

Patents have a limited lifespan. The terms of individual patents depend upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest non provisional filing date in the applicable country. However, the actual protection afforded by a patent varies from country to country, and also depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent, and whether a portion of the patent term has been terminally disclaimed based on other patents. Various extensions including patent term extension (PTE) and patent term adjustment (PTA) may be available, but the lives of such extensions, and the protections they afford, are limited. Even if patents covering Serina’s product candidates are obtained, once the patent life has expired, Serina may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting Serina’s product candidates might expire before or shortly after Serina or its partners commercialize those candidates. As a result, Serina’s owned and/or licensed patent portfolio may not provide Serina with sufficient rights to exclude others from commercializing products similar or identical to Serina’s for an adequate time period.

 

If Serina is unable to protect the confidentiality of its trade secrets, its business and competitive position could be harmed.

 

In addition to seeking patents for its technologies and product candidates, Serina also relies on trade secret protection, as well as confidentiality agreements, non-disclosure agreements and assignment agreements with its employees, consultants and third parties, to protect its know-how and other confidential and proprietary information, especially where it does not believe patent protection is appropriate or obtainable.

 

100

 

 

It is Serina’s policy to require its employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties to execute confidentiality agreements upon the commencement of employment or consulting relationships with it. These agreements generally provide that all confidential information concerning Serina’s business or financial affairs developed by or made known to an individual or entity during the course of that party’s relationship with Serina is to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements also provide that all inventions conceived by the individual, and that are related to Serina’s current or planned business or research and development or made during normal working hours, on Serina’s premises or using Serina’s equipment or proprietary information, are Serina’s exclusive property. In the case of consultants and other third party service providers, the agreements provide Serina with certain rights to all inventions arising from the services provided to it by those individuals or entities. However, Serina cannot guarantee that it has entered into such agreements with each party that may have or have had access to its trade secrets or proprietary technologies and processes. Additionally, the assignment of intellectual property rights may not be self-executing, or assignment agreements may be breached, and Serina may be forced to bring claims against third parties, or defend claims that they may bring against it, to determine the ownership of what Serina regards as its intellectual property. Serina may not be able to obtain adequate remedies for any breaches of such agreements. Ultimately, enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time consuming, and the outcome is unpredictable.

 

In addition to contractual measures, Serina protects the confidential nature of its proprietary information through other appropriate precautions, such as physical and technological security measures. However, trade secrets and know-how can be difficult to protect despite these precautions. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for Serina’s proprietary information. Serina’s security measures may not prevent an employee or consultant from misappropriating its trade secrets and providing them to a competitor, and any recourse it might take against this type of misconduct may not provide an adequate remedy to protect its interests fully. In addition, Serina’s trade secrets may be independently developed by others in a manner that could prevent it from receiving legal recourse. If any of Serina’s confidential or proprietary information, such as its trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, its competitive position could be harmed.

 

If Serina chooses to go to court to stop a third party from using any of Serina’s trade secrets, it may incur substantial costs. In addition, courts inside and outside the United States are sometimes less willing or unwilling to protect trade secrets. Even if Serina is successful, these types of lawsuits may consume, in addition to substantial costs, significant amounts of its time and other resources. Any of the foregoing could have a material adverse effect on its business, financial condition, results of operations and prospects.

 

101

 

 

Third parties may assert that Serina’s employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets.

 

As is common in the biotechnology and pharmaceutical industries, Serina employs individuals that are currently or were previously employed at universities, research institutions or other biotechnology or pharmaceutical companies, including Serina’s competitors or potential competitors. Although Serina employs measures to ensure that its employees, consultants, and advisors do not use the proprietary information or know how of others in their work for it, Serina may be subject to claims that it or these individuals have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Serina may then be directly or indirectly involved in litigation proceedings to defend against these claims. If it fails in defending against any such claims, in addition to potentially paying monetary damages, it may lose valuable intellectual property rights and/or personnel. Even if it is successful in defending against such claims, litigation could result in substantial costs and distract its technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of Serina’s common stock. Ultimately, any such litigation could substantially increase Serina’s operating losses and reduce its resources available for development activities, and it may not have sufficient financial or other resources to adequately engage in such litigation. For example, some of Serina’s competitors may be able to sustain the costs of such litigation more effectively than it can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect Serina’s ability to compete in the marketplace.

 

Any trademarks Serina may obtain may be infringed or successfully challenged, resulting in harm to its business.

 

Serina expects to rely on trademarks as one means to distinguish any of its product candidates that are approved for marketing from the products of its competitors. However, Serina’s trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. Serina may not be able to protect its rights to these trademarks and trade names, which it benefits from to build name recognition among potential partners or customers in its markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to Serina’s, thereby impeding its ability to build brand identity and possibly leading to market confusion. In addition, there could be allegations of trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of Serina’s registered or unregistered trademarks or trade names. Over the long term, if Serina is unable to establish name recognition based on its trademarks and trade names, then it may not be able to compete effectively, and its business may be adversely affected. Serina’s efforts to enforce or protect its proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversions of resources and could adversely affect Serina’s business, financial condition, results of operations and growth prospects.

 

In addition, any proprietary name Serina proposes to use with any product candidate in the United States must be approved by the FDA, regardless of whether it have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of Serina’s proposed proprietary product names, Serina may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA.

 

102

 

 

Intellectual property rights do not necessarily address all potential threats.

 

The degree of future protection afforded by Serina’s intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect Serina’s business or permit it to maintain its competitive advantage. For example:

 

any of Serina’s current and future product candidates, if approved, may eventually become commercially available in generic or biosimilar product forms;
others may be able to make immunotherapies that are similar to any of Serina’s current and future product candidates or utilize lymph node targeting technology but that are not covered by the claims of the patents that Serina licenses or may own in the future;
Serina, or its licensors or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that it licenses or may own in the future, potentially resulting in the invalidation of such patents or refusal of such applications;
Serina, or its licensors or current or future collaborators, might not have been the first to file patent applications covering certain of its or their inventions;
Serina, or its licensors or current or future collaborators, may fail to meet its obligations to the U.S. government regarding any in licensed patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights;
others may independently develop similar or alternative technologies or duplicate any of Serina’s technologies without infringing on its owned or licensed intellectual property rights;
it is possible that Serina’s pending, owned or licensed patent applications or those that it may own or license in the future will not lead to issued patents;
it is possible that there are prior public disclosures that could invalidate Serina’s owned or in licensed patents, or parts of its owned or in licensed patents;
it is possible that there are unpublished patent applications that may later issue with claims covering Serina’s product candidates or technology similar to Serina’s;
it is possible that Serina’s owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable or result in a change in ownership;
issued patents to which Serina holds rights may be held invalid, unenforceable, or narrowed in scope, including as a result of legal challenges by its competitors;
the claims of Serina’s owned or in licensed issued patents or patent applications, if and when issued, may not cover its product candidates or narrowly cover its product candidates in such a way that competitors may be able to design around to avoid infringement allegations;
the laws of foreign countries may not protect Serina’s proprietary rights or the proprietary rights of its licensors or current or future collaborators to the same extent as the laws of the United States;
the inventors of Serina’s owned or in licensed patents or patent applications may become involved with competitors, develop products or processes that design around its patents, or become hostile to it or the patents or patent applications on which they are named as inventors;
Serina’s competitors might conduct research and development activities in countries where Serina does not have patent rights and then use the information learned from such activities to develop competitive products for sale in its major commercial markets;
Serina has engaged in scientific collaborations in the past and it intends to continue to do so in the future, and its collaborators may develop adjacent or competing products that are outside the scope of its patents;
Serina may not develop additional proprietary technologies that are patentable;
any product candidates Serina develops may be covered by third party patents or other exclusive rights;
the patents of others may prohibit or otherwise harm Serina’s business; or
Serina may choose not to file a patent in order to maintain certain trade secrets or know how, and a third party may subsequently commercialize the technology and/or file a patent covering such intellectual property.

 

103

 

 

Should any of these events occur, they could have a material adverse effect on Serina’s business, financial condition, results of operations, and prospects.

 

Risks Related to Regulatory and Compliance Matters

 

The FDA regulatory approval process is lengthy, time consuming, and inherently unpredictable, and Serina may experience significant delays in the clinical development and regulatory approval, if any, of its product candidates.

 

The research, testing, manufacturing, labeling, approval, selling, import, export, adverse event reporting, record keeping, advertising, promotion, and distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States. Serina is not permitted to market any drug product in the United States until it receives approval from the FDA. It has not previously submitted a NDA to the FDA, or similar approval filings to comparable foreign authorities. A NDA must include extensive nonclinical and clinical data and supporting information to establish that the product candidate is safe, pure, potent, and effective for each desired indication. The NDA must also include significant information regarding the chemistry, manufacturing, and controls for the product, and the manufacturing facilities must complete a successful pre license inspection. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not binding, may have a significant impact on Serina’s ability to obtain licensure of the product candidates based on the completed clinical trials. Accordingly, the regulatory approval pathway for Serina’s product candidates may be uncertain, complex, expensive, and lengthy, and approval may not be obtained.

 

Even if Serina receives regulatory approval of its product candidates, it will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and it may be subject to penalties if it fails to comply with regulatory requirements.

 

If Serina’s product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record keeping, conduct of post marketing studies, and submission of safety, efficacy, and other post market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.

 

Manufacturers and manufacturers’ facilities must comply with extensive FDA, and comparable foreign regulatory authority, requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, Serina and its contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing applications, and previous responses to inspection observations. Accordingly, Serina and others with whom it works must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.

 

Any regulatory approvals that Serina receives for its product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of Serina’s product candidates, which could entail requirements for long term patient follow up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves Serina’s product candidates, it will have to comply with requirements including submissions of safety and other post marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any clinical trials that it conducts post approval.

 

104

 

 

The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability.

 

Failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

 

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
fines, warning letters or other enforcement related letters or clinical holds on post approval clinical trials;
refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;
product seizure or detention, or refusal to permit the import or export of products;
injunctions or the imposition of civil or criminal penalties; and
consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.

 

The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of Serina’s product candidates. Serina cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If Serina is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Serina is not able to maintain regulatory compliance, Serina may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability.

 

Additional regulatory burdens and other risks and uncertainties in foreign markets may limit Serina’s growth.

 

Serina’s future growth may depend, in part, on its ability to develop and commercialize product candidates in foreign markets for which it may rely on strategic partnership with third parties. Serina will not be permitted to market or promote any product candidate before it receives regulatory approval from the applicable regulatory authority in a foreign market, and it may never receive such regulatory approval. To obtain separate regulatory approval in foreign countries, Serina generally must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing, and distribution of a product candidate, and it cannot predict success in these jurisdictions. If Serina obtains approval of any of its potential future product candidates and ultimately commercialize any such product candidate in foreign markets, Serina would be subject to risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.

 

105

 

 

In addition, obtaining and maintaining regulatory approval of Serina’s product candidates in one jurisdiction does not guarantee that it will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical studies or clinical trials as trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that Serina intends to charge for its products is also subject to approval.

 

Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for Serina and could delay or prevent the introduction of its products in certain countries. If Serina fails to comply with the regulatory requirements in international markets and/or to receive applicable marketing approvals, its target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed.

 

Health care and other reform legislation may increase the difficulty and cost for Serina and any collaborators it may have to obtain marketing approval of and commercialize its product candidates and affect the prices it, or they, may obtain.

 

All aspects of Serina’s business, including research and development, manufacturing, marketing, pricing, sales, litigation, and intellectual property rights, are subject to extensive legislation and regulation. Changes in applicable U.S. federal and state laws and agency regulation, as well as foreign laws and regulations, could have a materially negative impact on Serina’s business. In the United States and in some other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of Serina’s product candidates or any potential future product candidates of Serina’s, restrict or regulate post approval activities, or affect Serina’s ability to profitably sell any product candidates for which it obtains marketing approval. Increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject Serina to more stringent product labeling and post marketing testing and other requirements. Congress also must reauthorize the FDA’s user fee programs every five years and often makes changes to those programs in addition to policy or procedural changes that may be negotiated between the FDA and industry stakeholders as part of this periodic reauthorization process. Congress most recently reauthorized the user fee programs in September 2022 without any substantive policy changes.

 

106

 

 

Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in health care systems with the stated goals of containing health care costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, Congress passed the ACA, which substantially changed the way health care is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry.

 

There remain judicial and Congressional challenges to certain aspects of the ACA, and as a result certain sections of the ACA have not been fully implemented or effectively repealed. However, following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court upheld the ACA when it dismissed a legal challenge to the law’s constitutionality. Further legislative and regulatory changes under the ACA remain possible. It is unknown what form any such changes or any law would take, and how or whether it may affect the pharmaceutical industry as a whole or Serina’s business in the future. Serina expects that changes or additions to the ACA, the Medicare and Medicaid programs, and changes stemming from other health care reform measures, especially with regard to health care access, financing, or other legislation in individual states, could have a material adverse effect on the health care industry in the United States.

 

The uncertainty around the future of the ACA, and in particular the impact to reimbursement levels, may lead to uncertainty or delay in the purchasing decisions of Serina’s customers, which may in turn negatively impact Serina’s product sales. If there are not adequate reimbursement levels, Serina’s business and results of operations could be adversely affected.

 

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and was extended by the Consolidated Appropriations Act for 2023 and will remain in effect through 2032 unless additional Congressional action is taken.

 

In addition, the Drug Supply Chain Security Act enacted in 2013 imposed obligations on manufacturers of pharmaceutical products related to product tracking and tracing, and in February 2022, FDA released proposed regulations to amend the national standards for licensing of wholesale drug distributors by the states; establish new minimum standards for state licensing third party logistics providers; and create a federal system for licensure for use in the absence of a State program, each of which is mandated by the Drug Supply Chain Security (DSCSA). As another example, on December 20, 2019, President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116 94) that includes a piece of bipartisan legislation called the CREATES Act. The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. The CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on “commercially reasonable, market based terms.” Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on Serina’s future commercial products are unknown. Other legislative and regulatory proposals have been made to expand post approval requirements and restrict sales and promotional activities for pharmaceutical products. Serina is unsure whether additional legislative changes will be enacted, or whether the current regulations, guidance or interpretations will be changed, or whether such changes will have any impact on its business.

 

107

 

 

Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices considering the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, state legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states’ ability to regulate pharmaceutical benefit managers (PBMs) and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area.

 

At the federal level, the Department of Health and Human Services (HHS) has solicited feedback on various measures intended to lower drug prices and reduce the out of pocket costs of drugs and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS’s policy change that was effective January 1, 2019.

 

Most recently, in August 2022, President Biden signed into the law the Inflation Reduction Act of 2022 (IRA). Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the product’s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease.

 

Many EEA countries periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status. We expect that legislators, policymakers and healthcare insurance funds in the EEA countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for Serina’s products in some European countries, including some EEA countries, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EEA countries. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EEA countries.

 

108

 

 

In December 2021, Regulation No 2021/2282 on HTA amending Directive 2011/24/EU, was adopted in the EU. This Regulation, which entered into force in January 2022 and will apply as of January 2025, is intended to boost cooperation among EEA countries in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EEA level for joint clinical assessments in these areas. The Regulation foresees a three-year transitional period and will permit EEA countries to use common HTA tools, methodologies, and procedures across the EEA, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EEA countries will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EEA countries for drug candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EEA could be negatively affected.

 

Legislators, policymakers and healthcare insurance funds in the EEA may continue to propose and implement cost-containing measures to keep healthcare costs down; particularly due to the financial strain that the COVID-19 pandemic placed on national healthcare systems of the EEA countries. These measures could include limitations on the prices we would be able to charge for drug candidates that we may successfully develop and for which we may obtain regulatory approval or the level of reimbursement available for these products from governmental authorities or third-party payors. Further, an increasing number of EEA and other foreign countries use prices for medicinal products established in other countries as “reference prices” to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere.

 

Serina cannot predict whether future healthcare initiatives will be implemented at the federal or state level, supranational or national level, or how any future legislation or regulation may affect us, any of which may have a materially adverse effect on our business, financial condition, results of operations and prospects.

 

Any additional federal or state health care reform measures could limit the amounts that third party payers will pay for future health care products and services, and, in turn, could significantly reduce the projected value of certain development projects and reduce Serina’s profitability.

 

Serina’s employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

 

109

 

 

Serina is exposed to the risk of fraud or other misconduct by its employees, consultants, and commercial partners, and its principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA or other regulatory authorities, comply with health care fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to Serina. In particular, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to Serina’s reputation. It is not always possible to identify and deter employee misconduct, and the precautions Serina takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Serina from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against Serina, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.

 

Laws and regulations governing any international operations Serina may have in the future may preclude it from developing, manufacturing, and selling certain product candidates outside of the United States and require it to develop and implement costly compliance programs.

 

Serina is subject to numerous laws and regulations in each jurisdiction outside the United States in which it operates. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.

 

The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment, or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the U.S. Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.

 

Similarly, the U.K. Bribery Act 2010 has extra territorial effect for companies and individuals having a connection with the United Kingdom. The U.K. Bribery Act prohibits inducements both to public officials and private individuals and organizations. Compliance with the FCPA and the U.K. Bribery Act is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.

 

110

 

 

Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If Serina expands its business outside of the United States, it will be required to dedicate additional resources to comply with these laws, and these laws may preclude it from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit Serina’s growth potential and increase its development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violations of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. A conviction under the FCPA can result in long term disqualification as a government contractor. The termination of a government contract or relationship as a result of Serina’s failure to satisfy any of its obligations under laws governing international business practices could have a negative impact on its operations and harm its reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions.

 

Risks Related to Employee and Operations Matters, Managing Growth and Information Technology

 

A pandemic, epidemic, or outbreak of an infectious disease, such as the COVID 19 pandemic, may materially and adversely affect Serina’s business and its financial results and could cause a disruption to the development of product candidates.

 

Public health crises such as pandemics or similar outbreaks could adversely impact Serina’s business. The extent to which an outbreak impacts Serina’s operations or those of its collaborators will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the virus and the actions to contain it or treat its impact, among others.

 

The spread of any outbreak globally could adversely impact any preclinical or clinical trial operations in the United States and Europe, including Serina’s ability to recruit and retain patients and principal investigators and site staff who, as health care providers, may have heightened exposure to an infectious disease if an outbreak occurs in their geography. For example, similar to other biotechnology companies, Serina has experienced, and may in the future experience, delays in initiating IND enabling studies, delays in manufacturing, protocol deviations, enrolling patients in clinical trials and dosing patients in clinical trials, as well as in activating trial sites. An outbreak may also result in the need to suspend enrollment in clinical studies, subject withdrawals, postponement of planned clinical or nonclinical studies, redirection of site resources from studies, study modification, suspension, or termination, the introduction of remote study procedures and modified informed consent procedures, study site changes, direct delivery of investigational products to patient homes requiring state licensing, study deviations or noncompliance, and changes or delays in site monitoring. The foregoing may require that Serina consult with relevant review and ethics committees, IRBs, and the FDA. The foregoing may also impact the integrity of Serina’s study data. The effects of an outbreak may also increase the need for clinical trial patient monitoring and regulatory reporting of adverse effects. The pandemic could further impact Serina’s ability to interact with the FDA or other regulatory authorities and may result in delays in the conduct of inspections or review of pending applications or submissions. For example, the FDA may delay pre approval inspections. Although the FDA lifted restrictions relating to COVID 19 and affecting its inspection and other compliance operations in July 2022, the agency currently faces a significant backlog on compliance monitoring and enforcement activities for both domestic and foreign manufacturers, which may affect the scheduling of necessary pre approval inspections of manufacturing facilities for drug and biological product candidates.

 

111

 

 

In addition, the patient populations that Serina product candidates target may be particularly susceptible to COVID 19, which may make it more difficult for Serina to identify patients able to enroll in its current and future clinical trials and may impact the ability of enrolled patients to complete any such trials. Any negative impact the COVID 19 pandemic has on patient enrollment or treatment, or the execution of any product candidates could cause costly delays to clinical trial activities, which could adversely affect Serina’s ability to obtain regulatory approval for and to commercialize its product candidates, increase its operating expenses and have a material adverse effect on its financial results. Additionally, timely enrollment in planned clinical trials is dependent upon clinical trial sites which could be adversely affected by global health matters, such as pandemics. The COVID 19 pandemic has also impacted, and may continue to impact, Serina’s third party suppliers and manufacturers, including through the effects of facility closures, reductions in operating hours, staggered shifts and other social distancing efforts, labor shortages, decreased productivity and the unavailability of materials or components. While Serina maintains an inventory of materials used to conduct Serina’s research and development activities, a prolonged pandemic could lead to shortages in the raw materials necessary to manufacture Serina’s product candidates. If any of these third parties are adversely impacted by the COVID 19 pandemic or the restrictions resulting from the outbreak, if they cannot obtain the necessary supplies, or if such third parties need to prioritize other products or customers over Serina, including under the Defense Production Act, Serina may experience additional delays or disruptions in its supply chain, which could have a material and adverse impact on its business. CMOs may also need to implement measures and changes or deviate from typical requirements because of the COVID 19 pandemic that may otherwise adversely impact Serina’s supply chains or the quality of the resulting products or supplies. Depending on the change, Serina may need to obtain FDA pre approval or otherwise provide the FDA with a notification of the change.

 

An outbreak may additionally result in changes in laws and regulations. By example, in March 2020, the U.S. Congress passed the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which includes various provisions regarding FDA drug shortage reporting requirements, as well as provisions regarding supply chain security, such as risk management plan requirements, and the promotion of supply chain redundancy and domestic manufacturing. This and any future changes in law may require that Serina changes its internal processes and procedures to ensure continued compliance.

 

Even after an outbreak or pandemic subsides, Serina may continue to experience an adverse impact to its business as a result of its global economic impact, including from increased inflation and the prospect that policy responses to inflation could delay economic recovery or lead to another recession.

 

Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on Serina’s business, financial condition, results of operation or prospects. Further, uncertainty around these and related issues could continue to adversely impact the economies of the United States and other countries, which could impact Serina’s ability to raise the necessary capital needed to develop and commercialize its product candidates.

 

112

 

 

Serina’s future success depends on its ability to recruit and retain its executive team and key scientists and to attract, retain, and motivate qualified personnel.

 

Serina is highly dependent on the principal members of its management and scientific teams. These principal members are employed “at will,” meaning Serina or they may terminate the employment relationship at any time. The loss of the services of any of these persons could impede the achievement of Serina’s research, development, and commercialization objectives.

 

Recruiting and retaining qualified scientific, clinical, manufacturing, business development, general and administrative and sales and marketing personnel will also be critical to Serina’s success. Serina may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. Serina also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, Serina relies on consultants and advisors, including scientific and clinical advisors, to assist it in formulating its research and development and commercialization strategy. Serina’s consultants and advisors may be employed by employers other than Serina and may have commitments under consulting or advisory contracts with other entities that may limit their availability to Serina. In addition, inflation has had, and Serina expects that it will continue to have, an impact on the costs that it incurs to attract and retain qualified personnel and may make it more difficult for it to attract and retain such personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants, or advisors, may impede the progress of Serina’s research, development, and commercialization objectives and have a material adverse effect on its business, financial condition, results of operations, and prospects.

 

If Serina is unable to hire additional qualified personnel, its ability to grow its business may be harmed.

 

Over time Serina will need to hire additional qualified personnel with expertise in drug development, product registration, clinical, preclinical, and nonclinical research, quality compliance, government regulation, formulation and manufacturing, financial matters and sales and marketing. Serina competes for qualified individuals with numerous biopharmaceutical companies, universities, and other research institutions. Competition for such individuals is intense, and Serina’s search for such personnel may not be successful. Attracting and retaining qualified personnel will be critical to Serina’s success.

 

Serina expects to expand its development, regulatory, and future sales and marketing capabilities, and as a result, it may encounter difficulties in managing its growth, which could disrupt its operations.

 

As of November 9, 2023, Serina had 10 full time employees and, in connection with the growth and advancement of its pipeline and becoming a public company, it expects to increase the number of its employees and the scope of its operations, particularly in the areas of product development, business development, regulatory affairs, and sales and marketing. To manage its anticipated future growth, Serina must continue to implement and improve its managerial, operational, and financial systems, expand its facilities, and continue to recruit and train additional qualified personnel. Due to its limited financial resources and the limited experience of its management team in managing a company with such anticipated growth, Serina may not be able to effectively manage the expected expansion of its operations or recruit and train additional qualified personnel. Moreover, the expected physical expansion of its operations may lead to significant costs and may divert its management and business development resources. Any inability to manage growth could delay the execution of its business plans or disrupt its operations.

 

113

 

 

As a growing biotechnology company, Serina is actively pursuing new product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources, and corporate processes in order to allow simultaneous execution across multiple areas. Due to its limited resources, Serina may not be able to effectively manage this simultaneous execution and the expansion of its operations or recruit and train additional qualified personnel. This may result in weaknesses in its infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of Serina’s operations may lead to significant costs and may divert financial resources from other projects, such as the development of its product candidates. If Serina’s management is unable to effectively manage its expected development and expansion, its expenses may increase more than expected, its ability to generate or increase its revenue could be reduced, and it may not be able to implement its business strategy. Serina’s future financial performance and its ability to compete effectively and commercialize its product candidates, if approved, will depend in part on its ability to effectively manage the future development and expansion of its company.

 

Serina’s internal computer systems, or those of its vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of its product development programs, compromise sensitive information related to its business or prevent it from accessing critical information, potentially exposing it to liability or otherwise adversely affecting its business.

 

Serina’s internal computer systems and those of its current and any future third party vendors, collaborators and other contractors or consultants are vulnerable to damage, interruption or data theft from computer viruses, computer hackers, malicious code, employee theft or misuse, ransomware, social engineering (including phishing attacks), denial of service attacks, sophisticated nation state and nation state supported actors, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Cybersecurity incidents, which may not be immediately or ever detected, are increasing in frequency and evolving in nature. Additionally, due to geopolitical tensions related to Russia’s invasion of Ukraine, the risk of cyber-attacks may be elevated.

 

While Serina seeks to protect its information technology systems from system failure, accident, and security breach, if such an event were to occur and cause interruptions in its operations, it could result in a disruption of Serina’s development programs and its business operations, whether due to a loss of its trade secrets or other proprietary information or other disruptions. For example, the loss of clinical trial data from future clinical trials could result in delays in Serina’s regulatory approval efforts and significantly increase its costs to recover or reproduce the data. If Serina were to experience a significant cybersecurity breach of its information systems or data, the costs associated with the investigation, remediation, and potential notification of the breach to counterparties and data subjects could be material. In addition, Serina’s remediation efforts may not be successful. If it does not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, it could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information. In addition, in response to the ongoing COVID 19 pandemic, some of Serina’s workforce began to work remotely. This has continued and is now considered normal business. This could increase Serina’s cyber security risk, create data accessibility concerns, and make Serina more susceptible to communication disruption.

 

114

 

 

To the extent that any disruption or security breach were to result in a loss of, or damage to, Serina’s or its third party vendors’, collaborators’ or other contractors’ or consultants’ data or applications, or inappropriate disclosure of confidential or proprietary information, Serina could incur liability including litigation exposure, penalties and fines, Serina could become the subject of regulatory actions or investigations, its competitive position could be harmed and the further development and commercialization of its product candidates could be delayed. Any of the above could have a material adverse effect on Serina’s business, financial condition, results of operations or prospects. While Serina maintains cyber liability insurance (covering security and privacy matters), such insurance may not be adequate to cover any losses experienced as a result of a cybersecurity incident.

 

If Serina fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.

 

Serina has material weaknesses in its internal control systems over financial reporting and will need to hire additional personnel and design and implement proper and effective internal controls over financial reporting commensurate with the accounting and reporting requirements of a public company Serina may identify additional material weaknesses in the future that may cause us to fail to meet its reporting obligations or result in material misstatements in our financial statements. If Serina fails to remediate its material weaknesses, Serina may not be able to report its financial results accurately or to prevent fraud. Serina’s management is responsible for establishing and maintaining internal control over financial reporting, disclosure controls, and compliance with the other requirements of the Sarbanes-Oxley Act and the rules promulgated by the SEC thereunder.

 

General Risk Factors

 

Unfavorable global economic conditions could adversely affect Serina’s business, financial condition, or results of operations.

 

Serina’s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in 2008, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and the current COVID 19 pandemic has caused significant volatility and uncertainty in U.S. and international markets. See “Risks Related to Employee and Operations Matters, Managing Growth and Information Technology.” A pandemic, epidemic, or outbreak of an infectious disease, such as the COVID 19 pandemic, may materially and adversely affect Serina’s business and its financial results and could cause a disruption to the development of Serina’s product candidates. A severe or prolonged economic downturn, or additional global financial crises, could result in a variety of risks to Serina’s business, including weakened demand for its product candidates, if approved, or its ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain Serina’s suppliers, possibly resulting in supply disruption. Any of the foregoing could harm Serina’s business and it cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business.

 

115

 

 

U.S. federal income tax reform could adversely affect Serina’s business and financial condition.

 

The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect Serina or holders of its common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, on March 27, 2020, former President Trump signed into law the CARES Act which included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID 19 coronavirus outbreak, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Additionally, on December 22, 2017, former President Trump signed into law the Tax Cuts and Jobs Act of 2017 (TCJA), which significantly reformed the Code. The TCJA included significant changes to corporate and individual taxation, some of which could adversely impact an investment in Serina’s common stock. Under the TCJA, in general, NOLs generated in taxable years beginning after December 31, 2017 may offset no more than 80 percent of such year’s taxable income and there is no ability for such NOLs to be carried back to a prior taxable year. The CARES Act modifies the TCJA with respect to the TCJA’s limitation on the deduction of NOLs and provides that NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021, may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminates the limitation on the deduction of NOLs to 80 percent of current year taxable income for taxable years beginning before January 1, 2021. As a result of such limitation, Serina may be required to pay federal income tax in some future year notwithstanding that it had a net loss for all years in the aggregate. Future changes in tax laws could have a material adverse effect on Serina’s business, cash flow, financial condition, or results of operations. Serina urges investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in Serina’s common stock.

 

Serina faces risks associated with increased political uncertainty.

 

The invasion of Ukraine by Russia and the sanctions, bans and other measures taken by governments, organizations and companies against Russia and certain Russian citizens in response thereto has increased the political uncertainty in Europe and has strained the relations between Russia and a significant number of governments, including the U.S. Any retaliatory actions taken by Russia, the duration and outcome of this conflict and the conflict among Israel, Hamas and Hezbollah, and the impact on regional or global economies is unknown but could have a material adverse effect on Serina’s business, financial condition and results of its operations.

 

Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact Serina’s business and operating results.

 

The U.S. government has made statements and taken actions in recent years that have led to certain changes and may lead to additional changes to U.S. and international trade policies, including imposing several rounds of tariffs affecting certain products manufactured in China. In March 2018, the Trump administration announced the imposition of tariffs on steel and aluminum entering the United States and in June 2018 announced further tariffs targeting goods imported from China. Both China and the United States have each imposed tariffs indicating the potential for further trade barriers. It is unknown whether and to what extent new tariffs (or other new laws or regulations) will be adopted, or the effect that any such actions would have on us or our industry, and it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. Any unfavorable government policies on international trade, such as export controls, capital controls or tariffs, may affect the use of testing facilities in China that we use, including pursuant to Serina’s testing arrangements with WuXi AppTec (HongKong) Limited. If any new tariffs, export controls, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if the U.S. government takes retaliatory trade actions due to the recent U.S.-China trade tension, such changes could have an adverse effect on our business, financial condition and results of operations.

 

116

 

 

Risks Related to the Combined Company

 

In determining whether you should vote approve the proposals contained in this proxy statement/prospectus/information statement, you should carefully read the following risk factors in addition to the risks described above.

 

The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all.

 

The combined company will require substantial additional funds to support its continued research and development activities, including the anticipated costs of nonclinical studies and clinical trials, regulatory approvals, and potential commercialization. The combined company’s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could significantly dilute stockholders’ ownership interests or inhibit the combined company’s ability to achieve its business objectives. If the combined company raises additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect the rights of its common stockholders. Further, to the extent that the combined company raises additional capital through the sale of common stock or securities convertible or exchangeable into common stock, its stockholder’s ownership interest in the combined company will be diluted. In addition, any debt financing may subject the combined company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the combined company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the combined company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the combined company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the combined company or its stockholders.

 

The market price of the combined company’s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.

 

The market price of the combined company’s common stock following the Merger could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of the combined company’s common stock to fluctuate include:

 

the ability of the combined company to obtain regulatory approvals for its product candidates, and delays or failures to obtain such approvals;

 

117

 

 

failure of any of the combined company’s product candidates, if approved, to achieve commercial success;
failure by the combined company to maintain its existing third-party license and supply agreements;
failure by the combined company or its licensors to prosecute, maintain, or enforce its intellectual property rights;
changes in laws or regulations applicable to the combined company’s product candidates;
any inability to obtain adequate supply of the combined company’s product candidates or the inability to do so at acceptable prices;
adverse regulatory authority decisions;
introduction of new products, services or technologies by the combined company’s competitors;
failure to meet or exceed financial and development projections the combined company may provide to the public;
failure to meet or exceed the financial and development projections of the investment community;
the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;
announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors;
disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company’s ability to obtain patent protection for its technologies;
additions or departures of key personnel;
significant lawsuits, including patent or stockholder litigation;
if securities or industry analysts do not publish research or reports about the combined company’s business, or if they issue an adverse or misleading opinion regarding its business and stock;
changes in the market valuations of similar companies;
general market or macroeconomic conditions;
sales of its common stock by the combined company or its stockholders in the future;
trading volume of the combined company’s common stock;
failure to maintain compliance with the listing requirements of the NYSE American;
announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;
adverse publicity generally, including with respect to other products and potential products in such markets;
the introduction of technological innovations or new therapies that compete with potential products of the combined company;
changes in the structure of health care payment systems; and
period-to-period fluctuations in the combined company’s financial results.

 

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company’s common stock.

 

In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm the combined company’s profitability and reputation.

 

118

 

 

Additionally, a decrease in the stock price of the combined company may cause the combined company’s common stock to no longer satisfy the continued listing standards of the NYSE American. If the combined company is not able to maintain the requirements for listing on the NYSE American, it could be delisted, which could have a materially adverse effect on its ability to raise additional funds as well as the price and liquidity of its common stock.

 

The combined company will incur costs and demands upon management as a result of complying with the laws, rules and regulations affecting public companies.

 

The combined company will incur significant legal, accounting and other expenses that Serina did not incur as a private company, including costs associated with public company reporting requirements. The combined company will also incur costs associated with corporate governance requirements, including requirements under the laws, rules and regulations of the SEC as well as the NYSE American rules. These laws, rules and regulations are expected to increase the combined company’s legal and financial compliance costs and to make some activities more time consuming and costly. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. These laws, rules and regulations also may make it difficult and expensive for the combined company to obtain directors’ and officers’ liability insurance. As a result, it may be more difficult for the combined company to attract and retain qualified individuals to serve on the Combined Company Board or as executive officers of the combined company, which may adversely affect investor confidence in the combined company and could cause the combined company’s business or stock price to suffer.

 

Anti-takeover provisions in the Combined Company governance documents and under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by the combined company stockholders to replace or remove the combined company management.

 

Provisions in the Combined Company Charter and the Combined Company Bylaws may delay or prevent an acquisition or a change in management. In addition, because the combined company will be incorporated in Delaware, it is governed by the provisions of Section 203 of the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined company voting stock from merging or combining with the combined company. Although AgeX and Serina believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with the Combined Company Board, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by the combined company’s stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.

 

The Combined Company Charter will provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between the combined company and its stockholders, which could limit its stockholders’ ability to obtain a favorable judicial forum for disputes with the combined company or its directors, officers or other employees.

 

The Combined Company Charter and the Combined Company Bylaws provide, among other things, that that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on the combined company’s behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against the combined company arising pursuant to the DGCL, the Combined Company Charter or the Combined Company Bylaws, or any action asserting a claim against the combined company that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. The Combined Company Charter and the Combined Company Bylaws will also provide the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against the combined company or any of its directors, officers, employees, or agents and arising under the Securities Act. Nothing in the Combined Company Charter or the Combined Company Bylaws will preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.

 

119

 

 

AgeX and Serina do not anticipate that the combined company will pay any cash dividends in the foreseeable future.

 

The current expectation is that the combined company will retain its future earnings, if any, to fund the development and growth of the combined company’s business. As a result, capital appreciation, if any, of the common stock of the combined company will be its stockholders’ sole source of gain, if any, for the foreseeable future.

 

An active trading market for the combined company’s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.

 

Prior to the Merger, there had been no public market for Serina’s common stock. An active trading market for the combined company’s shares of common stock may never develop or be sustained. If an active market for its common stock does not develop or is not sustained, it may be difficult for its stockholders to sell their shares at an attractive price or at all.

 

Future sales of shares by existing stockholders could cause the combined company’s stock price to decline.

 

If existing stockholders of AgeX and Serina sell, or indicate an intention to sell, substantial amounts of the combined company’s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus/information statement lapse, the trading price of the common stock of the combined company could decline. Neither AgeX nor Serina is able to predict the effect that sales may have on the prevailing market price of the combined company’s common stock.

 

If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline.

 

The trading market for the combined company’s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect not to provide research coverage of the combined company’s common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts, or the content and opinions included in their reports. The price of the combined company’s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.

 

120

 

 

The pro forma condensed combined financial statements included in this proxy statement/prospectus/information statement are presented for illustrative purposes only and may not be an indication of the combined company’s financial condition or results of operations following the completion of the Merger.

 

The pro forma condensed combined financial statements contained in this proxy statement/prospectus/information statement are presented for illustrative purposes only and may not be an indication of the combined company’s financial condition or results of operations following the Merger for several reasons. The pro forma condensed combined financial statements have been derived from the historical audited financial statements of AgeX and Serina and certain adjustments and assumptions have been made regarding the combined company after giving effect to the Merger. The information upon which these adjustments and assumptions have been made is preliminary, and these kinds of adjustments and assumptions are difficult to make with accuracy. Moreover, the pro forma condensed combined financial statements do not reflect all costs that are expected to be incurred by the combined company in connection with the Merger. For example, the impact of any incremental costs incurred in integrating the two companies is not reflected in the pro forma condensed combined financial statements. As a result, the actual financial condition of the combined company following the Merger may not be consistent with, or evident from, these pro forma condensed combined financial statements. The assumptions used in preparing the pro forma condensed combined financial statements may not prove to be accurate, and other factors may affect the combined company’s financial condition following the Merger. For more information, please see the section titled “Unaudited Pro Forma Condensed Combined Financial Statements” in this proxy statement/prospectus/information statement.

 

If the combined company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.

 

The combined company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of the NYSE American. The Sarbanes-Oxley Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and internal control over financial reporting. The combined company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act. As a private company, Serina has never been required to test its internal controls within a specified period. This will require that the combined company incur substantial professional fees and internal costs to expand its accounting and finance functions and that it expends significant management efforts. The combined company may experience difficulty in meeting these reporting requirements in a timely manner.

 

121

 

 

The combined company may discover weaknesses in its system of internal financial and accounting controls and procedures that could result in a material misstatement of its financial statements. The combined company’s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.

 

If the combined company is not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if it is unable to maintain proper and effective internal controls, the combined company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by the NYSE American, the SEC or other regulatory authorities.

 

If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.

 

The combined company’s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The combined company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the combined company’s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or in-licensing or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the combined company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The combined company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.

 

The combined company is expected to take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies and emerging growth companies, which could result in its common stock being less attractive to investors.

 

Following the Merger, the combined company is expected to have a public float of less than $250 million and therefore will qualify as a smaller reporting company under the rules of the SEC. As a smaller reporting company, the combined company will be able to take advantage of reduced disclosure requirements, such as simplified executive compensation disclosures and reduced financial statement disclosure requirements in its SEC filings. Decreased disclosures in the combined company’s SEC filings due to its status as a smaller reporting company may make it harder for investors to analyze its results of operations and financial prospects. AgeX and Serina cannot predict if investors will find the combined company’s common stock less attractive if it relies on these exemptions. If some investors find its common stock less attractive as a result, there may be a less active trading market for its common stock and its stock price may be more volatile. The combined company may take advantage of the reporting exemptions applicable to a smaller reporting company until it is no longer a smaller reporting company, which status would end once it has a public float greater than $250 million. In that event, the combined company could still be a smaller reporting company if its annual revenues were below $100 million and it has a public float of less than $700 million.

 

122

 

 

Following the Merger, the combined company is expected to be an emerging growth company (EGC), as defined in the Jumpstart Our Business Startups Act of 2012, as amended. For as long as the combined company continues to be an EGC, it may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus/information statement and its periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. The combined company may remain an EGC until the earlier of (a) December 31, 2026, (b) the last day of the fiscal year in which the combined company has total annual gross revenue of at least $1.235 billion or more, (c) the date the combined company is deemed to be a large accelerated filer, which requires the market value of its common stock that is held by non-affiliates to exceed $700.0 million as of the prior June 30th, and (d) the date on which the combined company has issued more than $1.0 billion in non-convertible debt during the prior three-year period.

 

Changes in tax laws may materially adversely affect the combined company’s business, prospects, financial condition and operating results.

 

New tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect the combined company’s business, prospects, financial condition and operating results. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to the combined company. For example, the Tax Act, the CARES Act, and the IRA enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect the combined company, and certain aspects of such legislation could be repealed or modified in future legislation. Such tax law changes could have a material adverse impact on the combined company. In addition, it is uncertain if and to what extent various states will conform to newly enacted federal tax legislation. While it is too early to assess the overall impact of these changes, as these and other tax laws and related regulations are revised, enacted, and implemented, the combined company’s financial condition, results of operations, and cash flows could be materially adversely impacted.

 

The combined company’s ability to use net operating loss (NOL) carryforwards and other tax attributes may be limited, including as a result of the Merger.

 

Each of AgeX and Serina has incurred losses during its history, and the combined company does not expect to become profitable in the near future and may never achieve profitability. To the extent that the combined company continues to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, if at all. As of December 31, 2022, AgeX had U.S. federal NOL carryforwards of $52.8 million, which includes $24.9 million that will expire at various dates between 2028 and 2037 and $27.9 million that have an unlimited carryforward period. Additionally, for state income tax purposes, AgeX had NOLs of $14.9 million that will expire at various dates between 2028 and 2042. As of December 31, 2022, Serina had U.S. federal NOL carryforwards of $35.2 million, which includes $23.2 million that will expire at various dates beginning in 2027 and $12.0 million that have an unlimited carryforward period. Additionally, for state income tax purposes, Serina had NOLs of $35.5 million that will expire at various dates beginning in 2023. Under current law, U.S. federal NOL carryforwards generated in taxable periods beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such NOL carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections 382 and 383 of the Code, federal NOL carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An “ownership change” pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The combined company’s ability to utilize its NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If the combined company earns taxable income, such limitations could result in increased future income tax liability to the combined company, and the combined company’s future cash flows could be adversely affected.

 

Conflicts of interest may arise from the combined company’s relationship with Juvenescence, which will own a significant percentage of the combined company’s common stock as well as warrants to purchase additional shares of the combined company’s common stock and will be able to substantially influence the combined company and exert control over matters subject to stockholder approval.

 

Upon the closing of the Merger, Juvenescence is expected to own approximately 27.14% of the outstanding shares of the combined company’s common stock, including combined company common stock subject to warrants held by Juvenescence. See “Principal Stockholders of the Combined Company” for additional information.

 

One member of the combined company’s board of directors is expected to be the Executive Chairman and Co-Founder of Juvenescence and another member of the combined company’s board of directors is expected to be the Chief Executive Officer of Juvenescence, and based on Juvenescence’s ownership of shares of the combined company’s common stock, Juvenescence will be able to substantially influence the combined company and exert control over matters subject to stockholder approval, the elections of directors, approval of our equity incentive plans, amendments to our organizational documents, or approval of any merger, amalgamation, sale of assets or other major corporate transaction.

  

Juvenescence’s interests may not always coincide with the combined company’s corporate interests or the interests of other stockholders of the combined company, and it may exercise its voting and other rights in a manner with which other stockholders may not agree or that may not be in the best interests of the combined company or stockholders other than Juvenescence. So long as Juvenescence owns a significant amount of the combined company’s equity, it will be able to strongly influence the combined company’s decisions. While the directors affiliated with Juvenescence will be obligated to act in accordance with their fiduciary duty, they may have equity or other interests in Juvenescence and, accordingly, their interests may be aligned with Juvenescence’s interests, which may not always coincide with the combined company’s corporate interests or the interests of the combined company’s other stockholders.

 

123

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This proxy statement/prospectus/information statement contains forward-looking statements. These forward-looking statements are based on current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. These forward-looking statements should not be relied upon as predictions of future events and neither AgeX nor Serina can assure you that the events or circumstances reflected in these statements will be achieved or will occur. You can identify forward-looking statements by the use of forward-looking terminology including “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “pro forma,” “should,” “would” or the negative of these words and phrases or other variations of these words and phrases or comparable terminology. For example, forward-looking statements include, but are not limited to, statements about:

 

the strategies, prospects, plans, expectations and objectives of management of AgeX or Serina for future operations of the combined company following the closing of the Merger;
the progress, scope or duration of the development of product candidates or programs;
the benefits that may be derived from, or the commercial or market opportunity of, the product candidates of AgeX, Serina and the combined company;
the ability of AgeX and Serina to protect their intellectual property rights;
the ability of AgeX and the combined company to maintain compliance with NYSE American listing standards;
the level of net cash held by the combined company at the closing of the Merger;
the anticipated operations, financial position, losses, costs or expenses of AgeX, Serina or the combined company following the closing of the Merger;
statements regarding future economic conditions or performance;
statements concerning proposed products or product candidates;
the approval and closing of the Merger, including the timing of the Merger, the ability of AgeX to obtain a sufficient number of proxies to approve the Merger, other conditions to the completion of the Merger, the exchange ratio, and relative ownership levels as of the closing of the Merger;
the expected benefits of and potential value created by the Merger for the stockholders of AgeX; and
statements of belief and any statement of assumptions underlying any of the foregoing.

 

For a discussion of the factors that may cause AgeX, Serina or the combined company’s actual results, performance or achievements following closing of the Merger to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, and for a discussion of risk associated with the ability of AgeX and Serina to complete the Merger and the effect of the Merger on the business of AgeX, Serina and the combined company following the completion of the Merger, see “Risk Factors” beginning on page 24 of this proxy statement/prospectus/information statement. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC by AgeX. See “Where You Can Find More Information” beginning on page 398 of this proxy statement/prospectus/information statement. There can be no assurance that the Merger will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the Merger will be realized.

 

If any of these risks or uncertainties materializes or any of these assumptions proves incorrect, the results of AgeX, Serina or the combined company following completion of the Merger could differ materially from the forward-looking statements. All forward-looking statements in this proxy statement/prospectus/information statement are current only as of the date on which the statements were made. AgeX and Serina do not undertake any obligation (and expressly disclaim any such obligation) to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events, except as required by applicable law.

 

In addition, statements that “AgeX believes” or “Serina believes” and similar statements reflect AgeX’s or Serina’s beliefs and opinions on the relevant subject. These statements are based upon information available to AgeX or Serina, as the case may be, as of the date of this proxy statement/prospectus/information statement, and while AgeX or Serina, as the case may be, believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that such party has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

 

124

 

 

THE SPECIAL MEETING OF AGEX’S STOCKHOLDERS

 

Date, Time and Place

 

The AgeX special meeting will be held on    , commencing at    , unless postponed or adjourned to a later date. The AgeX special meeting will be held entirely online. AgeX is sending this proxy statement/prospectus/information statement to its stockholders in connection with the solicitation of proxies by the AgeX Board for use at the AgeX special meeting and any adjournments or postponements of the AgeX special meeting. This proxy statement/prospectus/information statement is first being mailed to AgeX stockholders on or about    .

 

Purpose of the AgeX Special Meeting

 

The purpose of the AgeX special meeting is:

 

1.Proposal No. 1 (the Stock Issuance Proposal)—To approve (i) the issuance of shares of AgeX common stock, which will represent more than 20% of the shares of AgeX common stock outstanding immediately prior to the Merger, to stockholders of Serina, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex A to this proxy statement/prospectus/information statement, and (ii) the change of control of AgeX resulting from the Merger, pursuant to Sections 712(b) and 713(b) of the NYSE American Company Guide;

 

2.Proposal No. 2 (the Reverse Stock Split Proposal)—To approve an amendment to the AgeX Charter to effect a reverse stock split of AgeX common stock at a ratio within the range between 1-for-35 to 1-for-36 with such ratio resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the Effective Time, unless otherwise mutually agreed upon by the AgeX Board and the Serina Board prior to the effectiveness of the Merger or, if the Stock Issuance Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal is not approved, by AgeX stockholders, determined solely by the AgeX Board;

 

3.Proposal No. 3 (the Warrant Issuance Proposal)—To approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants, which will represent securities convertible into or exercisable for AgeX common stock of more than 20% of the shares of AgeX common stock outstanding at the time of issuance;

 

4.Proposal No. 4 (the A&R Charter Proposal)—To approve the Combined Company Charter, in the form attached as Annex B to this proxy statement/prospectus/information statement;
  
5.Proposal No. 5 (the Non-Binding Governance Proposals)—To approve, on a non-binding, advisory basis, nine separately presented governance provisions in the Combined Company Charter, which are being separately presented in accordance with guidance from the SEC to give shareholders the opportunity to present their separate views on important corporate governance provisions;

 

6. Proposal No. 6 (the 2024 Equity Incentive Plan Proposal)—To approve the Serina Therapeutics, Inc. 2024 Equity Incentive Plan, in the form attached as Annex C to this proxy statement/prospectus/information statement; and

 

125

 

 

7. Proposal No. 7 (the Adjournment Proposal)—To approve a postponement or adjournment of the AgeX special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal.

 

These proposals are referred to collectively as the AgeX Proposals. No AgeX Proposal is conditioned upon any other AgeX Proposal. However, each of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal is a condition to the consummation of the Merger. Therefore, the Merger cannot be consummated without the approval of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal. 

 

Recommendation of the AgeX Board

 

The AgeX Board has determined and believes that the issuance of shares of AgeX common stock pursuant to the Merger Agreement is in the best interests of AgeX and its stockholders and has approved such proposal. The AgeX Board recommends that AgeX stockholders vote “FOR” the Stock Issuance Proposal as described in this proxy statement/prospectus/information statement.

 

The AgeX Board has determined and believes that it is advisable to, and in the best interests of, AgeX and its stockholders to approve the amendment to the AgeX Charter effecting a reverse stock split at a ratio in the range from 1-for-35 to 1-for-36, with such specific ratio resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the Effective Time, unless otherwise mutually agreed upon by the respective AgeX and Serina boards of directors or, if the Stock Issuance Proposal is not approved by AgeX stockholders, determined solely by the AgeX Board following the AgeX special meeting as described in this proxy statement/prospectus/information statement. The AgeX Board recommends that AgeX stockholders vote “FOR” the Reverse Stock Split Proposal as described in this proxy statement/prospectus/information statement.

 

The AgeX Board has determined and believes that the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants is in the best interests of AgeX and its stockholders and has approved such proposal. The AgeX Board recommends that AgeX stockholders vote “FOR” the Warrant Issuance Proposal as described in this proxy statement/prospectus/information statement.

 

The AgeX Board has determined and believes that the adoption of the Combined Company Charter at the Effective Time is in the best interests of AgeX and its stockholders and has approved such proposal. The AgeX Board recommends that AgeX stockholders vote “FOR” the A&R Charter Proposal as described in this proxy statement/prospectus/information statement.

 

  The AgeX Board has determined and believes that the adoption of nine separately presented governance provisions in the Combined Company Charter at the Effective Time is in the best interests of AgeX and its stockholders and has approved such proposals. The AgeX Board recommends that AgeX stockholders vote “FOR” the Non-Binding Governance Proposals as described in this proxy statement/prospectus/information statement.

 

The AgeX Board has determined and believes that the adoption of the Serina Therapeutics, Inc. 2024 Equity Incentive Plan is in the best interests of AgeX and its stockholders and has approved such proposal. The AgeX Board recommends that AgeX stockholders vote “FOR” the 2024 Equity Incentive Plan Proposal as described in this proxy statement/prospectus/information statement.

 

The AgeX Board has determined and believes that adjourning the AgeX special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal is advisable to, and in the best interests of, AgeX and its stockholders and has approved and adopted the proposal. The AgeX Board recommends that AgeX stockholders vote “FOR” the Adjournment Proposal as described in this proxy statement/prospectus/information statement.

 

126

 

 

Record Date and Voting Power

 

Only holders of record of AgeX common stock at the close of business on the record date,    , 2024, are entitled to notice of, and to vote at, the AgeX special meeting. There were approximately     holders of record of AgeX common stock at the close of business on the record date. At the close of business on the record date,     shares of AgeX common stock were issued and outstanding. Each share of AgeX common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval. See the section titled “Principal Stockholders of AgeX” beginning on page 387 of this proxy statement/prospectus/information statement for information regarding persons known to AgeX’s management to be the beneficial owners of more than 5% of the outstanding shares of AgeX common stock.

 

Voting and Revocation of Proxies

 

The proxy accompanying this proxy statement/prospectus/information statement is solicited on behalf of the AgeX Board for use at the AgeX special meeting.

 

If you are a stockholder of record of AgeX as of the record date referred to above, you may vote in person at the AgeX special meeting or vote by proxy on the internet, by telephone, or using the enclosed proxy card. Whether or not you plan to attend the AgeX special meeting, AgeX urges you to vote by proxy to ensure your vote is counted. You may still attend the AgeX special meeting and vote in person if you have already voted by proxy. As a stockholder of record, you are entitled:

 

to vote at the AgeX special meeting, attend the AgeX special meeting online and follow the instructions posted at www.virtualshareholdermeeting.com/   ;
to vote using the proxy card, simply mark, sign and date your proxy card and return it promptly in the postage-paid envelope provided. If you return your signed proxy card to AgeX before the AgeX special meeting, AgeX will vote your shares in accordance with the proxy card;
to vote on the internet, go to the website on the proxy card or voting instruction form to complete an electronic proxy card. You will be asked to provide the company number and control number from the enclosed proxy card. Your vote must be received by 11:59 p.m. Eastern Time on    , 2024 to be counted; and
to vote by telephone, go to the website on the proxy card or voting instruction form to complete an electronic proxy card, or call the toll-free number on the proxy card or voting instruction form to vote. You will be asked to provide the company number and control number from the enclosed proxy card. Your vote must be received by 11:59 p.m. Eastern Time on    , 2024 to be counted.

 

If your AgeX shares are held by your broker as your nominee, that is, in “street name,” the enclosed voting instruction card is sent by the institution that holds your shares. Please follow the instructions included on that proxy card regarding how to instruct your broker to vote your AgeX shares.

 

If you do not give instructions to your broker, bank or other nominee, the question of whether your broker, bank or other nominee will still be able to vote your shares depends on whether the NYSE American deems the particular proposal to be a “routine” matter and how your broker, bank or other nominee exercises any discretion they may have in the voting of the shares that you beneficially own. Brokers, banks and other nominees can use their discretion to vote “uninstructed” shares with respect to matters that are considered to be “routine,” but not with respect to “non-routine” matters. Whether a proposal is considered “routine” or “non-routine” is subject to stock exchange rules and final determination by the stock exchange.

 

127

 

 

For any AgeX Proposal that is considered a “routine” matter, your broker, bank or other nominee may vote your shares in its discretion either for or against the proposal even in the absence of your instruction. For any AgeX Proposal that is considered a “non-routine” matter for which you do not give your broker, bank or other nominee instructions, the AgeX shares will be treated as broker non-votes. Broker non-votes occur when a beneficial owner of shares held in street name does not give instructions to the broker, bank or other nominee holding the shares as to how to vote on matters deemed “non-routine.”

 

All properly executed proxies that are not revoked will be voted at the AgeX special meeting and at any adjournments or postponements of the AgeX special meeting in accordance with the instructions contained in the proxy. If a holder of AgeX common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted:

 

FOR” the Stock Issuance Proposal to approve the issuance of shares of AgeX common stock pursuant to the Merger Agreement;
FOR” the Reverse Stock Split Proposal to approve the amendment to the AgeX Charter effecting a reverse stock split at a ratio in the range from 1-for-35 to 1-for-36 with such specific ratio resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the Effective Time, unless otherwise mutually agreed upon by the respective AgeX and Serina boards of directors or, if the Stock Issuance Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal is not approved by AgeX stockholders, determined solely by the AgeX Board following the AgeX special meeting;
FOR” the Warrant Issuance Proposal to approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants;
FOR” the A&R Charter Proposal to approve the adoption of the Combined Company Charter at the Effective Time;

  FOR” the Non-Binding Governance Proposals to approve the adoption of the nine separately presented governance provisions in the Combined Company Charter at the Effective Time;

FOR” the 2024 Equity Incentive Plan Proposal to approve the adoption of the Serina Therapeutics, Inc. 2024 Equity Incentive Plan; and
FOR” the Adjournment Proposal to adjourn the AgeX special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal.

 

AgeX stockholders as of the record date, other than the AgeX stockholder that executed the AgeX Support Agreement, may change their vote at any time before their proxy is voted at the AgeX special meeting in one of three ways. You can revoke your proxy at any time before it is exercised by delivering a properly executed, later-dated proxy (including a proxy submitted by internet or telephone), by delivering a written revocation before the AgeX special meeting or by voting at the AgeX special meeting. Executing your proxy in advance will not limit your right to vote at the AgeX special meeting if you decide to attend the AgeX special meeting. However, if your shares are held in the name of a broker, bank or other holder of record, you cannot vote at the AgeX special meeting unless you have a legal proxy, executed in your favor, from the holder of record. If an AgeX stockholder of record or a stockholder who owns AgeX shares in “street name” has instructed a broker to vote its shares of AgeX common stock, the stockholder must follow directions received from its broker to change those instructions.

 

128

 

 

A complete list of AgeX stockholders entitled to vote at the AgeX special meeting will be available for examination by any AgeX stockholder in the Corporate Secretary’s Office at AgeX Therapeutics, Inc., 1101 Marina Village Parkway, Suite 201, Alameda, California 94501, for purposes pertaining to the AgeX special meeting, during ordinary business hours for a period of 10 days before the AgeX special meeting, and at the AgeX special meeting. A complete list of AgeX stockholders entitled to vote at the AgeX special meeting will also be available for inspection during the AgeX special meeting at www.virtualshareholdermeeting.com/       by logging in with your 16-digit control number(s).

 

Required Vote

 

The presence, in person or represented by proxy, at the AgeX special meeting of the holders of a majority of the shares of AgeX common stock outstanding and entitled to vote at the AgeX special meeting is necessary to constitute a quorum at the meeting. Abstentions and broker non-votes, if any, will be counted towards a quorum. Assuming a quorum is present, the required vote for each of the AgeX Proposals is as follows:

 

Proposal Number   Proposal Description   Vote Required for Approval   Effect of Abstentions   Effect of Broker Non-Votes
                 
1   Stock Issuance Proposal   FOR votes from the holders of a majority of shares voting affirmatively or negatively (excluding abstentions and broker non-votes) on the matter   None   None
                 
2   Reverse Stock Split Proposal   FOR votes from the holders of a majority of shares voting affirmatively or negatively (excluding abstentions and broker non-votes) on the matter   None   None
                 
3   Warrant Issuance Proposal   FOR votes from the holders of a majority of shares voting affirmatively or negatively (excluding abstentions and broker non-votes) on the matter   None   None
                 
4   A&R Charter Proposal   FOR votes from the holders of a majority of outstanding shares of AgeX common stock   Against   Against
                 
5   Non-Binding Governance Proposals  

FOR votes from the holders of a majority of shares voting affirmatively or negatively (excluding abstentions and broker non-votes) on the matter

  None  

None

                 
6   2024 Equity Incentive Plan Proposal   FOR votes from the holders of a majority of shares voting affirmatively or negatively (excluding abstentions and broker non-votes) on the matter   None   None
                 
7   Adjournment Proposal   FOR votes from the holders of a majority of shares voting affirmatively or negatively (excluding abstentions and broker non-votes) on the matter   None   None

 

129

 

 

The information in the preceding table with respect to the effect of broker non-votes may be incorrect or change before the AgeX special meeting. Therefore, if you are a beneficial owner and want to ensure that shares you beneficially own are voted in favor of or against any or all of the AgeX Proposals, the only way you can do so is to give your broker or nominee specific instructions as to how the shares are to be voted.

 

If on the date of the AgeX special meeting, or a date preceding the date on which the AgeX special meeting is scheduled, AgeX reasonably believes that (i) it will not receive proxies sufficient to obtain the required vote to approve the AgeX Proposals, whether or not a quorum would be present, or (ii) it will not have sufficient shares of AgeX common stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the AgeX special meeting, AgeX may postpone or adjourn, or make one or more successive postponements or adjournments of, the AgeX special meeting as long as the date of the AgeX special meeting is not postponed or adjourned more than an aggregate of 30 calendar days in connection with any postponements or adjournments.

 

No AgeX Proposal is conditioned upon any other AgeX Proposal. However, each of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal is a condition to the consummation of the Merger. Therefore, the Merger cannot be consummated without the approval of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal and the 2024 Equity Incentive Plan Proposal.

 

Concurrently with the execution of the Merger Agreement, Juvenescence entered into the AgeX Support Agreement, which provides, among other things, that Juvenescence will vote all of its shares of AgeX capital stock in favor of the AgeX Proposals. As of January 3, 2024, Juvenescence is a stockholder of AgeX holding approximately 43.3% of the outstanding shares of AgeX common stock, 100% of the outstanding shares of AgeX Series A preferred stock and 100% of the outstanding shares of AgeX Series B preferred stock.

 

Attendance at the AgeX Special Meeting and Voting at the AgeX Special Meeting

 

You or your authorized proxy may attend the AgeX special meeting virtually if you were a registered or beneficial stockholder of AgeX common stock as of the AgeX record date.

 

To participate in the AgeX special meeting, visit www.virtualshareholdermeeting.com/    and enter the 16-digit control number included on your proxy card or on the instructions that accompanied your proxy materials. If you wish to submit a question during the AgeX special meeting, log into the virtual meeting platform at www.virtualshareholdermeeting.com/   , type your question into the “Ask a Question” field, and click “Submit.” AgeX will respond to as many properly submitted questions during the relevant portion of the AgeX special meeting agenda as time allows.

 

130

 

 

If AgeX experiences technical difficulties during the AgeX special meeting (e.g., a temporary or prolonged power outage), it will determine whether the AgeX special meeting can be promptly reconvened (if the technical difficulty is temporary) or whether the AgeX special meeting will need to be reconvened on a later day (if the technical difficulty is more prolonged). In any situation, AgeX will promptly notify stockholders of the decision via    . AgeX will have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting website. If you encounter any difficulties accessing the virtual meeting website during the check-in or meeting time, please call the technical support number that will be posted on the virtual meeting website log-in page at www.virtualshareholdermeeting.com/   .

 

Please note that you will not be able to attend the AgeX special meeting in person.

 

The AgeX special meeting will be held virtually conducted via live audio webcast. You will be able to attend the AgeX special meeting by visiting www.virtualshareholdermeeting.com/    and entering your 16-digit control number as further explained in this proxy statement/prospectus/information statement. AgeX recommends that you log in at least 15 minutes before the AgeX special meeting to ensure you are logged in when the meeting starts.

 

If you own shares in street name through an account with a bank, broker or other nominee, please send proof of your AgeX share ownership as of the AgeX record date (for example, a brokerage firm account statement or a “legal proxy” from your intermediary) along with your registration request. If you are not sure what proof to send, check with your intermediary.

 

If your shares are registered in your name with AgeX’s stock registrar and transfer agent, Equiniti, no proof of ownership is necessary because AgeX can verify your ownership.

 

Solicitation of Proxies; Expenses of Solicitation

 

The AgeX Board is soliciting proxies for the AgeX special meeting from its stockholders. AgeX will bear a portion of the cost of the solicitation of proxies, including preparation, assembly and delivery, as applicable, of this joint proxy statement/prospectus/information statement, the AgeX proxy card and any additional materials furnished to AgeX stockholders. Proxies may be solicited by directors, officers and a small number of AgeX’s regular employees by mail, email, text message, in person and by telephone, but such persons will not receive any additional compensation for these activities.

 

Tabulation of Votes

 

AgeX will appoint Equiniti to serve as the Inspector of Election for the AgeX special meeting. Equiniti will independently tabulate affirmative and negative votes and abstentions.

 

131

 

 

Other Matters

 

As of the date of this proxy statement/prospectus/information statement, the AgeX Board does not know of any business to be presented at the AgeX special meeting other than as set forth in the notice accompanying this proxy statement/prospectus/information statement. If any other matters should properly come before the AgeX special meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.

 

Your vote is very important regardless of the number of shares of AgeX common stock that you own, and the matters to be considered at the AgeX special meeting are of great importance to the stockholders of AgeX. Accordingly, you are urged to read and carefully consider the information contained in this proxy statement/prospectus/information statement and promptly submit your proxy via the internet or by telephone or complete, date, sign and promptly return the enclosed AgeX proxy card or voting instruction form in the enclosed postage-paid envelope. If you submit your proxy via the internet or by telephone, you do not need to return the enclosed AgeX proxy card.

 

Please vote your shares via the internet or by telephone, or sign, date and return an AgeX proxy card or voting instruction form promptly to ensure that your shares can be represented, even if you otherwise plan to attend the AgeX special meeting.

 

132

 

 

THE MERGER

 

Background of the Merger

 

In an effort to enhance stockholder value, the AgeX Board and AgeX management regularly review and discuss AgeX’s business, performance, financial condition, near and long-term operations and strategic priorities. These reviews and discussions have included, among other things, the risks associated with AgeX’s product candidates, current and anticipated business and industry trends, the competitive landscape, regulatory conditions, the financial markets and macroeconomic environment (including the financing challenges associated with the broad weakness in the biopharmaceutical market), opportunities for strategic relationships, collaborations and other potential long-term strategic options to strengthen AgeX’s balance sheet, strategies around obtaining financing to support the clinical development of AgeX’s product candidates and product discovery and development efforts, and other potential strategic transactions, in each case with the goal of maximizing stockholder value.

 

AgeX was incorporated during 2017 as a subsidiary of Lineage, formerly known as BioTime, Inc. On August 17, 2017, AgeX entered into an Asset Contribution and Separation Agreement with Lineage pursuant to which Lineage contributed certain assets and cash to AgeX in exchange for 28,800,000 shares of AgeX common stock. Concurrently with the acquisition of assets and licensing of certain intellectual property from Lineage, AgeX sold 4,950,000 shares of common stock for $10 million in cash primarily to investors other than Lineage. At the close of the financing, Lineage owned 85.4% of AgeX’s issued and outstanding shares of common stock. On June 7, 2018, AgeX sold 2,000,000 shares of common stock for $2.50 per share to Juvenescence for aggregate cash proceeds to AgeX of $5 million.

 

On August 30, 2018, Lineage sold 14,400,000 of its shares of AgeX common stock to Juvenescence in exchange for an aggregate purchase price of $43.2 million. Upon completion of the transaction, Lineage’s ownership in AgeX was reduced from 80.4% to 40.2%, and Juvenescence’s ownership in AgeX was increased from 5.6% to 45.8%. On November 28, 2018, Lineage distributed to its shareholders, on a pro rata basis, 12,697,028 shares of the AgeX common stock it then held (the Distribution). Immediately after the Distribution, Lineage retained 1,718,972 shares of AgeX common stock, representing approximately 4.8% of the AgeX common stock. Following the Distribution, AgeX common stock began publicly trading on the NYSE American under the symbol “AGE.”

 

On September 4, 2019, AgeX published a paper describing its iTR technology and announced the formation of a wholly owned subsidiary, Reverse Bio that would be wholly focused on the development of iTR as a therapeutic modality.

 

In April 2020, based on a strategic review of AgeX’s operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, the AgeX Board and management modified its corporate strategy to focus on non-dilutive measures to explore the value of the AgeX platform technology through partnerships and prioritized further development of mature assets such as AgeX-BAT1 and VASC1 over the basic science being done by AgeX in-house.

 

In May 2020, AgeX conducted layoffs that impacted half of its employees. Of the 11 employees impacted, 10 were employed in the research and development department. The remaining research employee’s employment was changed to be on a part-time basis instead of full-time. There have been no new hires in research and development since the layoffs.

 

133

 

 

In lieu of internal research and development, AgeX concentrated on partnering with external collaborators that could provide validation of core AgeX technologies. AgeX has sponsored research and development programs at the University of California, Irvine (UCI) for the manufacturing of neural stem cells in the potential treatment of Huntington’s Disease and partnered with a group at UCI in the use of exosomes and other extracellular vesicles for the potential treatment of adverse neurocognitive effects of cancer chemotherapy and radiation therapy on brain function. The neural stem cell sponsored research and development program led to the creation of NeuroAirmid, which is a subsidiary of AgeX equally owned with certain of the UCI researchers. UCI filed an Investigational New Drug Application (IND) on June 30, 2023, which has recently been amended in response to FDA comments. UCI and NeuroAirmid intend to apply for a $12 million grant from California Institute for Regenerative Medicine (CIRM) which is contingent upon approval of the IND. AgeX has also sponsored research at Ohio State University to investigate the potential of brown adipocytes to treat metabolic conditions. Finally, AgeX entered into research collaboration agreements with a certain Japanese biopharmaceutical company and Sernova Corp., each which ultimately expired with limited research completed due to the COVID-19 pandemic.

 

During the second half of 2020, Reverse Bio retained Oliver Summerfield as Chief Executive Officer. AgeX encouraged Dr. Summerfield to raise an independent financing for Reverse Bio in order to develop its lead candidate, AGEX-iTR1547.

 

During March 2021, AgeX disposed of its interest in LifeMap Sciences, Inc. (LifeMap Sciences), a subsidiary that operated an on-line data base for use by researchers in the stem cell field. During the course of AgeX’s ownership of LifeMap Sciences, the subsidiary was unable to grow its revenue base and operated at a financial loss.

 

On March 2, 2021, AgeX announced that it would negotiate a merger with a Juvenescence-affiliated privately-held biotechnology company that developed cell therapies that enable organ regeneration. At the closing of the proposed merger, AgeX would have issued to the privately-held biotechnology company’s stockholders shares of AgeX common stock representing two-thirds of the total number of shares of AgeX common stock to be outstanding immediately following the consummation of the proposed merger on a fully-diluted basis, and then it would issue additional shares in a capital raise. However, on July 23, 2021, AgeX and the privately-held company announced that negotiations for the merger were discontinued. The AgeX Board and the board of directors of the potential target each determined that it was in the best interest of their respective shareholders not to proceed with the merger given the diversity of the companies’ technology platforms and product development focus.

 

On July 2, 2021, Serina entered into a Feasibility Study Agreement with a potential licensing partner regarding a specific formulation of its POZ-lipid nanoparticle technology for use with mRNA delivery.

 

On July 23, 2021, AgeX additionally announced it would continue to consider new strategic opportunities as they arise and remained committed to creating shareholder value through third-party collaborations and licensing agreements for its core technologies UniverCyte™ and PureStem®, and its cell therapy programs, including AGEX-VASC1 and AGEX-BAT1. AgeX also announced that it was exploring financing alternatives for its iTR™ technology and a potential spinout of Reverse Bio.

 

After being unable to raise a successful financing, Dr. Summerfield resigned as Chief Executive Officer of Reverse Bio on or about October 13, 2021. Dr. West assumed the position of Chief Executive Officer of Reverse Bio.

 

From July 2021 through the signing of the Merger Agreement, AgeX continued to incur operating losses and negative cash flows despite reducing operating expenses by out-sourcing research and development and seeking licensing arrangements for AgeX technologies. This approach made it more difficult to make progress in developing target product candidates and technologies, which in turn made it more difficult to raise capital.

 

134

 

 

As a result, from 2019 through the signing of the Merger Agreement, AgeX has had to borrow approximately $35.7 million from Juvenescence (Juvenescence loans) to continue to finance operations pursuant to the 2019 Loan Agreement (as defined below), the 2020 Loan Agreement (as defined below), the 2022 Secured Note and the 2023 Secured Note. The Juvenescence loans included a grant of a first lien security interest on AgeX’s assets (including the stock of all of AgeX’s subsidiaries, subject to limited exceptions), guarantees from all of AgeX’s subsidiaries, as well as negative covenants which, among other things, prohibit AgeX and its subsidiaries from borrowing funds from other lenders while the Juvenescence loans remain outstanding, with exceptions to permit Reverse Bio to borrow funds through convertible debt. In addition, the prohibition on AgeX and its subsidiaries incurring other debt would no longer apply if and when Reverse Bio raised $15 million in debt or equity financing by February 14, 2023, which date was subsequently extended to June 20, 2023, and then to October 31, 2023. The Juvenescence loans did not limit equity offerings so long as the proceeds of any stock issuance were applied for research and development work (including through third-party contractors), professional and administrative expenses, and for general working capital only in accordance with a budget approved by the AgeX Board and provided to Juvenescence, or to repay the Juvenescence loans. For information regarding AgeX’s borrowing from Juvenescence, see the section titled “AgeX Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” beginning on page 329 of this proxy statement/prospectus/information statement. For information regarding the impact of the Merger on the Juvenescence loans, see the section titled “Agreements Related to the MergerSide Letter” beginning on page 197 of this proxy statement/prospectus/information statement.

 

On November 17, 2021, AgeX received a letter from the staff of the NYSE American indicating that AgeX did not meet certain of the NYSE American’s continued listing standards. On January 28, 2022, the NYSE American accepted a plan of action for AgeX to bring itself into compliance by May 17, 2023 through a successful financing of Reverse Bio. On November 22, 2022, AgeX received a notification from the NYSE American accepting a revised listing compliance plan; however, in such notification, the NYSE American warned that if AgeX was not in compliance with the continued listing standards by May 17, 2023, or if AgeX did not make progress consistent with the plan during the plan period, the NYSE American would initiate delisting proceedings.

 

On April 19, 2022, Serina entered into a Feasibility Study Agreement with an additional potential licensing partner regarding a specific formulation of its POZ-lipid nanoparticle technology for use with mRNA delivery.

 

On July 21, 2022, Serina’s board authorized an offering of up to $5 million of convertible notes with interest accruing thereon at the rate of 6% per annum. The convertible notes were convertible into Serina’s Series A-5 Preferred Stock at $13 per share, and also provided a warrant to purchase an additional share of the Series A-5 Preferred Stock for each share received upon conversion with an exercise price of $20 per share. That offering was fully subscribed on November 11, 2022.

 

On September 6, 2022, a potential licensing partner submitted to Serina a nonbinding term sheet regarding licensing Serina’s POZ-lipid nanoparticle technology for use with mRNA delivery.

 

In early September, 2022, Mr. Alexander Pickett, Managing Director at Juvenescence, spoke with Remy Gross III, the Vice President, Business Development at the Buck Institute for Research on Aging. Mr. Gross, an advisor to Serina, spoke to Mr. Pickett about Serina’s interest in financing and provided a non-confidential update on work done by the Serina team on its POZ-lipid nanoparticle technology for use with mRNA delivery. Mr. Gross indicated that Serina was looking to raise a substantial investment in order to properly exploit its new platform, including that Serina was making progress on a nonbinding term sheet regarding the licensing of its POZ-lipid nanoparticle technology for use with mRNA delivery, with an expected upfront payment of $10 million. After an initial call with Serina’s management team, Mr. Pickett and colleagues visited Serina’s site at Huntsville Alabama on September 12, 2022. After this meeting, Mr. Pickett proposed to Dr. Gregory Bailey, then CEO of Juvenescence and a Director of AgeX, the idea of merging Serina into AgeX. Dr. Bailey viewed the idea favorably and began to socialize it with other AgeX Directors on September 22, 2022.

 

On October 7, 2022, the potential licensing partner of Serina began its due diligence on Serina’s POZ-lipid nanoparticle technology for use with mRNA delivery pursuant to the nonbinding term sheet.

 

Also on October 7, 2022, Mr. Pickett had a preliminary call to assess deal terms with Serina’s management team, including Dr. Milton Harris, Dr. Randall Moreadith, and Mr. Steve Ledger. During the call, Serina signaled that any proposed transaction would require a minimum of $10 million in capital and a valuation of Serina similar to that of its then-outstanding convertible notes offering. Shortly thereafter, Mr. Pickett prepared a draft nonbinding term sheet for the transactions, encompassing a $10 million convertible loan note that was comparable in amount to the upfront license fee Serina would have received had it entered into a POZ-lipid nanoparticle license and proposed merger terms between AgeX and Serina. The convertible loan note was to be structured so that it would be issued by AgeX as opposed to Juvenescence, so that it would reflect the valuation of Serina and would not dilute the ownership of Serina’s current stockholders should a merger between AgeX and Serina be consummated.

 

On October 14, 2022, Serina received a draft license agreement from a potential licensing partner for Serina’s POZ-lipid nanoparticle technology for use with mRNA delivery, which included a proposed term for an upfront payment of $10 million.

 

On October 18, 2022, Mr. Pickett had individual calls with AgeX Directors, Dr. Michael May and Dr. Mike West, to provide background on Serina and to describe the possibility of a business combination transaction.

 

135

 

 

On October 19, 2022, the AgeX Board met and Mr. Pickett was invited to present the term sheet. During this meeting, the AgeX Board was advised of its fiduciary duties and was informed that Juvenescence did not have any relationship with Serina that would pose a conflict of interest. The AgeX Board also discussed the risks of the structure of the deal, including (i) the fact that reverse mergers usually require concurrent financings to support the ongoing public company but there was little certainty as to the ability to attract such a financing, (ii) the length of time required to negotiate and close a reverse merger transaction given the need to conduct a stockholder vote and negotiate and file a Form S-4, and (iii) uncertainty as to AgeX’s ability to obtain an acceptance from Serina of any offer made by AgeX, including an exchange ratio, that would deliver an appropriate value to AgeX stockholders. In addition, Dr. West presented a proposal for a spin-out and financing of Reverse Bio by a syndicate of investors. The AgeX Board formed a Special Committee comprised of Dr. Joanne Hackett, the Chair of the AgeX Board, and Dr. Gregory Bailey to manage the transaction process. The AgeX Board also requested that Mr. Pickett work with AgeX’s external transaction counsel, Gibson, Dunn & Crutcher LLP (Gibson Dunn), to revise the term sheet, provide support in negotiating the deal, and arrange due diligence.

 

On October 21, 2022, Dr. Hackett sent the initial term sheet to Serina’s management for the transaction, encompassing a $10 million convertible loan note and proposed merger terms between AgeX and Serina. Additional key terms of the term sheet included: (i) customary terms of a convertible note, (ii) collateral for the note to include a security interest in all of Serina’s assets, including its intellectual property, (iii) structuring the note to reflect the valuation of Serina and to not dilute the ownership of Serina’s current stockholders if a merger between the parties occurred, (iv) the combined company board of directors to be selected by both companies such that neither company controlled the board, (v) the continuation of AgeX’s NeuroAirmid business at the combined company, (vii) the repositioning the focus of the combined company to reflect the mutual interest of the two companies in central nervous system diseases using the operations of NeuroAirmid and Serina to accomplish such repositioning, (vii) the financing and spinoff of Reverse Bio prior to the closing of the merger, (viii) the financing terms for the loan of funds by Juvenescence to AgeX to fund the purchase of such convertible note, (ix) the right of AgeX to appoint a member to the board of Serina as long as the convertible loan note was outstanding, and (x) exclusivity provisions. The term sheet set a valuation for Serina of $100 million (which AgeX had understood was approximately the same value as Serina’s last private financing) and a valuation of AgeX at $50 million (a 213% increase to AgeX’s market capitalization as of such date), which reflected a 67:33 relative value split. Later that day, Mr. Pickett spoke with Serina’s management team regarding the term sheet.

 

On October 24, 2022, Serina’s management sent a letter to AgeX expressing that Serina believed that a merger agreement without a guarantee that AgeX would provide material financing to Serina would be difficult to accept and that, without material financing from AgeX, Serina desired to re-open discussions with AgeX in the first quarter of 2023 after finishing negotiations with a third-party licensee. Further discussion between Mr. Pickett and Mr. Ledger revealed that Serina viewed the proposed valuation as a key sticking point, particularly in light of ongoing license negotiations between Serina and a third party regarding the POZ-lipid nanoparticle and Serina’s then-outstanding convertible notes offering. In addition, the discussion revealed that Serina believed that (i) its board and its stockholders would likely view the security interest in all of Serina’s assets as a potential sale of Serina for $10 million, (ii) its board and its stockholders would also likely view the outstanding debt of AgeX, if not isolated from Serina and NeuroAirmid, to be a sale of Serina for $10 million, and (iii) it had two potential licensing partners that should be exempt from the exclusivity provisions.

 

On October 31, 2022, Serina’s management met to review the terms of the draft license agreement received by Serina on October 14, 2022. In addition, Serina’s management met to discuss (i) the status of the negotiations with AgeX and (ii) the need for notice to third parties regarding potential disclosure of information in due diligence if the negotiations with AgeX produced an acceptable term sheet.

 

Mr. Pickett and Mr. Ledger continued negotiations that led to a revised term sheet prepared by Mr. Pickett, Susan Bergin, another employee of Juvenescence, and Goodwin Proctor LLP (Goodwin), counsel to Juvenescence, that valued Serina at $105 million, the same value as its last private financing, while AgeX was valued at $45 million (a 182% increase to AgeX’s market capitalization as of November 2, 2022). Dr. Hackett sent a revised version of the term sheet incorporating this proposal on November 2, 2022.

 

On November 3, 2022, Serina’s management met to discuss the term sheet. On the same day, AgeX’s management received a term sheet for a spin-off and financing of Reverse Bio from a syndicate of investors.

 

On November 4, 2022, Mr. Ledger sent a redline of the November 2nd term sheet to Mr. Pickett. This redline of the term sheet included specific language exempting two ongoing negotiations with potential third party licensees from the exclusivity provisions of the term sheet, removing the collateral language, setting the valuation, and stating that Greg Bailey would be the director appointed to the Serina Board by AgeX.

 

Discussions from this point shifted from discussion of absolute valuations to relative values (70:30 rather than $105 million:$45 million), because each side was focused ultimately on the relative percentage ownership of the combined company and this metric better matched the discussions each was having internally.

 

On November 9, 2022, the AgeX Board held a meeting. Among other things, the AgeX Board discussed the composition of the Special Committee and determined, given Juvenescence’s potential participation in a transaction with Serina as a lender to AgeX, and that Serina had requested that Dr. Bailey be the person appointed by AgeX to the Serina Board to provide strategic guidance on its ongoing licensing negotiations, that membership on the Special Committee should be restricted to directors who are not affiliates of Juvenescence and who are not members, or potential members, of the Serina Board. Accordingly, Dr. Bailey agreed to resign as a member of the Special Committee and was replaced by Dr. May. Separately, the AgeX Board encouraged Dr. West to pursue financing for Reverse Bio with the intent to spin out Reverse Bio concurrently with the Serina merger.

 

Dr. Hackett sent a revised version of the term sheet to Serina’s management, which included proposed terms that the convertible loan note would be the most senior debt of Serina and that the convertible loan note would in no case be subordinated without the written consent of AgeX, removed the receipt of a fairness opinion as a condition precedent to closing, and added a consent requirement to the exclusivity clause that prohibited Serina from engaging in discussions for a competing transaction without the prior written consent of AgeX. The fairness opinion was removed in light of the AgeX Board’s view that its potential cost outweighed its potential benefit considering the extensive amount of time AgeX had been exploring alternative strategic transactions without success.

 

On November 14, 2022, Serina’s management team met to discuss the term sheet.

 

On November 15, 2022, Mr. Ledger provided Mr. Pickett feedback from Serina’s management team—namely that members of Serina’s board of directors objected to the proposed valuation on the basis that Serina’s ongoing license discussions provided an alternative, non-dilutive source of capital, and that Serina has just closed its $5 million convertible notes offering. Mr. Pickett and Mr. Ledger negotiated a change in relative values to 75:25 (if holding Serina’s value steady at $105 million, it implies a valuation of AgeX of $35 million, a 146% increase to AgeX’s market capitalization as of November 15, 2022) alongside the creation of a set of out-of-money warrants that would issue to existing AgeX shareholders upon consummation of the transaction that if fully exercised would result in a 63:37 relative value. The warrants were arranged in three tranches of partial warrants that summed to 75% warrant coverage for AgeX Shareholders at multiples of the closing share price (150%, 200%, and 250%). This term sheet also spelled out a carveout of certain AgeX assets intended to be placed into Reverse Bio upon its successful financing. A revision of the term sheet incorporating these changes of terms was sent to Dr. Hackett on November 18, 2022. On November 20, 2022, the AgeX Special Committee met to consider the revised deal.

 

On November 18, 2022, Serina notified one of its potential licensing partners that Serina was pausing the negotiations of the draft license agreement due to other negotiations regarding a possible investment in Serina by a third party (AgeX).

 

136

 

 

On November 23, 2022 Dr. Hackett sent a revised term sheet to Serina management. This version of the term sheet expanded warrant coverage to 100% that if fully exercised would result in a 60:40 relative value. Warrants were divided into funding warrants with an 18-month term and 125% exercise price and long-dated incentive warrants priced at 175% and 225% of the closing price that were issued after the exercise of the incentive warrants. Furthermore, AgeX was entitled to participate in the ongoing third-party license negotiations and had the right to approve deal terms for the duration of the exclusivity period.

 

On November 28, 2022, the AgeX Board met and the members of the Special Committee gave an update to the AgeX Board on the status of negotiations with Serina.

 

Following further discussion between Mr. Ledger and Mr. Pickett, Mr. Pickett sent a revised term sheet to Dr. Hackett on December 2, 2022, which provided a definition for incentive warrants and clarified that no fractional shares would be issued upon the exercise of the warrants.

 

The AgeX Special Committee met on December 5, 2022 and approved the term sheet, subject to revisions from Gibson Dunn.

 

On December 5, 2022, Dr. Hackett sent the term sheet to Serina’s management.

 

On December 5, 2022, the Serina Board, as part of Serina’s annual stockholder meeting, met to initially review the term sheet. The Serina Board agreed that it needed more time to review the term sheet and also agreed to meet on December 8, 2022 to further discuss the term sheet.

 

From December 5, 2022 to December 8, 2022, Serina management and the directors of the Serina Board had numerous conversations regarding the term sheet.

 

On December 8, 2022, the Serina Board met to discuss the term sheet and authorized Serina’s chief executive officer, Dr. Moreadith, to execute the term sheet.

 

On December 12, 2022, AgeX provided its countersignature to the term sheet. The term sheet provided for a $10 million convertible note to be issued by Serina to AgeX with certain conditions outlined therein. In addition, the term sheet outlined a proposed merger between Serina and AgeX, which included, among other things, that if the merger occurred, (i) AgeX would issue to Serina the number of shares of AgeX as would bring Serina’s aggregate shareholding of AgeX to 75% of the fully-diluted company, (ii) the combined company would consider strategic alternatives for the business of Reverse Bio, and (iii) during the duration of the term sheet, Serina would not solicit or enter into any competing transactions to the ones contemplated by the term sheet with AgeX, but AgeX was not subject to any exclusivity provisions with Serina under the term sheet or at any time prior to entering into the Merger Agreement.

 

On December 16, 2022, Ms. Bergin provided the AgeX Board with an update on the proposed transaction with Serina and informed the AgeX Board that due diligence had begun.

 

On December 20, 2022, AgeX, Gibson Dunn, transaction counsel to AgeX, Thompson, Welch, Soroko & Gilbert LLP (Thompson Welch), corporate counsel to AgeX, Serina, and Bradley Arant Boult Cummings LLP (Bradley), counsel to Serina, participated in a video conference to discuss the timeline to execution of definitive documentation, allocation of drafting responsibilities, AgeX’s due diligence review of Serina, Serina’s due diligence of AgeX and certain other topics.

 

137

 

 

Over the next few weeks, AgeX formally engaged the following advisors to conduct formal due diligence: Alberto J Espay, MD, the Professor and Endowed Chair of the James J. and Joan A. Gardner Center for Parkinson’s Disease at the University of Cincinnati on January 24, 2023 for review of SER-252; Robert Hauser, MD, MBA, the Professor of Neurology, Pharmacology and Experimental Therapeutics at University of South Florida Director at Parkinson’s Disease and Movement Disorders Center on February 23, 2023 for review of SER-252; Andy McElroy, PhD, a former Pfizer medicinal chemist and the CEO and founder of The Research Network, Ltd. on February 24, 2023 for review of the breadth and depth of the Serina chemistry platform; Glenn Prestwich, the Presidential Professor of Medicinal Chemistry at the University of Utah and manager of Clear Solutions Biomedical on January 24, 2023 for review of the breadth and depth of the Serina chemistry platform; Peter Bungay PhD of Sympetrus, Ltd. on February 15, 2023 for review of the drug metabolism and pharmacokinetic properties of SER-252 in particular and the Serina platform technology in general; S. Moein Moghimi, PhD, Professor of Pharmaceutics and Nanomedicine at the School of Pharmacy and the Translational and Clinical Research Institute at Newcastle University on February 12, 2023 for review of Serina’s lipid nanoparticle technology; Gaurav Sahay, PhD, Professor in the Department of Pharmaceutical Sciences, College of Pharmacy at Oregon State University on February 10, 2023 for review of Serina’s lipid nanoparticle technology; Yizhou Dong, PhD, a Professor at the Icahn School of Medicine at Mount Sinai on February 9, 2023 for review of Serina’s lipid nanoparticle technology; and Justin Stebbing MD, a Professor of Biomedical Sciences at ARU, Cambridge on February 15, 2022 for commercial perspectives on mRNA vaccines and lipid nanoparticle technology.

 

AgeX retained Finnegan, Henderson, Farabow, Garrett & Dunner LLP in relation to intellectual property diligence. Furthermore, AgeX engaged Mr. Pickett and Ms. Bergin, to support the AgeX management team in relation to scientific and IP diligence pursuant to an intracompany services agreement. These advisors worked in cooperation with AgeX management and Gibson Dunn when appropriate, to conduct due diligence on Serina’s business and report to the AgeX Board.

 

From the execution of the term sheet through March 13, 2023, AgeX, Serina and certain of their respective advisors, including advisors from Juvenescence, participated in a number of telephone calls and video conferences to discuss the issuance of a $10 million loan from AgeX to Serina (the AgeX-Serina Loan) in order to provide financing to Serina in contemplation of a potential merger between AgeX and Serina, the terms and conditions proposed in the AgeX-Serina Loan transaction documents, due diligence matters and also exchanged due diligence materials. To provide the capital to fund the AgeX-Serina Loan, the parties discussed the issuance of a $10 million loan from Juvenescence to AgeX (the Juvenescence March Loan).

 

On January 11, 2023, Gibson Dunn sent the AgeX Board an initial draft of the AgeX-Serina Loan transaction documents. Between January 11, 2023 and January 20, 2023, Gibson Dunn, Dr. May, who at the time was a director of AgeX, and Mr. Pickett and Ms. Bergin, each of whom are employed by Juvenescence, discussed the AgeX-Serina Loan and Juvenescence loan transaction documents, which were revised through rounds of review and comment. The initial draft of the AgeX-Serina Loan transaction documents did not contain any restrictions on AgeX’s ability to enter into any strategic transactions with a party other than Serina.

 

On January 20, 2023, the AgeX-Serina Loan transaction documents were circulated to Bradley.

 

During February 2023, Bradley, Gibson Dunn, and Goodwin circulated proposed revisions on the AgeX-Serina Loan transaction documents.

 

On February 3, 2023, the AgeX Board met and discussed the status of the negotiations with Serina.

 

On February 27, 2023, Goodwin sent Thompson Welch an initial draft of the Juvenescence March Loan, which was based on the existing note between AgeX and Juvenescence. Between February 27, 2023 and March 13, 2023, Thompson Welch and Goodwin traded several drafts of the Juvenescence March Loan with AgeX’s primary issue being an ability to assign the AgeX-Serina Loan to Juvenescence in order to settle the Juvenescence March Loan if a potential merger between AgeX and Serina was not consummated.

 

138

 

 

On February 28, 2023 and periodically through August 2023, management of AgeX and certain of their advisors met to review diligence and timelines associated with the potential merger with Serina.

 

On March 2, 2023, Bradley sent Gibson Dunn a revised draft of each of the AgeX-Serina Loan transaction documents.

 

On March 3, 2023, Bradley, Gibson Dunn and Goodwin discussed on a video conference an issues list from Serina regarding the Serina convertible note, one of the primary AgeX-Serina Loan transaction documents, prepared by Serina’s management.

 

On March 5, 2023, Gibson Dunn sent revised drafts of the AgeX-Serina Loan transaction documents to members of AgeX management, which in turn shared it with the AgeX Board. After review by members of AgeX management, Gibson Dunn sent revised drafts of each of the AgeX-Serina Loan transaction documents to Bradley.

 

On March 7, 2023, members of AgeX management and Serina management met to discuss the AgeX-Serina Loan transaction documents.

 

On March 7, 2023, the AgeX Board sent Dr. West, the Chief Executive Officer of AgeX at the time, an amendment to his employment agreement and a new employment agreement in his contemplated role as Chief Executive Officer of Reverse Bio, each in preparation for the potential Reverse Bio financing. On April 3, 2023, Dr. West sent comments to such agreements to the AgeX Board. Between April 2023 and August 2023, the AgeX Board and Dr. West discussed revisions to the agreements on multiple occasions.

 

On March 8, 2023, Juvenescence informed AgeX that Juvenescence’s board of directors had approved the issuance of the Juvenescence March Loan to AgeX so that AgeX could use the proceeds thereof to issue the AgeX-Serina Loan.

 

On March 8, 2023, Bradley sent Gibson Dunn revised AgeX-Serina Loan transaction documents that were consistent with the management discussions on March 7, 2023, and a disclosure schedule for the Serina representations and warranties. AgeX management and Juvenescence noted to Gibson Dunn that they had no more comments on the AgeX-Serina Loan transaction documents, which in turn Gibson Dunn communicated to Bradley. The final draft of the AgeX-Serina Loan transaction documents did not have any restrictions on AgeX’s ability to enter into any strategic transactions with a party other than Serina.

 

On March 9, 2023, Dr. Hackett and Dr. May had separate, one-on-one calls with Mr. Pickett to review the outcome of scientific diligence on Serina. Later that day, Dr. West resigned from the AgeX Board, but informed AgeX that he would continue to serve as AgeX’s Chief Executive Officer. Dr. West’s resignation as a director was not because of a disagreement with AgeX on any matter relating to AgeX’s operations, policies, or practices, but was instead related to his desire to focus on the completion of the Reverse Bio financing.

 

On March 10, 2023, Dr. May met with Gibson Dunn to discuss the material terms of the AgeX-Serina Loan transaction documents.

 

139

 

 

On March 10, 2023, the AgeX Board and the Special Committee met to discuss the results of its due diligence efforts regarding Serina, including information concerning the financial condition, capitalization, technologies and intellectual property, research and development programs, and prospects of Serina, including Serina’s plans to advance certain therapy related products into clinical trials. The information considered by the AgeX Board included the findings of a panel of independent advisers who reviewed and evaluated the products being developed by Serina, including Serina’s POZ-apomorphine program SER-252, and a diligence summary of patentability of Serina technologies. The AgeX Board considered and discussed (i) the expected benefits and risks of the proposed merger, including a potential timeline related thereto, between AgeX and Serina on terms outlined the term sheet; (ii) the terms of the AgeX-Serina Loan documents; and (iii) the expected benefits and risks of making the $10 million loan to Serina on terms presented to the directors.

 

The AgeX Board considered the objectives of AgeX in obtaining the Juvenescence March Loan and providing the AgeX-Serina Loan, the financial risks associated with the Juvenescence March Loan and the AgeX-Serina Loan, and the potential impact of the Investment Company Act of 1940 on AgeX that might arise from the acquisition and holding of the AgeX-Serina Loan by means of the AgeX-Serina Note or shares of Serina capital stock. After the discussion, the AgeX Board determined that to mitigate those risks the Juvenescence March Loan should include the right of AgeX to pay off the financial obligations under the Juvenescence March Loan by tendering to Juvenescence the AgeX-Serina Note and any shares of Serina capital stock issued upon conversion of the AgeX-Serina Note into Serina capital stock. The AgeX Board instructed AgeX management to negotiate with Juvenescence a right of AgeX to assign the AgeX-Serina Loan to Juvenescence in full satisfaction of the Juvenescence March Loan by executing the 2023 Secured Note on the same day.

 

On March 10, 2023, the Serina Board met to consider and discuss (i) the terms of the AgeX-Serina Loan documents and (ii) the expected benefits and risks of the $10 million loan from AgeX. After discussion and deliberation, the Serina Board authorized Dr. Moreadith to execute the AgeX-Serina Loan documents with such additional changes as Dr. Moreadith deemed appropriate.

 

On March 13, 2023, Juvenescence agreed to the assignment of the AgeX-Serina Loan and, on March 14, 2023, the AgeX Board confirmed over electronic communication consent to the revised Juvenescence March Loan. Juvenescence and AgeX entered into the Juvenescence March Loan on the same day.

 

On March 15, 2023, AgeX and Serina entered into the AgeX-Serina Loan by executing the AgeX-Serina Note. In accordance with the AgeX-Serina Note, on March 15, 2023, Serina appointed Dr. Bailey, a director of the AgeX Board, to Serina’s Board. In the Form 8-K announcing the execution of the AgeX-Serina Note, AgeX noted that it agreed to borrow $10 million from Juvenescence pursuant to the 2023 Secured Note and to lend the loan proceeds of the 2023 Secured Note to Serina in order to provide financing to Serina in contemplation of AgeX’s corporate restructuring plans that include a potential merger between AgeX and Serina in which AgeX would be the surviving company. The Form 8-K specifically noted that “[n]o definitive agreement regarding a merger between AgeX and Serina has been negotiated or executed nor has the merger been approved by the respective boards of directors of AgeX and Serina. Further, a merger cannot be consummated unless approved by the stockholders of AgeX and Serina.” The Form 8-K also disclosed, in a section entitled “Restrictive Covenants,” that Serina was prohibited from soliciting and entering into any “material sale or transfer transactions outside the ordinary course of business, other than in a merger between AgeX and Serina,” but AgeX was not subject to any similar exclusivity provision with Serina in the AgeX-Serina Loan transaction documents or at any time prior to entering into the Merger Agreement. Additionally, the Form 8-K noted that AgeX’s restructuring plans also included a potential spinoff of Reverse Bio through a distribution of some or all of the shares of capital stock of Reverse Bio held by AgeX to AgeX stockholders which was contingent upon the successful completion of a potential financing of Reverse Bio through the sale of shares of Reverse Bio common stock to private investors.

 

140

 

 

On March 20, 2023, Gibson Dunn sent the AgeX Board an initial draft of the Merger Agreement and, on March 21, 2023, Gibson Dunn sent the AgeX Board an initial draft of the Support Agreements, which are between Serina and certain AgeX stockholders in one form and AgeX and certain Serina stockholders on the other. Pursuant to each form, the AgeX stockholders and Serina stockholders would agree to, among other things, vote their shares to take all action necessary to consummate the Merger. Between March 20, 2023 and March 27, 2023, Gibson Dunn and members of AgeX management and the AgeX Board discussed the Merger Agreement and Support Agreements, which were revised through rounds of review and comment.

 

On March 27, 2023, Gibson Dunn sent Bradley an initial draft of the Merger Agreement that was largely consistent with the terms set forth in the term sheet. The initial draft of the Merger Agreement contemplated, among other items: (i) the Merger, (ii) no survival of the representations and warranties post-closing, (iii) listing of the shares of AgeX common stock issued to Serina equityholders as merger consideration on a national securities exchange following completion of the Merger, (iv) certain director designation rights, (v) the entry into certain ancillary agreements concurrently with the execution of the Merger Agreement, including the Support Agreements, (vi) issuance of the post-merger warrants and incentive warrants to pre-Merger AgeX stockholders, (vii) the potential transfer and restructuring of certain assets of AgeX pre-closing of the Merger, (viii) termination and reverse termination fees, and (ix) representations, warranties and other covenants customary for transactions of this type.

 

From the March 27, 2023 through the execution of the Merger Agreement, AgeX, Serina and certain of their respective advisors participated in a number of telephone calls and video conferences to discuss the Merger, the terms and conditions proposed in the Merger Agreement and ancillary agreements, due diligence matters and also exchanged due diligence materials.

 

On March 29, 2023, the AgeX Board, with Gibson Dunn present, discussed matters related to the Merger Agreement.

 

The directors also authorized the Special Committee to negotiate transaction termination fee provisions for the Merger Agreement and discussed the expected range of the amount of a termination fee as a percentage of deal value. The directors also discussed requesting Support Agreements and stock Lock-Up Agreements from the officers, directors, and largest stockholders of AgeX and from the officers, directors, and principal stockholders of Serina.

 

On April 6, 2023, Gibson Dunn sent Bradley initial drafts of the Support Agreements and Lock-Up Agreement, each of which had representations, warranties and other covenants customary for transactions of this type.

 

On April 11, 2023, AgeX and Serina executed an extension of AgeX’s exclusivity period, which was set to expire on April 11, 2023 pursuant to the term sheet, to negotiate the Merger with Serina through May 31, 2023.

 

141

 

 

On April 19, 2023, Ms. Hackett, Ms. Bergin and Gibson Dunn met to discuss how the potential failure of Reverse Bio to raise independent financing could impact on the NYSE American deadline of May 17, 2023 to cure certain listing deficiencies.

 

On April 20, 2023, AgeX received a letter (the 2023 Deficiency Letter) from the staff of the NYSE American indicating that AgeX did not meet certain of the NYSE American’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide because AgeX had stockholders equity of less than (A) $2 million and had incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4 million and had incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6 million or more and had reported losses from continuing operations and/or net losses in its five most recent fiscal years. The 2023 Deficiency Letter informed AgeX that it remained subject to the conditions set forth in prior deficiency letters from the NYSE American and stated that if AgeX was not in compliance with the NYSE American’s stockholders equity standards, or did not make progress consistent with an agreed-upon plan to bring AgeX into compliance with the NYSE American’s continued listing standards, by May 17, 2023, then NYSE American would initiate delisting proceedings as appropriate.

 

On May 3, 2023, Ms. Bergin and Gibson Dunn met to discuss Dr. West’s progress towards the potential Reverse Bio financing in anticipation of the May 17, 2023 deadline for compliance by the NYSE American. AgeX corresponded with the NYSE American on several occasions from April 2023 through August 2023 regarding potential remediations to regain compliance under the continued listing standards.

 

On May 11, 2023, Bradley sent Gibson Dunn a revised draft of the Merger Agreement that proposed various revisions, most notably the notion that certain post-merger warrants held by major shareholders of the merged company would be callable at the company’s election. This was intended to provide financial runway for the newly merged company.

 

On May 17, 2023, AgeX received a notice from the NYSE American indicating that they intended to commence proceedings to delist AgeX common stock from the NYSE American.

 

On May 19, 2023, the AgeX Board authorized AgeX to request an appeal to the NYSE American. Thereafter, AgeX notified a committee of the board of directors of the NYSE American that it requested an appeal of such decision, and such request stayed any further action by the NYSE American pending a decision on the appeal. The appeal was scheduled for July 25, 2023.

 

On May 18, 2023, AgeX management, Juvenescence and certain of their advisors met via videoconference to discuss the timing of a potential reverse stock split. Initially, AgeX and Serina had planned to conduct a reverse stock split shortly after the merger with the intent of achieving a target trading price range for the post-merger AgeX common stock. However, Serina communicated that it believed that this approach would make it difficult to communicate the economics of the transaction to its shareholders and instead proposed to AgeX that it consider an approach of effecting a reverse stock split prior to the merger close based on a target share count of approximately 2.5 million shares of common stock outstanding immediately prior to the Merger. After the videoconference, AgeX management met with Serina management to confirm that AgeX would be willing to agree in principle to such reverse stock split.

 

142

 

 

On May 20, 2023, Ms. Hackett met with Dr. West to inform him that the AgeX Board was prepared to terminate his employment as Chief Executive Officer; however, the AgeX Board was willing to let Dr. West transition into the role of Chief Executive Officer of Reverse Bio if he could close the potential financing of Reverse Bio by June 20, 2023. The AgeX Board agreed to this solution in part because, once the potential Reverse Bio financing was complete, Reverse Bio would be spun off from AgeX into a separate entity, which Serina understood and agreed with. Ms. Hackett followed up the conversation with a written notice to Dr. West confirming their conversation.

 

On May 24, 2023, AgeX filed a request for a review of the delisting determination by a committee of the board of directors of the NYSE American. On May 31, 2023, AgeX received notice that a hearing with the board of directors of the NYSE American had been scheduled for July 25, 2023.

 

On May 31, 2023, AgeX and Serina executed an extension of AgeX’s exclusivity period to negotiate the Merger with Serina through June 30, 2023.

 

On June 7, 2023, Gibson Dunn sent Bradley a revised draft of the Merger Agreement that proposed various revisions, including revisions to the representations and warranties of AgeX and Serina, foregoing the two classes of post-merger warrants (callable and non-callable post-merger warrants) and instead introduced the Side Letter, pursuant to which (i) AgeX would have an option to call the post-merger warrants held by Juvenescence and (ii) Juvenescence would agree to cancel all out-of-the-money warrants prior to the Merger.

 

Between June 7, 2023 and June 16, 2023, AgeX and Serina management discussed updates to the transaction model, including revising the structure for incentive warrants and creating a side-agreement between Juvenescence and Serina that entitled Serina to call post-merger warrants held by Juvenescence to address the lack of a concurrent private placement in the transaction. On June 13, 2023, Bradley called Gibson Dunn to discuss some of these changes.

 

On June 15, 2023, certain of AgeX’s advisors discussed potential plans for remediation of the listing standards; however, it was agreed that the Merger Agreement was unlikely to be executed prior to the June 22, 2023 deadline for submitting written responses for the appeal.

 

On June 16, 2023, Bradley sent Gibson Dunn a revised draft of the Merger Agreement which was further updated by a draft sent by Bradley to Gibson Dunn on June 19, 2023 that proposed various revisions, including revisions to the representations and warranties of AgeX and Serina, adding the reverse stock split as a closing condition, adding that the closing price of AgeX immediately prior to the Merger must be at least $12.00 as a closing condition in order to make the effect of conversion privileges attached to Serina’s existing preferred shares more predictable, adding that Juvenescence must hold at least one million post-merger warrants as a closing condition, adding termination provisions if the new closing conditions are not met and proposing $1 million in the aggregate as a termination fee, reverse termination fee and third party expense reimbursement.

 

On June 20, 2023, the AgeX Board met and agreed to extend the date for termination of Dr. West’s employment in order to close a potential financing of Reverse Bio. The deadline for termination of Dr. West’s employment was subsequently extended until October 31, 2023. Also during this meeting, Gibson Dunn provided an update on the status of the negotiations with Serina.

 

143

 

 

On June 22, 2023, Gibson Dunn sent Bradley an initial draft of the Side Letter. After delivery of the Side Letter, Mr. Pickett and Mr. Ledger discussed changes to the warrant structure over the next few weeks, including a tranche concept for the callable post-merger warrants, whereby the post-merger warrants held by Juvenescence must be exercised in a series of tranches, and revisions to the post-merger warrants and incentive warrants coverage and pricing that were favorable to AgeX shareholders.

 

On June 30, 2023, AgeX and Serina executed an extension of AgeX’s exclusivity period to negotiate the Merger with Serina through July 31, 2023.

 

On July 1, 2023, Gibson Dunn sent Bradley a revised draft of the Merger Agreement that proposed various revisions, including revisions to the representations and warranties of AgeX and Serina, changing the amount of post-merger warrants received by an AgeX stockholder from one post-merger warrant for each two shares to three post-merger warrants for each five shares, agreeing that Juvenescence will convert certain Juvenescence loans into shares of AgeX common stock prior to the reverse split in accordance with the Side Letter, adding that the terms of the AgeX-Serina Loan pursuant to the AgeX-Serina Note will be amended such that it converts into shares of AgeX common stock immediately prior to the Merger, changing the terms of the incentive warrants such that each incentive warrant is exercisable for one share of AgeX common stock at a price equal to 1.5 multiplied by the lower of the volume weighted average price of a share of AgeX common stock for the 60 day period following the closing of the Merger or the actual closing price as of the Closing Date.

 

On July 7, 2023, Bradley sent Gibson Dunn a revised draft of the Merger Agreement that proposed various revisions, including that Juvenescence will convert all the AgeX notes set forth in the Side Letter, adding the Combined Company Charter to be approved by the AgeX stockholders, adding amended and restated AgeX bylaws, increasing the amount of post-merger warrants held by Juvenescence as a closing condition, excluding Serina warrants from calculation of exchange ratio, and reducing the post-merger warrant multiple from 1.25 to 1.1. Additionally, Bradley noted that before Serina was willing to sign the Merger Agreement, Serina wanted to better understand the assets and liabilities in AgeX prior to closing of the Merger, including (i) the current costs associated with the operations of AgeX, NeuroAirmid, and Reverse Bio, (ii) the likelihood of the Reverse Bio financing and/or disposition, and (iii) the transfer and/or disposition of certain assets to a new subsidiary of AgeX which in consideration for such transfer and/or disposition would assume all remaining liabilities of AgeX other than transaction expenses (or the corporate restructuring plans) in order to protect the interests in NeuroAirmid and Serina after the Merger.

 

On July 7, 2023, Bradley sent Gibson Dunn a revised draft of the Side Letter that proposed various revisions, including having Juvenescence’s post-merger warrants automatically exercised on a certain schedule, conversion of Juvenescence loans to AgeX, requiring unanimous approval of the AgeX Board to amend the Side Letter following the closing of the Merger because Serina would not be in control of the AgeX Board, and a release of certain security interests and guarantees regarding the AgeX debt owed to Juvenescence. Gibson Dunn sent the Side Letter to Goodwin for Juvenescence’s review.

 

On July 8, 2023, the Serina Board called a special meeting of the Serina stockholders to be held on July 19, 2023.

 

On July 10, 2023, Gibson Dunn and Bradley met via videoconference to discuss treatment of certain compensation and benefits plans impacting all employees in the Merger and the structuring of the remaining assets in AgeX prior to the closing of the Merger, including (i) the likelihood of the Reverse Bio financing and/or disposition and (ii) the transfer and/or disposition of any other remaining assets to a new subsidiary of AgeX, other than the stock of NeuroAirmid and the Merger Sub (eventually Serina). On July 12, 2023, Bradley sent Gibson Dunn a revised draft of the Merger Agreement addressing the compensation and benefits plans items the parties discussed.

 

On July 14, 2023, the Serina Board met to discuss the status of the negotiations of the Merger Agreement and the ancillary documents. Later that day, Bradley sent Gibson Dunn a proposed version of the Combined Company Charter.

 

144

 

 

On July 18, 2023, representatives of Juvenescence and Serina met to discuss the Side Letter, including amending the tranches for mandatory exercise of the warrants. Additionally, Bradley sent comments to AgeX’s disclosure schedules and included a due diligence request list.

 

Between July 17, 2023 and July 21, 2023, Thompson Welch, on behalf of AgeX, and Goodwin, on behalf of Juvenescence, negotiated an exchange agreement (or the 2023 Exchange Agreement) pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized AgeX Series A preferred stock and 148,400 shares of a newly authorized AgeX Series B preferred stock in exchange for the cancellation of a total of $36 million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and certain loan origination fees accrued with respect to those loans. The exchange of the indebtedness for shares of AgeX Series A preferred stock and AgeX Series B preferred stock was implemented for the purpose of bringing AgeX common stock back into compliance with the continued listing requirements of the NYSE American that require AgeX to have at least $6 million of stockholders equity; however the continued listing remained dependent upon a determination by the NYSE American that AgeX has regained compliance with their listing standards.

 

On July 19, 2023, the stockholders of Serina met for an informational meeting regarding the status of the negotiations of the potential merger.

 

On July 20, 2023, AgeX management and its advisors met to discuss the appeal of the NYSE American delisting which was to occur on July 25, 2023. The meeting included discussions on whether it would be possible to sign the Merger Agreement prior to the appeal as an executed deal would help support the appeal. Gibson Dunn informed the group that the execution of the Merger Agreement on this timeline was unlikely to occur because Bradley had communicated that it would take several weeks to obtain the necessary Support Agreement signatures from Serina’s stockholders and Serina would not execute the Merger Agreement until these signatures were obtained. Additionally, Serina planned on seeking Support Agreements from its stockholders once the Merger Agreement was in final form. Nonetheless, the parties agreed that signing the Merger Agreement is an important step to showing long-term compliance with NYSE American standards.

 

On July 20, 2023, Juvenescence sent Serina a revised draft of the Side Letter that proposed various revisions, including having Juvenescence’s post-merger warrants callable but not automatically exercised, revising the call right from two equal tranches to three equal tranches, and removing conversion of Juvenescence’s loans as a requirement since Juvenescence was entering into the 2023 Exchange Agreement and would be exchanging loans for AgeX preferred stock. Between July 20, 2023 and July 31, 2023, representatives of Juvenescence and Serina continued to discuss the changes to the Side Letter to reach agreement on the call feature of the warrants and the tranches.

 

On July 21, 2023, Bradley sent to Gibson Dunn a proposed amended and restated bylaws for the post-closing company.

 

On July 24, 2023, AgeX issued the AgeX preferred stock to Juvenescence in exchange for the cancellation of indebtedness as contemplated by the 2023 Exchange Agreement. Shortly thereafter, the NYSE American staff withdrew its delisting determination and cancelled the scheduled hearing of AgeX’s appeal.

 

145

 

 

On July 25, 2023, Gibson Dunn sent to the AgeX Board a draft of Dr. West’s transition and separation agreement, which included a requirement to secure financing for Reverse Bio by October 31, 2023 or his employment with Reverse Bio would terminate. On July 27, 2023, Ms. Hackett sent a draft of the transition and separation agreement to Dr. West. Dr. West and members of the AgeX Board negotiated the terms of transition and separation agreement through August 9, 2023.

 

On July 25, 2023, the Serina Board met to approve the conversion of the outstanding convertible notes held by Serina stockholders in exchange for Serina’s Series A-5 preferred stock and a warrant to purchase additional share of Series A-5 preferred stock in an amount equal to the number of Series A-5 preferred stock received in the conversion.

 

On July, 27, 2023, all of the convertible notes held by Serina stockholders were converted into Serina’s Series A-5 preferred stock and warrants as approved by the Serina Board on July 25, 2023.

 

On July 27, 2023, Goodwin sent Gibson Dunn comments to the Merger Agreement, including removing the Juvenescence loan conversion covenant and updating the third party beneficiary language to address certain Juvenescence rights. Additionally, on July 27, 2023, Serina’s management team sent certain written questions regarding AgeX’s operations, assets, liabilities and corporate restructuring plans to the AgeX management team.

 

On July 31, 2023, AgeX and Serina executed an extension of AgeX’s exclusivity period to negotiate the Merger with Serina through August 31, 2023.

 

On July 31, 2023, Goodwin sent Gibson Dunn comments to the Side Letter, including a provision automatically exercising the tranches of post-merger warrants and a covenant that the parties use reasonable best efforts to elect certain board designees that had been agreed upon between Serina, AgeX and Juvenescence. On July 31, 2023, Gibson Dunn sent Bradley Goodwin’s comments to the Side Letter, Merger Agreement and the Combined Company Charter. Additionally, Gibson Dunn sent Bradley additional comments on the Merger Agreement, including that Serina will use commercial reasonable efforts to obtain elections from each convertible note holder to convert such notes into share of Serina capital stock prior to the Merger, a required vote to remove the cap restricting conversion of the AgeX Series B preferred stock, revising the amount of post-merger warrants to be held by Juvenescence at closing to 1,000,000 warrants, and updating the expiration of the post-merger warrants to July 31, 2025.

 

On August 2, 2023, AgeX, Serina and Bradley had a call to discuss AgeX’s current operations and corporate restructuring plans. In addition, on August 3, 2023, AgeX responded to Serina’s written questions on such corporate restructuring plans. Bradley sent follow up questions on August 4, 2023, which Gibson Dunn responded to on August 5, 2023.

 

On August 3, 2023, Goodwin sent Gibson Dunn comments to the amended and restated bylaws to remove a provision that vacancies and newly created directorships will be filled exclusively by the board, and to add provisions providing that (i) a majority of voting stock can also fill vacant or newly created directorships, (ii) directors may be removed with or without cause, (iii) stockholders holding 10% or more of the voting shares can call special meetings, and (iv) removing supermajority vote requirements. Gibson Dunn sent these comments to Bradley on the same day.

 

On August 3, 2023, Goodwin and Bradley met by telephone to discuss the Combined Company Charter, the amended and restated bylaws, and the Side Letter.

 

146

 

 

On August 4, 2023, Gibson Dunn sent Bradley minor comments on the Lock-Up Agreement and Support Agreements. On August 5, 2023, Bradley confirmed that these agreements were in final form.

 

On August 5, 2023, Bradley sent Gibson Dunn comments to the Merger Agreement, Side Letter, Combined Company Charter and amended and restated bylaws. Bradley’s comments to the Combined Company Charter and amended and restated bylaws mainly restored Bradley’s prior comments. Bradley’s comments on the Merger Agreement include (i) the creation of a new entity (or Newco) that will assume all liabilities of AgeX in existence as of the Effective Time as had been previously discussed on July 7, 2023 and July 10, 2023 such that the NeuroAirmid and Serina assets after the Merger would not be encumbered by the debt and liabilities of AgeX, (ii) Juvenescence converting all AgeX preferred stock that it owns into AgeX common stock prior to the reverse stock split, (iii) adopting certain amendments to AgeX’s and Serina’s existing equity award stock plans, (iv) reserving 1,750,000 shares of AgeX common stock for the 2024 Equity Incentive Plan, (v) revising the amount of post-merger warrants to be held by Juvenescence at closing to 1,113,308, and (vi) including a new closing condition and termination right that required AgeX to have $500,000 of nonrestricted cash immediately prior to the Effective Time. Bradley’s comments on the Side Letter included Juvenescence agreeing to convert AgeX preferred stock into AgeX common stock prior to the reverse stock split, and Juvenescence releasing security interests in all collateral other than upon the assets transferred to Newco. Gibson Dunn forwarded all the comments and revised documents to Goodwin.

 

On August 7, 2023, representatives of AgeX and Serina met to discuss the outstanding issues raised by recent transaction document drafts and timing of executing the Merger Agreement.

 

On August 8, 2023, Goodwin sent comments to Gibson Dunn on the Merger Agreement, Side Letter, Combined Company Charter and amended and restated bylaws. Goodwin’s comments on the Merger Agreement included reducing the closing condition and termination right related to nonrestricted cash in an amount equal to $500,000. Goodwin’s comments on the Side Letter included removing release language and updating the assignment language to permit a transfer of the rights and obligations in the Side Letter to an affiliate. Goodwin’s comments on the Combined Company Charter and amended and restated bylaws mainly restored Goodwin’s prior comments.

 

On August 9, 2023, the AgeX Board met and approved a Transition Services and Separation Agreement pursuant to which Dr. West stepped down as Chief Executive Officer of AgeX but agreed to continue to serve as Chief Executive Officer and as a director of Reverse Bio during a transition period. Following the board meeting, Dr. West and AgeX entered into that agreement. To address the vacancy in the office of Chief Executive Officer, the AgeX Board appointed Joanne Hackett as interim Chief Executive Officer and approved a compensation agreement with her for services in that role. Ms. Hackett stepped down from the Audit Committee and Compensation Committee. The directors, desiring to fill the vacancy on the board created when Dr. West resigned from the board earlier in the year, considered the qualifications of Jean-Christophe Renondin and the recommendation of the Nominating & Corporate Governance Committee and appointed Dr. Renondin to serve as a member of the AgeX Board.

 

Also at the August 9, 2023 AgeX Board meeting, Gibson Dunn provided an update on the status of the negotiations with Serina. The AgeX Board determined that no “majority of the minority” vote would be required to approve a merger transaction with Serina because Juvenescence has no equity interest in Serina and as a result, Juvenescence was not on both sides of the transaction. The AgeX Board made this determination based on (i) the due diligence performed on Serina’s stock ownership and (ii) inquiries to Juvenescence about whether it held any equity interests in Serina. Additionally, Dr. Bailey decided to abstain from voting as a director on approval matters related to the Merger because of his position as a director of the Serina Board.

 

147

 

 

On August 9, 2023, Gibson Dunn sent comments to Bradley on the Merger Agreement, Side Letter, Combined Company Charter and amended and restated bylaws. Gibson Dunn’s comments on the Merger Agreement included minor edits to the representation and warranties in addition to Goodwin’s comments. Additionally, on the same date, Gibson Dunn sent over to Bradley a revised draft of the AgeX disclosure schedule and responses to diligence requests.

 

On August 10, 2023, Bradley and Goodwin met to discuss the outstanding issues raised by recent transaction document drafts. Reflecting discussions among the parties and their respective counsel, the parties agreed that the final form of the Combined Company Charter and amended and restated bylaws would be the version Bradley delivered on August 5, 2023, and the final form of the Side Letter would be the version Gibson Dunn sent on August 9, 2023. On the same day, Bradley sent comments to Gibson Dunn on the Merger Agreement including decreasing the reserve shares of AgeX common stock for the 2024 Equity Incentive Plan from 1,750,000 to 1,725,000, adding a solicitation covenant for Serina pursuant to Internal Revenue Code section 280G, and clarifying that the closing cash condition shall be net of AgeX’s transaction expenses.

 

On August 11, 2023, Bradley sent clean-up comments to the Merger Agreement and Side Letter fixing minor non-substantive issues identified by Gibson Dunn and Goodwin. On the same day, Bradley sent over a revised Serina disclosure schedule addressing most of Gibson Dunn’s prior comments.

 

On August 11, 2023, the Serina Board was provided with the draft Merger Agreement and ancillary agreements. On that same date, a board meeting was called for August 15, 2023, to review the Merger Agreement and the ancillary agreements.

 

On August 14, 2023, Gibson Dunn sent Bradley minor comments to the Serina disclosure schedules.

 

On August 15, 2023, Bradley sent Gibson Dunn comments on the schedules to the Merger Agreement and the Serina disclosure schedules. Additionally, Serina sent AgeX a three year operating budget (including projected sources and uses of funds) for Serina that was prepared by Serina’s management (the Serina Budget Projections), and the Serina Budget Projections were reviewed by AgeX management and its advisors.

 

On August 15, 2023, the Serina Board met to discuss the Merger Agreement and all ancillary agreements. Serina’s management and Bradley were also in attendance. While Dr. Bailey received notice of the meeting and all documents provided to the Serina Board in advance thereof, Dr. Bailey determined that it was in the best interest of the Serina Board, Serina, and the stockholders of Serina, to recuse himself from the Serina Board meeting so that the Serina Board could independently review and vote upon the proposed Merger Agreement, the ancillary documents thereto, and the various transactions contemplated thereby. The Serina Board reviewed its fiduciary duties under Alabama law in connection with a merger. After further discussion and after reviewing and considering the Merger Agreement, the ancillary agreements and the transactions contemplated by each of those documents and after consulting with management and counsel, based on the factors cited in “—Serina Reasons for the Merger,” the Serina Board (other than Dr. Bailey who had voluntarily recused himself): (i) determined that the Merger Agreement, the ancillary agreements, and the contemplated transactions, including the Merger, are fair to, advisable and in the best interests of Serina and its stockholders; (ii) authorized, approved and declared advisable the Merger Agreement and the contemplated transactions, including the Merger; (iii) recommended, upon the terms and subject to the conditions set forth in the Merger Agreement, that the stockholders of Serina vote or consent to approve the matters required to be approved by the Merger Agreement; (iv) approved each of the ancillary agreements and the transaction contemplated thereby; and (v) authorized the officers to make such additional changes as they deemed appropriate in consultation with counsel. Also at that meeting, the Serina Board called a special meeting of the stockholders of Serina for August 25, 2023, to provide additional information to Serina’s stockholders regarding the Merger and the required documents to be executed in connection therewith.

 

148

 

 

On August 17, 2023, Gibson Dunn sent Bradley comments on the Serina disclosure schedules. Later in the day, Bradley sent Gibson Dunn comments on the Serina and AgeX disclosure schedules.

 

On August 18, 2023, Bradley sent Gibson Dunn additional comments and corrections to the Merger Agreement. Later in the day, Gibson Dunn and Bradley met to discuss the status of the transaction documents and timing of the Merger. Based on the timing of expected signatures and board approvals, Bradley and Gibson Dunn agreed to target August 28, 2023 to sign and announce the Merger Agreement.

 

On August 22, 2023, Gibson Dunn and AgeX met to discuss any remaining diligence and substantive issues in the transaction documents. Following the meeting, Gibson Dunn sent to Bradley comments on the Merger Agreement, the post-closing director and officer list, and the AgeX disclosure schedule. Gibson Dunn’s comments to the Merger Agreement included updating AgeX’s capitalization representation and non-substantive clean up edits. Bradley and Gibson Dunn confirmed to each other that all the transaction documents were in final form.

 

On August 24, 2023, the AgeX Board held a meeting by videoconference, at which members of AgeX management and representatives of Gibson Dunn were present. After addressing other unrelated matters, Dr. Bailey informed the other members of the AgeX Board that he was recusing himself from the remainder of the meeting as a result of being a director of Serina and left the videoconference. Representatives of Gibson Dunn communicated that the Merger Agreement, the Side Letter and all other ancillary documents associated with the proposed Merger with Serina were in final form, with no material changes to any of the previously communicated terms. Representatives of Gibson Dunn then reminded the AgeX Board of its fiduciary duties under Delaware law in connection with a merger. After further discussion, based on the factors cited in “—AgeX Reasons for the Merger,” the AgeX Board (other than Dr. Bailey who had recused himself): (i) determined that the Merger and the related transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of AgeX and its stockholders; (ii) approved and declared advisable the Merger Agreement and the related transactions contemplated by the Merger Agreement, including the issuance of shares of AgeX common stock in connection with the Merger; and (iii) recommended that AgeX’s stockholders vote in favor of the Merger Agreement and related AgeX Proposals.

 

On August 25, 2023, Serina held its stockholders meeting at which Serina’s management provided its stockholders with additional information regarding the Merger Agreement and the ancillary documents and answered questions from stockholders. After the meeting, the Serina management team began the process of collecting the Support Agreements and Lock-up Agreements from Serina’s stockholders.

 

Subsequently, on August 29, 2023, AgeX and Serina entered into the Merger Agreement. On August 30, 2023, before opening of the NYSE American for trading that day, AgeX and Serina issued a joint press release announcing the execution of the Merger Agreement. AgeX also filed a current report on Form 8-K with the SEC announcing, among other things, the execution of the Merger Agreement.

 

149

 

 

AgeX Reasons for the Merger

 

The AgeX Board, in consultation with its advisors, evaluated the terms of the Merger Agreement and the related transactions contemplated thereby and (i) determined that the Merger and the other related transactions contemplated by the Merger Agreement (collectively, the Contemplated Transactions) are fair to, advisable and in the best interests of AgeX and its stockholders; (ii) approved and declared advisable the Merger Agreement and the Contemplated Transactions, including the issuance of shares of AgeX common stock to the stockholders of Serina pursuant to the terms of the Merger Agreement; and (iii) recommends that the stockholders of AgeX vote to approve the AgeX Proposals.

 

In reaching its conclusion to approve the Merger Agreement, the Merger and the other Contemplated Transactions, and to recommend that the stockholders of AgeX vote to approve the AgeX Proposals, the AgeX Board considered a number of factors, including, but not limited to, the following (all of which the AgeX Board viewed as supporting its decision to approve the Merger with Serina), which are not necessarily presented in order of their relative importance to the AgeX Board:

 

  the AgeX Board undertook a process of reviewing and analyzing potential strategic options, including remaining a standalone company pursuing AgeX’s pipeline of product candidates and technology platforms by exploring potential partnerships and seeking to develop more mature assets, seeking to raise independent financing for certain product candidates and disposing of certain assets, pursuing strategic mergers and acquisitions, including through a reverse merger, to identify the opportunity that would, in the AgeX Board’s opinion, create the most value for AgeX stockholders (given (i) AgeX’s amount of indebtedness, (ii) that reverse mergers typically require the public company to have cash to obtain a higher relative equity split, (iii) the risk that AgeX may fail to execute on its business strategy or identify any potential strategic alternatives with respect to its assets and development programs if the Merger were not to occur and (iv) the risk that Juvenescence may decide to stop funding AgeX’s operations if the Merger were not to occur, which would likely result in its delisting and dissolution). The AgeX Board believed, after such review of strategic alternatives (including reverse mergers, third-party collaborations and licensing agreements for its core technologies UniverCyte™ and PureStem®, and its cell therapy programs, including AGEX-VASC1 and AGEX-BAT1, financing alternatives for its iTR™ technology and a potential spinout of Reverse Bio) and discussions with its advisors that the Merger is more favorable to AgeX stockholders than the potential value that might have resulted from other strategic options available to AgeX;

 

  the prospects of and risks associated with the other strategic options that the AgeX Board had reviewed and analyzed with its advisors;

 

  the AgeX Board’s belief, as a result of arm’s length negotiations with Serina, that AgeX and its representatives negotiated the most favorable exchange ratio for AgeX’s stockholders to which Serina was willing to agree and that the terms of the Merger Agreement include the most favorable terms to AgeX in the aggregate to which Serina was willing to agree;

 

  the AgeX Board’s belief, following its review with its advisors and Serina management, that Serina’s product candidates and the product candidate of NeuroAirmid have the potential to create meaningful value for stockholders of the combined company and an opportunity for AgeX’s pre-Merger stockholders to participate in the growth of the combined company based on the business, scientific, regulatory, intellectual property, financial, accounting and legal due diligence conducted by its advisors (which included numerous diligence calls and a comprehensive review of Serina’s due diligence materials) regarding:

 

  the regulatory pathway for, and market opportunity of, Serina’s product candidates, including the stage of development of Serina’s product candidates;

 

  the quality and scope of the clinical and preclinical results for Serina’s product candidates;

 

150

 

 

  Serina’s plans for, among other things, advancing Serina’s lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease through preclinical studies towards the goal of an IND submission to the FDA for the initiation of a Phase I clinical trial; and

 

  Serina having additional product candidates in preclinical studies, providing possible additional pathways to regulatory approval; and

 

  the AgeX Board’s view, following its review with its advisors and Serina management, of Serina’s current development and clinical trial plans, the expected operations, management structure, operating plans and cash burn rate of the combined company, and the expected cash resources of the combined company, including the impact of the additional capital expected to be provided to the combined company by Juvenescence through its exercise of post-merger warrants pursuant to the Side Letter, and the ability of such expected cash resources to support the combined company’s current and planned preclinical and clinical trials and operations;

 

  the AgeX Board’s consideration of the potential benefits of the Warrant Dividend to AgeX stockholders, including the potential for AgeX stockholders that receive post-merger warrants to increase their relative ownership of the combined company upon exercise of the post-merger warrants and incentive warrants;

 

  the AgeX Board’s consideration of the possibility that the combined company would be able to take advantage of the potential benefits resulting from becoming a public reporting company listed on NYSE American with Serina’s business to raise additional funds in the future;

 

  the AgeX Board’s view that the combined company will be led by (i) a management team with operational and drug development experience (including that the Chief Executive Officer and Chief Financial Officer positions would be held by interim persons until the combined company’s board of directors could find permanent positions), and (ii) a board of directors with representation from each of the current AgeX Board and Serina Board;

 

  the financial condition and prospects of AgeX, including:

 

  the risks associated with AgeX remaining a standalone company pursuing its pipeline of product candidates, preclinical programs and technology platforms, including the stage of development of AgeX’s assets, which, in the future, may not be successfully developed into products that are marketed and sold; and

 

  the risks associated with the need to obtain substantial amounts of financing to continue its operations and to continue the development of its current programs if AgeX were to remain a standalone company.

 

151

 

 

The AgeX Board also reviewed the terms and conditions of the Merger Agreement and the Contemplated Transactions, as well as the safeguards and protective provisions included therein intended to mitigate risks, including those described below, and concluded that the terms of the Merger Agreement and the Contemplated Transactions, in the aggregate, were reasonable and in the best interests of AgeX and its stockholders under the circumstances:

 

  the calculation of the exchange ratio and the estimated number of shares of AgeX common stock to be issued in the Merger;

 

  the number and nature of the conditions to Serina’s and AgeX’ respective obligations to consummate the Merger, as more fully described below under the caption “The Merger Agreement—Conditions to the Completion of the Merger,” beginning on page 174 in this proxy statement/prospectus/information statement, and the risk of non-satisfaction of such conditions as well as the likelihood that the Merger will be consummated on a timely basis;

 

  the respective rights of, and limitations on, AgeX and Serina under the Merger Agreement to consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances should AgeX or Serina receive a superior offer, and the limitations on the board of directors of each party to change its recommendation in favor of the Merger, as more fully described below under the caption “The Merger Agreement—Non-Solicitation,” beginning on page 180 in this proxy statement/prospectus/information statement;

 

  the $1,000,000 termination fee, payable by AgeX to Serina upon the termination of the Merger Agreement in certain circumstances, the $1,000,000 termination fee payable by Serina to AgeX upon the termination of the Merger Agreement in certain circumstances and the up to $1,000,000 in expense reimbursement payable by AgeX to Serina or by Serina to AgeX, as applicable, in the event of a termination of the Merger Agreement in certain circumstances, as more fully described below under the caption “The Merger Agreement—Termination and Termination Fees” and “—Expenses,” beginning on pages 190 and 195, respectively, in this proxy statement/prospectus/information statement;

 

  the Support Agreements, pursuant to which, certain stockholders of AgeX and Serina have agreed, solely in their capacity as stockholders of AgeX and Serina, respectively, to vote all of their shares of AgeX common stock or Serina capital stock (or execute a written consent) in favor of the proposals submitted to them in connection with the Merger Agreement and the Contemplated Transactions, as more fully described below under the caption “Agreements Related to the Merger—Support Agreements,” beginning on page 196 in this proxy statement/prospectus/information statement;

 

  the agreement of Serina to mail the written consent of Serina’s stockholders necessary to adopt the Merger Agreement thereby approving the Merger and the other Contemplated Transactions within three business days of the registration statement becoming effective;

 

  the expectation that the Merger will qualify as a reorganization within the meaning of Section 368(a) of the Code, and will constitute a “plan of reorganization” within the meaning of Treasury Regulations Section 1.368-2(g), with the result that Serina stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes upon the exchange of Serina common stock for AgeX common stock pursuant to the Merger Agreement, as more fully described below under the caption “The Merger—Material U.S. Federal Income Tax Consequences of the Merger” beginning on page 165 in this proxy statement/prospectus/information statement; and

 

  the belief that the terms of the Merger Agreement, including the parties’ representations, warranties and covenants, and the conditions to their respective obligations, are reasonable and in the best interests of AgeX and its stockholders under the circumstances.

 

152

 

 

The AgeX Board determined that it did not need to engage an independent financial advisor to assess its strategic options and to shop AgeX at any point from 2020 onwards based on the relevant experience of its board members, management and other advisors. As more fully described in the section titled “The Merger—Background of the Merger,” prior to negotiations with Serina, the AgeX Board was unsuccessful in identifying any other strategic alternatives. In the absence of any other strategic alternatives, and given (i) AgeX’s amount of indebtedness, (ii) the risk that AgeX may fail to execute on its business strategy or identify any potential strategic alternatives with respect to its assets and development programs and (iii) the risk that Juvenescence may decide to stop funding AgeX’s operations, which would likely result in its delisting and dissolution, the AgeX Board believes that the relative 75:25 ownership of the combined company alongside the creation of a set of out-of-money warrants that if fully exercised would result in a 58:42 relative value creates the most value for AgeX stockholders.

 

Additionally, after publicly announcing that it was pursuing a transaction with Serina in March 2023, no offers or proposals were received. As a result of years of exploring a potential strategic transaction, including six months where other potential bidders were aware of its pending transaction with Serina prior to AgeX entering into the Merger Agreement, the AgeX Board concluded that the cost of a fairness opinion, which would have required additional indebtedness to obtain, outweighed its benefit.

 

In the course of its deliberations, the AgeX Board also considered a variety of risks and other countervailing factors related to entering into the Merger, which are not necessarily presented in order of their relative importance to the AgeX Board, including:

 

  the $1,000,000 termination fee, payable by AgeX to Serina upon the termination of the Merger Agreement in certain circumstances, and the up to $1,000,000 in expense reimbursement payable by AgeX to Serina in the event of a termination of the Merger Agreement in certain circumstances, and the potential effect of the fees in deterring other potential acquirers from proposing an alternative transaction that may be more advantageous to AgeX’s stockholders;

 

  the prohibition on AgeX to solicit alternative acquisition proposals during the pendency of the Merger;

 

  the substantial expenses to be incurred in connection with the Merger, including the costs associated with any related litigation and the corporate restructuring plans;

 

  the likelihood of disruptive stockholder litigation following announcement of the Merger;

 

  the possible volatility of the trading price of AgeX common stock resulting from the announcement, pendency or completion of the Merger;

 

  the risk that the Merger might not be consummated in a timely manner, or at all, and the potential adverse effect of the public announcement of the Merger or delay or failure to complete the Merger on the reputation of AgeX;

 

  the likely detrimental effect on AgeX’s cash position, stock price and ability to pursue other business and operating plans or to initiate another process and to successfully complete an alternative transaction should the Merger not be completed;

 

  the risk to AgeX’s business, operations and financial results in the event that the Merger is not consummated, including the diminution of AgeX’s cash and the significant challenges associated with the need to raise additional capital through the public or private sale of equity securities;

 

  the risk that the potential benefits of the Merger may not be fully achieved or may not be achieved within the expected timeframe;

 

  the early stage of development of Serina’s product candidates, which, in the future, may not be successfully developed into products that are marketed and sold;

 

  the scientific, technical, regulatory and other risks and uncertainties associated with development and commercialization of AgeX’s product candidates;

 

153

 

 

  the scientific, technical, regulatory and other risks and uncertainties associated with development and commercialization of Serina’s product candidates;

 

  various risks impacting the financial condition, results of operations and prospects for AgeX, including:

 

  the risks and challenges associated with pursuing any strategic alternative to the Merger available to AgeX, including the discussions that its advisors and the AgeX Board previously conducted with other potential transaction partners, including discontinued negotiations of a reverse merger transaction in 2021, and the time to negotiate and complete an alternative strategic transaction and anticipated cash burn;

 

  the risks associated with AgeX remaining a standalone company pursuing its pipeline of product candidates, preclinical programs and technology platforms, including the stage of development of AgeX’s assets, which, in the future, may not be successfully developed into products that are marketed and sold;

 

  the risks associated with the need to obtain substantial amounts of financing to continue its operations and to continue the development of its current programs if AgeX were to remain a standalone company; and

 

  various other risks associated with the combined company and the Merger, including those described in the section titled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” beginning on pages 24 and 124, respectively, of this proxy statement/prospectus/information statement.

 

The foregoing information and factors considered by the AgeX Board are not intended to be exhaustive but are believed to include all of the material factors considered by the AgeX Board. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, the AgeX Board did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the AgeX Board may have given different weight to different factors. The AgeX Board conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, it advisors, and considered the factors overall to be favorable to, and to support, its determination. In arriving at their respective recommendations, the members of the AgeX Board considered the interests of AgeX’s executive officers and directors as described under the caption “The Merger—Interests of the AgeX Directors and Executive Officers in the Merger.”

 

Certain Unaudited Budget Projections for Serina

 

As a matter of course, Serina does not publicly disclose long-term projections of future financial performance given, among other things, the inherent difficulty of predicting financial performance for future periods and the possibility that the underlying assumptions and estimates may not be realized. However, in connection with the exploration of strategic opportunities described in this proxy statement/prospectus/information statement, and in accordance with the Merger Agreement, Serina management prepared and provided to AgeX certain non-public, unaudited projections of sources and uses of funds for Serina (the Serina Budget Projections).

 

The Serina Budget Projections were prepared solely for internal use and are subjective in many respects. As a result, there can be no assurance that the forecasted results will be realized or that actual results will not be significantly higher or lower than estimated. The estimates and assumptions underlying the Serina Budget Projections involve judgments with respect to, among other things, future economic, competitive, regulatory and financial market conditions that may not materialize and are inherently subject to significant uncertainties and contingencies, all of which are difficult to predict and many of which are beyond Serina’s control. There can be no assurance that the Serina Budget Projections will be realized and actual results may vary materially from those shown.

 

The prospective financial information included in this proxy statement/prospectus/information statement was not prepared with a view toward public dissemination or compliance with published guidelines of the SEC or established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information or GAAP, but, in the view of Serina management, was prepared on a reasonable basis, reflected, at the time the prospective financial information was prepared, the best currently available estimates and judgments of Serina management, and presented, to the best of Serina management’s knowledge and belief at that time, the expected course of action and the expected future financial performance of Serina. However, this information is not fact and should not be relied upon as necessarily predictive of actual future results or guidance of any kind, and readers of this proxy statement/prospectus/information statement are strongly cautioned not to rely on the prospective financial information.

 

The summary of the Serina Budget Projections is included in this proxy statement/prospectus/information statement solely to disclose to AgeX’s and Serina’s stockholders certain long-term financial analyses and forecasts that were made available to AgeX and its advisors. The summary of the Serina Budget Projections is not included in this proxy statement/prospectus/information statement to influence an AgeX stockholder’s decision whether to vote for the AgeX Proposals or for any other purpose, and no AgeX stockholder should rely on the Serina Budget Projections in making such a decision. The inclusion of the summary of the Serina Budget Projections in this proxy statement/prospectus/information statement does not constitute an admission or representation that the information is material. The inclusion of the summary of the Serina Budget Projections should not be regarded as an indication that Serina and/or its affiliates, officers, directors, advisors or other representatives consider the summary of the Serina Budget Projections to be necessarily predictive of actual future events or guidance of any kind, and this information should not be relied upon as such. None of Serina, AgeX and/or their respective affiliates, officers, directors, advisors or other representatives give any stockholder of AgeX or Serina any assurance that actual results will not differ materially from the summary of the Serina Budget Projections. The summary of the Serina Budget Projections do not take into account any circumstances, transactions or events occurring after the date on which the information was prepared.

 

154

 

 

Financial measures provided in this section are excluded from the definition of non-GAAP financial measures and, therefore, are not subject to SEC rules regarding disclosures of non-GAAP financial measures, which would otherwise require a reconciliation of a non-GAAP financial measure to a GAAP financial measure. Reconciliations of financial measures included in the summary of the Serina Budget Projections were not relied upon by the AgeX Board in connection with its consideration of the Merger for purposes of its financial analyses. Accordingly, Serina has not provided a reconciliation of such financial measures included in the summary of the Serina Budget Projections.

 

Readers of this proxy statement/prospectus/information statement are strongly cautioned not to rely on the summary of the Serina Budget Projections set forth below. The inclusion of a summary of the Serina Budget Projections in this proxy statement/prospectus/information statement should not be regarded as a representation or guarantee that the targets will be achieved nor that they should place undue reliance, if any, on the summary of the Serina Budget Projections. The summary of the Serina Budget Projections constitutes forward-looking statements and is subject to risks and uncertainties that could cause actual results to differ materially from the projected results. See also “Cautionary Note Regarding Forward-Looking Statements” beginning on page 124 of this proxy statement/prospectus/information statement. The summary of the Serina Budget Projections is also subject to many risks and uncertainties, and you are urged to review the section entitled “Risk Factors” beginning on page 24 of this proxy statement/prospectus/information statement for a description of risk factors relating to the Merger and Serina’s business.

 

EXCEPT AS REQUIRED BY APPLICABLE SECURITIES LAWS, NONE OF SERINA, AGEX OR THE COMBINED COMPANY INTEND TO MAKE PUBLICLY AVAILABLE ANY UPDATE OR OTHER REVISION TO THE SUMMARY OF THE SERINA BUDGET PROJECTIONS SET FORTH BELOW TO REFLECT CIRCUMSTANCES EXISTING AFTER THE DATE ON WHICH THE INFORMATION WAS PREPARED OR TO REFLECT THE OCCURRENCE OF FUTURE EVENTS, EVEN IN THE EVENT THAT ANY OR ALL OF THE ASSUMPTIONS UNDERLYING SUCH SUMMARY OF THE SERINA BUDGET PROJECTIONS ARE NO LONGER APPROPRIATE.

 

The summary of the Serina Budget Projections is based on numerous variables and assumptions that were deemed reasonable as of the date on which such projections were finalized, including, among other things, the following material assumptions (dollar amounts in the following assumptions are in thousands):

 

Sources of Total Additional Cash

 

Total additional cash for 2023E assumes cash of approximately $10,000 from the AgeX-Serina Note issuance and $3,000 from license agreement(s).
Total additional cash for 2024E assumes cash of approximately $10,000 from the exercise of Juvenescence’s post-merger warrants.
Total additional cash for 2025E assumes cash of approximately $5,000 from the exercise of Juvenescence’s post-merger warrants and $5,000 from license agreement(s).

 

Total Operating Expenses

 

Total operating expenses (excluding SER 252 clinical expenses and POZ LNP development expenses) assumes 2023E, 2024E and 2025E year-end, full-time equivalent headcounts of 13, 15 and 16 employees, respectively.

 

The following table presents a summary of the summary of the Serina Budget Projections prepared by Serina management and reviewed by AgeX management and its advisors.

 

($ in thousands)  2023E  2024E  2025E
Starting cash balance  $500   $6,828   $7,243 
Total additional cash   13,100    10,000    10,000 
Total operating expenses (excluding SER 252 clinical expenses and POZ LNP development expenses)   4,525    7,484    8,085 
Total clinical expenses (SER 252)(1)   1,548    4,112    3,335 
Total capital expenses(2)   438    500    500 
Total expenses   6,772    9,585    10,383 
Ending cash balance   6,828    7,243    1,860 

 

(1)Total clinical expenses includes contract research organization costs, patient costs, clinical supply, plasma bioanalysis, lab work, monitoring, auditing, data lock, PK analysis and reports, FDA regulatory and IND submission expenses, and costs to manufacture drug and clinical supplies for Phase Ia, Phase Ib and Phase II.

 

(2)Total capital expenses relate to the acquisition of POZ LNP lab equipment.

 

155

 

 

Serina Reasons for the Merger

 

The following discussion sets forth material factors considered by the Serina Board in reaching its determination to approve the terms and authorize the execution of the Merger Agreement for the purpose of implementing the Merger; however, it may not include all of the factors considered by the Serina Board. In light of the number and wide variety of factors considered in connection with its evaluation of the Merger Agreement, the Serina Board did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors it considered in reaching its determination. The Serina Board viewed its position and determinations as being based on all of the information available and the factors presented to and considered by it. In addition, individual directors may have given different weight to different factors.

 

In the course of reaching its decision to approve the terms and authorize the execution of the Merger Agreement for the purpose of consummating the Merger, the Serina Board consulted with Serina’s senior management and legal counsel, reviewed a significant amount of information and considered a number of factors, including, among others:

 

historical and current information concerning Serina’s business, including its financial performance and condition, operations, management and competitive position;
Serina’s prospects if it were to remain an independent privately held company, including its need to obtain additional financing and the terms on which it would be able to obtain such financing, if at all;
the Serina Board’s belief that no alternatives to the Merger were reasonably likely to create greater value for Serina stockholders, after reviewing the various financing and other strategic options to enhance stockholder value that were considered by the Serina Board;
the cash resources of the combined company expected to be available at the closing of the Merger and the anticipated burn rate of the combined organization;
the broader range of investors to support the development of Serina’s product candidates than it could otherwise obtain if it continued to operate as a privately held company;
the potential to provide its current stockholders with greater liquidity by owning stock in a public company;
the expectation that the Merger with AgeX would be a more time- and cost-effective means to access capital than other options considered;
the expectation that substantially all of Serina’s employees, particularly its management, will serve in similar roles at the combined organization;
the fact that shares of AgeX common stock issued to Serina stockholders will be registered on a Form S-4 registration statement and will become freely tradable for Serina stockholders who are not affiliates of Serina and who are not parties to the Lock-Up Agreements;
the Support Agreements, pursuant to which certain directors, officers and stockholders of AgeX and Serina, respectively, have agreed, solely in their capacity as stockholders of AgeX and Serina, respectively, to vote all of their shares of Serina capital stock or AgeX common stock in favor of the adoption or approval, respectively, of the Merger Agreement;
the ability to obtain an NYSE American listing and comply with the NYSE American listing requirements;

 

156

 

 

the terms and conditions of the Merger Agreement, including, without limitation, the following:

 

the expected relative percentage ownership of AgeX securityholders and Serina securityholders in the combined organization initially at the closing of the Merger and the value of Serina;
the parties’ representations, warranties and covenants and the conditions to their respective obligations;
the number and nature of the conditions of the obligation of AgeX to consummate the Merger; and
the likelihood that the Merger will be consummated on a timely basis.

 

The Serina Board also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:

 

the risk that the potential benefits of the Merger Agreement may not be realized;
the risk that future sales of common stock by existing AgeX stockholders may cause the price of AgeX common stock to fall, thus reducing the value of the consideration received by Serina stockholders in the Merger;
the termination fee of $1,000,000 or the expense reimbursements of up to $1,000,000, but not both, payable by Serina to AgeX upon the occurrence of certain events;
the price volatility of AgeX’s common stock, which may reduce the value of AgeX common stock that Serina stockholders will receive upon the closing of the Merger;
the possibility that AgeX could under certain circumstances consider unsolicited acquisition proposals if superior to the Merger;
the possibility that the Merger might not be completed for a variety of reasons, such as the failure of AgeX to obtain the required stockholder vote, and the potential adverse effect on the reputation of Serina and the ability of Serina to obtain financing in the future in the event the Merger is not completed;
the risk that the Merger might not be consummated in a timely manner or at all;
the expenses to be incurred in connection with the Merger and related administrative challenges associated with combining the organizations;
the additional expenses that Serina’s business will be subject to as a public company following the closing of the Merger to which it has not previously been subject; and
various other risks associated with the combined organization and the Merger, including the risks described in the section titled “Risk Factors” beginning on page 24.

 

The Serina Board weighed the benefits, advantages and opportunities of a potential transaction against the uncertainties and risks described above, as well as the possible diversion of management attention for an extended period of time. After taking into account these and other factors, the Serina Board approved the terms and authorized execution of the Merger Agreement for the purpose of implementing the Merger.

 

157

 

 

Interests of the AgeX Directors and Executive Officers in the Merger

 

In considering the recommendation of the AgeX Board with respect to the issuance of AgeX common stock pursuant to the Merger Agreement and the other matters to be acted upon by AgeX’s stockholders at the AgeX special meeting, AgeX’s stockholders should be aware that certain members of the AgeX Board and current and former executive officers of AgeX have interests in the Merger that may be different from, or in addition to, interests they have as AgeX’s stockholders. These interests may present them with actual or potential conflicts of interest.

 

Treatment of Equity Awards

 

Each of AgeX’s named executive officers and non-employee directors holds vested and unvested equity awards. For information regarding the treatment of AgeX’s named executive officers and non-employee directors stock options, see the section titled “The Merger Agreement—Treatment of AgeX Stock Options” beginning on page 174 of this proxy statement/prospectus/information statement.

 

Employment Agreement and Change of Control Provisions

 

AgeX is party to an employment agreement with Andrea E. Park that provides change of control and severance benefits to Ms. Park upon termination of her employment by AgeX without “cause” or by Ms. Park for “good reason” (each as defined in her employment agreement) following a change of control. If, within 12 months following a change of control of AgeX (which would include the Merger), Ms. Park’s employment is terminated by AgeX or Serina without “cause” or Ms. Park resigns for “good reason,” then Ms. Park would be entitled to receive, subject to signing and not revoking a release:

 

full payment of Ms. Park’s pro-rated target bonus due for such year;
severance in an amount equal to nine months of Ms. Park’s base salary;
for a period of six months, all benefits under any health insurance plan of AgeX under which Ms. Park participated in prior to termination;
all of Ms. Park’s unvested options and restricted stock units, if any, will become fully vested and exercisable immediately; and
with respect to any outstanding vested but unexercised options, the exercise period following termination or resignation will be extended to the earlier of (A) 12 months after termination or (B) the natural expiration date of the applicable option.

 

Under the Transition Agreement, described below in the section titled “AgeX Executive and Director Compensation—Employment Agreements and Change of Control Provisions” beginning on page 359 of this proxy statement/prospectus/information statement, Michael D. West is no longer eligible to receive severance payments or other benefits in connection with a change in control under his employment agreement.

 

On June 4, 2021, the Compensation Committee of the AgeX Board approved by way of a meeting (the June 4, 2021 Compensation Committee Meeting) certain acceleration rights of the equity awards held by Nafees N. Malik that mirrors the acceleration rights of Ms. Park in connection with a change of control. Like Ms. Park, if Mr. Malik is terminated by AgeX without “cause” or resigns for “good reason” (each as defined in the June 4, 2021 Compensation Committee Meeting) within 12 months following a change of control of AgeX (which would include the Merger), then Mr. Malik would be entitled to, subject to signing and not revoking a release, the full vesting of all of Mr. Malik’s unvested options and restricted stock units (if any), which will become exercisable immediately. Further, with respect to any outstanding vested but unexercised options held by Mr. Malik, the exercise period following termination or resignation will be extended to the earlier of (A) 12 months after termination or (B) the natural expiration date of the applicable option.

 

158

 

 

The AgeX Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching their respective decisions to approve the Merger Agreement and the Merger, and to recommend, as applicable, that AgeX’s stockholders approve the proposals to be presented to AgeX’s stockholders for consideration at the AgeX special meeting as contemplated by this proxy statement/prospectus/information statement.

 

Ownership Interests

 

As of January 3, 2024, AgeX’s non-employee directors and executive officers beneficially owned, in the aggregate, approximately 16,489,966 shares of AgeX common stock, which for purposes of this subsection (i) excludes any shares of AgeX common stock issuable upon exercise or settlement of AgeX options held by such individual and (ii) includes shares of AgeX common stock held by an affiliate of a non-employee director other than shares of AgeX common stock issuable upon exercise, settlement or conversion of AgeX warrants, outstanding loans or preferred stock held by such affiliate. As of January 3, 2024, Juvenescence, an AgeX stockholder affiliated with one of AgeX’s non-employee directors, beneficially owned 211,600 of the shares of AgeX Series A preferred stock and 148,400 of the shares of AgeX Series B preferred stock.

 

The affirmative vote of the holders of a majority of AgeX common stock outstanding and entitled to vote at the AgeX special meeting is required for the approval of Proposal No. 4 (the A&R Charter Proposal). The affirmative vote of a majority of the voting power of the shares of AgeX common stock present or represented by proxy at the AgeX special meeting and entitled to vote on the matter is required for the approval each of Proposal Nos. 1, 2, 3, 5, 6 and 7 (the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the Non-Binding Governance Proposals, the 2024 Equity Incentive Plan Proposal and the Adjournment Proposal).

 

On August 29, 2023, Juvenescence entered into the AgeX Support Agreement in connection with the Merger. Juvenescence is an AgeX stockholder affiliated with one of AgeX’s non-employee directors holding approximately 43.3% of the outstanding shares of AgeX common stock, 100% of the outstanding shares of AgeX Series A preferred stock and 100% of the outstanding shares of AgeX Series B preferred stock as of January 3, 2024. For a more detailed discussion of the Support Agreements, please see the section titled “Agreements Related to the Merger” beginning on page 196 of this proxy statement/prospectus/information statement.

 

AgeX Stock Options

 

As of September 12, 2023, AgeX’s named executive officers and directors collectively owned unvested stock options to purchase 200,614 shares of AgeX common stock and vested stock options to purchase 2,451,741 shares of AgeX common stock, for a total of options to purchase 2,652,355 shares of AgeX common stock. All outstanding and unexercised options to purchase shares of AgeX common stock will remain effective and outstanding.

 

159

 

 

The following table presents certain information concerning the outstanding AgeX stock options held by each of AgeX’s named executive officers and directors as of September 12, 2023:

 

Name  Grant Date 

Option

 

Expiration Date

 

Option

 

Exercise Price

   Number of Vested Shares of Common Stock Underlying Options as of September 12, 2023   Number of Unvested Shares of Common Stock Underlying Options as of September 12, 2023 
Michael D. West  6/4/2021  6/3/2031  $1.45    67,500    52,500 
   3/11/2019  3/10/2029  $4.28    100,000    - 
   10/18/2018  10/17/2028  $3.00    500,000    - 
   10/10/2017  10/9/2027  $2.00    660,000    - 
                      
Andrea E. Park  6/4/2021  6/3/2031  $1.45    42,187    32,813 
   5/21/2020  5/20/2030  $0.738    243,750    56,250 
   10/1/2019  9/30/2029  $1.77    19,583    417 
                      
Nafees N. Malik  6/4/2021  6/3/2031  $1.45    42,187    32,813 
   3/11/2019  3/10/2029  $4.28    70,000    - 
   10/18/2018  10/17/2028  $3.00    350,000    - 
                      
Gregory H. Bailey  6/21/2021  6/20/2031  $1.48    65,000    - 
   3/11/2019  3/10/2029  $4.28    100,000    - 
                      
Joanne M. Hackett  2/2/2022  2/1/2032  $0.8336    65,000    - 
                      
Michael H. May  6/21/2021  6/20/2031  $1.48    100,000    - 
   8/5/2019  8/4/2029  $2.40    26,534    - 
                      
Jean-Christophe Renondin  8/9/2023  8/8/2033  $0.76    -    25,821 

 

Indemnification and Insurance

 

For a discussion of the indemnification and insurance provisions related to the AgeX directors and officers under the Merger Agreement, please see the section titled, see the section titled “The Merger Agreement—Other Agreements—Indemnification and Insurance.

 

Management Following the Merger

 

As described elsewhere in this proxy statement/prospectus/information statement, including in the section titled “Management Following the Merger,” upon the closing of the Merger, Gregory H. Bailey, M.D., a member of the AgeX Board, will serve on the Combined Company Board and Andrea E. Park, AgeX’s Chief Financial Officer, will serve as the Interim Chief Financial Officer and Chief Accounting Officer of the combined company.

 

160

 

 

Interests of the Serina Directors and Executive Officers in the Merger

 

In considering the recommendation of the Serina Board with respect to approving the Merger, Serina stockholders should be aware that certain members of the Serina Board and executive officers of Serina have interests in the Merger that may be different from, or in addition to, interests they have as Serina stockholders. All of Serina’s executive officers and directors have options to purchase shares of Serina capital stock that will be converted into and become options to purchase shares of AgeX common stock. Certain of Serina’s directors and executive officers are expected to become directors and executive officers of the combined organization upon the closing of the Merger and all of Serina’s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement.

 

Ownership Interests

 

Certain of Serina’s directors and executive officers currently hold shares of Serina capital stock. The table below sets forth the anticipated ownership of Serina capital stock by Serina’s directors and executive officers immediately prior to the closing of the Merger based on their ownership of Serina’s capital stock as of January 3, 2024.

 

Directors and Executive Officers  Number of Shares of Serina Capital Stock Held Immediately Prior to Closing(1) 
Randall Moreadith    
Michael D. Bentley   500,000 
Barbara M. Fisk   509,993 
Tacey Viegas   60,000 
James R. Hudson, Jr.   212,000 
Steve Ledger   233,334 
J. Milton Harris    
Gregory Bailey    

 

(1)The number of shares of Serina capital stock (i) excludes any shares of Serina common stock issuable upon exercise or settlement of Serina options held by such individual, (ii) includes shares of Serina common stock held by an affiliate of a non-employee director other than shares of Serina common stock issuable upon exercise, settlement or conversion of Serina warrants and (iii) assumes a 1 to 1 conversion of Serina preferred stock to Serina common stock. The actual number of shares of Serina common stock that a holder of Serina preferred stock may receive upon conversion the conversion of a share of Serina preferred stock may be different.

 

161

 

 

Serina Stock Options

 

Under the terms of the Merger Agreement, at the Effective Time, each outstanding and unexercised Serina option immediately prior to the Effective Time under the Serina Plan will be converted into and become an option to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the option and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume the Serina Plan and each Serina option in accordance with the terms of the Serina Plan and the terms of the Serina option.

 

The following table presents certain information concerning the outstanding Serina options held by Serina’s directors and current executive officers, as of November 5, 2023:

 

Optionholder Name  Grant Date 

Expiration

Date

 

Exercise

Price

   Number of Shares of Serina Common Stock Underlying Option as of November 5, 2023   Number of Shares of Serina Common Stock Underlying Option Vested as of November 5, 2023 
Randall Moreadith  5/6/2021  5/6/2031  $0.06    533,550    533,550 
   7/29/2021  7/29/2021  $0.06    96,000    96,000 
Michael D. Bentley  5/6/2021  5/6/2031  $0.06    36,000    36,000 
   7/29/2021  7/29/2021  $0.06    36,000    36,000 
Tacey Viegas  5/6/2021  5/6/2031  $0.06    208,392    208,392 
   7/29/2021  7/29/2021  $0.06    141,608    141,608 
Steve Ledger  7/29/2021  7/29/2031  $0.06    116,666    116,666 
J. Milton Harris  5/6/2021  5/6/2031  $0.06    36,000    36,000 
   7/29/2021  7/29/2021  $0.06    36,000    36,000 

 

Serina Warrants

 

As of November 5, 2023, Serina’s named executive officers and directors and such directors affiliates held warrants exercisable into 34,616 shares of Serina common stock. Under the terms of the Merger Agreement, at the Effective Time, each outstanding and unexercised Serina warrant immediately prior to the Effective Time, if any, will be converted into and become a warrant to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the warrant and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume each Serina warrant in accordance with its terms.

 

162

 

 

Management Following the Merger

 

As described elsewhere in this proxy statement/prospectus/information statement, including in the section captioned “Management Following the Merger,” certain of Serina’s directors and executive officers are expected to become the directors and executive officers of the combined company upon the closing of the Merger.

 

Indemnification and Insurance

 

For a discussion of the indemnification and insurance provisions related to the Serina directors and officers under the Merger Agreement, please see the section titled, see the section titled “The Merger Agreement—Other Agreements—Indemnification and Insurance.

 

Form of Merger

 

Subject to the terms and conditions of the Merger Agreement, and in accordance with Alabama law, at the completion of the Merger, Merger Sub, an Alabama corporation and wholly owned subsidiary of AgeX, will merge with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX.

 

Merger Consideration and Exchange Ratio

 

Pursuant to the Merger Agreement, at the Effective Time, each outstanding share of Serina common stock (after giving effect to the Serina preferred stock conversion and including all such shares that are so converted, other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares) will be automatically converted solely into the right to receive a number of shares of AgeX common stock equal to the exchange ratio. The exchange ratio is currently estimated to be equal to approximately 0.83217216 shares of AgeX common stock for each share of Serina common stock, which estimated exchange ratio assumes (i) the Actual Closing Price of a share of AgeX common stock is equal to $12.00 per share (on a post-reverse stock split basis), (ii) the number of Company Outstanding Shares (as defined below) is equal to 9,012,558, (iii) the number of Company Merger Shares (as defined below) is equal to 7,500,000 and (iv) the implementation of the reverse stock split and the AgeX preferred stock conversion prior to the consummation of the Merger, as described elsewhere in this proxy statement/prospectus/information statement. There can be no assurance any of these assumptions will be accurate when the final exchange ratio is determined.

 

No fractional shares of AgeX common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any holder of Serina capital stock who would otherwise be entitled to receive a fraction of a share of AgeX common stock (after aggregating all fractional shares of AgeX common stock issuable to such holder) will receive from AgeX, in lieu of such fraction of a share and upon such holder’s surrender of a letter of transmittal in accordance with the Merger Agreement and any accompanying documentation required therein, (i) one share of AgeX common stock if the aggregate amount of fractional shares of AgeX common stock such holder of Serina capital stock would otherwise be entitled to is equal to or exceeds 0.50 or (ii) no shares of AgeX common stock if the aggregate amount of fractional shares of AgeX common stock such holder of Serina capital stock would otherwise be entitled to is less than 0.50.

 

The exchange ratio formula is based upon a fixed percentage of the post-Merger outstanding shares of AgeX common stock, expressed on a fully-diluted and as-converted basis, subject to certain adjustments and exclusions.

 

For a more complete description of the Merger, the potential adjustments in the exchange ratio, please see the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio.”

 

163

 

 

Procedures for Exchanging Stock Certificates

 

Prior to the Closing Date, AgeX and Serina will select an exchange agent and, at the Effective Time, AgeX will deposit with the exchange agent evidence of book-entry shares representing the shares of AgeX common stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Serina common stock (after giving effect to the Serina preferred stock conversion and including all such shares that are so converted, other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares).

 

Promptly after the Effective Time, the exchange agent will mail to each record holder of Serina common stock (after giving effect to the Serina preferred stock conversion and including all such shares that are so converted, other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares) (i) a letter of transmittal and (ii) instructions for effecting the surrender of the record holder’s stock certificates or uncertificated shares of capital stock in exchange for the merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent’s instructions and the declaration for tax withholding purposes, the surrender of the record holder’s stock certificates or other reasonable evidence of the ownership of uncertificated capital stock and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or AgeX, the record holder of such stock certificates or book-entry shares, as applicable, will be entitled to receive in exchange therefor book-entry shares representing the number of whole shares of AgeX common stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Serina capital stock will be canceled.

 

After the Effective Time, each certificate representing Serina capital stock that has not been surrendered will represent only the right to receive shares of AgeX common stock issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.

 

Effective Time of the Merger

 

The Merger will become effective on the date and at the time the Statement of Merger has been duly filed with the Secretary of State of the State of Alabama or at such later time as may be specified in the Statement of Merger with the consent of AgeX and Serina in accordance with the ABCL.

 

Regulatory Approvals

 

In the United States, AgeX must comply with applicable federal and state securities laws and the rules and regulations of the NYSE American in connection with the issuance of shares of AgeX common stock to Serina’s stockholders in connection with the Contemplated Transactions and the filing of this proxy statement/prospectus/information statement with the SEC. AgeX does not intend to seek any regulatory approval from antitrust authorities to consummate the Contemplated Transactions.

 

164

 

 

Material U.S. Federal Income Tax Consequences of the Merger

 

The following discussion summarizes material U.S. federal income tax consequences of the Merger that are generally expected to be applicable to Serina stockholders and AgeX stockholders who are U.S. holders (as defined below), assuming the Merger is consummated as contemplated herein. This summary is based on current law, including the provisions of the Code, Treasury Regulations promulgated thereunder, judicial authority, and administrative rulings and practice, each as in effect as of the date of this proxy statement/prospectus/information statement and all of which are subject to change, possibly with retroactive effect.

 

This summary is not a complete description of all tax consequences of the Merger and does not address U.S. federal income tax consequences that may be relevant to particular Serina stockholders in light of their personal circumstances or to Serina stockholders who are subject to special treatment under U.S. federal income tax laws, such as Serina stockholders who: do not hold their Serina capital stock as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment); are banks, insurance companies, tax-exempt entities, mutual funds, financial institutions, real estate investment trusts, regulated investment companies, government entities or broker-dealers; hold their Serina capital stock as “qualified small business stock” under Section 1202 of the Code or as “Section 1244 stock” under Section 1244 of the Code; hold their Serina capital stock as part of a hedging, “straddle,” conversion or other integrated transaction or are treated as having sold their Serina stock pursuant to the constructive sale provisions of the Code; are not U.S. holders; acquired their Serina capital stock pursuant to the exercise of compensatory options, or in other compensatory transactions; acquired their Serina capital stock pursuant to the exercise of warrants or conversion rights under convertible instruments; are subject to special tax accounting rules under Section 451(b) of the Code; hold their Serina capital stock through individual retirement or other tax-deferred accounts; acquired their Serina capital stock in a transaction subject to the gain rollover provisions of Section 1045 of the Code; have a functional currency other than the U.S. dollar; or are partnerships or entities or arrangements classified as partnerships or disregarded entities for U.S. federal income tax purposes, S corporations, or other pass-through entities (including hybrid entities) and investors therein.

 

In addition, this summary does not address (i) the tax consequences of the Merger under U.S. federal non-income tax law (including estate, gift, or other non-income taxes), (ii) the tax consequences of the Merger under state, local or non-U.S. tax laws, (iii) the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, (iv) the tax consequences of transactions effectuated before, subsequent to or concurrently with the Merger (whether or not any such transactions are consummated in connection with the Merger), including, without limitation, any transaction in which shares of Serina capital stock are acquired, (v) the tax consequences to holders of Serina stock options, Serina warrants or similar rights to acquire Serina capital stock, or (vi) the tax consequences of the Merger to Serina stockholders who exercise appraisal or appraisal rights.

 

If a partnership or other entity or arrangement taxable as a partnership for U.S. federal income tax purposes holds Serina capital stock, the tax treatment of a partner in such partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Such partner should consult its tax advisors as to the tax consequences of the Merger.

 

165

 

 

This summary is limited to beneficial owners of Serina or AgeX stock who are U.S. holders. A U.S. holder is a beneficial owner of Serina capital stock that is for U.S. federal income tax purposes:

 

an individual who is a citizen or resident of the United States;
a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;
an estate the income of which is subject to U.S. federal income tax regardless of its source; or
a trust with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions, or an electing trust that was in existence on August 19, 1996 and was treated as a domestic trust on that date.

 

No opinions of counsel or rulings from the Internal Revenue Service (IRS) have been requested or obtained in connection with the Merger. Accordingly, all Serina stockholders should consult their own tax advisors as to the specific tax consequences to them of the Merger, including applicable tax reporting requirements.

 

IN VIEW OF THE FOREGOING AND BECAUSE THE FOLLOWING DISCUSSION IS INTENDED AS A GENERAL SUMMARY ONLY, EACH SERINA STOCKHOLDER SHOULD CONSULT SUCH STOCKHOLDER’S OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES, INCLUDING THE APPLICABLE U.S. FEDERAL, STATE, LOCAL AND NON-U.S. TAX CONSEQUENCES, AND ANY TAX REPORTING REQUIREMENTS OF THE MERGER AND RELATED TRANSACTIONS IN LIGHT OF SUCH STOCKHOLDER’S OWN TAX SITUATION.

 

Treatment of U.S. Holders in the Merger

 

Each of AgeX and Serina intends the Merger to qualify as a “reorganization” within the meaning of Section 368(a) of the Code. Assuming the Merger so qualifies, U.S. holders of Serina stock will not recognize gain or loss upon the exchange of their Serina capital stock for AgeX common stock. U.S. holders of Serina stock will obtain a basis in the AgeX common stock they receive in the Merger equal to their basis in the Serina capital stock exchanged therefor. The holding period of the shares of AgeX common stock received by a U.S. holder of Serina stock in the Merger will include the holding period of the shares of Serina capital stock surrendered in exchange therefor.

 

If the Merger does not qualify as a reorganization within the meaning of Section 368(a) of the Code, then each U.S. holder of Serina stock would be treated as exchanging its Serina capital stock in a fully taxable transaction in exchange for AgeX common stock. U.S. holders of Serina stock generally would recognize capital gain or loss in such exchange equal to the difference between (i) the fair market value of the AgeX common stock received in the Merger and (ii) such holder’s tax basis in the Serina capital stock surrendered in the Merger. The aggregate tax basis of a U.S. holder in the AgeX common stock received in the Merger would equal the fair market value at the Effective Time of the U.S. holder’s Serina capital stock exchanged in the Merger, and the holding period of AgeX common stock received in the Merger would begin on the day after the Effective Time of the Merger.

 

For purposes of the above discussion of the bases and holding periods for shares of Serina capital stock acquired by U.S. holders at different times for different prices, such U.S. holders must calculate their gains and losses and holding periods separately for each identifiable block of such stock exchanged in the Merger.

 

For U.S. holders of AgeX stock, because they did not engage in any exchange in the Merger, the Merger is not a realization event and therefore there are no tax consequences with respect to such U.S. holders of AgeX stock by reason of the Merger.

 

U.S. holders are urged to consult their tax advisors regarding the U.S. federal income tax consequences of the Merger in light of their personal circumstances and the consequences to them under state, local and non-U.S. tax laws and other federal tax laws.

 

166

 

 

Information Reporting

 

Each U.S. holder who receives shares of AgeX common stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. U.S. holders who owned immediately before the Merger at least one percent (by vote or value) of the total outstanding stock of Serina are required to attach a statement to their tax returns for the year in which the Merger is consummated that contains the information listed in Treasury Regulation Section 1.368-3(b). Such statement must include the U.S. holder’s tax basis in such U.S. holder’s Serina capital stock surrendered in the Merger, the fair market value of such Serina capital stock, the date of the Merger and the name and employer identification number of each of Serina and AgeX. U.S. holders are urged to consult with their tax advisors to comply with these rules.

 

This summary does not take into account your particular circumstances and does not address consequences that may be particular to you. Therefore, you should consult your tax advisor regarding the particular consequences of the Merger to you.

 

NYSE American Listing

 

AgeX common stock currently is listed on the NYSE American under the symbol “AGE.” AgeX has agreed to use commercially reasonable efforts (i) to maintain its existing listing on the NYSE American until the Effective Time and obtain approval of the listing of the combined company on the NYSE American, (ii) to the extent required by the rules and regulations of the NYSE American, to prepare and submit to the NYSE American market a notification for the listing of the shares of AgeX common stock to be issued in connection with the Merger, and to cause such shares to be approved for listing (subject to official notice of issuance), (iii) to effect the reverse stock split, and (iv) to the extent required by the NYSE American market rules, to file an initial listing application for the AgeX common stock on the NYSE American market and to cause the listing application to be conditionally approved prior to the Effective Time.

 

In addition, under the Merger Agreement, each of Serina’s and AgeX’s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the Merger, of various conditions, including that the shares of AgeX common stock to be issued in the Merger have been approved for listing on the NYSE American market as of the closing of the Merger. Both AgeX and Serina have agreed to use commercially reasonable efforts to coordinate with respect to compliance with the NYSE American rules and regulations. AgeX has agreed to pay all fees associated with the listing application. Serina has agreed to cooperate with AgeX as reasonably requested by AgeX with respect to the listing application and promptly furnish AgeX all information concerning Serina and its members that may be required or reasonably requested in connection with any action contemplated by the listing agreement.

 

If the NYSE American Listing Application is accepted, AgeX anticipates that the common stock of the combined company will be listed on the NYSE American following the closing of the Merger under the trading symbol “SER.”

 

167

 

 

Anticipated Accounting Treatment

 

The Merger will be treated by AgeX as a reverse recapitalization under GAAP. For accounting purposes, Serina is considered to be the accounting acquirer in this transaction.

 

Appraisal Rights

 

AgeX

 

Under the DGCL, AgeX stockholders are not entitled to appraisal rights in connection with the Merger.

 

Serina

 

Holders of Serina capital stock as of the record date are entitled to appraisal rights under the ABCL. Pursuant to Section 10A-2A-13.02 of the ABCL, a Serina stockholder who does not wish to accept the merger consideration to be received pursuant to the terms of the merger agreement may elect to receive the fair value of such stockholder’s Serina capital stock (as determined immediately prior to the consummation of the merger), excluding any appreciation or depreciation in anticipation of the merger unless exclusion would be inequitable, but including interest from the effective date of the merger until the date of payment. Under the terms of the merger agreement, if 5% or more of the outstanding shares of Serina capital stock validly exercise their appraisal rights, then AgeX will not be obligated to complete the merger.

 

In order to exercise appraisal rights, a Serina stockholder must strictly comply with the statutory procedures of Sections 10A-2A-13.01 through 10A-2A-13.40 of the ABCL, which are summarized below. A copy of the full text of those Sections is included as Annex D to this proxy statement/prospectus/information statement. Serina stockholders are urged to read Annex D in its entirety and to consult with their legal advisors. Each Serina stockholder who desires to assert appraisal rights is cautioned that failure to adhere strictly to the requirements of Alabama law in any regard will cause a forfeiture of any appraisal rights. Serina stockholders who do not properly follow appraisal rights procedures will receive the merger consideration if the merger is effected.

 

Procedures for Exercising Rights of Appraisal. The following summary of Alabama law is qualified in its entirety by reference to the full text of the applicable provisions of the ABCL, a copy of which is included as Annex D to this proxy statement/prospectus/information statement.

 

A holder of Serina capital stock electing to exercise its appraisal rights shall not sign and return the written consent adopting the Merger Agreement approve the transactions and actions contemplated by the Merger Agreement, including the Merger.

 

No later than ten days after the merger, Serina, as the continuing corporation of the merger, will send a written notice to each stockholder exercising its appraisal rights who did not vote in favor of the merger and who duly filed a written notice of intent to demand payment in accordance with the foregoing procedures. The appraisal rights notice will specify, among other things, the deadline by which time Serina must receive a payment demand from such stockholders, the deadline for depositing the stockholders’ shares and the location for such deposit, the deadline by which time such stockholder may withdraw from the appraisal process, and Serina’s estimate of the fair value of the stock, and will include a form for demanding payment. The deadline for demanding payment will be no fewer than 40 days and no more than 60 days after the date the appraisal rights notice is delivered. It is the obligation of any stockholder electing to exercise appraisal rights to initiate all necessary action to perfect such stockholder’s appraisal rights within the time periods prescribed in Article 13 of the ABCL and the appraisal rights notice. If no payment demand is timely received from a stockholder exercising appraisal rights, all appraisal rights of said stockholder will be lost, notwithstanding any previously submitted written notice of intent to demand payment. Each stockholder exercising appraisal rights who demands payment retains all other rights of a stockholder unless and until those rights are cancelled or modified by the merger. A stockholder exercising appraisal rights who demands payment in accordance with the foregoing and does not withdraw from the appraisal process before the deadline set forth in the appraisal rights notice provided by Serina may not thereafter withdraw that demand and accept the terms offered under the merger agreement unless Serina consents thereto.

 

168

 

 

On or before the stock certificate delivery deadline, which may not be before the deadline for demanding formal payment, a stockholder exercising appraisal rights who has made a demand must submit such stockholder’s stock certificate or certificates to Serina. A stockholder’s failure to submit shares of capital stock for notation will, at Serina’s option, terminate the holder’s appraisal rights, unless a court of competent jurisdiction determines otherwise.

 

Promptly after the merger, or upon receipt of a payment demand, Serina shall offer to pay each stockholder exercising appraisal rights who complied with Article 13 of the ABCL the amount Serina estimates to be the fair value of such stockholder’s shares of capital stock plus accrued interest. Each stockholder exercising appraisal rights who agrees to accept the offer of payment in full satisfaction of such stockholder’s demand must surrender to Serina the certificate or certificates representing such shares of capital stock in accordance with the terms of the appraisal rights notice. Upon receiving the certificate or certificates, Serina will pay each stockholder exercising appraisal rights the fair value of such stockholder’s shares of capital stock, plus accrued interest. Upon receiving payment, each stockholder exercising appraisal rights ceases to have any interest in the shares.

 

Each stockholder exercising appraisal rights who has made a payment demand may notify Serina in writing such stockholder’s own estimate of the fair value of such stockholder’s shares of capital stock plus interest, and demand payment of such estimate, or reject the offer made to such stockholder as described above and demand payment of the fair value of such stockholder’s shares of capital stock and interest due, if: (1) the stockholder exercising appraisal rights believes that the amount offered is less than the fair value of the shares of capital stock or that the interest due is incorrectly calculated; or (2) Serina fails to make an offer as required by Article 13 of the ABCL within 60 days after the date set for demanding payment; provided, however, that a stockholder exercising appraisal rights waives the right to demand payment different from that offered unless such stockholder notifies Serina of its demand in writing within 30 days after Serina offered payment for the shares of capital stock.

 

If a demand for payment remains unsettled, Serina will commence a proceeding within 60 days after receiving the payment demand and petition the court to determine the fair value of the shares of capital stock and accrued interest. If the proceeding is not commenced within the 60-day period, each stockholder exercising appraisal rights whose demand remains unsettled shall be entitled to receive the amount demanded plus interest. Such a proceeding will be filed in the Circuit Court of Madison County, Alabama. Each stockholder exercising appraisal rights made a party to the proceeding is entitled to judgment for the amount the court finds to be the fair value of the shares of capital stock, plus accrued interest. The court’s finding may set a value above or below the value the stockholder believes is appropriate. Upon payment of the judgment and surrender to Serina of the certificate or certificates representing the judicially appraised shares of capital stock, a stockholder exercising appraisal rights will cease to have any interest in the shares of capital stock. The Court may assess costs incurred in such a proceeding against Serina or may assess the costs against all or some of the stockholders exercising appraisal rights, in amounts the court finds equitable, to the extent the Court finds that such stockholders acted arbitrarily, vexatiously or not in good faith in demanding payment different from that initially offered by Serina. The Court may also assess the reasonable fees and expenses of counsel and experts against Serina, if the Court finds that it did not substantially comply with its requirements regarding providing notice of appraisal rights and the procedures associated therewith under Article 13 of the ABCL or against either Serina or all or some of the dissenting stockholders if the Court finds that the party against whom the fees and expenses are assessed acted arbitrarily, vexatiously or not in good faith with respect to the rights provided in Article 13 of the ABCL. If the Court finds that services of counsel for any stockholder exercising appraisal rights were of substantial benefit to other similarly situated stockholders, and that fees for such services should not be assessed against Serina, then the Court may award reasonable fees to such counsel that will be paid out of the amounts awarded to stockholders exercising appraisal rights who benefited from such services.

 

BECAUSE OF THE COMPLEXITY OF THE PROVISIONS OF ALABAMA LAW RELATING TO APPRAISAL RIGHTS, STOCKHOLDERS WHO ARE CONSIDERING EXERCISING APPRAISAL RIGHTS WITH RESPECT TO THE MERGER ARE URGED TO CONSULT THEIR OWN LEGAL ADVISORS.

 

169

 

 

THE MERGER AGREEMENT

 

The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached as Annex A to this proxy statement/prospectus/information statement and is incorporated by reference herein. The Merger Agreement has been attached to this proxy statement/prospectus/information statement to provide you with information regarding its terms. It is not intended to provide any other factual information about AgeX, Serina or Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.

 

The Merger Agreement contains representations and warranties that AgeX and Merger Sub, on the one hand, and Serina, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if such statements made in the representations and warranties prove to be incorrect. In addition, the assertions made in the representations and warranties are qualified by the information in confidential disclosure schedules exchanged by the parties in connection with the signing of the Merger Agreement. While AgeX and Serina do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about AgeX, Serina or Merger Sub, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between AgeX and Merger Sub on the one hand, and Serina on the other hand, and are modified by the disclosure schedules.

 

Structure

 

Subject to the terms and conditions of the Merger Agreement, and in accordance with Alabama law, at the completion of the Merger, Merger Sub, an Alabama corporation and wholly owned subsidiary of AgeX, will merge with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX.

 

Completion and Effectiveness of the Merger

 

The Merger will be completed as promptly as practicable (but no later than the second business day) after all of the conditions to the closing of the Merger are satisfied or waived, including the adoption of the Merger Agreement by the Serina stockholders and the approval by the AgeX stockholders of the issuance of AgeX common stock and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger, but subject to the satisfaction or waiver of each of such conditions, or at such other time, date and place as AgeX and Serina may mutually agree in writing. The Merger will become effective on the date and at the time the Statement of Merger has been duly filed with the Secretary of State of the State of Alabama or at such later time as may be specified in the Statement of Merger with the consent of AgeX and Serina in accordance with the ABCL (such date, the Closing Date, and such time, the Effective Time).

 

170

 

 

Merger Consideration and Exchange Ratio

 

Merger Consideration

 

At the Effective Time, each outstanding share of Serina common stock (after giving effect to the Serina preferred stock conversion and including all such shares that are so converted, other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares) will be automatically converted solely into the right to receive a number of validly issued, fully paid and nonassessable shares of AgeX common stock equal to exchange ratio as more fully described below.

 

No fractional shares of AgeX common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any holder of Serina common stock who would otherwise be entitled to receive a fraction of a share of AgeX common stock (after aggregating all fractional shares of AgeX common stock issuable to such holder) will, in lieu of such fraction of a share and upon such holder’s surrender of a letter of transmittal in accordance with the Merger Agreement and any accompanying documentation required therein, receive (i) one share of AgeX common stock if the aggregate amount of fractional shares of AgeX common stock such holder of Serina common stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii) no shares of AgeX common stock if the aggregate amount of fractional shares of AgeX common stock such holder of Serina common stock would otherwise be entitled to is less than 0.50.

 

Exchange Ratio

 

The exchange ratio formula is based upon a fixed percentage of the post-Merger outstanding shares of AgeX common stock, expressed on a fully-diluted and as-converted basis, subject to certain adjustments and exclusions. Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions. The exchange ratio is currently estimated to be equal to approximately 0.83217216 shares of AgeX common stock for each share of Serina common stock, which estimated exchange ratio assumes (i) the Actual Closing Price of a share of AgeX common stock is equal to $12.00 per share (on a post-reverse stock split basis), (ii) the number of Company Outstanding Shares is equal to 9,012,558, (iii) the number of Company Merger Shares is equal to 7,500,000 and (iv) the implementation of the reverse stock split and the AgeX preferred stock conversion prior to the consummation of the Merger, as described elsewhere in this proxy statement/prospectus/information statement. There can be no assurance any of these assumptions will be accurate when the final exchange ratio is determined.

 

While the final exchange ratio is subject to adjustment prior to the closing of the Merger based upon the Actual Closing Price of a share of AgeX common stock determined in accordance with the Merger Agreement, the fixed percentage of the post-Merger outstanding shares of AgeX common stock is subject to adjustment prior to closing of the Merger only if the Actual Closing Price of a share of AgeX common stock is less than $12.00 per share (on a post-reverse stock split basis) as more fully described under the sections titled “—Conditions to the Completion of the Merger” and “—Termination and Termination Fees” below, and, in such circumstances, AgeX stockholders immediately prior to the closing of the Merger could own a smaller percentage, and Serina stockholders immediately prior to the closing of the Merger could own a larger percentage, of the combined company following the closing of the Merger. Accordingly, while the final exchange ratio may be higher or lower than the estimated exchange ratio depending on the Actual Closing Price when the final exchange ratio is determined, the allocation of outstanding shares of the common stock of the combined company to AgeX stockholders and Serina stockholders pursuant to the exchange ratio formula may only be adjusted if the Actual Closing Price of a share of AgeX common stock is less than $12.00 per share (on a post-reverse stock split basis).

 

171

 

 

The exchange ratio is the quotient obtained by dividing (a) the Company Merger Shares (defined below) by (b) the Company Outstanding Shares (defined below), in which:

 

Company Allocation Percentage” means 75.00%.

 

Company Merger Shares” means the product (rounded to the nearest whole share) obtained by multiplying (a) Post-Closing Parent Shares by (b) the Company Allocation Percentage.

 

Company Outstanding Shares” means the total number of shares of Serina capital stock outstanding immediately prior to the Effective Time after giving effect to the Serina preferred stock conversion, expressed on a fully-diluted and as-converted to Serina common stock basis assuming, without limitation or duplication, (i) the exercise of all Serina options outstanding as of immediately prior to the Effective Time, (ii) the issuance of shares of Serina capital stock upon the conversion of all Serina convertible notes (but excluding any Serina convertible notes issued to AgeX) and (iii) the issuance of shares of Serina capital stock in respect of all other outstanding options, restricted stock awards, restricted stock units or rights to receive such shares, whether conditional or unconditional and including any outstanding options, restricted stock awards, restricted stock units or rights triggered by or associated with the consummation of the Merger (but excluding any shares of Serina capital stock reserved for issuance other than with respect to outstanding Serina options under the Serina incentive plan as of immediately prior to the Effective Time). No Serina warrants will be included in the total number of shares of Serina common stock for purposes of determining the Company Outstanding Shares.

 

Parent Outstanding Shares” means, subject to, among other things, the reverse stock split and the immediately following sentence, the total number of shares of AgeX common stock outstanding immediately prior to the Effective Time expressed on a fully-diluted and as-converted to AgeX common stock basis and using the treasury stock method (and shall include, for the avoidance of doubt, all in the money AgeX options and warrants, shares to be received upon the AgeX preferred stock conversion and shares issuable upon the conversion of AgeX’s convertible note with Juvenescence), but assuming, without limitation or duplication, the issuance of shares of AgeX common stock in respect of all AgeX options, AgeX RSUs, AgeX warrants and other outstanding options, warrants or rights to receive such shares, in each case, outstanding as of immediately prior to the Effective Time (assuming cashless exercise using the AgeX closing price), whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or associated with the consummation of the Merger (but excluding any shares of AgeX common stock reserved for issuance other than with respect to outstanding AgeX options, AgeX RSUs and AgeX warrants as of immediately prior to the Effective Time and as set forth above). No (i) post-merger warrants, or (ii) incentive warrants, in each case, shall be included in the total number of shares of AgeX common stock outstanding for purposes of determining the Parent Outstanding Shares.

 

Post-Closing Parent Shares” means the quotient obtained by dividing (a) the Parent Outstanding Shares by (b)(i) 1.00 minus (ii) the Company Allocation Percentage.

 

172

 

 

Treatment of Serina Stock Options

 

Under the terms of the Merger Agreement, at the Effective Time, each Serina option that is outstanding and unexercised immediately prior to the Effective Time under the Serina Plan, whether or not vested, will be converted into and become an option to purchase shares of AgeX common stock, and AgeX will assume the Serina Plan (if necessary) and each such Serina option in accordance with the terms of the Serina Plan and the terms of the Serina option (but with changes to such documents as AgeX in good faith determines are appropriate to reflect the substitution of the Serina options by AgeX to purchase shares of AgeX common stock). All rights, terms, and restrictions with respect to Serina common stock under Serina options assumed by AgeX will be converted into rights with respect to AgeX common stock.

 

Accordingly, from and after the Effective Time: (i) each Serina option assumed by AgeX may be exercised solely for shares of AgeX common stock; (ii) the number of shares of AgeX common stock subject to each Serina option assumed by AgeX will be determined by multiplying (A) the number of shares of Serina common stock that were subject to such Serina option assumed by AgeX, by (B) the exchange ratio, as determined in accordance with the allocation certificate to be delivered by Serina pursuant to the Merger Agreement; (iii) the per share exercise price for the AgeX common stock issuable upon exercise of each Serina option assumed by AgeX will be determined by dividing (A) the per share exercise price of Serina common stock subject to such Serina option, by (B) the exchange ratio, as determined in accordance with the allocation certificate to be delivered by Serina pursuant to the Merger Agreement; and (iv) any restriction on the exercise of any Serina option assumed by AgeX will continue in full force and effect and the term, exercisability, vesting schedule and other provisions of such Serina option will otherwise remain unchanged; provided, however, that (A) the determination in the allocation certificate of the number of shares of AgeX common stock subject to each Serina option assumed by AgeX will be based on the exchange ratio as that applied to the Serina common stock to determine the number of shares of AgeX common stock each holder of Serina common stock will receive, (B) the determination in the allocation certificate of the per share exercise price for the AgeX common stock issuable upon exercise of each Serina option assumed by AgeX will be adjusted equitably to reflect the exchange ratio, (C) to the extent provided under the terms of the respective stock option agreements governing the Serina option and the Serina Plan, AgeX may amend the terms of the Serina options and the Serina Plan, in accordance with the terms thereof, to reflect AgeX’s substitution of the Serina options with options to purchase AgeX common stock (such as by making any change in control or similar definition relate to AgeX and having any provision that provides for the adjustment of Serina options upon the occurrence of certain corporate events relate to corporate events that relate to AgeX and/or AgeX common stock), and such Serina options will be subject to further adjustment as appropriate and necessary to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization, or other similar transaction with respect to AgeX common stock subsequent to the Effective Time, and (D) the AgeX Board or a committee thereof will succeed to the authority and responsibility of the Serina Board or any committee thereof with respect to each Serina option assumed by AgeX.

 

Treatment of Serina Warrants

 

Under the terms of the Merger Agreement, at the Effective Time, each Serina warrant that is outstanding and unexercised immediately prior to the Effective Time, if any, will be converted into and become a warrant to purchase shares of AgeX common stock, and AgeX will assume each such Serina warrant in accordance with its terms. All rights with respect to Serina common stock under Serina warrants assumed by AgeX will be converted into rights with respect to AgeX common stock.

 

173

 

 

Accordingly, from and after the Effective Time: (i) each Serina warrant assumed by AgeX may be exercised solely for shares of AgeX common stock; (ii) the number of shares of AgeX common stock subject to each Serina warrant assumed by AgeX will be determined by multiplying (A) the number of shares of Serina capital stock that were subject to such Serina warrant assumed by AgeX, by (B) the exchange ratio, as determined in accordance with the allocation certificate to be delivered by Serina pursuant to the Merger Agreement; (iii) the per share exercise price for the AgeX common stock issuable upon exercise of each Serina warrant assumed by AgeX will be determined by dividing (A) the per share exercise price of AgeX common stock subject to such Serina warrant, by (B) the exchange ratio, as determined in accordance with the allocation certificate to be delivered by Serina pursuant to the Merger Agreement; and (iv) any restriction on any Serina warrant assumed by AgeX will continue in full force and effect and the term and other provisions of such Serina warrant will otherwise remain unchanged; provided, however, that: (A) the determination in the allocation certificate of the number of shares of AgeX common stock subject to each Serina warrant assumed by AgeX will be based on the exchange ratio as that applied to the Serina common stock to determine the number of shares of AgeX common stock each holder of Serina common stock will receive; and (B) the determination in the allocation certificate of the per share exercise price for the AgeX common stock issuable upon exercise of each Serina warrant assumed by AgeX be adjusted equitably to reflect the exchange ratio.

 

Treatment of AgeX Stock Options

 

Immediately prior to the reverse stock split, each outstanding and unexercised out of the money AgeX option as of immediately prior to the reverse stock split, if any, will be canceled without payment. In accordance with the terms and conditions set forth in the Incentive Plan, AgeX will notify each holder of an out of the money AgeX option that each such option will become exercisable at least 10 days prior to the reverse stock split and will thereafter be canceled if not exercised. All other outstanding and unexercised options to purchase shares of AgeX common stock will remain outstanding and exercisable in accordance with their terms immediately following the Effective Time.

 

Directors and Executive Officers of the Combined Company Following the Merger

 

The Merger Agreement provides that the parties will use reasonable best efforts and take all necessary action so that effective as of the Effective Time, the Combined Company Board is comprised of seven members, with two of such members designated by Serina, two of such members designated by AgeX, two of such members designated by mutual agreement of Serina and AgeX that meet the director independence requirements of the NYSE American and one member designated by mutual agreement of Serina and AgeX. Steve Ledger, Chief Financial Officer of Serina, will serve as the Interim Chief Executive Officer of the combined company, Andrea Park, Chief Financial Officer of AgeX will serve as Interim Chief Financial Officer and Chief Accounting Officer of the combined company, Randall Moreadith, M.D., Ph.D., President and Chief Executive Officer of Serina, will serve as Chief Scientific Officer of the combined company and Tacey Viegas, Ph.D., Chief Operating Officer of Serina, will serve as Chief Operating Officer and Secretary of the combined company.

 

Conditions to the Completion of the Merger

 

The obligations of each party to consummate the Merger and the Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the closing of the Merger, of the following conditions:

 

there must not have been any temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Contemplated Transactions issued by any court of competent jurisdiction or other governmental body of competent jurisdiction and that remains in effect, and there must not be any law that has the effect of making the consummation of the Contemplated Transactions illegal;
the AgeX stockholders must have approved the AgeX Stockholder Matters;
Serina must have delivered an action by written consent (Serina Stockholder Written Consent) executed by the holders of (a) 60% of the then outstanding shares of Series A Preferred Stock voting as a separate class, (b) 60% of the then outstanding shares of Series A-1 Preferred Stock voting as a separate class, (c) 60% of the then outstanding shares of Series A-2 Preferred Stock voting as a separate class, (d) 60% of the then outstanding shares of Series A-3 Preferred Stock voting as a separate class, (e) 60% of the then outstanding shares of Series A-4 Preferred Stock voting as a separate class, (f) 60% of the then outstanding shares of Series A-5 Preferred Stock voting as a separate class, and (g) a majority of the then outstanding shares of the capital stock of the Company on an as-converted to Company Common Stock basis and as a single class (collectively, the Required Serina Stockholder Vote): (i) adopting and approving the Merger Agreement and the Contemplated Transactions, (ii) acknowledging that the approval given thereby is irrevocable, (iii) agreeing that such stockholder is aware of its rights to demand appraisal, or assert any dissenters’ rights, for its shares pursuant to ABCL Article 13, (iv) agreeing that such stockholder has received and read a copy of ABCL Article 13, (v) acknowledging that by such stockholder’s approval of the Merger such stockholder is not entitled to appraisal rights and thereby waives any right to receive payment of the fair value of its shares of Serina capital stock under the ABCL, (vi) electing that the consummation of the Merger is not a deemed liquidation event, and (vii) electing an automatic conversion of each share of Serina preferred stock into shares of Serina common stock immediately prior to the Effective Time in accordance with the relevant provisions of Serina’s organizational documents.

 

174

 

 

the existing shares of AgeX common stock will have been continually listed on New York Stock Exchange (NYSE) (including the NYSE American) as of and from the date of the Merger Agreement through the Closing Date, and the shares of AgeX common stock to be issued in the Merger and the other Contemplated Transactions pursuant to the Merger Agreement will have been approved for listing (subject to official notice of issuance) on NYSE (including the NYSE American) as of the closing of the Merger;
the registration statement will have become effective in accordance with the Securities Act and will not be subject to any stop order or proceeding (or threatened proceeding by the SEC) seeking a stop order with respect to the registration statement that has not been withdrawn;
AgeX, Serina and Juvenescence will have entered into the Side Letter, and Juvenescence will have converted all of its shares of AgeX Series A preferred stock and AgeX Series B preferred stock into shares of AgeX common stock prior to the reverse stock split;
The reverse stock split will have occurred and the shares of AgeX common stock outstanding immediately prior to the Effective Time shall be approximately 2,500,000.

 

In addition, the obligation of AgeX and Merger Sub to consummate the Merger and otherwise consummate the Contemplated Transactions is subject to the satisfaction or waiver by AgeX, at or prior to the closing of the Merger, of the following conditions:

 

the representations and warranties of Serina set forth in the Merger Agreement under Sections 2.1 (Due Organization; Subsidiaries), 2.3 (Authority; Binding Nature of Agreement), 2.4 (Vote Required), 2.6(a) and (c) (Capitalization) and 2.20 (No Financial Advisors) must have been true and correct in all material respects as of the date of the Merger Agreement and must be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties must have been true and correct in all material respects as of such date);
the representations and warranties of Serina set forth in the Merger Agreement (other than the Serina representations and warranties listed above) must have been true and correct as of the date of the Merger Agreement and must be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Serina Material Adverse Effect (as defined below) (without giving effect to any references therein to any Serina Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations must have been true and correct, subject to the qualifications set forth in the preceding clause (a), as of such particular date);

 

175

 

 

Serina must have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the Effective Time;
AgeX must have received from Serina (i) an officer’s certificate certifying (x) that certain conditions set forth in the Merger Agreement have been duly satisfied and (y) that the information set forth in the allocation certificate delivered by Serina containing information regarding Serina’s capitalization is true and accurate in all respects as of the Closing Date; and (ii) a copy of such allocation certificate;
since the date of the Merger Agreement, there must not have occurred a Serina Material Adverse Effect that is continuing;
certain of Serina’s investor agreements must have been terminated (or will be terminated as of the closing of the Merger);
AgeX must have received duly executed copies of the required Lock-Up Agreements from certain stockholders of Serina and each executive officer and director of Serina who is elected or appointed, as applicable, as an executive officer or director of AgeX as of immediately following the closing of the Merger, each of which must be in full force and effect as of immediately following the Effective Time;
the Serina Stockholder Written Consent executed by the required stockholders of Serina must be in full force and effect;
the holders of no more than 5% of the shares of Serina capital stock will have exercised statutory appraisal rights pursuant to ABCL Article 13 with respect to their shares of Serina capital stock; and
AgeX must have received (i) an original signed statement from Serina that Serina is not, and has not been at any time during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code, a “United States real property holding corporation,” as defined in Section 897(c)(2) of the Code, conforming to the requirements of Treasury Regulations Section 1.1445-2(c)(3) and 1.897-2(h), and (ii) an original signed notice from Serina to be delivered to the IRS in accordance with the provisions of Treasury Regulations Section 1.897-2(h)(2), together with written authorization for AgeX to deliver such notice to the IRS on behalf of Serina following the closing of the Merger, each dated as of the Closing Date, duly executed by an authorized officer of Serina, and in form and substance reasonably acceptable to AgeX; and
the holders of Serina’s convertible promissory notes, other than any convertible promissory note held by AgeX, will have elected to convert such notes into shares of Serina common stock prior to the Effective Time.

 

In addition, the obligation of Serina to consummate the Merger and otherwise consummate the Contemplated Transactions is subject to the satisfaction or waiver by Serina, at or prior to the closing of the Merger, of the following conditions:

 

the representations and warranties of AgeX and Merger Sub set forth in the Merger Agreement under Sections 3.1 (Due Organization; Subsidiaries), 3.3 (Authority; Binding Nature of Agreement), 3.4 (Vote Required), 3.6(a) and (c) (Capitalization) and 3.21 (No Financial Advisors) must have been true and correct in all material respects as of the date of the Merger Agreement and must be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties must have been true and correct in all material respects as of such date);
the representations and warranties of AgeX and Merger Sub set forth in the Merger Agreement (other than the AgeX and Merger Sub representations and warranties listed above) must have been true and correct as of the date of the Merger Agreement and must be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have an AgeX Material Adverse Effect (as defined below) (without giving effect to any references therein to any AgeX Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations must have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date);

 

176

 

 

AgeX and Merger Sub must have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under the Merger Agreement at or prior to the Effective Time;
Serina must have received from AgeX (i) an officer’s certificate confirming that certain conditions of the Merger Agreement have been duly satisfied; (ii) a certificate containing information regarding AgeX’s capitalization; and (iii) a reasonably satisfactory written resignation dated as of the Closing Date and effective as of the closing of the Merger executed by the directors of AgeX who will not continue as directors of AgeX after closing of the Merger;
since the date of the Merger Agreement, there must not have occurred an AgeX Material Adverse Effect that is continuing;
Serina must have received satisfactory evidence that (a) specified AgeX contracts have been terminated, assigned or fully performed by AgeX, and (b) all obligations of AgeX thereunder have been fully satisfied, waived or otherwise discharged;
the Lock-Up Agreements executed by certain stockholders of AgeX must be in full force and effect as of immediately following the Effective Time;
the Actual Closing Price of a share of AgeX common stock must not be less than $12.00 and Juvenescence must hold at least 1,133,308 post-merger warrants upon AgeX’s issuance of the post-merger warrants; and
immediately prior to the closing of the Merger, AgeX must have on hand at least $500,000 of immediately spendable nonrestricted cash, net of all payable and other liabilities (including Transaction Expenses (as defined in “—Expenses”).

 

“AgeX Material Adverse Effect” means any effect, change, event, circumstance or development (collectively, Effect) that, considered together with all other Effects, has or would reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of AgeX or its subsidiaries, taken as a whole; provided, however, that Effects arising or resulting from the following will not be taken into account in determining whether there has been an AgeX Material Adverse Effect: (a) general business, political or economic conditions generally affecting the industry in which AgeX and its subsidiaries operate, (b) acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics (including COVID-19 and any evolutions or mutations thereof) and related or associated epidemics, disease outbreaks or quarantine restrictions, (c) changes in financial, banking or securities markets, (d) any change in the stock price or trading volume of AgeX common stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of AgeX common stock may be taken into account in determining whether an AgeX Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (e) the failure of AgeX to meet internal or analysts’ expectations or projections or the results of operations of AgeX, (f) any changes in or affecting clinical trial programs or studies conducted by or on behalf of AgeX or its subsidiaries, including any adverse data, event or outcome arising out of or related to any such programs or studies, (g) any change in, or any compliance with or action taken for the purpose of complying with, any law or GAAP (or interpretations of any law or GAAP), (h) the announcement of the Merger Agreement or the pendency of the Contemplated Transactions, (i) the Asset Dispositions (as defined below), (j) any reduction in the amount of AgeX’s cash and cash equivalents as a result of expenditures made by AgeX related to wind down activities of AgeX associated with the termination of its research and development activities (including the termination of ongoing contractual obligations relating to AgeX current products or product candidates), (k) resulting from the taking of any action required to be taken by the Merger Agreement, or (l) as set forth in Section B of AgeX’s disclosure schedule, except in each case, with respect to clauses (a) through (c), to the extent disproportionately affecting AgeX and its subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which AgeX and its subsidiaries operate.

 

177

 

 

“Serina Material Adverse Effect” means any Effect that, considered together with all other Effects, has or would reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Serina or its subsidiaries, taken as a whole; provided, however, that Effects arising or resulting from the following will not be taken into account in determining whether there has been a Serina Material Adverse Effect: (a) general business, political or economic conditions generally affecting the industry in which Serina and its subsidiaries operate, (b) acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics (including COVID-19 and any evolutions or mutations thereof) and related or associated epidemics, disease outbreaks or quarantine restrictions, (c) changes in financial, banking or securities markets, (d) any change in, or any compliance with or action taken for the purpose of complying with, any law or GAAP (or interpretations of any law or GAAP), (e) the announcement of the Merger Agreement or the pendency of the Contemplated Transactions, (f) the taking of any action required to be taken by the Merger Agreement, or (g) continued losses from operations or decreases in cash balances of Serina or any of its subsidiaries or on a consolidated basis among Serina and its subsidiaries; except, in each case, with respect to clauses (a) through (c), to the extent disproportionately affecting Serina and its subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Serina and its subsidiaries operate.

 

“Actual Closing Price” means the volume weighted average closing trading price of a share of the AgeX common stock as reported on the NYSE American for the 10 trading days preceding the date that is the fifth business day preceding the Effective Time.

 

Post-Merger Warrants; Incentive Warrants

 

Prior to the consummation of the Merger, AgeX will issue to each holder of AgeX common stock three post-merger warrants for each five shares of AgeX common stock held by such holder. Each post-merger warrant will be exercisable at an exercise price equal to $13.20 per warrant (such exercise price reflecting the planned reverse stock split) for (i) one share of AgeX common stock and (ii) one incentive warrant and will expire on July 31, 2025. Each incentive warrant will be exercisable at an exercise price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split) for one share of AgeX common stock and will expire on the four-year anniversary of the Closing Date. For additional information, see the section titled “Agreements Related to the Merger—Warrant Agreement” beginning on page 197 of this proxy statement/prospectus/information statement.

 

Potential Asset Disposition; Legacy Assets

 

AgeX is entitled, but under no obligation, to sell, transfer, license, assign or otherwise divest certain assets to the extent relating exclusively to the business of Reverse Bioengineering, Inc. (Potentially Transferrable Assets) to one or more third parties in one or a series of transactions prior to or substantially concurrently with the closing of the Merger (Asset Dispositions); provided, that any such Asset Disposition will require, to the extent consistent with applicable laws, the written consent of Serina, not to be unreasonably withheld, conditioned or delayed, if such Asset Disposition would create any post-disposition material liabilities for AgeX following the closing of the Merger. If the Asset Dispositions are not completed prior to, concurrently with, or immediately following the closing of the Merger, the Potentially Transferrable Assets will be retained by AgeX.

 

178

 

 

Prior to the closing of the Merger, any assets of AgeX that remain after the Asset Dispositions other than certain assets as agreed between AgeX and Serina, assets related to NeuroAirmid and cash required to satisfy the applicable closing condition under the Merger Agreement as described above (Legacy Assets) shall be sold, transferred, licensed, assigned or conveyed into a newly formed subsidiary of AgeX (Newco). In consideration of the transfer of such assets, Newco will assume (i) any indebtedness of AgeX issued to Juvenescence that has not been previously converted into AgeX Series A preferred stock or AgeX Series B preferred stock, which will be secured by the Legacy Assets and (ii) all other liabilities of AgeX in existence as of the Effective Time (other than Transaction Expenses).

 

AgeX Preferred Stock

 

In accordance with the Side Letter, Juvenescence will convert all of the shares of AgeX Series A preferred stock and AgeX Series B preferred stock owned by Juvenescence or any affiliate thereof into shares of AgeX common stock prior to the reverse stock split. The AgeX preferred stock conversion is expected to occur on February 1, 2024 in accordance with the Certificates of Designation of the AgeX Series A preferred stock and AgeX Series B preferred stock.

 

Convertible Note

 

Any convertible note issued by Serina to AgeX will be amended prior to the closing of the Merger so that it automatically converts immediately prior to the Merger into shares of Serina capital stock, which shares will be canceled for no consideration in connection with the Merger.

 

Equity Plans

 

AgeX and Serina will amend their existing equity incentive plans to make certain administrative changes agreed upon between the parties.

 

Representations and Warranties

 

The Merger Agreement contains customary representations and warranties of Serina, AgeX and Merger Sub for a transaction of this type relating to, among other things:

 

Due Organization; Subsidiaries
Organizational Documents
Authority; Binding Nature of Agreement
Vote Required
Non-Contravention; Consents
Capitalization
Financial Statements and, with respect to AgeX and Merger Sub, SEC Filings
Absence of Changes
Absence of Undisclosed Liabilities
Title to Assets
Real Property; Leasehold

 

179

 

 

Intellectual Property
Agreements, Contracts and Commitments
Compliance; Permits; Restrictions
Legal Proceedings; Orders
Tax Matters
Employee and Labor Matters; Benefit Plans
Environmental Matters
Insurance
No Financial Advisors
Disclosure
Transactions with Affiliates
Anti-Bribery
with respect to AgeX and Merger Sub, Valid Issuance
Disclaimer of Other Representations and Warranties

 

The representations and warranties of Serina, AgeX and Merger Sub contained in the Merger Agreement or any certificate or instrument delivered pursuant to the Merger Agreement will terminate at the Effective Time.

 

Non-Solicitation

 

AgeX, Serina and their respective subsidiaries are prohibited by the terms of the Merger Agreement, other than, in the case of AgeX, with respect to any Asset Disposition, from, directly or indirectly, (i) soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any Acquisition Proposal (as defined below) or Acquisition Inquiry (as defined below) or taking any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) furnishing any non-public information regarding itself or its respective subsidiaries to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii) engaging in discussions (other than to inform any person of the existence of these prohibitions) or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv) approving, endorsing or recommending any Acquisition Proposal (subject to, in the case of AgeX, AgeX’s special meeting and the AgeX Proposals); (v) executing or entering into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction (as defined below) (other than, in the case of AgeX, a confidentiality agreement permitted as described below); or (vi) publicly proposing to do any of the foregoing.

 

Pursuant to the terms of the Merger Agreement, each of AgeX and Serina agreed to immediately cease and cause to be terminated any existing discussions, negotiations and communications with any person relating to any Acquisition Proposal or Acquisition Inquiry (other than, in the case of AgeX, any Asset Dispositions) as of the date of the Merger Agreement and request the destruction or return of any of AgeX’s or Serina’s non-public information, as applicable, provided to such person as soon as practicable after the date of the Merger Agreement.

 

Subject to certain restrictions and prior to obtaining the approval of the AgeX Stockholder Matters by the Required AgeX Stockholder Vote, AgeX and its subsidiaries may furnish non-public information regarding AgeX or any of its subsidiaries to, and enter into discussions or negotiations with, any person in response to a bona fide Acquisition Proposal by such person, which the AgeX Board determines in good faith, after consultation with its outside financial advisor and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (as defined below) (and is not withdrawn) if: (A) none of AgeX, any of its subsidiaries or any of their respective representatives have breached the non-solicitation restrictions in the Merger Agreement in any material respect, (B) the AgeX Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action is reasonably likely to be inconsistent with the fiduciary duties of the AgeX Board under applicable law; (C) substantially contemporaneously with furnishing any such non-public information to such person, AgeX gives Serina notice of AgeX’s intention to furnish non-public information to, or enter into discussions with, such person and furnishes such nonpublic information to Serina (to the extent such information has not been previously furnished by AgeX to Serina), and (D) AgeX receives from such person an executed confidentiality agreement containing provisions (including nondisclosure provisions, use restrictions, non-solicitation provisions, no hire and “standstill” provisions), in the aggregate, at least as favorable to AgeX as those contained in the confidentiality agreement entered into between AgeX and Serina in connection with the Merger.

 

180

 

 

If AgeX, Serina or any of their respective subsidiaries or representatives receives an Acquisition Proposal or Acquisition Inquiry during the period following the date of the Merger Agreement and continuing until the earlier of the termination of the Merger Agreement or the Effective Time, then such party will promptly (and in no event later than one business day after such party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other party orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the person making or submitting such Acquisition Proposal or Acquisition Inquiry and the material terms thereof). Each party will keep the other party reasonably informed with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or proposed material modification thereto.

 

“Acquisition Inquiry” means, with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, an indication of interest or request for information made or submitted by Serina, on the one hand, or AgeX, on the other hand, to the other party) that could reasonably be expected to lead to an Acquisition Proposal; provided, however, that the term Acquisition Inquiry does not include the Merger, the Contemplated Transactions or any transactions related to the Asset Dispositions.

 

“Acquisition Proposal” means, with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Serina or any of its affiliates, on the one hand, or by or on behalf of AgeX or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to any Acquisition Transaction with such party, other than the Asset Dispositions.

 

“Acquisition Transaction” means any transaction or series of related transactions (other than the Asset Dispositions) involving:

 

any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a party is a constituent entity; (ii) in which a person or “group” (as defined in the Exchange Act and the rules promulgated thereunder) of persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a party or any of its subsidiaries; or (iii) in which a party or any of its subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries; or

 

181

 

 

any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a party and its subsidiaries, taken as a whole.

 

“Superior Offer” means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to greater than 50% for these purposes) that: (a) was not obtained or made as a direct or indirect result of a breach of (or in violation of) the Merger Agreement; and (b) is on terms and conditions that the AgeX Board determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and outside financial advisors, if any, are more favorable, from a financial point of view, to AgeX’s stockholders than the terms of the Contemplated Transactions and is not subject to any financing condition (and if financing is required, such financing is then fully committed to the third party).

 

AgeX Stockholder Meeting

 

Promptly after the registration statement has been declared effective by the SEC under the Securities Act, AgeX will take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of AgeX common stock for the purpose of seeking approval of the Contemplated Transactions, including: (i) the amendment of AgeX’s certificate of incorporation to effect the reverse stock split, (ii) if applicable, the consummation of the Asset Dispositions, (iii) the issuance of AgeX common stock or other securities of AgeX that represent (or are convertible into) more than 20% of the shares of AgeX common stock outstanding immediately prior to the Merger to the holders of Serina capital stock, Serina stock options and Serina warrants in connection with the Contemplated Transactions and the change of control of AgeX resulting from the Contemplated Transactions, in each case pursuant to the NYSE American rules, (iv) the issuance of the post-merger warrants to the holders of AgeX common stock, (v) the amendment and restatement of AgeX’s certificate of incorporation, (vi) the adoption of the Serina Therapeutics, Inc. 2024 Equity Incentive Plan (the 2024 Equity Incentive Plan), along with the reservation of 1,725,000 shares of AgeX common stock under the 2024 Equity Incentive Plan, (vii) if not previously approved by AgeX stockholders, the issuance of shares of AgeX common stock that represent more than 20% of the shares of AgeX common stock outstanding immediately prior to conversion of the AgeX Series B preferred stock in connection with the AgeX preferred stock conversion and (viii) any other proposals the parties deem necessary or desirable to consummate the Contemplated Transactions (together with the proposals set forth in the foregoing clauses (i) through (viii), the AgeX Stockholder Matters).

 

The AgeX special meeting will be held as promptly as practicable after the registration statement is declared effective under the Securities Act and, in any event, no later than 45 calendar days after the effective date of the registration statement. AgeX will take reasonable measures to ensure that all proxies solicited in connection with the AgeX special meeting are solicited in compliance with all applicable laws. If, on or before the date of the AgeX special meeting, AgeX reasonably believes that it (i) will not receive proxies sufficient to obtain the required approvals of the AgeX Stockholder Matters in accordance with the Merger Agreement (Required AgeX Stockholder Vote), whether or not a quorum would be present or (ii) will not have sufficient shares of AgeX common stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the AgeX special meeting, AgeX may postpone or adjourn, or make one or more successive postponements or adjournments of, the AgeX special meeting as long as the date of the AgeX special meeting is not postponed or adjourned more than an aggregate of 60 calendar days in connection with any postponements or adjournments.

 

182

 

 

AgeX agreed that, subject to certain exceptions in the Merger Agreement: (i) the AgeX Board will recommend that the holders of AgeX common stock vote to approve the AgeX Stockholder Matters and will use commercially reasonable efforts to solicit such approval within the timeframe set forth above, (ii) this proxy statement/prospectus/information statement will include a statement to the effect that the AgeX Board recommends that AgeX’s stockholders vote to approve the AgeX Stockholder Matters (the recommendation of the AgeX Board with respect to the AgeX Stockholder Matters being referred to as the AgeX Board Recommendation); and (iii) the AgeX Board Recommendation will not be withheld, amended, withdrawn or modified (and the AgeX Board will not publicly propose to withhold, amend, withdraw or modify the AgeX Board Recommendation) in a manner adverse to Serina, and no resolution by the AgeX Board or any committee thereof to withdraw or modify the AgeX Board Recommendation in a manner adverse to Serina or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (iii), collectively, an AgeX Board Adverse Recommendation Change).

 

The terms of the Merger Agreement provide that, subject to the limitations set forth in the Merger Agreement, if at any time prior to the approval of the AgeX Stockholder Matters at the AgeX special meeting by the Required AgeX Stockholder Vote, AgeX receives a bona fide Acquisition Proposal (which did not arise out of a material breach of the non-solicitation provisions of the Merger Agreement) from any person that has not been withdrawn and after consultation with outside legal counsel, the AgeX Board determines, in good faith, that such Acquisition Proposal is a Superior Offer, the AgeX Board may make an AgeX Board Adverse Recommendation Change or AgeX may terminate the Merger Agreement to enter into a definitive agreement with respect to such Superior Offer, if and only if: (A) the AgeX Board determines in good faith, after consultation with AgeX’s outside legal counsel, that the failure to do so would be reasonably likely to be inconsistent with the fiduciary duties of the AgeX Board to AgeX’s stockholders under applicable law; (B) AgeX has given Serina prior written notice of its intention to consider making an AgeX Board Adverse Recommendation Change or terminate the Merger Agreement to enter into a definitive agreement with respect to such Superior Offer at least four business days prior to making any such AgeX Board Adverse Recommendation Change or termination (an AgeX Determination Notice, and such period, the AgeX Notice Period) (which notice will not constitute an AgeX Board Adverse Recommendation Change); and (C)(1) AgeX provided to Serina a summary of the material terms and conditions of the Acquisition Proposal in accordance with the Merger Agreement, (2) AgeX has and has caused its representatives to, during the AgeX Notice Period, negotiate in good faith with Serina (to the extent Serina desires to negotiate) to enable Serina to propose in writing an offer binding on Serina to effect such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal no longer constitutes a Superior Offer, and (3) after considering the results of such negotiations and giving effect to the proposals made by Serina, if any, after consultation with outside legal counsel, the AgeX Board determines, in good faith, that such Acquisition Proposal is a Superior Offer and that the failure to make the AgeX Board Adverse Recommendation Change or terminate the Merger Agreement to enter into a definitive agreement with respect to such Superior Offer would be inconsistent with the fiduciary duties of the AgeX Board to AgeX’s stockholders under applicable law; provided that (x) Serina receives written notice from AgeX confirming that the AgeX Board has determined to change its recommendation during the AgeX Notice Period, which includes a description in reasonable detail of the reasons for such AgeX Board Adverse Recommendation Change and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer or to terminate the Merger Agreement pursuant to the terms set forth therein during the AgeX Notice Period; (y) during any AgeX Notice Period, Serina shall be entitled to deliver to AgeX one or more counterproposals to such Acquisition Proposal and AgeX will, and will cause its representatives to, negotiate with Serina in good faith (to the extent Serina desires to negotiate) to enable Serina to propose in writing an offer binding on Serina to effect such adjustments to the terms and conditions of the Merger Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer; and (z) in the event of any material amendment to any Superior Offer (including any revision in price or percentage of the combined company that AgeX’s stockholders would receive), AgeX must provide Serina with notice of such material amendment and the AgeX Notice Period will be extended, if applicable, to ensure that at least two business days remain in the AgeX Notice Period (it being understood that there may be multiple extensions).

 

183

 

 

The terms of the Merger Agreement also provide that, other than in connection with an Acquisition Proposal, the AgeX Board may make an AgeX Board Adverse Recommendation Change in response to an AgeX Change in Circumstance (as defined below), if and only if: (A) the AgeX Board determines in good faith, after consultation with AgeX’s outside legal counsel, that the failure to do so would be reasonably likely to be inconsistent with the fiduciary duties of the AgeX Board to AgeX’s stockholders under applicable law; (B) AgeX has given Serina an AgeX Determination Notice at least four business days prior to making any such AgeX Board Adverse Recommendation Change; and (C) (1) AgeX has specified the AgeX Change in Circumstance in reasonable detail, including the material facts and circumstances related to the applicable AgeX Change in Circumstance, (2) AgeX has given Serina four business days after the AgeX Determination Notice to propose revisions to the terms of the Merger Agreement or make another proposal, and has made its representatives reasonably available to negotiate in good faith with Serina (to the extent Serina desires to do so) with respect to such proposed revisions or other proposal, if any, and (3) after considering the results of any such negotiations and giving effect to the proposals made by Serina, if any, after consultation with outside legal counsel, the AgeX Board determines, in good faith, that the failure to make the AgeX Board Adverse Recommendation Change in response to such AgeX Change in Circumstance or terminate the Merger Agreement pursuant to the terms set forth therein would be inconsistent with the fiduciary duties of the AgeX Board to AgeX’s stockholders under applicable law. The provisions of the Merger Agreement described in this paragraph also apply to any material change to the facts and circumstances relating to such AgeX Change in Circumstance and require a new AgeX Determination Notice, except that the references to four business days will be deemed to be two business days.

 

“AgeX Change in Circumstance” means a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry or the consequences thereof or (B) the fact, in and of itself, that AgeX meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of AgeX that occurs or arises after the date of the Merger Agreement.

 

Serina Stockholder Action by Written Consent

 

The Merger Agreement contemplates that, promptly after the registration statement is declared effective under the Securities Act, and in any event no later than three business days thereafter, Serina will prepare, with the cooperation of AgeX, and cause to be mailed to its stockholders an information statement, which shall include a copy of this proxy statement/prospectus/information statement to solicit the approval by written consent from Serina’s stockholders sufficient for the Required Serina Stockholder Vote in lieu of a meeting pursuant to the ABCL, for purposes of approving the Serina Stockholder Matters.

 

184

 

 

Serina agreed that: (i) the Serina Board will recommend that the Serina stockholders vote to approve the Serina Stockholder Matters and will use commercially reasonable efforts to solicit such approval from certain stockholders of Serina within the timeframe set forth above (the recommendation of the Serina Board that Serina’s stockholders vote to adopt and approve the Serina Stockholder Matters being referred to as the Serina Board Recommendation); and (ii) the Serina Board Recommendation will not be withdrawn or modified (and the Serina Board will not publicly propose to withdraw or modify the Serina Board Recommendation) in a manner adverse to AgeX, and no resolution by the Serina Board or any committee thereof to withdraw or modify the Serina Board Recommendation in a manner adverse to AgeX or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal will be adopted or proposed.

 

Appraisal Rights

 

Under the DGCL, AgeX stockholders are not entitled to appraisal rights in connection with the Merger.

 

Holders of Serina capital stock as of the record date are entitled to appraisal rights under the ABCL. Pursuant to Section 10A-2A-13.02 of the ABCL, a Serina stockholder who does not wish to accept the merger consideration to be received pursuant to the terms of the merger agreement may elect to receive the fair value of such stockholder’s Serina capital stock (as determined immediately prior to the consummation of the merger), excluding any appreciation or depreciation in anticipation of the merger unless exclusion would be inequitable, but including interest from the effective date of the merger until the date of payment. Under the terms of the merger agreement, if 5% or more of the outstanding shares of Serina capital stock validly exercise their appraisal rights, then AgeX will not be obligated to complete the merger.

 

In order to exercise appraisal rights, a Serina stockholder must strictly comply with the statutory procedures of Sections 10A-2A-13.01 through 10A-2A-13.40 of the ABCL, which are summarized below. A copy of the full text of those Sections is included as Annex D to this proxy statement/prospectus/information statement. Serina stockholders are urged to read Annex D in its entirety and to consult with their legal advisors. Each Serina stockholder who desires to assert appraisal rights is cautioned that failure to adhere strictly to the requirements of Alabama law in any regard will cause a forfeiture of any appraisal rights. Serina stockholders who do not properly follow appraisal rights procedures will receive the merger consideration if the merger is effected.

 

Procedures for Exercising Rights of Appraisal. The following summary of Alabama law is qualified in its entirety by reference to the full text of the applicable provisions of the ABCL, a copy of which is included as Annex D to this proxy statement/prospectus/information statement.

 

A holder of Serina capital stock electing to exercise its appraisal rights shall not sign and return the written consent adopting the Merger Agreement approve the transactions and actions contemplated by the Merger Agreement, including the Merger.

 

185

 

 

No later than ten days after the merger, Serina, as the continuing corporation of the merger, will send a written notice to each stockholder exercising its appraisal rights who did not vote in favor of the merger and who duly filed a written notice of intent to demand payment in accordance with the foregoing procedures. The appraisal rights notice will specify, among other things, the deadline by which time Serina must receive a payment demand from such stockholders, the deadline for depositing the stockholders’ shares and the location for such deposit, the deadline by which time such stockholder may withdraw from the appraisal process, and Serina’s estimate of the fair value of the stock, and will include a form for demanding payment. The deadline for demanding payment will be no fewer than 40 days and no more than 60 days after the date the appraisal rights notice is delivered. It is the obligation of any stockholder electing to exercise appraisal rights to initiate all necessary action to perfect such stockholder’s appraisal rights within the time periods prescribed in Article 13 of the ABCL and the appraisal rights notice. If no payment demand is timely received from a stockholder exercising appraisal rights, all appraisal rights of said stockholder will be lost, notwithstanding any previously submitted written notice of intent to demand payment. Each stockholder exercising appraisal rights who demands payment retains all other rights of a stockholder unless and until those rights are cancelled or modified by the merger. A stockholder exercising appraisal rights who demands payment in accordance with the foregoing and does not withdraw from the appraisal process before the deadline set forth in the appraisal rights notice provided by Serina may not thereafter withdraw that demand and accept the terms offered under the merger agreement unless Serina consents thereto.

 

On or before the stock certificate delivery deadline, which may not be before the deadline for demanding formal payment, a stockholder exercising appraisal rights who has made a demand must submit such stockholder’s stock certificate or certificates to Serina. A stockholder’s failure to submit shares of capital stock for notation will, at Serina’s option, terminate the holder’s appraisal rights, unless a court of competent jurisdiction determines otherwise.

 

Promptly after the merger, or upon receipt of a payment demand, Serina shall offer to pay each stockholder exercising appraisal rights who complied with Article 13 of the ABCL the amount Serina estimates to be the fair value of such stockholder’s shares of capital stock plus accrued interest. Each stockholder exercising appraisal rights who agrees to accept the offer of payment in full satisfaction of such stockholder’s demand must surrender to Serina the certificate or certificates representing such shares of capital stock in accordance with the terms of the appraisal rights notice. Upon receiving the certificate or certificates, Serina will pay each stockholder exercising appraisal rights the fair value of such stockholder’s shares of capital stock, plus accrued interest. Upon receiving payment, each stockholder exercising appraisal rights ceases to have any interest in the shares.

 

Each stockholder exercising appraisal rights who has made a payment demand may notify Serina in writing such stockholder’s own estimate of the fair value of such stockholder’s shares of capital stock plus interest, and demand payment of such estimate, or reject the offer made to such stockholder as described above and demand payment of the fair value of such stockholder’s shares of capital stock and interest due, if: (1) the stockholder exercising appraisal rights believes that the amount offered is less than the fair value of the shares of capital stock or that the interest due is incorrectly calculated; or (2) Serina fails to make an offer as required by Article 13 of the ABCL within 60 days after the date set for demanding payment; provided, however, that a stockholder exercising appraisal rights waives the right to demand payment different from that offered unless such stockholder notifies Serina of its demand in writing within 30 days after Serina offered payment for the shares of capital stock.

 

186

 

 

If a demand for payment remains unsettled, Serina will commence a proceeding within 60 days after receiving the payment demand and petition the court to determine the fair value of the shares of capital stock and accrued interest. If the proceeding is not commenced within the 60-day period, each stockholder exercising appraisal rights whose demand remains unsettled shall be entitled to receive the amount demanded plus interest. Such a proceeding will be filed in the Circuit Court of Madison County, Alabama. Each stockholder exercising appraisal rights made a party to the proceeding is entitled to judgment for the amount the court finds to be the fair value of the shares of capital stock, plus accrued interest. The court’s finding may set a value above or below the value the stockholder believes is appropriate. Upon payment of the judgment and surrender to Serina of the certificate or certificates representing the judicially appraised shares of capital stock, a stockholder exercising appraisal rights will cease to have any interest in the shares of capital stock. The Court may assess costs incurred in such a proceeding against Serina or may assess the costs against all or some of the stockholders exercising appraisal rights, in amounts the court finds equitable, to the extent the Court finds that such stockholders acted arbitrarily, vexatiously or not in good faith in demanding payment different from that initially offered by Serina. The Court may also assess the reasonable fees and expenses of counsel and experts against Serina, if the Court finds that it did not substantially comply with its requirements regarding providing notice of appraisal rights and the procedures associated therewith under Article 13 of the ABCL or against either Serina or all or some of the dissenting stockholders if the Court finds that the party against whom the fees and expenses are assessed acted arbitrarily, vexatiously or not in good faith with respect to the rights provided in Article 13 of the ABCL. If the Court finds that services of counsel for any stockholder exercising appraisal rights were of substantial benefit to other similarly situated stockholders, and that fees for such services should not be assessed against Serina, then the Court may award reasonable fees to such counsel that will be paid out of the amounts awarded to stockholders exercising appraisal rights who benefited from such services.

 

Covenants; Operation of Business Pending the Merger

 

During the period from the date of the Merger Agreement and continuing until the earlier of the termination of the Merger Agreement or the Effective Time, except (i) as set forth in AgeX’s disclosure schedule, (ii) as expressly permitted by or required in accordance with the Merger Agreement, (iii) as required by applicable law or (iv) as may be consented to in writing by Serina (not to be unreasonably withheld, delayed or conditioned), each of AgeX and its subsidiaries has agreed to (A) conduct its business and operations in the ordinary course of business (which includes actions required to effect the Asset Dispositions or effect the winding down of AgeX’s prior research and development activities, including the termination of ongoing contractual obligations relating to AgeX’s current products or product candidates) and in compliance in all material respects with all applicable laws and the requirements of all of its material contracts and (B) continue to pay material outstanding accounts payable and other material current liabilities (including payroll) when due and payable, and will not, and will not cause or permit any of its subsidiaries to:

 

declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except repurchases of shares of AgeX common stock from terminated employees, directors or consultants of AgeX or in connection with the payment of the exercise price and/or withholding taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under the Incentive Plan in accordance with the terms of such award in effect on the date of the Merger Agreement);
sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any capital stock or other security of AgeX or any of its subsidiaries (except for AgeX common stock issued upon the valid exercise of outstanding AgeX options or AgeX warrants or upon settlement of AgeX restricted stock units); (B) any option, warrant or right to acquire any capital stock or any other security other than AgeX stock options or restricted stock unit awards granted to directors, employees and service providers in the ordinary course of business which are included in the calculation of the AgeX Outstanding Shares; or (C) any instrument convertible into or exchangeable for any capital stock or other security of AgeX or any of its subsidiaries;

 

187

 

 

except as required to give effect to anything in contemplation of the closing of the Merger, amend any of its or its subsidiaries’ organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;
form any subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;
(A) lend money to any person (except for the advancement of reasonable and customary expenses to employees, directors and consultants in the ordinary course of business), (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others, (D) other than the incurrence or payment of Transaction Expenses, make any capital expenditure in excess of $100,000 of the budgeted capital expenditure amounts set forth in AgeX’s operating budget delivered to Serina concurrently with the execution of the Merger Agreement (AgeX Budget), or (E) forgive any loans to any persons, including AgeX’s employees, officers, directors or affiliates;
other than as required by applicable law or the terms of any AgeX benefit plan as in effect on the date of the Merger Agreement: (A) adopt, terminate, establish or enter into any AgeX benefit plan; (B) cause or permit any AgeX benefit plan to be amended; (C) pay any bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or bonus or other compensation or remuneration payable to, any of its directors, officers, consultants or employees other than increases in base salary and annual cash bonus opportunities and payments made, in each case, in the ordinary course of business; (D) hire any officer or employee; or (E) increase the severance or change of control benefits offered to any current or new employees, directors or consultants;
recognize any labor union or labor organization, except as otherwise required by applicable law and after prior written consent of Serina (not to be unreasonably withheld, conditioned or delayed);
enter into any material transaction other than in the ordinary course of business;
acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties, except in the ordinary course of business;
sell, assign, transfer, license, sublicense or otherwise dispose of any material AgeX intellectual property (other than pursuant to non-exclusive licenses in the ordinary course of business);
make, change or revoke any material tax election, file any amendment making any material change to any tax return, settle or compromise any income or other material tax liability or submit any voluntary disclosure application, enter into any tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the ordinary course of business the principal subject matter of which is not taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material taxes (other than pursuant to an extension of time to file any tax return granted in the ordinary course of business of not more than seven months), or adopt or change any material accounting method in respect of taxes;
enter into, materially amend or terminate any AgeX material contract;
except as otherwise set forth in the AgeX Budget and the incurrence or payment of any Transaction Expenses, make any expenditures, incur any liabilities or discharge or satisfy any liabilities, in each case, in amounts that exceed the aggregate amount of the AgeX Budget by $100,000;
other than as required by law or GAAP, take any action to change accounting policies or procedures;
initiate or settle any legal proceeding; or other claim or dispute involving or against AgeX or any of its subsidiaries;
enter into or amend a material contract that would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the consummation of the Contemplated Transactions; or
agree, resolve or commit to do any of the foregoing.

 

188

 

 

During the period from the date of the Merger Agreement and continuing until the earlier of the termination of the Merger Agreement or the Effective Time, except (i) as set forth in Serina’s disclosure schedule, (ii) as expressly permitted by or required in accordance with the Merger Agreement, (iii) as required by applicable law or (iv) as may be consented to in writing by AgeX (not to be unreasonably withheld, delayed or conditioned), each of Serina and its subsidiaries has agreed to (A) conduct its business and operations in the ordinary course of business and in compliance in all material respects with all applicable laws and the requirements of all of its material contracts and (B) continue to pay material outstanding accounts payable and other material current liabilities (including payroll) when due and payable, and will not, and will not cause or permit any of its subsidiaries to:

 

declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except repurchases of shares of Serina common stock from terminated employees, directors or consultants of AgeX or in connection with the payment of the exercise price and/or withholding taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under the Serina Plan in accordance with the terms of such award in effect on the date of the Merger Agreement);
sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any capital stock or other security of Serina or any of its subsidiaries (except for shares of Serina common stock issued upon the valid exercise of outstanding Serina stock options or Serina warrants); (B) any option, warrant or right to acquire any capital stock or any other security other than Serina stock options or restricted stock unit awards granted to directors, employees and service providers in the ordinary course of business which are included in the calculation of the Company Outstanding Shares; or (C) any instrument convertible into or exchangeable for any capital stock or other security of Serina or any of its subsidiaries;
except as required to give effect to anything in contemplation of the closing of the Merger, amend any of its or its subsidiaries’ organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;
form a subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;
(A) lend money to any person (except for the advancement of reasonable and customary expenses to employees, directors and consultants in the ordinary course of business), (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others, (D) other than the incurrence or payment of Transaction Expenses, make any capital expenditure in excess of $100,000 of the budgeted capital expenditure amounts set forth in Serina’s operating budget delivered to AgeX concurrently with the execution of the Merger Agreement (Serina Budget) or (E) forgive any loans to any persons, including Serina’s employees, officers, directors or affiliates;
other than as required by applicable law or the terms of any Serina benefit plan as in effect on the date of the Merger Agreement: (A) adopt, terminate, establish or enter into any Serina benefit plan; (B) cause or permit any Serina benefit plan to be amended; (C) pay any bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or bonus or other compensation or remuneration payable to, any of its directors, officers, consultants or employees other than increases in base salary and annual cash bonus opportunities and payments made, in each case, in the ordinary course of business; (D) increase the severance or change of control benefits offered to any current or new employees, directors or consultants; or (E) terminate or give notice to any officer other than for cause;

 

189

 

 

recognize any labor union or labor organization, except as otherwise required by applicable law and after prior written consent of AgeX (not to be unreasonably withheld, conditioned or delayed);
enter into any material transaction other than in the ordinary course of business;
acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties, except in the ordinary course of business;
sell, assign, transfer, license, sublicense or otherwise dispose of any Serina intellectual property (other than pursuant to non-exclusive licenses in the ordinary course of business);
make, change or revoke any material tax election, file any amendment making any material change to any tax return, settle or compromise any income or other material tax liability or submit any voluntary disclosure application, enter into any tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the ordinary course of business the principal subject matter of which is not taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material taxes (other than pursuant to an extension of time to file any tax return granted in the ordinary course of business of not more than seven months), or adopt or change any material accounting method in respect of taxes;
enter into, materially amend or terminate any Serina material contract (other than statements of work entered into or amended in the ordinary course of business);
except as otherwise set forth in the Serina Budget and the incurrence or payment of any Transaction Expenses, make any expenditures, incur any liabilities or discharge or satisfy any liabilities, in each case, in amounts that exceed the aggregate amount of the Serina Budget by $150,000;
other than as required by law or GAAP, take any action to change accounting policies or procedures;
initiate or settle any legal proceeding or other claim or dispute involving or against Serina or any of its subsidiaries;
enter into or amend a contract that would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the consummation of the Contemplated Transactions; or
agree, resolve or commit to do any of the foregoing.

 

Termination and Termination Fees

 

The Merger Agreement may be terminated prior to the Effective Time (whether before or after the required stockholder approvals to consummate the Merger have been obtained, unless otherwise specified below):

 

(a)by mutual written consent of AgeX and Serina;
   
(b)by either AgeX or Serina if the Contemplated Transactions have not been consummated by February 29, 2024 (subject to possible extension as provided in this paragraph, the End Date); provided, however, that the right to terminate the Merger Agreement under this paragraph will not be available to a party if such party’s (or, in the case of AgeX, Merger Sub’s) action or failure to act has been a principal cause of the failure of the Contemplated Transactions to occur on or before the End Date and such action or failure to act constitutes a breach of the Merger Agreement; provided, further, however, that, in the event that a request for additional information has been made by any governmental body or in the event that the SEC has not declared the registration statement effective under the Securities Act by the date which is 30 calendar days prior to the End Date, then AgeX will be entitled to extend the End Date for an additional 60 calendar days by written notice to Serina;

 

190

 

 

(c)by either AgeX or Serina if a court of competent jurisdiction or other governmental body has issued a final and non-appealable order, decree or ruling, or has taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;
   
(d)by AgeX if the Serina Stockholder Written Consent has not been obtained within three business days of the date of the registration statement becoming effective in accordance with the provisions of the Securities Act; provided, however, that once the Serina Stockholder Written Consent has been obtained, AgeX may not terminate the Merger Agreement pursuant to this paragraph;
   
(e)by either AgeX or Serina if (i) the AgeX special meeting (including any adjournments and postponements thereof) was held and completed and (ii) the AgeX Stockholder Matters were not approved at such AgeX special meeting by the Required AgeX Stockholder Vote; provided, however, that the right to terminate the Merger Agreement pursuant to this paragraph will not be available to AgeX where the failure to obtain the Required AgeX Stockholder Vote was caused by the action or failure to act of AgeX and such action or failure to act constitutes a material breach by AgeX of the Merger Agreement;
   
(f)by Serina (at any time prior to the approval of the AgeX Stockholder Matters by the Required AgeX Stockholder Vote) if an AgeX Triggering Event (as defined below) has occurred;
   
(g)by AgeX (at any time prior to the Required Serina Stockholder Vote being obtained) if a Serina Triggering Event (as defined below) has occurred;
   
(h)by Serina, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement by AgeX or Merger Sub or if any representation or warranty of AgeX or Merger Sub has become inaccurate, in either case, such that certain closing conditions set forth in the Merger Agreement would not be satisfied as of the time of such breach or as of the time such representation or warranty has become inaccurate; provided that Serina is not then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement; provided, further, that if such inaccuracy in AgeX’s or Merger Sub’s representations and warranties or breach by AgeX or Merger Sub is curable by the End Date by AgeX or Merger Sub, then the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy until the earlier of (i) the End Date and (ii) the expiration of a 30 calendar day period commencing upon delivery of written notice from Serina to AgeX or Merger Sub of such breach or inaccuracy and its intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by AgeX or Merger Sub is cured prior to such termination becoming effective);
   
(i)by AgeX, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement by Serina or if any representation or warranty of Serina has become inaccurate, in either case, such that certain closing conditions set forth in the Merger Agreement would not be satisfied as of the time of such breach or as of the time such representation or warranty has become inaccurate; provided that AgeX is not then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement; provided, further, that if such inaccuracy in Serina’s representations and warranties or breach by Serina is curable by the End Date by Serina then the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy until the earlier of (i) the End Date and (ii) the expiration of a 30 calendar day period commencing upon delivery of written notice from AgeX to Serina of such breach or inaccuracy and its intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Serina is cured prior to such termination becoming effective);

 

191

 

 

(j)by AgeX, at any time prior to the approval of the AgeX Stockholder Matters by the Required AgeX Stockholder Vote, if (i) AgeX has received a Superior Offer, (ii) AgeX has complied with its obligations under the non-solicitation and AgeX Board Adverse Recommendation Change provisions of the Merger Agreement, (iii) the AgeX Board has determined in good faith, after consultation with its outside legal counsel, that the failure to terminate the Merger Agreement would be reasonably likely to be inconsistent with its fiduciary duties under applicable law, (iv) AgeX concurrently terminates the Merger Agreement and enters into a definitive agreement with respect to such Superior Offer and (v) AgeX concurrently pays to Serina the applicable termination fee;
   
(k)by AgeX, if Serina has not provided to AgeX the audited consolidated financial statements for the fiscal year ended 2022 in accordance with the Merger Agreement;
   
(l)by Serina, if the closing condition related to the Actual Closing Price being not less than $12.00 is not satisfied or waived; provided, however, that if Serina exercises its termination rights under this paragraph then Serina will provide AgeX with written notice five days prior to such termination and AgeX will have the option to within five business days of receipt by AgeX of such notice to provide Serina with a written offer to adjust the exchange ratio such that additional shares of AgeX common stock will be issued to the Serina stockholders in the amount necessary to equal the Target Merger Consideration Minimum Value (as defined below), and if AgeX provides that written offer, then Serina may not exercise its termination right under this paragraph and the related closing condition will be deemed to have been satisfied;
   
(m)by Serina, if the closing condition related to Juvenescence holding at least 1,133,308 post-merger warrants upon issuance is not satisfied or waived; provided, however, that if Serina exercises its termination rights under this paragraph then Serina will provide AgeX with written notice five days prior to such termination and AgeX will have the option to within five business days of receipt by AgeX of such notice to provide a sufficient number of post-merger warrants to Juvenescence such that the aggregate number of post-merger warrants subject to the Side Letter is at least 1,133,308, and if AgeX provides that additional post-merger warrants to Juvenescence, then Serina may not exercise its termination right under this paragraph and the related closing condition will be deemed to have been satisfied; or
   
(n)by Serina, if the closing condition related to AgeX holding at least $500,000 in unrestricted cash is not satisfied or waived; provided, however, that if Serina exercises its termination rights under this paragraph then Serina will provide AgeX with written notice prior to such termination and AgeX will have the option to within five business days of receipt by AgeX of such notice to obtain sufficient net funds, and if AgeX obtains such sufficient net funds to satisfy the contemplated closing condition, then Serina may not exercise its termination right under this paragraph and the related closing condition will be deemed to have been satisfied.

 

The party desiring to terminate the Merger Agreement will give the other party written notice of such termination, specifying the provisions of the Merger Agreement pursuant to which such termination is made and the basis therefor described in reasonable detail.

 

“Serina Triggering Event” will be deemed to have occurred if: (a) the Serina Board has made a Serina Board Adverse Recommendation Change; (b) the Serina Board or any committee thereof has publicly approved, endorsed or recommended any Acquisition Proposal; or (c) Serina has entered into any letter of intent or similar document or any contract relating to any Acquisition Proposal.

 

“AgeX Triggering Event” will be deemed to have occurred if: (a) AgeX has failed to include in the proxy statement/prospectus/information statement the AgeX Board Recommendation or has made an AgeX Board Adverse Recommendation Change; (b) the AgeX Board or any committee thereof has approved, endorsed or recommended any Acquisition Proposal; (c) AgeX has entered into any letter of intent or similar document or any contract relating to any Acquisition Proposal (other than a confidentiality agreement permitted pursuant to the Merger Agreement); or (d) AgeX or any director or officer of AgeX has willfully and intentionally breached the provisions set forth in the non-solicitation or AgeX stockholders’ meeting provisions of the Merger Agreement.

 

192

 

 

“Target Merger Consideration Minimum Value” means an amount equal to $12.00 multiplied by the anticipated aggregate number of shares of AgeX common stock to be issued (approximately 7,500,000 on a post-reverse stock split basis prior to any adjustment described in “—Termination and Termination Fees”).

 

AgeX must pay Serina a nonrefundable termination fee of $1,000,000 if (A) the Merger Agreement is terminated by Serina pursuant to clause (b), (e) or (h) above, (B) an Acquisition Proposal with respect to AgeX has been publicly announced, disclosed or otherwise communicated to AgeX or the AgeX Board at any time after the date of the Merger Agreement but prior to the termination of the Merger Agreement (which has not been withdrawn) and (C) within 12 months after the date of such termination, AgeX enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction in respect of such Acquisition Proposal. AgeX must pay Serina a nonrefundable termination fee of $1,000,000 if the Merger Agreement is terminated by Serina pursuant to clause (f) above (or at the time the Merger Agreement is terminated, Serina has the right to terminate the Merger Agreement pursuant to clause (f) above) or the Merger Agreement is terminated by AgeX pursuant to clause (j) above.

 

Serina must pay AgeX a nonrefundable termination fee of $1,000,000 if (i) (A) the Merger Agreement is terminated by AgeX pursuant to clause (b), (d) or (i) above, (B) an Acquisition Proposal with respect to Serina has been publicly announced, disclosed or otherwise communicated to Serina or the Serina Board at any time after the date of the Merger Agreement but prior to the termination of the Merger Agreement (which has not been withdrawn) and (C) within 12 months after the date of such termination, Serina enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction in respect of such Acquisition Proposal; or (ii) the Merger Agreement is terminated by AgeX pursuant to clause (g) above (or at the time the Merger Agreement is terminated, AgeX has the right to terminate the Merger Agreement pursuant to clause (g) above).

 

If the Merger Agreement is terminated by Serina pursuant to clause (h) above or in the event of the failure of Serina to consummate the transactions to be contemplated at the closing of the Merger solely as a result of an AgeX Material Adverse Effect as set forth in the Merger Agreement (provided, that at such time all other conditions precedent to AgeX’s obligation to close set forth in the Merger Agreement have been satisfied by Serina, are capable of being satisfied by Serina or have been waived by AgeX), then AgeX will reimburse Serina for all reasonable out-of-pocket fees and expenses incurred by Serina in connection with the Merger Agreement and the Contemplated Transactions, up to a maximum of $1,000,000, by wire transfer of same-day funds within ten business days following the date on which Serina submits to AgeX true and correct copies of reasonable documentation supporting such expenses; provided, however, that such expenses shall not include any amounts paid to Juvenescence or any affiliate thereof or any amounts for financial advisors to Serina except for reasonably documented out-of-pocket expenses otherwise reimbursable by Serina to such financial advisors pursuant to the terms of Serina’s engagement letter or similar arrangement with such financial advisors.

 

193

 

 

If the Merger Agreement is terminated by AgeX pursuant to clause (i) or in the event of the failure of AgeX to consummate the transactions to be consummated to the closing of the Merger solely as a result of a Serina Material Adverse Effect as set forth in the Merger Agreement (provided, that at such time all other conditions precedent to Serina’s obligation to close set forth in the Merger Agreement have been satisfied by AgeX, are capable of being satisfied by AgeX or have been waived by Serina), then Serina will reimburse AgeX for all reasonable out-of-pocket fees and expenses incurred by AgeX in connection with the Merger Agreement and the Contemplated Transactions, up to a maximum of $1,000,000, by wire transfer of same-day funds within ten business days following the date on which AgeX submits to Serina true and correct copies of reasonable documentation supporting such expenses; provided, however, that such expenses shall not include any amounts paid to Juvenescence or any affiliate thereof or any amounts for financial advisors to AgeX except for reasonably documented out-of-pocket expenses otherwise reimbursable by AgeX to such financial advisors pursuant to the terms of AgeX’s engagement letter or similar arrangement with such financial advisors.

 

Both AgeX and Serina shall be entitled only to either the termination fee or the reimbursement of expenses, but not both.

 

Other Agreements

 

Indemnification and Insurance

 

The Merger Agreement provides that, subject to certain limitations as set forth in the Merger Agreement, from the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, AgeX and the combined company will indemnify each person who is, has been at any time prior to the date of the Merger Agreement, or who becomes prior to the Effective Time, a director, officer, fiduciary or agent of AgeX or Serina or their respective subsidiaries.

 

The Merger Agreement also provides that the provisions relating to the indemnification, advancement of expenses and exculpation of present and former directors and officers of AgeX or any of its subsidiaries set forth in the organizational documents of AgeX or any of its subsidiaries will not be amended, modified or repealed for a period of six years from the Effective Time in any manner that would adversely affect the rights of individuals who, at or prior to the Effective Time, were officers or directors of AgeX or any of its subsidiaries, unless required by applicable law. After the closing of the Merger, the organizational documents of the combined company will contain provisions at least as favorable as the provisions relating to the indemnification, advancement of expenses and exculpation of present and former directors and officers presently set forth in AgeX’s organizational documents as of the date of the Merger Agreement. AgeX has agreed to purchase a six year “tail policy” with an effective date as of the Closing Date for the non-cancellable extension of AgeX’s existing directors’ and officers’ liability insurance policies and AgeX’s existing fiduciary liability insurance policies (if any).

 

Listing

 

AgeX common stock currently is listed on the NYSE American market under the symbol “AGEX.” AgeX has agreed to use commercially reasonable efforts (i) to maintain its existing listing on NYSE American until the Closing Date and to obtain approval of the listing of the combined company on NYSE American, (ii) without derogating from the requirements of the foregoing clause (i) and to the extent required by the rules and regulations of NYSE American, to prepare and submit to NYSE American a notification form for the listing of the shares of AgeX common stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance), (iii) to effect the reverse stock split and (iv) to the extent required by Section 101 of the NYSE American Company Guide, to file an initial NYSE American listing application for the AgeX common stock on NYSE American and to cause such listing application to be conditionally approved prior to the Effective Time.

 

194

 

 

The parties will use commercially reasonable efforts to coordinate with respect to compliance with NYSE American rules and regulations. Serina will cooperate with AgeX as reasonably requested by AgeX with respect to the NYSE American listing application and promptly furnish to AgeX all information concerning Serina and its stockholders that may be required or reasonably requested in connection with any action contemplated by the foregoing paragraph.

 

Expenses

 

Pursuant to the Merger Agreement, all the Transaction Expenses (as defined below) will be paid by the party incurring such expense, whether or not the Merger is consummated, except as described above in the section titled “—Termination and Termination Fees” beginning on page 190 of this proxy statement/prospectus/information statement.

 

“Transaction Expenses” means, with respect to each party, all fees and expenses incurred by such party at or prior to the Effective Time in connection with the Contemplated Transactions and the Merger Agreement, including (a) any fees and expenses of legal counsel and accountants and the maximum amount of fees and expenses payable to financial advisors, investment bankers, brokers, consultants, and other advisors of such party in connection with the negotiation, preparation and execution of the Merger Agreement and the consummation of the Contemplated Transactions (including in connection with any stockholder litigation relating to the Merger Agreement or any of the Contemplated Transactions), including finders’ fees; (b) only with respect to AgeX, fees paid to the SEC in connection with filing the Registration Statement, the proxy statement/prospectus/information statement, and any amendments and supplements hereto or thereto, with the SEC; (c) only with respect to AgeX, any fees and expenses in connection with the printing, mailing and distribution of the Registration Statement and any amendments and supplements hereto; (d) 50% of the fees and expenses payable to NYSE American in connection with the NYSE American listing application; (e) any bonus, severance, change-in-control or retention payments or similar payment obligations (including payments with “single-trigger” provisions triggered at and as of the closing of the Merger) that become due or payable to any director, officer, employee or consultant of AgeX or any of its subsidiaries in connection with the consummation of the Contemplated Transactions; (f) only with respect to AgeX, any fees and expenses incurred in connection with the directors’ and officers’ tail policy described above; (g) only with respect to AgeX, any notice payments, change-of-control payments, fines or other payments to be made by Parent in connection with terminating any existing contract to which AgeX is a party or winding down any of AgeX’s clinical trial obligations; and (i) only with respect to AgeX, any wind-down costs of AgeX associated with discontinued lab, research and development and related operations.

 

Amendment of Merger Agreement

 

The Merger Agreement may be amended by the parties at any time with the written approval of the respective boards of directors of Serina, Merger Sub and AgeX, except that after the Merger Agreement has been adopted and approved by a party’s stockholders, no amendment which by law requires further approval by the stockholders of that party will be made without such further stockholder approval.

 

195

 

 

AGREEMENTS RELATED TO THE MERGER

 

Support Agreements

 

Concurrently with the execution of the Merger Agreement, Juvenescence entered into the AgeX Support Agreement in favor of Serina, providing, among other things, that Juvenescence will vote all of its shares of AgeX capital stock: (i) in favor of the AgeX Stockholder Matters, (ii) against any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii) against any acquisition proposal involving a third party other than Serina. As of January 3, 2024, Juvenescence is a stockholder of AgeX holding approximately 43.3% of the outstanding shares of common stock of AgeX, 100% of the outstanding shares of Series A preferred stock of AgeX and 100% of the outstanding shares of Series B preferred stock of AgeX.

 

In connection with the execution of the Merger Agreement, stockholders of Serina holding 100% of the outstanding shares of common stock of Serina, 100% of the outstanding shares of Series A preferred stock of Serina, 100% of the outstanding shares of Series A-1 preferred stock of Serina, 100% of the outstanding shares of Series A-2 preferred stock of Serina, 100% of the outstanding shares of Series A-3 preferred stock of Serina, 100% of the outstanding shares of Series A-4 preferred stock of Serina, and 100% of the outstanding shares of Series A-5 preferred stock of Serina, in each case effective as of August 29, 2023, entered into the Serina Support Agreements in favor of AgeX, providing, among other things, that such stockholders will vote all of their shares of Serina capital stock (or execute a written consent): (i) in favor of Serina Stockholder Matters, (ii) against any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii) against any acquisition proposal involving a third party other than AgeX.

 

Lock-Up Agreements

 

Concurrently with the execution of the Merger Agreement, (i) certain executive officers, directors, and stockholders of Serina and (ii) certain stockholders of AgeX, entered into the Lock-Up Agreements, pursuant to which such persons accepted certain restrictions on transfers of the shares of AgeX common stock held by such persons for the 180-day period following the Effective Time.

 

196

 

 

Side Letter

 

Concurrently with the execution of the Merger Agreement, AgeX, Serina and Juvenescence entered into the Side Letter, which will become effective immediately prior to the closing of the Merger. The Side Letter provides that:

 

(vii)immediately prior to the Effective Time, Juvenescence will cancel all out of the money AgeX warrants held by Juvenescence;

 

(viii)Juvenescence will exercise all of the post-merger warrants it holds to provide the combined company approximately an additional $15 million in capital according to the following schedule: (x) at least one-third on or before May 31, 2024, (y) at least one-third on or before November 30, 2024, and (z) at least one-third on or before June 30, 2025;

 

(ix)AgeX and Serina shall use reasonable best efforts to appoint certain directors, including Steve Ledger and Dr. J. Milton Harris, who are each affiliated with Serina, and Dr. Gregory Bailey and Dr. Richard Marshall, who are each affiliated with Juvenescence, to the Combined Company Board effective as of the Effective Time;

 

(x)Juvenescence will not sell any shares of AgeX Series A preferred stock or AgeX Series B preferred stock and will take all actions necessary to effect the AgeX preferred stock conversion, whereby all of such preferred stock will be converted into AgeX common stock prior to the reverse stock split;

 

(xi)Juvenescence will release all security interests, guarantees, pledges, assignments and other forms of collateral that it may have in AgeX’s assets pursuant to the terms of certain loans to AgeX; and

 

(xii)Juvenescence will consent to a newly formed subsidiary of AgeX assuming AgeX’s obligations with respect to loans agreements and promissory notes governing loans payable to Juvenescence, including obligations for amounts currently owed and future advances of loan funds, and Juvenescence shall release AgeX from those loan obligations.

 

Warrant Agreement

 

In connection with the closing of the Merger, AgeX will enter into a warrant agreement (the warrant agreement) with Equiniti (the warrant agent). Pursuant to the terms of the warrant agreement, AgeX will issue to each holder of AgeX common stock three post-merger warrants for each five shares of AgeX common stock held by such holder. Each post-merger warrant will be exercisable at an exercise price equal to $13.20 per warrant (such exercise price reflecting the planned reverse stock split) for (i) one share of AgeX common stock and (ii) one incentive warrant. Each incentive warrant will be exercisable at an exercise price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split) for one share of AgeX common stock. Each post-merger warrant will expire on July 31, 2025, and each incentive warrant will expire on the four-year anniversary of the Closing Date. Each post-merger warrant and incentive warrant will be issued pursuant to the terms of a warrant agreement to be entered into by AgeX and a warrant agent in connection with the closing of the Merger. The terms of the warrant agreement remain subject to agreement between AgeX and Serina.

 

197

 

 

MATTERS BEING SUBMITTED TO A VOTE OF AGEX’S STOCKHOLDERS

 

PROPOSAL NO. 1 (THE STOCK ISSUANCE PROPOSAL):

APPROVAL OF THE ISSUANCE OF SHARES OF AGEX COMMON STOCK PURSUANT TO THE MERGER AGREEMENT

 

General

 

At the AgeX special meeting, AgeX’s common stockholders will be asked to approve the issuance of AgeX common stock to Serina’s stockholders pursuant to the Merger Agreement, which shares of AgeX common stock to be issued pursuant to the Merger will represent more than 20% of the shares of AgeX common stock outstanding immediately prior to the Merger in connection with the Merger and result in a change of control resulting from the Merger, pursuant to Sections 712(b) and 713(b) of the NYSE American Company Guide.

 

Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price of AgeX common stock being equal to or greater than $12.00 per share (on a post-reverse stock split basis), giving effect to the reverse stock split and the AgeX preferred stock conversion and excluding the impact of any post-merger warrant, incentive warrant or the issuance of any share of AgeX common stock upon exercise of any post-merger warrant or incentive warrant.

 

The terms of, reasons for and other aspects of the Merger Agreement, the Merger, the issuance of AgeX common stock pursuant to the Merger Agreement are described in more detail in the other sections in this proxy statement/prospectus/information statement.

 

Reason for the Proposal

 

Under Section 712(b) of the NYSE American Company Guide, stockholder approval is required prior to the issuance of common stock, or of securities convertible into common stock, in which the sales, issuance or potential issuance is equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance of the common stock or securities convertible into common stock. AgeX will issue to Serina’s equityholders shares representing 20% or more of the number of shares of AgeX common stock outstanding immediately prior to the Merger pursuant to the Merger Agreement. Accordingly, in order to ensure compliance with Section 712(b) of the NYSE American Company Guide, AgeX is asking for the approval of AgeX’s stockholders for the issuance of these shares of AgeX common stock.

 

Under Section 713(b) of the NYSE American Company Guide, stockholder approval is required prior to the issuance or potential issuance of additional shares which will result in a change of control, including in connection with a reverse merger as defined in the NYSE American rules. It is expected that NYSE American will determine that the Merger constitutes a “change of control” of AgeX. Accordingly, in order to ensure compliance with Section 713(b) of the NYSE American Company Guide, AgeX is asking for the approval of AgeX’s stockholders of the change of control of AgeX resulting from the issuance of such shares of AgeX common stock in connection with the Merger.

 

Required Vote; Recommendation of the AgeX Board

 

The affirmative vote of a majority of the voting power of the shares of AgeX common stock present or represented by proxy at the AgeX special meeting and entitled to vote is required to approve Proposal No. 1. Abstentions and broker non-votes, if any, will have no effect on the outcome of this proposal.

 

THE AGEX BOARD RECOMMENDS THAT AGEX’S COMMON STOCKHOLDERS VOTE “FOR” THE STOCK ISSUANCE PROPOSAL. THE APPROVAL OF EACH OF PROPOSAL NOS. 1, 2, 3, 4 AND 6 IS REQUIRED TO CONSUMMATE THE MERGER.

 

198

 

 

PROPOSAL NO. 2 (THE REVERSE STOCK SPLIT PROPOSAL):

APPROVAL OF AN AMENDMENT TO THE AGEX CERTIFICATE OF
INCORPORATION EFFECTING THE REVERSE STOCK SPLIT AT A RATIO IN THE RANGE FROM 1-FOR-35 TO 1-FOR-36

 

General

 

At the AgeX special meeting, AgeX’s common stockholders will be asked to approve an amendment to the AgeX Charter, attached to this proxy statement/prospectus/information statement as Annex E, to effect the reverse stock split of AgeX common stock at a ratio anywhere in the range between one new share for every 35 shares and one new share for every 36 shares outstanding. Prior to the effectiveness of the Merger, AgeX and Serina will mutually agree upon the exact reverse split ratio within such range. Upon the effectiveness of the amendment to the AgeX Charter effecting the reverse stock split, or the split effective time, the issued shares of AgeX common stock immediately prior to the split effective time will be reclassified into a smaller number of shares within the specified range, such that a stockholder of AgeX will own one new share of AgeX common stock for the specified number of shares of issued AgeX common stock held by that stockholder immediately prior to the split effective time. Based upon the reverse stock split ratio as mutually agreed by the AgeX Board and Serina Board or as selected by the AgeX Board, as applicable, proportionate adjustments will be made to the per share exercise price, and/or the number of shares issuable upon the exercise or vesting of all then outstanding AgeX existing warrants and stock options, if any, which will result in a proportional decrease in the number of shares of AgeX common stock reserved for issuance upon exercise or vesting of such AgeX warrants and stock options and a proportional increase in the exercise price of all such warrants and stock options.

 

If Proposal No. 2 is approved, AgeX stockholders will be approving the combination of a number of shares of AgeX common stock in the range between 35 to 36 into one share of AgeX common stock, with the actual ratio to be mutually agreed upon by the AgeX Board and the Serina Board prior to the effectiveness of the Merger. AgeX may effect only one reverse stock split in connection with this Proposal No. 2.

 

If Proposals No. 1, 3, 4 or 6 are not approved and the Merger is not effected, the AgeX Board may still choose to implement the reverse stock split in order to effectively increase the per share price of AgeX common stock.

 

The form of the amendment to the AgeX Charter to effect the reverse stock split, as more fully described below, will effect the reverse stock split but will not change the number of authorized shares of AgeX common stock or preferred stock, or the par value of AgeX common stock or preferred stock. The final ratio and effectiveness of such amendment and the abandonment of such amendment will be mutually agreed by the AgeX Board and the Serina Board prior to the Effective Time or, if Proposals No. 1, 3, 4 or 6 are not approved by AgeX stockholders, determined solely by the AgeX Board.

 

Purpose

 

The AgeX Board approved the proposal approving the amendment to the AgeX Charter for the purpose of effecting the reverse stock split pursuant to the terms of the Merger Agreement.

 

NYSE American Requirements for Listing on the NYSE American

 

AgeX common stock is listed on the NYSE American under the symbol “AGE.” AgeX intends to file an initial listing application with the NYSE American, as described below, to seek a listing upon the closing of the Merger. According to the NYSE American rules, an issuer must, in a case such as this, submit an initial listing application for a post-transaction entity prior to the consummation of a transaction whereby the issuer combines with a non-NYSE American entity, resulting in a change of control of the issuer and potentially allowing the non-NYSE American entity to obtain an NYSE American listing. Accordingly, the listing standards of the NYSE American will require AgeX to have, among other things, a $3.00 per share minimum bid price upon the closing of the Merger. Therefore, the reverse stock split may be necessary in order to consummate the Merger.

 

199

 

 

One of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in AgeX’s management being able to issue more shares without further stockholder approval. For example, before the reverse stock split, as of    , 2024, AgeX’s authorized shares of common stock immediately prior to the closing of the Merger is 200,000,000 compared to shares issued and outstanding of    . If AgeX effects the reverse stock split using a    :1 ratio, its authorized shares of common stock immediately prior to the closing of the Merger would still be 200,000,000 compared to shares issued and outstanding of    . The reverse stock split will not affect the number of authorized shares of AgeX common stock which will continue to be authorized pursuant to the certificate of incorporation of AgeX.

 

Potential Increased Investor Interest

 

On    , 2024, AgeX common stock closed at $     per share. An investment in AgeX common stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower priced stocks. Also, the AgeX Board believes that most investment funds are reluctant to invest in lower priced stocks.

 

There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of AgeX common stock.

 

AgeX cannot predict whether the reverse stock split will increase the market price for AgeX common stock in the future. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that:

 

the market price per share of AgeX common stock after the reverse stock split will rise in proportion to the reduction in the number of shares of AgeX common stock outstanding before the reverse stock split;
the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks;
the reverse stock split will result in a per share price that will increase the ability of AgeX to attract and retain employees; and
AgeX will continue to meet the listing standards of the NYSE American.

 

The market price of AgeX common stock will also be based on performance of AgeX and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of AgeX common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of AgeX may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of AgeX common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.

 

200

 

 

Criteria to be Used for Determining Which Reverse Stock Split Ratio to Implement

 

In determining which reverse stock split ratio to implement, if any, following receipt of stockholder approval of the Reverse Stock Split Proposal, AgeX and/or Serina may consider the ratio that results in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the Effective Time.

 

If Proposals No. 1, 3, 4 or 5 are not approved and the Merger is not effected, then, in determining which reverse stock split ratio to implement, if any, following receipt of stockholder approval of the Reverse Stock Split Proposal, the AgeX Board may consider, among other things, various factors, such as:

 

the historical trading price and trading volume of AgeX common stock;
the then-prevailing trading price and trading volume of AgeX common stock and the expected impact of the reverse stock split on the trading market for AgeX common stock in the short- and long-term;
the ability of the combined company to satisfy the NYSE American initial listing requirements for its common stock on the NYSE American;
which reverse stock split ratio would result in the least administrative cost to AgeX; and
prevailing general market and economic conditions.

 

Principal Effects of the Reverse Stock Split

 

The amendment to the AgeX Charter effecting the reverse stock split is set forth in Annex E to this proxy statement/prospectus/information statement.

 

The reverse stock split will be effected simultaneously for all outstanding shares of AgeX common stock. The reverse stock split will affect all of AgeX’s stockholders uniformly and will not affect any stockholder’s percentage ownership interest in AgeX, except to the extent that the reverse stock split results in any of AgeX’s stockholders owning a fractional share. Shares of AgeX common stock issued pursuant to the reverse stock split will remain fully paid and nonassessable. The reverse stock split does not affect the total proportionate ownership of AgeX following the Merger. The reverse stock split will not affect AgeX continuing to be subject to the periodic reporting requirements of the Exchange Act.

 

As an example, the following table illustrates the effects of a 1-for-35 to 1-for-36 reverse stock split (without giving effect to the treatment of fractional shares):

 

  

Prior to Reverse

Stock Split

  

After 1-for-35

Reverse Stock Split

  

After 1-for-36

Reverse Stock Split

 
Common stock outstanding                                 
Common stock issuable pursuant to outstanding equity awards(1)               

 

(1) Substantially all such options have an exercise price higher than $ per share, the closing price of AgeX common stock on    , 2024.

 

In addition, if the reverse stock split is implemented, it will increase the number of AgeX stockholders who own “odd lots” of fewer than 100 shares of common stock. Brokerage commission and other costs of transactions in odd lots are generally higher than the costs of transactions of more than 100 shares of common stock. Accordingly, the reverse stock split may not achieve the desired results of increasing marketability and liquidity of AgeX common stock that have been described above.

 

201

 

 

After the effective date of the reverse stock split, AgeX common stock would have a new committee on uniform securities identification procedures (CUSIP number), a number used to identify AgeX common stock.

 

AgeX common stock is currently registered under Section 12(b) of the Exchange Act, and AgeX is subject to the periodic reporting and other requirements of the Exchange Act. The proposed reverse stock split will not affect the registration of AgeX common stock under the Exchange Act.

 

Procedure for Effecting the Reverse Stock Split and Exchange of Stock Certificates

 

If AgeX’s common stockholders approve the amendment to the AgeX Charter effecting the reverse stock split, and if the AgeX Board still believes that a reverse stock split is in the best interests of AgeX and its stockholders, AgeX will file the amendment to the AgeX Charter with the Secretary of State of the State of Delaware at such time as the AgeX Board has determined to be the appropriate split effective time. The AgeX Board may delay effecting the reverse stock split without resoliciting stockholder approval. Beginning at the split effective time, each certificate representing pre-split shares will be deemed for all corporate purposes to evidence ownership of post-split shares.

 

Beneficial Owners of Common Stock. Upon the implementation of the reverse stock split, AgeX intends to treat shares held by stockholders in “street name” (i.e., through a bank, broker, custodian or other nominee), in the same manner as registered stockholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding AgeX common stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the reverse stock split and making payment for fractional shares. If a stockholder holds shares of AgeX common stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee.

 

Registered Holders of Common Stock in Book-Entry Form. Certain of AgeX’s registered holders of common stock hold some or all of their shares electronically in book-entry form with AgeX’s transfer agent, Equiniti. These stockholders do not hold physical stock certificates evidencing their ownership of AgeX common stock. However, they are provided with a statement reflecting the number of shares of AgeX common stock registered in their accounts. If a stockholder holds registered shares in book-entry form with AgeX’s transfer agent, no action needs to be taken to receive post-reverse stock split shares or payment in lieu of fractional shares, if applicable. If a stockholder is entitled to post-reverse stock split shares, a transaction statement will automatically be sent to the stockholder’s address of record indicating the number of shares of AgeX common stock held following the reverse stock split.

 

Registered Holders of Common Stock in Certificate Form. As soon as practicable after the split effective time, AgeX’s stockholders will be notified that the reverse stock split has been effected. AgeX expects that the AgeX transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of pre-split shares will be asked to surrender to the exchange agent certificates representing pre-split shares held in certificated form in exchange for certificates representing post-split shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by AgeX. No new certificates will be issued to a stockholder until such stockholder has surrendered such stockholder’s outstanding certificate(s) together with the properly completed and executed letter of transmittal to the exchange agent. Any pre-split shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post-split shares. Stockholders should not destroy any stock certificate(s) and should not submit any certificate(s) unless and until requested to do so.

 

202

 

 

Fractional Shares

 

No fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of pre-split shares not evenly divisible by the number of pre-split shares for which each post-split share is to be reclassified, will be entitled, upon surrender to the exchange agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing price of AgeX common stock, as reported on the NYSE American, on the last trading day prior to the split effective time (or if such price is not available, the average of the last bid and asked prices of AgeX common stock on such day or other price determined by the AgeX Board), as adjusted in good faith by AgeX to account for the reverse stock split ratio. For the foregoing purposes, all fractional shares of AgeX common stock held by a stockholder of record will be aggregated (thus resulting in no more than one fractional share per stockholder). The ownership of a fractional interest will not give the holder thereof any voting, dividend, or other rights except to receive payment therefor as described herein.

 

Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where AgeX is domiciled, and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the reverse stock split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by AgeX or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.

 

Accounting Consequences

 

The par value per share of AgeX common stock will remain unchanged at $0.0001 per share after the reverse stock split. As a result, at the split effective time, the stated capital on AgeX’s balance sheet attributable to AgeX common stock will be reduced proportionately based on the reverse stock split ratio, from its present amount, and the additional paid-in capital account will be increased for the amount by which the stated capital is reduced. After the reverse stock split (and disregarding the impact of shares of AgeX common stock issued in the Merger), net income or loss per share, and other per share amounts will be increased because there will be fewer shares of AgeX common stock outstanding. In future financial statements, net income or loss per share and other per share amounts for periods ending before the reverse stock split will be recast to give retroactive effect to the reverse stock split.

 

Potential Anti-Takeover Effect

 

Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the AgeX Board or contemplating a tender offer or other transaction for the combination of AgeX with another company, the Reverse Stock Split Proposal is not being proposed in response to any effort of which AgeX is aware to accumulate shares of AgeX common stock or obtain control of AgeX, other than in connection with the Merger, nor is it part of a plan by management to recommend a series of similar amendments to the AgeX Board and stockholders. Other than the proposals being submitted to AgeX’s common stockholders for their consideration at the AgeX special meeting, the AgeX Board does not currently contemplate recommending the adoption of any other actions that could be construed to affect the ability of third parties to take over or change control of AgeX.

 

203

 

 

Material U.S. Federal Income Tax Consequences of the Reverse Stock Split

 

The following is a discussion of material U.S. federal income tax consequences of the reverse stock split that are applicable to U.S. holders (as defined below) of AgeX common stock, but does not purport to be a complete analysis of all potential tax effects. This summary is based upon current provisions of the Code, existing Treasury regulations, judicial decisions, and published rulings and administrative pronouncements of the IRS, all in effect as of the date hereof and all of which are subject to differing interpretations or change. Any such change or differing interpretation, which may be retroactive, could alter the tax consequences to AgeX stockholders as described in this summary.

 

This summary is not a complete description of all tax consequences of the reverse stock split and does not address U.S. federal income tax consequences that may be relevant to particular AgeX stockholders in light of their personal circumstances or to AgeX stockholders who are subject to special treatment under U.S. federal income tax laws, such as AgeX stockholders who: do not hold their AgeX common stock as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment); are banks, insurance companies, tax-exempt entities, mutual funds, financial institutions, real estate investment trusts, regulated investment companies, government entities or broker-dealers; hold their AgeX common stock as “qualified small business stock” under Section 1202 of the Code or as “Section 1244 stock” under Section 1244 of the Code; hold their AgeX common stock as part of a hedging, “straddle,” conversion or other integrated transaction or are treated as having sold their AgeX common stock pursuant to the constructive sale provisions of the Code; are not U.S. holders (as defined below); acquired their AgeX common stock pursuant to the exercise of compensatory options, or in other compensatory transactions; acquired their AgeX common stock pursuant to the exercise of warrants or conversion rights under convertible instruments; are subject to special tax accounting rules under Section 451(b) of the Code; hold their AgeX common stock through individual retirement or other tax-deferred accounts; acquired their AgeX common stock in a transaction subject to the gain rollover provisions of Section 1045 of the Code; have a functional currency other than the U.S. dollar; or are partnerships or entities or arrangements classified as partnerships or disregarded entities for U.S. federal income tax purposes, S corporations, or other pass-through entities (including hybrid entities) and investors therein.

 

In addition, the following discussion does not address: (a) the tax consequences of transactions effectuated before, after or at the same time as the reverse stock split, whether or not they are in connection with the reverse stock split; (b) any U.S. federal non-income tax consequences of the reverse stock split, including estate, gift or other tax consequences; (c) any state, local or non-U.S. tax consequences of the reverse stock split; or (d) the Medicare contribution tax on net investment income. No ruling from the IRS or opinion of counsel, has been or will be requested in connection with the reverse stock split. AgeX stockholders should be aware that the IRS could adopt a position which could be sustained by a court contrary to that set forth in this discussion.

 

If an entity that is treated as a partnership for U.S. federal income tax purposes holds AgeX common stock prior to the reverse stock split, the tax treatment of a partner in such partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Such partner should consult its tax advisors as to the tax consequences of the reverse stock split.

 

204

 

 

No opinions of counsel or rulings from the IRS have been requested or obtained in connection with the reverse stock split. Accordingly, all AgeX stockholders should consult their own tax advisors as to the specific tax consequences to them of the reverse stock split.

 

IN VIEW OF THE FOREGOING AND BECAUSE THE FOLLOWING DISCUSSION IS INTENDED AS A GENERAL SUMMARY ONLY, EACH AGEX STOCKHOLDER SHOULD CONSULT SUCH STOCKHOLDER’S TAX ADVISOR REGARDING THE TAX CONSEQUENCES, INCLUDING THE APPLICABLE U.S. FEDERAL, STATE, LOCAL AND NON-U.S. TAX CONSEQUENCES, AND ANY TAX REPORTING REQUIREMENTS OF THE REVERSE STOCK SPLIT IN LIGHT OF SUCH STOCKHOLDER’S OWN TAX SITUATION.

 

Definition of “U.S. Holder”

 

For purposes of this discussion, a “U.S. holder” is a beneficial owner of AgeX common stock that is, for U.S. federal income tax purposes:

 

an individual who is a citizen or resident of the United States;
a corporation or any other entity taxable as a corporation created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;
a trust if either (i) a court within the United States is able to exercise primary supervision over the administration of such trust, and one or more United States persons (within the meaning of Section 7701(a)(30) of the Code) are authorized or have the authority to control all substantial decisions of such trust, or (ii) the trust was in existence on August 20, 1996 and has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes; or
an estate, the income of which is subject to U.S. federal income tax regardless of its source.

 

Treatment of U.S. Holders in the Reverse Stock Split

 

AgeX intends to treat the reverse stock split as a “recapitalization” for U.S. federal income tax purposes within the meaning of Section 368(a) of the Code. Assuming the reverse stock split qualifies as a recapitalization within the meaning of Section 368(a) of the Code, a U.S. holder will not recognize gain or loss upon the reverse stock split, except with respect to cash received in lieu of a fractional share of AgeX common stock (which fractional share will be treated as received and then exchanged for such cash). A U.S. holder’s aggregate tax basis in the shares of AgeX common stock received pursuant to the reverse stock split will equal the aggregate tax basis of the shares of the AgeX common stock surrendered (excluding any portion of such basis that is allocated to any fractional share of AgeX common stock), and such U.S. holder’s holding period in the shares of AgeX common stock received will include the holding period in the shares of AgeX common stock surrendered. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of AgeX common stock surrendered to the shares of AgeX common stock received in a recapitalization pursuant to the reverse stock split. U.S. holders of shares of AgeX common stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares.

 

205

 

 

A U.S. holder that receives cash in lieu of a fractional share of AgeX common stock pursuant to the reverse stock split will generally recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S. holder’s tax basis in the shares of AgeX common stock surrendered that is allocated to such fractional share of AgeX common stock. Any such gain or loss will be long-term capital gain or loss if, as of the effective time of the reverse stock split, the U.S. holder’s holding period for such fractional share exceeds one year. Long-term capital gains of certain non-corporate taxpayers, including individuals, are generally taxed at preferential rates. The deductibility of capital losses is subject to limitations.

 

Information Reporting and Backup Withholding

 

If the reverse stock split qualifies as a recapitalization within the meaning of Section 368(a) of the Code, each U.S. holder who receives shares of AgeX common stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split, and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. U.S. holders who owned immediately before the reverse stock split at least five percent (by vote or value) of the total outstanding stock of AgeX is required to attach a statement to their tax returns for the year in which the reverse stock split is consummated that contains the information listed in Treasury Regulation Section 1.368-3(b). Such statement must include the U.S. holder’s tax basis in such holder’s AgeX common stock surrendered in the reverse stock split, the fair market value of such stock, the date of the reverse stock split and the name and employer identification number of AgeX. U.S. holders are urged to consult with their tax advisors to comply with these rules.

 

A U.S. holder may be subject to information reporting and backup withholding for U.S. federal income tax purposes on cash paid in lieu of fractional shares in connection with the reverse stock split. Backup withholding will not apply, however, to a U.S. holder who (i) furnishes a correct taxpayer identification number and certifies the holder is not subject to backup withholding on IRS Form W-9 or a substantially similar form, or (ii) certifies the holder is otherwise exempt from backup withholding. If a U.S. holder does not provide a correct taxpayer identification number on IRS Form W-9 or other proper certification, the stockholder may be subject to penalties imposed by the IRS. Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the federal income tax liability of a U.S. holder of AgeX capital stock, if any, provided the required information is timely furnished to the IRS. U.S. holders should consult their tax advisors regarding their qualification for an exemption from backup withholding, the procedures for obtaining such an exemption, and in the event backup withholding is applied, to determine if any tax credit, tax refund or other tax benefit may be obtained.

 

The foregoing summary is of a general nature only and is not intended to be, and should not be construed to be, legal, business or tax advice to any particular AgeX stockholder. This summary does not take into account your particular circumstances and does not address consequences that may be particular to you. Therefore, you should consult your tax advisor regarding the particular consequences of the reverse stock split to you.

 

Vote Required; Recommendation of the AgeX Board

 

The affirmative vote of a majority of the voting power of the shares of AgeX common stock present or represented by proxy at the AgeX special meeting and entitled to vote is required to approve Proposal No. 2. Abstentions and broker non-votes, if any, will have no effect on the outcome of this proposal.

 

THE AGEX BOARD RECOMMENDS THAT AGEX’S COMMON STOCKHOLDERS VOTE “FOR” THE REVERSE STOCK SPLIT PROPOSAL. THE APPROVAL OF EACH OF PROPOSAL NOS. 1, 2, 3, 4 AND 6 IS REQUIRED TO CONSUMMATE THE MERGER.

 

206

 

 

PROPOSAL NO. 3 (THE WARRANT ISSUANCE PROPOSAL):

APPROVAL OF THE ISSUANCE OF POST-MERGER WARRANTS AND INCENTIVE WARRANTS PURSUANT TO THE MERGER aGREEMENT

 

General

 

At the AgeX special meeting, AgeX’s common stockholders will be asked to approve the issuance of the post-merger warrants to the pre-Merger holders of AgeX common stock pursuant to the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the post-merger incentive warrants, which will represent an issuance by AgeX of securities convertible into or exercisable for AgeX common stock of more than 20% of the shares of AgeX common stock outstanding at the time of issuance.

 

Following the reverse stock split and the AgeX preferred stock conversion and prior to the closing of the Merger, AgeX will issue to each holder of AgeX common stock as of the Warrant Dividend Record Date three post-merger warrants for each five shares of AgeX common stock held by such holder as of the Warrant Dividend Record Date, or the Warrant Dividend. Each post-merger warrant will be exercisable at an exercise price equal to $13.20 per warrant (such exercise price reflecting the planned reverse stock split) for (i) one share of AgeX common stock and (ii) one incentive warrant. Each incentive warrant will be exercisable at an exercise price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split) for one share of AgeX common stock. Each post-merger warrant will expire on July 31, 2025, and each incentive warrant will expire on the four-year anniversary of the Closing Date. Each post-merger warrant and incentive warrant will be issued pursuant to the terms of the warrant agreement to be entered into by AgeX and a warrant agent in connection with the closing of the Merger.

 

The terms of, reasons for and other aspects of the Merger Agreement, the Merger and the Warrant Dividend are described in more detail in the other sections in this proxy statement/prospectus/information statement.

 

Reason for the Proposal

 

Under Section 712(b) of the NYSE American Company Guide, stockholder approval is required prior to the issuance of common stock, or of securities convertible into common stock, in which the sales, issuance or potential issuance is equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance of the common stock or securities convertible into common stock. AgeX will issue the Warrant Dividend to pre-Merger holders of AgeX common stock, which will represent an issuance by AgeX of securities convertible into or exercisable for AgeX common stock of more than 20% of the shares of AgeX common stock outstanding at the time of issuance. Accordingly, in order to ensure compliance with Section 712(b) of the NYSE American Company Guide, AgeX is asking for the approval of AgeX stockholders for the issuance of post-merger warrants to the pre-Merger holders of AgeX common stock pursuant to the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants.

 

207

 

 

Under Section 713(a) of the NYSE American Company Guide, stockholder approval is required prior to the issuance or potential issuance of additional shares when such shares will be issued in connection with a transaction involving the sale, issuance, or potential issuance by the issuer of common stock (or securities convertible into or exercisable for common stock) at a price less than the greater of book or market value which together with sales by officers, directors or principal shareholders of the issuer equals 20% or more of presently outstanding common stock, or the sale, issuance, or potential issuance by the issuer of common stock (or securities convertible into or exercisable for common stock) equal to 20% or more of presently outstanding stock for less than the greater of book or market value of the stock. AgeX will issue the Warrant Dividend to pre-Merger holders of AgeX common stock, which will represent an issuance by AgeX of securities convertible into or exercisable for AgeX common stock of more than 20% of the shares of AgeX common stock outstanding at the time of issuance. Accordingly, in order to ensure compliance with Section 713(a) of the NYSE American Company Guide, AgeX is asking for the approval of AgeX stockholders of the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants.

 

Material U.S. Federal Income Tax Consequences of the Issuance of Post-Merger Warrants and Incentive Warrants Pursuant To The Merger Agreement

 

The following discussion summarizes material U.S. federal income tax consequences of (1) the issuance of post-merger warrants (such issuance, the Warrant Distribution) and the ownership, exercise, and disposition of post-merger warrants, and (2) the ownership, exercise and disposition of incentive warrants that are issued pursuant to the exercise of post-merger warrants, in each case, that are generally expected to be applicable to AgeX stockholders who are U.S. holders (as defined in the section titled “Matters Being Submitted to a Vote of AgeX’s StockholdersProposal No. 2: Approval of an Amendment to the Certificate of Incorporation of AgeX Effecting the Reverse Stock SplitMaterial U.S. Federal Income Tax Consequences of the Reverse Stock Split” beginning on page 204 of this proxy statement/prospectus/information statement) assuming the Merger is consummated as contemplated herein. This summary is based on current law, including the provisions of the Code, Treasury Regulations promulgated thereunder, judicial authority, and administrative rulings and practice, each as in effect as of the date of this proxy statement/prospectus/information statement and all of which are subject to change, possibly with retroactive effect.

 

This summary is not a complete description of all tax consequences of the Warrant Distribution and the ownership, exercise and disposition of post-merger warrants or incentive warrants and does not address U.S. federal income tax consequences that may be relevant to particular AgeX stockholder in light of their personal circumstances or to AgeX stockholders who are subject to special treatment under U.S. federal income tax laws, such as AgeX stockholder who: do not hold their AgeX common stock as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment); are banks, insurance companies, tax-exempt entities, mutual funds, financial institutions, real estate investment trusts, regulated investment companies, government entities or broker-dealers; hold their AgeX common stock as “qualified small business stock” under Section 1202 of the Code or as “Section 1244 stock” under Section 1244 of the Code; hold their AgeX common stock as part of a hedging, “straddle,” conversion or other integrated transaction or are treated as having sold their AgeX common stock pursuant to the constructive sale provisions of the Code; are not U.S. holders; acquired their AgeX common stock pursuant to the exercise of compensatory options, or in other compensatory transactions; acquired their AgeX common stock pursuant to the exercise of warrants or conversion rights under convertible instruments; are subject to special tax accounting rules under Section 451(b) of the Code; hold their AgeX common stock through individual retirement or other tax-deferred accounts; acquired their AgeX common stock in a transaction subject to the gain rollover provisions of Section 1045 of the Code; have a functional currency other than the U.S. dollar; or are partnerships or entities or arrangements classified as partnerships or disregarded entities for U.S. federal income tax purposes, S corporations, or other pass-through entities (including hybrid entities) and investors therein.

 

208

 

 

In addition, this summary does not address (i) the tax consequences of the Warrant Distribution and the ownership, exercise, and disposition of post-merger warrants under U.S. federal non-income tax law (including estate, gift, or other non-income taxes), (ii) the tax consequences of the Warrant Distribution and the ownership, exercise, and disposition of post-merger warrants under state, local or non-U.S. tax laws, (iii) the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, or (iv) the tax consequences of transactions effectuated before, subsequent to or concurrently with the Merger (whether or not any such transactions are consummated in connection with the Warrant Distribution).

 

If an entity that is treated as a partnership for U.S. federal income tax purposes holds AgeX common stock prior to the Warrant Distribution, the tax treatment of a partner in such partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Such partner should consult its tax advisors as to the tax consequences of the Warrant Distribution.

 

No opinions of counsel or rulings from the IRS have been requested or obtained in connection with the Warrant Distribution and the ownership, exercise, and disposition of post-merger warrants or the incentive warrants. Accordingly, all AgeX stockholders should consult their own tax advisors as to the specific tax consequences to them of the Warrant Distribution and the ownership, exercise, and disposition of post-merger warrants and incentive warrants, including applicable tax reporting requirements.

 

IN VIEW OF THE FOREGOING AND BECAUSE THE FOLLOWING DISCUSSION IS INTENDED AS A GENERAL SUMMARY ONLY, EACH AGEX STOCKHOLDER SHOULD CONSULT SUCH STOCKHOLDER’S TAX ADVISOR REGARDING THE TAX CONSEQUENCES, INCLUDING THE APPLICABLE U.S. FEDERAL, STATE, LOCAL AND NON-U.S. TAX CONSEQUENCES, AND ANY TAX REPORTING REQUIREMENTS OF THE WARRANT DISTRIBUTION AND THE OWNERSHIP, EXERCISE, AND DISPOSITION OF POST-MERGER WARRANTS AND INCENTIVE WARRANTS AND RELATED TRANSACTIONS IN LIGHT OF SUCH STOCKHOLDER’S OWN TAX SITUATION.

 

Tax Consequences of the Warrant Distribution and the Ownership, Exercise and Disposition of Post-Merger Warrants

 

Tax Consequences of the Warrant Distribution

 

The Warrant Distribution is intended to be treated as a non-taxable distribution under Section 305(a) of the Code. If, however, the Warrant Distribution were treated as a distribution subject to Section 305(b) of the Code, a U.S. holder would be treated for U.S. federal income tax purposes as receiving a distribution equal to the fair market value of the post-merger warrants received in the Warrant Distribution. In such case, the Warrant Distribution would generally be taxable as a dividend to the extent paid out of AgeX’s current or accumulated earnings and profits (as determined under U.S. federal income tax principles). The remainder of this discussion assumes that the Warrant Distribution will be treated as a non-taxable distribution under Section 305(a) of the Code.

 

209

 

 

Tax Basis and Holding Period in the Post-Merger Warrants

 

Except as provided in the following sentence, a U.S. holder’s tax basis in the post-merger warrants received in the Warrant Distribution will be zero. However, a U.S. holder’s aggregate tax basis in its AgeX common stock will be allocated between such AgeX common stock and the post-merger warrants received in the Warrant Distribution in proportion to their respective fair market values on the date of the Warrant Distribution if either (i) the fair market value of the Warrants received by a U.S. holder is equal to at least 15% of the fair market value of the AgeX common stock with respect to which such warrants are received, or (ii) the U.S. holder irrevocably elects, on its U.S. federal income tax return for the taxable year in which the Warrant Distribution occurs, to allocate a portion of its tax basis in its AgeX common stock to the post-merger warrants received in the Warrant Distribution.

 

The holding period of the post-merger warrants received by a U.S. holder in the Warrant Distribution will generally include the holding period of the AgeX common stock with respect to which such post-merger warrants are received.

 

Possible Constructive Distributions with respect to the Post-Merger Warrants

 

The number of shares of AgeX common stock that a U.S. holder is entitled to receive upon the exercise of a post-merger warrant and the exercise price of the post-merger warrant are subject to certain anti-dilution adjustments. Certain of these adjustments (including adjustments as a result of a taxable distribution to holders of AgeX common stock) could cause a U.S. holder to be deemed to receive a “constructive distribution” that is includible in income for U.S. federal income tax purposes. AgeX stockholders should consult their tax advisors regarding the possibility of constructive distributions with respect to the post-merger warrants.

 

Lapse of a Post-Merger Warrant

 

A U.S. holder will not recognize gain or loss with respect to a post-merger warrant received in the Warrant Distribution upon the failure to exercise such warrant prior to expiration. If a post-merger warrant expires unexercised, any portion of the U.S. holder’s tax basis in its AgeX common stock that was previously allocated to such warrant, as described above, will generally be allocated back to such AgeX common stock. AgeX stockholders should consult their tax advisors regarding the ability to recognize a loss (if any) with respect to post-merger warrants that expire unexercised after a disposition of the AgeX common stock with respect to which the post-merger warrants were received.

 

Exercise of a Post-Merger Warrant

 

The exercise of a post-merger warrant received in the Warrant Distribution will generally not be a taxable event to a U.S. holder. A U.S. holder’s aggregate tax basis in the AgeX common stock and incentive warrants acquired upon the exercise of a post-merger warrant will generally equal the exercise price of the post-merger warrants plus the U.S. holder’s tax basis in the post-merger warrant (if any), and such aggregated basis will be allocated between such AgeX common stock and the incentive warrants in proportion to their respective fair market values on the date of the exercise. The holding period of the AgeX common stock and incentive warrants acquired upon the exercise of a post-merger warrants will generally begin on the date of exercise of such post-merger warrants.

 

210

 

 

Sale or Other Taxable Disposition of a Post-Merger Warrant

 

A U.S. holder generally will recognize gain or loss on the sale or other taxable disposition of a post-merger warrant equal to the difference between the amount realized on the disposition and the U.S. holder’s tax basis in the post-merger warrants (if any). Any such gain or loss will generally be capital gain or loss, and will be long-term capital gain or loss if the U.S. holder’s holding period for the warrant disposed of (determined as described above) exceeds one year. For non-corporate taxpayers, long-term capital gains are generally eligible for preferential U.S. federal income tax rates. The deductibility of capital losses is subject to limitations.

 

Tax Consequences the Ownership, Exercise and Disposition of Incentive Warrants

 

Tax Basis and Holding Period in the Incentive Warrants

 

As discussed above in “— Exercise of a Post-Merger Warrant”, a U.S. holder’s aggregate tax basis in the AgeX common stock and incentive warrants acquired upon the exercise of a post-merger warrant will generally equal the exercise price of the post-merger warrant plus the U.S. holder’s tax basis in the post-merger warrant (if any), and such aggregated basis will be allocated between such AgeX common stock and the incentive warrants in proportion to their respective fair market values on the date of the exercise. The holding period of the incentive warrants acquired upon the exercise of a post-merger warrants will generally begin on the date of exercise of such post-merger warrants.

 

Possible Constructive Distributions with respect to the Incentive Warrants

 

The number of shares of AgeX common stock that a U.S. holder is entitled to receive upon the exercise of an incentive warrant and the exercise price of the incentive warrant are subject to certain anti-dilution adjustments. Certain of these adjustments (including adjustments as a result of a taxable distribution to holders of AgeX common stock) could a U.S. holder to be deemed to receive a “constructive distribution” that is includible in income for U.S. federal income tax purposes. U.S. holders should consult their tax advisors regarding the possibility of constructive distributions with respect to the incentive warrants.

 

Lapse of an Incentive Warrant

 

If an incentive warrant is allowed to lapse unexercised, a U.S. holder generally will recognize a capital loss equal to such holder’s tax basis in the incentive warrants.

 

Exercise of an Incentive Warrant

 

The exercise of an incentive warrant generally will not be a taxable event to a U.S. holder. A U.S. holder’s aggregate tax basis in the AgeX common stock acquired upon the exercise of an incentive warrant will generally equal the exercise price of the incentive warrant plus the U.S. holder’s tax basis in the incentive warrant. The holding period of the AgeX common acquired upon the exercise of an incentive warrants will generally begin on the date of exercise of such incentive warrant.

 

Sale or Other Taxable Disposition of an Incentive Warrant

 

A U.S. holder will generally recognize gain or loss on the sale or other taxable disposition of an incentive warrant equal to the difference between the amount realized on the disposition and the U.S. holder’s tax basis in the incentive warrant. Any such gain or loss will generally be capital gain or loss, and will be long-term capital gain or loss if the U.S. holder’s holding period for the warrant disposed of (determined as described above) exceeds one year. For non-corporate taxpayers, long-term capital gains are generally eligible for preferential U.S. federal income tax rates. The deductibility of capital losses is subject to limitations.

 

Required Vote; Recommendation of the AgeX Board

 

The affirmative vote of a majority of the voting power of the shares of AgeX common stock present or represented by proxy at the AgeX special meeting and entitled to is required to approve Proposal No. 3. Abstentions and broker non-votes, if any, will have no effect on the outcome of this proposal.

 

THE AGEX BOARD RECOMMENDS THAT AGEX’S COMMON STOCKHOLDERS VOTE “FOR” THE WARRANT ISSUANCE PROPOSAL. THE APPROVAL OF EACH OF PROPOSAL NOS. 1, 2, 3, 4 AND 6 IS REQUIRED TO CONSUMMATE THE MERGER.

 

211

 

 

PROPOSAL NO. 4 (THE A&R COMBINED COMPANY CHARTER PROPOSAL):

 

APPROVAL OF THE ADOPTION OF THE COMBINED COMPANY CHARTER

 

Overview

 

At the AgeX special meeting, AgeX’s common stockholders will be asked to approve the adoption of the Combined Company Charter in the form attached to this proxy statement/prospectus/information statement as Annex B, which, in the judgment of the AgeX Board, is necessary to adequately address the needs of the combined company following the consummation of the Merger. If the Merger is consummated, the certificate of incorporation of the combined company will be the Combined Company Charter.

 

The following is a summary of the key proposed changes effected by the Combined Company Charter, but this summary is qualified in its entirety by reference to the full text of the Combined Company Charter, a copy of which is included as Annex B:

 

Authorized Capital Stock — the AgeX Charter authorizes the issuance of (a) 200,000,000 shares of common stock, $0.0001 par value per share, and (b) 5,000,000 shares of preferred stock, $0.0001 par value per share. The Combined Company Charter will authorize the issuance of (a) 40,000,000 shares of common stock, $0.0001 par value per share, and (b) 5,000,000 shares of preferred stock, $0.0001 par value per share;

 

No Class Vote on Changes in Authorized Number of Shares—the Combined Company Charter will provide that the number of authorized shares of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the DGCL;

 

Required Vote to Amend the Charter — the Combined Company Charter will require that any provision of Articles 5, 6, 7, 8, and 9 of the Combined Company Charter can only be altered, amended or repealed, or any provision inconsistent therewith can only be adopted, upon the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class;

 

Required Vote to Amend the Bylaws — with respect to the powers of stockholders to make, alter, amend or repeal the Combined Company Bylaws, the Combined Company Charter will require the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class, is required to make, alter amend or repeal the Combined Company Bylaws or to adopt any provision inconsistent therewith;

 

Classification of Board of Directors —the Combined Company Charter will create a classified board of directors consisting of three classes, Class I, Class II and Class III, with members of each class elected for three-year terms expiring in sequential years;

 

Limiting Stockholder Action by Consent —the Combined Company Charter will provide that any action required or permitted to be taken by stockholders of the combined company must be effected at a duly called annual or special meeting of stockholders and may not be effected by a consent or consents (written, electronic, or otherwise) of such stockholders;

 

Officer Exculpation —the Combined Company Charter will authorize provisions limiting personal liability for officers of the combined company for monetary damages for breach of fiduciary duty as an officer to the extent permissible under the DGCL; and

 

Forum Selection —the Combined Company Charter will provide for the forum selection provisions in the Combined Company Charter.

 

212

 

 

Reasons for the Amendments

 

The AgeX Board’s reasons for proposing each of these key changes effected by the Combined Company Charter are set forth below.

 

Authorized Capital Stock

 

At present, the AgeX Charter authorizes the issuance of (a) 200,000,000 shares of common stock, $0.0001 par value per share, and (b) 5,000,000 shares of preferred stock, $0.0001 par value per share. The Combined Company Charter, if approved, will authorize the issuance of (a) 40,000,000 shares of common stock, $0.0001 par value per share, and (b) 5,000,000 shares of preferred stock, $0.0001 par value per share.

 

The AgeX Board believes that it is important for the combined company to have available for issuance a number of authorized shares of common stock and preferred stock sufficient to support the combined company’s growth and to provide flexibility for future corporate needs (including, if needed, as part of financing for future growth acquisitions). The shares would be issuable as consideration for the Merger and the other transactions contemplated by the Merger Agreement in this proxy statement/prospectus/information statement and for any proper corporate purpose, including future acquisitions, capital raising transactions consisting of equity or convertible debt, stock dividends or issuances under current and any future stock incentive plans.

 

Following the reverse stock split, fewer shares are needed and the AgeX Board believes that the new amount of shares of common stock and preferred stock is sufficient to provide the combined company with needed flexibility to issue shares in the future in a timely manner and under circumstances the AgeX Board considers favorable without incurring the risk, delay and potential expense incident to obtaining stockholder approval for a particular issuance.

 

No Class Vote on Changes in Authorized Number of Shares

 

At present, the AgeX Charter does not contain any provision regarding the required vote to change the authorized shares of any class of stock. The Combined Company Charter, if approved, will provide that, subject to the rights of holders of any preferred stock, any vote with respect to the increase or decrease of the number of authorized shares of common stock or preferred stock (but not below the number of shares then outstanding) requires the affirmative vote of the holders of a majority in voting power of the stock entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the DGCL.

 

The AgeX Board believes that vesting the power to authorize changes in the authorized number of shares in the holders of stock entitled to vote will give the combined company greater flexibility to use its share capital.

 

Required Vote to Amend the Charter

 

Pursuant to the DGCL, an amendment to the AgeX Charter generally requires: (a) recommendation of the AgeX Board; (b) the affirmative vote of a majority of the voting power of the outstanding stock entitled to vote; and (c) the affirmative vote of a majority of the voting power of the outstanding stock of each class entitled to vote. The Combined Company Charter, if approved, will require that in addition to recommendation of the combined company’s board of directors, any provision of Articles 5, 6, 7, 8, and 9 of the Combined Company Charter can only be altered, amended or repealed, or any provision inconsistent therewith can only be adopted, upon the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class.

 

213

 

 

The AgeX Board believes that supermajority voting requirements for purposes of Articles 5, 6, 7, 8, and 9 of the Combined Company Charter are appropriate to protect all stockholders of the combined company against the potential self-interested actions by one or a few large stockholders. In reaching this conclusion, AgeX Board is cognizant of the potential for certain stockholders to hold a substantial beneficial ownership of the combined company’s common stock following the Merger. If approved, a supermajority voting requirement will make it more difficult to modify the Combined Company Charter in the future, including if a group of stockholders with substantial beneficial ownership of the combined company’s common stock following the Merger vote against any such modifications to the Combined Company Charter, even where the Combined Company Board is supportive of such an amendment.

 

Required Vote to Amend the Bylaws

 

At present, the AgeX Charter and the AgeX Bylaws provide that the AgeX Bylaws can be altered, amended or repealed (i) by AgeX’s stockholders by a majority of the voting power of the shares represented and entitled to vote or (ii) by the AgeX Board by a majority vote of the board members present at any board meeting where a quorum is present. The Combined Company Charter, if approved, will require an affirmative vote of holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class, shall be required to make, alter amend or repeal the Combined Company Bylaws or to adopt any provision inconsistent therewith. The ability of the majority of the board to amend the bylaws remains unchanged.

 

The AgeX Board believes that supermajority voting requirements to approve stockholder-proposed bylaw amendments are appropriate to protect all stockholders of the combined company against the potential self-interested actions by one or a few large stockholders. In reaching this conclusion, the AgeX Board is cognizant of the potential for certain stockholders to hold a substantial beneficial ownership of the combined company’s common stock following the Merger. If approved, a supermajority voting requirement to approve stockholder-proposed bylaw amendments will make it more difficult for stockholders to modify the Combined Company Bylaws in the future, including if a group of stockholders with substantial beneficial ownership of the combined company’s common stock following the Merger votes against any such shareholder proposal to modify the Combined Company Bylaws.

 

Classification of Board of Directors

 

The AgeX Charter does not provide for the division of the AgeX Board into staggered classes. The Combined Company Charter, if approved, will provide that, subject to the rights of holders of any preferred stock, the Combined Company Board will be classified into three classes, designated as Class I, Class II and Class III, as nearly equal in number as possible. The term of the initial Class I, II and III directors will expire at the first, second and third annual meeting of stockholders of the combined company following the effective date of the Combined Company Charter, respectively. At each annual meeting beginning with the first annual meeting of stockholders of the combined company following the effective date the Combined Company Charter, successors to the class of directors whose term expires at such annual meeting will be elected for a three-year term.

 

The AgeX Board believes that the classification of the Combined Company Board is desirable because it will enhance the likelihood of continuity and stability in the composition of the Combined Company Board by ensuring that at any given time a majority of the directors will have prior experience with the combined company and, therefore, be familiar with its business and operations; and assist the Combined Company Board in protecting the interests of its stockholders of the combined company in the event of an unsolicited offer to Combined Company Board by encouraging any potential acquiror to negotiate directly with Combined Company Board.

 

214

 

 

Limiting Stockholder Action by Consent 

 

The AgeX Bylaws provide that any action that may be taken at any annual or special meeting of stockholders may be taken without a meeting and without prior notice, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take that action at a meeting at which all shares entitled to vote on that action were present and voted. The Combined Company Charter, if approved, will require that, subject to the rights of holders of any preferred stock, any actions taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by a consent or consents (written, electronic, or otherwise) of such stockholders.

 

The AgeX Board believes that limiting the ability of stockholder action by consent will help facilitate corporate governance stability by requiring broad stockholder consensus to effect corporate governance changes, protect minority stockholder interests and enable the Combined Company Board to preserve and maximize value for all stockholders in the context of an opportunistic and unsolicited takeover attempt.

 

Officer Exculpation 

 

At present, the AgeX Charter provides that the liability of the AgeX directors to AgeX or its stockholders for monetary damages for breach of fiduciary duty as a director is eliminated to the fullest extent permissible under DGCL. The Combined Company Charter, if approved, will contain provisions limiting personal liability for both directors and officers of the combined company for monetary damages for breach of fiduciary duty as a director or as an officer to the extent permissible under the DGCL.

 

The AgeX Board believes that eliminating personal monetary liability under certain circumstances for officers, in addition to directors as already provided for under the AgeX Charter, is reasonable and appropriate because the nature of the role of officers often requires them to make decisions on crucial matters in time-sensitive situations, which can create substantial risk of investigations, claims, actions, suits or proceedings seeking to impose liability on the basis of hindsight, especially in the current litigious environment and regardless of merit. Limiting concern about personal risk would empower officers to best exercise their business judgment in furtherance of stockholder interests. The AgeX Board also believes that officer exculpation provisions may become necessary for Delaware corporations to attract and retain experienced and qualified corporate directors and officers. Further, Delaware corporations that fail to adopt officer exculpation provisions may experience a disproportionate amount of nuisance litigation and disproportionately increased costs in the form of increased officer liability insurance premiums, as well as diversion of management attention from the business of the corporation.

 

The officer exculpation provisions in the Combined Company Charter may discourage stockholders from bringing a lawsuit against the combined company’s officers for breach of their fiduciary duty of care.

 

Forum Selection 

 

At present, neither the AgeX Charter nor the AgeX Bylaws contains any forum selection provisions. The Combined Company Charter, if approved, will provide that, unless the combined company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or if such court does not have subject matter jurisdiction another state or federal court (as appropriate) located within the State of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the combined company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee or stockholder of the combined company to the combined company or to the combined company’s stockholders, creditors or other constituents, (iii) any action asserting a claim against the combined company or any current or former director or officer of the combined company arising pursuant to any provision of the DGCL or the Combined Company Charter or the Combined Company Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv) any action asserting a claim governed by the internal affairs doctrine. The Combined Company Charter will further provide that, unless the combined company consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, U.S. federal district courts will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under U.S. federal securities laws.

 

215

 

 

The Combined Company Charter will further provide that, if any action the subject matter of which is within the scope of the forum selection provisions is filed in a court other than a court located within the State of Delaware (a “Foreign Action”) in the name of any stockholder, such stockholder shall be deemed to have consented to: (a) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the forum selection provisions (an “Enforcement Action”), and (b) having service of process made upon such stockholder in any such Enforcement Action by service upon such stockholder’s counsel in the Foreign Action as agent for such stockholder.

 

The AgeX Board believes that the forum selection provisions will help the combined company to avoid having to litigate claims in multiple jurisdictions regarding the same subject matter. The ability to require such claims to be brought in a single forum will help to ensure consistent consideration of the issues and application of a relatively known body of case law by judges with appropriate levels of expertise, which should promote efficiency and cost-savings in the resolutions of such claims. The AgeX Board believes that the Delaware courts are best suited to address disputes involving internal corporate governance matters relating to the combined company because the combined company will be incorporated in the State of Delaware and Delaware law generally applies in such matters and the Delaware courts have a reputation for expertise in corporate law matters. The AgeX Board believes that the U.S. federal district courts are best suited to address disputes involving actions arising under U.S. federal securities laws given that such laws have been enacted by the U.S. federal government. Although the AgeX Board believes that the forum provisions in the Combined Company Charter are enforceable, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that, in connection with any action, a court could find the choice of forum provisions contained in the Combined Company Charter to be unenforceable in such action.

 

Although the AgeX Board believes these provisions may benefit the combined company by providing increased consistency in the application of Delaware and U.S. federal securities laws for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against the combined company or its directors and officers. Alternatively, if a court were to find the choice of forum provision contained in the Combined Company Charter to be unenforceable in an action, the combined company may incur additional costs associated with resolving such action in other jurisdictions, which could harm the combined company’s business, financial condition, and operating results. Any person or entity purchasing or otherwise acquiring any interest in the combined company’s shares of capital stock shall be deemed to have notice of and consented to these exclusive forum provisions but will not be deemed to have waived the combined company’s compliance with the federal securities laws and the rules and regulations thereunder.

 

Required Vote; Recommendation of the AgeX Board

 

The affirmative vote of the holders of a majority of AgeX common stock outstanding and entitled to vote at the AgeX special meeting is required for the approval of Proposal No. 4. Abstentions and broker non-votes, if any, will be counted as “shares entitled to vote” for Proposal No. 4 and therefore will have the same effect of a vote “AGAINST” this proposal.

 

Notwithstanding the approval of this Proposal No. 4, if the Merger is not consummated for any reason, the actions contemplated by this Proposal No. 4 will not be effected. The AgeX Board will abandon this Proposal No. 4 in the event the Merger is not consummated.

 

THE AGEX BOARD RECOMMENDS THAT AGEX’S COMMON STOCKHOLDERS VOTE “FOR” THE A&R COMBINED COMPANY CHARTER PROPOSAL. THE APPROVAL OF EACH OF PROPOSAL NOS. 1, 2, 3, 4 AND 6 IS REQUIRED TO CONSUMMATE THE MERGER.

 

216

 

 

PROPOSAL NO. 5 (THE NON-BINDING GOVERNANCE PROPOSALS):

 

APPROVAL, ON A NON-BINDING, ADVISORY BASIS, OF CERTAIN GOVERNANCE PROVISIONS IN THE COMBINED COMPANY CHARTER

 

Overview

 

AgeX’s common stockholders are also being asked to vote on separate proposals with respect to certain governance provisions in the Combined Company Charter, which are separately being presented in accordance with SEC guidance and which will be voted upon on a non-binding, advisory basis. The AgeX Board believes these provisions are necessary to adequately address the needs of the combined company. Accordingly, regardless of the outcome of the non-binding, advisory vote on these proposals, AgeX and Serina intend that the Combined Company Charter in the form set forth on Annex B will take effect at consummation of the Merger, assuming approval of Proposals Nos. 1, 2, 3, 4 and 6.

 

Proposal 5A: Authorized Capital Stock

 

See “Proposal No. 4—The A&R Combined Company Charter Proposal—Reasons for the Amendments—Authorized Capital Stock” for a description and reasons for this proposed change.

 

Proposal 5B: No Class Vote on Changes in Authorized Number of Shares

 

See “Proposal No. 4—The A&R Combined Company Charter Proposal—Reasons for the Amendments—No Class Vote on Changes in Authorized Number of Shares” for a description and reasons for this proposed change.

 

Proposal 5C: Required Vote to Amend the Charter

 

See “Proposal No. 4—The A&R Combined Company Charter Proposal—Reasons for the Amendments—Required Vote to Amend the Charter” for a description and reasons for this proposed change.

 

Proposal 5D: Required Vote to Amend the Bylaws

 

See “Proposal No. 4—The A&R Combined Company Charter Proposal—Reasons for the Amendments—Required Vote to Amend the Bylaws” for a description and reasons for this proposed change.

 

Proposal 5E: Classification of Board of Directors

 

See “Proposal No. 4—The A&R Combined Company Charter Proposal—Reasons for the Amendments—Classification of Board of Directors” for a description and reasons for this proposed change.

 

Proposal 5F: Limiting Stockholder Action by Consent

 

See “Proposal No. 4—The A&R Combined Company Charter Proposal—Reasons for the Amendments—Limiting Stockholder Action by Consent” for a description and reasons for this proposed change.

 

Proposal 5G: Officer Exculpation

 

See “Proposal No. 4—The A&R Combined Company Charter Proposal—Reasons for the Amendments—Officer Exculpation” for a description and reasons for this proposed change.

 

Proposal 5H: Forum Selection

 

See “Proposal No. 4—The A&R Combined Company Charter Proposal—Reasons for the Amendments—Forum Selection” for a description and reasons for this proposed change.

 

Vote Required for Approval

 

The affirmative vote of a majority of the voting power of the shares of AgeX common stock present or represented by proxy at the AgeX special meeting and entitled to vote is required to approve each of the Proposal Nos. 5A, 5B, 5C, 5D, 5E, 5F, 5G and 5H. Abstentions and broker non-votes, if any, will have no effect on the outcome of the proposals.

 

As discussed above, each vote to approve the Non-Binding Governance Proposals is an advisory vote and, therefore, is not binding on AgeX, Serina or their respective boards of directors. Accordingly, regardless of the outcome of each non-binding, advisory vote, AgeX and Serina intend that the Combined Company Charter, in the form set forth on Annex B and containing the provisions noted above, will take effect at consummation of the Merger, assuming approval of Proposals Nos. 1, 2, 3, 4 and 6.

 

THE AGEX BOARD RECOMMENDS THAT AGEX’S COMMON STOCKHOLDERS VOTE “FOR” EACH OF THE NON-BINDING GOVERNANCE PROPOSALS. THE APPROVAL OF THE NON-BINDING GOVERNANCE PROPOSALS IS NOT REQUIRED TO CONSUMMATE THE MERGER.

 

217

 

 

PROPOSAL NO. 6 (THE 2024 equity incentive plan PROPOSAL):

APPROVAL OF THE Serina Therapeutics, INc. 2024 Equity INcentive Plan

 

At the AgeX special meeting, AgeX’s common stockholders will be asked to approve the 2024 Equity Incentive Plan. The AgeX Board has approved the 2024 Equity Incentive Plan, subject to stockholder approval at the special meeting.

 

The purpose of the 2024 Equity Incentive Plan is to promote and closely align the interests of the combined company’s employees, officers, non-employee directors, and other service providers and the combined company’s stockholders by providing stock-based compensation. The objectives of the 2024 Equity Incentive Plan are to attract and retain the best available personnel for positions of substantial responsibility and to motivate Participants to optimize the profitability and growth of the combined company through incentives that are consistent with the combined company’s goals and that link the personal interests of Participants to those of the combined company’s stockholders.

 

Summary of the 2024 Equity Incentive Plan

 

The following description of the 2024 Equity Incentive Plan is not intended to be complete and is qualified in its entirety by the complete text of the 2024 Equity Incentive Plan, a copy of which is attached as Annex C to this proxy statement/prospectus/information statement. AgeX stockholders are urged to read the 2024 Equity Incentive Plan in its entirety. Any capitalized terms that are used in this summary description but not defined here or elsewhere in this proxy statement have the meanings assigned to them in the 2024 Equity Incentive Plan.

 

Administration

 

The 2024 Equity Incentive Plan will be administered by the board of directors of the combined company, or such other committee designated by the combined company’s board of directors to administer the 2024 Equity Incentive Plan, which is referred to herein as the “2024 EIP Administrator.” The 2024 EIP Administrator has broad authority, subject to the provisions of the 2024 Equity Incentive Plan, to administer and interpret the 2024 Equity Incentive Plan and Awards granted thereunder. All decisions and actions of the 2024 EIP Administrator are final and binding. To the maximum extent permissible under Applicable Law, the combined company board of directors may also delegate any or all of its authority to one or more committees composed of two or more non-employee directors of the combined company. Such committee will act pursuant to a vote of the majority of its members or, in the case of a committee comprised of only two members, the unanimous consent of its members.

 

Stock Subject to the 2024 Equity Incentive Plan

 

A total of 1,725,000 shares of the combined company’s common stock will be available for the grant of Awards under the 2024 Equity Incentive Plan. The shares of combined company common stock issuable under the 2024 Equity Incentive Plan will be shares of authorized but unissued or reacquired common stock, including shares repurchased by the combined company on the open market or otherwise. The maximum number of shares of the combined company common stock that may be issued pursuant to the exercise of Incentive Stock Options granted under the 2024 Equity Incentive Plan will not exceed 1,725,000.

 

218

 

 

On cancellation, forfeiture, or expiration of an Award under the 2024 Equity Incentive Plan, in whole or in part, the number of shares of combined company common stock subject to such Award will again become available for grant under the 2024 Equity Incentive Plan. Shares subject to an Award under the 2024 Equity Incentive Plan will not again be made available for issuance or delivery under the 2024 Equity Incentive Plan if such shares are (a) shares tendered in payment of an Option, (b) shares delivered or withheld by the combined company to satisfy any tax withholding obligation, (c) shares covered by a stock-settled Stock Appreciation Right or other Awards that were not issued upon the settlement of the Award, or (d) shares repurchased by the combined company using Option proceeds.

 

Eligibility

 

Prospective or current members of the board, employees (including executive officers), and other service providers of the combined company and its affiliates are eligible to participate in the 2024 Equity Incentive Plan. Only employees of the combined company may be granted Incentive Stock Options under the 2024 Equity Incentive Plan.

 

Types of Awards

 

Stock Options

 

All Options granted under the 2024 Equity Incentive Plan will be evidenced by a written agreement with the Participant, which provides, among other things, the term of the Option, which may not generally exceed 10 years (or 5 years for grants of Incentive Stock Options to Ten Percent Shareholders), and other terms and conditions. The Option Exercise Price for any Option granted may not be less than the Fair Market Value per share of combined company common stock on the grant date (or 110% of such Fair Market Value for grants of Incentive Stock Options to Ten Percent Shareholders); provided that an Option may be granted with a lower Option Exercise Price if such Option is granted pursuant to an assumption or substitution of another Option that satisfied the provisions of section 409A or 424(a) of the Code, as applicable.

 

Stock Appreciation Rights

 

Stock Appreciation Rights may be granted alone or in conjunction with all or part of an Option. Upon exercising a Stock Appreciation Right, the Participant is entitled to receive the amount equal to the number of shares of combined company common stock subject to the Stock Appreciation Right that is being exercised multiplied by the excess by which the Fair Market Value of combined company common stock at the time of exercise exceeds the exercise price of the Stock Appreciation Right. All freestanding Stock Appreciation Rights shall be granted subject to the same terms and conditions as applicable to Options, including exercise price and term, as set forth above, and all tandem Stock Appreciation Rights shall have the same exercise price as the Option to which they relate. Stock Appreciation Rights may be settled in combined company common stock, cash, Restricted Stock, or a combination thereof, at the 2024 EIP Administrator’s discretion.

 

219

 

 

Restricted Stock and RSUs

 

The 2024 Equity Incentive Plan provides for Awards of actual shares of combined company common stock or hypothetical combined company common stock units having a value equal to the Fair Market Value of an identical number of shares of combined company common stock. The 2024 EIP Administrator will determine the restrictions and conditions applicable to each Award of Restricted Stock or Restricted Stock Units, which may include performance vesting conditions. Participants are entitled to receive all dividends and other distributions paid with respect to shares of combined company common stock subject to Restricted Stock Awards. Participants are entitled to receive Dividend Equivalents with respect to shares of combined company Common Stock subject to Restricted Stock Units only to the extent provided by the 2024 EIP Administrator.

 

Notwithstanding the above, dividends or Dividend Equivalents will be withheld with respect to Restricted Stock or Restricted Stock Units that are subject to restrictions until the date the restrictions are released.

 

Transferability

 

Awards generally may not be sold, transferred for value, pledged, assigned or otherwise alienated or hypothecated by a Participant other than by will or the laws of descent and distribution or upon approval by the 2024 EIP Administrator, to the extent provided in the Award Agreement or by subsequent consent granted by the 2024 EIP Administrator. Each Option may be exercisable only by the Participant during his or her lifetime.

 

Adjustments

 

In the event any change is made to the combined company’s outstanding common stock as a result of any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of shares of combined company common stock outstanding, then equitable and proportional adjustments will be made to the maximum number and class(es) of securities issuable under the 2024 Equity Incentive Plan (including pursuant to Incentive Stock Options). The terms of any outstanding Award shall also be equitably adjusted by the 2024 EIP Administrator as to price, number, or kind of shares of combined company common stock subject to such Award, vesting, and other terms to reflect the foregoing events.

 

Change in Control

 

In the discretion of the 2024 EIP Administrator, any Award Agreement may provide, or the 2024 EIP Administrator may provide by amendment of any Award Agreement or otherwise, notwithstanding any provision of the 2024 Equity Incentive Plan to the contrary, that in the event of a Change in Control, Options and/or Stock Appreciation Rights will become immediately exercisable and/or the restrictions will be released immediately with respect to all or a specified portion of the shares of Restricted Stock or Restricted Stock Units. In addition, in the event of a Change in Control, the 2024 EIP Administrator may, in its discretion and upon at least 10 days’ advance notice to the affected persons, cancel any outstanding Awards and pay to the holders thereof, in cash or stock, or any combination thereof, the value of such Awards based upon the price per share of combined company common stock received or to be received by other stockholders of the combined company in the event. In the case of any Option or Stock Appreciation Right with an exercise price that equals or exceeds the price paid for a share of combined company common stock in connection with the Change in Control, the 2024 EIP Administrator may cancel the Option or Stock Appreciation Right without the payment of consideration therefor.

 

220

 

 

Clawback/Recoupment

 

Awards granted under the 2024 Equity Incentive Plan will be subject to recoupment in accordance with any law, government regulation, or stock exchange listing requirement (or any policy adopted by the combined company pursuant to any such law, government regulation or stock exchange listing requirement).

 

Amendment and Termination

 

The combined company’s board of directors has the right to amend or terminate the 2024 Equity Incentive Plan at any time, provided certain amendments may not be made without the combined company stockholder approval in compliance with Applicable Law. No amendment to the 2024 Equity Incentive Plan or an Award or Award Agreement may be made that would materially impair the rights of the Participant without such Participant’s consent.

 

Federal Income Tax Considerations

 

The following is a summary of the U.S. federal income tax treatment applicable to the combined company and the Participants who receive Awards under the 2024 Equity Incentive Plan based on the federal income tax laws in effect on the date of this proxy statement. This summary is not intended to be exhaustive and does not address all matters relevant to a particular Participant based on their specific circumstances. The summary expressly does not discuss the income tax laws of any state, municipality, or non-U.S. taxing jurisdiction, or the gift, estate, excise (including the rules applicable to deferred compensation under Section 409A of the Code), or tax laws other than U.S. federal income tax law. Because individual circumstances may vary, AgeX recommends that all Participants consult their own tax advisor concerning the tax implications of Awards granted under the 2024 Equity Incentive Plan.

 

Incentive Stock Options

 

Options granted under the 2024 Equity Incentive Plan may be either Incentive Stock Options, which satisfy the requirements of Section 422 of the Code, or Non-qualified Stock Options, which are not intended to meet such requirements.

 

No taxable income is recognized by the Optionholder at the time of the Option grant, and no taxable income is recognized for ordinary income tax purposes at the time the Option is exercised, although taxable income may arise at that time for alternative minimum tax purposes. Unless there is a “disqualifying disposition,” as described below, the Optionholder will recognize long-term capital gain in an amount equal to the excess, if any, of (i) the amount realized upon the sale or other disposition of the purchased shares over (ii) the Option Exercise Price paid for the shares. A disqualifying disposition occurs if the disposition is less than two years after the date of grant or less than one year after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i) the Fair Market Value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii) the Option Exercise Price paid for the shares will be taxable as ordinary income to the Optionholder. Any additional gain or loss recognized upon the disposition will be a capital gain or loss.

 

If the Optionholder makes a disqualifying disposition of the purchased shares, then the combined company will be entitled to an income tax deduction for the taxable year in which such disposition occurs equal to the amount of ordinary income recognized by the Optionholder as a result of the disposition. The combined company will not be entitled to any income tax deduction if the Optionholder makes a qualifying disposition of the shares.

 

221

 

 

Nonqualified Stock Options

 

No taxable income is recognized by an Optionholder upon the grant of a Non-qualified Stock Option. The Optionholder in general will recognize ordinary income, in the year in which the Option is exercised, equal to the excess of the Fair Market Value of the purchased shares on the exercise date over the Option Exercise Price paid for the shares, and the Optionholder will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the Optionholder with respect to the exercised Non-qualified Stock Option.

 

Stock Appreciation Rights

 

No taxable income is recognized upon receipt of a Stock Appreciation Right. The Participant will recognize ordinary income in the year in which the Stock Appreciation Right is exercised, in an amount equal to the excess of the Fair Market Value of the underlying shares of combined company common stock on the exercise date over the base price in effect for the exercised right, and the Participant will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the Participant in connection with the exercise of the Stock Appreciation Right.

 

Restricted Stock Awards

 

A Participant who receives unvested shares of combined company common stock will not recognize any taxable income at the time those shares are granted but will have to report as ordinary income, as and when those shares subsequently vest, an amount equal to the excess of (i) the Fair Market Value of the shares on the vesting date over (ii) the cash consideration (if any) paid for the shares. The Participant may, however, elect under Section 83(b) of the Code to include as ordinary income in the year the unvested shares are issued an amount equal to the excess of (a) the Fair Market Value of those shares on the issue date over (b) the cash consideration (if any) paid for such shares. If the Section 83(b) election is made, the Participant will not recognize any additional income as and when the shares subsequently vest. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the Participant at the time such ordinary income is recognized by the Participant.

 

Restricted Stock Units

 

Generally, no taxable income is recognized upon the grant of Restricted Stock Units. The Participant will recognize ordinary income in the year in which the Award is settled in shares or cash. The amount of that income will be equal to the Fair Market Value of the shares on the date of issuance or the amount of the cash paid in settlement of the Award, and the Participant will be required to satisfy the tax withholding requirements applicable to the income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the Participant at the time the shares are issued or the cash amount is paid.

 

222

 

 

Deductibility of Executive Compensation

 

Section 162(m) of the Code limits the deductibility for federal income tax purposes of certain compensation paid to any “covered employee” in excess of $1 million. For purposes of Section 162(m) of the Code, the term “covered employee” includes any individual who serves as chief executive officer, chief financial officer, or one of the other three most highly compensated executive officers for 2017 or any subsequent calendar year. It is expected that compensation deductions for any covered employee with respect to awards granted under the 2024 Equity Incentive Plan will be subject to the $1 million annual deduction limitation. The 2024 Equity Incentive Plan Administrator may grant Awards under the 2024 Equity Incentive Plan or otherwise that are or may become non-deductible when it believes doing so is in the best interests of the combined company and the combined company’s stockholders.

 

New Plan Benefits

 

AgeX cannot currently determine the benefits or number of shares subject to Awards that may be granted in the future to eligible Participants under the 2024 Equity Incentive Plan because the grant of Awards and terms of such Awards are to be determined in the sole discretion of the 2024 EIP Administrator. As of , 20 , the closing price of a share of AgeX’s common stock was $ .

 

Registration with the SEC

 

The combined company intends to file with the SEC a registration statement on Form S-8 covering the shares reserved for issuance under the 2024 Equity Incentive Plan if permitted by the SEC.

 

Required Vote; Recommendation of the AgeX Board

 

The affirmative vote of a majority of the voting power of the shares of AgeX common stock present or represented by proxy at the AgeX special meeting and entitled to vote is required to approve Proposal No. 6. Abstentions and broker non-votes, if any, will have no effect on the outcome of this proposal.

 

THE AGEX BOARD RECOMMENDS THAT AGEX’S COMMON STOCKHOLDERS VOTE “FOR” THE 2024 EQUITY INCENTIVE PLAN PROPOSAL. THE APPROVAL OF EACH OF PROPOSAL NOS. 1, 2, 3, 4 AND 6 IS REQUIRED TO CONSUMMATE THE MERGER.

 

223

 

 

PROPOSAL NO. 7 (THE ADJOURNMENT PROPOSAL):

APPROVAL OF POSSIBLE ADJOURNMENT OF THE AGEX SPECIAL MEETING

 

If AgeX fails to receive a sufficient number of votes to approve the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal, AgeX may propose to adjourn the AgeX special meeting for the purpose of soliciting additional proxies to approve the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Warrant Issuance Proposal, the A&R Charter Proposal or the 2024 Equity Incentive Plan Proposal.

 

If on the date of the AgeX special meeting, or a date preceding the date on which the AgeX special meeting is scheduled, AgeX reasonably believes that (i) it will not receive proxies sufficient to obtain the required vote to approve the AgeX Proposals, whether or not a quorum would be present, or (ii) it will not have sufficient shares of AgeX common stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the AgeX special meeting, AgeX may postpone or adjourn, or make one or more successive postponements or adjournments of, the AgeX special meeting as long as the date of the AgeX special meeting is not postponed or adjourned more than an aggregate of 30 calendar days in connection with any postponements or adjournments.

 

Required Vote; Recommendation of the AgeX Board

 

The affirmative vote of a majority of the voting power of the shares of AgeX common stock present or represented by proxy at the AgeX special meeting and entitled to vote is required to approve Proposal No. 7. Abstentions and broker non-votes, if any, will have no effect on the outcome of this proposal.

 

The Merger is not conditioned upon the approval of the Adjournment Proposal.

 

THE AGEX BOARD RECOMMENDS THAT AGEX STOCKHOLDERS VOTE “FOR” THE ADJOURNMENT PROPOSAL, IF NECESSARY.

 

224

 

 

DESCRIPTION OF AGEX’S BUSINESS

 

References to “we,” “us” and “our” in this section titled “Description of AgeX’s Business” refer to AgeX.

 

Overview of Business

 

We are a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Our mission is to apply our comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions. We believe that demand for therapeutics addressing such conditions is on the rise, commensurate with the demographic shift of aging in the United States and many other industrialized countries.

 

Our proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows us to utilize telomerase-expressing regenerative PSCs for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. We own or have licenses to a number of patents and patent applications used in the generation of these product candidates, including intellectual property related to PureStem® technology. Our technology platform also includes UniverCyte™ which uses the HLA-G gene to potentially confer low immune observability to cells, so as to suppress rejection of transplanted cells and tissues. AgeX plans to use or license the use of this patented technology to produce genetically-modified master cell banks of pluripotent stem cells that can then be differentiated into any young cell type of the human body that now express the immune tolerogenic molecule.

 

Our product candidates in the discovery stage include two cell-based therapies derived from telomerase-positive PSCs and two product candidates derived from our proprietary iTRTM technology. We have also sponsored a research program to derive neural stem cells from PSCs to treat degenerative diseases such as Huntington’s Disease. We will need to conduct or sponsor research and development work, or license our technology to other biotechnology or pharma companies interested in furthering research and development in order to develop these cell- and drug-based therapies, each targeting large unmet needs in age-related medicine.

 

Recent Developments

 

Termination of License and Sublicence

 

On November 9, 2023, AgeX sent a notice to the licensee and the sublicensees of patent rights for certain uses of HyStem® hydrogel products, informing them that AgeX was exercising its rights to terminate, respectively: (i) a License Agreement, dated August 17, 2017, as amended, by and between AgeX and Lineage (formerly BioTime, Inc.) and (ii) a Sublicense Agreement, dated August 17, 2017, as amended, by and among AgeX, Lineage, and OrthoCyte Corporation.

 

The license agreement and sublicense agreement granted AgeX rights to use certain HyStem® hydrogel patents on a non-exclusive, world-wide, royalty bearing basis, but only for therapeutic uses with (a) cells covered by specified patents related to human embryonic progenitor cell technology, brown adipose fat progenitors, vascular cell progenitors, and human pluripotent stem cell lines and technology, and (b) products covered by specified AgeX iTR patents, and in either case only for use outside the fields of (i) orthopedic indications, (ii) ophthalmological indications, and (iii) medical aesthetics, as defined in the license and sublicense agreements.

 

225

 

 

AgeX’s decision to terminate the license and sublicence was based on certain considerations, including the scope of the rights licensed or sublicensed to AgeX, the extent to which HyStem® was used in AgeX research and development programs, the expected availability of alternative products for use as a cell transplant matrix or for therapeutic molecular iTR drug delivery that could be used in AgeX product development programs, the expiration dates of the licensed and sublicensed patents, and the expected cost of maintaining the license and sublicense rights to use HyStem®, including annual payment obligations and fees that would become payable upon a change of control of AgeX such as the expected Merger with Serina. AgeX was required to pay minimal annual royalties of $30,000 under the agreements. The termination of the license agreement and sublicense agreement eliminates AgeX’s obligation to pay such minimum annual royalties for periods after the termination date. AgeX has not incurred royalty payment obligations in excess of the minimum annual royalties because AgeX has not yet competed development and received any regulatory approvals required to market and sell any products for which the use of HyStem® was permitted by the license agreement and sublicense agreement. If AgeX were to determine to obtain rights to use alternative patented products to replace HyStem® for use as a cell transplant matrix or for therapeutic molecular iTR drug delivery, AgeX expects that it would need to obtain a license for such use which would likely include new fee, royalty, and other payment obligations which cannot presently be determined or estimated.

 

Lineage is the original parent corporation of AgeX. OrthoCyte Corporation is a subsidiary of Lineage. HyStem® is a registered trademark of Lineage.

 

226

 

 

Overview of Our Product Candidates

 

Our product pipeline includes two cell-based and two iTR-based product candidates in development.

 

Our lead cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1:

 

AGEX-BAT1 is our lead cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity.
AGEX-VASC1 is a cell-based therapy in the discovery stage of development comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.

 

Our lead small molecule drug-based therapeutic candidate for iTRTM in discovery is AGEX-iTR1547 and our lead biologic candidate for iTR is AGEX-iTR1550:

 

AGEX-iTR1547 is a drug-based formulation and AGEX-iTR1550 (also known as Renelon™) is a gene delivery technology, both of which are in the discovery stage of development. Initial indications for use may include scarless wound repair.

 

Our research related to the reprogramming of aging has also led to novel insights into cancer. We have filed patent applications on inventions that relate to these discoveries. These technologies may provide novel targets for cancer therapy and diagnosis. One such cancer therapeutic in the early stages of development is designated “EPROTM” (embryonic promoter-regulated oncolysis). EPRO is an oncolytic gene therapy strategy that may provide a novel means of selectively destroying an array of different types of cancer cells. Successful development of EPRO will be dependent, in part, on the availability of financing and licensing or joint development opportunities.

 

Our currently marketed research products include cGMP ES Cells (human embryonic stem or hES) cells produced under cGMP and PSC-derived cells for research:

 

cGMP PSC lines and PSC-derived cells for research: Through our ESI BIO division, we market cGMP PSC lines as well as PSC-derived cells.

 

Overview of Our Technology Platforms

 

The technology underlying our product development programs is based on telomerase-mediated cellular immortality and regenerative biology. By “telomerase-mediated cellular immortality” we refer to the fact that cells that express sufficient levels of a protein called telomerase are capable of replicating without limit. By “regenerative biology,” we refer to novel methods to regenerate tissues afflicted with age-related chronic degenerative disease such as peripheral vascular disease and ischemic heart disease as well as age-related metabolic disorders such as those associated with Type II diabetes and obesity, as well as others. We utilize telomerase-expressing regenerative Pluripotent Stem Cells, or PSCs, for the manufacture of cell-based therapies. We own or have licensed numerous patents and patent applications covering methods and compositions relating to this technology platform.

  

227

 

 

We believe our core technology platforms provide us with a strong foundation for successfully addressing many of the diseases of ageing by focusing on broad therapeutic applicability and commercially scalable technologies:

 

1. PureStem®: AgeX’s allogeneic cell derivation and manufacturing platform, based on human embryonic progenitors, which are cells in state of development between embryonic stem cells and adult cells. We believe PureStem has the potential to solve several major challenges faced by the cell therapy industry by generating cellular therapeutics which would:

 

be commercialized as “off-the-shelf” products;

 

be pure and industrially scalable;

 

have lower cost of goods per unit;

 

be amenable to traditional pharmaceutical supply chain logistics’

 

have the potential for acceptable reimbursement prices, unlike the relatively expensive autologous products; and

 

have higher clinical adoption from expected cost savings and more simplified processes.

 

In addition, we believe PureStem cells may have advantages over mesenchymal stem cells (MSCs), which may only survive transiently in the body and exert any short-term benefit by releasing paracrine factors, which may limit their potential of MSCx.

 

MSCs neither engraft nor become specialized cells. On the other hand, cells derived from PureStem progenitors will be engineered to be young, not prone to the disadvantages associated with older cells, and are expected to become permanently engrafted in the body to deliver a true regenerative outcome. To date, AgeX has isolated more than 200 cell types from PureStem.

 

2. UniverCyte™: AgeX’s pioneering technology designed to genetically modify allogeneic donor cells to potentially become hypoimmunogenic/universal, so they can potentially be transplanted into all patients in an off-the- shelf manner, without the normal need for human leukocyte antigen (HLA) matching between donor and receipt or immunosuppression. UniverCyte utilizes a potent molecule called HLA-G. HLA is a group of related proteins that helps the immune system distinguish the body’s own proteins from proteins made by foreign invaders such as viruses and bacteria. HLA-G’s only known physiological role in nature is to prevent destruction of a semi-allogeneic fetus by the maternal immune system. We believe that UniverCyte could potentially avoid immune rejection of transplanted cells, solving a major challenge facing the allogeneic cell therapy industry. In addition to utilizing UniverCyte™ for its own future cell therapy products, AgeX may make UniverCyte™ available to other cell therapy companies through licensing arrangements.

 

228

 

 

3. Induced Tissue Regeneration (iTRTM): The aim of iTR is to return aged cells back to a youthful state, thereby inducing a capacity for scarless regeneration characteristic of early developing tissues, without reverting cells to pluripotency. This technology is sometimes referred to as “partial reprogramming” or “epigenetic reprogramming of aging.” We believe this novel approach may trigger complete regeneration of cells, and potentially even complex tissues, damaged as a result of age-related degenerative processes or trauma. The premise behind iTR is that aging, and in turn degenerative diseases of old age, are a result of the loss of two characteristics of cells; namely, replicative immortality and regenerative capacity. These two characteristics are present in embryonic cells but are lost at the embryonic to fetal transition (EFT). With this loss, humans can no longer generate new cells or repair damaged cells scarlessly and in sufficient numbers to maintain health. We discovered that cells begin expressing the gene COX7A1 at the EFT when regeneration is commonly lost. Therefore, we believe the gene may be a key inhibitor of cellular regeneration. For example, we have discovered that restoring a regenerative pattern of COX7A1 gene expression may facilitate hair regeneration in mouse models. In addition, we have invented multiple platforms for delivering iTR using small molecules as well as biologic strategies such as those using gene therapy to transiently express reprogramming factors. We have filed patent applications on the use of iTR in a wide array of degenerative conditions including cancer.

 

4. ESI Cell Lines: AgeX has six clinical-grade human embryonic stem cell lines, they are distinguished as the first clinical-grade human pluripotent stem cell lines created under current Good Manufacturing Practice as described in Cell Stem Cell (2007;1:490-4). They are listed on the NIH Stem Cell Registry in the USA and are among the best characterized and documented stem cell lines in the world. ESI-053 is among only a few pluripotent stem cell lines from which a derived cell therapy product candidate has been granted FDA IND clearance for human studies. The FDA cleared an IND application from ImStem Biotechnology, one of our sublicensees, for a MSC product derived from ESI-053 for multiple sclerosis. This was believed to be the first MSC product derived from a pluripotent stem line to be accepted for a human trial by the FDA. The ESI cell lines are available as research or clinical grade product, and have been offered since 2006.

 

The Merger

 

On August 29, 2023, we entered into the Merger Agreement with Serina and Merger Sub, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Serina, with Serina surviving as our wholly owned subsidiary. For additional information, see the sections titled “The Merger” and “The Merger Agreement” beginning on pages 133 and 170 of this proxy statement/prospectus/information statement, respectively.

 

Prior to the closing of the Merger, any assets of AgeX other than the Legacy Assets will be transferred into Newco. In consideration of the transfer of such assets, Newco will assume (i) any indebtedness of AgeX issued to Juvenescence that has not been previously converted into AgeX Series A preferred stock or AgeX Series B preferred stock, which will be secured by the Legacy Assets and (ii) all other liabilities of AgeX in existence as of the Effective Time (other than Transaction Expenses (as defined below)). If the potential spinoff of Reverse Bio is not completed, it is currently expected that the Legacy Assets would include the assets related to Reverse Bio.

 

229

 

 

If the Merger is completed, the combined company will primarily focus on developing Serina’s product candidates, which are described on page 253 under the section titled “Description of Serina’s Business,” and it is anticipated that the combined company will not continue to develop our product candidates, other than potentially the development program of NeuroAirmid, which is described on page 234 under the section titled “Description of AgeX’s Business—Products and Product Candidates.” If the Merger is not completed, we expect to continue to execute on our current business strategies described under the section titled “—Business Strategy” below while seeking out and evaluating potential strategic alternatives with respect to our assets and development programs, which may include a merger, business combination, investment into AgeX, sale or other disposition of assets or other strategic transaction. In such case, we may not be successful in executing such strategies or identifying or implementing any such strategic alternatives, and there is a risk that Juvenescence may decide to stop funding our operations, which would likely result in our delisting and dissolution.

 

Additional Information

 

AgeX was incorporated in the State of Delaware on January 6, 2017. Our common stock began trading on the NYSE American on November 29, 2018 and trade under the symbol “AGE.” Our principal executive offices are located at 1101 Marina Village Parkway, Suite 201, Alameda, CA 94501, and our phone number at that address is (510) 671-8370. Our website address is www.agexinc.com. The information on, or that can be accessed through our website is not part of this proxy statement/prospectus/information statement. We make available, free of charge through our website, our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports, as soon as reasonably practicable after the reports are electronically filed with or furnished to the SEC.

 

iTRTM, UniverCyteTM, Renelon™, and EPRO™ are trademarks of AgeX. PureStem® is a registered trademark of Lineage.

 

Emerging Growth Company

 

We are an “emerging growth company” under the Jumpstart our Business Startups Act of 2012 or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable, in general, to public companies that are not emerging growth companies. These provisions include:

 

reduced disclosure about our executive compensation arrangements;

 

no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and

 

exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.

 

We will remain an “emerging growth company” until the earliest of: (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt securities during the previous three years; or (iv) the date on which we are deemed to be a “large accelerated filer” under the Securities Exchange Act of 1934, as amended (the Exchange Act).

 

230

 

 

The JOBS Act permits an emerging growth company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. However, we have elected to comply with newly adopted or revised accounting standards when they become applicable to public companies because our financial statements were previously consolidated with those of our former parent company Lineage which is not an emerging growth company under the JOBS Act and is therefore not permitted to delay the adoption of new or revised accounting standards that become applicable to public companies. This election under the JOBS Act to not delay the adoption of new or revised accounting standards is irrevocable.

 

Business Strategy

 

We believe our four proprietary platform technologies, PureStem® for cell derivation and manufacturing, UniverCyte™ for generation of hypoimmunogenic cells and iTRTM for reversing the age of cells already in the body present AgeX with a multiplicity of attractive opportunities which we may pursue. Given these platform technologies may be highly desirable to multiple academic and biopharma companies due to their broad applicability and potentially important clinical and commercial benefits, AgeX plans to pursue different business models for these platforms:

 

Co-Development and Licensing: Our PureStem® and UniverCyte™ technologies as well as our ESI cell lines may have applications in the development of a broad range of cell therapy products. We will seek opportunities to license these AgeX technologies to other cell therapy or biopharma companies to bring in early revenue streams, especially for therapies that AgeX does not presently intend to develop.

 

Cellular Therapy: AgeX presently does not have the laboratory and research staff required to conduct in-house research and development for its product candidates, including AGEX-BAT1 and AGEX-VASC1. Instead, AgeX may conduct research and development of those product candidates through a variety of alternative strategies, including but not limited to, sponsoring research and development work at research laboratories at universities or other educational institutions, entering into co-development and marketing arrangements with researchers or other companies in the cell therapy or biopharma industry, and engaging contract service providers to conduct research and development and manufacturing for AgeX for particular product candidates. Our sponsored Huntington’s Disease research program at UCI has led to the organization of an AgeX subsidiary, NeuroAirmid, of which we equally owned with certain UCI researchers, to pursue clinical studies of the use of derived neural stem cell to treat that disease. The new subsidiary is still in the organizational stage and commencement of clinical study work will depend on its ability to obtain financing through grants or third-party investment.

 

Reverse Bioengineering, Inc. (Reverse Bio): Partial cellular reprogramming using our iTRTM technology may one day allow us to revert aged or diseased cells inside the body back to a more youthful, healthy and functional state. We incorporated Reverse Bio as an AgeX subsidiary to develop our iTRTM platform. Reverse Bio is intended to allow for a dedicated focus on iTRTM in terms of equity financing and advancing our iTRTM technology to proof-of-concept in an animal model. We have assigned to Reverse Bio our patent portfolio for iTR development, but the future operations of Reverse Bio will depend in large measure on its ability to raise its own capital.

 

231

 

 

Each of these models may provide particular benefits to AgeX in terms of financing and efficiency of operations. However, each alternative has potential disadvantages as well. If AgeX out-licenses its technology it will avoid the costs and risks of research and development, clinical trials, regulatory approval, manufacturing, and commercialization of product candidates, but the revenues AgeX would receive from commercialization of products developed under those arrangements would likely be limited to royalties on product sales and potentially licensing fees and milestone payments representing a relatively small portion of total product revenues. Similarly, co-development and marketing or similar arrangements would permit AgeX to share costs and risks but would also require AgeX to share revenues from the product candidates that may be successfully developed and commercialized. See elsewhere in this proxy statement prospectus for information about certain risks associated with reliance on arrangements with third parties for research, product development, clinical trials, manufacturing, and commercializing product candidates.

 

We plan to finance our iTRTM and AGEX-BAT1 research and development through Reverse Bio. To the extent that such financing is obtained through the sale of capital stock or other equity securities to investors or other biopharma companies by Reverse Bio, or the sale of Reverse Bio shares held by AgeX, our equity interest in Reverse Bio and our iTRTM and AGEX-BAT1 business would be diluted.

 

However, if the Merger is completed, the combined company will primarily focus on developing Serina’s product candidates, which are described on page 253 under the section titled “Description of Serina’s Business,” and it is anticipated that the combined company will not continue to develop our product candidates, other than potentially the development program of NeuroAirmid, which is described on page 234 under the section titled “—Products and Product Candidates.” See the section titled “—The Merger” above.

 

Our Technology Platforms

 

PureStem® Technology

 

Regulatory approval of cell- and tissue-based products require high standards of quality control. In the case of stem cell-derived products, there is a high standard for ensuring the known identity, purity, and reproducibility of the cells to be administered. PSCs provide certain advantages over adult stem cell products when used in the manufacture of cell-based therapeutics for the treatment of age-related disease. These advantages include:

 

The replicative immortality of the PSCs which facilitates the indefinite scale-up of PSC master cell banks for the manufacture of uniform product, as well as an immortal substrate for targeted genetic modifications.

 

Since most PSCs maintain long and stable telomere lengths, the replicative capacity of derived differentiated cell types is typically longer (younger) than adult or even fetal-derived cells.

 

Using PureStem® technology, it is possible to clonally expand hundreds of purified, identified, and reproducibly scalable cell types that retain regenerative potential (have not passed the regeneration limit).

 

232

 

 

PureStem® technology is based on the observation that embryonic anlagen of many tissues in the human body are naturally comprised of highly proliferative cells with relatively long telomere length. Therefore, it is possible to generate clonal lineages of these cells in vitro. Cells derived from adult tissues commonly permanently cease to divide after a certain number of doublings, a condition known as senescence. In addition, adult and even fetal tissues largely contain differentiated cells often with limited or no capacity of replication in vitro. As a result, the clonal expansion of human embryonic progenitor cell types allows not only a novel and more facile point of scalability but also generates populations of cells that are multipotent instead of pluripotent, and therefore markedly easier to define identity, purity, and potency.

 

We have studied the fate of over 200 diverse PureStem cell lines in thousands of differentiation conditions. This was accomplished by thawing individual cryopreserved PureStem cell lines, culturing them in the laboratory, and then exposing the cells to factors that differentiate cells such as protein growth and differentiation factors, hormones, and small molecules implicated in causing cells to change from one type of cell into another (differentiation). Using individual cells from the over 200 diverse PureStem cell lines previously isolated and cryopreserved, we treated the diverse cells with thousands of differentiation conditions, prepared RNA, and determined the gene expression pattern of the cells using gene expression microarrays. These experiments have shown that the PureStem cell lines display site-specific markers that identify not only the type of cells, but also where in the body the cells would normally reside. Therefore, in the example of cartilage cells, it was possible to produce diverse types of cartilage in this manner. We have licensed from our former parent company Lineage PureStem applications outside of orthopedics, medical aesthetics, and certain ophthalmological applications.

 

We have chosen two PureStem applications for our initial product development based on unmet medical need along with other factors. The first product candidates are AGEX-BAT1, brown adipose tissue or BAT cells for the treatment of metabolic disorders such as obesity or Type II diabetes, and AGEX-VASC1, vascular endothelial progenitors for the treatment of age-related ischemic disease such as that leading to peripheral vascular disease and ischemic heart disease.

 

UniverCyte

 

Our UniverCyte™ technology uses a proprietary, novel, modified form of HLA-G and is intended to permit donor cells to be transplanted into patients without donor-patient tissue matching and without administering immunosuppressant medication. Immunosuppressive drugs can reduce patient resistance to infectious diseases and cancers as well as cause organ and other toxicities. Reducing or eliminating the need for immunosuppressants after cell transplantation by use of hypoimmunogenic cells may make therapies universally available. We plan to use or license the use of this patented technology to produce genetically-modified master cell banks of pluripotent stem cells that can then be differentiated into any young cell type of the human body that now express the immune tolerogenic molecule.

 

233

 

 

Products and Product Candidates

 

Our Therapeutic Product Candidates

 

AGEX-BAT1 - Brown Adipose Tissue (BAT) Progenitors

 

Brown adipose tissue (BAT) is abundant early in life but lost precipitously with age. This tissue is believed to generate heat through expression of a gene called UCP1. In addition, the high levels of glucose and lipid uptake by the tissue is believed to balance metabolism in young people. In contrast, central obesity and Type II diabetes has been correlated with low levels of BAT.

 

 

Figure 6. Human tissue-derived BAT cells (left) stained red for the presence of UCP1 show a minority of cells being true BAT cells. PureStem-derived AGEX-BAT1 cells are uniformly UCP1 positive.

 

The demonstration in published literature in the public domain that the transplantation of BAT from young mice to obese diabetic mice resulted in weight loss and increased insulin sensitivity has led to a search for a source of industrially-scalable clinical grade BAT cells as well as an appropriate matrix for lipotransfer. There currently is no FDA-approved matrix for cell transplantation. As shown in Figure 6, the AGEX-BAT1 progenitors strongly express the BAT marker UCP1 when induced to differentiate and show a relatively high degree of purity compared to human tissue-derived BAT.

 

We entered into a Sponsored Research Agreement with Ohio State University using AGEX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may lead to improvements in diet-induced obesity, metabolic health including glucose metabolism, and cardiac function. For purposes of this proof of concept work, two different cell transplant matrices were tested, HyStem® and a 3-D silk scaffold. We consider this work to be an early stage study and expect to conduct or sponsor additional research on the potential therapeutic benefits of AGEX-BAT1.

 

A number of new GLP-1 receptor agonist drugs, including Mounjaro, Ozempic, Rybelsus, and Trulicity for treating type 2 diabetes, and Wegovy and Zepbound for weight management, have entered the market. Ozempic is also being used off label for weight loss. The attention and acceptance that these new drugs have attained in the medical field for the treatment of type 2 diabetes and chronic weight management may substantially limit or eliminate the prospects for developing and commercializing any product based on AGEX-BAT1, brown adipose tissue, for those uses. Although the GLP-1 receptor agonist drugs may in certain patients be contraindicated, carry unacceptable medical risks, lead to intolerable side effects, or may not be satisfactorily effective, it is not clear whether those patients would constitute a large enough market for an alternative therapy to warrant the time and expense of developing AGEX-BAT1 for the uses addressed by the products currently on the market. Further, it is likely that the administration of a AGEX-BAT1 cell therapy product would entail a surgical implant procedure which would be expensive and would pose risks to the patient related to the surgical procedure that are not faced by users of the injectable or pill GLP-1 receptor agonist drugs currently on the market.

 

234

 

 

AGEX-VASC1 - Vascular Progenitors

 

PureStem® technology can also yield highly purified embryonic vascular components. As shown below, select clonal lines express markers such as VE-Cadherin (CDH5) and PECAM1, as well as VWF and other markers of venous, arterial, and lymphatic endothelium. Flow cytometry shows purity indistinguishable from 100%.

 

In addition to vascular endothelial cells, we have characterized vascular smooth muscle cell progenitors. This makes it possible for us to construct two of the key cellular components of arterial vessels, such as those compromised in coronary artery disease.

 

 

Figure 7. PureStem-derived vascular endothelial cell lines are capable of regenerating young vasculature (bottom left) and appear to have essentially 100% purity by fluorescence activated cell sorting analysis.

 

235

 

 

Leveraging our assets in pluripotency and bioinformatics, we have performed research manipulating cellular immortality and regenerative biology in human cells. In 2010, our scientists while at Lineage demonstrated the reversal of the developmental aging of human cells using transcriptional reprogramming technology. In 2017, we published certain markers of the Weismann barrier, and the high prevalence of a reversion back before the Weismann barrier in diverse cancer cell types cultured in vitro.

 

We extended this research to determine whether reprogramming can be modified to only reverse the aging of cells back before the Weismann Barrier, not back to pluripotency. We have utilized for example the gene COX7A1 as a marker of cells that have lost regenerative potential (crossed the Weismann Barrier). As shown in Figure 8, our proprietary formulation AGEX-iTR1547 has demonstrated initial capability of reducing the expression of the marker gene COX7A1 back to before the Weismann Barrier without reverting the cells to pluripotency. When implemented in vivo, this partial reprogramming, or iTR, would be expected to induce tissue regeneration, and when combined with telomerase, may be able to modulate both cellular immortality and regenerative biology for therapeutic effect. In addition to the small molecule product candidate designated iTR1547, we have invented biological interventions based, for example, on gene therapy. Our inventions relating to iTR biologics disclose both DNA and RNA-based strategies. Our gene delivery iTR product candidate is designated iTR1550. We are performing research to optimize AGEX-iTR1547 and in parallel a gene delivery formulation designated AGEX-iTR1550 in order to initiate preclinical studies of one or both of the agents on the scarless regeneration of the skin.

 

 

Figure 8. PSCs such as ES Cells and PureStem EP Cells display a regenerative capacity like cells that have not crossed the Weismann Barrier. During pre- and post-natal development, skin cells become increasingly incapable of scarless regeneration as reflected in increasing COX7A1 expression. iPS cell reprograming reverts cells back to pluripotency, while AgeX-iTR1547 reverts cells back only to a point prior to the Weismann Barrier (regenerative state).

 

236

 

 

Status and Development Plan

 

The product candidates we have chosen are in the discovery stage of development. Prior to filing an investigational new drug application (IND) for the initiation of clinical trials of our initial product candidates, AGEX-BAT1, AGEX-VASC1, and AGEX-ITR1547/AGEX-iTR1550, a number of important research and development goals will need to be achieved, including discovery-level research for the qualification of reagents used in the manufacture of the product, completion of the standard operating procedures (SOPs) to be used, completion of the methods and documentation for characterization of the product; and producing and testing the genetic modifications in the master cell banks of the pluripotent stem cells under cGMP in order to produce product that will not illicit immune rejection following transplantation. In addition, we will be required to expand the numbers of the pluripotent stem cell master cell banks for future use; produce working cell banks from which the product will be manufactured for clinical trials; produce the relevant product under cGMP conditions; and expand the number of relevant cells and cryopreserve them under cGMP conditions. In addition, we will be required to design the pre-clinical studies including the study endpoints, perform biosafety testing and release the first clinical batch based on preliminary characterization results, and complete full product characterization. Biosafety testing will necessarily include pilot testing in animals such as (NOD/SCID) mice, dosing spiking studies at early and later endpoints, tumorgenicity and biodistribution studies to determine whether the cells form undesired tumors or migrate to inappropriate sites respectively in the animal. Lastly, we will need to define the clinical trial and regulatory strategy and hold various meetings with the U.S. Food and Drug Administration (FDA), as well as successfully submit an IND to the FDA and receive clearance to begin trials. Thereafter, we will need to demonstrate safety and efficacy of the product in human clinical trials in Phase I and II trials, and continued safety and efficacy for achieving the desired endpoint in Phase III trials, potentially then leading to product registration. See “Risk Factors—Risks Related to Our Business Operations” for discussion of risks relating to product development and clinical trials. These include, but are not limited to, failure to successfully complete the aforementioned studies due to the failure of the product, processes, or skills of our employees, unforeseen delays in the development process, failure to raise requisite financing, or failure to receive permission from the FDA to advance product development. To the extent we license development of one or more product candidates to third parties or enter into collaboration arrangements for product development, our licensees or collaborators would need to undertake and achieve the foregoing goals.

 

Because our product candidates are still in the discovery stage, our choice of product candidates and development plans are subject to change based on a variety of factors. We may determine to abandon the development of one or more of our product candidates, or we may prioritize the development of one or more product candidates, or we may select or acquire and prioritize the development of new product candidates. Our choice and prioritization of product candidates for development will be influenced by a variety of factors, including but not limited to:

 

Results of our laboratory research and any animal and clinical trials that we or any licensees or collaborators may conduct;

 

Our ability to enter into licensing or collaborative arrangements with other biotechnology or biopharma companies or universities with their own laboratory facilities and research staffs to conduct research and development of one or more product candidates;

 

Our analysis of third-party competitive and alternative technology that may lead us to conclude that our product candidates or technologies may be non-competitive or obsolete;

 

Our analysis of market demand and market prices for the products we plan to develop could lead us to conclude that market conditions are not favorable for receiving an adequate return on our investment in product development and commercialization;

 

237

 

 

The amount of capital that we will have for our development programs and our projected costs for those programs;

 

The issuance of patents to third parties that might block our use of the same or similar technology to develop a product candidate; and

 

The views of the FDA and comparable foreign regulatory agencies on the pre-clinical product characterization studies required to file an IND in order to initiate human clinical testing of a therapeutic product candidate or to attain marketing approval for that product candidate, or to obtain an investigational device exemption for clinical trials, or clearance for a 510(k) application to market a medical device.

 

Other Products and Product Candidates

 

Neural Stem Cells

 

AgeX has sponsored a research and development program at the University of California, Irvine (UCI) for the manufacture of neural stem cells for use in the treatment of Huntington’s Disease and potentially other neurological diseases and disorders. AgeX has also collaborated with a research group at UCI studying the potential use of exosomes and other extracellular vesicles for the treatment of adverse neurocognitive effects of cancer chemotherapy and radiation therapy on brain function. The neural stem cell sponsored research and development program led to the creation of NeuroAirmid, which is a subsidiary of AgeX co-owned with certain of the UCI researchers and in which UCI will also receive an equity interest if UCI grants NeuroAirmid a license to use a UCI patent.

 

UCI has made an IND submission to the FDA for the use of neural stem cells in a clinical trial for the treatment of Huntington’s Disease. The IND has recently been amended in response to FDA comments. UCI and NeuroAirmid will apply to the California Institute for Regenerative Medicine (CIRM) for a $12,000,000 CLIN2 grant to fund the proposed clinical trial once the FDA informs NeuroAirmid that the clinical hold on the IND has been lifted and the clinical trial may proceed.

 

There can be no assurance that: (i) UCI and NeuroAirmid will successfully conclude negotiations and enter into a license of the UCI patent; (ii) the FDA will permit the clinical trial to proceed under the IND; (iii) CIRM will provide a grant to finance a clinical trial or that the amount of any grant that may be awarded will ultimately be sufficient to complete the initial phase of the clinical trial; (iv) NeuroAirmid will be able to raise capital needed to finance its operations that will not be funded by a CIRM clinical trial grant or to finance any further clinical trials after any initial CIMR grant funding is exhausted; and (v) if a clinical trial is commenced, it will lead to the successful clinical development and subsequent FDA marketing approval of a therapeutic cellular product for the treatment of Huntington’s Disease or any other neurological disease or disorder.

 

ESI BIO Research Products

 

We, through our ESI BIO research product division, market a number of products related to pluripotent stem cells including research-grade as well as cGMP-grade human PSC lines. We plan to contract with third parties where the third parties to allow them to utilize cGMP PSC lines in defined fields of application in exchange for certain compensation including the payment of royalties to us if they are successful in developing and commercializing a product.

 

Subsidiaries

 

AgeX has four subsidiaries, Reverse Bio, ReCyte Therapeutics, Inc. (ReCyte), NeuroAirmid and Merger Sub. Reverse Bio, ReCyte and NeuroAirmid are early stage pre-clinical research and development companies.

 

AgeX intends to develop its iTRTM platform and AGEX-BAT1 through Reverse Bio. Reverse Bio will allow for a dedicated focus on iTRTM in terms of equity financing and advancing the iTRTM technology to proof-of-concept in an animal model. AgeX’s patent portfolio for iTR and AGEX-BAT1 development have been assigned to Reverse Bio, but the future operations of Reverse Bio will depend in large measure on its ability to raise its own capital. ReCyte is involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 100%, 94.8%, and 50% of the outstanding capital stock of Reverse Bio, ReCyte, and NeuroAirmid, respectively. We expect that our ownership interests in Reverse Bio and NeuroAirmid will be diluted if those subsidiaries are successful in obtaining financing from investors or product development collaborators. All material intercompany accounts and transactions have been eliminated in consolidation.

 

238

 

 

Manufacturing

 

We presently do not have any manufacturing facilities and we will need to rely on third party contract manufacturers for the production of our cell lines and product candidates and to comply with quality manufacturing processes and controls.

 

Facilities

 

We presently occupy 101 square feet of leased office space in a building in an office and research park at 1101 Marina Village Parkway, Suite 201, Alameda, California pursuant to a lease that is set to expire on December 31, 2023. We do not have our own research laboratory facilities.

 

Commercialization Plan

 

With the exception of our research product sales which generate a trivial amount of revenues, we currently have no commercialized or marketed products such as FDA-approved drugs in our portfolio. As a result, we have not yet assembled an infrastructure for sales and marketing. At the point in time, if ever, that our product candidates approach clearance or approval, we plan to develop a commercial plan that may initially include strategic marketing partnerships.

 

Intellectual Property

 

Patents and Trade Secrets

 

We rely primarily on patents and contractual obligations with employees and third parties to protect our proprietary rights. We have sought, and intend to continue to seek, appropriate patent protection for important and strategic components of our proprietary technologies by filing patent applications in the U.S. and certain foreign countries. There are no assurances that any of our intellectual property rights will guarantee protection or market exclusivity for our products and product candidates. We also use license agreements both to access technologies developed by other companies and universities and to convey certain intellectual property rights to others. Our financial success will be dependent, in part, on our ability to obtain commercially valuable patent claims, to protect and enforce our intellectual property rights, and to operate without infringing upon the proprietary rights of others if we are unable to obtain enabling licenses.

 

The patents for our core programs are summarized below.

 

239

 

 

AGEX-BAT1

 

Brown Adipose Tissue (BAT) Progenitor Cells: The pending patent applications related to BAT progenitor cells, which are owned by AgeX, include U.S. and international patent applications. The applications are directed to the differentiation of pluripotent stem cells (including hES cells) into progenitor cell types capable of making the cellular components of brown fat. The patents also describe culture and purification methods. The approximate expiration dates of the BAT patents, if issued, will range from 2034 to 2036.

 

AGEX-VASC1

 

Vascular Progenitors: The pending patent application pertaining to purified vascular progenitor cells and embryonic vascular components are owned by AgeX or an AgeX subsidiary or licensed from Lineage. The patents include U.S. patent applications and are directed to methods to enhance vascular tube networks, compositions of pericyte progenitor cells, compositions of exosomes containing angiogenic molecules, compositions of vascular and lymphatic cells, and methods to culture and purify the cells or components thereof. The approximate expiration dates of the vascular progenitor patents, if issued, range from 2032 to 2038. We plan to file an international patent application claiming priority from a pending US provisional application by the filing deadline, which could lead to a patent that if issued would expire in 2039.

 

AGEX-iTR1547 and AGEX-iTR1550

 

Induced Tissue Regeneration (iTRTM): The pending patent applications related to the iTR programs, which are owned by AgeX, include applications pending, for example, in the United States, Australia, Canada, China, Europe, Japan and a pending international patent application. These patents and patent applications are directed to compositions and methods for healing damaged tissue using the iTR treatment methods. The patent applications are also directed to treatment methods by regenerating aging tissue by modulating genes involved in tissue regeneration, including reprogramming cells and tissues back to a regenerative state. The approximate expiration dates of the iTR patents, if issued, will range from 2034 to 2041.

 

Other AGEX Licensed and Sublicensed Patents

 

PureStem® Progenitor Cells: The patents and pending applications related to our PureStem® technology include patents and applications in the United States, Canada, Europe and Australia. These patents are directed to methods for generating diverse isolated progenitor cell lines which generally do not express COX7A1 and combinations of other methods for employing pluripotent stem cell lines suitable for clinical use. The pending applications are directed to clonally purified human embryonic progenitor cell lines and methods for reproducible, large scale production of clonally purified human embryonic progenitor cells, compositions and methods for generating diverse cell types, and assays useful in identifying hES cell lines and pluripotent cells resulting from the transcriptional reprogramming of somatic cells that have embryonic telomere length. The approximate expiration date of the PureStem® issued patents is 2031 and the approximate date of expiration of the pending patents, if issued, will range from 2029 to 2032.

 

240

 

 

The PureStem® patent portfolio includes patents and pending applications licensed from Advanced Cell Technology, Inc., which later became Ocata Therapeutics, Inc. (Ocata). The Ocata issued patents cover methods for reprogramming animal differentiated somatic cells to undifferentiated cells and methods for producing differentiated progenitor cells using morula-derived or inner cell mass cells from a blastocyst and expire from approximately 2023 to 2026. The Ocata pending applications relate to methods for the derivation of cells that have a reduced differentiation potential using PSCs, methods for reprogramming animal differentiated somatic cells to undifferentiated cells and methods for producing differentiated progenitor cells using morula-derived or inner cell mass cells from a blastocyst. The Ocata pending patents, if issued, will expire between 2023 and 2026.

 

ESI Human Embryonic Stem Cell (hES) Cell Lines: AgeX licenses rights to the ES Cell International Pte. Ltd. patent portfolio with patents issued in the United States, Australia, Israel, UK, Singapore, Japan, and applications pending in the US and Europe. The patents are directed to methods for the differentiation of or enhancing the differentiation of stem cells into cardiomyocytes, neural cells, and pancreatic endoderm cells, compositions of pancreatic progenitor cells, methods of promoting the attachment, survival and/or proliferation of substantially undifferentiated stem cells in culture, methods for identifying and selecting cardiomyocytes, methods of freezing stem cells or progenitor cells, methods for identifying cardiogenic factors, compositions and methods for modulating spontaneous differentiation of a stem cell, methods of modulating the differentiation of undifferentiated, pluripotent human embryonic stem cells in culture, isolated endodermal progenitor cells, methods for transducing human embryonic stem cells, cell culture systems. The pending applications are directed to methods for the differentiation of hES cells into the three cell lineages, including for example cardiomyocytes, skeletal muscle cells, vascular endothelial cells, and pancreatic endoderm cells, as well as various culture and purification methods and compositions and methods of treatment. The ESI issued patents will expire from 2023 to 2027, and the approximate date of expiration of the pending patents, if issued, will range from 2023 to 2027.

 

UniverCyteTM Human Leukocyte Antigen-G (HLA-G) Technology: In August 2018, we acquired from Escape Therapeutics patents and patent applications related to HLA-G-modified cells and methods of generating allogeneic cells with reduced risk of being rejected by patients regardless of the HLA class I haplotype. The patents and pending application related to our HLA-G modified cells technology include patents issued in the United States, Australia and Japan and applications are pending in the United States, Australia, Canada, China, Europe, Japan, Korea, and Singapore. The patents are directed to cells which are genetically modified to express a HLA-G and have reduced immunogenicity, and nucleic acid compositions useful for generating the genetically modified cells. The pending applications are directed to compositions and methods for generating cells which are genetically modified to express HLA-G having reduced immunogenicity, nucleic acid compositions useful for generating the genetically modified cells, and methods of producing artificial tissues using the genetically modified cells. The approximate expiration date of the UniverCyte™ HLA-G issued patents is 2033 and the approximate date of expiration of the pending patents, if issued, will also be 2033. We intend to use the UniverCyte™ technology in the development of our two lead product candidates, AGEX-BAT1 and AGEX-VASC1 for the treatment of Type II diabetes and peripheral vascular disease and ischemic heart disease, respectively. In addition, we may seek to license out or form collaborations for the use of our UniverCyte™ technology.

 

241

 

 

General Risks Related to Obtaining and Enforcing Patent Protection

 

There is a risk that any patent applications that we file and any patents that we hold or later obtain could be challenged by third parties and be declared invalid or infringing on third-party claims. Litigation, interferences, oppositions, inter partes reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity. Litigation, interference, oppositions, inter partes reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed any amounts that we may accrue on our consolidated financial statements as a reserve for contingent liabilities. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.

 

The enforcement of patent rights often requires litigation against third-party infringers, and such litigation can be costly to pursue. Even if we succeed in having new patents issued or in defending any challenge to issued patents, there is no assurance that our patents will be comprehensive enough to provide us with meaningful patent protection against our competitors.

 

In addition to relying on patents, we rely on trade secrets, know-how, and continuing technological advancement to maintain our competitive position. We have entered into intellectual property, invention, and non-disclosure agreements with our employees, and it is our practice to enter into confidentiality agreements with our consultants. There can be no assurance, however, that these measures will prevent the unauthorized disclosure or use of our trade secrets and know-how, or that others may not independently develop similar trade secrets and know-how or obtain access to our trade secrets, know-how, or proprietary technology.

 

Our Licensing Arrangements

 

License Agreement with Lineage: iTRTM, PureStem® and Telomere Length

 

Concurrently with the contribution of assets to us by Lineage under an Asset Contribution and Separation Agreement, we entered into a License Agreement with Lineage pursuant to which Lineage has licensed to us, with rights to sublicense, certain intellectual property, including patents and patent applications and know-how for use in the development, manufacture and commercialization of products or services for the prevention, treatment, amelioration, diagnosis or monitoring of all human and non-human animal diseases and conditions except for the field of medical products, devices and services for the reserved Lineage Exclusive Field of orthopedic, ophthalmic, and medical aesthetic uses. In addition, Lineage retains an option right, on terms to be negotiated, to license iTR patents in research, development, manufacturing and commercialization of treatments based on iTR in the Lineage Exclusive Field. The licensed patents and know-how relate generally to (a) Lineage’s PureStem® human embryonic progenitor cell lines, and (b) telomere length and DNA quality control analysis in pluripotent stem cells.

 

242

 

 

The Lineage patent rights licensed to us are exclusive and worldwide except for existing third-party licenses, and for medical products, devices, and services related to tendon. We additionally received an option to license certain Lineage retained rights outside of orthopedic indications unless a license grant would compete with a Lineage program or products in the Lineage Exclusive Field.

 

The License Agreement contains customary provisions pertaining to patent maintenance, enforcement, and defense and related cost allocations, insurance, indemnification, and termination of the license in the event of a breach or default by a party, or the bankruptcy or other insolvency event with respect to a party.

 

Additional License and Sublicense Agreements

 

Lineage and certain Lineage subsidiaries also entered into agreements pursuant to which they have licensed or sublicense to us, on a non-exclusive, world-wide, royalty bearing basis, certain additional patents and patent rights and know-how relating to human embryonic progenitor cell technology and human pluripotent stem cell lines and technology for use outside the Lineage Exclusive Fields, or in the case of certain sublicense rights, fields previously licensed to third parties.

 

Sublicense of Certain Progenitor Patents

 

Lineage has granted to us a sublicense of certain patents licensed to Lineage that pertain to the derivation of human embryonic progenitor cell lines. The sublicense will permit us to use the sublicensed patents for the treatment, palliation, diagnosis, or prevention of any disease, disorder or health condition outside of the Lineage Exclusive Field. The sublicense expires the later of July 10, 2028 or the latest expiration date of a sublicensed patent, unless terminated earlier pursuant to the terms of the sublicense.

 

We will pay Lineage a royalty on “net sales,” as defined in the sublicense agreement, until the royalty payments to Lineage’s licensor by Lineage total $1.2 million and thereafter will pay to Lineage a low single digit royalty on its own net sales and a low double digit royalty on sublicensing consideration.

 

If we grant a sublicense to use the patents, we will pay Lineage a portion of any consideration received for a sublicense, including but not limited to, upfront payments and milestones, and non-cash exchanges or considerations, but not payments for developing a product, service or process. If we become obligated to pay royalties to one or more affiliates of Lineage for the use of patent rights related to this sublicense and as a result, the royalties payable to Lineage with respect to royalties under the sublicense plus the royalties payable to the affiliates would exceed a designated amount of net sales, the royalties due to Lineage may be reduced but not less than the designated amount. In addition, we will pay to Lineage a royalty on “net sales,” as defined in the sublicense agreement, by the sublicensee. If we become obligated to pay royalties to one or more affiliates of Lineage for the use of patent rights related to this sublicense and as a result, the royalties payable to Lineage with respect to sales by a sublicensee plus the royalties payable to the affiliates would exceed a designated amount of net sales, the royalty due on net sales by the sublicensee may be reduced but not less than the designated amount.

 

The sublicense agreement includes reciprocal cross-licenses between Lineage and us with respect to any new patents that may be issued based on the use of the sublicensed patents. Any such license to Lineage will be exclusive in the Lineage Exclusive Field and nonexclusive in all other licensed fields. Any such license from Lineage to us will be for use outside the Lineage Exclusive Field and for medical products or services involving tendon. Each license will be for a term of 10 years.

 

ESI License

 

Lineage’s subsidiary ES Cell International Pte (ESI) has granted to us non-exclusive rights to certain ESI patents and human pluripotent stem cell lines, or ESI Cell Lines, for use outside of the ESI Exclusive Field of orthopedic, ophthalmic, medical aesthetic, and spinal cord injury uses, and outside certain other fields for which ESI has previously granted licenses. We will pay ESI a 2% royalty on “net sales,” as defined in the license agreement. If we become obligated to pay royalties to one or more third party or to Lineage for the use of patent rights related to this license and as a result the royalties payable to ESI with respect to this license agreement plus the royalties payable to such third party or Lineage would exceed a designated amount of net sales, the royalty due on net sales by the sublicensee may be reduced. The patent license expires upon the latest expiration date of a licensed patent, unless terminated earlier pursuant to the terms of the license. All other rights under the license are terminable by either party under the conditions specified in the license.

 

243

 

 

If we grant rights to any third party to use ESI Cell Lines derived under cGMP, we will pay ESI a share of all consideration that we receive as consideration for the grant of those rights, including all cash and non-cash consideration but not royalties. We are not permitted to grant sublicenses to the licensed ESI patents but may sublicense the use of ESI Cell Lines.

 

AgeX also will pay ESI 5% of any fees that AgeX may receive for providing third parties with a “drug master file” for submission to the FDA or similar regulatory agencies in other jurisdictions that may be used to provide confidential detailed information about facilities, processes or articles used in the manufacturing, processing, packaging and storing of one or more human drugs, including but not limited to biologics, cell lines and cell products.

 

Competition

 

The biotechnology industry is highly competitive and characterized by rapid change (even disruptive advances) that challenge the ability of any one company to maintain leadership. Therefore, we face competition on multiple fronts, including from other biotechnology companies, large pharmaceutical companies, academic institutions and government research entities. We believe the competitive advantages of our technology platform and resulting product candidates arise from the large market opportunities addressed by our product candidates, their anticipated safety profile, the expected cost of manufacture of off-the-shelf products, our intellectual property, as well the fundamental and widespread role of cell aging and regeneration in human age-related degenerative disease.

 

There are numerous biotechnology companies developing therapeutics for human aging, with each company often focusing on a specific molecular pathway within cells. For example, ResTORbio, Inc. is developing modulators of the mechanistic target of rapamycin (mTOR) pathway to treat immunological and cardiovascular disorders. Calico Life Sciences LLC is a Google-founded research and development company aimed at identifying molecular pathways that control animal lifespan and translating these insights into novel therapeutics designed to increase human healthspan. Calico has not disclosed its lead product development plans. Unity Biotechnology, Inc. focuses on cellular senescence, in particular, the use of agents that can target senescent cells for selective ablation (senolysis). Unity’s stated targeted age-related diseases include osteoarthritis as well as other ophthalmological and pulmonary diseases. In addition, Altos Labs, Inc. (Altos) has reportedly received funding commitments in excess of $3 billion for research and development of products relating to age-reprogramming. The initial technology focus disclosed by Altos may compete with the iTR program within AgeX and its subsidiary Reverse Bio.

 

244

 

 

Our therapeutic product candidates in development are likely to face competition from a large number of companies and technological strategies including therapeutics intended to address our lead indications, including:

 

Type II diabetes: current standard of care treatments (though not necessarily focused on the root cause of the disease) include dieting and exercise programs to reduce weight, or pharmacological interventions with a wide array of medications, including: Metformin (Glucophage, Glumetza, or others); (DiaBeta, Glynase), glipizide (Glucotrol) and glimepiride (Amaryl); Meglitinides (repaglinide (Prandin) and nateglinide (Starlix)); Thiazolidinediones (rosiglitazone (Avandia) and pioglitazone (Actos)); DPP-4 (sitagliptin (Januvia), saxagliptin (Onglyza) and linagliptin (Tradjenta)); GLP-1 receptor agonists (exenatide (Byetta), liraglutide (Victoza), semaglutide (Ozempic and Rybelsus), dulaglutide (Trulicity), and tirzepatide (Mounjaro); SGLT2 inhibitors (canagliflozin (Invokana) and dapagliflozin (Farxiga)); and insulin therapy (Insulin glulisine (Apidra), Insulin lispro (Humalog), Insulin asgpart (Novolog), Insulin glargine (Lantus), Insulin detemir (Levemir), Insulin isophane (Humulin N, Novolin N)).

 

Vascular ischemia, including myocardial ischemia: current standard of care treatments including dieting, lowered intake of cholesterol, daily aspirin as a blood thinner; pharmacological agents including but not limited to nitrates as vasodilators (nitroglycerin sublingual tablet (Nitrostat), nitroglycerin transdermal ointment (Nitro-Bid), and isosorbide mononitrate and dinitrate (Isordil, Isordil Titradose, Dilatrate-SR)); beta blockers (atenolol (Tenormin), metoprolol (Lopressor, Toprol XL), and nadolol (Corgard)); calcium channel blockers (amlodipine (Norvasc), amlodipine and atorvastatin (Caduet), amlodipine and benazepril (Lotrel), diltiazem (Cardizem), felodipine (Cardene, Cardene SR), and verapamil (Calan); cholesterol-lowering medications such as statins atorvastatin (Lipitor), rosuvastatin (Crestor), and simvastatin (Zocor); Angiotensin-converting enzyme (ACE) inhibitors (Ranolazine (Ranexa), benazepril (Lotensin), and lisinopril (Prinivil, Zestril, Qbrelis); and surgical procedures to increase circulation including but not limited to angioplasty and stenting, coronary artery bypass surgery, and enhanced external counterpulsation.

 

Many of our competitors have greater financial, collaborative, technical, regulatory, and human resources as well as products more advanced in development than our product pipeline, including products already marketed for our target indications. As a result, these competitors may have great success in obtaining regulatory approvals, reimbursement, or market acceptance. Our competitors, may have greater success in attracting qualified personnel, recruiting clinical trial sites, or in establishing strategic partnerships with larger pharmaceutical companies to fund large late-stage clinical trials or product marketing. In addition, our future business could be limited should our competitors commercialize products demonstrated to be more effective, safer, or less expensive than our comparable products.

 

Government Regulation and Product Approval

 

Government authorities at the federal, state, and local level, and in other countries, extensively regulate among other things, the development, testing, manufacture, quality, approval, safety, efficacy, distribution, labeling, packaging, storage, record keeping, marketing, import/export, and promotion of drugs, biologics, and medical devices. Authorities also heavily regulate many of these activities for human cells, tissues, and cellular and tissue-based products (HCT/Ps).

 

FDA and Foreign Regulation of Therapeutic Products

 

The FDA and foreign regulatory authorities will regulate our proposed products as drugs, biologicals, or medical devices, depending upon such factors as: the use to which the product will be put, the chemical composition of the product, and the interaction of the product with the human body. In the United States, the FDA regulates drugs and biologicals under the Federal Food, Drug and Cosmetic Act (FDCA), the Public Health Service Act (PHSA), and implementing regulations. In addition, establishments that manufacture human cells, tissues, and cellular and tissue-based products are subject to additional registration and listing requirements, including current good tissue practice regulations. To the extent AgeX develops cellular and tissue-based products or therapies, its products will be subject to review by the FDA staff in its Center for Biologics Evaluation and Research (CBER) Office of Cellular, Tissue, and Gene Therapies. In some instances, AgeX’s clinical study protocol for a cell therapy product must be reviewed by the National Institute of Health through its Recombinant DNA Advisory Committee.

 

245

 

 

Any human drug and biological products that we may develop for testing, marketing, or use in the United States will be subject to rigorous FDA review and approval procedures. After testing in animals to evaluate the potential efficacy and safety of the product candidate, an IND submission must be made to the FDA to obtain authorization for human testing. Extensive clinical testing, which is generally done in three phases, must then be undertaken at a hospital or medical center to demonstrate optimal use, safety, and efficacy of each product in humans. Each clinical study is conducted under the auspices of an independent institutional review board (IRB). The IRB will consider, among other things, ethical factors, the safety of human subjects, and the possible liability of the institution.

 

Clinical trials are generally conducted in three “phases.” Phase I clinical trials are conducted in a small number of healthy volunteers or volunteers with the target disease or condition to assess safety. Phase II clinical trials are conducted with groups of patients afflicted with the target disease or condition in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety. In some cases, an initial trial is conducted in diseased patients to assess both preliminary efficacy and preliminary safety, in which case it is referred to as a Phase I/II trial. Phase III trials are large-scale, multi-center, comparative trials and are conducted with patients afflicted with the target disease or condition in order to provide enough data to demonstrate the efficacy and safety required by the FDA. The FDA closely monitors the progress of each of the three phases of clinical testing and may, at its discretion, re-evaluate, alter, suspend, or terminate the clinical trial based upon the data which have been accumulated to that point and its assessment of the risk/benefit ratio to the intended patient population. All adverse events must be reported to the FDA. Monitoring of all aspects of the study to minimize risks is a continuing process. The time and expense required to perform this clinical testing can far exceed the time and expense of the research and development initially required to create the product.

 

No action can be taken to market any therapeutic product in the U.S. until an appropriate New Drug Application (NDA) or BLA has been approved by the FDA. Submission of the application is no guarantee that the FDA will find it complete and accept it for filing. If an application is accepted for filing, following the FDA’s review, the FDA may grant marketing approval, request additional information, or deny the application if it determines that the application does not provide an adequate basis for approval. FDA regulations also restrict the export of therapeutic products for clinical use prior to FDA approval. To date, the FDA has not granted marketing approval to any pluripotent stem-based therapeutic products and it is possible that the FDA or foreign regulatory agencies may subject our product candidates to additional or more stringent review than drugs or biologicals derived from other technologies.

 

The FDA offers several programs to expedite development of products that treat serious or life-threatening illnesses and that provide meaningful therapeutic benefits to patients over existing treatments. A product may be eligible for breakthrough therapy designation if it treats a serious or life-threatening disease or condition and preliminary clinical evidence indicates it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. In 2017, FDA established a new regenerative medicine advanced therapy (RMAT) designation as part of its implementation of the 21st Century Cures Act. An RMAT is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions that is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and preliminary clinical evidence indicates that it has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.

 

246

 

 

Some of our future products may be eligible for RMAT designation. There is no assurance that the FDA will grant breakthrough therapy, accelerated approval or RMAT status to any of our product candidates.

 

In addition to regulations in the United States, we are subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a drug candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the European Union, before we can commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.

 

Combination Products

 

If we develop any products that are used with medical devices, they may be considered combination products, which are defined by the FDA to include products comprised of two or more regulated components or parts such as a biologic and a device. When regulated independently, biologics and devices each have their own regulatory requirements. However, regulatory requirements for a combination product comprised of a biologic administered with a delivery device can be more complex, because in addition to the individual regulatory requirements for each component, additional combination product regulatory requirements may apply.

 

510(k) Medical Devices & Notification

 

Product marketing in the U.S. for most Class II and limited Class I devices typically follows a 510(k) pathway. To obtain 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a legally marketed device, referred to as the predicate device. A predicate device may be a previously 510(k) cleared device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for submission of PMA applications, or a product classification created by FDA when it granted de novo authorization. The manufacturer must show that the proposed device has the same intended use as the predicate device, and it either has the same technological characteristics, or it is shown to be equally safe and effective and does not raise different questions of safety and effectiveness as compared to the predicate device.

 

247

 

 

There are three types of 510(k)s: traditional; special, for devices that are modified and the modification needs a new 510(k) but the modification does not affect the intended use or alter the fundamental scientific technology of the device; and abbreviated, for devices that conform to a recognized standard. The special and abbreviated 510(k)s are intended to streamline review. The FDA intends to process special 510(k)s within 30 days of receipt and abbreviated 510(k)s within 90 days of receipt. Though statutorily required to clear a traditional 510(k) within 90 days of receipt, the clearance pathway for traditional 510(k)s can take substantially longer.

 

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require a PMA approval. The FDA requires each manufacturer to make this determination in the first instance, but the FDA can review any such decision. If the FDA disagrees with a manufacturer’s decision not to seek a new 510(k) clearance, the agency may retroactively require the manufacturer to seek 510(k) clearance or PMA approval. The FDA also can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or PMA approval is obtained.

 

Post-Approval Matters

 

Even after initial FDA approval has been obtained, further studies may be required to provide additional data on safety or to gain approval for the use of a product as a treatment for clinical indications other than those initially targeted. Data resulting from these clinical trials may result in expansions or restrictions to the labeled indications for which a product has already been approved.

 

FDA Regulation of Manufacturing

 

The FDA regulates the manufacturing process of pharmaceutical products, human tissue and cell products, and medical devices, requiring that they be produced in compliance with cGMP. The FDA regulates and inspects equipment, facilities, laboratories, and processes used in the manufacturing and testing of products prior to providing approval to market products. If after receiving approval from the FDA, a material change is made to manufacturing equipment or to the location or manufacturing process, additional regulatory review may be required. The FDA also conducts regular, periodic visits to re-inspect the equipment, facilities, laboratories and processes of manufacturers following an initial approval. If, as a result of those inspections, the FDA determines that that equipment, facilities, laboratories or processes do not comply with applicable FDA regulations and conditions of product approval, the FDA may seek civil, criminal or administrative sanctions and/or remedies against the manufacturer, including suspension of manufacturing operations. Issues pertaining to manufacturing equipment, facilities or processes may also delay the approval of new products undergoing FDA review.

 

Federal Funding of Research

 

The NIH has adopted guidelines on the use of hES cells in federally funded research, consistent with President Obama’s Executive Order which rescinded President Bush’s Executive Orders that permitted federal funding of research on hES cells using only the limited number of hES cell lines. The central focus of the guidelines is to assure that hES cells used in federally funded research are derived from human embryos that were created for reproductive purposes, are no longer needed for this purpose, and are voluntarily donated for research purposes with the informed written consent of the donors. Those hES cells that were derived from embryos created for research purposes rather than reproductive purposes, and other hES cells that were not derived in compliance with the guidelines, are not eligible for use in federally funded research.

 

248

 

 

California State Regulations

 

The state of California has adopted legislation and regulations that require institutions that conduct stem cell research to notify, and in certain cases obtain approval from, a Stem Cell Research Oversight Committee (SCRO Committee) before conducting the research. Under certain California regulations, all hES cell lines that will be used in our research must be acceptably derived. California regulations further require certain records to be maintained with respect to stem cell research and the materials used. AgeX programs that involve the use of stem cells will be reviewed by a SCRO Committee to confirm compliance with federal and state guidelines. The hES cell lines that we use are all on the NIH registry of lines that have been reviewed and meet standards for federal funding grants.

 

Health Insurance Portability and Accountability Act

 

Under HIPAA, HHS has issued regulations to protect the privacy and security of protected health information used or disclosed by health care providers. HIPAA also regulates standardization of data content, codes, and formats used in health care transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA regulations include civil and criminal penalties.

 

The requirements under these regulations may periodically change and could have an effect on our business operations if compliance becomes substantially more costly than under current requirements. New laws governing privacy may also be adopted in the future. We can provide no assurance that we will remain in compliance with diverse privacy requirements in all of the jurisdictions in which we do business. Failure to comply with privacy requirements could result in civil or criminal penalties, which could have a materially adverse effect on our business.

 

Federal and State Fraud and Abuse Laws

 

We are also subject to various laws pertaining to healthcare “fraud and abuse,” including anti-kickback laws and false claims laws. Anti-kickback laws make it illegal to solicit, offer, receive or pay any remuneration in exchange for or to induce the referral of business, including the purchase or prescription of a particular drug that is reimbursed by a state or federal program. The term “remuneration” has been broadly interpreted to include anything of value. Several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act (ACA), among other things, amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate, in order to commit a violation. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as by the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid). Liability under the false claims laws may also arise when a violation of certain laws or regulations related to the underlying products (e.g., violations regarding improper promotional activity or unlawful payments) contributes to the submission of a false claim.

 

249

 

 

Additionally, the FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.

 

Healthcare Reform

 

In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. There have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs.

 

In particular, the ACA has had, and is expected to continue to have, a significant impact on the healthcare industry. The ACA was designed to expand coverage for the uninsured while at the same time containing overall healthcare costs. Substantial new provisions affecting compliance have also been enacted, which may require us to modify our business practices with healthcare providers and entities, and a significant number of provisions are not yet, or have only recently become, effective.

 

Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and there may be additional challenges and amendments to the ACA in the future, including efforts to implement changes to the law that may impact reimbursement for drugs and biologics.

 

Further, there has been heightened government scrutiny over the manner in which manufacturers set prices for their marketed pharmaceutical products. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to pharmaceutical product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. Such proposals have included, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B and to allow some states to negotiate drug prices under Medicaid. The Department of Health and Human Services has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. Although some of these and other proposals will require authorization through additional legislation to become effective, Congress and the President are likely to continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

 

It is uncertain whether and how future legislation, whether domestic or foreign, could affect prospects for our product candidates or what actions foreign, federal, state, or private payors for health care treatment and services may take in response to any such health care reform proposals or legislation. Adoption of price controls and other cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures reforms may prevent or limit our ability to generate revenue, attain profitability or commercialize our product candidates.

 

250

 

 

Moreover, the DSCSA imposes obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. While some requirements of the DSCSA began in November 2014, many key requirements, development of standards, and the system for product tracing will continue to be phased in until 2023. Among the requirements of the DSCSA, manufacturers will be required to provide certain information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. The transfer of information to subsequent product owners by manufacturers will eventually be required to be done electronically. Manufacturers will also be required to verify that purchasers of the manufacturers’ products are appropriately licensed. Further, under this new legislation, manufacturers will have drug product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or that are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.

 

Reimbursement

 

Medicare, Medicaid, and Third-Party Reimbursement Programs

 

Sales of the therapeutic products and medical devices that we and our subsidiaries may develop will depend, in part, on the extent to which the costs of those products will be covered by third-party payors, such as government health programs, commercial insurance, and managed healthcare organizations.

 

The containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. In the United States, the federal and many state governments have adopted or proposed initiatives relating to Medicaid and other health programs that may limit reimbursement or increase rebates that providers are required to pay to the state. The ACA increased many of the mandatory discounts and rebates and imposed a new Branded Prescription Pharmaceutical Manufacturers and Importers fee payable by manufacturers. Provisions of the Inflation Reduction Act of 2022 may impact the prices of drug products that are sold in the United States, particularly through Medicare programs. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the product’s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease.

 

In addition to government regulation, managed care organizations in the United States, which include medical insurance companies, medical plan administrators, health-maintenance organizations, hospital and physician alliances and pharmacy benefit managers, continue to put pressure on the price and usage of healthcare products. Managed care organizations and third-party payers seek to contain healthcare expenditures, and their purchasing strength has been increasing due to their consolidation into fewer, larger organizations and a growing number of enrolled patients. Adoption of price controls, cost-containment measures, and more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If third-party payors do not consider the products we develop to be cost-effective compared to other therapies, they may not cover our products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.

 

251

 

 

Other legislative and regulatory actions that would have a significant impact include: changes to coverage and payment for biosimilars, including the current Medicare biosimilar coverage and payment policies intended to encourage biosimilar adoption, or other policies that provide easier substitution or reimbursement advantages. The adoption of new healthcare legislation remains uncertain, but impending changes will likely impact the number of patient lives covered, the quality of the insurance, Medicaid eligibility and the level of patient protections provided.

 

We face similar issues outside of the United States. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for aa medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of placing a medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the United States and generally tend to be significantly lower.

 

Employees

 

As of September 30, 2023, we employed five persons on a full-time basis and four persons on a part-time basis. Three of these employees hold a Ph.D.

 

Legal Proceedings

 

AgeX may from time to time be a party to litigation and subject to claims incident to the ordinary course of business. In the future, AgeX may become a party to an increasing number of litigation matters and claims, including in connection with Merger Agreement and the transactions contemplated thereby. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of these matters could materially affect AgeX’s future results of operations, cash flows or financial position.

 

As of January 9, 2024, one purported stockholder of AgeX has filed a lawsuit in connection with the Merger. On December 11, 2023, Edward Buttner, a purported stockholder of AgeX, filed a putative shareholder class action and derivative lawsuit in the Superior Court of the State of California, County of Alameda, captioned Buttner, et al. v. AgeX Therapeutics, Inc., et al., Case No. 23CV057083 (the Buttner Complaint). The Buttner Complaint names AgeX, the AgeX Board, an officer of AgeX, Juvenescence Limited and Juvenescence US Corp. as defendants. The Buttner Complaint alleges direct claims against the individual defendants for breaches of fiduciary duty in connection with their approval of the Merger and disclosures made by AgeX in connection therewith and, in the alternative, alleges derivative claims, purportedly on behalf of AgeX, against the individual defendants for such alleged breaches of fiduciary duty. The Buttner Complaint also alleges direct and derivative claims against Juvenescence Limited, Juvenescence US Corp., and one member of the AgeX Board for breaches of fiduciary duty as alleged controlling stockholders of AgeX. The Buttner Complaint seeks, among other relief, (i) injunctive relief preventing the parties from proceeding with the Merger until the alleged disclosure deficiencies have been remedied, (ii) an award of damages for plaintiff and the putative class (or, alternatively, an award of damages on behalf of AgeX in connection with the derivative claims), (iii) rescission in the event the Merger is consummated or alternatively rescissory damages, (iv) an order requiring the defendants to disgorge any ill-gotten gains and profits purportedly realized in connection with the Merger, (v) an award of costs, including attorneys’ fees, and (vi) any other relief the court may deem just and proper.

Additional complaints may be filed against AgeX, the AgeX Board, Serina or the Serina Board in connection with the Merger. If such additional complaints are filed, AgeX will not necessarily announce such additional complaints absent a legal requirement to do so.

 

252

 

 

DESCRIPTION OF SERINA’S BUSINESS

 

References to “we,” “us” and “our” in this section titled “Description of Serina’s Business” refer to Serina.

 

Overview

 

Serina is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina’s POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an increase in efficacy and safety of the resulting polymeric drug conjugate. Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection.

 

The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic (PK) profiles that can include toxicity, side effects and short half-life. We believe that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. We believe that POZ technology can be applied to small molecules, proteins, antibody drug conjugates, and other classes of molecules.

 

The chemical attachment of water-soluble polymers, in particular polyethylene glycol (PEG), to drugs has become a valuable technique for improving the properties of pharmaceuticals. This technique has been successfully employed in producing many FDA-approved drugs. Serina believes that there is an unmet need for polymer delivery technology that addresses the limitations of PEG and other biocompatible polymers and that the POZ technology has the following advantages:

 

Synthesis and stability – POZ is produced using inexpensive starting materials in essentially a “one pot” synthesis and is stable at room temperature. PEG is comprised of repeating units of ethylene glycol. PEG is synthesized by ring opening polymerization of ethylene oxide. Ethylene oxide is a flammable, toxic, explosive and colorless gas. High quality PEG is available from only a few industrial-scale facilities, and is relatively expensive. The manufacturing process is quite dangerous and is typically not done in research laboratories and not in FDA-approved GMP manufacturing facilities. The final PEG product is susceptible to air oxidation and must be stored with great care, in the dark and under inert atmosphere. In contrast, POZ is synthesized by ring opening polymerization of 2-ethyl 2-oxazoine or 2-methyl 2-oxazoline. These monomers are clear liquids, stable at ambient conditions, not explosive or toxic, are available from many sources at relatively low cost, readily purified and easily handled in the average chemical laboratory. Moreover, drug-POZ conjugates are not susceptible to air oxidation and can be stored at room temperature or in a refrigerator. Serina has not performed comparisons of PEG-conjugated molecules versus POZ-conjugated molecules in humans. However, Serina has made these comparisons in certain PEG-conjugated molecules versus POZ -conjugated molecules in vitro and in animal studies.
Non-immunogenic or reduced immunogenicity – in studies to date, POZ has not elicited an immune response or stimulated significant development of antibodies to POZ. Preclinical studies were conducted by Serina, where repeat dosing of POZ polymer in rabbits did not generate anti-POZ antibodies. Serina’s clinical trial of SER-214, a first example of POZ in humans, also showed no toxicity concerns.
Drug loading and release – POZ enables greater drug loading than PEG, with highly programmable drug release kinetics to enable continuous drug delivery. Drug loading with PEG is low and can occur only at the end of the polymer chains (n=1 or 2 copies of drug). Drug loading with POZ is high and is accomplished by attaching multiple drug copies (n= 10 or higher) to the side chain of the polymer back bone as shown in Figure 1 on page 258 and Figure 9 on page 270. The number of POZ attachment points can be controlled and appears to be unlimited. Higher drug loading per mole of polymer means that less amount of POZ polymer is required when compared to PEG polymer for delivery of the same amount of active drug. Programmable drug release kinetics was demonstrated in preclinical studies with the POZ-buprenorphine compound. Serina believes that the ease of working with POZ compared to PEG allows facile manipulation of release kinetics to achieve the desired properties. As examples of the advantageous release kinetics for POZ conjugates, SER-226 with the short linker releases drug more rapidly than SER-227 with the relatively longer linker, as shown in Figure 11 on page 272 . Use of similar linkages between PEG and attached small molecules such as rotigotine showed that PEG releases the drug within minutes.
No accumulation –studies to date indicate that POZ does not accumulate in tissues when given at dose levels anticipated to be given to humans, is not metabolized, and is cleared almost entirely through renal filtration. Preclinical IND-enabling studies in rodents and monkeys indicate that POZ is cleared from the body by renal filtration and as an intact polymer with no evidence of accumulation in any tissue. In contrast PEG is known to accumulate in several tissues including liver, spleen, muscle, brain and kidney.
Targeting – POZ offers multiple substitution sites, which allows for simultaneous attachment of several copies of a drug along with a targeting molecule. Multiple copies of drugs can be attached to a single POZ polymer backbone. The end of the POZ polymer chain has a different, orthogonal functional group from those along the backbone, and this property has been used to attach a targeting moiety such as an antibody or peptide.

 

Serina has not performed comparisons of PEG-conjugated molecules versus POZ-conjugated molecules in humans. However, Serina has made these comparisons in certain PEG-conjugated molecules versus POZ -conjugated molecules in vitro and in animal studies.

 

Serina’s business is largely focused on the development of a wholly-owned pipeline of POZ-enabled drug candidates for central nervous system (CNS) indications, including Parkinson’s disease, epilepsy, and pain. Serina’s lead product candidate, SER 252 (POZ-apomorphine), is a POZ conjugate of the potent dopamine agonist apomorphine being developed for the treatment of Parkinson’s disease and is in preclinical development. SER 252 is designed to provide CDS via a subcutaneous injection delivered one to two times per week. CDS is a long-sought clinical strategy for Parkinson’s disease that currently approved therapies fall short of delivering. Other POZ-conjugate candidates, including SER 227 (POZ-buprenorphine) for long-acting pain relief and SER 228 (POZ-cannabidiol) for epilepsy, are in preclinical development. We intend to develop other potential applications of the POZ technology, such as therapeutics delivered through ADCs and lipid-nanoparticle (LNP), through partnerships. Serina’s SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, was Serina’s first product candidate advanced into human study and has completed a Phase Ia study in 19 subjects. Serina intends to out-license this product candidate. Serina has not received FDA approval for any of its product candidates and its lead product candidate remains in pre-clinical development.

 

253

 

 

Serina is led by a management team with extensive experience in drug discovery, platform technologies, clinical development, general management, financing, and business development transactions. Serina’s team also has specific experience in developing polymer therapeutics, including at Shearwater Polymers, Inc. (Shearwater), a company founded by Serina Executive Chairman J. Milton Harris and Serina’s former Chief Scientific Officer Michael Bentley, where they developed the first-generation polymer technology based on PEG conjugation, a technology platform that has been licensed to develop a wide array of “PEGylated” drugs. Shearwater was acquired by Inhale Therapeutics in 2001. Inhale subsequently changed its name to Nektar Therapeutics, Inc. The PEG technology platform has resulted in thirty-two (32) FDA approved drugs.

 

The members of Serina’s senior management team are:

 

Serina’s Chief Executive Officer and director, Randall Moreadith, M.D, Ph.D., has more than 13 years of experience as a life sciences CEO and over 25 years in executive roles. Prior to joining Serina, Dr. Moreadith served as the Chief Development Officer at Nektar Therapeutics where he led a clinical and drug development program that successfully moved several drugs into clinical trials, including the launch of NKTR-102 into four clinical cancer indications and the out-licensing efforts for the approved drug Movantik®. He has served in executive roles at Cardium Therapeutics, Inc., Renovis, Inc. and was a co-founder of ThromboGenics, Ltd. (now Oxurion).
Serina’s Executive Chairman of the Serina Board and Co-Founder, J. Milton Harris, Ph.D., has more than 30 years of experience as a senior life sciences executive. Prior to founding Serina, he founded and was CEO of Shearwater. Shearwater successfully patented, manufactured, and partnered PEG technology that enabled multiple drug products including Neulasta® (Amgen) and Pegasys® (Roche). Dr. Harris has also served on the board of directors of HudsonAlpha Institute for Biotechnology since its founding in 2004.
Serina’s Chief Operating Officer, Tacey Viegas, Ph.D., has more than 30 years of pharmaceutical industry experience in drug discovery, delivery, and development. Prior to joining Serina, he previously worked at R.P. Scherer Corporation (now Catalent, Inc.), MDV Technologies, Inc., BioCryst Pharmaceuticals, Inc. and Shearwater. During his tenures at Shearwater and BioCryst, he was a co-inventor of nalexogol (Movantik®) and was involved in the early development of peramivir (Rapivab™).
Serina’s Chief Financial Officer and Board Director, Steve Ledger, has more than 30 years of experience in private capital and public company equity investment management as an investor and strategic advisor. He is a Managing Partner at Form & Fiction Ventures, a seed stage venture capital investment firm and a co-founder and director at Entourage Genomics, Inc., a bioinformatics software company.

 

In addition to its management team, Serina has engaged a board of scientific advisors to advise Serina on its drug development efforts and offer technical guidance to help shape Serina’s scientific and strategic direction. While there are no formal rules or procedures for Serina’s scientific advisory board, Serina’s scientific advisors hold meetings throughout the year where they interact with the appropriate members of the Serina management team in real-time, lending expertise and guidance as needed. The members of the scientific advisory board may receive equity and cash compensation pursuant to their respective consulting agreements with Serina.

 

254

 

 

Serina’s scientific advisory board members are:

 

C. Warren Olanow, MD., is Professor Emeritus in and former Chairman of the Department of Neurology and Department of Neurosciences at the Mount Sinai School of Medicine in New York. He has served on the board of directors of the National Space Biomedical Research Institute and the executive committee of the Michael J. Fox Foundation Scientific Advisory Board, and he is the former Chairman of the Scientific Advisory Board of the Bachmann-Strauss Dystonia & Parkinson Foundation. Dr. Olanow is the former Co-Editor-in-Chief of the journal, Movement Disorders. He has been principal investigator of numerous studies leading to approval of drugs and devices for treating neurodegenerative diseases.
William Schmidt, Ph.D., is President of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs. Dr. Schmidt has more than 30 years of experience in pain medicine pharmaceutical development. He is President and CEO of Catalina Pharma, part-time Senior Vice President of Global Clinical Development for Helixmith Inc., part-time Vice President of Clinical Development for EicOsis, LLC and Chief Medical Officer for Ensysce Biosciences.
Gaurav Sahay., Ph.D., is a professor in the Department of Pharmaceutical Sciences and co-Director for the Center of Innovative Drug Delivery and Imaging (CIDDI), at the College of Pharmacy at Oregon State University. Dr. Sahay’s lab is developing novel nanotechnology-based platforms including lipid-based nanoparticles for effective delivery of messenger RNA therapeutics for treatment of cystic fibrosis, retinal degeneration and against SARS-CoV2. He has more than 60-peer-reviewed publications in top tier journals including Science Advances, Nature, Nature Communications, Nature Biotechnology, Nature Nanotechnology, Journal of Controlled Release, and Nano Letters.

 

255

 

 

Serina’s Development Pipeline

 

We believe that Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Among our development candidates, Serina intends to internally advance SER 252 for advanced Parkison’s disease and SER 227 for long-acting pain relief. Serina will not advance SER 214 internally and will seek to partner on any further development of this candidate. Serina is evaluating whether to internally advance SER 228 or to partner this candidate. Serina does not believe it will require a license to the active pharmaceutical ingredient associated with SER 214, SER 227, SER 228 or SER 252. Serina is advancing its research and development efforts for POZ technology in lipid nanoparticle delivered ribonucleic acid (RNA) vaccines for infectious diseases. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements. These applications may include other CNS disorders and POZ LNP disease fields. Serina has not received FDA approval for any of its product candidates and its lead product candidate remains in pre-clinical development.

 


 

1. SER 214 will not be advanced internally. Serina will seek to partner on any further clinical development. Serina retained consultants to aid in identifying partners who might be looking for an asset in the Parkinson’s disease space that had completed early studies in humans. From 2018 to 2022, Serina held discussions with potential partners for SER-214. The prospective partners evaluated SER-214 under confidentiality agreements. Over that time period the commercial market for the Neupro patch (transdermal rotigotine) changed substantially. UCB S.A., which markets the Neupro patch worldwide, stopped aggressively marketing the patch in the U.S. but continued to market it outside of the U.S. at a much lower daily cost of use. The declining market presence in the U.S., and the lowering of daily price for a rotigotine alternative outside of the U.S., essentially limited the licensing opportunities to a partner who would advance it in the U.S. only. Serina, to date, has not found a suitable partner but continues to entertain SER-214 as an out licensing opportunity.

 

2. SER 252 IND-enabling preclinical studies were initiated August 2023 and are anticipated to be completed in the third quarter of 2024. Serina intends to advance SER 252 into Phase I clinical trials in 2025 for patients with advanced Parkinson’s disease.

 

3. SER 227 has completed IND-enabling preclinical studies and is currently evaluating the design of a Phase I clinical trial to present to the FDA in the first quarter of 2024. Prospective timing on the start of a Phase I study is late 2024 to early 2025 time period, subject to raising additional capital (in addition to any proceeds expected to be received from Juvenescence through the exercise of post-merger warrants).

 

4. SER 228 has not yet initiated IND-enabling preclinical studies. Serina anticipates advancing this candidate into IND-enabling studies in 2024, subject to raising additional capital (in addition to any proceeds expected to be received from Juvenescence through the exercise of post-merger warrants).

 

Serina’s Strategy

 

Serina’s strategy is to develop and commercialize polymer therapeutics based on conjugation of suitable small molecules to our proprietary POZ. While prior polymer technologies such as PEG focused primarily on protein conjugation, Serina envisioned the need to develop a polymer therapeutics platform that could address the vast universe of small molecules and program their release. Serina has demonstrated in multiple preclinical animal studies that POZ can program the release of small molecules, particularly those that have solubility challenges and PK limitations. Serina believes that specific POZ conjugated small molecules can be delivered continuously following a single injection. As a “platform technology,” Serina anticipates this technology has the potential for development of drug candidates across a broad range of payloads and indications. Serina intends to focus on its current pipeline of candidates and selectively explore new molecules for potential internal development. In parallel, Serina intends to expand its collaboration activity with prospective partners that have compounds that could potentially benefit from the Serina POZ polymer platform technology. To achieve this, Serina intends to:

 

Advance its lead program, SER 252, which addresses a large unmet need for continuous dopaminergic stimulation for late stage Parkinson’s patients;
Develop its other CNS product candidates, SER 227 for long-acting pain relief, and SER 228 for treatment refractory epilepsy;
Seek to create economic and strategic value through POZ LNP licensing and partnerships across multiple RNA-based therapeutic indications;
Seek to create economic and strategic value for other applications of the POZ platform, including ADCs;
Continue to expand upon applications of the POZ platform with a view to capitalize on the potential of the technology to enable additional payloads and product opportunities; and
Continue to expand a network of academic and biopharmaceutical collaborations and commercial partnerships to develop and potentially validate other applications of the POZ platform.

 

256

 

 

Company and POZ Development Background

 

Over the past 25 years, chemical attachment of water-soluble polymers, in particular, polyethylene glycol, to drugs has become a valuable technique for improving the properties of pharmaceuticals. This technique has been successfully employed in producing second-generation forms of several FDA-approved drugs.

 

A polymer drug delivery approach involves using polymers, which are large molecules composed of repeating subunits, to design drug delivery systems that can control the release of medications in a controlled and targeted manner. Polymer-based drug delivery systems can enhance the therapeutic outcomes of drugs by optimizing their PKs, improving patient compliance, and reducing side effects. Some key aspects of polymer drug delivery are as follows:

 

Controlled Release: Polymers can be engineered to release drugs at a controlled and predetermined rate. This enables sustained drug levels in the body, reducing the need for frequent dosing and maintaining therapeutic concentrations over an extended period.
Targeted Delivery: Polymer drug delivery systems can be designed to target specific tissues, cells, or organs with a high concentration of the drug while minimizing systemic exposure. This precision targeting reduces the exposure of healthy tissues to the drug, minimizes side effects, and increases the drug’s effectiveness.
Improved Bioavailability: Some drugs have low solubility or stability in the body, limiting their absorption and therapeutic efficacy. Polymers can be used to improve the solubility and stability of such drugs, allowing for better bioavailability.
Protection of Labile Drugs: Polymers can protect labile or sensitive drugs from degradation in the harsh conditions of the gastrointestinal tract, allowing for oral delivery of drugs that would otherwise be ineffective when taken orally.
Reduced Toxicity: Polymer encapsulation can help reduce the toxicity of certain drugs by controlling their release and preventing peak concentrations that can lead to adverse effects.
Long-Acting Formulations: Polymer-based formulations can extend the duration of drug action, reducing the frequency of administration. This is particularly useful for chronic conditions where adherence to treatment is crucial.
Biodegradable Polymers: Some polymer drug delivery systems are made from biodegradable materials that gradually break down in the body, eliminating the need for removal or extraction of delivery devices.

 

Common polymer-based drug delivery systems include:

 

Microspheres and nanoparticles: Tiny particles made from biocompatible polymers that encapsulate and release drugs.
Hydrogels: Cross-linked polymer networks that can hold a large amount of water and release drugs in response to environmental cues.
Implants: Solid polymer devices that can be surgically implanted for long-term drug delivery.
Liposomes: Lipid-based vesicles that can encapsulate drugs and deliver them to specific sites.

 

257

 

 

Polymer drug delivery approaches offer versatility and customization, allowing for the design of drug delivery systems tailored to the specific needs of a drug and its intended therapeutic application. These approaches have the potential to enhance the safety and efficacy of medications while improving patient compliance and convenience.

 

Serina was formed with the goal of inventing a polymer that was distinct from PEG that could be used for modification of drugs. Research at Serina over the past fifteen years has led to the development of a new polymer technology based on poly(2-ethyl-2-oxazoline). Serina’s POZ technology is designed to be a “platform technology” in that Serina anticipates that other products can be developed using the same basic polymer.

 

Serina was first to develop and patent methods to produce polymers of POZ suitable for pharmaceutical applications. For the purposes of illustration, a simple form of POZ with ethyl side chains (pendent groups) and a carboxylic acid end group is shown below (note that in this structure the number of repeating units can be several hundred, with the individual units coming one after another):

 

 

Figure 1: Illustration of POZ with ethyl pendent groups and carboxylic acid end group

 

Figure 1: SER 214 Schematic representation of POZ-rotigotine. Rotigotine is attached to a 20 kDa pendent POZ polymer employing copper-catalyzed “click chemistry.” Each molecule of SER 214 contains approximately ten pendent rotigotine molecules.

 

During the synthesis of polymers of POZ, the expanding polymer incorporates a pendent 2-ethy-2-oxazoline pentynyl group. This pendent alkyne is capable of undergoing quantitative “click chemistry” with an azide to form a stable triazole ring structure. Click chemistry is an industry standard quantitative method for the efficient coupling of two molecules. The drug(s) of interest, in this case rotigotine, undergoes attachment of an azide-linker to a suitable chemical handle on the molecule. Rotigotine is a dopamine agonist and is the active drug ingredient in SER 214. All of the product candidates in our pipeline have a phenolic hydroxyl to which a variety of linkers may be attached depending on the nature of chemical release we desire. Cleavable linkers are designed to connect two molecular entities, and when exposed to the appropriate trigger (such as changes in pH, enzymatic activity), they undergo a chemical reaction that leads to the release of the linked components. Enzymatic activity requires water at biological pH. For example, SER 214 contains a 3-propionate linker that attaches rotigotine to the polymer backbone. The attachment of the linker to the hydroxyl group in these product candidates forms a stable ester linkage. Stable linkers are commonly used in various chemical and biological applications where the goal is to maintain the structural integrity and stability of the linked molecules. Serina believes that there is a single esterase activity in humans (and monkeys) in the vascular compartment that cleaves the ester thereby continuously releasing the attached drug. This enzyme is known as butyrylcholinesterase. When the drug is injected subcutaneously, the lymphatics clear the injection and eventually the drug finds its way to the vascular compartment. If the polymer has an extended circulation half-life in the body, the enzyme will continuously cleave the attached drug based on the PKs of the polymer conjugate in the circulation. Serina has empirically determined that a 20 kD polymer of POZ provides a one-week circulation time in both monkeys and humans.

 

258

 

 

Serina scientists have been able to engineer the foundational chemistry in the simple POZ structure in Figure 1 shown above to replace some of the pendent ethyl groups with reactive pendent acetylene groups. These reactive groups are used to attach drugs via linkages that can be programmed to provide controlled release of the drug. Serina scientists use “click chemistry,” which is a facile and quantitative method for attachment of azide-containing linker/drug conjugates to pendent acetylenes within POZ polymers. Serina’s first clinical drug candidate, SER 214, contains a POZ polymer backbone with multiple pendent groups to which are attached the potent dopamine agonist rotigotine.

 

Serina developed the idea of attaching rotigotine to POZ to develop a drug that would provide continuous dopaminergic stimulation in Parkinson’s disease patients who are responsive to dopamine agonists. Experimental studies in animals and humans suggest that CDS may prevent some of the adverse side effects of taking other dopamine agonists such as levodopa, which include “wearing off” and levodopa induced dyskinesias (LIDs). Based on preclinical studies using the industry standard monkey model of Parkinson’s disease, Serina progressed the development of SER 214, including completing the necessary basic science to design and create SER 214, obtaining the issuance of two key patents in 2013 that cover SER 214 composition of matter and use, advancing SER 214 through initial proof-of-concept in animal models (rat and monkey) of Parkinsonism, and receiving IND approval from the FDA in 2015.

 

Serina completed a successful SER 214 Phase Ia clinical study in 19 subjects in July 2017. For additional information on the SER 214 Phase Ia clinical study, see the section titled “Description of Serina’s Business— SER 214 – Provides Continuous Release of Rotigotine Following a Single Weekly Subcutaneous Injection in Parkinson’s Disease Patients with Early Stable Disease” beginning on page 263 of this proxy statement/prospectus/information statement. Through the development of SER 214, Serina demonstrated the applicability of the POZ platform to an indication with an unmet need and significant commercial potential, advancing into humans a drug designed to provide continuous dopaminergic stimulation to treat Parkinson’s disease and restless legs syndrome. SER 214 set the stage for Serina to pursue other molecules having the appropriate chemical handle for attachment and release from the POZ polymer.

 

In September 2015, Serina entered into an agreement with AbbVie Inc. for research and development efforts to create high drug to antibody ratio (DAR) ADCs. Serina’s POZ polymer technology allows for the attachment of multiple copies of a toxin to a single polymer, and then that POZ toxin is attached to multiple sites on the antibody. Serina believes that this approach has the potential to create POZ polymer ADCs with DARs well above the standard technology approach of approximately 2-4 toxins per antibody. Serina believes that this approach may be particularly useful in targeting antigens on the surface of cancers that are in low abundance (less than 10,000 copies per cell) and this may produce a greater chance of killing the targeted cancer. In January 2018, the collaboration was terminated when the companies could not reach agreeable terms to continue the studies. With limited resources to support POZ ADC development internally, this application of the POZ platform was not actively advanced. Serina is currently not pursuing the preclinical study of the POZ ADC application internally and is seeking to advance the program with partners. Serina believes that POZ ADC technology continues to have promising potential and that ADCs represent one of the most promising areas of cancer research today. There are 12 FDA-approved ADCs, with over 170 novel ADCs in the clinical stage of development.

 

259

 

 

In June 2020, Serina and Jazz Pharmaceuticals, Ltd. (Jazz) entered into an exclusive license agreement for polymer conjugates of cannabidiol, specifically Serina product candidates SER 228 and SER 229. The agreement granted Jazz exclusive rights to certain intellectual property, know-how, and proprietary technologies. The licensing agreement included a one-time upfront payment, milestone payments payable to Serina upon the achievement of specific development, regulatory, and commercial milestones, and a royalty on net sales of products incorporating the licensed technology. In July 2021, the collaboration and license agreement was terminated after Jazz acquired GW Pharmaceuticals, Inc. (GW) and its FDA approved drug Epidiolex®, a cannabidiol based drug, and the GW pipeline of cannabinoid product candidates.

 

In October 2023, Serina entered into a non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug delivery formulations. The agreement grants Pfizer non-exclusive rights to certain intellectual property, know-how, and proprietary technologies. Under the terms of the agreement, Pfizer is authorized to develop, manufacture, market, and commercialize products incorporating the licensed technology with respect to a specific POZ polymer structure in one field. The agreement outlines the protection and enforcement of intellectual property rights related to the licensed technology. Pfizer is obligated to use commercially reasonable diligent efforts to develop and commercialize licensed products, and to use such efforts to accomplish specified development and commercial objectives. The agreement includes a one-time upfront payment of $3 million that was received on December 15, 2023, milestone payments payable to Serina upon the achievement of specific development, regulatory, and commercial milestones, and a royalty on net sales of products incorporating the licensed technology in accordance with the terms outlined in the license agreement. The range of royalties on sales of products is between 2.75% – 3.5% and is tiered to achievement of certain sales milestones.

 

Serina’s Product Candidates

 

Serina intends to focus on its current pipeline of wholly-owned candidates and selectively explore new molecules for potential internal development, co-development and partnering. Current candidates include:

 

SER 214 (POZ-rotigotine) is the first product from Serina’s pipeline to be advanced into humans. Serina initiated a Phase Ia trial July 2015 in 19 stably treated Parkinson’s subjects. The trial was completed in January 2017 with data published in a June 2020 article in Movement Disorders. This was a single and multi-dose, dose-escalation study in patients who were not experiencing significant motor fluctuations. Patients in the study were allowed to be on existing therapy for Parkinson’s disease, or be on no therapy, but have a definitive diagnosis of Parkinson’s disease. Serina has not internally advanced SER 214 beyond Phase Ia and will seek to partner on any further development. Serina believes the SER 214 program, while not being advanced internally, provided data important to the development of a POZ dopamine agonist (such as rotigotine and apomorphine) conjugate to enable CDS in Parkinson’s patients. This research led to the development of SER 252.

 

SER 252 (POZ-apomorphine) has entered IND-enabling preclinical studies. Preclinical studies were initiated in August 2023 and are anticipated to be completed in the third quarter of 2024. Serina intends to advance SER 252 into Phase I clinical trials in 2025 for patients with advanced Parkinson’s disease. The treatment of advanced Parkinson’s disease relies on multiple therapies, including levodopa (L-DOPA), compounds that inhibit the breakdown of L-DOPA in the brain (catechol-O-methyl transferase, or COMT; for example, opicopone), dopamine agonists (transdermal rotigotine; for example, NeuproTM) and others. L-DOPA in escalating doses is the mainstay of therapy for advanced Parkinson’s Disease but is also the proximate cause of levodopa-induced dyskinesias (LIDS), one of the most troubling complications of prolonged high dose L-DOPA therapy. Approximately 90% of Parkinson’s disease patients who use L-DOPA for ten years will develop irreversible LIDS. An infusion therapy known as Apo-go (apomorphine) is available in the European Union, or EU, but is not yet available in the United States. Apo-go must be administered as a 12–16-hour continuous infusion through an electronic pump and a standard insulin infusion set. While effective in reducing daily “OFF” time, and simultaneously increasing daily “ON” time without troublesome dyskinesia, its use frequently requires a healthcare provider to hook up the device and infusion each day and remove it at night. “OFF” time refers to the time period the patient is unable to perform routine daily activities. “ON” time refers to those periods where the patient is able to perform routine daily activities. Apo-go is confounded by significant skin reactions in approximately 40% of patients, often leading to permanent scarring (nodules) on the abdomen. Serina’s preclinical studies in monkeys suggest SER 252 may be administered as a single subcutaneous injection twice a week, provides continuous delivery of apomorphine and has no skin liabilities. Its use is designed to be administered in the convenience of the patient’s home without the need for a healthcare provider. Serina believes that SER 252 may allow some patients to titrate completely off L-DOPA, thus simultaneously addressing the LIDS that is associated with its prolonged use.

 

260

 

 

SER 227 (POZ-buprenorphine) has completed IND-enabling preclinical studies. Subject to raising additional capital (in addition to any proceeds expected to be received from Juvenescence through the exercise of post-merger warrants), Serina intends to advance SER 227 into Phase Ia SAD trial in normal volunteers in 2024 to support its eventual use in the treatment of post-operative pain, a strategy that will simultaneously provide analgesia and target the initial gateway to use of potential addictive opioids in the immediate post-operative period. The opioid crisis in the United States claimed approximately 80,000 lives in 2022. Patients who are administered a prescription for an opioid following either major or minor surgery are fifteen times more likely to transition to chronic use of an opioid within 90-180 days than those who do not fill a prescription. SER 227 is designed to provide immediate and sustained release of buprenorphine following a single subcutaneous injection at the time of surgery, with the intended effect of providing immediate analgesia by the time the patient is in the recovery room. The sustained release kinetics for approximately eight days may prevent abuse of an opioid in the event patients take them.

 

SER 228 (POZ-cannabidiol) has completed early dose-ranging preclinical studies in rats and monkeys and expects to enter IND-enabling preclinical studies in 2024, subject to raising additional capital (in addition to any proceeds expected to be received from Juvenescence through the exercise of post-merger warrants). If the IND-enabling preclinical studies are successfully completed in 2024, and if Serina has sufficient funding, Serina intends to advance SER 228 into a Phase Ia trial in children with refractory epilepsy in 2025. The treatment of childhood epilepsy remains a pressing challenge. CBD, a compound found in Cannabis, has been shown to be an effective treatment for refractory epilepsy (approved product Epidiolex®, developed by GW Pharmaceuticals and acquired by Jazz Pharmaceuticals). Epidiolex® is a sesame seed oil preparation that must be taken twice daily at high doses (20 mg/kg) and is associated with high first-pass metabolism, low oral bioavailability, and diarrhea. Serina is developing SER 228 as a single weekly subcutaneous injection that is predicted to cover the PK profile of twice daily Epidiolex®.

 

Serina’s POZ platform is designed as an enabling technology for the development of multiple cannabinoids, all of which have limited PK profiles and solubility issues. Cannabis contains over 100 cannabinoid compounds and some of these compounds have already shown promise in preclinical studies in animals. The cannabinoid compounds appear to be constrained by limited PK, low oral bioavailability and high first pass metabolism. Serina has attached cannabidivarin (CBDV), tetrahydrocannabinol (THC), cannabigerol (CBG) and cannabichromene (CBC) to POZ polymers and early preclinical studies suggest they can be delivered as single weekly subcutaneous injections to provide continuous drug delivery. The spectrum of potential clinical applications of POZ-cannabinoids include some of the most challenging disorders in neuroscience such as autism spectrum disorder (CBDV), Huntington’s disease and neuroprotection (CBG), chemotherapy-induced nausea, vomiting and spasticity in multiple sclerosis (THC) and traumatic brain injury, and inflammatory diseases (CBC). Serina believes that POZ technology is an enabling technology platform for many of the cannabinoids that may be found to have therapeutic potential in humans.

 

POZ-lipids. Serina is advancing pre-clinical research focused on POZ-lipids as a non-immunogenic (or markedly reduced immunogenic) alternative to the PEG-lipids in the lipid nanoparticles (LNP) currently approved for the Covid-19 vaccines developed by Pfizer/BioNTech and Moderna. Both of the currently approved vaccines contain 1-2 mol% PEG-lipid, which is required to stabilize the LNP and prevent fusion of nascent particles. Serina has prepared LNPs from POZ-lipids and demonstrated these can stably incorporate oligonucleotides and transfect cell lines. Serina believes that it is likely that the global population is being progressively immunized against PEG due to the presence of PEG-lipids in the currently approved vaccines, combined with upwards of 70% of the population already having some level of anti-PEG antibodies. PEG is used at low molecular weights in a wide range of consumer products including cosmetics, toothpaste, deodorants, and laxatives. Anti-PEG antibodies are implicated in some of the serious adverse reactions such as anaphylactic reactions seen following the Covid-19 vaccine administration. Most infectious disease experts believe that Covid-19 will become an endemic challenge and that booster immunizations will be required. Serina believes that the anti-PEG antibody issue potentially has the unintended consequence of compromising the efficacy of the next generation of vaccines due to accelerated blood clearance. Serina has entered into preclinical feasibility studies with two major pharmaceutical companies toward the goal of developing “PEG-alternative” LNP vaccines for infectious diseases. The LNP delivered RNA therapeutics field represents one of the most promising areas of drug development, with over 1,200 LNP delivered RNA-based therapeutics in development. Serina’s intent is to license the POZ technology to companies developing LNP approaches in infectious diseases, cancer immunology, and gene therapy.

 

Serina has not received FDA approval for any of its product candidates and its lead product candidate remains in pre-clinical development.

 

261

 

 

Parkinson’s Disease

 

Parkinson’s disease is a chronic, disabling disorder that results from a deficiency of dopamine in the brain. Dopamine deficiency results from a degeneration of dopaminergic neurons in a portion of the brain known as the substantia nigra. Treatment for Parkinson’s disease has focused on mechanisms for delivery of dopamine precursors (levodopa, which can be delivered by daily pills or intestinal infusion), or on mechanisms that delay or prevent the breakdown of dopamine in the brain. The majority of patients who are diagnosed with Parkinson’s disease are treated with oral formulations of levodopa that include carbidopa, a compound that inhibits the breakdown of levodopa. Other approaches include selective inhibitors of monoamine oxidase enzymes in the brain (MAO-B), or dopamine agonists, such as rotigotine (the active ingredient in the transdermal patch NeuproTM), ropinirole or pramepexole. In almost all instances of oral treatment with any of these compounds, patients may experience “wearing off” where the drug fails to deliver an adequate dopaminergic stimulus after being used for months to years or the drugs may promote a disabling side effect known as dyskinesia (involuntary movements of the extremities). Serina believes that there is a major need for new therapies that can treat patients with Parkinson’s disease, extend their productive years, and ameliorate these unwanted side effects.

 

In recent years, the clinical strategy of continuous dopaminergic stimulation has been advanced in both animal and human studies. Most oral drugs, including the transdermal patch Neupro, deliver dopaminergic stimulation in a phasic peak and trough fashion. Animal studies show that such phasic alterations in dopaminergic tone may result in accelerated degeneration of dopaminergic neurons in the brain, and lead to motor complications known as dyskinesia. A preclinical animal study where one group of naïve MPTP monkeys received an apomorphine rod implant capable of providing continuous deliver of apomorphine and another group received an intermittent injection of apomorphine every 8 hours indicated that continuous delivery of apomorphine via the rod implant prevented any motor complications in MPTP monkeys, whereas intermittent apomorphine injections led to dyskinesis development within 2 days. These results underscore the challenge of treating Parkinson’s disease patients with intermittent stimulation. Preclinical animal studies also suggest that continuous delivery of apomorphine appears to delay the degeneration of dopaminergic neurons in the brains of affected animals, thus delaying some of the side effects of dopaminergic therapy as well as the onset of late-stage Parkinsonism. In a double-blind, double-dummy study in humans employing an intestinal infusion of levodopa-carbidopa gel (LCIG) in advanced Parkinson’s patients, continuous intestinal infusion of levodopa gel was shown to be superior in outcomes to oral, sustained release levodopa-carbidopa capsules. The results showed that an intestinal infusion of levodopa-carbidopa gel in the proximal small intestine (delivered by a percutaneous catheter) increased patients’ “ON” time without troublesome dyskinesia by approximately two hours per day, and decreased “OFF” time by the same amount. The approach has been approved by the FDA (AbbVie, Duodopa). This represented a substantial new treatment option for advanced Parkinson’s disease patients. Notwithstanding the significant increase in patient clinical outcomes in advanced Parkinson’s patients, the approach is invasive, requires surgery to place a percutaneous catheter (with risk of infection, perforation of the intestine or inadvertent removal), frequent loading of levodopa-carbidopa gel packs, and frequent flushing to keep the catheter flowing.

 

262

 

 

Serina’s POZ technology platform has attributes that Serina believes has the potential to allow POZ-conjugates to deliver on the approach of prolonging the PKs of attached drugs, thus enabling continuous drug delivery. The potent dopamine agonist rotigotine is attached to pendent POZ with programmable linkers that allow the rotigotine to be released slowly, following a single subcutaneous injection of SER 214 in a standard insulin syringe. Preclinical animal studies in rats and monkeys have shown that SER 214 appears to provide a continuous state of dopaminergic tone for approximately one week following a single subcutaneous injection. Repeat-dose preclinical studies in rats (12 weeks), dogs (single dose maximum tolerated dose study) and monkeys (results of a 4-week study, plus the 90-day study in cynomolgus macaques that was part of the IND toxicology program) show the week-to-week variation in plasma release of rotigotine (plasma half-life) and drug exposure do not change dramatically following a single subcutaneous injection each week.

 

SER 214 – Provides Continuous Release of Rotigotine Following a Single Weekly Subcutaneous Injection in Parkinson’s Disease Patients with Early Stable Disease

 

SER 214 is the first product from Serina’s pipeline to be advanced into humans and has completed the Phase Ia study in 19 subjects. The Phase Ia study demonstrated SER 214 was well-tolerated when delivered in a standard insulin syringe. The data for the final two weeks of Cohort 3 (high dose cohort) are shown in Figure 3. Subjects received an initial dose in week one of 50 mg SER 214, followed by a single dose of 100 mg SER 214 in week two, and then followed by a single 200 mg dose of SER 214 in weeks three and four. This dosing was followed by a one-week wash-out period. The SER 214 Phase Ia study was not designed with a placebo arm, and therefore statistical analysis of the observed data does not have p-values. SER 214 demonstrated predictable PK that paralleled the PK results observed in pre-clinical studies in monkeys. The results of the PK for released drug (rotigotine) are shown below, along with the published data for the 3 mg transdermal rotigotine patch.

 

Figure 2: Pharmacokinetic profile of SER 214 in Parkinson’s disease subjects in Phase Ia

 


 

Figure 2: PK profile of released drug in Parkinson’s disease subjects who received an initial dose of 50 mg SER 214, followed by a single dose of 100 mg SER 214, and then two weekly doses of 200 mg SER 214. Levels of released drug (rotigotine) are indicated in ng/ml. The yellow shaded area is the therapeutic window for rotigotine. Also shown in green is a 24-hour period for plasma levels of rotigotine from the 3 mg NeuproÔ patch (UCB, published data). From the data, it would appear a weekly injection of SER 214 of 200 mg (in 1 mL) approximates the levels of rotigotine from the daily 3 mg transdermal patch.

 

263

 

 

The results in Figure 2 show that a single weekly injection of SER 214 provided continuous drug delivery in the predicted therapeutic window where plasma levels of rotigotine would be expected to provide control of symptoms of early Parkinson’s (yellow shaded area). The 200 mg dose of SER 214 provided plasma levels of rotigotine that are approximately the same as the 3 mg Neupro™ patch but did so for an entire week. In data not shown, plasma levels of released rotigotine fell below detectable levels approximately nine days after the final injection, indicating that released rotigotine is released at a near steady-state level for an entire week following a single weekly subcutaneous injection.

 

The Phase Ia study also measured the potential for efficacy, which relies on a change from baseline in the Unified Parkinson’s Disease Rating Score (UPDRS). One component of the UPDRS measures the change in motor scores; this is known as UPDRS (Part III) and is measured by the physician who evaluates if there is a change in scores when the patient returns to the clinic for follow-up. A change from baseline of negative scores indicates improvement and the FDA has used UPDRS (Part III) as part of an approvable endpoint. In Cohort 3, subjects had a mean change from baseline of approximately - 6 at day 28 – indicating that SER 214 may be improving their signs and/or symptoms of Parkinson’s disease. There appeared to be a dose-dependent change from baseline as the doses were increased. This is shown in Figure 3 below.

 

Figure 3:

 

 

Figure 3: Effect of dose of SER 214 on change from baseline in UPDRS (Part III)

 

Subjects who completed the final two weeks of dosing were shown to be at steady-state release. The plot above shows the relationship between dose and change from baseline in UPDRS (Part III). At the highest dose evaluated (200 mg) there was an approximate -6 point change in UPDRS. When extrapolated to a 400 mg dose, which would approximate the 6 mg Neupro™ patch in terms of released rotigotine, there would be an estimated -13 point change in UPDRS (Part III). Serina believes such a degree of change would achieve an approvable endpoint. The extrapolated data was not an actual result of the study and there can be no assurance that this result is able to be achieved. The method of extrapolation is industry standard based on a near linear relationship (shown in figure as linear r2 = 0.88) with the data from the actual study.

 

264

 

 

The relationship between dose and steady-state PK levels of released rotigotine revealed a linear relationship as shown in Figure 4. Extrapolation of the dose of SER 214 to higher doses of 400-600 mg is predicted to result in steady-state levels of rotigotine equivalent to the 6 mg and 8 mg Neupro patch. Such higher doses would require a device to deliver the higher volumes (2-3 mL).

 

Figure 4:

 

 

Figure 4: Relationship between dose of SER 214 administered in the last two weeks of dosing in the 50 mg, 100 mg and 200 mg cohorts and mean (+/- SD) steady-state levels of released rotigotine.

 

The primary safety endpoint for the SER 214 Phase Ia study was adverse events. There were no deaths or serious adverse events during the study. One subject in cohort 2 discontinued because of the development of generalized hives shortly after the 50-mg injection of SER 214. These rapidly cleared with administration of a single antihistamine dose and were not associated with any additional systemic complaints. All adverse events were mild to moderate in intensity, and all recovered by the end of the study. There was no apparent dose relationship, and no patient experienced new onset or worsening of dyskinesia.

 

In summary, the Phase Ia study demonstrated SER 214 is well-tolerated injection when administered subcutaneously in stable patients with early signs of Parkinson’s disease. Steady-state levels of released rotigotine were linear with dose, and physician assessment of UPDRS (Part III) suggested evidence of a dose-dependent decline from baseline - even in these stably treated patients. Serina believes that SER 214 is a promising product candidate that may be used to treat patients with early Parkinson’s disease, and market research suggests patients and physicians would readily use this approach at home without the need for an office visit or home health care professional. In June 2020, the results of the Phase Ia trial were published in Movement Disorders. Serina has not internally advanced SER 214 beyond Phase Ia and will seek to partner on any further development.

 

SER 252 (POZ-apomorphine) – Addressing the Need for a Potent Dopamine Agonist to Treat Advanced Parkinson’s disease

 

Serina believes that the same polymer chemistry used in SER 214 to provide continuous delivery of rotigotine might be used to provide continuous release of other drugs that would be effective in advanced PD. One such drug is apomorphine, one of the most potent dopamine agonists known and the one most closely aligned chemically with the natural substance in the brain (dopamine). Apomorphine is approved as a “rescue” medication that is delivered as an injection (Apokyn injection) analogous to an epinephrine injection for acute anaphylaxis. In Europe and some other parts of the world, there is an approved liquid formulation called Apo-go (Britannia Pharmaceuticals, not yet approved in the United States). In PD patients who develop severe “OFF” periods as a result of advancing disease associated with the “wearing off” of their medications, an Apokyn injection can promote “ON” periods within a few minutes. Many patients carry an Apokyn injection pen as a precaution for abrupt “OFF” periods. In contrast, Apo-go can be administered via an electronic pump as a daily subcutaneous infusion 12-16 hours a day. In July 2018, the first randomized, placebo-controlled study of Apo-go versus placebo was published (known as the TOLEDO study). The results showed that daily subcutaneous delivery of apomorphine for 12-16 hours during the waking day resulted in a significant reduction of daily “OFF” time of approximately 2 hours.

 

265

 

 

While Apo-go resulted in a substantial improvement in “OFF” time, the subcutaneous route of administration is confounded by severe skin reactions. An example of these types of skin reactions is shown in Figure 5.

 

Figure 5: Skin reactions from subcutaneous Apo-go administration

 

 

Figure 5: A patient with advanced Parkinson’s disease who uses daily subcutaneous infusions of Apo-Go to reduce “OFF” time. Subcutaneous delivery of apomorphine resulted in ulceration of the skin with draining abscesses, and in rare instances, skin necrosis.

 

In the TOLEDO study, approximately 60% of subjects dose-adjusted their daily infusions of Apo-go downward based on skin reactions, and about 40% of patients experienced nodule formation. Nodules that result from subcutaneous apomorphine generally do not resolve.

 

While Apo-go represents a non-surgical approach to treatment of advanced disease in PD patients and provides the same degree of improvement in “OFF” time as the LCIG catheter and deep brain stimulation (DBS), many patients do not tolerate the daily subcutaneous infusions. The daily set-up often requires a healthcare provider to come in each day to help the patient administer the drug. Serina believes that development of a more convenient method of delivering apomorphine, without having to use a complicated infusion device or confounded by serious skin reactions, would be a major contribution to patient care.

 

SER 252 (POZ-apomorphine)

 

In early 2018, Serina initiated work on developing a polymer conjugate of apomorphine that could be delivered as a subcutaneous injection that is devoid of any skin reactions. The first step was attachment of apomorphine to the polymer. The chemistry of attachment and controlled release required attachment of ester-linked groups to both of the hydroxyl groups in apomorphine; one ester linkage attaches the apomorphine to the polymer backbone (linking group) and the other ester linkage caps the second hydroxyl (capping group). In the course of these studies, Serina discovered that the rate-limiting step in the release of apomorphine from the polymer was the release of the “capping linker.” After three and a half years of dedicated efforts to control the release kinetics of apomorphine, Serina identified SER 252 as the IND candidate. Importantly, SER 252 provides linear dose kinetics when administered in preclinical multi-dose studies in monkeys as shown in Figure 6 below.

 

266

 

 
Figure 6: Dose response of SER 252 in monkeys

 

 

Figure 6: Young adult monkeys were dosed subcutaneous with SER 252 semi-weekly (n=4) at three different dose levels (1.5 mg equivalents Apo/kg, 4.5 mg equivalents Apo/kg and 15 mg equivalents Apo/kg) and daily levels of released apomorphine were determined. The AUC (area under the curve) for each set of doses was plotted versus dose administered.

 

PK Simulations for SER 252 in Patients with Advanced Disease

 

Although studies in humans are required for confirmation, Serina conducted a simulation of human PK based on the results from its preclinical studies in monkeys. The PK parameters of SER 252 in monkeys were modeled with a standard one-compartment fit of the data with V/F (volume of distribution) derived from imputed data from NeuroDerm, Ltd. published human PK on ND0701, an apomorphine product being developed by NeuroDerm; the V/F was 13 L/kg. The following results, which represent industry standard methodology for simulation, were obtained:

 
Figure 7:

 

 

Figure 7: Simulations for human PK. The simulation demonstrated that doses from 0.25 mg eq Apo/kg to 1 mg eq Apo/kg would cover the PK profile of Apo-go and provide a range of doses that Serina intends to evaluate in early studies in humans.

 

267

 

 

There can be no assurance that the simulated result is able to be achieved. Serina believes these simulations suggest it may be possible to dose patients with advanced PD with a subcutaneous injection that would provide levels of released apomorphine similar to the Apo-go infusion pump (a) without a trough level that would lead to an “OFF” period, (b) no need to have a healthcare provider hook up the device each day, and (c) no onerous skin reactions. Serina believes that the requisite trough level is likely in the range of about 3-5 ng/mL free apomorphine; plasma levels of apomorphine that “rescue” an acute “OFF” period about 4-5 ng/mL and persist for approximately 50 minutes (data from Cynapsus/Sunovion publications on development of a buccal apomorphine). The range of doses employed in an individual patient will likely vary, but the doses envisioned may potentially treat advanced disease and provide consistent “ON” time without troublesome dyskinesia and prevent the patient going into an “OFF” state. In multiple experiments in monkeys, SER 252 has not led to any skin reactions as a single or multi-dose regimen to date. Serina believes that it may be possible that this product candidate can be delivered in the patient’s home without the need for a healthcare provider.

 

Serina has initiated IND-enabling preclinical studies with SER 252. We anticipate SER 252 could enter the Phase I SAD study in advanced PD in late 2024. If the results show SER 252 is well-tolerated with predictable PK, we expect to proceed to a Phase I MAD study in advanced patients in 2025. The results of the combined SAD/MAD studies will measure not only safety, PK and tolerability in these advanced patients but also daily “OFF” and “ON” time and will inform the design of the Phase II study. If Phase I is successful, Serina plans to have a meeting with the FDA to aid in design of a Phase II study.

 

Summary of Serina’s Parkinson’s Disease Programs

 

Serina believes that SER 214 could be used primarily in patients with early Parkinson’s disease and that SER 252 could be used in patients with advanced disease. A critically important observation was made in the TOLEDO study in that many patients down-titrated their oral L-DOPA doses by greater than 50% from their baseline dose. L-DOPA therapy is considered the mainstay of treatment of both early and advanced Parkinson’s disease, despite evidence that dopamine agonists are equally effective for early disease and do not promote the same degree of dyskinesia as levodopa. Approximately 50% of PD patients will develop levodopa induced dyskinesia (LIDS) within five years, and 90% within 10 years, of initiation of levodopa therapy. In one specialized center in Scotland, the Lees group has shown that fastidious titration of apomorphine (Apo-go) during the waking day can lead to complete off-titration of levodopa with a dramatic reduction in motor complications (45 of 64 patients achieved apomorphine monotherapy and titrated completely off oral levodopa). Patients who achieved monotherapy had an increase in “ON” time to 85% of the waking day. If SER 252 effectively prevents “OFF” time and delays or prevents dyskinesia in advanced disease, it might be possible to use SER 252 in patients with mid-stage disease to achieve significant control of symptoms without initiating levodopa therapy. At present, we are not aware of an effective alternative to oral levodopa. For patients who experience advancing disease that no longer responds to oral agonists, the default approach is to continue to escalate doses of levodopa with the consequence of accelerated onset of motor complications. Serina believes that there is significant potential for SER 252 to become such an alternative, potentially leading to a paradigm shift in how patients with Parkinson’s disease might be treated. Serina believes that SER 214 and SER 252 may be administered in the home setting with the convenience and compliance of a single or twice-weekly subcutaneous injection that does not require a healthcare provider to administer, and patients may not need to continue therapy with levodopa (levodopa sparing strategy).

 

268

 

 

SER 227 (POZ-buprenorphine) – An Injectable Drug for Management of Post-Operative Pain That Simultaneously Obviates the Need to Discharge a Patient on an Opioid

 

Buprenorphine is a mixed mu-agonist/antagonist that is 30-50 times more potent than morphine at binding to the mu-opioid receptor. The mu-opioid receptor (MOR) is the target of drugs in the opioid class, of which morphine is the prototype opioid. Other synthetic opioids include oxycodone and fentanyl. When molecules bind the MOR, they “blunt” the perception of pain at the level of the brain and are often associated with euphoria. Buprenorphine is an approved drug available in a transdermal formulation (Butrans) as well as an injectable formulation (Buprenex), but it does not promote euphoria and is thus considered to have low abuse liability. Buprenorphine has several mechanisms of action, one of which is a potent sodium channel inhibitor activity similar to lidocaine-like drugs, and thus has mild anesthetic effects locally when injected. Finally, buprenorphine is believed to have anti-hyperanalgesic effects at both local and central nociceptors that may contribute to its activity as a pain drug.

 

Buprenex has a relatively short half-life, which limits its usefulness as a post-operative pain drug following local injection in humans. However, Serina believes that buprenorphine’s multiple mechanisms of action make it a particularly attractive candidate for an injectable pain drug if the PK can be enhanced.

 

SER 226/227 – Synthetic Scheme

 

Buprenorphine was attached to POZ with the aim to increase its PK profile, in much the same way as SER 214. The synthetic scheme is shown below:

 

Figure 8: Synthetic scheme for linker attachment to buprenorphine

 

 

Source: Serina

 

Buprenorphine (compound 1) is converted to an azide-derivative by coupling the linker to the single phenolic hydroxyl to generate compound 2.

 

Compound 2 is then purified, and it is attached to the 20 kDa pendent POZ polymer employing “click chemistry”, as shown in Figure 9 below.

 

269

 

 


Figure 9: Synthetic scheme for POZ-buprenorphine – SER 226/227

 

 

Source: Serina

 

Figure 9: Compound 2 is attached to a pendent POZ polymer employing “click chemistry” to generate the desired SER 226 (alpha-methyl linker) or SER 227 (propyl linker, shown above).

 

The PK profiles of SER 226 (2-propionate linker) and SER 227 (3-propionate linker) have shown that a single injection has a prolonged profile with detectable buprenorphine levels out to seven days in preclinical rat studies. SER 227 releases buprenorphine at an essentially “steady-state,” similar to the PK results we observed for SER 214 in animals and subsequently in humans. These results suggested that the PK of buprenorphine has the potential to be markedly extended employing a POZ polymer approach, and that the levels of buprenorphine may be titrated to a level where buprenorphine has been shown to have analgesic effects in humans.

 

SER 226/227 – Evaluation in the Brennan Model

 

Serina advanced both conjugates into the Brennan model of post-operative pain. In brief, the Brennan model is an industry standard pain model that employs rats that have received a unilateral 1 cm incision in the fat pad of the paw in the hind limb. This wound has enhanced sensitivity to painful stimuli for up to seven days (tactile allodynia), and analgesics may be evaluated via injection into the wound site or systemically to determine if there is an analgesic effect. Both SER 226 and SER 227 produced prompt and sustained analgesia in the Brennan model that exceeded the known activity of both morphine and Exparel (a liposomal formulation of bupivacaine, Pacira Pharmaceuticals, Inc.). This is shown below in Figure 10.

 

270

 

 
Figure 10:

 

 

Figure 10: Analgesic activity of SER 226 and SER 227 versus morphine in the Brennan Model in the rat.

 

Rats were administered a single subcutaneous injection of either SER 226, SER 227, saline or morphine at the time of wound closure. Animals were then evaluated for withdrawal threshold employing a von Frey monofilament. Withdrawal thresholds were measured as a function of time for up to 144 hours. A low withdrawal threshold indicates little or no analgesia when the wound area is challenged with the von Frey monofilament. In this model, morphine provides immediate analgesia that returns to baseline (no analgesia) within 3-4 hours. Exparel (a liposomal preparation of bupivacaine that is also an approved pain drug) would provide immediate analgesia that would return to baseline (no analgesia) within 4-6 hours. Both SER 226 and SER 227 provide immediate and prolonged analgesia that remained statistically significant out to 48 hours.

 

271

 

 

The release kinetics for both SER 226 and SER 227 were also evaluated in monkeys. The results of that preclinical study are shown below in Figure 11.

 

Figure 11:

 

 

 

Figure 11: Pharmacokinetic Profile of Released Buprenorphine from SER 226 and SER 227.

 

A single subcutaneous injection of SER 226 or SER 227 was administered to adult male monkeys at a dose of 1.5 mg/kg. At 3, 6, 12 and 24 hours, and then daily for 10 days, plasma samples were taken for determination of released buprenorphine. SER 226 releases buprenorphine quickly and generates very high levels of released buprenorphine approaching 100 ng/mL within 24 hours. SER 227 reaches Cmax at approximately 1-3 hours and remains at near steady-state release for > 3 days without fluctuations in plasma levels.

 

The data in Figure 11 suggests that SER 227 has the desired PK profile for a long-acting analgesic that could be administered in the immediate post-operative period and potentially achieve therapeutic levels of released buprenorphine in the therapeutic window for analgesia (1-5 ng/ml).

 

Serina’s target product profile for POZ-buprenorphine in humans is as follows:

 

  A single injectable product that can be administered in the immediate post-operative period;
  Release of buprenorphine that provides prompt (within approximately two hours) plasma levels within the therapeutic window for analgesia;
  Sustained release of buprenorphine systemically (in the blood) that provides greater than three days of steady-state levels, such that patients would not need to transition to an intravenous or oral opioid;
  Release of buprenorphine at plasma levels that would also prevent the euphoria associated with other mu-agonists, such as morphine or oxycodone, should these be taken in the immediate three to four days following injection of SER 227; and
  Prolonged analgesia for three to four days, whereupon patients would be able to transition to over-the-counter analgesics that are non-addictive such as acetaminophen or non-steroidal anti-inflammatory drugs.

 

272

 

 

We are not aware of the target product profile described above being achievable by any injectable drug currently available. Exparel is an approved drug that is a liposomal formulation of bupivacaine that has a profile of about 12-24 hours of analgesia following injection into the wound bed (Exparel, Pacira Therapeutics). Research indicates that approximately 35-40% of patients who have undergone surgery (other than minor surgical procedures) will transition to an oral drug on day two to three, and in some cases an opioid depending on the type of surgical procedure. We believe that this is one of the contributing reasons for the “opioid epidemic” in the United States today. There are estimated to be more than two million people in the United States that are addicted to prescription pain drugs, and approximately 150 people die per day in the United States from opioid overdose. This is a major burden on the health care system in addition to the emotional burden on the addicted individual and the family. Serina believes that a product like SER 227 would represent a significant advance in the treatment of post-operative pain by providing up to three to four days of analgesia without transition to opioids due to its extended half-life, high activity at the mu-receptor, local lidocaine-like effect, and anti-hyperalgesia.

 

Finally, as buprenorphine is itself now an approved drug for the treatment of addiction as an implant (Probuphine, Titan Pharmaceuticals), a once-monthly injection (Sublocade, Indivior Pharmaceuticals), and as a sublingual formulation (Suboxone), it is possible that anyone who would take SER 227 post-operatively would not respond to that opioid with a “high,” as SER 227 may blunt the euphoria often experienced with opioids. Serina believes that SER 227 has the potential to be an excellent post-operative pain drug for many types of surgeries, while targeting the initial gateway of exposure to opioids in the hospital that may lead to subsequent opioid use disorder.

 

Buprenorphine is as Effective as Morphine Delivered by PCA

 

The current standard of treatment for post-operative pain, in particular for in-hospital procedures (those that require a hospital stay), is the administration of opioid drugs. This is frequently accomplished by an intravenous administration of morphine (or similar opioid) that can be controlled by the patient (patient-controlled analgesia, or PCA). In general, patients receive PCA for one to two days and are transitioned to an oral opioid on day two to three at which time they undergo progressive ambulation in preparation for discharge. Patients are often discharged with a prescription for an opioid with instructions to use as needed for control of pain.

 

There is a concern among some pain specialists that buprenorphine may not be as effective as morphine in the acute post-operative period. In a recent meta-analysis of studies which randomized patients to either IV morphine (via PCA) or buprenorphine in its current approved formulation (Buprenex), it was found that:

 

  Buprenorphine was equal to morphine in analgesic efficacy;
  Buprenorphine had a ceiling effect on respiratory depression but not analgesia;
  Respiratory depression increased with increase in morphine dose;
  There was no difference for major side effects such as nausea and sedation;
  There was no significant difference in the need for rescue analgesia or the time to rescue analgesia; and
  Buprenorphine was superior to morphine for some troublesome adverse events.

 

Serina believes that the view that buprenorphine might not be as effective as morphine is not supported by randomized, well-controlled studies.

 

273

 

 

Impact of Discharging a Patient with a Prescription for an Opioid

 

In one of the largest published studies of its kind (Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017), researchers made important observations regarding the impact of discharging a patient with a prescription for an opioid. In the event opioid-naïve patients fill a prescription for an opioid following discharge, independent of whether they have had minor or major surgery, the study found:

 

  The patient became 15 times (6-7% of patients) more likely to transition to chronic use of an opioid within the next 90-180 days;
  If patients are never exposed to an addictive opioid (such as morphine via PCA, or oral oxycodone) the incidence of transitioning to opioid use disorder is less than 0.4%; and
  Predictors of new and persistent opioid use were a history of substance abuse (tobacco, alcohol), mood disorders (primarily anxiety disorders) and pre-operative pain disorders where there was prior use of an opioid.

 

Serina believes that the development of SER 227 for control of post-operative pain may not only provide adequate analgesia, but simultaneously target the initial gateway to exposure of potentially addictive opioids. The market potential and competitive landscape for this program were assessed in formal market research conducted by inVentiv Health in 2018. In September 2019, the NIH, through the National Institute of Neurological Disorders and Stroke (NINDS), awarded Serina $1.7 million over two years to support the pre-clinical development of SER 227. The award is part of the NIH HEAL Initiative (Helping to End Addiction Long-term). The NIH HEAL Initiative award has funded the IND-enabling preclinical studies to prepare SER 227 for Phase Ia clinical trials.

 

POZ Cannabinoid Conjugates – Potential Product Candidates in Early Pre-clinical Studies

 

Cannabis extracts have been used to treat glaucoma, pain, nausea and vomiting, muscle spasms, insomnia, anxiety, and epilepsy. Evidence for efficacy varies substantially for different indications, with the best data in painful HIV-associated sensory neuropathy, chronic pain, chemotherapy-induced nausea and vomiting, and spasms in patients with multiple sclerosis. More recently, an enriched extract from cannabis has shown great promise in the treatment of refractory epilepsy in infantile epileptic syndromes such as Dravet syndrome and Lennox-Gastaux syndrome. In June 2018, Epidiolex® was approved by the FDA for use in children with those syndromes. In 2020, Epidiolex® was approved for tuberous sclerosis complex (TSC), a rare genetic disorder associated with benign tumors throughout the body but also a high incidence of refractory epilepsy. Other medicinal uses for cannabis have been proposed, but for many of these additional indications the use of cannabis extracts (or pure compounds from cannabis) will have to be examined in well-controlled clinical trials.

 

The approval of Epidiolex® was a milestone in the development of a new drug class for refractory epilepsy as there had not been a new anti-epileptic drug (AED) class in almost 20 years. However, its use is confounded by significant side effects. In the treatment group, the combined incidence of diarrhea and vomiting was 46% compared to 15% in the placebo group – suggesting that the adverse events are the combination of sesame seed oil + CBD, not just sesame seed oil alone. Other side effects are also significant and include fatigue, anorexia, and somnolence. It is possible that this side effect profile may be due to the phasic peak and trough PK profile of the mixture. Cannabidiol is insoluble in aqueous solutions and is dissolved in sesame seed oil. At the recommended dose of 20 mg/kg/day in divided doses, an average 40 kg child will need to consume almost 250 mL of sesame seed oil each month in divided doses.

 

Serina initiated work with one of the authorities in cannabinoid therapy for seizures at the University of Alabama at Birmingham, Dr. Jerzy Szaflarski, in 2016. Data provided by Dr. Szaflarski showed that among patients with refractory epilepsy that have been using Epidiolex® since 2014, approximately 30% of adults and 50% of children use maximal doses of anti-diarrheal therapy and diapers to deal with the diarrhea side effects of treatment.

 

SER 228 (POZ-cannabidiol) for the Treatment of Intractable Epilepsy

 

Two initial cannabinoid compounds were identified as attractive candidates for a POZ polymer approach based upon an accessible chemical handle, potential limitations in terms of solubility and undesirable PK properties (for example, a short half-life or need to deliver orally in a solution to solubilize the drug). These compounds are cannabidiol (CBD) and tetrahydrocannabinol (THC). CBD and THC are among the approximately 120 known terpenophenolic compounds (collectively known as cannabinoids) in the plant cannabis. Their chemical structures are shown below.

 


Figure 12: Chemical structures of cannabidiol (CBD, left) and tetrahydrocannabinol (THC, right)

 

 

Figure 12: Chemical structures of the major non-psychoactive cannabidiol and psychoactive delta-9- tetrahydrocannabinol compounds in Cannabis. THC is the component in the plant that is associated with a “high”; CBD has no similar psychoactive activity. The chemical point of attachment to POZ is indicated by the circle on each chemical structure.

 

Source: Serina

 

274

 

 

SER 228/229 – Synthetic Scheme

 

Serina believes that CBD is an ideal candidate for a POZ polymer approach. The synthetic scheme for POZ-cannabidiol takes advantage of the chemical handle(s) indicated in the structure above. This is illustrated below.

 

Figure 13: Synthetic scheme for POZ-cannabidiol – SER 228/229

 

 

Source: Serina

 

Figure 13: Cannabidiol is first derivatized with the linker of interest (acetyl, SER 228; alpha-methyl, SER 229) and attached to a 20 kDa POZ polymer employing “click chemistry” as seen previously for other POZ-conjugates. The final product is then purified over ion-exchange chromatography.

 

275

 

 

Preclinical Pharmacokinetic Study of SER 228/229 in Normal Rats

 

Serina obtained a Schedule I license from the DEA in the second quarter of 2016. The research study protocol was approved by both the DEA and FDA and preclinical studies commenced in the Serina laboratories in May 2016. CBD has been attached by two different linkers to a 20 kDa POZ polymer and the initial results in normal rats are shown below.

 
Figure 14:

 

 

Figure 14: PK profile of SER 228/229 in normal rats. CBD was attached to POZ via two different linkers to produce two potential candidate drugs; SER 228 employs an acetyl linker at one of the two phenolic hydroxyls, and SER 229 employs an alpha-methyl linker. These were dosed in normal rats via a single subcutaneous injection (at doses of 1.5 and 4.5 mg/kg) and plasma levels of CBD were obtained each day for seven days.

 

The PK profiles shown in Figure 14 demonstrated that POZ-cannabidiol has a prolonged PK profile in the rat. The PK profile of either SER 228 or SER 229 at a dose of 1.5 mg/kg in the rat was shown to be very similar to the PK profile of SER 214 in the rat (data not shown).

 

SER 214 has been shown to produce continuous drug delivery in humans following a single weekly subcutaneous injection. As the polymer backbone in SER 214 is a 20 kD polymer, Serina would expect that similar profiles might be obtained with other POZ-conjugates that employ a 20 kDa polymer. The POZ-cannabidiol conjugates have subsequently been advanced in preclinical single-dose PK studies in monkeys, with variable drug loaded 20 kDa POZ polymers. These data are shown in Figure 15.

 

276

 

 
Figure 15:

 

 

Figure 15: Plasma levels of released CBD following a single injection of the indicated POZ conjugates.

 

Adult male monkeys (N=3) were administered a single subcutaneous injection of the indicated POZ-conjugates at 4.5 mg/kg. SER 228 has CBD linked to the polymer via an acetate linker, whereas SER 229 employs an alpha-methyl linker. The respective POZ-conjugates were variably loaded with CBD as well. SER 229 PA is comprised of an additional “clicked” moiety – propionic acid – that is predicted to increase solubility. In prior preclinical studies, we have observed that decreasing the drug load in some instances leads to higher degrees of drug release both in vitro and in vivo.

 

In the approval trials of Epidiolex®, patients were dosed at variable doses of the sesame seed oil preparation, from 5 mg/kg to 50 mg/kg. It is unclear what the dose correlation is to seizure control and published data suggest that patients may respond across a wide range of doses. Serina sponsored a study with epilepsy experts at the University of Alabama at Birmingham who have treated approximately 200 patients (adult and pediatric) who are participants in the Expanded Access Program sponsored by GW Pharmaceuticals, Inc. (GW). Published data and results from our preclinical single-dose PK studies in monkeys suggest that in children with refractory epilepsy there is a response at lower plasma levels than those required in adults. Plasma PK determinations of CBD showed that at the approved dose of 20 mg/kg/day of Epidiolex® the levels were approximately 150 ng/mL (with a wide standard deviation, as would be predicted for a drug with limited PK). Serina believes that PK levels between 50-150 ng/mL is the target level for a POZ-cannabidiol conjugate that would achieve efficacy in Dravet syndrome and some other pediatric epilepsies based on published data. The multi-dose monkey PK results suggest that POZ-cannabidiol may have the potential to dramatically change the treatment paradigm for this disabling disorder by providing a single weekly injection that delivers CBD continuously. As shown below, we have identified SER 228 as the POZ-cannabidiol candidate for IND-enabling preclinical studies.

 

277

 

 


Figure 16

 

 

Figure 16: Multi-dose pharmacokinetics of release of CBD following a single weekly subcutaneous injection of either SER 228 or SER 229 at 7-8% drug load. SER 228 or SER 229 were dosed at 1.5 mg/kg in young adult monkeys for four successive weeks followed by a two-week washout period. Both conjugates provided virtually identical PK profiles. Serina has chosen SER 228 for IND-enabling preclinical studies.

 

The multi-dose PK data above were simulated to predict human PK based upon a standard one-compartment fit of the data. There can be no assurance that the simulated result is able to be achieved. The results are shown below.

 

278

 

 
Figure 17: SER 228 simulation of predicted human PK modeling compared to twice daily Epidiolex®

 

 

Figure 17: The multi-dose monkey PK was used to simulate human PK for SER 228 as a weekly or twice-weekly subcutaneous injection at doses of 0.5 mg/kg or 0.25 mg/kg, respectively. Epidiolex® data are derived from published information.

 

The results of the simulation illustrated in Figure 17 shows a single or twice-weekly subcutaneous injection of SER 228 may provide continuous release of CBD at levels that exceed the known PK of the 20 mg/kg/day dose of Epidiolex®. The simulation used the one-compartment model to predict the PK levels of CBD release from SER 228. In this modeling, Serina relied on the published volume of distribution for CBD in humans, and modeled the data for a two-fold accumulation of CBD that occurs in humans (data from the FDA Advisory Committee 2018). The steady-state levels from the simulation of SER 228 for human PK lie well above the target level of ~ 150 ng/mL CBD and trough levels of CBD release may not approach the trough levels of Epidiolex® (40 ng/mL). Serina has chosen SER 228 for further development and believes that a single or twice-weekly injection may represent a major contribution to patient care compared to CBD in a twice daily, orally delivered sesame seed oil preparation. There can be no assurance that the simulated result is able to be achieved.

 

SER 232 (POZ-tetrahydrocannabinol) - A Once Weekly Injectable for the Treatment of Chemotherapy-induced Nausea and Vomiting (CINV)

 

Serina obtained a Schedule I license from the DEA in early 2016, and the FDA has approved the research protocol for the delta-9-tetrahydrocannabinol (THC) program in early 2017. The chemical synthesis of SER 232 conjugates has been completed.

 

279

 

 

SER 232 – Synthetic Scheme

 

The synthetic scheme for SER 232 is virtually the same as in SER 228/229 except that the molecule is THC. This is shown below.

 

Figure 18: Synthetic scheme for POZ-tetrahydrocannabinol – SER 232

 

 

Source: Serina

 

THC is derivatized with the appropriate linker and coupled to a 20 kDa POZ polymer to generate SER 232 by employing “click chemistry.”

 

Serina will likely employ the same linkers that have been used in the SER 228/229 program to attach THC to the 20 kDa POZ polymer and evaluate release rates. As there is a single chemical handle in THC, and its chemical structure is very similar to CBD, we anticipate that programming THC release rates should be readily achievable. POZ-tetrahydrocannabinol is expected to be programmed to achieve relatively steady-state PK release, much like SER 214.

 

There is no animal model that has proven to be a reliable model for therapeutic potential of THC to treat CINV. The development of POZ-tetrahydrocannabinol is expected to rely on historical information regarding the PK levels that may be safe and efficacious in multiple potential clinical disorders, including CINV, spasticity in multiple sclerosis, neuropathic pain, dyskinesia in Parkinson’s disease, weight loss in AIDS and cancer patients and aggression / agitation in autism spectrum disorders and Alzheimer’s disease.

 

POZ-cannabinoids – Potential Enabling Technology for Other Cannabinoids Found in Cannabis (CBDV, CBG, CBC)

 

We believe that polymers of POZ could provide similar PK profiles for other cannabinoids. Serina has identified three additional cannabinoids for early preclinical studies – cannabidivarin (CBDV), cannabigerol (CBG) and cannabichromeme (CBC). Serina believes that cannabinoids as a class of compounds may hold potential for a myriad of CNS disorders.

 

280

 

 

Figure 19: Cannabinoids as a class of compounds may target some of the most challenging disorders in CNS and inflammatory disease. Many of the cannabinoids shown have multiple targets

 
Source: Serina

 

 

POZ-lipids – Development of a non-immunogenic lipid nanoparticle (LNP) by replacing the PEG-lipid in current infectious disease vaccines with a POZ-lipid

 

In early 2020, the formulations of the RNA-based Covid-19 vaccines from Pfizer/BioNTech and Moderna were revealed to use a PEG lipid nanoparticle delivery technology. In July 2021 and April 2022, Serina entered into feasibility study agreements (FSAs) with two major pharmaceutical companies to explore the potential of Serina’s POZ-lipid technology as a possible non-immunogenic replacement for the PEG polymer lipid nanoparticle formulation (PEG-lipid LNP).

 

Serina has demonstrated in animal experiments that rabbits do not produce detectable antibodies to the POZ polymer and Serina’s repeat-dose studies in animals and humans suggest the absence of an accelerated blood clearance phenomenon for POZ-conjugates. Accelerated blood clearance (ABC) has been demonstrated to occur in animals and in humans and Serina believes that it is likely due to the development of anti-PEG antibodies. In a study in mice, scientists at Moderna demonstrated that anti-PEG antibodies begin to clear LNPs by the second dose, and subsequent dosing of an mRNA LNP resulted in complete clearance of the LNP by the third, fourth and fifth dosing.

 

Both of the currently approved Covid-19 RNA-based vaccines contain 1-2 mol% PEG-lipid, which is required to stabilize the LNP and prevent fusion of nascent particles. In addition to the possibility that PEG may be the culprit in acute serious adverse events such as anaphylactic reactions, it is possible the efficacy of subsequent vaccines may be compromised. Many experts believe that Covid-19 will become an endemic challenge and that booster immunizations will be required. Formulation of a LNP with a POZ-lipid may provide a “PEG-free” alternative to development of future LNP delivered RNA vaccines for infectious diseases, cancer immunotherapy and rare diseases.

 

Serina has patents which cover the use of POZ-lipids for the formation of therapeutic LNPs, and we are continuing to advance the chemistry of POZ-lipids in the Serina laboratories. Serina intends to license the POZ-lipid technology to companies developing LNP approaches, potentially providing a vaccine delivery system with reduced immunogenicity compared to the current PEG-based standard approaches.

 

Licensing, Collaboration and Partnership Agreements

 

In early 2021, Serina entered into FSAs with several large pharmaceutical and biotechnology companies to advance POZ-lipids as a replacement strategy for PEG-lipids in the current mRNA vaccines. After two years of work with these partners, Serina entered into licensing discussions to advance POZ-lipids as a replacement for PEG-lipids.

 

In October 2023, Serina entered into a non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug delivery formulations. The agreement grants Pfizer non-exclusive rights to certain intellectual property, know-how, and proprietary technologies. Under the terms of the agreement, Pfizer is authorized to develop, manufacture, market, and commercialize products incorporating the licensed technology with respect to a specific POZ polymer structure in one field. The agreement outlines the protection and enforcement of intellectual property rights related to the licensed technology. Pfizer is obligated to use commercially reasonable diligent efforts to develop and commercialize licensed products, and to use such efforts to accomplish specified development and commercial objectives. The agreement includes a one-time upfront payment of $3 million that was received on December 15, 2023, milestone payments payable to Serina upon the achievement of specific development, regulatory, and commercial milestones, and a royalty on net sales of products incorporating the licensed technology in accordance with the terms outlined in the license agreement. The range of royalties on sales of products is between 2.75% – 3.5% and is tiered to achievement of certain sales milestones.

 

281

 

 

Clinical Manufacturing and Supply Agreement

 

In May 2023, Serina entered into a manufacturing agreement to manufacture SER 252 for IND enabling preclinical studies and clinical supply. Under the terms of the agreement, the manufacturer will manufacture and test SER 252 under cGMP. Serina retains all rights to SER 252 which includes data, methods, and process modifications.

 

Intellectual Property

 

Intellectual property is of vital importance in Serina’s field and in biotechnology generally. Serina seeks to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of its business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. Serina will also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity and patent term extensions where available.

 

Serina has sought patent protection in the United States and internationally related to the POZ technology. Serina owns an extensive issued patent estate covering POZ technology and certain product candidates enabled by the POZ technology. Serina has applied for additional patents seeking to further protect and extend the POZ patent portfolio owned by Serina. Such applications may not result in issued patents and, even if patents do issue, such patents may not be in a form or scope that will provide Serina with meaningful protection for its product candidates. Serina also relies on trade secrets that are important to the development of its business. Trade secrets are difficult to protect and provide Serina with only limited protection, as trade secrets do not protect against independent development of technology by third parties.

 

Serina expects to file additional patent applications in support of current and new clinical candidates as well as in support of new applications of POZ platform technology. Serina’s commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of current and future product candidates and the methods used to develop and manufacture them, as well as successfully defending any such patents against third party challenges and operating without infringing on the proprietary rights of others. Serina’s ability to stop third parties from making, using, selling, offering to sell, or importing its product candidates will depend on the extent to which Serina has rights under valid and enforceable patents or trade secrets that cover these activities. Serina cannot be sure that patents will be granted with respect to any of its pending patent applications or with respect to any patent applications filed by Serina in the future, nor can Serina be sure that any patents that may be granted in the future will be commercially useful in protecting its product candidates, discovery programs and processes.

 

282

 

 

The terms of individual patents depend upon the legal term of the patents in the countries in which they are obtained. In most countries in which Serina files, including the United States, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier filed patent. In the United States, the term of a patent that covers an FDA approved drug may also be eligible for extension, which permits patent term restoration to account for the patent term lost during the FDA regulatory review process. The Hatch Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the subject drug candidate is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions to extend the term of a patent that covers an approved drug are available in Europe and other foreign jurisdictions. In the future, if and when Serina products receive FDA approval, Serina expects to apply for patent term extensions on patents covering those products. Serina plans to seek patent term extensions to any issued patents it may obtain in any jurisdiction where such patent term extensions are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with Serina’s assessment that such extensions should be granted, and if granted, the length of such extensions.

 

In some instances, Serina has submitted and expects to submit patent applications directly to the USPTO as provisional patent applications. Corresponding non provisional patent applications must be filed not later than 12 months after the provisional application filing date. While Serina intends to timely file non provisional patent applications relating to its provisional patent applications, Serina cannot predict whether any such patent applications will result in the issuance of patents that provide it with any competitive advantage.

 

Serina files U.S. non provisional applications and Patent Cooperation Treaty (PCT) applications that claim the benefit of the priority date of earlier filed provisional applications, when applicable. The PCT system allows a single application to be filed within 12 months of the original priority date of the patent application, and to designate all of the PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national phase applications. At the end of the period of two and a half years from the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases by filing through a regional patent organization, such as the European Patent Office. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial savings where applications are abandoned within the first two and a half years of filing.

 

For all patent applications, Serina determines claiming strategy on a case by case basis. Advice of counsel and Serina business model and needs are always considered. Serina seeks to file patents containing claims for protection of all useful applications of its proprietary technologies and any products, as well as all new applications and/or uses that Serina discovers for existing technologies and products, assuming these are strategically valuable. Serina continuously reassesses the number and type of patent applications, as well as the pending and issued patent claims to pursue maximum coverage and value for its processes, and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet Serina’s intellectual property and business needs.

 

Serina recognizes that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty and nonobviousness of the invention, and the ability to satisfy the enablement requirement of the patent laws. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, Serina may not obtain or maintain adequate patent protection for any of its future product candidates or for its technology platform. Serina cannot predict whether the patent applications it is currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that Serina holds may be challenged, circumvented, or invalidated by third parties.

 

283

 

 

In addition to patent protection, Serina also relies on trade secrets, know how, other proprietary information and continuing technological innovation to develop and maintain its competitive position. Serina seeks to protect and maintain the confidentiality of proprietary information to protect aspects of its business that are not amenable to, or that it does not consider appropriate for, patent protection. Although Serina takes steps to protect its proprietary information and trade secrets, including through contractual means with its employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to its trade secrets or disclose its technology. Thus, Serina may not be able to meaningfully protect its trade secrets. It is Serina’s policy to require its employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with Serina. These agreements provide that all confidential information concerning Serina’s business or financial affairs developed or made known to the individual during the course of the individual’s relationship with Serina is to be kept confidential and not disclosed to third parties except in specific circumstances. Serina’s agreements with employees also provide that all inventions conceived by the employee in the course of employment with Serina or from the employee’s use of its confidential information are Serina’s exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached, and Serina may not have adequate remedies for any such breach. In addition, Serina’s trade secrets may otherwise become known or be independently discovered by competitors. To the extent that Serina’s consultants, contractors, or collaborators use intellectual property owned by others in their work for Serina, disputes may arise as to the rights in related or resulting trade secrets, know how and inventions.

 

The patent positions of biotechnology companies are generally uncertain and involve complex legal, scientific, and factual questions. Serina’s commercial success will also depend in part on not infringing upon the proprietary rights of third parties. Third party patents could require Serina to alter its development or commercial strategies, or its products or processes, obtain licenses or cease certain activities. Serina’s breach of any license agreements or its failure to obtain a license to proprietary rights required to develop or commercialize its future products may have a material adverse impact on it. If third parties prepare and file patent applications in the United States that also claim technology to which Serina has rights, Serina may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention. For more information, see “Risk Factors—Risks Related to Serina—Risks Related to Intellectual Property.”

 

When available to expand market exclusivity, Serina’s strategy is to obtain, or license additional intellectual property related to current or contemplated development platforms, core elements of technology and/or clinical candidates.

 

Serina-Owned Intellectual Property

 

Serina has been issued a series of patents on various forms of POZ. The following is a list of patents that have been issued and published pending applications in the United States and worldwide. The list is presented by the individual family dockets. Expiration dates for non-domestic patent rights are based on a strict calculation of 20 years from the earliest filing date and, as such, Patent Term Adjustment in accordance with the jurisdiction could extend this term further than indicated.

 

284

 

 

SER 01 Family: “Activated Polyoxazolines and Compositions Comprising the Same” (J. M. Harris et al.).

 

This family of patents provides methods of synthesis and compositions of terminally activated linear poly(oxazolines) having various terminal functional groups suitable for attaching to other molecules such as enzymes, proteins, lipids, and antibodies by stable linkages.

 

Country  Type  Status  App. Date  App. Number  Grant Date  Grant Number  Expiration Date
Japan  Utility  Granted  Feb-28-2008  2009-551999  Sep-19-2014  5,615,558  2-28-2028
Korea (South)  Utility  Granted  Feb-28-2008  10-2009-7020124  Mar-30-2015  10-1508617  2-28-2028
Korea (South)  Utility  Granted  Oct-25-2013  10-2013-7028233  Mar-30-2015  10-1508621  2-28-2028
US  Utility  Granted  Feb-28-2008  12/529,001 May-17-2011  7,943,141  2-28-2028
US  Utility  Granted  Mar-08-2017  15/453,686 Oct-02-2018  10,086,084  2-28-2028
US  Utility  Granted  Sep-27-2018  16/144,358 Dec-15-2020  10,864,276  2-28-2028

 

SER 02 Family: “Multi-armed Forms of Activated Polyoxazoline and Methods of Synthesis Thereof” (J. M. Harris et al.)

 

This patent provides branched poly(oxazolines) having a terminal activating group that can be linked to a second moiety such as a drug molecule. The branched or multi-arm composition generally comprises two or more linear poly(oxazolines) linked to a single branching point.

 

Country  Type  Status  App. Date  App. Number  Grant Date  Grant Number  Expiration Date
US  Utility  Granted  Sep-29-2008  16/680,448 Jan-03-2012  8,088,884  9-29-2028

 

SER 03/07 Family: “Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same” (K. Yoon et al.)

 

This family of patents provides for poly(oxazolines) having a set of pendent functional groups on the polymer backbone and a terminal functional group, wherein the pendent functional groups and the terminal functional groups are chemically orthogonal to one another. This family also covers mixtures of oxazoline monomers on the same polymer backbone e.g. ethyl oxazoline and pentynyl oxazoline. This family covers every class of molecule attached to POZ, including but not limited to small molecules, proteins, oligonucleotides, and lipids where the attached molecule can be a therapeutic, diagnostic, or targeting molecule. The family also covers such poly(oxazoline) polymers linked to various target molecules, such as therapeutic agents and targeting agents and of using such conjugates in the treatment or diagnosis of cancer:

 

Country  Type  Status  Application Date  Application Number  Grant Date  Grant Number  Expiration Date
US  Utility  Granted  Jan-12-2009  12/744,472 Feb-07-2012  8,110,651  3-21-2029
US  Utility  Granted (CIP)  May-25-2010  12/787,241 Jan-24-2012  8,101,706  3-20-2029
US  Utility  Granted (CIP)  Jan-23-2012  13/356,552 Aug-06-2013  8,501,899  1-29-2029
US  Utility  Granted (CIP)  Feb-06-2012  13/367,128 Oct-27-2015  9,169,354  1-12-2029
US  Utility  Granted (CIP)  Jul-08-2016  15/205,671 Jan-01-2019  10,166,294  1-12-2029
US  Utility  Granted (CIP)  Dec-28-2018  16/235,936 Jan-04-2022  11,213,588  1-12-2029
US  Utility  Pending  Jan-04-2022  17/568,042        
China  Utility  Granted  Jan-12-2009  200980106276.5  Dec-12-2012  1098857  1-12-2029
Japan  Utility  Granted  Jan-12-2009  2010-542410  Apr-04-2014  5,514,736  1-12-2029
Korea (South)  Utility  Granted  Jan-12-2009  10-2010-7017208  Jan-20-2015  10-1486449  1-12-2029
Belgium  Utility  Granted  Jan-12-2009  09701187.8  Sep-04-2013  2,235,090  1-12-2029
Belgium  Utility  Granted  Jan-12-2009  13181892.4  Mar-23-2016  2,669,313  1-12-2029
Belgium  Utility  Granted  Jan-12-2009  16154587.6  Jul-19-2017  3,042,922  1-12-2029
Switzerland  Utility  Granted  Jan-12-2009  09701187.8  Sep-04-2013  2,235,090  1-12-2029
Switzerland  Utility  Granted  Jan-12-2009  13181892.4  Mar-23-2016  2,669,313  1-12-2029
Switzerland  Utility  Granted  Jan-12-2009  16154587.6  Jul-19-2017  3,042,922  1-12-2029
Germany  Utility  Granted  Jan-12-2009  09701187.8  Sep-04-2013  2,235,090  1-12-2029
Germany  Utility  Granted  Jan-12-2009  13181892.4  Mar-23-2016  2,669,313  1-12-2029
Germany  Utility  Granted  Jan-12-2009  16154587.6  Jul-19-2017  3,042,922  1-12-2029
Denmark  Utility  Granted  Jan-12-2009  16154587.6  Jul-19-2017  3,042,922  1-12-2029
France  Utility  Granted  Jan-12-2009  09701187.8  Sep-04-2013  2,235,090  1-12-2029
France  Utility  Granted  Jan-12-2009  13181892.4  Mar-23-2016  2,669,313  1-12-2029
France  Utility  Granted  Jan-12-2009  16154587.6  Jul-19-2017  3,042,922  1-12-2029
United Kingdom  Utility  Granted  Jan-12-2009  09701187.8  Sep-04-2013  2,235,090  1-12-2029
United Kingdom  Utility  Granted  Jan-12-2009  13181892.4  Mar-23-2016  2,669,313  1-12-2029
United Kingdom  Utility  Granted  Jan-12-2009  16154587.6  Jul-19-2017  3,042,922  1-12-2029
Netherlands  Utility  Granted  Jan-12-2009  09701187.8  Sep-04-2013  2,235,090  1-12-2029
Netherlands  Utility  Granted  Jan-12-2009  13181892.4  Mar-23-2016  2,669,313  1-12-2029
Netherlands  Utility  Granted  Jan-12-2009  16154587.6  Jul-19-2017  3,042,922  1-12-2029
Sweden  Utility  Granted  Jan-12-2009  09701187.8  Sep-04-2013  2,235,090  1-12-2029
Sweden  Utility  Granted  Jan-12-2009  13181892.4  Mar-23-2016  2,669,313  1-12-2029
Sweden  Utility  Granted  Jan-12-2009  16154587.6  Jul-19-2017  3,042,922  1-12-2029

 

285

 

 

SER 08 family: “Poly(oxazoline) with Inert Terminating Groups, Polyoxazolines Prepared from Protected Initiating Groups and Related Compounds” (M. D. Bentley et al.)

 

This family of patents relates to linear, branched, multi-arm and pendent POZ with initiating functional groups. This patent family also covers compositions of POZ conjugates of phospholipids and glycolipids for use in making lipid nanoparticles (LNP) :

 

Country  Type  Status  App. Date  App. Number  Grant Date  Grant Number  Expiration Date
China  Utility  Granted  Jul-10-2009  200980135512.6  Jun-25-2014  102149749B 7-10-2029
Japan  Utility  Granted  Jul-10-2009  2011-517658  Nov-07-2014  5,642,673  7-10-2029
Korea (South)  Utility  Granted  Jul-10-2009  10-2011-7003132  Aug-04-2016  10-167334  7-10-2029
US  Utility  Granted  Jul-10-2009  13/003,306 Nov-11-2014  8,883,211  3-23-2031
US  Utility  Granted  Nov-10-2014  14/537,516 Mar-15-2016  9,284,411  7-10-2029

 

SER 16 Family: “Subcutaneous Delivery of Poly(oxazoline) Conjugates” (R. W. Moreadith et al.)

 

This family of patents provides for poly(oxazoline) conjugates of dopamine agonists and subcutaneous delivery of these conjugates for treatment of conditions related to dopamine insufficiency, such as Parkinson’s disease. In particular, this family includes claims to conjugates containing rotigotine, i.e., SER 214. The ʼ633 patent (US) has broader claims and would cover other molecules administered as subcutaneous injections, including but not limited to SER 226/227, SER 228/229 SER 232 and SER 252.

 

Country  Type  Status  App. Date  App. Number  Grant Date  Grant Number  Expiration Date
US  Utility  Granted  Jun-15-2012  13/524,994 Feb-26-2013  8,383,093  6-15-2032
US  Utility  Granted  Feb-22-2013  13/774,304 Dec-03-2013  8,597,633  6-15-2032
US  Utility  Granted  Jun-29-2016  15/197,336 Jun-11-2019  10,314,837  6-15-2032
US  Utility  Granted  Jun-10-2019  16/436,590 Jan-18-2022  11,224,595  6-15-2032
US  Utility  Granted  Apr-05-2017  15/480,122 Oct-01-2019  10,426,768  6-15-2032
US  Utility  Granted  Sep-30-2019  16/588,761 Apr-12-2022  11,298,350  6-15-2032
Canada  Utility  Granted  Nov-01-2012  2,854,361  Aug-11-2020  2,854,361  11-1-2032
Japan  Utility  Granted  Nov-01-2012  2014-540093  Jul-21-2017  6,177,787  11-1-2032
Japan  Utility  Granted  Jul-11-2017  2017-135578  Apr-26-2019  6,517,281  11-1-2032
Japan  Utility  Granted  Apr-16-2019  2019-077583  May-12-2021  6,883,605  11-1-2032
Korea (South)  Utility  Granted  Nov-01-2012  10-2014-7014846  May-21-2020  10-2115862  11-1-2032
Belgium  Utility  Granted  Nov-01-2012  12846647.1  Oct-09-2019  2,773,379  11-1-2032
Switzerland  Utility  Granted  Nov-01-2012  12846647.1  Oct-09-2019  2,773,379  11-1-2032
Germany  Utility  Granted  Nov-01-2012  12846647.1  Oct-09-2019  2,773,379  11-1-2032
Denmark  Utility  Granted  Nov-01-2012  12846647.1  Oct-09-2019  2,773,379  11-1-2032
United Kingdom  Utility  Granted  Nov-01-2012  12846647.1  Oct-09-2019  2,773,379  11-1-2032
France  Utility  Granted  Nov-01-2012  12846647.1  Oct-09-2019  2,773,379  11-1-2032
Netherlands  Utility  Granted  Nov-01-2012  12846647.1  Oct-09-2019  2,773,379  11-1-2032
Sweden  Utility  Granted  Nov-01-2012  12846647.1  Oct-09-2019  2,773,379  11-1-2032

 

SER 18 Family: “Polyoxazoline Antibody Drug Conjugates” (R. W. Moreadith et al.)

 

This patent family describes and claims polymer-ADCs to treat human disease. They provide a large drug-antibody-ratio (DAR).

 

Country   Type   Status   App. Date   App. Number   Grant Date   Grant Number   Expiration Date
China   Utility   Granted   Jul-31-2015   201580052259.3   Mar-13-2020   3716373   7-31-2035
Japan   Utility   Granted   Jul-31-2015   2017-505548   May-15-2020   6,704,900   7-31-2035
US   Utility   Granted   Jul-31-2015   14/815,718   Sep-11-2018   10,071,168   7-31-2035
US   Utility   Granted   Sep-10-2018   16/126,798   Jul-21-2021   11,065,340   7-31-2035

 

286

 

 

SER 22 Family: “Cleavable Conjugates of Catechol Compounds and Water-Soluble Polymers and Methods of Treatment Using the Same” (M. D. Bentley et al.)

 

This family covers conjugates including a water-soluble polymer linked to a compound including a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group. The rate of hydrolytic release of the compound including the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety such that the rate of hydrolytic release of the compound including the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety.

 

Country   Type   Status   App. Date   App. Number   Grant Date   Grant Number   Expiration Date
Australia   Utility   Pending   Jul-27-2019   2019309523            
Canada   Utility   Pending   Jul-27-2019   3,107,317            
China   Utility   Pending   Jul-27-2019   CN201980063964            
Hong Kong   Utility   Published   Jan-26-2022   62022045767.0            
Europe   Utility   Pending   Jul-27-2019   19841823.8            
Israel   Utility   Pending   Jul-27-2019   280364            
Japan   Utility   Pending   Jul-27-2019   2021-504354            
Korea (South)   Utility   Pending   Jul-27-2019   10-2021-7006020            
New Zealand   Utility   Pending   Jul-27-2019   772903            
Singapore   Utility   Abandoned   Jul-27-2019   11202100593P            
US   Utility   Granted   Jan-27-2021   17/263,723   Sept-26-2023   11,766,432   7-27-2039
US   Utility   Pending   Sept-19-2023   18/370,069            

 

SER 23 Family: “Polyoxazoline-Drug Conjugates with Novel Pharmacokinetic Properties” (J. M. Harris et al.)

 

This family relates to all POZ polymer conjugates of cannabinoids, including and not limited to SER 228, SER 229, SER 232 and POZ-cannabinoids of cannabidivarin, cannabigerol and cannabichromene.

 

Country   Type   Status   App. Date   App. Number   Grant Date   Grant Number   Expiration Date
World Intellectual Property Org. (WIPO)   Utility   Pending   Jun-29-2020   PCT/US2020/040140                                      
Australia   Utility   Pending   Dec-23-2021   2020301324            
Canada   Utility   Pending   Dec-21-2021   3,144,774            
China   Utility   Pending   Jun-29-2020   CN202080060438            
Europe   Utility   Pending   Dec-20-2021   20830744.7            
Israel   Utility   Pending   Dec-21-2021   28921721            
Japan   Utility   Pending   Dec-24-2021   2021576959            
Korea   Utility   Pending   Jan-27-2022   10-2022-7003221            
New Zealand   Utility   Pending   Jun-29-2020   783931            
Singapore   Utility   Pending   Jun-29-2020   11202114046V            
US       Pending   Dec-21-2021   17/621,613            

 

287

 

 

SER 24 family: “Polyoxazoline-lipid Conjugates and Lipid Nanoparticles and Pharmaceutical Compositions Including Same” (J. M. Harris et al.)

 

This family relates to the chemical synthesis of POZ polymer conjugates of lipids that may be used to make lipid nanoparticles. The patent application discloses multiple different architectures of POZ, including but not limited to releasable linkages, stable linkages, therapeutic oligonucleotides (DNA, mRNA) and use in, and manufacture of, vaccines for infectious diseases and various therapeutic approaches.

 

Country   Type   Status   Application Date   Application Number   Grant Date   Grant Number   Expiration Date
US   Utility   Pending   Feb-04-2022   17/665,190            
PCT   Utility   Pending   Feb-04-2022   PCT/US22/15314            
Canada   Utility   Pending   Jul-24-2023   3206128            
China   Utility   Pending   Sept-28-2023   10000513331914            
Japan   Utility   Pending   Aug-08-2023   2023-547812            
Israel   Utility   Pending   Jul-26-2023   304773            
Europe   Utility   Pending   Aug-24-2023   22753169.6            
Australia   Utility   Pending   Jul-24-2023   2022219902            
New Zealand   Utility   Pending   Jul-25-2023   802213            
South Korea       Pending   Sept-6-2023   10-2023-7030341            

 

SER-25: “Targeting of Antigen-Presenting Cells by Nanoparticles Containing POZ-Lipid Conjugates” (R. Moreadith et al.)

 

Serina co-owns, along with Georgia Tech Research Corporation (GTRC), a patent application related to a method of targeting antigen-presenting cells with lipid nanoparticles (LNPs) including polyoxazoline-lipid conjugates (or pharmaceutical compositions including such LNPs).

 

Country   Type   Status   App. Date   App. Number   Grant Date   Grant Number   Expiration Date
US   Utility   Pending   Jan-20-2023   63/440,210            
US   Utility   Pending   Dec-21-2023   18/391,869            
PCT   Utility   Pending   Dec-21-2023   PCT/US23/85316            

 

Competition

 

Serina faces substantial competition from multiple sources, including large and specialty pharmaceutical, biopharmaceutical, and biotechnology companies, academic research institutions and governmental agencies, and public and private research institutions. Serina’s competitors compete with it on the level of the technologies employed, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i) obtain support for their research, development, and commercialization of products or (ii) combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with Serina’s current or future product candidates. Serina anticipates it will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge within the field of drug delivery generally and, furthermore, within the treatment of diseases in which Serina expects to compete in the future.

 

288

 

 

In addition to the current treatments for patients, numerous commercial and academic preclinical studies and clinical trials are being undertaken by many parties to assess novel technologies and product candidates in the field of CNS disorders. Results from these studies and trials have fueled increasing levels of interest in the CNS field.

 

Several companies are in the business of developing and marketing polymer-modified therapeutics, with the majority using PEG polymers. The covalent attachment of PEG to therapeutic agents, termed PEGylation, is a well-established and clinically proven drug delivery approach to improve the PK and pharmacodynamics of drugs. Specifically, PEGylation can improve the parent drug’s solubility, extend its circulation time, and reduce its immunogenicity, with minimal undesirable properties. PEGylation technology has been applied to various therapeutic modalities or payloads including small molecules, aptamers, peptides, and proteins, leading to over 30 FDA approved PEGylated drugs currently in use and many investigational PEGylated agents under clinical trials.

 

Serina’s drug delivery technology competitors include:

 

Nektar Therapeutics, Inc. (Nektar) acquired Shearwater in 2001. Serina’s founders previously founded Shearwater. Shearwater developed the first generations of PEG, which became Nektar’s core technology platform after the acquisition. Nektar remains at the forefront of development of PEGylated compounds for use in humans. Nektar focuses primarily on developing products into early or mid-stage clinical trials before seeking a licensing partner to complete development (as in the example of NKTR-118, which was licensed to AstraZeneca in 2009 and is an approved product in both the US (under the name Movantik®) and the EU (under the name Moventig™). Despite the proven success of attaching PEG to proteins to enhance their pharmacokinetic properties, Nektar has had a series of recent setbacks with their approaches. In 2022 the Phase 3 trial for PEGylated IL-2 (bempegaldesleuken) failed in combination with Opdivo, resulting in Bristol-Myers Squibb returning the asset to Nektar. Nektar laid off 70% of its workforce as a result of the trial failure. In April 2023 Eli Lilly returned the IL-2 asset known as rezpeg to Nektar after it failed to meet clinical endpoints in a Phase 2 trial in atopic dermatitis. This prompted another reduction in workforce of 60%. The failures of these programs underscore the challenges of advancing some PEGylated product candidates beyond Phase 1 and into later stages of development.
Mersana Therapeutics Inc. (Mersana) develops ADCs by attaching toxins to a delivery system comprised of 60 kDa modified biodegradable dextran (doloflexin, dolosynthen), and then attaching this to multiple sites on an antibody. This polymer delivery system is complex and despite its success in preclinical animal models of cancer Mersana’s pipeline of dolosynthen ADCs has failed to advance through a randomized Phase 2 clinical trial to date. In 2018 the company began work on a newer version of its ADC technology referred to as immunosynthen which creates a more precise drug antibody ratio (DAR) aimed at immunostimulation. Mersana has ongoing partnerships with Merck KGaA and Asana to advance their newer platform programs into additional preclinical models and Phase 1.
Amunix, Inc. (Amunix) invented and patented a technology based upon E. coli synthesis of a tri-peptide (XTEN). These polypeptides have been shown to improve the pharmacokinetics of proteins in animals and in humans. Preliminary results suggest this peptide is broken down in the body and is non-immunogenic. Amunix’s technology has only been applied to proteins to date. Amunix advanced several of its proprietary XTEN conjugates into late-stage development with Roche and Biogen. In 2021 the company advanced its XTEN technology and began focusing on immune modulation of T-cells via a protease cleavable “mask” polypeptide (PRO-XTEN). The strategy is aimed at cleaving the mask polypeptide only in the tumor microenvironment to “unmask” the T-cell engagers and cytokines locally in the tumor. In 2021 Amunix was acquired by Sanofi.

 

289

 

 

Serina believes that its POZ Platform™ has the advantages of each of the major technology competitors without any known added risk to the development profile.

 

Product Competition

 

SER 214 – POZ-rotigotine (Parkinson’s disease)

 

Parkinson’s disease continues to be a progressive disorder and available treatments are symptomatic rather than disease-modifying. Treatment differs in early and late stage disease. However, levodopa and dopamine agonists are central to treatment in both stages. Levodopa has been used to treat Parkinson’s disease for many years and is considered to be one of the most effective treatments available in the Parkinson’s disease drug market. However, as the condition progresses, patients may begin to experience side effects from levodopa treatment, such as involuntary movements (known as dyskinesia). In recent years, several new drugs have been developed that offer promising results in clinical trials. Other Parkinson’s disease drugs include MAO-B inhibitors and COMT inhibitors. MAO-B inhibitors work by breaking down dopamine, while COMT inhibitors prevent dopamine from being broken down. These drugs can be used alone or in combination with each other or with levodopa.

 

Rotigotine is a non-ergolinic dopamine receptor agonist (not a chemical member of the ergot class of drugs). In vitro binding studies and functional assays indicate a high affinity for the dopaminergic system (Dl, D2, D3, D4, D5 receptors), particularly D3 receptors. Rotigotine is thought to elicit its beneficial effect by activation of the D3, D2 and Dl receptors of the caudate-putamen region of the brain.

 

Rotigotine is marketed by UCB, S.A. as Neupro®. Neupro® delivers rotigotine via a daily application of a transdermal patch and is indicated for the treatment of Parkinson’s disease and for the treatment of moderate-to-severe RLS. In early-stage Parkinson’s disease, the recommended starting dose of Neupro® is 2 mg / 24 hours. Dose may be increased on a weekly basis if additional therapeutic effect is needed, by 2 mg / 24 hours. The maximum recommended dose for early stage Parkinson’s disease is 6 mg / 24 hours. In patients with late stage disease the recommended starting dose is 4 mg / 24 hours up to a maximum of 8 mg / 24 hours (20).

 

SER 227 – POZ-buprenorphine (long-acting analgesic for post-operative pain)

 

The post-surgical pain marketplace is crowded with older generic drugs as well as drugs with novel mechanisms of action. The numerous reports of patient dissatisfaction with current approaches for many opioid and non-opioid drugs currently in development illustrate that there is still an unmet medical need in the area. Not surprisingly, the opioid drugs in development are mainly centered on lowering abuse potential and reducing adverse events. The non-opioid drugs under development consist of novel combinations of established drugs or drugs with novel mechanisms of action that make them compatible with the multimodal approach to pain management.

 

Among the non-opioid drugs currently being developed, Heron Therapeutics, Inc.’s pipeline of approved products includes Sustol (granisetron injection), Cinvanti (apepritant injection, emulsion), Zynrelef (bupivacaine + meloxicam, injection) and Aponvie (apepritant emulsion, injection). Durect Corporation’s POSIMIR®, Innocoll AG’s Xaracoll® and Heron Therapeutics’ Zynrelef employ the local anesthetic, bupivacaine, as the central element of their pain control strategy. The efficacy of bupivacaine has been demonstrated by Pacira Pharmaceuticals, Inc. (Pacira) in its development and commercialization of the drug Exparel®, the first extended-release version of bupivacaine approved in the United States for administration into the surgical site for post-surgical pain control. Zynrelef is now approved as an extended-release formulation.

 

290

 

 

Exparel® was approved by the FDA in October 2011 for administration into the surgical site for post-surgical pain control. Exparel® is a long-acting sustained release formulation of bupivacaine (brand name: Marcaine) formulated using Pacira’s proprietary DepoFoam® technology (a multilayer liposomal vesicle that encapsulates a drug and releases it slowly over time without altering the released drug). The half-life of Exparel® is approximately ten times longer than bupivacaine – approximately 24 hours versus approximately 2.7 hours, respectively (data based on a pharmacokinetic study and half-life does not appear to be proportional to duration of treatment). Reports have indicated that surgeons use Exparel® with bupivacaine (for more immediate pain relief) as well as potentially with NSAIDS and steroids. The Exparel® label prohibits or discourages other combinations and specifically prohibits combination with lidocaine.

 

SER 227 is a POZ-polymer conjugate of buprenorphine, a potent mixed mu-agonist/antagonist that binds with high affinity to the mu-receptor. When bound to the mu-receptor, it triggers the mu-agonist pathway leading to potent analgesia (pain relief), but it is neither addictive nor does it produce a euphoria. Buprenorphine is fifty times more potent than morphine in animals and humans, and as such could be used in the setting of post-operative pain relief. Indeed, buprenorphine injection (Buprenex®) was approved over 35 years ago for control of post-operative pain, but its pharmacokinetic profile was suboptimal for continued dosing, and it was not a commercial success for human use. It is widely used in the care of veterinary animals for post-operative pain control. Buprenorphine is a well-characterized and approved drug for opioid use disorder (OUD), but the formulations that are approved for that indication would not be suitable for pain relief in the immediate post-operative period. The implant (Probuphine, Titan Pharmaceuticals) and the monthly injection (Sublocade, Indivior) are approved for chronic therapy in subjects who are not naïve to opioids, and those formulations provide weeks to months of release of buprenorphine. While those formulations are approved for OUD, they are not used for post-operative pain control as they do not have a desirable PK profile. In the rat and monkey preclinical studies conducted by Serina in 2017, SER 227 was found to promote prompt and sustained analgesia in the Brennan model in the rat with a > 3 day profile of steady-state release in the monkey. This profile would likely provide sustained analgesia in humans as well. The Company believes that such a product would not only provide adequate analgesia in the immediate post-operative period, but would prevent the need to use other opioids such as morphine or oxycodone to control pain. Thus, SER 227 would simultaneously target the initial gateway in the hospital that results in patients being exposed to addictive opioids.

 

In 2017, Serina commissioned inVentiv Health to conduct a market research report on the potential use of SER 227 in the treatment of post-operative pain. The report involved surveys among health care providers, surgeons, anesthesiologists, and health care payers. If approved by the FDA, and if effective, SER 227 would be indicated for use in the in-hospital setting for major surgical procedures (thoracotomy, abdominoplasty, major abdominal surgery, knee, and hip replacements).

 

SER 228 (POZ-cannabidiol) and SER 232 (POZ-tetrahydrocannabinol)

 

There has been anecdotal evidence of the medical benefits of cannabis for centuries. However, it is only in the last few decades that the pharmaceutical industry has been able to investigate the plant’s clinical benefit through the development of pharmaceutical agents based on the major two components (cannabidiol (CBD) and tetrahydrocannabinol (THC)). The advancement of these as pure pharmaceutical preparations into controlled clinical trials that are acceptable to regulatory authorities is an area of active clinical research.

 

GW has clinically validated the use of CBD in its development of Epidiolex®, a proprietary sesame seed formulation of relatively pure plant-derived CBD (98% oil-based CBD extract of known and constant composition). This oily mix has been approved for the treatment of severe, rare childhood-onset, treatment-resistant epilepsy disorders including Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), and Tuberous Sclerosis Complex (TSC). Epidiolex® was approved by the FDA in June 2018, and became available in November 2018, for the treatment of seizures associated with LGS and DS in patients two years of age or older. It is the first prescription pharmaceutical formulation of highly purified, plant-derived CBD, and the first in a new category of anti-epileptic drugs. Epidiolex® when approved was a Schedule 1 drug. However, the Drug Enforcement Agency (DEA) put Epidiolex® in Schedule V, the least restrictive schedule of the Controlled Substances Act, in October 2018. GW was acquired by Jazz Pharmaceuticals (Jazz) in May 2021

 

291

 

 

Zynerba Pharmaceuticals (Zynerba) is developing ZYN002 (Zygel), a synthetic CBD formulation with a permeation enhancer gel for transdermal delivery. In late 2017, Zynerba announced the results of the Phase II study in adults with non-convulsive and convulsive seizures; the trial failed to meet the pre-specified endpoint. A post-hoc analysis of the data suggested there was a high response rate in the placebo group that may have confounded the study results. Zynerba continued the development of ZYN002 for both refractory epilepsy, osteoarthritis, and Fragile X Syndrome (FXS), with a focus on rare forms of epilepsy. Zygel failed to meet the primary endpoint in the osteoarthritis trial but in the INSPIRE trial of patients with the 22q11.2 deletion syndrome the open label Phase 2 trial met the primary endpoint. In August 2023 Zynerba was acquired by Harmony Biosciences (Harmony). Harmony will continue the development of Zygel for 22q11.2 deletion syndrome and will advance Zygel into Phase 3 for FXS.

 

GW developed a buccal spray known as nabiximols or Sativex®, which comprises delta-9-tetrahydrocannabinol (27 mg/mL) and cannabidiol (25 mg/mL), as an analgesic agent for the treatment of neuropathic pain, spasticity, cancer pain and for neuroprotection in Huntington’s disease. The product, which contains soft extracts from Cannabis sativa, is primarily indicated for the treatment of multiple sclerosis (MS) related spasticity. It has been launched in the UK, Canada, Denmark, Germany, Ireland, Italy, Finland, Austria, Poland, Portugal, Israel, Norway, Spain, Czech Republic, the Netherlands, New Zealand, Sweden, and Switzerland. Nabiximols has also been registered in Australia, Belgium, Iceland, Kuwait, Luxembourg, Slovakia, and France. Nabiximols is also awaiting approval for this indication in several countries in the Middle East. In Canada, the product is also launched for the adjunctive treatment of cancer pain and neuropathic pain in adults with MS. It is marketed in Israel for neuropathic pain in adults with MS. Clinical trials are underway in cancer pain in the US and Europe. Phase I/II development is underway in UK and Germany. Despite approval in the territories above, Sativex is not approved for any indication in the US. Phase III development for MS-related neuropathic pain has been discontinued in the UK, France, Spain and Czech Republic.

 

The drug Marinol® is one of the oldest pharmaceutical compositions of THC and was initially commercialized by AbbVie as dronabinol capsules. Dronabinol is a man-made compound containing THC in standard concentrations. It was approved by the FDA in 1985 for the management of loss of appetite associated with weight loss in AIDS and prevention of chemotherapy induced nausea and vomiting (CINV) in patients who have failed to respond to standard of care. Insys Therapeutics developed Syndros™ (dronabinol in an oral solution) for the same indications with approval in July 2016.

 

Meda Pharmaceuticals, Inc. markets Cesamet®. Cesamet® is nabilone, a synthetic THC, in capsules and is indicated for the treatment of CINV. Both Marinol™ and Cesamet® contain low amounts of THC, and absorption from the gut demonstrates low bioavailability and high first pass metabolism.

 

Vaccines that Employ Lipid Nanoparticle (LNP) Delivery of RNA

 

Serina’s patent estate includes POZ conjugates of lipids that may prove to be useful in development of LNP technologies. The exploitation of LNP technology for the delivery of infectious disease vaccines, gene therapies and cancer immunotherapies has exploded in the last three years. Following the approvals of the Pfizer/BioNTech and Moderna mRNA vaccines for SARS-CoV-2 (COVID-19 disease) in December 2020 hundreds of companies including both large and small pharma, and small biotechnology companies such as Serina, have advanced their pipelines with novel approaches for development of LNP approaches to disease.

 

292

 

 

Industry reports show over 1,200 LNP delivered therapeutics currently in development. This rapid growth in development activity, while presenting prospective partnering opportunities for Serina, highlights the level of competition in the field. Many of Serina’s competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than Serina does. Mergers and acquisition activity in the pharmaceutical, biopharmaceutical and biotechnology sector is likely to result in greater resource concentration among a smaller number of Serina’s competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with Serina in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, Serina’s programs.

 

Serina’s commercial opportunity could be reduced or eliminated if one or more of its competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than Serina’s proposed product offering. Serina’s competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before Serina is able to enter the market. The key competitive factors affecting the success of all of Serina’s programs are likely to be product safety, efficacy, convenience, and treatment cost.

 

Government Regulation and Product Approval

 

Government authorities in the United States, at the federal, state, and local level, and in other countries, extensively regulate, among other things, the research, development, testing, approval, manufacturing, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import, and export of biopharmaceutical products. In addition, sponsors of biopharmaceutical products participating in Medicaid, Medicare, and other government health care programs are required to comply with mandatory price reporting, discount, and rebate requirements. Serina, along with its third party contractors, will be required to navigate the various preclinical, clinical, and commercial approval requirements of the governing regulatory agencies of the countries in which Serina wishes to conduct studies or seek approval or licensure of its product candidates. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with compliance with applicable statutes and regulations, requires the expenditure of substantial time and financial resources.

 

FDA Regulation

 

In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Services Act, or PHSA, and their implementing regulations. The FDA further has issued a growing body of guidance documents, which, while not binding, provide the agency’s current interpretation of its statutes and regulations. Failure to comply with the applicable U.S. requirements may subject an applicant to administrative or judicial sanctions, such as FDA refusal to approve pending biologics license applications, or BLAs, or the agency’s issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution brought by the FDA and the U.S. Department of Justice or other governmental entities.

 

The process required by the FDA before product candidates may be marketed in the United States generally involves the following:

 

completion of preclinical (or nonclinical) laboratory tests and formulation studies in compliance with the FDA’s good laboratory practice, or GLP, regulations;

 

293

 

 

submission to the FDA of an IND, which must become effective before human clinical trials may begin at United States clinical trial sites;

 

approval by an institutional review board, or IRB, for each clinical site, or centrally, before each trial may be initiated;

 

performance of adequate and well controlled human clinical trials to establish the product candidate’s safety, purity, potency, and efficacy for its intended use, performed in accordance with good clinical practice, or GCP, as well as IND regulations and other clinical trial related regulations;

 

development of manufacturing processes to ensure the product candidate’s identity, strength, quality, purity, and potency in compliance with current good manufacturing practice, cGMP, regulations;

 

submission to the FDA of a BLA;

 

satisfactory completion of an FDA advisory committee review, if applicable;

 

satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product candidate is produced to assess compliance with cGMPs, and to assure that the facilities, methods, and controls are adequate to preserve the therapeutics’ identity, strength, quality, purity, and potency, as well as satisfactory completion of potential FDA inspection of selected clinical sites and selected clinical investigators to determine GCP compliance; and

 

FDA review and approval of the BLA to permit commercial marketing for particular indications for use.

 

Preclinical Studies and IND Submission

 

The testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. Preclinical studies include laboratory evaluation of chemistry, pharmacology, toxicity, and product formulation, and may involve in vitro testing or in vivo animal studies to assess the potential for toxicity, adverse events, and other safety characteristics of the product candidate, and in some cases to establish a rationale for therapeutic use. Such studies must generally be conducted in accordance with FDA GLP regulations. The Consolidated Appropriations Act for 2023, signed into law on December 29, 2022, (P.L. 117 328) amended the FDCA and the Public Health Service Act to specify that nonclinical testing for drugs and biologics may, but is not required to, include in vivo animal studies. According to the amended language, a sponsor may fulfill nonclinical testing requirements by completing various in vitro assays (e.g., cell based assays, organ chips, or microphysiological systems), in silico studies (i.e., computer modeling), other human or nonhuman biology based tests (e.g., bioprinting), or in vivo animal studies.

 

Prior to commencing the first clinical trial at a U.S. investigational site with a product candidate, an IND sponsor must submit the results of the nonclinical tests and literature, together with manufacturing information, analytical data, any available clinical data, or literature (including data from clinical trials conducted outside of the United States), and proposed clinical study protocols among other things, to the FDA as part of an IND. An IND is a request from a clinical study sponsor to obtain authorization from the FDA to administer an investigational drug or biologic product to humans, as well as authorization to administer the product candidate to humans in accordance with a specific clinical trial protocol. Some long term nonclinical testing to further establish the safety profile of the product candidate, as well as manufacturing process development and product quality evaluation, continues after the IND is submitted.

 

An IND goes into effect upon notification by FDA or automatically 30 days after receipt by the FDA, unless the FDA, within the 30 day time period, notifies the applicant of safety concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve all outstanding concerns or questions posed by the FDA before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or non-compliance with applicable regulations. As a result, submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development.

 

294

 

 

Clinical Trials

 

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with federal regulations and GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, as well as review and approval of the trial by an IRB. Investigators must also provide certain information to the clinical trial sponsors to allow the sponsors to make certain financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety, the effectiveness criteria to be evaluated, and a statistical analysis plan. A protocol for each clinical trial, and any subsequent protocol amendments, must be submitted to the FDA as part of the IND. In addition, an IRB at each site participating in the clinical trial, or a central IRB, must review and approve the plan for any clinical trial, informed consent forms, and communications to trial subjects before a trial commences at that site. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits, and whether the planned human subject protections are adequate. The IRB must continue to oversee the clinical trial while it is being conducted. If a product candidate is being investigated for multiple intended indications, separate INDs may also be required. Status reports summarizing the progress of the clinical trials must be submitted at least annually to the FDA and the IRB and more frequently if suspected unexpected serious adverse reactions occur, findings from other studies suggest a significant risk to humans exposed to the biologic, findings from animal or in vitro testing suggest a significant risk for human subjects, or other significant safety information is found.

 

The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions on various grounds, including if the agency believes that the clinical trial either is not being conducted in accordance with regulatory requirements or presents an unacceptable risk to the clinical trial patients. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements or if the trial poses an unexpected serious harm to subjects. The FDA or an IRB may also impose conditions on the conduct of a clinical trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities. Some clinical trials also include oversight by an independent group of qualified experts organized by the trial sponsor, known as an independent data monitoring committee, or IDMC, which provides authorization for whether a trial may move forward at designated check points based on review of certain data from the trial, to which only the IDMC has access, and may recommend halting the trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.

 

Sponsors of clinical trials of certain FDA regulated products generally must register and disclose certain clinical trial information to a public registry maintained by the NIH. In particular, information related to the investigational product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results may be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. The NIH’s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and the government has brought enforcement actions against non-compliant clinical trial sponsors. Sponsors or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions must also have a publicly available policy on evaluating and responding to requests for expanded access requests.

 

295

 

 

The manufacture of investigational biologics for the conduct of human clinical trials is subject to cGMP requirements. Investigational biologics and their therapeutic substances that are imported into the United States are also subject to regulation by the FDA. Further, the export of investigational products outside of the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the FDCA.

 

In general, for purposes of BLA approval, human clinical trials are typically conducted in three sequential phases, which may overlap or be combined.

 

Phase 1 The product candidate is initially administered to healthy human volunteers and tested for safety, dosage tolerance, structure activity relationships, mechanism of action, absorption, metabolism, distribution, and excretion. In the case of some products for severe or life threatening diseases, such as cancer, especially when the product may be too inherently toxic to administer ethically to healthy volunteers, the initial human testing is often conducted in patients with the target disease or condition. If possible, Phase 1 trials may also be used to gain an initial indication of product effectiveness.

 

Phase 2 Studies are conducted in limited subject populations with a specified disease or condition to evaluate preliminary efficacy, identify optimal dosages, dosage tolerance and schedule, possible adverse effects and safety risks, and expanded evidence of safety. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more extensive clinical trials.

 

Phase 3 Clinical trials are undertaken with expanded subject populations, generally at geographically dispersed clinical trial sites, to generate sufficient data to provide statistically significant evidence of clinical efficacy and safety of the product candidate, to establish the overall risk benefit profile of the product candidate, and to provide adequate information for the labeling of the product candidate. Typically, two adequate, well controlled trials are required by the FDA for biological product approval. Under some limited circumstances, however, the FDA may approve a BLA based upon a single clinical trial plus confirmatory evidence from a post market trial or, alternatively, a single large, robust, well controlled multicenter trial without confirmatory evidence.

 

Additional kinds of data may also help to support a BLA, such as patient experience and real world data. For appropriate indications sought through supplemental BLAs, data summaries may provide marketing application support. For genetically targeted products and variant protein targeted products intended to address an unmet medical need in one or more patient subgroups with a serious or life threatening rare disease or condition, the FDA may allow a sponsor to rely upon data and information previously developed by the sponsor or for which the sponsor has a right of reference, that was submitted previously to support an approved application for a product that incorporates or utilizes the same or similar genetically targeted technology or a product that is the same or utilizes the same variant protein targeted drug as the product that is the subject of the application.

 

The FDA may also require, or companies may voluntarily conduct, additional clinical trials for the same indication after a product is approved. These post approval trials, referred to as Phase 4 clinical trials, are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 trials as a condition of approval of a BLA. The results of Phase 4 studies can confirm or refute the effectiveness of a product candidate and can provide important safety information.

 

296

 

 

Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, manufacturers must develop methods for testing the identity, strength, quality, potency, and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

 

In the Consolidated Appropriations Act for 2023, Congress amended the FDCA to require sponsors of a Phase 3 clinical trial, or other “pivotal study” of a new drug to support marketing authorization, to submit a diversity action plan for such clinical trial. The action plan must include the sponsor’s diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. A sponsor must submit a diversity action plan to FDA by the time the sponsor submits the trial protocol to the agency for review. The FDA may grant a waiver for some or all of the requirements for a diversity action plan. It is unknown at this time how the diversity action plan may affect Phase 3 trial planning and timing or what specific information FDA will expect in such plans, but if FDA objects to a sponsor’s diversity action plan and requires the sponsor to amend the plan or take other actions, it may delay trial initiation.

 

Marketing Application Submission, Review by the FDA, and Marketing Approval

 

Assuming successful completion of the required clinical and preclinical testing in accordance with all applicable regulatory requirements, the results of product development, including chemistry, manufacture, and controls information, nonclinical studies, and clinical trial results, including negative or ambiguous results as well as positive findings, are all submitted to the FDA, along with the proposed labeling, as part of a BLA requesting approval to market the product for one or more indications. A BLA must contain sufficient evidence of the biological product candidate’s safety, purity, potency and efficacy for its proposed indication or indications. Data may come from company sponsored clinical trials intended to test the safety and efficacy of a product’s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.

 

Under the Prescription Drug User Fee Act, as amended, or PDUFA, each BLA submission is subject to a substantial application user fee, and the sponsor of an approved BLA is also subject to an annual program fee. The FDA adjusts the PDUFA user fees on an annual basis. The application user fee must be paid at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Product candidates that are designated as orphan products are also not subject to application user fees unless the application also includes a non orphan indication.

 

In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA for a new active ingredient, indication, dosage form, dosage regimen, or route of administration, must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan, or PSP, within sixty days of an end of Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials or other clinical development programs. Orphan products are exempt from the PREA requirements.

 

297

 

 

The FDA Reauthorization Act of 2017 introduced a provision regarding required pediatric studies. Under this statute, for product candidates intended for the treatment of adult cancer which are directed at molecular targets that the FDA determines to be substantially relevant to the growth or progression of pediatric cancer, original application sponsors must submit, with the marketing application, reports from molecularly targeted pediatric cancer investigations designed to yield clinically meaningful pediatric study data, gathered using appropriate formulations for each applicable age group, to inform potential pediatric labeling. The FDA may, on its own initiative or at the request of the applicant, grant deferrals or waivers of some or all of this data, as above. Unlike PREA, orphan products are not exempt from this requirement.

 

The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, if it determines that a REMS is necessary to ensure that the benefits of the product candidate outweigh the risks and to assure safe use of the biological product. The REMS plan could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case by case basis. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required. An assessment of the REMS must also be conducted at set intervals. Following product approval, a REMS may also be required by the FDA if new safety information is discovered and the FDA determines that a REMS is necessary to ensure that the benefits of the product outweigh the risks.

 

Once the FDA receives an application, it has 60 days to review the BLA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in depth substantive review.

 

Under the goals and policies agreed to by the FDA under PDUFA, the FDA has set the review goal of completing its review of 90% of BLAs within ten months of the filing date for a standard application and within six months of the filing date for an application with priority review. For all original BLAs, the ten and six month time periods run from the filing date; for all other submissions, including resubmissions, efficacy supplements and other supplements, the FDA’s stated review time periods, ranging from two to ten months, run from the submission date. This review goal is referred to as the PDUFA date. The PDUFA date is only a goal, and it is not uncommon for FDA review of a BLA to extend beyond the PDUFA date. The review process and the PDUFA date may also be extended if the FDA requests, or the sponsor otherwise provides, substantial additional information or clarification regarding the submission.

 

The FDA may also refer certain applications to an advisory committee. Before approving a product candidate for which no active ingredient has previously been approved by the FDA, the FDA must either refer that product candidate to an external advisory committee or provide in an action letter a summary of the reasons why the FDA did not refer the product candidate to an advisory committee. The FDA may also refer other product candidates to an advisory committee if FDA believes that the advisory committee’s expertise would be beneficial. An advisory committee is typically a panel that includes clinicians and other experts, which review, evaluate, and make a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making product approval decisions.

 

298

 

 

The FDA reviews a BLA to determine, among other things, whether a product candidate meets the agency’s approval standards, such as whether the application includes sufficient evidence that the product candidate is safe and effective for the proposed indications, and whether the manufacturing methods and controls are adequate to assure and preserve the product’s identity, strength, quality, potency, and purity. As part of its review, the FDA likely will re analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. Before approving a marketing application, the FDA typically will inspect the facility or facilities where the product is manufactured, referred to as a pre-approval inspection. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontractors, are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a marketing application the FDA will inspect one or more clinical trial sites to assure compliance with applicable IND trial requirements and GCP. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production, and quality control.

 

After evaluating the marketing application and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter, or CRL. A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form, and it describes all of the specific deficiencies that the FDA identified. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the marketing application and may require additional clinical or preclinical testing for the FDA to reconsider the application. The deficiencies identified may be minor, for example, requiring labeling changes; or major, for example, requiring additional Phase 3 clinical trials. If a CRL is issued, the applicant may either: resubmit the marketing application, addressing all of the deficiencies identified in the letter; withdraw the application; or request an opportunity for a hearing. The FDA has the goal of reviewing 90% of application resubmissions in either two or six months of the resubmission date, depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA’s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications.

 

Even if the FDA approves a product, it may limit the approved indications or populations for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, including a boxed warning, require that post approval studies, including Phase 4 clinical trials, be conducted to further assess a product’s safety and efficacy after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA also may not approve label statements that are necessary for successful commercialization and marketing or may prevent or limit further marketing of a product based on the results of post marketing trials or surveillance programs.

 

After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. The FDA may also withdraw the product approval if compliance with regulatory standards are not maintained or if problems occur after the product reaches the marketplace. Further, should new safety information arise, additional testing, product labeling, or FDA notification may be required.

 

299

 

 

Patent Term Restoration

 

Depending upon the timing, duration, and specifics of FDA approval of Serina’s biological product candidates, some of Serina’s U.S. patents may be eligible for limited patent term extension. These patent term extensions permit a patent restoration term of up to five years as compensation for any patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term restoration period is generally one half the time between the effective date of an IND, and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.

 

Biosimilars and Exclusivity

 

The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products shown to be biosimilar to or interchangeable with an FDA licensed reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.

 

Biosimilarity, which requires no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be demonstrated through analytical studies, animal studies, and a clinical trial or trials. There must be no difference between the reference product and a biosimilar in mechanism of action, conditions of use, route of administration, dosage form, and strength. A biosimilar product may be deemed interchangeable with the reference product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic without such alternation or switching. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product, although to date no such products have been approved for marketing in the United States. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.

 

A reference biologic is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biological product will be granted an exclusivity period of up to one year after it is first commercially marketed. However, certain changes and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do not qualify for the 12 year exclusivity period. As part of the Consolidated Appropriations Act for 2023, Congress amended the PHSA in order to permit multiple interchangeable products approved on the same day to receive and benefit from this one year exclusivity period. If pediatric studies are performed and accepted by the FDA as responsive to a written request, the 12 year exclusivity period will be extended for an additional six months. In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. “First licensure” typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the “first licensure” of a biological product is determined on a case by case basis with data submitted by the sponsor.

 

300

 

 

The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.

 

Pediatric Exclusivity

 

Pediatric exclusivity is a type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This six month exclusivity may be granted if a sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA’s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA      cannot approve another application. The issuance of a written request does not require the sponsor to undertake the described studies.

 

Orphan Product Designation and Exclusivity

 

The Orphan Drug Act provides incentives for the development of products for rare diseases or conditions. Specifically, sponsors may apply for and receive Orphan Drug Designation, or ODD, if a product candidate is intended to treat a rare disease or condition, which is generally a disease or condition affecting less than 200,000 individuals in the United States, or affecting more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States will be recovered from United States sales. Additionally, sponsors must present a plausible hypothesis for clinical superiority to obtain ODD if there is a product already approved by the FDA that that is considered by the FDA to be the same as the already approved product and is intended for the same indication. This hypothesis for clinical superiority must be demonstrated to obtain orphan exclusivity. Orphan drug designation must be requested before submitting a marketing application for the product candidate and does not convey any advantage in or shorten the duration of the regulatory review and approval process. If granted, ODD entitles the applicant to financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages, and certain user fee waivers. After the FDA grants ODD, the identity of the therapeutic agent and its potential orphan use will be disclosed publicly by the FDA; the posting will also indicate whether the drug or biologic is no longer designated as an orphan product. More than one product candidate may receive an orphan designation for the same indication.

 

301

 

 

In addition, if a product candidate receives FDA approval for the indication for which it has ODD, the product is generally entitled to orphan exclusivity, which means the FDA may not approve any other application to market a product containing the same active moiety for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. A product is clinically superior if it is safer, more effective or makes a major contribution to patient care. Thus, orphan drug exclusivity could block the approval of one of Serina’s potential products for seven years if a competitor obtains approval of the same product as defined by the FDA and Serina is not able to show the clinical superiority of its product candidate or if its product candidate’s indication is determined to be contained within the competitor’s product orphan indication. In addition, the FDA will not recognize orphan drug exclusivity if a sponsor fails to demonstrate upon approval that the product is clinically superior to a previously approved product containing the same active moiety for the same orphan condition, regardless of whether or not the previously approved product was designated an orphan drug or had orphan drug exclusivity. A product that has received ODD may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received the designation. Orphan exclusivity does not prevent the FDA from approving a different drug or biological product for the same disease or condition, or the same product for a different disease or condition.

 

Recent court cases have challenged FDA’s approach to determining the scope of orphan drug exclusivity; however, at this time the agency continues to apply its long standing interpretation of the governing regulations and has stated that it does not plan to change any orphan drug implementing regulations.

 

Fast Track, Breakthrough Therapy and Priority Review Designations

 

The FDA is authorized to designate certain products for expedited development or review if they are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs or present a significant improvement over existing therapy. These programs include fast track designation, breakthrough therapy designation and priority review designation.

 

To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product candidate is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. In addition, the FDA may initiate review of sections of a marketing application before the application is complete. This “rolling review” is available if the applicant provides and the FDA approves a schedule for the submission of the application sections and the sponsor pays any required user fees upon submission of the first section of the application. In some cases, a product with fast track designation may be eligible for accelerated approval or priority review if the relevant criteria are met. The FDA may rescind, or the sponsor may forfeit, fast track designation if the designation is no longer supported by data emerging from the clinical trial process.

 

Under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted in 2012, a sponsor may request designation of a product candidate as a “breakthrough therapy.” A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drug or biologic, to treat a serious or life threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Products designated as breakthrough therapies are eligible for the same benefits described above for fast-track designation, as well as intensive guidance on an efficient development program beginning as early as Phase 1 trials, and a commitment from the FDA to involve senior managers and experienced review staff in a proactive collaborative and cross disciplinary review. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval of their respective marketing applications.

 

302

 

 

Finally, the FDA may grant priority review designation to product candidates that are intended to treat serious conditions and, if approved, would provide significant improvements in the safety or effectiveness over existing therapies. The FDA determines at the time that the marketing application is submitted, on a case by case basis, whether the proposed drug or biologic represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment limiting reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application from ten months to six months for an original application from the date of filing.

 

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.

 

Accelerated Approval

 

In addition, products studied for their safety and effectiveness in treating serious or life threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA will require that a sponsor of a drug receiving accelerated approval perform post marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.

 

For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug or biologic, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long term clinical benefit of a drug or biologic.

 

The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a drug or biologic, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs and biologics for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.

 

303

 

 

The accelerated approval pathway is usually contingent on a sponsor’s agreement to conduct, in a diligent manner, additional post approval confirmatory studies to verify and describe the drug’s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post marketing compliance requirements, including the completion of Phase 4 or post approval clinical trials to establish the effect on the clinical endpoint. Failure to conduct required post approval studies, or to confirm the predicted clinical benefit of the product during post marketing studies, would allow the FDA to withdraw approval of the drug. As part of the Consolidated Appropriations Act for 2023, Congress provided FDA additional statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under the act’s amendments to the FDCA, FDA may require the sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval. The sponsor must also submit progress reports on a confirmatory trial every six months until the trial is complete, and such reports are published on FDA’s website. The amendments also give FDA the option of using expedited procedures to withdraw product approval if the sponsor’s confirmatory trial fails to verify the claimed clinical benefits of the product.

 

All promotional materials for product candidates being considered and approved under the accelerated approval program are subject to prior review by the FDA.

 

Post-Approval Requirements

 

Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and record keeping requirements, reporting of adverse experiences with the product, periodic reporting requirements, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, as well as advertising and promotion requirements, which include, among others, standards for direct to consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product’s approved uses (known as off label use), limitations on industry sponsored scientific and educational activities, and requirements for promotional activities involving the Internet.

 

After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval of a new BLA or a supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials. The FDA may also place other conditions on approvals, including the requirement for a REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products.

 

In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the quality and long term stability of the product. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for Serina’s product candidates must meet cGMP requirements and satisfy the FDA or comparable foreign regulatory authorities before any product is approved and Serina’s commercial products can be manufactured. Serina relies, and expects to continue to rely, on third parties for the production of clinical and commercial quantities of its products in accordance with cGMP regulations. These third-party manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers, including third party manufacturers, and other entities involved in the manufacture and distribution of approved biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of Serina’s CMOs that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, voluntary recall and regulatory sanctions as described below.

 

304

 

 

The FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. A company can make only those claims relating to a product that are approved by the FDA. Physicians, in their independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described in the product’s labeling and that differ from those tested and approved by the FDA. Biopharmaceutical companies, however, are required to promote their products only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability, including, but not limited to, criminal and civil penalties under the FDCA and False Claims Act, exclusion from participation in federal health care programs, mandatory compliance programs under corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts.

 

Moreover, the Drug Supply Chain Security Act, or DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA imposes phased in and resource intensive obligations on biopharmaceutical manufacturers, wholesale distributors, and dispensers related to product tracking and tracing over a 10 year period that is expected to culminate in November 2023. Among the requirements of this legislation, manufacturers are required to provide certain information regarding the products to wholesale distributors and dispensers to which product ownership is transferred, label products with a product identifier, and keep certain records regarding the product. A manufacturer must also verify that purchasers of the manufacturer’s products are appropriately licensed. Further, under this legislation, manufacturers have product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences of death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.

 

FDA’s post market requirements are continuously evolving, and additional requirements may apply. For instance, in March 2020, the U.S. Congress passed the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes various provisions regarding FDA drug shortage reporting requirements, as well as provisions regarding supply chain security, such as risk management plan requirements, and the promotion of supply chain redundancy and domestic manufacturing. Any changes of law may require that Serina modify how it conducts its business and may require additional expenditure to ensure that Serina is in compliance.

 

Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in significant regulatory actions. Such actions may include refusal to approve pending applications, license or approval suspension or revocation, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification of promotional materials or labeling, provision of corrective information, imposition of post market requirements including the need for additional testing, imposition of distribution or other restrictions under a REMS, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in federal and state health care programs, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, and adverse publicity, among other adverse consequences.

 

305

 

 

Additional Controls for Biologics

 

To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.

 

After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing the results of all of the manufacturer’s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer.

 

In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.

 

Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations

 

Although Serina currently does not have any products on the market, its business activities and current and future arrangements with investigators, health care professionals, consultants, third party payors and customers may be subject to regulation and enforcement by numerous federal and state regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Department of Justice, the Department of Health and Human Services and its various divisions, including the Centers for Medicare and Medicaid Services, or CMS, and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense, and state and local governments. Serina’s business activities must comply with numerous health care laws, including but not limited to, Anti-Kickback and false claims laws and regulations as well as data privacy and security laws and regulations, which are described below, as well as state and federal consumer protection and unfair competition laws.

 

The federal Anti-Kickback Statute, which regulates, among other things, marketing practices, educational programs, pricing policies, and relationships with health care providers or other entities, prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order, or the referral to another for the furnishing or arranging for the furnishing of any item or service reimbursable under Medicare, Medicaid, or other federal health care programs, in whole or in part. The term “remuneration” has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical industry members on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. There are certain statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly, and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case by case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, including purchases of products paid by federal health care programs, the statute has been violated. The Patient Protection and Affordable Care Act, or ACA, of 2010, as amended, also modified the intent requirement under the Anti-Kickback Statute to a stricter standard, such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.

 

306

 

 

The federal civil False Claims Act, or FCA, prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or avoiding, decreasing, or concealing an obligation to pay money to the federal government. A claim includes “any request or demand” for money or property presented to the U.S. government. The civil False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper use of Medicare provider or supplier numbers when detailing a provider of services, improper promotion of off label uses, and allegations as to misrepresentations with respect to products, contract requirements, and services rendered. Intent to deceive is not required to establish liability under the civil False Claims Act. Civil False Claims Act actions may be brought by the government or may be brought by private individuals on behalf of the government, called “qui tam” actions. If the government decides to intervene in a qui tam action and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. The civil FCA provides for treble damages and a civil penalty for each false claim, such as an invoice or pharmacy claim for reimbursement, which can aggregate into millions of dollars. For these reasons, since 2004, False Claims Act lawsuits against biopharmaceutical companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements regarding certain sales practices and promoting off label uses. Civil False Claims act liability may further be imposed for known Medicare or Medicaid overpayments, for example, overpayments caused by understated rebate amounts that are not refunded within 60 days of discovering the overpayment, even if the overpayment was not caused by a false or fraudulent act. In addition, conviction, or civil judgment for violating the FCA may result in exclusion from federal health care programs, suspension and debarment from government contracts, and refusal of orders under existing government contracts.

 

The government may further prosecute conduct constituting a false claim under the criminal False Claims Act.

 

The criminal False Claims Act prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious, or fraudulent and, unlike the civil False Claims Act, requires proof of intent to submit a false claim.

 

The civil monetary penalties statute is another potential statute under which biopharmaceutical companies may be subject to enforcement. Among other things, the civil monetary penalties statue imposes fines against any person who is determined to have knowingly presented, or caused to be presented, claims to a federal health care program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent.

 

The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, also created federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, a health care benefit program, regardless of whether the payor is public or private, in connection with the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, health care benefits, items, or services relating to health care matters. Additionally, the ACA amended the intent requirement of certain of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation.

 

Under the federal Physician Payments Sunshine Act and its implementing regulations, manufacturers of biologics for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program (with certain exceptions) must make annual reports to CMS regarding payments and other transfers of value made to or at the request of covered recipients, such as, but not limited to, physicians, physician assistants, nurse practitioners, clinical nurse specialists, and certified registered nurse anesthetists and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family. Certain payments for clinical trials are included within the ambit of this law. CMS makes the reported information publicly available.

 

Further, Serina may be subject to data privacy and security regulation by both the federal government and the states in which it conducts its business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act, and its respective implementing regulations impose requirements on covered entities relating to the privacy, security, and transmission of individually identifiable health information, known as protected health information. Among other things, the HITECH Act, through its implementing regulations, makes HIPAA’s security standards and certain privacy standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity’s workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a function or activity regulated by HIPAA. The HITECH Act also strengthened the civil and criminal penalties that may be imposed against covered entities, business associates, and individuals, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney’s fees and costs associated with pursuing federal civil actions. In addition, other federal and state laws, such as the California Consumer Privacy Act, may govern the privacy and security of health and other information in certain circumstances, many of which differ from each other in significant ways and may not be preempted by HIPAA, thus complicating compliance efforts.

 

Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third party payor, including commercial insurers. Certain state laws also regulate sponsors’ use of prescriber identifiable data. Certain states also require implementation of commercial compliance programs and compliance with the pharmaceutical industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments or the provision of other items of value that may be made to health care providers and other potential referral sources; impose restrictions on marketing practices; or require sponsors to track and report information related to payments, gifts, and other items of value to physicians and other health care providers. Furthermore, to distribute products commercially, Serina must comply with state laws requiring the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Recently, states have enacted or are considering legislation intended to make drug prices more transparent and deter significant price increases, typically as consumer protection laws. These laws may affect our future sales, marketing, and other promotional activities by imposing administrative and compliance burdens.

 

307

 

 

If Serina’s operations are found to be in violation of any of the laws or regulations described above or any other laws that apply to it, Serina may be subject to penalties or other enforcement actions, including criminal and significant civil monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government health care programs, corporate integrity agreements, suspension and debarment from government contracts and nonprocurement transactions such as grants, and refusal of orders under existing government contracts, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of Serina’s operations, any of which could adversely affect Serina’s ability to operate its business and its results operations. Any action against us for violation of these laws, even if Serina successfully defends against it, could cause Serina to incur significant legal expenses and divert its management’s attention from the operation of its business.

 

To the extent that any of Serina’s products are sold in a foreign country, Serina may be subject to similar foreign laws and regulations, which may include, for instance, applicable post marketing requirements, including safety surveillance, antifraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to health care professionals.

 

Coverage and Reimbursement Generally

 

The commercial success of Serina’s product candidates and its ability to commercialize any approved product candidates successfully will depend in part on the extent to which governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers, and other third party payors provide coverage for and establish adequate reimbursement levels for Serina’s product candidates. Government authorities, private health insurers, and other organizations generally decide which therapeutics they will pay for and establish reimbursement levels for health care. A growing trend in recent years is the containment of health care costs.

 

Accordingly, governmental payors are increasingly trying control therapeutic prices through reimbursement restrictions, rebates, mandatory discounts, and formulary restrictions, among other strategies.

 

Medicare is a federal health care program administered by the federal government that covers individuals aged 65 and over as well as individuals with certain disabilities. Drugs and biologics may be covered under one or more sections of Medicare depending on the nature of the product and the conditions associated with and site of administration. For example, under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which provide coverage for outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level.

 

Medicare Part B covers most injectable drugs and biologics given in an in-patient setting and some products administered by a licensed medical provider in hospital outpatient departments and doctors’ offices. Medicare Part B is administered by Medicare Administrative Contractors, which generally have the responsibility of making coverage decisions. Subject to certain payment adjustments and limits, Medicare generally pays for a Part B covered drug or biologic based on a percentage of manufacturer reported average sales price, which is regularly updated. Serina believes that its product candidates, which are intended to be administered by a health care professional in a clinical environment, will be subject to the Medicare Part B rules.

 

308

 

 

In the United States, the European Union, and other markets for Serina’s product candidates, government authorities and third party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than they would otherwise be and sometimes at or below the provider’s acquisition cost. In the United States, it is also common for government and private health plans to use coverage determinations to leverage rebates from sponsors in order to reduce the plans’ net costs. These restrictions and limitations influence the purchase of health care services and products and lower the realization on sponsors’ sales of prescription therapeutics. Third party payors are developing increasingly sophisticated methods of controlling health care costs. Third party payors may limit coverage to specific therapeutic products on an approved list, or formulary, which might not include all of the FDA approved products for a particular indication or might impose high copayment amounts to influence patient choice. Third party payors also control costs by requiring prior authorization or imposing other dispensing restrictions before covering certain products and by broadening therapeutic classes to increase competition. Third party payors are increasingly challenging the price and examining the medical necessity and cost effectiveness of medical products and services, in addition to their safety and efficacy. Absent clinical differentiators, third party payors may treat products as therapeutically equivalent and base formulary decisions on net cost. To lower the prescription cost, sponsors frequently rebate a portion of the prescription price to the third party payors. Recently, purchasers and third party payors have begun to focus on the value of new therapeutics and have sought agreements in which price is based on achievement of performance metrics.

 

Federal programs also impose price controls through mandatory ceiling prices on purchases by federal agencies and federally funded hospitals and clinics and mandatory rebates on retail pharmacy prescriptions paid by Medicaid and Tricare. By example, payment or reimbursement of prescription therapeutics by Medicaid or Medicare requires sponsors to submit certified pricing information to CMS. The Medicaid Drug Rebate statute and state statutes requires sponsors to calculate and report price points, which are used to determine mandatory rebate payments or negotiate supplemental rebate payments on both the state and federal level and Medicaid payment rates for certain therapeutics. For therapeutics paid under Medicare Part B, sponsors must also calculate and report their Average Sales Price, which is used to determine the Medicare Part B payment rate. Furthermore, as a condition of receiving Medicare Part B reimbursement for eligible drugs or biologicals, the manufacturer is required to participate in other government health care programs, including the Medicaid Rebate Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires biopharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer’s outpatient therapeutic products furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that participate in the program. In addition, therapeutics covered by certain government payor programs are subject to an additional inflation penalty which can substantially increase rebate payments. Certain states have also enacted laws that require that manufacturers report certain pricing information, including drug price increases. States laws may also limit the amount that prices may be increased or require negotiation of supplemental rebates for new drugs entering the market at price points determined to be high. Refusal to negotiate supplemental rebates can negatively affect market access and provider reimbursement.

 

Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a significant gating issue for successful introduction of a new product. In addition, government programs as a condition of participation mandate fixed discounts or rebates from sponsors regardless of formulary position or utilization and may utilize mechanisms such as formulary placement to attain further price reductions, which can greatly reduce realization on the sale.

 

Further, the increased emphasis on managed health care in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement, and utilization, which may adversely affect Serina’s future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, competition within therapeutic classes, judicial decisions and governmental laws and regulations related to Medicare, Medicaid, and health care reform, biopharmaceutical coverage and reimbursement policies, and pricing in general. Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third party payors to reimburse all or part of the associated health care costs. Sales of Serina’s product candidates will therefore depend substantially, both domestically and abroad, on the extent to which the costs of Serina’s products will be paid by health maintenance, managed care, pharmacy benefit and similar health care management organizations, or reimbursed by government health administration authorities, such as Medicare and Medicaid, private health insurers, and other third party payors.

 

309

 

 

In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of Serina’s product candidate to currently available therapies (so called health technology assessment, or HTA) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of Serina’s products. Historically, products launched in the European Union do not follow price structures of the United States and generally tend to by significantly lower.

 

As a result of the above, Serina may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost effectiveness of Serina’s products, in addition to the costs required to obtain marketing approvals in the United States and in other jurisdictions. Serina’s product candidates may not be considered medically necessary or cost effective, or the rebate percentages required to secure coverage may not yield an adequate margin over cost. Additionally, companies are increasingly finding it necessary to establish bridge programs to assist patients access new therapies during protracted initial coverage determination periods.

 

Moreover, a payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved or that significant price concessions will not be required to avoid restrictive conditions. High health plan copayment requirements may result in patients refusing prescriptions or seeking alternative therapies. Adequate third party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on Serina’s investment in therapeutic development. Coverage policies and third party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which Serina receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Legislative proposals to reform health care or reduce costs under government insurance programs may result in lower reimbursement for Serina’s products and product candidates or exclusion of Serina’s products and product candidates from coverage. The cost containment measures that health care payors and providers are instituting and any health care reform could significantly reduce Serina’s revenues from the sale of any approved product candidates. Serina cannot provide any assurances that it will be able to obtain and maintain third party coverage or adequate reimbursement for Serina’s product candidates in whole or in part.

 

Health Care Reform Measures

 

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of product and therapeutic candidates, restrict or regulate post approval activities, and affect the ability to profitably sell product and therapeutic candidates that obtain marketing approval. The FDA’s and other regulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of Serina’s product and therapeutic candidates. If Serina is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Serina is not able to maintain regulatory compliance, Serina may lose any marketing approval that it otherwise may have obtained and it may not achieve or sustain profitability, which would adversely affect Serina’s business, prospects, financial condition, and results of operations. Moreover, among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in health care systems with the stated goals of containing health care costs, improving quality and/or expanding access.

 

For example, the Patient Protection and the ACA, was enacted in March 2010, and has had a significant impact on the health care industry in the United States. The ACA expanded coverage for the uninsured while at the same time containing overall health care costs. With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program. Additionally, the CREATES Act, which became law on December 20, 2019, aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic product developers access to samples of brand products. Because generic product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic product developer to sue the brand manufacturer to compel it to furnish the necessary samples on “commercially reasonable, market based terms.” Whether and how generic product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on any of Serina’s future commercial products are unknown.

 

Following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court upheld the ACA when it dismissed a legal challenge to the ACA’s constitutionality. Further legislative and regulatory changes under the ACA remain possible, but it is unknown what form any such changes or any law would take and how or whether it may affect the biopharmaceutical industry as a whole or Serina’s business in the future. Serina expects that changes or additions to the ACA, the Medicare and Medicaid programs, and changes stemming from other health care reform measures, especially with regard to health care access, financing, or other legislation in individual states, could have a material adverse effect on the health care industry in the United States.

 

In addition, other legislative changes have been proposed and adopted in the United States since the ACA that affect health care expenditures. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and was extended by the Consolidated Appropriations Act for 2023 and will remain in effect through 2032 unless additional Congressional action is taken.

 

310

 

 

Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. In May 2019, HHS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified a HHS policy change that was effective January 1, 2019.

 

More recently, in August 2022, President Biden signed into the law the Inflation Reduction Act of 2022, or the IRA. Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the drug product’s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease.

 

Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states’ ability to regulate PBMs and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area.

 

Serina cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Serina expects that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, including any future drug products for which Serina secures marketing approval.

 

The Foreign Corrupt Practices Act

 

The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and suspension and debarment from government contracts, and refusal of orders under existing government contracts.

 

311

 

 

EU Drug Development

 

In the EU, Serina’s product candidates and products, should they receive marketing authorization in the EU, will be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU member states have transposed and applied the provisions of the Directive differently. This has led to some variations in the member state regimes.

 

In April 2014, the Clinical Trials Regulation, (EU) No 536/2014, was adopted and it became effective on January 31, 2022. The Clinical Trials Regulation will be directly applicable in all of the EU Member States, repealing the current Clinical Trials Directive 2001/20/EC. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the clinical trial is initiated or on the duration of an ongoing trial. As of January 2023, all new clinical trials must comply with the Clinical Trials Regulation. In addition, any clinical trial that was already under way as of January 1, 2023, and continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable (i.e., January 31, 2025), the Clinical Trials Regulation will at that time begin to apply to the clinical trial.

 

The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the “EU portal” or Clinical Trial Information System, or CTIS; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State.

 

European Data Collection

 

The collection and use of personal health data in the EU is governed by the General Data Protection Regulation, or GDPR. The GDPR applies to any company established in the European Economic Area, or EEA, (which includes the EU Member States plus Iceland, Liechtenstein, and Norway) and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR establishes stringent requirements applicable to the processing of personal data, including strict requirements relating to the validity of consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct data protection impact assessments for “high risk” processing, limitations on retention of personal data, special provisions affording greater protection to and requiring additional compliance measures for “special categories of personal data” including health and genetic information of data subjects, mandatory data breach notification (in certain circumstances), “privacy by design” requirements, and direct obligations on service providers acting as processors. The GDPR also prohibits the international transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place. Failure to comply with the GDPR requirements may subject an entity to litigation, regulatory investigations, enforcement notices and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.

 

312

 

 

The GDPR may also impose additional compliance obligations relating to the transfer of data between companies and their subsidiaries or other business partners. For example, on July 16, 2020, the Court of Justice of the European Union (CJEU), issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C 311/18), called Schrems II. This decision (a) calls into question commonly relied upon data transfer mechanisms as between the EU Member States and the United States (such as the Standard Contractual Clauses) and (b) invalidates the EU U.S. Privacy Shield on which many companies had relied as an acceptable mechanism for transferring such data from the EU to the United States. The CJEU is the highest court in Europe and the Schrems II decision heightens the burden on data importers to assess U.S. national security laws on their business and future actions of EU data protection authorities are difficult to predict.

 

United Kingdom Regulation

 

As of January 1, 2021, EU law no longer directly applies in the United Kingdom. The United Kingdom has adopted existing EU medicines regulation as standalone UK legislation with some amendments to reflect procedural and other requirements with respect to marketing authorizations and other regulatory provisions.

 

In order to market medicines in the United Kingdom, manufacturers must hold a UK authorization. On January 1, 2021, all EU marketing authorizations were converted to UK marketing authorizations subject to a manufacturer opt out. UK medicines legislation is subject to future regulatory change under the Medicines and Medical Devices Act 2021, which sets out a framework for the adoption of medicines regulation. Guidance issued by the Medicines and Healthcare products Regulatory Agency, or MHRA, states that the United Kingdom will have the power to take into account marketing authorizations made under the EU decentralized and mutual recognition procedures. In addition, the MHRA’s guidance has been updated to refer to new national licensing procedures including new routes of evaluation for novel and biotechnological products.

 

Different rules will apply in Northern Ireland following implementation of the Northern Ireland Protocol. In Northern Ireland, EU central marketing applications will continue to apply.

 

The Trade and Cooperation Agreement between the EU and the United Kingdom contains an Annex in relation to medicinal products with the objective of facilitating availability of medicines, promotion of public health and consumer protection in respect of medicinal products. The Annex provides for mutual recognition of good manufacturing practice (GMP) inspections and certificates, meaning that manufacturing facilities do not need to undergo duplicate inspections for the two markets. The Annex establishes a Working Group on Medicinal Products to deal with matters under the Trade and Cooperation Agreement, facilitate co-operation and for the carrying out of technical discussions. It is expected that further bilateral discussions will continue with respect to regulatory areas not the subject of the Trade and Cooperation Agreement, including pharmacovigilance. The Trade and Cooperation Agreement also does not include reciprocal arrangements for the recognition of batch testing certification. However, the United Kingdom has listed approved countries, including the EEA which will enable UK importers and wholesales to recognize certain certification and regulatory standards. The European Commission has not adopted such recognition procedures.

 

Relatedly, following the United Kingdom’s withdrawal from the EU, the GDPR has been implemented in the United Kingdom (as the UK GDPR). The UK GDPR sits alongside the UK Data Protection Act 2018 which implements certain derogations in the EU GDPR into United Kingdom law. Under the UK GDPR, companies not established in the United Kingdom but who process personal data in relation to the offering of goods or services to individuals in the United Kingdom, or to monitor their behavior will be subject to the UK GDPR the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to £17.5 million or 4% of global turnover. In 2022, the UK government proposed and debated the Data Protection and Digital Information Bill to harmonize the 2018 Data Protection Act, UK GDPR, and the Privacy and Electronic Communications Regulations under one legislative framework. However, progress on the bill stalled as the government continues to assess the most optimal approach to data protection reform.

 

313

 

 

Rest of the World Regulation

 

For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, clinical trials to support applications for marketing authorization in such jurisdictions must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If Serina fails to comply with applicable foreign regulatory requirements, Serina may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.

 

Human Capital

 

As of November 6, 2023, Serina had eleven employees, nine of whom were full time, four of whom have Ph.D. or M.D. degrees, and eight are engaged in research and development and manufacturing activities. Serina does not have any employees represented by a labor union or covered under a collective bargaining agreement.

 

Talent Acquisition and Retention

 

Serina recognizes its employees largely contribute to its success. To this end, Serina supports business growth by seeking to attract and retain best in class talent. Serina uses internal and external resources to recruit highly skilled candidates for open positions. Serina believes that it is able to attract and retain superior talent as measured by its minimal turnover rate and high employee service tenure.

 

Total Rewards

 

Serina’s total rewards philosophy has been to create investment in its workforce by offering a competitive compensation and benefits package. Serina provides employees with compensation packages including base salary, annual incentive bonuses, and long-term equity incentive awards. Serina also offers comprehensive employee benefits, such as life, disability, and health insurance, health savings and flexible spending accounts, paid time off, and a 401(k) plan. It is Serina’s express intent to be an employer of choice in its industry by providing a market competitive compensation and benefits package.

 

Diversity, Equity, and Inclusion

 

Serina believes that a diverse workforce is critical to its success. Serina’s mission is to value differences in races, ethnicities, religions, nationalities, genders, ages, and sexual orientations, as well as education, skill sets, and experience. Serina is focused on inclusive hiring practices, fair and equitable treatment, organizational flexibility, and training and resources.

 

Training and Development

 

Serina believes in encouraging employees in becoming lifelong learners by providing ongoing learning and leadership training opportunities. While Serina strives to provide real time recognition of employee performance, it has a formal annual review process not only to determine pay and equity adjustments tied to individual contributions, but to identify areas where training and development may be needed.

 

Facilities

 

Serina’s current headquarters is comprised of 7,641 square feet of office and laboratory space. The lease term is two years for the office space and five years for the laboratory space. The current annual rent is $224,802 with a no annual increase. The lease termination date is October 31, 2025 for the office space and January 31, 2028 for the laboratory space. Serina believes that the space is adequate to meet its near term needs.

 

Legal Proceedings

 

From time to time, Serina may become involved in litigation or legal proceedings relating to claims arising from the ordinary course of its business. Serina is not currently a party to any material legal proceedings.

 

314

 

 

AGEX MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of AgeX’s financial condition and results of operations should be read in conjunction with AgeX’s consolidated financial statements and notes thereto appearing elsewhere in this proxy statement/prospectus/information statement. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus/information statement, including information with respect to AgeX’s plans and strategy for AgeX’s business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, AgeX’s actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. References to “we,” “us” and “our” in this section titled “AgeX Management’s Discussion and Analysis of Financial Condition and Results of Operations” refer to AgeX.

 

Emerging Growth Company Status

 

The Jumpstart our Business Startups Act of 2012 (JOBS Act) permits an “emerging growth company” such as AgeX to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. However, we elected to comply with newly adopted or revised accounting standards when they become applicable to public companies because our financial statements were consolidated with those of Lineage Cell Therapeutics, Inc., which is not an emerging growth company under the JOBS Act and is therefore not permitted to delay the adoption of new or revised accounting standards that become applicable to public companies. This election under the JOBS Act to not delay the adoption of new or revised accounting standards is irrevocable.

 

Recent Developments

 

Amendment to Preferred Stock and Remediation of Stock Exchange Listing Deficiency

 

On July 24, 2023, AgeX issued shares of AgeX Series A preferred stock and AgeX Series B preferred stock to Juvenescence in exchange for the extinguishment of $36 million of indebtedness owed to Juvenescence with the intent of adding $36 million to stockholders equity to eliminate a stockholders equity deficiency that caused AgeX to be out of compliance with the NYSE American continued listing standards. However, upon subsequent consideration in consultation with AgeX’s independent registered public accountants, AgeX determined that, in accordance with applicable guidance to GAAP, the deemed liquidation preference provisions of the Preferred Stock could be considered contingent redemption provisions that are not solely within AgeX’s control, requiring that the Preferred Stock be presented outside of permanent equity in the mezzanine section of the condensed consolidated balance sheet as of September 30, 2023. To comply with the NYSE American listing requirement by permitting the Preferred Stock to qualify now as permanent equity, on November 7, 2023, Section 3(b) of the terms of the Series A Preferred Stock and Series B Preferred Stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as a deemed liquidation if the applicable transaction is approved by the Board of Directors or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of Preferred Stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock. AgeX has informed the NYSE American of the accounting issue and the remedy that has been implemented and AgeX believes it is in compliance with NYSE American’s continued listing standards.

 

315

 

 

Merger Agreement

 

On August 29, 2023, we entered into the Merger Agreement with Serina and Merger Sub, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Serina, with Serina surviving as our wholly owned subsidiary. For additional information, see the sections titled “The Merger” and “The Merger Agreement” beginning on pages 133 and 170 of this proxy statement/prospectus/information statement, respectively.

 

Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price of AgeX common stock being equal to or greater than $12.00 per share (on a post-reverse stock split basis), giving effect to the reverse stock split and the AgeX preferred stock conversion and excluding the impact of any post-merger warrant, incentive warrant or the issuance of any share of AgeX common stock upon exercise of any post-merger warrant or incentive warrant. For a more complete description of the exchange ratio, please see the section titled “The Merger Agreement—Merger Consideration and Exchange Ratio.”

 

Concurrently with the execution of the Merger Agreement, AgeX, Serina and Juvenescence entered into the Side Letter, which will become effective immediately prior to the closing of the Merger. The Side Letter provides, among other things, that (i) immediately prior to the Effective Time, Juvenescence will cancel all out of the money AgeX warrants held by Juvenescence; (ii) Juvenescence will exercise all post-merger warrants it holds to provide the combined company an additional $15 million in capital according to the following schedule: (x) at least one-third on or before May 31, 2024, (y) at least one-third on or before November 30, 2024, and (z) at least one-third on or before June 30, 2025; (iii) Juvenescence will not sell any shares of AgeX Series A preferred stock or AgeX Series B preferred stock and will take all actions necessary to convert all of such preferred stock into AgeX common stock before the reverse stock split; (iv) Juvenescence will release all security interests, guarantees, pledges, assignments and other forms of collateral that it may have in AgeX’s assets pursuant to the terms of certain loans to AgeX; and (v) Juvenescence will consent to a newly formed subsidiary of AgeX assuming AgeX’s obligations with respect to loan agreements and promissory notes governing loans payable to Juvenescence, including obligations for amounts currently owed and future advances of loan funds, and Juvenescence shall release AgeX from those loan obligations. For additional information, see the sections titled “Agreements Related to the Merger—Side Letter” beginning on page 197 of this proxy statement/prospectus/information statement.

 

The following discussion and analysis of AgeX’s financial condition and results of operations does not reflect material changes to AgeX’s business, assets, liabilities, financial condition, operations, management, and prospects that will occur if the Merger is consummated.

 

316

 

 

Increase in Secured Note Line of Credit and Additional Loans Under the 2022 Secured Note

 

During October 2023, AgeX drew an additional $1,000,000 under the 2022 Secured Note. On November 9, 2023, AgeX and Juvenescence entered into the 2022 Secured Note Fifth Amendment that increases the amount of the line of credit available to AgeX by $4,400,000, of which $1,500,000 has been drawn as of January 3, 2024. Under the terms of the 2022 Secured Note and Juvenescence has discretion to approve and fund each of AgeX’s future draws of available credit under the 2022 Secured Note. Concurrently with the execution of the 2022 Secured Note Fifth Amendment, AgeX also entered into an additional Pledge Agreement to add shares of a subsidiary to the collateral under the Security Agreement, and AgeX’s subsidiaries ReCyte, Reverse Bio, and UniverXome each entered into a Guaranty Agreement and Joinder Agreement pursuant to which each of them agreed to guaranty AgeX’s obligations to Juvenescence pursuant to the 2022 Secured Note, as amended by the 2022 Secured Note Fifth Amendment, and to grant Juvenescence a security interest in their respective assets pursuant to the Security Agreement to secure their obligations to Juvenescence.

 

Termination of License and Sublicence

 

On November 9, 2023, AgeX sent a notice to the licensee and the sublicensees of patent rights for certain uses of HyStem® hydrogel products, informing them that AgeX was exercising its rights to terminate, respectively: (i) a License Agreement, dated August 17, 2017, as amended, by and between AgeX and Lineage and (ii) a Sublicense Agreement, dated August 17, 2017, as amended, by and among AgeX, Lineage, and OrthoCyte Corporation. AgeX was required to pay minimal annual royalties of $30,000 under the agreements. The termination of the license agreement and sublicense agreement eliminates AgeX’s obligation to pay such minimum annual royalties for periods after the termination date. AgeX has not incurred royalty payment obligations in excess of the minimum annual royalties because AgeX has not yet competed development and received any regulatory approvals required to market and sell any products for which the use of HyStem® was permitted by the license agreement and sublicense agreement. If AgeX were to determine to obtain rights to use alternative patented products to replace HyStem® for use as a cell transplant matrix or for therapeutic molecular iTR drug delivery, AgeX expects that it would need to obtain a license for such use which would likely include new fee, royalty, and other payment obligations which cannot presently be determined or estimated. For additional information, see the section titled “Description of AgeX’s Business—Recent Developments.”

 

Overview

 

We are a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Our initial discovery and preclinical programs focus on utilizing brown adipose tissue in targeting diabetes, obesity, and heart disease; and induced tissue regeneration in utilizing the human body’s own abilities to scarlessly regenerate tissues damaged from age or trauma. We may also pursue other early-stage pre-clinical programs.

 

Since inception, our operations have focused on building our technology platform, identifying potential product candidates, establishing and protecting our intellectual property and raising capital.

 

Since inception, we have incurred significant operating losses and we will need to obtain additional financing in order to continue our operations, including our research and development programs. See “—Liquidity and Capital Resources” for a discussion of our available capital resources and our need for financing. Our net loss from continuing operations before interest and other expenses were $7.0 million and $8.0 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $116.2 million. Our net loss from operations before interest and other expenses were $6.4 million and $5.2 million for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, we had an accumulated deficit of $127.6 million. We expect to continue to incur operating losses and negative cash flows for the foreseeable future. 

 

Critical Accounting Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in our consolidated financial statements and related notes. Our significant accounting policies are described in Note 2, Summary of Significant Accounting Policies, to our consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement. We have identified below our critical accounting policies and estimates that we believe require the greatest amount of judgment. On an ongoing basis, we evaluate our estimates that are subject to significant judgment, including those related to going concern assessment of consolidated financial statements, allocations and adjustments necessary for carve-out basis of presentation, including the separate return method for income taxes, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. On an ongoing basis, we evaluate our estimates compared to historical experience and trends, which form the basis for making judgments about the carrying value of assets and liabilities. To the extent that there are material differences between our estimates and our actual results, our future consolidated financial statement presentation, financial condition, results of operations and cash flows will be affected.

 

317

 

 

We believe the assumptions and estimates associated with the following have the greatest potential impact on our consolidated financial statements. Management believes that there have been no significant changes during the nine months ended September 30, 2023 to the items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2022, except as disclosed in Note 2, Basis of Presentation and Summary of Significant Accounting Policies, of our condensed consolidated interim financial statements included elsewhere in this proxy statement/prospectus/information statement.

 

Going Concern Assessment

 

We assess going concern uncertainty for our consolidated financial statements to determine if we have sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date our consolidated financial statements are issued, which is referred to as the “look-forward period” as defined by FASB’s ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we consider various scenarios, forecasts, projections, and estimates, and we make certain key assumptions, including the timing and nature of projected cash expenditures or programs, among other factors, and our ability to delay or curtail those expenditures or programs within the look-forward period in accordance with ASU No. 2014-15, if necessary.

 

Principles of Consolidation

 

AgeX’s consolidated financial statements include the accounts of its subsidiaries and certain research and development departments. AgeX consolidated its direct and indirect wholly owned or majority owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of stockholders’ deficit on AgeX’s consolidated balance sheets.

 

AgeX’s consolidated balance sheets at December 31, 2022 and 2021 do not include consolidated assets and liabilities of LifeMap Sciences, Inc. (LifeMap Sciences) due to the deconsolidation of LifeMap Sciences on March 15, 2021.

 

AgeX’s consolidated statements of operations for the year ended December 31, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the deconsolidation due to the conversion of $1,761,296 of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021, followed by the completion of the cash-out merger on the same day.

 

318

 

 

Long-Lived Intangible Assets

 

Long-lived intangible assets, consisting primarily of acquired patents, acquired in-process research and development with alternative future uses, patent applications, and licenses to use certain patents, are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful lives of the assets, generally over 10 years.

 

Impairment of Long-Lived Assets

 

Long-lived assets, including long-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, we evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets. Through December 31, 2022, there have been no such impairment losses. 

 

Accounting for Warrants

 

We determine the accounting classification of warrants we issue, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate us to settle the warrants or the underlying shares by paying cash or other assets, and warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet the liability classification under ASC 480-10, we assess the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, we also assess whether the warrants are indexed to our common stock and whether the warrants are classified as equity under ASC 815-40 or other U.S. GAAP. After all such assessments, we conclude whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. We do not have any liability classified warrants as of September 30, 2023. AgeX had liability classified warrants as of December 31, 2022. See Note 5, Related Party Transactions, to our consolidated financial statements for the three and nine months ended September 30, 2023 and see Notes 5, Related Party Transactions, and 6, Warrant Liability, to our consolidated financial statements for the year ended December 31, 2022, respectively, included elsewhere in this proxy statement/prospectus/information statement for additional information regarding warrants.

 

Stock-Based Compensation

 

We recognize compensation expense related to employee stock option grants and other equity based awards, if any, in accordance with FASB ASC 718, Compensation – Stock Compensation (ASC 718).

 

We use the Black-Scholes option pricing model for estimating the fair value of options granted under our the Incentive Plan. The fair value of each restricted stock or restricted stock unit grant, if any, is determined based on the value of the common stock granted or sold. We have elected to treat stock-based awards with time-based service conditions as a single award and recognize stock-based compensation on a straight-line basis over the requisite service period.

 

319

 

 

Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. We record compensation expense based on the then-current fair values of the stock options at the grant date in accordance with ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies the accounting for non-employee share-based payment transactions. We adopted ASU 2018-07 on January 1, 2019. As we had one stock option grant issued to a nonemployee as of the adoption date and one additional stock option grant during 2019 to the same nonemployee, the application of the new standard did not have a material impact on our consolidated financial statements. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations.

 

The Black-Scholes option pricing model requires us to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield.

 

The fair value of the shares of common stock underlying the stock options has historically been determined by the AgeX Board. Because there was no public market for our common stock prior to November 29, 2018, the AgeX Board determined the fair value of the common stock at the time of the grant of options prior to that date by considering a number of objective and subjective factors including contemporaneous sales of our common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, amongst other factors. The fair value was determined in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled Valuation of Privately Held Company Equity Securities Issued as Compensation. Since our common stock began publicly trading on the NYSE American, the fair value of our common stock underlying stock options has been valued based on prevailing market prices.

 

The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. We estimate the expected term of options granted based upon the “simplified method” provided under Staff Accounting Bulletin, Topic 14, or SAB Topic 14.

 

Because our common stock had no publicly traded history prior to November 29, 2018, for the years ended December 31, 2022 and 2021, we estimated the expected volatility using our own stock price volatility to the extent applicable or a combination of our stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage.

 

The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of our stock options.

 

320

 

 

The dividend yield assumption is based on our history and expectation of dividend payouts. We have never declared or paid any cash dividends on our common stock, and we do not anticipate paying any cash dividends in the foreseeable future.

 

All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes, and a tax deficiency arises when the compensation cost exceeds the tax deduction.

 

Stock-based compensation expense for the years ended December 31, 2022 and 2021 consists of stock-based compensation under the Incentive Plan, and stock-based compensation of AgeX’s subsidiaries that have their own stock option plans.

 

Our consolidated subsidiary ReCyte and our former subsidiary LifeMap Sciences had their own share-based compensation plans. For share-based compensation awards granted by those privately-held consolidated subsidiaries under their respective equity plans, we determined the fair value of the options granted under those plans using similar methodologies and assumptions we used for our stock options discussed above. None of our consolidated subsidiaries have granted stock options or other equity awards for the years ended December 31, 2022 and 2021.

 

Although the fair value of stock options is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.

 

Income Taxes

 

As of December 31, 2022, the deferred tax assets and liabilities presented in Note 9, Income Taxes, included elsewhere in this proxy statement/prospectus/information statement, including net operating loss carryforwards and research and development credits, represent the tax attributes of AgeX and its subsidiaries.

 

We account for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. Our judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If our assumptions and consequently our estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on our consolidated financial statements.

 

The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. We provided a reserve against our federal and California research and development credits generated. The carryforward amounts for these credits have been reported net of these reserves. Accordingly, no accrued interest and penalties related to unrecognized tax benefits have been recorded as of December 31, 2022 and 2021. We do not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. We are currently unaware of any tax issues under review.

 

321

 

 

Revenue Recognition

 

We recognize revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, we follow a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. We consider the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. We apply the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. 

 

Subscription and advertisement revenues – LifeMap Sciences sold subscription-based products, including research databases and software tools, for biomedical, gene, and disease research. LifeMap Sciences sold these subscriptions primarily through the internet to biotech and pharmaceutical companies worldwide. LifeMap Sciences’ principal subscription product was the GeneCards® Suite, which includes the GeneCards® human gene database, and the MalaCards™ human disease database.

 

LifeMap Sciences’ performance obligations for subscriptions included a license of intellectual property related to its genetic information packages and premium genetic information tools. These licenses were deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue was recognized over a period of time, which was generally the subscription period. Payments were typically received at the beginning of a subscription period and revenue was recognized according to the type of subscription sold. For subscription contracts in which the subscription term commenced before a payment was due, LifeMap Sciences recorded an account receivable because the subscription was earned over time and billed the customer according to the contract terms. LifeMap Sciences deferred subscription revenues primarily represented subscriptions for which cash payment was received for the subscription term, but the subscription term was not completed as of the balance sheet date reported.

 

LifeMap Sciences licensed from third parties the databases and software it commercializes and had a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the consolidated statements of operations when the cash was received and the royalty obligation was incurred, as the royalty payments do not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs – Contracts with Customers.

 

LifeMap Sciences did not generate sufficient revenues to meet its operating expenses. On March 15, 2021, LifeMap Sciences was acquired by a third party in a cash-out merger. See Note 3, Disposition and Deconsolidation of LifeMap Sciences, to our consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement.

 

322

 

 

Grant revenues – AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements. At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.

 

In applying the provisions of Topic 606, we have determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.

 

On April 8, 2020, we were awarded a grant of up to approximately $386,000 from the NIH. The NIH grant provides funding for continued development of our technologies for treating stroke. The grant funds were made available by the NIH as allowable expenses were incurred. We recognized no grant revenues for the year ended December 31, 2022 as we had expended the full amount available under this grant as of December 31, 2021.

 

ESI BIO research products – Through ESI BIO, our research product division, we market a number of products related to human pluripotent stem cells, including research-grade PSC lines and PSC lines produced under current good manufacturing practices or cGMP. We offer cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to us for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from our PSC lines. Revenues from the sale of research products are included in other revenues.

 

Arrangements with multiple performance obligations – Future contracts with customers may include multiple performance obligations. For such arrangements, we will allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of and for the years ended December 31, 2022 and 2021, we did not have significant arrangements with multiple performance obligations. 

 

323

 

 

Research and Development

 

Research and development expenses consist primarily of personnel costs and related benefits, stock-based compensation, amortization of intangible assets, and collaborative and contracted research and development fees. Research and development costs which have an alternative future use will be capitalized as intangible assets, and costs with no future benefit or alternative use will be expensed as incurred. Research and development expenses incurred and reimbursed by grants from third parties approximate the grant revenues recognized in the consolidated statements of operations.

 

General and Administrative

 

General and administrative expenses include employee and director compensation allocated to general and administrative expenses, consulting fees other than those paid for science-related consulting, license fees paid to third parties to acquire patents or licenses to use patents and other technology, professional fees to maintain patents and trademarks, minimum annual royalties stipulated under license and sublicense agreements with third parties, insurance costs allocated to general and administrative expenses, stock exchange-related costs, depreciation expense, marketing costs, legal and accounting costs, office rent, and other miscellaneous expenses which are allocated to general and administrative expense.

 

Financial Operations Overview

 

Up until our disposition of LifeMap Sciences, our revenues were principally derived from subscription and advertising revenues from LifeMap Sciences’ online databases based upon applicable subscription or advertising periods. LifeMap Sciences was acquired by a third party through a cash-out merger during March 2021 and, as a result of that merger transaction, we no longer own interest in LifeMap Sciences and will no longer recognize any post-merger revenues attributable to LifeMap Sciences’ business. We do not have any therapeutic products approved for sale and have generated insignificant revenues from commercialized product sales, and we do not expect to generate any significant revenues from product sales for the foreseeable future.

 

Our operating expenses consist of research and development expenses primarily from our preclinical programs and general and administrative expenses. Since the layoffs of mostly research personnel in April 2020, research and development work has been scaled back and contracted out to third party service providers within the imposed budgetary constraints under a Secured Convertible Facility Agreement, dated March 30, 2020, between AgeX and Juvenescence (the 2020 Loan Agreement), the 2022 Secured Note and the 2023 Secured Note. As of September 30, 2023, AgeX had approximately $1,573,000 and $692,800 outstanding under the 2022 Secured Note and the 2023 Secured Note, respectively. Accordingly, the historical amounts of expense presented and discussed in this proxy statement/prospectus/information statement are likely not going to be indicative of expenses during future periods. See “—Liquidity and Capital Resources” for a discussion of our available capital resources and our need for financing.

 

Results of Operations

 

Comparison of Three and Nine Months Ended September 30, 2023 and 2022

 

Revenues and Cost of Sales

 

During the three and nine months ended September 30, 2023 we recognized income of approximately $21,000 from a grant awarded by the NIH in August 2023 with a one year grant period that commenced on September 1, 2023.

 

During the three and nine months ended September 30, 2023, we recognized revenues of $46,000 and $65,000, respectively, from the sale of research products. During the three and nine months ended September 30, 2022, we recognized revenues of $9,000 and $26,000, respectively from the sale of research products.

 

During the three and nine months ended September 30, 2023, we recognized cost of sales of $33,000 and $39,000, respectively, from the sale of research products. During the three and nine months ended September 30, 2022, we recognized cost of sales of $5,000 and $12,000, respectively from the sale of research products.

 

Operating Expenses

 

We continue to maintain a minimal workforce since our May 1, 2020 reduction in force which resulted in the layoff of most of our research and development personnel and certain administrative personnel. The following table shows our consolidated operating expenses for the periods presented (in thousands).

 

  

Three Months Ended

September 30,

   $ Increase/   % Increase/ 
   2023   2022   (Decrease)   (Decrease) 
Research and development expenses  $218   $162   $56    34.6%
General and administrative expenses   2,172    1,392    780    56.0%

 

324

 

 

  

Nine Months Ended

September 30,

   $ Increase/   % Increase/ 
   2023   2022   (Decrease)   (Decrease) 
Research and development expenses  $552   $817   $(265)   (32.4)%
General and administrative expenses   5,895    4,390    1,505    34.3%

 

Research and development expenses

 

Research and development expenses for the three months ended September 30, 2023 were approximately $0.2 million, consistent with the same period in 2022. The following table shows our research and development expenses allocated to our primary research and development programs for the periods presented (in thousands).

 

  

Three Months Ended

September 30,

   $ Increase/   % Increase/ 
   2023   2022   (Decrease)   (Decrease) 
iTRTM technology: AGEX-iTR1547 and AGEX-iTR1550  $56   $64   $(8)   (13)%
PureStem® progenitor cell lines, brown adipose fat,  neural stem cells (NSC), exosomes, and related research and development: AGEX-BAT1 and cGMP PSC-derived cells including NSC   162    98    64    65%
Total  $218   $162           

 

Research and development expenses for the nine months ended September 30, 2023 decreased by approximately $0.2 million to $0.6 million from $0.8 million during the same period in 2022. The net decrease was primarily attributable to reductions of $0.2 million in outside research and services allocable to research and development expenses. The following table shows our research and development expenses allocated to our primary research and development programs for the periods presented (in thousands).

 

  

Nine Months Ended

September 30,

   $ Increase/   % Increase/ 
   2023   2022   (Decrease)   (Decrease) 
iTRTM technology: AGEX-iTR1547 and AGEX-iTR1550  $136   $262   $(126)   (48)%
PureStem® progenitor cell lines, brown adipose fat,  neural stem cells (NSC), exosomes, and related research and development: AGEX-BAT1 and cGMP PSC-derived cells including NSC   416    555    (139)   (25)%
Total  $552   $817           

 

General and administrative expenses

 

General and administrative expenses for the three months ended September 30, 2023 increased by $0.8 million to $2.2 million as compared to $1.4 million during the same period in 2022. The net increase is attributable to increases of $0.7 million in professional fees for legal services related to the possible Merger between AgeX and Serina, $0.1 million in professional fees for non-merger related legal services, $0.1 million in patent and license maintenance related fees and $0.1 million in investor relations related expenses and insurance expense. These increases were offset to some extent by a $0.2 million decrease in noncash stock-based compensation to employees, consultants and directors.

 

General and administrative expenses for the nine months ended September 30, 2023 increased by $1.5 million to $5.9 million as compared to $4.4 million during the same period in 2022. The net increase is attributable to increases of $1.7 million in professional fees for legal services, consulting expenses incurred in connection with due diligence and other expenses related to the possible Merger between AgeX and Serina, $0.2 million in investor relations related expenses and insurance expense, $0.1 million in professional fees for other non-recurring legal services, and $0.1 million in salaries and payroll related expenses allocated to general and administrative expenses. These increases were offset to some extent by a $0.5 million decrease in noncash stock-based compensation to employees, consultants and directors, and $0.1 million in patent and license maintenance related fees, travel and lodging, and minimum royalty fees under certain license agreements.

 

325

 

 

General and administrative expenses include employee and director compensation allocated to general and administrative expenses, consulting fees other than those paid for science-related consulting, facilities and equipment rent and maintenance related expenses, insurance costs allocated to general and administrative expenses, stock exchange-related costs, depreciation expense, marketing costs, legal and accounting costs, and other miscellaneous expenses which are allocated to general and administrative expense.

 

Other expense, net

 

Total other expense, net for the three months ended September 30, 2023 consists primarily of $3.2 million amortization of deferred debt issuance costs to interest expense, write off of deferred debt cost upon $36 million debt exchanged for preferred stock in July 2023, and other debt related expenses included in interest expense offset by $0.2 million net interest income primarily earned from a $10,000,000 loan under the terms of our Convertible Promissory Note to Serina (the AgeX-Serina Note). Total other expense, net for the three months ended September 30, 2022 consists primarily of $0.9 million amortization of deferred debt issuance costs to interest expense and other debt related expenses included in interest expense.

 

Total other expense, net for the nine months ended September 30, 2023 consists primarily of $5.3 million amortization of deferred debt issuance costs to interest expense, write off of deferred debt cost upon $36 million debt exchanged for preferred stock in July 2023, and other debt related expenses included in interest expense offset by $0.4 million net interest income primarily earned from the AgeX-Serina Note. Total other expense, net for the nine months ended September 30, 2022 consists primarily of $2.3 million amortization of deferred debt issuance costs to interest expense and other debt related expenses included in interest expense and $0.2 million unrealized loss on change in fair value of warrants issued to Juvenescence in connection with borrowings under the 2022 Secured Note.

 

See Notes 4, Convertible Note Receivable, 5, Related Party Transactions, 6, Warrant Liability, and 7, Stockholders’ Equity (Deficit) to our condensed consolidated interim financial statements included elsewhere in this proxy statement/prospectus/information statement for additional information about our loan agreement with Serina, loan agreements with Juvenescence, liability classified warrants, and debt exchanged for preferred stock.

 

Income taxes

 

For the three and nine months ended September 30, 2023 and 2022, AgeX experienced a loss; therefore, no income tax provision was recorded for the three and nine months ended September 30, 2023 and 2022.

 

Due to losses incurred for all periods presented, we did not record a provision or benefit for income taxes. A valuation allowance will be provided when it is more likely than not that some portion of the deferred tax assets will not be realized. We established a full valuation allowance for all deferred tax assets for the periods presented due to the uncertainty of realizing future tax benefits from our net operating loss carryforwards and other deferred tax assets.

 

For years beginning after December 31, 2021, the Tax Cuts and Jobs Act of 2017 (the 2017 Tax) Act requires companies to capitalize their research and experimentation expenditures as defined under Section 174 and amortize those expenditures on a straight-line bases over a period of 5 years. Previously AgeX was able to immediately expense such costs. It is possible that Congress will defer or eliminate the ultimate implementation of this provision. AgeX has sufficient federal net operation loss carryforwards to offset the impact of this provision. 

 

Comparison of Years Ended December 31, 2022 and 2021

 

The following comparisons exclude the impact of the operations of LifeMap Sciences which have been presented in our consolidated financial results as discontinued operations. See Note 3, Disposition and Deconsolidation of LifeMap Sciences, to our consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement for a discussion of discontinued operations.

 

326

 

 

Revenues and Cost of Sales

 

The amounts in the table below show our consolidated revenues by source and cost of sales for the years ended December 31, 2022 and 2021 (in thousands).

 

   Year Ended December 31,   $ +Increase/   % +Increase/ 
   2022   2021   -Decrease   -Decrease 
Grant revenues  $-   $104   $-104   $-100.0%
Other revenues   34    40    -6    -15.0%
Total revenues   34    144    -110    -76.4%
Cost of sales   (13)   (19)   -6    -31.6%
Gross profit  $21   $125   $-104    -83.2%

 

During the year ended December 31, 2021, we recognized income of approximately $104,000 from a grant awarded by the NIH. During the year ended December 31, 2022, we did not recognize any grant revenues as we had expended the full amount available under the NIH grant as of December 31, 2021.

 

During the years ended December 31, 2022 and 2021, we recognized $34,000 and $40,000, respectively, from the sale of research products. Revenues from the sale of research products are included in other revenues.

 

Operating Expenses

 

We have maintained a minimal work force since the May 1, 2020 reduction in force which resulted in the layoff of most of our research and development personnel and certain administrative personnel. The following table shows our consolidated operating expenses for the years ended December 31, 2022 and 2021 (in thousands).

 

   Year Ended December 31,   $ +Increase/   % +Increase/ 
   2022   2021   -Decrease   -Decrease 
Research and development expenses  $1,025   $1,456   $-431    -29.6%
General and administrative expenses   5,971    6,708    -737    -11.0%

 

Research and Development Expenses

 

Research and development expenses for the year ended December 31, 2022 decreased by more than $0.4 million to $1.0 million as compared to approximately $1.5 million in 2021. The net decrease was primarily attributable to decreases of: $0.2 million in scientific consulting; $0.1 million in outside research and services expenses; $0.1 million in fees incurred related to sponsored research agreement with a university; and $0.1 million in cash and noncash stock-based compensation expense to employees. The following table shows our research and development expenses allocated to our primary research and development programs for the periods presented (in thousands).

 

  

Year Ended

December 31,

   $ Increase/   % Increase/ 
   2022   2021   (Decrease)   (Decrease) 
iTRTM technology: AGEX-iTR1547 and AGEX-iTR1550  $344   $295   $49    17%
PureStem® progenitor cell lines, brown adipose fat,  neural stem cells (NSC), exosomes, and related research and development: AGEX-BAT1 and cGMP PSC-derived cells including NSC   681    1,161    (480)   (41)%
Total  $1,025   $1,456           

 

General and Administrative Expenses

 

General and administrative expenses for the year ended December 31, 2022 decreased by $0.7 million to $6.0 million as compared to $6.7 million in 2021. The net decrease is attributable to decreases of $0.4 million in consulting expenses, $0.2 million in professional fees for legal services, $0.2 million in annual minimum royalties due under license agreements and patent and license maintenance related fees and $0.1 million in noncash stock-based compensation expense to directors. These decreases were offset to some extent by increases of $0.1 million in insurance expense and $0.1 million in professional fees for tax and accounting services.

 

327

 

 

Other Expense, Net

 

Other expense, net in 2022 consists primarily of $3.3 million of amortization of deferred debt issuance costs on loans from Juvenescence to interest expense, and $0.2 million change in fair value of warrants issued to Juvenescence in connection with borrowings under the 2022 Secured Note. Other expense, net in 2021 consists primarily of $1.1 million of amortization of deferred debt issuance costs on loans from Juvenescence to interest expense offset by approximately $437,000 of gain recognized upon forgiveness of our loan in the amount of $432,952 from a bank under the Paycheck Protection Program (PPP Loan) on February 19, 2021. See Notes 5, Related Party Transactions, and 6, Warrant Liability, to our consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement for additional information about our loan agreements with Juvenescence and liability classified warrants.

 

Income Taxes

 

Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2021, AgeX’s foreign entity operated at a loss; therefore, no GILTI was included in income. For the year ended December 31, 2022, there was no income or loss related to foreign activities as the entity deconsolidated from AgeX on March 15, 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.

 

For the year ended December 31, 2022, we experienced a domestic loss from continuing operations therefore, no income tax provision was recorded for the year ended December 31, 2022.

 

As of December 31, 2022, we had net operating loss carryforwards of approximately $52.8 million for U.S. federal income tax purposes. In general, NOLs and other tax credit carryforwards generated by legal entities in a consolidated federal tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the consolidated federal tax group. However, under the Tax Matters Agreement, dated August 17, 2017, between Lineage Cell Therapeutics, Inc. and AgeX (the Tax Matters Agreement), any use of a member’s NOLs and other tax credit carryforwards by the other member is subject to reimbursement by the benefiting member for the actual tax benefit realized.

 

As of December 31, 2022, we had net operating losses of approximately $14.9 million for California purposes.

 

Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2042.

 

328

 

 

As of December 31, 2022, we had research and development tax credit carryforwards for federal and state tax purposes of $0.9 million and $0.6 million, respectively. The federal tax credits expire between 2028 and 2042, while the state tax credits have no expiration date.

 

As of December 31, 2022, we had capital loss carryforwards for federal and state tax purposes of $12.4 million and $5.9 million, respectively. The federal and California capital loss carryforwards will expire in 2026.

 

A valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized. We established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

 

Liquidity and Capital Resources

 

Operating Losses and Going Concern Considerations

 

We have incurred operating losses and negative cash flows since inception and had an accumulated deficit of $127.6 million as of September 30, 2023 and $116.2 million as of December 31, 2022. We expect to continue to incur operating losses and negative cash flows. We have been funding our operations with loans from Juvenescence. As of October 31, 2023, we had drawn down in full the remaining credit available to us from Juvenescence pursuant to the 2022 Secured Note, but on November 9, 2023, we entered into the 2022 Secured Note Fifth Amendment that increases the amount of the line of credit available to us under the 2022 Secured Note by $4,400,000. As of January 3, 2024, we had drawn down $1,500,000 of the additional line of credit. The terms of the 2022 Secured Note provide that Juvenescence has discretion to approve and fund each of our future draws of available credit.

 

We have made certain adjustments to our operating plans and budgets to reduce our projected cash expenditures in order to extend the period over which we can continue our operations with our available cash resources. These adjustments entailed down-sizing of our leased office space effective January 1, 2021, a staff force reduction during 2020, primarily impacting research and development personnel, and the elimination of our leased laboratory facility. These down-sizing adjustments to our operations will require the deferral of certain work on the development of our product candidates and technologies. However, notwithstanding those adjustments, based on our most recent projected cash flows, our cash and cash equivalents and the amount of the 2022 Secured Note line of credit available to us from Juvenescence, including the $4,400,000 increase in the line of credit, and the proceeds we may receive from the sale of additional shares of our common stock in “at-the-market” transactions through our sales agreement (the Sales Agreement) with Chardan as a sales agent, would not be sufficient to satisfy our anticipated operating and other funding requirements for the next twelve months from the date of filing of our Quarterly Report on Form 10-Q for the nine months ended September 30, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern. See Note 5, Related Party Transactions, and Note 12, Subsequent Events, to our condensed consolidated interim financial statements and our consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement for additional information about our loan agreements with Juvenescence. We will need to raise additional capital in the near term to be able to meet our operating expenses.

 

329

 

 

The loans from Juvenescence that remain outstanding prohibit us and our subsidiaries ReCyte Therapeutics and Reverse Bio from borrowing funds from other lenders or engaging in certain other transactions without the consent of Juvenescence unless we repay all amounts owed to Juvenescence. AgeX and three of its subsidiaries have granted Juvenescence a security interest and lien on substantially all of their assets to secure AgeX’s obligations under the 2022 Secured Note, and AgeX has granted Juvenescence a security interest and lien on substantially all of AgeX’s assets to secure AgeX’s obligations for loans under the 2023 Secured Note.

 

On July 21, 2023, AgeX and Juvenescence entered into the 2023 Exchange Agreement pursuant to which AgeX issued to Juvenescence 211,600 shares of a newly authorized AgeX Series A preferred stock and 148,400 shares of a newly authorized AgeX Series B preferred stock in exchange for the cancellation of a total of $36,000,000 of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans.

 

The outstanding amounts under the 2022 Secured Note and the 2023 Secured Note will become due and payable upon maturity on February 14, 2024 and March 13, 2026, respectively. These factors and the impact of potential dilution through the issuance of shares of our common stock upon the conversion of the Juvenescence loans or shares of AgeX Series A preferred stock and Series B preferred stock into AgeX common stock and the exercise of warrants issued to Juvenescence in connection with the Juvenescence loans could make AgeX less attractive to new equity investors and could impair our ability to finance our operations or the operations of our subsidiaries unless Juvenescence agrees, in its discretion, to lend us additional funds.

 

Through the Sales Agreement with Chardan, we may sell during any 12 month period an amount of common stock in “at-the-market” transactions not to exceed one-third of the aggregate market value of our common stock held by stockholders who would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. We do not have any other committed sources of funds for additional financing.

 

Although we have been able to reduce our operating expenses by winding down our internal research and development activities following the May 2020 reduction in force and focusing instead on out-sourcing research and development and seeking license arrangements for our technologies, this approach has also made it more difficult for us to make progress in developing our target product candidates and technologies, which in turn may make it more difficult for us to raise capital. As a result of our focus on out-sourcing research and development, our internal research and development expenses decreased by $0.1 million for the nine months ended September 30, 2023 compared to same period in 2022 and by $0.4 million for the year ended December 31, 2022 compared to the same period in 2021. As of September 30, 2023, we have been awarded $1 million in research grants from the NIH for particular research and development projects relating to continued development of our technologies for treating osteoporosis, stroke, and cardiovascular disease. Through our subsidiary NeuroAirmid we intend to seek one or more grants from CIRM to finance initial clinical work with neuroprogenitor cells for the treatment of Huntington’s Disease. Unless the Merger is consummated or we obtain additional financing through grants or third-party financing, we expect to continue to focus on out-sourcing research and development and seeking licensing arrangements for our technologies. The following table shows our research and development expenses by category for the periods presented (in thousands).

 

  

Nine Months Ended

September 30,

  

Year Ended

December 31,

 
   2023   2022   2022   2021 
Salaries and payroll related expenses including noncash stock based compensation expense to employees  $281   $363   $467   $527 
Lab supplies, controlled storage and other expenses   60    76    80    123 
Amortization of intangible assets   98    98    131    131 
Total internal research and development expenses   439    537    678    781 
Outside research and services expenses   58    266    326    430 
Scientific consulting   18    14    21    175 
Fees incurred related to sponsored research agreement with a university   37            70 
Total research and development expenses  $552   $817   $1,025   $1,456 

 

The unavailability or inadequacy of financing to meet future capital needs could force us to modify, curtail, delay, or suspend some or all aspects of planned operations.

 

To the extent that we are able to raise additional capital through the sale of AgeX equity or convertible debt securities or the sale of equity or convertible debt securities of any of our subsidiaries, the ownership interest of our present stockholders will be diluted, and the terms of any securities we or our subsidiaries issue may include liquidation or other preferences that adversely affect the rights of our common stockholders. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and may involve the issuance of convertible debt or stock purchase warrants that would dilute the equity interests of our stockholders. If we raise funds through additional strategic partnerships or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.

 

330

 

 

Summary of Cash Flows

 

The following table summarizes the major sources and uses of cash for the periods set forth below (in thousands):

 

  

Nine Months Ended

September 30,

 
   2023   2022 
Net cash provided by (used in):          
Operating activities  $(5,748)  $(4,618)
Investing activities   (10,000)   - 
Financing activities   15,500    4,500 
Net change in cash, cash equivalents, and restricted cash  $(248)  $(118)

 

   Year Ended December 31, 
   2022   2021 
Net cash provided by (used in):          
Operating activities from continuing operations  $(5,939)  $(7,765)
Operating activities from discontinued operations   -    (90)
Investing activities from continuing operations   -    716 
Investing activities from discontinued operations   -    (50)
Financing activities from continuing operations   6,000    7,496 
Financing activities from discontinued operations   -    (250)
Net change in cash, cash equivalents, and restricted cash  $61   $57 

 

Operating Activities

 

Net loss attributable to us for the nine months ended September 30, 2023 amounted to $11.3 million. Net cash used in operating activities during this period amounted to $5.7 million. The $5.6 million difference between the net loss attributable to us and net cash used in operating activities during the nine months ended September 30, 2023 was primarily attributable to $5.4 million in amortization of intangible assets and deferred debt issuance costs, $1.1 million in prepaid expenses and other current assets, $0.6 million in accounts payables and accrued liabilities, and $0.1 million in stock-based compensation expense. The impact of these non-cash items was offset to some extent by a $1.1 million payment of a financed insurance premium liability, $0.4 million in accrued interest on convertible note receivable, and $0.1 million net change in working capital from operating activities. See Notes 4, Convertible Note Receivable, and 5, Related Party Transactions, to our condensed consolidated interim financial statements included elsewhere in this proxy statement/prospectus/information statement for additional information about our loan agreement with Serina and our loan agreements with Juvenescence.

 

Net loss attributable to us for the year ended December 31, 2022 amounted to $10.5 million. Net cash used in operating activities from continuing operations during this period amounted to $5.9 million. The difference between the net loss attributable to us and net cash used in operating activities from continuing operations during the year ended December 31, 2022 was primarily attributable to $3.3 million in amortization of intangible assets and deferred debt issuance costs, $1.1 million net change in working capital from operating activities, $0.8 million in stock-based compensation expense, $0.2 million loss on change in fair value of warrants, and more than $0.2 million in related party payables. These amounts were offset to some extent by $1.0 million of financed insurance premiums and $0.1 million in net loss attributable to noncontrolling interest. See Notes 5, Related Party Transactions, and 6, Warrant Liability, to our consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement for additional information about our loan agreements with Juvenescence and liability classified warrants.

 

331

 

 

Investing Activities

 

During the nine months ended September 30, 2023, net cash used by investing activities is entirely comprised of the $10 million loan made to Serina. See Note 4, Convertible Note Receivable, to our condensed consolidated interim financial statements included elsewhere in this proxy statement/prospectus/information statement for additional information about the AgeX-Serina Note.

 

During the nine months ended September 30, 2023 and the year ended December 31, 2022, AgeX had no investing activities.

 

Financing Activities

 

During the nine months ended September 30, 2023, net cash provided by financing activities amounted to $15.5 million which was entirely attributable to amounts drawn under the credit facilities from Juvenescence. See Notes 5, Related Party Transactions, and 7, Stockholders’ Equity (Deficit), to our condensed consolidated interim financial statements included elsewhere in this proxy statement/prospectus/information statement for additional information about our loan agreements with Juvenescence.

 

During the year ended December 31, 2022, net cash provided by financing activities from continuing operations amounted to $6.0 million, which was attributable to the $0.5 million drawn against the final remaining funds available under the 2020 Loan Agreement and the $12.7 million drawn against the $13.2 million made available under the 2022 Secured Note entered into with Juvenescence in February 2022 of which $7.2 million was used to refinance the $7.0 million outstanding principal amount of the loans and a $160,000 origination fee due under the Loan Facility Agreement, dated August 13, 2019, between AgeX and Juvenescence (as amended, the 2019 Loan Agreement). See Note 5, Related Party Transactions, to our consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement for additional information about our loan agreements with Juvenescence.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2022, we did not have any off-balance sheet arrangements, as defined in Item 303(a) (4) (ii) of SEC Regulation S-K.

 

332

 

 

SERINA MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of Serina’s financial condition and results of operations together with the section titled “Unaudited Pro Forma Condensed Combined Financial Information” and Serina’s audited consolidated financial statements and related notes for the period ended December 31, 2022, along with our unaudited consolidated financial statements and related notes for the period ended September 30, 2023 included elsewhere in this proxy statement/prospectus/information statement. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus/information statement, including information with respect to our plans and strategy for our business and related financing, includes forward looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section titled “Risk Factors” our actual results could differ materially from the results described in or implied by the forward looking statements contained in the following discussion and analysis. You should carefully read the section titled “Risk Factors” to gain an understanding of the important factors that could cause actual results to differ materially from our forward looking statements. Please also see the section titled “Cautionary Note Regarding Forward Looking Statements.” References to “the Company,” “we,” “us” and “our” in this section titled “Serina Management’s Discussion and Analysis of Financial Condition and Results of Operations” refer to Serina.

 

Overview

 

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Serina’s POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an increase in efficacy and safety of the resulting polymeric drug conjugate. Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.

 

Our operations through September 30, 2023, have been financed primarily by aggregate net proceeds of $46.91 million from the issuance of convertible preferred stock and convertible notes. Since our inception in 2006, we have had significant annual operating losses. Our operating loss was $3.37 million, $1.57 million, $2.27 million and $1.63 million for the nine months ended September 30, 2023 and 2022 and the years ended December 31, 2022 and 2021, respectively. As of September 30, 2023, we had an accumulated deficit of $34.2 million and $7.6 million in cash and cash equivalents.

 

Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations within one year of the unaudited consolidated financial statement issuance date, raise substantial doubt about our ability to continue as a going concern. We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development. Our unaudited consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Our unaudited consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

333

 

 

Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire additional personnel, pay fees to outside consultants, attorneys, and accountants, and, if the Merger is consummated, incur other increased costs associated with being a public company. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase significantly in connection with our ongoing activities as we:

 

  advance our lead product candidate, SER 252 into Phase I clinical trials;
  advance our other product candidates;
  advance our preclinical programs to clinical trials;
  further invest in our pipeline;
  seek regulatory approval for our investigational medicines;
  maintain, expand, protect, and defend our intellectual property portfolio;
  secure facilities to support continued growth in our research, development, and commercialization efforts;
  increase our headcount to support our development efforts and to expand our clinical development team.

 

We believe that our cash on hand, along with the approximately $15 million of cash proceeds expected to be received from Juvenescence through the exercise of all the post-merger warrants it holds pursuant to the terms of the Side Letter if the Merger is consummated, will enable us to fund our operations through calendar year 2025 based on our current plan. Approximately $8 million of these funds are expected to be allocated to advance Serina’s lead product candidate SER 252 from IND enabling pre- clinical studies through a Phase I clinical trial, and approximately $2.5 million is expected to be allocated to advance Serina’s POZ-LNP internal research and development programs. The balance of such funds is expected to be used as working capital to fund our operations through calendar year 2025 based on our current plan. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. If the Merger is not consummated, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements are prepared using GAAP as applicable to a going concern. Assuming the Merger is consummated, to finance our operations beyond calendar 2025, we will need to raise additional capital, which cannot be assured. We have not had any products approved for sale. We do not expect to generate any product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses, or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs.

 

334

 

 

The COVID-19 pandemic continues to evolve. While it appears its most severe effects have subsided, COVID-19 could reemerge or new public health threats could appear. The future impact of the COVID-19 pandemic or a similar health disruption is highly uncertain and subject to change. We cannot predict the full extent of potential delays or impacts on our business, our clinical trials, health care systems, third parties with whom we engage or the global economy as a whole, but if we or any of the third parties with whom we engage, including personnel at contract manufacturing operations, or CMOs, and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timeline presently planned could be materially and adversely impacted. While we have been able to continue to execute our overall business plan, some of our business activities have taken longer to complete than anticipated. Overall, we recognize the challenges of product development during a pandemic, and we will continue to closely monitor events as they develop and plan for alternative and mitigating measures if needed.

 

On August 29, 2023, Serina entered into the Merger Agreement with AgeX. The transaction is expected to close in the first quarter of 2024.

 

Prior to the execution of the Merger Agreement, Serina issued a convertible promissory note (or the AgeX-Serina Note) to AgeX in the principal amount of $10 million as described elsewhere in this proxy statement/prospectus/information statement. Immediately prior to completion of the merger, the AgeX-Serina Note will be converted into Serina capital stock as a capital contribution. It is expected that the funds provided by the AgeX-Serina Note, together with the approximately additional $15 million of proceeds from the Juvenescence through the post-merger warrant cash exercises, are expected to provide working capital for the combined company to help fund operations through calendar year 2025.

 

Recent Developments

 

On August 29, 2023, Serina entered into the Merger Agreement with AgeX and Merger Sub, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Serina will merge with and into Merger Sub, with Serina surviving as a wholly owned subsidiary of AgeX. The combined company will be renamed “Serina Therapeutics, Inc.”. For additional information, see the sections titled “The Merger” and “The Merger Agreement” beginning on pages 133 and 170 of this proxy statement/prospectus/information statement, respectively.

 

Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price of AgeX common stock being equal to or greater than $12.00 per share (on a post-reverse split basis), giving effect to the reverse stock split and the AgeX preferred stock conversion and excluding the impact of any post-merger warrant, incentive warrant or the issuance of any share of AgeX common stock upon exercise of any post-merger warrant or incentive warrant.

 

Concurrently with the execution of the Merger Agreement, Serina, AgeX and Juvenescence entered into the Side Letter, which will become effective immediately prior to the closing of the Merger. The Side Letter provides, among other things, that (i) immediately prior to the Effective Time, Juvenescence will cancel all out of the money AgeX warrants held by Juvenescence; (ii) Juvenescence will exercise all of the post-merger warrants it holds to provide the combined company approximately an additional $15 million in capital according to the following schedule: (x) at least one-third on or before May 31, 2024, (y) at least one-third on or before November 30, 2024, and (z) at least one-third on or before June 30, 2025; (iii) Juvenescence will not sell any shares of AgeX Series A preferred stock or AgeX Series B preferred stock and will take all actions necessary to effect the AgeX preferred stock conversion, whereby all of such preferred stock will be converted into AgeX common stock prior to the reverse stock split; (iv) Juvenescence will release all security interests, guarantees, pledges, assignments and other forms of collateral that it may have in AgeX’s assets pursuant to the terms of certain loans to AgeX; and (v) Juvenescence will consent to a newly formed subsidiary of AgeX assuming AgeX’s obligations with respect to loans agreements and promissory notes governing loans payable to Juvenescence, including obligations for amounts currently owed and future advances of loan funds, and Juvenescence shall release AgeX from those loan obligations. For additional information, see the sections titled “Agreements Related to the Merger—Side Letter” beginning on page 197 of this proxy statement/prospectus/information statement.

 

335

 

 

In October 2023, we entered into a non-exclusive license agreement with Pfizer, Inc. to use our POZ polymer technology for use in lipid nanoparticle drug delivery formulations. The agreement grants Pfizer non-exclusive rights to certain intellectual property, know-how, and proprietary technologies. Under the terms of the agreement, Pfizer is authorized to develop, manufacture, market, and commercialize products incorporating the licensed technology with respect to a specific POZ polymer structure in one field. The agreement outlines the protection and enforcement of intellectual property rights related to the licensed technology. Pfizer is obligated to use commercially reasonable diligent efforts to develop and commercialize licensed products, and to use such efforts to accomplish specified development and commercial objectives. The agreement includes a one-time upfront payment of $3 million that was received on December 15, 2023, milestone payments payable to Serina upon the achievement of specific development, regulatory, and commercial milestones, and a royalty on net sales of products incorporating the licensed technology in accordance with the terms outlined in the license agreement. The range of royalties on sales of products is between 2.75% – 3.5% and is tiered to achievement of certain sales milestones.

 

Components of Operating Results

 

Operating Expenses

 

Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costs.

 

Research and Development

 

Our research and development expenses consist primarily of costs incurred for the development of our product candidates and our drug discovery efforts, which include:

 

● personnel costs, which include salaries, benefits and equity-based compensation expense;

 

● expenses incurred under agreements with consultants and contract organizations that conduct research and development activities on our behalf;

 

● costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers;

 

● laboratory and vendor expenses related to the execution of preclinical studies and planned clinical trials; and

 

● laboratory supplies and equipment used for internal research and development activities.

 

We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and service providers.

 

Our research and development expenses are not currently tracked on a program-by-program basis. We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates and therefore have not implemented the systems and procedures to track research and development expenses on a program-by-program basis. We track research and development expenses based on the type of expense as further described on pages 339 and 341. Substantially all our research and development costs in the nine months ended September 30, 2023, and the years ended December 31, 2022, and 2021, were incurred on the development of our preclinical candidates and advancing research on our POZ lipid technology.

 

We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in conducting clinical trials, manufacturing and otherwise advancing our programs. The process of conducting the clinical research necessary to obtain regulatory approval is costly and time consuming, and the successful development of our product candidates is highly uncertain.

 

336

 

 

Because of the numerous risks and uncertainties associated with product development and the current stage of development of our product candidates and programs, we cannot reasonably estimate or know the nature, timing, and estimated costs necessary to complete the remainder of the development of our product candidates or programs. We are also unable to predict if, when, or to what extent we will obtain approval and generate revenues from the commercialization and sale of any of our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including:

 

successful completion of preclinical studies and initiation of clinical trials for future product candidates;
   
successful enrollment and completion of clinical trials for our current product candidates;
   
data from our clinical programs that support an acceptable risk benefit profile of our product candidates in the intended patient populations; acceptance by the U.S. Food and Drug Administration, or FDA, or other applicable regulatory agencies of the Investigational New Drug, or IND, applications, clinical trial applications and/or other regulatory filings for SER 252 and other product candidates.
   
expansion and maintenance of a workforce of experienced scientists and others to continue to develop our product candidates;
   
successful application for and receipt of marketing approvals from applicable regulatory authorities;
   
obtainment and maintenance of intellectual property protection and regulatory exclusivity for our product candidates;
   
making of arrangements with contract manufacturing organizations for, or establishment of, commercial manufacturing capabilities;
   
establishment of sales, marketing and distribution capabilities and successful launch of commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;
   
acceptance of our product candidates, if and when approved, by patients, the medical community and third party payors;
   
effective competition with other therapies;
   
obtainment and maintenance of coverage, adequate pricing, and adequate reimbursement from third party payors, including government payors;
   
maintenance, enforcement, defense, and protection of our rights in our intellectual property portfolio;
   
avoidance of infringement, misappropriation, or other violations with respect to others’ intellectual property or proprietary rights; and
   
maintenance of a continued acceptable safety profile of our products following receipt of any marketing approvals.

 

We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay, or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development.

 

337

 

 

Research and development activities account for a significant portion of our operating expenses. We expect our research and development expenses to increase for the foreseeable future as we continue to implement our business strategy, which includes advancing SER 252 and our other product candidates through clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, and seeking regulatory approvals for our product candidates that successfully complete clinical trials. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. As a result, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development. However, we do not believe that it is possible at this time to accurately project total program specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.

 

General and Administrative Expenses

 

Our general and administrative expenses consist primarily of personnel costs, including equity-based compensation, and other expenses for outside professional services, including legal, recruiting, audit and accounting and facility related costs not otherwise included in research and development expenses. Personnel costs consist of salaries, benefits and equity-based compensation expense for our personnel in executive and other administrative functions. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of expanding our operations and operating as a public company. These increases will likely include increases related to the hiring of additional personnel and legal, regulatory, and other fees and services associated with maintaining compliance with the NYSE American, the NYSE American Company Guide and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs and investor relations costs associated with being a public company.

 

Other Income/(Expense)

 

Our other income is comprised of interest from cash equivalents.

 

Our other expense is comprised of expenses related to the change in fair value of the embedded derivative and interest accrued from the convertible notes.

 

Results of Operations

 

Comparison of the Nine Months Ended September 30, 2023 and 2022

 

The following sets forth our results of operations for the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022:

 

           Change 
   2023   2022   Amount   Percent 
Revenues:                    
Contract Revenue  $-   $500,000   $(500,000)   -100%
Grant Revenue   66,867    33,897    32,970    97%
Total Revenue   66,867    533,897    (467,030)   -87%
Operating expenses:                    
Research and development   1,480,720    1,326,541    154,179    12%
General and administrative   1,954,833    781,240    1,173,593    150%
Total operating expenses   3,435,553    2,107,781    1,330,016    63%
Loss from operations   (3,368,686)   (1,573,884)   (1,794,802)   114%
Other income (expense):                    
Loss on equity securities, net   -    (7,586)   7,586    -100%
Interest expense   (381,644)   -    (464,339)   100%
Interest and dividend income   194,074    1,791    192,283    10,736%
Fair value inception adjustment on convertible promissory notes   2,240,000    (179,000)   2,419,000    1,351%
Change in fair value of convertible promissory notes   4,477,361    -    4,477,361    100%
Change in fair value of warrant liability   1,059,019    (326,094)   1,385,113    425%
Other income   -    1,084    (1,084)   -100%
Net income (loss)  $4,220,124   $(2,083,689)  $6,303,813    303%

 

338

 

 

Revenues

 

Contract revenue for the nine months ended September 30, 2023, was $0 compared to $500,000 for the nine months ended September 30, 2022. The decrease of $500,000 was due primarily to the absence of any contract revenue for the nine months ended September 30, 2023, compared to $500,000 in contract revenue related to partner collaboration activities for the nine months ended September 30, 2022. Grant revenue for the nine months ended September 30, 2023, was $66,867 compared to $33,897 for the nine months ended September 30, 2022. The increase of $32,970 was due to the Innovate Alabama Supplemental Grant awarded by the Alabama Innovation Corporation on August 24, 2022 recognized as revenue as eligible expenses under the grant were incurred.

 

Research and development expenses

 

Research and development expenses included costs associated with research performed pursuant to government grant agreements, including internal research, direct and indirect internal costs related to specific projects, employee compensation and benefits, included stock-based compensation expense, for employees in engineering and design, as well as fees paid to other that conduct certain research activities on Serina’s behalf.

 

The following table summarizes our research and development expenses for the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022:

 

       Change 
   2023   2022   Amount   Percent 
                 
Amortization expense  $11,673   $11,673   $-    - 
Consulting services   39,015    16,892    22,123    131%
Depreciation   97,539    27,494    70,045    255%
Freight   2,003    1,536    467    30%
Lab supplies   99,537    34,955    64,582    185%
Outside lab analysis   25,932    18,914    7,018    37%
Professional fees   160,325    196,723    (36,398)   (19%)
R&D labor   876,564    873,679    2,885    - 
Repairs & maintenance   12,814    7,577    5,237    69%
Travel   7,523    8,384    (861)   (10%)
Rent   147,795    128,714    19,081    15%
Research and development expenses  $1,480,720   $1,326,541   $154,179    12%

 

Research and development expenses were $1,480,720 for the nine months ended September 30, 2023, compared to $1,326,541 for the nine months ended September 30, 2022. The increase of $154,179 was due to primarily to an increase in contract manufacturing, chemicals, and supplies.

 

General and administrative expenses

 

General and administrative expenses were $1,954,833 for the nine months ended September 30, 2023, compared to $781,240 for the nine months ended September 30, 2022. The increase of $1,173,593 was due primarily to increases of approximately $298,000 in professional fees, approximately $679,000 in legal expenses, approximately $45,000 in general and administrative salaries and benefits, approximately $32,000 in rent expense, and approximately $103,500 in dues and subscriptions due to an annual fee for a new online platform for pharmaceutical companies and increase in cloud storage usage.

 

Other income (expense)

 

Interest and dividend income for the nine months ended September 30, 2023 was $194,074 compared to $1,791 for the nine months ended September 30, 2022. The increase of $192,283 was primarily due to higher interest earning cash balances.

 

Interest expense for the nine months ended September 30, 2023 was $381,644 compared to $0 for the nine months ended September 30, 2022. The increase of $381,644 was due to the interest recognized on the convertible notes.

 

339

 

 

The aggregate change in the fair value of the Serina Convertible Notes, the AgeX-Serina Note and Series A-5 preferred share warrants for the nine months ended September 30, 2023, was $7,776,380. The change in the fair value of the Serina Convertible Notes and Series A-5 preferred share warrants for the nine months ended September 30, 2022, was $(505,094). The increase of $8,281,474 million was due primarily to the change in the at inception fair value adjustment of $2,419,000, the change in the fair market value of the AgeX-Serina Note issued to AgeX in March 2023 of $4,477,361 during the period, and the change in the fair market value of the Series A-5 preferred share warrants.

 

Results of Operations

 

Comparison of the Years Ended December 31, 2022 and 2021

 

The following sets forth our results of operations for the year ended December 31, 2022 as compared to the year ended December 31, 2021:

 

           Change 
   2022   2021   Amount   Percent 
Revenues:                    
Contract Revenue  $500,000   $3,039,184   $(2,539,184)   -84%
Grant Revenue   91,500    425,569    (334,069)   -78%
Total Revenue   591,500    3,464,753    (2,873,253)   -83%
Operating expenses:                    
Research and development   1,573,085    3,798,593    (2,225,508)   -59%
General and administrative   1,288,783    1,297,668    (8,885)   -1%
Total operating expenses   2,861,868    5,096,261    (2,234,393)   -44%
Loss from operations   (2,270,368)   (1,631,508)   (638,860)   -39%
Other income (expense):                    
Loss on equity securities, net   (7,585)   (6,452)   (1,133)   18%
Interest expense   (15,878)   (3,094)   (12,784)   413%
Interest and dividend income   1,757    10,859    (9,102)   -84%
Fair value inception adjustment on convertible promissory notes   (179,000)   -    (179,000)   100%
Change in fair value of convertible promissory notes   (88,000)   -    (88,000)   100%
Change in fair value of warrant liability   (124,118)   205,287    (329,405)   -160%
Other income   1,084    -    1,084    100%
Forgiveness of SBA PPP loan   -    187,133    (187,133)   -100%
Loss on dissolution of subsidiary   -    (26,928)   26,928    -100%
Net loss  $(2,682,108)  $(1,264,703)  $(1,417,405)   112%

 

340

 

 

Revenues

 

Contract revenue for the year ended December 31, 2022, was $500,000 compared to $3,039,184 for the year ended December 31, 2021. The decrease of $2,539,184 was due primarily to completion of revenue from a licensing agreement in 2021. In June 2020, Serina and Jazz Pharmaceuticals, Ltd. entered into an exclusive license agreement for polymer conjugates of cannabidiol, specifically Serina product candidate SER 228. The licensing agreement included a one-time upfront payment, and milestone payments payable to Serina upon the achievement of specific development, regulatory, and commercial milestones, and a royalty on net sales of products incorporating the licensed technology. In July 2021, the collaboration and license agreement was terminated. Grant revenue for the year ended December 31, 2022, was $91,500 compared to $425,569 for the year ended December 31, 2021. The decrease of $334,069 was due to the timing of the grant program related to product candidate SER 227 in each year in which grant revenue is recognized as eligible expenses under the grants are incurred.

 

Research and development expenses

 

The following table summarizes our research and development expenses for the year ended December 31, 2022 as compared to the year ended December 31, 2021:

 

       Change 
   2022   2021   Amount   Percent 
                 
Amortization expense  $23,349   $-   $23,349    - 
Consulting services   29,014    195,330    (166,316)   (85)%
Depreciation   12,403    24,296    (11,893)   (49)%
Freight   1,831    5,587    (3,756)   (67)%
Lab supplies   58,803    147,606    (88,803)   (60)%
Outside lab analysis   34,895    848,913    (814,018)   (96)%
Professional fees   231,550    164,289    67,261    41%
R&D labor   1,127,146    2,366,042    (1,238,896)   (52)%
Repairs and maintenance   19,509    17,112    2,397    14%
Travel   8,427    452    7,975    1,764%
Rent   26,158    28,948    (2,790)   (10)%
Waste disposal   -    18    (18)   (100)%
Research and development expenses  $1,573,085   $3,798,593   $(2,225,508)   -59%

 

Research and development expenses were $1,573,085 for the year ended December 31, 2022, compared to $3,798,593 for the year ended December 31, 2021. The decrease of $2,225,508 was due to decreases of approximately $980,300 in the cost of outside lab analysis, approximately $1,119,200 of expenses related to contract manufacturing, approximately $119,700 in labor and related costs and approximately $68,000 in chemical costs, partially offset by an increase of approximately $67,300 in legal related expenses.

 

General and administrative expenses

 

General and administrative expenses were $1,288,783 for the year ended December 31, 2022, compared to $1,297,668 for the year ended December 31, 2021. The approximately flat level of expenditures recognized between the years was due to the Company’s strategy to control operating costs until additional working capital could be raised.

 

Other income (expense)

 

Interest and dividend income for the year ended December 31, 2022 was $1,757 compared to $10,859 for the year ended December 31, 2021. The decrease of $9,102 was mainly due to lower interest earning cash balances.

 

Interest expense for the year ended December 31, 2022 was $15,878 compared to $3,094 for the year ended December 31, 2021. The increase of $12,784 was due to the interest on the outstanding Serina Convertible Notes issued to certain Serina preferred stockholders between June 2022 and November 2022.

 

The aggregate change in the fair value of Serina Convertible Notes issued in 2022 was $267,000. Of this amount, $179,000 related to the fair value adjustment at the inception of the notes and $88,000 related to the change in fair value of the Convertible Notes during the year. No similar notes were issued and outstanding during the year ended December 31, 2021.

 

The change in the fair value of Series A-5 preferred stock warrants was $329,405 during the year ended December 31, 2022, as compared to the year ended December 31, 2021. The decrease was the result of the warrants mark to market adjustments.

 

The gain on forgiveness of the SBA PPP Loan recognized in the year ended December 31, 2021 was $187,133. No similar SBA PPA Loans remained outstanding during the year ended December 31, 2022.

 

Liquidity and Capital Resources

 

Sources of Liquidity

 

Our operations from inception through September 30, 2023 have been financed primarily by aggregate net proceeds of $46.91 million from the issuance of convertible preferred stock and convertible notes. Since inception, we have had significant operating losses. Our operating loss was $3,368,686, $1,573,884, $2,270,368, and $1,631,508 for the nine months ended September 30, 2023 and 2022 and years ended December 31, 2022 and 2021, respectively. As of September 30, 2023, we had an accumulated deficit of $34,226,358 and $7,580,764 in cash and cash equivalents. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

 

341

 

 

Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations within one year of the unaudited consolidated financial statement issuance date, raise substantial doubt about our ability to continue as a going concern. We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development. The unaudited consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

Funding Requirements

 

Any product candidates we may develop may never achieve commercialization, and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses, and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, costs related to pre-clinical clinical research, clinical studies, manufacturing, and development services; compensation and related expenses; costs relating to the build out of our laboratories at our headquarters; license payments or milestone obligations that may arise; laboratory expenses and costs for related supplies; manufacturing costs; legal and other regulatory expenses and general overhead costs.

 

We believe that our cash on hand, along with the approximately $15 million of cash proceeds expected to be received from Juvenescence through the exercise of all the post-merger warrants it holds pursuant to the terms of the Side Letter if the Merger is consummated, will enable us to fund our operations through calendar year 2025 based on our current plan. To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders, including investors in this offering, will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs.

 

342

 

 

Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

 

the impacts of the COVID 19 pandemic;
   
the progress, costs and results of IND enabling studies for our lead product candidate SER 252 and our potential future clinical trials for SER 252;
   
the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our other product candidates;
   
the costs, timing, and outcome of regulatory review of our product candidates;
   
our ability to enter into contract manufacturing arrangements for supply of active pharmaceutical
   
ingredient, or API, and manufacture of our product candidates and the terms of such arrangements;
   
our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;
   
the payment or receipt of milestones and receipt of other collaboration based revenues, if any; the costs and timing of any future commercialization activities, including product manufacturing, sales, marketing, and distribution, for any of our product candidates for which we may receive marketing approval;
   
the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;
   
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property related claims;
   
the extent to which we acquire or in license other products, product candidates, technologies, or data referencing rights;
   
the ability to receive additional nondilutive funding, including grants from organizations and foundations; and
   
the costs of operating as a public company

 

Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs.

 

Cash Flows

 

The following table summarizes our cash flows for the nine months ended September 30, 2023 and 2022 and the years ended December 31, 2022 and 2021:

 

Comparison of the Nine Months Ended September 30, 2023 and 2022

 

  

Nine Months Ended

September 30,

         
   2023   2022   $ Change   % Change 
Net cash used in operating activities  $(2,597,017)  $(1,216,482)  $(1,380,535)   113%
Net cash (used in) provided by investing activities   (434,141)   990,652    (1,424,793)   -144%
Net cash provided by financing activities   10,079,693    1,218,712    8,860,981    727%
Net increase in cash  $7,048,535   $992,882   $6,055,653    610%

 

343

 

 

Comparison of the Years Ended December 31, 2022 and 2021

 

   Year Ended December 31,         
   2022   2021   $ Change   % Change 
Net cash used in operating activities  $(2,075,624)  $(2,250,775)  $175,151    -8%
Net cash provided by investing activities   980,937    823,321    157,616    19%
Net cash provided by financing activities   1,312,070    1,077,245    234,825    22%
Net increase (decrease) in cash  $217,383   $(350,209)  $567,592    -162%

 

Operating Activities

 

Net cash used in operating activities increased by $1,380,535 to $2,597,017 during the nine months ended September 30, 2023, from $1,216,482 during the nine months ended September 30, 2022. Net cash used in operating activities is impacted by our net income (loss) adjusted for certain non-cash items, including changes in the fair value of convertible notes and warrants, among other non-cash items as well as the effect of changes in operating assets and liabilities. The increase was primarily due to the non-cash change in the fair value of the Serina Convertible Notes and the AgeX-Serina Note outstanding of $6,717,361 and the non-cash change in fair value of the Series A-5 preferred share warrants outstanding of $1,059,019. These increases were offset by changes related to various asset and liability accounts, notably an increase in accounts payable of approximately $523,000 and accrued interest of approximately $381,000.

 

Net cash used in operating activities decreased by $175,151 to $2,075,624 during the year ended December 31, 2022, from $2,250,775 during the year ended December 31, 2021. The decrease was primarily due to the decrease of contract liabilities of approximately $154,000. This decrease was partially offset by changes in asset and liability accounts such as accounts payable and operating lease liabilities.

 

Investing Activities

 

Net cash (used in) provided by investing activities decreased by $1,424,793 to $(434,141) during the nine months ended September 30, 2023 from $990,652 during the nine months ended September 30, 2022. The net cash used during the nine months ended September 30, 2023 related entirely to purchases of capital equipment of approximately $434,000. The net cash provided by in the nine months ended September 30, 2022 related entirely to proceeds of $991,000 from the sale of equity investments.

 

Net cash provided by investing activities increased by $157,616 to $980,937 during the year ended December 31, 2022 from $823,321 during the year ended December 31, 2021. The net cash provided by in the year ended December 31, 2022 related substantially to proceeds of $991,000 from the sale of equity investments. The net cash provided by in the year ended December 31, 2021 related to proceeds of $932,000 from the sale of equity investments offset by net cash used of approximately $85,000 to purchase of capital equipment as well as net cash used of approximately $24,000 to acquire a financed lease asset.

 

344

 

 

Financing Activities

 

Net cash provided by financing activities for the nine months ended September 30, 2023 was $10,079,693 comprised of $10,100,000 in net proceeds from the issuance of $100,000 of Serina Convertible Notes, $10,000,000 from the issuance of the AgeX-Serina Note, $14,936 in proceeds from common stock issued, partially offset by $35,243 in principal repayments on finance lease liabilities.

 

Net cash provided by financing activities for the nine months ended September 30, 2022 was $1,218,712 comprised of $1,250,000 from the issuance of Serina Convertible Notes, partially offset by $31,288 in principal repayments on finance lease liabilities.

 

Net cash provided by financing activities for the year ended December 31, 2022 was $1,312,070, comprised of $5,000,000 in net proceeds from the issuance of Serina Convertible Notes to certain Serina preferred stockholders, $4,422 in proceeds from common stock issued, partially offset by $3,650,000 in repayments of Serina Convertible Notes and $42,352 in principal repayments on finance lease liabilities.

 

Net cash provided by financing activities for the year ended December 31, 2021 was $1,077,245, comprised of $90,152 in net proceeds from preferred stock issued and $1,000,000 from the collection of a stock subscription receivable, partially offset by $12,907 in principal repayments on finance lease liabilities.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2023 and December 31, 2022, we did not have any relationships with special purpose or variable interest entities or other which would have been established for the purpose of facilitating off-balance sheet arrangements or other off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

 

Critical Accounting Policies and Use of Significant Judgments and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

 

Going Concern

 

Our evaluation of our ability to continue as a going concern requires us to evaluate our future sources and uses of cash sufficient to fund our currently expected operations in conducting research and development activities one year from the date our audited consolidated financial statements are issued. We evaluate the probability associated with each source and use of cash resources in making our going concern determination. The research and development of pharmaceutical products is inherently subject to uncertainty.

 

Research and Development Costs

 

We will incur substantial expenses associated with manufacturing, pre-clinical research, and clinical studies. Accounting for pre-clinical research and clinical studies relating to activities performed by contract research organizations, or CROs, and other external vendors requires management to exercise significant estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include the conduct of sponsored research, pre-clinical research, clinical studies, and contract manufacturing activities. The diverse nature of services being provided under CROs and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain pre-clinical and clinical activities complicates the estimation of accruals for services rendered by CROs and other vendors in connection with pre-clinical research and clinical studies. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and include these costs in the accrued expenses or prepaid expenses on the balance sheets and within research and development expense on the consolidated statements of operations. In estimating the duration of a clinical study, we evaluate the start up, treatment and wrap up periods, compensation arrangements and services rendered attributable to each clinical trial and fluctuations are regularly tested against payment plans and trial completion assumptions.

 

We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.

 

345

 

 

Our expenses related to clinical trials will be based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that may be used to conduct and manage clinical trials on our behalf. We will accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we will modify our estimates of accrued expenses accordingly on a prospective basis.

 

Fair market value of common stock

 

As there has been no public market for our common stock, the estimated fair value of our common stock has been determined by the Serina Board as of the date of each option grant, with input from management, considering Serina’s most recently available third-party valuations of common stock and the Serina Board’s assessment of additional objective and subjective factors it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation. The common stock valuations were prepared using the option pricing method. These third-party valuations were performed at various dates, which resulted in valuations of our common stock of $0.99 per share as of December 31, 2022 and $0.06 per share as of March 31, 2021.

 

Leases

 

ASU No. 2016 02, Leases (ASC 842), establishes a right of use model (ROU) that requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the unaudited statement of operations as well as the reduction of the right of use asset.

 

At the inception of an arrangement, Serina determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and Serina’s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, Serina will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

 

Serina has elected to combine lease and non lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU lease assets, current lease liabilities and non-current lease liabilities. Fixed rents are included in the calculation of the lease balances, while variable costs paid for certain operating and pass through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.

 

Stock based Compensation

 

Prior to the proposed Merger, we issued equity-based compensation awards through the granting of options, which generally vest over four years. We account for equity-based compensation in accordance with Accounting Standards Codification, or ASC, 718, Compensation Stock Compensation, or ASC 718. In accordance with ASC 718, compensation cost is measured at estimated fair value at grant date and is included as compensation expense over the vesting period during which service is provided in exchange for the award. Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period.

 

346

 

 

We use the Black Scholes option pricing model, or Black Scholes, to determine fair value of our options. Black Scholes includes various assumptions, including the fair value of common shares, expected life of incentive shares, the expected volatility and the expected risk-free interest rate. These assumptions reflect our best estimates, but they involve inherent uncertainties based on market conditions generally outside our control. As a result, if other assumptions had been used, equity-based compensation cost could have been materially impacted. Furthermore, if we use different assumptions for future grants, equity-based compensation cost could be materially impacted in future periods.

 

The risk-free interest rate is estimated using the weighted average rate of return on U.S. Treasury notes with a life that approximates the expected life of the option. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted average vesting period of the option. Serina uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to nonemployees. Expected volatility is based on the weighted average of the historical volatility of a peer group of publicly traded companies. The assumed dividend yield is based upon Serina’s expectation of not paying dividends in the foreseeable future.

 

No stock options to purchase common stock were granted during the nine months ended September 30, 2023.

 

We granted stock options to purchase 50,000 shares of common stock in the year ended December 31, 2022. The fair value of our awards in the year ended December 31, 2022 has been estimated using Black Scholes based on the following assumptions: expected term of 10 years; volatility of 88.57%; risk free rate of 3.96%; and no expectation of dividends.

 

We granted stock options to purchase 2,036,450 shares of common stock during the year ended December 31, 2021. The fair value of our awards in the year ended December 31, 2021 has been estimated using Black Scholes based on the following assumptions: expected term range of 5.15 – 10 years; volatility of 68.70%; risk free rate range of 0.73% - 0.81%; and no expectation of dividends.

 

We will continue to use judgment in evaluating the assumptions utilized for our equity-based compensation expense calculations on a prospective basis. In addition to the assumptions used in the Black Scholes model, the amount of equity-based compensation expense we recognize in our consolidated financial statements includes incentive share forfeitures as they occurred.

 

As there has been no public market for our common shares to date, the Serina Board, with input from management, has determined the estimated fair value of our common shares as of the date of each option grant considering our then most recently available third-party valuation of common shares. Valuations are updated when facts and circumstances indicate that the most recent valuation is no longer valid, such as changes in the stage of our development efforts, various exit strategies and their timing, and other scientific developments that could be related to the valuation of our company, or, at a minimum, annually. Third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation.

 

347

 

 

The estimates of fair value of our common stock are highly complex and subjective. There are significant judgments and estimates inherent in the determination of the fair value of our common shares. These judgments and estimates include assumptions regarding our future operating performance, the time to completing a liquidity event, the related valuations associated with these events, and the determinations of the appropriate valuation methods at each valuation date. The assumptions underlying these valuations represent our best estimates, which involve inherent uncertainties and the application of management judgment. If we had made different assumptions, our equity-based compensation expense, net loss, and net loss per share applicable to common stockholders could have been materially different. Following the completion of this Merger, we intend to determine the fair value of our common stock based on the closing price of our common stock as reported by New York American Stock Exchange on the date of grant.

 

Refer to Note 5, Redeemable Convertible Preferred Stock and Note 10, Stock Warrants within the September 30, 2023 financial statements for details on the equity-based awards outstanding.

 

Derivative Financial Instruments

 

On March 15, 2023, the Company issued a Convertible Promissory Note (or the AgeX-Serina Note) in the amount of $10,000,000 to AgeX. The AgeX-Serina Note bears interest at 7% per annum and matures on March 15, 2026. The Company issued the AgeX-Serina Note to provide for general working capital needs. As part of the Company’s strategic plan to access additional capital, the Company entered into the Merger Agreement with AgeX. In connection with the issuance of the AgeX-Serina Note, AgeX is entitled to elect one member to the board of directors of the Company and receive certain information and inspection rights as well as participation rights for subsequent equity issuances.

 

The AgeX-Serina Note has various conversion options. The principal balance of the AgeX-Serina Note with accrued interest will automatically convert into the Company’s preferred stock if the Company raises at least $25,000,000 through the sale of shares of the Company’s preferred stock. The conversion price per share shall be the lower of (a) 80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by the Company’s then fully diluted capitalization. AgeX has the option to convert the AgeX-Serina Note into the Company’s preferred stock after a sale of the Company’s preferred stock regardless of the amount sold by the Company. AgeX may (i) at its election, upon a change of control (as defined in the AgeX-Serina Note), convert the AgeX-Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the AgeX-Serina Note, plus interest, or (b) into the highest ranking shares of the Company then issued at a conversion price equal to the lowest price per share at which the most senior series of the Company’s shares has been sold in a single transaction or a series of related transactions through which the Company raised at least $5,000,000 or (ii) if the AgeX-Serina Note remains outstanding as of the maturity date, AgeX may convert the AgeX-Serina Note into the most senior shares of the Company issued at the time of conversion at a conversion price equal to the capped price. Upon the consummation of a merger between the Company and AgeX, the AgeX-Serina Note would remain outstanding and become an intercompany asset of AgeX and an intercompany liability of the Company.

 

The Company evaluated the AgeX-Serina Note in accordance with ASC Topic 815, Derivatives and Hedging, and determined it contains certain variable share settlement features tied to the price of a future financing which were not considered clearly and closely related to the host instruments. These provisions included automatic conversion upon the event of a Qualified Financing, the Holder’s option to convert the AgeX-Serina Note upon a Non-Qualified Financing, and the Holder’s option to convert or request repayment upon sale of the Company. The AgeX-Serina Note also contained a Change in Control Put and a Default Put which were not clearly and closely related to the host instrument. The Company elected to initially and subsequently measure the AgeX-Serina Note in its entirety at fair value, with changes in fair value recognized in earnings. The fair value inception date adjustment on the instrument is recorded as a component of other income in the Company’s statements of operations.

 

348

 

 

FASB ASC 825-10-25 allows the Company to elect the fair value option for recording financial instruments when they are initially recognized or if there is an event that requires re-measurement of the instruments at fair value, such as a significant modification of the debt. The Company elected the fair value option because they believed it to be the most appropriate method of encompassing the credit risk and exercise behavior that a market participant would consider when valuing the hybrid financial instrument.

 

As of March 15, 2023 (inception), the outstanding principal and interest on the AgeX-Serina Note was approximately $10,000,000 and the fair value recorded on the balance sheet was $7,760,000. From March 15, 2023 to September 30, 2023, the change in fair value was approximately $3,900,000 and was recorded as a component of other income in the Company’s statements of operations.

 

From June 2022 through February 2023, the Company issued interest-bearing Convertible Promissory Notes (the “Serina Convertible Notes”) to various investors in the principal amount of $1,450,000. The Serina Convertible Notes incur interest at 6% per annum and are payable by the Company two years from their issuance date. The Company may not voluntarily prepay the Serina Convertible Notes. Upon a Qualified Equity Financing event in which the Company sells shares of Preferred Stock for aggregate proceeds of at least $15 million, the principal and outstanding interest on the Serina Convertible Notes will automatically convert into shares of the Company’s Preferred Stock issued in the Qualified Financing at a conversion price of the lesser of i) a 20% discount to the price paid by purchasers in the Qualified Financing and ii) the quotient resulted from dividing $100 million by the fully diluted capitalization of the Company immediately prior to the Qualified Financing. If the Company enters into a Non-Qualified Equity Financing (less than $15 million in proceeds), the Holder has the option to convert the Serina Convertible Notes into shares of the Company’s Preferred Stock issued in the Non-Qualified Financing at the price paid per share. The Company may also choose to optionally convert the Serina Convertible Notes into Series A-5 Preferred Stock at a price of $13 per share, and a warrant to purchase shares of Series A-5 Preferred Stock with an exercise price of $20.00, and an expiration date of December 31, 2024. If a Change in Control or an IPO occurs prior to a Qualified Financing, then the Holder has the option to convert outstanding principal and interest into common stock at a price per share equal to an amount obtained by dividing i) the Post-Money Valuation Cap ($100,000,000) by ii) the Fully Diluted Capitalization immediately prior to the conversion. Upon a change in control, the Holder may also elect to require the Company to repay the outstanding principal and accrued but unpaid interest in cash.

 

The Company evaluated the Serina Convertible Notes in accordance with ASC Topic 815, Derivatives and Hedging, and determined they contained certain variable share settlement features tied to the price of a future financing which were not considered clearly and closely related to the host instruments. These provisions included mandatory conversion upon the event of a Qualified Financing and the Holder’s option to convert the Serina Convertible Notes upon a Non-Qualified Financing. The Serina Convertible Notes also contained a Change in Control Put and a Default Put which were not clearly and closely related to the host instrument. The Company elected to initially and subsequently measure the Serina Convertible Notes in their entirety at fair value, with changes in fair value recognized in earnings. The fair value inception date adjustment on the instrument is recorded as a component of other income in the Company’s statements of operations. The change in fair value of the instrument since inception date is recorded on a separate line item as a component of other income in the Company’s statements of operations.

 

On July 26, 2023, all of the Serina Convertible Notes described in this section (excluding the AgeX-Serina Note) previously issued for a total principal amount of $1,450,000 and accrued interest of $82,695 were converted to 117,903 shares of Series A-5 Preferred Stock. As provided for in the note agreements, the holders of the Serina Convertible Notes also received warrants to purchase an additional 117,903 shares of Series A-5 Preferred Stock. Refer to Note 14, Convertible Promissory Notes to the September 30, 2023 financial statements for additional details on the Serina Convertible Notes.

 

Recently Adopted Accounting Pronouncements

 

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in the notes to our consolidated financial statements for the years December 31, 2022 and 2021 appearing elsewhere in this prospectus.

 

349

 

 

Contractual Obligations and Commitments

 

The following table summarizes our contractual lease obligations as of September 30, 2023:

 

   Operating Leases   Finance Leases 
Three Months Ended December 31, 2023  $58,928   $13,799 
2024   214,294    38,055 
2025   175,762    629 
2026   158,283    - 
2027   116,592    - 
Thereafter   9,716    - 
Total undiscounted lease payments   733,575    52,483 
Less: imputed interest   (86,853)   (3,050)
Total lease obligations   646,722    49,433 

 

We enter into contracts in the normal course of business with third-party service providers for pre-clinical research, clinical studies, testing, manufacturing, supplier, and other services and products for operating purposes. We have not included our payment obligations under these contracts in the table as these contracts generally provide for termination upon notice, and therefore, we believe that our non-cancelable obligations under these agreements are not material, and we cannot reasonably estimate the timing of if and when they will occur. We could also enter into additional pre-clinical research, clinical studies, testing, manufacturing, supplier, and other agreements in the future, which may require up-front payments and even long-term commitments of cash.

 

350

 

 

MANAGEMENT FOLLOWING THE MERGER

 

The following table provides information regarding the expected directors and executive officers of the combined company following the closing of the Merger:

 

Name

 

Age

 

Position

Steve Ledger   64   Interim Chief Executive Officer and Class I Director
Andrea Park   51   Interim Chief Financial Officer and Chief Accounting Officer
Randall Moreadith, M.D., Ph.D.   69   Chief Scientific Officer
Tacey Viegas, Ph.D.   66   Chief Operating Officer; Secretary
Gregory M. Bailey, M.D.   67   Chairman of the Board and Class III Director
J. Milton Harris, Ph.D.   83   Class I Director
Remy Gross   53   Class II Director
Richard Marshall, M.D., Ph.D.   56   Class III Director

 

Executive Officers

 

Steve Ledger has served as Serina’s Chief Financial Officer since June 2021 and as a member of the Serina Board since December 2022. Mr. Ledger will serve as the Interim Chief Executive Officer of the combined company. Serina has engaged an executive search firm to recruit a permanent Chief Executive Officer for the combined company. Mr. Ledger will cease to be the Interim Chief Executive Officer of the combined company but will remain as a Class I Director upon the hiring of the Chief Executive Officer. Mr. Ledger has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early-stage companies. From 2018 to the present, Mr. Ledger serves as Managing Partner of Form & Fiction Ventures, Inc. (FFV), a venture studio that launches and invests in startup and seed stage companies focused on socially responsible initiatives. Mr. Ledger is a co-founder and board director of Entourage Genomics, Inc., a bioinformatics software company formed by FFV in June 2023. From 2018 to February 2022, Mr. Ledger served as an advisor at Caldwell Sutter Capital, Inc., an SEC registered broker dealer and investment management firm focused on value-based equity and debt securities. From 2002 to 2012, Mr. Ledger was the founder and managing member of Tamalpais Partners, LLC, the general partner to funds focused on special situations in the small capitalization public equity markets. Mr. Ledger received a B.A. in Economics from the University of Connecticut.

 

Andrea E. Park has served as Chief Financial Officer of AgeX since May 2020. Ms. Park served as AgeX’s Vice President of Finance and Controller from October 2019. Ms. Park will serve as the Interim Chief Financial Officer and Chief Accounting Officer of the combined company. Upon the hiring of the Chief Financial Officer, Ms. Park will cease to be the Interim Chief Financial Officer of the combined company but will remain the Chief Accounting Officer of the combined company. Ms. Park’s career spans over 24 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as Vice President of Finance and Controller from June 2016 to September 2019 and as Corporate Controller from August 2009 to June 2016 for Lineage Cell Therapeutics, Inc. (Lineage, formerly BioTime, Inc.). While at Lineage, Ms. Park was directly involved in the accounting and financial reporting of the public spin off and eventually the deconsolidation of three of its then subsidiaries including Asterias Biotherapeutics, Inc., Oncocyte Corporation and AgeX. Earlier in her career from 1996 to 2003, she worked in the audit and assurance practice at Deloitte. Ms. Park has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.

 

351

 

 

Randall Moreadith, M.D., Ph.D. has served as Serina’s President and Chief Executive Officer and as a member of the Serina Board since September 2010. Dr. Moreadith will serve as Chief Scientific Officer of the combined company. From July 2009 to December 2009, Dr. Moreadith was Chief Development Officer at Nektar Therapeutics (Nektar) where he led clinical and drug development programs that successfully moved several of the Nektar’s PEGylated small molecule drugs into clinical trials for four clinical indications (ovarian, breast, cervical and colorectal cancer) and the out-licensing efforts for the approved product now known as Movantik®. Prior to Nektar, Dr. Moreadith served as the Executive Vice President and Chief Medical Officer of Cardium Therapeutics, Inc. where he led the advancement of novel DNA-based adenoviral therapeutics into Phase IIb and Phase III late-stage development, from 2006 to 2008. Prior to Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. where he led the Clinical, Regulatory and Quality Assurance Groups in 2004 to 2005. From 1996 to 2003, Dr. Moreadith was co-Founder, President, and Chief Operating Officer of ThromboGenics, Ltd. (now Oxurion), a leader in the field of thrombosis drug development. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development, with one product later approved (Ocriplasmin™). Dr. Moreadith received his M.D. from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. Dr. Moreadith received his Ph.D. from Johns Hopkins University and following his Fellowship in Cardiology at Duke University, he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith was a member of the faculty of the University of Texas Southwestern Medical Center.

 

Tacey Viegas, Ph.D. has served as Serina’s Chief Operating Officer since 2006. Dr. Viegas will serve as Chief Operating Officer and Secretary of the combined company. Dr. Viegas has managed the discovery and early development activities for both synthetically- and biologically-derived therapeutic agents in the areas of oncology, neurology, influenza, psoriasis, and wound care. He has numerous patents and publications in the area of polymer therapeutics and pharmaceutics. Prior to joining Serina, Dr. Viegas served as Senior Director of Chemistry Manufacturing and Controls at Nektar. Prior to Nektar, Dr. Viegas was Executive Director in product development at Biocryst Pharmaceuticals, Inc. (BioCryst). During his combined tenures at Nektar and BioCryst, he was a co-inventor of nalexogol (Movantik®), etirinotecan pegol and was involved in the early development of peramivir (Rapivab™). Prior to Biocryst, Dr. Viegas was a Director, Product Development at MDV Technologies, Inc. from 1989 to 1994. Dr. Viegas received his B.S. in Chemistry and Pharmacy from Bangalore University, and his M.S. and Ph.D. in Pharmaceutical Sciences from the University of Mississippi.

 

Non-Employee Directors

 

Gregory H. Bailey, M.D. has served on the AgeX Board since August 2018 and served as the Chair of the AgeX Board from October 2018 until May 2022. Dr. Bailey has served as a member of the Serina Board since March 2023. Dr. Bailey is currently Executive Chairman of Juvenescence. From October 2017 until January 2023, Dr. Bailey served as the Chief Executive Officer of Juvenescence. Dr. Bailey is also a board director of Manx Financial Group, plc, BioHaven Pharmaceuticals, Inc., SalvaRx Group, plc., and Portage Biotech, Inc. Dr. Bailey founded and served as a director of a number of private and public companies and previously served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. Dr. Bailey practiced emergency medicine for ten years before entering finance. Dr. Bailey received his M.D. from the University of Western Ontario.

 

352

 

 

J. Milton Harris, Ph.D. has served as Chair of the Serina Board of Directors since he co-founded Serina in 2006. Dr. Harris has more than 30 years of experience as a senior life sciences executive. Prior to founding Serina, he was the Founder and Chief Executive Officer of Shearwater Polymers, Inc. (Shearwater). Shearwater was founded by Dr. Harris in 1992 and sold in 2001 to Inhale Therapeutics, Inc. (Inhale Therapeutics, Inc., subsequently changed its name to Nektar Therapeutics, Inc.). Shearwater successfully patented, manufactured, and partnered PEG technology that enabled multiple drug products including Neulasta® (Amgen) and Pegasys® (Roche). Dr. Harris has also served on the board of directors of HudsonAlpha Institute for Biotechnology since its founding in 2004. Dr. Harris earned a B.S. from McGill University, where he also was awarded an honorary Sc.D., and a Ph.D. from the Massachusetts Institute of Technology. Dr. Harris has co-authored more than 200 publications and is a co-inventor on more than 75 patents.

 

Remy Gross has served as Vice President, Business Development & Technology Advancement at the Buck Institute for Research (Buck) on Aging from 2006. Mr. Gross has advised and helped create multiple new biopharmaceutical startups at Buck, including Unity Biotechnology, Inc., Aeovian Therapeutics, Inc., and BhB Therapeutics, Inc. Prior to Buck, Mr. Gross held increasingly senior roles at Shearwater from 1994 to 2001, and at Nektar after its acquisition of Shearwater from 2001 to 2005, including Vice President of Operations. In 2013, Mr. Gross co-founded RCP Companies, Inc., a boutique real estate company providing acquisition, development, and asset management. Mr. Gross serves as a board director of BhB Therapeutics, Inc., Napa Therapeutics, Inc., and Selah Therapeutics, Inc. Mr. Gross serves on several non-profit boards including MidCity Accelerator Foundation, Hatch HSV and k3innovation. Mr. Gross received a B.S. in Chemistry from Loyola University New Orleans.

 

Dr. Richard Marshall, CBE, M.D., Ph.D. has served as the Chief Executive Officer of Juvenescence from January 2023. Dr. Marshall is a physician scientist and highly experienced executive with a 20-year track record of leadership in pharmaceutical Research & Development. From September 2019 to January 2023, Dr. Marshall was Senior Vice President and Global Head of Respiratory & Immunology Development at AstraZeneca plc, overseeing the development and approval of five new medicines. This included the SARS CoV-2 vaccine, Vaxzevria®, and combination antibody, EvushieldTM. In 2021 he was recognized in the Queen’s Honours List with a CBE for his contribution to UK science and the Covid response. From 2002 to 2018, Dr. Marshall held increasingly senior roles at GlaxoSmithKline plc, including Vice President of Fibrosis R&D. Dr. Marshall received a Bachelor of Science in Neuroscience, a Bachelor of Medicine, a Bachelor of Surgery, and a Doctor of Philosophy in Medical Sciences from University College London and has held visiting professor and honorary consultant roles in thoracic medicine at Newcastle University and the Royal Brompton Hospital. Dr. Marshall has co-authored more than 60 original publications in journals including The Lancet and The New England Journal of Medicine.

 

353

 

 

Family Relationships

 

There are no family relationships among any of the combined company’s proposed directors and executive officers.

 

Composition of the Board of Directors Following the Merger

 

At the Effective Time, the combined company is expected to initially have a seven-member Combined Company Board, comprised of (a) Remy Gross, designated by both AgeX and Serina, (b) J. Milton Harris and Steven Ledger, each as a Serina designee, (c) Gregory Bailey and Richard Marshall, each as an AgeX designee, and (d) and           , each as an independent director, until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal. The Combined Company Board will be divided into three classes. Each class has a three-year term. Vacancies on the Combined Company Board may be filled only by a majority of the directors then in office. A director elected by the Combined Company Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director’s successor is duly elected and qualified.

 

It is anticipated that these directors will be appointed to the three staggered director classes of the Combined Board as follows:

 

Class I directors (expiring in 2024): Mr. Ledger and Mr. Harris;
   
Class II directors (expiring in 2025): Mr. Bailey and Mr. Marshall; and
   
Class III directors (expiring in 2026): Mr. Gross and .

 

Rule 803 of the rules set forth in the NYSE American Company Guide (the NYSE American Listing Rules) requires a majority of a listed company’s board of directors to be comprised of independent directors. In addition, the NYSE American Listing Rules require that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act. Under Rule 803 of the NYSE American Listing Rules, a director will only qualify as an “independent director” if, in the opinion of the Board of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries.

 

It is anticipated that each individual expected to serve on the Combined Company Board upon the completion of the Merger, other than      and      , will qualify as an independent director under NYSE American listing standards.

 

Board Leadership Structure

 

The Combined Company Board is expected to have separate positions of Chair of the Combined Company Board and Chief Executive Officer in order to reinforce the independence of the board of directors from management, create an environment that encourages objective oversight of management’s performance and enhance the effectiveness of the board of directors as a whole. As such, the Combined Company Board shall be chaired by Dr. Bailey, and Mr. Ledger will serve as the combined company’s Interim Chief Executive Officer.

 

354

 

 

Role of Board in Risk Oversight

 

One of the key functions of the Combined Company Board will be to oversee the combined company’s risk management process. The Combined Company Board is not anticipated to have a standing risk management committee, but rather expects to administer this oversight function directly through the Combined Company Board as a whole, as well as through various standing committees of the Combined Company Board that address risks inherent in their respective areas of oversight. In particular, the Combined Company Board is responsible for monitoring and assessing strategic risk exposure and the combined company’s Audit Committee will have the responsibility to consider and discuss the major financial risk exposures and the steps its management should take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management will be undertaken. The Audit Committee is also expected to monitor compliance with legal and regulatory requirements. The combined company’s Compensation Committee will also assess and monitor whether the combined company’s compensation plans, policies and programs comply with applicable legal and regulatory requirements.

 

Committees of the Combined Company Board

 

The Combined Company Board will have an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee, each of which will have the composition and the responsibilities described below.

 

Audit Committee

 

The purpose of the Audit Committee of the Combined Company Board will be to oversee the corporate accounting and financial reporting processes and audits of financial statements. For this purpose, the Audit Committee will perform several functions, including among other things:

 

evaluate the independent registered public accounting firm’s qualifications, independence and performance;
determine whether to retain or terminate the engagement of the existing independent registered public accounting firm or to appoint and engage a different independent registered public accounting firm;
review all relationships between any prospective independent registered accounting firm and the combined company that may reasonably be thought to bear on independence prior to engagement of any prospective independent registered accounting firm;
review and approve the scope of the annual audit and pre-approves the audit and non-audit fees and services;
obtain and review a report by the independent outside auditor describing that firm’s internal quality-control procedures on an annual basis;
annually review all relationships between the independent outside auditor and the combined company that may reasonably be thought to bear on independence;
review and monitor compliance with programs and policies designed to ensure compliance with laws and regulations and the Code of Business Conduct and Ethics, including review and approval of all related party transactions on an ongoing basis;

 

355

 

 

establish procedures for the receipt, retention and treatment of complaints received regarding accounting, internal accounting controls or auditing matters;
discuss with management and the independent registered public accounting firm the results of the annual audit and the review of the combined company’s quarterly financial statements;
approve the retention of the independent outside auditor to perform any proposed permissible non-audit services;
monitor the rotation of partners of the independent outside auditors on the combined company’s engagement team in accordance with requirements established by the SEC;
discuss on a periodic basis, or as appropriate, with management the policies and procedures with respect to risk assessment and risk management;
review the combined company’s financial statements and its management’s discussion and analysis of financial condition and results of operations to be included in the combined company’s annual and quarterly reports to be filed with the SEC;
consider and adopt policies regarding Audit Committee preapproval of employment by the combined company of individuals employed or formerly employed by the combined company’s independent outside auditor;
investigate any reports received through the ethics helpline and report to the Combined Company Board periodically with respect to the information received through the ethics helpline and any related investigations;
review the combined company’s critical accounting policies and estimates; and
review the audit committee charter and the committee’s performance at least annually.

 

Following the completion of the Merger, the members of the combined company’s Audit Committee are expected to be        , who is expected to be the Chair,             and              . All members of the Audit Committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the NYSE American and at least one member of the Audit Committee will qualify as an audit committee financial expert as defined under the applicable rules of the SEC and have the requisite financial sophistication as defined under the applicable rules and regulations of the NYSE American. Under the rules of the SEC, members of the Audit Committee must also meet heightened independence standards. AgeX and Serina believe that, following the completion of the Merger, each member of the Audit Committee will be independent under the applicable rules of the SEC and the NYSE American. The Audit Committee will operate under a written charter that will satisfy the applicable standards of the SEC and the NYSE American.

 

Compensation Committee

 

The Compensation Committee of the Combined Company Board will oversee policies relating to compensation and benefits of officers and employees. The Compensation Committee will review and approve corporate goals and objectives relevant to compensation of the executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of these officers based on such evaluations. The Compensation Committee will also review and approve or make recommendations to the Combined Company Board regarding the issuance of stock options and other awards under the combined company’s stock plans to the executive officers. The Compensation Committee will review and evaluate, at least annually, the performance of the Compensation Committee and its members, including compliance by the Compensation Committee with its charter.

 

356

 

 

The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The proposed charter of the Compensation Committee will grant the Compensation Committee full access to all books, records, facilities and personnel of the company. In addition, under its proposed charter, the Compensation Committee will have the authority to obtain, at the expense of the Combined Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee will have direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Compensation Committee. In particular, the Compensation Committee will have the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant’s reasonable fees and other retention terms. Under its proposed charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and the NYSE American, that bear upon the adviser’s independence; however, there is no requirement that any adviser be independent.

 

Following the completion of the Merger, the members of the Compensation Committee are expected to be          , who is expected to be the Chair,            and          . To qualify as independent to serve on the combined company’s Compensation Committee, the NYSE American Listing Rules require a director not to accept any consulting, advisory, or other compensatory fee from the combined company, other than for service on the Combined Company Board, and that the Combined Company Board consider whether a director is affiliated with the combined company and, if so, whether such affiliation would impair the director’s judgment as a member of the combined company’s Compensation Committee. AgeX and Serina believe that, after the completion of the Merger, the composition of the Compensation Committee will meet the requirements for independence under, and the functioning of such Compensation Committee will comply with any applicable requirements of the rules and regulations of the SEC and the NYSE American.

 

Nominating and Corporate Governance Committee

 

The Nominating and Corporate Governance Committee of the Combined Company Board will be responsible for making recommendations to the Combined Company Board regarding candidates for directorships and the size and composition of the Combined Company Board. In addition, the Nominating and Corporate Governance Committee will be responsible for overseeing corporate governance policies and reporting and making recommendations to the Combined Company Board concerning governance matters.

 

The Combined Company Board and the Nominating and Corporate Governance Committee do not expect to set any specific minimum qualifications that a prospective nominee would need in order to be nominated to serve on the Combined Company Board. Rather, in evaluating any new nominee or incumbent director, the Nominating and Corporate Governance Committee will consider whether the particular person has the knowledge, skills, experience, and expertise needed to manage business affairs in light of the skills, experience, and expertise of the other members of the Combined Company Board as a whole. The Nominating and Corporate Governance Committee will also consider whether a nominee or incumbent director has any conflicts of interest with the combined company that might conflict with the Code of Business Conduct and Ethics or that might otherwise interfere with their ability to perform their duties in a manner that is in the best interest of the combined company and its stockholders. The Nominating and Corporate Governance Committee will also consider whether including a prospective director on the Combined Company Board will result in a board composition that complies with (a) applicable state corporate laws, (b) applicable federal and state securities laws, and (c) the rules of the SEC and each stock exchange on which the combined company’s shares are listed.

 

The Combined Company Board and the Nominating and Corporate Governance Committee do not expect to adopt specific policies with respect to a particular mix or diversity of skills, experience, expertise, perspectives, and background that nominees should have. However, the Combined Company Board is expected to be assembled with a focus on attaining a board comprised of people with substantial experience in bioscience, the pharmaceutical industry, corporate management, and finance.

 

Following the completion of the Merger, the members of the Nominating and Corporate Governance Committee are expected to be              , who will serve as Chair,                    and                       . Each of the members of the combined company’s Nominating and Corporate Governance Committee will be independent under the applicable rules and regulations of the NYSE American relating to nominating and corporate governance committee independence.

 

Compensation Committee Interlocks and Inside Participation

 

In connection with the completion of the Merger, the Combined Company Board is expected to select members of the Compensation Committee. Each member of the Compensation Committee is expected to be a “non-employee” director within the meaning of Rule 16b-3 of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of the NYSE American. None of the proposed combined company’s executive officers serves as a member of the board of directors or compensation committee of any entity that has one or more executive officers who is proposed to serve on the Combined Company Board or Compensation Committee following the completion of the Merger.

 

Code of Business Conduct and Ethics

 

The Combined Company Board will maintain a Code of Business Conduct and Ethics that applies to all directors, officers, and employees. The Code of Business Conduct and Ethics, and any applicable waivers or amendments, will be made available on the Combined Company’s website.

 

357

 

 

AGEX EXECUTIVE AND DIRECTOR COMPENSATION

 

Executive Officer Compensation

 

AgeX is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, and a “smaller reporting company” as defined in the rules and regulations of the SEC. As an emerging growth company and as a smaller reporting company, AgeX may take advantage of specified reduced disclosure and other requirements that are otherwise applicable, in general, to public companies that are not emerging growth companies or smaller reporting companies. Accordingly, this proxy statement/prospectus/information statement includes reduced disclosure about AgeX’s executive compensation arrangements.

 

Summary Compensation Table

 

The following table sets forth the compensation awarded to, earned by, or paid to AgeX’s Chief Executive Officer during fiscal year 2022 and the two highest paid individuals who were serving as executive officers as of December 31, 2022 (AgeX’s Named Executive Officers) in respect of their service to AgeX for the fiscal years ended December 31, 2022 and 2021.

 

Name and principal position  Year  Salary  

Option

Awards(1)

  

All Other

Compensation(2)

   Total 
Michael D. West(3)  2022  $546,782   $-   $15,250   $562,032 
Chief Executive Officer  2021   546,782    137,501(4)   14,500    698,783 
                        
Andrea E. Park  2022   281,228    -    14,061    295,289 
Chief Financial Officer  2021   266,019    85,938(5)   13,301    365,258 
                        
Nafees N. Malik(6)  2022   282,272(7)   -    -    282,272 
Chief Operating Officer  2021   282,272(7)   85,938(5)   -    368,210 

 

 

(1)Amounts shown in this column do not reflect dollar amounts actually received by AgeX’s Named Executive Officers. Instead, these amounts reflect the aggregate grant date fair value of each stock option granted, computed in accordance with the provisions of FASB ASC Topic 718, Compensation-Stock Compensation. AgeX used the Black-Scholes Pricing Model to compute option fair values based on applicable exercise and stock prices, an expected option term, volatility assumptions, and risk-free interest rates. AgeX’s Named Executive Officers will only realize compensation upon exercise of the stock options and to the extent the trading price of AgeX’s common stock is greater than the exercise price of such stock options at the time of exercise. One fourth of the options will vest upon completion of 12 full months of continuous employment measured from the date of grant, and the balance of the options vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on the completion of each month of continuous service as an employee or director of AgeX or its subsidiaries.

 

(2)Amounts represent 401(k) matching contributions by AgeX for the periods presented unless described otherwise.

 

(3)On August 9, 2023, Dr. West stepped down as Chief Executive Officer and Dr. Joanne Hackett was appointed as Interim Chief Executive Officer. As described elsewhere in this proxy statement/prospectus/information statement, immediately following the Merger, Steve Ledger, currently Chief Financial Officer of Serina, is expected to serve as Interim Chief Executive Officer of the combined company.

 

358

 

 

(4)Dr. West’s equity awards in 2021 reflect the fair value of 120,000 stock options awarded in June 2021.

 

(5)Equity awards in 2021 to Ms. Park and Dr. Malik reflect the fair value of 75,000 stock options awarded in June 2021.

 

(6)Dr. Malik served as AgeX’s Chief Operating Officer as a consultant, with his services provided by Juvenescence. Dr. Malik devoted a majority of his time to AgeX’s operations and AgeX reimbursed Juvenescence for his services. Dr. Malik’s service as Chief Operating Officer ended on December 31, 2023.

 

(7)Amounts represent consulting fees paid to Juvenescence for Dr. Malik’s services to AgeX.

 

Employment Agreements and Change of Control Provisions

 

Michael D. West: During 2022, AgeX and Dr. West were party to an employment agreement, effective October 18, 2018 (the West Employment Agreement). Pursuant to the West Employment Agreement, Dr. West’s annual base salary was initially set at $525,000. Under the West Employment Agreement, Dr. West was eligible to earn an annual incentive cash bonus with a target of no less than 50% of annual base salary. Actual bonus amounts were based on Dr. West’s attainment of individual performance goals at target levels set by the AgeX Board for the applicable calendar year. If such performance goals for the applicable year were fully achieved, the AgeX Board could approve a bonus amount exceeding the target bonus level.

 

Under the West Employment Agreement, Dr. West was granted options to purchase 500,000 shares of AgeX’s common stock with an exercise price of $3.00 per share, with one fourth of the options vesting following 12 full months of continuous service as an employee of AgeX, measured from the date of grant, and the balance vesting in 36 equal monthly installments commencing on the first anniversary of the date of grant, based upon the completion of each month of continuous service as an employee of AgeX.

 

On August 9, 2023, AgeX and Dr. West entered into a Transition Services and Separation Agreement (the Transition Agreement) pursuant to which Dr. West stepped down as Chief Executive Officer of AgeX but agreed to continue to serve as Chief Executive Officer and as a director of AgeX’s subsidiary Reverse Bio during a “Transition Period.” The Transition Period ended on October 31, 2023. If Dr. West complies with and does not revoke the Transition Agreement and the supplemental release set forth therein, (i) AgeX will transfer to Dr. West title to certain laboratory and other equipment that AgeX has fully amortized for financial reporting purposes, and (ii) Dr. West’s outstanding vested AgeX stock options as of August 9, 2023 will remain exercisable until October 9, 2027.

 

Under the West Employment Agreement, and as affirmed in the Transition Agreement, Dr. West has agreed to certain covenants regarding confidential information and assignment of inventions, as well as a covenant not to solicit AgeX’s employees during Dr. West’s employment with AgeX and for one year thereafter. The West Employment Agreement also includes a covenant not to compete with AgeX during his employment.

 

359

 

 

Andrea E. Park: AgeX has entered into an employment agreement with AgeX’s Chief Financial Officer, Andrea E. Park, effective May 15, 2020 (the Park Employment Agreement). Pursuant to the Park Employment Agreement, Ms. Park’s annual base salary was initially set at $265,000. Under the Park Employment Agreement, Ms. Park is eligible to earn an annual incentive cash bonus with a target of no less than 40% of annual base salary. Actual bonus amounts will be based on Ms. Park’s attainment of individual performance goals at target levels set by the AgeX Board for the applicable calendar year. If such performance goals for the applicable year are fully achieved, the AgeX Board may approve a bonus amount exceeding the target bonus level.

 

Under the Park Employment Agreement, Ms. Park has been granted options to purchase 300,000 shares of AgeX’s common stock with an exercise price of $0.738 per share, with one fourth of the options vesting following 12 full months of continuous service as an employee of AgeX, measured from the date of grant, and the balance vesting in 36 equal monthly installments commencing on the first anniversary of the date of grant, based upon the completion of each month of continuous service as an employee of AgeX. Such options expire on the earliest of (1) 10 years from the date of grant, (2) three months after Ms. Park’s ceases to provide continuous service to AgeX (other than due to death or disability) or (3) one year after Ms. Park ceases to provide continuous service to AgeX due to death or disability.

 

Pursuant to the Park Employment Agreement, Ms. Park is entitled to severance benefits under certain circumstances.

 

If AgeX terminates Ms. Park’s employment without “cause” or she resigns for “good reason” at any time (each as defined in the Park Employment Agreement), she will be entitled to (1) 9 months base salary, (2) all accrued but unpaid salary earned prior to or as of the date of termination or resignation, (3) full payment of Ms. Park’s pro-rated target bonus due for such year and (4) for a period of six months, all benefits under any health insurance plan of AgeX. In addition, if AgeX terminates Ms. Park’s employment without “cause” or she resigns for “good reason,” (1) all of Ms. Park’s outstanding equity awards that would otherwise have vested during the 12 months following termination or resignation will become fully vested and exercisable immediately and (2) with respect to any outstanding vested but unexercised options, the exercise period following termination or resignation will be extended to the earlier of (A) 12 months after termination or (B) the natural expiration date of the applicable option. If AgeX terminates Ms. Park’s employment without “cause,” or she resigns for “good reason,” following a “change of control,” (as defined in the Park Employment Agreement) (1) Ms. Park will be entitled to all of the benefits and payments that she would have been entitled to if her employment had been otherwise terminated without “cause” or if she resigned for “good reason,” as set forth above, and (2) all of Ms. Park’s unvested options and restricted stock units, if any, will become fully vested and exercisable immediately. The severance compensation may be paid in a lump sum or, at AgeX’s election, in installments consistent with the payment of Ms. Park’s salary while employed by AgeX. In order to receive the severance benefits, Ms. Park must execute a general release of all claims against AgeX.

 

Nafees N. Malik Dr. Malik did not have an employment agreement with AgeX, but has been provided certain acceleration rights with respect to his equity awards by the Compensation Committee of the AgeX Board. On June 4, 2021, the Compensation Committee of the AgeX Board approved by way of a meeting certain acceleration rights of the equity awards held by Mr. Malik. As a result to the termination of Dr. Malik’s employment by AgeX without “cause,” all outstanding stock options held by Dr. Malik automatically vested as to the number unvested shares that would otherwise have vested during the twelve months following termination; and with respect to his outstanding vested but unexercised stock option grants, the post-termination exercise period was extended to the earlier of the date twelve (12) months after termination or the expiration date of the stock option. Dr. Malik did not receive any severance benefits from other than the foregoing option vesting and expiration rights.

 

360

 

 

Outstanding Equity Awards at 2022 Fiscal Year End

 

The following table summarizes certain information concerning outstanding stock options and restricted stock units (RSUs) granted by AgeX under the Incentive Plan and held by AgeX’s Named Executive Officers as of December 31, 2022.

 

      Option Awards   Stock Awards 
     

Number of

Securities Underlying

Unexercised Options

  

Option

Exercise

  

Option

Expiration

  Number of Shares or Units of Stock That Have Not  

Market Value of Shares or

Units of Stock That Have Not

 
Name  Grant Date  Exercisable(1)   Unexercisable   Price   Date  Vested   Vested(2) 
Michael D. West  6/4/2021   45,000    75,000   $1.45   6/3/2031   -    - 
   3/11/2019   93,752    6,248   $4.28   3/10/2029   3,125(3)  $1,725 
   10/18/2018   500,000    -   $3.00   10/17/2028   -    - 
   10/10/2017   660,000    -   $2.00   10/9/2027   -    - 
                                
Andrea E. Park  6/4/2021   28,125    46,875   $1.45   6/3/2031   -    - 
   5/21/2020   193,750    106,250   $0.738   5/20/2030   -    - 
   10/1/2019   15,833    4,167   $1.77   9/30/2029   -    - 
                                
Nafees N. Malik  6/4/2021   28,125    46,875   $1.45   6/3/2031   -    - 
   3/11/2019   65,626    4,374   $4.28   3/10/2029   -    - 
   10/18/2018   350,000    -   $3.00   10/17/2028   -    - 

 

  (1) Vesting of all options is subject to continued service as an employee, director and/or consultant of AgeX or a subsidiary on the applicable vesting date. One fourth of the options vested or will vest on the first anniversary of the date of grant, and the remaining balance of the options vested or will vest in 36 equal monthly installments thereafter. As described above, effective August 9, 2023, Dr. West forfeited all of his unvested stock options and, subject to his continued compliance with the terms and conditions set forth in the Transition Agreement, his vested stock options will remain exercisable until October 9, 2027.

 

  (2) Value calculated based on $0.5519 closing price of AgeX common stock on the NYSE American on December 30, 2022.

 

  (3) Represents RSUs which have vested or will vest according to the following schedule: 12,500 of the shares vested on March 11, 2020, and the remaining 37,500 of the shares vested or will vest in equal quarterly installments over a period of 3 years through March 11, 2023. Each RSU represents a contingent right to receive one share of AgeX common stock.

 

361

 

 

Risk Considerations and Recoupment Policies

 

The Compensation Committee of the AgeX Board considers, in establishing and reviewing the executive compensation program, whether the program encourages unnecessary or excessive risk taking. Most of AgeX’s executive compensation arrangements include a fixed salary that provides a steady income so that executives do not feel pressured to focus exclusively on stock price performance or short term financial targets to the detriment of AgeX’s long-term operational and strategic objectives. AgeX supplements fixed salaries with discretionary bonus awards based on the executive’s performance as well as the performance of AgeX. The stock options and RSUs that AgeX has granted to its executive officers under the Incentive Plan vest over four years, assuring that the executives take a long-term perspective in viewing their equity ownership. Although AgeX has not adopted compensation plans, or made incentive awards, based on quantified financial performance measures, it has adopted a clawback policy intended to comply with Section 811 of the NYSE American Company Guide. In the event of certain restatements of AgeX financial statements, the Clawback Policy will require AgeX to recoup from its executive officers compensation that is granted, earned or vested based wholly or in part upon the attainment of a financial reporting measure, to the extent such compensation (a) was granted during the three fiscal years preceding a determination that AgeX financial statements must be restated, and (b) exceeds the amount of compensation that would have been granted had the grant been based on the restated financial statement amounts. A copy of the Clawback Policy has been posted on our internet website and can be found at www.agexinc.com.

 

Other Compensation Plans

 

AgeX does not have any pension plans, defined benefit plans, or non-qualified deferred compensation plans. AgeX may make contributions to 401(k) plan accounts for participating executive officers and other employees.

 

Non-Employee Director Compensation

 

Directors and members of committees of the AgeX Board who are AgeX’s employees are entitled to receive compensation as employees but are not compensated for serving as directors or attending meetings of the AgeX Board or committees of the AgeX Board. All directors are entitled to reimbursements for their out-of-pocket expenses incurred in attending meetings of the AgeX Board or committees of the AgeX Board.

 

For the year ended December 31, 2022, non-employee directors were entitled to receive the following annual cash fees for serving as a director or chair of a designated committee, pro-rated as applicable for length of time served in any particular position.

 

Service as a director: $35,000
Chair of the AgeX Board: $60,000
Chair of Audit Committee: $10,000
Chair of Compensation Committee: $5,000
Chair of Nominating & Corporate Governance Committee: $5,000

 

The following table summarizes certain information concerning the compensation paid during the past fiscal year to each of the persons who served as directors during the year ended December 31, 2022 and who were not AgeX’s employees on the date the compensation was earned.

 

Name

 

Fees Earned

or Paid in Cash

  

Option Awards (1)

  

Total

 
Gregory H. Bailey  $49,010   $-   $49,010 
Joanne M. Hackett (2)  $55,740   $47,325   $103,065 
Michael H. May  $44,875   $-   $44,875 

 

 

(1)In accordance with SEC rules, the amounts shown reflect the aggregate grant date fair value of stock awards granted to Non-Employee Directors during 2022, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (FASB ASC 718). The grant date fair value for the stock options is measured based on the closing price of AgeX’s common stock on the date of grant. See Note 8, Stock-Based Awards to AgeX’s consolidated financial statements included elsewhere in this proxy statement/prospectus/information statement for details as to the assumptions used to determine the fair value of the awards. As of December 31, 2022, Dr. Bailey held 165,000 stock options, Dr. Hackett held 65,000 stock options and Dr. May held 126,534 stock options. The foregoing options held by each of the directors are fully vested as of December 31, 2022.
(2)Dr. Hackett was elected as a director on December 29, 2021. On February 2, 2022, Dr. Hackett was awarded 65,000 stock options which had a fair value of $47,325 on the grant date. These options became exercisable in four equal calendar quarters and were fully vested as of December 31, 2022.

 

362

 

 

SERINA EXECUTIVE AND DIRECTOR COMPENSATION

 

Executive Officer Compensation

 

This section discusses the material components of the executive compensation program for Serina’s executive officers who are named in the 2022 Summary Compensation Table below. In 2022, Serina’s “named executive officers” and their positions were:

 

Randall Moreadith, M.D., Ph.D., President and Chief Executive Officer; and
Tacey Viegas, Ph.D., Chief Operating Officer.

 

None of Serina’s other executive officers received total compensation in excess of $100,000 in 2022.

 

Summary Compensation Table

 

The following table sets forth information concerning the compensation of Serina’s named executive officers for the years indicated.

 

Name and Principal Position  Year   Salary   Bonus  

Stock

Awards

  

Option

Awards (1)

   All Other Compensation (2)   Total 
Randall Moreadith, M.D., Ph.D.  2022   $323,772   $13,490           $12,146   $349,408 
President and Chief Executive Officer  2021   $305,445   $25,455       $22,075   $11,373   $364,348 
Tacey Viegas, Ph.D.  2022   $256,807   $10,700           $21,273   $288,780 
Chief Operating Officer  2021   $242,271   $20,189       $12,656   $23,752   $298,868 

 

 

(1) Amounts represent the aggregate grant date fair value of stock options issued during the years indicated, computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 718 (ASC Topic 718), rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of these awards in Note 9 to the consolidated financial statements for the years ended December 31, 2022 and 2021 included in this proxy statement/prospectus/information statement.
(2) Serina’s named executive officers received perquisites or other personal benefits in 2021 and 2022 towards payments of premiums for health, vision, short-term disability, long-term disability and life insurance.

 

Narrative Disclosure to Summary Compensation Table

 

2022 Salaries and Bonuses

 

Each of Dr. Moreadith and Dr. Viegas received a base salary in 2022 to provide a fixed component of compensation reflecting the executive’s skill set, experience, role, and responsibilities. Annual base salaries of executives are established at the date of hire and then reviewed periodically by the Serina Board.

 

For 2022, Serina’s executive bonus program was not based on pre-determined performance metrics. Serina’s executive officers were eligible to receive cash incentive compensation awarded at the discretion of the Serina Board of up to 25% of such executive officer’s base salary.

 

363

 

 

2022 Equity Compensation

 

Serina did not grant stock awards or stock options to any of its named executive officers in 2022. In 2021 Serina granted stock options to certain of its employees and service providers, including its named executive officers. Serina’s stock options generally allow employees to purchase shares of Serina common stock at a price per share equal to the fair market value of Serina common stock on the date of grant, as determined by the Serina Board.

 

Other Elements of Compensation

 

During their employment, Serina’s named executive officers are eligible to participate in employee benefit plans and programs to the same extent and on the same terms as Serina’s other full-time employees generally. We do not maintain any defined benefit pension plans or any nonqualified deferred compensation plans. Serina offers eligible full-time employees, including the NEOs, the opportunity to participate in a tax-qualified 401(k) plan. Employees can contribute eligible earnings up to the Internal Revenue Service’s annual limits on a before-tax basis, which is generally $22,500 for 2023.

 

Outstanding Equity Awards at 2022 Fiscal Year-End

 

The following table summarizes the outstanding equity incentive plan awards for each named executive officer as of December 31, 2022.

 

   Option Awards  Stock Awards 
Name  Grant Date 

Number of

securities

underlying

unexercised

options (#)

exercisable

  

Number of

securities

underlying

unexercised

options (#)

unexercisable

  

Option

exercise

price

($)

  

Option

expiration

date

 

Number of

shares or

units of

stock that

have not

vested

(#)

  

Market value of

shares of units

of stock that

have not

vested

($)

 
Randall Moreadith  5/6/2021(1)   533,550       $0.06   5/6/2031        
   7/29/2021(2)   96,000       $0.06   7/29/2031        
Tacey Viegas  5/6/2021(3)   208,392       $0.06   5/6/2031        
   7/29/2021(4)   141,608       $0.06   7/29/2031        

 

 

(1) This option fully vested as of the grant date.
(2) This option fully vested as of February 15, 2023 pursuant to an amendment to the named executive officer’s nonqualified stock option agreement.
(3) This option fully vested as of the grant date.
(4) This option fully vested as of February 15, 2023 pursuant to an amendment to the named executive officer’s nonqualified stock option agreement.

 

364

 

 

Executive Compensation Arrangements

 

Below are descriptions of Serina’s employment arrangements with Serina’s named executive officers, each of whom is employed “at will.”

 

Employment of Dr. Moreadith

 

Dr. Moreadith’s employment with Serina is not subject to any written agreement between Dr. Moreadith and Serina. Dr. Moreadith’s base salary is reviewed periodically by the Serina Board and the Serina Board may, but is not required to, increase his base salary at its discretion. For the year ended December 31, 2022, Dr. Moreadith’s annual base salary was $323,772.

 

Employment of Dr. Viegas

 

Dr. Viegas’ employment with Serina is not subject to any written agreement between Dr. Viegas and Serina. Dr. Viegas’ base salary is reviewed periodically by the Serina Board and the Serina Board may, but is not required to, increase his base salary at its discretion. For the year ended December 31, 2022, Dr. Viegas’ annual base salary was $256,807.

 

Post-Employment Compensation and Change in Control Payments and Benefits

 

Neither Dr. Moreadith nor Dr. Viegas is party to any agreement, plan or policy providing post-employment severance or change in control payments or benefits.

 

Compensation Changes in Connection with Merger

 

In connection with the Merger, we may enter into new or additional compensation arrangements with Serina’s named executive officers. The terms of any such arrangements are not yet known.

 

Director Compensation

 

During Serina’s year ended December 31, 2022, none of the non-employee directors who served on the Serina Board received compensation from Serina for their services as a director. In connection with the Merger, the Serina Board may approve new compensation arrangements for its board of directors. The terms of any such arrangements are not yet known.

 

The table below shows the aggregate number of outstanding option awards held as of December 31, 2022 by each non-employee director who was serving as of December 31, 2022. None of Serina’s non-employee directors held any other equity awards as of December 31, 2022.

 

Name 

Number of

Options Outstanding

 
Barbara Fisk    
James R. Hudson, Jr.    
Gregory Bailey    
J. Milton Harris, Ph.D.   72,000 

 

365

 

 

Incentive Compensation Plans

 

The Serina Board and stockholders previously adopted the Serina 2017 Stock Option Plan.

 

The following descriptions of the Serina 2017 Stock Option Plan is qualified by reference to the full text of the plan, which is included as an exhibit to the registration statement of which this prospectus is a part.

 

Serina’s 2017 Stock Option Plan

 

Serina’s 2017 Stock Option Plan was approved by the Serina Board and stockholders in January 2017.

 

Authorized Shares. The Serina 2017 Plan will continue to govern outstanding awards granted thereunder. As of September 30, 2023, options to purchase an aggregate of 1,756,816 shares of Serina’s common stock were outstanding under the Serina 2017 Stock Option Plan, and an additional aggregate of 20,550 shares of Serina’s common stock were reserved for future grants under Serina’s 2017 Stock Option Plan. Upon consummation of the Merger, the Serina 2017 Stock Option Plan will be frozen and no new awards will be granted thereunder.

 

Plan Administration. Subject to the terms of Serina’s 2017 Stock Option Plan, the Serina Board has the full authority to construe and interpret Serina’s 2017 Stock Option Plan. Serina’s 2017 Stock Option Plan provides that the interpretation and construction by the Serina Board of any provision of Serina’s 2017 Stock Option Plan or of any option granted thereunder is final and binding. The Serina Board is authorized, in its discretion, to select the eligible employees, officers, directors, consultants, and advisors of Serina to whom options are to be granted, the number of shares to be subject to such options, whether such options will be incentive stock options or nonstatutory stock options, any exceptions to non-transferability, any provisions relating to vesting, and the periods during which options may be exercised.

 

Stock Options. Each option is evidenced by a stock option agreement between Serina and the employee or other eligible person. Options granted under Serina’s 2017 Stock Option Plan are exercisable during a period fixed by the Serina Board, provided that no option will be exercisable after the expiration of 10 years from the date of its grant, and no incentive stock option granted to a person who at the time of the grant owns stock possessing more than 10% of the total combined voting power of all classes of stock of Serina will be exercisable after the expiration of five years from the date of its grant.

 

Serina’s 2017 Stock Option Plan provides for appropriate adjustments in the aggregate numbers of shares issuable, and in the number of shares subject to Serina’s 2017 Stock Option Plan and/or outstanding options and/or the option price of outstanding options granted, in the event of certain changes in Serina’s capitalization.

 

Options granted under Serina’s 2017 Stock Option Plan may be exercised, to the extent the right to exercise has accrued, in whole or in any lesser amount authorized by the option agreement at any time prior to the expiration or termination of such options. Exercise is accomplished by written notice to Serina accompanied by payment in full of the option price of the shares to be purchased.

 

An option may not be assigned or transferred by the employee or other eligible person except by will or by applicable laws of descent and distribution, and, during the lifetime of an employee or other such person may be exercised or accepted only by the employee or other such person. No transfer of an option by the participant by will or by the laws of descent will be effective unless Serina shall have been furnished with written notice thereof and such evidence as the Serina Board may deem necessary to establish the validity of the transfer and the acceptance by the transferee or transferees of the terms and conditions of Serina’s 2017 Stock Option Plan and applicable stock option agreement.

 

366

 

 

RELATED PERSON TRANSACTIONS OF THE COMBINED COMPANY

 

AgeX Related Party Transactions

 

Related Person Transactions Policy and Procedures

 

The AgeX Board has adopted a written Related Person Transaction Policy, which applies to transactions exceeding $120,000 in which any of AgeX’s officers, directors, beneficial owners of more than 5% of the outstanding shares of AgeX common stock, or any member of their immediate family, has a direct or indirect material interest, determined in accordance with the policy. Those transactions are referred to as Related Person Transactions. A Related Person Transaction will be subject to review and approval by the Audit Committee of the AgeX Board prior to effectiveness or consummation, to the extent practical. The Audit Committee will review the relevant information available to it about the Related Person Transaction. The Audit Committee may approve or ratify the Related Person Transaction only if the Audit Committee determines that, under the circumstances, the transaction is in, or is not in conflict with, AgeX’s best interests.

 

Certain Related Person Transactions

 

Compensation of AgeX’s Interim Chief Executive Officer

 

On August 9, 2023, AgeX entered into a Consulting Agreement with Dr. Hackett pursuant to which she will receive a fee in the amount of $160,000 per year for services rendered as Interim Chief Executive Officer of AgeX. Dr. Hackett will not be eligible to participate in any AgeX retirement, pension, life, health, accident and disability insurance, or other similar employee benefit plans for AgeX executive officers or employees other than the Incentive Plan.

 

Compensation of AgeX’s Chief Operating Officer

 

From October 2018 through December 31, 2023, AgeX’s Chief Operating Officer, Dr. Malik, who was an employee of Juvenescence, devoted a majority of his time to AgeX’s operations for which AgeX reimbursed Juvenescence for his services on an agreed upon fixed annual rate of approximately $272,000 from October 18, 2018 through March 10, 2019 and approximately $283,000 from March 11, 2019 through December 31, 2023. Additionally, Dr. Malik received a $50,000 bonus in March 2019. As of December 31, 2022 AgeX had accrued approximately $141,000 payable to Juvenescence for Dr. Malik’s services rendered.

 

2019 Loan Agreement and Warrant Agreement

 

On August 13, 2019, AgeX and Juvenescence entered into the 2019 Loan Agreement pursuant to which Juvenescence has provided to AgeX a $2.0 million line of credit for a period of 18 months. On February 10, 2021, AgeX entered into an amendment (the First Amendment) to the 2019 Loan Agreement. The First Amendment extended the maturity date of loans under the 2019 Loan Agreement to February 14, 2022 and increased the amount of the loan facility by $4.0 million. On November 8, 2021, AgeX entered into Amendment No. 2 (the Second Amendment) to the 2019 Loan Agreement. The Second Amendment increased the amount of the loan facility by another $1.0 million. As of December 31, 2021, AgeX had borrowed all of the $7.0 million total line of credit under the 2019 Loan Agreement. Concurrent with the first draw down of funds under the 2019 Loan Agreement, AgeX issued to Juvenescence 19,000 shares of AgeX common stock, with an approximate value of $56,000. On February 14, 2022, AgeX refinanced the $7.0 million outstanding principal amount of the loans and a $160,000 origination fee due under the 2019 Loan Agreement. See the discussion below regarding the 2022 Secured Note and repayment of the amounts borrowed under the 2019 Loan Agreement.

 

367

 

 

As consideration for the line of credit under the 2019 Loan Agreement, AgeX issued to Juvenescence warrants to purchase 150,000 shares of AgeX common stock, with an exercise price of $2.60 per share, which was the volume weighted average price on the NYSE American (VWAP) of AgeX common stock over the twenty trading days prior to the date the warrants were issued. The warrants expired on August 12, 2022.

 

2020 Loan Agreement and New Warrant Agreement

 

On March 30, 2020, AgeX and Juvenescence entered into the 2020 Loan Agreement, which was amended on March 13, 2023 to extend the maturity date by one year, pursuant to which AgeX borrowed $8.0 million from Juvenescence. During July 2023, the full $8 million of 2020 Loan Agreement indebtedness was extinguished in exchange for shares of AgeX Series A preferred stock pursuant to the 2023 Exchange Agreement between AgeX and Juvenescence described below.

 

Common Stock and 2020 Warrants – Under the terms of the 2020 Loan Agreement, AgeX issued to Juvenescence 28,500 shares of AgeX common stock as an arrangement fee for the loan facility when AgeX borrowed an aggregate of $3.0 million, and AgeX issued to Juvenescence warrants to purchase a total of 3,670,663 shares of AgeX common stock (the 2020 Warrants). The number of 2020 Warrants issued was determined as follows: each time AgeX received an advance of funds under the 2020 Loan Agreement, AgeX issued to Juvenescence a number of 2020 Warrants equal to 50% of the number determined by dividing the amount of the advance by the applicable market price of AgeX common stock. The market price for each 2020 Warrant when issued was the closing price per share of AgeX common stock on the NYSE American on the date of the applicable notice from AgeX requesting a draw of funds that triggered the obligation to issue the 2020 Warrant. The exercise price of the 2020 Warrants is the applicable market price of AgeX common stock. Each of the 2020 Warrants will expire at 5:00 p.m. New York time three years after the date of its issuance. AgeX had issued to Juvenescence 2020 Warrants to purchase a total of 3,670,663 shares of AgeX common stock of which 1,182,262 were outstanding as of September 30, 2023. The exercise prices of the 2020 Warrants that were still outstanding as of September 30, 2023 range from $0.81 per share to $1.895 per share representing the market closing price on the NYSE American of AgeX common stock on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the 2020 Warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

2022 Secured Convertible Promissory Note and Security Agreement

 

On February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (Original 2022 Secured Note) pursuant to which Juvenescence agreed to provide to AgeX a $13,160,000 line of credit for a period of 12 months. AgeX drew an initial $8,160,000 of the line of credit and used $7,160,000 to refinance the outstanding principal and the loan origination fees under the 2019 Loan Agreement with Juvenescence. On February 9, 2023, AgeX and Juvenescence entered into an Amended and Restated Secured Convertible Promissory Note (2022 Secured Note) which amends and restates the Original 2022 Secured Note and added $2 million to the line of credit available to be borrowed by AgeX under the Original 2022 Secured Note subject to Juvenescence’s discretion to approve each loan draw. On May 9, 2023, AgeX and Juvenescence entered into an Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (the 2022 Secured Note Second Amendment) that increased the amount of the line of credit available to AgeX by $4,000,000, subject to the terms of the 2022 Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. On June 2, 2023, AgeX and Juvenescence entered into a Third Amendment to Amended and Restated Convertible Promissory Note, to provide that (i) AgeX may draw on the available portion of the line of credit under the 2022 Secured Note until the earlier of the date a Qualified Offering (as defined in the 2022 Secured Note) is consummated by AgeX or October 31, 2023 (subject to Juvenescence’s discretion to approve each loan draw as provided in the 2022 Secured Note), (ii) AgeX will not be obligated to issue additional common stock purchase warrants to Juvenescence in connection with the receipt of loan funds made available pursuant to the 2022 Secured Note Second Amendment, and (iii) the definition of the Reverse Financing Condition as defined in the 2022 Secured Note was amended to extend to June 20, 2023, the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by Reverse Bio. On July 31, 2023, AgeX and Juvenescence entered into a Fourth Amendment to the 2022 Secured Note to provide that (i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023, the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bio, and (ii) Juvenescence may convert the outstanding amount of the 2022 Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion. The 19.9% Cap is a provision of the 2022 Secured Note that limits the amount of common stock that Juvenescence may acquire through the conversion of 2022 Secured Note loans in order to comply with NYSE American requirements pertaining to the amount of shares that a listed company, such as AgeX, may sell at a price less than the market prices prevailing at the time the loans were made (the Drawdown Market Prices) without shareholder approval. On November 9, 2023, AgeX and Juvenescence entered into a 2022 Secured Note Fifth Amendment that increases the amount of the line of credit available to AgeX by $4,400,000, subject to the terms of the 2022 Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit.

 

The date on which the outstanding principal balance of the 2022 Secured Note will become due and payable shall be February 14, 2024. As an arrangement fee for the 2022 Secured Note, AgeX will pay Juvenescence an origination fee in an amount equal to 4% of the amount each draw of loan funds, which will accrue as each draw is funded, and an additional 4% of all the total amount of funds drawn that will accrue following the end of the 12 month period during which funds may be drawn from the line of credit. The origination fee will become due and payable on the maturity date of the 2022 Secured Note or in a pro rata amount with any prepayment of in whole or in part of the outstanding principal balance of the 2022 Secured Note.

 

During July 2023, $17,992,800 of indebtedness and accrued loan origination fees under the 2022 Secured Note was extinguished in exchange for shares of AgeX Series A preferred stock and Series B preferred stock pursuant to the 2023 Exchange Agreement described below.

 

From October 3, 2023 through January 3, 2024, AgeX drew, in the aggregate, $2,500,000 of its credit available under the 2022 Secured Note.

 

368

 

 

Conversion of Loan Amounts into Common Stock – In lieu of repayment of funds borrowed, AgeX may convert the loan balance and any accrued but unpaid origination fees into AgeX common stock or “units” if AgeX raises at least $10,000,000 through sale of AgeX common stock (or AgeX common stock paired with warrants or other convertible securities in “units”). The conversion price per share or units shall be the lowest price at which such shares or units are sold. Juvenescence may convert the principal balance and accrued origination fee in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice of Juvenescence’s election to convert the 2022 Secured Note, in whole or in part, into AgeX common stock.

 

2022 Warrants – Upon each draw down of funds under the 2022 Secured Note prior to June 2, 2023, AgeX issued to Juvenescence warrants to purchase shares of AgeX common stock (the 2022 Warrants). The 2022 Warrants are governed by the terms of a Warrant Agreement, as amended by a Reaffirmation and Amendment Agreement, between AgeX and Juvenescence. The number of 2022 Warrants issued is equal to 50% of the number determined by dividing the amount of the applicable loan draw by the applicable market price. The market price was the last closing price per share of AgeX common stock on the NYSE American preceding the delivery of the notice from AgeX requesting a draw of funds that triggered the obligation to issue 2022 Warrants. The exercise price of the 2022 Warrants is the applicable market price. Each of the 2022 Warrants will expire at 5:00 p.m. New York time three years after the date of its issuance.

 

As of September 30, 2023, AgeX had issued to Juvenescence 2022 Warrants to purchase a total of 10,357,086 shares of AgeX common stock. The exercise prices of the 2022 Warrants range from $0.59 per share to $0.88 per share representing the market closing price of AgeX common stock on the NYSE American on the one day prior to delivery of the applicable drawdown notices. The number of shares issuable upon exercise of the 2022 Warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

Default Provisions –The loan balance and origination fees may become immediately due and payable prior to the mandatory repayment date if an Event of Default as defined in the 2022 Secured Note occurs. Events of Default under the 2022 Secured Note include the following: (a) AgeX fails to pay any principal amount payable by it in the manner and at the time provided under and in accordance with the 2022 Secured Note; (b) AgeX fails to pay any other amount payable by it in the manner and at the time provided under and in accordance with the 2022 Secured Note or the Security Agreement described below or any other agreement executed in connection with the 2022 Secured Note (the Loan Documents) and the failure is not remedied within three business days; (c) AgeX fails to perform any of its covenants or obligations or fails to satisfy any of the conditions under the 2022 Secured Note or any other Loan Document and, and such failure (if capable of remedy) remains unremedied to the satisfaction of Juvenescence (in its sole discretion) for 10 business days after the earlier of (i) notice requiring its remedy has been given by Juvenescence to AgeX and (ii) actual knowledge of the failure by senior officers of AgeX; (d) if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date; (e) AgeX stops payment of its debts generally or ceases or threatens to cease to carry on its business or is unable to pay its debts as they fall due or is deemed by a court of competent jurisdiction to be unable to pay its debts as they fall due, or enters into any arrangements with its creditors generally; (f) if (i) an involuntary proceeding (other than a proceeding instituted by Juvenescence or an affiliate of Juvenescence) shall be commenced or an involuntary petition shall be filed seeking liquidation, reorganization or other relief in respect of AgeX and any subsidiary, or of all or a substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) an involuntary appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for AgeX or a subsidiary or for a substantial part of its assets occurs (other than in a proceeding instituted by Juvenescence or an affiliate of Juvenescence), and, in any such case, such proceeding shall continue undismissed and unstayed for sixty (60) consecutive days without having been dismissed, bonded or discharged or an order of relief is entered in any such proceeding; (g) it becomes unlawful for AgeX to perform all or any of its obligations under the 2022 Secured Note or any authorization, approval, consent, license, exemption, filing, registration or other requirement of any governmental, judicial or public body or authority necessary to enable AgeX to comply with its obligations under the 2022 Secured Note or to carry on its business is not obtained or, having been obtained, is modified in a manner that precludes AgeX or its subsidiaries from conducting their business in any material respect, or is revoked, suspended, withdrawn or withheld or fails to remain in full force and effect; (h) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX or a subsidiary if such process is not released, vacated or fully bonded within 60 calendar days after its issue or levy; (i) any injunction, order, judgment or decision of any court is entered or issued which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX or a subsidiary to carry on its business or to pay amounts owed to Juvenescence under the 2022 Secured Note; (j) AgeX, whether in a single transaction or a series of related transactions, sells, leases, licenses, consigns, transfers or otherwise disposes of any material portion of its assets (with any such disposition with respect to any asset or assets with a fair value of at least $250,000 being deemed material), other than (i) certain permitted investments (ii) sales, transfers and dispositions of inventory in the ordinary course of business, (iii) any termination of a lease of real or personal property that is not necessary in the ordinary course of the AgeX’s business, could not reasonably be expected to have a material adverse effect and does not result from AgeX’s default, and (iv) any sale, lease, license, consignment, transfer or other disposition of assets that are no longer necessary in the ordinary course of business or which has been approved in writing by Juvenescence; (k) any of the following shall occur: (i) the security and/or liens created by the Security Agreement or any other Loan Document shall at any time cease to constitute valid and perfected security and/or liens on any material portion of the collateral intended to be covered thereby; (ii) except for expiration in accordance with its terms, the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall for whatever reason be terminated or shall cease to be in full force and effect; (iii) the enforceability of the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall be contested by AgeX or a subsidiary; (iv) AgeX shall assert that its obligations under the 2022 Secured Note or any other Loan Document shall be invalid or unenforceable; or (v) a loss, theft, damage or destruction occurs with respect to a material portion of the collateral; (l) there is any change in the financial condition of AgeX and its subsidiaries which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX to perform any of its obligations under the 2022 Secured Note; and (m) any representation, warranty or statement made, repeated or deemed made or repeated by AgeX in the 2022 Secured Note, or pursuant to the Loan Documents, is incomplete, untrue, incorrect or misleading in any material respect when made, repeated or deemed made.

 

369

 

 

Security Agreement – AgeX has entered into a Security Agreement granting Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs under the 2022 Secured Note, Juvenescence will have the right to foreclose on the assets pledged as collateral. Concurrently with the execution of the 2022 Secured Note Fifth Amendment, AgeX also entered into an additional Pledge Agreement to add shares of a subsidiary to the collateral under the Security Agreement, and AgeX’s subsidiaries ReCyte, Reverse Bio, and UniverXome each entered into a Guaranty Agreement and Joinder Agreement pursuant to which each of them agreed to guaranty AgeX’s obligations to Juvenescence pursuant to the Secured Note, as amended by the 2022 Secured Note Fifth Amendment, and to grant Juvenescence a security interest in their respective assets pursuant to the Security Agreement to secure their obligations to Juvenescence.

 

The 2023 Secured Convertible Promissory Note and Security Agreement

 

On March 13, 2023, AgeX and Juvenescence entered into the 2023 Secured Note pursuant to which Juvenescence loaned to AgeX $10,000,000. AgeX used the loan proceeds to finance a $10,000,000 loan to Serina which is evidenced by a promissory note payable by Serina to AgeX. In lieu of accrued interest, AgeX agreed to pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. During July 2023, the $10,000,000 principal balance of the 2023 Secured Note indebtedness and a portion of the loan origination fee was extinguished in exchange for shares of AgeX Series B preferred stock pursuant to the 2023 Exchange Agreement described below.

 

Conversion of Loan Amounts into Common Stock – AgeX may convert the any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. If less than $25,000,000 is raised through the sale of AgeX common stock or units, the conversion price per share or units shall be the lowest price at which shares or units are sold. If at least $25,000,000 is raised, the conversion price per share shall be 85% of the “Market Price” of AgeX common stock determined as provided in the 2023 Secured Note. Juvenescence may convert accrued origination fees into AgeX common stock at the market price per share of AgeX common stock. stock is listed.

 

Amended Security Agreement – AgeX has entered into an Amended and Restated Security Agreement that amended the February 14, 2022 Security Agreement between AgeX and Juvenescence and added the 2023 Secured Note to the obligations secured by the Security Agreement.

 

Debt Exchanged for Preferred Stock and Remediation of Stock Exchange Listing Deficiency

 

In order to eliminate a stockholders equity deficiency and to regain compliance with the continued listing requirements of the NYSE American, on July 24, 2023, AgeX issued to Juvenescence 211,600 shares of a newly authorized Series A preferred stock and 148,400 shares of a newly authorized Series B preferred stock in exchange for the cancellation of a total of $36 million of indebtedness consisting of the outstanding principal amount of loans then outstanding under the 2020 Loan Agreement, the 2022 Secured Note, and the 2023 Secured Note, plus the loan origination fees accrued with respect to the 2022 Secured Note and a portion of the loan origination fees accrued pursuant to the 2023 Secured Note. The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to the 2023 Exchange Agreement between AgeX and Juvenescence.

 

On November 7, 2023, Section 3(b) of the terms of the AgeX Series A preferred stock and AgeX Series B preferred stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as a deemed liquidation if the applicable transaction is approved by the AgeX Board or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of preferred stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock.

 

370

 

 

Dividends and Liquidation Preference

 

Shares of Series A preferred stock and Series B preferred stock are not entitled to receive any payment or distribution of cash or other dividends. In the event of any voluntary or involuntary liquidation, dissolution or other winding up of the affairs of AgeX, subject to the preferences and other rights of any senior stock, before any assets of AgeX shall be distributed to holders of common stock or other junior stock, all of the assets of AgeX available for distribution to stockholders shall be distributed among the holders of the Preferred Stock and any other “parity stock” that may be issued ranking parri passu with the Preferred Stock with respect to liquidation rights, in proportion to the number of shares of Series B preferred Stock and parity stock held by each such holder as of the record date for the determination of holders of Series A preferred stock, Series B preferred stock, and parity stock entitled to receive such distribution, until AgeX shall have distributed to the holders of those shares an amount of assets having a value equal to the subscription price per share. If the assets of AgeX shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of Series A preferred stock, Series B preferred stock and parity stock shall be ratably distributed among such holders. The (i) acquisition of AgeX by another entity by means of any transaction or series of transactions (including, without limitation, any reorganization, merger or consolidation) in which the stockholders of AgeX immediately before such transaction or series of transactions do not own a majority of the outstanding stock of the surviving or acquiring corporation upon completion of such transaction or series of transactions or (ii) a sale of all or substantially all of the assets of AgeX in a single transaction or series of related transactions, shall be deemed a liquidation.

 

Conversion of Preferred Stock into Common Stock

 

Each share of Preferred Stock shall be convertible into a number of shares of AgeX common stock determined by dividing (x) a number equal to the number of dollars and cents comprising the subscription price, by (y) a number equal to the number of dollars and cents comprising the conversion price. The subscription price per share of Preferred Stock is $100 which was paid through the exchange of indebtedness for shares of Preferred Stock. The conversion price per share of Series A preferred stock or Series B preferred stock is $0.72 which was the closing price of AgeX common stock on the NYSE American on the last trading day immediately preceding the execution of the 2023 Exchange Agreement.

 

Preferred Stock shall be convertible into AgeX common stock at the election of the holder of shares of Preferred Stock at any time and from time to time. The outstanding shares of Series A preferred stock and Series B preferred stock shall automatically be converted into AgeX common stock without any further act of AgeX or its stockholders (the Automatic Conversion) upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina, or a subsidiary thereof; and (y) February 1, 2024. Further, if the holders of at least a majority of the outstanding shares of Series A preferred stock approve or consent to the Automatic Conversion of the shares of that series, then the outstanding shares of Series A preferred stock shall be converted into common stock upon such approval or consent, and if the holders of at least a majority of the outstanding shares of Series B preferred stock approve or consent to the Automatic Conversion of the shares of that series then the outstanding shares of Series B preferred stock shall be converted into common stock upon such approval or consent.

 

371

 

 

Conversion of the Series B preferred stock into common stock was limited by certain rules of the NYSE American which required approval by AgeX stockholders in connection with the issuance of common stock (a) in excess of a “19.9% Cap” upon any conversion of Series B preferred stock, or (b) in an amount that, when added to other shares of common stock owned by a holder of Series B preferred stock immediately prior to such conversion, would cause such holder to own 50% or more of the outstanding shares of common stock. The 19.9% Cap means 7,550,302 shares of common stock, which is 19.9% of the shares of common stock outstanding on February 14, 2022 when the 2022 Secured Note, a portion of which has not been approved by AgeX stockholders for conversion into common stock without regard to the 19.9% Cap and 50% Cap, was issued. AgeX stockholders approved a proposal at the 2023 annual meeting of stockholders eliminating the 19.9% Cap and 50% Cap.

 

Adjustment of conversion price and subscription price

 

If AgeX shall (a) declare a dividend or make a distribution on its common stock in shares of common stock, (b) subdivide or reclassify the outstanding common stock into a greater number of shares, or (c) combine or reclassify the outstanding common stock into a smaller number of shares, the conversion price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. If AgeX shall (i) declare a dividend or make a distribution on a series of Preferred Stock in shares of Preferred Stock, (ii) subdivide or reclassify the outstanding shares of a series of Preferred Stock into a greater number of shares, or (iii) combine or reclassify the outstanding shares of a series of Preferred Stock into a smaller number of shares, the subscription price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. Successive adjustments in the conversion price or subscription price, as applicable, shall be made whenever any event specified above shall occur.

 

372

 

 

Voting Rights

 

The following matters shall require the approval of the holders of a majority of the shares of a series of Preferred Stock then outstanding, voting as a separate class: (i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the AgeX Board for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the DGCL requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the AgeX Board to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock. Except as may otherwise be required by the DGCL, as the same may be amended from time to time, the Preferred Stock will have no other voting rights.

 

Registration Rights Agreements

 

AgeX entered into a Registration Rights Agreement and certain amendments to the original agreement, pursuant to which it has agreed to register for sale under the Securities Act all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement and the 2022 Secured Note, and shares that they may acquire through the conversion of loans under the 2020 Loan Agreement and the 2022 Secured Note, including principal and accrued interest, and the amount of the loan origination fee under the 2022 Secured Note. AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of AgeX common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of a portion of the warrants held by Juvenescence. Juvenescence retains the right to require AgeX to register additional shares of AgeX common stock that Juvenescence may acquire through the exercise of warrants or the conversion of 2020 Loan Agreement loans, Secured Note loans, and the origination fee under the 2022 Secured Note. AgeX is obligated to pay the fees and expenses of each registered offering under such registration rights agreement except for underwriting discounts and commissions. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.

 

During July 2023, AgeX and Juvenescence entered into a Registration Rights Agreement pursuant to which AgeX has agreed to use commercially reasonable efforts to register the for sale under the Securities Act the shares of common stock issuable upon conversion of Preferred Stock. A registration statement must be filed upon request of Juvenescence if Form S-3 is available to AgeX. Juvenescence will also have “piggy-back” registration rights if AgeX files a registration statement for the sale of shares for itself or other stockholders, subject to certain customary exceptions based on the nature of the registration statement. AgeX will bear the expenses of the registration statement but not underwriting or broker’s commissions related to the sale of the common stock. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.

 

373

 

 

Stockholder Approval of Certain Matters

 

2020 Loan Agreement, Secured Note, 2020 Warrants, and 2022 Warrants

 

In order to comply with applicable NYSE American listing requirements, the 2020 Loan Agreement and the 2022 Secured Note and the related Warrant Agreements governing the 2020 Warrants and 2022 Warrants placed certain limits on the number of shares of AgeX common stock that may be issued to Juvenescence upon conversion of outstanding loan amounts or exercise of the 2020 Warrants or 2022 Warrants prior to stockholder approval of the issuance of shares to Juvenescence that would result in (a) Juvenescence receiving additional shares in excess of a 19.9% Cap based on the number of shares of AgeX common stock outstanding as of March 30, 2020 in the case of a conversion of the outstanding loan amounts under the 2020 Loan Agreement into AgeX common stock, or outstanding as of February 14, 2022 in the case of a conversion of the outstanding loan amounts under Secured Note into AgeX common stock, for less than the greater of book value or the applicable tranche market values of AgeX common stock as of March 20, 2020 or February 14, 2022, or (b) Juvenescence owning 50% or more of the outstanding AgeX common stock (the 50% Cap) in the case of a conversion of the outstanding loan amounts under the 2020 Loan Agreement or the 2022 Secured Note or the exercise of the 2020 Warrants or 2022 Warrants. As required by the terms of the 2020 Loan Agreement and the 2022 Secured Note, AgeX sought and obtained the vote of AgeX stockholders approving (i) the ability of AgeX and Juvenescence to convert the loans under the 2020 Loan Agreement and the 2022 Secured Note into shares of AgeX common stock under the applicable loan conversion provisions even if the conversion would result in (a) Juvenescence receiving additional shares in excess of the 19.9% Cap or the 50% Cap limits, and (ii) the ability of Juvenescence to exercise its 2020 Warrants and 2022 Warrants even if the exercise would cause Juvenescence’s ownership of AgeX common stock to equal or exceed the 50% Cap limit.

 

Series A Preferred Stock and Series B Preferred Stock

 

At the 2023 annual meeting of stockholders, AgeX sought and obtained the vote of AgeX stockholders approving a proposal eliminating the 19.9% Cap and 50% Cap that limited the number of shares of AgeX Series B preferred stock that may be converted into shares of AgeX common stock.

 

Indemnification Agreements

 

On March 13, 2023, AgeX executed a Letter of Indemnification in Lieu of or Supplemental to a Medallion Signature Guarantee (the Letter of Indemnification) pursuant to which AgeX agreed to indemnify Equiniti Trust Company, LLC (the Equiniti Indemnity) from and against any and all claims, damages, liabilities or losses arising out of the transfer of all of the AgeX common stock held by Juvenescence to its wholly-owned subsidiary, Juvenescence US Corp. (the Share Transfer). In connection with the execution of the Letter of Indemnification, AgeX and Juvenescence entered into a Transfer of Shares of AgeX Therapeutics, Inc. Common Stock – Indemnification Agreement, pursuant to which Juvenescence agreed to indemnify AgeX against any and all claims, damages, liabilities or losses arising out of the Share Transfer or the Equiniti Indemnity.

 

On December 21, 2023, AgeX executed that certain Letter of Indemnification in Lieu of or Supplemental to a Medallion Signature Guarantee (Letter of Indemnification), pursuant to which AgeX agreed to indemnify Equiniti Trust Company LLC and its affiliates, successors and assigns (the ETC Indemnity) from and against any and all claims, damages, liabilities or losses arising out of the transfer 16,447,500 shares of AgeX common stock held by Juvenescence US Corp. to JuvVentures (UK) Limited (the JUV US Share Transfer). In connection with AgeX’s execution of the Letter of Indemnification, AgeX and Juvenescence Limited, the ultimate parent company of Juvenescence US Corp. and JuvVentures (UK) Limited, entered into that certain Transfer of Shares of AgeX Therapeutics, Inc. Common Stock – Indemnification Agreement, pursuant to which Juvenescence agreed to indemnify AgeX against any and all claims, damages, liabilities or losses arising out of the JUV US Share Transfer or ETC Indemnity.

 

374

 

 

Serina Related Party Transactions

 

Related Person Transactions Policy and Procedures

 

While Serina does not have a formal written policy or procedure for the review, approval or ratification of related party transactions, the Serina Board reviews and considers the interests of its directors, executive officers and principal stockholders in its review and consideration of transactions and obtains the approval of non-interested directors when it determines that such approval is appropriate under the circumstances.

 

Certain Related Person Transactions

 

Convertible Note

 

On March 15, 2023, Serina entered into a Convertible Note Purchase Agreement (the AgeX-Serina Note Purchase Agreement) with AgeX, pursuant to which AgeX lent to Serina an aggregate principal amount of $10,000,000 as evidenced by the AgeX-Serina Note on that date. Interest on the principal amount under the AgeX-Serina Note accrues on the unpaid principal amount at a simple interest rate equal to 7% per annum, computed on the basis of the 360-day year of twelve 30-day months. The outstanding principal balance of the AgeX-Serina Note will become due and payable on March 15, 2026.

 

Currently, the AgeX-Serina Note provides that upon the consummation of a merger between AgeX and Serina, the AgeX-Serina Note would remain outstanding and become an intercompany asset of AgeX and an intercompany liability of Serina. Pursuant to the Merger Agreement, the AgeX-Serina Note will be amended prior to the closing of the Merger so that it automatically converts immediately prior to the Merger into shares of Serina capital stock, which shares will be canceled for no consideration in connection with the Merger, and will be treated as a capital contribution.

 

The outstanding principal balance of the AgeX-Serina Note with accrued interest may become immediately due and payable prior to the stated maturity date if an Event of Default as defined in the AgeX-Serina Note occurs. In addition to this and any other remedy, both in equity and in law, upon the occurrence of an Event of Default, an interest rate of 10% per annum and computed on the basis of the 360-day year of twelve 30-day months, shall apply to the Convertible Amount until fully paid. Events of Default under the AgeX-Serina Note include: (i) the commission of any act of bankruptcy by Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (ii) the execution by Serina of a general assignment for the benefit of creditors, (iii) the filing by or against Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) of a petition in bankruptcy or any petition for relief under the federal bankruptcy act (or, in each case, under any similar insolvency law) or the continuation of such petition without dismissal for a period of 60 calendar days or more, (iv) the appointment of a receiver or trustee to take possession of the property or assets of Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (v) failure of Serina to pay any amount due under the AgeX-Serina Note when due, which failure to pay is not cured by Serina within 5 business days of written notice thereof, (vi) unless waived by AgeX, Serina’s material breach of any representation, warranty or covenant of Serina under the AgeX-Serina Note Purchase Agreement, AgeX-Serina Note or other agreements entered in connection therewith, which breach, if curable, is not cured by Serina within 10 business days of written notice by AgeX thereof, (vii) Serina or any subsidiary shall default on any of its obligations under any indebtedness which default causes the indebtedness thereunder to (x) become prematurely due and payable, (y) be placed on demand or (z) become capable of being declared by or on behalf of a creditor thereunder to be prematurely due and payable or being placed on demand, in each case, as a result of such default or any provision having a similar effect (howsoever prescribed), (viii) any monetary judgment, writ or similar final process shall be entered or filed against Serina, any subsidiary or any of their respective property or other assets for more than $250,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period of 45 calendar days, and (ix) Serina experiences a Material Adverse Effect (as defined in the AgeX-Serina Note Purchase Agreement).

 

The AgeX-Serina Note Purchase Agreement and AgeX-Serina Note each includes certain covenants that among other matters require financial reporting and impose certain restrictions, including (i) restrictions on the incurrence of additional indebtedness by Serina and its subsidiaries; (ii) requiring that Serina use note proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, and for general working capital; and (iii) prohibiting Serina from entering into any material sale or transfer transactions outside of the ordinary course of business, other than in a merger between AgeX and Serina, without the consent of AgeX.

 

In connection with the issuance of the AgeX-Serina Note, AgeX was entitled to elect one member to the Serina Board and receive certain information and inspection rights as well as participation rights for subsequent equity issuances. AgeX designated Gregory Bailey, Executive Chairman of Juvenescence and a member of the AgeX Board, to serve on the Serina Board.

 

375

 

 

DESCRIPTION OF COMBINED COMPANY CAPITAL STOCK

 

The following information is a summary of the material terms of the capital stock of the combined company (upon effectiveness of the Merger). You are encouraged to read the Combined Company Charter and the Combined Company Bylaws, which, following completion of the Merger, will be substantially in the forms attached hereto as Annex A and Annex F of this proxy statement/prospectus/information statement, respectively. For more information, see the comparison of relative rights described in the section titled “Comparison of Rights of Stockholders of AgeX, Serina and the Combined Company” of this proxy statement/prospectus/information statement.

 

General

 

The combined company’s authorized capital stock will consist of 40,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value $0.0001 per share.

 

Common Stock

 

Voting. Each holder of record of common stock will have one vote for each share of common stock which is outstanding on all matters on which stockholders are entitled to vote generally. The holders of shares of common stock will not have cumulative voting rights. Except as otherwise required by law, holders of common stock will not be entitled to vote on any amendment to the Combined Company Charter that relates solely to the terms, number of shares, powers, designations, preferences or relative, participating, optional or other special rights, or to qualifications, limitations or restrictions thereof, of one or more outstanding series of preferred stock if the holders of such affected series are entitled to vote thereon pursuant to the Combined Company Charter or pursuant to the DGCL.

 

Other Rights. Holders of the combined company shares will not have any dividend, liquidation, preemptive, subscription or conversion rights, and there will not be any redemption or sinking fund provisions applicable to the combined company common stock.

 

Preferred Stock

 

The Combined Company Board is authorized to issue from time to time, without further vote or action by the stockholders, up to an aggregate of 5,000,000 shares of preferred stock in one or more series. The Combined Company Board is authorized, within the limitations and restrictions stated in the Combined Company Charter, to determine or alter the rights, preferences, privileges and restrictions granted to or imposed on any wholly unissued series of preferred shares, and the number of shares constituting such series and the designation thereof.

 

The combined company currently has no plans to issue any shares of preferred stock, but the combined company believes that the ability to issue shares of preferred stock without the expense and delay of a special stockholders’ meeting will provide the combined company with increased flexibility in structuring possible future financings and acquisitions, and in meeting other corporate needs that might arise. The Combined Company Board could issue shares of preferred stock having conversion privileges or having voting, dividend and liquidation rights superior to those of the shares of common stock, which could adversely affect the voting power of the common stockholders, including the loss of voting control to others, and delay, defer or prevent a change in control of the combined company without further action by the stockholders. This could discourage an acquisition attempt or other transaction that stockholders might believe to be in their best interests or in which they might receive a premium for their stock over the then-market price of the stock.

 

376

 

 

If the Combined Company Board were to issue a new series of preferred stock, the issuance of such shares could:

 

decrease the amount of earnings and assets available for distribution to any common stockholders;
make removal of the combined company management more difficult;
result in restrictions upon the payment of dividends and other distributions to any common stockholders;
delay or prevent a change in control of the combined company; and
limit the price that investors are willing to pay in the future for the shares of common stock.

 

Anti-takeover Effects of Delaware Law and Provisions of the Combined Company Charter and the Combined Company Bylaws

 

The combined company is subject to the provisions of Section 203 of the DGCL. Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:

 

prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.

 

Section 203 defines a business combination to include:

 

any merger or consolidation involving the corporation and the interested stockholder;
any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;
subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; or
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

 

In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person. The term “owner” is broadly defined to include any person that, individually, with or through that person’s affiliates or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not the right is immediately exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding with the beneficial owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock.

 

377

 

 

The restrictions in Section 203 do not apply to corporations that have elected, in the manner provided in Section 203, not to be subject to Section 203 of the DGCL or, with certain exceptions, which do not have a class of voting stock that is listed on a national securities exchange or held of record by more than 2,000 stockholders. The Combined Company Charter and the Combined Company Bylaws do not opt out of Section 203.

 

Section 203 could delay or prohibit mergers or other takeover or change in control attempts with respect to the combined company and, accordingly, may discourage attempts to acquire the combined company even though such a transaction may offer its stockholders the opportunity to sell their stock at a price above the prevailing market price.

 

Classified Board of Directors; Removal of Directors; Filling Vacancies. The Combined Company Charter provides that the directors shall be divided into three classes, with each class having a three-year term expiring on a staggered basis. In addition, the Combined Company Charter and Combined Company Bylaws provide that any or all of the directors (other than the directors elected by the holders of any series of preferred stock, voting separately as a series or together with one or more other such series) may be removed only for cause and only by the affirmative vote of the holders of at least a majority in voting power of all the then outstanding shares of stock of the combined company entitled to vote thereon, voting together as a single class. Subject to the rights granted to the holders of any one or more series of Preferred Stock then outstanding, any newly-created directorship on the Combined Company Board that results from an increase in the number of directors and any vacancy occurring on the Combined Company Board (whether by death, resignation, retirement, disqualification, removal or other cause) shall be filled only by a majority of the directors then in office, even if less than a quorum, or by a sole remaining director (and not by the stockholders). Each director so elected shall hold office until the next annual meeting of the stockholders and until a successor has been elected and qualified.

 

Special Meetings and Notice Procedures. The Combined Company Bylaws provide that, except as otherwise required by law and subject to the rights of the holders of any series of preferred stock, special meetings of stockholders may only be called by or at the direction of the board of directors or the chair of the board of directors. Stockholders shall not be permitted to propose business to be brought before a special meeting of stockholders and the only matters that may be brought before a special meeting are the matters specified in the notice of meeting given by or at the direction of the person calling the meeting. In addition, the Combined Company Bylaws establish an advance written notice procedure for stockholders seeking to nominate candidates for election to the Combined Company Board or to propose matters to be acted upon at stockholders’ meetings. As a result, these provisions of the Combined Company Bylaws may delay stockholder actions with respect to business combinations or a change in management and may make it more difficult for third parties to acquire control of the combined company.

 

Advanced Notice Bylaws. For director nominations or other business to be properly brought before an annual meeting by a stockholder, such stockholder must generally provide notice to the Secretary of the combined company no later than 90 days and no more than 120 days prior to the first anniversary of the date of the prior year’s annual meeting; provided, that if the date of the annual meeting is advanced by more than 30 days prior to or delayed by more than 70 days after the anniversary of the preceding year’s annual meeting or if no annual meeting was held in the preceding year, such notice must be delivered no more than 120 days prior to such annual meeting nor less than the later of (i) 90 days prior to such annual meeting and (ii) ten days after the day on which public disclosure of the date of such meeting is first made.

 

378

 

 

Exclusive Jurisdiction. The Combined Company Charter provide that unless the combined company selects or consents in writing to the selection of an alternative forum, (i) any derivative action or proceeding brought on behalf of the combined company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee or stockholder of the combined company to the combined company or the combined company’s stockholders, creditors or other constituents, (iii) any action asserting a claim against the combined company or any current or former director or officer of the combined company arising pursuant to any provision of the DGCL or the Combined Company Charter or the Combined Company Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv) any action asserting a claim governed by the internal affairs doctrine.

 

No Action by Consent. Any action required or permitted to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by a consent or consents (written, electronic, or otherwise) of such stockholders.

 

Amendment to the Combined Company Charter and the Combined Company Bylaws. Pursuant to the DGCL, an amendment to the Combined Company Charter generally requires: (a) recommendation of the Combined Company Board; (b) the affirmative vote of a majority of the voting power of the outstanding stock entitled to vote; and (c) the affirmative vote of a majority of the voting power of the outstanding stock of each class entitled to vote; provided that any provision of Articles 5, 6, 7, 8, and 9 of the Combined Company Charter can only be altered, amended or repealed upon the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class. Furthermore, the Combined Company Charter and Combined Company Bylaws provide that the Combined Company Board can make, alter, amend and repeal the Combined Company Bylaws subject to the power of the stockholders of the combined company to alter, amend or repeal the bylaws; provided, however, that with respect to the powers of stockholders to make, alter, amend or repeal the bylaws, the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class, shall be required to make, alter amend or repeal the Combined Company Bylaws or to adopt any provision inconsistent therewith.

 

Authorized but Unissued Shares of Capital Stock. The authorized but unissued shares of the combined company’s common stock and the combined company’s preferred stock will be available for future issuance following the closing of the Merger without stockholder approval, subject to any limitations imposed by the listing requirements of the NYSE American. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved shares of the combined company’s common stock and the combined company’s preferred stock could make it more difficult or discourage an attempt to obtain control of the combined company by means of a proxy contest, tender offer, merger or otherwise.

 

Post-Merger Warrants

 

Prior to the closing of the Merger, AgeX will issue to each holder of AgeX common stock three post-merger warrants for each five shares of AgeX common stock held by such holder. Each post-merger warrant will be exercisable at an exercise price equal to $13.20 per warrant (such exercise price reflecting the planned reverse stock split) for (i) one share of AgeX common stock and (ii) one incentive warrant and will expire on July 31, 2025. Each incentive warrant will be exercisable at an exercise price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split) for one share of AgeX common stock and will expire on the four-year anniversary of the Closing Date.

 

For additional information, see the section titled “Agreements Related to the Merger—Warrant Agreement” beginning on page 197 of this proxy statement/prospectus/information statement.

 

Incentive Warrants

 

Each incentive warrant will be exercisable for one share of AgeX common stock at a price equal to $18.00, subject to certain anti-dilution adjustments pursuant to the terms of the warrant agreement, and will expire on the four-year anniversary of the Closing Date.

 

For additional information, see the section titled “Agreements Related to the Merger—Warrant Agreement” beginning on page 197 of this proxy statement/prospectus/information statement.

 

379

 

 

COMPARISON OF RIGHTS OF STOCKHOLDERS OF AGEX, SERINA and the combined company

 

General

 

AgeX is incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of AgeX currently, and will continue to be, governed by the DGCL. Serina is incorporated under the laws of the State of Alabama and, accordingly, the rights of the stockholders of Serina are currently governed by the ABCL. If the Merger is completed, the AgeX stockholders and Serina stockholders will become the stockholders of the combined company. After giving effect to the Merger, the rights of stockholders of the combined company and the relative powers of the Combined Company Board will be governed by the Combined Company Charter, the Combined Company Bylaws and by the DGCL. Each share of the common stock of the combined company will be issued pursuant to, and will carry with it the rights and obligations set forth in, the Combined Company Charter. This section summarizes material differences between the rights of AgeX stockholders and Serina stockholders before consummation of the Merger and the rights of the combined company stockholders after consummation of the Merger. These differences in stockholder rights result from the differences between the respective organizational documents of AgeX, Serina and the combined company and the applicable governing law.

 

The following summary does not include a description of rights or obligations under the U.S. federal securities laws or relevant NYSE American listing requirements or standards.

 

The following summary is not a complete statement of the rights of the stockholders of AgeX, Serina or the combined company or a complete description of the specific provisions referred to below. The identification of specific differences is not intended to indicate that other equally significant or more significant differences do not exist. This summary is qualified in its entirety by reference to AgeX’s, Serina’s and the combined company’s organizational documents, which you are urged to read carefully.

 

The form of the Combined Company Charter, the form of the Combined Company Bylaws, the AgeX Charter, the AgeX Bylaws, Serina’s amended and restated certificate of incorporation (the Serina Charter) and Serina’s second amended and restated bylaws (the Serina Bylaws) are attached hereto as Annex B, Annex F, Exhibit 3.1, Exhibit 3.2, Exhibit 3.3 and Exhibit 3.4, respectively, of this proxy statement/prospectus/information statement and are incorporated herein by reference.

 

380

 

 

AgeX   Serina   Combined Company
Authorized Capital Stock
 

AgeX’s authorized capital stock consists of 200,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share.

 

Holders of AgeX common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to AgeX common stock. The rights, preferences and privileges of the holders of AgeX common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of AgeX preferred stock that it may designate in the future.

  The Serina Charter authorizes the issuance of up to 15,000,000 shares of common stock, $0.01 par value per share, and 10,000,000 shares of preferred stock, $0.01 par value per share (the Serina Preferred Stock), of which 400,000 shares are designated Series A Preferred Stock, 300,000 shares are designated Series A-1 Preferred Stock, 1,122,077 shares are designated Series A-2 Preferred Stock, 499,200 shares are designated Series A-3 Preferred Stock, 718,997 shares are designated Series A-4 Preferred Stock and 2,000,000 shares are designated Series A-5 Preferred Stock.  

The combined company’s authorized capital stock will consist of 40,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share.

         
Common Stock
 
AgeX’s authorized capital stock consists of 200,000,000 shares of common stock, $0.0001 par value per share.  

Serina is authorized to issue up to 15,000,000 shares of common stock, $0.01 par value per share.

 

The Serina Charter provides that every stockholder shall be entitled to one vote for each share of common stock of Serina held by them (including all Serina Preferred Stock on an as-converted basis) as of the record date for such meeting.

 

The combined company will be authorized to issue capital stock up to 40,000,000 shares of common stock, par value $0.0001 per share.

 

Each holder of record of the combined company common stock, as such, shall have one vote for each share of common stock which is outstanding in his, her or its name on the stock records of the combined company on the record date, as provided by the Combined Company Bylaws, on all matters on which stockholders are entitled to vote generally.

         
Preferred Stock
 

The AgeX Board is authorized, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions.

 

AgeX has 211,600 shares of Series A preferred stock and 148,400 shares of Series B preferred stock issued and outstanding (collectively, the AgeX preferred stock).

  The Serina Charter provides that each holder of shares of Serina Preferred Stock shall, subject to certain conditions, have the right to convert such shares into shares of Serina common stock at any time in accordance with the Serina Charter.   The Combined Company Board will be authorized to issue from time to time, without further vote or action by the stockholders, up to an aggregate of 5,000,000 shares of preferred stock in one or more series. The Combined Company Board will be authorized, within the limitations and restrictions stated in the Combined Company Charter, to determine or alter the rights, preferences, privileges and restrictions granted to or imposed on any wholly unissued series of preferred shares, and the number of shares constituting such series and the designation thereof.

 

381

 

 

Subject to certain limitations and restrictions, the outstanding shares of AgeX preferred stock shall automatically be converted into AgeX common stock without any further act of AgeX or its stockholders upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina, or a subsidiary thereof; and (y) February 1, 2024. Further, if the holders of at least a majority of the outstanding shares of AgeX preferred stock approve or consent to such automatic conversion of the shares of that series, then the outstanding shares of AgeX preferred stock of that series shall be converted into AgeX common stock upon such approval or consent.

 

AgeX preferred stock shall be convertible into common stock at the election of the holder of shares of preferred stock at any time and from time to time.

 

Certain matters require the approval of the holders of a majority of the shares of AgeX preferred stock, including but not limiting to (i) creation of any preferred stock ranking as senior stock to the AgeX preferred stock with respect to liquidation preferences; (ii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation, but only to the extent that the DGCL requires that such approval; and (iii) any amendment of the AgeX Charter or AgeX Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on AgeX preferred stock.

 

Upon the closing of the sale of shares of common stock to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act resulting in at least $160 million of proceeds to Serina, net of the underwriting discount and commissions or the affirmative vote or written consent of the holders of at least 60% of the outstanding shares of each series of preferred stock, voting or consenting together as a separate class, each share of Serina Preferred Stock is convertible into the greater of (a) the number of shares of Serina common stock equal to the applicable liquidation preference for one share of such series of Serina Preferred Stock divided by the value of one share of Serina common stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants), or (b) one share of Serina common stock.

 

The Serina Charter provides that for so long as any shares of its Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock or Series A-5 Preferred Stock is outstanding, Serina shall first obtaining the affirmative vote or written consent of the holders of at least 60% of the outstanding shares of such series of preferred stock, voting or consenting together as a separate class, before altering or changing the rights, preferences or privileges of the such preferred stock set forth in the Serina Charter.

  The combined company currently has no plans to issue any shares of preferred stock, but the combined company believes that the ability to issue shares of preferred stock without the expense and delay of a special stockholders’ meeting will provide the combined company with increased flexibility in structuring possible future financings and acquisitions, and in meeting other corporate needs that might arise. The Combined Company Board could issue shares of preferred stock having conversion privileges or having voting, dividend and liquidation rights superior to those of the shares of common stock, which could adversely affect the voting power of the common stockholders, including the loss of voting control to others, and delay, defer or prevent a change in control of the combined company without further action by the stockholders. This could discourage an acquisition attempt or other transaction that stockholders might believe to be in their best interests or in which they might receive a premium for their stock over the then-market price of the stock.

 

Number of Directors
 
The AgeX Charter and AgeX Bylaws provide the number of directors shall be set from time to time by the AgeX Board and shall be no less than one and not more than three directors. The AgeX Board currently has three members.   The Serina Bylaws provide that the number of directors shall be set from time to time by the Serina Board and shall be no less than one and not more than nine directors. The Serina Charter provides for the election of one or more directors as specified in the Serina Bylaws.   The Combined Company Charter and Combined Company Bylaws provide the number of directors shall be set from time to time by the Combined Company Board. At the Effective Time, the combined company is expected to initially have a seven-member board.
         
Stockholder Nominations and Proposals
 
The AgeX Bylaws provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder’s notice.   None.   The Combined Company Bylaws provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder’s notice.
         
Classification of Board of Directors
 
The AgeX Charter and AgeX Bylaws do not provide for the division of the AgeX Board into staggered classes.   The Serina Charter and the Serina Bylaws do not provide for the division of the Serina Board into staggered classes.   The Combined Company Charter provides that the directors shall be divided into three classes, with each class having a three-year term expiring on a staggered basis.

 

382

 

 

Removal of Directors
 
The AgeX Bylaws provide that entire AgeX Board or any individual director may be removed as provided by the DGCL.   The Serina Bylaws provide that, any director may be removed from the Serina Board at any time, with or without cause, by the holders of a majority of the shares then entitled to vote in an election of directors. If a director is elected by a voting group of stockholders, only the stockholders of that voting group may participate in the vote to remove that director.   The Combined Company Charter and Combined Company Bylaws provide that any or all of the directors (other than the directors elected by the holders of any series of preferred stock, voting separately as a series or together with one or more other such series) may be removed only for cause and only by the affirmative vote of the holders of at least a majority in voting power of all the then outstanding shares of stock of the combined company entitled to vote thereon, voting together as a single class.
         
Vacancies on the Board of Directors
 
Any vacancies on the AgeX Board resulting from death, resignation, or removal of any director, the increase in the number of directors authorized, or if the Court of Chancery has removed a director for conviction of a felony, or if the stockholders fail, at any meeting of stockholders at which any director or directors are elected, to elect the number of directors to be voted for at that meeting, shall, except as otherwise provided by law, be filled by a majority of the remaining directors, though less than a quorum, or by the sole remaining director. Each director so elected shall hold office until the next annual meeting of the stockholders and until a successor has been elected and qualified. The stockholders may elect a director or directors at any time to fill any vacancy or vacancies not filled by the directors, but any such election by written consent shall require the consent of a majority of the outstanding shares entitled to vote.   The Serina Bylaws provide that vacancies occurring on its board of directors may be filled by affirmative vote of the majority of directors then in office, even if less than a quorum, or the holders of a majority of the shares then entitled to vote in an election of directors. If the vacant office was held by a director elected by a voting group of stockholders, only the holders of shares of that voting group are entitled to vote to fill the vacancy if it is filled by the stockholders, and only the remaining directors elected by that voting group, even if less than a quorum, are entitled to fill the vacancy if it is filled by the directors.   Subject to the rights granted to the holders of any one or more series of preferred stock then outstanding, any newly-created directorship on the Combined Company Board that results from an increase in the number of directors and any vacancy occurring on the Combined Company Board (whether by death, resignation, retirement, disqualification, removal or other cause) shall be filled only by a majority of the directors then in office, even if less than a quorum, or by a sole remaining director (and not by the stockholders). Each director so elected shall hold office until the next annual meeting of the stockholders and until a successor has been elected and qualified.

 

383

 

 

Cumulative Voting
 
AgeX stockholders do not have cumulative voting rights.   The Serina Charter states that stockholders shall not be entitled to cumulative voting in the elections of directors.   The Combined Company Charter provides that the holders of shares of common stock shall not have cumulative voting rights.
         
Stockholder Action by Written Consent
 
The AgeX Bylaws provide that any action that may be taken at any annual or special meeting of stockholders may be taken without a meeting and without prior notice, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take that action at a meeting at which all shares entitled to vote on that action were present and voted.   The Serina Bylaws provide that any action required by the ABCL or permitted to be taken at any annual or special meeting of stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted.   Subject to the rights of holders of any preferred stock, any action required or permitted to be taken by the combined company’s stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by a consent or consents (written, electronic, or otherwise) of such stockholders.
         
Notice of Stockholder Meeting
 

The AgeX Bylaws provide that written notice of a meeting of the stockholders shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.

 

Notice need not be given to any stockholder who submits a written waiver of notice signed by him or her before or after the time stated therein. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.

 

The Serina Bylaws provide that notice of each annual or special meeting of the stockholders shall be given to each stockholder of record entitled to vote at such meeting not less than ten and nor more than 60 days before the day of the meeting to each stockholder entitled to vote at such meeting. Every such notice shall state the date, time, place, if any, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting must include the record date for determining the stockholders entitled to vote at the meeting. Notice of a special meeting shall also include a description of the purpose or purposes for which the meeting is called.

 

A stockholder’s attendance at a meeting shall constitute a waiver of objections to lack of or defective notice of a stockholders’ meeting or to consideration of particular matters at the meeting, in each case to the extent provided in the ABCL.

 

The Combined Company Bylaws provide that written notice of a meeting of the stockholders shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and hour of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.

 

Notice may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by the stockholder’s attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.

 

384

 

 

Special Stockholder Meetings
 
The AgeX Bylaws provide that a special meeting of stockholders may be called at any time by the chairman of the AgeX Board, a majority of the directors then in office even if less than a quorum of the authorized number of directors, or by one or more stockholders entitled to cast not less than 10% of the votes eligible to the cast at that meeting.  

The Serina Bylaws provide that a special meeting of the stockholders may be called at any time by the Serina Board.

  The Combined Company Bylaws provide that, except as otherwise required by law and subject to the rights of the holders of any series of preferred stock, special meetings of stockholders may only be called by or at the direction of the board of directors or the chair of the board of directors.
         
Exculpation and Indemnification
 

The DGCL permits a corporation to indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed legal action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that the person’s conduct was unlawful.

 

The AgeX Charter provides that the liability of the AgeX directors to AgeX or its stockholders for monetary damages for breach of fiduciary duty as a director is eliminated to the fullest extent permissible under DGCL; provided that this limitation of the liability does not apply: (i) for any breach of the director’s duty of loyalty to AgeX or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under § 174 of the DGCL; or (iv) for any transaction from which the director derived an improper personal benefit. The corporation is authorized to indemnify directors, officers, and agents to the fullest extent permissible under Delaware law. AgeX is authorized to indemnify directors, officers, and agents to the fullest extent permissible under DGCL.

 

The ABCL provides that a corporation may indemnify an individual made a party to a proceeding because such individual is or was a director or officer of the corporation against liability incurred in a proceeding if: (i) such individual’s conduct was in good faith; (ii) the individual reasonably believed (a) the conduct was in its best interest of the corporation in the case of conduct performed in an official capacity; and (b) in all other cases, the conduct was at least not opposed to the corporation’s best interest; and (iii) in the case of any criminal proceeding the individual had no reasonable cause to believe the conduct was unlawful. Under the ABCL a corporation may not indemnify a director or officer in connection with a proceeding by or in the right of the corporation in which the director or officer has not met the relevant standard of conduct; or in connection with any other proceeding with respect to conduct for which the director or officer received an improper financial benefit.

 

Under the ABCL, a corporation may advance funds to pay for or reimburse expenses incurred in connection with a proceeding by a director or officer.

 

Serina is authorized to indemnify directors, officers, and agents to the fullest extent permissible under law, including the ABCL.

 

Serina has entered into separate indemnification agreements with certain of its directors in addition to the indemnification provided for in the Serina Charter and the Serina Bylaws.

 

Pursuant to Serina’s Charter, the Serina directors shall not be personally liable to Serina or its stockholders for monetary damages for any actions or failures to act, except liability for (i) the amount of improper financial benefit received, (ii) an intentional infliction of harm on Serina or its stockholders, (iii) a violation of Section 10A-2A-8.32 of the ABCL, (iv) an intentional violation of law, or (v) a breach of the director’s duty of loyalty to Serina or its stockholders.

 

The DGCL permits a corporation to indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed legal action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that the person’s conduct was unlawful.

 

The Combined Company Bylaws provide that, to the fullest extent not prohibited by the DGCL or any other applicable law, the combined company shall indemnify its directors and executive officers; provided, however, that the combined company may modify the extent of such indemnification by individual contracts with its directors and executive officers.

 

The Combined Company Charter provides that no director of the combined company, and no officer of the combined company serving in such capacity, shall be personally liable to the combined company or its stockholders for monetary damages for breach of fiduciary duty as a director or officer to the fullest extent permissible under the DGCL or other Delaware law.

         
Amendment of Certificate of Incorporation
 
Pursuant to the DGCL, an amendment to the AgeX Charter generally requires: (a) recommendation of the AgeX Board; (b) the affirmative vote of a majority of the voting power of the outstanding stock entitled to vote; and (c) the affirmative vote of a majority of the voting power of the outstanding stock of each class entitled to vote. The AgeX Charter does not include any additional conditions on its amendment.  

Serina may amend, alter, change or repeal any provision of the Serina Charter, in a manner prescribed by statute; provided that any such amendment may be subject to the protective provisions described above.

  Pursuant to the DGCL, an amendment to the Combined Company Charter generally requires: (a) recommendation of the Combined Company Board; (b) the affirmative vote of a majority of the voting power of the outstanding stock entitled to vote; and (c) the affirmative vote of a majority of the voting power of the outstanding stock of each class entitled to vote; provided that any provision of Articles 5, 6, 7, 8, and 9 of the Combined Company Charter can only be altered, amended or repealed, or any provision inconsistent therewith can only be adopted, upon the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class.

 

385

 

 

Amendment of Bylaws
 
The AgeX Charter and AgeX Bylaws provide that the AgeX Bylaws can be altered, amended or repealed (i) by AgeX’s stockholders by a majority of the voting power of the shares represented and entitled to vote or (ii) by the AgeX Board by a majority vote of the board members present at any board meeting where a quorum is present.   Under the Serina Charter, the Serina Board is expressly authorized to make, repeal or alter any or all of its bylaws. The Serina Bylaws provide that the bylaws may be amended or repealed by the Serina Board; provided that the stockholders may adopt or amend a bylaw that fixes a greater quorum or voting requirement for stockholders and such bylaw may not be adopted, amended or repealed by the Serina Board and any bylaw that fixes a greater quorum or voting requirements for the Serina Board may be amended or repealed only by the stockholders if originally adopted by the stockholders or by either the stockholders or the Serina Board if originally adopted by the Serina Board.   The Combined Company Charter and Combined Company Bylaws provide that the Combined Company Board can make, alter, amend and repeal the Combined Company Bylaws subject to the power of the stockholders of the corporation to alter, amend or repeal the bylaws; provided, however, that with respect to the powers of stockholders to make, alter, amend or repeal the bylaws, the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class, shall be required to make, alter amend or repeal the Combined Company Bylaws or to adopt any provision inconsistent therewith.
         
Forum Selection
 

The AgeX Charter and the AgeX Bylaws do not provide for the forum selection provisions.

  The Serina Charter provides that unless Serina consents in writing to the selection of an alternative forum, the Circuit Court of Madison County Alabama shall be the sole and exclusive forum for (i) any claim that is based upon a violation of a duty under the laws of the State of Alabama by a current or former director, officer or stockholder in their capacities as such, (ii) any derivative action or proceeding brought on behalf of Serina, (iii) any action asserting a claim arising pursuant to any provision of the ABCL, the Serina Charter or the Serina Bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine. If the Circuit Court of Madison County does not have jurisdiction, then another circuit court of the State of Alabama shall be the sole and exclusive forum for such claims and actions and if no circuit court of the State of Alabama has jurisdiction, then the federal district court for the Northern District of Alabama sitting in Madison County, Alabama shall be the sole and exclusive forum for such claims and actions.   The Combined Company Charter provides that unless the combined company selects or consents in writing to the selection of an alternative forum, (i) any derivative action or proceeding brought on behalf of the combined company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee or stockholder of the combined company to the combined company or the combined company’s stockholders, creditors or other constituents, (iii) any action asserting a claim against the combined company or any current or former director or officer of the combined company arising pursuant to any provision of the DGCL or the Combined Company Charter or the Combined Company Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv) any action asserting a claim governed by the internal affairs doctrine.

 

386

 

 

PRINCIPAL STOCKHOLDERS OF AGEX

 

References to “we,” “us” and “our” in this section titled “Principal Stockholders of AgeX” refer to AgeX.

 

The following table sets forth information regarding the beneficial ownership of AgeX common stock as of January 3, 2024, by (i) each of our Named Executive Officers, (ii) each of our directors, (iii) all of our directors and executive officers as a group; and (iv) each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of AgeX common stock. Our calculation of the percentage of beneficial ownership is based on 37,951,261 shares of AgeX common stock outstanding as of January 3, 2024.

 

Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security, including options that are currently exercisable or exercisable within 60 days of January 3, 2024, and restricted stock units that will vest within 60 days of January 3, 2024. Shares of AgeX common stock issuable pursuant to stock options and restricted stock units currently exercisable or exercisable within 60 days of January 3, 2024, and restricted stock units that will vest within 60 days of January 3, 2024, are deemed outstanding for computing the percentage of the person holding such equity awards and the percentage of any group of which the person is a member but are not deemed outstanding for computing the percentage of any other person. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all shares they beneficially own, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Section 16 of the Exchange Act.

 

Name of Beneficial Owner 

Number of Shares

Beneficially Owned

  

Percentage of Shares

Beneficially Owned

 
5% Stockholders          
Juvenescence Limited and certain affiliates(1)   86,925,820    80.2%
Broadwood Partners, L.P. and certain affiliates(2)   3,003,446    7.9%
           
Named Executive Officers and Directors(8)          
Michael D. West(3)   1,371,982    3.5%
Andrea E. Park(4)   351,601    * 
Nafees N. Malik(5)   485,625    1.3%
Gregory H. Bailey(6)   165,000    * 
Joanne M. Hackett(6)   65,000    * 
Jean-Christophe Renondin(6)   25,821    * 
All executive officers and directors as a group (7 persons)(7)   2,533,495    6.3%

 

  * Less than 1%
     
  (1) Includes 16,447,500 shares of AgeX common stock held by JuvVentures (UK) Limited (JuvVentures), a wholly-owned subsidiary of Juvenescence Limited, 10,929,503 shares of AgeX common stock that may be acquired upon the exercise of common stock purchase warrants, 9,548,818 shares of AgeX common stock that may be acquired through the conversion of $4,000,000 of certain outstanding loans into shares of AgeX common stock at an assumed conversion price of $0.4189 per share based on the closing price of AgeX common stock on the NYSE American on January 2, 2024, and 29,388,888 shares of AgeX common stock that may be acquired through the conversion of 211,600 shares of Series A preferred stock, and 20,611,111 shares of AgeX common stock that may be acquired through the conversion of 148,400 shares of Series B preferred stock. Dr. Gregory Bailey is the executive chairman of Juvenescence Limited and may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to direct the disposition of, the shares held by JuvVentures. This response is not and shall not be construed as an admission that Dr. Bailey is the beneficial owner of any securities of AgeX other than the securities actually owned by Dr. Bailey (if any). The address of Juvenescence is 1st Floor, Viking House, St Paul’s Square, Ramsey, Isle of Man, British Isles, IM8 1GB. The foregoing information is based solely on a Schedule 13D/A filed with the SEC on January 9, 2024, which provides information only as of January 3, 2024 and consequently, Juvenescence’s beneficial ownership may have changed since that date.

 

387

 

 

  (2) Includes 2,997,156 shares of AgeX common stock owned by Broadwood Partners, L.P. and 6,290 shares of AgeX common stock owned by Neal Bradsher. Broadwood Capital, Inc. is the general partner of Broadwood Partners, L.P. Neal Bradsher is the President of Broadwood Capital, Inc. Mr. Bradsher and Broadwood Capital, Inc. have disclaimed beneficial ownership of the shares owned by Broadwood Partners, L.P. except to the extent of their respective pecuniary interests in such shares. The address of these entities is 142 West 57th Street, 11th Floor, New York, NY 10019. The foregoing information is based solely on a Schedule 13G filed with the SEC on December 10, 2018, which provides information only as of November 28, 2018, and, consequently, the beneficial ownership of these reporting entities or persons may have changed since that date.

 

  (3) Includes 1,330,000 shares of AgeX common stock that may be acquired upon the exercise of certain stock options that are presently exercisable. Dr. West served as Chief Executive Officer of AgeX and of Reverse Bio through August 9, 2023 and October 31, 2023, respectively.
     
  (4) Includes 351,250 shares of AgeX common stock that may be acquired upon the exercise of certain stock options that are presently exercisable or that will become exercisable within 60 days. Excludes 43,750 shares of AgeX common stock that may be acquired upon the exercise of certain stock options that are not presently exercisable and that will not become exercisable within 60 days.
     
  (5) Consists entirely shares of AgeX common stock that may be acquired upon the exercise of certain stock options that are presently exercisable. Dr. Malik served as AgeX’s Chief Operating Officer through December 27, 2023.
     
  (6) Consists entirely shares of AgeX common stock that may be acquired upon the exercise of certain stock options that are presently exercisable.
     
  (7) Includes 2,491,029 shares of AgeX common stock that may be acquired upon the exercise of certain stock options that are presently exercisable or that will become exercisable within 60 days. Excludes 45,417 shares of AgeX common stock that may be acquired upon the exercise of certain stock options that are not presently exercisable and that will not become exercisable within 60 days.
     
  (8) On January 8, 2024, Steven Mintz was appointed as a director to the AgeX Board, and, as of such date, Mr. Mintz beneficially owned 116,324 shares of AgeX common stock, which includes (i) 115,000 shares of AgeX common stock and (ii) 1,324 shares of AgeX common stock held by Mr. Mintz’s adult children, over which Mr. Mintz has voting and investment power. Shares of AgeX common stock beneficially owned by Mr. Mintz are excluded from the above table.

 

388

 

 

PRINCIPAL STOCKHOLDERS OF SERINA

 

The following table sets forth certain information with respect to the beneficial ownership of Serina common stock, on an as-converted to common stock basis assuming a 1 to 1 conversion of Serina preferred stock to Serina common stock, as of January 3, 2024, for:

 

each person, or group of affiliated persons, known by Serina to beneficially own more than 5% of Serina’s outstanding shares of Serina capital stock;
   
each of Serina’s directors;
   
each of Serina’s named executive officers; and
   
all directors and executive officers of Serina as a group.

 

The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days of January 3, 2024 through the exercise of stock options or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of capital stock held by that person.

 

The percentage of shares beneficially owned is computed on the basis of 5,987,562 shares of Serina common stock outstanding as of January 3, 2024, after giving effect to the automatic conversion of all 3,520,128 shares of Serina preferred stock outstanding as of January 3, 2024, into 3,520,128 shares of Serina common stock, assuming a 1 to 1 conversion of Serina preferred stock to Serina common stock, and includes 2,467,434 shares of Serina common stock outstanding as of January 3, 2024. Shares of Serina common stock that a person has the right to acquire within 60 days of January 3, 2024, are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Unless noted otherwise, the address of all listed stockholders is 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.

 

   Beneficial Ownership as of January 3, 2024 
Beneficial Owner 

Number of Shares(1)

   Percent of Total 
5% and Greater Stockholders:          
Puffinus L.P.(2)   1,004,482    16.56%
Helen W. McMillan(3)   857,354    14.00%
Randall Moreadith(4)   629,550    9.51%
Michael D. Bentley(5)   572,000    9.44%
Ruth C. Bentley(6)   572,000    9.44%
Barbara M. Fisk(7)   544,609    9.04%
Miguel A. Loya(8)   509,039    8.39%
Tacey Viegas(9)   410,000    6.47%
Steve Ledger(10)   350,000    5.73%
John Berton Chenault(11)   311,638    5.20%
Directors and Named Executive Officers:          
Randall Moreadith(4)   629,550    9.51%
Michael D. Bentley(5)   572,000    9.44%
Barbara M. Fisk(7)   544,609    9.04%
Tacey Viegas(9)   410,000    6.47%
James R. Hudson, Jr.(12)   212,000    3.54%
Steve Ledger(10)   350,000    1.90%
J. Milton Harris(13)   72,000    1.19%
Gregory Bailey        
All executive officers and directors as a group (8 persons)(14)   2,790,159    38.42%

 

389

 

 

Represents beneficial ownership of less than 1%.

 

(1)The number of shares assumes a 1 to 1 conversion of Serina preferred stock to Serina common stock. The actual number of shares of Serina common stock that a holder of Serina preferred stock may receive upon conversion of a share of Serina preferred stock may be different.

 

(2)Consists of (i) 750,000 shares of Serina common stock, (ii) 100,634 shares of Serina common stock issuable upon the conversion of 100,634 shares of Serina Series A-2 preferred stock, (iii) 76,924 shares of Serina common stock issuable upon the conversion of 76,924 shares of Serina Series A-5 preferred stock and (iv) 76,924 shares of Serina common stock subject to warrants that may be exercised within 60 days of January 3, 2024. Certain immediate family members of J. Milton Harris are limited partners or affiliates of the limited partners and the general partner of Puffinus, L.P., but such immediate family members do not share a household with Dr. Harris and Dr. Harris does not control the actions of Puffinus, L.P.

 

(3) Consists of (i) 98,000 shares of Serina common stock issuable upon the conversion of 98,000 shares of Serina Series A preferred stock, (ii) 251,571 shares of Serina common stock issuable upon the conversion of 251,571 shares of Serina Series A-2 preferred stock, (iii) 80,000 shares of Serina common stock issuable upon the conversion of 80,000 shares of Serina Series A-3 preferred stock, (iv) 153,847 shares of Serina common stock issuable upon the conversion of 153,847 shares of Serina Series A-4 preferred stock, (v) 136,968 shares of Serina common stock issuable upon the conversion of 136,968 shares of Serina Series A-5 preferred stock and (iv) 136,968 shares of Serina common stock subject to warrants that may be exercised within 60 days of January 3, 2024.

 

(4) Consists of 629,550 shares of Serina common stock subject to options that are exercisable within 60 days of January 3, 2024.

 

(5) Consists of (i) 250,000 shares of Serina common stock, (ii) 72,000 shares of Serina common stock subject to options that are exercisable within 60 days of January 3, 2024 and (iii) 250,000 shares of Serina common stock held by Ruth C. Bentley. Ruth C. Bentley is the spouse and member of Michael D. Bentley’s household.

 

(6) Consists of (i) 250,000 shares of Serina common stock, (ii) 250,000 shares of Serina common stock held by Michael D. Bentley and (iii) 72,000 shares of Serina common stock subject to options that are exercisable within 60 days of January 3, 2024 by Michael D. Bentley. Michael D. Bentley is the spouse and member of Ruth C. Bentley’s household.

 

(7) Consists of (i) 75,000 shares of Serina common stock issuable upon the conversion of 75,000 shares of Serina Series A-1 preferred stock, (ii) 75,476 shares of Serina common stock issuable upon the conversion of 75,476 shares of Serina Series A-2 preferred stock, (iii) 40,000 shares of Serina common stock issuable upon the conversion of 40,000 shares of Serina Series A-3 preferred stock, (iii) 11,539 shares of Serina common stock issuable upon the conversion of 11,539 shares of Serina Series A-5 preferred stock held by the Timothy Fisk 2012 GST-Exempt Family Trust, (iv) 11,539 shares of Serina common stock subject to warrants held by the Timothy Fisk 2012 GST-Exempt Family Trust that may be exercised within 60 days of January 3, 2024, (v) 4,000 shares of Serina common stock issuable upon the conversion of 4,000 shares of Serina Series A-3 preferred stock held by the Emily M. Robertson GST Trust, (vi) 50,317 shares of Serina common stock issuable upon the conversion of 50,317 shares of Serina Series A-2 preferred stock held by Orion Strategic Investments II, L.P., (vii) 40,000 shares of Serina common stock issuable upon the conversion of 40,000 shares of Serina Series A-3 preferred stock held by Orion Strategic Investments II, L.P., (viii) 100,000 shares of Serina common stock issuable upon the conversion of 100,000 shares of Serina Series A preferred stock held by Stoneway Enterprises, LLC, (ix) 90,584 shares of Serina common stock issuable upon the conversion of 90,584 shares of Serina Series A-2 preferred stock held by Stoneway Enterprises, LLC, (x) 23,077 shares of Serina common stock issuable upon the conversion of 23,077 shares of Serina Series A-5 preferred stock held by Stoneway Enterprises, LLC and (xi) 23,077 shares of Serina common stock subject to warrants held by Stoneway Enterprises, LLC that may be exercised within 60 days of January 3, 2024. Barbara M. Fisk is (a) the trustee of the Timothy Fisk 2012 GST-Exempt Family Trust and the Emily M. Robertson GST Trust and may be deemed to beneficially own the shares held by the Timothy Fisk 2012 GST-Exempt Family Trust and the Emily M. Robertson GST Trust, (b) a manager of Stoneway Enterprises, LLC and may be deemed to beneficially own the shares held by Stoneway Enterprises, LLC and (c) an authorized representative of Orion Strategic Investments II, L.P. and may be deemed to beneficially own the shares held by Orion Strategic Investments II, L.P.

 

390

 

 

(8) Consists of (i) 355,191 shares of Serina common stock issuable upon the conversion of 355,191 shares of Serina Series A-4 preferred stock, (ii) 76,924 shares of Serina common stock issuable upon the conversion of 76,924 shares of Serina Series A-5 preferred stock and (iii) 76,924 shares of Serina common stock subject to warrants that may be exercised within 60 days of January 3, 2024.

 

(9) Consists of (i) 60,000 shares of Serina common stock and (ii) 350,000 shares of Serina common stock subject to options that are exercisable within 60 days of January 3, 2024.

 

(10) Consists of (i) 116,666 shares of Serina common stock subject to options that are exercisable within 60 days of January 3, 2024 and (ii) 233,334 shares of Serina company common stock held by Ki Partners. Steve Ledger is a manager of Ki Partners and may be deemed to beneficially own the shares held by Ki Partners.

 

(11) Consists of (i) 250,000 shares of Serina common stock held by the J. Milton Harris Family Trust dated 12/19/12 and (ii) 61,638 shares of Serina common stock issuable upon the conversion of 61,638 shares of Serina Series A-2 preferred stock held by the J. Milton Harris Family Trust dated 12/19/12. John Berton Harris is the trustee of the Harris Family Trust dated 12/19/12 and may be deemed to beneficially own the shares held by the Harris Family Trust dated 12/19/12.

 

(12) Consists of (i) 200,000 shares of Serina common stock issuable upon the conversion of 200,000 shares of Serina Series A preferred stock and (ii) 12,000 shares of Serina common stock issuable upon the conversion of 12,000 shares of Serina Series A-3 preferred stock.

 

 

(13) Consists of 72,000 shares of Serina common stock subject to options that are exercisable within 60 days of January 3, 2024.

 

(14) Consists of (i) 1,515,327 shares of Serina common stock held by, or issuable upon conversion to, Serina’s executive officers and directors and (ii) 1,274,832 shares of Serina common stock subject to options or warrants that are exercisable within 60 days of January 3, 2024.

 

391

 

 

PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY

  

The following table and the related notes present certain information with respect to the beneficial ownership of the common stock of the combined company upon consummation of the Merger, assuming the closing of the Merger occurred on January 3, 2024, by: (i) each person or group of affiliated persons known by Serina or AgeX to become the beneficial owner of more than 5% of the common stock of the combined company upon the closing of the Merger; (ii) each of the directors of the combined company; (iii) each of the executive officers of the combined company; and (iv) all executive officers and directors of the combined company as a group.

 

Unless otherwise indicated in the footnotes to this table, Serina and AgeX believe that each of the persons named in this table have sole voting and investment power with respect to the shares indicated as beneficially owned.

 

The following table assumes (i) no exercise of outstanding options to purchase shares of AgeX common stock or Serina common stock prior to the closing of the Merger, (ii) an exchange ratio of 0.84132858, (iii) that the closing of the Merger occurred on January 3, 2024, (iv) that immediately prior to the Merger, AgeX will have 2,512,893 shares of its common stock outstanding and Serina will have 8,960,446 shares of its common stock outstanding, (v) a reverse stock split of 1-for-35, to be implemented immediately prior to the closing of the Merger, and (vi) the shares of AgeX common stock being reduced to 2,512,893 shares as a result of the reverse stock split and the 8,960,446 shares of Serina common stock being exchanged for a total of 7,538,679 shares of AgeX common stock as a result of the exchange ratio and the reverse stock split. Based on these assumptions, there will be a total of 10,051,572 shares of combined company common stock outstanding upon the closing of the Merger, after giving effect to the reverse stock split.

 

Shares of the combined company’s common stock that may be acquired by an individual or group within 60 days of January 3, 2024, pursuant to the exercise of options or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of the combined company’s common stock of any other person shown in the table. Unless otherwise indicated, the address for the following stockholders is: c/o AgeX Therapeutics, Inc. 1101 Marina Village Parkway, Suite 201, Alameda, California 94501.

 

   Beneficial Ownership
as of January 3, 2024
 
Beneficial Owner  Number of
Shares
   Percent of
Total
 
5% and Greater Stockholders:          
Juvenescence Limited and certain affiliates(1)   3,037,600    27.14%
Helen W. McMillan(2)   972,806    9.54%
Puffinus L.P.(3)   931,245    9.19%
Barbara M. Fisk(4)   622,589    6.17%
Miguel Loya(5)   551,457    5.44%
Randall Moreadith(6)   529,658    5.01%
Directors and Named Executive Officers(7):          
Steve Ledger(8)   294,465    2.90 
Andrea E. Park(9)   9,599    * 
Randall Moreadith(6)   529,658    5.01%
Tacey Viegas(10)   344,945    3.33%
Gregory H. Bailey(11)   4,714     
J. Milton Harris(12)   60,576    * 
Remy Gross(13)   100,959    * 
Richard Marshall   --    -- 
All executive officers and directors as a group (8 persons)(14)   1,344,917    12.06%

 

  * Represents beneficial ownership of less than 1%.

 

392

 

 

(1) Consists of (i) 1,898,500 shares of combined company common stock held by JuvVentures (UK) Limited (JuvVentures), a wholly-owned subsidiary of Juvenescence Limited and (ii) 1,139,100 shares of combined company common stock subject to warrants held by JuvVentures that may be exercised within 60 days of January 3, 2024 as the assumed closing date of the Merger. Dr. Gregory Bailey is the executive chairman of Juvenescence Limited and may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to direct the disposition of, the shares held by JuvVentures. This response is not and shall not be construed as an admission that Dr. Bailey is the beneficial owner of any securities of AgeX other than the securities actually owned by Dr. Bailey (if any). The address of Juvenescence is 1st Floor, Viking House, St Paul’s Square, Ramsey, Isle of Man, British Isles, IM8 1GB. The foregoing information is based solely on a Schedule 13D/A filed with the SEC on January 9, 2024, which provides information only as of January 3, 2024 and consequently, Juvenescence’s beneficial ownership may have changed since that date.
(2) Consists of (i) 824,425 shares of combined company common stock and (ii) 148,381 shares of combined company common stock subject to warrants that may be exercised within 60 days of January 3, 2024 as the assumed closing date of the Merger.
(3) Consists of (i) 847,912 shares of combined company common stock and (ii) 83,333 shares of combined company common stock subject to warrants that may be exercised within 60 days of January 3, 2024 as the assumed closing date of the Merger. Certain immediate family members of J. Milton Harris are limited partners or affiliates of the limited partners and the general partner of Puffinus, L.P., but such immediate family members do not share a household with Dr. Harris and Dr. Harris does not control the actions of Puffinus, L.P.
(4) Consists of (i) 223,882 shares of combined company common stock, (ii) 12,500 shares of combined company common stock held by the Timothy Fisk 2012 GST-Exempt Family Trust, (iii) 12,500 shares of combined company common stock subject to warrants held by the Timothy Fisk 2012 GST-Exempt Family Trust that may be exercised within 60 days of January 3, 2024 as the assumed closing date of the Merger, (iv) 4,167 shares of combined company common held by the Emily M. Robertson GST Trust, (v) 109,031 shares of combined company common stock held by Orion Strategic Investments II, L.P., (vi) 235,510 shares of combined company common held by Stoneway Enterprises, LLC and (vii) 25,000 shares of combined company common stock subject to warrants held by Stoneway Enterprises, LLC that may be exercised within 60 days of January 3, 2024 as the assumed closing date of the Merger. Barbara M. Fisk is (a) the trustee of the Timothy Fisk 2012 GST-Exempt Family Trust and the Emily M. Robertson GST Trust and may be deemed to beneficially own the shares held by the Timothy Fisk 2012 GST-Exempt Family Trust and the Emily M. Robertson GST Trust, (b) a manager of Stoneway Enterprises, LLC and may be deemed to beneficially own the shares held by Stoneway Enterprises, LLC and (c) an authorized representative of Orion Strategic Investments II, L.P. and may be deemed to beneficially own the shares held by Orion Strategic Investments II, L.P.
(5) Consists of (i) 468,124 shares of combined company common stock and (ii) 83,333 shares of combined company common stock subject to warrants that may be exercised within 60 days of January 3, 2024 as the assumed closing date of the Merger.
(6) Consists of 529,658 shares of combined company common stock subject to options that are exercisable within 60 days of January 3, 2024 as the assumed closing date of the Merger.
(7) The directors of the combined company upon consummation of the Merger have not been determined. Such individuals will be included in this table in a subsequent filing prior to the time this Registration Statement is declared effective under the Securities Act.
(8) Consists of (i) 98,154 shares of combined company common stock subject to options that are exercisable within 60 days of January 3, 2024 as the assumed closing date of the Merger and (ii) 196,311 shares of combined company common stock held by Ki Partners. Steve Ledger is a manager of Ki Partners and may be deemed to beneficially own the shares held by Ki Partners.
(9) Includes 9,589 shares of combined company common stock that may be acquired upon the exercise of certain stock options that are presently exercisable or that will become exercisable within 60 days of January 3, 2024 as the assumed closing date of the Merger.
(10) Consists of (i) 50,480 shares of combined company common stock and (ii) 294,465 shares of combined company common stock subject to options that are exercisable within 60 days of January 3, 2024 as the assumed closing date of the Merger.
(11) Consists entirely of shares of combined company common stock subject to options that are exercisable within 60 days of January 3, 2024 as the assumed closing date of the Merger.
(12) Consists of 60,576 shares of combined company common stock subject to options that are exercisable within 60 days of January 3, 2024 as the assumed closing date of the Merger.
(13) Consists of 529,658 shares of combined company common stock subject to options that are exercisable within 60 days of January 3, 2024 as the assumed closing date of the Merger.
(14) Consists of (i) 246,801 shares of combined company common stock held by the combined company’s executive officers and directors and (ii) 1,098,116 shares of combined company common stock subject to options or warrants that are exercisable within 60 days of January 3, 2024 as the assumed closing date of the Merger.

 

393

 

 

USE OF PROCEEDS

 

Upon any cash exercise of the post-merger warrants or the incentive warrants by any holders thereof, the combined company will receive cash proceeds per warrant equal to the exercise price of the post-merger warrants or the incentive warrants. Each post-merger warrant will have an exercise price equal to 13.20 per warrant (on a post-reverse stock split basis). Each incentive warrant will have an exercise price equal to $18.00 per warrant (on a post-reverse stock split basis). The combined company intends to use such proceeds, based on Serina’s current plan, primarily as follows:

 

approximately $8 million to advance Serina’s lead product candidate SER 252 from IND-enabling preclinical studies through a Phase I clinical trial; and

 

approximately $2.5 million to advance Serina’s POZ-LNP internal research and development programs.

 

The combined company intends to use the balance of such proceeds as working capital to fund its operations through calendar year 2025 based on Serina’s current plan.

 

394

 

 

DETERMINATION OF OFFERING PRICE

 

The prices at which the shares of common stock of the combined company covered by the registration statement on Form S-1 of which this proxy statement/prospectus/information statement forms a part may actually be sold will be determined by the prevailing public market price for shares of the combined company’s common stock.

 

395

 

 

LEGAL MATTERS

 

Certain legal matters, including the legality of the securities offered, will be passed upon for us by Gibson, Dunn & Crutcher LLP, San Francisco, California. Additional legal matters may be passed upon for AgeX or the combined company or any underwriters, dealers or agents, by counsel that will be named in the applicable prospectus supplement.

 

396

 

 

EXPERTS

 

AgeX

 

The consolidated financial statements of AgeX Therapeutics, Inc. (AgeX) as of December 31, 2022 and 2021 and for the years then ended included in this proxy statement/prospectus/information statement have been audited by WithumSmith+Brown, PC, an independent registered public accounting firm, as stated in their report. Such consolidated financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing. This report on the consolidated financial statements contains an explanatory paragraph regarding AgeX’s ability to continue as a going concern.

 

Serina

 

The consolidated financial statements of Serina Therapeutics, Inc. (Serina) as of and for the years ended December 31, 2022 and 2021 included in this proxy statement/prospectus/information statement have been audited by Frazier & Deeter, LLC, an independent registered public accounting firm, as stated in their report. Such consolidated financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing. This report on the consolidated financial statements contains an explanatory paragraph regarding Serina’s ability to continue as a going concern and a restatement of Serina’s December 31, 2022 and 2021 consolidated financial statements.

 

397

 

 

WHERE YOU CAN FIND MORE INFORMATION

 

AgeX has filed with the SEC a registration statement on Form S-4/S-1 (including exhibits, schedules, and amendments) under the Securities Act with respect to the securities offered by this proxy statement/prospectus/information statement. This proxy statement/prospectus/information statement is a part of the registration statement and constitutes a prospectus of AgeX, as well as a proxy statement of AgeX for the AgeX special meeting and an information statement for the purpose of Serina for its written consent.

 

This proxy statement/prospectus/information statement does not contain all the information set forth in the registration statement. For further information about AgeX and the securities to be registered in connection with the Merger, you should refer to the registration statement. Statements contained in this proxy statement/prospectus/information statement relating to the contents of any contract, agreement or other document are not necessarily complete and are qualified in all respects by the complete text of the applicable contract, agreement or other document, a copy of which has been filed as an exhibit to the registration statement.

 

AgeX is subject to the reporting and information requirements of the Exchange Act and, as a result, files, or will file, periodic reports, proxy statements and other information with the SEC. The SEC maintains an website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The SEC’s website can be found at http://www.sec.gov. AgeX also maintains a website at https://www.agexinc.com/ and makes available free of charge through this website AgeX’s annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act. AgeX makes these reports available through AgeX’s website as soon as reasonably practicable after AgeX electronically files such reports with, or furnishes such reports to, the SEC. The information contained on, or that can be accessed through, AgeX’s website is not a part of this proxy statement/prospectus/information statement.

 

This proxy statement/prospectus/information statement does not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered by this proxy statement/prospectus/information statement, or the solicitation of a proxy, in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer, solicitation of an offer or proxy solicitation in such jurisdiction. Neither the delivery of this proxy statement/prospectus/information statement nor any distribution of securities pursuant to this proxy statement/prospectus/information statement shall, under any circumstances, create any implication that there has been no change in the information set forth or incorporated into this proxy statement/prospectus/information statement by reference or in AgeX’s affairs since the date of this proxy statement/prospectus/information statement.

 

AgeX has supplied all information contained in this proxy statement/prospectus/information statement relating to AgeX and its business, and Serina has supplied all information contained in this proxy statement/prospectus/information statement relating to Serina and its business.

 

398

 

 

If you would like to request documents from AgeX or Serina, please send a request in writing or by telephone to either AgeX or Serina at the following addresses:

 

AgeX Therapeutics, Inc.
1101 Marina Village Parkway, Suite 201
Alameda, California 94501
Attention: Andrea Park
Phone Number: (510) 671-8370
Email: information@agexinc.com
Subject Line: Request for Proxy Materials
Serina Therapeutics, Inc.
601 Genome Way, Suite 2001
Huntsville, Alabama 35806
(256) 327-9630
investor.relations@serinatherapeutics.com

 

Householding of Proxy Materials

 

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.

 

A number of brokers with account holders who are AgeX stockholders will be householding AgeX’s proxy materials. A single copy of this proxy statement/prospectus/information statement will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once a stockholder has received notice from its broker that they will be householding communications to such stockholder’s address, householding will continue until such stockholder is notified otherwise or until the stockholder revokes his or her consent. If, at any time, a stockholder no longer wishes to participate in householding and would prefer to receive a separate copy of this proxy statement/prospectus/information statement and any annual disclosure documents, it may notify its broker, or direct its written request to AgeX Therapeutics, Inc. at AgeX’s principal executive offices at 1101 Marina Village Parkway, Suite 201, Alameda, California 94501, Attention: Investor Relations. Stockholders who currently receive multiple copies of the proxy statement/prospectus/information statement and annual disclosure documents at their address and would like to request householding of their communications should contact their broker.

 

399

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

 

On August 29, 2023, AgeX Therapeutics, Inc. (AgeX) entered into the Agreement and Plan of Merger and Reorganization (as may be amended from time to time, the Merger Agreement) with Serina Therapeutics Inc. (Serina) and Canaria Transaction Corporation (Merger Sub), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the Merger). AgeX following the Merger is referred to herein as the “combined company.”

 

At the effective time of the Merger (the Effective Time): (i) each outstanding share of common stock, $0.01 par value per share, of Serina (Serina common stock) (after giving effect to the conversion of each share of preferred stock of Serina into Serina common stock (the Serina preferred stock conversion) and including all such shares that are so converted other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares) will be automatically converted solely into the right to receive a number of shares of common stock of AgeX, $0.0001 par value per share (AgeX common stock) equal to the exchange ratio (the exchange ratio) determined in accordance with the Merger Agreement; (ii) each outstanding and unexercised option to purchase shares of Serina common stock (Serina option) immediately prior to the Effective Time under the Serina Therapeutics, Inc. 2017 Stock Option Plan, as amended (the Serina Plan), will be converted into and become an option to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the option and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume the Serina Plan and each Serina option in accordance with the terms of the Serina Plan and the terms of the Serina option; and (iii) each outstanding and unexercised warrant to purchase shares of Serina common stock (Serina warrant) immediately prior to the Effective Time, if any, will be converted into and become a warrant to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the warrant and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume each Serina warrant in accordance with its terms.

 

Through the application of the exchange ratio, immediately following closing of the Merger, the stockholders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the aggregate number of outstanding shares of AgeX common stock immediately after the Effective Time, and the stockholders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the aggregate number of outstanding shares of AgeX common stock immediately after the Effective Time, in each case on a pro forma fully-diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price of AgeX common stock being equal to or greater than $12.00 per share (on a post-reverse stock split basis), giving effect to the reverse stock split and the AgeX preferred stock conversion (as defined elsewhere in the proxy statement/prospectus/information statement) and excluding the impact of any post-merger warrant, incentive warrant or the issuance of any share of AgeX common stock upon exercise of any post-merger warrant or incentive warrant.

 

AgeX will ask its stockholders to approve an amendment to its certificate of incorporation to effect a reverse stock split, which approval is also necessary to complete the transactions contemplated by the Merger Agreement. Upon the effectiveness of the amendment to its certificate of incorporation effecting the reverse stock split, the outstanding shares of AgeX common stock will be combined into a lesser number of shares resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the Effective Time, unless otherwise mutually agreed upon by the respective AgeX and Serina boards of directors. As the proposed reverse stock split ratio of AgeX common stock is not definitive and is expected to occur following receipt of stockholder approval and prior to the consummation of the Merger, the unaudited pro forma condensed combined financial information does not reflect the reverse stock split, unless otherwise stated.

 

400

 

 

Following the reverse stock split and the AgeX preferred stock conversion and prior to the consummation of the Merger (the Closing), AgeX will issue to each holder of AgeX common stock as of the close of business on a business day following the reverse stock split and the AgeX preferred stock conversion and prior to the closing of the Merger (the Warrant Dividend Record Date) three warrants (each, a post-merger warrant) for each five shares of AgeX common stock issued and outstanding held by such holder as of the Warrant Dividend Record Date. Each post-merger warrant will be exercisable at an exercise price equal to $13.20 per warrant (such exercise price reflecting the planned reverse stock split) for (i) one share of AgeX common stock and (ii) one warrant (each, an incentive warrant). Each incentive warrant will be exercisable at an exercise price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split) for one share of AgeX common stock. Each post-merger warrant will expire on July 31, 2025, and each incentive warrant will expire on the four-year anniversary of the Closing. Each post-merger warrant and incentive warrant will be issued pursuant to the terms of a warrant agreement to be entered into by AgeX and a warrant agent in connection with the closing of the Merger.

 

The unaudited pro forma condensed combined financial information presents the combination of the financial information of AgeX and Serina to give effect to the Merger, which has been accounted for as a reverse recapitalization under accounting principles generally accepted in the United States of America (GAAP). Serina is considered the accounting acquirer for financial reporting purposes. This determination is primarily based on the expectation that, immediately following the Merger:

 

  The pre-Merger stockholders of Serina are expected to own approximately 75% of the combined company and to hold the majority of voting rights in the combined company;
  The pre-Merger stockholders of Serina will have the right to appoint or approve a majority of the directors on the combined company’s board of directors;
  Certain current members of the Serina executive management team are expected to assume key leadership roles of the combined company; and
  The combined company intends to focus primarily on developing Serina’s product candidates.

 

The transaction is expected to be accounted for as a reverse recapitalization of AgeX by Serina similar to as if Serina had issued equity for the net assets of AgeX. As a result of Serina being treated as the accounting acquirer, Serina’s assets and liabilities will be recorded at their pre-Merger carrying amounts with no goodwill or other intangible assets recorded. AgeX’s assets and liabilities will be measured and recognized at their fair values as of the Effective Time of the Merger, which are expected to approximate the carrying value of the acquired cash and other non-operating net assets. Any difference between the consideration transferred and the fair value of the net assets of AgeX following determination of the actual purchase consideration for AgeX will be reflected as an adjustment to additional paid-in capital. Upon consummation of the Merger, the historical financial statements of Serina will become the historical consolidated financial statements of the combined company.

 

The unaudited pro forma condensed combined balance sheet assumes that the Merger took place on September 30, 2023, and combines the historical balance sheets of AgeX and Serina as of such date. The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2023 and the year ended December 31, 2022 assumes that the Merger took place as of January 1, 2022 and combines the historical results of AgeX and Serina for those periods then ended. The unaudited pro forma condensed combined financial information was prepared pursuant to the rules and regulations of Article 11 of SEC Regulation S-X, as amended.

 

401

 

 

The unaudited pro forma condensed combined financial information is provided for illustrative purposes only, does not necessarily reflect what the actual consolidated results of operations and financial position would have been had the acquisition occurred on the dates assumed and may not be useful in predicting the future consolidated results of operations or financial position.

 

The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary accounting and estimates and the final accounting conclusions and amounts may occur as a result of changes in initial assumptions in the determination of the accounting acquirer and related accounting, and the amount of cash used in AgeX’s operations, and other changes in AgeX’s assets and liabilities, which are expected to be completed after the closing of the Merger, may occur and these differences could have a material impact on the unaudited pro forma condensed combined financial information and the combined company’s future results of operations and financial position.

 

The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited pro forma condensed combined financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information.

 

The unaudited pro forma condensed combined financial information is derived from:

 

  the historical audited consolidated financial statements of AgeX for the years ended December 31, 2022, and 2021 included elsewhere in this proxy statement/prospectus/information statement;
  the historical unaudited condensed consolidated financial information of AgeX as of and for the nine months ended September 30, 2023 included elsewhere in this proxy statement/prospectus/information statement;
  the historical audited financial statements of Serina for the years ended December 31, 2022, and 2021 included elsewhere in this this proxy statement/prospectus/information statement; and
  the historical unaudited condensed financial statements of Serina as of and for the nine months ended September 30, 2023, included elsewhere in this this proxy statement/prospectus/information statement.

 

Such unaudited pro forma condensed financial information has been prepared on a basis consistent with the financial statements of AgeX. This information should be read together with the financial statements of AgeX and Serina and related notes thereto, the discussion of the financial condition and results of operations of AgeX and Serina in the section entitled “AgeX Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Serina Management’s Discussion and Analysis of Financial Condition and Results of Operations,” respectively; and other information included elsewhere in this this proxy statement/prospectus/information statement.

 

The unaudited pro forma condensed combined financial information has been prepared in a manner consistent with the accounting policies adopted by Serina. Accounting rules require evaluation of certain assumptions, estimates, or determination of financial statement classifications. The accounting policies of AgeX may materially vary from those of Serina. During preparation of the unaudited pro forma condensed combined financial information, management has performed a preliminary analysis and is not aware of any material differences, and accordingly, this unaudited pro forma condensed combined financial information assumes no material differences in accounting policies. Following the completion of the Merger, management will perform a more detailed review of the accounting policies of AgeX and Serina in order to determine if differences in accounting policies require adjustment or reclassification of AgeX’s results of operations or reclassification of assets or liabilities to conform to Serina’s accounting policies and classifications. As a result of that review, differences could be identified between the accounting policies of the two companies that, when conformed, could have a material impact on the future combined financial statements if the transaction is consummated.

 

402

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

AS OF SEPTEMBER 30, 2023

(in thousands, except share and per share data)

 

   As Reported   Pre-Transaction
Accounting
      Adjusted   Transaction
Accounting
      Pro Forma
Combined
 
   AgeX   Serina   Adjustments   Notes  AgeX   Serina   Adjustments   Notes  Total 
ASSETS                                  
Current Assets:                                         
Cash and cash equivalents  $397   $7,581   $4,178   B  $4,575   $7,581   $(3,141)  E  $8,435 
                                (885)  F     
Accounts and grants receivable, net   67    -    -       67    -    -       67 
Related party receivables, net   4    -    -       4    -    -       4 
Prepaid expenses and other current assets   673    15    -       673    15    -       688 
Total current assets   1,141    7,596            5,319    7,596    (3,721)      9,194 
                                          
Restricted cash   50    -    -       50    -    -       50 
Property and equipment, net   -    442    -       -    442    -       442 
Right of use assets - operating leases   -    635    -       -    635    -       635 
Right of use assets - finance leases   -    116    -       -    116    -       116 
Intangible assets, net   640    -    -       640    -    -       640 
Convertible note receivable   10,379    -    -       10,379    -    (10,379)  G   - 
TOTAL ASSETS  $12,210   $8,789           $16,388   $8,789   $(14,100)     $11,077 
                                          
LIABILITIES AND STOCKHOLDERS’ DEFICIT                                         
Current Liabilities:                                         
Accounts payable and accrued liabilities  $1,671   $1,066    -      $1,671   $1,066   $(379)  G  $2,358 
Loans due to Juvenescence, net of debt issuance costs, current portion   1,526    -    4,178   B   5,704    -    -       5,704 
Contract liability   -    86    -       -    86    -       86 
Insurance premium liability and other current liabilities   7    -    -       7    -    -       7 
Current portion of operating lease liabilities   -    184    -       -    184    -       184 
Current portion of finance lease liabilities   -    48    -       -    48    -       48 
Convertible promissory notes   -    3,862    6,138   C   -    10,000    (10,000)  G   - 
Total current liabilities   3,204    5,246            7,382    11,384    (10,379)      8,387 
                                          
Warrant liability   -    18    -       -    18    22,320   H   22,338 
Operating lease liabilities, net of current portion   -    463    -       -    463    -       463 
Finance lease liabilities, net of current portion   -    1    -       -    1    -       1 
Loans due to Juvenescence, net of debt issuance costs, net of current portion   693    -    -       693    -    -       693 
Total liabilities   3,897    5,728            8,075    11,866    11,941       31,882 
                                          
Redeemable convertible preferred stock, Serina, $0.01 par value, 10,000,000 shares authorized; and 3,520,128 shares issued and outstanding   -    36,404    10,277   D   -    46,681    (46,681)  K   - 
Series A preferred stock, AgeX, no par value, stated value $100 per share, 211,600 shares issued and outstanding   21,135    -    (21,135)  A   -    -    -       - 
Series B preferred stock, AgeX, no par value, stated value $100 per share, 148,400 shares issued and outstanding   14,823    -    (14,823)  A   -    -    -       - 
                                          
Stockholders’ Equity (Deficit):                                         
Common stock, AgeX, $0.0001 par value, 200,000,000 shares authorized; and 37,951,261 shares issued and outstanding   4    -    5   A   9    -    (9)  I   - 
Common stock, Serina, $0.01 par value, 15,000,000 shares authorized; and 2,144,800 shares issued and outstanding   -    25    -       -    25    -       25 
Additional paid-in capital   100,017    858    35,953   A   135,970    858    (135,970)  I   33,532 
                                8,313   J     
                                (22,320)  H     
                                46,681   K     
Accumulated deficit   (127,557)   (34,226)   (6,138)  C   (127,557)   (50,641)   127,557   I   (54,362)
              (10,277)  D             (3,141)  E     
                                (580)  F     
Total pro forma combined stockholders’ equity (deficit)   (27,536)   (33,343)           8,422    (49,758)   20,531       (20,805)
Noncontrolling interest   (109)   -    -       (109)   -    109   I   - 
Total stockholders’ equity (deficit)   (27,645)   (33,343)           8,313    (49,758)   20,640       (20,805)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)  $12,210   $8,789           $16,388   $8,789   $(14,100)     $11,077 

 

The accompanying notes are an integral part of this unaudited pro forma condensed combined financial information.

 

403

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

NINE MONTHS ENDED SEPTEMBER 30, 2023

(in thousands, except share and per share data)

 

   As Reported   Pre-Transaction
Accounting
      Adjusted   Transaction
Accounting
      Pro Forma
Combined
 
   AgeX   Serina   Adjustments   Notes  AgeX   Serina   Adjustments   Notes  Total 
REVENUES                                
Contract revenues  $-   $-   $-      $-   $-   $-      $- 
Grant revenues   21    67    -       21    67    -       88 
Other revenues   65    -    -       65    -    -       65 
Total revenues   86    67            86    67    -       153 
                                          
Cost of sales   39    -    -       39    -    -       39 
                                          
Gross profit   47    67            47    67    -       114 
                                          
OPERATING EXPENSES                                         
Research and development expenses   552    1,480    -       552    1,480    -       2,032 
General and administrative expenses   5,895    1,955    -       5,895    1,955    -       7,850 
Total operating expenses   6,447    3,435            6,447    3,435    -       9,882 
                                          
Loss from operations   (6,400)   (3,368)           (6,400)   (3,368)   -       (9,768)
                                          
OTHER EXPENSE, NET                                         
Interest income (expense), net   (4,928)   (188)   -       (4,928)   (188)   379   EE   (5,116)
                                (379)  FF     
Change in fair value of warrants   (35)   1,059    -       (35)   1,059    -       1,024 
Fair value inception adjustment on convertible promissory notes   -    2,240    (2,240)  BB   -    -    -       - 
Change in fair value of convertible promissory notes   -    4,477    (579)  AA   -    -    -       - 
              (3,898)  BB                       
Other income, net   10    -    -       10    -    -       10 
Total other expense, net   (4,953)   7,588            (4,953)   871    -       (4,082)
                                          
NET INCOME (LOSS)   (11,353)   4,220            (11,353)   (2,497)   -       (13,850)
                                          
Net loss attributable to noncontrolling interest   6    -    -       6    -    -       6 
                                          
NET INCOME (LOSS) ATTRIBUTABLE TO COMBINED COMPANY  $(11,347)  $4,220           $(11,347)  $(2,497)  $-      $(13,844)
                                          
NET INCOME (LOSS) PER COMMON SHARE                                         
Basic  $(0.30)  $1.89                             $(0.04)
Diluted  $(0.30)  $0.56                             $(0.04)
                                          
Weighted average number of common shares outstanding                                         
Basic   37,950,732    2,228,026                          GG   351,788,608 
Diluted   37,950,732    7,473,149                          GG   351,788,608 

 

The accompanying notes are an integral part of this unaudited pro forma condensed combined financial information.

 

404

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

YEAR ENDED DECEMBER 31, 2022

(in thousands, except share and per share data)

 

   As Reported   Pre-Transaction
Accounting
      Adjusted   Transaction
Accounting
      Pro Forma
Combined
 
   AgeX   Serina   Adjustments   Notes  AgeX   Serina   Adjustments   Notes  Total 
REVENUES                                
Contract revenues  $-   $500   $-      $-   $500   $-      $500 
Grant revenues   -    92    -       -    92    -       92 
Other revenues   34    -    -       34    -    -       34 
Total revenues   34    592            34    592    -       626 
                                          
Cost of sales   13    -    -       13    -    -       13 
                                          
Gross profit   21    592            21    592    -       613 
                                          
OPERATING EXPENSES                                         
Research and development expenses   1,025    1,573    -       1,025    1,573    -       2,598 
General and administrative expenses   5,971    1,289    -       5,971    1,289    3,141   CC   10,981 
                                580   DD     
Total operating expenses   6,996    2,862            6,996    2,862    3,721       13,579 
                                          
Loss from operations   (6,975)   (2,270)           (6,975)   (2,270)   (3,721)      (12,966)
                                          
OTHER EXPENSE, NET                                         
Interest income (expense), net   (3,335)   (14)   -       (3,335)   (14)   -       (3,349)
Change in fair value of warrants   (225)   (124)   -       (225)   (124)   -       (349)
Fair value inception adjustment on convertible promissory notes   -    (179)   179   AA   -    -    -       - 
Change in fair value of convertible promissory notes   -    (88)   88   AA   -    -    -       - 
Loss on equity securities, net   -    (8)   -       -    (8)   -       (8)
Other income, net   13    1    -       13    1    -       14 
Total other expense, net   (3,547)   (412)           (3,547)   (145)   -       (3,692)
                                          
NET LOSS   (10,522)   (2,682)           (10,522)   (2,415)   (3,721)      (16,658)
                                          
Net loss attributable to noncontrolling interest   60    -    -       60    -    -       60 
                                          
NET LOSS ATTRIBUTABLE TO COMBINED COMPANY  $(10,462)  $(2,682)          $(10,462)  $(2,415)  $(3,721)     $(16,598)
                                          
NET LOSS PER COMMON SHARE                                         
Basic  $(0.28)  $(1.25)                            $(0.05)
Diluted  $(0.28)  $(1.25)                            $(0.05)
                                          
Weighted average number of common shares outstanding                                         
Basic   37,944,581    2,145,002                          GG   358,446,818 
Diluted   37,944,581    2,145,002                          GG   358,446,818 

 

The accompanying notes are an integral part of this unaudited pro forma condensed combined financial information.

 

405

 

 

NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

(in thousands, except share and per share data)

 

Note 1: Description of the Transaction

 

AgeX, Serina, and Canaria have entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX. At the Effective Time, each outstanding share of Serina common stock (other than shares held by Serina, AgeX, Merger Sub or any of their respective subsidiaries and appraisal shares) will be automatically converted solely into the right to receive a number of shares of AgeX common stock equal to the exchange ratio. The exchange ratio is currently estimated to be equal to approximately 0.83217216 shares of AgeX common stock for each share of Serina common stock, which estimated exchange ratio assumes (i) the Actual Closing Price (as defined elsewhere in this proxy statement/prospectus/information statement) of a share of AgeX common stock is equal to $12.00 per share (on a post-reverse stock split basis), (ii) the number of Company Outstanding Shares (as defined elsewhere in this proxy statement/prospectus/information statement) is equal to 9,012,558, (iii) the number of Company Merger Shares (as defined elsewhere in this proxy statement/prospectus/information statement) is equal to 7,500,000 and (iv) the implementation of the reverse stock split and the AgeX preferred stock conversion prior to the consummation of the Merger, as described in the accompanying proxy statement/prospectus/information statement. There can be no assurance that any of these assumptions will be accurate when the final exchange ratio is determined.

 

At the Effective Time, (i) each outstanding and unexercised Serina option immediately prior to the Effective Time under the Serina Plan will be converted into and become an option to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the option and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume the Serina Plan and each Serina option in accordance with the terms of the Serina Plan and the terms of the Serina option, and (ii) each outstanding and unexercised Serina warrant immediately prior to the Effective Time, if any, will be converted into and become a warrant to purchase AgeX common stock, with the number of shares of AgeX common stock subject to the warrant and exercise price being appropriately adjusted to reflect the exchange ratio, and AgeX will assume each Serina warrant in accordance with its terms.

 

Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price of AgeX common stock being equal to or greater than $12.00 per share (on a post-reverse stock split basis), giving effect to the reverse stock split and the AgeX preferred stock conversion and excluding the impact of any post-merger warrant, incentive warrant or the issuance of any share of AgeX common stock upon exercise of any post-merger warrant or incentive warrant.

 

Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the AgeX and Serina stockholders.

 

Note 2: Basis of Presentation

 

The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X, as amended by SEC Final Rule Release No. 33-10786, Amendments to Financial Disclosures About Acquired and Disposed Businesses. In accordance with Release No. 33-10786, the unaudited condensed combined pro forma statements of operations reflect transaction accounting adjustments. The historical financial information of AgeX and Serina has been adjusted in the unaudited pro forma condensed combined financial information to reflect transaction accounting adjustments related to the Merger in accordance with GAAP.

 

The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2023, and for the year ended December 31, 2022, combines the historical results of AgeX and Serina for the respective periods presented to give pro forma effect to the Merger was if such had occurred on January 1, 2022. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 combines the historical balance sheets of AgeX and Serina to give pro forma effect to the Merger as if such transactions were completed on September 30, 2023. The pro forma information does not purport to represent what the actual consolidated results of operations of the combined company would have been if the Merger had occurred on January 1, 2022, nor is it necessarily indicative of the future consolidated results of operations of the combined company. The actual results of operations of the combined company will likely differ, perhaps materially, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value not currently identified, and changes in operating results following the closing date of the Merger and the date of the pro forma financial information.

 

406

 

 

The pro forma financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated with the Merger and the related transactions. The unaudited pro forma condensed combined financial information does not reflect the income tax effects of the pro forma adjustments, as management believes income tax adjustments to not be meaningful given the combined entity incurred significant losses during the historical periods presented.

 

AgeX and Serina have incurred certain non-recurring charges and AgeX and Serina anticipate that additional non-recurring charges will be incurred in connection with the Merger, the substantial majority of which consist of transaction costs related to financial advisors, legal services and professional accounting services. Such non-recurring charges could affect the future results of the combined company in the period in which such charges are incurred; however, these costs are not expected to be incurred in any period beyond 12 months from the closing date of the Merger. Accordingly, the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022, reflect the effects of these non-recurring charges, which are not accrued for in the historical balance sheets of AgeX and Serina as of September 30, 2023.

 

Note 3: Accounting Treatment for the Merger

 

For accounting purposes, Serina is considered to be the acquiring company and the Merger is expected to be accounted for as a reverse recapitalization of AgeX by Serina. This determination is primarily based on the expectation that, immediately following the Merger:

 

  The pre-Merger stockholders of Serina are expected to own approximately 75% of the combined company and to hold the majority of voting rights in the combined company;
  The pre-Merger stockholders of Serina will have the right to appoint or approve a majority of the directors on the combined company’s board of directors;
  Certain current members of the Serina executive management team are expected to continue in key leadership roles of the combined company; and
  The combined company intends to primarily focus on developing Serina’s product candidates, and it is anticipated that the combined company will not continue to develop AgeX’s product candidates, other than potentially the development program of AgeX’s subsidiary, NeuroAirmid Therapeutics, Inc.

 

Under reverse recapitalization accounting, Serina’s assets and liabilities will be recorded at their pre-Merger carrying amounts with no goodwill or other intangible assets recorded. The assets and liabilities of AgeX will be recorded, as of the completion of the Merger, at their fair value, which are expected to approximate the carrying value of the acquired cash and other non-operating net assets. Fair value was determined in accordance with the fair value concepts defined in ASC 820, Fair Value Measurements and Disclosures (ASC 820). Fair value is defined in ASC 820 as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Fair value measurements can be highly subjective and can involve a high degree of estimation. Any difference between the final fair value of the consideration transferred and the fair value of the net assets of AgeX following determination of the actual purchase price consideration for AgeX will be reflected as an adjustment to additional paid-in capital. As a result, any change in fair value of the consideration transferred is not expected to materially affect the unaudited pro forma condensed combined financial information. The subsequent financial statements of Serina will reflect the combined operations of Serina, as the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the stockholders of the legal acquirer, AgeX, immediately prior to the Effective Time, and a recapitalization of the equity of the accounting acquirer, Serina.

 

407

 

 

For purposes of these unaudited pro forma condensed combined financial information, the estimated purchase price consideration consists of the following:

 

(in thousands, except share and per share data)    
Estimated number of shares of the combined company to be owned by AgeX’s stockholders (i)   87,951,261 
Multiplied by the estimated fair value per share of AgeX’s common stock (ii)  $0.68 
Total  $59,807 
Post-merger warrants issued to AgeX stockholders (iii)  $22,320 
Total estimated purchase price consideration  $82,127 

 

(i) Reflects the number of shares of common stock of the combined company that AgeX stockholders are expected to own as of the Effective Time pursuant to the Merger Agreement. This amount is calculated, for purposes of this unaudited pro forma condensed combined financial information, based on the shares of AgeX common stock outstanding as of September 30, 2023 and giving effect to the AgeX preferred stock conversion. On July 21, 2023, AgeX entered into the certain Exchange Agreement (the 2023 Exchange Agreement) with Juvenescence Limited (Juvenescence) pursuant to which AgeX issued to Juvenescence 211,600 shares of a newly authorized Series A preferred stock and 148,400 shares of a newly authorized Series B preferred stock in exchange for the cancellation of a total of $36,000 of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans. The cancellation of indebtedness in exchange for the preferred stock was conducted pursuant to the 2023 Exchange Agreement. The transaction closed on July 24, 2023. By completing the exchange of indebtedness for shares of Series A preferred stock and Series B preferred stock, AgeX satisfied stockholders equity requirements to under the NYSE American continued listing requirements. Accordingly, the NYSE American staff withdrew its delisting determination and a scheduled hearing of AgeX’s appeal of that determination was cancelled. The NYSE American has approved the listing of the 36,939,190 shares of AgeX common stock into which the Series A and Series B preferred stock is presently convertible.

(ii) Reflects the price per share of AgeX common stock, which is the closing bid price of AgeX common stock as reported by NYSE American on September 29, 2023. The fair value of common stock included in the estimated purchase price consideration will change based on fluctuations in the share price of AgeX common stock and the number of equity instruments held by preexisting stockholders of AgeX at the Effective Time.

 

(iii) Reflects the fair value of post-merger warrants to be issued to the holders of AgeX common stock (including Juvenescence) prior to the consummation of the Merger. The fair value of the post-merger warrants was determined using level 3 inputs utilizing the Black-Scholes-Merton option pricing model.

 

408

 

 

The actual purchase price consideration transferred for the net assets of AgeX will vary based on, among other things, the exchange ratio and the Actual Closing Price of AgeX common stock, and those differences could be material. As such, the estimated purchase price consideration reflected in these unaudited pro forma condensed combined financial statements does not purport to represent what the actual purchase price consideration will be when the Merger is completed. The actual purchase price will fluctuate until the Effective Time, and the final valuation of the purchase price consideration could differ significantly from the current estimate.

 

Note 4: Transaction Accounting Adjustments

 

Adjustments included in the column under the heading “Pre-Transaction Accounting Adjustments” are primarily related to transactions that are conditions to the closing of the Merger and occur prior to the closing of the Merger or automatically upon the Merger but are not part of the required accounting directly related to the Merger. Adjustments included in the column under the heading “Transaction Accounting Adjustments” reflect the application of the required accounting to the Merger, applying the effects of the Merger to the AgeX and Serina historical financial information.

 

Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2023

 

Pre-Transaction Accounting Adjustments

 

The pre-transaction accounting adjustments included in the unaudited pro forma condensed combined balance sheet as of September 30, 2023, are as follows:

 

A As a condition to the closing of the Merger, represents the conversion of 211,600 shares of AgeX Series A preferred stock and 148,400 shares of AgeX Series B preferred stock into 49,999,999 shares of AgeX common stock. Each share of AgeX preferred stock is convertible into a number of shares of AgeX common stock determined by dividing (x) a number equal to the number of dollars and cents comprising the subscription price, by (y) a number equal to the number of dollars and cents comprising the conversion price. The conversion price per share of AgeX Series A preferred stock and AgeX Series B preferred stock is $0.72, which was the closing price of AgeX common stock on the NYSE American on the last trading day immediately preceding the execution of the 2023 Exchange Agreement.
   
B As a condition to the closing of the Merger, AgeX must have on hand at least $500 of immediately spendable non-restricted cash net of all payables and other liabilities (including Transaction Expenses (as defined elsewhere in this proxy statement/prospectus/information statement)) immediately prior to the closing. The adjustment represents additional loans due to Juvenescence necessary for AgeX to obtain to satisfy the closing condition to the Merger. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 reflects an increase to cash with a corresponding increase in loans due to Juvenescence, net of debt issuance costs, current portion of $4,178. The additional loans due to Juvenescence would not be considered as additional payables in accordance with this closing condition.

 

409

 

 

C Upon the consummation of the Merger, the $10,000 convertible promissory note between AgeX and Serina remains outstanding and becomes an intercompany asset of AgeX and an intercompany liability of Serina. The adjustment reverses any previous fair value adjustments recorded by Serina to bring the balance of the convertible promissory note liability back to its principal amount of $10,000. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 reflects an increase to the convertible promissory note liability of $6,138 with a corresponding adjustment to accumulated deficit.
   
D Represents an adjustment of $10,277 to Serina’s redeemable convertible preferred stock to reflect the preferred stock at its max redemption value as of September 30, 2023. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 reflects an increase to redeemable convertible preferred stock with a corresponding increase in accumulated deficit.

 

Transaction Accounting Adjustments

 

The transaction accounting adjustments included in the unaudited pro forma condensed combined balance sheet as of September 30, 2023 are as follows:

 

E Represents payment of AgeX’s estimated transaction costs subsequent to September 30, 2023. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 reflects payment of these estimated costs with a corresponding increase in accumulated deficit, which excludes amounts which were previously paid and expensed of $1,659 during the nine months ended September 30, 2023. Refer to the table below for a summary of estimated transaction costs associated with the Merger:

 

(in thousands)    
Advisory, legal, and other professional fees  $1,397 
D&O insurance   1,500 
Other transaction costs and fees   244 
Total  $3,141 

 

410

 

 

F Represents payment of Serina’s estimated transaction costs subsequent to September 30, 2023. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 reflects payment of these estimated costs with a corresponding increase in accumulated deficit, which excludes amounts which were previously paid and expensed of $738 during the nine months ended September 30, 2023. Refer to the table below for a summary of estimated transaction costs associated with the Merger:

 

(in thousands)    
Advisory, legal, and other professional fees  $580 
Total  $580 

 

G Upon the consummation of the Merger, the aggregate principal amount of $10,000 pursuant to the AgeX-Serina Note between AgeX and Serina remains outstanding and becomes an intercompany asset of AgeX and an intercompany liability of Serina that is eliminated in the combined company’s consolidation. As of September 30, 2023, accrued interest on the AgeX-Serina Note was $379. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 reflects a reduction to the AgeX-Serina Note asset recorded by AgeX of $10,379 comprising the principal and accrued interest, a reduction of accrued interest recorded in accounts payable and accrued liabilities of $379 recorded by Serina, and a reduction to the AgeX-Serina Note liability of $10,000 recorded by Serina.
   
H Represents the estimated fair value of post-merger warrants to be issued to the holders of AgeX common stock (including Juvenescence) prior to the consummation of the Merger. The Black-Scholes-Merton option pricing model was utilized to determine the fair value of the warrants. A total of 39,868,484 post-merger warrants (on a pre-reverse stock split basis) are expected to be issued to Juvenescence and a total of 12,899,772 post-merger warrants (on a pre-reverse stock split basis) are expected to be issued to other AgeX stockholders. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 include an estimated adjustment of $22,320 to the post-merger warrant liability representing the fair value of the post-merger warrants issued with a corresponding change to additional paid-in capital.
   
I Represents the derecognition of the AgeX adjusted stockholders’ equity (deficit) balances. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 include an adjustment of $9 to AgeX common stock, $135,970 to additional paid-in capital, $127,557 to accumulated deficit, and $109 to noncontrolling interest.
   
J Represents an adjustment of $8,313 to account for the adjusted AgeX net assets acquired in the reverse recapitalization as of September 30, 2023.
   
K Represents an adjustment of $46,681 to account for the conversion of Serina’s adjusted redeemable convertible preferred stock into shares of common stock in the combined company.

 

411

 

 

Adjustments to the Unaudited Pro Forma Condensed Combined Statements of Operations for the Nine Months Ended September 30, 2023, and Year Ended December 31, 2022

 

Pre-Transaction Accounting Adjustments

 

The pre-transaction accounting adjustments included in the unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2023, and year ended December 31, 2022, are as follows:

 

AA Represents the derecognition of Serina’s as reported changes in the fair value at inception and through the end of the period of the convertible promissory notes (other than the AgeX-Serina Note held by AgeX) of $(579) and $267 in the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2023 and the year ended December 31, 2022, respectively.
   
BB Represents the derecognition of Serina’s as reported change in fair value of the AgeX-Serina Note held by AgeX at its inception on March 15, 2023 of $2,240 and through September 30, 2023 of $3,898 in the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2023 and the year ended December 31, 2022, respectively. Upon the consummation of the Merger, the aggregate principal amount of $10,000 pursuant to the AgeX-Serina Note between AgeX and Serina remains outstanding and becomes an intercompany asset of AgeX and an intercompany liability of Serina that is eliminated in the combined company’s consolidation.

 

Transaction Accounting Adjustments

 

The transaction accounting adjustments included in the unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2023, and year ended December 31, 2022, are as follows:

 

CC Recognition of estimated transaction costs related to the Merger expected to be incurred by AgeX in the amount of $3,141 that would be expensed. The unaudited pro forma condensed combined statement of operations reflects payment of these costs as an increase in general and administrative expense for the year ended December 31, 2022. The unaudited pro forma condensed combined statement of operations already includes amounts that were previously paid and expensed of $1,659 during the nine months ended September 30, 2023.
   
DD Recognition of estimated transaction costs related to the Merger expected to be incurred by Serina in the amount of $580 that would be expensed. The unaudited pro forma condensed combined statement of operations reflects payment of these costs as an increase in general and administrative expense for the year ended December 31, 2022. The unaudited pro forma condensed combined statement of operations already includes amounts that were previously paid and expensed of $738 during the nine months ended September 30, 2023.

 

412

 

 

EE Represents the derecognition of Serina’s as reported interest expense from the convertible promissory note with AgeX of $379 in the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2023. Upon the consummation of the Merger, the $10,000 convertible promissory note between AgeX and Serina remains outstanding and becomes an intercompany asset of AgeX and an intercompany liability of Serina with the balances eliminated in consolidation.
   
FF Represents the derecognition of AgeX’s as reported interest income from the AgeX-Serina Note of $379 in the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2023. Upon the consummation of the Merger, the $10,000 AgeX-Serina Note between AgeX and Serina remains outstanding and becomes an intercompany asset of AgeX and an intercompany liability of Serina with the balances eliminated in consolidation.
   
GG The pro forma basic and diluted earnings per share of capital stock of AgeX and Serina have been adjusted to reflect the pro forma net loss for the nine months ended September 30, 2023 and the year ended December 31, 2022. In addition, the number of shares of capital stock of AgeX and Serina used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company for the respective periods.

 

For the nine months ended September 30, 2023, the pro forma weighted average shares of capital stock of AgeX and Serina outstanding has been calculated as follows:

 

(in thousands, except share and per share data)    
Historical Serina weighted average shares of Serina common stock outstanding   2,180,532 
Impact of historical Serina options to purchase shares converted into options to purchase AgeX common stock as of January 1, 2022 on an as exercised basis   1,756,816 
Impact of historical Serina Series A Preferred Stock outstanding on an as converted basis (giving effect to the Serina preferred stock conversion as of January 1, 2022) (iv)   4,788,308 
Total   8,725,656 
Application of the exchange ratio to historical Serina weighted average shares of Serina capital stock outstanding on an as converted basis   30.2370 
Adjusted Serina weighted average shares outstanding on an as converted basis   263,837,877 
Historical AgeX weighted average shares of AgeX common stock outstanding   37,950,732 
Impact of historical AgeX weighted average shares of AgeX Series A preferred stock and Series B preferred stock outstanding on an as converted basis (giving effect to the AgeX preferred stock conversion as of January 1, 2022)   49,999,999 
Total pro forma weighted average shares outstanding   351,788,608 

 

For the year ended December 31, 2022, the pro forma weighted average shares of capital stock of AgeX and Serina outstanding has been calculated as follows:

 

(in thousands, except share and per share data)    
Historical Serina weighted average shares of Serina common stock outstanding   2,145,002 
Impact of historical Serina options to purchase shares converted into options to purchase AgeX common stock as of January 1, 2022 on an as exercised basis   2,012,750 
Impact of historical Serina Series A Preferred outstanding on an as converted basis (giving effect to the Serina preferred stock conversion as of January 1, 2022) (iv)   4,788,308 
Total   8,946,060 
Application of the exchange ratio to historical Serina weighted average shares of Serina capital stock outstanding on an as converted basis   30.2370 
Adjusted Serina weighted average shares outstanding on an as converted basis   270,502,238 
Historical AgeX weighted average shares of AgeX common stock outstanding   37,944,581 
Impact of historical AgeX weighted average shares of AgeX Series A preferred stock and Series B preferred stock outstanding on an as converted basis (giving effect to the AgeX preferred stock conversion as of January 1, 2022)   49,999,999 
Total pro forma weighted average shares outstanding   358,446,818 

 

(iv) The AgeX common stock allocated to the Serina Series A Preferred Stock is based on the “Minimum Share Price” of $12.00 (on a post-reverse split basis) as defined in the Merger Agreement.

 

As the proposed reverse stock split ratio of AgeX common stock is not definitive and is expected to occur following receipt of stockholder approval and prior to the consummation of the Merger, the exchange ratio and the estimated weighted average shares of AgeX common stock issued to Serina stockholders have not been adjusted to give retrospective effect to the reverse stock split.

 

413

 

 

INDEX TO FINANCIAL STATEMENTS

 

AgeX Therapeutics, Inc.

 

Index to Consolidated Financial Statements

 

Years ended December 31, 2022 and 2021   Page Number
Report of Independent Registered Public Accounting Firm (PCAOB ID: 100)   F-2
Audited Consolidated Financial Statements:    
Consolidated Balance Sheets   F-4
Consolidated Statements of Operations   F-5
Consolidated Statements of Comprehensive Loss   F-6
Consolidated Statements of Stockholders’ Deficit   F-7
Consolidated Statements of Cash Flows   F-8
Notes to Consolidated Financial Statements   F-9

 

 

Nine months ended September 30, 2023 and 2022

  Page Number
     
Interim Financial Statements (Unaudited):    
Consolidated Balance Sheets   F-36
Consolidated Statements of Operations   F-37
Consolidated Statements of Stockholders’ Deficit   F-38
Consolidated Statements of Cash Flows   F-40
Notes to Consolidated Financial Statements   F-41

 

Serina Therapeutics, Inc. Financial Statements

 

Index to Consolidated Financial Statements

 

Years ended December 31, 2022 and 2021

  Page Number
Independent Auditor’s Report   F-66
Consolidated Financial Statements:    
Consolidated Balance Sheets   F- 67
Consolidated Statements of Operations   F- 69
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit   F- 70
Consolidated Statements of Cash Flows   F- 72
Notes to Consolidated Financial Statements   F- 74

 

Nine months ended September 30, 2023 and 2022

  Page Number
     
Interim Financial Statements (Unaudited):    
Consolidated Balance Sheets   F- 96
Consolidated Statements of Operations   F- 97
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit   F- 98
Consolidated Statements of Cash Flows   F- 99
Notes to Consolidated Financial Statements   F- 100

 

F-1
 

 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and Board of Directors

AgeX Therapeutics, Inc.

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of AgeX Therapeutics, Inc. and Subsidiaries (collectively, the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders’ deficit, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

The Company’s Ability to Continue as a Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1, the Company has had recurring losses and negative operating cash flows since inception, an accumulated deficit at December 31, 2022, and insufficient cash and cash equivalents and loan proceeds at December 31, 2022 to fund operations for twelve months from the date of issuance. All of these matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the Audit Committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements; and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Intangible Assets Impairment Assessment – Long-Lived Intangible Assets

 

Description of the Matter

 

As described in Note 2 to the consolidated financial statements, the Company’s long-lived net intangible assets, which consisted primarily of patents and acquired in-process research and development, had a balance of $0.7 million as of December 31, 2022.

 

F-2
 

 

Long-lived intangible assets are assessed for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. Recoverability of a long-lived intangible asset that will continue to be used in the Company’s operations is measured by comparing the carrying amount of the asset to the forecasted undiscounted future cash flows related to the asset.

 

Auditing the Company’s impairment analysis of its long-lived intangible assets is complex because of the significant judgment used by management in the identification of events that suggest an asset group may not be recoverable, and the highly subjective assumptions used by management in the impairment testing process.

 

How We Addressed the Matter in Our Audit

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, obtaining an understanding of and evaluating management’s process for identifying potential impairment events; evaluating the appropriateness of the cash flow model used in the impairment testing process; testing the completeness, accuracy, and relevance of underlying data used in the model; and evaluating the reasonableness of the significant assumptions used by management, including the future cash flow projections. We evaluated the reasonableness of management’s assumptions for future cash flow projections in consideration of (i) the current and past performance of the asset group, (ii) the consistency with external market and industry data, (iii) peer companies and (iv) whether these assumptions were consistent with evidence obtained in other areas of the audit.

 

/s/ WithumSmith+Brown, PC  
   
We have served as the Company’s auditor since 2017.
San Francisco, California
March 31, 2023
   
PCAOB ID Number 100

 

F-3
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except par value amounts)

 

   2022   2021 
   December 31, 
   2022   2021 
ASSETS        
Current assets:          
Cash and cash equivalents  $645   $584 
Accounts and grants receivable, net   4    25 
Prepaid expenses and other current assets   1,804    1,625 
Total current assets   2,453    2,234 
           
Restricted cash   50    50 
Intangible assets, net   738    870 
TOTAL ASSETS  $3,241   $3,154 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable and accrued liabilities  $1,034   $771 
Loan due to Juvenescence, net of debt issuance costs, current portion   7,646    7,140 
Related party payables, net   141    70 
Warrant liability   180    - 
Insurance premium liability and other current liabilities   1,077    986 
Total current liabilities   10,078    8,967 
           
Loan due to Juvenescence, net of debt issuance costs, net of current portion   10,478    6,062 
TOTAL LIABILITIES   20,556    15,029 
           
Commitments and contingencies (Note 10)   -     -  
           
Stockholders’ deficit:          
Preferred stock, $0.0001 par value, 5,000 shares authorized; none issued and outstanding   -    - 
Common stock, $0.0001 par value, 200,000 and 100,000 shares authorized, respectively; 37,949 and 37,941 shares issued and outstanding, respectively   4    4 
Additional paid-in capital   98,994    93,912 
Accumulated deficit   (116,210)   (105,748)
Total AgeX Therapeutics, Inc. stockholders’ deficit   (17,212)   (11,832)
Noncontrolling interest   (103)   (43)
Total stockholders’ deficit   (17,315)   (11,875)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $3,241   $3,154 

 

See accompanying notes to the consolidated financial statements.

 

F-4
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
REVENUES        
Grant revenues  $-   $104 
Other revenues   34    40 
Total revenues   34    144 
           
Cost of sales   (13)   (19)
           
Gross profit   21    125 
           
OPERATING EXPENSES          
Research and development   1,025    1,456 
General and administrative   5,971    6,708 
Total operating expenses   6,996    8,164 
           
Gain on deconsolidation of LifeMap Sciences (Note 3)   -    106 
           
Loss from operations   (6,975)   (7,933)
           
OTHER EXPENSE, NET          
Interest expense, net   (3,335)   (1,097)
Change in fair value of warrants (Note 6)   (225)   - 
Other income, net   13    448 
Total other expense, net   (3,547)   (649)
           
NET LOSS FROM CONTINUING OPERATIONS   (10,522)   (8,582)
           
NET LOSS FROM DISCONTINUED OPERATIONS (Note 3)   -    (103)
           
NET LOSS   (10,522)   (8,685)
Net loss attributable to noncontrolling interest from continuing operations   60    3 
Net loss attributable to noncontrolling interest from discontinued operations   -    7 
           
NET LOSS ATTRIBUTABLE TO AGEX  $(10,462)  $(8,675)
           
NET LOSS PER COMMON SHARE:          
BASIC AND DILUTED          
Continuing operations  $(0.28)  $(0.23)
Discontinued operations   -    - 
  $(0.28)  $(0.23)
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:          
BASIC AND DILUTED   37,945    37,886 
           
AMOUNTS ATTRIBUTABLE TO AGEX:          
Loss from continuing operations  $(10,462)  $(8,579)
Loss from discontinued operations   -    (96)
NET LOSS ATTRIBUTABLE TO AGEX  $(10,462)  $(8,675)

 

See accompanying notes to the consolidated financial statements.

 

F-5
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
NET LOSS  $(10,522)  $(8,685)
Other comprehensive expense, net of tax:          
Foreign currency translation adjustments from discontinued operations   -    (143)
COMPREHENSIVE LOSS   (10,522)   (8,828)
Less: Comprehensive loss attributable to noncontrolling interest from continuing operations   60    3 
Less: Comprehensive loss attributable to noncontrolling interest from discontinued operations   -    7 
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX COMMON STOCKHOLDERS  $(10,462)  $(8,818)

 

See accompanying notes to the consolidated financial statements.

 

F-6
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(In thousands)

 

  

Number

of Shares

  

Par

Value

  

Paid-In

Capital

  

Accumulated

Deficit

  

Noncontrolling

Interest

  

Comprehensive

Income

  

Stockholders’

Deficit

 
   Common Stock   Additional          

Accumulated

Other

   Total 
  

Number

of Shares

  

Par

Value

  

Paid-In

Capital

  

Accumulated

Deficit

  

Noncontrolling

Interest

  

Comprehensive

Income

  

Stockholders’

Deficit

 
BALANCE AT DECEMBER 31, 2020   37,691   $4   $91,810   $(97,073)  $(280)  $143   $(5,396)
                                    
Issuance of common stock   242    -    475    -    -    -    475 
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes   8    -    (7)   -    -    -    (7)
Issuance of warrants   -    -    757    -    -    -    757 
Stock-based compensation   -    -    1,003    -    -    -    1,003 
Transactions with noncontrolling interests – LifeMap Sciences   -    -    (269)   -    269    -    - 
Deconsolidation of LifeMap Sciences   -            -    143    -    (22)   (143)   (22)
Net loss   -    -    -    (8,675)   (10)   -    (8,685)
BALANCE AT DECEMBER 31, 2021   37,941    4    93,912    (105,748)   (43)   -    (11,875)
                                    
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes   8    -    (4)   -    -    -    (4)
Issuance of warrants   -    -    178    -    -    -    178 
Fair value of liability classified warrants issued   -    -    4,148    -    -    -    4,148 
Stock-based compensation   -    -    760    -    -    -    760 
Net loss   -    -    -    (10,462)   (60)   -    (10,522)
BALANCE AT DECEMBER 31, 2022   37,949   $4   $98,994   $(116,210)  $(103)  $-   $(17,315)

 

See accompanying notes to the consolidated financial statements.

 

F-7
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
OPERATING ACTIVITIES:          
Net loss attributable to AgeX from continuing operations  $(10,462)  $(8,579)
Net loss attributable to noncontrolling interest   (60)   (3)
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:          
Gain on deconsolidation of LifeMap Sciences (Note 3)   -    (106)
Gain on extinguishment of debt (Paycheck Protection Program loan)   -    (437)
Change in fair value of warrants (Note 6)   225    - 
Amortization of intangible assets   132    131 
Amortization of debt issuance costs   3,137    1,114 
Stock-based compensation   760    999 
Changes in operating assets and liabilities:          
Accounts and grants receivable   21    128 
Prepaid expenses and other current assets   896    760 
Accounts payable and accrued liabilities   144    (772)
Related party payables   255    - 
Insurance premium liability   (983)   (921)
Other current liabilities   (4)   (79)
Net cash used in operating activities from continuing operations   (5,939)   (7,765)
Net cash used in operating activities from discontinued operations (Note 3)   -    (90)
Net cash used in operating activities   (5,939)   (7,855)
           
INVESTING ACTIVITIES:          
Proceeds from the sale of LifeMap Sciences (Note 3)   -    466 
Partial collection on loan due from LifeMap Sciences   -    250 
Net cash provided by investing activities from continuing operations   -    716 
Deconsolidation of cash and cash equivalents from discontinued operations (Note 3)   -    (50)
Net cash provided by investing activities   -    666 
           
FINANCING ACTIVITIES:          
Draw down on loan facilities from Juvenescence   6,000    7,000 
Proceeds from the issuance of common stock   -    496 
Net cash provided by financing activities from continuing operations   6,000    7,496 
Partial payment on loan due to AgeX from discontinued operations (Note 3)   -    (250)
Net cash provided by financing activities   6,000    7,246 
           
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH   61    57 
           
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:          
At beginning of the year   634    577 
At end of the year  $695   $634 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid during the year for interest  $14   $13 
           
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES:          
Issuance of common stock upon vesting of restricted stock units (Note 8)  $8   $16 
Issuance of warrants for debt issuance under the 2020 Loan Agreement  $178   $757 
Issuance of warrants for debt issuance under the Secured Note (Note 6)  $4,148   $- 
Debt refinanced with new debt (Note 5)  $7,160   $- 

 

See accompanying notes to the consolidated financial statements.

 

F-8
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

1. Organization, Basis of Presentation and Liquidity

 

AgeX Therapeutics, Inc. (“AgeX,” “we,” “our,” or “us”) was incorporated in January 2017 in the state of Delaware as a subsidiary of Lineage Cell Therapeutics, Inc. (“Lineage,” formerly known as BioTime, Inc.), a publicly traded, clinical-stage biotechnology company.

 

AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions.

 

AgeX’s main technology platforms and product candidates are:

 

PureStem® PSC-derived clonal embryonic progenitor cell lines that may be capable of generating a broad range of cell types for use in cell-based therapies;

 

UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells;

 

AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes;

 

AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and

 

Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair.

 

AgeX is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012.

 

Lineage’s Sale of Significant Ownership Interest in AgeX to Juvenescence

 

On August 30, 2018, Lineage consummated the sale of 14,400,000 shares of common stock of AgeX owned by Lineage to Juvenescence Limited (“Juvenescence”). Prior to the transaction, Juvenescence owned 5.6% of AgeX’s issued and outstanding common stock. Upon completion of the transaction, Lineage’s ownership in AgeX was reduced from 80.4% to 40.2% of AgeX’s issued and outstanding shares of common stock, and Juvenescence’s ownership in AgeX was increased from 5.6% to 45.8% of AgeX’s issued and outstanding shares of common stock. AgeX did not receive any proceeds from the transaction. As a result of that transaction, AgeX ceased to be a subsidiary of Lineage because Lineage experienced a “loss of control” of a subsidiary, as defined by U.S. GAAP. Loss of control is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock in the subsidiary, lacks a controlling financial interest in the subsidiary and, is unable to unilaterally control the subsidiary through other means such as having, or being able to obtain, the power to elect a majority of the subsidiary’s Board of Directors based solely on contractual rights or ownership of shares holding a majority of the voting power of the subsidiary’s voting securities. All of these loss-of-control factors were present with respect to Lineage’s ownership interest in AgeX as of August 30, 2018. Accordingly, Lineage deconsolidated AgeX’s consolidated financial statements and results from its consolidated financial statements and results beginning on August 30, 2018.

 

On November 28, 2018 (the “Distribution Date”), Lineage distributed to its shareholders, on a pro rata basis, 12,697,028 shares of the AgeX common stock it then held (the “Distribution”). Immediately after the Distribution, Lineage retained 1,718,972 shares of AgeX common stock, representing approximately 4.8% of the common stock then issued and outstanding. Following the Distribution, AgeX common stock began publicly trading on the NYSE American under the symbol “AGE.”

 

Disposition and Deconsolidation of LifeMap Sciences

 

On March 6, 2021, AgeX and its then majority-owned subsidiary LifeMap Sciences, Inc. (“LifeMap Sciences”) entered into an Agreement and Plan of Merger (the “LifeMap Merger Agreement”) with Atlas Capital Partners Limited, a British Virgin Islands company limited by shares (“Atlas”), and GCLMS Acquisition Corporation (“GCLMS”), a Delaware corporation that was a wholly-owned subsidiary of Atlas. On March 15, 2021, the merger was completed pursuant to the terms of the LifeMap Merger Agreement. As a result of the merger, GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of a $500,000 cash payment for all shares of LifeMap Sciences common stock in the aggregate (the “LifeMap Merger Consideration”), with each LifeMap Sciences shareholder’s pro rata portion of the LifeMap Merger Consideration to be determined in accordance with the number of shares of LifeMap Sciences common stock owned by such shareholder as a percentage of shares of LifeMap Sciences common stock outstanding immediately before the effective date of the merger, and (b) the outstanding shares of GCLMS common stock were converted into shares of LifeMap Sciences common stock so that Atlas is now the sole shareholder of LifeMap Sciences.

 

F-9
 

 

AgeX received approximately $466,400 in cash as its pro rata share of the LifeMap Merger Consideration in the merger. Prior to and as a condition to the merger under the terms of the LifeMap Merger Agreement, $1,761,296 of LifeMap Sciences’ indebtedness to AgeX was converted into shares of LifeMap Sciences common stock. LifeMap Sciences also paid AgeX $250,000 in cash to pay off a portion of LifeMap Sciences’ indebtedness to AgeX that was not converted into shares of LifeMap Sciences common stock.

 

As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Accordingly, AgeX has deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from AgeX, effective March 15, 2021 (the “LifeMap Deconsolidation”), in accordance with Accounting Standards Codification (“ASC”) 810-10-40, Consolidation.

 

See Note 3, Disposition and Deconsolidation of LifeMap Sciences for additional information regarding the disposition and deconsolidation of LifeMap Sciences.

 

Going Concern

 

AgeX primarily finances its operations through loans from its largest stockholder Juvenescence. AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $116.2 million as of December 31, 2022. AgeX expects to continue to incur operating losses and negative cash flows.

 

Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have adopted operating plans and budgets to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those operating plans and budgets, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $0.6 million as of December 31, 2022 plus the loan facilities provided by Juvenescence to advance up to an additional $1.0 million for operating capital discussed in Note 11, Subsequent Events and the proceeds we may receive from the sale of additional shares of our common stock in “at-the-market” transactions through a Sales Agreement with Chardan Capital Markets, LLC (“Chardan”) as a sales agent, would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of these consolidated financial statements. These conditions raise substantial doubt about AgeX’s ability to continue as a going concern. AgeX will need to obtain substantial additional funding in connection with its continuing operations. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Principles of Consolidation

 

The consolidated financial statements of AgeX are presented in accordance with U.S. GAAP. AgeX’s consolidated financial statements include the accounts of its subsidiaries and certain research and development departments. AgeX consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of stockholders’ deficit on AgeX’s consolidated balance sheets.

 

AgeX’s consolidated balance sheets at December 31, 2022 and 2021 do not include LifeMap Sciences’ consolidated assets and liabilities due to the deconsolidation of LifeMap Sciences on March 15, 2021. LifeMap Sciences’ consolidated financial statements and consolidated results of operations include its wholly-owned and consolidated subsidiary, LifeMap Sciences, Ltd.

 

AgeX’s consolidated statements of operations for the year ended December 31, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the deconsolidation due to the conversion of $1,761,296 of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021 followed by the completion of the cash-out merger on the same day.

 

AgeX has three subsidiaries, Reverse Bioengineering, Inc. (“Reverse Bio”), ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTRTM research and development efforts. To the extent that such financing is obtained through the sale of capital stock or other equity securities to investors or other biopharma companies by Reverse Bio, AgeX’s equity interest in Reverse Bio and its iTRTM business would be diluted. ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 94.8% of the outstanding capital stock of ReCyte. NeuroAirmid is jointly owned by AgeX with the University of California – Irvine and certain researchers and was recently organized to pursue clinical development and commercialization of cell therapies, focusing initially on Huntington’s Disease. AgeX owns 50% of the outstanding capital stock of NeuroAirmid. AgeX consolidates NeuroAirmid despite not having majority ownership interest as it has the ability to influence decision making and financial results through contractual rights and obligations as per ASC 810, Consolidation.

 

All material intercompany accounts and transactions between AgeX and its subsidiaries have been eliminated in consolidation.

 

F-10
 

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, allocations and adjustments necessary for carve-out basis of presentation, including the separate return method for income taxes, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected. See Note 6, Warrant Liability for discussion on estimated change in fair value of warrant liability.

 

Transactions with Noncontrolling Interests of Subsidiaries

 

AgeX accounts for a change in ownership interests in its subsidiaries that does not result in a change of control of the subsidiary under the provisions of ASC 810-10-45-23, Consolidation – Other Presentation Matters, which prescribes the accounting for changes in ownership interest that do not result in a change in control of the subsidiary, as defined by U.S. GAAP, before and after the transaction. Under this guidance, changes in a controlling stockholder’s ownership interest that do not result in a change of control, as defined by U.S. GAAP, in the subsidiary are accounted for as equity transactions. Accordingly, if the controlling stockholder retains control, no gain or loss is recognized in the statements of operations of the controlling stockholder. Similarly, the controlling stockholder will not record any additional acquisition adjustments to reflect its subsequent purchases of additional shares in the subsidiary if there is no change of control. Only a proportional and immediate transfer of carrying value between the controlling and the noncontrolling stockholders occurs based on the respective ownership percentages.

 

Liquidity and Impact of COVID-19

 

In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in out-licensing its technologies and development of its product candidates. Although AgeX has been able to reduce its operating expenses by eliminating internal research and development activities and focusing instead on out-sourcing research and development and seeking licensing arrangements for AgeX technologies, this approach has also made it more difficult for AgeX to make progress in developing its target product candidates and technologies, which in turn may make it more difficult for AgeX to raise capital. The availability of financing also may be adversely impacted by the COVID-19 pandemic which disrupt aspects of AgeX’s operations. The extent to which the ongoing COVID-19 pandemic will ultimately impact AgeX’s business, results of operations, financial condition, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside AgeX’s control. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its stockholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all.

 

2. Summary of Significant Accounting Policies

 

Going Concern Assessment

 

AgeX assesses going concern uncertainty for its consolidated financial statements to determine if AgeX has sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date the consolidated financial statements are issued or are available to be issued, which is referred to as the “look-forward period” as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to AgeX, AgeX will consider various scenarios, forecasts, projections, and estimates, and AgeX will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, AgeX makes certain assumptions concerning its ability to curtail or delay research and development programs and expenditures within the look-forward period in accordance with ASU No. 2014-15 (see Note 1, Organization, Basis of Presentation and Liquidity).

 

F-11
 

 

Fair Value Measurements of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.

 

The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. The credit facility is reported at fair value as it bears market rates of interest. Fair values for the AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.

 

To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures):

 

Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.

 

Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

 

The following table summarizes fair value measurements by level as of December 31, 2022 for liabilities measured at fair value on a recurring basis (in thousands):

 

   Level 1   Level 2   Level 3   Total 
Warrant liability  $-   $-   $180   $180 

 

There were no warrant liabilities as of December 31, 2021. See Note 6, Warrant Liability for additional information on accounting for liability classified warrants and level 3 rollforward table.

 

In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.

 

The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items.

 

The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.

 

The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations, are discussed further in Note 6, Warrant Liability. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date.

 

Cash and Cash Equivalents

 

AgeX considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2022 and 2021, AgeX’s cash balances totaled $0.6 million and $0.6 million, respectively, and consist entirely of bank account deposits and amounts held in money market funds.

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject AgeX to significant concentrations of credit risk consist primarily of cash and cash equivalents. AgeX limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, AgeX has not experienced any losses on such accounts.

 

F-12
 

 

Restricted Cash

 

In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands):

 

         
   December 31, 
   2022   2021 
Cash and cash equivalents  $645   $584 
Restricted cash (1)   50    50 
Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows  $695   $634 

 

 

(1)Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits in the consolidated balance sheets.

 

Accounts Receivable, Net

 

AgeX establishes an allowance for doubtful accounts based on the evaluation of the collectability of its receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. There were no amounts reserved for doubtful accounts as of December 31, 2022 and 2021.

 

Long-Lived Intangible Assets, Net

 

Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 years (see Note 4, Selected Balance Sheet Components).

 

Impairment of Long-Lived Assets

 

AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consist entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of December 31, 2022, there has been no impairment of long-lived assets.

 

Leases

 

AgeX accounts for leases in accordance with ASU 2016-02, Leases (Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX, which are: (i) ASU 2018-10, Codification Improvements to Topic 842, Leases, and (ii) ASU 2018-11, Leases (Topic 842): Targeted improvements, using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheets.

 

ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.

 

F-13
 

 

On November 3, 2020, AgeX entered into a one-year lease effective January 1, 2021 for 135 square feet of office space in a building in an office and research park in Alameda, California. Base monthly rent was $947 over the lease term. AgeX renewed this lease for 12 months effective January 1, 2022 for base monthly rent of $1,074. In October 2022, AgeX entered into a new 12 month lease for a slightly less space in the same building effective January 1, 2023 for base monthly rent of $844. AgeX elected to not apply the recognition requirements under ASC 842 and instead recognized the lease payments as lease costs on a straight-line basis over the lease term, as the amount of the lease payments were not deemed material.

 

Accounting for Warrants

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of December 31, 2022. See Notes 5, Related Party Transactions and 6, Warrant Liability for additional information regarding AgeX warrants.

 

Stock-Based Compensation

 

AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718, Compensation – Stock Compensation.

 

AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09.

 

AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under the Incentive Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.

 

Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations.

 

The Black-Scholes option pricing model requires AgeX to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 8, Stock-Based Awards).

 

The fair value of the shares of common stock underlying the stock options is determined in accordance with the Incentive Plan and is based on prevailing market prices on the NYSE American where AgeX common stock is traded.

 

The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. AgeX estimates the expected term of options granted using the “simplified method” provided under Staff Accounting

 

F-14
 

 

Bulletin, Topic 14, or SAB Topic 14.

 

Because AgeX’s common stock has public trading history of fewer than five years, AgeX has estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options, which may exceed five years. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage.

 

The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of AgeX’s stock options.

 

The dividend yield assumption is based on AgeX’s history and expectation of dividend payouts. AgeX has never declared or paid any cash dividends on its common stock, and AgeX does not anticipate paying any cash dividends in the foreseeable future.

 

All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.

 

Stock-based compensation expense for the years ended December 31, 2022 and 2021 consists of stock-based compensation under the AgeX 2017 Equity Incentive Plan (see Note 8, Stock-Based Awards).

 

Certain of AgeX’s consolidated subsidiaries have had their own share-based compensation plans; however, there are no awards granted and outstanding under those plans as of December 31, 2022 and 2021. For share-based compensation awards granted by privately held consolidated subsidiaries under their respective equity plans, AgeX determines the fair value of the options granted under those plans using similar methodologies and assumptions AgeX used for its stock options discussed above.

 

Although the fair value of stock options and restricted stock units is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.

 

Income Taxes

 

AgeX accounts for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. AgeX’s judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If AgeX’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on AgeX’s consolidated financial statements.

 

The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. AgeX recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No unrecognized tax benefits have been recorded and no amounts were accrued for the payment of interest and penalties as of December 31, 2022 and 2021. AgeX does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. AgeX is currently unaware of any tax issues under review.

 

Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2021, AgeX’s foreign entity operated at a loss; therefore, no GILTI was included in income. For the year ended December 31, 2022, there was no income or loss related to foreign activity as the entity deconsolidated from AgeX on March 15, 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.

 

F-15
 

 

Revenue Recognition

 

AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.

 

In the applicable paragraphs below, AgeX has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606.

 

Revenue recognition by source and geography – Revenues are recognized when control of the promised goods or services is transferred to customers, or in the case of governmental entities funding a grant, when allowable expenses are incurred, in an amount that reflects the consideration AgeX or a subsidiary, depending on which company has the customer or the grant, expects to be entitled to in exchange for those goods or services.

 

The following table presents AgeX’s consolidated revenues disaggregated by source for continuing operations (in thousands):

 

         
   Year Ended December 31, 
REVENUES:  2022   2021 
Grant revenues  $-   $104 
Other revenues   34    40 
Total revenues  $34   $144 

 

The following table presents consolidated revenues for continuing operations (in thousands), disaggregated by geography, based on the billing addresses of customers:

 

         
   Year Ended December 31, 
REVENUES:  2022   2021 
United States  $10   $107 
Foreign   24    37 
Total revenues  $34   $144 

 

Subscription and advertisement revenues – LifeMap Sciences sold subscription-based products, including research databases and software tools, for biomedical, gene, and disease research. LifeMap Sciences sold these subscriptions primarily through the internet to biotech and pharmaceutical companies worldwide. LifeMap Sciences’ principal subscription product was the GeneCards® Suite, which includes the GeneCards® human gene database, and the MalaCards™ human disease database. LifeMap Sciences’ performance obligations for subscriptions included a license of intellectual property related to its genetic information packages and premium genetic information tools. These licenses were deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue was recognized over a period of time, which was generally the subscription period. Payments were typically received at the beginning of a subscription period and revenue was recognized according to the type of subscription sold. For subscription contracts in which the subscription term commenced before a payment was due, LifeMap Sciences recorded an account receivable because the subscription was earned over time and billed the customer according to the contract terms. LifeMap Sciences deferred subscription revenues primarily represented subscriptions for which cash payment was received for the subscription term, but the subscription term was not completed as of the balance sheet date reported.

 

LifeMap Sciences licensed from third parties the databases and software it commercialized and had a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the consolidated statements of operations when the cash was received and the royalty obligation was incurred as the royalty payments did not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers.

 

LifeMap Sciences recognized $0.3 million in subscription and advertisement revenues for the year ended December 31, 2021, which is included in operating loss from discontinued operations, and is for revenues earned through March 15, 2021. As a result of the LifeMap Deconsolidation, AgeX does not expect to earn subscription and advertising revenues in subsequent accounting periods. See Note 3, Disposition and Deconsolidation of LifeMap Sciences for further information on the disposition and deconsolidation of LifeMap Sciences.

 

F-16
 

 

Grant revenues – AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements. At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.

 

In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.

 

On April 8, 2020, AgeX was awarded a grant of up to approximately $386,000 from the National Institutes of Health (“NIH”). The NIH grant provided funding for continued development of AgeX’s technologies for treating stroke. The grant funds were made available by the NIH to AgeX as allowable expenses were incurred. For the year ended December 31, 2021, AgeX incurred approximately $104,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. AgeX recognized no grant revenues for the year ended December 31, 2022 as AgeX had expended the full amount available under this grant as of December 31, 2021.

 

ESI BIO research products – AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP.” AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products are included in other revenues.

 

Arrangements with multiple performance obligations – AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of and for the years ended December 31, 2022 and 2021, AgeX did not have significant arrangements with multiple performance obligations.

 

Research and Development

 

Research and development expenses consist primarily of personnel costs and related benefits, stock-based compensation, amortization of intangible assets, and collaborative and contracted research and development fees. Research and development costs which have an alternative future use will be capitalized as intangible assets, and costs with no future benefit or alternative use will be expensed as incurred. Research and development expenses incurred and reimbursed by grants from third parties approximate the grant revenues recognized in the consolidated statements of operations.

 

General and Administrative

 

General and administrative expenses include employee and director compensation allocated to general and administrative expenses, consulting fees other than those paid for science-related consulting, license fees paid to third parties to acquire patents or licenses to use patents and other technology, professional fees to maintain patents and trademarks, minimum annual royalties stipulated under license and sublicense agreements with third parties, insurance costs allocated to general and administrative expenses, stock exchange-related costs, depreciation expense, marketing costs, legal and accounting costs, office rent, and other miscellaneous expenses which are allocated to general and administrative expense.

 

Foreign Currency Transaction Gains and Losses

 

For transactions denominated in other than the functional currency of AgeX or its subsidiaries, AgeX recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it.

 

F-17
 

 

Segments

 

AgeX’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, AgeX’s executive management team has viewed AgeX’s operations as one segment that includes the research and development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders, oncology, and neurological diseases and disorders, blood and vascular system diseases and disorders, and pluripotent cell technologies. As a result, the financial information disclosed materially represents all of the financial information related to AgeX’s sole operating segment.

 

Basic and Diluted Net Loss per Share Attributable to Common Stockholders

 

Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted-average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted-average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.

 

For the years ended December 31, 2022 and 2021, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.

 

The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):

 

   Year Ended December 31, 
   2022   2021 
Stock options   3,297    3,145 
Warrants (1)   9,558    3,492 
Restricted stock units        10         23 

 

 

(1)As of December 31, 2022 and 2021, AgeX issued Juvenescence warrants to purchase 12,129,260 and 3,512,098 shares, respectively, of AgeX common stock as consideration for the loan agreements discussed in Note 5, Related Party Transactions.

 

Recently Adopted Accounting Pronouncements

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The amendment in this update addresses how an issuer should account for modifications made to equity-classified written call options. The guidance in the standard requires the issuer to treat a modification of an equity-classified call option that does not cause the instrument to become liability-classified as an exchange of the original call option for a new call option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the call option or as termination of the original call option and issuance of a new call option. The Emerging Issues Task Force (EITF) concluded that the recognition of the modification depends on the nature of the transaction in which a warrant is modified. If there is more than one element in a transaction (for example, if the modification involves both a debt modification and an equity issuance), then the guidance requires the issuer to allocate the effect of the option modification to each element. Amendments in the new standard are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this ASU in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.

 

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity’s financial statements. The amendments are effective for all entities within their scope, which excludes not-for-profit entities and employee benefit plans, for financial statements issued for annual periods beginning after December 15, 2021. Early application of the amendment is permitted. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.

 

F-18
 

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. ASU 2016-13 is effective for AgeX beginning January 1, 2023 and is not expected to have a material impact on the consolidated financial statements.

 

In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance is effective for AgeX on January 1, 2023, including interim periods. Early adoption is permitted, and the amendment applied prospectively, except for the recognition and remeasurement of troubled debt restructurings. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. AgeX does not expect the adoption of this guidance to have a material impact on the consolidated financial statements.

 

CARES Act

 

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act but does not expect it to have a material impact to its tax provision or its consolidated financial statements. AgeX obtained a loan under the Paycheck Protection Program under the CARES Act, the repayment of which was forgiven in February 2021.

 

3. Disposition and Deconsolidation of LifeMap Sciences

 

Discontinued Operations

 

On March 6, 2021, AgeX and LifeMap Sciences entered into the LifeMap Merger Agreement with Atlas and GCLMS. On March 15, 2021, the merger was completed pursuant to the terms of the LifeMap Merger Agreement. As a result of the merger, GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of the $500,000 total LifeMap Merger Consideration, with each LifeMap Sciences shareholder’s pro rata portion of the LifeMap Merger Consideration determined in accordance with the number of shares of LifeMap Sciences common stock owned by such shareholder as a percentage of shares of LifeMap Sciences common stock outstanding immediately before the effective date of the merger, and (b) the outstanding shares of GCLMS common stock were converted into shares of LifeMap Sciences common stock so that Atlas is now the sole shareholder of LifeMap Sciences.

 

AgeX received approximately $466,400 in cash as its pro rata share of the LifeMap Merger Consideration in the merger. Prior to and as a condition to the merger under the terms of the LifeMap Merger Agreement, $1,761,296 of LifeMap Sciences’ indebtedness to AgeX was converted into shares of LifeMap Sciences common stock. LifeMap Sciences also paid AgeX $250,000 in cash to pay off a portion of LifeMap Sciences’ indebtedness to AgeX that was not converted into shares of LifeMap Sciences common stock.

 

The results of operations and cash flows for LifeMap Sciences are reported as discontinued operations under U.S. GAAP in accordance with ASC 205-20, Discontinued Operations, for all periods presented in our consolidated financial statements. AgeX will not have any continuing involvement in LifeMap Sciences subsequent to the consummation of the merger on March 15, 2021. The following table presents the operating results of LifeMap Sciences that have been treated as discontinued operations for the periods presented:

 

 

  

Year Ended

December 31, 2021

 
Net revenues  $277 
Costs, operating and other expenses   (380)
Loss from discontinued operations   (103)
Net loss from discontinued operations attributable to noncontrolling interest   7 
Loss from discontinued operations (1)  $(96)

 

 

(1)Does not include $106,000 gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement. The gain on the sale of LifeMap Sciences is presented in the line item Gain on deconsolidation of LifeMap Sciences. There were no gains or losses resulting from the sale of businesses or assets that did not meet the criteria for a discontinued operation during the year ended December 31, 2021.

 

F-19
 

 

Deconsolidation

 

As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Effective March 15, 2021, AgeX deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from those of AgeX under U.S. GAAP ASC 810-10-40-4, Deconsolidation of a Subsidiary or Derecognition of a Group of Assets, due to the disposition of LifeMap Sciences on that date.

 

AgeX’s consolidated balance sheets at December 31, 2022 and 2021 do not include LifeMap Sciences’ consolidated assets and liabilities due to the deconsolidation of LifeMap Sciences on March 15, 2021.

 

AgeX’s consolidated statement of operations for the year ended December 31, 2021 includes LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the LifeMap Deconsolidation due to the conversion of $1,761,296 of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021 followed by the completion of the cash-out merger on the same day.

 

AgeX recognized a gain of $106,000 from the LifeMap Deconsolidation. The sale of LifeMap Sciences was a taxable transaction to AgeX; however, no income tax is due as the transaction resulted in a taxable loss primarily due to AgeX’s tax basis in the subsidiary.

 

4. Selected Balance Sheet Components

 

Intangible Assets, Net

 

On August 13, 2018, AgeX entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Escape Therapeutics, Inc. (“Escape”) pursuant to which AgeX acquired certain patents and patent applications related primarily to methods of modifying cells and tissues and certain pluripotent stem cell lines so as to reduce their risk of being rejected when transplanted. This technology is called “UniverCyte™.” AgeX paid Escape $1,072,436 in cash and issued 80,000 shares of AgeX common stock, with an approximate value of $240,000, for aggregate acquisition cost of $1.3 million for the UniverCyte™ assets. The Purchase Agreement was considered an asset acquisition rather than a business combination in accordance with ASC 805-50, Business Combinations.

 

ASC 730-10-25(c), Research and Development – Intangible Assets Purchased from Others, provides guidance for acquisition and capitalization of the cost of intangible assets purchased from others in an asset acquisition that have alternative future uses in other research and development projects. These intangible assets are referred to as acquired IPR&D with alternative future uses and are accounted for as intangible assets and amortized to research and development over their useful life. Acquired IPR&D in an asset acquisition that does not have any alternative future uses is expensed under the same guidance. As an initial focus, AgeX intends to use the UniverCyte™ technology in the development of its two lead products, AGEX-BAT1 and AGEX-VASC1 for the treatment of Type II diabetes and cardiovascular aging, respectively. Accordingly, AgeX recorded the UniverCyte™ technology acquired from Escape as IPR&D intangible assets with alternative future uses in accordance with ASC 730-10-25(c) and is amortizing those assets to research and development expense over their estimated 10-year useful life.

 

In addition to the purchase price, AgeX will pay Escape a royalty of less than 1% on net sales of products, processes and services under the acquired patents, if the assets are commercialized. Additional shares of AgeX common stock totaling up to $4.3 million of market value will also be issued to Escape upon the attainment of development and regulatory approval milestones by AgeX for each product covered by the acquired patents. Contingent consideration in an asset acquisition is generally recorded when probable and estimable in accordance with ASC 450, Contingencies. Accordingly, none of the milestone payments have been accrued since the attainment of any milestone in the Purchase Agreement was not probable as of December 31, 2022.

 

AgeX has also agreed to engage Escape’s chief executive officer as a consultant for a period of up to three years to assist AgeX in utilizing the acquired patents. AgeX paid $200,000 per year in consulting fees as services were performed, included in research and development expenses up until the agreement expired in August 2021.

 

F-20
 

 

AgeX estimated the future undiscounted cash flows expected to be received from the assets developed through the use of the UniverCyte™ technology when commercialized. The estimate of the future undiscounted cash flows considered AgeX’s financial condition and the royalties that may become payable to Escape.

 

At December 31, 2022 and 2021, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands):

 

         
   December 31, 
   2022   2021 
Intangible assets  $1,312   $1,312 
Accumulated amortization   (574)   (442)
Total intangible assets, net  $738   $870 

 

AgeX recognized $132,000 and $131,000 in amortization expense of intangible assets for continuing operations, included in research and development expenses, for the years ended December 31, 2022 and 2021, respectively.

 

Amortization expense of intangible assets for discontinued operations for the year ended December 31, 2021 amounted to $89,000. See Note 3, Disposition and Deconsolidation of LifeMap Sciences for discussion of discontinued operations.

 

Amortization of intangible assets for periods subsequent to December 31, 2022 is as follows (in thousands):

 

Year Ending December 31, 

Amortization

Expense

 
2023  $131 
2024   132 
2025   131 
2026   131 
Thereafter   213 
Total  $738 

 

Accounts Payable and Accrued Liabilities

 

At December 31, 2022 and 2021, accounts payable and accrued liabilities were comprised of the following (in thousands):

 

         
   December 31, 
   2022   2021 
Accounts payable  $568   $193 
Accrued compensation   193    212 
Accrued vendors and other expenses   273    366 
Total accounts payable and accrued liabilities  $1,034   $771 

 

5. Related Party Transactions

 

2019 Loan Agreement

 

On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence provided to AgeX a $2.0 million line of credit for a period of 18 months. On February 10, 2021, AgeX entered into an amendment (the “First Amendment”) to the 2019 Loan Agreement which extended the maturity date of loans under the 2019 Loan Agreement to February 14, 2022 and increased the amount of the loan facility by $4.0 million. On November 8, 2021, AgeX entered into Amendment No. 2 to the 2019 Loan Agreement which increased the amount of the loan facility by another $1.0 million. As of December 31, 2021, AgeX had borrowed all of the $7.0 million total line of credit under the 2019 Loan Agreement, as amended. On February 14, 2022, AgeX refinanced the $7.0 million outstanding principal amount of the loans and a $160,000 origination fee due under the 2019 Loan Agreement, as amended. See discussion regarding 2022 Secured Convertible Promissory Note within this Note 5.

 

F-21
 

 

2020 Loan Agreement

 

On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence provided to AgeX an $8.0 million line of credit for a period of 18 months. Through December 31, 2022, AgeX had drawn the full $8.0 million line of credit. AgeX issued to Juvenescence 28,500 shares of AgeX common stock as an arrangement fee for the loan facility when AgeX borrowed an aggregate of $3.0 million under the 2020 Loan Agreement, and AgeX issued to Juvenescence warrants to purchase a total of 3,670,663 shares of AgeX common stock (“2020 Warrants”). The number of 2020 Warrants issued was determined by the warrant formula described below. The repayment date for the outstanding principal balance of the loan under the 2020 Loan Agreement will be March 30, 2024 (see Note 11, Subsequent Events).

 

Default Provisions – The loan balance may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the 2020 Loan Agreement include the following: (i) AgeX fails to pay any amount in the manner and at the time provided in the 2020 Loan Agreement and the failure to pay is not remedied within 10 business days; (ii) AgeX fails to perform any of its obligations under the 2020 Loan Agreement and if the failure can be remedied it is not remedied to the satisfaction of Juvenescence within 10 business days after notice to AgeX; (iii) other indebtedness for money borrowed in excess of $100,000 becomes due and payable or can be declared due and payable prior to its due date or if indebtedness for money borrowed in excess of $25,000 is not paid when due; (iv) AgeX stops payment of its debts generally or discontinues its business or becomes unable to pay its debts as they become due or enters into any arrangement with creditors generally; (v) AgeX becoming insolvent or in liquidation or administration or other insolvency procedures, or a receiver, trustee or similar officer is appointed in respect of all or any part of its assets and such appointment continues undischarged or unstayed for sixty days; (vi) it becomes illegal for AgeX to perform its obligations under the 2020 Loan Agreement or any governmental permit, license, consent, exemption or similar requirement for AgeX to perform its obligations under the 2020 Loan Agreement or to carry out its business is not obtained or ceases to remain in effect; (vii) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX if such process is not released, vacated or fully bonded within sixty calendar days after its issue or levy; (viii) any injunction, order or judgement of any court is entered or issued which in the opinion of Juvenescence materially and adversely affects the ability of AgeX to carry out its business or to pay amounts owed to Juvenescence under the 2020 Loan Agreement; (ix) there is a change in AgeX’s financial condition that in the opinion of Juvenescence materially and adversely affects, or is likely to so affect, its ability to perform any of its obligations under the 2020 Loan Agreement; (x) AgeX or a designated subsidiary sells, leases, licenses, consigns, transfers, or otherwise disposes of a material part of their assets other than inventory in the ordinary course of business or certain intercompany transactions, or certain other limited permitted transactions, unless Juvenescence approves; (xi) AgeX or a designated subsidiary contests the validity of its obligations under the 2020 Loan Agreement or other related agreement with Juvenescence; (xii) any representation, warranty, or other statement made by AgeX or a designated subsidiary under the 2020 Loan Agreement is incomplete, untrue, incorrect, or misleading: and (xiii) AgeX or a designated subsidiary suspends or ceases to carry on all or a material part of its business or threatens to do so.

 

2020 Warrants — Under the terms of the 2020 Loan Agreement, each time AgeX received an advance of funds under the 2020 Loan Agreement, AgeX issued to Juvenescence a number of 2020 Warrants equal to 50% of the number determined by dividing the amount of the advance by the applicable Market Price. The Market Price set each 2020 Warrant when issued was the closing price per share of AgeX common stock on the NYSE American on the date of the applicable notice from AgeX requesting a draw of funds that triggered the obligation to issue the 2020 Warrant. The exercise price of the 2020 Warrants is the applicable Market Price. The 2020 Warrants will expire at 5:00 p.m. New York time three years after the date of issue. As of December 31, 2022, AgeX had issued to Juvenescence 2020 Warrants to purchase 3,670,663 shares of AgeX common stock. The exercise prices of the 2020 Warrants issued through December 31, 2022 range from $0.70 per share to $1.895 per share representing the market closing price on the NYSE American of AgeX common stock on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

Conversion of Loan Amounts to Common Stock – In lieu of repayment of funds borrowed, AgeX may convert the loan balance into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock.

 

2022 Secured Convertible Promissory Note and Security Agreement

 

On February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence agreed to provide to AgeX a $13,160,000 line of credit for a period of 12 months. AgeX drew an initial $8,160,000 of the line of credit and used $7,160,000 to refinance the outstanding principal and the loan origination fees under the 2019 Loan Agreement with Juvenescence. During the year ended December 31, 2022, AgeX borrowed an additional $4.5 million under the Secured Note. During January 2023, AgeX borrowed an additional $500,000 under the Secured Note and during February 2023 the Secured Note was amended and restated to increase the total line of credit available by $2,000,000 and the date by which additional funds can be drawn was extended to May 9, 2023. The outstanding principal balance of the Secured Note, as amended will become due and payable on February 14, 2024. See Note 11, Subsequent Events for additional information on the amended and restated Secured Note.

 

F-22
 

 

As an arrangement fee for the Secured Note, AgeX will pay Juvenescence an origination fee in an amount equal to 4% of the amount each draw of loan funds, which will accrue as each draw is funded, and an additional 4% of all the total amount of funds drawn that will accrue following the end of the period during which funds may be drawn from the line of credit. The origination fee will become due and payable on the repayment date or in a pro rata amount with any prepayment of in whole or in part of the outstanding principal balance of the Secured Note.

 

2022 Warrants – Upon each drawdown of funds under the Secured Note, AgeX will issue to Juvenescence warrants to purchase shares of AgeX common stock (“2022 Warrants”). The 2022 Warrants will be governed by the terms of a Warrant Agreement between AgeX and Juvenescence. The number of 2022 Warrants to be issued will be equal to 50% of the number determined by dividing the amount of the applicable loan draw by the applicable Market Price. The Market Price will be the last closing price per share of AgeX common stock on the NYSE American or other national securities exchange preceding the delivery of the notice from AgeX requesting a draw of funds that triggers the obligation to issue 2022 Warrants; provided, however that if AgeX common stock is not traded on a national securities exchange the Market Price shall be determined with reference to closing prices quoted or bid and asked prices on an interdealer quotation system averaged over twenty consecutive trading days. The exercise price of the 2022 Warrants will be the applicable Market Price. The 2022 Warrants will expire at 5:00 p.m. New York time three years after the date of issue.

 

As of December 31, 2022, AgeX had issued to Juvenescence 2022 Warrants to purchase 8,458,597 shares of AgeX common stock. The exercise prices of the 2022 Warrants issued through December 31, 2022 range from $0.59 per share to $0.88 per share representing the market closing price of AgeX common stock on the NYSE American on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

Conversion of Loan Amounts to Common Stock – In lieu of repayment of funds borrowed, AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock.

 

Default Provisions – The loan balance and origination fees may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the Secured Note include the following: (a) AgeX fails to pay any principal amount payable by it in the manner and at the time provided under and in accordance with the Secured Note; (b) AgeX fails to pay any other amount payable by it in the manner and at the time provided under and in accordance with the Secured Note or the Security Agreement described below or any other agreement executed in connection with the Secured Note (the “Loan Documents”) and the failure is not remedied within three business days; (c) AgeX fails to perform any of its covenants or obligations or fail to satisfy any of the conditions under the Secured Note or any other Loan Document and, such failure (if capable of remedy) remains unremedied to the satisfaction of Juvenescence (in its sole discretion) for 10 business days after the earlier of (i) notice requiring its remedy has been given by Juvenescence to AgeX and (ii) actual knowledge of the failure by senior officers of AgeX; (d) if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date; (e) AgeX stops payment of its debts generally or ceases or threatens to cease to carry on its business or is unable to pay its debts as they fall due or is deemed by a court of competent jurisdiction to be unable to pay its debts as they fall due, or enters into any arrangements with its creditors generally; (f) if (i) an involuntary proceeding (other than a proceeding instituted by Juvenescence or an affiliate of Juvenescence) shall be commenced or an involuntary petition shall be filed seeking liquidation, reorganization or other relief in respect of AgeX and any subsidiary, or of all or a substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) an involuntary appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for AgeX or a subsidiary or for a substantial part of its assets occurs (other than in a proceeding instituted by Juvenescence or an affiliate of Juvenescence), and, in any such case, such proceeding shall continue undismissed and unstayed for sixty (60) consecutive days without having been dismissed, bonded or discharged or an order of relief is entered in any such proceeding; (g) it becomes unlawful for AgeX to perform all or any of its obligations under the Secured Note or any authorization, approval, consent, license, exemption, filing, registration or other requirement of any governmental, judicial or public body or authority necessary to enable AgeX to comply with its obligations under the Secured Note or to carry on its business is not obtained or, having been obtained, is modified in a manner that precludes AgeX or its subsidiaries from conducting their business in any material respect, or is revoked, suspended, withdrawn or withheld or fails to remain in full force and effect; (h) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX or a subsidiary if such process is not released, vacated or fully bonded within 60 calendar days after its issue or levy; (i) any injunction, order, judgment or decision of any court is entered or issued which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX or a subsidiary to carry on its business or to pay amounts owed to Juvenescence under the Secured Note; (j) AgeX, whether in a single transaction or a series of related transactions, sells, leases, licenses, consigns, transfers or otherwise disposes of any material portion of its assets (with any such disposition with respect to any asset or assets with a fair value of at least $250,000 being deemed material), other than (i) certain permitted investments (ii) sales, transfers and dispositions of inventory in the ordinary course of business, (iii) any termination of a lease of real or personal property that is not necessary in the ordinary course of the AgeX’s business, could not reasonably be expected to have a material adverse effect and does not result from AgeX’s default, and (iv) any sale, lease, license, consignment, transfer or other disposition of assets that are no longer necessary in the ordinary course of business or which has been approved in writing by Juvenescence; (k) any of the following shall occur: (i) the security and/or liens created by the Security Agreement or any other Loan Document shall at any time cease to constitute valid and perfected security and/or liens on any material portion of the collateral intended to be covered thereby; (ii) except for expiration in accordance with its terms, the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall for whatever reason be terminated or shall cease to be in full force and effect; (iii) the enforceability of the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall be contested by AgeX or a subsidiary; (iv) AgeX shall assert that its obligations under the Secured Note or any other Loan Document shall be invalid or unenforceable; or (v) a loss, theft, damage or destruction occurs with respect to a material portion of the collateral; (l) there is any change in the financial condition of AgeX and its subsidiaries which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX to perform any of its obligations under the Secured Note; and (m) any representation, warranty or statement made, repeated or deemed made or repeated by AgeX in the Secured Note, or pursuant to the Loan Documents, is incomplete, untrue, incorrect or misleading in any material respect when made, repeated or deemed made.

 

F-23
 

 

Restrictive Covenants – The Secured Note includes certain covenants that among other matters such as financial reporting: (i) impose financial restrictions on AgeX while the Secured Note remains unpaid, including restrictions on the incurrence of additional indebtedness by AgeX and its subsidiaries, except that AgeX’s subsidiary Reverse Bio will be permitted to incur debt convertible into equity not guaranteed or secured by the assets of AgeX or any other AgeX subsidiary, and the restrictions on the incurrence of indebtedness applicable to Reverse Bio will end if it raises more than $15.0 million in debt or equity financing by May 15, 2023 (ii) require that AgeX use loan proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, for general working capital, and for repayment of all or a portion of AgeX’s indebtedness to Juvenescence; and (iii) prohibit AgeX from making additional investments in subsidiaries, unless AgeX obtains the written consent of Juvenescence to a transaction that otherwise would be prohibited or restricted.

 

Security Agreement – AgeX has entered into a Security Agreement granting Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral.

 

Registration Rights

 

AgeX entered into certain Registration Rights Agreements pursuant to which it has agreed to register for sale under the Securities Act all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement, and shares that they may acquire through the conversion of the loans into AgeX common stock. AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of our common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence. Juvenescence retains the right to require AgeX to register additional shares of common stock that Juvenescence may acquire through the exercise of warrants or the conversion of loans. AgeX is obligated to pay the fees and expenses of each registered offering under such registration rights agreement except for underwriting discounts and commissions. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.

 

AgeX entered into an amendment to its Registration Rights Agreement with Juvenescence to include the 2022 Warrants and underlying shares and any shares issuable upon the conversion of the Secured Note into common stock as registrable securities under the Registration Rights Agreement.

 

Debt Issuance Costs

 

In accordance with ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, all debt issuance costs are recorded as a discount on the debt and amortized to interest expense over the term of the loan agreement using the effective interest method. Direct debt issuance costs include but are not limited to legal fees, debt origination fees, estimated fair market value of common stock and warrants issued in connection with the loan agreements, and NYSE American additional listing fees for the underlying shares of warrants issued with each drawdown of funds.

 

F-24
 

 

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2022 (in thousands):

 

   Drawdown of Funds   Origination Fee   Amount Refinanced   Total Debt   Debt Issuance Costs   Amortization of Debt Issuance Costs   Total Debt, Net 
2019 Loan Agreement  $7,000   $160   $(7,160)  $-   $(494)  $494   $- 
2020 Loan Agreement   8,000    -    -    8,000    (2,805)   2,451    7,646 
2022 Secured Note   12,660    691    -    13,351    (4,720)   1,847    10,478 
   $27,660   $851   $(7,160)  $21,351   $(8,019)  $4,792   $18,124 

 

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2021 (in thousands):

 

   Drawdown of Funds   Origination Fee   Amount Refinanced   Total Debt   Debt Issuance Costs   Amortization of Debt Issuance Costs   Total Debt, Net 
2019 Loan Agreement  $7,000   $160   $     -   $7,160   $(494)  $474   $7,140 
2020 Loan Agreement   7,500    -    -    7,500    (2,620)   1,182    6,062 
   $14,500   $160   $-   $14,660   $(3,114)  $1,656   $13,202 

 

Related Party Payables

 

Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, has been devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $280,000. As of December 31, 2022 and 2021, AgeX had approximately $141,000 and $70,000, respectively, payable to Juvenescence for COO services rendered, included in related party payables, net of certain expenses owed by Juvenescence to AgeX, on the consolidated balance sheets.

 

6. Warrant Liability

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, Distinguishing Liabilities from Equity, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or the warrants must or may require AgeX to issue a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP.

 

As a condition of each amount drawn from the Secured Note, on receipt of each amount drawn AgeX shall grant to Juvenescence a number of warrants equal to 50% of the gross value of the relevant advance made. The gross value is the quotient of the drawdown amount and the exercise price. The exercise price is based on the market closing price of AgeX’s common stock on the NYSE American on the one day preceding the delivery of the relevant drawdown notice (see Note 5, Related Party Transactions).

 

Given AgeX’s history, it is AgeX’s judgement that it is more likely than not that AgeX will utilize the full credit available under the Secured Note and accordingly warrants will be issued for each of the advances made within the credit availability period consisting of the 12 month period starting February 14, 2022. After all relevant assessments, AgeX determined that the warrants issued under the Secured Note require classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity. In accordance with the accounting guidance, the number of warrants that would have been issued if the amount of credit under the Secured Note was drawn in full is measured at the inception date at fair value and recognized as a warrant liability on the balance sheet, adjusted for the fair value of warrants actually issued upon each advance, and subsequently the number of warrants that may be issued for the remaining credit available is re-measured at each reporting period with changes being recorded as a component of net other expense in the consolidated statements of operations.

 

F-25
 

 

The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:

 

Black-Scholes Assumptions 

Exercise

Price (1)

   Warrant Expiration Date (2) 

Stock

Price (3)

   Interest Rate (annual) (4)   Volatility (annual) (5)   Time to Maturity (Years)   Calculated Fair Value per Share 
Inception Date: 2/14/2022  $0.780   13-Feb-25  $0.691    1.80%    122.99%    3   $0.486 
Issuance Date: 2/14/2022  $0.780   13-Feb-25  $0.691    1.80%    122.99%    3   $0.486 
Issuance Date: 2/15/2022  $0.780   14-Feb-25  $0.747    1.80%    123.28%    3   $0.535 
Period Ended 3/31/2022  $0.940   30-Mar-25  $0.854    2.45%    123.28%    3   $0.607 
Issuance Date: 4/4/2022  $0.880   3-Apr-25  $0.819    2.61%    123.31%    3   $0.585 
Issuance Date: 6/6/2022  $0.711   5-Jun-25  $0.800    2.94%    122.62%    3   $0.592 
Period Ended 6/30/2022  $0.600   29-Jun-25  $0.576    2.99%    122.21%    3   $0.413 
Issuance Date: 8/16/2022  $0.670   15-Aug-25  $0.640    3.19%    121.37%    3   $0.457 
Period Ended 9/30/2022  $0.610   29-Sep-25  $0.562    4.25%    121.49%    3   $0.401 
Issuance Date: 10/21/2022  $0.690   20-Oct-25  $0.620    4.52%    120.51%    3   $0.439 
Issuance Date: 12/14/2022  $0.590   13-Dec-25  $0.540    3.94%    120.01%    3   $0.381 
Period Ended 12/31/2022  $0.550   30-Dec-25  $0.552    4.22%    119.31%    3   $0.396 

 

 

(1)Based on the market closing price of AgeX’s common stock on the NYSE American on the one day prior to the debt inception date and each presented period ending date and also the market closing price of AgeX’s common stock on the NYSE American on the one trading day preceding the delivery of the relevant drawdown notice in accordance with terms per the Secured Note.

 

(2)Warrants are exercisable over a three-year period from each issuance date.

 

(3)Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.

 

(4)Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.

 

(5)Based on the historical daily volatility of AgeX common stock as of each date presented.

 

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

Warrant Liability 

Credit Line and Draw Amounts

(in thousands)

   Warrants  

Fair Value

per Share

  

Fair Value

(in thousands)

 
Fair value as of January 1, 2022  $               -                         -   $          -   $           - 
Fair value at initial measurement date of 2/14/2022   13,160(1)       8,435,897(2)    0.4864       4,103 
Fair value of warrants issued on 2/14/2022   (7,160)(3)    (4,589,743)(4)    0.4864    (2,232)
Fair value of warrants issued on 2/15/2022   (1,000)(3)       (641,025)(4)    0.5349       (343)
Fair value of warrants issued on 4/4/2022   (1,000)(3)       (568,440)(4)    0.5854       (333)
Fair value of warrants issued on 6/6/2022   (1,000)(3)       (703,234)(4)    0.5924       (417)
Fair value of warrants issued on 8/16/2022   (1,000)(3)       (746,380)(4)    0.4569       (341)
Fair value of warrants issued on 10/21/2022     (500)(3)       (362,318)(4)    0.4386       (159)
Fair value of warrants issued on 12/14/2022   (1,000)(3)       (847,457)(4)    0.3810       (323)
Change in fair value of warrant liability                  -                         -              -          225 
Fair value as of December 31, 2022  $     500(1)       454,545(2)   $0.3960   $     180 

 

 

(1)Amount of credit available under the Secured Note on date of inception and as of each period end date.

 

(2)Number of warrants issuable if the amount of credit available were drawn for measurement as of inception date and subsequently for remeasurement as of each period end date.

 

(3)Amount of drawdown as of each date presented.

 

(4)Number of warrants issued upon receipt of amounts drawn against the Secured Note as of each date presented.

 

During the year ended December 31, 2022, AgeX recorded a loss of $225,000 on changes in the fair value of warrant liability. There were no warrant liabilities or corresponding changes in valuation during the year ended December 31, 2021.

 

The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and AgeX’s stock prices and historical volatility as inputs. During the year ended December 31, 2022, none of the warrants issued were exercised.

 

F-26
 

 

 

7. Stockholders’ Deficit

 

Preferred Stock

 

AgeX is authorized to issue up to 5,000,000 shares of preferred stock, $0.0001 par value per share. At December 31, 2022 and 2021, there were no preferred shares issued and outstanding.

 

Common Stock

 

AgeX has 200,000,000 shares of common stock, $0.0001 par value per share, authorized. The holders of AgeX’s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of AgeX common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of AgeX outstanding preferred shares, if any.

 

The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of AgeX stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable.

 

As of December 31, 2022 and 2021, there were 37,949,196 and 37,941,220 shares of AgeX common stock issued and outstanding, respectively.

 

Issuance of Warrants by AgeX

 

In connection with the $12,660,000 of drawdowns of loan funds from Juvenescence under the Secured Note during the year ended December 31, 2022, AgeX has issued to Juvenescence 2022 Warrants to purchase 8,458,597 shares of AgeX common stock.

 

As consideration for $8.0 million in loans made to AgeX under the 2020 Loan Agreement, AgeX issued to Juvenescence warrants to purchase 3,670,663 shares of AgeX common stock.

 

See Notes 5, Related Party Transactions and 6, Warrant Liability for additional information on warrants issued to Juvenescence.

 

At-the-Market Offering Facility

 

On January 8, 2021, AgeX entered into a Sales Agreement with Chardan, relating to the sale of shares of AgeX common stock, in at-the-market transactions. In accordance with the terms of the Sales Agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $12.6 million from time to time through Chardan, acting as the sales agent. The actual market value of common shares that AgeX may sell through its Sales Agreement with Chardan during any 12 month period will be limited to one-third of aggregate market value of our common stock held by stockholders that would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. During the years ended December 31, 2022 and 2021, AgeX raised nil and $496,000, respectively, in gross proceeds through the sale of shares of common stock through the Sales Agreement with Chardan.

 

8. Stock-Based Awards

 

Equity Incentive Plan

 

Under the 2017 Equity Incentive Plan, as amended (the “Incentive Plan”), AgeX has reserved 8,500,000 shares of common stock for the grant of stock options or the sale of restricted stock (“Restricted Stock”) or for the settlement of restricted stock units which are hypothetical units issued with reference to common stock (“Restricted Stock Units” or “RSUs”). AgeX may also grant stock appreciation rights (“SARs”) under the Incentive Plan. The Plan also permits AgeX to issue such other securities as its Board of Directors (the “Board”) or the Compensation Committee (the “Committee”) administering the Incentive Plan may determine. Awards of stock options, Restricted Stock, SARs, and RSUs (“Awards”) may be granted under the Incentive Plan to AgeX employees, directors, and consultants.

 

Awards may vest and thereby become exercisable or have restrictions on forfeiture lapse on the date of grant or in periodic installments or upon the attainment of performance goals, or upon the occurrence of specified events.

 

No person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than 1,000,000 shares in the aggregate, or any Awards of Restricted Stock or RSUs with respect to more than 500,000 shares in the aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual share limit.

 

No Awards may be granted under the Incentive Plan more than ten years after the date upon which the Incentive Plan was adopted by the Board, and no options or SARS granted under the Incentive Plan may be exercised after the expiration of ten years from the date of grant.

 

F-27
 

 

Stock Options

 

Options granted under the Incentive Plan may be either “incentive stock options” within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the “Code”), or “non-qualified” stock options that do not qualify incentive stock options. Incentive stock options may be granted only to AgeX employees and employees of subsidiaries. The exercise price of stock options granted under the Incentive Plan must be equal to the fair market of AgeX common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of AgeX stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $100,000.

 

The exercise price of an option may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board or Committee may approve.

 

Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter, but in the case of the termination of an employee, director, or consultant’s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option.

 

Restricted Stock and RSUs

 

In lieu of granting options, AgeX may enter into purchase agreements with employees under which they may purchase or otherwise acquire Restricted Stock or RSUs subject to such vesting, transfer, and repurchase terms, and other restrictions. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value. Employees or consultants, but not executive officers or directors, who purchase Restricted Stock may be permitted to pay for their shares by delivering a promissory note or an installment payment agreement that may be secured by a pledge of their Restricted Stock. Restricted Stock may also be issued for services actually performed by the recipient prior to the issuance of the Restricted Stock. Unvested Restricted Stock for which AgeX has not received payment may be forfeited, or AgeX may have the right to repurchase unvested shares upon the occurrence of specified events, such as termination of employment.

 

Subject to the restrictions set with respect to the particular Award, a recipient of Restricted Stock generally shall have the rights and privileges of a stockholder, including the right to vote the Restricted Stock and the right to receive dividends; provided that, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld for the recipient’s account, and interest may be credited on the amount of the cash dividends withheld. The cash dividends or stock dividends so withheld and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to the recipient in cash or, at the discretion of the Board or Committee, in shares of common stock having a fair market value equal to the amount of such dividends, if applicable, upon the release of restrictions on the Restricted Stock and, if the Restricted Stock is forfeited, the recipient shall have no right to the dividends.

 

The terms and conditions of a grant of RSUs shall be determined by the Board or Committee. No shares of common stock shall be issued at the time a RSU is granted. A recipient of RSUs shall have no voting rights with respect to the RSUs. Upon the expiration of the restrictions applicable to a RSU, AgeX will either issue to the recipient, without charge, one share of common stock per RSU or cash in an amount equal to the fair market value of one share of common stock.

 

At the discretion of the Board or Committee, each RSU (representing one share of common stock) may be credited with cash and stock dividends paid in respect of one share (“Dividend Equivalents”). Dividend Equivalents shall be withheld for the recipient’s account, and interest may be credited on the amount of cash Dividend Equivalents withheld. Dividend Equivalents credited to a recipient’s account and attributable to any particular RSU (and earnings thereon, if applicable) shall be distributed in cash or in shares of common stock having a fair market value equal to the amount of the Dividend Equivalents and earnings, if applicable, upon settlement of the RSU. If a RSU is forfeited, the recipient shall have no right to the related Dividend Equivalents.

 

SARs

 

A SAR is the right to receive, upon exercise, an amount payable in cash or shares, or a combination of shares and cash, equal to the number of shares subject to the SAR that is being exercised, multiplied by the excess of (a) the fair market value of a common stock on the date the SAR is exercised, over (b) the exercise price specified in the SAR Award agreement. SARs may be granted either as free standing SARs or in tandem with options. No SAR may be exercised later than 10 years after the date of grant.

 

F-28
 

 

The exercise price of a SAR shall not be less than 100% of the fair market value of one share of common stock on the date of grant. A SAR granted in conjunction with an option shall have the same exercise price as the related option, shall be transferable only upon the same terms and conditions as the related option, and shall be exercisable only to the same extent as the related option; provided, however, that the SAR by its terms shall be exercisable only when the fair market value per share exceeds the exercise price per share of the SAR or related option. Upon any exercise of a SAR granted in tandem with an option, the number of shares for which the related option shall be exercisable shall be reduced by the number of shares for which the SAR has been exercised. The number of shares for which a SAR issued in tandem with an option shall be exercisable shall be reduced by the number of shares for which the related option has been exercised.

 

Equity Incentive Plan Awards

 

A summary of the Incentive Plan activity and related information follows (in thousands except weighted-average exercise price):

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted-

Average

Exercise Price

 
Balance at January 1, 2021   1,046    2,854      28   $2.51 
Increase option pool      500            -         -         - 
Options granted   (568)        568         -    1.46 
Options forfeited, cancelled or expired        57       (57)         -    2.56 
Restricted stock units vested           -            -    (12)         - 
Balance at December 31, 2021   1,035    3,365      16   $2.32 
Increase option pool   4,000            -         -          - 
Options granted   (105)        105         -    0.79 
Options forfeited, cancelled or expired       209    (209)         -    2.82 
Restricted stock units vested           -            -    (13)         - 
Balance at December 31, 2022   5,139    3,261         3   $2.25 
Options exercisable at December 31, 2022        2,913        $2.37 

 

There were no exercises of stock options during the years ended December 31, 2022 and 2021. Total proceeds if all options granted and outstanding as of December 31, 2022 were exercised would be approximately $7.3 million.

 

At December 31, 2022, AgeX had approximately $0.3 million of total unrecognized compensation costs related to the stock options and unvested RSUs under the Incentive Plan that will be recognized as expense over a weighted-average period of approximately 2.02 years.

 

The aggregate intrinsic value of options outstanding was $1,700 and options exercisable was nil as of December 31, 2022.

 

Stock-Based Compensation Expense

 

AgeX recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021 (in thousands):

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Research and development – continuing operations  $32   $62 
General and administrative – continuing operations   728    937 
Total stock-based compensation expense – continuing operations   760    999 
General and administrative – discontinued operations   -    4 
Total stock-based compensation expense  $760   $1,003 

 

The weighted-average estimated fair value of stock options granted during the years ended December 31, 2022 and 2021 was $0.70 per share and $1.15 per share, respectively, using the Black-Scholes option pricing model with the following weighted-average assumptions:

 

   Year Ended December 31, 
   2022   2021 
Grant Price  $       0.79   $        1.46 
Expected life (in years)          5.58             5.71 
Risk-free interest rates       1.74%        0.99% 
Volatility   130.71%    102.34% 
Dividend yield            -%              -% 

 

F-29
 

 

The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If AgeX had made different assumptions, its stock-based compensation expense and net loss for the years ended December 31, 2022 and 2021 may have been significantly different. See Note 2, Summary of Significant Accounting Policies for a discussion of the factors used in determining these assumptions.

 

AgeX does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

 

9. Income Taxes

 

Net loss from operations before income taxes as of December 31, 2022 and 2021 are approximately $10.5 million and $8.7 million, respectively.

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

 

The primary components of the net deferred tax assets and liabilities as of December 31, 2022 and 2021 were as follows (in thousands):

 

         
   December 31, 
Deferred tax assets/(liabilities):  2022   2021 
Net operating loss carryforwards  $12,408   $12,000 
Capital loss carryforwards   3,120    3,120 
Research and development credit carryforwards   1,138    1,426 
Patents and fixed assets   879    901 
Stock-based compensation   643    690 
Capitalized Research Expenses   211    - 
Other, net   62    80 
Valuation allowance   (18,461)   (18,217)
Total net deferred tax assets  $-   $- 

 

A valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

 

Income taxes differed from the amounts computed by applying the U.S. federal income tax rate indicated to pretax losses from operations as a result of the following:

 

   December 31, 
   2022   2021 
Computed tax benefit at federal statutory rate    21%      21% 
Research and development and other credits      1%        1% 
State tax benefit, net of effect on federal income taxes   (7)%      14% 
Permanent differences      -%     (1)% 
Stock Based Compensation   (2)%        -% 
Loss and deconsolidation of LifeMap Sciences       -%   (31)% 
Debt finance equity costs   (6)%        -% 
Return to provision & other adjustments   (5)%        -% 
Change in valuation allowance   (2)%     (4)% 
       -%         -% 

 

AgeX has established an accrual for uncertain tax positions related to its U.S. research and development credits. As of December 31, 2022 and 2021, there was no accrued interest related to uncertain tax positions. AgeX does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):

 

       
   December 31, 
   2022   2021 
Balance at January 1  $ -   $       - 
Additions for tax positions related to the current year   23    - 
Additions for tax positions related to prior years   356    - 
Reductions for tax positions related to prior years   -    - 
Reductions related to settlements   -    - 
Reductions related to a lapse of statute   -    - 
Balance at December 31  $379   $- 

 

F-30
 

 

AgeX monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2022, AgeX had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.

 

As of December 31, 2022, AgeX has net operating loss carryforwards of approximately $52.8 million for U.S. federal income tax purposes. In general, NOLs and other tax credit carryforwards generated by legal entities in a consolidated federal tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the consolidated federal tax group.

 

As of December 31, 2022, AgeX has net operating losses of approximately $14.9 million for California purposes. As AgeX and its subsidiaries have been included in the combined California tax return with Lineage, up to the date of deconsolidation on August 30, 2018, those state net operating losses will remain with AgeX. In general, NOLs and other tax credit carryforwards generated by legal entities in a combined state tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the combined state tax group. Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2042.

 

As of December 31, 2022, AgeX has research and development tax credit carryforwards for federal and state tax purposes of $0.9 million and $0.6 million, respectively. The federal tax credits expire between 2028 and 2042, while the state tax credits have no expiration date.

 

As of December 31, 2022, AgeX has capital loss carryforwards for federal and state tax purposes of $12.4 million and $5.9 million, respectively. The federal and California capital loss carryforwards will expire in 2026.

 

Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (“R&E”) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. We will continue to monitor this issue for future developments, but we does not expect R&E capitalization and amortization to require us to pay cash taxes now or in the near future.

 

Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. stockholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2021, AgeX’s foreign entity operated at an immaterial loss; therefore, no GILTI was included in income. For the year ended December 31, 2022, there was no income or loss related to foreign activity as the entity deconsolidated from AgeX on March 15, 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.

 

For the year ended December 31, 2022, we experienced a domestic loss from continuing operations; therefore, no income tax provision was recorded for the year ended December 31, 2022.

 

The sale of LifeMap Sciences resulted in a taxable loss primarily due to AgeX’s tax basis in the subsidiary.

 

Other Income Tax Matters

 

Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods.

 

AgeX and its subsidiaries may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. AgeX filed its first consolidated federal tax return in 2018. AgeX and its current subsidiaries are not subject to tax examination by federal tax authorities for tax years beginning before 2019 and for state tax authorities beginning before 2018. However, the tax authorities may still make adjustments to the net operating loss and credit carryforwards used in open years by AgeX or any of its subsidiaries. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.

 

F-31
 

 

10. Commitments and Contingencies

 

Office Lease Agreement

 

Effective January 1, 2021, AgeX relocated its principal offices to a 135 square foot leased space in a building located in an office and research park in Alameda, California. Base monthly rent was $947 for the first year of the lease term. In September 2021, AgeX extended its office lease for another year, effective January 1, 2022, at a monthly rent of $1,074. In October 2022, AgeX entered into a new one-year lease that became effective January 1, 2023 for a different space, comprising of 101 square feet, in the same building, at a monthly rent of $844. The lease also includes office furniture rental, janitorial services, utilities, and internet service.

 

ASC 842

 

For the office lease, AgeX has elected to not apply the recognition requirements under ASC 842 and instead recognized the lease payments as lease costs on a straight-line basis over the lease term, as the amount of the lease payments is not deemed material.

 

There were no future minimum lease commitments as of December 31, 2022.

 

Litigation – General

 

AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.

 

Tax Filings

 

AgeX tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes AgeX has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the consolidated financial statements.

 

Employment Contracts

 

AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations.

 

Indemnification

 

In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s research and development programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s research and development. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property licensed from AgeX to third parties. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The sales agreement between AgeX and Chardan also includes indemnification provisions pursuant to which the parties have agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock through the ATM facility, including liabilities under the Securities Act. Similarly, the Registration Rights Agreement between Juvenescence and AgeX includes indemnification provisions pursuant to which the parties will indemnify each other from certain liabilities in connection with the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular license, lease, or agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements as of December 31, 2022 and 2021.

 

Paycheck Protection Program Loan

 

On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from a bank under the Paycheck Protection Program (the “PPP Loan”). The PPP Loan bore interest at a rate of 1% per annum. No payments were due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest became due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date was April 13, 2022. The principal amount of the PPP Loan was subject to forgiveness under the Paycheck Protection Program (the “Program”) to the extent of PPP Loan proceeds that were used to pay expense permitted by the Program, including payroll, rent, and utilities during the time frame permitted by the Program. On February 19, 2021, the PPP Loan was forgiven in full.

 

On December 27, 2020, the Consolidated Appropriations Act of 2021 was signed into law, retroactively allowing a federal deduction of the expenses that gave rise to the PPP Loan forgiveness. California does not allow a deduction for these expenses for publicly traded companies.

 

F-32
 

 

Notice of Delisting

 

On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders’ equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan.

 

On April 15, 2021, AgeX regained compliance with all of the Exchange’s continued listing standards set forth in Part 10 of the Exchange Company Guide. Specially, the Exchange has resolved the continued listing deficiency with respect to Section 1003(a)(i) of the Exchange Company Guide.

 

On November 17, 2021, AgeX received a second deficiency letter (“2021 Deficiency Letter”) from the staff of the Exchange indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX had stockholders equity of less than $2,000,000 and had incurred losses from continuing operations and/or net losses during the two most recent fiscal years, and that AgeX had stockholders equity of less than $4,000,000 and had incurred losses from continuing operations and/or net losses during three out of four of the most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the 2021 Deficiency Letter, AgeX provided the Exchange staff with an updated plan (the “2021 Plan”) during December 2021 advising the Exchange staff of action that AgeX had taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards. The Exchange staff accepted the 2021 Plan which was subsequently revised by AgeX in the course of the Exchange’s continued monitoring of AgeX’s progress to attain compliance with the continued listing standards. During November 2022, the Exchange sent AgeX a notification indicating that the Exchange has accepted the revised 2021 Plan and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide by increasing stockholders equity to not less than $4,000,000. The Exchange staff will periodically review AgeX’s adherence to the revised 2021 Plan milestones. If we are not in compliance with the continued listing standards by May 17, 2023, or if AgeX does not make progress consistent with the revised 2021 Plan during the plan period, the Exchange will initiate delisting proceedings as appropriate.

 

AgeX intends to make arrangements to have its common stock quoted on an interdealer quotation system if its common stock is delisted from the Exchange.

 

11. Subsequent Events

 

2022 Secured Convertible Promissory Note

 

On January 25, 2023, AgeX borrowed an additional $500,000 under the Secured Note. In connection with that draw of loan funds under the Secured Note, AgeX issued to Juvenescence warrants to purchase 340,136 shares of AgeX common stock at an exercise price of $0.735 per share.

 

Amended and Restated Secured Convertible Promissory Note

 

On February 9, 2023, AgeX and Juvenescence entered into an Amended and Restated Secured Convertible Promissory Note which amends and restates the February 14, 2022 Secured Note and provides that AgeX may borrow up to an additional $2,000,000 from Juvenescence until May 9, 2023 subject to Juvenescence’s discretion to approve each loan draw. References to the Secured Note include the Amended and Restated Secured Note. AgeX may not draw more than $1 million in any single draw. The date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024, consistent with the original terms of the Secured Note.

 

The other material provisions of the Secured Note, including but not limited to those pertaining to loan origination fees, default provisions, provisions governing the rights of AgeX and Juvenescence to convert the loan balance and any accrued but unpaid origination fees into shares of AgeX common stock, and provisions requiring AgeX to issue common stock purchase warrants to Juvenescence in connection with borrowings remain in effect and will apply to any draw down of the additional $2,000,000 credit available under the Secured Note as amended.

 

AgeX’s obligations under the Secured Note, including with respect to any additional borrowings, will continue to be secured by the security interests in AgeX assets granted to Juvenescence pursuant to the Security Agreement.

 

On February 15, 2023, AgeX drew $1,000,000 of its available credit under the Secured Note. In connection with that draw of loan funds, AgeX issued to Juvenescence warrants to purchase 801,924 shares of AgeX common stock at an exercise price of $0.6235 per share, the closing price of AgeX common stock on the NYSE American on February 10, 2023, the trading day immediately preceding delivery of AgeX’s drawdown notice of loan funds.

 

F-33
 

 

2020 Loan Agreement

 

On March 13, 2023, the 2020 Loan Agreement was amended to extend the maturity date to March 30, 2024.

 

$10 Million Secured Convertible Promissory Note

 

On March 13, 2023, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “$10 Million Secured Note”) pursuant to which Juvenescence has loaned to AgeX $10,000,000. AgeX used the loan proceeds to finance the purchase of a Convertible Promissory Note (the “Serina Note”) issued by Serina Therapeutics Inc., an Alabama corporation (“Serina”) to AgeX on March 15, 2023, pursuant to the terms of a Convertible Note Purchase Agreement (the “Serina Note Purchase Agreement”)

 

The outstanding principal balance of the $10 Million Secured Note will become due and payable on March 13, 2026. In lieu of accrued interest, AgeX will pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.

 

If (a) AgeX and Serina have not entered into a definitive merger agreement by June 13, 2023; (b) a merger between AgeX and Serina is terminated or either party gives notice to terminate the merger agreement; or (c) the merger is not consummated by March 13, 2024, then AgeX may, after written notice to Juvenescence, pay and satisfy in full the principal balance and accrued origination fees under the $10 Million Secured Note by tendering to Juvenescence the Serina Note and shares of capital stock of Serina, if any, that may have been issued to AgeX upon conversion of the Serina Note in whole or in part.

 

AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. If less than $25,000,000 is raised through the sale of common stock or units, the conversion price per share or units shall be the lowest price at which shares or units are sold. If at least $25,000,000 is raised, the conversion price per share shall be 85% of the “Market Price” of AgeX common stock determined as provided in the $10 Million Secured Note.

 

Juvenescence may convert the outstanding principal amount of the $10 Million Secured Note plus the accrued origination fee into AgeX common stock at the market price per share of AgeX common stock. Juvenescence may not convert the $10 Million Secured Note to AgeX common stock before the earlier of (i) a merger between AgeX and Serina, and (ii) March 13, 2024. Any conversion of the $10 Million Secured Note into AgeX common stock is subject to certain restrictions to comply with applicable requirements of the NYSE American where AgeX common stock is listed.

 

The outstanding principal amount of the $10 Million Secured Note and the accrued origination fee may become immediately due and payable prior to the maturity date if an Event of Default as defined in the $10 Million Secured Note occurs. Events of Default under the $10 Million Secured Note are substantially the same events as those constituting an Event of Default under the Secured Note except that such events pertain to the $10 Million Secured Note and related loan documents.

 

The $10 Million Secured Note includes certain covenants that among other matters require financial reporting and impose certain restrictions on AgeX that are substantially the same as those under the Secured Note.

 

AgeX has entered into an Amended and Restated Security Agreement that amends the February 14, 2022 Security Agreement between AgeX and Juvenescence and adds the $10 Million Secured Note to the obligations secured by the Security Agreement. The Security Agreement grants Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral.

 

Serina Note

 

On March 15, 2023, AgeX and Serina entered into the Serina Note Purchase Agreement, pursuant to which AgeX has agreed to lend to Serina an aggregate principal amount of $10,000,000 as evidenced by the Serina Note. Interest on the principal amount under the Serina Note accrues on the unpaid principal amount at a simple interest rate equal to 7% per annum, computed on the basis of the 360-day year of twelve 30-day months. The outstanding principal balance of the Serina Note will become due and payable on March 15, 2026.

 

F-34
 

 

In connection with the issuance of the Serina Note, AgeX is entitled to elect one member to the board of directors of Serina and receive certain information and inspection rights as well as participation rights for subsequent equity issuances.

 

The principal balance of the Serina Note with accrued interest will automatically convert into Serina preferred stock if Serina raises at least $25,000,000 through the sale of shares of Serina preferred stock. The conversion price per share shall be the lower of (a) 80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by Serina’s then fully diluted capitalization. AgeX has the option to convert the Serina Note into Serina preferred stock after a sale of Serina preferred stock regardless of the amount sold by Serina.

 

AgeX may (i) at its election, upon a change of control (as defined in the Serina Note), convert the Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the Serina Note, plus interest, or (b) into the highest ranking shares of Serina then issued at a conversion price equal to the lowest price per share at which the most senior series of Serina shares has been sold in a single transaction or a series of related transactions through which Serina raised at least $5,000,000 or (ii) if the Serina Note remains outstanding as of the maturity date, AgeX may convert the Serina Note into the most senior shares of Serina issued at the time of conversion at a conversion price equal to the capped price.

 

Upon the consummation of a merger between AgeX and Serina, the Serina Note would remain outstanding and become an intercompany asset of AgeX and an intercompany liability of Serina.

 

The outstanding principal balance of the Serina Note with accrued interest may become immediately due and payable prior to the stated maturity date if an Event of Default as defined in the Serina Note occurs. In addition to this and any other remedy, both in equity and in law, upon the occurrence of an Event of Default, an interest rate of 10% per annum and computed on the basis of the 360-day year of twelve 30-day months, shall apply to the Convertible Amount until fully paid. Events of Default under the Serina Note include: (i) the commission of any act of bankruptcy by Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (ii) the execution by Serina of a general assignment for the benefit of creditors, (iii) the filing by or against Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) of a petition in bankruptcy or any petition for relief under the federal bankruptcy act (or, in each case, under any similar insolvency law) or the continuation of such petition without dismissal for a period of 60 calendar days or more, (iv) the appointment of a receiver or trustee to take possession of the property or assets of Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (v) failure of Serina to pay any amount due under the Serina Note when due, which failure to pay is not cured by Serina within 5 business days of written notice thereof, (vi) unless waived by AgeX, Serina’s material breach of any representation, warranty or covenant of Serina under the Serina Note Purchase Agreement, Serina Note or other agreements entered in connection therewith, which breach, if curable, is not cured by Serina within 10 business days of written notice by AgeX thereof, (vii) Serina or any subsidiary shall default on any of its obligations under any indebtedness which default causes the indebtedness thereunder to (x) become prematurely due and payable, (y) be placed on demand or (z) become capable of being declared by or on behalf of a creditor thereunder to be prematurely due and payable or being placed on demand, in each case, as a result of such default or any provision having a similar effect (howsoever prescribed), (viii) any monetary judgment, writ or similar final process shall be entered or filed against Serina, any subsidiary or any of their respective property or other assets for more than $250,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period of 45 calendar days, and (ix) Serina experiences a Material Adverse Effect (as defined in the Serina Note Purchase Agreement).

 

The Serina Note Purchase Agreement and Serina Note each includes certain covenants that among other matters require financial reporting and impose certain restrictions, including (i) restrictions on the incurrence of additional indebtedness by Serina and its subsidiaries; (ii) requiring that Serina use note proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, and for general working capital; and (iii) prohibiting Serina from entering into any material sale or transfer transactions outside of the ordinary course of business, other than in a merger between AgeX and Serina, without the consent of AgeX.

 

Subordination Agreement

 

In connection with the issuance of the Serina Note, Serina, each other holder of Serina indebtedness (each a “Serina Lender”), and AgeX entered into a Subordination Agreement, dated March 15, 2023, pursuant to which each Serina Lender agreed to subordinate to AgeX’s rights of repayment with respect to the obligations owed under the Serina Note Purchase Agreement and the Serina Note (i) all Serina indebtedness owed to such Serina Lender under certain convertible notes between each Serina Lender and Serina, which aggregate principal amount of all of such convertible notes equals $1,450,000, and (ii) any related security interests.

 

F-35
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value amounts)

(unaudited)

 

   September 30, 2023   December 31, 2022 
ASSETS          
Current assets:          
Cash and cash equivalents  $397   $645 
Accounts and grants receivable, net   67    4 
Related party receivables, net   4    - 
Prepaid expenses and other current assets   673    1,804 
Total current assets   1,141    2,453 
           
Restricted cash   50    50 
Intangible assets, net   640    738 
Convertible note receivable   10,379    - 
TOTAL ASSETS  $12,210   $3,241 
           
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable and accrued liabilities  $1,671   $1,034 
Loans due to Juvenescence, net of debt issuance costs, current portion   1,526    7,646 
Related party payables, net   -    141 
Warrant liability   -    180 
Insurance premium liability and other current liabilities   7    1,077 
Total current liabilities   3,204    10,078 
           
Loans due to Juvenescence, net of debt issuance costs, net of current portion   693    10,478 
TOTAL LIABILITIES   3,897    20,556 
           
Commitments and contingencies (Note 11)   -     -  
           
Series A preferred stock; no par value; stated value $100 per share; 212 and nil shares issued and outstanding, respectively   21,135    - 
Series B preferred stock; no par value; stated value $100 per share; 148 and nil shares issued and outstanding, respectively   14,823    - 
           
Stockholders’ deficit:          
Preferred stock, $0.0001 par value, 5,000 shares authorized   -    - 
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively   4    4 
Additional paid-in capital   100,017    98,994 
Accumulated deficit   (127,557)   (116,210)
Total AgeX Therapeutics, Inc. stockholders’ deficit   (27,536)   (17,212)
Noncontrolling interest   (109)   (103)
Total stockholders’ deficit   (27,645)   (17,315)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT  $12,210   $3,241 

 

See accompanying notes to these condensed consolidated interim financial statements.

 

F-36
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

 

   2023   2022   2023   2022 
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022   2023   2022 
REVENUES                    
Grant revenues  $21   $-   $21   $- 
Other revenues   46    9    65    26 
Total revenues   67    9    86    26 
Cost of sales   (33)   (5)   (39)   (12)
                     
Gross profit   34    4    47    14 
                     
OPERATING EXPENSES                    
Research and development   218    162    552    817 
General and administrative   2,172    1,392    5,895    4,390 
Total operating expenses   2,390    1,554    6,447    5,207 
                     
Loss from operations   (2,356)   (1,550)   (6,400)   (5,193)
                     
OTHER EXPENSE, NET:                    
Interest expense, net   (3,036)   (923)   (4,928)   (2,357)
Change in fair value of warrants   -    35    (35)   (220)
Other income, net   3    2    10    9 
Total other expense, net   (3,033)   (886)   (4,953)   (2,568)
                     
NET LOSS   (5,389)   (2,436)   (11,353)   (7,761)
Net (income) loss attributable to noncontrolling interest   (12)   1    6    2 
                     
NET LOSS ATTRIBUTABLE TO AGEX  $(5,401)  $(2,435)  $(11,347)  $(7,759)
                     
NET LOSS PER COMMON SHARE:                    
BASIC AND DILUTED  $(0.14)  $(0.06)  $(0.30)  $(0.20)
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:                    
BASIC AND DILUTED   37,951    37,946    37,951    37,944 

 

See accompanying notes to these condensed consolidated interim financial statements.

 

F-37
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

(in thousands)

(unaudited)

 

  B                                        
     Three Months Ended September 30, 2023 
     Preferred Stock   AgeX’s Stockholders’ Deficit         
     Series A   Series B   Common Stock   Additional        Non   Total 
     Number of
Shares
   Amount   Number of
Shares
   Amount   Number of
Shares
   Par Value   Paid-In Capital   Accumulated Deficit   controlling Interest   Stockholders’
Deficit
 
BALANCE AT JUNE 30, 2023 --   -   $-    -   $-    37,951   $        4   $99,977   $(122,156)  $       (121)  $          (22,296)
Issuance of preferred stock     212    21,160    148    14,840    -    -    -    -    -    - 
Preferred stock issuance costs                      -    (25)                      -    (17)   -    -    -    -    -    - 
Stock-based compensation     -    -    -    -    -    -    40    -    -    40 
Net loss --   -    -    -    -    -    -    -    (5,401)   12    (5,389)
BALANCE AT SEPTEMBER 30, 2023 --   212   $21,135    148   $14,823    37,951   $4   $100,017   $(127,557)  $(109)  $(27,645)

 

                         
   Three Months Ended September 30, 2022 
   AgeX’s Stockholders’ Deficit         
   Common Stock   Additional       Non   Total  
  

Number of
Shares

   Par Value  

Paid-In

Capital

  

Accumulated

Deficit

   controlling
Interest
  

Stockholders’
Deficit

 
BALANCE AT JUNE 30, 2022   37,945   $4   $97,850   $(111,072)  $(44)  $(13,262)
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes   2    -    (1)   -    -    (1)
Fair value of liability classified warrants issued   -    -    341    -    -    341 
Stock-based compensation   -    -    209    -    -    209 
Net loss   -    -    -    (2,435)   (1)   (2,436)
BALANCE AT SEPTEMBER 30, 2022   37,947   $     4   $98,399   $(113,507)  $        (45)  $(15,149)

 

See accompanying notes to these condensed consolidated interim financial statements.

 

F-38
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

(in thousands)

(unaudited)

 

                                         
   Nine Months Ended September 30, 2023 
   Preferred Stock   AgeX’s Stockholders’ Deficit         
   Series A   Series B   Common Stock              
   Number of Shares   Amount   Number of Shares   Amount   Number of Shares   Par Value  

Additional

Paid-In Capital

   Accumulated Deficit  

Non

controlling Interest

  

Total
Stockholders’
Deficit

 
BALANCE AT DECEMBER 31, 2022   -   $-    -   $-    37,949   $    4   $98,994   $   (116,210)  $      (103)  $      (17,315)
Issuance of preferred stock   212    21,160    148    14,840    -    -    -    -    -    - 
Preferred stock issuance costs   -    (25)   -    (17)   -    

-

    -    -    -    - 
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes                     -    -                      -    -    2    -    (1)   -    -    (1)
Fair value of liability classified warrants issued   -    -    -    -    -    -    879    -    -    879 
Stock-based compensation   -    -    -    -    -    -    145    -    -    145 
Net loss   -    -    -    -    -    -    -    (11,347)   (6)   (11,353)
BALANCE AT SEPTEMBER 30, 2023   212   $21,135    148   $14,823    37,951   $4   $100,017   $(127,557)  $(109)  $(27,645)

 

                         
   Nine Months Ended September 30, 2022 
   AgeX’s Stockholders’ Deficit         
   Common Stock   Additional       Non    Total 
  

Number of

Shares

   Par Value   Paid-In
Capital
   Accumulated
Deficit
  

controlling

Interest

  

Stockholders’
Deficit

 
BALANCE AT DECEMBER 31, 2021   37,941   $4   $93,912   $(105,748)  $(43)  $      (11,875)
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes   6    -    (3)   -    -    (3)
Issuance of warrants   -    -    178    -    -    178 
Fair value of liability classified warrants issued   -    -    3,666    -    -    3,666 
Stock-based compensation   -    -    646    -    -    646 
Net loss   -    -    -    (7,759)   (2)   (7,761)
BALANCE AT SEPTEMBER 30, 2022   37,947   $4   $98,399   $(113,507)  $(45)  $(15,149)

 

See accompanying notes to these condensed consolidated interim financial statements.

 

F-39
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

   2023   2022 
  

Nine Months Ended

September 30,

 
   2023   2022 
OPERATING ACTIVITIES:          
Net loss attributable to AgeX  $(11,347)  $(7,759)
Net loss attributable to noncontrolling interest   (6)   (2)
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:          
Change in fair value of warrants   35    220 
Amortization of intangible assets   98    99 
Amortization of debt issuance costs   5,170    2,221 
Stock-based compensation   145    646 
Changes in operating assets and liabilities:          
Accounts and grants receivable   (63)   24 
Prepaid expenses and other current assets   1,131    906 
Interest on convertible note receivable   (379)   - 
Accounts payable and accrued liabilities   571    (98)
Related party payables, net   (33)   110 
Insurance premium liability   (1,075)   (983)
Other current liabilities   5    (2)
Net cash used in operating activities   (5,748)   (4,618)
           
INVESTING ACTIVITIES:          
Cash advanced on convertible note receivable   (10,000)   - 
Net cash used in investing activities   (10,000)   - 
           
FINANCING ACTIVITIES:          
Drawdown on loan facilities from Juvenescence   15,500    4,500 
Net cash provided by financing activities   15,500    4,500 
           
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH   (248)   (118)
           
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:          
At beginning of the period   695    634 
At end of the period  $447   $516 

 

See accompanying notes to these condensed consolidated interim financial statements.

 

F-40
 

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(unaudited)

 

1. Organization, Business Overview and Liquidity

 

AgeX Therapeutics, Inc. (“AgeX”) was incorporated in January 2017 in the state of Delaware. AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions.

 

AgeX’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows AgeX to utilize telomerase-expressing regenerative pluripotent stem cells (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX’s main technology platforms and product candidates are:

 

  PureStem® PSC-derived clonal embryonic progenitor cell lines that may be capable of generating a broad range of cell types for use in cell-based therapies;
     
  UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells;
     
  AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes;
     
  AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and
     
  Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair.

 

Restructuring Plans and Merger Agreement

 

During March 2023, AgeX borrowed $10,000,000 from Juvenescence Limited (“Juvenescence”) under the terms of a Secured Convertible Promissory Note (the “$10 Million Secured Note”) and used the loan proceeds to make a $10,000,000 loan under the terms of a Convertible Promissory Note to Serina (the “Serina Note”), in order to provide financing to Serina Therapeutics, Inc. (“Serina”) in advance of corporate restructuring plans that include a potential merger between AgeX and Serina in which AgeX would be the surviving company.

 

On August 29, 2023, AgeX entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Serina and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“Merger Sub”). Serina currently has a pipeline of small molecule candidates targeting central nervous system (“CNS”) indications, enabled by the company’s proprietary POZ PlatformTM delivery technology. In addition to advancing Serina’s wholly owned pipeline assets, Serina is working with pharma partners currently advancing pre-clinical studies exploring POZ polymer lipid-nanoparticles (“LNPs”) in next generation LNP delivered RNA vaccines. In addition, Serina is advancing a lead drug candidate, SER-252 (POZ-apomorphine) for the treatment of advanced Parkinson’s Disease through pre-clinical studies towards the goal of an investigational new drug submission or “IND” to the Food and Drug Administration for the initiation of a Phase I clinical trial during the fourth quarter of 2024. Serina has two other pipeline assets that are positioned to enter IND enabling studies, SER-227 (POZ-buprenorphine) for certain post-operative pain indications, and SER-228 (POZ-cannabidiol) for treatment refractory epilepsy indications. Serina is also focused on expanding its LNP and anti-body drug conjugate partnering collaborations.

 

Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including that the Merger is approved by the stockholders of Serina and the issuance of AgeX common stock to Serina in the Merger is approved by the stockholders of AgeX, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the “Merger”). There is no assurance the necessary approvals by AgeX stockholders and Serina stockholders will be obtained or that the other conditions to the Merger as provided in the Merger Agreement will be met.

 

AgeX’s restructuring plans also include a potential spinoff of AgeX’s subsidiary Reverse Bioengineering, Inc. (“Reverse Bio”) through a distribution of some or all of the shares of capital stock of Reverse Bio held by AgeX to AgeX stockholders following a financing of Reverse Bio through the sale of shares of Reverse Bio common stock to private investors (the “Reverse Bio Financing”). If the Reverse Bio spinoff is completed, Reverse Bio would become a separate publicly traded company.

 

F-41
 

 

Definitive agreements regarding the Reverse Bio Financing and a Reverse Bio spinoff have not yet been executed, nor has AgeX’s board of directors approved the Reverse Bio spinoff. Accordingly, there is a risk that the Reverse Bio Financing and the Reverse Bio spinoff may never be consummated.

 

Emerging Growth Company

 

AgeX is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012.

 

Going Concern

 

AgeX primarily finances its operations through loans from its largest stockholder, Juvenescence Limited (“Juvenescence”). AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $127.6 million as of September 30, 2023. AgeX expects to continue to incur operating losses and negative cash flows.

 

Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have adopted operating plans and budgets to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those operating plans and budgets, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $0.4 million as of September 30, 2023 plus the loan facilities provided by Juvenescence to advance up to an additional $1 million to AgeX which was drawn in full in October 2023 and an additional $4.4 million line of credit made available to AgeX through an Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note with Juvenescence (the “Fifth Amendment”) on November 9, 2023 would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of these condensed consolidated interim financial statements. These conditions raise substantial doubt about AgeX’s ability to continue as a going concern. AgeX will need to obtain substantial additional funding in connection with its continuing operations. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should AgeX not continue as a going concern. See Note 12, Subsequent Events, for further details on the Fifth Amendment.

 

Liquidity and Impact of COVID-19

 

In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in out-licensing its technologies and development of its product candidates. Although AgeX has been able to reduce its operating expenses, with the exception of certain non-recurring expenses incurred related to the possible Merger between AgeX and Serina, by eliminating internal research and development activities and focusing instead on outsourcing research and development and seeking licensing arrangements for AgeX technologies, this approach has also made it more difficult for AgeX to make progress in developing its target product candidates and technologies, which in turn may make it more difficult for AgeX to raise capital. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its stockholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all.

 

2. Basis of Presentation and Summary of Significant Accounting Policies

 

The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by U.S. GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

The accompanying condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of AgeX’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

Principles of consolidation

 

The consolidated financial statements include the accounts of AgeX and its subsidiaries in which AgeX has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which AgeX is the primary beneficiary (as described in more detail below). For consolidated entities where AgeX has less than 100% of ownership, AgeX records net loss attributable to noncontrolling interest on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. The noncontrolling interest is reflected as a separate element of stockholders’ equity (deficit) on AgeX’s consolidated balance sheets. Any material intercompany transactions and balances have been eliminated upon consolidation.

 

F-42
 

 

AgeX assesses whether it is the primary beneficiary of a variable interest entity (“VIE”) at the inception of the arrangement and at each reporting date. This assessment is based on its power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and AgeX’s obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. If the entity is within the scope of the variable interest model and meets the definition of a VIE, AgeX considers whether it must consolidate the VIE or provide additional disclosures regarding its involvement with the VIE. If AgeX determines that it is the primary beneficiary of the VIE, AgeX will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event. For entities AgeX holds as an equity investment that are not consolidated under the VIE model, AgeX will consider whether its investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.

 

AgeX has four subsidiaries, Reverse Bio, ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”), Canaria Transaction Corporation (“Merger Sub”), and has incorporated but not yet capitalized a fourth subsidiary UniverXome Bioengineering, Inc.(“UniverXome”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTRTM research and development efforts. AgeX is actively seeking equity financing for Reverse Bio and to the extent that such Reverse Bio Financing is obtained through the sale of capital stock or other equity securities by Reverse Bio, AgeX’s equity interest in Reverse Bio and its iTRTM business would be diluted. AgeX’s restructuring plans also include a potential spinoff of Reverse Bio through a distribution of some or all of the shares of capital stock of Reverse Bio held by AgeX to AgeX stockholders following the Reverse Bio Financing. ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 94.8% of the outstanding capital stock of ReCyte. NeuroAirmid is jointly owned by AgeX with the University of California – Irvine and certain researchers and was recently organized to pursue clinical development and commercialization of cell therapies, focusing initially on Huntington’s Disease. AgeX owns 50% of the outstanding capital stock of NeuroAirmid. AgeX consolidates NeuroAirmid despite not having majority ownership interest as it has the ability to influence decision making and financial results through contractual rights and obligations as per Accounting Standards Codification (“ASC”) 810, Consolidation. Merger Sub was incorporated for the purpose of merging with Serina to implement the Merger. UniverXome is expected, in connection with the planned Merger, to hold certain AgeX assets and assume AgeX indebtedness obligations to Juvenescence.

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of AgeX’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected.

 

See Note 6, Warrant Liability, for discussion on estimated change in fair value of warrant liability.

 

Concentration of credit risk and other risks and uncertainties

 

Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

 

AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, Convertible Note Receivable and 5, Related Party Transactions.

 

Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX.

 

F-43
 

 

Fair value measurements of financial instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.

 

The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. Fair values for AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.

 

To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures):

 

  Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
     
  Level 2 – Inputs to the valuation methodology include observable quoted prices (other than quoted market prices included within Level 1) for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.
     
  Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

 

In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. The discounted conversion prices triggered by certain qualified events in the Serina Note and the $10 Million Secured Note are Level 3 on the fair value hierarchy and subject to fair valuation at inception and remeasurement at each reporting period. The fair value of the discounted conversion prices under both notes were determined to have an immaterial value at inception and life to date of the notes, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period. For additional information regarding the convertible notes and derivatives, see Notes 4, Convertible Note Receivable, 5, Related Party Transactions, and 12, Subsequent Events.

 

The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.

 

The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations are discussed further in Note 6, Warrant Liability. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date. As of September 30, 2023, AgeX has utilized the full credit subject to warrants, and accordingly, the warrants were fully issued for each of the advances of loan funds under the Secured Note.

 

See Note 6, Warrant Liability, for additional information on accounting for liability classified warrants and certain Level 3 warrant valuation tables.

 

Cash, cash equivalents, and restricted cash

 

In accordance with Accounting Standards Update (“ASU”) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the condensed consolidated balance sheets to cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows for all periods presented is as follows (in thousands):

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Cash and cash equivalents  $397   $645 
Restricted cash (1)   50    50 
Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows  $447   $695 

 

(1) Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.

 

F-44
 

 

Long-lived intangible assets, net

 

Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 years. See Note 3, Selected Balance Sheet Components.

 

Impairment of long-lived assets

 

AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consists entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of September 30, 2023, there has been no impairment of long-lived assets.

 

Leases

 

AgeX accounts for leases in accordance with ASU 2016-02, Leases (Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX: (i) ASU 2018-10, Codification Improvements to Topic 842, Leases, and (ii) ASU 2018-11, Leases (Topic 842): Targeted Improvements, using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensed consolidated balance sheets.

 

ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.

 

AgeX leases office space in Alameda, California. For 2022 base monthly rent was $1,074 and for 2023 base monthly rent is $844 for slightly less space at the same building. AgeX has elected to not apply the recognition requirements under ASC 842 for the lease agreements and instead recognizes the lease payments as lease cost on a straight-line basis over the lease term as lease payments are not deemed material.

 

Accounting for warrants

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of September 30, 2023. See Notes 5, Related Party Transactions and 6, Warrant Liability, for additional information regarding warrants.

 

F-45
 

 

Revenue recognition

 

AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.

 

Grant revenues – AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements. At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.

 

In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, AgeX’s policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health (“NIH”) supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.

 

AgeX believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606.

 

In August 2023, AgeX was awarded a grant of up to approximately $341,000 from the NIH, National Heart, Lung and Blood Institute. The NIH grant will provide funding for continued development of AgeX’s technologies toward treating cardiovascular disease over a one year period starting September 1, 2023. Based on our evaluation under the accounting guidance aforementioned, this grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred. Accordingly, grant funds are made available by the NIH as allowable expenses are incurred. For the three and nine months ended September 30, 2023, AgeX incurred approximately $21,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues.

 

ESI BIO Research Products – AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP”. AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products have not been significant during the periods presented in the condensed consolidated interim financial statements included in this Report.

 

Arrangements with multiple performance obligations – AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of September 30, 2023 and December 31, 2022, AgeX did not have significant arrangements with multiple performance obligations.

 

F-46
 

 

Research and development

 

Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and contractors, sponsored research agreements with certain universities, and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations.

 

General and administrative

 

General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees.

 

Basic and diluted net loss per share attributable to common stockholders

 

Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.

 

For the three and nine months ended September 30, 2023 and 2022, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.

 

The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022   2023   2022 
Stock options   3,276    3,264    3,266    3,310 
Warrants (1)   12,132    10,616    12,716    8,947 
Restricted stock units   -    9    -    12 

 

(1) As of September 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 11,539,348 and 10,919,485 shares, respectively, of AgeX common stock as consideration for certain loan agreements discussed in Note 5, Related Party Transactions.

 

Reclassifications

 

Certain reclassifications have been made to the prior period’s condensed consolidated interim financial statements to conform to current year presentation. Additionally, certain financial information is presented on a rounded basis, which may cause minor differences.

 

Recently adopted accounting pronouncements

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.

 

F-47
 

 

In March 2022, the FASB issued ASU No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method, which clarifies the guidance in ASC 815 on fair value hedge accounting of interest rate risk for portfolios of financial assets. The ASU amends the guidance in ASU 2017-12 (released on August 28, 2017) that, among other things, established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible. ASU 2022-01 renames that method the “portfolio layer” method and addresses feedback from stakeholders regarding its application. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.

 

In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance became effective for AgeX on January 1, 2023 and includes interim periods. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. This ASU did not have a material impact on the condensed consolidated interim financial statements.

 

On July 14, 2023, the FASB issued ASU No. 2023-02, Presentation of Financial Statements (Topic 205), Income Statement – Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation, which amends or supersedes various SEC paragraphs within the codification to conform to past announcements and guidance issued by the SEC. Specifically, the ASU responds to (1) the issuance of SEC Staff Accounting Bulletin (SAB) 120; (2) the SEC staff announcement at the March 24, 2022, EITF meeting; and (3) SAB Topic 6.B, “Accounting Series Release No. 280 — General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.” This ASU is effective immediately and did not have a material impact on AgeX’s condensed consolidated interim financial statements.

 

3. Selected Balance Sheet Components

 

Intangible assets, net

 

At September 30, 2023 and December 31, 2022, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands):

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Intangible assets  $1,312   $1,312 
Accumulated amortization   (672)   (574)
Total intangible assets, net  $640   $738 

 

AgeX recognized $33,000 and $98,000 in amortization expense of intangible assets, included in research and development expenses, for the three and nine months ended September 30, 2023, respectively and $33,000 and $99,000 for the same periods in 2022, respectively.

 

Amortization of intangible assets for periods subsequent to September 30, 2023 is as follows (in thousands):

 

Year Ending December 31, 

Amortization

Expense

 
2023  $33 
2024       131 
2025   131 
2026   132 
Thereafter   213 
Total  $640 

 

Accounts payable and accrued liabilities

 

At September 30, 2023 and December 31, 2022, accounts payable and accrued liabilities were comprised of the following (in thousands):

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Accounts payable  $1,172   $568 
Accrued compensation   206    193 
Accrued vendors and other expenses   293    273 
Total accounts payable and accrued liabilities  $1,671   $1,034 

 

F-48
 

 

4. Convertible Note Receivable

 

On March 15, 2023, AgeX and Serina entered into a Convertible Note Purchase Agreement (the “Serina Note Purchase Agreement”), pursuant to which AgeX lent to Serina an aggregate principal amount of $10,000,000 as evidenced by the Serina Note on that date. Interest on the principal amount under the Serina Note accrues on the unpaid principal amount at a simple interest rate equal to 7% per annum, computed on the basis of the 360-day year of twelve 30-day months. The outstanding principal amount and accrued interest of $10,379,000 under the Serina Note will become due and payable on March 15, 2026.

 

In connection with the issuance of the Serina Note, AgeX is entitled to elect one member to the board of directors of Serina and receive certain information and inspection rights as well as participation rights for subsequent equity issuances.

 

The principal balance of the Serina Note with accrued interest will automatically convert into Serina preferred stock if Serina raises at least $25,000,000 through the sale of shares of Serina preferred stock (“qualifying event”). The conversion price per share shall be the lower of (a) 80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by Serina’s then fully diluted capitalization. AgeX has the option to convert the Serina Note into Serina preferred stock after a sale of Serina preferred stock regardless of the amount sold by Serina. AgeX evaluated the 20% discounted conversion feature of the Serina Note under ASC 815-15, Derivatives and Hedging—Embedded Derivatives, and concluded that it was an embedded derivative which should be bifurcated from the note and accounted for separately. The 20% discount was determined to have an immaterial value at inception and life to date of the Serina Note, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period and any adjustments will be included in Interest (income) expense, net in the Other (income) expense, net section of the condensed consolidated statements of operations.

 

AgeX may (i) at its election, upon a change of control (as defined in the Serina Note), convert the Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the Serina Note, plus interest, or (b) into the highest ranking shares of Serina then issued at a conversion price equal to the lowest price per share at which the most senior series of Serina shares has been sold in a single transaction or a series of related transactions through which Serina raised at least $5,000,000 or (ii) if the Serina Note remains outstanding as of the maturity date, AgeX may convert the Serina Note into the most senior shares of Serina issued at the time of conversion at a conversion price equal to the capped price.

 

If the Merger is consummated, the Serina Note will be canceled for no consideration.

 

The outstanding principal balance of the Serina Note with accrued interest may become immediately due and payable prior to the stated maturity date if an Event of Default as defined in the Serina Note occurs. In addition to this and any other remedy, both in equity and in law, upon the occurrence of an Event of Default, an interest rate of 10% per annum and computed on the basis of the 360-day year of twelve 30-day months, shall apply to the Convertible Amount until fully paid. Events of Default under the Serina Note include: (i) the commission of any act of bankruptcy by Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (ii) the execution by Serina of a general assignment for the benefit of creditors, (iii) the filing by or against Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) of a petition in bankruptcy or any petition for relief under the federal bankruptcy act (or, in each case, under any similar insolvency law) or the continuation of such petition without dismissal for a period of 60 calendar days or more, (iv) the appointment of a receiver or trustee to take possession of the property or assets of Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (v) failure of Serina to pay any amount due under the Serina Note when due, which failure to pay is not cured by Serina within 5 business days of written notice thereof, (vi) unless waived by AgeX, Serina’s material breach of any representation, warranty or covenant of Serina under the Serina Note Purchase Agreement, Serina Note or other agreements entered in connection therewith, which breach, if curable, is not cured by Serina within 10 business days of written notice by AgeX thereof, (vii) Serina or any subsidiary shall default on any of its obligations under any indebtedness which default causes the indebtedness thereunder to (x) become prematurely due and payable, (y) be placed on demand or (z) become capable of being declared by or on behalf of a creditor thereunder to be prematurely due and payable or being placed on demand, in each case, as a result of such default or any provision having a similar effect (howsoever prescribed), (viii) any monetary judgment, writ or similar final process shall be entered or filed against Serina, any subsidiary or any of their respective property or other assets for more than $250,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period of 45 calendar days, and (ix) Serina experiences a Material Adverse Effect (as defined in the Serina Note Purchase Agreement).

 

The Serina Note Purchase Agreement and Serina Note each includes certain covenants that among other matters require financial reporting and impose certain restrictions, including (i) restrictions on the incurrence of additional indebtedness by Serina and its subsidiaries; (ii) requiring that Serina use note proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, and for general working capital; and (iii) prohibiting Serina from entering into any material sale or transfer transactions outside of the ordinary course of business, other than in a merger between AgeX and Serina, without the consent of AgeX.

 

Subordination Agreement

 

In connection with the issuance of the Serina Note, Serina, each other holder of Serina indebtedness (each a “Serina Lender”), and AgeX entered into a Subordination Agreement, dated March 15, 2023, pursuant to which each Serina Lender agreed to subordinate to AgeX’s rights of repayment with respect to the obligations owed under the Serina Note Purchase Agreement and the Serina Note (i) all Serina indebtedness owed to such Serina Lender under certain convertible notes between each Serina Lender and Serina, which aggregate principal amount of all of such convertible notes equals $1,450,000, and (ii) any related security interests.

 

F-49
 

 

5. Related Party Transactions

 

During July 2023, AgeX and Juvenescence entered into an Exchange Agreement pursuant to which AgeX issued shares of Series A Preferred Stock and Series B Preferred Stock to Juvenescence in exchange for the extinguishment of a total of $36 million of indebtedness under the 2020 Loan Agreement, the Secured Note, and the $10 Million Secured Note discussed below. The unused portion of the line of credit under the Secured Note remains available to AgeX subject to the terms and conditions of the Secured Note.

 

2019 Loan Agreement

 

On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence provided to AgeX a $2 million line of credit for a period of 18 months. On February 10, 2021, AgeX entered into an amendment (the “First Amendment”) to the 2019 Loan Agreement which extended the maturity date of loans under the 2019 Loan Agreement to February 14, 2022, and increased the amount of the loan facility by $4 million. On November 8, 2021, AgeX entered into Amendment No. 2 to the 2019 Loan Agreement which increased the amount of the loan facility by another $1 million. As of December 31, 2021, AgeX had borrowed all of the $7 million total line of credit under the 2019 Loan Agreement, as amended. On February 14, 2022, AgeX refinanced the $7 million outstanding principal amount of the loans and a $160,000 origination fee due under the 2019 Loan Agreement, as amended. See discussion regarding the 2022 Secured Convertible Promissory Note within this Note 5.

 

2020 Loan Agreement

 

On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence provided to AgeX an $8 million line of credit for a period of 18 months. Through September 30, 2023, AgeX had drawn the full $8 million line of credit. AgeX issued to Juvenescence 28,500 shares of AgeX common stock as an arrangement fee for the loan facility when AgeX borrowed an aggregate of $3 million under the 2020 Loan Agreement, and AgeX issued to Juvenescence warrants to purchase a total of 3,670,663 shares of AgeX common stock (“2020 Warrants”) as determined by the warrant formula described below of which 1,182,262 are outstanding as of September 30, 2023. On March 13, 2023, the 2020 Loan Agreement was amended to extend the maturity date to March 30, 2024. During July 2023, the full $8 million of 2020 Loan Agreement indebtedness was extinguished in exchange for shares of Series A Preferred Stock pursuant to the Exchange Agreement.

 

2020 Warrants — Under the terms of the 2020 Loan Agreement, each time AgeX received an advance of funds under the 2020 Loan Agreement, AgeX issued to Juvenescence a number of 2020 Warrants equal to 50% of the number determined by dividing the amount of the advance by the applicable Market Price. The Market Price set each 2020 Warrant when issued was the closing price per share of AgeX common stock on the NYSE American on the date of the applicable notice from AgeX requesting a draw of funds that triggered the obligation to issue the 2020 Warrant. The 2020 Warrants will expire at 5:00 p.m. New York time three years after the date of issue. AgeX had issued to Juvenescence 2020 Warrants to purchase a total of 3,670,663 shares of AgeX common stock of which 1,182,262 are outstanding as of September 30, 2023. The exercise prices of the 2020 Warrants issued through and that are still outstanding as of September 30, 2023 range from $0.81 per share to $1.895 per share representing the market closing price on the NYSE American of AgeX common stock on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

2022 Secured Convertible Promissory Note and Security Agreement

 

On February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence agreed to provide to AgeX a $13,160,000 line of credit for a period of 12 months. AgeX drew an initial $8,160,000 of the line of credit and used $7,160,000 to refinance the outstanding principal and the loan origination fees under the 2019 Loan Agreement with Juvenescence. On February 9, 2023, AgeX and Juvenescence entered into an Amended and Restated Secured Convertible Promissory Note which amends and restates the Secured Note and added $2 million to the line of credit available to be borrowed by AgeX under the Secured Note subject to Juvenescence’s discretion to approve each loan draw. On May 9, 2023, AgeX and Juvenescence entered into an Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (the “Second Amendment”) that increased the amount of the line of credit available to AgeX by $4,000,000, subject to the terms of the Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. On June 2, 2023, AgeX and Juvenescence entered into a Third Amendment to Amended and Restated Convertible Promissory Note (the “Third Amendment’), to provide that (i) AgeX may draw on the available portion of the line of credit under the Secured Note until the earlier of the date a Qualified Offering as defined in the Secured Note is consummated by AgeX or October 31, 2023 (subject to Juvenescence’s discretion to approve each loan draw as provided in the Secured Note), (ii) AgeX will not be obligated to issue additional common stock purchase warrants to Juvenescence in connection with the receipt of loan funds made available pursuant to the Second Amendment, and (iii) the definition of Reverse Financing Condition was amended to extend to June 20, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by Reverse Bioengineering, Inc. The date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.

 

F-50
 

 

On July 31, 2023, AgeX and Juvenescence entered into a Fourth Amendment (the “Fourth Amendment”) to the Secured Note to provide that (i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bio, and (ii) Juvenescence may convert the outstanding amount of the Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion. The 19.9% Cap is a provision of the Secured Note that limits the amount of common stock that Juvenescence may acquire through the conversion of Secured Note loans in order to comply with NYSE American requirements pertaining to the amount of shares that a listed company, such as AgeX, may sell at a price less than the market prices prevailing at the time the loans were made (the “Drawdown Market Prices”) without shareholder approval.

 

As of September 30, 2023, AgeX had borrowed a total of $18,160,000 under the Secured Note, of which $5,500,000 was borrowed during the nine months ended September 30, 2023. During July 2023, $17,992,800 of Secured Note indebtedness, comprised of $16,660,000 borrowing and $1,332,800 of accrued loan origination fees, was extinguished in exchange for shares of Series A Preferred Stock and Series B Preferred Stock pursuant to the Exchange Agreement. See Note 7, Stockholders’ Equity (Deficit).

 

As an arrangement fee for the Secured Note, AgeX will pay Juvenescence an origination fee in an amount equal to 4% of the amount each draw of loan funds, which will accrue as each draw is funded, and an additional 4% of all the total amount of funds drawn that will accrue following the end of the period during which funds may be drawn from the line of credit. The origination fee will become due and payable on the repayment date or in a pro rata amount with any prepayment of in whole or in part of the outstanding principal balance of the Secured Note.

 

2022 Warrants – Upon each drawdown of funds under the Secured Note prior to June 2, 2023 when the Third Amendment went into effect, AgeX issued to Juvenescence warrants to purchase shares of AgeX common stock (“2022 Warrants”). The 2022 Warrants are governed by the terms of a Warrant Agreement between AgeX and Juvenescence. The number of 2022 Warrants issued with respect to each draw of loan funds was equal to 50% of the number determined by dividing the amount of the applicable loan draw by the applicable Market Price. The Market Price was the last closing price per share of AgeX common stock on the NYSE American o preceding the delivery of the notice from AgeX requesting the draw of funds that triggered the obligation to issue 2022 Warrants. The exercise price of the 2022 Warrants is the applicable Market Price used to determine the number of Warrants issued. The 2022 Warrants will expire at 5:00 p.m. New York time three years after the date of issue.

 

As of September 30, 2023, AgeX had issued to Juvenescence 2022 Warrants to purchase a total of 10,357,086 shares of AgeX common stock, of which 2022 Warrants to purchase 1,898,489 shares of AgeX common stock were issued during the nine months ended September 30, 2023. The exercise prices of the 2022 Warrants issued through September 30, 2023 range from $0.59 per share to $0.88 per share representing the market closing price of AgeX common stock on the NYSE American on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

Conversion of Loan Amounts to Common Stock – In lieu of repayment of funds borrowed, AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock.

 

F-51
 

 

Default Provisions – The loan balance and origination fees may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the Secured Note include the following: (a) AgeX fails to pay any principal amount payable by it in the manner and at the time provided under and in accordance with the Secured Note; (b) AgeX fails to pay any other amount payable by it in the manner and at the time provided under and in accordance with the Secured Note or the Security Agreement described below or any other agreement executed in connection with the Secured Note (the “Loan Documents”) and the failure is not remedied within three business days; (c) AgeX fails to perform any of its covenants or obligations or fail to satisfy any of the conditions under the Secured Note or any other Loan Document and, such failure (if capable of remedy) remains unremedied to the satisfaction of Juvenescence (in its sole discretion) for 10 business days after the earlier of (i) notice requiring its remedy has been given by Juvenescence to AgeX and (ii) actual knowledge of the failure by senior officers of AgeX; (d) if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date; (e) AgeX stops payment of its debts generally or ceases or threatens to cease to carry on its business or is unable to pay its debts as they fall due or is deemed by a court of competent jurisdiction to be unable to pay its debts as they fall due, or enters into any arrangements with its creditors generally; (f) if (i) an involuntary proceeding (other than a proceeding instituted by Juvenescence or an affiliate of Juvenescence) shall be commenced or an involuntary petition shall be filed seeking liquidation, reorganization or other relief in respect of AgeX and any subsidiary, or of all or a substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) an involuntary appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for AgeX or a subsidiary or for a substantial part of its assets occurs (other than in a proceeding instituted by Juvenescence or an affiliate of Juvenescence), and, in any such case, such proceeding shall continue undismissed and unstayed for sixty (60) consecutive days without having been dismissed, bonded or discharged or an order of relief is entered in any such proceeding; (g) it becomes unlawful for AgeX to perform all or any of its obligations under the Secured Note or any authorization, approval, consent, license, exemption, filing, registration or other requirement of any governmental, judicial or public body or authority necessary to enable AgeX to comply with its obligations under the Secured Note or to carry on its business is not obtained or, having been obtained, is modified in a manner that precludes AgeX or its subsidiaries from conducting their business in any material respect, or is revoked, suspended, withdrawn or withheld or fails to remain in full force and effect; (h) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX or a subsidiary if such process is not released, vacated or fully bonded within 60 calendar days after its issue or levy; (i) any injunction, order, judgment or decision of any court is entered or issued which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX or a subsidiary to carry on its business or to pay amounts owed to Juvenescence under the Secured Note; (j) AgeX, whether in a single transaction or a series of related transactions, sells, leases, licenses, consigns, transfers or otherwise disposes of any material portion of its assets (with any such disposition with respect to any asset or assets with a fair value of at least $250,000 being deemed material), other than (i) certain permitted investments (ii) sales, transfers and dispositions of inventory in the ordinary course of business, (iii) any termination of a lease of real or personal property that is not necessary in the ordinary course of the AgeX’s business, could not reasonably be expected to have a material adverse effect and does not result from AgeX’s default, and (iv) any sale, lease, license, consignment, transfer or other disposition of assets that are no longer necessary in the ordinary course of business or which has been approved in writing by Juvenescence; (k) any of the following shall occur: (i) the security and/or liens created by the Security Agreement or any other Loan Document shall at any time cease to constitute valid and perfected security and/or liens on any material portion of the collateral intended to be covered thereby; (ii) except for expiration in accordance with its terms, the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall for whatever reason be terminated or shall cease to be in full force and effect; (iii) the enforceability of the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall be contested by AgeX or a subsidiary; (iv) AgeX shall assert that its obligations under the Secured Note or any other Loan Document shall be invalid or unenforceable; or (v) a loss, theft, damage or destruction occurs with respect to a material portion of the collateral; (l) there is any change in the financial condition of AgeX and its subsidiaries which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX to perform any of its obligations under the Secured Note; and (m) any representation, warranty or statement made, repeated or deemed made or repeated by AgeX in the Secured Note, or pursuant to the Loan Documents, is incomplete, untrue, incorrect or misleading in any material respect when made, repeated or deemed made.

 

Restrictive Covenants – The Secured Note includes certain covenants that among other matters such as financial reporting: (i) impose financial restrictions on AgeX while the Secured Note remains unpaid, including restrictions on the incurrence of additional indebtedness by AgeX and its subsidiaries, except that AgeX’s subsidiary Reverse Bio will be permitted to incur debt convertible into equity not guaranteed or secured by the assets of AgeX or any other AgeX subsidiary, (ii) require that AgeX use loan proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, for general working capital, and for repayment of all or a portion of AgeX’s indebtedness to Juvenescence; and (iii) prohibit AgeX from making additional investments in subsidiaries, unless AgeX obtains the written consent of Juvenescence to a transaction that otherwise would be prohibited or restricted.

 

Security Agreement – AgeX has entered into a Security Agreement granting Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral.

 

$10 Million Secured Convertible Promissory Note

 

On March 13, 2023, AgeX and Juvenescence entered into a $10 Million Secured Convertible Promissory Note (the “$10 Million Secured Note”) pursuant to which Juvenescence has loaned to AgeX $10,000,000. AgeX used the loan proceeds to finance the $10,000,000 loan to Serina under the Serina Note. See Note 4, Convertible Note Receivable, for further information on the Serina Note and the related Serina Note Purchase Agreement.

 

F-52
 

 

On July 31, 2023, AgeX and Juvenescence also entered into an amendment to the $10 Million Secured Note that mirrors the amendments of the Secured Note described above, and also creates an earlier time window, ending October 31, 2023, during which Juvenescence may elect to convert any amount outstanding under the $10 Million Secured Note into shares of AgeX common stock. After October 31, 2023, Juvenescence may convert outstanding amounts under the $10 Million Secured Note into AgeX common stock on any date more than ninety (90) days after the earlier of (a) the occurrence of a Qualified Merger as defined, and (b) March 13, 2024.

 

The outstanding principal balance of the $10 Million Secured Note was scheduled to become due and payable on March 13, 2026. In lieu of accrued interest, AgeX agreed to pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.

 

During July 2023, the $10 Million Secured Note indebtedness, plus a portion of the accrued loan origination fees, was exchanged for Series B Preferred Stock pursuant to the Exchange Agreement.

 

The $10 Million Secured Note includes a provision allowing AgeX to convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. If less than $25,000,000 is raised through the sale of common stock or units, the conversion price per share or units shall be the lowest price at which shares or units are sold. If at least $25,000,000 is raised, the conversion price per share shall be 85% of the “Market Price” of AgeX common stock determined as provided in the $10 Million Secured Note. AgeX evaluated the 15% discounted conversion feature of the $10 Million Secured Note under ASC 815-15, Derivatives and Hedging—Embedded Derivatives, and concluded that it was an embedded derivative which should be bifurcated from the $10 Million Secured Note and accounted for separately. The 15% discount was determined to have an immaterial value at inception and life to date of the $10 Million Secured Note, as the probability of a future financing event described above is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period and any adjustments will be included in Interest (income) expense, net in the Other (income) expense, net section of the condensed consolidated statements of operations.

 

The $10 Million Secured Note includes certain covenants that among other matters require financial reporting and impose certain restrictions on AgeX that are substantially the same as those under the Secured Note.

 

AgeX has entered into an Amended and Restated Security Agreement that amends the February 14, 2022 Security Agreement between AgeX and Juvenescence and adds the $10 Million Secured Note to the obligations secured by the Security Agreement. The Security Agreement grants Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default as defined in the $10 Million Secured Note occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral with respect to any accrued loan origination fees remaining unpaid under the $10 Million Secured Note.

 

Registration Rights

 

AgeX entered into certain Registration Rights Agreements, as amended, pursuant to which AgeX has agreed to register for sale under the Securities Act of 1933, as amended (the “Securities Act”) all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement and pursuant to the Secured Note, and shares that they may acquire through the conversion of those loans into AgeX common stock. AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of AgeX common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence. Juvenescence retains the right to require AgeX to register additional shares of common stock that Juvenescence may acquire through the exercise of warrants or the conversion of loans. AgeX is obligated to pay the fees and expenses of each registered offering under such registration rights agreement except for underwriting discounts and commissions. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.

 

AgeX and Juvenescence have entered into a second Registration Rights Agreement pursuant to which AgeX has agreed to use commercially reasonable efforts to register the for sale under the Securities Act the shares of common stock issuable upon conversion of Preferred Stock. A registration statement must be filed upon request of Juvenescence if Form S-3 is available to AgeX. Juvenescence will also have “piggy-back” registration rights if AgeX files a registration statement for the sale of shares for itself or other stockholders, subject to certain customary exceptions based on the nature of the registration statement. AgeX will bear the expenses of the registration statement but not underwriting or broker’s commissions related to the sale of the common stock. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.

 

F-53
 

 

Debt Issuance Costs

 

In accordance with ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, all debt issuance costs are recorded as a discount on the debt and amortized to interest expense over the term of the applicable loan agreement using the effective interest method. Direct debt issuance costs include but are not limited to legal fees, debt origination fees, estimated fair market value of common stock and warrants issued in connection with the loan agreement, and NYSE American additional listing fees for the underlying shares of warrants issued with each drawdown of funds.

 

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of September 30, 2023 (in thousands):

 

   Drawdown of Funds   Origination Fee   Debt Exchanged for Preferred Stock   Total Debt   Debt Issuance Costs  

Amortization

of Debt Issuance Costs

   Total Debt, Net 
Current                                   
2020 Loan Agreement  $8,000   $-   $(8,000)  $-   $(2,806)  $2,806   $- 
Secured Note   18,160    1,406    (17,993)   1,573    (6,044)   5,997    1,526 
 Total current, net   26,160    1,406    (25,993)   1,573    (8,850)   8,803    1,526 
Non-current                                   
 $10 Million Secured Note   10,000    700    (10,007)   693    (666)   666    693 
Total debt, net  $36,160   $2,106   $(36,000)  $2,266   $(9,516)  $9,469   $2,219 

 

Related Party Receivables/Payables, net

 

Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, is devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $280,000. AgeX reimburses Juvenescence for services provided by other Juvenescence employees on a work order basis under a shared services agreement effective January 1, 2023. As of September 30, 2023, AgeX had approximately $4,000 receivable from Juvenescence included in related party receivables, net, on the condensed consolidated balance sheet. As of December 31, 2022, AgeX had approximately $141,000 payable to Juvenescence included in related party payables, net, on the condensed consolidated balance sheet.

 

Indemnification Agreements

 

On March 13, 2023, AgeX executed that certain Letter of Indemnification in Lieu of or Supplemental to a Medallion Signature Guarantee (“Letter of Indemnification”), pursuant to which AgeX agreed to indemnify American Stock Transfer & Trust Company, LLC and its affiliates, successors and assigns (the “AST Indemnity”) from and against any and all claims, damages, liabilities or losses arising out of the transfer of all of the AgeX common stock held by Juvenescence to its wholly-owned subsidiary, Juvenescence US Corp. (the “Share Transfer”). In connection with AgeX’s execution of the Letter of Indemnification, AgeX and Juvenescence entered into that certain Transfer of Shares of AgeX Therapeutics, Inc. Common Stock – Indemnification Agreement, pursuant to which Juvenescence agreed to indemnify AgeX against any and all claims, damages, liabilities or losses arising out of the Share Transfer or AST Indemnity.

 

6. Warrant Liability

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, Distinguishing Liabilities from Equity, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP.

 

As a condition of each amount drawn up to $15,160,000 from the Secured Note, on receipt of each amount drawn AgeX granted to Juvenescence a number of warrants equal to 50% of the gross value of the relevant advance made. The gross value is the quotient of the drawdown amount and the exercise price. The exercise price was based on the market closing price of AgeX’s common stock on the NYSE American on the one day preceding the delivery of the relevant drawdown notice. See Note 5, Related Party Transactions.

 

F-54
 

 

AgeX has utilized the full credit available under the Secured Note that is subject to warrants and accordingly the warrants were issued for each of the advances of loan funds under the Secured Note. After all relevant assessments, AgeX determined that the warrants issued under the Secured Note require classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity. In accordance with the accounting guidance, for each reporting period prior to the full drawdown of the entire $15,160,000 of the Secured Note line of credit subject to warrants, the amount of warrant liability was determined and recognized on the balance sheet for the applicable reporting period based on the number of warrants that would have been issued if $15,160,000 of the Secured Note line of credit was drawn. The amount of warrant liability attributed to the expected future issuance of warrants upon subsequent loan draws was subsequently adjusted for the fair value of warrants actually issued upon each loan draw, and the number of warrants that could be issued for the remaining credit available was re-measured for the applicable reporting period with changes being recorded as a component of net other expense in the condensed consolidated statements of operations.

 

Under the Third Amendment, AgeX is not obligated to issue additional warrants to Juvenescence in connection with the receipt of loan funds up to $4 million made available pursuant to the Second Amendment. See Note 5, Related Party Transactions, for further details of the Second Amendment and the Third Amendment.

 

The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date, the date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:

 

Black-Scholes Assumptions 

Exercise

Price (1)

  

Warrant

Expiration

Date (2)

 

Stock

Price (3)

  

Interest

Rate

(annual) (4)

  

Volatility

(annual) (5)

  

Time to

Maturity (Years)

  

Calculated

Fair Value per Share

 
Inception Date: 2/14/2022  $0.780   2/13/2025  $0.691    1.80%   122.99%   3   $0.486 
Issuance Date: 2/14/2022  $0.780   2/13/2025  $0.691    1.80%   122.99%   3   $0.486 
Issuance Date: 2/15/2022  $0.780   2/14/2025  $0.747    1.80%   123.28%   3   $0.535 
Period Ended 3/31/2022  $0.940   3/30/2025  $0.854    2.45%   123.28%   3   $0.607 
Issuance Date: 4/4/2022  $0.880   4/3/2025  $0.819    2.61%   123.31%   3   $0.585 
Issuance Date: 6/6/2022  $0.711   6/5/2025  $0.800    2.94%   122.62%   3   $0.592 
Period Ended 6/30/2022  $0.600   6/29/2025  $0.576    2.99%   122.21%   3   $0.413 
Issuance Date: 8/16/2022  $0.670   8/15/2025  $0.640    3.19%   121.37%   3   $0.457 
Period Ended 9/30/2022  $0.610   9/29/2025  $0.562    4.25%   121.49%   3   $0.401 
Issuance Date: 10/21/2022  $0.690   10/20/2025  $0.620    4.52%   120.51%   3   $0.439 
Issuance Date: 12/14/2022  $0.590   12/13/2025  $0.540    3.94%   120.01%   3   $0.381 
Period Ended 12/31/2022  $0.550   12/30/2025  $0.552    4.22%   119.31%   3   $0.396 
Issuance Date: 1/25/2023  $0.735   1/24/2026  $0.751    3.84%   119.17%   3   $0.540 
Inception Date: 2/9/2023  $0.703   2/8/2026  $0.660    4.15%   118.94%   3   $0.466 
Issuance Date: 2/15/2023  $0.624   2/14/2026  $0.600    4.35%   118.93%   3   $0.426 
Period Ended 3/31/2023  $0.661   3/30/2026  $0.663    3.81%   113.43%   3   $0.459 
Issuance Date: 4/4/2023  $0.661   4/3/2026  $0.673    3.60%   113.01%   3   $0.466 

 

 

(1) Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit.
   
(2) Warrants are exercisable over a three-year period from each Issuance Date.
   
(3) Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.
   
(4) Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.
   
(5) Based on the historical daily volatility of AgeX common stock as of each date presented.

 

F-55
 

 

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

Warrant Liability 

Credit Line and

Draw Amounts

(in thousands)

   Warrants  

Fair Value

per Share

  

Fair Value

(in thousands)

 
Fair value as of January 1, 2022  $-    -   $-   $- 
Fair value at initial measurement date of 2/14/2022   13,160(1)   8,435,897(2)   0.4864    4,103 
Fair value of warrants issued on 2/14/2022   (7,160)(3)   (4,589,743)(4)   0.4864    (2,232)
Fair value of warrants issued on 2/15/2022   (1,000)(3)   (641,025)(4)   0.5349    (343)
Fair value of warrants issued on 4/4/2022   (1,000)(3)   (568,440)(4)   0.5854    (333)
Fair value of warrants issued on 6/6/2022   (1,000)(3)   (703,234)(4)   0.5924    (417)
Fair value of warrants issued on 8/16/2022   (1,000)(3)   (746,380)(4)   0.4569    (341)
Fair value of warrants issued on 10/21/2022   (500)(3)   (362,318)(4)   0.4386    (159)
Fair value of warrants issued on 12/14/2022   (1,000)(3)   (847,457)(4)   0.3810    (323)
Change in fair value of warrants   -    -    -    225 
Fair value as of December 31, 2022  $500(1)   454,545(2)  $0.3960   $180 
Fair value of warrants issued on 1/25/2023   (500)(3)   (340,136)(4)   0.5395    (184)
Fair value at initial measurement date of 2/9/2023   2,000(1)   1,422,879(2)   0.4657    663 
Fair value of warrants issued on 2/15/2023   (1,000)(3)   (801,924)(4)   0.4263    (342)
Fair value of warrants issued on 4/4/2023   (1,000)(3)   (756,429)(4)   0.4660    (352)
Change in fair value of warrants   -    -    -    35 
Fair value as of September 30, 2023  $-(1)   -(2)  $-   $- 

 

 

(1) Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit.
   
(2) Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.
   
(3) Amount of drawdown as of the date presented.
   
(4) Number of warrants issued upon receipt of amounts drawn against the Secured Note as of the date presented.

 

During the nine months ended September 30, 2023, AgeX recorded a loss on change in fair value of warrants of $35,000. During the three and nine months ended September 30, 2022, AgeX recorded a loss on change in fair value of warrants of $35,000 and $220,000, respectively.

 

The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and AgeX’s stock prices and historical volatility as inputs. None of the warrants issued have been exercised.

 

7. Stockholders’ Equity (Deficit)

 

Preferred Stock

 

On July 24, 2023, AgeX issued to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 million of indebtedness consisting of the outstanding principal amount of loans then outstanding under the 2020 Loan Agreement, the Secured Note, and the $10 Million Secured Note, plus the loan origination fees accrued with respect to the 2022 Secured Note and a portion of the loan origination fees accrued pursuant to the $10 Million Secured Note. The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to the Exchange Agreement between AgeX and Juvenescence. By completing the exchange of indebtedness for shares of Series A Preferred Stock and Series B Preferred Stock (collectively referred to as the “Preferred Stock”).

 

Classification of Preferred Stock

 

The deemed liquidation preference provisions of the preferred stock are considered contingent redemption provisions that are not solely within AgeX’s control. Accordingly, the preferred stock has been presented outside of permanent equity in the mezzanine section of the condensed consolidated balance sheet. Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values to the preferred stock would be made only when a deemed liquidation event becomes probable.

 

On November 7, 2023, certain terms of the Series A Preferred Stock and Series B Preferred Stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as adeemed liquidation if the applicable transaction is approved by the Board of Directors or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of Preferred Stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock. This amendment permits the classification of the Series A Preferred Stock and Series B Preferred Stock as permanent equity effective November 7, 2023. See Note 12, Subsequent Events, for illustration of the Preferred Stock presented in permanent equity in the condensed consolidated pro forma balance sheet.

 

F-56
 

 

Dividends – The Preferred Stock is not entitled to receive any payment or distribution of cash or other dividends.

 

Liquidation Preference – In the event of any voluntary or involuntary liquidation, dissolution or other winding up of the affairs of AgeX, subject to the preferences and other rights of any senior stock, before any assets of AgeX shall be distributed to holders of common stock or other junior stock, all of the assets of AgeX available for distribution to stockholders shall be distributed among the holders of Series A Preferred Stock and Series B Preferred Stock and any other “parity stock” that may be issued ranking parri passu with those series of Preferred Stock with respect to liquidation rights, in proportion to the number of shares of Series B Preferred Stock and parity stock held by each such holder as of the record date for the determination of holders of Series A Preferred Stock, Series B Preferred Stock, and parity stock entitled to receive such distribution, until AgeX shall have distributed to the holders of those shares an amount of assets having a value equal to the subscription price per share. If the assets of AgeX shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of Series A Preferred Stock, Series B Preferred Stock and parity stock shall be ratably distributed among such holders. The (i) acquisition of AgeX by another entity by means of any transaction or series of transactions (including, without limitation, any reorganization, merger or consolidation) in which the stockholders of AgeX immediately before such transaction or series of transactions do not own a majority of the outstanding stock of the surviving or acquiring corporation upon completion of such transaction or series of transactions or (ii) a sale of all or substantially all of the assets of AgeX in a single transaction or series of related transactions, shall be deemed a liquidation. On November 7, 2023, certain terms of the liquidation preference were amended. See Note 12 Subsequent Transactions.

 

Conversion of Preferred Stock into Common Stock – Each share of Preferred Stock shall be convertible into a number of shares of AgeX common stock determined by dividing (x) a number equal to the number of dollars and cents comprising the subscription price, by (y) a number equal to the number of dollars and cents comprising the conversion price. The subscription price per share of Preferred Stock is $100 which was paid through the exchange of indebtedness for shares of Preferred Stock. The conversion price per share of Series A Preferred Stock or Series B Preferred Stock is $0.72 which was the closing price of AgeX common stock on the NYSE American on the last trading day immediately preceding the execution of the Exchange Agreement.

 

Optional Conversion – Preferred Stock shall be convertible into common stock at the election of the holder of shares of Preferred Stock at any time and from time to time subject to the limitations on conversion of Series B Preferred Stock discussed below.

 

Automatic Conversion – The outstanding shares of Series A Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders (“Automatic Conversion”) upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina, or a subsidiary thereof; and (y) February 1, 2024. Further, if the holders of at least a majority of the outstanding shares of Series A Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, then the outstanding shares of Series A Preferred Stock shall be converted into common stock upon such approval or consent.

 

The outstanding shares of Series B Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina or a subsidiary thereof; and (y) February 1, 2024, provided that such conversion is not limited by the 19.9% Cap or the 50% Cap as described below; and if Automatic Conversion would then be limited by the 19.9% Cap or the 50% Cap, the Automatic Conversion shall take place on the tenth day after such stockholder approvals have been obtained as may be required to permit such Automatic Conversion without the limitations of the 19.9% Cap and the 50% Cap. Further, if the holders of at least a majority of the outstanding shares of Series B Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, and the conversion is not then limited by the 19.9% Cap or the 50% Cap, then the outstanding shares of Series B Preferred Stock shall be converted into common stock upon such approval or consent.

 

Certain Limitations on Conversion of Series B Preferred StockIf under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the “19.9% Cap” upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued upon conversion of all shares of Series B Preferred Stock shall be an amount equal to the 19.9% Cap. The 19.9% Cap means 7,550,302 shares of common stock, which is 19.9% of the shares of common stock outstanding on February 14, 2022 when the Secured Note, a portion of which has not been approved by AgeX stockholders for conversion into common stock without regard to the 19.9% Cap and 50% Cap, was issued.

 

F-57
 

 

If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the 50% Cap upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued to a holder of Series B Preferred Stock upon conversion of such shares shall be an amount that, when added to other shares of common stock owned by such holder immediately prior to such conversion would equal one share less than the 50% Cap.

 

Adjustment of conversion price and subscription price – If AgeX shall (a) declare a dividend or make a distribution on its common stock in shares of common stock, (b) subdivide or reclassify the outstanding common stock into a greater number of shares, or (c) combine or reclassify the outstanding common stock into a smaller number of shares, the conversion price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. If AgeX shall (i) declare a dividend or make a distribution on a series of Preferred Stock in shares of Preferred Stock, (ii) subdivide or reclassify the outstanding shares of a series of Preferred Stock into a greater number of shares, or (iii) combine or reclassify the outstanding shares of a series of Preferred Stock into a smaller number of shares, the subscription price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. Successive adjustments in the conversion price or subscription price, as applicable, shall be made whenever any event specified above shall occur.

 

No Fractional Shares – No fractional share of common stock or scrip shall be issued upon conversion of Preferred Stock. Instead of any fractional share of common stock which would otherwise be issuable upon conversion of any Preferred Stock, AgeX will pay a cash adjustment in respect of such fractional interest in an amount equal to that fractional interest at the then fair value determined in accordance with the terms of the Preferred Stock.

 

Voting Rights – The following matters shall require the approval of the holders of a majority of the shares of a series of Preferred Stock then outstanding, voting as a separate class: (i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock. Except as may otherwise be required by the Delaware General Corporation Law, as the same may be amended from time to time, the Preferred Stock will have no other voting rights.

 

Governing Law – The powers, designations, preferences, rights, qualifications, limitations, and restrictions of either series of Preferred Stock, the validity, authorization and issuance of such Preferred Stock, and the conversion of such Preferred Stock into common stock shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof, and all legal proceedings pursuant or with respect to or concerning such matters (a “Proceeding”), whether brought by or against a holder of Preferred Stock or AgeX or any of their respective directors, officers, stockholders, employees or agents, shall be commenced in the state and federal courts sitting in the State of Delaware (the “Delaware Courts”). The Preferred Stock provides that (a) AgeX and each holder of Preferred Stock irrevocably submits to the exclusive jurisdiction of the Delaware Courts for the adjudication of any Proceeding, and irrevocably waives, and agrees not to assert in any Proceeding any claim that they are not personally subject to the jurisdiction of such Delaware Courts, or such Delaware Courts are an improper or inconvenient venue for such Proceeding, and (b) AgeX and each holder of Preferred Stock irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to such party and agrees that such service shall constitute good and sufficient service of process and notice

 

Common Stock

 

AgeX has 200,000,000 shares of $0.0001 par value common stock authorized. At September 30, 2023 and December 31, 2022, there were 37,951,261 and 37,949,196 shares of AgeX common stock issued and outstanding, respectively.

 

Issuance and Sale of Warrants by AgeX

 

In connection with the $2,500,000 of drawdowns of loan funds from Juvenescence under the Secured Note during the nine months ended September 30, 2023, AgeX issued to Juvenescence 2022 Warrants to purchase 1,898,489 shares of AgeX common stock. See Note 6, Warrant Liability.

 

F-58
 

 

At-the-Market Offering Facility

 

On January 8, 2021, AgeX entered into a sales agreement with Chardan Capital Markets, LLC (“Chardan”) relating to the sale of shares of AgeX common stock, par value $0.0001 per share, through an at-the-market (“ATM”) offering as described in the prospectus supplement filed with the Form S-3 which was declared effective by the SEC on January 29, 2021. In accordance with the terms of the sales agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $12.6 million from time to time through Chardan, acting as the sales agent. The actual market value of shares of common stock that AgeX may sell through the ATM offering during any 12 month period will be limited to one-third of the aggregate market value of AgeX common stock held by stockholders that would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. During the nine months ended September 30, 2023 and 2022, no proceeds were raised through the sale of shares of common stock under the ATM.

 

8. Stock-Based Awards

 

Equity Incentive Plan Awards

 

AgeX has an Equity Incentive Plan (the “Plan”) under which a maximum of 8,500,000 shares of common stock are available for the grant of stock options, the sale of restricted stock, the settlement of restricted stock units, and the grant of stock appreciation rights. The Plan also permits AgeX to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine.

 

A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price):

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted-

Average

Exercise Price

 
Balance at December 31, 2022   5,139    3,261    3   $2.25 
Options granted   (26)   26    -    0.76 
Restricted stock units vested   -    -    (3)   - 
Balance at September 30, 2023   5,113    3,287          -   $       2.24 
Options exercisable at September 30, 2023        3,067        $2.32 

 

There have been no exercises of stock options to date.

 

Stock-based Compensation Expense

 

AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC 718, Compensation – Stock Compensation (“ASC 718”). AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09.

 

AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under AgeX’s 2017 Equity Incentive Plan (the “Incentive Plan”). The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.

 

Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations.

 

F-59
 

 

Operating expenses include stock-based compensation expense as follows (in thousands):

 

   2023   2022   2023   2022 
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022   2023   2022 
Research and development  $1   $8   $8   $25 
General and administrative   39    201    137    621 
Total stock-based compensation expense  $40   $209   $145   $646 

 

The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions including expected life, risk-free interest rates, volatility, and dividend yield. The assumptions that were used to calculate the grant date fair value of employee and non-employee stock option grants for the three and nine months ended September 30, 2022 were as follows:

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022(1)   2023   2022 
Grant price  $0.76   $-   $0.76   $0.79 
Market price  $0.76   $-   $0.76   $0.79 
Expected life (in years)   5.15    -    5.15    5.58 
Volatility   118.12%   -%   118.12%   130.71%
Risk-free interest rates   4.12%   -%   4.12%   1.74%
Dividend yield   -%   -%   -%   -%

 

(1)There were no stock options granted under the Plan during the three months ended September 30, 2022.

 

The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If AgeX had made different assumptions, its stock-based compensation expense and net loss for the nine months ended September 30, 2023 and 2022 may have been significantly different.

 

AgeX does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

 

9. Income Taxes

 

The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where AgeX conducts business.

 

For the three and nine months ended September 30, 2023 and 2022, AgeX experienced a loss; therefore, no income tax provision was recorded for the three and nine months ended September 30, 2023 and 2022.

 

Due to losses incurred for all periods presented, AgeX did not record a provision or benefit for income taxes. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all of its deferred tax assets for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

 

10. Supplemental Cash Flow Information

 

Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022 are as follows (in thousands):

 

   2023   2022 
  

Nine Months Ended

September 30,

 
   2023   2022 
Cash paid during the period for interest  $27   $14 
Issuance of preferred stock in exchange for debt  $36,000   $- 
Issuance of common stock upon vesting of restricted stock units (Note 8)  $2   $6 
Issuance of warrants for debt issuance under the 2020 Loan Agreement  $-   $178 
Fair value of liability classified warrants at debt inception date (Note 6)  $663   $3,666 
Debt refinanced with new debt (Note 5)  $-   $7,160 

 

F-60
 

 

11. Commitments and Contingencies

 

Office Lease Agreement

 

AgeX leases office space in Alameda, California. For 2022 base monthly rent was $1,074 and for 2023 base monthly rent is $844 for slightly less space at the same building. The lease also includes office furniture rental, janitorial services, utilities, and internet service.

 

ASC 842

 

For the office lease, AgeX has elected to not apply the recognition requirements under ASC 842 as lease cost on a straight-line basis over the lease term because the amount of the lease payments is not deemed material.

 

There were no future minimum lease commitments as of September 30, 2023.

 

Litigation – General

 

AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.

 

Tax Filings

 

AgeX tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes AgeX has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the unaudited condensed consolidated interim financial statements.

 

Employment Contracts

 

AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations.

 

Indemnification

 

In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s research and development programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s research and development. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property licensed from AgeX to third parties. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The sales agreement between AgeX and Chardan also includes indemnification provisions pursuant to which the parties have agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock through the ATM facility, including liabilities under the Securities Act. Similarly, the Registration Rights Agreement between Juvenescence and AgeX includes indemnification provisions pursuant to which the parties will indemnify each other from certain liabilities in connection with the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. AgeX has also agreed to provide the AST Indemnity pursuant to the Letter of Indemnification described in Note 5, Related Party Transactions. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular license, lease, or agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure and in the case of the AST Indemnity AgeX has received a cross-indemnity from Juvenescence against all claims, damages, liabilities or losses arising out of the AST Indemnity. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements to date.

 

F-61
 

 

Notice of Delisting 

 

On April 20, 2023, AgeX received a letter (the “2023 Deficiency Letter”) from the staff of the Exchange indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6,000,000 or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The 2023 Deficiency Letter states that as AgeX remains subject to the conditions set forth in prior letters from the Exchange with respect to AgeX’s deficiencies in stockholders equity, and if AgeX is not in compliance with all of the Exchange’s stockholders equity standards, or does not make progress consistent with AgeX’s Exchange approved plan to come into compliance with the Exchange’s continued listing standards, by May 17, 2023, the Exchange will initiate delisting proceedings as appropriate.

 

On May 17, 2023 AgeX received a notice from the staff of the Exchange indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange’s Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX did not meet the continued listing standards because it had stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6,000,000 or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years.

 

On May 24, 2023, AgeX filed a request for a review of the delisting determination by a Committee of the Board of Directors of the Exchange. On May 31, 2023, AgeX received a notice from the staff of the Exchange which scheduled a hearing for July 25, 2023. On July 24, 2023, AgeX issued shares of preferred stock to Juvenescence in exchange for the extinguishment of $36 million of indebtedness owed to Juvenescence for the purpose of remediating the deficiency in stockholders equity, and the hearing at the Exchange scheduled for July 25 was cancelled. See Note 7, Stockholders’ Equity (Deficit) and Note 12, Subsequent Events for further discussion on the classification of preferred stock and amendment to Section 3(b) of the terms of the Series A Preferred Stock and Series B Preferred Stock.

 

12. Subsequent Events

 

Additional Loans Under Secured Note

 

On October 3, 2023, AgeX drew $500,000 of its credit available under the Secured Note. On October 31, 2023 AgeX drew the final $500,000 of the credit line available under the Secured Note.

 

Increase in Secured Note Line of Credit

 

On November 9, 2023, AgeX and Juvenescence entered into the Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note (the “Fifth Amendment”) that increases the amount of the line of credit available to AgeX by $4,400,000, subject to the terms of the Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. Concurrently with the execution of the Fifth Amendment, AgeX also entered into an additional Pledge Agreement to add shares of a subsidiary to the collateral under the Security Agreement, and AgeX’s subsidiaries ReCyte, Reverse Bio, and UniverXome each entered into a Guaranty Agreement and Joinder Agreement pursuant to which each of them agreed to guaranty AgeX’s obligations to Juvenescence pursuant to the Secured Note, as amended by the Fifth Amendment, and to grant Juvenescence a security interest in their respective assets pursuant to the Security Agreement to secure their obligations to Juvenescence.

 

Amendment to Preferred Stock and Remediation of Stock Exchange Listing Deficiency

 

On July 24, 2023, AgeX issued shares of AgeX Series A Preferred Stock and AgeX Series B Preferred Stock to Juvenescence in exchange for the extinguishment of $36 million of indebtedness owed to Juvenescence with the intent of adding $36 million to stockholders equity to eliminate a stockholders equity deficiency that caused AgeX to be out of compliance with the NYSE American continued listing standards. However, upon subsequent consideration in consultation with AgeX’s independent registered public accountants, AgeX determined that, in accordance with applicable guidance to GAAP, the deemed liquidation preference provisions of the Preferred Stock could be considered contingent redemption provisions that are not solely within AgeX’s control, requiring that the Preferred Stock be presented outside of permanent equity in the mezzanine section of the condensed consolidated balance sheet as of September 30, 2023. To comply with the NYSE American listing requirement by permitting the Preferred Stock to qualify now as permanent equity, on November 7, 2023, Section 3(b) of the terms of the Series A Preferred Stock and Series B Preferred Stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as a deemed liquidation if the applicable transaction is approved by the Board of Directors or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of Preferred Stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock. AgeX has informed the NYSE American of the accounting issue and the remedy that has been implemented and AgeX believes it is in compliance with NYSE American’s continued listing standards.

 

The following pro-forma condensed consolidated balance sheet illustrates the effect of the Preferred Stock in permanent equity.

 

F-62
 

 

Non-GAAP Financial Measures

 

The condensed consolidated interim financial statements include stockholders equity (deficit) prepared in accordance with accounting principles generally accepted in the United States (GAAP). The following pro-forma condensed consolidated balance sheet includes certain pro forma historical non-GAAP adjustments to the balance sheet. In particular, AgeX has provided a non-GAAP pro forma presentation of Series A Preferred Stock and Series B Preferred Stock classified as permanent equity, eliminating the stockholders deficit, based on a post-September 30, 2023 amendment to the liquidation provisions of the Preferred Stock. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable financial measures prepared in accordance with GAAP. However, AgeX believes the non-GAAP presentation of stockholders equity, when viewed in conjunction with our GAAP presentation, is helpful in understanding AgeX’s current capital structure.

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED PRO FORMA BALANCE SHEET

(in thousands, except par value amounts)

(unaudited)

   September 30, 2023   Adjustment   Adjusted Balance 
             
ASSETS               
Current assets:               
Cash and cash equivalents  $397   $-   $397 
Accounts and grants receivable, net   67    -    67 
Related party receivables, net   4    -    4 
Prepaid expenses and other current assets   673    -    673 
Total current assets   1,141    -    1,141 
                
Restricted cash   50    -    50 
Intangible assets, net   640    -    640 
Convertible note receivable   10,379    -    10,379 
TOTAL ASSETS  $12,210   $-   $12,210 
                
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)               
Current liabilities:               
Accounts payable and accrued liabilities  $1,671   $-   $1,671 
Loan due to Juvenescence, net of debt issuance costs, current portion   1,526    -    1,526 
Insurance premium liability and other current liabilities   7    -    7 
Total current liabilities   3,204    -    3,204 
                
Loan due to Juvenescence, net of debt issuance costs, net of current portion   693    -    693 
TOTAL LIABILITIES  3,897   -   3,897 
                
Commitments and contingencies   -     -     -  
                
Series A preferred stock; no par value; stated value $100 per share; 212 and nil shares issued and outstanding, respectively   21,135    (21,135)   - 
Series B preferred stock; no par value; stated value $100 per share; 148 and nil shares issued and outstanding, respectively   14,823    (14,823)   - 
               
Stockholders’ equity (deficit):              
Preferred stock, $0.0001 par value, 5,000 shares authorized; and                
Series A Preferred stock - 212 and nil shares issued and outstanding, respectively   -    -    - 
Series B Preferred stock - 148 and nil shares issued and outstanding, respectively   -    -    - 
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively   4    -    4 
Additional paid-in capital   100,017    35,958    135,975 
Accumulated deficit   (127,557)   -    (127,557)
Total AgeX Therapeutics, Inc. stockholders’ equity (deficit)   (27,536)   35,958    8,422 
Noncontrolling interest   (109)   -    (109)
Total stockholders’ equity (deficit)   (27,645)   35,958    8,313 
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)  $12,210   $-   $12,210 

 

F-63
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2022 AND 2021

 

F-64
 

 

TABLE OF CONTENTS

 

INDEPENDENT AUDITOR’S REPORT F-66
   
CONSOLIDATED FINANCIAL STATEMENTS  
   
Consolidated Balance Sheets F-67
   
Consolidated Statements of Operations F-69
   
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit F-70
   
Consolidated Statements of Cash Flows F-72
   
Notes to Consolidated Financial Statements F-74

 

F-65
 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors

of Serina Therapeutics, Inc.

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Serina Therapeutics, Inc. (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations, redeemable convertible preferred stock and stockholders’ deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of their operations and cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Substantial Doubt About the Company’s Ability to Continue as a Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has losses from operations, negative operating cash flows, accumulated deficit, and additional capital needs. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

Management’s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB and auditing standards generally accepted in the United States of America (GAAS). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Frazier & Deeter, LLC

 

We have served as the Company’s auditor since 2021.

Tampa, Florida

November 10, 2023

 

F-66
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

AS OF December 31, 2022 AND 2021

 

 

 

   2022   2021 
ASSETS          
Current Assets          
Cash  $532,229   $314,846 
Prepaid expenses   16,346    17,853 
Accounts receivable   -    1,109 
Investments in equity securities   -    996,447 
           
Total Current Assets   548,575    1,330,255 
Property and equipment, net   91,569    122,893 
Right of use assets - operating leases   84,752    234,764 
Right of use assets - finance leases   133,146    156,495 
           
Total Assets  $858,042   $1,844,407 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-67
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS - CONTINUED

AS OF December 31, 2022 AND 2021

 

 

LIABILITIES, REDEEMABLE CONVERTIBLE PREFFERED STOCK,

AND STOCKHOLDERS’ DEFICIT

 

   2022   2021 
Current Liabilities          
Accounts payable  $143,337   $145,468 
Credit card payable   5,520    4,307 
Payroll liabilities   6,925    9,898 
Contract liabilities   153,500    - 
Current portion of operating lease liabilities   80,696    169,442 
Current portion of finance lease liabilities   47,708    42,352 
           
Total Current Liabilities   437,686    371,467 
           
Warrant liability   1,076,766    952,648 
Convertible promissory notes   1,617,000    - 
Operating lease liabilities, net of current portion   26,283    101,701 
Finance lease liabilities, net of current portion   36,968    84,676 
           
Total Liabilities   3,194,703    1,510,492 
           
Redeemable Convertible Preferred Stock, Par Value $0.01 (Note 5)   35,441,500    35,441,500 
           
Stockholders’ Deficit          
Common stock , $0.01 par value, 15,000,000 shares authorized; 2,218,500 and 2,144,800 shares issued and outstanding at December 31, 2022 and 2021, respectively   22,185    21,448 
Additional paid-in capital   646,136    635,341 
Accumulated deficit   (38,446,482)   (35,764,374)
           
Total Stockholders’ Deficit   (37,778,161)   (35,107,585)
          
Total Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Deficit  $858,042   $1,844,407 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-68
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED December 31, 2022 AND 2021

 

 

   2022   2021 
Revenue          
Contract revenue  $500,000   $3,039,184 
Grant revenue   91,500    425,569 
           
Total Revenue   591,500    3,464,753 
           
Operating Expenses          
Research and development expenses   1,573,085    3,798,593 
General and administrative expenses   1,288,783    1,297,668 
           
Total Operating Expenses   2,861,868    5,096,261 
           
Operating Loss   (2,270,368)   (1,631,508)
           
Other Income (Expense)          
Loss on equity securities, net   (7,585)   (6,452)
Interest expense   (15,878)   (3,094)
Interest and dividend income   1,757    10,859 
Fair value inception adjustment on convertible          
promissory notes   (179,000)   - 
Change in fair value of convertible promissory notes   (88,000)   - 
Change in fair value of warrant liability   (124,118)   205,287 
Other income   1,084    - 
Forgiveness of SBA PPP loan   -    187,133 
Loss on dissolution of subsidiary   -    (26,928)
           
Total Other (Expense) Income   (411,740)   366,805 
           
Net Loss  $(2,682,108)  $(1,264,703)
           
Net Loss Per Common Share          
Basic  $(1.25)  $(0.59)
Diluted  $(1.25)  $(0.59)
           
Weighted-Average Shares Used in Computation of Net Loss Per Common Share          
Basic   2,145,002    2,144,800 
Diluted   2,145,002    2,144,800 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-69
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED December 31, 2022 AND 2021

 

  

   Redeemable Convertible Preferred Stock 
       Preferred       Preferred       Preferred       Preferred 
       Stock -Series       Stock -Series       Stock -Series       Stock -Series 
   Shares   A Amount   Shares   A-1 Amount   Shares   A-2 Amount   Shares   A-3 Amount 
As of December 31, 2020   400,000   $      2,000,000    300,000    $      1,998,000    1,117,013   $     11,085,291    499,200   $       6,240,000 
Issuance of preferred stock   -    -    -    -    -    -    -    - 
As of December 31, 2021   400,000    2,000,000    300,000    1,998,000    1,117,013    11,085,291    499,200    6,240,000 
As of December 31, 2022   400,000    $2,000,000    300,000    $1,998,000    1,117,013   $11,085,291    499,200   $6,240,000 

 

 Redeemable Convertible Preferred Stock 
       Preferred       Preferred         
      

Stock -Series

       Stock -Series         
   Shares   A-4 Amount   Shares   A-5 Amount   Total Shares   Total Amount 
As of December 31, 2020   718,997   $       9,346,961    360,081   $       4,681,096          3,395,291   $     35,351,348 
Issuance of preferred stock   -    -    6,934    90,152    6,934    90,152 
As of December 31, 2021   718,997    9,346,961    367,015    4,771,248    3,402,225    35,441,500 
As of December 31, 2022   718,997   $9,346,961    367,015   $4,771,248    3,402,225   $35,441,500 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-70
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT - CONTINUED

FOR THE YEARS ENDED December 31, 2022 AND 2021

 

 

               Stock       Non-   Total 
   Common Stock   Common Stock   Additional Paid   Subscriptions   Accumulated   Controlling   Stockholders’ 
   Shares   Amount   in Capital   Receivable   Deficit   Interest   Equity (Deficit) 
As of December 31, 2020 - continued              2,144,800                   21,448    597,761    (1,000,769)   (34,520,876)   3,537          (34,898,899)
Dissolution of Canaria Therapeutics, Inc.   -    -    (45,365)   769    21,205    (3,537)   (26,928)
Collection of stock subscription receivable   -    -    -    1,000,000    -    -    1,000,000 
Stock based compensation   -    -    82,945    -    -    -    82,945 
Consolidated net loss   -    -    -    -    (1,264,703)   -    (1,264,703)
As of December 31, 2021 - continued   2,144,800    21,448    635,341    -    (35,764,374)   -    (35,107,585)
Exercise of stock options   73,700    737    3,685    -    -    -    4,422 
Stock based compensation   -    -    7,110    -    -    -    7,110 
Consolidated net loss   -    -    -    -    (2,682,108)   -    (2,682,108)
As of December 31, 2022 - continued   2,218,500   $22,185   $646,136   $-   $(38,446,482)  $-   $(37,778,161)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-71
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED December 31, 2022 AND 2021

 

 

 

   2022   2021 
Cash Flows from Operating Activities          
Net loss  $(2,682,108)  $(1,264,703)
           
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   61,272    33,368 
Loss on disposal of property and equipment   3,083    380 
Stock based compensation   7,110    82,945 
Loss on equity securities, net   7,585    6,452 
Reinvested interest and dividend income   (1,757)   (10,624)
Change in fair value of warrant liability   124,118    (205,287)
Non-cash lease expense   150,012    75,546 
Fair value inception adjustment on convertible promissory notes   179,000    - 
Change in fair value of convertible promissory notes   88,000    - 
Forgiveness of SBA PPP loan   -    (187,133)
Loss on dissolution of subsidiary   -    (26,928)
Changes in asset and liability accounts:          
Accounts receivable   1,109    1,001,284 
Contract assets   -    273,044 
Prepaid expenses   1,507    284 
Accounts payable   (2,131)   (367,289)
Credit card payable   1,213    1,481 
Accrued rent   -    (13,437)
Payroll liabilities   (2,973)   (2,940)
Operating lease liabilities   (164,164)   (40,075)
Contract liabilities   153,500    (1,607,143)
           
Net Cash Used in Operating Activities   (2,075,624)   (2,250,775)
           
Cash Flows from Investing Activities          
Proceeds from sale of investments in equity securities   990,619    931,755 
Purchases of property and equipment   (9,682)   (84,929)
Acquisition of right of use asset - finance lease   -    (23,505)
           
Net Cash Provided by Investing Activities   980,937    823,321 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-72
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS - CONTINUED

FOR THE YEARS ENDED December 31, 2022 AND 2021

 

  

   2022   2021 
Cash Flows from Financing Activities        
Issuance of convertible promissory notes   5,000,000    - 
Repayment of convertible promissory note   (3,650,000)   - 
Proceeds from common stock issued   4,422    - 
Principal repayments on finance lease liabilities   (42,352)   (12,907)
Proceeds from preferred stock issued   -    90,152 
Collection of stock subscription receivable   -    1,000,000 
Net Cash Provided by Financing Activities   1,312,070    1,077,245 
Net Increase (Decrease) in Cash   217,383    (350,209)
Cash, Beginning of Year   314,846    665,055 
Cash, End of Year  $532,229   $314,846 
Supplemental Schedule of Noncash Investing and Financing Activities          
Cash paid for interest  $15,878   $3,094 
Fixed asset purchases in accounts payable as of December 31  $-   $39,060 
Acquisition of right of use assets in exchange for finance lease liabilities  $-   $139,935 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-73
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2022 AND 2021

 

 

Note 1 - Summary of Significant Accounting Policies

 

Nature of Business

 

Serina Therapeutics, Inc. (the “Company” or “Serina”) is a privately-held, clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Serina’s POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an increase in efficacy and safety of the resulting polymeric drug conjugate. Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. Serina was the majority shareholder of Canaria Therapeutics, Inc. (“Canaria”) from its inception through its dissolution in 2021. Canaria was founded in 2018 and had minimal activity during the year ended December 31,2021. Serina was founded in 2006 and is headquartered in Huntsville, Alabama.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of Serina and its subsidiary, Canaria (collectively, the Company). In July 2021, Canaria was dissolved.

 

Basis of Accounting

 

The accompanying consolidated financial statements reflect the operations of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

 

Liquidity

 

The Company incurred net losses of approximately $2,700,000 for the year ended December 31, 2022. The Company used approximately $2,100,000 in net cash from operating activities for the year ended December 31, 2022 and has historically incurred losses from operations and expects to continue to generate negative cash flows as the Company implements its business plan. There is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements are prepared using GAAP as applicable to a going concern.

 

The Company had cash on hand of approximately $7,600,000 as of September 30, 2023. As discussed in Note 17, subsequent to year-end the Company raised $10,100,000 in additional debt. The debt is expected to fund operations through approximately March 2024.

 

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of therapeutic candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel and infrastructure.

 

F-74
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

December 31, 2022 AND 2021

 

 

Note 1 - Summary of Significant Accounting Policies - Continued

 

Liquidity - Continued

 

Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. The Company largely relies on raising capital from equity investors for funding its operations. Some funding is obtained through licensing agreements or other arrangements with commercial entities.

 

As a result of recurring losses from operations and recurring negative cash flows from operations, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively. If sufficient capital is not available, the Company would be required to delay, limit, reduce, or terminate its product development or future commercialization efforts or grant rights to develop and market therapeutic candidates to other entities. There can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings will be workable or acceptable to the Company or its shareholders. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Cash

 

Cash includes cash held in readily available checking and money market accounts.

 

Accounts Receivable

 

Accounts receivable consists primarily of payments due to the Company on contracts with customers. Bad debts arising from contracts are estimated using the allowance method. Management determines the allowance for doubtful accounts based on historical losses and current economic conditions. On a continuing basis, management analyzes delinquent receivables; and once receivables are determined to be uncollectible, they are written off through a charge against an existing allowance account or against earnings. No allowance for doubtful accounts has been provided at December 31, 2021, and there were no accounts receivable at December 31, 2022.

 

Contract Assets

 

Contract assets include the unbilled amount typically resulting from sales under contracts where the revenue recognized exceeds the amounts billed to the customer. The amounts may not exceed their estimated net realizable value. Contract assets are classified as current based on the Company’s contract operating cycle.

 

Contract Liabilities

 

Contract liabilities include billings in excess of revenue recognized. Contract liabilities are classified as current based on the Company’s contract operating cycle and reported on a contract-by-contract basis, net of revenue recognized, at the end of each reporting period.

 

Investments in Equity Securities

 

Investments in equity securities consist of mutual funds at fair value which are highly liquid. These investments are therefore classified as current assets and as trading securities. Net realized and unrealized gains and losses on trading securities are included in net earnings. For the purpose of determining realized gains and losses, the cost of securities sold is based on specific identification.

 

Property and Equipment

 

Property and equipment are carried at cost less accumulated depreciation. The costs of additions and betterments are capitalized and expenditures for repairs and maintenance are expensed as incurred. When items of property and equipment are sold or retired, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is included in the statements of operations. Depreciation of property and equipment is provided utilizing the straight-line method over the range of lives used of the respective assets, which is 3 - 10 years.

 

F-75
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

December 31, 2022 AND 2021

 

 

Note 1 - Summary of Significant Accounting Policies - Continued

 

Property and Equipment - Continued

 

Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if its carrying amount exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. No impairment loss was recognized during the years ended December 31, 2022 and 2021, respectively.

 

Revenue Recognition

 

Contract revenue - The Company recognizes contract revenue under licensing agreements with commercial entities. Under revenue sharing licensing agreements, the Company receives reimbursement for eligible costs as well as payments upon the achievement of certain milestones as defined by the contract. These licensing agreements provide for the Company to receive a certain percentage of revenue from sales of their product; however, no sales have occurred to date. Under other licensing agreements, the Company receives payment for the production and use of their polymer technology.

 

The Company accounts for a contract after it has been approved by all parties to the arrangement, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and it is probable that substantially all of the consideration entitled in exchange for the goods or services that will be transferred to the customer will be collected.

 

Each contract is assessed at inception to determine whether it should be combined with other contracts. When making this determination, factors such as whether two or more contracts were negotiated or executed at or near the same time or were negotiated with an overall profit objective. If combined, the Company treats the combined contracts as a single contract for revenue recognition purposes.

 

The Company evaluates the services promised in each contract at inception to determine whether the contract should be accounted for as having one or more performance obligations. The services in the contracts are typically not distinct from one another due to the requirements to perform under the contract. Accordingly, the contracts are typically accounted for as one performance obligation.

 

The Company determines the transaction price for each contract based on the consideration expected to be received for the services being provided under the contract. For contracts where a portion of the price may vary, the Company estimates variable consideration at the most likely amount, which is included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company analyzes the risk of a significant reversal and if necessary, constrains the amount of variable consideration recognized in order to mitigate the risk. At inception of a contract, the transaction price is estimated based on current rights and do not contemplate future modifications (including unexercised options) or follow-on contracts until they become legally enforceable. Depending on the nature of the modification, the Company considers whether to account for the modification as an adjustment to the existing contract or as a separate contract.

 

For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation based on the estimated standalone selling price of the service underlying each performance obligation. Revenue is recognized as performance obligations are satisfied and the customer obtains control of the service. Substantially all of the revenue is recognized over time using the input method as the Company performs under the contract because control of the work in process transfers continuously to the customer.

 

For performance obligations in which control does not continuously transfer to the customer, revenue is recognized at the point in time that each performance obligation is fully satisfied.

 

F-76
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

December 31, 2022 AND 2021

 

 

Note 1 - Summary of Significant Accounting Policies - Continued

 

Revenue Recognition - Continued

 

Grant revenue - The Company recognizes revenue in accordance with the grant accounting under a cost-reimbursement grant model with a grant from a federal agency and a grant from a commercial entity under federal funding. Under the cost-reimbursement grant, the Company receives reimbursement for eligible costs as defined by the contract. Under the commercial grant, the Company received substantially all funding upon award of the grant, and recognizes revenue as eligible expenses under the grant are incurred. The Company has concluded that it is a principal in these transactions and, accordingly, recognizes revenue in the gross amount of consideration to which it is entitled from the agency in exchange for the services provided. The periods of performance for the cost-reimbursable grant was September 2019 - June 2021. The period of performance for the commercial grant is August 2022 - December 2023.

 

At December 31, 2022, the Company is obligated under a grant to continue its research and development related to the treatment of neurological disorders and stroke. The Company expects to complete the remaining performance obligation and recognize the remainder of contract liabilities during the year ending December 31, 2023.

 

Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.

 

Various economic factors affect revenues and cash flows. Services are primarily provided under grants from U.S. Government agencies and a licensing agreement with a commercial entity, with amounts invoiced quarterly or upon the achievement of a milestone and typically being collected within 1 month.

 

Research and Development

 

Research and development costs are expensed as they are incurred and include compensation for scientists, support personnel, outside contracted services, and material costs associated with product development. The Company continually evaluates new product opportunities and engages in intensive research and product development efforts. Research and development expenses include both direct costs tied to a specific contract or grant, and indirect costs.

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash in accounts with high quality, federally insured financial institutions. The balances in these accounts may be in excess of federally insured limits and were in excess by approximately $282,000 and $61,000 at December 31, 2022 and 2021, respectively.

 

For the year ended December 31, 2022, 85% of the Company’s revenue was related to a single customer. As of December 31, 2021, 100% of the Company’s accounts receivable was related to a licensing agreement, and for the year then ended, 69% of its revenue was related to the same agreement.

 

Fair Value of Financial Instruments

 

The Company has adopted ASC Topic 820 for certain financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value.

 

F-77
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

December 31, 2022 AND 2021

 

 

Note 1 - Summary of Significant Accounting Policies - Continued

 

Fair Value of Financial Instruments - Continued

 

The Company has adopted ASC Topic 820 for certain financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value.

 

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

 

The three levels of inputs that may be used to measure fair value are as follows:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities.
     
  Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. Level 2 inputs also include non-binding market consensus prices that can be corroborated with observable market data, as well as quoted prices that were adjusted for security-specific restrictions.
     
  Level 3: Unobservable inputs to the valuation methodology are significant to the measurement of the fair value of assets or liabilities. Level 3 inputs also include non-binding market consensus prices or non-binding broker quotes that we were unable to corroborate with observable market data.

 

Redeemable Convertible Preferred Stock

 

The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company’s control outside of permanent equity.

 

Earnings (Loss) per Share

 

Basic earnings (loss) per share (“EPS”) of common stock is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period.

 

Diluted EPS give effect to all dilutive potential common shares outstanding during the period using the treasury stock method for stock options and warrants and the if-converted method for redeemable, convertible preferred stock and convertible promissory notes. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options and/or warrants. Diluted EPS excluded all dilutive potential shares if their effect is anti-dilutive.

 

Basic loss per common share is computed based on the weighted average number of shares outstanding during the period. Diluted loss per share is computed in a manner similar to the basic loss per share, except the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of convertible debt and other such convertible instruments. Diluted loss per share contemplates a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share.

 

F-78
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

December 31, 2022 AND 2021

 

 

Note 1 - Summary of Significant Accounting Policies - Continued

 

Income Taxes

 

Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred taxes related primarily to differences between the basis of loss carryovers and depreciation differences for financial and income tax reporting. Deferred taxes represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the differences are expected to be recovered or settled.

 

Segment Reporting

 

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment in the United States.

 

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. This change in classification does not affect previously reported net loss.

 

Note 2 - Accounts Receivable and Contract Balances

 

The beginning and ending accounts receivable and contract balances were as follows as of December 31:

 

   2022   2021   2020 
Accounts receivable  $-   $1,109   $1,002,393 
Unbilled revenue  $-   $-   $273,044 
Deferred revenue  $153,500   $-   $1,607,143 

 

There were no contracts in progress at December 31, 2021; therefore there were no reportable contract assets or liabilities.

 

Receipts of $153,500 were included in contract liabilities at December 31, 2022 related to a contract in progress.

 

Note 3 - Profit Sharing Plan

 

Serina has established a 401(k) profit sharing plan (the PSP) for all eligible employees of Serina. The PSP provides for eligible employee contributions subject to certain annual Internal Revenue Code limits. For participants who are age 50 or older during any calendar year, additional employee contributions are allowed under the PSP, subject to Internal Revenue Code limits.

 

Employer contributions, if any, may include matching contributions and profit sharing contributions, both of which are made on a discretionary basis and are subject to service and employment requirements. Employer matching contributions and employer profit sharing contributions vest based on a graded vesting schedule. Serina made no discretionary employer matching or employer profit sharing contributions for the years ended December 31, 2022 and 2021.

 

F-79
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 4 - Common Stock

 

The holders of the common stock are entitled to one vote for each share of common stock on all matters that may be submitted to the holders of common stock of Serina. The holders of common stock shall vote together with the holders of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock as a single class. Serina shall not plan a merger or conversion, sale or dispose of property, or dissolve the Company without the written consent or affirmative vote of the entire single class.

 

Note 5 - Redeemable Convertible Preferred Stock

 

Serina has authority to issue 10,000,000 shares of preferred stock with a par value of $0.01 per share. All outstanding preferred stock is redeemable upon a Deemed Liquidation Event and convertible and has been classified as temporary stockholders’ equity at December 31, 2022 and 2021, as the shares are redeemable for cash or other assets upon the occurrence of an event that is not solely within the control of the Company.

 

As of December 31, 2022 and 2021, all outstanding preferred stock was not initially redeemable and was not considered probable of being redeemed upon consideration of the events that would constitute a Deemed Liquidation Event.

Redeemable convertible preferred stock was as follows as of December 31, 2022 and 2021:

 

 

Preference

Order

 

 

Designation

 

 

Shares

Designated

  

 

Shares

Issued

  

 

Shares

Outstanding

  

Issue

Price per

Share

  

 

Liquidation

Preference

 
#1  Series A Preferred Stock   400,000    400,000    400,000   $5.00   $2,000,000 
#2  Series A-1 Preferred Stock   300,000    300,000    300,000   $6.66   $1,998,000 
#3  Series A-2 Preferred Stock   1,122,077    1,117,013    1,117,013   $9.93793   $11,085,291 
#4  Series A-3 Preferred Stock   499,200    499,200    499,200   $12.50   $6,240,000 
#5  Series A-4 Preferred Stock   718,997    718,997    718,997   $13.00   $9,346,961 
#6  Series A-5 Preferred Stock   2,000,000    367,015    367,015   $13.00   $4,771,248 
       5,040,274    3,402,225    3,402,225        $35,441,500 

 

Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock all have the same rights, preferences, powers, privileges, restrictions, qualifications, and limitations.

 

Dividends

 

From and after the date of the issuance of any shares of Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock, they accrued dividends at the rate per annum of 6% of the original issue price until June 30, 2019. The dividends accrued from day to day, whether or not declared, compounded annually, were calculated on the basis of a 365 day year, and were cumulative. Effective June 30, 2019, Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock no longer accrued dividends. The holders of the Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock were entitled to receive dividends when and if declared by the Board of Directors. The Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall not accrue dividends. Dividends on Preferred Stock are in preference to and prior to any payment of any dividends on common stock. As of December 31, 2022 and 2021, $10,276,653 in Preferred Stock dividends have been accrued, but not declared. As such, these dividends are not currently an obligation of the Company.

 

F-80
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 5 - Redeemable Convertible Preferred Stock - Continued

 

Convertibility

 

Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall be convertible, at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder into common stock. The number of shares will be determined by dividing the original issue price by the conversion price of the Preferred Stock. The conversion price initially is the same as the issue price of the Preferred Stock, but may be adjusted based on certain events as provided in the amended Articles of Incorporation.

 

Liquidation Preference

 

In the event of Deemed Liquidation Event for Serina (described below), the holders of the various series of Preferred Stock are entitled to receive prior to, and in preference to, any distribution to the holders of common stock or any other class or series of stock ranking on liquidation junior to the series of Preferred Stock they hold, an amount equal to the original issue price plus any accrued dividends (excepting Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock) together with any other dividends declared that have not yet been paid. The preference order is noted above.

 

The following events will constitute a Deemed Liquidation Event:

 

  a) The consummation of a plan of merger or conversion in accordance with various sections of Alabama Business Corporation Law (“ABCL”), with some exceptions as provided in the amended Articles of Incorporation;
  b) The sale, lease, exchange, license, or other disposal, in a single transaction or series of related transactions, of all, or substantially all, of the corporation’s property (with or without goodwill), other than in the usual course of business in accordance with Section 10A-2A-12.02 of the ABCL;
  c) Dissolution of the corporation in accordance with Section 10A-2A-14.02 of the ABCLE, or liquidation or winding-up of the business and affairs of the corporation; or
  d) The sale, lease, exchange, license, or other disposal, other than in the usual and regular course of business, of all, or substantially all, of the intellectual property of the corporation in a single transaction or a series of related transactions.

 

The holders of at least 60% of the Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock, acting as a single class of stock, may elect that any such events described above shall not be a Deemed Liquidation Event as provided in the amended Articles of Incorporation.

 

The Series A Preferred Stock liquidation preference, the Series A-1 Preferred Stock liquidation preference, the Series A-2 liquidation preference, the Series A-3 liquidation preference, the Series A-4 liquidation preference, and the Series A-5 liquidation preference shall be on parity with one another. In the event that upon liquidation or dissolution, the assets and funds of the Company are insufficient to permit the payment to holders of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock the full amount to which they shall be entitled, the holders of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock then outstanding and any class or series of stock ranking on liquidation on a parity with the Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall share in any distribution of the remaining assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

 

After the distributions described above have been paid in full, the remaining assets of the Company available for distribution shall be distributed pro-rata to the holders of the shares of common stock.

 

F-81
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 6 - Income Taxes

 

Deferred tax assets and liabilities reflect the effects of tax losses, credits, and the future income tax effects of temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

 

At December 31, 2022, the Company had the following carryovers subject to expiration:

 

Carryover  Amount   Begin to Expire In 
1231 loss carryover  $798    2024 
Net capital loss carryover  $17,472    2026 
NOL carryover - Federal - indefinite life  $12,027,696    N/A 
NOL carryover - Federal - subject to expiration  $23,207,997    2027 
NOL carryover - State  $35,509,627    2023 
Charitable contributions carryover  $6,875    2027 
General business credit carryover ESB*  $129,310    2030 
General business credit carryover NonESB*  $1,824,263    2026 

 

The Company’s effective tax rate is 0% for the periods ended December 31, 2022 and December 31, 2021. The Company’s effective tax rate is different than what would be expected if the federal statutory rate was applied to income before income taxes primarily because certain expenses are deductible for financial reporting purposes that are not deductible for tax purposes and valuation allowances applied to the Company’s net deferred tax assets. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The major temporary differences that give rise to the deferred tax assets and liabilities are as follows: NOL carryovers, general business credit carryovers, charitable contribution carryovers, operating and finance lease assets and liabilities, and depreciation and amortization.

 

The Company evaluates the recoverability of these future tax deductions and credits by assessing the adequacy of future expected taxable income from all sources, including reversal of taxable temporary differences, forecasted operating earnings and available tax planning strategies. To the extent that management does not consider it more likely than not that a deferred tax asset will be recovered, a valuation allowance is established. The Company has provided a valuation allowance against the deferred income taxes at December 31, 2022 and 2021. The valuation allowance increased by $1,004,315 during the year ended December 31, 2022.

 

F-82
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 6 - Income Taxes - Continued

 

The components of the deferred income tax asset and liability as of December 31, 2022 and 2021 are as follows:

 

   2022   2021 
Deferred Tax Assets (Liabilities):          
General business credit carryover ESB  $129,310   $129,310 
General business credit carryover NonESB   1,824,263    1,824,263 
1231 loss carryover   219    168 
Net capital loss carryover   4,805    4,106 
NOL carryover - Federal   7,399,496    6,909,074 
NOL carryover - State   2,308,126    2,183,730 
Research and development   389,339    - 
Unrealized loss on investments   -    1,195 
Charitable contributions carryover   6,875    - 
Right of use assets - operating leases   (23,307)   (64,560)
Right of use assets - finance leases   -    (43,036)
Operating lease liabilities   29,419    74,564 
Finance lease liabilities   -    34,933 
Depreciation of property and equipment   20,776    31,259 
Total deferred tax asset   12,089,321    11,085,006 
Valuation allowance   (12,089,321)   (11,085,006)
Net Deferred Tax Asset  $-   $- 

 

The Company only recognizes tax benefits from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statement from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. To date, the Company has not recognized such tax benefits in its financial statements.

 

On January 1, 2022, a provision of the Tax Cuts and Jobs Act of 2017 went into effect which eliminates the option to deduct research and development expenditures currently and requires tax payers to amortize such costs incurred in the U.S. over five years and 15 years for costs incurred overseas. While it is possible that Congress may modify or repeal this provision retroactively, the Company implemented such provision into its accounting for income taxes for the year ended December 31, 2022.

 

Note 7 - Leases

 

The Company leases many of its operating and office facilities for various terms under long-term, non-cancelable operating lease agreements. The leases expire at various dates through 2024 and provide for renewal periods of two years. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. The Company also leases equipment for various terms under long-term, non-cancelable finance lease agreements. These leases expire at various dates through 2025.

 

F-83
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 7 - Leases - Continued

 

The following represents information on leases as of and for the years ended December 31:

 

   2022   2021 
Finance lease cost (including amortization of right-of use assets of $23,349 and $6,945 and interest on lease liabilities of $12,843 and $3,094 in 2022 and 2021, respectively)  $36,192   $10,039 
Operating lease expense   101,399    140,846 
Total lease cost  $137,591   $150,885 
Other information          
Weighted average remaining lease term (yrs) - finance leases   1.71    2.71 
Weighted average remaining lease term (yrs) - operating leases   1.30    1.42 
Weighted average discount rate - finance leases   11.90%   11.90%
Weighted average discount rate - operating leases   6.67%   6.67%

 

The following is a maturity analysis of the annual undiscounted cash flows of the lease liabilities as of December 31, 2022:

 

   Operating   Finance 
   Leases   Leases 
2023  $84,781   $55,195 
2024   26,869    38,055 
2025   -    625 
Total future minimum lease payments   111,650    93,875 
Less: imputed interest   (4,671)   (9,199)
Total lease liabilities   106,979    84,676 
Less: current portion   (80,696)   (47,708)
Lease liabilities, non-current  $26,283   $36,968 

 

F-84
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 8 - Property and Equipment, net

 

Property and equipment at December 31, 2022 and 2021 consists of:

 

   2022   2021 
Computer equipment  $24,061   $24,061 
Equipment   353,343    348,017 
Software   81,676    81,676 
Total property and equipment   459,080    453,754 
Less accumulated depreciation   (367,511)   (330,861)
Total property and equipment, net  $91,569   $122,893 

 

Note 9 - Stock Option Plan

 

Stock Option Plan Description

 

In 2007, the Company’s Board of Directors (“the Board”) adopted the Serina Therapeutics, Inc. 2007 Stock Option Plan (the 2007 Plan) that provides for the granting of stock options to employees. The 2007 Plan as amended in March 2014 reserved 2,000,000 shares of common stock for grant. Options are granted at the discretion of the Board. Options granted under the 2007 Plan shall be either incentive stock options (ISOs) or nonstatutory stock options (NSOs), as designated by the Board. The options will be granted at an exercise price set by the Board at the time of grant, but in no event will the price for ISOs be less than 100% of the fair market value of the common stock on the date of the grant, or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, not less than 110%; and not less than the par value of the common stock at grant, in the case of NSOs.

 

In 2017, the Serina Therapeutics, Inc. 2007 Plan by its terms expired, except with respect to unexercised stock options outstanding under the 2007 Plan. No future stock options shall be awarded under the 2007 Plan.

 

In 2017, the Company’s Board adopted the Serina Therapeutics, Inc. 2017 Stock Option Plan (the 2017 Plan) that provides for the granting of stock options to employees. The 2017 Plan reserved 1,000,000 shares of common stock for grant. In 2021, the 2017 Plan was amended to increase the reserved shares to 2,000,000, and then later in 2021 further amended to increase the reserved shares to 2,100,000. Options are granted at the discretion of the Board. Options granted under the 2017 Plan shall be either incentive stock options (ISOs) or nonstatutory stock options (NSOs), as designated by the Board. The options will be granted at an exercise price set by the Board at the time of grant, but in no event will the price for ISOs be less than 100% of the fair market value of the common stock on the date of the grant or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, not less than 110%; and not less than the par value of the common stock at grant, in the case of NSOs.

 

Vesting and Exercisability

 

Stock options are exercisable at such time or times and subject to such terms and conditions as determined by the Board at or after grant. If the Board provides, in its sole discretion, that any stock option is exercisable only in installments, the Board may waive such installment exercise provisions at any time at or after the grant, in whole or in part, based on such factors as the Board shall determine, in its sole discretion.

 

The terms of the grants are generally for ten years (or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, the term shall be five years) and vest over a period of time as determined on the date of the grant.

 

Stock-Based Compensation

 

The Company follows the provisions of the FASB ASC 718, Compensation - Stock Compensation (“FASB ASC 718”). FASB ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense in the consolidated financial statements based on their fair value at the grant date.

 

F-85
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 9 - Stock Option Plan - Continued

 

Valuation and Expense

 

The Company recognizes compensation expense related to stock options on a straight-line basis over the requisite service period of the awards, which is generally three to four years. The Company estimates the fair value of options on the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions:

 

   2022   2021 
Expected volatility   88.57%   68.70%
Expected term (in years)   10.00    5.15 - 10.00 
Risk-free interest rate   3.96%   0.73% - 0.81%
Expected dividend yield   0.00%   0.00%

 

Expected volatility is estimated using the historical volatility of an industry sector index for the years ended December 31, 2022 and 2021. The Company estimates the expected term using historical option exercise data to determine the expected employee exercise behavior. The risk-free interest rate is the yield on a U.S. Treasury zero-coupon issue with a remaining term equal to or approximating the expected term of the option at the grant date.

 

Using the Black-Scholes-Merton option pricing model, management has determined that the options issued in 2022 and 2021 have a grant date fair value of $0.05 and $0.03 - $0.04 per share, respectively.

 

The Company recorded stock-based compensation expense related to the stock options of $7,110 and $82,945 during the years ended December 31, 2022 and 2021, respectively. In 2021, all options outstanding as of December 31, 2020 were canceled and replaced, with the exception of 3,300 options, which were not replaced due to termination of the grantee. Total replacement options issued were 1,294,042. Incremental compensation cost of $878 and $35,533 was recognized during the years ended December 31, 2022 and 2021, respectively, as a result of the accounting for the modification required by FASB ASC 718. As of December 31, 2022, the Company had $22,728 of unrecognized compensation cost related to nonvested stock options.

 

F-86
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Details of stock option activity for the years ended December 31, 2022 and 2021 are as follows:

 

        Weighted 
    Number of   Average 
    Options   Exercise Price 
Outstanding at December 31, 2020    1,297,342   $1.35 
Canceled    (1,297,342)   1.35 
Granted    2,036,450    0.06 
Outstanding at December 31, 2021    2,036,450    0.06 
Exercised    (73,700)   0.06 
Granted    50,000    0.06 
Outstanding at December 31, 2022    2,012,750   $0.06 

 

The following table summarizes information about stock options exercisable at December 31, 2022: 

 

        Weighted Average     
    Number   Remaining   Weighted 
Exercise   of Shares   Contractual   Average 
Price   Exercisable   Life in Years   Exercise Price 
$ 0.06    1,463,943    8.74   $0.06 

 

The following table summarizes information about nonvested stock options at December 31, 2022:

 

   

 

Nonvested

Options

  

Weighted Average
Grant Date

Fair Value

 
Nonvested options at December 31, 2021    656,742   $0.04 
Granted    50,000    0.05 
Vested    (84,235)   0.04 
Exercised    (73,700)   0.03 
Forfeited/cancelled    -    - 
Nonvested options at December 31, 2022    548,807   $0.05 

 

Note 10 - Stock Warrants

 

Grants

 

During the year ended December 31, 2021, the Company granted warrants to purchase 6,934 shares of Series A-5 Preferred Stock at an exercise price of $20.00 per share. No warrants were granted during the year ended December 31, 2022. The warrants are accounted for as a liability and remeasured to fair value at each reporting period.

 

Vesting and Exercisability

 

The warrants vest immediately upon grant. All outstanding warrants at December 31, 2022 are exercisable at any time prior to close of business on December 31, 2024.

 

F-87
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Valuation and Expense

 

The Company estimates the fair value of warrants using the Black-Scholes-Merton option pricing model with the following assumptions at December 31, 2022 and 2021:

 

   To Calculate Fair Value of
Warrant Liability at December 31,
 
   2022   2021 
Expected volatility   88.57%   68.70%
Expected term (in years)   1.00 - 1.50    1.50 - 2.00 
Risk-free interest rate   4.41 - 4.73%   1.26%
Expected dividend yield   0.00%   0.00%

  

                Change in Fair Value   Change in Fair Value 
                of Warrant Liability   of Warrant Liability 
    2022   2021   2020   in 2022   in 2021 
Fair value of warrant liability   $1,076,766   $952,648   $1,157,935   $124,118   $(205,287)

 

Expected volatility is estimated using the historical volatility of comparable public entities. The Company estimates the expected term using historical option exercise data to determine the expected employee exercise behavior. The risk-free interest rate is the yield on a U.S. Treasury zero-coupon issue with a remaining term equal to or approximating the expected term of the option at the grant date.

 

The Company recorded an expense related to the warrants due to an increase in the liability of $124,118 during the year ended December 31, 2022, and a benefit related to the warrants due to a decrease in the liability of $205,287 during the year ended December 31, 2021, which are recorded in other expenses and income on the Company’s consolidated statements of operations.

 

Details of stock warrant activity for the year ended December 31, 2022, are as follows:

 

       Weighted 
   Number of   Average 
   Warrants   Exercise Price 
Outstanding at December 31, 2020   360,081   $20.00 
Issued   6,934    20.00 
Outstanding at December 31, 2021   367,015    20.00 
Outstanding at December 31, 2022   367,015   $20.00 

 

Note 11 - Long Term Debt

 

In 2020, the Company obtained an unsecured note payable in the amount of $187,133 under the Paycheck Protection Program (PPP) as part of the Coronavirus Aid, Relief, and Economic Security Act. Loans obtained under the PPP are eligible for debt forgiveness through guarantees provided to the lender by the U.S. Small Business Administration (“SBA”). The Company received notification from the SBA in 2021 that the loan had been fully forgiven. The Company recognized $187,133 in forgiveness of debt income in 2021.

 

F-88
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 12 - Investments in Marketable Equity Securities

 

Realized and unrealized gains and losses for marketable equity securities for the years ended December 31, 2022 and 2021, are summarized below: 

 

   2022   2021 
Realized (loss) gain for equity securities sold  $(7,585)  $5,609 
Unrealized loss on equity securities held   -    (12,061)
           
Total loss on equity securities  $(7,585)  $(6,452)

 

Note 13 - Research and Development

 

At December 31, 2022, the Company is performing under a grant provided by a corporation via funding provided by a federal government agency to continue its research and development related to treatment of neurological disorders and strokes. The grant is structured such that the Company received $245,000 upon execution of the award, and recognizes eligible costs as they are incurred. Grant revenue and related research and development costs under the grant was $91,500 for the year ended December 31, 2022.

 

The Company performed under a grant provided by a federal governmental agency for research and development related to opioids during the year ended December 31, 2021. The grant was structured as a cost-reimbursement grant and was completed in 2021. Grant revenue and related research and development costs under the grant was $425,569 for the year ended December 31, 2021.

 

The Company performed under a contract for licensing with a research and development component with a commercial entity during the year ended December 31, 2021. The research and development component was structured as cost-reimbursable. This contract was terminated in 2021. Research and development revenue and related costs under this contract were $782,041 for the year ended December 31, 2021.

 

Note 14 - Commitments and Contingencies

 

The Company is subject to legal proceedings, claims, and litigation arising in the ordinary course of business. In the opinion of management, all such matters would be adequately covered by insurance or accruals or would be such that disposition would not have a material adverse effect on the consolidated financial position, results of operations, or cash flows of the Company.

 

Note 15 - Convertible Promissory Notes

 

From June 2022 through December 31, 2022, the Company issued interest-bearing Convertible Promissory Notes (the “Notes”) to various third-party investors in the principal amount of $1,350,000. In addition, on November 10, 2022, the Company issued a Convertible Promissory Note to a related party investor in the principal amount of $3,650,000 which was repaid in full on December 14, 2022. The Notes incur interest at 6% per annum and are payable by the Company two years from their issuance date. The Company may not voluntarily prepay. Upon a Qualified Equity Financing event in which the Company sells shares of Preferred Stock for aggregate proceeds of at least $15 million, the principal and outstanding interest on the Notes will automatically convert into shares of the Company’s Preferred Stock issued in the Qualified Financing at a conversion price of the lesser of i) a 20% discount to the price paid by purchasers in the Qualified Financing and ii) the quotient resulted from dividing $100 million by the fully diluted capitalization of the Company immediately prior to the Qualified Financing. If the Company enters into a Non-Qualified Equity Financing (less than $15 million in proceeds), the Holder has the option to convert the Notes into shares of the Company’s Preferred Stock issued in the Non-Qualified Financing at the price paid per share. The Company may also choose to optionally convert the Notes into Series A-5 Preferred Stock at a price of $13 per share, and a warrant to purchase shares of Series A-5 Preferred Stock with an exercise price of $20.00, and an expiration date of December 31, 2024.

 

F-89
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

If a Change in Control or an IPO occurs prior to a Qualified Financing, then the Holder has the option to convert outstanding principal and interest into common stock at a price per share equal to an amount obtained by dividing i) the Post-Money Valuation Cap ($100,000,000) by ii) the Fully Diluted Capitalization immediately prior to the conversion. Upon a change in control, the Holder may also elect to require the Company to repay the outstanding principal and accrued but unpaid interest in cash.

 

The Company evaluated the Notes in accordance with ASC Topic 815, Derivatives and Hedging, and determined they contained certain variable share settlement features tied to the price of a future financing which were not considered clearly and closely related to the host instruments. These provisions included mandatory conversion upon the event of a Qualified Financing and the Holder’s option to convert the Notes upon a Non-Qualified Financing. The Notes also contained a Change in Control Put and a Default Put which were not clearly and closely related to the host instrument. The Company elected to initially and subsequently measure the Notes in their entirety at fair value, with changes in fair value recognized in earnings. The fair value inception date adjustment on the instrument is recorded as a component of other income in the Company’s consolidated statements of operations. The change in fair value of the instrument since inception date is recorded on a separate line item as a component of other income in the Company’s consolidated statements of operations.

 

FASB ASC 825-10-25 allows the Company to elect the fair value option for recording financial instruments when they are initially recognized or if there is an event that requires re-measurement of the instruments at fair value, such as a significant modification of the debt. The Company elected the fair value option because they believed it to be the most appropriate method of encompassing the credit risk and exercise behavior that a market participant would consider when valuing the hybrid financial instrument.

 

Because the Notes are carried in their entirety at fair value, the value of the compound embedded conversion features and the redemption features are embodied in that fair value. The Company estimated the fair value of the hybrid instrument based on a probability weighted cash flow analysis. A Monte Carlo model, which considered the present value of the cash flows under the different scenarios using a credit risk adjusted rate, was considered by management to be the most appropriate method of encompassing credit risk and exercise behavior. Inputs used to value the hybrid instrument at inception (July 19, 2022) included, (i) present value of future cash flows using a credit risk adjusted rate of 16%, (ii) remaining term of approximately 2 years, (iii) volatility of 90% based on the volatility of comparable guideline public companies, (iv) closing stock price on the valuation date, and (v) 70% probability the Notes will be converted upon a Non-Qualified Financing, at the expected price of the Non-Qualified Financing, and 30% probability the Notes will be optionally converted at their stated conversion price ($13 per share plus one warrant). Management expects the probability of a change in control, default, or Qualified Financing event occurring over the remaining term of the Notes to be minimal. However, this assumption will be considered each reporting period. Material changes due to instrument-specific credit risk are recorded in Other Comprehensive Income with all other changes in value being recorded in net income.

 

As of July 19, 2022, the outstanding principal amount of the Notes was $1,350,000 and the fair value of the hybrid instrument, recorded on the consolidated balance sheet, was $1,529,000. As of December 31, 2022, the outstanding principal and interest on the Notes was approximately $1,384,000 and the fair value recorded on the consolidated balance sheet was $1,617,000. From July 19, 2022 to December 31, 2022, the change in value was approximately $88,000 and was recorded as a component of other income in the Company’s consolidated statements of operations.

 

Company had liabilities that they elected to be measured at fair value on a recurring basis as follows at December 31, 2022. There were no convertible promissory notes at December 31, 2021.

 

   Total   Level 1   Level 2   Level 3 
Assets  $ -  $    -   $    -   $ - 
Liabilities:                
Convertible Notes at fair value   $1,617,000   $-   $-   $1,617,000 

 

The following is a reconciliation of the beginning and ending balances for the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the year December 31, 2022:

 

Balance as of December 31, 2021  $- 
Convertible debt issuance   1,529,000 
Loss on change in fair value   88,000 
Balance as of December 31, 2022  $1,617,000 

 

F-90
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 16 - Net Loss per Common Share

 

Net loss per common share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic and diluted net loss per common share attributable to common shareholders is calculated as follows for the years ended December 31, 2022 and 2021: 

 

  2022   2021 
Basic net loss per common share allocable to common shareholders        
NUMERATOR          
Net loss  $(2,682,108)  $(1,264,703)
Less: net earnings allocable to participating securities   -    - 
Net loss allocable to common shareholders  $(2,682,108)  $(1,264,703)
DENOMINATOR          
Weighted average shares of common stock outstanding used to calculate basic net loss per common share   2,145,002    2,144,800 
Basic net loss per common share allocable to common shareholders  $(1.25)  $(0.59)
           
Diluted net loss per common share allocable to shareholders          
NUMERATOR          
Net loss allocable to common shareholders  $(2,682,108)  $(1,264,703)
Add back: interest on convertible promissory notes   -    - 
Net loss allocable to common shareholders  $(2,682,108)  $(1,264,703)
DENOMINATOR          
Weighted average shares of common stock outstanding used to calculate basic net loss per common share    2,145,002    2,144,800 
Add: dilutive effect of stock options    -    - 
Add: dilutive effect of warrants    -    - 
Add: dilutive effect of common stock issued for convertible promissory notes    -    - 
Add: dilutive effect of redeemable convertible preferred stock    -    - 
Weighted average shares of common stock outstanding used to calculate diluted net loss per common share   2,145,002    2,144,800 
Diluted net loss per common share allocable to common shareholders   $(1.25)  $(0.59)

 

F-91
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 16 - Net Loss per Common Share - Continued

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per common share for the years ended December 31, 2022 and 2021 because to do so would be anti-dilutive: 

 

   2022   2021 
Redeemable convertible preferred stock   3,402,225    3,402,225 
Convertible promissory notes   220,008    - 
Stock options   2,012,750    2,036,450 
Warrants   367,015    367,015 
Total anti-dilutive securities   6,001,998    5,805,690 

 

Note 17 - Subsequent Events

 

Management’s Evaluation

 

Management has evaluated subsequent events through November 10, 2023, the date the consolidated financial statements were issued.

 

Conversion of Promissory Notes

 

On July 26, 2023, all of the Convertible Promissory Notes described in Note 15 (excluding the AgeX Note) previously issued for a total principal amount of $1,450,000 and accrued interest of $82,695 were converted to 117,903 shares of Series A-5 Preferred Stock. As provided for in the note agreements, the holders of the notes also received warrants to purchase an additional 117,903 shares of Series A-5 Preferred Stock.

 

Convertible Note

 

On March 15, 2023, The Company issued a convertible promissory note (the “AgeX Note”) in the amount of $10,000,000 to AgeX Therapeutics (“AgeX”). The AgeX Note bears interest at 7% per annum and matures on March 15, 2026. The Company issued the AgeX Note to provide for general working capital needs. As described further in this note, the Company and AgeX have entered into a Merger Agreement. In connection with the issuance of the AgeX Note, AgeX is entitled to elect one member to the board of directors of the Company and receive certain information and inspection rights as well as participation rights for subsequent equity issuances.

 

The AgeX Note has various conversion options. The principal balance of the AgeX Note with accrued interest will automatically convert into the Company’s preferred stock if the Company raises at least $25,000,000 through the sale of shares of the Company’s preferred stock. The conversion price per share shall be the lower of (a) 80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by the Company’s then fully diluted capitalization. AgeX has the option to convert the AgeX Note into the Company’s preferred stock after a sale of the Company’s preferred stock regardless of the amount sold by the Company. AgeX may (i) at its election, upon a change of control (as defined in the AgeX Note), convert the AgeX Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the AgeX Note, plus interest, or (b) into the highest ranking shares of the Company then issued at a conversion price equal to the lowest price per share at which the most senior series of the Company’s shares has been sold in a single transaction or a series of related transactions through which the Company raised at least $5,000,000 or (ii) if the AgeX Note remains outstanding as of the maturity date, AgeX may convert the AgeX Note into the most senior shares of the Company issued at the time of conversion at a conversion price equal to the capped price. Upon the consummation of a merger between the Company and AgeX, the AgeX Note would remain outstanding and become an intercompany asset of AgeX and an intercompany liability of the Company.

 

F-92
 

 

SERINA THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

DECEMBER 31, 2022 AND 2021

 

 

Note 17 - Subsequent Events - Continued

 

License Agreement

 

In October 2023, the Company entered into a non-exclusive license agreement with Pfizer, Inc. to use the Company’s POZ polymer technology for use in lipid nanoparticle drug delivery formulations. The agreement grants Pfizer non-exclusive rights to certain intellectual property, know-how, and proprietary technologies. Under the terms of the agreement, Pfizer is authorized to develop, manufacture, market, and commercialize products incorporating the licensed technology with respect to a specific POZ polymer structure in one field. The agreement outlines the protection and enforcement of intellectual property rights related to the licensed technology. Pfizer is obligated to use commercially reasonable diligent efforts to develop and commercialize licensed products, and to use such efforts to accomplish specified development and commercial objectives. The agreement includes a one-time upfront payment of $3 million that was received on December 15, 2023, milestone payments payable to Serina upon the achievement of specific development, regulatory, and commercial milestones, and a royalty on net sales of products incorporating the licensed technology in accordance with the terms outlined in the license agreement. The range of royalties on sales of products is between 2.75% – 3.5% and is tiered to achievement of certain sales milestones.

 

Merger Agreement

 

On August 29, 2023, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with AgeX and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“Merger Sub”). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including that the Merger is approved by the stockholders of AgeX and the stockholders of Serina, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the “Merger”). There is no assurance the necessary approvals by AgeX stockholders and Serina stockholders will be obtained or that the other conditions to the Merger as provided in the Merger Agreement will be met.

 

Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of AgeX common stock, and stockholders of AgeX immediately prior to the closing of the Merger are expected to own, excluding the impact of the exercise of any of the Post-Merger Warrants or Incentive Warrants described below, approximately 25% of the outstanding shares of AgeX common stock, in each case, on a fully diluted basis, subject to certain assumptions, including giving effect to a planned reverse stock split and the conversion of AgeX Preferred Stock into shares of AgeX common stock. Accordingly, the Merger is anticipated to be accounted for as a reverse acquisition, with the Company treated as the acquiror for financial accounting purposes.

 

Prior to the closing of the Merger, AgeX will issue to each holder of AgeX common stock three warrants (each, a “Post-Merger Warrant”) for each five shares of AgeX common stock held by such stockholder. Each Post-Merger Warrant will be exercisable for (i) one share of AgeX common stock and (ii) one warrant (each, an “Incentive Warrant”) at an exercise price equal to $13.20 per warrant (such exercise price reflecting a planned reverse stock split of AgeX common stock) and will expire on July 31, 2025. Each Incentive Warrant will be exercisable for one share of AgeX common stock at a price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split of AgeX common stock) and will expire on the four-year anniversary of the closing of the Merger. Each Post-Merger Warrant and Incentive Warrant will be issued pursuant to the terms of a warrant agreement to be entered into by AgeX and a warrant agent in connection with the closing of the Merger.

 

F-93
 

 

SERINA THERAPEUTICS, INC.

FINANCIAL STATEMENTS

SEPTEMBER 30, 2023 and 2022

 

F-94
 

 

TABLE OF CONTENTS

 

FINANCIAL STATEMENTS

 

Balance Sheets F-96
Statements of Operations F-97
Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit F-98
Statements of Cash Flows F-100

Notes to Financial Statements

F-101

 

F-95
 

 

SERINA THERAPEUTICS, INC.

BALANCE SHEETS

AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022

 

   (Unaudited)     
   September 30,   December 31, 
   2023   2022 
ASSETS          
Current Assets          
Cash  $7,580,764   $532,229 
Prepaid expenses   15,197    16,346 
Total Current Assets   7,595,961    548,575 
Property and equipment, net   441,978    91,569 
Right of use assets - operating leases   635,110    84,752 
Right of use assets - finance leases   115,635    133,146 
Total Assets  $8,788,684   $858,042 
           
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ DEFICIT          
Current Liabilities          
Accounts payable  $666,351   $143,337 
Credit card payable   12,635    5,520 
Accrued interest   381,644    - 
Payroll liabilities   5,157    6,925 
Contract liabilities   86,632    153,500 
Current portion of operating lease liabilities   184,069    80,696 
Current portion of finance lease liabilities   47,886    47,708 
Total Current Liabilities   1,384,374    437,686 
Warrant liability   17,747    1,076,766 
Convertible promissory notes, at fair value   3,861,700    1,617,000 
Operating lease liabilities, net of current portion   462,653    26,283 
Finance lease liabilities, net of current portion   1,547    36,968 
Total Liabilities   5,728,021    3,194,703 
           
Redeemable Convertible Preferred Stock          
Redeemable convertible preferred stock, $0.01 par value; 10,000,000 authorized; 3,520,128 and 3,402,225 issued and outstanding at September 30, 2023 and December 31, 2022, respectively   36,404,084    35,441,500 
           
Stockholders’ Deficit          
Common stock, $0.01 par value, 15,000,000 shares authorized, 2,467,434 and 2,218,500 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively   24,674    22,185 
Additional paid-in capital   858,263    646,136 
Accumulated deficit   (34,226,358)   (38,446,482)
Total Stockholders’ Deficit   (33,343,421)   (37,778,161)
           
Total Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Deficit  $8,788,684   $858,042 

 

The accompanying notes are an integral part of these financial statements.

 

F-96
 

 

SERINA THERAPEUTICS, INC.

STATEMENTS OF OPERATIONS

FOR THE NINE MONTHS ENDED

 

   (Unaudited)   (Unaudited) 
   September 30,   September 30, 
   2023   2022 
Revenue          
Contract revenue  $-   $500,000 
Grant revenue   66,867    33,897 
Total Revenue   66,867    533,897 
Operating Expenses          
Research and development expenses   1,480,720    1,326,541 
General and administrative expenses   1,954,833    781,240 
Total Operating Expenses   3,435,553    2,107,781 
Operating Loss   (3,368,686)   (1,573,884)
Other Income (Expense)          
Loss on equity securities, net   -    (7,586)
Interest expense   (381,644)   - 
Interest and dividend income   194,074    1,791 
Fair value inception adjustment on convertible promissory notes   2,240,000    (179,000)
Change in fair value of convertible promissory notes   4,477,361    - 
Change in fair value of warrant liability   1,059,019    (326,094)
Other income   -    1,084 
Total Other Income (Expense)   7,588,810    (509,805)
           
Net Income (Loss)  $4,220,124   $(2,083,689)
           
Net Earnings (Loss) Per Common Share          
Basic  $1.89   $(0.97)
Diluted  $0.56   $(0.97)
           
Weighted-Average Shares Used in Computation of Net
Earnings (Loss) Per Common Share
          
Basic   2,228,026    2,144,800 
Diluted   7,473,149    2,144,800 

 

The accompanying notes are an integral part of these financial statements.

 

F-97
 

 

SERINA THERAPEUTICS, INC.

STATEMENT OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

 

(Unaudited)  Redeemable Convertible Preferred Stock 
  

Preferred Stock –

Series A

  

Preferred Stock –

Series A-1

  

Preferred Stock –

Series A-2

  

Preferred Stock –

Series A-3

 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount 
As of December 31, 2021   400,000   $2,000,000    300,000   $1,998,000    1,117,013   $11,085,291    499,200   $6,240,000 
                                         
As of September 30, 2022   400,000    2,000,000    300,000    1,998,000    1,117,013    11,085,291    499,200    6,240,000 
                                         
As of December 31, 2022   400,000    2,000,000    300,000    1,998,000    1,117,013    11,085,291    499,200    6,240,000 
                                         
Conversion of convertible notes   -    -    -    -    -    -    -    - 
                                         
As of September 30, 2023   400,000   $2,000,000    300,000   $1,998,000    1,117,013   $11,085,291    499,200   $6,240,000 

 

(Unaudited)  Redeemable Convertible Preferred Stock 
  

Preferred Stock –

Series A-4

  

Preferred Stock –

Series A-5

  

Preferred Stock –

Totals

 
   Shares   Amount   Shares   Amount   Shares   Amount 
As of December 31, 2021   718,997   $9,346,961    367,015   $4,771,248    3,402,225   $35,441,500 
                               
As of September 30, 2022   718,997    9,346,961    367,015    4,771,248    3,402,225    35,441,500 
                               
As of December 31, 2022   718,997    9,346,961    367,015    4,771,248    3,402,225    35,441,500 
                               
Conversion of convertible notes   -    -    117,903    

962,584

    117,903    962,584 
                               
As of September 30, 2023   718,997   $9,346,961    484,918   $5,733,832    3,520,128   $36,404,084 

 

The accompanying notes are an integral part of these financial statements.

 

F-98
 

 

SERINA THERAPEUTICS, INC.

STATEMENT OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

 

(Unaudited)  Common Stock Shares   Common Stock Amount   Additional Paid in Capital   Accumulated Deficit   Total Stockholders’ Equity (Deficit) 
As of December 31, 2021   2,144,800   $21,448   $635,341   $(35,764,374)  $(35,107,585)
Stock based compensation   -    -    5,323    -    5,323 
Net loss   -    -    -    (2,083,689)   (2,083,689)
                          
As of September 30, 2022   2,144,800   $21,448   $640,664   $(37,848,063)  $      (37,185,951)

 

(Unaudited)  Common Stock Shares   Common Stock Amount   Additional Paid in Capital   Accumulated Deficit   Total Stockholders’ Equity (Deficit) 
As of December 31, 2022   2,218,500   $22,185   $646,136   $(38,446,482)  $(37,778,161)
Exercise of stock options   248,934    2,489    12,447    -    14,936 
Warrants issued   -    -    175,355    -    175,355 
Stock based compensation   -    -    24,325    -    24,325 
Net income   -    -    -    4,220,124    4,220,124 
                          
As of September 30, 2023   2,467,434   $24,674   $858,263   $(34,226,358)  $        (33,343,421)

 

The accompanying notes are an integral part of these financial statements.

 

F-99
 

 

SERINA THERAPEUTICS, INC.

STATEMENT OF CASH FLOWS

FOR THE NINE MONTHS ENDED

 

   (Unaudited)   (Unaudited) 
   September 30,   September 30, 
   2023   2022 
Cash Flows from Operating Activities          
Net income (loss)  $4,220,124   $(2,083,689)
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Depreciation and amortization   100,404    45,005 
Loss on disposal of property & equipment   839    3,083 
Stock based compensation   24,325    5,323 
Loss on equity securities, net   -    7,586 
Reinvested interest and dividend income   -    (1,791)
Change in fair value of warrant liability   (1,059,019)   326,094 
Non-cash lease expense   121,788    111,496 
Fair value inception adjustment on convertible promissory notes   (2,240,000)   179,000 
Change in fair value of convertible promissory notes   (4,477,361)   - 
Changes in operating assets and liabilities:          
Accounts receivable   -    1,109 
Prepaid expenses   1,149    - 
Accounts payable   523,014    107,185 
Credit card payable   7,115    (1,058)
Accrued interest   381,644    - 
Payroll liabilities   (1,768)   (4,817)
Operating lease liabilities   (132,403)   (122,111)
Contract liabilities   (66,868)   211,103 
Net Cash Used in Operating Activities   (2,597,017)   (1,216,482)
           
Cash Flows from Investing Activities          
Proceeds from sale of investments in equity securities   -    990,652 
Purchases of property and equipment   (434,141)   - 
Net Cash (Used in) Provided by Investing Activities   (434,141)   990,652 
           
Cash Flows from Financing Activities          
Proceeds from issuance of convertible promissory notes   10,100,000    1,250,000 
Proceeds from exercise of stock options   14,936    - 
Principal repayments on finance lease liabilities   (35,243)   (31,288)
Net Cash Provided by Financing Activities   10,079,693    1,218,712 
           
Net Increase in Cash   7,048,535    992,882 
Cash, Beginning of Period   532,229    314,846 
Cash, End of Period  $7,580,764   $1,307,728 

 

The accompanying notes are an integral part of these financial statements.

 

F-100
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Note 1 - Summary of Significant Accounting Policies

 

Nature of Business

 

Serina Therapeutics, Inc. (the “Company” or “Serina”) is a privately-held clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Serina’s POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an increase in efficacy and safety of the resulting polymeric drug conjugate. Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. Serina is headquartered in Huntsville, Alabama.

 

Basis of Accounting

 

The accompanying financial statements reflect the operations of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

 

Plan of Merger

 

As described in Note 16, on August 29, 2023, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with AgeX Therapeutics, Inc. (“AgeX”) and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“Merger Sub”). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including that the Merger is approved by the stockholders of AgeX and the stockholders of Serina, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the “Merger”). Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of the combined company, and stockholders of AgeX immediately prior to the closing of the Merger are expected to own, excluding the impact of the exercise of any of the Post-Merger Warrants or Incentive Warrants described in the Merger Agreement, approximately 25% of the outstanding shares of common stock of the combined company, in each case, on a fully diluted basis, subject to certain assumptions, including giving effect to a planned reverse stock split and the conversion of AgeX Preferred Stock into shares of AgeX common stock. Accordingly, the Merger is anticipated to be accounted for as a reverse acquisition, with the Company treated as the acquirer for financial accounting purposes.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

 

Liquidity

 

The Company recognized net income of approximately $4,200,000 for the nine months ended September 30, 2023. The Company used approximately $2,600,000 in net cash from operating activities for the nine months ended September 30, 2023 and has historically incurred losses from operations and expects to continue to generate negative cash flows as the Company implements its business plan. There is substantial doubt about the Company’s ability to continue as a going concern. The financial statements are prepared using GAAP as applicable to a going concern.

 

The Company had cash on hand of approximately $7,631,000 as of December 31, 2023. As discussed in Note 14, during the nine months ended September 30, 2023, the Company raised $10,100,000 of additional capital. Additionally, the Company received an upfront payment of $3,000,000 from a licensing agreement in November 2023 as described in Note 17.

 

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of therapeutic candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. The Company largely relies on raising capital from equity investors for funding its operations. Some funding is obtained through licensing agreements or other arrangements with commercial entities.

 

As a result of recurring losses from operations and recurring negative cash flows from operations, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively. If sufficient capital is not available, the Company would be required to delay, limit, reduce, or terminate its product development or future commercialization efforts or grant rights to develop and market therapeutic candidates to other entities. There can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings will be workable or acceptable to the Company or its shareholders. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

F-101
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Cash

 

Cash includes cash held in readily available checking and money market accounts.

 

Contract Liabilities

 

Contract liabilities include billings in excess of revenue recognized. Contract liabilities are classified as current based on the Company’s contract operating cycle and reported on a contract-by-contract basis, net of revenue recognized, at the end of each reporting period.

 

Property and Equipment

 

Property and equipment are carried at cost less accumulated depreciation. The costs of additions and betterments are capitalized and expenditures for repairs and maintenance are expensed as incurred. When items of property and equipment are sold or retired, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is included in the statements of operations. Depreciation of property and equipment is provided utilizing the straight-line method over the range of lives used of the respective assets, which is 3 - 10 years.

 

Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if its carrying amount exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. No impairment loss was recognized during the nine months ended September 30, 2023 and 2022, respectively.

 

Revenue Recognition

 

The Company recognizes revenue under a grant contract with a commercial entity under federal funding and under licensing agreements with commercial entities in accordance with ASC 606, Revenue from Contracts with Customers. Under the commercial grant, the Company received substantially all funding upon award of the grant, and recognizes revenue as eligible expenses under the grant are incurred. The Company has concluded that it is a principal in these transactions and, accordingly, recognizes revenue in the gross amount of consideration to which it is entitled from the agency in exchange for the services provided. The period of performance for the commercial grant is August 2022 - December 2023.

 

Under revenue sharing licensing agreements, the Company receives reimbursement for eligible costs as well as payments upon the achievement of certain milestones as defined by the contract. These licensing agreements provide for the Company to receive a certain percentage of revenue from sales of their product; however, no sales have occurred to date.

 

Under other licensing agreements, the Company receives payment for the production and use of their polymer technology.

 

The Company accounts for a contract after is has been approved by all parties to the arrangement, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collection is probable.

 

Each contract is assessed at inception to determine whether it should be combined with other contracts. When making this determination, factors such as whether two or more contracts were negotiated or executed at or near the same time or were negotiated with an overall profit objective. If combined, the Company treats the combined contracts as a single contract for revenue recognition purposes.

 

The Company evaluates the services promised in each contract at inception to determine whether the contract should be accounted for as having one or more performance obligations. The services in the contracts are typically not distinct from one another due to the requirements to perform under the contract. Accordingly, the contracts are typically accounted for as one performance obligation.

 

The Company determines the transaction price for each contract based on the consideration expected to be received for the services being provided under the contract. For contracts where a portion of the price may vary, the Company estimates variable consideration at the most likely amount, which is included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company analyzes the risk of a significant reversal and if necessary, constrains the amount of variable consideration recognized in order to mitigate the risk. At inception of a contract, the transaction price is estimated based on current rights and do not contemplate future modifications (including unexercised options) or follow-on contracts until they become legally enforceable. Depending on the nature of the modification, the Company considers whether to account for the modification as an adjustment to the existing contract or as a separate contract.

 

F-102
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation based on the estimated standalone selling price of the service underlying each performance obligation. Revenue is recognized as performance obligations are satisfied and the customer obtains control of the service. Substantially all of the revenue is recognized over time using the input method as the Company performs under the contract because control of the work in process transfers continuously to the customer.

 

For performance obligations in which control does not continuously transfer to the customer, revenue is recognized at the point in time that each performance obligation is fully satisfied.

 

At September 30, 2023, the Company is obligated under a grant to continue its research and development related to the treatment of neurological disorders and stroke. The Company expects to complete the remaining performance obligation and recognize the remainder of contract liabilities during the fourth quarter of fiscal year 2023.

 

Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.

 

Various economic factors affect revenues and cash flows. Services are primarily provided under grants from U.S. Government agencies and a licensing agreement with a commercial entity, with amounts invoiced quarterly or upon the achievement of a milestone and typically being collected within one month.

 

Research and Development

 

Research and development costs are expensed as they are incurred and include compensation for scientists, support personnel, outside contracted services, and material costs associated with product development. The Company continually evaluates new product opportunities and engages in intensive research and product development efforts. Research and development expenses include both direct costs tied to a specific contract or grant, and indirect costs.

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash in accounts with high quality, federally insured financial institutions. At times, the balances in these accounts may be in excess of federally insured limits and were in excess by approximately $7,300,000 and $280,000 at September 30, 2023 and December 31, 2022, respectively.

 

For the nine months ended September 30, 2023, 100% of the Company’s revenue was related to a single grantor. For the nine months ended September 30, 2022, 94% of the Company’s revenue was related to a single contract with a customer.

 

Fair Value of Financial Instruments

 

The Company has adopted ASC Topic 820 for certain financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value.

 

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

 

The three levels of inputs that may be used to measure fair value are as follows:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities.
     
  Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. Level 2 inputs also include non-binding market consensus prices that can be corroborated with observable market data, as well as quoted prices that were adjusted for security-specific restrictions.
     
  Level 3: Unobservable inputs to the valuation methodology are significant to the measurement of the fair value of assets or liabilities. Level 3 inputs also include non-binding market consensus prices or non-binding broker quotes that we were unable to corroborate with observable market data.

 

F-103
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

The Company has elected to measure the convertible promissory notes at fair value on a recurring basis.

 

Redeemable Convertible Preferred Stock

 

The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company’s control outside of permanent equity.

 

Income Taxes

 

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to differences between the basis of loss carryovers and depreciation differences for financial and income tax reporting. Deferred taxes represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the differences are expected to be recovered or settled.

 

Earnings (Loss) Per Share

 

Basic earnings (loss) per share (“EPS”) of common stock is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period.

 

Diluted EPS give effect to all dilutive potential common shares outstanding during the period using the treasury stock method for stock options and warrants and the if-converted method for redeemable, convertible preferred stock and convertible promissory notes. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options and/or warrants. Diluted EPS excluded all dilutive potential shares if their effect is anti-dilutive.

 

Basic loss per common share is computed based on the weighted average number of shares outstanding during the period. Diluted loss per share is computed in a manner similar to the basic loss per share, except the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of convertible debt and other such convertible instruments. Diluted loss per share contemplates a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share.

 

Segments

 

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment in the United States of America.

 

F-104
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Note 2 – Fair Value Measurements

 

The Company had the following assets and liabilities measured at fair value on a recurring basis at September 30, 2023.

 

   Total   Level 1   Level 2   Level 3 
Assets  $-   $     -   $      -   $- 
                     
Liabilities:                    
Convertible promissory notes   3,861,700    -    -    3,861,700 
Warrant liability   17,747    -    -    17,747 
Total  $3,879,447   $-   $-   $3,879,447 

 

The Company had the following assets and liabilities measured at fair value on a recurring basis at December 31, 2022.

 

   Total   Level 1   Level 2   Level 3 
Assets  $-   $     -   $     -   $- 
                     
Liabilities:                    
Convertible promissory notes   1,617,000    -    -    1,617,000 
Warrant liability   1,076,766    -    -    1,076,766 
Total  $2,693,766   $-   $-   $2,693,766 

 

The following is a reconciliation of the beginning and ending balances for the convertible promissory notes and warrant liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2023 and 2022:

 

   AgeX-Serina
Promissory Note
   Serina
Promissory Notes
   Warrant
Liability
 
Balance as of December 31, 2021  $              -   $-   $952,648 
Convertible debt issuance   -    1,250,000    - 
Inception adjustment   -    179,000    - 
Change in fair value   -    -    326,094 
Balance as of September 30, 2022  $-   $1,429,000   $1,278,742 

 

   AgeX-Serina
Promissory Note
   Serina
Promissory Notes
   Warrant Liability 
Balance as of December 31, 2022  $-   $1,617,000   $1,076,766 
Convertible debt issuance   10,000,000    100,000    - 
Inception adjustment   (2,240,000)   -    - 
Notes converted to Series A-5 Preferred Stock   -    (962,584)     
Notes converted to warrants   -    (175,355)     
Change in fair value   (3,898,300)   (579,061)   (463,404)
Balance as of September 30, 2023  $3,861,700   $-   $613,362 

 

F-105
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Note 3 - Contract Balances

 

The beginning and ending contract balances were as follows:

 

  

September 30, 2023

  

December 31, 2022

  

December 31, 2021

 
Deferred revenue  $86,632   $153,500   $             - 

 

Receipts of $86,632 were included in contract liabilities at September 30, 2023 related to a contract in progress.

 

Note 4 - Profit Sharing Plan

 

Serina has established a 401(k) profit sharing plan (the PSP) for all eligible employees of Serina. The PSP provides for eligible employee contributions subject to certain annual Internal Revenue Code limits. For participants who are age 50 or older during any calendar year, additional employee contributions are allowed under the PSP, subject to Internal Revenue Code limits.

 

Employer contributions, if any, may include matching contributions and profit sharing contributions, both of which are made on a discretionary basis and are subject to service and employment requirements. Employer matching contributions and employer profit sharing contributions vest based on a graded vesting schedule. Serina made no discretionary employer matching or employer profit sharing contributions for the nine months ended September 30, 2023 and 2022.

 

Note 5 - Common Stock

 

The holders of the common stock are entitled to one vote for each share of common stock on all matters that may be submitted to the holders of common stock of Serina. The holders of common stock shall vote together with the holders of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock as a single class. Serina shall not plan a merger or conversion, sale or dispose of property, or dissolve the Company without the written consent or affirmative vote of the entire single class.

 

Note 6 - Redeemable Convertible Preferred Stock

 

Serina has authority to issue 10,000,000 shares of preferred stock with a par value of $0.01 per share. All outstanding preferred stock is redeemable upon a Deemed Liquidation Event and convertible and has been classified as temporary stockholders’ equity at September 30, 2023 and December 31, 2022, as the shares are redeemable for cash or other assets upon the occurrence of an event that is not solely within the control of the Company. As of September 30, 2023 and December 31, 2022, all outstanding preferred stock was not initially redeemable and was not considered probable of being redeemed upon consideration of the events that would constitute a Deemed Liquidation Event. As such, accrued dividends are not included in the redeemable convertible preferred stock balances.

 

Redeemable convertible preferred stock was as follows as of September 30, 2023:

 

Preference Order  Designation  Shares Designated   Shares Issued   Shares Outstanding   Issue Price per Share   Liquidation Preference 
#1  Series A Preferred Stock   400,000    400,000    400,000   $5.00   $2,000,000 
#2  Series A-1 Preferred Stock   300,000    300,000    300,000   $6.66   $1,998,000 
#3  Series A-2 Preferred Stock   1,117,013    1,117,013    1,117,013   $9.93793   $11,085,291 
#4  Series A-3 Preferred Stock   499,200    499,200    499,200   $12.50   $6,240,000 
#5  Series A-4 Preferred Stock   718,997    718,997    718,997   $13.00   $9,346,961 
#6  Series A-5 Preferred Stock   2,000,000    484,918    484,918   $13.00   $5,733,832 
       5,035,210    3,520,128    3,520,128        $36,404,084 

 

Redeemable convertible preferred stock was as follows as of December 31, 2022:

 

Preference Order  Designation  Shares Designated   Shares Issued   Shares Outstanding   Issue Price per Share   Liquidation Preference 
#1  Series A Preferred Stock   400,000    400,000    400,000   $5.00   $2,000,000 
#2  Series A-1 Preferred Stock   300,000    300,000    300,000   $6.66   $1,998,000 
#3  Series A-2 Preferred Stock   1,122,077    1,117,013    1,117,013   $9.93793   $11,085,291 
#4  Series A-3 Preferred Stock   499,200    499,200    499,200   $12.50   $6,240,000 
#5  Series A-4 Preferred Stock   718,997    718,997    718,997   $13.00   $9,346,961 
#6  Series A-5 Preferred Stock   2,000,000    367,015    367,015   $13.00   $4,771,248 
       5,040,274    3,402,225    3,402,225        $35,441,500 

 

F-106
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock all have the same rights, preferences, powers, privileges, restrictions, qualifications, and limitations.

 

Dividends

 

From and after the date of the issuance of any shares of Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock, they accrued dividends at the rate per annum of 6% of the original issue price until June 30, 2019. The dividends accrued from day to day, whether or not declared, compounded annually, were calculated on the basis of a 365-day year, and were cumulative. Effective June 30, 2019, Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock no longer accrued dividends. The holders of the Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock were entitled to receive dividends when and if declared by the Board of Directors. The Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall not accrue dividends. Dividends on Preferred Stock are in preference to and prior to any payment of any dividends on common stock. As of September 30, 2023 and December 31, 2022, $10,276,653 in Preferred Stock dividends have been accrued, but not declared. As such, these dividends are not currently an obligation of the Company and are not included in the redeemable convertible preferred stock balances.

 

Convertibility

 

Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall be convertible, at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder into common stock. The number of shares will be determined by dividing the original issue price by the conversion price of the Preferred Stock. The conversion price initially is the same as the issue price of the Preferred Stock, but may be adjusted based on certain events as provided in the amended Articles of Incorporation.

 

Liquidation Preference

 

In the event of Deemed Liquidation Event for Serina (described below), the holders of the various series of Preferred Stock are entitled to receive prior to, and in preference to, any distribution to the holders of common stock or any other class or series of stock ranking on liquidation junior to the series of Preferred Stock they hold, an amount equal to the original issue price plus any accrued dividends (excepting Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock) together with any other dividends declared that have not yet been paid. The preference order is noted above.

 

The following events will constitute a Deemed Liquidation Event:

 

  a) The consummation of a plan of merger or conversion in accordance with various sections of Alabama Business Corporation Law (“ABCL”), with some exceptions as provided in the amended Articles of Incorporation;
     
  b) The sale, lease, exchange, license, or other disposal, in a single transaction or series of related transactions, of all, or substantially all, of the corporation’s property (with or without goodwill), other than in the usual course of business in accordance with Section 10A-2A-12.02 of the ABCL;
     
  c) Dissolution of the corporation in accordance with Section 10A-2A-14.02 of the ABCLE, or liquidation or winding-up of the business and affairs of the corporation; or
     
  d) The sale, lease, exchange, license, or other disposal, other than in the usual and regular course of business, of all, or substantially all, of the intellectual property of the corporation in a single transaction or a series of related transactions.

 

F-107
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

The holders of at least 60% of the Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock, acting as a single class of stock, may elect that any such events described above shall not be a Deemed Liquidation Event as provided in the amended Articles of Incorporation.

 

The Series A Preferred Stock liquidation preference, the Series A-1 Preferred Stock liquidation preference, the Series A-2 liquidation preference, the Series A-3 liquidation preference, the Series A-4 liquidation preference, and the Series A-5 liquidation preference shall be on parity with one another. In the event that upon liquidation or dissolution, the assets and funds of the Company are insufficient to permit the payment to holders of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock the full amount to which they shall be entitled, the holders of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock then outstanding and any class or series of stock ranking on liquidation on a parity with the Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall share in any distribution of the remaining assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

 

After the distributions described above have been paid in full, the remaining assets of the Company available for distribution shall be distributed pro-rata to the holders of the shares of common stock.

 

Note 7 - Income Taxes

 

Deferred tax assets and liabilities reflect the effects of tax losses, credits, and the future income tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

 

The Company’s effective tax rate is 0% for the nine months ended September 30, 2023 and 2022. The Company’s effective tax rate is different than what would be expected if the federal statutory rate was applied to income before income taxes primarily because certain expenses are deductible for financial reporting purposes that are not deductible for tax purposes and valuation allowances applied to the Company’s net deferred tax assets. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The major temporary differences that give rise to the deferred tax assets and liabilities are as follows: NOL carryovers, general business credit carryovers, charitable contribution carryovers, operating and finance lease assets and liabilities, and depreciation and amortization.

 

The Company evaluates the recoverability of these future tax deductions and credits by assessing the adequacy of future expected taxable income from all sources, including reversal of taxable temporary differences, forecasted operating earnings and available tax planning strategies. To the extent that management does not consider it more likely than not that a deferred tax asset will be recovered, a valuation allowance is established. The Company has provided a valuation allowance against the deferred income taxes at September 30, 2023 and December 31, 2022. The valuation allowance increased by $613,655 during the nine months ended September 30, 2023.

 

F-108
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

The components of the deferred income tax asset and liability as of September 30, 2023 and December 31, 2022 are as follows:

 

   September 30, 2023   December 31, 2022 
Deferred Tax Assets (Liabilities):          
General business credit carryover ESB  $129,310   $129,310 
General business credit carryover NonESB   1,824,263    1,824,263 
1231 loss carryover   219    219 
Net capital loss carryover    4,805    4,805 
NOL carryover - Federal   8,114,121    7,399,496 
NOL carryover - State    2,501,918    2,308,126 
Research and development   -    389,339 
Charitable contributions carryover   6,875    6,875 
Right of use assets - operating leases   (174,655)   (23,307)
Operating lease liabilities   177,849    29,419 
Depreciation of property and equipment   118,271    20,776 
Total deferred tax asset   12,702,976    12,089,321 
Valuation allowance    (12,702,976)   (12,089,321)
Net Deferred Tax Asset  $-   $- 

 

The Company only recognizes tax benefits from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statement from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. To date, the Company has not recognized such tax benefits in its financial statements.

 

Note 8 - Leases

 

The Company leases many of its operating and office facilities for various terms under long-term, non-cancelable operating lease agreements. The leases expire at various dates through 2028. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. The Company also leases equipment for various terms under long-term, non-cancelable finance lease agreements. These leases expire at various dates through 2025.

 

The following represents information on leases as of and for the nine months ended September 30:

 

   2023   2022 
Finance lease cost (including amortization of right-of use assets of $17,512 and $17,512 and interest on lease liabilities of $6,154 and $10,109 in 2023 and 2022, respectively)  $23,666   $27,621 
Operating lease expense   148,181    125,144 
           
Total lease cost  $171,847   $152,765 
           
Other information          
Weighted average remaining lease term (years) - finance   0.89    1.71 
Weighted average remaining lease term (years) - operating   3.66    1.30 
Weighted average discount rate - finance leases   11.90%   11.90%
Weighted average discount rate - operating leases   6.67%   6.67%

 

F-109
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

The following is a maturity analysis of the annual undiscounted cash flows of the lease liabilities as of September 30, 2023:

 

   Operating Leases   Finance Leases 
Three months ended December 31, 2023  $58,928   $13,799 
Year ending December 31, 2024   214,294    38,055 
Year ending December 31, 2025   175,762    629 
Year ending December 31, 2026   158,283    - 
Year ending December 31, 2027   116,592    - 
Thereafter   9,716    - 
Total undiscounted lease payments   733,575    52,483 
Less: imputed interest   (86,853)   (3,050)
Total lease obligations   646,722    49,433 
Less: current portion   (184,069)   (47,886)
Long-term lease obligations  $462,653   $1,547 

 

 

Right of use assets - operating leases obtained in exchange for new operating lease liabilities was $672,145 for the nine months ended September 30, 2023.

 

Note 9 - Property and Equipment

 

Property and equipment at September 30, 2023 and December 31, 2022 consists of:

 

   September 30, 2023   December 31, 2022 
Computer  $29,581   $24,061 
Equipment   725,974    353,343 
Software   96,517    81,676 
Total property and equipment   852,072    459,080 
Less: accumulated depreciation   (410,094)   (367,511)
Property and equipment, net  $441,978   $91,569 

 

Note 10 - Stock Option Plan

 

Stock Option Plan Description

 

In 2007, the Company’s Board of Directors (“the Board”) adopted the Serina Therapeutics, Inc. 2007 Stock Option Plan (the 2007 Plan) that provides for the granting of stock options to employees. The 2007 Plan as amended in March 2014 reserved 2,000,000 shares of common stock for grant. Options are granted at the discretion of the Board. Options granted under the 2007 Plan shall be either incentive stock options (ISOs) or nonstatutory stock options (NSOs), as designated by the Board. The options will be granted at an exercise price set by the Board at the time of grant, but in no event will the price for ISOs be less than 100% of the fair market value of the common stock on the date of the grant, or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, not less than 110%; and not less than the par value of the common stock at grant, in the case of NSOs.

 

In 2017, the Serina Therapeutics, Inc. 2007 Plan by its terms expired, except with respect to unexercised stock options outstanding under the 2007 Plan. No future stock options shall be awarded under the 2007 Plan.

 

In 2017, the Company’s Board adopted the Serina Therapeutics, Inc. 2017 Stock Option Plan (the 2017 Plan) that provides for the granting of stock options to employees. The 2017 Plan reserved 1,000,000 shares of common stock for grant. In 2021, the 2017 Plan was amended to increase the reserved shares to 2,000,000, and then later in 2021 further amended to increase the reserved shares to 2,100,000. Options are granted at the discretion of the Board. Options granted under the 2017 Plan shall be either incentive stock options (ISOs) or nonstatutory stock options (NSOs), as designated by the Board. The options will be granted at an exercise price set by the Board at the time of grant, but in no event will the price for ISOs be less than 100% of the fair market value of the common stock on the date of the grant or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, not less than 110%; and not less than the par value of the common stock at grant, in the case of NSOs.

 

F-110
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Vesting and Exercisability

 

Stock options are exercisable at such time or times and subject to such terms and conditions as determined by the Board at or after grant. If the Board provides, in its sole discretion, that any stock option is exercisable only in installments, the Board may waive such installment exercise provisions at any time at or after the grant, in whole or in part, based on such factors as the Board shall determine, in its sole discretion.

 

The terms of the grants are generally for ten years (or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, the term shall be five years) and vest over a period of time as determined on the date of the grant.

 

Stock-Based Compensation

 

The Company follows the provisions of the FASB ASC 718, Compensation - Stock Compensation (“FASB ASC 718”). FASB ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense in the financial statements based on their fair value at the grant date.

 

Valuation and Expense

 

The Company recognizes compensation expense related to stock options on a straight-line basis over the requisite service period of the awards, which is generally three to four years. The Company estimates the fair value of options on the date of grant using the Black-Scholes-Merton option pricing model. There were no options issued during the nine months ended September 30, 2023 or 2022.

 

The Company recorded stock-based compensation expense related to the stock options of $24,325 and $5,323 during the nine months ended September 30, 2023 and 2022, respectively.

 

In 2021, all options outstanding as of December 31, 2020 were canceled and replaced, with the exception of 3,300 options, which were not replaced due to termination of the grantee. Total replacement options issued were 1,294,042. Incremental compensation cost of $113 and $659 was recognized during the nine months ended September 30, 2023 and 2022, respectively, as a result of the accounting for the modification required by FASB ASC 718.

 

In February 2023, by vote of the Board all remaining unvested options became fully vested. Therefore as of September 30, 2023, the Company had no unrecognized compensation cost related to nonvested stock options.

 

F-111
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Details of stock option activity for the nine months ended September 30, 2023 and 2022 are as follows:

 

   Number of Options  

Weighted Average

Exercise Price

 
Outstanding at December 31, 2021    2,036,450   $0.06 
Outstanding at September 30, 2022   2,036,450   $    0.06 

 

   Number of Options   Weighted Average Exercise Price 
Outstanding at December 31, 2022    2,012,750   $0.06 
Forfeited   (7,000)   0.06 
Exercised    (248,934)         0.06 
Outstanding at September 30, 2023   1,756,816   $0.06 

 

The following table summarizes information about stock options exercisable at September 30, 2023:

 

Exercise Price  

Number of Shares

Exercisable

  

Weighted Average Remaining Contractual

Life in Years

  

Weighted Average

Exercise Price

 
$0.06    1,756,816    7.71   $0.06 

 

The following table summarizes information about nonvested stock options for the nine months ended September 30, 2023 and 2022:

 

   Nonvested Options   Weighted Average
Grant Date Fair Value
 
Nonvested options at December 31, 2021   656,742   $        0.04 
Vested   (18,000)   0.03 
Nonvested options at September 30, 2022   638,742    0.04 

 

   Nonvested Options   Weighted Average Grant Date Fair Value 
Nonvested options at December 31, 2022   548,807   $0.05 
Forfeited/cancelled   (1,000)   0.03 
Vested   (547,807)              0.04 
Nonvested options at September 30, 2023   -   $- 

 

Note 11 - Stock Warrants

 

Grants

 

Warrants for 117,903 Series A-5 Preferred Stock were granted during the nine months ended September 30, 2023 pursuant to the conversion of the promissory notes as described in Note 14. No warrants were granted during the nine months ended September 30, 2022.

 

The warrants contain both put and call options. The Company may call the warrants at any time following the date the warrants become exercisable. Warrants issued prior to 2023 are accounted for as a liability and remeasured to fair value at each reporting period. The liability as of September 30, 2023 and December 31, 2022 was $17,747 and $1,076,766, respectively. The warrants issued in 2023 with a fair value of $175,355 are accounted for as equity pursuant to FASB ASC 480 as they were issued in connection with the conversion of promissory notes to equity.

 

Vesting and Exercisability

 

The warrants vest immediately upon grant. All outstanding warrants at September 30, 2023 are exercisable at any time prior to close of business on December 31, 2024.

 

F-112
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Valuation and Expense

 

The Company estimates the fair value of warrants using the Black-Scholes-Merton option pricing model with the following assumptions at the reporting date:

 

   September 30, 2023   September 30, 2022 
Expected volatility   97-99%   89%
Expected term (in years)   0.3 - 0.8    1.3 – 1.8 
Risk-free interest rate   5.09% - 5.55%   4.05% - 4.22%
Expected dividend yield   0.00%   0.00%

 

Expected volatility is estimated using the historical volatility of comparable public entities. The Company estimates the expected term using historical option exercise data to determine the expected employee exercise behavior. The risk-free interest rate is the yield on a U.S. Treasury zero-coupon issue with a remaining term equal to or approximating the expected term of the option at the grant date.

 

Related to the warrants, the Company recorded a benefit of $1,059,019 due to the decrease in the liability and an expense of $326,094 due to the increase in the liability during the nine months ended September 30, 2023 and 2022, respectively.

 

Details of stock warrant activity for the nine months ended September 30, 2023 and 2022, are as follows:

 

   Number of Warrants   Weighted Average Exercise Price 
Outstanding at December 31, 2021   367,015   $20.00 
Outstanding at September 30, 2022   367,015    20.00 
Outstanding at December 31, 2022   367,015    20.00 
Granted   117,903    20.00 
Outstanding at September 30, 2023   484,918   $20.00 

 

Note 12 - Research and Development

 

At September 30, 2023, the Company is performing under a grant provided by a corporation via funding provided by a federal government agency to continue its research and development related to treatment of neurological disorders and strokes. The grant is structured such that the Company received $245,000 upon execution of the award in August 2022 which is recognized as revenue as eligible costs are incurred.

 

Note 13 - Commitments and Contingencies

 

The Company is subject to legal proceedings, claims, and litigation arising in the ordinary course of business. In the opinion of management, all such matters would be adequately covered by insurance or accruals or would be such that disposition would not have a material adverse effect on the financial position, results of operations, or cash flows of the Company.

 

Note 14 - Convertible Promissory Notes

 

On March 15, 2023, the Company issued a convertible promissory note (the “AgeX-Serina Note”) in the amount of $10,000,000 to AgeX Therapeutics (“AgeX”). The AgeX-Serina Note bears interest at 7% per annum and matures on March 15, 2026. The Company issued the AgeX-Serina Note to provide for general working capital needs. As described in Note 16, the Company and AgeX have entered into a Merger Agreement. In connection with the issuance of the AgeX-Serina Note, AgeX is entitled to elect one member to the board of directors of the Company and receive certain information and inspection rights as well as participation rights for subsequent equity issuances.

 

F-113
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

The AgeX-Serina Note has various conversion options. The principal balance of the AgeX-Serina Note with accrued interest will automatically convert into the Company’s preferred stock if the Company raises at least $25,000,000 through the sale of shares of the Company’s preferred stock. The conversion price per share shall be the lower of (a) 80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by the Company’s then fully diluted capitalization. AgeX has the option to convert the AgeX-Serina Note into the Company’s preferred stock after a sale of the Company’s preferred stock regardless of the amount sold by the Company. AgeX may (i) at its election, upon a change of control (as defined in the AgeX-Serina Note), convert the AgeX-Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the AgeX-Serina Note, plus interest, or (b) into the highest ranking shares of the Company then issued at a conversion price equal to the lowest price per share at which the most senior series of the Company’s shares has been sold in a single transaction or a series of related transactions through which the Company raised at least $5,000,000 or (ii) if the AgeX-Serina Note remains outstanding as of the maturity date, AgeX may convert the AgeX-Serina Note into the most senior shares of the Company issued at the time of conversion at a conversion price equal to the capped price. Upon the consummation of a merger between the Company and AgeX, the AgeX-Serina Note would remain outstanding and become an intercompany asset of AgeX and an intercompany liability of the Company.

 

The Company evaluated the AgeX-Serina Note in accordance with ASC Topic 815, Derivatives and Hedging, and determined it contains certain variable share settlement features tied to the price of a future financing which were not considered clearly and closely related to the host instruments. These provisions included automatic conversion upon the event of a Qualified Financing, the Holder’s option to convert the AgeX-Serina Note upon a Non-Qualified Financing, and the Holder’s option to convert or request repayment upon sale of the Company. The AgeX-Serina Note also contains a Change in Control Put and a Default Put which were not clearly and closely related to the host instrument. The Company elected to initially and subsequently measure the AgeX-Serina Note in its entirety at fair value, with changes in fair value recognized in earnings. The fair value inception date adjustment on the instrument is recorded as a component of other income in the Company’s statements of operations.

 

The change in fair value of the instrument since inception date is recorded on a separate line item as a component of other income in the Company’s statements of operations.

 

FASB ASC 825-10-25 allows the Company to elect the fair value option for recording financial instruments when they are initially recognized or if there is an event that requires re-measurement of the instruments at fair value, such as a significant modification of the debt. The Company elected the fair value option because they believed it to be the most appropriate method of encompassing the credit risk and exercise behavior that a market participant would consider when valuing the hybrid financial instrument.

 

As of March 15, 2023 (inception), the outstanding principal and interest on the AgeX-Serina Note was approximately $10,000,000 and the fair value recorded on the balance sheet was $7,760,000. From March 15, 2023 to September 30, 2023, the change in value was approximately $3,900,000 and was recorded as a component of other income in the Company’s statements of operations.

 

From June 2022 through February 2023, the Company issued interest-bearing Convertible Promissory Notes (the “Serina Convertible Notes”) to various investors in the principal amount of $1,450,000. The Serina Convertible Notes incur interest at 6% per annum and are payable by the Company two years from their issuance date. The Company may not voluntarily prepay the Serina Convertible Notes. Upon a Qualified Equity Financing event in which the Company sells shares of Preferred Stock for aggregate proceeds of at least $15 million, the principal and outstanding interest on the Serina Convertible Notes will automatically convert into shares of the Company’s Preferred Stock issued in the Qualified Financing at a conversion price of the lesser of i) a 20% discount to the price paid by purchasers in the Qualified Financing and ii) the quotient resulted from dividing $100 million by the fully diluted capitalization of the Company immediately prior to the Qualified Financing. If the Company enters into a Non-Qualified Equity Financing (less than $15 million in proceeds), the Holder has the option to convert the Serina Convertible Notes into shares of the Company’s Preferred Stock issued in the Non-Qualified Financing at the price paid per share. The Company may also choose to optionally convert the Serina Convertible Notes into Series A-5 Preferred Stock at a price of $13 per share, and a warrant to purchase shares of Series A-5 Preferred Stock with an exercise price of $20.00, and an expiration date of December 31, 2024. If a Change in Control or an IPO occurs prior to a Qualified Financing, then the Holder has the option to convert outstanding principal and interest into common stock at a price per share equal to an amount obtained by dividing i) the Post-Money Valuation Cap ($100,000,000) by ii) the Fully Diluted Capitalization immediately prior to the conversion. Upon a change in control, the Holder may also elect to require the Company to repay the outstanding principal and accrued but unpaid interest in cash.

 

F-114
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

The Company evaluated the Serina Convertible Notes in accordance with ASC Topic 815, Derivatives and Hedging, and determined they contained certain variable share settlement features tied to the price of a future financing which were not considered clearly and closely related to the host instruments. These provisions included mandatory conversion upon the event of a Qualified Financing and the Holder’s option to convert the Serina Convertible Notes upon a Non-Qualified Financing. The Serina Convertible Notes also contained a Change in Control Put and a Default Put which were not clearly and closely related to the host instrument. The Company elected to initially and subsequently measure the Serina Convertible Notes in their entirety at fair value, with changes in fair value recognized in earnings. The fair value inception date adjustment on the instrument is recorded as a component of other income in the Company’s statements of operations. The change in fair value of the instrument since inception date is recorded on a separate line item as a component of other income in the Company’s statements of operations.

 

Because the Serina Convertible Notes are carried in their entirety at fair value, the value of the compound embedded conversion features and the redemption features are embodied in that fair value. The Company estimated the fair value of the hybrid instrument based on a probability weighted cash flow analysis. A Monte Carlo model, which considered the present value of the cash flows under the different scenarios using a credit risk adjusted rate, was considered by management to be the most appropriate method of encompassing credit risk and exercise behavior. Inputs used to value the hybrid instrument at inception (July 19, 2022) included, (i) present value of future cash flows using a credit risk adjusted rate of 16%, (ii) remaining term of approximately 2 years, (iii) volatility of 90% based on the volatility of comparable guideline public companies, (iv) closing stock price on the valuation date, and (v) 70% probability the Serina Convertible Notes will be converted upon a Non-Qualified Financing, at the expected price of the Non-Qualified Financing, and 30% probability the Serina Convertible Notes will be optionally converted at their stated conversion price ($13 per share plus one warrant).

 

Management expects the probability of a change in control, default, or Qualified Financing event occurring over the remaining term of the Serina Convertible Notes to be minimal. However, this assumption will be considered each reporting period. Material changes due to instrument-specific credit risk are recorded in Other Comprehensive Income with all other changes in value being recorded in net income.

 

For the nine months ended September 30, 2023, interest expense associated with the convertible notes was $381,644.

 

On July 26, 2023, all of the Convertible Promissory Notes described in this Note (excluding the AgeX-Serina Note) previously issued for a total principal amount of $1,450,000 and accrued interest of $82,695 were converted to 117,903 shares of Series A-5 Preferred Stock. In accordance with FASB ASC 470, upon conversion, the carrying value of the debt, $962,584, was recognized in the Series A-5 Preferred Stock balance. As provided for in the note agreements, the holders of the notes also received warrants to purchase an additional 117,903 shares of Series A-5 Preferred Stock (See Note 11).

 

F-115
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Note 15 - Net Earnings (Loss) Per Common Share

 

Net earnings (loss) per common share is calculated in accordance with ASC 260, Earnings Per Share. Basic and diluted net earnings (loss) per common share attributable to common shareholders is calculated as follows for the nine months ended September 30, 2023 and 2022:

 

   2023   2022 
Basic net earnings (loss) per common share allocable to common shareholders          
           
NUMERATOR          
Net income (loss)  $4,220,124   $(2,083,689)
Less: net earnings allocable to participating securities   -    - 
Net earnings (loss) allocable to common shareholders   4,220,124    (2,083,689)
DENOMINATOR          
Weighted-average shares of common stock outstanding used to calculate basic net earnings (loss) per common share   2,228,036    2,144,800 
           
Basic net earnings (loss) per common share allocable to common          
shareholders  $1.89   $(0.97)
           
Diluted net earnings (loss) per common share allocable to common shareholders          
          
NUMERATOR           
Net earnings (loss) allocable to common shareholders  $4,220,124   $(2,083,689)
Add back: interest on convertible promissory notes   -    - 
Net earnings (loss) allocable to common shareholders   4,220,124    (2,083,689)
DENOMINATOR          
Weighted-average shares of common stock outstanding used to calculate basic net earnings (loss) per common share   2,228,036    2,144,800 
Add: dilutive effect of stock options   1,724,985    - 
Add: dilutive effect of warrants   -    - 
Add: dilutive effect of common stock issued for convertible promissory notes   -    - 
Add: dilutive effect of redeemable convertible preferred stock   3,520,128    - 
Weighted-average shares of common stock outstanding used to calculate diluted net earnings (loss) per common share   7,473,149    2,144,800 
           
Diluted net earnings (loss) per common share attributable to common shareholders  $0.56   $(0.97)

 

F-116
 

 

SERINA THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net earnings (loss) per common share for the nine months ended September 30, 2023 and 2022 because to do so would be anti-dilutive:

 

   2023   2022 
Redeemable convertible preferred stock   -    3,402,225 
Convertible promissory notes   -    203,970 
Stock options   -    2,036,450 
Warrants   484,918    367,015 
Total anti-dilutive securities   484,918    6,009,660 

 

Note 16 - Merger Agreement

 

On August 29, 2023, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with AgeX Therapeutics, Inc. and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“Merger Sub”). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including that the Merger is approved by the stockholders of AgeX and the stockholders of Serina, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the “Merger”). There is no assurance the necessary approvals by AgeX stockholders and Serina stockholders will be obtained or that the other conditions to the Merger as provided in the Merger Agreement will be met.

 


Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of AgeX common stock, and stockholders of AgeX immediately prior to the closing of the Merger are expected to own, excluding the impact of the exercise of any of the Post-Merger Warrants or Incentive Warrants described below, approximately 25% of the outstanding shares of AgeX common stock, in each case, on a fully diluted basis, subject to certain assumptions, including giving effect to a planned reverse stock split and the conversion of AgeX Preferred Stock into shares of AgeX common stock. Accordingly, the Merger is anticipated to be accounted for as a reverse acquisition, with the Company treated as the acquiror for financial accounting purposes.

 

Prior to the closing of the Merger, AgeX will issue to each holder of AgeX common stock three warrants (each, a “Post-Merger Warrant”) for each five shares of AgeX common stock held by such stockholder. Each Post-Merger Warrant will be exercisable for (i) one share of AgeX common stock and (ii) one warrant (each, an “Incentive Warrant”) at an exercise price equal to $13.20 per warrant (such exercise price reflecting a planned reverse stock split of AgeX common stock) and will expire on July 31, 2025. Each Incentive Warrant will be exercisable for one share of AgeX common stock at a price equal to $18.00 per warrant (such exercise price reflecting the planned reverse stock split of AgeX common stock) and will expire on the four-year anniversary of the closing of the Merger. Each Post-Merger Warrant and Incentive Warrant will be issued pursuant to the terms of a warrant agreement to be entered into by AgeX and a warrant agent in connection with the closing of the Merger.

 

Note 17 - Subsequent Events

 

License Agreement

 

In October 2023, the Company entered into a non-exclusive license agreement with Pfizer, Inc. to use the Company’s POZ polymer technology for use in lipid nanoparticle drug delivery formulations. The agreement grants Pfizer non-exclusive rights to certain intellectual property, know-how, and proprietary technologies. Under the terms of the agreement, Pfizer is authorized to develop, manufacture, market, and commercialize products incorporating the licensed technology with respect to a specific POZ polymer structure in one field. The agreement outlines the protection and enforcement of intellectual property rights related to the licensed technology. Pfizer is obligated to use commercially reasonable diligent efforts to develop and commercialize licensed products, and to use such efforts to accomplish specified development and commercial objectives. The agreement includes a one-time upfront payment of $3 million that was received on December 15, 2023, milestone payments payable to Serina upon the achievement of specific development, regulatory, and commercial milestones, and a royalty on net sales of products incorporating the licensed technology in accordance with the terms outlined in the license agreement. The range of royalties on sales of products is between 2.75% – 3.5% and is tiered to achievement of certain sales milestones.

 

F-117
 

 

Annex A

 

AGREEMENT AND PLAN OF MERGER

AND REORGANIZATION

 

among:

 

AgeX Therapeutics, Inc.,

a Delaware corporation;

 

CANARIA TRANSACTION CORPORATION,

an Alabama corporation; and

 

Serina THERAPEUTICS, INC.,

an Alabama corporation

 

Dated as of August 29, 2023

 

A-1
 

 

TABLE OF CONTENTS

 

    Page
     
SECTION 1. DESCRIPTION OF TRANSACTION A-2
     
1.1 The Merger A-2
1.2 Effects of the Merger A-2
1.3 Closing; Effective Time A-2
1.4 Certificate of Incorporation and Bylaws; Directors and Officers A-3
1.5 Conversion of Shares A-4
1.6 Closing of the Company’s Transfer Books A-5
1.7 Delivery of Merger Consideration A-6
1.8 Appraisal Shares A-7
1.9 Further Action A-8
1.10 Withholding A-8
     
SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY A-8
     
2.1 Due Organization; Subsidiaries A-8
2.2 Organizational Documents A-9
2.3 Authority; Binding Nature of Agreement A-9
2.4 Vote Required A-10
2.5 Non-Contravention; Consents A-10
2.6 Capitalization A-11
2.7 Financial Statements A-13
2.8 Absence of Changes A-14
2.9 Absence of Undisclosed Liabilities A-15
2.10 Title to Assets A-15
2.11 Real Property; Leasehold A-15
2.12 Intellectual Property A-16
2.13 Agreements, Contracts and Commitments A-18
2.14 Compliance; Permits; Restrictions A-20
2.15 Legal Proceedings; Orders A-22
2.16 Tax Matters A-22
2.17 Employee and Labor Matters; Benefit Plans A-25
2.18 Environmental Matters A-28
2.19 Insurance A-29
2.20 No Financial Advisors A-29
2.21 Disclosure A-29
2.22 Transactions with Affiliates A-30
2.23 Anti-Bribery A-30
2.24 Disclaimer of Other Representations or Warranties A-31
     
SECTION 3. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB A-31
     
3.1 Due Organization; Subsidiaries A-31
3.2 Organizational Documents A-32
3.3 Authority; Binding Nature of Agreement A-32
3.4 Vote Required A-33
3.5 Non-Contravention; Consents A-33
3.6 Capitalization A-34

 

 i 

 

 

TABLE OF CONTENTS

(continued)

 

    Page
3.7 SEC Filings; Financial Statements A-36
3.8 Absence of Changes A-38
3.9 Absence of Undisclosed Liabilities A-38
3.10 Title to Assets A-38
3.11 Real Property; Leasehold A-39
3.12 Intellectual Property A-39
3.13 Agreements, Contracts and Commitments A-42
3.14 Compliance; Permits; Restrictions A-44
3.15 Legal Proceedings; Orders A-45
3.16 Tax Matters A-45
3.17 Employee and Labor Matters; Benefit Plans A-48
3.18 Environmental Matters A-51
3.19 Transactions with Affiliates A-52
3.20 Insurance A-52
3.21 No Financial Advisors A-52
3.22 Disclosure A-52
3.23 Anti-Bribery A-53
3.24 Valid Issuance A-53
3.25 Disclaimer of Other Representations or Warranties A-53
     
SECTION 4. CERTAIN COVENANTS OF THE PARTIES A-53
     
4.1 Operation of Parent’s Business A-53
4.2 Operation of the Company’s Business A-56
4.3 Access and Investigation A-59
4.4 Parent Non-Solicitation A-60
4.5 Company Non-Solicitation A-61
4.6 Notification of Certain Matters A-61
4.7 Potentially Transferable Assets A-62
4.8 Parent Legacy Note A-62
4.9 Post-Merger Warrant A-63
4.10 Sarbanes-Oxley Certification. A-63
4.11 Parent Preferred Stock. A-63
4.12 Company Notes A-63
4.13 Company Incentive Plan and Parent Incentive Plan. A-63
     
SECTION 5. ADDITIONAL AGREEMENTS OF THE PARTIES A-64
     
5.1 Registration Statement; Proxy Statement A-64
5.2 Company Information Statement; Stockholder Written Consent A-65
5.3 Parent Stockholders’ Meeting A-67
5.4 Regulatory Approvals A-71
5.5 Options and Warrants. A-71
5.6 Indemnification of Officers and Directors A-73
5.7 Additional Agreements A-75
5.8 Public Announcement A-75
5.9 Listing A-76

 

 ii 

 

 

TABLE OF CONTENTS

(continued)

 

    Page
5.10 Tax Matters A-76
5.11 Directors and Officers A-77
5.12 Termination of Certain Agreements and Rights A-77
5.13 Section 16 Matters A-77
5.14 Cooperation A-78
5.15 Allocation Certificates A-78
5.16 Company Financial Statements A-78
5.17 Takeover Statutes A-79
5.18 Stockholder Litigation A-79
5.19 Parent Benefit Plans A-79
5.20 Company 280G Actions. A-80
     
SECTION 6. CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY A-80
     
6.1 No Restraints A-80
6.2 Stockholder Approval A-80
6.3 Listing A-80
6.4 Effectiveness of Registration Statement A-81
6.5 Side Letter A-81
6.6 NYSE Reverse Split. A-81
     
SECTION 7. ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB A-81
     
7.1 Accuracy of Representations A-81
7.2 Performance of Covenants A-81
7.3 Documents A-82
7.4 No Company Material Adverse Effect A-82
7.5 Termination of Investor Agreements A-82
7.6 Company Lock-Up Agreements A-82
7.7 Company Stockholder Written Consent A-82
7.8 Appraisal Shares A-82
7.9 FIRPTA Certificate A-82
7.10 Company Notes. A-82
     
SECTION 8. ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY A-83
     
8.1 Accuracy of Representations A-83
8.2 Performance of Covenants A-83
8.3 Documents A-83
8.4 No Parent Material Adverse Effect A-83
8.5 Termination of Contracts A-84
8.6 Parent Lock-Up Agreements A-84
8.7 Actual Closing Price and Post-Merger Warrants. A-84
8.8 Cash at Closing. A-84
     
SECTION 9. TERMINATION A-84
     
9.1 Termination A-84

 

 iii 

 

 

TABLE OF CONTENTS

(continued)

 

    Page
9.2 Effect of Termination A-87
9.3 Expenses; Termination Fees A-87
     
SECTION 10. MISCELLANEOUS PROVISIONS A-90
     
10.1 Non-Survival of Representations and Warranties A-90
10.2 Amendment A-90
10.3 Waiver A-91
10.4 Entire Agreement; Counterparts; Exchanges by Electronic Transmission A-91
10.5 Applicable Law; Jurisdiction A-91
10.6 Attorneys’ Fees A-92
10.7 Assignability A-92
10.8 Notices A-92
10.9 Cooperation A-93
10.10 Severability A-93
10.11 Other Remedies; Specific Performance A-93
10.12 No Third Party Beneficiaries A-94
10.13 Construction A-94

 

 iv 

 

 

Exhibits:

 

  Exhibit A Certain Definitions
  Exhibit B-1 Form of Company Stockholder Support Agreement
  Exhibit B-2 Form of Parent Stockholder Support Agreement
  Exhibit C-1 Form of Company Lock-Up Agreement
  Exhibit C-2 Form of Parent Lock-Up Agreement
  Exhibit D Form of Company Stockholder Written Consent
  Exhibit E Surviving Corporation Amended and Restated Certificate of Incorporation
  Exhibit F Parent Amended and Restated Certificate of Incorporation
  Exhibit G Surviving Corporation Amended and Restated Bylaws
  Exhibit H Parent Amended and Restated Bylaws
  Exhibit I Amended and Restated Company Incentive Plan
  Exhibit J Amended and Restated Parent Incentive Plan
  Exhibit K New Incentive Plan
  Exhibit L Post-Closing Officers and Directors
  Exhibit M Side Letter

 

Schedules:

 

Company Disclosure Schedule

Parent Disclosure Schedule

 

 v 

 

 

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION

 

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of August 29, 2023, by and among AgeX Therapeutics, Inc., a Delaware corporation (“Parent”), CANARIA TRANSACTION CORPORATION, an Alabama corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Serina Therapeutics, Inc., an Alabama corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

 

RECITALS

 

A. Parent and the Company intend to effect a merger of Merger Sub with and into the Company (the “Merger”) in accordance with this Agreement and the ABCL. Upon consummation of the Merger, Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent.

 

B. The Parties intend that the Merger qualify as a “reorganization” within the meaning of Section 368(a) of the Code, and by executing this Agreement, the Parties hereby adopt a “plan of reorganization” within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a).

 

C. The Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii) authorized, approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Common Stock to the stockholders of the Company pursuant to the terms of this Agreement, the change of control of Parent and other actions contemplated by this Agreement, and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Parent Stockholder Matters and such other actions as contemplated by this Agreement.

 

D. The Merger Sub Board has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder, (ii) authorized, approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole stockholder of Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.

 

E. The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) authorized, approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to approve the Company Stockholder Matters and such other actions as contemplated by this Agreement.

 

F. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent’s willingness to enter into this Agreement, (a) the officers, directors and stockholders of the Company listed in Section A-1 of the Company Disclosure Schedule (the “Company Signatories”) (solely in their capacity as stockholders of the Company), are executing support agreements in favor of Parent in substantially the form attached hereto as Exhibit B-1 (the “Company Stockholder Support Agreement”) and (b) the officers, directors and stockholders of the Company listed in Section A-2 of the Company Disclosure Schedule (the “Company Lock-Up Signatories”) (solely in their capacity as stockholders of the Company) are executing lock-up agreements in substantially the form attached hereto as Exhibit C-1 (the “Company Lock-Up Agreement”).

 

 

 

 

G. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company’s willingness to enter into this Agreement, (a) the officers, directors and stockholders of Parent listed in Section A-1 of the Parent Disclosure Schedule (solely in their capacity as stockholders of Parent) are executing support agreements in favor of the Company in substantially the form attached hereto as Exhibit B-2 (the “Parent Stockholder Support Agreement”) and (b) the officers, directors and stockholders of Parent listed in Section A-2 of the Parent Disclosure Schedule (solely in their capacity as stockholders of Parent) are executing lock-up agreements in substantially the form attached hereto as Exhibit C-2 (the “Parent Lock-Up Agreement”).

 

H. It is expected that, within three (3) Business Days after the Registration Statement is declared effective under the Securities Act, the holders of shares of Company Capital Stock sufficient to approve the Company Stockholder Matters as required under the ABCL and the Company’s certificate of incorporation and the Company’s bylaws (hereinafter collectively referred to as the “Company’s Organizational Documents”) will execute and deliver an action by written consent in substantially the form attached hereto as Exhibit D (each, a “Company Stockholder Written Consent” and collectively, the “Company Stockholder Written Consents”).

 

AGREEMENT

 

The Parties, intending to be legally bound, agree as follows:

 

SECTION 1. DESCRIPTION OF TRANSACTION

 

1.1 The Merger. Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time, Merger Sub shall be merged with and into the Company, and the separate existence of Merger Sub shall cease. The Company will continue as the surviving corporation in the Merger (the “Surviving Corporation”).

 

1.2 Effects of the Merger. The Merger shall have the effects set forth in this Agreement, the Statement of Merger and in the applicable provisions of the ABCL. As a result of the Merger, the Company will become a wholly owned subsidiary of Parent.

 

A-2
 

 

1.3 Closing; Effective Time. Unless this Agreement is earlier terminated pursuant to the provisions of Section 9.1, and subject to the satisfaction or waiver of the conditions set forth in Sections 6, 7 and 8, the consummation of the Merger (the “Closing”) shall take place remotely as promptly as practicable (but in no event later than the second (2nd) Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in Sections 6, 7 and 8, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the “Closing Date.” At the Closing, the Parties shall cause the Merger to be consummated by executing and filing with the Secretary of State of the State of Alabama a Statement of Merger with respect to the Merger, satisfying the applicable requirements of the ABCL and in a form reasonably acceptable to Parent and the Company (the “Statement of Merger”). The Merger shall become effective at the time of the filing of such Statement of Merger with the Secretary of State of the State of Alabama or at such later time as may be specified in such Statement of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the “Effective Time”).

 

1.4 Certificate of Incorporation and Bylaws; Directors and Officers. At the Effective Time:

 

(a) the certificate of incorporation of the Surviving Corporation shall be amended and restated in its entirety at or immediately prior to the Effective Time as set forth in Exhibit E, to, among other things, change the name of the Surviving Corporation to “Serina Operating Company, Inc.” or such other name as shall be mutually agreed upon by Parent and the Company prior to filing such amendment and restatement, and shall be the certificate of incorporation of the Surviving Corporation until thereafter amended as provided by the ABCL and such amended and restated certificate of incorporation;

 

(b) the certificate of incorporation of Parent shall be amended and restated in its entirety, as contemplated in Section 5.3(a)(v) (the “First Amended and Restated Certificate of Incorporation”) and as set forth in Exhibit F, at or immediately prior to the Effective Time, until thereafter amended as provided by the DGCL and the First Amended and Restated Certificate of Incorporation; provided, however, that at or immediately prior to the filing of the First Amended and Restated Certificate of Incorporation, Parent shall file an amendment to its current certificate of incorporation to (i) as contemplated by Section 5.3(a)(i), effect the NYSE Reverse Split and (ii) make such other changes as shall be mutually agreed upon by Parent and the Company prior to filing such amendment;

 

(c) the bylaws of the Surviving Corporation shall be amended and restated in their entirety at or immediately prior to the Effective Time as set forth in Exhibit G, and shall be the bylaws of the Surviving Corporation until thereafter amended as provided by the ABCL and such amended and restated bylaws;

 

(d) the bylaws of the Parent shall be amended and restated in their entirety at or immediately prior to the Effective Time as set forth in Exhibit H, and shall be the bylaws of the Parent until thereafter amended as provided by the DGCL and such amended and restated bylaws;

 

(e) the directors and officers of Parent, each to hold office in accordance with the First Amended and Restated Certificate of Incorporation and bylaws of Parent, shall be as set forth in Section 5.11 after giving effect to the provisions of Section 5.11, or such other persons as shall be mutually agreed upon by Parent and the Company; and

 

(f) the directors and officers of the Surviving Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Corporation, shall be the directors and officers of Parent, or such other persons as shall be mutually agreed upon by Parent and the Company.

 

A-3
 

 

1.5 Conversion of Shares.

 

(a) At the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any stockholder of the Company or Parent:

 

(i) any shares of Company Capital Stock held as treasury stock by the Company or held or owned by Parent, Merger Sub or any Subsidiary of Parent or the Company immediately prior to the Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and

 

(ii) subject to Section 1.5(c), each share of Company Capital Stock outstanding immediately prior to the Effective Time (excluding shares to be canceled pursuant to Section 1.5(a)(i) and excluding Appraisal Shares), after giving effect to the Preferred Stock Conversion, shall be automatically converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio (the “Merger Consideration”).

 

(b) If any shares of Company Capital Stock outstanding immediately prior to the Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of Parent Common Stock issued in exchange for such shares of Company Capital Stock at the Effective Time will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Common Stock shall accordingly be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement in accordance with its terms.

 

(c) No fractional shares of Parent Common Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Any holder of Company Capital Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (after aggregating all fractional shares of Parent Common Stock issuable to such holder) shall receive from Parent, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with Section 1.7 and any accompanying documents as required therein: (i) one share of Parent Common Stock, if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Capital Stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii) no shares of Parent Common Stock, if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Capital Stock would otherwise be entitled to is less than 0.50.

 

A-4
 

 

(d) All Company Options outstanding immediately prior to the Effective Time under the Company Incentive Plan shall be treated in accordance with Section 5.5(a).

 

(e) All Company Warrants outstanding immediately prior to the Effective Time shall be treated in accordance with Section 5.5(c)

 

(f) Each share of common stock, $0.0001 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.0001 par value per share, of the Surviving Corporation. Each stock certificate or book-entry share of Merger Sub evidencing ownership of any such shares shall, as of the Effective Time, evidence ownership of such shares of common stock of the Surviving Corporation.

 

(g) If, between the time of calculating the Exchange Ratio and the Effective Time, the outstanding shares of Company Capital Stock or Parent Common Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the NYSE Reverse Split to the extent such split has not been previously taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital Stock, Parent Common Stock, Company Options and Company Warrants with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split (including the NYSE Reverse Split), combination or exchange of shares or other like change; provided, however, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Common Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.

 

1.6 Closing of the Company’s Transfer Books. At the Effective Time: (a) all shares of Company Capital Stock outstanding immediately prior to the Effective Time shall be treated in accordance with Section 1.5(a), and all holders of certificates or book-entry shares representing shares of Company Capital Stock that were outstanding immediately prior to the Effective Time shall cease to have any rights as stockholders of the Company; and (b) the stock transfer books of the Company shall be closed with respect to all shares of Company Capital Stock outstanding immediately prior to the Effective Time. No further transfer of any such shares of Company Capital Stock shall be made on such stock transfer books after the Effective Time. If, after the Effective Time, a valid certificate previously representing any shares of Company Capital Stock outstanding immediately prior to the Effective Time (including any certificates representing the Company Preferred Stock or Company Warrants that were converted or exercised in connection with the conversion of Company Preferred Stock or exercise of Company Warrants, as applicable) (a “Company Stock Certificate”) is presented to the Exchange Agent or to the Surviving Corporation, such Company Stock Certificate shall be canceled and shall be exchanged as provided in Sections 1.5 and 1.7.

 

A-5
 

 

1.7 Delivery of Merger Consideration.

 

(a) On or prior to the Closing Date, Parent and the Company shall agree upon and select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the “Exchange Agent”). At the Effective Time, Parent shall deposit with the Exchange Agent evidence of book-entry shares representing the Parent Common Stock issuable pursuant to Section 1.5(a). The Parent Common Stock so deposited with the Exchange Agent, together with any dividends or distributions received by the Exchange Agent with respect to such shares, are referred to collectively as the “Exchange Fund.”

 

(b) Promptly after the Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of Company Capital Stock that were converted into the right to receive the Merger Consideration: (i) a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (including a provision confirming that delivery of any Company Stock Certificates shall be effected, and risk of loss and title to such Company Stock Certificates shall pass, only upon proper delivery of such Company Stock Certificates to the Exchange Agent); and (ii) instructions for effecting the surrender of any Company Stock Certificates, or uncertificated shares of Company Capital Stock, in exchange for shares of Parent Common Stock. Upon surrender of a Company Stock Certificate or other reasonable evidence of the ownership of uncertificated Company Capital Stock to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent (including a properly completed IRS Form W-9 or the appropriate version of IRS Form W-8, as applicable): (A) the holder of such Company Capital Stock shall be entitled to receive in exchange therefor shares representing the Merger Consideration (in a number of whole shares of Parent Common Stock) that such holder has the right to receive pursuant to the provisions of Section 1.5(a) (B) such Company Stock Certificate so surrendered shall be canceled. Until surrendered as contemplated by this Section 1.7(b), each Company Stock Certificate shall be deemed, from and after the Effective Time, to represent only the right to receive shares of Parent Common Stock representing the Merger Consideration. If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of Parent Common Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate and post a bond indemnifying Parent against any claim suffered by Parent related to the lost, stolen or destroyed Company Stock Certificate as Parent may reasonably request. In the event of a transfer of ownership of a Company Stock Certificate that is not registered in the transfer records of the Company, payment of the Merger Consideration may be made to a Person other than the Person in whose name such Company Stock Certificate so surrendered is registered if such Company Stock Certificate shall be properly endorsed or otherwise be in proper form for transfer and the Person requesting such payment shall pay any transfer or other Taxes required by reason of the transfer or establish to the satisfaction of Parent that such Taxes have been paid or are not applicable. The Merger Consideration and any dividends or other distributions as are payable pursuant to Section 1.7(c) shall be deemed to have been in full satisfaction of all rights pertaining to Company Capital Stock formerly represented by such Company Stock Certificates.

 

A-6
 

 

(c) No dividends or other distributions declared or made with respect to Parent Common Stock with a record date on or after the Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Common Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent, or provides an affidavit of loss, theft or destruction in lieu thereof in accordance with this Section 1.7 (at which time (or, if later, on the applicable payment date) such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest).

 

(d) Any portion of the Exchange Fund that remains undistributed to holders of Company Capital Stock as of the date that is one (1) year after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates who have not theretofore surrendered their Company Stock Certificates in accordance with this Section 1.7 shall thereafter look only to Parent for satisfaction of their claims for Parent Common Stock and any dividends or distributions with respect to shares of Parent Common Stock.

 

(e) No Party to this Agreement shall be liable to any holder of any Company Capital Stock or to any other Person with respect to any shares of Parent Common Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law.

 

1.8 Appraisal Shares.

 

(a) Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the Effective Time and which are held by any Person who is entitled to exercise that Person’s appraisal rights and properly perfects that Person’s appraisal rights with respect to such shares of Company Capital Stock in accordance with the ABCL (collectively, the “Appraisal Shares”) shall not be converted into or represent the right to receive the Merger Consideration described in Section 1.5 attributable to such Appraisal Shares. Such stockholders shall be entitled to receive payment of the “fair value” (as defined in Section 10A-2A-13.01 et seq. of the ABCL (the “ABCL Article 13”)) of such shares of Company Capital Stock held by them in accordance with the ABCL, unless and until such stockholders fail to perfect or waive, withdraw or lose the right to appraisal under ABCL Article 13. All Appraisal Shares held by stockholders who have failed to perfect or who have waived, withdrawn, or lost the right to appraisal rights under ABCL Article 13 of such shares of Company Capital Stock under the ABCL (whether occurring before, at or after the Effective Time) shall thereupon be deemed to be converted into and to have become exchangeable for, as of the Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Appraisal Shares upon their surrender in the manner provided in Sections 1.5 and 1.7.

 

(b) The Company shall give prompt written notice to Parent of any demand received by the Company from a holder of shares of Company Common Stock pursuant to Section 13.21 of ABCL Article 13, and Parent shall have the right to participate in all negotiations and proceedings with respect to such demands. Prior to the Effective Time, the Company shall not, without the prior written consent of Parent (not to be unreasonably withheld, delayed or conditioned), make any payment with respect to, or settle or offer to settle, any such demands, or waive any failure by any holder of Company Common Stock to timely deliver a written demand for appraisal or the taking of any other action by any such holder as may be necessary to perfect appraisal rights under the ABCL, or agree to do any of the foregoing.

 

A-7
 

 

1.9 Further Action. If, at any time after the Effective Time, any further action is determined by the Surviving Corporation to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the Surviving Corporation shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of Merger Sub, in the name of the Surviving Corporation and otherwise) to take such action.

 

1.10 Withholding. The Parties and the Exchange Agent shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this Agreement to any holder of Company Capital Stock or any other Person such amounts as such Party or the Exchange Agent reasonably determines it is required to deduct and withhold under the Code or any other Law with respect to the making of such payment. To the extent that amounts are so deducted and withheld and paid to the appropriate Governmental Body, such deducted and withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding was made. To the extent it is determined that any such deduction or withholding is required in respect of payment to a holder of Company Capital Stock (other than by reason of failure of the Company to provide the FIRPTA Certificate in accordance with Section 7.9 or such holder to provide an IRS Form W-9 or appropriate IRS Form W-8 to the Exchange Agent or in respect of any payments in the nature of compensation), the Parties shall use commercially reasonable efforts (including using commercially reasonable efforts to cause the Exchange Agent) (x) to notify the Person in respect of which such deduction or withholding is being made and (y) to the extent permitted by applicable Law, cooperate with such Person to the extent reasonably requested to establish an exemption or reduction of, or otherwise minimize, such deduction and withholding.

 

SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

Subject to Section 10.13(h), except as set forth in the written disclosure schedule delivered by the Company to Parent (the “Company Disclosure Schedule”), the Company represents and warrants to Parent and Merger Sub as follows:

 

2.1 Due Organization; Subsidiaries.

 

(a) The Company is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Alabama and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted; (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except where the failure to have such power or authority would not reasonably be expected to prevent or materially delay the ability of the Company to consummate the Contemplated Transactions.

 

A-8
 

 

(b) The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.

 

(c) The Company has no Subsidiaries, except for the Entities identified in Section 2.1(c) of the Company Disclosure Schedule; and neither the Company nor any of the Entities identified in Section 2.1(c) of the Company Disclosure Schedule own any capital stock of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity other than the Entities identified in Section 2.1(c) of the Company Disclosure Schedule. Each of the Company’s Subsidiaries is a corporation or other legal entity duly organized, validly existing and, if applicable, in good standing under the Laws of the jurisdiction of its organization and has all necessary corporate or other power and authority to conduct its business in the manner in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used, except where the failure to have such power or authority would not be reasonably expected to have a Company Material Adverse Effect.

 

(d) Neither the Company nor any of its Subsidiaries are or have otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Neither the Company nor any of its Subsidiaries have agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Neither the Company nor any of its Subsidiaries have, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.

 

2.2 Organizational Documents. The Company has made available to Parent accurate and complete copies of the Organizational Documents of the Company and each of its Subsidiaries in effect as of the date of this Agreement. Neither the Company nor any of its Subsidiaries are in breach or violation of its respective Organizational Documents in any material respect.

 

2.3 Authority; Binding Nature of Agreement. The Company has all necessary corporate power and authority to enter into this Agreement and, subject, with respect to the Company, to receipt of the Required Company Stockholder Vote, to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Company Board (at meetings duly called and held or by written consent in lieu of a meeting) has: (a) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders; (b) authorized, approved and declared advisable this Agreement and the Contemplated Transactions; (c) recommended, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to approve the Company Stockholder Matters; and (d) approved the Company Stockholder Support Agreements and the transactions contemplated thereby.

 

A-9
 

 

This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by Parent and Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions.

 

2.4 Vote Required. The affirmative vote (or written consent) of the holders of at least (a) 60% of the then outstanding shares of Series A Preferred Stock voting as a separate class, (b) 60% of the then outstanding shares of Series A-1 Preferred Stock voting as a separate class, (c) 60% of the then outstanding shares of Series A-2 Preferred Stock voting as a separate class, (d) 60% of the then outstanding shares of Series A-3 Preferred Stock voting as a separate class, (e) 60% of the then outstanding shares of Series A-4 Preferred Stock voting as a separate class, (f) 60% of the then outstanding shares of Series A-5 Preferred Stock voting as a separate class, and (g) a majority of the then outstanding shares of the capital stock of the Company on an as-converted to Company Common Stock basis and as a single class (collectively, the “Required Company Stockholder Vote”), is the only vote (or written consent) of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions.

 

2.5 Non-Contravention; Consents. Subject to obtaining the Required Company Stockholder Vote and the filing of the Statement of Merger required by the ABCL, neither (a) the execution, delivery, or performance of this Agreement by the Company, nor (b) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):

 

(i) contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of the Company or any of its Subsidiaries;

 

(ii) contravene, conflict with or result in a violation of, or give any Governmental Body or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which the Company or any of its Subsidiaries, or any of the assets owned or used by the Company or any of its Subsidiaries, is subject, except as would not reasonably be expected to constitute, individually or in the aggregate, a Company Material Adverse Effect;

 

(iii) contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or its Subsidiaries, except as would not reasonably be expected to constitute, individually or in the aggregate, a Company Material Adverse Effect;

 

A-10
 

 

(iv) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (A) declare a default or exercise any remedy under any Company Material Contract; (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract; (C) accelerate the maturity or performance of any Company Material Contract; or (D) cancel, terminate or modify any term of any Company Material Contract, except in the case of any non-material breach, default, penalty or modification; or

 

(v) result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company or any of its Subsidiaries (except for Permitted Encumbrances).

 

Except for (A) any Consent set forth in Section 2.5 of the Company Disclosure Schedule under any Company Material Contract, (B) the Required Company Stockholder Vote, (C) the filing of the Statement of Merger with the Secretary of State of the State of Alabama pursuant to the ABCL, and (D) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings, as may be required under applicable federal and state securities Laws, neither the Company nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement, or (y) the consummation of the Contemplated Transactions, which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially delay the ability of the Company to consummate the Contemplated Transactions. The Company Board has taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in the ABCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement, the Company Stockholder Support Agreements, the Company Lock-Up Agreements and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Stockholder Support Agreements, the Company Lock-Up Agreements or any of the Contemplated Transactions.

 

2.6 Capitalization.

 

(a) The authorized Company Capital Stock as of the date of this Agreement consists of (i) 15,000,000 shares of Company Common Stock, par value $0.01 per share, of which 2,234,100 shares are issued and outstanding as of the date of this Agreement, and (ii) 10,000,000 shares of preferred stock, par value $0.01 per share (the “Company Preferred Stock”), 400,000 shares of which have been designated Series A Preferred Stock (the “Series A Preferred Stock”), all of which have been issued and are outstanding as of the date of this Agreement, 300,000 shares of which have been designated Series A-1 Preferred Stock (the “Series A-1 Preferred Stock”), all of which have been issued and are outstanding as of the date of this Agreement, 1,122,077 shares of which have been designated Series A-2 Preferred Stock (the “Series A-2 Preferred Stock”), 1,117,013 shares of which have been issued and are outstanding on the date of this Agreement, 499,200 shares of which have been designated Series A-3 Preferred Stock (the “Series A-3 Preferred Stock”), all of which have been issued and are outstanding on the date of this Agreement, 718,997 shares of which have been designated Series A-4 Preferred Stock (the “Series A-4 Preferred Stock”), all of which have been issued and are outstanding on the date of this Agreement, 4,620,000 shares of which have been designated Series A-5 Preferred Stock (the “Series A-5 Preferred Stock”), 484,918 shares of which have been issued and are outstanding on the date of this Agreement, and the balance is available for designation by the Company Board. Section 2.6(a) of the Company Disclosure Schedule lists, as of the date of this Agreement (A) each record holder of issued and outstanding Company Capital Stock and the number and type of shares of Company Capital Stock held by such holder; (B)(1) each holder of issued and outstanding Company Warrants, (2) the number and type of shares subject to each Company Warrant, (3) the exercise price of each Company Warrant and (4) the termination date of each Company Warrant; and (C)(1) each holder of issued and outstanding Company Notes, (2) the number and type of shares subject to each Company Note, (3) the conversion triggers for each Company Note and (4) the maturity date of each Company Note.

 

A-11
 

 

(b) All of the outstanding shares of Company Common Stock and Company Preferred Stock have been duly authorized and validly issued, and are fully paid and nonassessable. Except as set forth in the Investor Agreements or Section 2.6(b) of the Company Disclosure Schedule, none of the outstanding shares of Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein and in the Investor Agreements, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Company Capital Stock. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Company Capital Stock or other securities. Section 2.6(b) of the Company Disclosure Schedule accurately and completely lists all repurchase rights held by the Company with respect to shares of Company Capital Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.

 

(c) Except for (i) the Serina Therapeutics, Inc. 2017 Stock Option Plan, as amended (the “Company Incentive Plan”), (ii) the Company Warrants as set forth in Section 2.6(a) of the Company Disclosure Schedule, and (iii) the Company Notes as set forth in Section 2.6(a) of the Company Disclosure Schedule, the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As of the date of this Agreement, the Company has reserved 2,100,000 shares of Company Common Stock for issuance under the Company Incentive Plan, the Company has granted Company Options for 2,086,450 shares of Company Common Stock, of which 1,990,150 Company Options are fully vested but have not yet been exercised, and 20,550 shares of Company Common Stock remain available for future issuance of Company Options pursuant to the Company Incentive Plan. Section 2.6(c) of the Company Disclosure Schedule sets forth the following information with respect to each Company Option outstanding as of the date of this Agreement: (i) the name of the optionee; (ii) the number of shares of Company Common Stock subject to the Company Option at the time of grant; (iii) the number of shares of Company Common Stock subject to the Company Option as of the date of this Agreement; (iv) the exercise price of the Company Option; (v) the date on which the Company Option was granted; (vi) the applicable vesting schedule, including the number of vested and unvested Company Options as of the date of this Agreement; (vii) the date on which the Company Option expires; and (viii) whether the Company Option is intended to constitute an “incentive stock option” (as defined in the Code) or a non-qualified stock option. The Company has made available to Parent an accurate and complete copy of the Company Incentive Plan and all stock option agreements evidencing outstanding options granted thereunder. Section 2.6(c) of the Company Disclosure Schedule sets forth a list of Company Options that have accelerated vesting in connection with the closing of the Contemplated Transactions.

 

A-12
 

 

(d) Except for Company Warrants as set forth in Section 2.6(a) of the Company Disclosure Schedule, Company Notes as set forth in Section 2.6(a) of the Company Disclosure Schedule, and the Company Options set forth in Section 2.6(c) of the Company Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of the Company or any of its Subsidiaries; (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company or any of its Subsidiaries; or (iii) condition or circumstance that could be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company or any of its Subsidiaries. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company or any of its Subsidiaries.

 

(e) All outstanding shares of Company Common Stock, Company Preferred Stock, Company Options, Company Warrants, and Company Notes and other securities of the Company have been issued and granted in material compliance with (i) all applicable securities Laws and other applicable Laws, and (ii) all requirements set forth in applicable Contracts.

 

2.7 Financial Statements.

 

(a) Section 2.7(a) of the Company Disclosure Schedules includes true and complete copies of (i) the Company’s audited consolidated balance sheets at December 31, 2022, 2021, and 2020, together with related audited consolidated statements of operations, preferred stock and stockholders’ deficit and cash flows, and notes thereto, of the Company for the fiscal years then ended and (ii) the Company Unaudited Interim Balance Sheet, together with the unaudited consolidated statements of operations, preferred stock and stockholders’ deficit and cash flows of the Company for the period reflected in the Company Unaudited Interim Balance Sheet (collectively, the “Company Financials”). The Company Financials were prepared in accordance with GAAP applied on a consistent basis unless otherwise noted therein throughout the periods covered thereby (except as may be indicated in the notes to such Company Financials and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments, none of which are reasonably expected to be material in amount) and fairly present, in all material respects, the financial position and operating results of the Company and its consolidated Subsidiaries as of the dates and for the periods indicated therein.

 

A-13
 

 

(b) The Company and each of its Subsidiaries maintains accurate books and records reflecting their assets and liabilities and maintains a system of internal accounting controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of the financial statements in conformity with GAAP and to maintain accountability of the Company’s and its Subsidiaries’ assets; (iii) access to the Company’s and its Subsidiaries’ assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for the Company’s and its Subsidiaries’ assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences; and (v) accounts, notes and other payables are recorded accurately, and proper and adequate procedures are implemented to effect the collection or payment thereof on a current and timely basis. The Company and each of its Subsidiaries maintain internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

 

(c) Section 2.7(c) of the Company Disclosure Schedule lists, and the Company has delivered to Parent accurate and complete copies of the documentation creating or governing, all securitization transactions and “off-balance sheet arrangements” (as described in Instruction 8 to Item 303(b) of Regulation S-K as promulgated under the Securities Act) effected by the Company or any of its Subsidiaries since January 1, 2020.

 

(d) Since January 1, 2020, there have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof. Except as set forth in Section 2.7(d) of the Company Disclosure Schedule, since January 1, 2020, neither the Company nor its independent auditors have identified (i) any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company and its Subsidiaries, (ii) any fraud, whether or not material, that involves the Company, any of its Subsidiaries, the Company’s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company and its Subsidiaries or (iii) any claim or allegation regarding any of the foregoing.

 

2.8 Absence of Changes. Except as set forth in Section 2.8 of the Company Disclosure Schedule and except for reasonable and good faith actions or omissions taken to comply with applicable Law or guidance by a Governmental Body in connection with the COVID-19 pandemic, between the date of the Company Unaudited Interim Balance Sheet and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto, including the Contemplated Transactions) and there has not been any (a) Company Material Adverse Effect or (b) action, event or occurrence that would have required the consent of Parent pursuant to Section 4.2(b) of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.

 

A-14
 

 

2.9 Absence of Undisclosed Liabilities. As of the date of this Agreement, neither the Company nor any of its Subsidiaries have any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise (whether or not required to be reflected in the financial statements in accordance with GAAP) (each a “Liability”), individually or in the aggregate, of a type required to be recorded or reflected on a balance sheet or disclosed in the footnotes thereto under GAAP except for: (a) Liabilities disclosed, reflected or reserved against in the Company Unaudited Interim Balance Sheet; (b) normal and recurring current Liabilities that have been incurred by the Company or its Subsidiaries since the date of the Company Unaudited Interim Balance Sheet in the Ordinary Course of Business and which are not in excess of $100,000 in the aggregate; (c) Liabilities for performance of obligations of the Company or any of its Subsidiaries under Company Material Contracts which have not resulted from a breach of such Company Material Contracts, breach of warranty, tort, infringement or violation of Law; (d) Liabilities incurred in connection with the Contemplated Transactions; and (e) Liabilities described in Section 2.9 of the Company Disclosure Schedule.

 

2.10 Title to Assets. The Company and each of its Subsidiaries owns, and have good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets reflected on the Company Unaudited Interim Balance Sheet; and (b) all other tangible assets reflected in the books and records of the Company or any of its Subsidiaries as being owned by the Company or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased by the Company or its applicable Subsidiary free and clear of any Encumbrances, other than Permitted Encumbrances.

 

2.11 Real Property; Leasehold. Neither the Company nor any of its Subsidiaries owns or has ever owned any real property. The Company has made available to Parent an accurate and complete list of all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company or any of its Subsidiaries, and the Company has made available to Parent copies of all leases under which any such real property is possessed (the “Company Real Estate Leases”), each of which is in full force and effect, with no existing material default thereunder. The Company’s or its applicable Subsidiary’s use and operation of each such leased property conforms to all applicable Laws in all material respects, and the Company or its applicable Subsidiary has exclusive possession of each such leased property and has not granted any occupancy rights to tenants or licensees with respect to such leased property. In addition, each such leased property is free and clear of all Encumbrances other than Permitted Encumbrances.

 

A-15
 

 

2.12 Intellectual Property.

 

(a) Section 2.12(a) of the Company Disclosure Schedule accurately identifies (i) the name of the applicant/registrant, (ii) the jurisdiction of application/registration, (iii) the application or registration number and (iv) any other co-owners, for each item of Registered IP owned in whole or in part by the Company or its Subsidiaries (the “Company Owned Registered IP”). Each of the patents and patent applications included in the Company Owned Registered IP properly identifies by name each and every inventor of the inventions claimed therein as determined in accordance with applicable Laws of the United States. To the Company’s Knowledge, (A) the Company Owned Registered IP is valid, enforceable and subsisting, (B) none of the Company Owned Registered IP has been misused, withdrawn, canceled or abandoned, and (C) all application, registration, issuance, renewal and maintenance fees for the Company Owned Registered IP having a final due date on or before the date of this Agreement have been timely paid in full. To the Company’s Knowledge, with respect to each item of Company Owned Registered IP and each patent application from which such Company Owned Registered IP claims priority, all statements made and information presented to the applicable patent office by or on behalf of the Company or its Subsidiaries or any inventor thereof, or their respective patent counsel, during the prosecution thereof are accurate and complete and comply with 37 CFR 1.56. As of the date of this Agreement, no interference, opposition, reissue, reexamination or other proceeding of any nature (other than initial examination proceedings) is pending or, to the Company’s Knowledge, threatened in writing, in which the scope, validity, enforceability or ownership of any Company Owned Registered IP is being or has been contested or challenged.

 

(b) The Company or its Subsidiaries solely owns all right, title and interest in and to all Company IP (other than as disclosed in Section 2.12(a) of the Company Disclosure Schedule and except for any failure to own or have such right to use, or have the right to bring actions that would not reasonably be expected to have a Company Material Adverse Effect), free and clear of all Encumbrances other than Permitted Encumbrances and, to the Company’s Knowledge, has the right, pursuant to a Company In-bound License to use all other material Intellectual Property Rights used by the Company or its Subsidiaries in their respective businesses as currently conducted or as proposed to be conducted as of the date of this Agreement. The Company IP and the Intellectual Property Rights licensed to the Company or its Subsidiaries pursuant to a Company In-bound License (the “Company In-Licensed IP”) are all the Intellectual Property Rights necessary to operate the business of the Company and its Subsidiaries as currently conducted and to the Company’s Knowledge, as proposed to be conducted, as of the date of this Agreement. No Company Associate owns or has any claim, right (whether or not currently exercisable) or interest to or in any Company IP, and each Company Associate involved in the creation or development of any material Company IP, pursuant to such Company Associate’s activities on behalf of the Company or its Subsidiaries, has signed a valid, enforceable written agreement containing a present assignment of all of such Company Associate’s rights in such Company IP to the Company or its Subsidiaries (without further payment being owed to any such Company Associate and without any restrictions or obligations on the Company’s or its Subsidiaries’ ownership or use thereof) and confidentiality provisions protecting the Company IP, which, to the Company’s Knowledge, has not been breached by such Company Associate. Without limiting the foregoing, the Company and its Subsidiaries have taken commercially reasonable steps to protect, maintain and enforce all Company IP, and as required, Company In-Licensed IP, including the secrecy, confidentiality and value of trade secrets and other confidential information therein (as applicable), and to the Company’s Knowledge there have been no unauthorized disclosures by Company or its Subsidiaries of any confidential information or trade secrets associated with Company IP or Company In-Licensed IP. Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will conflict with, alter or impair any of the Company’s or its Subsidiaries’ or, following the Closing, Parent’s, rights in or to any Company IP or Company In-Licensed IP or cause any payments of any kind to be due or payable to any Person.

 

A-16
 

 

(c) Other than the Company IP identified as co-owned in Section 2.12(a) of the Company Disclosure Schedule, to the Company’s Knowledge, no funding, facilities or personnel of any Governmental Body or any university, college, research institute or other educational or academic institution has been used, in whole or in part, to create any Company IP or any Company In-Licensed IP, except for any such funding or use of facilities or personnel that does not result in such Governmental Body or institution obtaining ownership or other rights (including any “march in” rights or a right to direct the location of manufacturing of products) to such Company IP or the right to receive royalties or other consideration for the practice of such Company IP.

 

(d) Section 2.12(d) of the Company Disclosure Schedule sets forth each license agreement pursuant to which the Company or any of its Subsidiaries (i) is granted a license under any Intellectual Property Right owned by any third party that is used by the Company or its Subsidiaries in its business as currently conducted or, to the Company’s Knowledge, as proposed to be conducted as of the date of this Agreement (each a “Company In-bound License”) or (ii) grants to any third party a license, option, covenant not to sue or other right under any Company IP or any Company In-Licensed IP (each a “Company Out-bound License”) (provided, that Company In-bound Licenses shall not include material transfer agreements, clinical trial agreements, services agreements, non-disclosure agreements, commercially available Software-as-a-Service offerings, off-the-shelf software licenses or generally available patent license agreements, in each case entered into in the Ordinary Course of Business on a non-exclusive basis and that do not grant any commercial rights to any products or services of the Company or its Subsidiaries; and Company Out-bound Licenses shall not include material transfer agreements, clinical trial agreements, services agreements, non-disclosure agreements, or non-exclusive outbound licenses, in each case entered into in the Ordinary Course of Business on a non-exclusive basis and that do not grant any commercial rights to any products or services of the Company or its Subsidiaries). Neither the Company nor its Subsidiaries nor, to the Company’s Knowledge, any other party to any Company In-bound License or Company Out-bound License has breached or is in breach of any of its obligations under any Company In-bound License or Company Out-bound License.

 

(e) To the Company’s Knowledge: (i) the operation of the businesses of the Company and its Subsidiaries as currently conducted or as proposed to be conducted as of the date of this Agreement does not infringe or misappropriate or otherwise violate any Intellectual Property Right owned by any other Person; and (ii) no other Person is infringing, misappropriating or otherwise violating any Company IP or any Intellectual Property rights exclusively licensed to the Company or its Subsidiaries. As of the date of this Agreement, no Legal Proceeding is pending (or, to the Company’s Knowledge, is threatened in writing) (A) against the Company or its Subsidiaries alleging that the operation of the businesses of the Company or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights of another Person or (B) by the Company or its Subsidiaries alleging that another Person has infringed, misappropriated or otherwise violated any of the Company IP or any Company In-Licensed IP. Since January 1, 2020, neither the Company nor any of its Subsidiaries have received any written notice or other written communication alleging that the operation of the business of the Company or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another Person.

 

A-17
 

 

(f) None of the Company IP or, to the Company’s Knowledge, any Company In-Licensed IP (i) is subject to any pending or outstanding injunction, directive, order, decree, settlement, judgment or other disposition of dispute that adversely and materially restricts the use, transfer, registration or licensing by the Company or its Subsidiaries or (ii) would reasonably be expected to adversely affect the validity, scope, use, registrability, or enforceability thereof.

 

(g) To the Company’s Knowledge, the Company, its Subsidiaries and the operation of the Company’s and its Subsidiaries’ business are in substantial compliance with all applicable Laws pertaining to data privacy and data security of any personally identifiable information and sensitive business information (collectively, “Sensitive Data”) except to the extent that such noncompliance has not and would not reasonably be expected to have a Company Material Adverse Effect. To the Company’s Knowledge, since January 1, 2020, there have been (i) no material losses or thefts of data or security breaches relating to Sensitive Data used in the business of the Company or its Subsidiaries, (ii) no violations of any security policy of the Company or its Subsidiaries regarding any such Sensitive Data, (iii) no unauthorized access or unauthorized use of any Sensitive Data used in the business of the Company or its Subsidiaries and (iv) no unintended or improper disclosure of any personally identifiable information in the possession, custody or control of the Company or its Subsidiaries, or a contractor or agent acting on behalf of the Company or its Subsidiaries, in each case of (i) through (iv), except as would not reasonably be expected to, individually or in the aggregate, have a Company Material Adverse Effect.

 

(h) None of the Company or its Subsidiaries are now nor has ever been a member or promoter of, or a contributor to, any industry standards body or any similar organization that would reasonably be expected to require or obligate any of the Company or its Subsidiaries to grant or offer to any other Person any license or right to any Company IP or Company In-Licensed IP.

 

2.13 Agreements, Contracts and Commitments.

 

(a) Section 2.13(a) of the Company Disclosure Schedule lists the following Company Contracts in effect as of the date of this Agreement (other than any Company Benefit Plans) (each, a “Company Material Contract” and collectively, the “Company Material Contracts”):

 

(i) each Company Contract that would be a material contract as defined in Item 601(b)(10) of Regulation S-K as promulgated under the Securities Act (assuming the Company was subject to the public reporting requirements of the Exchange Act);

 

(ii) each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;

 

A-18
 

 

(iii) each Company Contract containing (A) any covenant limiting the freedom of the Company, its Subsidiaries or the Surviving Corporation to engage in any line of business or compete with any Person, (B) any “most-favored nations” pricing provisions or marketing or distribution rights related to any products or territory, (C) any exclusivity provision, (D) any agreement to purchase a minimum quantity of goods or services, or (E) any material non-solicitation provisions applicable to the Company or any of its Subsidiaries;

 

(iv) each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $50,000 pursuant to its express terms and not cancelable without penalty;

 

(v) each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity;

 

(vi) each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $50,000 or creating any material Encumbrances with respect to any assets of the Company or any of its Subsidiaries or any loans or debt obligations with officers or directors of the Company or any of its Subsidiaries;

 

(vii) each Company Contract requiring payment by or to the Company or any of its Subsidiaries after the date of this Agreement in excess of $300,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions); (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company or any of its Subsidiaries; (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, collaboration, development or other agreement currently in force under which the Company or any of its Subsidiaries have continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company or any of its Subsidiaries have continuing obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by the Company or any of its Subsidiaries; or (D) any Contract to license any third party to manufacture or produce any product, service or technology of the Company or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of the Company or any of its Subsidiaries, in each case, except for Contracts entered into in the Ordinary Course of Business;

 

(viii) each Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions;

 

(ix) each Company Real Estate Lease;

 

(x) each Company Contract with any Governmental Body;

 

A-19
 

 

(xi) each Company Out-bound License and Company In-bound License;

 

(xii) each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company or any of its Subsidiaries; or

 

(xiii) any other Company Contract that is not terminable at will (with no penalty or payment) by the Company or its Subsidiaries, as applicable, and (A) which involves payment or receipt by the Company or its Subsidiaries after the date of this Agreement under any such agreement, contract or commitment of more than $300,000 in the aggregate, or (B) that is material to the business or operations of the Company and its Subsidiaries, taken as a whole.

 

(b) The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto. Except as set forth in Section 2.13(b) of the Company Disclosure Schedule, there are no Company Material Contracts that are not in written form. As of the date of this Agreement, none of the Company, any of its Subsidiaries, nor, to the Company’s Knowledge, any other party to a Company Material Contract, has breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of, or Laws applicable to, any Company Material Contract in such manner as would permit any other party to cancel or terminate any such Company Material Contract, or would permit any other party to seek damages or pursue other legal remedies which would reasonably be expected to be material to the Company or its business or operations. As to the Company and its Subsidiaries, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material amount paid or payable to the Company or any of its Subsidiaries under any Company Material Contract or any other material term or provision of any Company Material Contract.

 

2.14 Compliance; Permits; Restrictions.

 

(a) The Company and each of its Subsidiaries are, and since January 1, 2020, have been, in compliance in all material respects with all applicable Laws, including the Federal Food, Drug, and Cosmetic Act (“FDCA”), the U.S. Food and Drug Administration (“FDA”) regulations adopted thereunder, the Public Health Service Act and any other similar Law administered or promulgated by the FDA or other comparable Governmental Body responsible for the regulation of the development, clinical testing, manufacturing, sale, marketing, distribution and importation or exportation of drug and biopharmaceutical products (each, a “Drug Regulatory Agency”), except for any noncompliance, either individually or in the aggregate, which would not be material to the Company. No investigation, claim, suit, proceeding, audit or other action by any Governmental Body is pending or, to the Company’s Knowledge, threatened against the Company or any of its Subsidiaries. There is no agreement, judgment, injunction, order or decree by or with a Drug Regulatory Agency binding upon the Company or any of its Subsidiaries which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of material property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on the Company’s ability to comply with or perform any covenant or obligation under this Agreement, or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.

 

A-20
 

 

(b) The Company and its Subsidiaries hold all required Governmental Authorizations which are material to the operation of the business of the Company and its Subsidiaries as currently conducted (the “Company Permits”). Section 2.14(b) of the Company Disclosure Schedule identifies each Company Permit. The Company and its Subsidiaries hold all right, title and interest in and to all Company Permits free and clear of any Encumbrance. The Company and each of its Subsidiaries are in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Company’s Knowledge, threatened, which seeks to revoke, limit, suspend, or materially modify any Company Permit. The rights and benefits of each Company Permit will be available to the Surviving Corporation or its Subsidiaries, as applicable, immediately after the Effective Time on terms substantially identical to those enjoyed by the Company and its Subsidiaries as of the date of this Agreement and immediately prior to the Effective Time.

 

(c) There are no proceedings pending or, to the Company’s Knowledge, threatened with respect to an alleged material violation by the Company or any of its Subsidiaries of the FDCA, FDA regulations adopted thereunder, the Controlled Substances Act, the Public Health Service Act or any other similar Law administered or promulgated by any Drug Regulatory Agency.

 

(d) The Company is not currently conducting or addressing, and to the Company’s Knowledge there is no basis to expect that it will be required to conduct or address, any corrective actions, including, without limitation, product recalls or clinical holds.

 

(e) All clinical, pre-clinical and other studies and tests conducted by or, to the Company’s Knowledge, on behalf of, or sponsored by, the Company or any of its Subsidiaries, or in which the Company or any of its Subsidiaries or their respective current products or product candidates have participated, were and, if still pending, are being conducted in all material respects in accordance with standard medical and scientific research procedures and in compliance in all material respects with the applicable regulations of any applicable Drug Regulatory Agency and other applicable Law, including 21 C.F.R. Parts 50, 54, 56, 58 and 312. Since January 1, 2020, neither the Company nor any of its Subsidiaries have received any notices, correspondence, or other communications from any Drug Regulatory Agency requiring, or, to the Company’s Knowledge, threatening to initiate, the termination or suspension of any clinical studies conducted by or on behalf of, or sponsored by, the Company or any of its Subsidiaries or in which the Company or any of its Subsidiaries or their respective current products or product candidates have participated.

 

A-21
 

 

(f) Neither the Company nor any of its Subsidiaries are the subject of any pending or, to the Company’s Knowledge, threatened investigation in respect of its business or products by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto. To the Company’s Knowledge, neither the Company nor any of its Subsidiaries have committed any acts, made any statement, or failed to make any statement, in each case in respect of its business or products that would violate the FDA’s “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy, and any amendments thereto. None of the Company, any of its Subsidiaries or any of their respective officers, employees or agents has been convicted of any crime or engaged in any conduct that could result in a debarment or exclusion (i) under 21 U.S.C. Section 335a or (ii) any similar applicable Law. To the Company’s Knowledge, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against the Company, any of its Subsidiaries or any of their respective officers, employees or agents.

 

2.15 Legal Proceedings; Orders.

 

(a) As of the date of this Agreement, there is no pending Legal Proceeding and, to the Company’s Knowledge, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves (A) the Company, (B) any of its Subsidiaries, (C) any director or officer of the Company (in his or her capacity as such) or (D) any of the material assets owned or used by the Company or its Subsidiaries; or (ii) that challenges, or that would reasonably be expected to have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.

 

(b) Except as set forth in Section 2.15(b) of the Company Disclosure Schedule, since January 1, 2020, no Legal Proceeding has been pending against the Company or any of its Subsidiaries that resulted in material liability to the Company or any of its Subsidiaries.

 

(c) There is no order, writ, injunction, judgment or decree to which the Company or any of its Subsidiaries, or any of the material assets owned or used by the Company or any of its Subsidiaries, is subject. To the Company’s Knowledge, no officer or other employee of the Company or any of its Subsidiaries are subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of the Company or any of its Subsidiaries or to any material assets owned or used by the Company or any of its Subsidiaries.

 

2.16 Tax Matters.

 

(a) The Company and each of its Subsidiaries have timely filed all income Tax Returns and other material Tax Returns that they were required to file under applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in compliance with all applicable Law. No written claim has ever been made by any Governmental Body in any jurisdiction where the Company or any of its Subsidiaries does not file a particular Tax Return or pay a particular Tax that the Company or such Subsidiary is subject to taxation by that jurisdiction.

 

A-22
 

 

(b) All income and other material Taxes due and owing by the Company or any of its Subsidiaries (whether or not shown on any Tax Return) have been fully paid. The unpaid Taxes of the Company and its Subsidiaries did not, as of the date of the Company Unaudited Interim Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax items) set forth on the face of the Company Unaudited Interim Balance Sheet. Since the date of the Company Unaudited Interim Balance Sheet, neither the Company nor any of its Subsidiaries have incurred any material Liability for Taxes outside the Ordinary Course of Business.

 

(c) All Taxes that the Company or any of its Subsidiaries are or were required by Law to withhold or collect have been duly and timely withheld or collected in all material respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers or other third parties and, have been timely paid to the proper Governmental Body or other Person or properly set aside in accounts for this purpose. The Company and its Subsidiaries have complied in all material respects with applicable Laws relating to information reporting and record retention (including to the extent necessary to claim any exemption from sales Tax collection and maintaining adequate and current resale certificates to support any such claimed exemptions).

 

(d) There are no Encumbrances for material Taxes (other than Taxes not yet due and payable) upon any of the assets of the Company or any of its Subsidiaries.

 

(e) No deficiencies for income or other material Taxes with respect to the Company or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Body in writing. There are no pending or ongoing, and, to the Company’s Knowledge, threatened audits, assessments or other actions for or relating to any liability in respect of a material amount of Taxes of the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries (or any of their predecessors) have waived any statute of limitations in respect of any income or other material Taxes or agreed to any extension of time with respect to any income or other material Tax assessment or deficiency.

 

(f) Neither the Company nor any of its Subsidiaries have been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code.

 

(g) Neither the Company nor any of its Subsidiaries are a party to any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement, other than customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes.

 

A-23
 

 

(h) Neither the Company nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of accounting for Tax purposes made on or prior to the Closing Date; (ii) use of an improper method of accounting for a Tax period ending on or prior to the Closing Date; (iii) “closing agreement” as described in Section 7121 of the Code (or any similar provision of state, local or foreign Law) executed on or prior to the Closing Date; (iv) intercompany transaction or excess loss account described in Treasury Regulations under Section 1502 of the Code (or any similar provision of state, local or foreign Law) entered into on or prior to the Closing Date; (v) installment sale or open transaction disposition made on or prior to the Closing Date; (vi) prepaid amount received or deferred revenue accrued on or prior to the Closing Date; (vii) application of Section 367(d) of the Code to any transfer of intangible property on or prior to the Closing Date; (viii) application of Sections 951 or 951A of the Code (or any similar provision of state, local or foreign Law) to any income received or accrued on or prior to the Closing Date; or (ix) election under Section 108(i) of the Code (or any similar provision of state, local or foreign Law) made on or prior to the Closing Date. The Company has not made any election under Section 965(h) of the Code.

 

(i) Neither the Company nor any of its Subsidiaries have ever been (i) a member of a consolidated, combined or unitary Tax group (other than such a group the common parent of which is the Company) or (ii) a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. Neither the Company nor any of its Subsidiaries have any Liability for any material amount of Taxes of any Person (other than the Company and any of its Subsidiaries) under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local, or foreign Law), by contract, as a transferee or successor, or otherwise.

 

(j) Neither the Company nor any of its Subsidiaries (i) are a “controlled foreign corporation” as defined in Section 957 of the Code, (ii) is a “passive foreign investment company” within the meaning of Section 1297 of the Code, or (iii) has ever had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed place of business in a country other than the country in which it is organized.

 

(k) Neither the Company nor any of its Subsidiaries have participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a “reportable transaction” that is required to be reported to the IRS pursuant to Section 6011 of the Code and applicable Treasury Regulations thereunder.

 

(l) Neither the Company nor any of its Subsidiaries have taken any action, nor to the Company’s Knowledge is there any fact, that would reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment.

 

(m) Neither the Company nor any of its Subsidiaries have availed itself of any Tax relief pursuant to any Pandemic Response Laws that could reasonably be expected to materially impact the Tax payment and/or Tax reporting obligations of Parent and its Affiliates (including the Company and its Subsidiaries) after the Closing Date.

 

A-24
 

 

For purposes of this Section 2.16, each reference to the Company or any of its Subsidiaries shall be deemed to include any Person that was liquidated into, merged with, or otherwise a predecessor to, the Company or any of its Subsidiaries.

 

2.17 Employee and Labor Matters; Benefit Plans.

 

(a) Section 2.17(a) of the Company Disclosure Schedule lists, as of the date of this Agreement, all material Company Benefit Plans. “Company Benefit Plan” means each (i) “employee benefit plan,” as defined in Section 3(3) of ERISA, whether or not subject to ERISA, and (ii) any other pension, retirement, deferred compensation, excess benefit, profit-sharing, bonus, incentive, equity or equity-based, phantom equity, employment (other than at-will employment offer letters on Company’s standard form that may be terminated without notice and with no penalty to Company or any of its Subsidiaries and other than individual Company Options, or other compensatory equity award grants made pursuant to Company’s standard forms, in which case only representative standard forms of such agreements shall be scheduled), consulting, severance, change-of-control, stay or retention, medical, dental, vision, health, prescription drug, life, disability, cafeteria plan, flexible spending account, employee assistance program, travel assistance, accidental death & dismemberment, group insurance, retiree medical or life insurance, paid-time-off, holiday, welfare or fringe benefit plan, program, agreement, contract, or arrangement (other than regular salary or wages) (whether written or unwritten, qualified or nonqualified, funded or unfunded and including any that have been frozen), in each case, maintained, contributed to, or required to be contributed to, by the Company or any of its Subsidiaries for the benefit of any current or former employee, director, officer, or independent contractor of the Company or any of its Subsidiaries or under which the Company or any of its Subsidiaries have or could have any actual or contingent liability (including, without limitation, as to the result of it being treated as a single employer under Section 414 of the Code with any other person).

 

(b) As applicable with respect to each material Company Benefit Plan, the Company has made available to Parent, true and complete copies of (i) each material Company Benefit Plan, including all amendments thereto, and in the case of an unwritten material Company Benefit Plan, a written description thereof, (ii) all current trust documents, investment management contracts, custodial agreements, administrative services agreements, insurance, and annuity contracts relating thereto, (iii) the current summary plan description and each summary of material modifications thereto, (iv) the three most recently filed annual reports on Form 5500 and all schedules thereto, (v) the most recent IRS determination or opinion letter, (vi) the three most recent nondiscrimination testing reports, actuarial reports and financial statements, (vii) all notices and filings concerning IRS, United States Department of Labor or other Governmental Body audits or investigations since January 1, 2020, (viii) each written report constituting a valuation of Company Capital Stock for purposes of Sections 409A or 422 of the Code, whether prepared internally by the Company or by an outside, third-party valuation firm, and (ix) all material written materials provided to employees or participants relating to the amendment, termination, establishment, or increase or decrease in benefits under any Company Benefit Plan.

 

A-25
 

 

(c) Each Company Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and any related documents or agreements and the applicable provisions of ERISA, the Code and all other applicable Laws.

 

(d) The Company Benefit Plans that are “employee pension benefit plans” within the meaning of Section 3(2) of ERISA and that are intended to meet the qualification requirements of Section 401(a) of the Code have received determination or opinion letters from the IRS on which they may currently rely to the effect that such plans are qualified under Section 401(a) of the Code, and, to the Company’s Knowledge, nothing has occurred that would reasonably be expected to materially adversely affect the qualification of such Company Benefit Plan.

 

(e) None of the Company or any Company ERISA Affiliate sponsors, maintains, contributes to, is required to contribute to, or has any actual or contingent liability with respect to, or has within the past six (6) years sponsored, maintained, contributed to, or been required to contribute to, (i) any “employee pension benefit plan” (within the meaning of Section 3(2) of ERISA) that is subject to Title IV or Section 302 of ERISA or Section 412 of the Code, (ii) any “multiemployer plan” (within the meaning of Section 3(37) of ERISA), (iii) any “multiple employer plan” (within the meaning of Section 413 of the Code), or (iv) any “multiple employer welfare arrangement” (within the meaning of Section 3(40) of ERISA), and none of the Company or any Company ERISA Affiliate has, within the preceding six (6) years, incurred a complete or partial withdrawal from any “multiemployer plan” or otherwise incurred any liability under Section 4202 of ERISA.

 

(f) There are no pending audits or investigations by any Governmental Body involving any Company Benefit Plan, and no pending or, to the Company’s Knowledge, threatened claims (except for individual claims for benefits payable in the normal operation of the Company Benefit Plans), suits, or proceedings involving any Company Benefit Plan. All contributions and premium payments required to have been made under any of the Company Benefit Plans or by applicable Law have been timely made, and neither the Company nor any of its Subsidiaries have any liability for any unpaid contributions with respect to any Company Benefit Plan (other than contributions that are accrued in the Ordinary Course of Business).

 

(g) Neither the Company nor any of its Subsidiaries, nor, to the Company’s Knowledge, any fiduciary, trustee, or administrator of any Company Benefit Plan has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Company Benefit Plan that would subject any such Company Benefit Plan, the Company or any of its Subsidiaries or Parent to a Tax, penalty, or liability for a “prohibited transaction” under Section 406 of ERISA or Section 4975 of the Code.

 

(h) No Company Benefit Plan provides (i) death, medical, dental, vision, life insurance, or other welfare benefits beyond termination of service or retirement, other than coverage mandated by Law (including COBRA, for which the covered individual pays the full cost of coverage), or (ii) death or retirement benefits under a Company Benefit Plan qualified under Section 401(a) of the Code, and neither the Company nor any of its Subsidiaries have made a written or oral representation promising the same.

 

A-26
 

 

(i) Except as set forth in Section 2.17(i) of the Company Disclosure Schedules, neither the execution of this Agreement, nor the consummation of the Contemplated Transactions will either alone or in connection with any other event(s) (i) result in any payment becoming due to any current or former employee, director, officer, independent contractor or other service provider of the Company or any of its Subsidiaries, (ii) increase any amount of compensation or benefits otherwise payable to any current or former employee, director, officer, independent contractor or other service provider of the Company or any of its Subsidiaries, (iii) result in the acceleration of the time of payment, funding or vesting of any benefits under any Company Benefit Plan, (iv) require any contribution or payment to fund any obligation under any Company Benefit Plan or (v) limit the right to merge, amend or terminate any Company Benefit Plan.

 

(j) Neither the execution of this Agreement, nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) will result in the receipt or retention by any person who is a “disqualified individual” (within the meaning of Section 280G of the Code) with respect to the Company and its Subsidiaries of any payment or benefit that is or could be characterized as a “parachute payment” (within the meaning of Section 280G of the Code), determined without regard to the application of Section 280G(b)(5) of the Code.

 

(k) Each Company Benefit Plan providing for deferred compensation that constitutes a “nonqualified deferred compensation plan” (as defined in Section 409A(d)(1) of the Code and the regulations promulgated thereunder) is, and has been, established, administered and maintained in all material respects in compliance with the requirements of Section 409A of the Code and the regulations promulgated thereunder.

 

(l) No Person has any “gross-up” agreements with the Company or any of its Subsidiaries or other assurance of reimbursement or compensation by the Company or any of its Subsidiaries for any Taxes imposed under Section 409A or Section 4999 of the Code.

 

(m) The Company does not have any Company Benefit Plan that is maintained for service providers located outside of the United States.

 

(n) Neither the Company nor any of its Subsidiaries are a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union or labor organization representing any of its employees, and there is no labor union or labor organization representing or, to the Company’s Knowledge, purporting to represent or seeking to represent any employees of the Company or its Subsidiaries, including through the filing of a petition for representation election.

 

A-27
 

 

(o) The Company and each of its Subsidiaries is, and since January 1, 2020, has been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including, without limitation, worker classification, discrimination, wrongful termination, harassment and retaliation, equal employment opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health, wages (including overtime wages), unemployment and workers’ compensation, leaves of absence, and hours of work. Except as would not be reasonably likely to result in a material liability to the Company or any of its Subsidiaries, with respect to employees of the Company or any of its Subsidiaries, each of the Company and its Subsidiaries, since January 1, 2020: (i) has withheld and reported all amounts required by Law or by agreement to be withheld and reported with respect to wages, salaries, and other payments, benefits or compensation to employees, (ii) is not liable for any arrears of wages (including overtime wages), severance pay or any Taxes or penalties for failure to comply with any of the foregoing in any material respect, and (iii) is not liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Body with respect to unemployment compensation benefits, disability, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business or as required by Law). There are no actions, suits, claims, charges, demands, lawsuits, investigations, audits or administrative matters pending or, to the Company’s Knowledge, threatened or reasonably anticipated against the Company or any of its Subsidiaries relating to any current or former employee, applicant for employment, consultant, employment agreement or Company Benefit Plan (other than routine claims for benefits). All employees of the Company and its Subsidiaries are employed “at-will” and their employment can be terminated without advance notice or payment of severance.

 

(p) Except as would not be reasonably likely to result in a material liability to the Company or any of its Subsidiaries, with respect to each individual who currently renders services to the Company or any of its Subsidiaries, the Company and each of its Subsidiaries have accurately classified each such individual as an employee, independent contractor, or otherwise under all applicable Laws and, for each individual classified as an employee, the Company and each of its Subsidiaries have accurately classified him or her as overtime eligible or overtime ineligible under all applicable Laws. Neither the Company nor any of its Subsidiaries have any material liability with respect to any misclassification of: (a) any Person as an independent contractor rather than as an employee, (b) any employee leased from another employer, or (c) any employee currently or formerly classified as exempt from overtime wages.

 

(q) There is not and has not been since January 1, 2020, nor is there or has there been since January 1, 2020, any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or, to the Company’s Knowledge, any union organizing activity, against the Company or any of its Subsidiaries. No event has occurred, and, to the Company’s Knowledge, no condition or circumstance exists, that might directly or indirectly give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute.

 

A-28
 

 

2.18 Environmental Matters. The Company and each of its Subsidiaries are in compliance, and since January 1, 2020, have complied, with all applicable Environmental Laws, which compliance includes the possession by the Company and its Subsidiaries of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected to result in a Company Material Adverse Effect. Neither the Company nor any of its Subsidiaries have received since January 1, 2020, any written notice or other communication (in writing or otherwise), whether from a Governmental Body or other Person, that alleges that the Company or any of its Subsidiaries are not in compliance with or has liability pursuant to any Environmental Law and, to the Company’s Knowledge, there are no circumstances that would reasonably be expected to prevent or interfere with the Company’s or any of its Subsidiaries’ compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Company Material Adverse Effect. To the Company’s Knowledge, no current or (during the time a prior property was leased or controlled by the Company or any of its Subsidiaries) prior property leased or controlled by the Company or any of its Subsidiaries have had a release of or exposure to Hazardous Materials in material violation of or as would reasonably be expected to result in any material liability of the Company or any of its Subsidiaries pursuant to Environmental Law. No consent, approval or Governmental Authorization of or registration or filing with any Governmental Body is required by Environmental Laws in connection with the execution and delivery of this Agreement or the consummation of the Contemplated Transactions. Prior to the date of this Agreement, the Company has provided or otherwise made available to Parent true and correct copies of all material environmental reports, assessments, studies and audits in the possession or control of the Company or any of its Subsidiaries with respect to any property leased or controlled by the Company or any of its Subsidiaries or any business operated by them.

 

2.19 Insurance. The Company has delivered or made available to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company and each of its Subsidiaries, as of the date of this Agreement. Each of such insurance policies is in full force and effect and the Company and each of its Subsidiaries are in compliance in all material respects with the terms thereof. Other than customary end-of-policy notifications from insurance carriers, since January 1, 2020, neither the Company nor any of its Subsidiaries have received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy; or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. The Company and each of its Subsidiaries have provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against the Company or any of its Subsidiaries for which the Company or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company or any of its Subsidiaries of its intent to do so.

 

2.20 No Financial Advisors. Except as set forth in Section 2.20 of the Company Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder’s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company or any of its Subsidiaries.

 

A-29
 

 

2.21 Disclosure. The information supplied by or on behalf of the Company and each of its Subsidiaries for inclusion or incorporation by reference in the Registration Statement, or to be included or supplied by or on behalf of the Company and each of its Subsidiaries for inclusion in any filing pursuant to Rule 165 and Rule 425 under the Securities Act or Rule 14a-12 under the Exchange Act (each a “Regulation M-A Filing”), shall not at the time the Registration Statement or any such Regulation M-A Filing is filed with the SEC, at any time it is amended or supplemented or at the time the Registration Statement is declared effective by the SEC, as applicable, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material fact, or omit to state any material fact necessary in order to make the statements therein not false or misleading, or omit to state any material fact necessary to correct any statement therein that has become false or misleading. The information supplied by or on behalf of the Company and each of its Subsidiaries for inclusion or incorporation by reference in the Proxy Statement, which information shall be deemed to include all information about or related to the Company or any of its Subsidiaries and/or the Company Stockholder Matters, shall not, on the date the Proxy Statement is first mailed to Parent’s stockholders, or at the time of the Parent Stockholders’ Meeting or as of the Effective Time, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material fact, or omit to state any material fact necessary in order to make the statements made in the Proxy Statement not false or misleading, or omit to state any material fact necessary to correct any statement in any earlier communication with respect to the solicitation of proxies for the Parent Stockholders’ Meeting that has become false or misleading.

 

2.22 Transactions with Affiliates.

 

(a) Except as set forth in Section 2.22(a) of the Company Disclosure Schedule, there are no material transactions or relationships, since January 1, 2020, between, on one hand, the Company or any of its Subsidiaries and, on the other hand, any (i) executive officer or director of the Company or, to the Company’s Knowledge, any of its Subsidiaries or any of such executive officer’s or director’s immediate family members, (ii) owner of more than 5% of the voting power of the outstanding Company Capital Stock or (iii) to the Company’s Knowledge, any “related person” (within the meaning of Item 404 of Regulation S-K as promulgated under the Securities Act) of any such executive officer, director or stockholder (other than the Company or its Subsidiaries) in the case of each of (i), (ii) or (iii) that is of the type that would be required to be disclosed under Item 404 of Regulation S-K as promulgated under the Securities Act (assuming the Company was subject to the public reporting requirements of the Exchange Act).

 

(b) Section 2.22(b) of the Company Disclosure Schedule lists each stockholders’ agreement, voting agreement, registration rights agreement, co-sale agreement or other similar Contract between the Company and any holders of Company Capital Stock, including any such Contract granting any Person investor rights, rights of first refusal, rights of first offer, registration rights, director designation rights or similar rights (collectively, the “Investor Agreements”).

 

2.23 Anti-Bribery. None of the Company or any of its Subsidiaries or any of their respective directors, officers, employees or, to the Company’s Knowledge, agents or any other Person acting on their behalf has, directly or indirectly, made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of the Foreign Corrupt Practices Act of 1977, the UK Bribery Act of 2010 or any other anti-bribery or anti-corruption Law (collectively, the “Anti-Bribery Laws”). Neither the Company nor any of its Subsidiaries are or has been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws.

 

A-30
 

 

2.24 Disclaimer of Other Representations or Warranties. Except as previously set forth in this Section 2 or in any certificate delivered by the Company to Parent and/or Merger Sub pursuant to this Agreement, the Company makes no representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets, liabilities or operations, and any such other representations or warranties are hereby expressly disclaimed.

 

SECTION 3. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

 

Subject to Section 10.13(h), except (a) as set forth in the written disclosure schedule delivered by Parent to the Company (the “Parent Disclosure Schedule”) or (b) as disclosed in the Parent SEC Documents filed with, or furnished to, the SEC at least two Business Days prior to the date of this Agreement and publicly available on the SEC’s Electronic Data Gathering Analysis and Retrieval system that is reasonably apparent on the face of such disclosure to be applicable to the representations and warranties herein (but (i) without giving effect to any amendment thereof filed with, or furnished to, the SEC on or after the date of this Agreement and (ii) excluding any disclosures contained under the heading “Risk Factors” and any disclosure of risks included in any “forward-looking statements” disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), Parent and Merger Sub represent and warrant to the Company as follows:

 

3.1 Due Organization; Subsidiaries.

 

(a) Each of Parent and Merger Sub is a corporation duly incorporated, validly existing and in good standing under the Laws of its jurisdiction of incorporation, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted; (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except where the failure to have such power or authority would not reasonably be expected to prevent or materially delay the ability of Parent and Merger Sub to consummate the Contemplated Transactions. Since the date of its incorporation, Merger Sub has not engaged in any activities other than activities incident to its formation or in connection with or as contemplated by this Agreement.

 

(b) Parent is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect.

 

(c) Parent has no Subsidiaries, except for the Entities identified in Section 3.1(c) of the Parent Disclosure Schedule; and neither Parent nor any of the Entities identified in Section 3.1(c) of the Parent Disclosure Schedule owns any capital stock of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity other than the Entities identified in Section 3.1(c) of the Parent Disclosure Schedule. Each of Parent’s Subsidiaries is a corporation or other legal entity duly organized, validly existing and, if applicable, in good standing under the Laws of the jurisdiction of its organization and has all necessary corporate or other power and authority to conduct its business in the manner in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used, except where the failure to have such power or authority would not be reasonably expected to have a Parent Material Adverse Effect.

 

A-31
 

 

(d) Neither Parent nor any of its Subsidiaries are or has otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Neither Parent nor any of its Subsidiaries have agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Neither Parent nor any of its Subsidiaries have, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership, or other Entity.

 

3.2 Organizational Documents. Parent has made available to the Company accurate and complete copies of the Organizational Documents of Parent and each of its Subsidiaries in effect as of the date of this Agreement. Neither Parent nor any of its Subsidiaries are in breach or violation of its respective Organizational Documents in any material respect.

 

3.3 Authority; Binding Nature of Agreement. Each of Parent and Merger Sub has all necessary corporate power and authority to enter into this Agreement and, subject, with respect to Parent, to receipt of the Required Parent Stockholder Vote and, with respect to Merger Sub, the adoption of this Agreement by Parent in its capacity as sole stockholder of Merger Sub, to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Parent Board (at meetings duly called and held or by written consent in lieu of a meeting) has: (a) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders; (b) authorized, approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Common Stock to the stockholders of the Company pursuant to the terms of this Agreement, the change of control of Parent and other actions contemplated by this Agreement; (c) recommended, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Parent Stockholder Matters; and (d) approved the Parent Stockholder Support Agreements and the transactions contemplated thereby. The Merger Sub Board (by written consent) has: (x) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Merger Sub and its sole stockholder; (y) authorized, approved and declared advisable this Agreement and the Contemplated Transactions; and (z) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole stockholder of Merger Sub vote to approve this Agreement and the Contemplated Transactions. This Agreement has been duly executed and delivered by Parent and Merger Sub and, assuming the due authorization, execution and delivery by the Company, constitutes the legal, valid and binding obligation of Parent and Merger Sub, enforceable against each of Parent and Merger Sub in accordance with its terms, subject to the Enforceability Exceptions.

 

A-32
 

 

3.4 Vote Required. The affirmative vote (i) of the holders of a majority of the outstanding Parent Common Stock, Parent Series A Preferred Stock and Parent Series B Preferred Stock, each as a separate class, is the only vote of the holders of any class or series of Parent Capital Stock necessary to approve the proposal in Sections 5.3(a)(v), (ii) of a majority of the votes cast by the Parent Common Stock is the only vote of the holders of any class or series of Parent Capital Stock necessary to approve the proposals in Section 5.3(a)(i), Section 5.3(a)(iii), Sections 5.3(a)(iv), Sections 5.3(a)(vi), Section 5.3(a)(vii) and Section 5.3(a)(viii) and (iii) if determined to be required by Parent and subject to the structure and timing of the Asset Dispositions, if any, of the holders of a majority of the votes cast by the Parent Common Stock and of the holders of a majority of the outstanding Parent Series A Preferred Stock and Parent Series B Preferred Stock, each as a separate class, is the only vote of the holders of any class or series of Parent Capital Stock necessary to approve the proposals in Section 5.3(a)(ii) (the “Required Parent Stockholder Vote”).

 

3.5 Non-Contravention; Consents. Subject to obtaining the Required Parent Stockholder Vote, the adoption of this Agreement (effective immediately following the execution of this Agreement) by Parent as the sole stockholder of Merger Sub and the filing of the Statement of Merger required by the ABCL, neither (a) the execution, delivery or performance of this Agreement by Parent or Merger Sub, nor (b) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):

 

(i) contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or any of its Subsidiaries;

 

(ii) contravene, conflict with or result in a violation of, or give any Governmental Body or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which Parent or any of its Subsidiaries, or any of the assets owned or used by Parent or any of its Subsidiaries, is subject, except as would not reasonably be expected to constitute, individually or in the aggregate, a Parent Material Adverse Effect;

 

(iii) contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries, except as would not reasonably be expected to constitute, individually or in the aggregate, a Parent Material Adverse Effect;

 

(iv) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (A) declare a default or exercise any remedy under any Parent Material Contract; (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Parent Material Contract; (C) accelerate the maturity or performance of any Parent Material Contract; or (D) cancel, terminate or modify any term of any Parent Material Contract, except in the case of any non-material breach, default, penalty or modification; or

 

A-33
 

 

(v) result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or any of its Subsidiaries (except for Permitted Encumbrances).

 

Except for (A) any Consent set forth in Section 3.5 of the Parent Disclosure Schedule under any Parent Material Contract, (B) the Required Parent Stockholder Vote, (C) the filing of the Statement of Merger with the Secretary of State of the State of Alabama pursuant to the ABCL, and (D) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities Laws, neither Parent nor any of its Subsidiaries were, are or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement, or (y) the consummation of the Contemplated Transactions, which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially delay the ability of Parent and Merger Sub to consummate the Contemplated Transactions. The Parent Board and the Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in the ABCL and Section 203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement, the Parent Stockholder Support Agreements, the Parent Lock-Up Agreements, and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Parent Stockholder Support Agreements, the Parent Lock-Up Agreements or any of the Contemplated Transactions.

 

3.6 Capitalization.

 

(a) The authorized capital stock of Parent consists of (i) 100,000,000 shares of Parent Common Stock, par value $0.0001 per share, of which 37,951,261 shares have been issued and are outstanding as of the close of business on the Reference Date, and (ii) 5,000,000 shares of preferred stock of Parent, par value $0.0001 per share (the “Parent Preferred Stock”), 211,600 shares of which have been designated as Series A Preferred Stock (the “Parent Series A Preferred Stock”), all of which have been issued and are outstanding as of the date of this Agreement, and 148,400 shares of which have been designated as Series B Preferred Stock (the “Parent Series B Preferred Stock”), all of which have been issued and are outstanding as of the date of this Agreement, and the balance is available for designation by the Parent Board. Parent does not hold any shares of its capital stock in its treasury. Section 3.6(a) of the Parent Disclosure Schedule lists, on the date of the Reference Date, (A) each holder of issued and outstanding Parent Preferred Stock, (B) each holder of issued and outstanding Parent Warrants, (C) the number and type of shares subject to each Parent Warrant, (D) the exercise price of each Parent Warrant and (E) the termination date of each Parent Warrant.

 

(b) All of the outstanding shares of Parent Common Stock and Parent Preferred Stock have been duly authorized and validly issued, and are fully paid and nonassessable. None of the outstanding shares of Parent Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. Except as contemplated herein and as set forth in Section 3.6(b)(i) of the Parent Disclosure Schedule, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Capital Stock. Except as set forth in Section 3.6(b)(ii) of the Parent Disclosure Schedule, Parent is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Capital Stock or other securities. Section 3.6(b)(iii) of the Parent Disclosure Schedule accurately and completely describes all repurchase rights held by Parent with respect to shares of Parent Capital Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.

 

A-34
 

 

(c) Except for the Parent Incentive Plan, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As of the date of the Reference Date, Parent has reserved 4,000,000 shares of Parent Common Stock for issuance under the Parent Incentive Plan, of which no shares have been issued and are currently outstanding, of which no shares are subject to Parent’s right of repurchase, 3,286,800 shares have been reserved for issuance upon exercise of Parent Options previously granted and currently outstanding under the Parent Incentive Plan, no shares have been reserved for issuance upon the settlement of Parent RSUs granted under the Parent Incentive Plan that are outstanding as of the close of business on the Reference Date and 713,200 shares remain available for future issuance pursuant to the Parent Incentive Plan. Section 3.6(c) of the Parent Disclosure Schedule sets forth the following information with respect to each Parent Option outstanding as of the Reference Date: (i) the name of the optionee; (ii) the number of shares of Parent Common Stock subject to such Parent Option at the time of grant; (iii) the number of shares of Parent Common Stock subject to such Parent Option as of the Reference Date; (iv) the exercise price of such Parent Option; (v) the date on which such Parent Option was granted; (vi) the applicable vesting schedule, including the number of vested and unvested shares as of the Reference Date; (vii) the date on which such Parent Option expires; and (viii) whether such Parent Option is an “incentive stock option” (as defined in the Code) or a non-qualified stock option. Parent has made available to the Company accurate and complete copies of equity incentive plans pursuant to which Parent has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Parent Incentive Plan and any amendments thereto.

 

(d) Except for the Parent Warrants, the Parent Incentive Plan, including the Parent Options, the Parent RSUs, and as otherwise set forth in Section 3.6(d) of the Parent Disclosure Schedule, as of the Reference Date there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Parent or any of its Subsidiaries; (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent or any of its Subsidiaries; (iii) stockholder rights plan (or similar plan commonly referred to as a “poison pill”) or Contract under which Parent or any of its Subsidiaries are or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities; or (iv) condition or circumstance that could be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent or any of its Subsidiaries. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent or any of its Subsidiaries.

 

A-35
 

 

(e) All outstanding shares of Parent Common Stock, Parent Preferred Stock, Parent Options, Parent RSUs, Parent Warrants and other securities of Parent have been issued and granted in material compliance with (i) all applicable securities Laws and other applicable Laws, and (ii) all requirements set forth in applicable Contracts.

 

3.7 SEC Filings; Financial Statements.

 

(a) Other than such documents that can be obtained on the SEC’s website at www.sec.gov, Parent has delivered or made available to the Company accurate and complete copies of all registration statements, proxy statements, Certifications (as defined below) and other statements, reports, schedules, forms and other documents filed by Parent with the SEC since March 29, 2022 (the “Parent SEC Documents”). All material statements, reports, schedules, forms and other documents required to have been filed by Parent or its officers with the SEC have been so filed on a timely basis. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and, as of the time they were filed, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i) Rule 13a-14 under the Exchange Act and (ii) 18 U.S.C. §1350 (Section 906 of the Sarbanes-Oxley Act) relating to the Parent SEC Documents (collectively, the “Certifications”) are accurate and complete and comply as to form and content with all applicable Laws. As used in this Section 3.7, the term “file” and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC.

 

(b) The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii) were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, except as permitted by the SEC on Form 10-Q under the Exchange Act, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated; and (iii) fairly present, in all material respects, the financial position of Parent and its consolidated Subsidiaries as of the respective dates thereof and the results of operations and cash flows of Parent and its consolidated Subsidiaries for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date of this Agreement, there has been no material change in Parent’s accounting methods or principles that would be required to be disclosed in Parent’s financial statements in accordance with GAAP. The books of account and other financial records of Parent and each of its Subsidiaries are true and complete in all material respects.

 

A-36
 

 

(c) As of the date of this Agreement, Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act and the applicable current listing and governance rules and regulations of NYSE.

 

(d) Parent maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures designed to provide reasonable assurance (i) that Parent maintains records that in reasonable detail accurately and fairly reflect Parent’s transactions and dispositions of assets, (ii) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with authorizations of management and the Parent Board and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent’s assets that could have a material effect on Parent’s financial statements. Parent has evaluated the effectiveness of Parent’s internal control over financial reporting as of December 31, 2022, and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed, based on its most recent evaluation of internal control over financial reporting, to Parent’s auditors and the audit committee of the Parent Board (and made available to the Company a summary of the significant aspects of such disclosure) (A) all significant deficiencies and material weaknesses, if any, in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent’s ability to record, process, summarize and report financial information and (B) any known fraud, whether or not material, that involves management or other employees who have a significant role in Parent’s or its Subsidiaries’ internal control over financial reporting. Parent has not identified, based on its most recent evaluation of internal control over financial reporting, any material weaknesses in the design or operation of Parent’s internal control over financial reporting.

 

(e) Parent maintains “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are reasonably designed to ensure that information required to be disclosed by Parent in the periodic reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the required time periods, and that all such information is accumulated and communicated to Parent’s management as appropriate to allow timely decisions regarding required disclosure and to make the Certifications.

 

(f) To the Knowledge of Parent, Parent’s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act); (ii) with respect to Parent, “independent” with respect to Parent within the meaning of Regulation S-X under the Exchange Act; and (iii) to the Knowledge of Parent, in compliance with subsections (g) through (l) of Section 10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder.

 

A-37
 

 

(g) Except as set forth in Section 3.7(g) of the Parent Disclosure Schedule, since March 29, 2022, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from NYSE or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on NYSE that has not been disclosed in the Parent SEC Documents. Parent has not disclosed any unresolved comments.

 

(h) Since March 29, 2022, there have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act.

 

3.8 Absence of Changes. Except as set forth in Section 3.8 of the Parent Disclosure Schedule and except for reasonable and good faith actions or omissions taken to comply with applicable Law or guidance by a Governmental Body in connection with the COVID-19 pandemic, between the date of the Parent Balance Sheet and the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto, including the Contemplated Transactions) and there has not been any (a) Parent Material Adverse Effect or (b) action, event or occurrence that would have required the consent of the Company pursuant to Section 4.1(b) had such action, event or occurrence taken place after the execution and delivery of this Agreement.

 

3.9 Absence of Undisclosed Liabilities. As of the date of this Agreement, neither Parent nor any of its Subsidiaries have any Liability, individually or in the aggregate, of a type required to be recorded or reflected on Parent’s balance sheet or disclosed in the footnotes thereto under GAAP except for: (a) Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet; (b) normal and recurring current Liabilities that have been incurred by Parent or any of its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business and which are not in excess of $100,000 in the aggregate; (c) Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Material Contracts which have not resulted from a breach of such Parent Material Contracts, breach of warranty, tort, infringement or violation of Law; (d) Liabilities incurred in connection with the Contemplated Transactions; and (e) Liabilities described in Section 3.9 of the Parent Disclosure Schedule.

 

3.10 Title to Assets. Parent and each of its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets reflected on the Parent Balance Sheet; and (b) all other tangible assets reflected in the books and records of Parent or any of its Subsidiaries as being owned by Parent or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased by Parent or its applicable Subsidiary free and clear of any Encumbrances, other than Permitted Encumbrances.

 

A-38
 

 

3.11 Real Property; Leasehold. Neither Parent nor any of its Subsidiaries owns or has ever owned any real property. Parent has made available to the Company (a) an accurate and complete list of all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries, and (b) copies of all leases under which any such real property is possessed (the “Parent Real Estate Leases”), each of which is in full force and effect, with no existing material default thereunder. Parent’s or its applicable Subsidiary’s use and operation of each such leased property conforms to all applicable Laws in all material respects, and Parent or its applicable Subsidiary has exclusive possession of each such leased property and has not granted any occupancy rights to tenants or licensees with respect to such leased property. In addition, each such leased property is free and clear of all Encumbrances other than Permitted Encumbrances.

 

3.12 Intellectual Property.

 

(a) Section 3.12(a) of the Parent Disclosure Schedule identifies each item of Registered IP owned in whole or in part by Parent or its Subsidiaries (“Parent Owned Registered IP”). To Parent’s Knowledge, each of the patents and patent applications included in the Parent Owned Registered IP properly identifies by name each and every inventor of the inventions claimed therein as determined in accordance with applicable Laws of the United States. To Parent’s Knowledge, (A) Parent Owned Registered IP is valid, enforceable and subsisting, (B) none of Parent Owned Registered IP has been misused, withdrawn, canceled or abandoned, and (C) all application, registration, issuance, renewal and maintenance fees for Parent Owned Registered IP having a final due date on or before the date of this Agreement have been timely paid in full. To Parent’s Knowledge, with respect to each item of Parent Owned Registered IP and each patent application from which such Parent Owned Registered IP claims priority, all statements made and information presented to the applicable patent office by or on behalf of Parent or its Subsidiaries or any inventor thereof, or their respective patent counsel, during the prosecution thereof are accurate and complete and comply with 37 CFR 1.56. As of the date of this Agreement, no interference, opposition, reissue, reexamination or other proceeding of any nature (other than initial examination proceedings) is pending or, to Parent’s Knowledge, threatened in writing, in which the scope, validity, enforceability or ownership of any Parent Owned Registered IP is being or has been contested or challenged.

 

(b) Parent or its Subsidiaries solely owns all right, title and interest in and to all Parent IP (other than as disclosed in Section 3.12(a) of the Parent Disclosure Schedule and except for any failure to own or have such right to use, or have the right to bring actions that would not reasonably be expected to have a Parent Material Adverse Effect), free and clear of all Encumbrances other than Permitted Encumbrances and, to Parent’s Knowledge, has the right, pursuant to a Parent In-bound License to use all other material Intellectual Property Rights used by Parent or its Subsidiaries in their respective businesses as currently conducted. The Parent IP and the Intellectual Property Rights licensed to Parent or its Subsidiaries pursuant to a Parent In-bound License (the “Parent In-Licensed IP”) are all the Intellectual Property Rights necessary to operate the business of Parent and its Subsidiaries as currently conducted and to the Parent’s Knowledge, as proposed to be conducted, as of the date of this Agreement. No Parent Associate owns or has any claim, right (whether or not currently exercisable) or interest to or in any Parent IP, and each Parent Associate involved in the creation or development of any material Parent IP, pursuant to such Parent Associate’s activities on behalf of Parent or its Subsidiaries, has signed a valid, enforceable written agreement containing a present assignment of all of such Parent Associate’s each Parent Associate involved in the creation or development of any material Parent IP, pursuant to such Parent Associate’s activities on behalf of Parent or its Subsidiaries, has signed a valid, enforceable written agreement containing a present assignment of all such Parent Associate’s rights in such material Parent IP to Parent or its Subsidiaries (without further payment being owed to any such Parent Associate and without any restrictions or obligations on Parent’s or its Subsidiaries’ ownership or use thereof) and confidentiality provisions protecting the Parent IP, which, to Parent’s Knowledge, has not been materially breached by such Parent Associate. Without limiting the foregoing, Parent and its Subsidiaries have taken commercially reasonable steps to protect, maintain and enforce all Parent IP, and, as required, Parent In-Licensed IP, including the secrecy, confidentiality and value of trade secrets and other confidential information therein (as applicable), and to Parent’s Knowledge there have been no unauthorized disclosures by Parent or its Subsidiaries of any confidential information or trade secrets associated with Parent IP or Parent In-Licensed IP.

 

A-39
 

 

(c) Except as disclosed in Section 3.12(c) of the Parent Disclosure Schedule, to Parent’s Knowledge, no funding, facilities or personnel of any Governmental Body or any university, college, research institute or other educational or academic institution has been used, in whole or in part, to create any Parent IP or any Parent In-Licensed IP, except for any such funding or use of facilities or personnel that does not result in such Governmental Body or institution obtaining ownership or other rights (including any “march in” rights or a right to direct the location of manufacturing of products) to such Parent IP or the right to receive royalties or other consideration for the practice of such Parent IP.

 

(d) Section 3.12(d) of Parent Disclosure Schedule sets forth each license agreement pursuant to which Parent or any of its Subsidiaries (i) is granted a license under any Intellectual Property Right owned by any third party that is used by Parent or any of its Subsidiaries in its business as currently conducted or, to Parent’s Knowledge, as proposed to be conducted as of the date of this Agreement (each a “Parent In-bound License”) or (ii) grants to any third party a license under any material Parent IP or any material Intellectual Property Right licensed to Parent or any of its Subsidiaries under a Parent In-bound License (each a “Parent Out-bound License”) (provided, that Parent In-bound Licenses shall not include material transfer agreements, clinical trial agreements, services agreements, non-disclosure agreements, commercially available Software-as-a-Service offerings, off-the-shelf software licenses or generally available patent license agreements, in each case, entered into in the Ordinary Course of Business on a non-exclusive basis and that do not grant any commercial rights to any products or services of Parent or any of its Subsidiaries; and Parent Out-bound Licenses shall not include material transfer agreements, clinical trial agreements, services agreements, non-disclosure agreements, or non-exclusive outbound licenses entered into in the Ordinary Course of Business on a non-exclusive basis and that do not grant any commercial rights to any products or services of Parent or any of its Subsidiaries). Neither Parent nor its Subsidiaries nor, to Parent’s Knowledge, any other party to any Parent In-bound License or Parent Out-bound License has breached or is in breach of any of its obligations under any Parent In-bound License or Parent Out-bound License.

 

A-40
 

 

(e) To Parent’s Knowledge, (i) the operation of the businesses of Parent and its Subsidiaries as currently conducted or as proposed to be conducted as of the date of this Agreement does not infringe or misappropriate or otherwise violate any other Intellectual Property Right owned by any other Person; and (ii) no other Person is infringing, misappropriating or otherwise violating any Parent IP or any Intellectual Property Rights exclusively licensed to Parent or any of its Subsidiaries. As of the date of this Agreement, no Legal Proceeding is pending (or, to Parent’s Knowledge, is threatened in writing) (A) against Parent or any of its Subsidiaries alleging that the operation of the businesses of Parent or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights of another Person or (B) by Parent or any of its Subsidiaries alleging that another Person has infringed, misappropriated or otherwise violated any of Parent IP or any Parent In- Licensed IP. Since January 1, 2020, neither Parent nor any of its Subsidiaries have received any written notice or other written communication alleging that the operation of the businesses of Parent or any of its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another Person.

 

(f) None of the Parent IP or, to the Parent’s Knowledge, any Parent In-Licensed IP (i) is subject to any pending or outstanding injunction, directive, order, decree, settlement, judgment or other disposition of dispute that adversely and materially restricts the use, transfer, registration or licensing by the Parent or its Subsidiaries or (ii) would reasonably be expected to adversely affect the validity, scope, use, registrability, or enforceability thereof.

 

(g) To Parent’s Knowledge, the Parent, its Subsidiaries, and the operation of Parent’s and its Subsidiaries’ business are in substantial compliance with all applicable Laws pertaining to data privacy and data security of Sensitive Data, except to the extent that such noncompliance has not and would not reasonably be expected to have a Parent Material Adverse Effect. To Parent’s Knowledge, since January 1, 2020, there have been (i) no material losses or thefts of data or security breaches relating to Sensitive Data used in the business of Parent or its Subsidiaries, (ii) no violations of any security policy of Parent or its Subsidiaries regarding any such Sensitive Data, (iii) no unauthorized access or unauthorized use of any Sensitive Data used in the business of Parent or its Subsidiaries and (iv) no unintended or improper disclosure of any personally identifiable information in the possession, custody or control of Parent or its Subsidiaries or a contractor or agent acting on behalf of Parent or its Subsidiaries, in each case of (i) through (iv), except as would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect.

 

(h) None of Parent or its Subsidiaries are now or has ever been a member or promoter of, or a contributor to, any industry standards body or any similar organization that would reasonably be expected to require or obligate Parent or any of its Subsidiaries to grant or offer to any other Person any license or right to any Parent IP or Parent In-Licensed IP.

 

A-41
 

 

3.13 Agreements, Contracts and Commitments.

 

(a) Section 3.13 of the Parent Disclosure Schedule lists the following Parent Contracts in effect as of the date of this Agreement (other than any Parent Benefit Plan) (each, a “Parent Material Contract” and collectively, the “Parent Material Contracts”):

 

(i) a material contract as defined in Item 601(b)(10) of Regulation S-K as promulgated under the Securities Act;

 

(ii) each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;

 

(iii) each Parent Contract containing (A) any covenant limiting the freedom of Parent or any of its Subsidiaries to engage in any line of business or compete with any Person, (B) any “most-favored nations” pricing provisions or marketing or distribution rights related to any products or territory, (C) any exclusivity provision, (D) any agreement to purchase minimum quantity of goods or services, or (E) any material non-solicitation provisions applicable to Parent or any of its Subsidiaries;

 

(iv) each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $50,000 pursuant to its express terms and not cancelable without penalty;

 

(v) each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity;

 

(vi) each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $50,000 or creating any material Encumbrances with respect to any assets of Parent or any of its Subsidiaries or any loans or debt obligations with officers or directors of Parent or any of its Subsidiaries;

 

(vii) each Parent Contract requiring payment by or to Parent or any of its Subsidiaries after the date of this Agreement in excess of $300,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions); (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Parent or any of its Subsidiaries; (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, collaboration, development or other agreement currently in force under which Parent or any of its Subsidiaries have continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent or any of its Subsidiaries have continuing obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by Parent or any of its Subsidiaries; or (D) any Contract to license any third party to manufacture or produce any product, service or technology of Parent or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Parent or any of its Subsidiaries, in each case, except for Contracts entered into in the Ordinary Course of Business;

 

A-42
 

 

(viii) each Parent Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Parent in connection with the Contemplated Transactions;

 

(ix) each Parent Real Estate Lease;

 

(x) each Parent Contract with any Governmental Body;

 

(xi) each Parent Out-bound License and Parent In-bound License;

 

(xii) each Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent or any of its Subsidiaries; or

 

(xiii) any other Parent Contract that is not terminable at will (with no penalty or payment) by Parent or its Subsidiaries, as applicable, and (A) which involves payment or receipt by Parent or its Subsidiaries after the date of this Agreement under any such agreement, contract or commitment of more than $300,000 in the aggregate, or (B) that is material to the business or operations of Parent and its Subsidiaries, taken as a whole.

 

(b) Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are no Parent Material Contracts that are not in written form. As of the date of this Agreement, none of Parent, any of its Subsidiaries or, to Parent’s Knowledge, any other party to a Parent Material Contract, has breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of, or Laws applicable to, any Parent Material Contract in such manner as would permit any other party to cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages or pursue other legal remedies which would reasonably be expected to be material to Parent or its business or operations. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent or any of its Subsidiaries under any Parent Material Contract or any other material term or provision of any Parent Material Contract.

 

A-43
 

 

3.14 Compliance; Permits; Restrictions.

 

(a) Parent and each of its Subsidiaries are, and since January 1, 2020, have been, in compliance in all material respects with all applicable Laws, including the FDCA, the FDA regulations adopted thereunder, the Public Health Service Act and any other similar Law administered or promulgated by the FDA or other Drug Regulatory Agency, except for any noncompliance, either individually or in the aggregate, which would not be material to Parent. No investigation, claim, suit, proceeding, audit or other action by any Governmental Body is pending or, to Parent’s Knowledge, threatened against Parent or any of its Subsidiaries. There is no agreement, judgment, injunction, order or decree by or with a Drug Regulatory Agency binding upon Parent or any of its Subsidiaries which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on Parent’s ability to comply with or perform any covenant or obligation under this Agreement, or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.

 

(b) Parent and its Subsidiaries hold all required Governmental Authorizations which are material to the operation of the business of Parent and its Subsidiaries as currently conducted (the “Parent Permits”). Section 3.14(b) of the Parent Disclosure Schedule identifies each Parent Permit. Parent and its Subsidiaries hold all right, title and interest in and to all Parent Permits free and clear of any Encumbrance. Parent and each of its Subsidiaries are in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to Parent’s Knowledge, threatened, which seeks to revoke, limit, suspend, or materially modify any Parent Permit.

 

(c) There are no proceedings pending or, to the Parent’s Knowledge, threatened with respect to an alleged material violation by Parent or any of its Subsidiaries of the FDCA, FDA regulations adopted thereunder, the Controlled Substances Act, the Public Health Service Act or any other similar Law administered or promulgated by any Drug Regulatory Agency.

 

(d) Parent is not currently conducting or addressing, and to Parent’s Knowledge there is no basis to expect that it will be required to conduct or address, any corrective actions, including, without limitation, product recalls or clinical holds.

 

(e) All clinical, pre-clinical and other studies and tests conducted by or, to Parent’s Knowledge, on behalf of, or sponsored by, Parent or any of its Subsidiaries, or in which Parent or any of its Subsidiaries or their respective current products or product candidates have participated, were and, if still pending, are being conducted in all material respects in accordance with standard medical and scientific research procedures and in compliance in all material respects with the applicable regulations of any applicable Drug Regulatory Agency and other applicable Law, including 21 C.F.R. Parts 50, 54, 56, 58 and 312. Since January 1, 2020, neither Parent nor any of its Subsidiaries have received any notices, correspondence, or other communications from any Drug Regulatory Agency requiring, or, to Parent’s Knowledge, threatening to initiate, the termination or suspension of any clinical studies conducted by or on behalf of, or sponsored by, Parent or any of its Subsidiaries or in which Parent or any of its Subsidiaries or their respective current products or product candidates have participated.

 

A-44
 

 

(f) Neither Parent nor any of its Subsidiaries are the subject of any pending or, to Parent’s Knowledge, threatened investigation in respect of its business or products by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto. To Parent’s Knowledge, neither Parent nor any of its Subsidiaries have committed any acts, made any statement, or failed to make any statement, in each case in respect of its business or products that would violate the FDA’s “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy, and any amendments thereto. None of Parent, any of its Subsidiaries or any of their respective officers, employees or agents have been convicted of any crime or engaged in any conduct that could result in a debarment or exclusion (i) under 21 U.S.C. Section 335a or (ii) any similar applicable Law. To Parent’s Knowledge, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Parent, any of its Subsidiaries or any of their respective officers, employees or agents.

 

3.15 Legal Proceedings; Orders.

 

(a) As of the date of this Agreement, there is no pending Legal Proceeding and, to Parent’s Knowledge, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves (A) Parent, (B) any of its Subsidiaries, (C) any Parent Associate (in his or her capacity as such) or (D) any of the material assets owned or used by Parent or its Subsidiaries; or (ii) that challenges, or that would reasonably be expected to have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.

 

(b) Except as set forth in Section 3.15(b) of the Parent Disclosure Schedule, since January 1, 2020, no Legal Proceeding has been pending against Parent or any of its Subsidiaries that resulted in material liability to Parent or any of its Subsidiaries.

 

(c) There is no order, writ, injunction, judgment or decree to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries, is subject. To Parent’s Knowledge, no officer or other employee of Parent or any of its Subsidiaries is subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or to any material assets owned or used by Parent or any of its Subsidiaries.

 

3.16 Tax Matters.

 

(a) Parent and each of its Subsidiaries have timely filed all income Tax Returns and other material Tax Returns that they were required to file under applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in compliance with all applicable Law. No written claim has ever been made by any Governmental Body in any jurisdiction where Parent or any of its Subsidiaries does not file a particular Tax Return or pay a particular Tax that Parent or such Subsidiary is subject to taxation by that jurisdiction.

 

A-45
 

 

(b) All income and other material Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been fully paid. The unpaid Taxes of Parent and its Subsidiaries did not, as of the date of the Parent Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax items) set forth on the face of the Parent Balance Sheet. Since the date of the Parent Balance Sheet, neither Parent nor any of its Subsidiaries have incurred any material Liability for Taxes outside the Ordinary Course of Business.

 

(c) All Taxes that Parent or any of its Subsidiaries are or were required by Law to withhold or collect have been duly and timely withheld or collected in all material respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers or other third parties and, have been timely paid to the proper Governmental Body or other Person or properly set aside in accounts for this purpose. The Parent and its Subsidiaries have complied in all material respects with applicable Laws relating to information reporting and record retention (including to the extent necessary to claim any exemption from sales Tax collection and maintaining adequate and current resale certificates to support any such claimed exemptions).

 

(d) There are no Encumbrances for material Taxes (other than Taxes not yet due and payable) upon any of the assets of Parent or any of its Subsidiaries.

 

(e) No deficiencies for income or other material Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Body in writing. There are no pending or ongoing, and, to Parent’s Knowledge, threatened audits, assessments or other actions for or relating to any liability in respect of a material amount of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries (or any of their predecessors) has waived any statute of limitations in respect of any income or other material Taxes or agreed to any extension of time with respect to any income or other material Tax assessment or deficiency.

 

(f) Neither Parent nor any of its Subsidiaries have been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code.

 

(g) Neither Parent nor any of its Subsidiaries are a party to any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement, other than customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes.

 

(h) Neither Parent nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of accounting for Tax purposes made on or prior to the Closing Date; (ii) use of an improper method of accounting for a Tax period ending on or prior to the Closing Date; (iii) “closing agreement” as described in Section 7121 of the Code (or any similar provision of state, local or foreign Law) executed on or prior to the Closing Date; (iv) intercompany transaction or excess loss account described in Treasury Regulations under Section 1502 of the Code (or any similar provision of state, local or foreign Law) entered into on or prior to the Closing Date; (v) installment sale or open transaction disposition made on or prior to the Closing Date; (vi) prepaid amount received or deferred revenue accrued on or prior to the Closing Date; (vii) application of Section 367(d) of the Code to any transfer of intangible property on or prior to the Closing Date; (viii) application of Sections 951 or 951A of the Code (or any similar provision of state, local or foreign Law) to any income received or accrued on or prior to the Closing Date; or (ix) election under Section 108(i) of the Code (or any similar provision of state, local or foreign Law) made on or prior to the Closing Date. Parent has not made any election under Section 965(h) of the Code.

 

A-46
 

 

(i) Neither Parent nor any of its Subsidiaries have ever been (i) a member of a consolidated, combined or unitary Tax group (other than such a group the common parent of which is Parent) or (ii) a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. Neither Parent nor any of its Subsidiaries have any Liability for any material amount of Taxes of any Person (other than Parent and any of its Subsidiaries) under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local, or foreign Law), by contract, as a transferee or successor, or otherwise.

 

(j) Neither Parent nor any of its Subsidiaries (i) are a “controlled foreign corporation” as defined in Section 957 of the Code; (ii) is a “passive foreign investment company” within the meaning of Section 1297 of the Code; or (iii) has ever had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed place of business in a country other than the country in which it is organized.

 

(k) Neither Parent nor any of its Subsidiaries have participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a “reportable transaction” that is required to be reported to the IRS pursuant to Section 6011 of the Code and applicable Treasury Regulations thereunder.

 

(l) Neither Parent nor any of its Subsidiaries have taken any action, nor to Parent’s Knowledge is there any fact, that would reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment.

 

(m) Neither Parent nor any of its Subsidiaries have availed itself of any Tax relief pursuant to any Pandemic Response Laws that could reasonably be expected to materially impact the Tax payment and/or Tax reporting obligations of Parent and its Affiliates (including the Company and its Subsidiaries) after the Closing Date.

 

For purposes of this Section 3.16, each reference to Parent or any of its Subsidiaries shall be deemed to include any Person that was liquidated into, merged with, or is otherwise a predecessor to, Parent of any of its Subsidiaries.

 

A-47
 

 

3.17 Employee and Labor Matters; Benefit Plans.

 

(a) Section 3.17(a) of the Parent Disclosure Schedule lists, as of the date of this Agreement, all material Parent Benefit Plans. “Parent Benefit Plan” means each (i) “employee benefit plan,” as defined in Section 3(3) of ERISA, whether or not subject to ERISA, and (ii) any other pension, retirement, deferred compensation, excess benefit, profit-sharing, bonus, incentive, equity or equity-based, phantom equity, employment (other than at-will employment offer letters on Parent’s standard form that may be terminated without notice and with no penalty to Parent or any of its Subsidiaries and other than individual Parent Options, Parent RSUs, or other compensatory equity award grants made pursuant to Parent’s standard forms, in which case only representative standard forms of such agreements shall be scheduled), consulting, severance, change-of-control, stay or retention, medical, dental, vision, health, prescription drug, life, disability, cafeteria plan, flexible spending account, employee assistance program, travel assistance, accidental death & dismemberment, group insurance, retiree medical or life insurance, paid-time-off, holiday, welfare or fringe benefit plan, program, agreement, contract, or arrangement (other than regular salary or wages) (whether written or unwritten, qualified or nonqualified, funded or unfunded and including any that have been frozen), in each case, maintained, contributed to, or required to be contributed to, by Parent or any of its Subsidiaries for the benefit of any current or former employee, director, officer, or independent contractor of Parent or any of its Subsidiaries or under which Parent or any of its Subsidiaries have or could have any actual or contingent liability (including, without limitation, as to the result of it being treated as a single employer under Section 414 of the Code with any other person).

 

(b) As applicable with respect to each material Parent Benefit Plan, Parent has made available to the Company, true and complete copies of (i) each material Parent Benefit Plan, including all amendments thereto, and in the case of an unwritten material Parent Benefit Plan, a written description thereof, (ii) all current trust documents, investment management contracts, custodial agreements, administrative services agreements, insurance, and annuity contracts relating thereto, (iii) the current summary plan description and each summary of material modifications thereto, (iv) the three most recently filed annual reports on Form 5500 and all schedules thereto, (v) the most recent IRS determination or opinion letter, (vi) the three most recent nondiscrimination testing reports, actuarial reports, and financial statements, (vii) all notices and filings concerning IRS, United States Department of Labor, or other Governmental Body audits or investigations since January 1, 2020, (viii) each written report constituting a valuation of Parent’s capital stock for purposes of Sections 409A or 422 of the Code, whether prepared internally by Parent or by an outside, third-party valuation firm, and (ix) all material written materials provided to employees or participants relating to the amendment, termination, establishment, or increase or decrease in benefits under any Parent Benefit Plan.

 

(c) Each Parent Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and any related documents or agreements and the applicable provisions of ERISA, the Code and all other applicable Laws.

 

A-48
 

 

(d) The Parent Benefit Plans that are “employee pension benefit plans” within the meaning of Section 3(2) of ERISA and that are intended to meet the qualification requirements of Section 401(a) of the Code have received determination or opinion letters from the IRS on which they may currently rely to the effect that such plans are qualified under Section 401(a) of the Code and, to Parent’s Knowledge, nothing has occurred that would reasonably be expected to materially adversely affect the qualification of such Parent Benefit Plan.

 

(e) None of Parent or any Parent ERISA Affiliate sponsors, maintains, contributes to, is required to contribute to, or has any actual or contingent liability with respect to, or has within the past six (6) years sponsored, maintained, contributed to, or been required to contribute to, (i) any “employee pension benefit plan” (within the meaning of Section 3(2) of ERISA) that is subject to Title IV or Section 302 of ERISA or Section 412 of the Code, (ii) any “multiemployer plan” (within the meaning of Section 3(37) of ERISA), (iii) any “multiple employer plan” (within the meaning of Section 413 of the Code), or (iv) any “multiple employer welfare arrangement” (within the meaning of Section 3(40) of ERISA), and none of Parent or any Parent ERISA Affiliate has, within the preceding six (6) years, incurred a complete or partial withdrawal from any “multiemployer plan” or otherwise incurred any liability under Section 4202 of ERISA.

 

(f) There are no pending audits or investigations by any Governmental Body involving any Parent Benefit Plan, and no pending or, to Parent’s Knowledge, threatened claims (except for individual claims for benefits payable in the normal operation of the Parent Benefit Plans), suits, or proceedings involving any Parent Benefit Plan. All contributions and premium payments required to have been made under any of the Parent Benefit Plans or by applicable Law have been timely made, and neither Parent nor any of its Subsidiaries have any liability for any unpaid contributions with respect to any Parent Benefit Plan (other than contributions that are accrued in the Ordinary Course of Business).

 

(g) Neither Parent nor any of its Subsidiaries, nor, to Parent’s Knowledge, any fiduciary, trustee, or administrator of any Parent Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Parent Benefit Plan that would subject any such Parent Benefit Plan, Parent or any of its Subsidiaries or the Company to a Tax, penalty, or liability for a “prohibited transaction” under Section 406 of ERISA or Section 4975 of the Code.

 

(h) No Parent Benefit Plan provides (i) death, medical, dental, vision, life insurance or other welfare benefits beyond the termination of service or retirement, other than coverage mandated by Law (including COBRA, for which the covered individual pays the full cost of coverage) or (ii) death or retirement benefits under a Parent Benefit Plan qualified under Section 401(a) of the Code, and neither the Parent nor any of its Subsidiaries have made a written or oral representation promising the same.

 

(i) Except as set forth in Section 3.17(i) of the Parent Disclosure Schedules, neither the execution of this Agreement, nor the consummation of the Contemplated Transactions will either alone or in connection with any other event(s) (i) result in any payment becoming due to any current or former employee, director, officer, independent contractor or other service provider of Parent or any of its Subsidiaries, (ii) increase any amount of compensation or benefits otherwise payable to any current or former employee, director, officer, independent contractor or other service provider of Parent or any of its Subsidiaries, (iii) result in the acceleration of the time of payment, funding or vesting of any benefits under any Parent Benefit Plan, (iv) require any contribution or payment to fund any obligation under any Parent Benefit Plan or (v) limit the right to merge, amend or terminate any Parent Benefit Plan.

 

A-49
 

 

(j) Neither the execution of this Agreement, nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) will result in the receipt or retention by any person who is a “disqualified individual” (within the meaning of Section 280G of the Code) with respect to Parent and its Subsidiaries of any payment or benefit that is or could be characterized as a “parachute payment” (within the meaning of Section 280G of the Code), determined without regard to the application of Section 280G(b)(5) of the Code.

 

(k) Each Parent Benefit Plan providing for deferred compensation that constitutes a “nonqualified deferred compensation plan” (as defined in Section 409A(d)(1) of the Code and the regulations promulgated thereunder) is, and has been, established, administered and maintained in all material respects in compliance with the requirements of Section 409A of the Code and the regulations promulgated thereunder.

 

(l) No Person has any “gross-up” agreements with Parent or any of its Subsidiaries or other assurance of reimbursement or compensation by Parent or any of its Subsidiaries for any Taxes imposed under Section 409A or Section 4999 of the Code.

 

(m) Parent does not have any Parent Benefit Plan that is maintained for service providers located outside of the United States.

 

(n) Neither Parent nor any of its Subsidiaries are a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union or labor organization representing any of its employees, and there is no labor union or labor organization representing or, to Parent’s Knowledge, purporting to represent or seeking to represent any employees of Parent or its Subsidiaries, including through the filing of a petition for representation election.

 

(o) Parent and each of its Subsidiaries is, and since January 1, 2020, has been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including, without limitation, worker classification, discrimination, wrongful termination, harassment and retaliation, equal employment opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health, wages (including overtime wages), unemployment and workers’ compensation, leaves of absence, and hours of work. Except as would not be reasonably likely to result in a material liability to Parent or any of its Subsidiaries, with respect to employees of Parent or any of its Subsidiaries, each of Parent and its Subsidiaries, since January 1, 2020: (i) has withheld and reported all amounts required by Law or by agreement to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees, (ii) is not liable for any arrears of wages (including overtime wages), severance pay or any Taxes or penalties for failure to comply with any of the foregoing in any material respect, and (iii) is not liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Body, with respect to unemployment compensation benefits, disability, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business or as required by Law). There are no actions, suits, claims, charges, demands, lawsuits, investigations, audits or administrative matters pending or, to Parent’s Knowledge, threatened or reasonably anticipated against Parent or any of its Subsidiaries relating to any current or former employee, applicant for employment, consultant, employment agreement or Parent Benefit Plan (other than routine claims for benefits). All employees of Parent and its Subsidiaries are employed “at-will” and their employment can be terminated without advance notice or payment of severance.

 

A-50
 

 

(p) Except as would not be reasonably likely to result in a material liability to Parent or any of its Subsidiaries, with respect to each individual who currently renders services to Parent or any of its Subsidiaries, Parent and each of its Subsidiaries have accurately classified each such individual as an employee, independent contractor, or otherwise under all applicable Laws and, for each individual classified as an employee, Parent and each of its Subsidiaries have accurately classified him or her as overtime eligible or overtime ineligible under all applicable Laws. Neither Parent nor any of its Subsidiaries have any material liability with respect to any misclassification of: (a) any Person as an independent contractor rather than as an employee, (b) any employee leased from another employer, or (c) any employee currently or formerly classified as exempt from overtime wages.

 

(q) There is not and has not been since January 1, 2020, nor is there or has there been since January 1, 2020, any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or, to Parent’s Knowledge, any union organizing activity, against Parent or any of its Subsidiaries. No event has occurred, and, to Parent’s Knowledge, no condition or circumstance exists, that might directly or indirectly give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute.

 

3.18 Environmental Matters. Parent and each of its Subsidiaries are in compliance, and since January 1, 2020, have complied, with all applicable Environmental Laws, which compliance includes the possession by Parent and its Subsidiaries of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected to result in a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries have received since January 1, 2020, any written notice or other communication (in writing or otherwise), whether from a Governmental Body or other Person, that alleges that Parent or any of its Subsidiaries are not in compliance with or has liability pursuant to any Environmental Law and, to Parent’s Knowledge, there are no circumstances that would reasonably be expected to prevent or interfere with Parent’s or any of its Subsidiaries’ compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Parent Material Adverse Effect. To the Parent’s Knowledge, no current or (during the time a prior property was leased or controlled by Parent or any of its Subsidiaries) prior property leased or controlled by Parent or any of its Subsidiaries have had a release of or exposure to Hazardous Materials in material violation of or as would reasonably be expected to result in any material liability of Parent or any of its Subsidiaries pursuant to Environmental Law. No consent, approval or Governmental Authorization of or registration or filing with any Governmental Body is required by Environmental Laws in connection with the execution and delivery of this Agreement or the consummation of the Contemplated Transactions. Prior to the date of this Agreement, Parent has provided or otherwise made available to the Company true and correct copies of all material environmental reports, assessments, studies and audits in the possession or control of Parent or any of its Subsidiaries with respect to any property leased or controlled by Parent or any of its Subsidiaries or any business operated by them.

 

A-51
 

 

3.19 Transactions with Affiliates. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent’s proxy statement filed in 2022 with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K as promulgated under the Securities Act.

 

3.20 Insurance. Parent has delivered or made available to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and each of its Subsidiaries, as of the date of this Agreement. Each of such insurance policies is in full force and effect and Parent and each of its Subsidiaries are in compliance in all material respects with the terms thereof. Other than customary end-of-policy notifications from insurance carriers, since January 1, 2020, neither Parent nor any of its Subsidiaries have received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy; or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Parent and each of its Subsidiaries have provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against Parent or any of its Subsidiaries for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so.

 

3.21 No Financial Advisors. Except as set forth in Section 3.21 of the Parent Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder’s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent or any of its Subsidiaries.

 

3.22 Disclosure. The information supplied by or on behalf of Parent and each of its Subsidiaries for inclusion or incorporation by reference in the Registration Statement, or to be included or supplied by or on behalf of Parent and each of its Subsidiaries for inclusion in any Regulation M-A Filing, shall not at the time the Registration Statement or any such Regulation M-A Filing is filed with the SEC, at any time it is amended or supplemented or at the time the Registration Statement is declared effective by the SEC, as applicable, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material fact, or omit to state any material fact necessary in order to make the statements therein not false or misleading, or omit to state any material fact necessary to correct any statement therein that has become false or misleading. The information supplied by or on behalf of Parent and each of its Subsidiaries for inclusion or incorporation by reference in the Proxy Statement, which information shall be deemed to include all information about or related to Parent and each of its Subsidiaries, the Parent Stockholder Matters and the Parent Stockholder Meeting, shall not, on the date the Proxy Statement is first mailed to Parent’s stockholders, or at the time of the Parent Stockholders’ Meeting or as of the Effective Time, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material fact, or omit to state any material fact necessary in order to make the statements made in the Proxy Statement not false or misleading, or omit to state any material fact necessary to correct any statement in any earlier communication with respect to the solicitation of proxies for the Parent Stockholders’ Meeting that has become false or misleading.

 

A-52
 

 

3.23 Anti-Bribery. None of Parent, any of its Subsidiaries or any of their respective directors, officers, employees or, to Parent’s Knowledge, agents or any other Person acting on their behalf has directly or indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of Anti-Bribery Laws. Neither Parent nor any of its Subsidiaries are or has been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws.

 

3.24 Valid Issuance. The Parent Common Stock to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable.

 

3.25 Disclaimer of Other Representations or Warranties. Except as previously set forth in this Section 3 or in any certificate delivered by Parent or Merger Sub to the Company pursuant to this Agreement, neither Parent nor Merger Sub makes any representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets, liabilities, or operations, and any such other representations or warranties are hereby expressly disclaimed.

 

SECTION 4. CERTAIN COVENANTS OF THE PARTIES

 

4.1 Operation of Parent’s Business.

 

(a) Except (i) as set forth in Section 4.1(a) of the Parent Disclosure Schedule, (ii) as expressly permitted by or required in accordance with this Agreement, including in connection with the Asset Dispositions pursuant to Section 4.7, (iii) as required by applicable Law or (iv) as may be consented to in writing by the Company (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to Section 9 and the Effective Time (the “Pre-Closing Period”): each of Parent and its Subsidiaries shall (A) conduct its business and operations in the Ordinary Course of Business and in compliance in all material respects with all applicable Laws and the requirements of all Contracts that constitute Parent Material Contracts and (B) continue to pay material outstanding accounts payable and other material current Liabilities (including payroll) when due and payable.

 

A-53
 

 

(b) Except (i) as expressly permitted by this Agreement, (ii) as set forth in Section 4.1(b) of the Parent Disclosure Schedule, (iii) as required by applicable Law, (iv) in connection with the Asset Dispositions pursuant to Section 4.7 or the winding down of Parent’s prior research and development activities (including the termination of ongoing contractual obligations related to Parent’s current products or product candidates), or (v) with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:

 

(i) declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except repurchases of shares of Parent Common Stock from terminated employees, directors or consultants of Parent or in connection with the payment of the exercise price and/or withholding Taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under the Parent Incentive Plan in accordance with the terms of such award in effect on the date of this Agreement);

 

(ii) sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any capital stock or other security of Parent or any of its Subsidiaries (except for shares of Parent Common Stock issued upon the valid exercise of outstanding Parent Options or Parent Warrants or upon settlement of Parent RSUs); (B) any option, warrant or right to acquire any capital stock or any other security, other than Parent Options or Parent RSUs granted to directors, employees and service providers in the Ordinary Course of Business which are included in the calculation of the Parent Outstanding Shares; or (C) any instrument convertible into or exchangeable for any capital stock or other security of Parent or any of its Subsidiaries;

 

(iii) except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries’ Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;

 

(iv) form any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;

 

(v) (A) lend money to any Person (except for the advancement of reasonable and customary expenses to employees, directors and consultants in the Ordinary Course of Business), (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others, (D) other than the incurrence or payment of Transaction Expenses, make any capital expenditure in excess of $100,000 of the budgeted capital expenditure amounts set forth in Parent’s operating budget delivered to the Company concurrently with the execution of this Agreement (the “Parent Budget”) or (E) forgive any loans to any Persons, including Parent’s employees, officers, directors or Affiliates;

 

A-54
 

 

(vi) other than as required by applicable Law or the terms of any Parent Benefit Plan as in effect on the date of this Agreement: (A) adopt, terminate, establish or enter into any Parent Benefit Plan; (B) cause or permit any Parent Benefit Plan to be amended; (C) pay any bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or bonus or other compensation or remuneration payable to, any of its directors, officers, consultants or employees, other than increases in base salary and annual cash bonus opportunities and payments made, in each case, in the Ordinary Course of Business; (D) hire any officer or employee; or (E) increase the severance or change of control benefits offered to any current or new employees, directors or consultants;

 

(vii) recognize any labor union or labor organization, except as otherwise required by applicable Law and after prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned);

 

(viii) enter into any material transaction other than in the Ordinary Course of Business;

 

(ix) acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business;

 

(x) sell, assign, transfer, license, sublicense or otherwise dispose of any material Parent IP (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);

 

(xi) make, change or revoke any material Tax election, file any amendment making any material change to any Tax Return, settle or compromise any income or other material Tax liability or submit any voluntary disclosure application, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than seven (7) months), or adopt or change any material accounting method in respect of Taxes;

 

(xii) enter into, materially amend or terminate any Parent Material Contract;

 

(xiii) except as otherwise set forth in the Parent Budget and the incurrence or payment of any Transaction Expenses, make any expenditures, incur any Liabilities or discharge or satisfy any Liabilities, in each case, in amounts that exceed the aggregate amount of the Parent Budget by $100,000;

 

A-55
 

 

(xiv) other than as required by Law or GAAP, take any action to change accounting policies or procedures;

 

(xv) initiate or settle any Legal Proceeding or other claim or dispute involving or against Parent or any Subsidiary of Parent;

 

(xvi) enter into or amend a Parent Material Contract that would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the consummation of the Contemplated Transactions; or

 

(xvii) agree, resolve or commit to do any of the foregoing.

 

(c) Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the Effective Time. Prior to the Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.

 

4.2 Operation of the Company’s Business.

 

(a) Except (i) as set forth in Section 4.2(a) of the Company Disclosure Schedule, (ii) as expressly permitted by or required in accordance with this Agreement, (iii) as required by applicable Law, or (iv) as may be consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period: each of the Company and its Subsidiaries shall (A) conduct its business and operations in the Ordinary Course of Business and in compliance in all material respects with all applicable Laws and the requirements of all Contracts that constitute Company Material Contracts and (B) continue to pay material outstanding accounts payable and other material current Liabilities (including payroll) when due and payable.

 

(b) Except (i) as expressly permitted by this Agreement, (ii) as set forth in Section 4.2(b) of the Company Disclosure Schedule, (iii) as required by applicable Law or (iv) with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:

 

(i) declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except repurchases of shares of Company Common Stock from terminated employees, directors or consultants of Company or in connection with the payment of the exercise price and/or withholding Taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under the Company Incentive Plan in accordance with the terms of such award in effect on the date of this Agreement);

 

A-56
 

 

(ii) sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any capital stock or other security of the Company or any of its Subsidiaries (except for shares of Company Common Stock issued upon the valid exercise of outstanding Company Options or Company Warrants); (B) any option, warrant or right to acquire any capital stock or any other security, other than Company options or restricted stock unit awards granted to directors, employees and service providers in the Ordinary Course of Business which are included in the calculation of the Company Outstanding Shares; or (C) any instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries;

 

(iii) except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries’ Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;

 

(iv) form any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;

 

(v) (A) lend money to any Person (except for the advancement of reasonable and customary expenses to employees, directors and consultants in the Ordinary Course of Business), (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others, (D) other than the incurrence or payment of Transaction Expenses, make any capital expenditure in excess of $100,000 of the budgeted capital expenditure amounts set forth in the Company operating budget delivered to Parent concurrently with the execution of this Agreement (the “Company Budget”) or (E) forgive any loans to any Persons, including the Company’s employees, officers, directors or Affiliates;

 

(vi) other than as required by applicable Law or the terms of any Company Benefit Plan as in effect on the date of this Agreement: (A) adopt, terminate, establish or enter into any Company Benefit Plan; (B) cause or permit any Company Benefit Plan to be amended; (C) pay any bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or bonus or other compensation or remuneration payable to, any of its directors, officers, consultants or employees, other than increases in base salary and annual cash bonus opportunities and payments made, in each case, in the Ordinary Course of Business; (D) increase the severance or change of control benefits offered to any current or new employees, directors or consultants; or (E) terminate or give notice to any officer other than for cause;

 

(vii) recognize any labor union or labor organization, except as otherwise required by applicable Law and after prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned);

 

(viii) enter into any material transaction other than in the Ordinary Course of Business;

 

A-57
 

 

(ix) acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business;

 

(x) sell, assign, transfer, license, sublicense or otherwise dispose of any Company IP (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);

 

(xi) make, change or revoke any material Tax election, file any amendment making any material change to any Tax Return, settle or compromise any income or other material Tax liability or submit any voluntary disclosure application, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than seven (7) months), or adopt or change any material accounting method in respect of Taxes;

 

(xii) enter into, materially amend or terminate any Company Material Contract (other than statements of work entered into or amended in the Ordinary Course of Business);

 

(xiii) except as otherwise set forth in the Company Budget and the incurrence or payment of any Transaction Expenses, make any expenditures, incur any Liabilities or discharge or satisfy any Liabilities, in each case, in amounts that exceed the aggregate amount of the Company Budget by $150,000;

 

(xiv) other than as required by Law or GAAP, take any action to change accounting policies or procedures;

 

(xv) initiate or settle any Legal Proceeding or other claim or dispute involving or against the Company or any Subsidiary of the Company; or

 

(xvi) enter into or amend a Contract that would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the consummation of the Contemplated Transactions; or

 

(xvii) agree, resolve or commit to do any of the foregoing.

 

(c) Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the Effective Time. Prior to the Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.

 

A-58
 

 

4.3 Access and Investigation. Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party’s Representatives to: (a) provide the other Party and such other Party’s Representatives with reasonable access during normal business hours to such Party’s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries; (b) provide the other Party and such other Party’s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request; (c) permit the other Party’s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party’s financial statements and the internal controls of such Party to discuss such matters as the other Party may reasonably deem necessary or appropriate; and (d) make available to the other Party copies of unaudited financial statements, material operating and financial reports prepared for senior management or the board of directors of such Party, and any material notice, report or other document filed with or sent to or received from any Governmental Body in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this Section 4.3 shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party.

 

Notwithstanding the foregoing, any Party may restrict the foregoing access to the extent that any Law, and, with respect to the Company, any contract listed in Section 4.3 of the Company Disclosure Schedule, applicable to such Party requires such Party to restrict or prohibit access to any such properties or information or may redact any of the foregoing documents or reports to the extent necessary to preserve the attorney-client privilege under any circumstances in which such privilege may be jeopardized by the disclosure of such document or report.

 

A-59
 

 

4.4 Parent Non-Solicitation.

 

(a) Parent agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of their respective Representatives to, directly or indirectly, other than relating to communicating, discussing, negotiating or consummating the Asset Dispositions: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) furnish any non-public information regarding Parent or any of its Subsidiaries to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii) engage in discussions (other than to inform any Person of the existence of the provisions in this Section 4.4) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv) approve, endorse or recommend any Acquisition Proposal (subject to Section 5.3); (v) execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction (other than a confidentiality agreement permitted under this Section 4.4(a)); or (vi) publicly propose to do any of the foregoing; provided, however, that, notwithstanding anything contained in this Section 4.4 and subject to compliance with this Section 4.4, prior to obtaining the Required Parent Stockholder Vote, Parent and its Subsidiaries may furnish non-public information regarding Parent or any of its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide Acquisition Proposal by such Person, which the Parent Board determines in good faith, after consultation with Parent’s outside financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) none of Parent, any of its Subsidiaries or any of their respective Representatives shall have breached this Section 4.4 in any material respect; (B) the Parent Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action is reasonably likely to be inconsistent with the fiduciary duties of the Parent Board under applicable Law; (C) substantially contemporaneously with furnishing any such non-public information to such Person, Parent gives the Company notice of Parent’s intention to furnish nonpublic information to, or enter into discussions with, such Person and furnishes such non-public information to the Company (to the extent such information has not been previously furnished by Parent to the Company); and (D) Parent receives from such Person an executed confidentiality agreement containing provisions (including nondisclosure provisions, use restrictions, non-solicitation provisions, no hire and “standstill” provisions), in the aggregate, at least as favorable to Parent as those contained in the Confidentiality Agreement. Without limiting the generality of the foregoing, Parent acknowledges and agrees that, in the event any Representative of Parent or any of its Subsidiaries (whether or not such Representative is purporting to act on behalf of Parent or any of its Subsidiaries) takes any action that, if taken by Parent or any of its Subsidiaries, would constitute a breach of this Section 4.4, the taking of such action by such Representative shall be deemed to constitute a breach of this Section 4.4 by Parent for purposes of this Agreement.

 

(b) If Parent, any of its Subsidiaries or any of their respective Representatives receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then Parent shall promptly (and in no event later than one (1) Business Day after Parent becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the Company orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the material terms thereof). Parent shall keep the Company reasonably informed with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or proposed material modification thereto.

 

(c) Parent shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry (other than any Asset Disposition) that has not already been terminated as of the date of this Agreement and request the destruction or return of any non-public information of Parent or any of its Subsidiaries provided to such Person as soon as practicable after the date of this Agreement.

 

A-60
 

 

4.5 Company Non-Solicitation.

 

(a) The Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of their respective Representatives to, directly or indirectly: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) furnish any non-public information regarding the Company or any of its Subsidiaries to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii) engage in discussions (other than to inform any Person of the existence of the provisions in this Section 4.5) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv) approve, endorse or recommend any Acquisition Proposal; (v) execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction; or (vi) publicly propose to do any of the foregoing. Without limiting the generality of the foregoing, the Company acknowledges and agrees that, in the event any Representative of the Company or any of its Subsidiaries (whether or not such Representative is purporting to act on behalf of the Company or any of its Subsidiaries) takes any action that, if taken by the Company, would constitute a breach of this Section 4.5, the taking of such action by such Representative shall be deemed to constitute a breach of this Section 4.5 by the Company for purposes of this Agreement.

 

(b) If the Company, any of its Subsidiaries or any of their respective Representatives receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then the Company shall promptly (and in no event later than one (1) Business Day after the Company becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise Parent orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the material terms thereof). The Company shall keep Parent reasonably informed with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or proposed material modification thereto.

 

(c) The Company shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement and request the destruction or return of any non-public information of the Company or any of its Subsidiaries provided to such Person as soon as practicable after the date of this Agreement.

 

4.6 Notification of Certain Matters.

 

(a) During the Pre-Closing Period, the Company shall promptly (and in no event later than one (1) Business Day after the Company becomes aware of the same) notify Parent (and, if in writing, furnish copies of any relevant documents) if any of the following occurs: (i) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions; (ii) any Legal Proceeding against or involving or otherwise affecting the Company or its Subsidiaries are commenced, or, to the Company’s Knowledge, threatened against the Company or its Subsidiaries or, to the Company’s Knowledge, any director or officer of the Company or its Subsidiaries; (iii) the Company becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv) the failure of the Company to comply with any covenant or obligation of the Company; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in Sections 6 or 7, as applicable, impossible or materially less likely. No notification given to Parent pursuant to this Section 4.6(a) shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations of the Company or any of its Subsidiaries contained in this Agreement or the Company Disclosure Schedule for purposes of Sections 6 and 7, as applicable.

 

A-61
 

 

(b) During the Pre-Closing Period, Parent shall promptly (and in no event later than one (1) Business Day after Parent becomes aware of the same) notify the Company (and, if in writing, furnish copies of any relevant documents) if any of the following occurs: (i) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions; (ii) any Legal Proceeding against or involving or otherwise affecting Parent or any of its Subsidiaries are commenced, or, to Parent’s Knowledge, threatened against Parent or any of its Subsidiaries or, to Parent’s Knowledge, any director or officer of Parent or any of its Subsidiaries; (iii) Parent becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv) the failure of Parent to comply with any covenant or obligation of Parent or Merger Sub; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in Sections 6 or 8, as applicable, impossible or materially less likely. No notification given to the Company pursuant to this Section 4.6(b) shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations of Parent or any of its Subsidiaries contained in this Agreement or the Parent Disclosure Schedule for purposes of Sections 6 and 8, as applicable.

 

4.7 Potentially Transferable Assets. Parent shall be entitled, but under no obligation, to sell, transfer, license, assign, dividend, spin-off, reclassification, corporate rearrangement, scheme of arrangement or otherwise divest the Potentially Transferable Assets to one or more third parties in one or a series of transactions prior to or substantially concurrently with the Closing (each an “Asset Disposition” and collectively, the “Asset Dispositions”); provided, that any such Asset Disposition shall require, to the extent consistent with applicable Laws, the written consent of the Company, not to be unreasonably withheld, conditioned or delayed, if such Asset Disposition would create any post-disposition material Liabilities for Parent following the Closing. Each Party acknowledges that Parent may not be successful in completing, or may determine not to proceed with, any Asset Dispositions. For clarity, if the Asset Dispositions are not completed prior to, concurrently with, or immediately following the Closing, the Potentially Transferable Assets shall be retained by Parent.

 

4.8 Parent Legacy Note. Prior to the Closing, any Parent IP and other assets and technology of Parent that remain after the Asset Disposition other than the Parent Excluded Assets (“Parent Legacy Assets”) shall be sold, transferred, licensed, assigned, or conveyed into a newly formed Subsidiary of Parent (“Newco”). In consideration of the transfer of such assets, Newco shall assume (i) the Parent Legacy Note, which will be secured by the Parent Legacy Assets and (ii) all other Liabilities of Parent in existence as of the Effective Time (for the avoidance of doubt, such Liabilities shall not include Transaction Expenses).

 

A-62
 

 

4.9 Post-Merger Warrant. Prior to the Closing, Parent shall issue to the holders of shares of Parent Common Stock three Post-Merger Warrants for each five shares of Parent Common Stock held by such holder. Each Post-Merger Warrant shall have the terms set forth in a warrant agreement to be entered into by Parent and a warrant agent (the “Warrant Agreement”). The Warrant Agreement will be on terms reasonably satisfactory to the Company. The parties agree that the Warrant Agreements shall not be assignable or transferable (except in the case of the death of a natural person) and shall not be listed on any securities exchange.

 

4.10 Sarbanes-Oxley Certification. The principal executive officer and the principal financial officer of Parent shall have provided, with regard to any SEC Document file (or to be filed) with the SEC on or after the date of this Agreement, any required certification in the form required under Rule 13a-14 under the Exchange Act and 18 U.S.C. 1350.

 

4.11 Parent Preferred Stock. Subject to requisite Parent stockholder approval and in accordance with the Side Letter, Juvenescence Limited, a company incorporated under the Isle of Man (“Juvenescence”) will convert all of the Parent Preferred Stock owned by Juvenescence, or an Affiliate thereof, into Parent Common Stock prior to the NYSE Reverse Split.

 

4.12 Company Notes. Any Company Note issued to Parent shall be amended prior to Closing so they automatically convert immediately prior to the Merger into shares of Company Capital Stock (which for the avoidance of doubt, such shares of Company Capital Stock will be treated as set forth in Section 1.5(a)(i)).

 

4.13 Company Incentive Plan and Parent Incentive Plan. The Company agrees to cause the Amended and Restated Company Incentive Plan, attached hereto as Exhibit I, to become effective prior to the Effective Time. Parent agrees to cause the Amended and Restated Parent Incentive Plan, attached hereto as Exhibit J, to become effective prior to the Effective Time. The Parties agree that such amendment and restatement shall not require stockholder approval of either the Company or the Parent.

 

A-63
 

 

SECTION 5. ADDITIONAL AGREEMENTS OF THE PARTIES

 

5.1 Registration Statement; Proxy Statement.

 

(a) As promptly as practicable after the date of this Agreement, and in no event more than sixty (60) days following the date of this Agreement unless agreed to in writing by the Parties, the Parties shall prepare, and Parent shall cause to be filed with the SEC, the Registration Statement, in which the Proxy Statement will be included as a prospectus. Parent covenants and agrees that the Registration Statement (and the letter to Parent’s stockholders, a notice of meeting and form of proxy included therewith) will not, at the time that the Proxy Statement or any amendments or supplements thereto are filed with the SEC or are first mailed to Parent’s stockholders, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company covenants and agrees that the information provided by or on behalf of the Company or its Subsidiaries or their respective Representatives to Parent for inclusion in the Registration Statement (including the Company’s audited consolidated financial statements for the fiscal years ended 2022 and 2021, or the Company Interim Financial Statements, as the case may be) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information not misleading. Notwithstanding the foregoing, Parent makes no covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to Parent’s stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by or on behalf of the Company or any of its Representatives for inclusion therein, and the Company makes no covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to Parent’s stockholders, notice of meeting and form of proxy included therewith), if any, other than with respect to the information provided by or on behalf of the Company, any of its Subsidiaries or any of their respective Representatives for inclusion therein. The Company and its legal counsel shall be given a reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. Parent shall use commercially reasonable efforts to cause the Registration Statement and the Proxy Statement to comply with the applicable rules and regulations promulgated by the SEC, to respond promptly to any comments of the SEC or its staff and to have the Registration Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC. Each of the Parties shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent’s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. Each Party shall promptly furnish to the other Party all information concerning such Party and such Party’s Affiliates and such Party’s stockholders that may be required or reasonably requested in connection with any action contemplated by this Section 5.1. If Parent, Merger Sub or the Company becomes aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in filing such amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to Parent’s stockholders. The Company and Parent shall each use commercially reasonable efforts to cause the Registration Statement and the Proxy Statement to comply with applicable federal and state securities Laws requirements.

 

(b) The Parties shall reasonably cooperate with each other and provide, and require their respective Representatives to provide, the other Party and its Representatives, with all true, correct and complete information regarding such Party or its Subsidiaries that is required by Law to be included in the Registration Statement and the Proxy Statement or reasonably requested by the other Party to be included in the Registration Statement and the Proxy Statement.

 

(c) Parent and the Company shall mutually agree on the form and substance of a Current Report on Form 8-K setting forth the anticipated Exchange Ratio as of the anticipated Closing Date, which the Parties shall cause to be filed with the SEC as early as practicable prior to the Parent Stockholders’ Meeting.

 

A-64
 

 

(d) If, in connection with the preparation and filing of the Registration Statement or any other filing required by applicable Law or the SEC’s review thereof, the SEC requests or requires that a tax opinion with respect to the U.S. federal income tax consequences of the Merger be prepared and submitted (a “Tax Opinion”), (i) the Company, Parent and Merger Sub shall each use their reasonable best efforts to deliver to Gibson, Dunn & Crutcher LLP, Bradley Arant Boult Cummings LLP or such other counsel as is reasonably acceptable to Parent and the Company, respectively, in connection with any Tax Opinion to be rendered by such counsel, customary Tax representation letters satisfactory to such counsel, dated and executed as of the date such relevant filing shall have been declared effective by the SEC and such other date(s) as determined to be reasonably necessary by such counsel in connection with the preparation and filing of such Registration Statement or any other filing required by applicable Law, and (ii) the Company and Parent shall each use its reasonable best efforts to cause Gibson, Dunn & Crutcher LLP, Bradley Arant Boult Cummings LLP or such other counsel as is reasonably acceptable to Parent and the Company, respectively, to furnish a Tax Opinion, subject to customary assumptions and limitations, to the effect that the Intended Tax Treatment should apply to the Merger. Gibson, Dunn & Crutcher LLP, Bradley Arant Boult Cummings LLP or such other counsel as is reasonably acceptable to Parent and the Company shall be entitled to rely on the Tax representation letters in rendering the Tax Opinions. For the avoidance of doubt, in no event shall any such Tax Opinion be a condition to Closing.

 

5.2 Company Information Statement; Stockholder Written Consent.

 

(a) Promptly after the Registration Statement shall have been declared effective under the Securities Act, and in any event no later than three (3) Business Days thereafter, the Company shall prepare, with the cooperation of Parent, and cause to be mailed to Company’s stockholders an information statement, which shall include a copy of the Proxy Statement (the “Information Statement”), to solicit the approval by written consent from the Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to the ABCL, for purposes of (i) adopting and approving this Agreement and the Contemplated Transactions, (ii) acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its appraisal rights for its shares of Company Capital Stock pursuant to ABCL Article 13, a true and correct copy of which will be attached thereto, and that such stockholder has received and read a copy of ABCL Article 13, (iii) acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares of Company Capital Stock in connection with the Merger and thereby waives any rights to receive payment of the fair value of its shares of Company Capital Stock under the ABCL, (iv) electing that the consummation of the Merger (and any plan of merger related thereto) is not a Deemed Liquidation Event, as such term is defined in the Company’s Organizational Documents, and (v) electing an automatic conversion of each share of Company Preferred Stock into shares of Company Common Stock immediately prior to the Effective Time in accordance with the relevant provisions of the Company’s Organizational Documents (the “Preferred Stock Conversion”) (collectively, the “Company Stockholder Matters”). Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this Section 5.2(a) shall be subject to Parent’s advance review and reasonable approval. The Parties shall reasonably cooperate with each other and provide, and require their respective Representatives to provide, the other Party and its Representatives with all true, correct and complete information regarding such Party or its Subsidiaries that is required by Law to be included in the Information Statement or reasonably requested by the other Party to be included in the Information Statement.

 

A-65
 

 

(b) The Company covenants and agrees that the Information Statement, including any pro forma financial statements included therein (and the letter to stockholders and form of Company Stockholder Written Consent included therewith), will not, at the time that the Information Statement or any amendment or supplement thereto is first mailed, distributed or otherwise made available to the stockholders of the Company, at the time of receipt of the Required Company Stockholder Vote and at the Effective Time, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, the Company makes no covenant, representation or warranty with respect to statements made in the Information Statement (and the letter to the stockholders and form of Company Stockholder Written Consent included therewith), if any, based on information furnished in writing by Parent, any of its Subsidiaries or any of their respective Representatives for inclusion therein. Each of the Parties shall use commercially reasonable efforts to cause the Information Statement to comply with the applicable rules and regulations promulgated by the SEC and applicable federal and state securities Laws requirements in all material respects.

 

(c) Promptly following receipt of the Required Company Stockholder Vote, the Company shall prepare and mail a notice (the “Stockholder Notice”) to every stockholder of the Company that did not execute the Company Stockholder Written Consent. The Stockholder Notice shall (i) be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with the ABCL and in the best interests of the stockholders of the Company and authorized, approved and adopted this Agreement, the Merger and the other Contemplated Transactions, (ii) provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with the ABCL and the Organizational Documents of the Company and (iii) include a description of the appraisal rights of the Company’s stockholders available under the ABCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this Section 5.2(c) shall be subject to Parent’s advance review and reasonable approval.

 

(d) The Company agrees that: (i) the Company Board shall recommend that the Company’s stockholders vote to approve the Company Stockholder Matters and shall use commercially reasonable efforts to solicit such approval from each of the Company Signatories within the time set forth in Section 5.2(a) (the recommendation of the Company Board that the Company’s stockholders vote to adopt and approve the Company Stockholder Matters being referred to as the “Company Board Recommendation”); and (ii) the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (ii), collectively, a “Company Board Adverse Recommendation Change”).

 

A-66
 

 

(e) The Company’s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with Section 5.2(a) and Section 5.2(d) shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal.

 

5.3 Parent Stockholders’ Meeting.

 

(a) Promptly after the Registration Statement has been declared effective by the SEC under the Securities Act, Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock for the purpose of seeking approval of this Agreement and the Contemplated Transactions, including:

 

(i) the amendment of Parent’s certificate of incorporation to effect the NYSE Reverse Split;

 

(ii) if applicable, the consummation of the Asset Dispositions pursuant to Section 4.7;

 

(iii) the issuance of Parent Common Stock or other securities of Parent that represent (or are convertible into) more than twenty percent (20%) of the shares of Parent Common Stock outstanding immediately prior to the Merger to the holders of Company Capital Stock, Company Options and Company Warrants in connection with the Contemplated Transactions and the change of control of Parent resulting from the Contemplated Transactions, in each case pursuant to the NYSE rules;

 

(iv) the issuance of the Post-Merger Warrants to the holders of Parent Common Stock in connection with the Contemplated Transactions;

 

(v) the amendment and restatement of the Parent’s certificate of incorporation, attached hereto as Exhibit F, upon the Effective Time;

 

(vi) the adoption of the new Parent Incentive Plan, attached hereto as Exhibit K, along with the reservation of 1,725,000 shares of Parent Common Stock for use under the new Parent Incentive Plan;

 

(vii) if not previously approved by Parent’s stockholders, the issuance of shares of Parent Common Stock that represent more than twenty percent (20%) of the shares of Parent Common Stock outstanding immediately prior to conversion of the Parent Series B Preferred Stock in connection with the conversion of the Parent Preferred Stock required in Section 4.11 and the change of control of Parent resulting from the conversion of the Parent Preferred Stock, in each case pursuant to the NYSE rules; and

 

A-67
 

 

(viii) any other proposals the Parties deem necessary or desirable to consummate the Contemplated Transactions.

 

(the matters contemplated by Section 5.3(a)(i) through Section 5.3(a)(viii) are referred to as the “Parent Stockholder Matters,” and such meeting, the “Parent Stockholders’ Meeting”).

 

(b) The Parent Stockholders’ Meeting shall be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act and, in any event, no later than forty-five (45) calendar days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholders’ Meeting are solicited in compliance with all applicable Laws. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholders’ Meeting, or a date preceding the date on which the Parent Stockholders’ Meeting is scheduled, Parent reasonably believes that (i) it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present, or (ii) it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholders’ Meeting, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholders’ Meeting as long as the date of the Parent Stockholders’ Meeting is not postponed or adjourned more than an aggregate of sixty (60) calendar days in connection with any postponements or adjournments.

 

(c) Parent agrees that, subject to Section 5.3(d): (i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in Section 5.3(b) above, (ii) the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent’s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board with respect to the Parent Stockholder Matters being referred to as the “Parent Board Recommendation”); and (iii) the Parent Board Recommendation shall not be withheld, amended, withdrawn or modified (and the Parent Board shall not publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company, and no resolution by the Parent Board or any committee thereof to withdraw or modify the Parent Board Recommendation in a manner adverse to the Company or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (iii), collectively, a “Parent Board Adverse Recommendation Change”).

 

A-68
 

 

(d) Notwithstanding anything to the contrary contained in this Agreement, and subject to compliance with Section 4.4 and this Section 5.3(d), if at any time prior to the approval of the Parent Stockholder Matters at the Parent Stockholders’ Meeting by the Required Parent Stockholder Vote:

 

(i) if Parent has received a bona fide Acquisition Proposal (which Acquisition Proposal did not arise out of a material breach of Section 4.4) from any Person that has not been withdrawn and after consultation with outside legal counsel, the Parent Board shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer, (x) the Parent Board may make a Parent Board Adverse Recommendation Change or (y) Parent may terminate this Agreement pursuant to Section 9.1(j) to enter into a Permitted Alternative Agreement with respect to such Superior Offer, if and only if: (A) the Parent Board determines in good faith, after consultation with Parent’s outside legal counsel, that the failure to do so would be reasonably likely to be inconsistent with the fiduciary duties of the Parent Board to Parent’s stockholders under applicable Law; (B) Parent shall have given the Company prior written notice of its intention to consider making a Parent Board Adverse Recommendation Change or terminate this Agreement pursuant to Section 9.1(j) at least four (4) Business Days prior to making any such Parent Board Adverse Recommendation Change or termination (a “Determination Notice”; and such period, the “Parent Notice Period”) (which notice shall not constitute a Parent Board Adverse Recommendation Change); and (C)(1) Parent shall have provided to the Company a summary of the material terms and conditions of the Acquisition Proposal in accordance with Section 4.4(b), (2) Parent shall, and shall have caused its Representatives to, during the Parent Notice Period, negotiate in good faith with the Company (to the extent the Company desires to negotiate) to enable the Company to propose in writing an offer binding on the Company to effect such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, and (3) after considering the results of such negotiations and giving effect to the proposals made by the Company, if any, after consultation with outside legal counsel, the Parent Board shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer and that the failure to make the Parent Board Adverse Recommendation Change or terminate this Agreement pursuant to Section 9.1(j) would be inconsistent with the fiduciary duties of the Parent Board to Parent’s stockholders under applicable Law; provided, that (x) the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation during the Parent Notice Period, which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer or to terminate this Agreement pursuant to Section 9.1(j) during the Parent Notice Period; (y) during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to enable the Company to propose in writing an offer binding on the Company to effect such adjustments to the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer; and (z) in the event of any material amendment to any Superior Offer (including any revision in price or percentage of the combined company that Parent’s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least two (2) Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this Section 5.3(d) and the Parent Board shall not make a Parent Board Adverse Recommendation Change or terminate this Agreement pursuant to Section 9.1(j) prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions); and

 

A-69
 

 

(ii) other than in connection with an Acquisition Proposal, the Parent Board may make a Parent Board Adverse Recommendation Change in response to a Parent Change in Circumstance, if and only if: (A) the Parent Board determines in good faith, after consultation with Parent’s outside legal counsel, that the failure to do so would be reasonably likely to be inconsistent with the fiduciary duties of the Parent Board to Parent’s stockholders under applicable Law; (B) Parent shall have given the Company a Determination Notice at least four (4) Business Days prior to making any such Parent Board Adverse Recommendation Change; and (C)(1) Parent shall have specified the Parent Change in Circumstance in reasonable detail, including the material facts and circumstances related to the applicable Parent Change in Circumstance, (2) Parent shall have given the Company the four (4) Business Days after the Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with the Company (to the extent the Company desires to do so) with respect to such proposed revisions or other proposal, if any, and (3) after considering the results of any such negotiations and giving effect to the proposals made by the Company, if any, after consultation with outside legal counsel, the Parent Board shall have determined, in good faith, that the failure to make the Parent Board Adverse Recommendation Change in response to such Parent Change in Circumstance or terminate this Agreement pursuant to Section 9.1(j) would be inconsistent with its fiduciary duties of the Parent Board to Parent’s stockholders under applicable Law. For the avoidance of doubt, the provisions of this Section 5.3(d)(ii) shall also apply to any material change to the facts and circumstances relating to such Parent Change in Circumstance and require a new Determination Notice, except that the references to four (4) Business Days shall be deemed to be two (2) Business Days.

 

(e) Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i) complying with Rules 14d-9 and 14e-2(a) promulgated under the Exchange Act, (ii) issuing a “stop, look and listen” communication or similar communication of the type contemplated by Section 14d-9(f) under the Exchange Act or (iii) otherwise making any disclosure to Parent’s stockholders; provided, however, that any disclosure made by Parent or the Parent Board pursuant to the foregoing shall be limited to a statement that Parent is unable to take a position with respect to the bidder’s tender offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that failure to make additional disclosure would be inconsistent with its fiduciary duties under applicable Law. Parent shall not withdraw or modify in a manner adverse to the Company the Parent Board Recommendation unless specifically permitted pursuant to the terms of Section 5.3(d). Unless the Parent Board has effected a Parent Board Adverse Recommendation Change in accordance with this Section 5.3 and this Agreement is otherwise terminated pursuant to Section 9.1, Parent’s obligation to call, give notice of and hold the Parent Stockholders’ Meeting in accordance with Section 5.3(b) shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Acquisition Proposal, or by any Parent Board Adverse Recommendation Change.

 

A-70
 

 

5.4 Regulatory Approvals. Each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports, filings and other documents required to be filed by such Party with or otherwise submitted by such Party to any Governmental Body with respect to the Contemplated Transactions, to submit promptly any additional information requested by any such Governmental Body, and to keep the other Party promptly informed of any communication from or to any Governmental Body.

 

5.5 Options and Warrants.

 

(a) At the Effective Time, each Company Option that is outstanding and unexercised immediately prior to the Effective Time under the Company Incentive Plan, whether or not vested, shall be converted into and become an option to purchase Parent Common Stock, and Parent shall assume the Company Incentive Plan (if necessary) and each such Company Option in accordance with the terms (as in effect as of the date of this Agreement) of the Company Incentive Plan and the terms of the stock option agreement by which such Company Option is evidenced (but with changes to such documents as Parent in good faith determines are appropriate to reflect the substitution of the Company Options by Parent to purchase shares of Parent Common Stock). All rights, terms, and restrictions with respect to Company Common Stock under Company Options assumed by Parent shall thereupon be converted into rights with respect to Parent Common Stock. Accordingly, from and after the Effective Time: (i) each Company Option assumed by Parent may be exercised solely for shares of Parent Common Stock; (ii) the number of shares of Parent Common Stock subject to each Company Option assumed by Parent shall be determined in accordance with the Allocation Certificate as provided in Section 5.15; (iii) the per share exercise price for the Parent Common Stock issuable upon exercise of each Company Option assumed by Parent shall be determined in accordance with the Allocation Certificate as provided in Section 5.15; and (iv) any restriction on the exercise of any Company Option assumed by Parent shall continue in full force and effect and the term, exercisability, vesting schedule, and other provisions of such Company Option shall otherwise remain unchanged; provided, however, that: (A) the determination in the Allocation Certificate of the number of shares of Parent Common Stock subject to each Company Option assumed by Parent shall be based on the same ratio as that applied to the Company Common Stock to determine the number of shares of Parent Common Stock each holder of Company Common Stock shall receive; (B) the determination in the Allocation Certificate of the per share exercise price for the Parent Common Stock issuable upon exercise of each Company Option assumed by Parent shall be adjusted equitably to reflect the ratio described in clause (A); (C) to the extent provided under the terms of the respective stock option agreements governing the Company Options and the Company Incentive Plan, Parent may amend the terms of the Company Options and the Company Incentive Plan, in accordance with the terms thereof, to reflect Parent’s substitution of the Company Options with options to purchase Parent Common Stock (such as by making any change in control or similar definition relate to Parent and having any provision that provides for the adjustment of Company Options upon the occurrence of certain corporate events relate to corporate events that relate to Parent and/or Parent Common Stock), and such Company Options shall be subject to further adjustment as appropriate and necessary to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization, or other similar transaction with respect to Parent Common Stock subsequent to the Effective Time; and (D) the Parent Board or a committee thereof shall succeed to the authority and responsibility of the Company Board or any committee thereof with respect to each Company Option assumed by Parent. Each Company Option so assumed by Parent is a nonqualified stock option (that is, an option that is not intended to qualify as an incentive stock option as defined in Section 422 of the Code), and, further, the assumption of such Company Option pursuant to this Section 5.5(a) shall be effected in a manner that satisfies the requirements of Section 409A of the Code and the Treasury Regulations promulgated thereunder (including the applicable portions of Treasury Regulation Section 1.424-1 as applied under Treasury Regulation Section 1.409A-1(b)(5)(v)(D)), and this Section 5.5(a) will be construed consistent with this intent.

 

A-71
 

 

(b) Parent shall file with the SEC, promptly, but no later than thirty (30) calendar days, after the Effective Time, a registration statement on Form S-8 (or any successor form), if available for use by Parent, relating to the shares of Parent Common Stock that are issuable with respect to Company Options assumed by Parent in accordance with Section 5.5(a).

 

(c) At the Effective Time, each Company Warrant that is outstanding and unexercised as of immediately prior to the Effective Time, if any, shall be converted into and become a warrant to purchase Parent Common Stock and Parent shall assume each such Company Warrant in accordance with its terms. All rights with respect to Company Capital Stock under Company Warrants assumed by Parent shall thereupon be converted into rights with respect to Parent Common Stock. Accordingly, from and after the Effective Time: (i) each Company Warrant assumed by Parent may be exercised solely for shares of Parent Common Stock; (ii) the number of shares of Parent Common Stock subject to each Company Warrant assumed by Parent shall be determined in accordance with the Allocation Certificate as provided in Section 5.15; (iii) the per share exercise price for the Parent Common Stock issuable upon exercise of each Company Warrant assumed by Parent shall be determined in accordance with the Allocation Certificate as provided in Section 5.15; and (iv) any restriction on any Company Warrant assumed by Parent shall continue in full force and effect and the term and other provisions of such Company Warrant shall otherwise remain unchanged; provided, however, that: (A) the determination in the Allocation Certificate of the number of shares of Parent Common Stock subject to each Company Warrant assumed by Parent shall be based on the same ratio as that applied to the Company Common Stock to determine the number of shares of Parent Common Stock each holder of Company Common Stock shall receive; and (B) the determination in the Allocation Certificate of the per share exercise price for the Parent Common Stock issuable upon exercise of each Company Warrant assumed by Parent shall be adjusted equitably to reflect the ratio described in clause (A).

 

A-72
 

 

(d) Prior to the Effective Time, the Company shall take all actions that may be necessary (under the Company Incentive Plan, the Company Warrants and otherwise) to effectuate the provisions of this Section 5.5 and to ensure that, from and after the Effective Time, holders of Company Options and Company Warrants have no rights with respect thereto other than those specifically provided in this Section 5.5.

 

(e) Immediately prior to the NYSE Reverse Split, each Out of the Money Parent Option that is outstanding and unexercised as of immediately prior to the NYSE Reverse Split, if any, shall be canceled without the payment of consideration therefor. In accordance with the terms and conditions set forth in the Parent Incentive Plan, Parent shall notify each holder of an Out of the Money Parent Option that each such Out of the Money Parent Option shall become exercisable at least ten days prior to the NYSE Reverse Split and shall thereafter be canceled.

 

5.6 Indemnification of Officers and Directors.

 

(a) From the Effective Time through the sixth (6th) anniversary of the date on which the Effective Time occurs, each of Parent and the Surviving Corporation, jointly and severally, shall indemnify and hold harmless each person who is now, or has been at any time prior to the date of this Agreement, or who becomes prior to the Effective Time, a director, officer, fiduciary or agent of Parent or the Company and their respective Subsidiaries, respectively (the “D&O Indemnified Parties”), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys’ fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&O Indemnified Party is or was a director, officer, fiduciary or agent of Parent or of the Company or their respective Subsidiaries, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest extent permitted under applicable Law for directors or officers of corporations in the relevant jurisdiction. Each D&O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Corporation, jointly and severally, upon receipt by Parent or the Surviving Corporation from the D&O Indemnified Party of a request therefor; provided, that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by applicable Law, to repay such advances if it is ultimately determined that such person is not entitled to indemnification.

 

(b) The provisions of the Organizational Documents of Parent or any of its Subsidiaries with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Parent or any of its Subsidiaries that are set forth in the Organizational Documents of Parent or any of its Subsidiaries as of the date of this Agreement shall not be amended, modified or repealed for a period of six (6) years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Parent or any of its Subsidiaries, unless such modification is required by applicable Law. The Organizational Documents of the Surviving Corporation shall contain, and Parent shall cause the Organizational Documents of the Surviving Corporation to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those set forth in the Organizational Documents of Parent as of the date of this Agreement.

 

A-73
 

 

(c) From and after the Effective Time, (i) the Surviving Corporation shall fulfill and honor in all respects the obligations of the Company or any of its Subsidiaries to its D&O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Organizational Documents of the Company or any of its Subsidiaries and pursuant to any indemnification agreements between the Company or any of its Subsidiaries and such D&O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii) Parent shall fulfill and honor in all respects the obligations of Parent or any of its Subsidiaries to its D&O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Organizational Documents of Parent or any of its Subsidiaries and pursuant to any indemnification agreements between Parent or any of its Subsidiaries and such D&O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time.

 

(d) From and after the Effective Time, Parent shall maintain directors’ and officers’ liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase, prior to the Effective Time, a six (6)-year prepaid “tail policy” for the non-cancellable extension of the directors’ and officers’ liability coverage of Parent’s and any of its Subsidiaries’ existing directors’ and officers’ insurance policies and Parent’s existing fiduciary liability insurance policies (if any), in each case, for a claims reporting or discovery period of at least six (6) years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time. During the term of the “tail” policy, Parent shall not take any action following the Effective Time to cause such “tail” policy to be canceled or any provision therein to be amended or waived in any manner that would adversely affect in any material respect the rights of its or any of its Subsidiaries’ former and current officers and directors.

 

(e) From and after the Effective Time, Parent shall pay all expenses, including reasonable attorneys’ fees, that are incurred by the persons referred to in this Section 5.6 in connection with their successful enforcement of the rights provided to such persons in this Section 5.6.

 

(f) All rights to exculpation, indemnification and advancement of expenses for acts or omissions occurring at or prior to the Effective Time, whether asserted or claimed prior to, at or after the Closing, now existing in favor of the current or former directors, officers or employees, as the case may be, of Parent or the Company or any of their respective Subsidiaries as provided in their respective Organizational Documents or in any agreement shall survive the Merger and shall continue in full force and effect. The provisions of this Section 5.6 are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company and any of their respective Subsidiaries by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&O Indemnified Parties, their heirs and their representatives.

 

A-74
 

 

(g) From and after the Effective Time, in the event Parent or the Surviving Corporation or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Corporation, as the case may be, shall succeed to the obligations set forth in this Section 5.6. Parent shall cause the Surviving Corporation to perform all of the obligations of the Surviving Corporation under this Section 5.6. The obligations set forth in this Section 5.6 shall not be terminated, amended or otherwise modified in any manner that adversely affects any D&O Indemnified Party, or any person who is a beneficiary under the policies referred to in this Section 5.6 and their heirs and representatives, without the prior written consent of such affected D&O Indemnified Party or other person

 

5.7 Additional Agreements. The Parties shall (a) use commercially reasonable efforts to cause to be taken all actions necessary to consummate the Contemplated Transactions and (b) reasonably cooperate with the other Parties and provide the other Parties with such assistance as may be reasonably requested for the purpose of facilitating the performance by each Party of its respective obligations under this Agreement and to enable the Surviving Corporation to continue to meet its obligations under this Agreement following the Closing. Without limiting the generality of the foregoing, each Party to this Agreement: (i) shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions; (ii) shall use reasonable best efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract (with respect to Contracts set forth in Section 5.7 of the Company Disclosure Schedule or Section 5.7 of the Parent Disclosure Schedule, as applicable) to remain in full force and effect; (iii) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions; and (iv) shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement.

 

5.8 Public Announcement. The initial press release relating to this Agreement shall be a joint press release issued by the Company and Parent and thereafter Parent and the Company shall consult with each other before issuing any further press release(s) or otherwise making any public statement or making any announcement to Parent Associates or Company Associates (to the extent not previously issued or made in accordance with this Agreement) with respect to the Contemplated Transactions and shall not issue any such press release, public statement or announcement to Parent Associates or Company Associates without the other Party’s written consent (which shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing: (a) each Party may, without such consultation or consent, make any public statement in response to specific questions from the press, analysts, investors or those attending industry conferences, make internal announcements to employees and make disclosures in Parent SEC Documents, so long as any such statements, announcements or disclosures are consistent with and do not disclose material information not previously disclosed in previous press releases, public disclosures or public statements made jointly by the Parties (or individually, if approved by the other Party) in compliance with this Section 5.8; (b) a Party may, without the prior consent of the other Party hereto but subject to giving advance notice to the other Party of, and consulting with the other Party regarding, the text of such press release, announcement or statement, issue any such press release or make any such public announcement or statement which Parent shall have determined in good faith, upon the advice of outside legal counsel, is required by any applicable Law; and (c) Parent need not consult with the Company in connection with such portion of any press release, public statement or filing to be issued or made pursuant to Section 5.3(e) or with respect to any Acquisition Proposal or Parent Board Adverse Recommendation Change.

 

A-75
 

 

5.9 Listing. Parent shall use its commercially reasonable efforts, (a) to maintain its existing listing on NYSE until the Closing Date and to obtain approval of the listing of the combined company on NYSE; (b) without derogating from the generality of the requirements of the foregoing clause (a) and to the extent required by the rules and regulations of NYSE, (i) to prepare and submit to NYSE a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and (ii) to cause such shares to be approved for listing (subject to official notice of issuance); (c) to effect the NYSE Reverse Split and (d) to the extent required by to Section 101 of the NYSE American Company Guide, to file an initial listing application for the Parent Common Stock on NYSE (the “NYSE Listing Application”) and to cause such NYSE Listing Application to be conditionally approved prior to the Effective Time. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with NYSE rules and regulations. The Company will cooperate with Parent as reasonably requested by Parent with respect to the NYSE Listing Application and promptly furnish to Parent all information concerning the Company and its stockholders that may be required or reasonably requested in connection with any action contemplated by this Section 5.9.

 

5.10 Tax Matters.

 

(a) For United States federal income Tax purposes, (i) the Parties intend that the Merger qualify as a “reorganization” within the meaning of Section 368(a) of the Code (the “Intended Tax Treatment”), and (ii) this Agreement is intended to be, and is hereby adopted as, a “plan of reorganization” for purposes of Section 354 and 361 of the Code and Treasury Regulations Sections 1.368-2(g) and 1.368-3(a), to which Parent, Merger Sub and the Company are parties under Section 368(b) of the Code.

 

(b) The Parties shall use their respective commercially reasonable efforts to cause the Merger to qualify, and will not take any action or cause any action to be taken which action would reasonably be expected to prevent the Merger from qualifying, for the Intended Tax Treatment. The Parties shall use commercially reasonable efforts to operate the Surviving Corporation so as to meet the “continuity of business enterprise” requirement. The Parties shall not file any U.S. federal, state or local Tax Return in a manner that is inconsistent with the Intended Tax Treatment, unless otherwise required by applicable Law.

 

A-76
 

 

5.11 Directors and Officers. The Parties shall use reasonable best efforts and take all necessary action so that (a) effective as of the Effective Time, the Parent Board is comprised of seven (7) members, with two (2) of such members designated by Parent, two (2) of such members designated by the Company, two (2) of such member whom shall meet NYSE director independence requirements and be designated by mutual agreement of Parent and the Company, and one (1) member which shall be the Company’s Chief Executive Officer as of immediately following the Closing, (b) the Persons listed in Exhibit L under the heading “Officers” are elected or appointed, as applicable, to the positions of officers of Parent, as set forth therein, to serve in such positions effective as of the Effective Time until successors are duly appointed and qualified in accordance with applicable Law and (c) the Persons listed in Exhibit L under the heading “Directors” are elected or appointed, as applicable, to the positions of directors of Parent, as set forth therein, to serve in such positions effective as of the Effective Time until successors are duly appointed and qualified in accordance with applicable Law. If any Person listed in Exhibit L is unable or unwilling to serve as an officer of Parent, as set forth therein, as of the Effective Time, the Parties shall mutually agree upon a successor. If any Person listed in Exhibit L is unable or unwilling to serve as a director of Parent, as set forth therein, as of the Effective Time, the Party appointing such Person (as set forth on Exhibit L) shall designate a successor. The Persons listed in Exhibit L under the heading “Board Designees - Parent” shall be Parent’s designees pursuant to clause (a) of this Section 5.11 (which list may be changed by Parent at any time prior to the Closing by written notice to the Company to include different board designees who are reasonably acceptable to the Company). The Persons listed in Exhibit L under the heading “Board Designees - Company” shall be the Company’s designees pursuant to clause (a) of this Section 5.11 (which list may be changed by the Company at any time prior to the Closing by written notice to Parent to include different board designees who are reasonably acceptable to Parent). The Persons listed in Exhibit L under the heading “Board Designees - Independent” shall be the independent members mutually agreed upon between the Company and Parent pursuant to clause (a) of this Section 5.11 (which list may be changed by mutual written agreement of the Company and Parent at any time prior to the Closing).

 

5.12 Termination of Certain Agreements and Rights.

 

(a) The Company shall cause any Investor Agreements (excluding the Company Stockholder Support Agreements) to be terminated immediately prior to the Effective Time, without any liability being imposed on the part of Parent or the Surviving Corporation.

 

(b) Parent agrees to use commercially reasonable efforts to (a) terminate, assign or fully perform all Parent Contracts (except (i) Parent Contracts with obligations that do not exceed $25,000 for Parent over a 12-month period, (ii) Parent Contracts set forth on Schedule 5.12 of the Parent Disclosure Schedule and (iii) any other Parent Contract agreed to by Parent and Company) (the “Specified Parent Contracts”) and (b) fully satisfy, waive or otherwise discharge all obligations of Parent under all Specified Parent Contracts, in each case prior to the Closing.

 

5.13 Section 16 Matters. Prior to the Effective Time, Parent and the Company shall take all such steps as may be required (to the extent permitted under applicable Laws) to cause any acquisitions of Parent Common Stock, restricted stock awards to acquire Parent Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section 16(a) of the Exchange Act with respect to Parent, to be exempt under Rule 16b-3 promulgated under the Exchange Act. Promptly following the date of this Agreement and at least ten (10) calendar days prior to the Closing Date, the Company shall furnish the following information to Parent for each individual who, immediately after the Effective Time, will become subject to the reporting requirements of Section 16(a) of the Exchange Act with respect to Parent: (a) the number of shares of Company Capital Stock owned by such individual and expected to be exchanged for shares of Parent Common Stock pursuant to the Merger, and (b) the number of other derivative securities (if any) with respect to Company Capital Stock owned by such individual and expected to be converted into shares of Parent Common Stock, restricted stock awards to acquire Parent Common Stock or derivative securities with respect to Parent Common Stock in connection with the Merger.

 

A-77
 

 

5.14 Cooperation. Each Party shall cooperate reasonably with the other Party and shall provide the other Party with such assistance as may be reasonably requested for the purpose of facilitating the performance by each Party of its respective obligations under this Agreement and to enable the combined entity to continue to meet its obligations following the Effective Time.

 

5.15 Allocation Certificates.

 

(a) The Company will prepare and deliver to Parent no later than three (3) Business Days prior to the Closing Date a certificate signed by the Chief Financial Officer of the Company in a form reasonably acceptable to Parent setting forth (as of immediately prior to the Effective Time) (i) each holder of Company Capital Stock, Company Options and Company Warrants, (ii) such holder’s name, address and email address; (iii) the number and type of Company Capital Stock held and/or underlying the Company Options and Company Warrants as of the immediately prior to the Effective Time for each such holder; (iv) the number of shares of Parent Common Stock to be issued to such holder, or to underlie any Parent Option, Parent Warrant or Parent RSU to be issued to such holder, pursuant to this Agreement in respect of the Company Capital Stock, Company Options or Company Warrants held by such holder as of immediately prior to the Effective Time; and (v) the exercise price of any Parent Option, Parent Warrant or Parent RSU to be issued to such holder, pursuant to this Agreement in respect of the Company Options or Company Warrants held by such holder as of immediately prior to the Effective Time (the “Allocation Certificate”).

 

(b) Parent will prepare and deliver to the Company at least three (3) Business Days prior to the Closing Date a certificate signed by the Chief Financial Officer of Parent in a form reasonably acceptable to the Company, setting forth, as of immediately prior to the Effective Time (i) each record holder of Parent Common Stock, Parent Warrants, Parent Options or Parent RSUs, (ii) such record holder’s name and address and (iii) the number of shares of Parent Common Stock held and/or underlying the Parent Warrants, Parent Options or Parent RSUs as of the Effective Time for such holder (the “Parent Outstanding Shares Certificate”).

 

5.16 Company Financial Statements. As promptly as reasonably practicable following the date of this Agreement: (i) and no later than fifteen (15) calendar days after the date hereof, the Company will furnish to Parent audited consolidated financial statements for the fiscal year ended 2022 (the “Company Audited Financial Statements”); and (ii) the Company will furnish to Parent unaudited interim consolidated financial statements for each interim period completed prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the “Company Interim Financial Statements”). Each of the Company Audited Financial Statements and the Company Interim Financial Statements will be suitable for inclusion in the Proxy Statement and the Registration Statement and prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on that basis will present fairly, in all material respects, the consolidated financial position and the results of operations, changes in stockholders’ equity, and cash flows of the Company and its consolidated Subsidiaries as of the dates of and for the periods referred to in the Company Financial Statements, the Company Audited Financial Statements and Company Interim Financial Statements, as the case may be.

 

A-78
 

 

5.17 Takeover Statutes. If any Takeover Statute is or may become applicable to the Contemplated Transactions, each of the Company, the Company Board, Parent and the Parent Board, as applicable, shall grant such approvals and take such actions as are necessary so that the Contemplated Transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such Takeover Statute on the Contemplated Transactions.

 

5.18 Stockholder Litigation. Until the earlier of the termination of this Agreement in accordance with its terms or the Effective Time, Parent shall (a) promptly advise the Company in writing of any stockholder litigation or investigation against it or its directors relating to this Agreement, the Merger or the Contemplated Transactions and keep the Company fully informed regarding such stockholder litigation and (b) give the Company the opportunity to participate in the defense or settlement of any stockholder litigation or investigation relating to this Agreement or any of the Contemplated Transactions, and not settle any such litigation or investigation without the Company’s written consent, which will not be unreasonably withheld, conditioned or delayed.

 

5.19 Parent Benefit Plans. No later than five (5) Business Days before the Closing Date, the Parent shall terminate, effective as of the day immediately preceding the date the Company becomes a member of the same controlled group of corporations (as defined in Section 414(b) of the Code) as Parent, any and all 401(k) plans maintained by the Parent or any of its Subsidiaries. The Parent shall promptly provide Company with evidence that the 401(k) plan(s) of the Parent and/or its Subsidiaries have been terminated pursuant to resolutions of the Parent’s Board of Directors or the board of directors of its Subsidiaries, as applicable. The form and substance of such resolutions shall be subject to review and approval of the Company, which shall not be unreasonably withheld, conditioned or delayed. The Parent shall also take such other actions in furtherance of terminating any such 401(k) plan(s) as Company may reasonably request. The intent of the Parties is to have the Company’s 401(k) plan and its other employee benefit plans become the employee benefit plans of the Parent and its Subsidiaries in order to reduce the disruption of the employees of the Company and avoid the duplication of plans. Following the Effective Time, the parties agree to cooperate to transition all Parent Benefit Plans (other than the Parent Incentive Plan, employment agreements, and severance arrangements) to Company Benefit Plans as soon after the Effective Time as practicable. The Parent shall promptly provide Company with evidence that such Parent Benefit Plans are being transitioned and terminated pursuant to resolutions of the Parent’s Board of Directors or the board of directors of its Subsidiaries, as applicable. The form and substance of such resolutions shall be subject to review and approval of the Company, which shall not be unreasonably withheld. The Parent shall also take such other actions in furtherance of transitioning and terminating such Parent Benefit Plans as the Company may reasonably request.

 

A-79
 

 

5.20 Company 280G Actions. To the extent that any “disqualified individual” (within the meaning of Section 280G(c) of the Code and the regulations thereunder) has the right to receive any payments or benefits that could be deemed to constitute “parachute payments” (within the meaning of Section 280G(b)(2) of the Code and the regulations thereunder), then, the Company shall (i) no later than five Business Days prior to the Effective Time, solicit and use reasonable efforts to obtain from each such “disqualified individual” a waiver of such disqualified individual’s rights to some or all of such payments or benefits (to the extent such waiver is obtained, these amounts are referred to as the “Waived 280G Benefits”) so that any remaining payments and/or benefits shall not be deemed to be “excess parachute payments” (within the meaning of Section 280G(a) of the Code and the regulations thereunder), and (ii) no later than three Business Days prior to the Effective Time, with respect to each individual who agrees to the waiver described in clause (i), submit to a vote or consent of the holders of the Company Capital Stock entitled to vote on such matters, in the manner required under Section 280G(b)(5) of the Code and the regulations promulgated thereunder, along with disclosure intended to satisfy such requirements (including Q&A 7 of Section 1.280G-1 of such regulations), the right of any such “disqualified individual” to receive the Waived 280G Benefits. Prior to soliciting such waivers and approval, the Company shall provide drafts of such waivers and disclosure and approval materials to Parent for its review and comment no later than two Business Days prior to soliciting such waivers and soliciting such approvals. Prior to the Effective Time, the Company shall deliver to Parent evidence reasonably acceptable to Parent that a vote or consent of the holders of the Company Capital Stock was solicited in accordance with the foregoing provisions of this Section 5.20 and that either (i) the requisite number of votes or consents of the holders of the Company Capital Stock was obtained with respect to the Waived 280G Benefits (the “280G Approval”) or (ii) the 280G Approval was not obtained.

 

SECTION 6. CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY

 

The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable Law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions:

 

6.1 No Restraints. No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Body of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.

 

6.2 Stockholder Approval. (a) Parent shall have obtained the Required Parent Stockholder Vote and (b) the Company shall have obtained the Required Company Stockholder Vote.

 

6.3 Listing. (a) The existing shares of Parent Common Stock shall have been continually listed on NYSE as of and from the date of this Agreement through the Closing Date and (b) the shares of Parent Common Stock to be issued in the Contemplated Transactions pursuant to this Agreement shall have been approved for listing (subject to official notice of issuance) on NYSE as of the Closing.

 

A-80
 

 

6.4 Effectiveness of Registration Statement. The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or proceeding (or threatened proceeding by the SEC) seeking a stop order with respect to the Registration Statement that has not been withdrawn.

 

6.5 Side Letter. Parent, the Company and Juvenescence shall have entered into a letter agreement in substantially the form attached hereto as Exhibit M (the “Side Letter”). Juvenescence shall have converted all of the Parent Preferred Stock into Parent Common Stock prior to the NYSE Reverse Split.

 

6.6 NYSE Reverse Split. The NYSE Reverse Split shall have occurred and the shares of Parent Common Stock outstanding immediately prior to the Effective Time shall be approximately 2,500,000.

 

SECTION 7. ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB

 

The obligations of Parent and Merger Sub to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:

 

7.1 Accuracy of Representations. The Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct in all material respects as of such date). The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications), or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded).

 

7.2 Performance of Covenants. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the Effective Time.

 

A-81
 

 

7.3 Documents. Parent shall have received the following documents, each of which shall be in full force and effect:

 

(a) a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i) that the conditions set forth in Sections 7.1, 7.2, 7.5 and 7.6 have been duly satisfied and (ii) that the information set forth in the Allocation Certificate delivered by the Company in accordance with Section 5.15 is true and accurate in all respects as of the Closing Date; and

 

(b) the Allocation Certificate.

 

7.4 No Company Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect that is continuing.

 

7.5 Termination of Investor Agreements. The Investor Agreements shall have been terminated (or will be terminated as of the Closing).

 

7.6 Company Lock-Up Agreements. Parent shall have received the Company Lock-Up Agreements duly executed by each of the Company Lock-Up Signatories and each executive officer and director of the Company who is elected or appointed, as applicable, as an executive officer and director of Parent as of immediately following the Closing, each of which shall be in full force and effect as of immediately following the Effective Time.

 

7.7 Company Stockholder Written Consent. The Company Stockholder Written Consent executed by each Company Signatory shall be in full force and effect.

 

7.8 Appraisal Shares. The holders of no more than 5% of shares of Company Capital Stock shall have exercised statutory appraisal rights pursuant to ABCL Article 13 with respect to such shares of Company Capital Stock.

 

7.9 FIRPTA Certificate. Parent shall have received (i) an original signed statement from the Company that the Company is not, and has not been at any time during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code, a “United States real property holding corporation,” as defined in Section 897(c)(2) of the Code, conforming to the requirements of Treasury Regulations Section 1.1445-2(c)(3) and 1.897-2(h), and (ii) an original signed notice from the Company to be delivered to the IRS in accordance with the provisions of Treasury Regulations Section 1.897-2(h)(2), together with written authorization for Parent to deliver such notice to the IRS on behalf of the Company following the Closing, each dated as of the Closing Date, duly executed by an authorized officer of the Company, and in form and substance reasonably acceptable to Parent.

 

7.10 Company Notes. The holders of the Company Notes, other than any Company Note held by the Parent, shall have elected to convert the Company Notes into Company Common Stock prior to the Effective Time.

 

A-82
 

 

SECTION 8. ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY

 

The obligations of the Company to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:

 

8.1 Accuracy of Representations. The Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct in all material respects as of such date). The representations and warranties of Parent and Merger Sub contained in this Agreement (other than the Parent Fundamental Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications), or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded).

 

8.2 Performance of Covenants. Parent and Merger Sub shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the Effective Time.

 

8.3 Documents. The Company shall have received the following documents, each of which shall be in full force and effect:

 

(a) a certificate executed by the Chief Executive Officer or Chief Financial Officer of Parent certifying that the conditions set forth in Sections 8.1, 8.2, and 8.4 have been duly satisfied;

 

(b) the Parent Outstanding Shares Certificate; and

 

(c) a written resignation, in a form reasonably satisfactory to the Company, dated as of the Closing Date and effective as of the Closing, executed by each of the directors of Parent who are not to continue as directors of Parent after the Closing pursuant to Section 5.11 hereof.

 

8.4 No Parent Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect that is continuing.

 

A-83
 

 

8.5 Termination of Contracts. The Company shall have received evidence, in form and substance reasonably satisfactory to it, that the Specified Parent Contracts have been (a) terminated, assigned, or fully performed by Parent and (b) all obligations of Parent thereunder have been fully satisfied, waived or otherwise discharged.

 

8.6 Parent Lock-Up Agreements. The Parent Lock-Up Agreements will continue to be in full force and effect immediately following the Effective Time.

 

8.7 Actual Closing Price and Post-Merger Warrants. (a) The Actual Closing Price of a share of the Parent Common Stock must not be less than the Minimum Share Price and (b) Juvenescence must hold at least 1,133,308 Post-Merger Warrants upon the Parent’s issuance of the Post-Merger Warrants.

 

8.8 Cash at Closing. Immediately prior to the Closing, Parent must have on hand at least $500,000 (USD) of immediately spendable nonrestricted cash, net of all payables and other Liabilities (for the avoidance of doubt, such payables and Liabilities shall include Transaction Expenses).

 

SECTION 9. TERMINATION

 

9.1 Termination. This Agreement may be terminated prior to the Effective Time (whether before or after approval of the Company Stockholder Matters by the Company’s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent’s stockholders, unless otherwise specified below):

 

(a) by mutual written consent of Parent and the Company;

 

(b) by either Parent or the Company if the Contemplated Transactions shall not have been consummated by February 29, 2024 (subject to possible extension as provided in this Section 9.1(b), the “End Date”); provided, however, that the right to terminate this Agreement under this Section 9.1(b) shall not be available to the Company, on the one hand, or to Parent, on the other hand, if such Party’s (or, in the case of Parent, Merger Sub’s) action or failure to act has been a principal cause of the failure of the Contemplated Transactions to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement, provided, further, however, that, in the event that a request for additional information has been made by any Governmental Body, or in the event that the SEC has not declared the Registration Statement effective under the Securities Act by the date which is thirty (30) calendar days prior to the End Date, then Parent shall be entitled to extend the End Date for an additional sixty (60) calendar days by written notice to the Company;

 

(c) by either Parent or the Company if a court of competent jurisdiction or other Governmental Body shall have issued a final and nonappealable order, decree or ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;

 

A-84
 

 

(d) by Parent if the Company Stockholder Written Consent shall not have been obtained within three (3) Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; provided, however, that once the Company Stockholder Written Consent has been obtained, Parent may not terminate this Agreement pursuant to this Section 9.1(d);

 

(e) by either Parent or the Company if (i) the Parent Stockholders’ Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent’s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii) the Parent Stockholder Matters shall not have been approved at the Parent Stockholders’ Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; provided, however, that the right to terminate this Agreement under this Section 9.1(e) shall not be available to Parent where the failure to obtain the Required Parent Stockholder Vote shall have been caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement;

 

(f) by the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred;

 

(g) by Parent (at any time prior to the Required Company Stockholder Vote being obtained) if a Company Triggering Event shall have occurred;

 

(h) by the Company, upon a breach of any representation, warranty, covenant, or agreement set forth in this Agreement by Parent or Merger Sub or if any representation or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in Section 8.1 or Section 8.2 would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided, that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided, further, that if such inaccuracy in Parent’s or Merger Sub’s representations and warranties or breach by Parent or Merger Sub is curable by the End Date by Parent or Merger Sub, then this Agreement shall not terminate pursuant to this Section 9.1(h) as a result of such particular breach or inaccuracy until the earlier of (i) the End Date and (ii) the expiration of a thirty (30) calendar day period commencing upon delivery of written notice from the Company to Parent or Merger Sub of such breach or inaccuracy and its intention to terminate pursuant to this Section 9.1(h) (it being understood that this Agreement shall not terminate pursuant to this Section 9.1(h) as a result of such particular breach or inaccuracy if such breach by Parent or Merger Sub is cured prior to such termination becoming effective);

 

A-85
 

 

(i) by Parent, upon a breach of any representation, warranty, covenant, or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in Section 7.1 or Section 7.2 would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided, that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided, further, that if such inaccuracy in the Company’s representations and warranties or breach by the Company is curable by the End Date by the Company then this Agreement shall not terminate pursuant to this Section 9.1(i) as a result of such particular breach or inaccuracy until the earlier of (i) the End Date and (ii) the expiration of a thirty (30) calendar day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this Section 9.1(i) (it being understood that this Agreement shall not terminate pursuant to this Section 9.1(i) as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective);

 

(j) by Parent, at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote, if (i) Parent has received a Superior Offer, (ii) Parent has complied with its obligations under Section 4.4 and Section 5.3(d), (iii) the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to terminate this Agreement would be reasonably likely to be inconsistent with its fiduciary duties under applicable Law, (iv) Parent concurrently terminates this Agreement and enters into a Permitted Alternative Agreement with respect to such Superior Offer and (v) Parent concurrently pays to the Company the amount contemplated by Section 9.3(b)(ii);

 

(k) by Parent, if the Company Audited Financial Statements have not been provided by the Company to Parent in accordance with Section 5.16(i); or

 

(l) by Company, if the condition set forth in Section 8.7(a) is not satisfied and is not, to the extent permitted by applicable Law, waived by the Company at or prior to the Closing; provided, however, that if the Company exercises its termination rights under this Section 9.1(l) then the Company shall provide the Parent with written notice five (5) days prior to such termination and the Parent shall have the option, but not the obligation, to, within five (5) business days of receipt by the Parent of that written notice, provide the Company with a written offer to adjust the Exchange Ratio such that additional Parent Common Stock shall be issued to the stockholders of the Company in the amount necessary to equal the Target Merger Consideration Minimum Value, and if the Parent provides that written offer, the Company may not exercise its termination rights under this Section 9.1(l) and the condition set forth in Section 8.7(a) shall be deemed to have been satisfied.

 

(m) by Company, if the condition set forth in Section 8.7(b) is not satisfied and is not, to the extent permitted by applicable Law, waived by the Company at or prior to the Closing; provided, however, that if the Company exercises its termination rights under this Section 9.1(m) then the Company shall provide the Parent with written notice five (5) days prior to such termination and the Parent shall have the option, but not the obligation, to, within five (5) business days of receipt by the Parent of that written notice, to provide a sufficient number of additional holders of Post-Merger Warrants who have agreed to, and are bound by, the Side Letter such that the aggregate number of Post-Merger Warrants subject to the Side letter is at least 1,133,308, and if the Parent provides the said additional Post-Merger Warrant holders to be bound by the Side Letter, then the Company may not exercise its termination rights under this Section 9.1(m) and the condition set forth in Section 8.7(b) shall be deemed to have been satisfied.

 

A-86
 

 

(n) by Company, if the condition set forth in Section 8.8 is not satisfied and is not, to the extent permitted by applicable Law, waived by the Company at or prior to the Closing; provided, however, that if the Company exercises its termination rights under this Section 9.1(n), then the Company shall provide the Parent with written notice prior to such termination and the Parent shall have the option, but not the obligation, to, within five (5) business days of receipt by the Parent of that written notice, obtain sufficient net funds to meet the condition set forth in Section 8.8, and if the Parent obtains such sufficient net funds to meet the condition set forth in Section 8.8, then the Company may not exercise its termination rights under this Section 9.1(n) and the condition set forth in Section 8.8 shall be deemed to have been satisfied.

 

The Party desiring to terminate this Agreement pursuant to this Section 9.1, shall give the other Party written notice of such termination, specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail.

 

9.2 Effect of Termination. In the event of the termination of this Agreement as provided in Section 9.1, this Agreement shall be of no further force or effect; provided, however, that (a) Section 5.8, this Section 9.2, Section 9.3, Section 10 and the definitions of the defined terms in such Sections (including the definitions of such defined terms set forth in Exhibit A) shall survive the termination of this Agreement and shall remain in full force and effect, and (b) the termination of this Agreement and the provisions of Section 9.3 shall not relieve any Party of any liability for intentional fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.

 

9.3 Expenses; Termination Fees.

 

(a) Except as set forth in this Section 9.3, the Transaction Expenses shall be paid by the Party incurring such expenses, whether or not the Merger is consummated.

 

(b) If:

 

(i) (A) this Agreement is terminated by the Company pursuant to Section 9.1(b), Section 9.1(e) or Section 9.1(h), (B) an Acquisition Proposal with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to Parent or the Parent Board at any time after the date of this Agreement but prior to the termination of this Agreement (which shall not have been withdrawn) and (C) within twelve (12) months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction in respect of the Acquisition Proposal referred to in clause (B); or

 

(ii) (A) this Agreement is terminated by the Company pursuant to Section 9.1(f) (or, at the time this Agreement is terminated, the Company had the right to terminate this Agreement pursuant to Section 9.1(f)) or (B) this Agreement is terminated by Parent pursuant to Section 9.1(j),

 

then the Parent shall pay to the Company a nonrefundable fee in an amount equal to $1,000,000 (the “Company Termination Fee”) upon the consummation of such Subsequent Transaction or termination of this Agreement, as applicable, plus any amount payable to the Company pursuant to Section 9.3(f).

 

A-87
 

 

(c) If:

 

(i) (A) this Agreement is terminated by Parent pursuant to Section 9.1(b), Section 9.1(d), or Section 9.1(i), (B) an Acquisition Proposal with respect to the Company shall have been publicly announced, disclosed or otherwise communicated to the Company or the Company Board at any time after the date of this Agreement but prior to the termination of this Agreement (which shall not have been withdrawn) and (C) within twelve (12) months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction in respect of the Acquisition Proposal referred to in clause (B); or

 

(ii) this Agreement is terminated by Parent pursuant to Section 9.1(g) (or, at the time this Agreement is terminated, Parent had the right to terminate this Agreement pursuant to Section 9.1(g)),

 

then the Company shall pay to Parent a nonrefundable fee in an amount equal to $1,000,000 (the “Parent Termination Fee”) upon the consummation of such Subsequent Transaction or termination of this Agreement, as applicable, plus any amount payable to Parent pursuant to Section 9.3(f).

 

(d) (i) If this Agreement is terminated by the Company pursuant to Section 9.1(h) or (ii) in the event of the failure of the Company to consummate the transactions to be contemplated at the Closing solely as a result of a Parent Material Adverse Effect as set forth in Section 8.4 (provided, that at such time all of the other conditions precedent to Parent’s obligation to close set forth in Section 6 and Section 7 have been satisfied by the Company, are capable of being satisfied by the Company or have been waived by Parent), then Parent shall reimburse the Company for all reasonable out-of-pocket fees and expenses incurred by the Company in connection with this Agreement and the Contemplated Transactions (such expenses, collectively, the “Third Party Expenses”), up to a maximum of $1,000,000, by wire transfer of same-day funds within ten (10) Business Days following the date on which the Company submits to Parent true and correct copies of reasonable documentation supporting such Third Party Expenses; provided, however, that such Third Party Expenses shall not include (i) any amounts paid to Juvenescence or any Affiliate thereof, or (ii) any amounts for financial advisors to the Company except for reasonably documented out-of-pocket expenses otherwise reimbursable by the Company to such financial advisors pursuant to the terms of the Company’s engagement letter or similar arrangement with such financial advisors.

 

A-88
 

 

(e) (i) If this Agreement is terminated by Parent pursuant to Section 9.1(i) or (ii) in the event of the failure of Parent to consummate the transactions to be consummated to the Closing solely as a result of a Company Material Adverse Effect as set forth in Section 7.5 (provided, that at such time all of the other conditions precedent to the Company’s obligation to close set forth in Section 6 and Section 8 have been satisfied by Parent are capable of being satisfied by Parent or have been waived by the Company), the Company shall reimburse Parent for all Third Party Expenses incurred by Parent up to a maximum of $1,000,000, by wire transfer of same-day funds within ten (10) Business Days following the date on which Parent submits to the Company true and correct copies of reasonable documentation supporting such Third Party Expenses; provided, however, that such Third Party Expenses shall not include (i) any amounts paid to Juvenescence or any Affiliate thereof, or (ii) any amounts for financial advisors to Parent except for reasonably documented out-of-pocket expenses otherwise reimbursable by Parent to such financial advisors pursuant to the terms of Parent’s engagement letter or similar arrangement with such financial advisors.

 

(f) The Company agrees it shall be entitled only to a Company Termination Fee or the reimbursement of Third Party Expenses, but not both, and the Parent agrees that it shall be entitled only to a Parent Termination Fee or the reimbursement of Third Party Expenses, but not both. Any Company Termination Fee, Parent Termination Fee, or Third Party Expenses due under this Section 9.3 shall be paid by wire transfer of same day funds. If a Party fails to pay when due any amount payable by it under this Section 9.3, then (i) such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this Section 9.3, and (ii) such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to other Party in full) at a rate per annum equal to the “prime rate” (as published in The Wall Street Journal or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent (3%).

 

(g) The Parties agree that, subject to Section 9.2, (i) payment of the Company Termination Fee or Third Party Expenses, as the case may be, shall, in the circumstances in which it is owed in accordance with the terms of this Agreement, constitute the sole and exclusive remedy of the Company following the termination of this Agreement under the circumstances described in Section 9.3(b), it being understood that in no event shall Parent be required to pay the amounts payable pursuant to this Section 9.3 on more than one occasion and (ii) following payment of the Company Termination Fee or Third Party Expenses, as the case may be, (x) Parent shall have no further liability to the Company in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by Parent giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (y) neither the Company nor any of its Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against Parent or Merger Sub or seek to obtain any recovery, judgment or damages of any kind against such Parties (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Parties) in connection with or arising out of this Agreement or the termination thereof, any breach by any such Parties giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (z) the Company and its Affiliates shall be precluded from any other remedy against Parent, Merger Sub and their respective Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated; provided, however, that nothing in this Section 9.3(g) shall limit the rights of Parent and Merger Sub under Section 10.11.

 

A-89
 

 

(h) The Parties agree that, subject to Section 9.2, (i) payment of the Parent Termination Fee or Third Party Expenses, as the case may be, shall, in the circumstances in which it is owed in accordance with the terms of this Agreement, constitute the sole and exclusive remedy of Parent following the termination of this Agreement under the circumstances described in Section 9.3(c), it being understood that in no event shall the Company be required to pay the amounts payable pursuant to this Section 9.3 on more than one occasion and (ii) following payment of the Parent Termination Fee or Third Party Expenses, as the case may be, (x) the Company shall have no further liability to Parent in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the Company giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (y) neither Parent nor any of its Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against the Company or seek to obtain any recovery, judgment or damages of any kind against the Company (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of the Company) in connection with or arising out of this Agreement or the termination thereof, any breach by the Company giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (z) Parent and its Affiliates shall be precluded from any other remedy against the Company and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated; provided, however, that nothing in this Section 9.3(h) shall limit the rights of the Company under Section 10.11.

 

(i) Each of the Parties acknowledges that (i) the agreements contained in this Section 9.3 are an integral part of the Contemplated Transactions, (ii) without these agreements, the Parties would not enter into this Agreement and (iii) any amount payable pursuant to this Section 9.3 is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the applicable Party in the circumstances in which such amount is payable.

 

SECTION 10. MISCELLANEOUS PROVISIONS

 

10.1 Non-Survival of Representations and Warranties. The representations and warranties of the Company, Parent and Merger Sub contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the Effective Time, and only the covenants that by their terms survive the Effective Time and this Section 10 shall survive the Effective Time.

 

10.2 Amendment. This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Sub and Parent at any time (whether before or after obtaining the Required Company Stockholder Vote or before or after obtaining the Required Parent Stockholder Vote); provided, however, that after any such approval of this Agreement by a Party’s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Sub and Parent.

 

A-90
 

 

10.3 Waiver.

 

(a) No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.

 

(b) No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

 

10.4 Entire Agreement; Counterparts; Exchanges by Electronic Transmission. This Agreement, the Company Disclosure Schedule, the Parent Disclosure Schedule and the other agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; provided, however, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by electronic transmission in .PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.

 

10.5 Applicable Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this Section 10.5; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party; (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with Section 10.8 of this Agreement; and (f) irrevocably and unconditionally waives the right to trial by jury. Notwithstanding the foregoing, all matters relating to the fiduciary obligations of the Company Board and the internal affairs of the Company or the Company Board (including, without limitation, the interpretation of the Company’s Organizational Documents and the ABCL) shall be governed by and construed in accordance with the Laws of Alabama without regard to the conflicts of law principles thereof to the extent that such principles would direct a matter to another jurisdiction.

 

A-91
 

 

10.6 Attorneys’ Fees. In any action at law or suit in equity to enforce this Agreement or the rights of any of the Parties, the prevailing Party in such action or suit (as determined by a court of competent jurisdiction) shall be entitled to recover its reasonable out-of-pocket attorneys’ fees and all other reasonable costs and expenses incurred in such action or suit.

 

10.7 Assignability. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; provided, however, that neither this Agreement nor any of a Party’s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party’s prior written consent shall be void and of no effect.

 

10.8 Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a) one (1) Business Day after being sent for the next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b) upon delivery in the case of delivery by hand, or (c) on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00 p.m. New York time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:

 

if to Parent or Merger Sub:

 

AgeX Therapeutics, Inc.

1101 Marina Village Parkway, Suite 201

Alameda, California 94501

Attention: Chief Financial Officer

 

with a copy to (which shall not constitute notice):

 

Gibson, Dunn & Crutcher LLP

555 Mission Street

San Francisco, California 94105-0921

  Attention: Robert Phillips
    Chris Trester

Email:

 

if to the Company:

 

Serina Therapeutics, Inc.

601 Genome Way, Suite 2001

Huntsville, Alabama 35806

Attention: Steve Ledger

Email:

 

A-92
 

 

with a copy to (which shall not constitute notice):

 

Bradley Arant Boult Cummings LLP

200 Clinton Avenue, Suite 900

Huntsville, Alabama 35801

Attention: Scott E. Ludwig

Email:

 

10.9 Cooperation. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement.

 

10.10 Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.

 

10.11 Other Remedies; Specific Performance. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not perform the provisions of this Agreement (including failing to take such actions as are required of it hereunder to consummate this Agreement) in accordance with their specified terms or otherwise breaches such provisions. Accordingly, the Parties acknowledge and agree that the Parties shall be entitled to an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state thereof having jurisdiction, in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. Any Party seeking an injunction or injunctions to prevent breaches of this Agreement shall not be required to provide any bond, surety or other security in connection with any such order or injunction.

 

A-93
 

 

10.12 No Third Party Beneficiaries. Other than (a) the Parties and the D&O Indemnified Parties to the extent of their respective rights pursuant to Section 5.6 and (b) Juvenescence to the extent of its rights pursuant to Sections 5.11 and 6.5, nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

10.13 Construction.

 

(a) References to “cash,” “dollars” or “$” are to U.S. dollars.

 

(b) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.

 

(c) The Parties have participated jointly in the negotiating and drafting of this Agreement and agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement.

 

(d) As used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.”

 

(e) Except as otherwise indicated, all references in this Agreement to “Sections,” “Exhibits” and “Schedules” are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement, respectively.

 

(f) Any reference to legislation or to any provision of any legislation shall include any modification, amendment, re- enactment thereof, any legislative provision substituted therefore and all rules, regulations, and statutory instruments issued or related to such legislations.

 

(g) The bold-faced headings and table of contents contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

 

(h) The Parties agree that each of the Company Disclosure Schedule and the Parent Disclosure Schedule shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in this Agreement. The disclosures in any section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule shall qualify other sections and subsections in this Agreement to the extent it is readily apparent on its face from a reading of the disclosure that such disclosure is applicable to such other sections and subsections.

 

(i) Each of “delivered” or “made available” means, with respect to any documentation, that prior to 11:59 p.m. (New York time) on the date that is two (2) calendar days prior to the date of this Agreement (i) a copy of such material has been posted to and made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party or (ii) such material is disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly made available on the SEC’s Electronic Data Gathering Analysis and Retrieval system.

 

(j) Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Saturday, Sunday, or any date on which banks in New York, New York are authorized or obligated by Law to be closed, the Party having such privilege or duty may exercise such privilege or discharge such duty on the next succeeding day which is a regular Business Day.

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first above written.

 

(Remainder of page intentionally left blank)

 

A-94
 

 

AGREEMENT AND PLAN OF MERGER
AND REORGANIZATION

 

(Signature Page for AgeX Therapeutics, Inc. and Merger Sub)

 

  AgeX Therapeutics, Inc.
     
  By: /s/ Joanne Hackett, Ph.D.
     
  Name: Joanne Hackett, Ph.D.
  Title: Interim Chief Executive Officer
     
  CANARIA TRANSACTION CORPORATION
     
  By: /s/ Joanne Hackett, Ph.D.
     
  Name: Joanne Hackett, Ph.D.
  Title: Director and Secretary

 

[Signature Page to Agreement and Plan of Merger and Reorganization]

 

   

 

 

AGREEMENT AND PLAN OF MERGER
AND REORGANIZATION

 

(Signature Page for Serina Therapeutics, Inc.)

 

  SERINA THERAPEUTICS, INC.
     
  By: /s/ Randall Moreadith
    Randall Moreadith, its President and Chief Executive Officer

 

[Signature Page to Agreement and Plan of Merger and Reorganization]

 

   

 

 

EXHIBIT A

CERTAIN DEFINITIONS

 

For purposes of this Agreement (including this Exhibit A):

 

ABCL” means the Alabama Business Corporation Law.

 

Acquisition Inquiry” means, with respect to a Party, an inquiry, indication of interest or request for information (other than an inquiry, an indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other Party) that could reasonably be expected to lead to an Acquisition Proposal; provided, however, that the term “Acquisition Inquiry” shall not include the Merger or the other Contemplated Transactions or any transactions related to the Asset Dispositions.

 

Acquisition Proposal” means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party, other than the Asset Dispositions.

 

Acquisition Transaction” means any transaction or series of related transactions (other than the Asset Dispositions) involving:

 

(i) any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a Party is a constituent entity; (ii) in which a Person or “group” (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries; or (iii) in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or

 

(ii) any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole.

 

Actual Closing Price” means the volume weighted average closing trading price of a share of the Parent Common Stock as reported on the NYSE for the ten (10) Trading Days preceding the date that is the fifth (5th) business day preceding the Effective Time.

 

Affiliate” of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 

   

 

 

Agreement” shall have the meaning set forth in the Preamble.

 

Allocation Certificate” shall have the meaning set forth in Section 5.15(a).

 

Business Day” means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be closed.

 

Code” means the Internal Revenue Code of 1986, as amended.

 

Company Associate” means any current or former employee, independent contractor, officer or director of the Company or any of its Subsidiaries.

 

Company Board” means the board of directors of the Company.

 

Company Capital Stock” means the Company Common Stock and the Company Preferred Stock.

 

Company Common Stock” means the Common Stock, $0.01 par value per share, of the Company.

 

Company Contract” means any Contract: (a) to which the Company or any of its Subsidiaries is a party; (b) by which the Company or any of its Subsidiaries or any Company IP or any other asset of the Company or its Subsidiaries are or may become bound or under which the Company or any of its Subsidiaries have, or may become subject to, any obligation; or (c) under which the Company or any of its Subsidiaries have or may acquire any right or interest.

 

Company ERISA Affiliate” means any corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with the Company or any of its Subsidiaries as a single employer within the meaning of Section 414 of the Code.

 

Company Fundamental Representations” means the representations and warranties of the Company set forth in Sections 2.1 (Due Organization; Subsidiaries.), 2.3 (Authority; Binding Nature of Agreement), 2.4 (Vote Required), 2.6(a) and (c) (Capitalization) and 2.20 (No Financial Advisors).

 

Company IP” means all Intellectual Property Rights that are owned or co-owned or purported to be owned or co-owned by the Company or its Subsidiaries.

 

Company Material Adverse Effect” means any Effect that, considered together with all other Effects, has or would reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of the Company or its Subsidiaries, taken as a whole; provided, however, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Company Material Adverse Effect: (a) general business, political or economic conditions generally affecting the industry in which the Company and its Subsidiaries operate, (b) acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics (including COVID-19 and any evolutions or mutations thereof) and related or associated epidemics, disease outbreaks or quarantine restrictions, (c) changes in financial, banking or securities markets, (d) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), (e) the announcement of this Agreement or the pendency of the Contemplated Transactions, (f) the taking of any action required to be taken by this Agreement, or (g) continued losses from operations or decreases in cash balances of the Company or any of its Subsidiaries or on a consolidated basis among the Company and its Subsidiaries; except, in each case, with respect to clauses (a) through (c), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate.

 

   

 

 

Company Notes” means convertible notes or similar instruments that convert into shares of Company Capital Stock issued by the Company.

 

Company Options” means options or other rights to purchase shares of Company Capital Stock issued by the Company pursuant to the Company Incentive Plan.

 

Company Triggering Event” shall be deemed to have occurred if: (a) the Company Board shall have made a Company Board Adverse Recommendation Change; (b) the Company Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal; or (c) the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal.

 

Company Unaudited Interim Balance Sheet” means the unaudited consolidated balance sheet of the Company and its consolidated Subsidiaries for the period ended March 31, 2023, provided to Parent prior to the date of this Agreement.

 

Company Warrant” means the warrants to purchase capital stock of the Company listed in Section 2.6(a) of the Company Disclosure Schedule.

 

Company’s Knowledge” or “Knowledge of the Company” means the actual knowledge of Randall Moreadith, Steve Ledger, and Tacey Viegas and such knowledge as such Persons would reasonably be expected to have obtained in the ordinary course of their performance of their employment or consulting duties to the Company or any of its Subsidiaries.

 

Confidentiality Agreement” means the Confidentiality Agreement, dated as of October 20, 2022, between the Company and Parent.

 

Consent” means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).

 

Contemplated Transactions” means the Merger and the other transactions and actions contemplated by this Agreement, including the NYSE Reverse Split, the Asset Dispositions, and the Post-Merger Warrants.

 

Contract” means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, sublicense or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law.

 

   

 

 

COVID-19” means the novel coronavirus (SARS-CoV-2) and related variants thereof.

 

DGCL” means the General Corporation Law of the State of Delaware.

 

Effect” means any effect, change, event, circumstance or development.

 

Encumbrance” means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).

 

Enforceability Exceptions” means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (b) rules of law governing specific performance, injunctive relief and other equitable remedies.

 

Entity” means any corporation (including any non-profit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.

 

Environmental Law” means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including any Law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.

 

ERISA” means the Employee Retirement Income Security Act of 1974, as amended.

 

Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

Exchange Ratio” means, subject to Section 1.5(g), the following ratio: the quotient obtained by dividing (a) the Company Merger Shares by (b) the Company Outstanding Shares, in which:

 

  Company Allocation Percentage” means 75.00%.
     
  Company Merger Shares” means the product (rounded to the nearest whole share) obtained by multiplying (a) Post-Closing Parent Shares by (b) the Company Allocation Percentage.

 

   

 

 

  Company Outstanding Shares” means the total number of shares of Company Capital Stock outstanding immediately prior to the Effective Time after giving effect to the Preferred Stock Conversion, expressed on a fully-diluted and as-converted to Company Common Stock basis assuming, without limitation or duplication, (i) the exercise of all Company Options outstanding as of immediately prior to the Effective Time, (ii) the issuance of shares of Company Capital Stock upon the conversion of all Company Notes (but excluding any Company Notes issued to Parent) and (iii) the issuance of shares of Company Capital Stock in respect of all other outstanding options, restricted stock awards, restricted stock units, or rights to receive such shares, whether conditional or unconditional and including any outstanding options, restricted stock awards, restricted stock units or rights triggered by or associated with the consummation of the Merger (but excluding any shares of Company Capital Stock reserved for issuance other than with respect to outstanding Company Options under the Company Incentive Plan as of immediately prior to the Effective Time). No Company Warrants shall be included in the total number of shares of Company Common Stock outstanding for purposes of determining the Company Outstanding Shares.
     
  Parent Outstanding Shares” means, subject to Section 1.5(g) (that addresses, among other things, the NYSE Reverse Split) and the immediately following sentence, the total number of shares of Parent Common Stock outstanding immediately prior to the Effective Time expressed on a fully-diluted and as-converted to Parent Common Stock basis and using the treasury stock method (and shall include, for the avoidance of doubt, all Parent Note Shares, Parent Common Stock to be received upon the conversion of the Parent Preferred Stock, In the Money Parent Options and Parent Warrants), but assuming, without limitation or duplication, the issuance of shares of Parent Common Stock in respect of all Parent Options, Parent RSUs, Parent Warrants and other outstanding options, warrants or rights to receive such shares, in each case, outstanding as of immediately prior to the Effective Time (assuming cashless exercise using the Parent Closing Price), whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or associated with the consummation of the Merger (but excluding any shares of Parent Common Stock reserved for issuance other than with respect to outstanding Parent Options, Parent RSUs and Parent Warrants as of immediately prior to the Effective Time and as set forth above). No (i) Post-Merger Warrants, or (ii) Incentive Warrants, in each case, shall be included in the total number of shares of Parent Common Stock outstanding for purposes of determining the Parent Outstanding Shares.
     
  Post-Closing Parent Shares” means the quotient obtained by dividing (a) the Parent Outstanding Shares by (b)(i) 1.00 minus (ii) the Company Allocation Percentage.

 

   

 

 

GAAP” means generally accepted accounting principles and practices in effect from time to time within the United States applied consistently throughout the period involved.

 

Governmental Authorization” means any: (a) permit, license, certificate, franchise, permission, variance, exception, order, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Law; or (b) right under any Contract with any Governmental Body.

 

Governmental Body” means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority); or (d) self-regulatory organization (including NYSE).

 

Hazardous Materials” means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or by-products.

 

Incentive Warrants” means the warrants of Parent, each whole warrant exercisable for one share of Parent Common Stock at a price equal to 1.5 multiplied by the Minimum Share Price, and expiring on the four year anniversary of the Closing Date, upon the terms and conditions set forth in the Warrant Agreement.

 

Intellectual Property Rights” means and includes all past, present, and future rights of the following types, which may exist or be created under the laws of any jurisdiction in the world: (a) rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, software, databases, and mask works; (b) trademarks, service marks, trade dress, logos, trade names and other source identifiers, domain names and URLs and similar rights and any goodwill associated therewith; (c) rights associated with trade secrets, know how, inventions, invention disclosures, methods, processes, protocols, specifications, techniques and other forms of technology; (d) patents and industrial property rights; and (e) other similar proprietary rights in intellectual property of every kind and nature; (f) rights of privacy and publicity; and (g) all registrations, renewals, extensions, statutory invention registrations, provisionals, continuations, continuations-in-part, divisions, or reissues of, and applications for, any of the rights referred to in clauses “(a)” through “(f)” above (whether or not in tangible form and including all tangible embodiments of any of the foregoing, such as samples, studies and summaries), along with all rights to prosecute and perfect the same through administrative prosecution, registration, recordation or other administrative proceeding, and all causes of action and rights to sue or seek other remedies arising from or relating to the foregoing.

 

In the Money Parent Options and Parent Warrants” shall mean any Parent Options and Parent Warrants with an exercise price less than the Parent Closing Price.

 

   

 

 

IRS” means the United States Internal Revenue Service.

 

Juvenescence Note Conversion” means that certain Exchange Agreement entered into by and between Parent and Juvenescence on July 21, 2023, and closed on July 24, 2023, whereby certain notes totaling $36,000,000 owed to Juvenescence by Parent were converted into 211,600 shares of Parent Series A Preferred Stock and 148,400 shares Parent Series B Preferred Stock.

 

Law” means any federal, state, national, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of NYSE or the Financial Industry Regulatory Authority).

 

Legal Proceeding” means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel.

 

Merger Sub Board” means the board of directors of Merger Sub.

 

Minimum Share Price” means $12.00.

 

NYSE” means the New York Stock Exchange, including the NYSE American or such other NYSE market on which shares of Parent Common Stock are then listed.

 

NYSE Reverse Split” means a reverse stock split of all outstanding shares of Parent Common Stock that is effected by Parent for the purpose of resulting in approximately 2,500,000 shares of Parent Common Stock being outstanding immediately prior to the Effective Time, unless otherwise mutually agreed to by Parent and the Company.

 

Ordinary Course of Business” means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its and its Subsidiaries’ normal operations and consistent with its and its Subsidiaries’ past practices; provided, however, that the Ordinary Course of Business of (a) Parent shall also include actions required to effect the Asset Dispositions or effect the winding down of Parent’s prior research and development activities (including the termination of ongoing contractual obligations relating to Parent’s current products or product candidates), and (b) each Party shall also include any actions expressly required or permitted by this Agreement, including the Contemplated Transactions.

 

Organizational Documents” means, with respect to any Person (other than an individual), (a) the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented.

 

   

 

 

Out of the Money Parent Options or Parent Warrants” shall mean Parent Options and Parent Warrants with an exercise price equal to or greater than the Parent Closing Price.

 

Pandemic Response Laws” means the Coronavirus Aid, Relief, and Economic Security Act, the Families First Coronavirus Response Act, the COVID-related Tax Relief Act of 2020, the Presidential Memorandum on Deferring Payroll Tax Obligations in Light of the Ongoing COVID-19 Disaster (as issued on August 8, 2020, and including any administrative or other guidance published with respect thereto by any Tax authority (including IRS Notice 2020-65)), and any other similar or additional U.S. federal, state, or local or non-U.S. Law, or administrative guidance intended to benefit taxpayers in response to the COVID-19 pandemic and associated economic downturn.

 

Parent Associate” means any current or former employee, independent contractor, officer or director of Parent or any of its Subsidiaries.

 

Parent Balance Sheet” means the audited balance sheet of Parent as of December 31, 2022, included in Parent’s Report on Form 10-K for the annual period ended December 31, 2022, as filed with the SEC.

 

Parent Board” means the board of directors of Parent.

 

Parent Change in Circumstance” means a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry or the consequences thereof or (B) the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of Parent that occurs or arises after the date of this Agreement.

 

Parent Closing Price” means the volume weighted average closing trading price of a share of Parent Common Stock on NYSE for the five (5) consecutive trading days ending three (3) trading days immediately prior to the date of the public announcement of this Agreement.

 

Parent Capital Stock” means the Parent Common Stock and the Parent Preferred Stock.

 

Parent Common Stock” means the Common Stock, $0.0001 par value per share, of Parent.

 

Parent Contract” means any Contract: (a) to which Parent or any of its Subsidiaries is a party; (b) by which Parent or any of its Subsidiaries or any Parent IP or any other asset of Parent or its Subsidiaries are or may become bound or under which Parent or any of its Subsidiaries have, or may become subject to, any obligation; or (c) under which Parent or any of its Subsidiaries have or may acquire any right or interest.

 

Parent ERISA Affiliate” means any corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with Parent or any of its Subsidiaries as a single employer within the meaning of Section 414 of the Code.

 

   

 

 

Parent Excluded Assets” means the right, title and interest in and to the enumerated assets in Section C of the Parent Disclosure Schedule.

 

Parent Fundamental Representations” means the representations and warranties of Parent and Merger Sub set forth in Sections 3.1 (Due Organization; Subsidiaries), 3.3 (Authority; Binding Nature of Agreement), 3.4 (Vote Required), 3.6(a) and (c) (Capitalization) and 3.21 (No Financial Advisors).

 

Parent Incentive Plan” means Parent’s 2017 Equity Incentive Plan.

 

Parent IP” means all Intellectual Property Rights that are owned or co-owned or purported to be owned or co-owned by Parent or its Subsidiaries.

 

Parent Legacy Note” means any Parent Notes not converted in the Juvenescence Note Conversion.

 

Parent Material Adverse Effect” means any Effect that, considered together with all other Effects, has or would reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Parent or its Subsidiaries, taken as a whole; provided, however, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a) general business, political or economic conditions generally affecting the industry in which Parent and its Subsidiaries operate, (b) acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics (including COVID-19 and any evolutions or mutations thereof) and related or associated epidemics, disease outbreaks or quarantine restrictions, (c) changes in financial, banking or securities markets, (d) any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (e) the failure of Parent to meet internal or analysts’ expectations or projections or the results of operations of Parent, (f) any changes in or affecting clinical trial programs or studies conducted by or on behalf of Parent or its Subsidiaries, including any adverse data, event or outcome arising out of or related to any such programs or studies, (g) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), (h) the announcement of this Agreement or the pendency of the Contemplated Transactions, (i) the Asset Dispositions, (j) any reduction in the amount of Parent’s cash and cash equivalents as a result of expenditures made by Parent related to wind down activities of Parent associated with the termination of its research and development activities (including the termination of ongoing contractual obligations relating to Parent current products or product candidates), (k) resulting from the taking of any action required to be taken by this Agreement or (l) as set forth in Section B of the Parent Disclosure Schedule, except in each case, with respect to clauses (a) through (c), to the extent disproportionately affecting Parent and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Parent and its Subsidiaries operate.

 

   

 

 

Parent Notes” means (i) that certain Secured Convertible Promissory Note, dated March 13, 2023, by and between Parent and Juvenescence; (ii) that certain Secured Convertible Promissory Note, dated February 14, 2022, by and between Parent and Juvenescence; (iii) that certain Convertible Facility Agreement by and among Parent, Juvenescence, ReCyte Therapeutics, Inc., and Reverse Bioengineering, Inc, dated March 30, 2020; (iv) that certain Amended and Restated Secured Convertible Promissory Note, dated February 9, 2023, by and between Parent and Juvenescence, as amended on March 13, 2023, and May 9, 2023; (v) any other indebtedness entered into by and between Parent and Juvenescence after the date hereof.

 

Parent Note Shares” means any shares of Parent Common Stock that are issued or issuable upon conversion of the Parent Notes (excluding the Parent Legacy Note).

 

Parent Options” means options or other rights to purchase shares of Parent Common Stock issued by Parent.

 

Parent RSUs” means any restricted stock unit award granted pursuant to the Parent Incentive Plan or otherwise.

 

Parent Triggering Event” shall be deemed to have occurred if: (a) Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation or shall have made a Parent Board Adverse Recommendation Change; (b) the Parent Board or any committee thereof shall have approved, endorsed or recommended any Acquisition Proposal; (c) Parent shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than a confidentiality agreement permitted pursuant to Section 4.4); or (d) Parent or any director or officer of Parent shall have willfully and intentionally breached the provisions set forth in Section 4.4 or Section 5.3 of this Agreement.

 

Parent Unit” means the units of Parent, each unit consisting of one share of Parent Common Stock and one Incentive Warrant.

 

Parent Warrants” means the warrants to purchase capital stock of Parent listed in Section 3.6(a) of the Parent Disclosure Schedule.

 

Parent’s Knowledge” or “Knowledge of Parent” means the actual knowledge of the members of the Parent Board and Parent’s Chief Executive Officer, Chief Financial Officer and Chief Operating Officer and such knowledge as such Persons would reasonably be expected to have obtained in the ordinary course of their performance of their director or employment duties, as applicable, to Parent or any of its Subsidiaries.

 

Party” or “Parties” means the Company, Merger Sub and Parent.

 

Permitted Alternative Agreement” means a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a Superior Offer.

 

   

 

 

Permitted Encumbrance” means: (a) any liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith and for which adequate reserves have been made on the Company Unaudited Interim Balance Sheet or the Parent Balance Sheet, as applicable; (b) minor liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets or properties subject thereto or materially impair the operations of the Company or any of its Subsidiaries or Parent or any of its Subsidiaries, as applicable; (c) statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements; (d) deposits or pledges made in connection with, or to secure payment of, workers’ compensation, unemployment insurance or similar programs mandated by Law; (e) non-exclusive licenses of Intellectual Property Rights or options to such non-exclusive licenses granted by the Company or any of its Subsidiaries or Parent or any of its Subsidiaries, as applicable, in the Ordinary Course of Business; and (f) statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies.

 

Person” means any individual, Entity or Governmental Body.

 

Post-Merger Warrant” means the warrants of Parent, each whole warrant exercisable for one Parent Unit at a price equal to 1.1 multiplied by the Minimum Share Price, and expiring on July 31, 2025, upon the terms and conditions set forth in the Warrant Agreement.

 

Potentially Transferable Assets” means the Reverse Bio Business.

 

Proxy Statement” means the definitive proxy statement/prospectus to be sent to Parent’s stockholders in connection with the Parent Stockholders’ Meeting.

 

Reference Date” means August 14, 2023.

 

Registered IP” means all Intellectual Property Rights that are registered or issued under the authority of any Governmental Body, including all patents, registered copyrights, registered mask works, and registered trademarks, service marks and trade dress, registered domain names, and all applications for any of the foregoing.

 

Registration Statement” means the registration statement on Form S-4 (or any other applicable form under the Securities Act to register Parent Common Stock) to be filed with the SEC by Parent registering the public offering and sale of Parent Common Stock to some or all holders of Company Capital Stock in the Merger, including all shares of Parent Common Stock to be issued in exchange for all shares of Company Capital Stock in the Merger, as said registration statement may be amended prior to the time it is declared effective by the SEC.

 

Representatives” means directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and representatives.

 

Reverse Bio Business” means the right, title and interest in and to the enumerated assets in Section D of the Parent Disclosure Schedule to the extent relating exclusively to the business of Reverse Bioengineering, Inc., a wholly-owned subsidiary of Parent, and the liabilities and obligations arising out of, relating to or otherwise in respect thereof.

 

Sarbanes-Oxley Act” means the Sarbanes-Oxley Act of 2002.

 

SEC” means the United States Securities and Exchange Commission.

 

   

 

 

SEC Document” means any registration statement, proxy statement, form, document, report, notice or other filing filed by a Person or any Subsidiary of a Person with the SEC pursuant to the securities Laws.

 

Securities Act” means the Securities Act of 1933, as amended.

 

Subsequent Transaction” means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes).

 

Subsidiary” means, an Entity of a Person that such Person directly or indirectly owns or purports to own, beneficially or of record, (a) a number of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such Entity’s board of directors or other governing body, or (b) at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.

 

Superior Offer” means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to greater than 50% for these purposes) that: (a) was not obtained or made as a direct or indirect result of a breach of (or in violation of) this Agreement; and (b) is on terms and conditions that the Parent Board determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following consultation with its outside legal counsel and outside financial advisors, if any, are more favorable, from a financial point of view, to Parent’s stockholders than the terms of the Contemplated Transactions and is not subject to any financing condition (and if financing is required, such financing is then fully committed to the third party).

 

Target Merger Consideration Minimum Value” means an amount equal to the Minimum Share Price multiplied by the anticipated aggregate number (approximately 7,500,000) of shares of Parent Common Stock to be issued (prior to any adjustment that may be made under Section 9.1(l)) to the Company stockholders.

 

Takeover Statute” means any “fair price,” “moratorium,” “control share acquisition” or other similar anti-takeover Law.

 

Tax” means any federal, state, local, foreign or other tax, including any income, capital gain, gross receipts, capital stock, profits, transfer, estimated, registration, stamp, premium, escheat, unclaimed property, customs duty, ad valorem, occupancy, occupation, alternative, add- on, windfall profits, value added, severance, property, business, production, sales, use, license, excise, franchise, employment, payroll, social security, disability, unemployment, workers’ compensation, national health insurance, withholding and any escheat or unclaimed property obligations, or other taxes, duties, fees, assessments or governmental charges, surtaxes or deficiencies thereof in the nature of a tax, whether or not disputed and however denominated, and including any fine, penalty, addition to tax or interest imposed by a Governmental Body with respect thereto.

 

   

 

 

Tax Return” means any return (including any information return), report, statement, declaration, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed with or submitted to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax.

 

Trading Day” means any day on which the NYSE is open for trading; provided, that a “Trading Day” includes only those days that have a scheduled closing time of 4:00 p.m. (Eastern Time).

 

Transaction Expenses” means, with respect to each Party, all fees and expenses incurred by such Party at or prior to the Effective Time in connection with the Contemplated Transactions and this Agreement, including (a) any fees and expenses of legal counsel and accountants and the maximum amount of fees and expenses payable to financial advisors, investment bankers, brokers, consultants, and other advisors of such Party in connection with the negotiation, preparation and execution of this Agreement and the consummation of the Contemplated Transactions (including in connection with any stockholder litigation relating to this Agreement or any of the Contemplated Transactions), including finders’ fees; (b) only with respect to Parent, fees paid to the SEC in connection with filing the Registration Statement, the Proxy Statement, and any amendments and supplements thereto, with the SEC; (c) only with respect to Parent, any fees and expenses in connection with the printing, mailing and distribution of the Registration Statement and any amendments and supplements thereto; (d) 50% of the fees and expenses payable to NYSE in connection with the NYSE Listing Application; (e) any bonus, severance, change-in-control or retention payments or similar payment obligations (including payments with “single-trigger” provisions triggered at and as of the Closing) that become due or payable to any director, officer, employee or consultant of such Party or any of its Subsidiaries in connection with the consummation of the Contemplated Transactions; (f) only with respect to Parent, any fees and expenses in connection with the D&O tail policy described in Section 5.6(d); (g) only with respect to Parent, any notice payments, change-of-control payments, fines or other payments to be made by Parent in connection with terminating any existing Contract to which Parent is a party or winding down any of Parent’s clinical trial obligations; and (i) only with respect to Parent, any wind-down costs of Parent associated with discontinued lab, research and development and related operations.

 

Treasury Regulations” means the United States Treasury regulations promulgated under the Code.

 

   

 

 

Annex B

 

FIRST AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

AGEX Therapeutics, INC.

 

The undersigned, AgeX Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, for the purpose of amending and restating its Certificate of Incorporation in its entirety, DOES HEREBY CERTIFY:

 

FIRST: That the current name of the corporation is AgeX Therapeutics, Inc., and the original Certificate of Incorporation of this corporation was filed with the Secretary of State of Delaware on January 6, 2017, as amended by that Certificate of Amendment filed on December 8, 2022, and as further amended by that Certificate of Amendment filed on ______________, 2023.

 

SECOND: That at a meeting of the board of directors (the “Board”) of AgeX Therapeutics, Inc., the Board approved, subject to approval by the stockholders, The First Amended and Restated Certificate of Incorporation of this corporation attached hereto as Exhibit A.

 

THIRD: That thereafter, pursuant to a resolution of the Board, a meeting of the stockholders of said corporation was dully called and held upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statue were voted in favor of The First Amended and Restated Certificate of Incorporation, attached hereto as Exhibit A.

 

FOURTH: The First Amended and Restated Certificate of Incorporation of this corporation as set forth in Exhibit A has been duly adopted in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware by the directors and stockholders of the corporation.

 

FIFTH: The First Amended and Restated Certificate of Incorporation so adopted reads in full as set forth in Exhibit A and is incorporated herein by reference.

 

IN WITNESS WHEREOF, this corporation has caused this First Amended and Restated Certificate of Incorporation to be signed by its President and duly authorized on the ____ day of __________________, 2024.

 

  AgeX Therapeutics, Inc.
     
  By:  
    As its President

 

B-1
 

 

EXHIBIT A

FIRST AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

SERINA Therapeutics, Inc.

 

Article 1

Name

 

The name of the corporation is Serina Therapeutics, Inc.

 

Article 2

Address

 

The address of the registered office of the corporation in the State of Delaware is 1675 South State Street, Suite B, Dover, Delaware 19901 in Kent County. The name of its registered agent at such address is Capitol Services, Inc.

 

Article 3

Purpose

 

The purpose of the corporation is to engage in any lawful act or activity for which a corporation may be organized under the DGCL.

 

Article 4

Capital Stock

 

4.1 Authorized Shares. The corporation is authorized to issue two classes of stock, which shall be designated “Common Stock” and “Preferred Stock.” The number of shares of Common Stock which the corporation is authorized to issue is forty million (40,000,000), with a par value of $0.0001 per share. The number of shares of Preferred Stock which the corporation is authorized to issue is five million (5,000,000), with a par value of $0.0001 per share.

 

4.2 Preferred Stock. Shares of Preferred Stock may be issued in one or more series, from time to time, with each such series to consist of such number of shares and to have such voting powers, full or limited, or no voting powers, and such designations, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, as shall be stated in the resolution or resolutions providing for the issuance of such series adopted by the board of directors (the “Board of Directors”) of the corporation, and the Board of Directors is hereby expressly vested with the authority, to the full extent now or hereafter provided by law, to adopt any such resolution or resolutions. The authority of the Board of Directors with respect to each series of Preferred Stock shall include, but not be limited to, determination of the following:

 

(i) The number of shares constituting that series and the distinctive designation of that series;

 

B-2
 

 

(ii) The dividend rate or rates on the shares of that series, the terms and conditions upon which and the periods in respect of which dividends shall be payable, whether dividends shall be cumulative, and, if so, from which date or dates, and the relative rights of priority, if any, of payment of dividends on shares of that series;

 

(iii) Whether that series shall have voting rights, in addition to the voting rights provided by law, and, if so, the terms of such voting rights;

 

(iv) Whether that series shall have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for adjustment of the conversion rate in such events as the Board of Directors shall determine;

 

(v) Whether the shares of that series shall be redeemable, and, if so, the terms and conditions of such redemption, including the date or dates upon or after which they shall be redeemable, and the amount per share payable in the event of redemption, which amount may vary under different conditions and at different redemption dates;

 

(vi) Whether that series shall have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such sinking fund;

 

(vii) The rights of the shares of that series in the event of voluntary or involuntary liquidation, distribution of assets, dissolution or winding up of the corporation, and the relative rights of priority, if any, of payment of shares of that series; and

 

(viii) Any other relative rights, powers, and preferences, and the qualifications, limitations and restrictions thereof, of that series.

 

4.3 Voting Rights. Each holder of record of Common Stock, as such, shall have one vote for each share of Common Stock which is outstanding in his, her or its name on the books of the corporation on all matters on which stockholders are entitled to vote generally. The holders of shares of Common Stock shall not have cumulative voting rights. Except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any certificate of designation relating to any series of Preferred Stock) that relates solely to the terms, number of shares, powers, designations, preferences or relative, participating, optional or other special rights (including, without limitation, voting rights), or to qualifications, limitations or restrictions thereof, of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation (including any certificate of designation relating to any series of Preferred Stock) or pursuant to the DGCL. Except as otherwise required by law, holders of any series of Preferred Stock shall be entitled to only such voting rights, if any, as shall expressly be granted thereto by this Certificate of Incorporation (including any certificate of designation relating to such series of Preferred Stock).

 

4.4 No Class Vote on Changes in Authorized Number of Shares. The number of authorized shares of Preferred Stock or Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the corporation entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the DGCL (or any successor provision thereto), and no vote of the holders of any of the Common Stock or the Preferred Stock voting separately as a class shall be required therefor, unless a vote of any such holder is required pursuant to this Certificate of Incorporation (including any certificate of designation relating to any series of Preferred Stock).

 

B-3
 

 

Article 5

Board of Directors

 

5.1 Authority/Number of Directors. Except as otherwise provided in this Certificate of Incorporation or the DGCL, the business and affairs of the corporation shall be managed by or under the direction of the Board of Directors. Except as otherwise provided for or fixed pursuant to the provisions of Article 4 (including any certificate of designation with respect to any series of Preferred Stock) and this Article 5 relating to the rights of the holders of any series of Preferred Stock to elect additional directors, the precise number of directors shall be determined from time to time exclusively by resolution adopted by the Board of Directors.

 

5.2 Classified Board of Directors. Subject to the special right of the holders of one or more series of Preferred Stock to elect directors, the Board of Directors, shall be classified with respect to the time for which they severally hold office into three classes, as nearly equal in number as possible. The initial Class I Directors shall serve for a term expiring at the first annual meeting of stockholders of the corporation following the effective date of this Certificate of Incorporation; the initial Class II Directors shall serve for a term expiring at the second annual meeting of stockholders following the effective date of this Certificate of Incorporation; and the initial Class III Directors shall serve for a term expiring at the third annual meeting of stockholders following the effective date of this Certificate of Incorporation. Each director in each class shall hold office until his or her successor is duly elected and qualified. At each annual meeting of stockholders beginning with the first annual meeting of stockholders following the effective date of this Certificate of Incorporation, the successors of the class of directors whose term expires at that annual meeting shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in the third year following the year of their election, with each director in each such class to hold office until his or her successor is duly elected and qualified. If the number of such directors is changed, any increase or decrease shall be apportioned by the Board of Directors among the classes so as to maintain the number of directors in each class as nearly equal as possible, and any such additional director of any class elected to fill a newly created directorship resulting from an increase in such class shall hold office for a term that shall coincide with the remaining term of that class, but in no case shall a decrease in the number of directors remove or shorten the term of any incumbent director. The Board of Directors is authorized to assign members of the Board of Directors already in office to their respective class.

 

5.3 Vacancies. Subject to the rights granted to the holders of any one or more series of Preferred Stock then outstanding, any newly-created directorship on the Board of Directors that results from an increase in the number of directors and any vacancy occurring on the Board of Directors (whether by death, resignation, retirement, disqualification, removal or other cause) shall be filled only by a majority of the directors then in office, even if less than a quorum, or by a sole remaining director (and not by the stockholders). Any director elected to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall have been chosen and until his or her successor shall be elected and qualified, or until his or her earlier death, resignation, retirement, disqualification or removal.

 

B-4
 

 

5.4 Removal. Any or all of the directors (other than the directors elected by the holders of any series of Preferred Stock of the corporation, voting separately as a series or together with one or more other such series, as the case may be) may be removed only for cause and only by the affirmative vote of the holders of at least a majority in voting power of all the then outstanding shares of stock of the corporation entitled to vote thereon, voting together as a single class.

 

5.5 Election. Elections of directors need not be by written ballot unless the bylaws shall so provide.

 

5.6 Election by Holders of Preferred Stock. During any period when the holders of any series of Preferred Stock, voting separately as a series or together with one or more series, have the right to elect additional directors, then upon commencement and for the duration of the period during which such right continues: (i) the then otherwise total authorized number of directors of the corporation shall automatically be increased by such specified number of directors, and the holders of such Preferred Stock shall be entitled to elect the additional directors so provided for or fixed pursuant to said provisions, and (ii) each such additional director shall serve until such director’s successor shall have been duly elected and qualified, or until such director’s right to hold such office terminates pursuant to said provisions, whichever occurs earlier, subject to his or her earlier death, resignation, retirement, disqualification or removal. Notwithstanding any other provision of this Certificate of Incorporation, except as otherwise provided by the Board of Directors in the resolution or resolutions establishing such series, whenever the holders of any series of Preferred Stock having such right to elect additional directors are divested of such right pursuant to the provisions of such stock, the terms of office of all such additional directors elected by the holders of such stock, or elected to fill any vacancies resulting from the death, resignation, disqualification or removal of such additional directors, shall forthwith terminate (in which case each such director shall thereupon cease to be qualified as, and shall cease to be, a director) and the total authorized number of directors of the corporation shall automatically be reduced accordingly.

 

Article 6

Limitation of Director and Officer Liability

 

6.1 Limitation of Liability. To the fullest extent that the General Corporation Law of the State of Delaware or any other law of the State of Delaware as it exists on the date hereof or as it may hereafter be amended permits the limitation or elimination of the liability of directors and officers, no director of the corporation, and with respect to officers serving as such on or after the effective date of this Certificate of Incorporation, no officer of the corporation, shall be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer.

 

6.2 Effect of Amendment. Neither the amendment nor repeal of this Article 6, or any portion thereof, nor the adoption of any provision of this Certificate of Incorporation, nor, to the fullest extent permitted by the DGCL, any modification of law shall eliminate, reduce or otherwise adversely affect any right or protection of a current or former director or officer of the corporation existing hereunder with respect to any act or omission occurring prior to such amendment, repeal. adoption, or modification.

 

B-5
 

 

Article 7

Meetings of Stockholders

 

7.1 No Action by Consent. Any action required or permitted to be taken by the stockholders of the corporation must be effected at a duly called annual or special meeting of stockholders and may not be effected by a consent or consents (written, electronic, or otherwise) of such stockholders; provided, however, that any action required or permitted to be taken by the holders of Preferred Stock, voting separately as a series or separately as a class with one or more other such series, may be taken by consent, without a meeting, without prior notice and without a vote, but only if that right is expressly provided by this Certificate of Incorporation (including any certificate of designation relating to that series of Preferred Stock).

 

7.2 Annual Meetings. An annual meeting of stockholders for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, on such date, and at such time as shall be fixed exclusively by resolution of the Board of Directors or a duly authorized committee thereof.

 

7.3 Special Meetings. Except as otherwise required by law and subject to the rights of the holders of any series of Preferred Stock, special meetings of the stockholders of the corporation for any purpose or purposes may be called at any time only by or at the direction of the Board of Directors or the chair of the Board of Directors. Stockholders shall not be permitted to propose business to be brought before a special meeting of stockholders and the only matters that may be brought before a special meeting are the matters specified in the notice of meeting given by or at the direction of the person calling the meeting. The Board of Directors may postpone, reschedule or cancel any special meeting of stockholders.

 

7.4 Advance Notice. Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the corporation shall be given in the manner and to the extent provided in the bylaws of the corporation.

 

Article 8

Amendment of the Certificate of Incorporation and Bylaws

 

8.1 Certificate of Incorporation. Notwithstanding any other provisions of this Certificate of Incorporation (including any certificate of designation relating to any series of Preferred Stock), and notwithstanding that a lesser percentage may be permitted from time to time by applicable law, no provision of Articles 5, 6, 7, 8, and 9 may be altered, amended or repealed in any respect (including by merger, division, conversion, transfer, domestication, consolidation or otherwise), nor may any provision inconsistent therewith be adopted, unless such alteration, amendment, repeal or adoption is approved by the affirmative vote of the holders of at least two-thirds (66 2/3%) of the capital stock of the corporation entitled to vote generally in an election of directors, voting together as a single class.

 

B-6
 

 

8.2 Bylaws. In furtherance and not in limitation of the powers conferred by law, the board of directors is expressly authorized to make, alter, amend and repeal the bylaws of the corporation subject to the power of the stockholders of the corporation to alter, amend or repeal the bylaws; provided, however, that with respect to the powers of stockholders to make, alter, amend or repeal the bylaws, the affirmative vote of the holders of at least two-thirds (66 2/3%) of the capital stock of the corporation entitled to vote generally in an election of directors, voting together as a single class, shall be required to make, alter amend or repeal the bylaws of the corporation or to adopt any provision inconsistent therewith.

 

Article 9

Corporate Governance Matters

 

9.1 Validity and Construction. If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever: (i) the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not, to the fullest extent permitted by law, in any way be affected or impaired thereby and (ii) to the fullest extent permitted by law, the provisions of this Certificate of Incorporation (including, without limitation, each such portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the corporation to protect its directors, officers, employees and agents from personal liability in respect of their good faith service or for the benefit of the corporation to the fullest extent permitted by law.

 

9.2 Forum Selection. Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or if such court does not have subject matter jurisdiction another state or federal court (as appropriate) located within the State of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee or stockholder of the corporation to the corporation or the corporation’s stockholders, creditors or other constituents, (iii) any action asserting a claim against the corporation or any current or former director or officer of the corporation arising pursuant to any provision of the DGCL or this Certificate of Incorporation or the bylaws (as either may be amended and/or restated from time to time) or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv) any action asserting a claim governed by the internal affairs doctrine. Unless the corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the federal securities laws of the United States of America.

 

In addition to the above, if any action the subject matter of which is within the scope of this Section 9.2 is filed in a court other than a court located within the State of Delaware (a “Foreign Action”) in the name of any stockholder, such stockholder shall be deemed to have consented to: (a) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce this Section 9.2 (an “Enforcement Action”), and (b) having service of process made upon such stockholder in any such Enforcement Action by service upon such stockholder’s counsel in the Foreign Action as agent for such stockholder.

 

To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the corporation shall be deemed to have notice of and consented to the provisions of this Section 9.2 and this Certificate of Incorporation. Failure to enforce the foregoing provisions would cause the corporation irreparable harm and the corporation shall be entitled to equitable relief, including injunction and specific performance, to enforce the forgoing provisions.

 

B-7
 

 

Annex C

 

SERINA THERAPEUTICS, INC.

2024 EQUITY INCENTIVE PLAN

 

1. Purpose; Eligibility.

 

1.1 General Purpose. The name of this plan is the Serina Therapeutics, Inc. 2024 Equity Incentive Plan. The purposes of the Plan are to (a) enable the Company to attract and retain the types of Employees, Consultants, and Directors who will contribute to the Company’s long-range success; (b) provide incentives that align the interests of Employees, Consultants, and Directors with those of the stockholders of the Company; and (c) promote the success of the Company’s business.

 

1.2 Eligible Award Recipients. The persons eligible to receive Awards are the Employees, Consultants, and Directors of the Company.

 

1.3 Available Awards. Awards that may be granted under the Plan include: (a) Incentive Stock Options, (b) Non-qualified Stock Options, (c) Stock Appreciation Rights, and (d) Stock Awards.

 

2. Definitions.

 

Applicable Laws” means the requirements related to or implicated by the administration of the Plan under applicable state corporate law, United States federal and state securities laws, the Code, any stock exchange or quotation system on which the shares of Common Stock are listed or quoted, and the applicable laws of any foreign country or jurisdiction where Awards are granted under the Plan.

 

Award” means any right granted under the Plan, including an Incentive Stock Option, a Non-qualified Stock Option, a Stock Appreciation Right, or a Stock Award.

 

Award Agreement” means a written agreement, contract, certificate, or other instrument or document evidencing the terms and conditions of an individual Award granted under the Plan, which may, in the discretion of the Company, be transmitted electronically to any Participant. Each Award Agreement will be subject to the terms and conditions of the Plan.

 

“AgeX” means AgeX Therapeutics, Inc., a Delaware corporation, and any successor company or any parent company.

 

Board” means the Board of Directors of Serina, as constituted at any time.

 

Cause” means:

 

With respect to any Employee or Consultant: (a) if the Employee or Consultant is a party to an employment or service agreement with the Company and such agreement provides for a definition of Cause, the definition contained therein; or (b) if no such agreement exists, or if such agreement does not define Cause: (i) the commission of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude or the commission of any other act involving willful malfeasance or material fiduciary breach with respect to the Company; (ii) conduct that results in or is reasonably likely to result in harm to the reputation or business of the Company; (iii) willful conversion or misappropriation of corporate funds; (iv) gross negligence or willful misconduct with respect to the Company; or (v) material violation of any state or federal securities law.

 

With respect to any Director, a determination by a majority of the disinterested Board members that the Director has engaged in any of the following: (a) malfeasance in office; (b) gross misconduct or neglect; (c) false or fraudulent misrepresentation inducing the Director’s appointment;(d) willful conversion or misappropriation of corporate funds; or (e) repeated failure to participate in Board meetings on a regular basis despite having received proper notice of the meetings in advance.

 

C-1
 

 

The Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to whether a Participant has been discharged for Cause.

 

Change in Control” (a) the direct or indirect sale, transfer, conveyance, or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of the Company, taken as a whole, to any Person that is not a subsidiary of the Company; (b) the date that is 10 business days prior to the consummation of a complete liquidation or dissolution of the Company; (c) the acquisition by any Person of Beneficial Ownership of 50% or more (on a fully diluted basis) of either (i) the then-outstanding shares of Common Stock of the Company, taking into account as outstanding for this purpose such Common Stock issuable upon the exercise of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire such Common Stock (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of Directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this Plan, the following acquisitions will not constitute a Change in Control: (A) any acquisition by the Company or any Subsidiary, (B) any acquisition by any employee benefit plan sponsored or maintained by the Company or any Subsidiary, (C) any acquisition that complies with clauses, (i), (ii), and (iii) of subsection (d) of this definition, or (D) in respect of an Award held by a particular Participant, any acquisition by the Participant or any group of persons including the Participant (or any entity controlled by the Participant or any group of persons including the Participant); or (d) the consummation of a reorganization, merger, consolidation, statutory share exchange, or similar form of corporate transaction involving the Company that requires the approval of the Company’s stockholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination: (i) more than 50% of the total voting power of (A) the entity resulting from such Business Combination (the “Surviving Company”), or (B) if applicable, the ultimate parent entity that directly or indirectly has beneficial ownership of sufficient voting securities eligible to elect a majority of the members of the board of directors (or the analogous governing body) of the Surviving Company (the “Parent Company”), is represented by the Outstanding Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which the Outstanding Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of the Outstanding Company Voting Securities among the holders thereof immediately prior to the Business Combination; (ii) no Person (other than any employee benefit plan sponsored or maintained by the Surviving Company or the Parent Company) is or becomes the Beneficial Owner, directly or indirectly, of 50% or more of the total voting power of the outstanding voting securities eligible to elect members of the board of directors of the Parent Company (or the analogous governing body) (or, if there is no Parent Company, the Surviving Company); and (iii) at least a majority of the members of the board of directors (or the analogous governing body) of the Parent Company (or, if there is no Parent Company, the Surviving Company) following the consummation of the Business Combination were Board members at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination.

 

Code” means the Internal Revenue Code of 1986, as it may be amended from time to time. Any reference to a section of the Code will be deemed to include a reference to any regulations promulgated thereunder.

 

Committee” means a committee of the Board appointed by the Board to administer the Plan in accordance with Section 3.3 and Section 3.4.

 

Common Stock” means the common stock, par value $0.0001 per share, of Serina, or such other securities of Serina as may be designated by the Board or Committee from time to time in substitution thereof.

 

Company” means Serina and any or all of its Subsidiaries.

 

Consultant” means any individual who is engaged by the Company to render consulting or advisory services.

 

C-2
 

 

Continuous Service” means that the Participant’s service with the Company, whether as an Employee, Consultant, or Director, is not interrupted or terminated. The Participant’s Continuous Service will not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company as an Employee, Consultant, or Director or a change in the entity for which the Participant renders such service (such as a change of employment from one Subsidiary to another Subsidiary), provided that there is no interruption or termination of the Participant’s Continuous Service; provided further that if any Award is subject to Section 409A of the Code, this sentence will only be given effect to the extent consistent with Section 409A of the Code. For example, a change in status from an Employee to a Director will not constitute an interruption of Continuous Service. The Board or Committee, in its sole discretion, may determine whether Continuous Service will be considered interrupted in the case of any leave of absence approved by the Board or Committee, such as sick leave, military leave, or any other personal or family leave of absence. The Board or Committee, in its sole discretion, may determine whether a Company transaction, such as a sale or spin-off of a division or Subsidiary that employs a Participant, will be deemed to result in a termination of Continuous Service for purposes of affected Awards, and such decision will be final, conclusive, and binding.

 

Director” means a member of the Board.

 

Disability” means that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment; provided, however, for purposes of determining the term of an Incentive Stock Option pursuant to Section 6.10 hereof, the term Disability will have the meaning ascribed to it under Section 22(e)(3) of the Code. The determination of whether an individual has a Disability will be determined by the Board or Committee or under procedures adopted by the Board or Committee. Except for a determination of Disability within the meaning of Section 22(e)(3) of the Code for purposes of an Incentive Stock Option, the Board or Committee may rely on any determination that a Participant is disabled for purposes of benefits under any long-term disability plan maintained by the Company in which a Participant participates.

 

Effective Date” means the date as of which this Plan was adopted by the board of directors of AgeX.

 

Employee” means any person employed by the Company; provided, that, for purposes of determining eligibility to receive Incentive Stock Options, an Employee means an employee of the Company or a parent corporation within the meaning of Code Section 424. Mere service as a Director or payment of a director’s fee by the Company will not be sufficient to constitute “employment” by the Company.

 

Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

Fair Market Value” means, as of any date, the value of the Common Stock as determined below. If the Common Stock is listed on any national stock exchange, inter-dealer quotation system, or over-the-counter market that reports closing prices, including without limitation, the New York Stock Exchange, NYSE MKT, Nasdaq, or the OTC Bulletin Board, the Fair Market Value will be the closing price of a share of Common Stock (or if no sales were reported the closing price on the date immediately preceding such date) as quoted on such exchange or system on the day of determination, as reported in the Wall Street Journal or such other source as the Board or Committee deems reliable. In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Board or Committee, using such methods as the Board or Committee determines to be reasonable under the circumstances, and such determination will be conclusive and binding on all persons.

 

Free Standing Rights” has the meaning set forth in Section 7.1(a).

 

Good Reason” means: (a) if an Employee or Consultant is a party to an employment or service agreement with the Company and such agreement provides for a definition of Good Reason, the definition contained therein; or (b) if no such agreement exists or if such agreement does not define Good Reason, the occurrence of one or more of the following without the Participant’s express written consent, which circumstances are not remedied by the Company within thirty (30) days of its receipt of a written notice from the Participant describing the applicable circumstances (which notice must be provided by the Participant within ninety (90) days of the Participant’s knowledge of the applicable circumstances): (i) any material increase in the Participant’s duties (other than by way of promotion attendant with additional responsibilities, authority, or title and an increase in salary commensurate therewith), (ii) any material diminution of responsibilities, authority, title, status, or reporting structure; (iii) a material reduction in the Participant’s base salary or bonus opportunity; or (iv) a geographical relocation of the Participant’s principal office location by more than fifty (50) miles.

 

C-3
 

 

Grant Date” means the date on which the Board or Committee adopts a resolution, or takes other appropriate action, expressly granting an Award to a Participant that specifies the key terms and conditions of the Award or, if a later date is set forth in such resolution, then such date as is set forth in such resolution.

 

Incentive Stock Option” means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code.

 

Non-Employee Director” means a Director who is a “non-employee director” within the meaning of Rule 16b-3.

 

Non-qualified Stock Option” means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.

 

Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.

 

Option” means an Incentive Stock Option or a Non-qualified Stock Option granted pursuant to the Plan.

 

Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.

 

Option Exercise Price” means the price at which a share of Common Stock may be purchased upon the exercise of an Option.

 

Participant” means an eligible person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.

 

Performance Goals” means one or more goals established by the Board or Committee that must be attained by Serina or a Subsidiary, or a division, business unit or operational unit of Serina or a Subsidiary in order for an Award to vest or for the determination of the amount of an Award. A Performance Goal may be based on financial results or performance or upon the attainment of any other goal or milestone designated by the Board or Committee such as, by way of example only and not by way of limitation, the attainment of a specified amount of sales, revenues, or net income, an increase in the Fair Market Value of the Common Stock, or the commencement or successful completion of a clinical trial of a new drug, biological product, or medical device.

 

Permitted Transferee” means: (a) a member of the Optionholder’s immediate family (child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships), any person sharing the Optionholder’s household (other than a tenant or employee), a trust in which these persons have more than 50% of the beneficial interest, a foundation in which these persons (or the Optionholder) control the management of assets, and any other entity in which these persons (or the Optionholder) own more than 50% of the voting interests; and (b) in conjunction with the exercise of an Option, and for the purpose of obtaining financing for such exercise, the Optionholder may arrange for a securities broker/dealer to exercise an Option on the Optionholder’s behalf, to the extent necessary to obtain funds required to pay the exercise price of the Option, provided that the Fair Market Value of the Common Stock determined as of the date immediately before the date of such transfer exceeded the exercise price of the Option.

 

Plan” means this Serina Therapeutics, Inc. 2024 Equity Incentive Plan, as amended and/or amended and restated from time to time.

 

Related Rights” has the meaning set forth in Section 7.1(a).

 

Restricted Period” has the meaning set forth in Section 7.2(a).

 

C-4
 

 

Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.

 

Securities Act” means the Securities Act of 1933, as amended.

 

“Serina” means Serina Therapeutics, Inc., a Delaware corporation, and any successor company or any parent company.

 

Stock Appreciation Right” means the right pursuant to an Award granted under Section 7.1 to receive, upon exercise, an amount payable in cash or shares equal to the number of shares subject to the Stock Appreciation Right that is being exercised multiplied by the excess of (a) the Fair Market Value of a share of Common Stock on the date the Award is exercised, over (b) the exercise price specified in the Stock Appreciation Right Award Agreement.

 

Stock Award” means any Award granted pursuant to Section 7.2(a).

 

“Subsidiary” means (i) any corporation or other entity in which the Company possesses directly or indirectly equity interests representing at least 50% of the total ordinary voting power or at least 50% of the total value of all classes of equity interests of such corporation or other entity and (ii) any other entity in which the Company has a direct or indirect economic interest that is designated as a Subsidiary by the Board or Committee.

 

Ten Percent Shareholder” means a person who owns (or is deemed to own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or of any of its Subsidiaries.

 

“Voting Securities” means any class or series of stock or other securities entitling the holder vote for the election of Directors generally but will exclude any such security that entitles the holder to designate, appoint, or vote for the election of a minority of the Directors.

 

3. Administration.

 

3.1 Authority of Committee. The Plan will be administered by the Board or, in the Board’s sole discretion, by a Committee. Subject to the terms of the Plan, the Board or Committee will have the authority:

 

(a) to construe and interpret the Plan and apply its provisions;

 

(b) to promulgate, amend, and rescind rules and regulations relating to the administration of the Plan;

 

(c) to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan;

 

(d) to determine when Awards are to be granted under the Plan and the applicable Grant Date;

 

(e) from time to time to select those Participants to whom Awards will be granted;

 

(f) to determine the number of shares of Common Stock to be made subject to each Award;

 

(g) to determine whether each Option is to be an Incentive Stock Option or a Non-qualified Stock Option;

 

(h) to prescribe the terms and conditions of each Award, including, without limitation, the exercise price and medium of payment and vesting provisions, and to specify the provisions of the Award Agreement relating to such grant;

C-5
 

 

(i) to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting, or the term of any outstanding Award; provided, however, that if any such amendment impairs a Participant’s rights or increases a Participant’s obligations under his or her Award or creates or increases a Participant’s federal income tax liability with respect to an Award, such amendment will also be subject to the Participant’s consent;

 

(j) to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of their employment for purposes of the Plan, which periods will be no shorter than the periods generally applicable to Employees under the Company’s employment policies;

 

(k) to make decisions with respect to outstanding Awards that may become necessary upon a change in corporate control or an event that triggers anti-dilution adjustments;

 

(l) to interpret, administer, reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any instrument or agreement relating to, or Award granted under, the Plan; and

 

(m) to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for the administration of the Plan.

 

The Board or Committee also may modify the purchase price or the exercise price of any outstanding Award, consistent with requirements under the Code applicable to the Award, provided that if the modification effects a repricing, stockholder approval will be required before the repricing is effective. As used in this paragraph, repricing means (i) reduction in the exercise price of an outstanding Option or SAR, and (ii) cancellation of an “underwater” or “out-of-the money” Award in exchange for other Awards or cash. An “underwater” or “out-of-the money” Award is one for which the exercise price is greater than the Fair Market Value of the underlying Common Stock.

 

3.2 Decisions Final. All decisions made by the Board or Committee pursuant to the provisions of the Plan will be final and binding on the Company and the Participants.

 

3.3 Delegation. The Board may delegate administration of the Plan to a committee or committees of the Board, and the term “Committee” will apply to any such committee. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan. The members of the Committee will be appointed by and serve at the pleasure of the Board. From time to time, the Board may increase or decrease the size of the Committee, add additional members to, remove members (with or without cause) from, appoint new members in substitution therefor, and fill vacancies, however caused, in the Committee. The Committee will act pursuant to a vote of the majority of its members or, in the case of a Committee comprised of only two members, the unanimous consent of its members, whether present or not, or by the written consent of the majority of its members and minutes will be kept of all of its meetings and copies thereof will be provided to the Board. Subject to the limitations prescribed by the Plan and the Board, the Committee may establish and follow such rules and regulations for the conduct of its business as it may determine to be advisable.

 

3.4 Committee Composition. Except as otherwise determined by the Board, the Committee will consist solely of two or more Non-Employee Directors. The Board will have discretion to determine whether or not it intends to comply with the exemption requirements of Rule 16b-3. However, if the Board intends to satisfy such exemption requirements, with respect to any insider subject to Section 16 of the Exchange Act, the Committee will be a compensation committee of the Board that at all times consists solely of two or more Non-Employee Directors. Nothing herein will create an inference that an Award is not validly granted under the Plan in the event Awards are granted under the Plan by a compensation committee of the Board that does not at all times consist solely of two or more Non-Employee Directors.

 

C-6
 

 

4. Shares Subject to the Plan.

 

4.1 Subject to adjustment in accordance with Section 11, a total of 1,750,000 shares of Common Stock will be available for the grant of Awards under the Plan. The shares of Common Stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards.

 

4.2 Any shares of Common Stock subject to an Award that is cancelled, forfeited, or expires prior to exercise or realization, either in full or in part, will again become available for issuance under the Plan. Notwithstanding anything to the contrary contained herein, shares subject to an Award under the Plan will not again be made available for issuance or delivery under the Plan if such shares are (a) shares tendered in payment of an Option, (b) shares delivered or withheld by the Company to satisfy any tax withholding obligation, (c) shares covered by a stock-settled Stock Appreciation Right or other Awards that were not issued upon the settlement of the Award, or (d) shares repurchased by the Company using Option proceeds.

 

4.3 Subject to adjustment in accordance with Section 11, the aggregate maximum number of shares of Common Stock that may be issued on the exercise of Incentive Stock Options will be 1,750,000 shares of Common Stock.

 

5. Eligibility.

 

5.1 Eligibility for Specific Awards. Incentive Stock Options may be granted only to Employees. Awards other than Incentive Stock Options may be granted to Employees, Consultants and Directors. Awards may be granted to individuals whom the Committee determines are reasonably expected to become Employees, Consultants and Directors; provided that such grant and the Grant Date will become effective only the individual becoming an Employee, Consultant, or Director.

 

5.2 Ten Percent Shareholders. A Ten Percent Shareholder will not be granted an Incentive Stock Option unless the Option Exercise Price is at least 110% of the Fair Market Value of the Common Stock at the Grant Date and the Option is not exercisable after the expiration of five years from the Grant Date.

 

6. Option Provisions.

 

Each Option granted under the Plan will be evidenced by an Award Agreement. Each Option so granted will be subject to the conditions set forth in this Section 6, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. All Options will be separately designated Incentive Stock Options or Non-qualified Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. Notwithstanding the foregoing, the Company will have no liability to any Participant or any other person if an Option designated as an Incentive Stock Option fails to qualify as such at any time or if an Option is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code and the terms of such Option do not satisfy the requirements of Section 409A of the Code. The provisions of separate Options need not be identical, but each Option will include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:

 

6.1 Term. An Option will expire, and thereafter no longer be exercisable, on such date as the Board or Committee may designate; provided, however, no Option will be exercisable after the expiration of 10 years from the Grant Date, and no Incentive Stock Option granted to a Ten Percent Shareholder will be exercisable after the expiration of 5 years from the Grant Date. The expiration date of each Option will be stated in the Award Agreement pertaining to the Option.

 

6.2 Exercise Price of An Incentive Stock Option. Subject to the provisions of Section 5.2 pertaining to Incentive Stock Options granted to Ten Percent Shareholders, the Option Exercise Price of each Incentive Stock Option will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing, an Incentive Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code.

 

C-7
 

 

6.3 Exercise Price of a Non-qualified Stock Option. The Option Exercise Price of each Non-qualified Stock Option will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing, a Non-qualified Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 409A of the Code.

 

6.4 Consideration. The Option Exercise Price of Common Stock acquired pursuant to an Option will be paid, to the extent permitted by applicable statutes and regulations, either (a) in cash or by certified or bank check at the time the Option is exercised or (b) to the extent approved by the Board or Committee, the Option Exercise Price may be paid: (i) by delivery to the Company of other Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date of delivery equal to the Option Exercise Price (or portion thereof) due for the number of shares being acquired; (ii) a “cashless” exercise program established with a broker pursuant to which the broker exercises or arranges for the coordination of the exercise of the Option with the sale of some or all of the underlying Common Stock; (iii) any combination of the foregoing methods; or (iv) in any other form of consideration that is legal consideration for the issuance of Common Stock and that may be acceptable to the Board or Committee. Unless otherwise specifically provided in the Option, the exercise price of Common Stock acquired pursuant to an Option that is paid by delivery to the Company of other Common Stock acquired, directly or indirectly from the Company, will be paid only by shares of the Common Stock of the Company that have been held for more than six months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes). Notwithstanding the foregoing, during any period for which the Common Stock is publicly traded (i.e., the Common Stock is listed on any national securities exchange or an interdealer quotation system, or is traded in an over-the-counter market that reports closing prices) an exercise by a Director or Officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company, directly or indirectly, in violation of Section 402(a) of the Sarbanes-Oxley Act of 2002 is prohibited with respect to any Award under this Plan.

 

6.5 Transferability of An Incentive Stock Option. An Incentive Stock Option will not be transferable except by will or by the laws of descent and distribution and will be exercisable during the lifetime of the Optionholder only by the Optionholder.

 

6.6 Transferability of a Non-qualified Stock Option. A Non-qualified Stock Option may, in the sole discretion of the Board or Committee, be transferable to a Permitted Transferee, upon approval by the Board or Committee, to the extent provided in the Award Agreement or by subsequent consent granted by the Board or Committee. If the Non-qualified Stock Option does not provide for transferability or consent to transfer to a Permitted Transferee is not granted by the Board or Committee, then the Non-qualified Stock Option will not be transferable except by will or by the laws of descent and distribution and will be exercisable during the lifetime of the Optionholder only by the Optionholder.

 

6.7 Vesting of Options. Each Option may, but need not, vest and therefore become exercisable in periodic instalments as determined by the Board or Committee or based upon the attainment of a Performance Goal or the occurrence of a specified event. The vesting provisions of individual Options may vary. No Option may be exercised for a fraction of a share of Common Stock.

 

6.8 Termination of Continuous Service. Unless otherwise provided in an Award Agreement or in an employment agreement the terms of which have been approved by the Board or Committee, in the event an Optionholder’s Continuous Service terminates (other than upon the Optionholder’s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination) but only within such period of time ending on the earlier of (a) the date three months following the termination of the Optionholder’s Continuous Service or (b) the expiration of the term of the Option as set forth in the Award Agreement The Board or Committee or its respective delegate, in its sole discretion, may determine whether a Company transaction, such as a sale or spin-off of a division or subsidiary that employs a Participant, shall be deemed to result in a termination of Continuous Service for purposes of affected Awards, and such decision shall be final, conclusive and binding. If, after termination, the Optionholder does not exercise his or her Option within the time specified in the Award Agreement, the Option will terminate.

 

C-8
 

 

6.9 Extension of Termination Date. An Optionholder’s Award Agreement may also provide that if the exercise of the Option following the termination of the Optionholder’s Continuous Service for any reason would be prohibited at any time because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act or any other state or federal securities law or the rules of any securities exchange or interdealer quotation system, then the Option will terminate on the earlier of (a) the expiration of the term of the Option in accordance with Section 6.1 or (b) the expiration of a period after termination of the Participant’s Continuous Service that is three months after the end of the period during which the exercise of the Option would be in violation of such registration or other securities law requirements.

 

6.10 Disability of Optionholder. Unless otherwise provided in an Award Agreement, in the event that an Optionholder’s Continuous Service terminates as a result of the Optionholder’s Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only within such period of time ending on the earlier of (a) the date 12 months following such termination or (b) the expiration of the term of the Option as set forth in the Award Agreement. If, after termination, the Optionholder does not exercise his or her Option within the time specified herein or in the Award Agreement, the Option will terminate.

 

6.11 Death of Optionholder. Unless otherwise provided in an Award Agreement, in the event an Optionholder’s Continuous Service terminates as a result of the Optionholder’s death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholder’s estate, executor, or personal representative, by a person who acquired the right to exercise the Option by bequest, but only within the period ending on the earlier of (a) the date 12 months following the date of death or (b) the expiration of the term of such Option as set forth in the Award Agreement. If, after the Optionholder’s death, the Option is not exercised within the time specified herein or in the Award Agreement, the Option will terminate.

 

6.12 Incentive Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company) exceeds $100,000, the Options or portions thereof which exceed such limit (according to the order in which they were granted) will be treated as Non-qualified Stock Options.

 

7. Provisions of Awards Other Than Options.

 

7.1 Stock Appreciation Rights.

 

(a) General

 

Each Stock Appreciation Right granted under the Plan will be evidenced by an Award Agreement. Each Stock Appreciation Right so granted will be subject to the conditions set forth in this Section 7.1, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. Stock Appreciation Rights may be granted alone (“Free Standing Rights”) or in tandem with an Option granted under the Plan (“Related Rights”).

 

(b) Grant Requirements

 

Any Related Right that relates to a Non-qualified Stock Option may be granted at the same time the Option is granted or at any time thereafter but before the exercise or expiration of the Option. Any Related Right that relates to an Incentive Stock Option must be granted at the same time the Incentive Stock Option is granted.

 

C-9
 

 

(c) Term of Stock Appreciation Rights

 

The term of a Stock Appreciation Right granted under the Plan will be determined by the Board or Committee; provided, however, no Stock Appreciation Right will be exercisable later than the tenth anniversary of the Grant Date.

 

(d) Vesting of Stock Appreciation Rights

 

Each Stock Appreciation Right may, but need not, vest and therefore become exercisable in periodic instalments as determined by the Board or Committee or based upon the attainment of a Performance Goal or the occurrence of a specified event. The vesting provisions of individual Stock Appreciation Rights may vary. No Stock Appreciation Right may be exercised for a fraction of a share of Common Stock.

 

(e) Exercise and Payment

 

Upon exercise of a Stock Appreciation Right, the holder will be entitled to receive from the Company an amount equal to the number of shares of Common Stock subject to the Stock Appreciation Right that is being exercised multiplied by the excess of (i) the Fair Market Value of a share of Common Stock on the date the Award is exercised, over (ii) the exercise price specified in the Stock Appreciation Right or related Option. Payment with respect to the exercise of a Stock Appreciation Right will be made on the date of exercise. Payment will be made in the form of shares of Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Board or Committee in its sole discretion), cash or a combination thereof, as determined by the Board or Committee.

 

(f) Exercise Price

 

The exercise price of a Free Standing Stock Appreciation Right will be determined by the Board or Committee, but will not be less than 100% of the Fair Market Value of one share of Common Stock on the Grant Date of the Stock Appreciation Right. A Related Right granted simultaneously with or subsequent to the grant of an Option and in conjunction therewith or in the alternative thereto will have the same exercise price as the related Option, will be transferable only upon the same terms and conditions as the related Option, and will be exercisable only to the same extent as the related Option; provided, however, that a Stock Appreciation Right, by its terms, will be exercisable only when the Fair Market Value per share of Common Stock subject to the Stock Appreciation Right and related Option exceeds the exercise price per share thereof. No Stock Appreciation Rights may be granted in tandem with an Option unless the Board or Committee determines that the requirements of Section 7.1(b) are satisfied.

 

(g) Reduction in the Underlying Option Shares

 

Upon any exercise of a Related Right, the number of shares of Common Stock for which any related Option will be exercisable will be reduced by the number of shares for which the Stock Appreciation Right has been exercised. The number of shares of Common Stock for which a Related Right will be exercisable will be reduced upon any exercise of any related Option by the number of shares of Common Stock for which such Option has been exercised.

 

7.2 Stock Awards.

 

(a) General

 

A Stock Award is an Award of actual shares of Common Stock (“Restricted Stock”) or hypothetical Common Stock units (“Restricted Stock Units”) having a value equal to the Fair Market Value of an identical number of shares of Common Stock. A Stock Award may, but need not, provide that such Stock Award may not be sold, assigned, transferred or otherwise disposed of, or pledged or hypothecated as collateral for a loan or as security for the performance of any obligation or for any other purpose for such period as the Board or Committee shall determine (the “Restricted Period”). Each Stock Award granted under the Plan will be evidenced by an Award Agreement. Each Stock Award so granted will be subject to the conditions set forth in this Section 7.2, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement.

 

C-10
 

 

(b) Restricted Stock and Restricted Stock Units

 

(i) Each Participant granted Restricted Stock shall execute and deliver to the Company an Award Agreement with respect to the Restricted Stock setting forth the applicable payment terms, if any, for the Restricted Stock, and restrictions and other terms and conditions applicable to such Restricted Stock.

 

(ii) Restricted Stock may be issued to a Participant without payment or without the delivery of a promissory note or instalment payment agreement only for services actually performed by the Participant prior to the issuance of the Restricted Stock.

 

(iii) In the case of Restricted Stock sold to a Participant on an instalment payment basis, the Company may require, as a condition of the grant, that the Participant execute and deliver to the Company a promissory note or instalment payment agreement and a stock pledge or security agreement, and a blank stock power with respect to the Restricted Stock, in such form and containing such terms as the Board or Committee may require. No Restricted Stock will be sold to an Officer or Director on instalment payment terms that would constitute an extension of credit in violation of Section 402(a) of the Sarbanes-Oxley Act of 2002.

 

(iv) If the Committee determines that the Restricted Stock shall be held by the Company or in escrow rather than delivered to the Participant pending the release of the applicable restrictions, the Committee may require the Participant to additionally execute and deliver to the Company (A) an escrow agreement satisfactory to the Committee, if applicable and (B) the appropriate blank stock power with respect to the Restricted Stock covered by such agreement.

 

(v) If a Participant fails to execute an agreement evidencing an Award of Restricted Stock and, if applicable, a promissory note or instalment payment agreement, stock pledge or security agreement, escrow agreement, and stock power, the Award will be null and void. Subject to the restrictions set forth in the Award, the Participant generally will have the rights and privileges of a stockholder as to such Restricted Stock, including the right to vote such Restricted Stock and the right to receive dividends; provided that, any cash dividends and stock dividends with respect to the Restricted Stock will be withheld by the Company for the Participant’s account, and interest may be credited on the amount of the cash dividends withheld at a rate and subject to such terms as determined by the Board or Committee. The cash dividends or stock dividends so withheld and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) will be distributed to the Participant in cash or, at the discretion of the Board or Committee, in shares of Common Stock having a Fair Market Value equal to the amount of such dividends, if applicable, upon the release of restrictions on such share and, if such share is forfeited, the Participant will have no right to such dividends.

 

(vi) The terms and conditions of a grant of Restricted Stock Units will be reflected in an Award Agreement. No shares of Common Stock will be issued at the time a Restricted Stock Unit is granted, and the Company will not be required to set aside a fund for the payment of any such Award. A Participant will have no voting rights with respect to any Restricted Stock Units granted hereunder. At the discretion of the Committee, each Restricted Stock Unit (representing one share of Common Stock) may be credited with cash and stock dividends paid by the Company in respect of one share of Common Stock (“Dividend Equivalents”). Dividend Equivalents will be withheld by the Company for the Participant’s account, and interest may be credited on the amount of cash Dividend Equivalents withheld at a rate and subject to such terms as determined by the Board or Committee. Dividend Equivalents credited to a Participant’s account and attributable to any particular Restricted Stock Unit (and earnings thereon, if applicable) will be distributed in cash or, at the discretion of the Board or Committee, in shares of Common Stock having a Fair Market Value equal to the amount of such Dividend Equivalents and earnings, if applicable, to the Participant upon settlement of such Restricted Stock Unit and, if such Restricted Stock Unit is forfeited, the Participant will have no right to such Dividend Equivalents.

 

C-11
 

 

(c) Restrictions

 

(i) Restricted Stock awarded to a Participant will be subject to the following restrictions until the expiration of the Restricted Period, and to such other terms and conditions as may be set forth in the applicable Award Agreement: (A) if an escrow arrangement is used, the Participant will not be entitled to delivery of the stock certificate; (B) the shares will be subject to the restrictions on transferability set forth in the Award Agreement; (C) the shares will be subject to forfeiture to the extent provided in the applicable Award Agreement; and (D) to the extent such shares are forfeited, the stock certificates will be returned to the Company, and all rights of the Participant to such shares and as a stockholder with respect to such shares will terminate without further obligation on the part of the Company.

 

(ii) Restricted Stock Units awarded to any Participant will be subject to (A) forfeiture until the expiration of the Restricted Period, and satisfaction of any applicable Performance Goals during such period, to the extent provided in the applicable Award Agreement, and to the extent such Restricted Stock Units are forfeited, all rights of the Participant to such Restricted Stock Units will terminate without further obligation on the part of the Company and (B) such other terms and conditions as may be set forth in the applicable Award Agreement.

 

(iii) The Board or Committee will have the authority to remove any or all of the restrictions on the Restricted Stock and Restricted Stock Units whenever it may determine that, by reason of changes in Applicable Laws or other changes in circumstances arising after the date the Restricted Stock or Restricted Stock Units are granted, such action is appropriate.

 

(d) Restricted Period

 

With respect to Stock Awards, the Restricted Period will commence on the Grant Date and end at the time or times set forth on a schedule established by the Board or Committee in the applicable Award Agreement. The Board or Committee may, but will not be required to, provide for an acceleration of the expiration of a Restricted Period upon the occurrence of a specified event.

 

(e) Delivery of Restricted Stock and Settlement of Restricted Stock Units

 

Upon the expiration of the Restricted Period with respect to any shares of Restricted Stock, the restrictions set forth in Section 7.2(c) and the applicable Award Agreement will be of no further force or effect with respect to such shares, except as set forth in the applicable Award Agreement. If an escrow arrangement is used, upon such expiration, the Company shall deliver to the Participant, or his or her beneficiary, without charge, the stock certificate evidencing the shares of Restricted Stock which have not then been forfeited and with respect to which the Restricted Period has expired (provided, that no fractional shares will be issued) and any cash dividends or stock dividends credited to the Participant’s account with respect to such Restricted Stock and the interest thereon, if any. Upon the expiration of the Restricted Period with respect to any outstanding Restricted Stock Units, the Company shall deliver to the Participant, or his or her beneficiary, without charge, one share of Common Stock for each such outstanding Restricted Stock Unit (“Vested Unit”); provided, however, that, if explicitly provided in the applicable Award Agreement, the Company may, in its sole discretion, elect to pay cash or part cash and part Common Stock in lieu of delivering only shares of Common Stock for Vested Units. If a cash payment is made in lieu of delivering shares of Common Stock, the amount of such payment will be equal to the Fair Market Value of the Common Stock as of the date on which the Restricted Period lapsed with respect to each Vested Unit.

 

(f) Stock Restrictions

 

Each certificate representing Restricted Stock awarded under the Plan will, in addition to any other legends as may be required by law or by the Board or Committee, bear a legend to the following effect:

 

THESE SHARES MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

 

C-12
 

 

8. Securities Law Compliance.

 

All Awards, including all Options, Stock Appreciation Rights, and Stock Awards granted under the Plan will be subject to the requirement that, if at any time the Board or the Committee shall determine, in its discretion, that the listing upon any securities exchange, or the registration under the Securities Act, or registration or qualification under any state law is required for the grant, exercise, issue, or sale of any Options, Stock Appreciation Rights, Common Stock, or Restricted Stock Units under the Plan, or the consent or approval of any government regulatory body, is necessary or desirable as a condition of, or in connection therewith, such Option, Stock Appreciation Rights, or Stock Award may not be exercised in whole or in part unless such listing, registration, qualification, consent or approval will have been effected or obtained free of any conditions not acceptable to the Board or the Committee. Furthermore, if the Board or the Committee determines that any amendment to any Award (including, but not limited to, an increase in the exercise price of any Option or Stock Award) is necessary or desirable in connection with the registration or qualification of any of its shares under any state securities or “blue sky” law, then the Board or the Committee will have the unilateral right to make such changes without the consent of the Participant to whom the Award was granted.

 

8.1 Each Award Agreement will provide that no shares of Common Stock will be purchased or sold thereunder unless and until (i) any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel and (ii) if required to do so by the Company, the Participant has executed and delivered to the Company a letter of investment intent in such form and containing such provisions as the Committee may require.

 

8.2 Except as may otherwise be required by the Securities Act, the Company will not be required to register under the Securities Act the Plan, any Award or any Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, or any Common Stock issued or issuable pursuant to any such Award, and the Company will have no liability for any delay in issuing or failure to issue or sell any Option, Stock Appreciation Right, Common Stock, or Restricted Stock Unit prior to the date on which a registration statement under the Securities Act becomes effective with respect to the offer, sale, and issuance of such Award, Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, or Common Stock.

 

9. Use of Proceeds from Stock.

 

Proceeds from the sale of Common Stock pursuant to Awards, or upon exercise thereof, will constitute general funds of the Company.

 

10. Miscellaneous.

 

10.1 Acceleration of Exercisability and Vesting. The Board or Committee will have the power to accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest.

 

10.2 Stockholder Rights. Except as provided in the Plan or an Award Agreement, no Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until such Participant has satisfied all requirements for exercise of the Award pursuant to its terms and no adjustment will be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions of other rights for which the record date is prior to the date such Common Stock certificate is issued, except as provided in Section 11 hereof.

 

10.3 No Employment or Other Service Rights. Nothing in the Plan or any instrument executed or Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company in the capacity in effect at the time the Award was granted or will affect the right of the Company to terminate (a) the employment of an Employee with or without notice and with or without Cause, except as may otherwise be provided in a written employment agreement between the Company and the Participant, or (b) the service of a Director pursuant to the By-laws of Serina or a Subsidiary, and any applicable provisions of the corporate law of the state in which Serina or the Subsidiary is incorporated, as the case may be.

 

C-13
 

 

10.4 Withholding Obligations. To the extent provided by the terms of an Award Agreement or as may be approved by the Board or Committee, a Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under an Award by any of the following means (in addition to the Company’s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the exercise or acquisition of Common Stock under the Award, provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law; or (c) delivering to the Company previously owned and unencumbered shares of Common Stock.

 

11. Adjustments Upon Changes in Stock.

 

In the event of changes in the outstanding Common Stock or in the capital structure of the Company by reason of any stock or extraordinary cash dividend, stock split, reverse stock split, an extraordinary corporate transaction such as any recapitalization, reorganization, merger, consolidation, combination, exchange, or other relevant change in capitalization occurring after the Grant Date of any Award, Awards granted under the Plan and any Award Agreements, including the exercise price of Options and Stock Appreciation Rights and the number of shares of Common Stock subject to such Options, Stock Appreciation Rights, or Stock Awards, the maximum number of shares of Common Stock subject to all Awards stated in Section 4, and the maximum number of shares of Common Stock with respect to which any one person may be granted Awards during any period stated in Section 4 will be equitably adjusted or substituted, as to the number, price or kind of a share of Common Stock or other consideration subject to such Awards to the extent necessary to preserve the economic intent of such Award. In the case of adjustments made pursuant to this Section 11, unless the Board or Committee specifically determines that such adjustment is in the best interests of the Company, Board or the Committee shall, in the case of Incentive Stock Options, ensure that any adjustments under this Section 11 will not constitute a modification, extension or renewal of the Incentive Stock Options within the meaning of Section 424(h)(3) of the Code and in the case of Non-qualified Stock Options, ensure that any adjustments under this Section 11 will not constitute a modification of such Non-qualified Stock Options within the meaning of Section 409A of the Code. Any adjustments made under this Section 11 will be made in a manner which does not adversely affect the exemption provided pursuant to Rule 16b-3 under the Exchange Act. The Company shall give each Participant notice of an adjustment hereunder and, upon notice, such adjustment will be conclusive and binding for all purposes.

 

12. Effect of Change in Control.

 

12.1 In the discretion of the Board and the Committee, any Award Agreement may provide, or the Board or the Committee may provide by amendment of any Award Agreement or otherwise, notwithstanding any provision of the Plan to the contrary, that in the event of a Change in Control, Options and/or Stock Appreciation Rights will become immediately exercisable with respect to all or a specified portion of the shares subject to such Options or Stock Appreciation Rights, and/or the Restricted Period will expire immediately with respect to all or a specified portion of the shares of Restricted Stock or Restricted Stock Units.

 

12.2 In addition, in the event of a Change in Control, the Committee may, in its discretion and upon at least 10 days’ advance notice to the affected persons, cancel any outstanding Awards and pay to the holders thereof, in cash or stock, or any combination thereof, the value of such Awards based upon the price per share of Common Stock received or to be received by other stockholders of the Company in the event. In the case of any Option or Stock Appreciation Right with an exercise price (or SAR Exercise Price in the case of a Stock Appreciation Right) that equals or exceeds the price paid for a share of Common Stock in connection with the Change in Control, the Committee may cancel the Option or Stock Appreciation Right without the payment of consideration therefor.

 

12.3 The obligations of the Company under the Plan will be binding upon any successor corporation or organization resulting from the merger, consolidation or other reorganization of the Company, or upon any successor corporation or organization succeeding to all or substantially all of the assets and business of the Company and its Subsidiaries, taken as a whole.

 

C-14
 

 

13. Amendment of the Plan and Awards.

 

13.1 Amendment of Plan. The Board at any time, and from time to time, may amend or terminate the Plan. However, except as provided in Section 11 relating to adjustments upon changes in Common Stock, and Section 13.3 and Section 14.14, no amendment will be effective unless approved by the stockholders of the Company to the extent stockholder approval is necessary to satisfy any Applicable Laws. At the time of such amendment, the Board shall determine, upon advice from counsel, whether such amendment will be contingent on stockholder approval.

 

13.2 Stockholder Approval. The Board may, in its sole discretion, submit any amendment to the Plan or any Award for stockholder approval. Further, the Board or Committee may make the payment of any Award contingent upon stockholder approval.

 

13.3 No Impairment of Rights. Rights under any Award granted before amendment of the Plan will not be impaired by any amendment of the Plan unless (a) the Company requests the consent of the Participant and the Participant consents in writing, or (b) the Award was granted subject to the terms of the amendment.

 

14. General Provisions.

 

14.1 Forfeiture Events. The Committee may specify in an Award Agreement that the Participant’s rights, payments and benefits with respect to an Award will be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain events, in addition to applicable vesting conditions of an Award. Such events may include, without limitation, breach of non-competition, non-solicitation, confidentiality, or other restrictive covenants that are contained in the Award Agreement or otherwise applicable to the Participant, a termination of the Participant’s Continuous Service for Cause, or other conduct by the Participant that is detrimental to the business or reputation of the Company and/or its Subsidiaries.

 

14.2 Clawback. Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement).

 

14.3 Other Compensation Arrangements. Nothing contained in this Plan will prevent the Board or Committee from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases.

 

14.4 Sub-plans. The Committee may from time to time establish sub-plans under the Plan for purposes of satisfying blue sky, securities, tax or other laws of various jurisdictions in which the Company intends to grant Awards. Any sub-plans will contain such limitations and other terms and conditions as the Committee determines are necessary or desirable. All sub-plans will be deemed a part of the Plan, but each sub-plan will apply only to the Participants in the jurisdiction for which the sub-plan was designed.

 

14.5 Deferral of Awards. The Committee may establish one or more programs under the Plan to permit selected Participants the opportunity to elect to defer receipt of consideration upon exercise of an Award, satisfaction of performance criteria, or other event that absent the election would entitle the Participant to payment or receipt of shares of Common Stock or other consideration under an Award. The Committee may establish the election procedures, the timing of such elections, the mechanisms for payments of, and accrual of interest or other earnings, if any, on amounts, shares or other consideration so deferred, and such other terms, conditions, rules and procedures that the Committee deems advisable for the administration of any such deferral program.

 

14.6 Unfunded Plan. The Plan will be unfunded. Neither the Company, the Board nor the Committee will be required to establish any special or separate fund or to segregate any assets to assure the performance of its obligations under the Plan.

 

C-15
 

 

14.7 Recapitalizations. Each Award Agreement will contain provisions required to reflect the provisions of Section 11.

 

14.8 Delivery. Subject to Section 8 and Section 7.2(c), upon exercise of an Option or Stock Appreciation Right or Restricted Stock Unit granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period of time thereafter. A period of 30 days will be considered a reasonable period of time.

 

14.9 No Fractional Shares. No fractional shares of Common Stock will be issued or delivered pursuant to the Plan. The Board or Committee shall determine whether cash, additional Awards or other securities or property will be issued or paid in lieu of fractional shares of Common Stock or whether any fractional shares should be rounded down, forfeited, or otherwise eliminated.

 

14.10 Other Provisions. The Award Agreements authorized under the Plan may contain such other provisions not inconsistent with this Plan, including, without limitation, restrictions upon the exercise of the Awards, as the Committee may deem advisable.

 

14.11 Section 409A. The Plan is intended to comply with Section 409A of the Code to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan will be interpreted and administered to be in compliance therewith. Any payments described in the Plan that are due within the short-term deferral period described in Treasury Regulation Section 1.409A-1(b)(4) will not be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6) month period immediately following the Participant’s termination of Continuous Service will instead be paid on the first payroll date after the six-month anniversary of the Participant’s separation from service (or the Participant’s death, if earlier). Notwithstanding the foregoing, neither the Company nor the Committee will have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Participant under Section 409A of the Code and neither the Company nor the Committee will have any liability to any Participant for such tax or penalty.

 

14.12 Disqualifying Dispositions. Any Participant who makes a “disposition” (as defined in Section 424 of the Code) of all or any portion of shares of Common Stock acquired upon exercise of an Incentive Stock Option within two years from the Grant Date of such Incentive Stock Option or within one year after the issuance of the shares of Common Stock acquired upon exercise of such Incentive Stock Option will be required to immediately advise the Company in writing as to the occurrence of the sale and the price realized upon the sale of such shares of Common Stock.

 

14.13 Section 16. It is the intent of the Company that the Plan satisfy, and be interpreted in a manner that satisfies, the applicable requirements of Rule 16b-3 as promulgated under Section 16 of the Exchange Act so that Participants will be entitled to the benefit of Rule 16b-3, or any other rule promulgated under Section 16 of the Exchange Act, and will not be subject to short-swing liability under Section 16 of the Exchange Act. Accordingly, if the operation of any provision of the Plan would conflict with the intent expressed in this Section 14.13, such provision to the extent possible will be interpreted and/or deemed amended so as to avoid such conflict.

 

14.14 Expenses. The costs of administering the Plan will be paid by the Company.

 

14.15 Severability. If any of the provisions of the Plan or any Award Agreement is held to be invalid, illegal or unenforceable, whether in whole or in part, such provision will be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability and the remaining provisions will not be affected thereby.

 

14.16 Plan Headings. The headings in the Plan are for purposes of convenience only and are not intended to define or limit the construction of the provisions hereof.

 

14.17 Non-Uniform Treatment. The determinations of the Board or Committee under the Plan need not be uniform and may be made selectively among persons who are eligible to receive, or actually receive, Awards. Without limiting the generality of the foregoing, the Board and Committee will be entitled to make non-uniform and selective determinations, amendments and adjustments, and to enter into non-uniform and selective Award Agreements.

 

C-16
 

 

15. Effective Date of Plan.

 

The Plan will become effective as of the Effective Date, but no Award will be exercised (or, in the case of a stock Award, will be granted) unless and until the Plan has been approved by the stockholders of the Company, which approval will be within twelve (12) months before or after the date the Plan is adopted by the Board.

 

16. Termination or Suspension of the Plan.

 

The Plan will terminate automatically on [__________, 20__], which is ten years from the date the Plan was approved by AgeX’s board of directors. No Award will be granted pursuant to the Plan after such date, but Awards theretofore granted may extend beyond that date.

 

17. Effect of Dissolution, Merger or Other Reorganization.

 

Upon the dissolution or liquidation of Serina, or upon a reorganization, merger or consolidation of Serina as a result of which the outstanding Common Stock or other securities of the class then subject to Awards are changed into or exchanged for cash or property or securities not of Serina’s issue, or upon a sale of substantially all the property of Serina to, or the acquisition of more than eighty percent (80%) of the Voting Securities of Serina then outstanding by, another corporation or person, this Plan will terminate, and all unexercised Awards theretofore granted hereunder will terminate, unless provision can be made in writing in connection with such transaction for the continuance of the Plan and/or for the assumption of Awards theretofore granted, or the substitution for Awards options or other rights covering the shares of a successor corporation, or a parent or a subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices, in which event the Plan and Awards theretofore granted will continue in the manner and under the terms so provided, subject to such adjustments. The grant of an Award pursuant to the Plan will not affect in any way the right or power of Serina or any Subsidiary or parent corporation to make adjustments, reclassifications, reorganizations or changes or its capital or business structure or to merge or to consolidate or to dissolve, liquidate or sell, or transfer all or any part of its business or assets.

 

18. Choice of Law.

 

The law of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such state’s conflict of law rules.

 

Adopted by the board of directors on [__________, ____].

Approved by stockholders on [__________, ____].

 

C-17
 

 

Annex D

 

 

D-1
 

 

 

D-2
 

 

 

D-3
 

 

 

D-4
 

 

 

D-5
 

 

 

D-6
 

 

 

D-7
 

 

 

D-8
 

 

 

D-9
 

 

Annex E

 

STATE OF DELAWARE

SECOND CERTIFICATE OF AMENDMENT

OF CERTIFICATE OF INCORPORATION

OF AGEX THERAPEUTICS, INC.

 

AgeX Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify:

 

FIRST: That at a meeting of the Board of Directors of AgeX Therapeutics, Inc. resolutions were duly adopted setting forth a proposed second amendment of the Certificate of Incorporation of said corporation. The resolution setting forth the proposed amendment is as follows:

 

RESOLVED, that subject to approval by the stockholders, Article 4 of the Certificate of the Incorporation of the corporation is amended to read as follows:

 

Article 4

Capital Stock

 

4.1 Authorized Stock.

 

The corporation is authorized to issue two classes of stock, which shall be designated “Common Stock” and “Preferred Stock.” The number of shares of Common Stock which the corporation is authorized to issue is two hundred million (200,000,000), with a par value of $0.0001 per share. The number of shares of Preferred Stock which the corporation is authorized to issue is five million (5,000,000), with a par value of $0.0001 per share. The Preferred Stock may be issued in one or more series as the board of directors of the corporation may by resolution or resolutions designate. The board of directors of the corporation is authorized to fix by resolution or resolutions the designations and the powers, preferences and rights, and the qualifications, limitations or restrictions and the number of shares of any series of Preferred Stock and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed upon the Preferred Stock as a class, or upon any wholly unissued series of Preferred Stock. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of Preferred Stock subsequent to the issue of shares of that series.

 

4.2 Reverse Stock Split.

 

Upon the effectiveness of the Second Certificate of Amendment of the Certificate of Incorporation (the “Effective Time”), each               shares of Common Stock issued and outstanding immediately prior to the Effective Time shall, automatically and without any action on the part of the corporation or the respective holder thereof, be reclassified and combined into one validly issued, fully paid and nonassessable share of outstanding Common Stock without increasing or decreasing the par value of each share of Common Stock, subject to the treatment of fractional share interests as described below (such reclassification and combination of shares, the “Reverse Stock Split”). Any fractional shares of Common Stock resulting from the Reverse Stock Split and held by a single holder of record shall be aggregated. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Effective Time of a certificate or book entry position which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, after aggregating all fractional shares of Common Stock that such person would otherwise be entitled, following the Effective Time, shall be entitled to receive a cash payment (without interest and subject to applicable withholding taxes) equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the closing price of the Common Stock, as reported on the NYSE American, on the last trading day prior to the Effective Time (or if such price is not available, the average of the last bid and asked prices of the Common Stock on such day or other price determined by the Board of Directors), as adjusted in good faith by the corporation to account for the reverse stock split ratio. The Reverse Stock Split shall occur whether or not the certificates representing such shares of Common Stock are surrendered to the corporation or its transfer agent. Each certificate or book entry position that, immediately prior to the Effective Time, represented shares of Common Stock shall thereafter represent the number of shares of Common Stock into which the shares of Common Stock represented by such certificate or book entry position has been reclassified and combined, subject to the treatment of fractional interests set forth above.”

 

E-1
 

 

SECOND: This Second Certificate of Amendment of the Certificate of Incorporation shall be effective as of _______ a.m. Eastern Time on _______, 2024.

 

THIRD: That thereafter, pursuant to resolution of its Board of Directors, a meeting of the stockholders of said corporation was duly called and held upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the amendment.

 

FOURTH: That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

 

IN WITNESS WHEREOF, said corporation has caused this certificate to be signed this __ day of _______, 2024.

 

  By:  
    Joanne M. Hackett
    Interim Chief Executive Officer

 

E-2
 

 

Annex F

 

AMENDED AND RESTATED

BYLAWS

OF

SERINA THERAPEUTICS, INC.

(A DELAWARE CORPORATION)

 

ARTICLE 1

 

OFFICES

 

Section 1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent.

 

Section 1.2 Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Delaware, as the Board of Directors may from time to time determine or the business of the corporation may require.

 

ARTICLE 2

 

CORPORATE SEAL

 

The Board of Directors may adopt a corporate seal. The corporate seal shall consist of a die bearing the name of the corporation and the inscription, “Corporate Seal-Delaware.” Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.

 

ARTICLE 3

 

STOCKHOLDERS’ MEETINGS

 

Section 3.1 Place of Meetings. Meetings of the stockholders of the corporation may be held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors, or, if not so designated, then at the principal offices of the corporation required to be maintained pursuant to Section 1.2 of these bylaws (“Bylaws”). The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the General Corporation Law of the State of Delaware (the “DGCL”).

 

Section 3.2 Annual Meetings.

 

(a) The annual meeting of the stockholders of the corporation, for the purpose of the election of directors and for such other business as may properly come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors or a duly authorized committee thereof. At an annual meeting, only such business shall be conducted as is a proper matter for stockholder action under the DGCL and as shall have been properly brought before the meeting. Matters shall be properly brought before the annual meeting only as follows: (i) brought before the meeting and specified pursuant to the corporation’s notice of meeting (or any supplement thereto) of stockholders; (ii) otherwise brought specifically by or at the direction of the Board of Directors; and (iii) by any stockholder of the corporation who was a stockholder of record as of the time of the giving of the stockholder’s notice provided for in Section 3.2(b) below and as of the record date for the meeting who is entitled to vote at the meeting and who complied with the notice procedures set forth in Section 3.2(b) below; provided, that if such matter is proposed on behalf of a beneficial owner, it may only be properly brought before the meeting if such beneficial owner was the beneficial owner of shares of the corporation at the time of the giving of the stockholder’s notice provided for in Section 3.2(b) below. Clause (iii) above shall be the exclusive means for a stockholder to make nominations and submit other business (other than matters properly included in the corporation’s notice of meeting of stockholders and proxy statement under Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “1934 Act”)) before an annual meeting of stockholders. The Board of Directors may postpone, reschedule or cancel any annual meeting of stockholders previously called by the Board of Directors.

 

F-1
 

 

(b) At an annual meeting of the stockholders, the following procedures shall apply in order for a matter to be properly brought before the meeting by a stockholder.

 

(i) For nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii) of Section 3.2(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section 3.2(b)(iii) and must update and supplement the information contained in such written notice on a timely basis as set forth in Section 3.2(c). Such stockholder’s notice shall set forth (or include, as appropriate): (A) as to each nominee such stockholder proposes to nominate at the meeting: (1) the name, age, business address and residence address of such nominee, (2) the principal occupation or employment of such nominee, (3) the class and number of shares of each class of capital stock of the corporation which are owned of record and beneficially by such nominee and list of any pledge of or encumbrances on such shares, (4) the date or dates on which such shares were acquired and the investment intent of such acquisition, (5) a statement whether such nominee, if elected, (x) intends to tender, promptly following such person’s failure to receive the required vote for election or re-election at the next meeting at which such person would face election or re-election, a resignation effective upon acceptance of such resignation by the Board of Directors, in accordance with the corporation’s corporate governance policies and guidelines related to conflicts of interest and confidentiality, stock ownership and trading policies and guidelines and any other policies and guidelines applicable to directors, and (y) currently intends to serve as a director for the full term for which such person is standing for election, (6) with respect to each nominee for election or re-election to the Board of Directors, a completed and signed questionnaire, representation and agreement required by Section 3.2(e) of these Bylaws, and (7) such other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved), or that is otherwise required to be disclosed or provided to the corporation pursuant to Section 14 of the 1934 Act and the rules and regulations promulgated thereunder (including such person’s written consent to being named in a proxy statement and associated proxy card as a nominee of the stockholder and to serving as a director if elected); and (B) the information required by Section 3.2(b)(iv). The corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as a director of the corporation and to determine the independence of such proposed nominee (as such term is used in any applicable stock exchange listing requirements or applicable law) or to determine the eligibility of such proposed nominee to serve on any committee or sub-committee of the Board of Directors under any applicable stock exchange listing requirements or applicable law, or that the Board of Directors determines, in its sole discretion, could be material to a reasonable stockholder’s understanding of the background, qualifications, experience, independence, or lack thereof, of such proposed nominee. The number of nominees a stockholder may nominate for election at the annual meeting on its own behalf (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the annual meeting on behalf of the beneficial owner) shall not exceed the number of directors to be elected at such annual meeting.

 

F-2
 

 

(ii) For business other than (i) proposals sought to be included in the corporation’s proxy statement pursuant to Rule 14a-8 under the 1934 Act, or (ii) nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii) of Section 3.2(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section 3.2(b)(iii), and must update and supplement such written notice on a timely basis as set forth in Section 3.2(c). Such stockholder’s notice shall set forth: (A) as to each matter such stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend these Bylaws, the language of the proposed amendment), the reasons for conducting such business at the meeting, and any material interest (including any anticipated benefit of such business to any Proponent (as defined below) other than solely as a result of its ownership of the corporation’s capital stock, that is material to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent; and (B) all of the information required by Section 3.2(b)(iv).

 

(iii) To be timely, the written notice required by Section 3.2(b)(i) or 3.2(b)(ii) must be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred twentieth (120th) day prior to the first anniversary of the prior year’s annual meeting of stockholders; provided, however, that in the event that the date of the annual meeting is advanced more than thirty (30) days prior to, or delayed by more than seventy (70) days after, the anniversary of the preceding year’s annual meeting or if no annual meeting was held in the preceding year, for notice by the stockholder to be timely, such stockholder’s written notice must be delivered to the Secretary not earlier than the close of business on the one hundred twentieth (120th) day prior to such annual meeting and not later than the close of business on the ninetieth (90th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made by the corporation, whichever is later. Notwithstanding the foregoing, in no event shall an adjournment or postponement (or the public announcement thereof) of an annual meeting for which notice has been given or with respect to which there has been a public announcement of the date of the meeting commence a new time period for the giving of a stockholder’s notice as described above.

 

F-3
 

 

(iv) The written notice required by Section 3.2(b)(i) or 3.2(b)(ii) shall also set forth, as of the date of the notice and as to the stockholder, including all control persons, as defined below, of a stockholder that is an entity, giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made, including all control persons of a beneficial owner that is an entity (each, a “Proponent” and collectively, the “Proponents,” including any person who is a member of a “group” (as such term is used in Rule 13d-5 promulgated under the 1934 Act) with any other Proponent with respect to the stock of the corporation, including any proposed nominee, and any person Acting in Concert, as defined below, with any Proponent): (A) the name and address of the stockholder giving notice, as they appear on the corporation’s books, and of each other Proponent; (B) the class, series and number of shares of the corporation that are owned beneficially (within the meaning of Rule 13d-3 under the 1934 Act) and of record by each Proponent (provided, that for purposes of this Section 3.2(b)(iv), such Proponent shall in all events be deemed to beneficially own all shares of any class or series of capital stock of the corporation as to which such Proponent has a right to acquire beneficial ownership at any time in the future); (C) a description of any agreement, arrangement or understanding (whether oral or in writing, and regardless to whether it relates specifically to the corporation) with respect to such nomination or proposal (and/or the voting of shares of any class or series of capital stock of the corporation) between or among any Proponent and any of its affiliates or associates and/or any other persons (including their names), including, in the case of a nominee, including any agreement, arrangement or understanding (whether oral or in writing) relating to any compensation or payments to be paid to any such proposed nominee(s); (D) a representation that the stockholder giving the notice is a holder of record of shares of the corporation entitled to vote at the meeting and that such stockholder (or its qualified representative, as defined below) intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice (with respect to a notice under Section 3.2(b)(i)) or to propose the business that is specified in the notice (with respect to a notice under Section 3.2(b)(ii)); (E) a representation that the beneficial owner, if any, on whose behalf the nomination or proposal is made is the beneficial owner of shares of the corporation; (F) a representation as to whether the Proponents or any other participant (as defined in Item 4 of Schedule 14A under the Exchange Act) will engage in a solicitation with respect to such nomination or proposal and, if so, the name of each participant in such solicitation and the amount of the cost of solicitation that has been and will be borne, directly or indirectly, by each participant in such solicitation and a representation whether the stockholder intends or is part of a group that intends (x) to solicit proxies from the required number of the corporation’s shares of capital stock entitled to vote in the election of directors in support of any proposed nominee in accordance with and as required by Rule 14a-19 promulgated under the 1934 Act, (y) to deliver, or make available, a proxy statement and form of proxy to holders of at least the percentage of the corporation’s voting shares required to approve or adopt the proposal or elect the nominee and/or (z) to otherwise solicit proxies or votes from stockholders in support of any nominee or any such proposal; (G) a description of all Derivative Transactions (as defined below) by each Proponent during the previous twelve (12) month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic or voting terms of, such Derivative Transactions; (H) a certification that each Proponent has complied with all applicable federal, state and other legal requirements in connection with such Proponent’s acquisition of shares of capital stock or other securities of the corporation and/or such Proponent’s acts or omissions as a stockholder or beneficial owner of the corporation; and (I) any other information relating to the Proponents required to be disclosed in a proxy statement or other filings made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in a contested election pursuant to and in accordance with Section 14 of the 1934 Act and the rules and regulations promulgated thereunder (whether or not such Proponent intends to deliver a proxy statement or conduct a proxy solicitation).

 

For purposes of Sections 3.2 and 3.3, a “Derivative Transaction” means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial:

 

(i) the value of which is derived in whole or in part from the value of any class or series of shares or other securities of the corporation,

 

F-4
 

 

(ii) which otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of the corporation,

 

(iii) the effect or intent of which is to mitigate loss, manage risk or benefit from changes in value or price with respect to any securities of the corporation, or

 

(iv) which provides the right to vote or increase or decrease the voting power of, such Proponent, or any of its affiliates or associates, directly or indirectly, with respect to any securities of the corporation, which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right or similar right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proponent in the securities of the corporation held by any general or limited partnership, or any limited liability company, of which such Proponent is, directly or indirectly, a general partner or managing member.

 

A person shall be deemed to be “Acting in Concert” with another person for purposes of these Bylaws if such person knowingly acts (whether or not pursuant to an express agreement, arrangement or understanding) in concert with, or towards a common goal relating to the management, governance or control of the corporation in parallel with, such other person where (A) each person is conscious of the other person’s conduct or intent and this awareness is an element in their decision-making processes and (B) at least one additional factor suggests that such persons intend to act in concert or in parallel, which such additional factors may include, without limitation, exchanging information (whether publicly or privately), attending meetings, conducting discussions, or making or soliciting invitations to act in concert or in parallel; provided, that a person shall not be deemed to be Acting in Concert with any other person solely as a result of the solicitation or receipt of revocable proxies or consents from such other person in response to a solicitation made pursuant to, and in accordance with, Section 14(a) of the Exchange Act by way of a proxy or consent solicitation statement filed on Schedule 14A. A person Acting in Concert with another person shall be deemed to be Acting in Concert with any third party who is also Acting in Concert with such other person.

 

F-5
 

 

For purposes of this Section 3.2, a “control person” of a stockholder that is an entity or a beneficial owner that is an entity includes each individual who is a director, executive officer, general partner, or managing member of such entity or of any other entity that has or shares control of that entity.

 

(c) A stockholder providing written notice required by Section 3.2(b)(i) or (ii) shall update and supplement such notice in writing, if necessary, so that the information (other than the representations required by Section 3.2(b)(iv)(F)) provided or required to be provided in such notice is true and correct in all material respects as of (i) the record date for the determination of stockholders entitled to notice of the meeting and (ii) the date that is five (5) business days prior to the meeting and, in the event of any adjournment or postponement thereof, five (5) business days prior to any adjournment or postponement thereof; provided, that no such update or supplement shall cure or affect the accuracy (or inaccuracy) of any representations made by any Proponent, any of its affiliates or associates, or a nominee or the validity (or invalidity) of any nomination or proposal that failed to comply with this Section 3.2 or is rendered invalid as a result of any inaccuracy therein. In the case of an update and supplement pursuant to clause (i) of this Section 3.2(c), such update and supplement shall be delivered to the Secretary at the principal executive offices of the corporation not later than five (5) business days after the later of the record date for the determination of stockholders entitled to notice of the meeting or the public announcement of such record date. In the case of an update and supplement pursuant to clause (ii) of this Section 3.2(c), such update and supplement shall be delivered to the Secretary at the principal executive offices of the corporation not later than two (2) business days prior to the date for the meeting, and, in the event of any adjournment or postponement thereof, two (2) business days prior to any adjournment or postponement thereof.

 

(d) Notwithstanding anything in Section 3.2(b)(iii) to the contrary, in the event that the number of directors is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the corporation at least ten (10) days before the last day a stockholder may deliver a notice of nomination in accordance with Section 3.2(b)(iii), a stockholder’s notice required by this Section 3.2 and which complies with the requirements in Section 3.2(b)(i), other than the timing requirements in Section 3.2(b)(iii), shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the corporation.

 

F-6
 

 

(e) To be eligible to be a nominee for election or re-election as a director of the corporation pursuant to a nomination under clause (iii) of Section 3.2(a), such nominee or a person on his or her behalf must deliver (in accordance with the time periods prescribed for delivery of notice under Section 3.2(b)(iii) or 3.2(d), as applicable) to the Secretary at the principal executive offices of the corporation a completed and signed written questionnaire with respect to the background, qualifications, stock ownership and independence of such proposed nominee and the background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided by the Secretary upon written request) and a written representation and agreement (in the form provided by the Secretary upon written request) that such person (i) is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the corporation in the questionnaire or (B) any Voting Commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the corporation, with such person’s fiduciary duties under applicable law; (ii) is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director of the corporation or as a nominee that has not been disclosed to the corporation in the questionnaire; and (iii) in such person’s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, would be in compliance, if elected as a director of the corporation, and will comply with, all applicable publicly disclosed corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the corporation, and (iv) if elected as a director of the corporation, intends to serve the entire term until the next meeting at which such candidate would face re-election.

 

(f) A person shall not be eligible for election or re-election as a director unless the person is nominated, in the case of an annual meeting, in accordance with clause (i), (ii), or (iii) of Section 3.2(a), or, in the case of a special meeting, in accordance with clause (c)(ii) of Section 3.3 of these Bylaws. Except as otherwise required by law, the chair of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before an annual or special meeting was made, or proposed, as the case may be, in accordance with the procedures and requirements set forth in these Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws (including, without limitation, compliance with Rule 14a-19), or the Proponent does not act in accordance with the representations required in this Section 3.2, to declare that such proposal or nomination shall not be presented for stockholder action at the meeting and shall be disregarded, or that such business shall not be transacted, notwithstanding that such proposal or nomination is set forth in the corporation’s proxy statement, notice of meeting or other proxy materials and notwithstanding that proxies or votes in respect of such nomination or such business may have been solicited or received. Notwithstanding anything in these Bylaws to the contrary, unless otherwise required by law, if (i) a stockholder intending to make a nomination at a meeting pursuant to Section 3.2(b)(i) (or Section 3.3(c) with respect to a special meeting) or to propose business at a meeting pursuant to Section 3.2(b)(ii) does not provide the information in the stockholder’s notice required under Section 3.2(b)(i) or 3.2(b)(ii), as applicable, and Section 3.2(b)(iv) within the applicable time periods specified in this Section 3.2, or Section 3.3 as applicable, (including any update and supplement required under Section 3.2(c)), (ii) the stockholder (or a qualified representative of the stockholder) does not appear at the meeting to make such nomination or to propose such business (whether pursuant to the requirements of these Bylaws or in accordance with Rule 14a-8 under the 1934 Act), or (iii) the Proponents shall not have acted in accordance with the representations required under Section 3.2(b)(iv)(F), such nomination or proposal shall not be presented for stockholder action at the meeting and shall be disregarded (and any such nominee shall be disqualified), as determined by the chair of the meeting as described above, notwithstanding that proxies in respect of such nominations or such business may have been solicited or received. To be considered a qualified representative of a stockholder for purposes of these Bylaws, a person must be a duly authorized officer, manager or partner of such stockholder or authorized by a writing executed by such stockholder (or a reliable reproduction of the writing) delivered to the corporation prior to the making of such nomination or proposal at such meeting (and in any event not fewer than five (5) business days before the meeting) stating that such person is authorized to act for such stockholder as proxy at the meeting of stockholders. Notwithstanding anything to the contrary in these Bylaws, unless otherwise required by law, if any Proponent (i) provides notice pursuant to Rule 14a-19(b) under the 1934 Act with respect to any proposed nominee and either subsequently (x) fails to comply with the requirements of Rule 14a-19 under the 1934 Act (or fails to timely provide reasonable evidence sufficient to satisfy the corporation that such Proponent has met the requirements of Rule 14a-19(a)(3) under the 1934 Act in accordance with the following sentence) or (y) fails to inform the corporation that they no longer plan to solicit proxies in accordance with the requirements of Rule 14a-19 under the 1934 Act by delivering a written notice to the Secretary at the principal executive offices of the corporation within two (2) business days after the occurrence of such change, then the nomination of each such proposed nominee shall be disregarded (and such nominees shall be disqualified), notwithstanding that the nominee is included as a nominee in the corporation’s proxy statement, notice of meeting or other proxy materials for any annual meeting (or any supplement thereto) and notwithstanding that proxies or votes in respect of the election of such proposed nominees may have been received by the corporation (which proxies and votes shall be disregarded). If any Proponent provides notice pursuant to Rule 14a-19(b) under the 1934 Act, such Proponent shall deliver to the corporation, no later than five (5) business days prior to the applicable meeting, reasonable evidence that it has met the requirements of Rule 14a-19(a)(3) under the 1934 Act. Notwithstanding anything to the contrary set forth herein, and for the avoidance of doubt, the nomination of any person whose name is included as a nominee in the corporation’s proxy statement, notice of meeting or other proxy materials for any annual meeting (or any supplement thereto) as a result of any notice provided by any Proponent and any of its affiliates of associates pursuant to Rule 14a-19(b) promulgated under the 1934 Act with respect to such proposed nominee and whose nomination is not made by or at the direction of the Board of Directors or any authorized committee thereof shall not be deemed (for purposes of clause (i) of Section 3.2(a) or otherwise) to have been made pursuant to the corporation’s notice of meeting (or any supplement thereto) and any such nominee may only be nominated by a Proponent pursuant to clause (iii) of Section 3.2(a) (and, in the case of a special meeting of stockholders pursuant to and to the extent permitted under Section 3.3(c)).

 

F-7
 

 

(g) Notwithstanding the foregoing provisions of this Section 3.2, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholders’ meeting, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation’s proxy statement pursuant to Rule 14a-8 under the 1934 Act; provided, however, that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to proposals and/or nominations to be considered pursuant to Section 3.2(a) of these Bylaws.

 

(h) For purposes of Sections 3.2 and 3.3,

 

(i) “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the 1934 Act;

 

(ii) “affiliates” and “associates” shall have the meanings set forth in Rule 405 under the 1933 Act; and

 

(iii) “close of business” shall mean 5:00 p.m. local time at the principal place of business of the corporation on any calendar day, whether or not the day is a business day.

 

Section 3.3 Special Meetings.

 

(a) Except as otherwise required by law and subject to the rights of the holders of any series of Preferred Stock, special meetings of the stockholders of the corporation for any purpose or purposes may be called at any time only by or at the direction of the Board of Directors or the chair of the Board of Directors. The Board of Directors may postpone, reschedule or cancel any special meeting of stockholders.

 

(b) Stockholders shall not be permitted to propose business to be brought before a special meeting of stockholders and the only matters that may be brought before a special meeting are the matters specified in the notice of meeting given by or at the direction of the person calling the meeting. The Board of Directors shall determine the time and place of such special meeting. Upon determination of the time and place of the meeting, the officer receiving the request shall cause notice to be given to the stockholders entitled to vote, in accordance with the provisions of Section 3.4 of these Bylaws. Nothing contained in this paragraph (b) shall be construed as limiting, fixing, or affecting the time when a meeting of stockholders called by action of the Board of Directors may be held.

 

(c) Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected pursuant to the corporation’s notice of meeting (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the corporation who is a stockholder of record at the time of giving notice provided for in these Bylaws who shall be entitled to vote at the meeting and who delivers written notice to the Secretary of the corporation setting forth the information required by Section 3.2(b)(i) and (iv); provided, that if such nominee(s) are proposed on behalf of a beneficial owner, such nominations may only be properly brought before the meeting if such beneficial owner was the beneficial owner of shares of the corporation at the time of the giving of the stockholder’s notice set forth in this paragraph. In the event the corporation calls a special meeting of stockholders for the purpose of electing of one or more directors to the Board of Directors, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the corporation’s notice of meeting, if the stockholder’s notice required by this Section 3.3(c) that includes the information required by Section 3.2(b)(i) and (iv) of these Bylaws shall be delivered to the Secretary at the principal executive offices of the corporation not earlier than the close of business on the one hundred twentieth (120th) day prior to such special meeting and not later than the close of business on the later of the ninetieth (90th) day prior to such meeting or the tenth (10th) day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. The stockholder shall also update and supplement such information as required under Section 3.2(c). In no event shall an adjournment or postponement (or the public announcement thereof) of a special meeting commence a new time period for the giving of a stockholder’s notice as described above. The number of nominees a stockholder may nominate for election at the special meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the special meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such special meeting.

 

F-8
 

 

(d) Notwithstanding the foregoing provisions of this Section 3.3, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth in this Section 3.3. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation’s proxy statement pursuant to Rule 14a--8 under the 1934 Act; provided, however, that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to nominations for the election to the Board of Directors to be considered pursuant to Section 3.3(c) of these Bylaws.

 

Section 3.4 Notice of Meetings. Except as otherwise provided by law, notice, given in writing or by electronic transmission in the manner provided by Section 232 of the DGCL, of each meeting of stockholders shall be given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. If mailed, notice is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the corporation. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by the stockholder’s attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given.

 

Section 3.5 Quorum. At all meetings of stockholders, except where otherwise provided by statute or by the Certificate of Incorporation, or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the voting power of all the then-outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chair of the meeting or by vote of the holders of a majority of the voting power of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules or the rules of The New York Stock Exchange, or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, a majority of the voting power of the then-outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority of the voting power of the shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series.

 

F-9
 

 

Section 3.6 Adjournment and Notice of Adjourned Meetings. Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chair of the meeting or by the vote of a majority of the voting power of the shares casting votes present in person, by remote communication, if applicable, or represented by proxy at the meeting. When a meeting is adjourned to another time or place, if any, (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the time and place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication, or (iii) set forth in the notice of meeting given in accordance with Section 3.4. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.

 

Section 3.7 Voting Rights. For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in Section 3.9 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Unless otherwise provided in the corporation’s Certificate of Incorporation each stockholder, shall at every meeting of the stockholders, be entitled to one vote for each share of capital stock having voting power held by such stockholder. Every person entitled to vote shall have the right to do so in person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in accordance with the DGCL. An agent so appointed need not be a stockholder. No proxy shall be voted or acted upon after three (3) years from its date of creation unless the proxy provides for a longer period. Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the Board of Directors.

 

Section 3.8 Joint Owners of Stock. If shares or other securities having voting power stand of record in the names of two (2) or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two (2) or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect: (a) if only one (1) votes, his act binds all; (b) if more than one (1) votes, the act of the majority so voting binds all; (c) if more than one (1) votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the DGCL, Section 217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of subsection (c) shall be a majority or even-split in interest.

 

F-10
 

 

Section 3.9 List of Stockholders. The officer in charge of the stock ledger of the corporation or the transfer agent shall prepare, no later than the tenth day before each meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting; provided, however, if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth day before the meeting date, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Nothing contained in this section shall require the corporation to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of 10 days ending on the day before the meeting date: (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the principal place of business of the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. For purposes of this Section 3.9, “stock ledger” means 1 or more records administered by or on behalf of the corporation in which the names of all of the corporation’s stockholders of record, the address and number of shares registered in the name of each such stockholder, and all issuances and transfers of stock of the corporation are recorded in accordance with § 224 of the DGCL. The stock ledger shall be the only evidence as to who are the stockholders entitled by this Section 3.9 to examine the list required by this Section 3.9 or to vote in person or by proxy at any meeting of stockholders.

 

Section 3.10 No Action Without Meeting. Any action required or permitted to be taken by the stockholders of the corporation must be effected at a duly called annual or special meeting of stockholders and may not be effected by a consent or consents (written, electronic, or otherwise) of such stockholders.

 

Section 3.11 Organization.

 

(a) At every meeting of stockholders, the Chair of the Board of Directors, or, if a Chair has not been appointed or is absent, the Chief Executive Officer and President, or, if the Chief Executive Officer and President has not been appointed or is absent, a chair of the meeting chosen by the a majority of the Board of Directors shall act as chair of the meeting. The Secretary, or in his or her absence any person appointed by the chair of the meeting, shall act as secretary of the meeting.

 

(b) The corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chair of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chair, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, making a determination concerning whether business is properly brought before the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other persons as the chair shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the chair of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure.

 

F-11
 

 

ARTICLE 4

 

DIRECTORS

 

Section 4.1 Number and Term of Office.

 

(a) Except as otherwise provided for or fixed pursuant to the provisions of the Certificate of Incorporation relating to the rights of the holders of any series of Preferred Stock to elect additional directors, the precise number of directors shall be determined from time to time exclusively by resolution adopted by the Board of Directors. Directors need not be stockholders unless so required by the Certificate of Incorporation.

 

(b) At any meeting of stockholders for the election of one or more directors at which a quorum is present, each such director shall be elected by the affirmative vote of the majority of the votes cast with respect to that director, provided that if the number of nominees at such meeting, determined at any time, including as of the record date for such meeting, exceeds the number of directors to be elected (a “Contested Election”), the directors shall be elected by the vote of a plurality of the shares represented in person or by proxy at any such meeting and entitled to vote on the election of directors. For purposes of this Section, a majority of the votes cast means that the number of shares voted “for” a director must exceed the number of votes cast as “against” for that director. “Abstentions” and “broker non-votes” with respect to that director’s election shall not be counted as votes cast. In an election other than a Contested Election, stockholders will be given the choice to cast votes “for” or “against” the election of directors or to “abstain” from such vote and shall not have the ability to cast any other vote with respect to such election of directors. In a Contested Election, stockholders will be given the choice to cast “for” or “withhold” votes for the election of directors and shall not have the ability to cast any other vote with respect to such election of directors. If a director then serving on the Board of Directors does not receive the necessary votes, the director shall offer to tender his or her resignation to the Board. The Nominating and Corporate Governance Committee or other committee that may be designated by the Board will make a recommendation to the Board on whether to accept or reject the resignation, or whether other action should be taken. The Board will act on such committee’s recommendation and publicly disclose its decision and the rationale within 90 days from the date of the certification of the election results. In making their decision, the Committee and the Board will evaluate the best interests of the Company and its stockholders and shall consider all factors and information deemed relevant. The director who tenders his or her resignation will not participate in the Committee’s recommendation or the Board’s decision.

 

F-12
 

 

Section 4.2 Nomination of Director Candidates. Nominations for the election of Directors at the annual meeting, by or at the direction of the Board of Directors, may be made by any nominating committee or person appointed by the Board of Directors. Nominations may also be made by any stockholder of record of the corporation entitled to vote for the election of directors at the annual meeting who complies with the notice procedures set forth in Section 3.2 hereof. Nominations for the election of directors at a special meeting of stockholders shall be made pursuant to the procedures of Section 3.3 hereof.

 

Section 4.3 Powers. The powers of the corporation shall be exercised, its business conducted and its property controlled by or under the direction of the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation.

 

Section 4.4 Classes of Directors. Subject to the next sentence hereof and to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the Board of Directors is and shall remain divided into three classes (Class I, Class II, and Class III), with the directors in each class serving for a term expiring at the third annual meeting of stockholders held after their election. The initial terms of the members of the Board of Directors shall be as follows: the initial Class I Directors shall serve for a term expiring at the second annual meeting of stockholders of the corporation following the effective date of the First Amended and Restated Certificate of Incorporation of the corporation; the initial Class II Directors shall serve for a term expiring at the third annual meeting of stockholders following the effective date of the First Amended and Restated Certificate of Incorporation of the corporation; and the initial Class III Directors shall serve for a term expiring at the fourth annual meeting of stockholders following the effective date of the First Amended and Restated Certificate of Incorporation of the corporation. Each director in each class shall hold office until his or her successor is duly elected and qualified. At each annual meeting of stockholders beginning with the first annual meeting of stockholders following the effective date of the Fist Amended and Restated Certificate of Incorporation, the successors of the class of directors whose term expires at that annual meeting shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in the third year following the year of their election, with each director in each such class to hold office until his or her successor is duly elected and qualified. Notwithstanding the foregoing provisions of this Section 4.4, each director shall serve until his successor is duly elected and qualified or until his death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

 

Section 4.5 Vacancies. Subject to the rights granted to the holders of any one or more series of Preferred Stock then outstanding, any newly-created directorship on the Board of Directors that results from an increase in the number of directors and any vacancy occurring on the Board of Directors (whether by death, resignation, retirement, disqualification, removal or other cause) shall be filled only by a majority of the directors then in office, even if less than a quorum, or by a sole remaining director (and not by the stockholders). Any director elected to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall have been chosen and until his or her successor shall be elected and qualified, or until his or her earlier death, resignation, retirement, disqualification or removal.

 

F-13
 

 

Section 4.6 Resignation. Any director may resign at any time by delivering his or her notice in writing or by electronic transmission to the Secretary, such resignation to specify whether it will be effective at a particular time, upon receipt by the Secretary or at the pleasure of the Board of Directors. If no such specification is made, it shall be deemed effective at the pleasure of the Board of Directors. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each Director so chosen shall hold office for the unexpired portion of the term of the Director whose place shall be vacated and until his successor shall have been duly elected and qualified.

 

Section 4.7 Removal. Any or all of the directors (other than the directors elected by the holders of any series of Preferred Stock of the corporation, voting separately as a series or together with one or more other such series, as the case may be) may be removed only for cause and only by the affirmative vote of the holders of at least a majority in voting power of all the then outstanding shares of stock of the corporation entitled to vote thereon, voting together as a single class.

 

Section 4.8 Meetings.

 

(a) Regular Meetings. Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may be held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors. No notice shall be required for regular meetings of the Board of Directors.

 

(b) Special Meetings. Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State of Delaware whenever called in writing, including electronic communication, by the Chair of the Board, the Chief Executive Officer and President, any two directors or any one director in the event there is only one director in office.

 

(c) Meetings by Electronic Communications Equipment. Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting.

 

(d) Notice of Special Meetings. Notice of the time and place of all special meetings of the Board of Directors shall be delivered orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means, during normal business hours, at least twenty-four (24) hours before the date and time of the meeting. If notice is sent by US mail, it shall be sent by first class mail, charges prepaid, at least three (3) days before the date of the meeting.

 

F-14
 

 

(e) Waiver of Notice. Notice of any meeting may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though the business was transacted at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting.

 

Section 4.9 Quorum and Voting.

 

(a) Unless the Certificate of Incorporation requires a greater number, and except with respect to indemnification questions arising under Section 12.1 hereof, for which a quorum shall be one-third of the exact number of directors fixed from time to time, and except with respect to certain transactions questions arising under Section 9.1, for which a quorum is set by Section 9.2 hereof, a quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation; provided, however, at any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting.

 

(b) At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws.

 

Section 4.10. Action without Meeting. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission, and such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

 

Section 4.11 Fees and Compensation. Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor.

 

F-15
 

 

Section 4.12 Committees.

 

(a) Committees. The Board of Directors may, from time to time, appoint such committees as may be permitted by law. Such other committees appointed by the Board of Directors shall consist of one (1) or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees.

 

(b) Term. The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock, and the provisions of subsection (a) of this Section 4.12 may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.

 

(c) Meetings. Unless the Board of Directors shall otherwise provide, regular meetings of any committee appointed pursuant to this Section 4.12 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by the chair of such committee or a member of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee.

 

Section 4.13 Organization. At every meeting of the directors, the Chair of the Board of Directors, or, if a Chair has not been appointed or is absent, the Chief Executive Officer and President (if a director), or, if the Chief Executive Officer and President has not been appointed or is absent the most senior Vice President (if a director), or, in the absence of any such person, a chair of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his or her absence, any person directed to do so by the chair of the meeting, shall act as secretary of the meeting.

 

F-16
 

 

ARTICLE 5

 

OFFICERS

 

Section 5.1 Officers Designated. The officers of the corporation shall include, if and when designated by the Board of Directors, the Chair of the Board of Directors (provided that notwithstanding anything to the contrary contained in these Bylaws, the Chair of the Board of Directors shall not be deemed an officer of the corporation unless so designated by the Board of Directors), the Chief Executive Officer and President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors may also appoint one or more Assistant Secretaries, Assistant Treasurers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors.

 

Section 5.2 Tenure and Duties of Officers.

 

(a) General. All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors.

 

(b) Duties of Chair of the Board of Directors. The Chair of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors. The Chair of the Board of Directors shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time.

 

(c) Duties of Chief Executive Officer and President. The Chief Executive Officer and President shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chair of the Board of Directors has been appointed and is present. The Chief Executive Officer and President shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation, perform other duties commonly incident to the office, and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time.

 

(d) Duties of Vice Presidents. The Vice Presidents may assume and perform the duties of the President in the absence or disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.

 

F-17
 

 

(e) Duties of Secretary. The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. The Chief Executive Officer and President may direct any Assistant Secretary or other office or director to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer and President shall designate from time to time.

 

(f) Duties of Chief Financial Officer. The Chief Financial Officer shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the Chief Executive Officer and President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer and President shall designate from time to time. The Chief Executive Officer and President may direct the Vice President of Finance, Treasurer or any Assistant Treasurer, or the Controller or Assistant Controller, to assume and perform the duties of the Chief Financial Officer in the absence or disability of the Chief Financial Officer and, in the absence or disability of the Chief Financial Officer, each Vice President of Finance, Treasurer or any Assistant Treasurer, or the Controller or Assistance Controller shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer and President shall designate from time to time.

 

(g) Treasurer. The Treasurer shall have such duties as may be specified by the Chief Financial Officer to assist the Chief Financial Officer in the performance of his or her duties to perform such other duties and have other powers as may from time to time be prescribed by the Board of Directors or the Chief Executive Officer and President.

 

(h) Assistant Treasurer. The Chief Executive Officer and President may direct any Assistant Treasurer to assume and perform the duties of the Treasurer in the absence or disability of the Treasurer, and each Assistant Treasurer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer and President shall designate from time to time.

 

Section 5.3 Delegation of Authority. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof.

 

Section 5.4 Resignations. Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer.

 

F-18
 

 

Section 5.5 Removal. Any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written or electronic consent of the directors in office at the time, or by any committee of the Board of Directors or by superior officers upon whom such power of removal may have been conferred by the Board of Directors.

 

ARTICLE 6

 

EXECUTION OF CORPORATE INSTRUMENTS AND VOTING

OF SECURITIES OWNED BY THE CORPORATION

 

Section 6.1 Execution of Corporate Instruments.

 

(a) The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation.

 

(b) Unless otherwise specifically determined by the Board of Directors or otherwise required by law, promissory notes, deeds of trust, mortgages and other evidences of indebtedness of the corporation, and other corporate instruments or documents requiring the corporate seal, if any, and certificates of shares of stock owned by the corporation, shall be executed, signed or endorsed by the Chair of the Board of Directors, or the Chief Executive Officer and President or any Vice President, and by the Secretary or Treasurer or any Assistant Secretary or Assistant Treasurer. All other instruments and documents requiring the corporate signature, but not requiring the corporate seal, may be executed as aforesaid or in such other manner as may be directed by the Board of Directors.

 

(c) Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge the corporation’s credit or to render it liable for any purpose or for any amount.

 

(d) All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do.

 

Section 6.2 Voting of Securities Owned by the Corporation. All stock and other securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chair of the Board of Directors, the Chief Executive Officer and President, or any Vice President.

 

F-19
 

 

ARTICLE 7

 

SHARES OF STOCK

 

Section 7.1 Form and Execution of Certificates. The shares of the corporation shall be represented by certificates, or shall be uncertificated. Certificates for the shares of stock of the corporation shall be in such form as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock in the corporation represented by certificates shall be entitled to have a certificate signed by or in the name of the corporation by the Chair of the Board of Directors, or the Chief Executive Officer and President, or any Vice President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by the holder in the corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. Each certificate shall state upon the face or back thereof, in full or in summary, all of the powers, designations, preferences, and rights, and the limitations or restrictions of the shares authorized to be issued or shall, except as otherwise required by law, set forth on the face or back a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional, or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated stock, the corporation shall send to the registered owner thereof a written notice containing the information required by the DGCL or a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.

 

Section 7.2 Lost Certificates. A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed and on such terms and conditions as the corporation may require. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner’s legal representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost, stolen, or destroyed.

 

F-20
 

 

Section 7.3 Transfers.

 

(a) Transfers of record of shares of stock of the corporation shall be made only upon the corporation’s books by the holders thereof, in person or by attorney duly authorized, and upon the surrender of a properly endorsed certificate or certificates for a like number of shares and proper evidence of compliance with other conditions of applicable law, by contract or otherwise to rightful transfer.

 

(b) Upon receipt of proper transfer instructions and proper evidence of compliance of other conditions of applicable law, by contract or otherwise to rightful transfer from the registered owner of the uncertificated or certificated shares, such uncertificated or certificated shares, as applicable, shall be cancelled and issuance of new equivalent uncertificated shares or certificated shares shall be made to the person entitled thereto and the transaction shall be recorded upon the books of the corporation.

 

(c) The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.

 

Section 7.4 Fixing Record Dates.

 

(a) In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable law, not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

 

(b) In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

 

Section 7.5 Registered Stockholders. The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.

 

F-21
 

 

ARTICLE 8

 

OTHER SECURITIES OF THE CORPORATION

 

All bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered in Section 7.1), may be signed by the Chair of the Board of Directors, the Chief Executive Officer and President, or any Vice President, or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant Treasurer; provided, however, that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may be authorized by the Board of Directors or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation.

 

ARTICLE 9

 

CERTAIN TRANSACTIONS

 

Section 9.1 Transactions with Interested Parties. No contract or transaction between the corporation and one or more of its directors or officers, or between the corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers, are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorized the contract or transaction or solely because any such director’s or officer’s votes are counted for such purposes, if:

 

(a) the material facts as to the director’s or officer’s relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or

 

F-22
 

 

(b) the material facts as to the director’s or officer’s relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or

 

(c) the contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee thereof, or the stockholders.

 

Section 9.2 Quorum. Interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee thereof, which authorizes the contract or transaction.

 

ARTICLE 10

 

DIVIDENDS

 

Section 10.1 Declaration of Dividends. Dividends upon the capital stock of the corporation, subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law.

 

Section 10.2 Dividend Reserve. Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created.

 

ARTICLE 11

 

FISCAL YEAR

 

The fiscal year of the corporation shall be fixed by resolution of the Board of Directors.

 

ARTICLE 12

 

INDEMNIFICATION

 

Section 12.1. Indemnification of Directors, Executive Officers, Other Officers, Employees and Other Agents.

 

(a) Directors and Executive Officers. The corporation shall indemnify its directors and executive officers (for the purposes of this Article 12, “executive officers” shall have the meaning defined in Rule 3b-7 promulgated under the 1934 Act) to the fullest extent not prohibited by the DGCL or any other applicable law; provided, however, that the corporation may modify the extent of such indemnification by individual contracts with its directors and executive officers.

 

F-23
 

 

(b) Other Officers, Employees and Other Agents. The corporation shall have power to indemnify its other officers, employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person (other than as specified in clause (a) above) to such officers or other persons as the Board of Directors shall determine.

 

(c) Expenses. The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or executive officer, of the corporation, or is or was serving at the request of the corporation as a director or executive officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director or executive officer in connection with such proceeding; provided, however, that if the DGCL requires, an advancement of expenses incurred by a director or an executive officer in his or her capacity as a director or an executive officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking (hereinafter an “undertaking”), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a “final adjudication”) that such indemnitee is not entitled to be indemnified for such expenses under this Section 12.1 or otherwise.

 

Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph (e) of this Section 12.1, no advance shall be made by the corporation to an executive officer of the corporation (except by reason of the fact that such executive officer is or was a director of the corporation, in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i) by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii) by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation.

 

F-24
 

 

(d) Enforcement. Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and executive officers under this Section 12.1 shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the corporation and the director or executive officer. Any right to indemnification or advances granted by this Section 12.1 to a director or executive officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in whole or in part, or (ii) no disposition of such claim is made within ninety (90) days of request therefor. The claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. In connection with any claim by an executive officer of the corporation (except in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such executive officer is or was a director of the corporation) for advances, the corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct was lawful. Neither the failure of the corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a director or executive officer to enforce a right to indemnification or to an advancement of expenses hereunder or brought by the corporation to recover an advancement of expenses pursuant to the terms of any undertaking, the burden of proving that the director or executive officer is not entitled to be indemnified, or to such advancement of expenses under this Section 12.1 or otherwise shall be on the corporation.

 

(e) Non-Exclusivity of Rights. The rights conferred on any person by this Section 12.1 shall not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law.

 

(f) Survival of Rights. The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director or executive officer and shall inure to the benefit of the heirs, executors and administrators of such a person.

 

(g) Insurance. To the fullest extent permitted by the DGCL, or any other applicable law, the corporation, upon approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Section 12.1.

 

F-25
 

 

(h) Amendments. Any amendment, alteration or repeal of this Section 12.1 that adversely affects any right of an indemnitee or its successors shall be prospective only and shall not limit or eliminate any such right with respect to any proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment or repeal.

 

(i) Saving Clause. If this Section 12.1 or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify each director and executive officer to the full extent not prohibited by any applicable portion of this Section 12.1 that shall not have been invalidated, or by any other applicable law. If this Section 12.1 shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and executive officer to the full extent under any other applicable law.

 

(j) Certain Definitions. For the purposes of this Bylaw, the following definitions shall apply:

 

(1) The term “proceeding” shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.

 

(2) The term “expenses” shall be broadly construed and shall include, without limitation, court costs, attorneys’ fees, witness fees, fines, amounts paid in settlement or judgment, interest assessments and any other costs and expenses of any nature or kind incurred in connection with any proceeding.

 

(3) The term the “corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Section 12.1 with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued.

 

(4) References to a “director,” “executive officer,” “officer,” “employee,” or “agent” of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as, respectively, a director, executive officer, officer, employee, trustee or agent of another corporation, partnership, joint venture, trust or other enterprise.

 

(5) References to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to “serving at the request of the corporation” shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the corporation” as referred to in this Section 12.1.

 

F-26
 

 

ARTICLE 13

 

NOTICES

 

(a) Notice to Stockholders. Notice to stockholders of stockholder meetings shall be given as provided in Section 3.4 herein. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by law, notice to stockholders for purposes other than stockholder meetings may be sent by US mail or nationally recognized overnight courier, or by facsimile, telegraph or telex or by electronic mail or other electronic transmission in the manner provided in Section 232 of the DGCL.

 

(b) Notice to Directors. Any notice required to be given to any director may be given by the method stated in subsection (a), or by overnight delivery service, facsimile, telex or telegram, except that such notice other than one which is delivered personally shall be sent to such address as such director shall have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director.

 

(c) Affidavit of Mailing. An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained.

 

(d) Time Notices Deemed Given. All notices given by mail or by overnight delivery service, as above provided, shall be deemed to have been given as at the time of mailing, and all notices given by facsimile, telex or telegram or by electronic mail or other electronic means shall be deemed to have been given as of the sending time recorded at time of transmission.

 

(e) Failure to Receive Notice. The period or limitation of time within which any stockholder may exercise any option or right, or enjoy any privilege or benefit, or be required to act, or within which any director may exercise any power or right, or enjoy any privilege, pursuant to any notice sent in the manner above provided, shall not be affected or extended in any manner by the failure of such stockholder or such director to receive such notice.

 

(f) Methods of Notice. It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others.

 

F-27
 

 

(g) Notice to Person with Whom Communication Is Unlawful. Whenever notice is required to be given, under any provision of law or of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.

 

(h) Notice to Stockholders Sharing an Address. Except as otherwise prohibited under DGCL, any notice given under the provisions of DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the corporation within sixty (60) days of having been given notice by the corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the corporation.

 

ARTICLE 14

 

AMENDMENTS

 

Subject to the limitation set forth in Section 12.1(h) of these Bylaws or the provisions of the Certificate of Incorporation, the Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the corporation required by law or by the Certificate of Incorporation, such action by the stockholders shall require the affirmative vote of the holders of at least two-thirds (66-2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class.

 

[Certificate of Adoption attached on next page]

 

F-28
 

 

CERTIFICATE OF ADOPTION OF

AMENDED AND RESTATED BYLAWS

OF

SERINA THERAPEUTICS, INC.

 

The undersigned hereby certifies that they are the duly elected, qualified, and acting Secretary of Serina Therapeutics, Inc., a Delaware corporation (the “Corporation”), and that the foregoing amended and restated bylaws were adopted as the Corporation’s bylaws as of _________________, by the Corporation’s Board of Directors.

 

The undersigned has executed this Certificate as of ______________.

 

____________________________

 

___________________

 

As its Secretary

 

F-29
 

 

PART II
INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS/INFORMATION
STATEMENT

 

Item 13. Other Expenses of Issuance and Distribution*

 

The following table sets forth the costs and expenses in connection with the distribution of the securities being registered hereunder. All amounts are estimates except the SEC registration fee.

 

SEC registration fee  $7,036.83 
Legal fees and expenses  $* 
Accounting fees and expenses  $* 
Printing and miscellaneous expenses  $* 
Total  $* 

 

* The amount of securities and the expenses cannot be estimated at this time. An estimate of the costs and expenses in connection with the distribution of the securities being registered hereunder will be included by amendment.

 

Item 15. Recent Sales of Unregistered Securities

 

During the three years preceding the filing of this registration statement on Form S-4/S-1, of which this proxy statement/prospectus/information statement is a part, the registrant has granted or issued the following securities of the registrant which were not registered under the Securities Act.

 

On July 24, 2023, AgeX issued to Juvenescence 211,600 shares of AgeX Series A preferred stock and 148,400 shares of AgeX Series B preferred stock in exchange for the cancellation of a total of $36 million of indebtedness consisting of the outstanding principal amount of loans then outstanding under the 2020 Loan Agreement, the 2022 Secured Note, and the 2023 Secured Note, plus the loan origination fees accrued with respect to the 2022 Secured Note and a portion of the loan origination fees accrued pursuant to the 2023 Secured Note. The cancellation of indebtedness in exchange for Series A preferred stock and AgeX Series B preferred stock was conducted pursuant to the 2023 Exchange Agreement between AgeX and Juvenescence.

 

During the three years preceding the filing of this registration statement, AgeX issued to Juvenescence warrants to purchase a total of 3,670,663 shares of AgeX common stock.

 

The sales of the above securities were exempt from the registration requirements of the Securities Act in reliance on the exemptions afforded by Section 4(a)(2) of the Securities Act. No sales mentioned above involved underwriters, underwriting discounts or commissions or public offerings of securities of the registrant.

 

Item 20. Indemnification of Directors and Officers

 

The registrant’s Certificate of Incorporation provides that the liability of the directors to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director is eliminated to the fullest extent permissible under Delaware law, except for the liability of a director: (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under §174 of the Delaware General Corporation Law; or (iv) for any transaction from which the director derived an improper personal benefit. The corporation is authorized to indemnify directors, officers, and agents to the fullest extent permissible under Delaware law.

 

II-1

 

 

Section 145 of the Delaware General Corporation Law permits a corporation to indemnify any director or officer of the corporation against expenses (including attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding brought by reason of the fact that such person is or was a director or officer of the corporation, if such person acted in good faith and in a manner that he reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, if he or she had no reason to believe his or her conduct was unlawful. In a derivative action, (i.e., one brought by or on behalf of the corporation), indemnification may be provided only for expenses actually and reasonably incurred by any director or officer in connection with the defense or settlement of such an action or suit if such person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be provided if such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the court in which the action or suit was brought shall determine that the defendant is fairly and reasonably entitled to indemnity for such expenses despite such adjudication of liability.

 

The foregoing summary is subject to the complete text of the applicable statutes and the Certificate of Incorporation and Bylaws of the registrant and is qualified in its entirety by reference to such documents.

 

The registrant also maintains directors’ and officers’ liability insurance coverage and may enter into indemnification agreements with its officers and directors.

 

Item 21. Exhibits

 

(a)The following exhibits are filed herewith or incorporated herein by reference:

 

Exhibit      

Incorporated by
Reference

  Filed    To be Filed by    Previously 
Number   Exhibit Description   Form   Date   Number   Herewith   Amendment   Filed
2.1†   Agreement and Plan of Merger and Reorganization, dated as of August 29, 2023, by and among AgeX Therapeutics, Inc., Canaria Transaction Corporation and Serina Therapeutics, Inc.   8-K   8/30/2023   2.1           X
2.2   Agreement and Plan of Merger, dated March 6, 2021, by Atlas Capital Partners Limited, GCLMS Acquisition Corporation, LifeMap Sciences, Inc. and AgeX Therapeutics, Inc.  

8-K

 

3/8/2021

 

10.1

          X
3.1   Certificate of Incorporation, as amended, of AgeX Therapeutics, Inc.   8-K   12/12/2022   3.1           X
3.2   Bylaws of AgeX Therapeutics, Inc.   10-12(b)   6/8/2018               X
3.3   Amended and Restated Certificate of Incorporation of Serina Therapeutics, Inc.   S-4   11/14/2023   3.3           X
3.4   Second Amended and Restated Bylaws of Serina Therapeutics, Inc.  

S-4

  11/14/2023   3.4          

X

3.5   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Serina Therapeutics, Inc.               X        
4.1   Specimen of Common Stock Certificate AgeX Therapeutics, Inc.   10-12(b) A-2   8/30/2018   4.1           X
4.2   Form of Warrant included in Warrant Agreement dated March 30, 2020.   10-K   3/30/2020   10.25           X

 

II-2

 

 

Exhibit      

Incorporated by
Reference

  Filed    To be Filed by    Previously 
Number   Exhibit Description   Form   Date   Number   Herewith   Amendment   Filed
4.3   Form of Warrant included in Warrant Agreement dated February 14, 2022.   8-K   2/15/2022   4.1           X
4.4   Description of Securities of AgeX Therapeutics, Inc.   10-K   3/31/2023   4.4           X
4.5   Amended and Restated Certificate of Designation of Series A Preferred Stock   10-Q   11/14/2023   4.1           X
4.6   Amended and Restated Certificate of Designation of Series B Preferred Stock   10-Q   11/14/2023   4.2           X
5.1   Opinion of Gibson, Dunn & Crutcher LLP                   X    
8.1   Opinion of Gibson, Dunn & Crutcher LLP regarding certain tax matters                   X    
8.2   Opinion of Bradley Arant Boult Cummings LLP regarding certain tax matters                   X    
10.1#   Asset Contribution and Separation Agreement dated August 17, 2017, between Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc.   10-Q   11/9/2017   10.1           X
10.2#   License Agreement, dated August 17, 2017, between Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc.   10-Q   11/9/2017   10.2           X
10.3+   AgeX Therapeutics, Inc. 2017 Equity Incentive Plan.   S-8   1/30/2019   99.1           X
10.4+   Form of AgeX Therapeutics, Inc. Employee Stock Option Agreement.   S-8   1/30/2019   99.2           X
10.5+   Form of AgeX Therapeutics, Inc. Non-Employee Director Stock Option Agreement.   S-8   1/30/2019   99.3           X
10.6+   Form of AgeX Therapeutics, Inc. Restricted Stock Agreement.   S-8   1/30/2019   99.4           X
10.7+   Form of AgeX Therapeutics, Inc. Restricted Stock Unit Agreement.   S-8   1/30/2019   99.5           X
10.8#   Sublicense Agreement, dated September 26, 2017, between Lineage Cell Technology, Inc. and AgeX Therapeutics, Inc.   10-12(b) A-1   7/19/2018   10.7           X
10.9   First Amendment, dated November 8, 2017, to License Agreement, dated August 17, 2017, between Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc.   10-12(b) A-1   7/19/2018   10.8           X
10.10#   Sublicense Agreement, dated August 17, 2017, by and among OrthoCyte Corporation, Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc.   10-12(b) A-1   7/19/2018   10.9           X
10.11   First Amendment, dated November 8, 2017, to Sublicense Agreement, dated August 17, 2017, between OrthoCyte Corporation, Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc.   10-12(b) A-1   7/19/2018   10.10           X
10.12#   License Agreement, dated August 17, 2017, by and between ES Cell International Ptd Ltd., Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc.   10-12(b) A-1   7/19/2018   10.11           X
10.13+   Employment Agreement, by and between AgeX Therapeutics, Inc. and Hal Sternberg, dated August 21, 2017.   10-12(b)   6/8/2018   10.17           X
10.14   Tax Matters Agreement, dated August 17, 2017, between Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc.   10-12(b) A-1   7/19/2018   10.15           X

 

II-3

 

 

Exhibit      

Incorporated by
Reference

  Filed    To be Filed by    Previously 
Number   Exhibit Description   Form   Date   Number   Herewith   Amendment   Filed
10.15   Form of Registration Rights Agreement.   10-12(b) A-1   7/19/2018   10.16           X
10.16#   License Agreement, dated August 17, 2017, between Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc.   10-12(b) A-1   7/19/2018   10.17           X
10.17+   Employment Agreement, by and between AgeX Therapeutics, Inc. and Michael D. West, dated October 18, 2018.   10-12(b) A-3   10/22/2018   10.19           X
10.18   Registration Rights Agreement, dated August 13, 2019, between AgeX Therapeutics, Inc. and Juvenescence Limited.   10-Q   8/14/2019   10.3           X
10.19   Secured Convertible Facility Agreement, dated March 30, 2020, by and among AgeX Therapeutics, Inc., ReCyte Therapeutics, Inc., Reverse Bioengineering, Inc., and Juvenescence Limited.   10-K   3/30/2020   10.24           X
10.20   Warrant Agreement, dated March 30, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited, including form of warrant.   10-K   3/30/2020   10.25           X
10.21   Amendment No. 1 to Registration Rights Agreement, dated March 30, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited.   10-K   3/30/2020   10.26           X
10.22+   Employment Agreement, by and between AgeX Therapeutics, Inc. and Andrea E. Park, dated May 15, 2020.   10-Q   8/14/2020   10.3           X
10.23   First Amendment to Secured Convertible Facility Agreement, dated July 21, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited.   10-Q   8/14/2020   10.1           X
10.24   First Amendment to Warrant Agreement, dated July 21, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited   10-Q   8/14/2020   10.2           X
10.25   Second Amendment to Secured Convertible Facility Agreement, dated November 12, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited.   10-Q   11/16/2020   10.1           X
10.26   Amendment No. 2 to Registration Rights Agreement, dated February 10, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited.   8-K   2/11/2021   10.2           X
10.27   Amendment No. 2 to Loan Facility Agreement, dated November 8, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited.   8-K   11/9/2021   10.1           X
10.28+   Amendment to AgeX Therapeutics, Inc. 2017 Equity Incentive Plan.   S-8   1/4/2022   99.1           X
10.29†   Secured Note dated February 14, 2022, executed by AgeX Therapeutics, Inc. and Juvenescence Limited.   8-K   2/15/2022   10.1           X

 

II-4

 

 

Exhibit      

Incorporated by
Reference

  Filed    To be Filed by    Previously 
Number   Exhibit Description   Form   Date   Number   Herewith   Amendment   Filed
10.30†   Security Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited.   8-K   2/15/2022   10.2           X
10.31   Warrant Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited.   8-K   2/15/2022   10.3           X
10.32   Amendment No. 3 to Registration Rights Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited.   8-K   2/15/2022   10.4           X
10.33+   Amendment to AgeX Therapeutics, Inc. 2017 Equity Incentive Plan   8-K   12/12/2022   10.1           X
10.34†   Amended and Restated Secured Convertible Promissory Note, dated February 9, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited   8-K   2/10/2023   10.1           X
10.35   Reaffirmation Agreement, dated February 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited   8-K   2/10/2023   10.2           X
10.36†   Secured Convertible Promissory Note dated March 13, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited   8-K   3/15/2023   10.1           X
10.37†   Amended and Restated Security Agreement, dated March 13, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited.   8-K   3/15/2023   10.2           X
10.38†   Convertible Note Purchase Agreement, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc.   8-K   3/15/2023   10.3           X
10.39   Convertible Promissory Note, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc.   8-K   3/15/2023   10.4           X
10.40†   Subordination Agreement, dated March 15, 2023, between AgeX Therapeutics, Inc., Serina Therapeutics, Inc. and the other investors signatory thereto   8-K   3/15/2023   10.5           X
10.41†   Third Amendment to that certain Secured Convertible Facility Agreement, dated March 30, 2020, by and between AgeX Therapeutics, Inc. and Juvenescence Limited   8-K   3/15/2023   10.6           X
10.42   Allonge and Second Amendment to Amended and Restated Convertible Promissory Note dated May 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited.   10-Q   5/12/2023   10.9           X
10.43   Third Amendment to Amended and Restated Secured Convertible Promissory Note, dated June 2, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited.   8-K   6/8/2023   10.1           X

 

II-5

 

 

Exhibit      

Incorporated by
Reference

  Filed    To be Filed by    Previously 
Number   Exhibit Description   Form   Date   Number   Herewith   Amendment   Filed
10.44   Exchange Agreement, dated July 21, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited   8-K   7/21/2023   10.1           X
10.45   Registration Rights Agreement, dated July 21, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited   8-K   7/21/2023   10.2           X
10.46   Fourth Amendment to Amended and Restated Secured Convertible Promissory Note, executed by AgeX Therapeutics, Inc. and Juvenescence Limited on July 21, 2023.   8-K   8/4/2023   10.1           X
10.47   Amendment to Secured Convertible Promissory Note, executed by AgeX Therapeutics, Inc. and Juvenescence Limited on July 21, 2023.   8-K   8/4/2023   10.2           X
10.48+†   Transition Services and Separation Agreement, dated August 9, 2023, between AgeX Therapeutics, Inc. and Michael D. West.   10-Q   8/14/2023   10.7           X
10.49+   Consulting Agreement, dated August 9, 2023, between AgeX Therapeutics, Inc. and Joanne Hackett   10-Q   8/14/2023   10.8           X
10.50   Form of AgeX Therapeutics, Inc. Stockholder Support Agreement.   8-K   8/30/2023   10.1           X
10.51   Form of Serina Therapeutics, Inc. Stockholder Support Agreement.   8-K   8/30/2023   10.2           X
10.52   Form of AgeX Therapeutics, Inc. Lock-Up Agreement.   8-K   8/30/2023   10.3           X
10.53   Form of Serina Therapeutics, Inc. Lock-Up Agreement.   8-K   8/30/2023   10.4           X
10.54   Letter Agreement, dated August 29, 2023, by and among AgeX Therapeutics, Inc., Serina Therapeutics, Inc. and Juvenescence Limited.   8-K   8/30/2023   10.5           X
10.55   Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note, dated November 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited.   10-Q   11/14/2023   10.13           X
10.56†   Form of Pledge Agreement by AgeX Therapeutics, Inc.   10-Q   11/14/2023   10.14           X
10.57   Guaranty Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc. and Juvenescence Limited.  

10-Q

  11/14/2023   10.15           X
10.58†   Joinder Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc., AgeX Therapeutics, Inc. and Juvenescence Limited.   10-Q   11/14/2023   10.16           X
10.59+†   Amendment to Transition Services and Separation Agreement, dated October 31, 2023, between AgeX Therapeutics, Inc. and Michael D. West   10-Q   11/14/2023   10.12           X
21.1   List of Subsidiaries of AgeX Therapeutics, Inc.   10-K   3/31/2023   21.1           X
23.1   Consent of WithumSmith+Brown, PC, independent registered public accounting firm of AgeX Therapeutics, Inc.               X        
23.2   Consent of Frazier & Deeter, LLC, independent registered public accounting firm of Serina Therapeutics, Inc.               X        
23.3   Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1)                   X    
23.4   Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 8.1)                   X    
23.5   Consent of Bradley Arant Boult Cummings LLP (included in Exhibit 8.2)                   X    
24.1   Power of Attorney (included on the signature page of the Registration Statement on Form S-4/S-1)   S-4   11/14/2023   24.1           X
24.2   Power of Attorney (included on the signature page of the Registration Statement on Form S-4/S-1)              

X

       
99.1   Form of AgeX Therapeutics, Inc. proxy card                   X    
99.2   Form of Certificate of Amendment to Certificate of Incorporation, as amended, of AgeX Therapeutics, Inc. — Reverse Stock Split (included as Annex E to the proxy statement/prospectus/information statement and incorporated herein by reference).               X        

 

II-6

 

 

Exhibit      

Incorporated by
Reference

  Filed    To be Filed by    Previously 
Number   Exhibit Description   Form   Date   Number   Herewith   Amendment   Filed
99.3   Form of First Amended and Restated Certificate of Incorporation of Serina Therapeutics, Inc., as the combined company (included as Annex B to the proxy statement/prospectus/information statement forming a part of this registration statement and incorporated herein by reference)   S-4   11/14/2023   99.3           X
99.4   Form of Amended and Restated Bylaws of Serina Therapeutics, Inc., as the combined company (included as Exhibit H to Annex A to the proxy statement/prospectus/information statement forming a part of this registration statement and incorporated herein by reference)   S-4   11/14/2023   99.4           X
99.5   Consent of Remy Gross to be named as a Director   S-4   11/14/2023   99.5           X
99.6   Consent of J. Milton Harris to be named as a Director   S-4   11/14/2023   99.6           X
99.7   Consent of Steve Ledger to be named as a Director   S-4   11/14/2023   99.7           X
99.8   Consent of Gregory Bailey to be named as a Director   S-4   11/14/2023  

99.8

          X
99.9   Consent of Richard Marshall to be named as a Director   S-4   11/14/2023   99.9           X
101.INS   Inline XBRL Instance Document.               X        
101.SCH   Inline XBRL Taxonomy Extension Schema Document.               X        
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.               X        
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.               X        
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.               X        
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.               X        
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)               X        
107   Filing Fee Table   S-4   11/14/2023   107           X

 

+ Indicates a management contract or any compensatory plan, contract or arrangement.
Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.
# Confidential treatment has been granted with respect to portions of this exhibit (indicated by asterisks) and those portions have been separately filed by Lineage Cell Therapeutics, Inc. with the Securities and Exchange Commission.

 

II-7

 

 

(b) Financial Statements

 

The financial statements filed with this registration statement on Form S-4/S-1 are set forth on the Index to Financial Statements and is incorporated herein by reference.

 

(d) Filing Fee

 

See Exhibit 107

 

Item 22. Undertakings

 

(b)The undersigned registrant hereby undertakes as follows:

 

(1)To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

(i)to include any prospectus required by Section 10(a)(3) of the Securities Act;

 

(ii)to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

 

(iii)to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

 

(2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(4)That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

II-8

 

 

(5)That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of securities, in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

(i)any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

 

(ii)any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

 

(iii)the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

 

(iv)any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

 

(6)That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.

 

(7)That every prospectus (i) that is filed pursuant to paragraph (7) immediately preceding, or (ii) that purports to meet the requirements of Section 10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(8)To respond to requests for information that is incorporated by reference into this proxy statement/prospectus/information statement pursuant to Items 4, 10(b), 11, or 13 of this form, within one (1) business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means; this includes information contained in documents filed subsequent to the effective date of this registration statement through the date of responding to the request.
  
(9)To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in this registration statement when it became effective.

 

(10)Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event a claim of indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in a successful defense of any action, suit or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

II-9

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on each of Form S-4 and Form S-1 and has duly caused this Registration Statement to be signed on its behalf by the undersigned thereunto duly authorized, in the City of Alameda, State of California, on this 16th day of January, 2024.

 

  AGEX THERAPEUTICS, INC.
   
  By: /s/ Andrea E. Park
    Andrea E. Park
    Chief Financial Officer

 

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joanne M. Hackett and Andrea E. Park as his or her true and lawful attorney-in-fact and agent, with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments and any related registration statements filed pursuant to Rule 462 and otherwise), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent and full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute or resubstitute, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ *   Interim Chief Executive Officer and Chair of the Board   January 16, 2024
JOANNE M. HACKETT, PH.D.   (Principal Executive Officer)    
         
/s/ Andrea E. Park   Chief Financial Officer   January 16, 2024
ANDREA E. PARK   (Principal Financial and Accounting Officer)    
         
/s/ *   Director   January 16, 2024
GREGORY BAILEY, M.D.        
         
/s/ Steven Mintz   Director   January 16, 2024
STEVEN MINTZ        
         
/s/ *   Director   January 16, 2024
JEAN-CHRISTOPHE RENONDIN, M.D.        

 

*By: /s/ Andrea E. Park                   
Attorney-in-Fact  

 

 

 

EX-3.5 2 ex3-5.htm

 

Exhibit 3.5

 

CERTIFICATE OF AMENDMENT TO THE

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION OF

SERINA THERAPEUTICS, INC.

 

Pursuant to Section 10A-2A-10.06 of the Alabama Business Corporation Law, as amended (the “ABCL”), the undersigned corporation, Serina Therapeutics, Inc., an Alabama corporation (the “Corporation”), hereby adopts the following Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Corporation:

 

FIRST: The name of the Corporation is “Serina Therapeutics, Inc.”

 

SECOND: The Corporation’s Amended and Restated Certificate of Incorporation, filed on January 3, 2020, as amended by that certain Certificate of Designation, filed on February 19, 2020 (the “Amended and Restated Certificate of Incorporation”), is hereby amended to restate Section 3(c)(iv)(B) of the Amended and Restated Certificate of Incorporation in its entirety as set forth below.

 

“(B) Fractional Shares. If a conversion occurs pursuant to Section 3(c)(iv)(A) with respect to the outstanding shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and/or Series A-5 Preferred Stock, as applicable, the Corporation shall not issue, and the holders of such shares shall have no right to receive, any fractional shares of Common Stock, and no certificates, scrip, or cash for any such fractional shares shall be issued. Any holder of Preferred Stock who would otherwise be entitled to receive a fraction of a share of Common Stock (after aggregating all fractional shares of Common Stock issuable to such holder) as a result of a conversion pursuant to Section 3(c)(iv)(A) shall receive from the Corporation, in lieu of such fractional share: (i) one share of Common Stock, if the aggregate amount of fractional shares of Common Stock such holder would otherwise be entitled to receive is equal to or exceeds .50; or (ii) no shares of Common Stock, if the aggregate amount of fractional shares of Common Stock such holder would otherwise be entitled to receive is less than .50.”

 

THIRD: The Amended and Restated Certificate of Incorporation, is hereby amended to restate Section 3(c)(vi) of the Amended and Restated Certificate of Incorporation in its entirety as set forth below. Except as provided in paragraph SECOND and this paragraph THIRD, all other provisions of the Amended and Restated Certificate of Incorporation shall remain the same.

 

(vi) Mandatory Conversion.

 

(A) Upon the occurrence of (l) the closing of the sale of shares of Common Stock to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $160 million of proceeds to the Corporation, net of the underwriting discount and commissions (a “Qualifying Public Offering”) or (2) the affirmative vote of at least 60% of the outstanding shares of Series A Preferred Stock, 60% of the outstanding shares of Series A-1 Preferred Stock, 60% of the outstanding shares of Series A-2 Preferred Stock, 60% of the outstanding shares of Series A-3 Preferred Stock, 60% of the outstanding shares of Series A-4 Preferred Stock, and 60% of the outstanding shares of Series A-5 Preferred Stock, with each such series of Preferred Stock voting as a separate class:

 

1
 

 

(I) each outstanding share of Series A Preferred Stock shall automatically be converted into the greater of (a) number of shares of Common Stock equal to the Series A Preferred Stock Liquidation Preference for one share of Series A Preferred Stock divided by the value of one share of Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants), or (b) one share of Common Stock;

 

(II) each outstanding share of Series A-1 Preferred Stock shall automatically be converted into the greater of (a) the number of shares of Common Stock equal to the Series A-1 Preferred Stock Liquidation Preference for one share of Series A-1 Preferred Stock divided by the value of one share of Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants), or (b) one share of Common Stock;

 

(III) each outstanding share of Series A-2 Preferred Stock shall automatically be converted into the greater of (a) the number of shares of Common Stock equal to the Series A-2 Preferred Stock Liquidation Preference for one share of Series A-2 Preferred Stock divided by the value of one share of Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants), or (b) one share of Common Stock;

 

(IV) each outstanding share of Series A-3 Preferred Stock shall automatically be converted into the greater of (a) the number of shares of Common Stock equal to the Series A-3 Preferred Stock Liquidation Preference for one share of Series A-3 Preferred Stock divided by the value of one share of Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants), or (b) one share of Common Stock;

 

(V) each outstanding share of Series A-4 Preferred Stock shall automatically be converted into the greater of (a) the number of shares of Common Stock equal to the Series A-4 Preferred Stock Liquidation Preference for one share of Series A-4 Preferred Stock divided by the value of one share of Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants, or (b) one share of Common Stock; and

 

2
 

 

(VI) each outstanding share of Series A-5 Preferred Stock shall automatically be converted into the greater of (a) the number of shares of Common Stock equal to the Series A-5 Preferred Stock Liquidation Preference for one share of Series A-5 Preferred Stock divided by the value of one share of Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants), or (b) one share of Common Stock.

 

By way of example and illustration only for this Section 3(c)(vi)(A):

 

(1) Assume that (i) the holders of at least 60% of the outstanding shares of Series A-3 Preferred Stock affirmatively approve the conversion of Series A-3 Preferred Stock into Common Stock, (ii) the Series A-3 Preferred Stock Liquidation Preference is $12.50, (iii) the value of the Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants) is $5.00, and (iv) the rounding required for fractional shares this Section 3(c)(vi)(A) has not been applied. Based on the foregoing assumptions, the Series A-3 Preferred Stock would be converted, on a per-share basis, into shares of Common Stock at the greater of: (a) the number of shares of Common Stock equal to the Series A-3 Preferred Stock Liquidation Preference for one share of Series A-3 Preferred Stock ($12.50) divided by the value of one share of Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants)($5.00) or (12.50 / 5 = 2.50), or (b) one share of Common Stock. Because 2.50 shares of Common Stock is greater than one share of Common Stock, under this set of assumptions, each share of Series A-3 Preferred Stock outstanding would convert into 2.50 shares of Common Stock.

 

(2) Assume the same facts as set forth in paragraph (1) above, except the value of the Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants) is $13.00. Based on the foregoing assumptions, the Series A-3 Preferred Stock would be converted, on a per-share basis, into shares of Common Stock at the greater of: (a) the number of shares of Common Stock equal to Series A-3 Preferred Stock Liquidation Preference for one share of Series A-3 Preferred Stock ($12.50) divided by the value of one share of Common Stock (determined on a fully diluted basis as if all outstanding stock options have been exercised, but not including any outstanding warrants)($13.00) or (12.50 / 13 = ~.96), or (b) one share of Common Stock. Because ~.96 shares of Common Stock is less than one share of Common Stock, under this set of assumptions, each share of Series A-3 Preferred Stock outstanding would convert into one share of Common Stock.

 

3
 

 

If a mandatory conversion occurs pursuant to Section 3(c)(vi)(A) with respect to the outstanding shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and/or Series A-5 Preferred Stock, as applicable, the Corporation shall not issue, and the holders of such shares shall have no right to receive, any fractional shares of Common Stock, and no certificates, scrip, or cash for any such fractional shares shall be issued. Any holder of Preferred Stock who would otherwise be entitled to receive a fraction of a share of Common Stock (after aggregating all fractional shares of Common Stock issuable to such holder) as a result of a mandatory conversion pursuant to Section 3(c)(vi)(A) shall receive from the Corporation, in lieu of such fractional share: (i) one share of Common Stock, if the aggregate amount of fractional shares of Common Stock such holder would otherwise be entitled to receive is equal to or exceeds .50; or (ii) no shares of Common Stock, if the aggregate amount of fractional shares of Common Stock such holder would otherwise be entitled to receive is less than .50.

 

Notwithstanding anything in this Section 3(c)(vi)(A) to the contrary, in the event that the Board determines that the conversion ratio applicable to any series of Preferred Stock upon a mandatory conversion does not properly reflect the intent of the provisions set forth in this Section 3(c)(vi)(A), the Board may adjust the conversion ratio to align with the intent of the provisions set forth in this Section 3(c)(vi)(A).

 

(B) All holders of record of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock that have not voted for or consented to a mandatory conversion pursuant to Section 3(c)(vi)(A) shall be given written notice of the effective date of any mandatory conversion pursuant to Section 3(c)(vi)(A) above (the “Mandatory Conversion Date’’). Such notice need not be given in advance of the occurrence of the Mandatory Conversion Date. Such notice shall be sent to each record holder of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and/or Series A-5 Preferred Stock. Upon sending of such notice, each holder of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and/or Series A-5 Preferred Stock shall be deemed to have surrendered his, her or its certificate or certificates for all such shares (if such shares are certificated) to the Corporation, and shall thereafter receive certificates (or, if the Corporation chooses to utilize a book-entry system, a notice of issuance of uncertificated shares) for the number of shares of Common Stock to which such holder is entitled pursuant to this Section 3(c)(vi). On the Mandatory Conversion Date, all outstanding shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall be deemed to have been converted into shares of Common Stock, which shall be deemed to be outstanding of record, and all rights with respect to the Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock so converted, including the rights, if any, to receive accrued dividends, notices and to vote (other than as a holder of Common Stock), will terminate, except for the rights of the holders thereof to receive certificates (or, if the Corporation chooses to utilize a book-entry system, a notice of issuance of uncertificated shares) for the number of shares of Common Stock into which such Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock has been converted, and payment of any declared but unpaid dividends thereon (as opposed to, as the case may be, Series A Preferred Stock Accruing Dividends, Series A-1 Preferred Stock Accruing Dividends, or Series A-2 Preferred Stock Accruing Dividends). As soon as practicable after the Mandatory Conversion Date, the Corporation shall cause to be issued and delivered to such holder, a certificate or certificates (or, if the Corporation chooses to utilize a book-entry system, a notice of issuance of uncertificated shares) for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof.

 

4
 

 

(C) If the shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock are certificated, all certificates evidencing such shares of Preferred Stock shall, from and after the Mandatory Conversion Date, be deemed to have been retired and cancelled and the shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock represented thereby converted into Common Stock for all purposes. If any shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, or Series A-5 Preferred Stock that are subject to a mandatory conversion pursuant to Section 3(c)(vi)(A) have been issued using a book-entry system, then all such uncertificated shares shall, from and after the Mandatory Conversion Date, automatically be deemed to have been retired and cancelled and the shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock represented thereby converted into Common Stock for all purposes.”

 

FOURTH: This Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Corporation was authorized, approved, and adopted by the stockholders of the Corporation as of December 5, 2023.

 

FIFTH: This Certificate of Amendment to the Amended and Restated Certificate of Incorporation was duly approved by the stockholders of the Corporation in the manner required by the ABCL and by the Amended and Restated Certificate of Incorporation.

 

SIXTH: The unique identifying number of the Corporation is 000-249-619.

 

[Signature Page Follows]

 

5
 

 

CERTIFICATE OF AMENDMENT TO THE

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION OF

SERINA THERAPEUTICS, INC.

 

[SIGNATURE PAGE]

 

IN WITNESS WHEREOF, the undersigned, in his capacity as the President and Chief Executive Officer of the Corporation, executed this Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Corporation on December 5, 2023.

 

    SERINA THERAPEUTICS, INC.,
    an Alabama Corporation
     
  By: /s/ Randall Moreadith
    Randall Moreadith
    President and Chief Executive Officer

 

This instrument prepared by:

Daniel S. Culpepper

Bradley Arant Boult Cummings LLP

200 Clinton Avenue West, Suite 900

Huntsville, Alabama 35801

 

 

 

EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the use in this Registration Statement on Form S-4/S-1, Amendment No. 1, of our report dated March 31, 2023 (which includes an explanatory paragraph relating to AgeX Therapeutics, Inc.’s ability to continue as a going concern), relating to the consolidated financial statements of AgeX Therapeutics, Inc., which is contained in such Registration Statement. We also consent to the reference to our Firm under the caption “Experts” in such Registration Statement.

 

/s/ WithumSmith+Brown, PC

 

San Francisco, California

January 16, 2024

 

 

EX-23.2 4 ex23-2.htm

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the use in this Registration Statement on Amendment No. 1 to Form S-4/S-1 of AgeX Therapeutics, Inc. of our report dated November 10, 2023, with respect to our audits of Serina Therapeutics, Inc.’s consolidated financial statements as of and for the years ended December 31, 2022 and 2021, which is contained in such Registration Statement.

 

We also consent to the reference to our Firm under the caption “Experts” in such Registration Statement.

 

/s/ Frazier & Deeter, LLC  
   
Tampa, Florida  

January 16, 2024

 

 

 

GRAPHIC 5 log_001.jpg begin 644 log_001.jpg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end GRAPHIC 6 audit_001.jpg begin 644 audit_001.jpg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forms-4_01.jpg begin 644 forms-4_01.jpg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end GRAPHIC 8 forms-4_02.jpg begin 644 forms-4_02.jpg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end GRAPHIC 9 forms-4_03.jpg begin 644 forms-4_03.jpg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forms-4_04.jpg begin 644 forms-4_04.jpg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forms-4_05.jpg begin 644 forms-4_05.jpg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end GRAPHIC 12 forms-4_06.jpg begin 644 forms-4_06.jpg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end GRAPHIC 13 forms-4_002.jpg begin 644 forms-4_002.jpg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end GRAPHIC 14 forms-4_003.jpg begin 644 forms-4_003.jpg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end GRAPHIC 15 forms-4_004.jpg begin 644 forms-4_004.jpg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end GRAPHIC 16 forms-4_005.jpg begin 644 forms-4_005.jpg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end GRAPHIC 17 forms-4_006.jpg begin 644 forms-4_006.jpg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end GRAPHIC 18 forms-4_007.jpg begin 644 forms-4_007.jpg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forms-4_008.jpg begin 644 forms-4_008.jpg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�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end GRAPHIC 20 forms-4_009.jpg begin 644 forms-4_009.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0'X:'1T<#HO+VYS+F%D;V)E+F-O;2]X M87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[OR<@:60])UG)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T82!X;6QN&UL;G,Z"UN&UL.FQA;F<](G@M9&5F875L="(^/"]R9&8Z;&D^/"]R9&8Z06QT/@T* M"0D)/"]D8SIR:6=H=',^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO M>#IX;7!M971A/@T*/#]X<&%C:V5T(&5N9#TG=R<_/O_A ")%>&EF !-30 J M " !@I@ @ $ /_; $, P(" P(" P,# P0# P0%" 4% M! 0%"@<'!@@,"@P,"PH+"PT.$A -#A$."PL0%A 1$Q05%14,#Q<8%A08$A05 M%/_; $,! P0$!00%"04%"10-"PT4%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!04%/_ !$( ,,! P,!(@ "$0$#$0'_ MQ ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " 0,# @0# M!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*" M"0H6%Q@9&B4F)R@I*C0U-C+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$! M 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G< M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J" M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@ , P$ A$#$0 _ /')K[^S M+;_I^_Y9Q?['][_9_P K6)YG_+;_ );UE0S_ &K]]_RWE_UDM7(:^0E+G/M8 MQY"SOJ:&.B&.IME1REB4W[+]JJRD%7(8*""M#8U-#!5]+7[56E#8UIJ::/]FN?.KL(?&GVJV@LM2TVUG@B MC\O]S'L^[\M4YHZOV?AS^T[;]S61?QE._P#".C:Y_P @V:*"?_GE-]RO/?%7 M@.:U_P"/RSKO+SPS-:_\]8/^V=5IO$=[IG^N_?\ _;O3C()1/G[7/",UK^^A M_P!17,7,?^D^37TG_:OA_P 3?N9H?[*G_P"F/W/^^6K@/'GPRFTS_3;/RIX/ M^>L/_P 37J4:_P#.8GF\,,U9&N>=<:E!#$/W_P#K/]8J?^/-74O'_I/[G]_6 M#JMC]HNO)\GS_P#GG7HQF>5B(RY"AH]K_H_G?\MY?\K75:;X9F_UTU;'A[P_ M_9G[Z;_7_P#HNMAXYO\ 4P_\LJCG,(1Y#'ATW[+^YJY]E^RT/'5GS*C490_L MW_GM3_LL%3;X:/,HU ?YD/\ SQHJ/RZ*-2#M+>>MZQ@K$T>.M[S_ /EC7@'T M9<\RI:KVO>MBS@K34@?;6M:4-K]EI\,=64Z4:@/2.K,,=0PQU9HU'$?Y=.IO MF4>769MRALAHHHH+Y0\NG^10D=3)2-.4A^PT?9:M44!RF>\-0O:UI>73'CI\ MQA*)Q.O1_9?WU=G\-(/M6F^=-_J*RM5TW[55"SNM9T.V^Q0S13V,7^KBF_Y9 M_P#?-(S.VUZ2'_EC7#7]C#5"_P#$VI_\^?\ Y$_^QJA#XFF_Y;0^1004->\/ MPW7_ "Q\^N8A\0:GX9N?)\[SX/\ GE-_<_WJ[]YX;JN8UO3?M5:ZAS'-^(=' MT;7--GU/3?\ 0;Z+]Y):_P $G][_ '6K@]'C_P")WYW_ #QC_P#0O\M6]JNF M_P"DS_ZV"LW3?)M;GR?.\_S9/];_ ,!VUZ%*7N'GUZ7O&Q1977_+&H;7R?^6-7[F' M_EM6NI!E36L/_/&JNM/F^T2?OHNM%;$\IZ3I_\ QZ^3#6Q9P53L+7[+6W;1UX.I]&6;:.MB&.J< M,%:5M'5@3)5E(Z$CJ>HU-.4C3K5FH4CJ:&"C4L*?3_LM68;6LC>,2GY=3)'5 ME[6F/'07RD+QT]*'JMY\'_/:@TU(=2\ZZ_U,WD4RV^V_:?\ IA4TE36TE/F, MBXD=/2.F?:X*F22H)![/_GM5.:QK2\SWJ&J,^4P;G2JP=2\/UV;QU0N(Z?,1 M[,\WN+&:UK$N9[W[3Y/_ "P_Y9R__%5Z1>6L-U^YKF-2T>HYB.4X/5;6:N;O M+&O2+RUKGM8T?_1O.A__ '=;PF9F)IMQ]JMO^F\7^LJYY?VJL&;SM,N?.A_[ M:5O0R?:K;SH:].$CR*M+DF3)'1#_ ,MX:>G6H;G_ )[0U9 R:.J'E_Z3^Y_U M%:4TG_+:&J$TE!GS'&:L99]2N9%F^5G)%%:VGR3_ &*']]_"**Z">>9[%;1U ML6]95G6Q9QUXA] :4,=:4-9L-:5M'4:@64ZU92.BV@JYY=&I8RV@K22UIEG: MUI)'69O&)32QI_V&K]3>9[TCKB9KP56F@K2NJX#QEX^L_#?_ !^7D4'[SR_W MW_+1F_AVK3C[Y4C5U*/[5;?N:YO^S9OM/[ZM71-<_M/R)OW4_F_ZOR9-];#V MOVJKYN0/@,=()OLU7+:'_1JU;"UJS-;_ &6HYCFD4[:"&UMJFHMI_M5S^YJ_ M;04@*"25#6OV6O1;R"L'5=*^U5! MF>5ZK8_:O]36/IM]_9ESY,W^HE_\A_[5=S?Z/]E_ZX5S&MV/_+:NVE5,:M+G M-A)*9-7*Z;KG]F?N+S_4?\LY?^>==#YG_/']_7H'D2B,MI_LMSY/_+"6J>L? MZ+;3UJS:'>W5M_QYR_\ ?NL34I)OLT\,T/D3_P#3:M(FIO,H M2.IO)K(WB8/B&^O;6V_T.'SYZN:)']JMOWU7WL?M568;3[+3-O:>Z5KR"N5\ M0_#*R\36W[[_ )Z>9^^C^2NS\O\ TJGO)#]I_P!=6T3'F.5T?PK#IEMY,/\ MJ(JZ2'2JN)'#3_M=F77: M@SY3F-8M8?W\-<'J5C_SV_ZYR?\ LK5Z+>0US>I6O_+:K)U/,=8TJJWAO7)M M#N?)FFE^PR_N_-A^_'_N_P"S_LUV=_IW^C5R6I:;7H4I'#5IW7[Z MSUCSX/\ EG+\W_Q596O6NL_\OGE:K8_\M/[\?^TM4_A=XC_LRY_L:;_42_O+ M?_?_ (EKMO%5]#:Z)/-_VS_[ZK>)YTH'EK>&]4W'[)%-<6W_ "SE_O#UHKIX MV'EKM^[VHK?F,.4[VV[5JV<%9MG6W9QUY![QJV<=:5M:U0L*V+:HU++\,=/2 MH?,]Z>G2C4WB/ADFJ^D]4TCHADK(V-7S*>\_^C537_EA4TT]:Z@#QU32QFNK MGS_.J9+C[56E;^3:VWG3?ZC_ )9Q?\]*-3FY2AY\U3))#_G[]4YKK_EM3$OJ MPD;\IJO4+SPU3FDFJ&&";_/ST 7$OH:9))_SV_[]4R&"H;^^AM: &75]]EK- M_M+[5_TPI_G_ &FKZ6M9R**=M/3WGIERDWVFJ>R>CE-=2&:>;_EC5":K_D3? M::AF@IF9P=S\.?M7B3^V?.E\_P#ZZ?)L_P!VNMFL?]&J>D2>KE+G(.>U*U^R MUB7-K_KZZ>\DA^S?OJS7C^U4&*JWB3Q_-=7,$,UG+Y$6SS/^FC_WJZW6--KF[:Q_XF7DS0_\M$D_ M[Y_RM>G2D>=6C[AT>GZI975E#*LWRNN117+:AX#\0M?3-HTW_$N9MT?[SN>6 M_P#'MU%:?_GM+4SP?],:TH?)_ MY;4)4 <];_P!"-%>=>(M:OM4UR]GM M#']F$ABC\O[N$^3C_OFBO0/)]T]HL)*WK:N>LZV[.2O$/<-A*TK:L>SDJ_#) M4FI?\RK,-5H_^6%7(: U+\-350AGA^U5?H*C(?'5Q)ZP;;Q!#=7/DPPRUMV= M$C0M58V0U0>2H9HYJPB!,G^DT^&/_GM-5:SA^RUJI'1(N)#-_P!,:>DE%4[F MZFM;;_4T1]\VD:225FW,E/MI)OLW^I\BJ%_YUU^YA_[^UOR\I'LN<8]]3/(^ MU4Q()K6GQR?9:SYPC2F6;.QAM:N/)#59)*)K7[51&1O[,IWE4/+K5>.JR05L M$C*>.AXZO^15::I.61CZE'_HU>:>-M'_ +V&E^:8D"L_JW\1_/-%=79>3JEG!>6TW[B=%D3Z$9HKT>4\D9I_6MBV@K'T_ MK6Q;25X!] ;%M'5R&J%M)6JE2!UJMM6_NJFT7PC-J=S!/>?N+'_P ?DKKA#G.6<^0X^:UFU/\ U,/_ -KK MGO&?@"RU/Q)I5[>?\Q"X2V\J'_EG^[58]K?\!7_OJO?KG2X;7]S##Y$%>>_$ M*#[+HEC-_P ^NHV\G\7W%D7^[_NUU0CR'D2J^TF82_ _3[51$LB(J >J=/;25I0R5SUG/6Q#)4E&K#)5 ME)*H0SU<22H++\-688ZK6]:4,=1J;Q(?+JS#!4WV>K,-9';$AA@JSY-/2GS1 MUJ:&)>:E]E_[;5?L*S=2T?[5Y%:MG'_J/.K8WB:J59\NH4_Z8T7-U0;1&34Q M^M0_:J2H+*\T=4W_ -&J::2H9IZC4UU*%S)6?5WS(?M-4WNIJ-3GE*1I6T%, M>.J::E5"YU6JB>?RS-*ZGJA-/6:^I56N;ZMXF$O<)KBZAK'>2;4[GR88?/GK MI-'\'7NN?OIO]!L?_'Y/]VNPL/#]EIEMY-G#Y'_H=5K_R''Z/ MX#^R_P"FZEY4\_\ SR_YY_\ Q5;;0?9;;_MIY=;>I?\ 'N*QYI__ $97H0B> M1*?.4+F.:O/?BI:_\4!JO^J_=?O/X?OJW^U7ITW_ ![UY[\2Y/LO@G7/^O=_ M^6FS_9_YZ+_G^%ONU)C]H[&UA_T>/Z45%I,W_$JLO^N"?^@BBNHL\+L)*V+. M2N8L)ZWK.:O!U/8.GMIZTK:2N;LYZV+:>LBC>AGK2MI*Q+:2M*&2I WH9*U; M6N>22MBSNJ"S82K*53MI*N>96?*=$9$M2)5;S*>EU3.R),\=0[*F^T5"\E1J M;QD3/?4SSZK/)5"\D_[84:F\35>H9I*RO/\ LMM_KJA>^HU-B^\G^D_ZZJ=S M/_I-4WU;[+5"YU6C4"_-)5":>JTVJPUE7FJU9C(N33UFS3UF^9-J?^I_S_P* MM70?AY>ZY<^3YTO_ $T\G[D?_ JN$3AJUX0&6$?]J7/V+38?/G_]%_[3-_#7 MI>B> (;7]]J7[^?_ ,I2I/RHKH ^;K.ZK;L[JN,MKJM6SNJ\>43V#L[:ZK2MKJN2MKJM6&ZK MD%J=G;7U:4.I5QEK?5JVU]0;'9PWU;%K?5P<.I5JVVI4#.VAOJN0ZE_TVKC[ M;5:OIJ4-!1V"75&^N8AU*&K*:M4F_.;]1_\ ;:LK^U:'NIO^6-!I&4S2FGJA MW50_V7/\ \]J@N-68/)5.ZNH?^>U7_P#A'_>ID\/U&IO]8.>F_P"N M,O\ W[JF\'VK_EC79_V'[4_[##_RQHU(]J<8GAR:Z_UU64\*V5K_ ,L?^_U= M/-/_ *3Y,/FSS_\ /*&MO2O!_P!J_?7D/_;+_P"*K:%*];&.IFO3+F3_1ZF=/\ 2JQ->OOLMM09F5YGVKSYO^V?_P 53(X_ M]14T,?\ Q+8/^FLGF5#-_P ?4%=! S6X_P#45YI\19)O^$)U6'_?N:Z5***]*!YZHWE%%:&)-#4:_ M\?,]%%69%&:N.\0?\?7_ &THHK>)$BU<=8/^N=4IJ**8%75J\X\:6ZR>"=6^ I:1-D2N/+D9.=W?!&1['BBBLY& GRAPHIC 21 forms-4_010.jpg begin 644 forms-4_010.jpg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end GRAPHIC 22 forms-4_011.jpg begin 644 forms-4_011.jpg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forms-4_012.jpg begin 644 forms-4_012.jpg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

R?1K[T;5%8O]MZA_T*VK_P#?VT_^/T?\ M)3I__/OJ_P#X)[O_ .-TP.< GL:/^$P\,?]#'I'_@='_P#%4/_LX_P#)/M1_["LG_HJ*O8* "BBB@ HHHH *PO"_[F'5 M;!N9;34[G>1]T^<_VAHP3/XFN[#3_#=_>:I+-%9P1&20P7#02'' M(575E(8G R,DX[U\W6?Q-2U\0ZE>MIVIR:?>;&2S'B"Z1XI%15+&4-E\A?X M@2,* 0!@^M@,OJXNE/DZ6^_[UT;_ ,S.4U%JY]3T50T4V;Z+9RZ?-/-9S1": M&2>621V1_F!+2$OW[].G&*OUY-\T\@1%R<#+'@ZW?7T(;69[BW662VEMG;.8I2I9>>^TD>_!J:BBK,6TW=!1 M110(**H:EK>DZ/Y7]J:I96/FY\O[5<)%OQC.-Q&<9'YBJ/\ PF.AOS:7,VH1 M]Y=-M)KR,'^Z7A5E#=#M)S@@XY%:1HU)*ZB[>G]+\171NT5A?\)%)[SPKH.O:+IT_B/4+>26\*7D1UR[8I$87V[_W MI\L;VA.3CCGH&KNM"CTU=-$FDWKWMI*Q=9VOGNPQ^Z<.[,< C& < Y[YKY"\ M6:=K&F^)K^/78W%_)/)))*8RBSDNV9$R!E&()! KWOX4Z#XQTOP1'')>VMB MDD\DD=IJ%A-++"N<8QYL>P$AFV@'[V<_-@?19CE\*6%A/VMV^]K.^NEE?3\N MST,83O*UCU2BL+[7XL_Z NB_^#>7_P"1J/[0\2P_O+C0+*6(?>2RU,R3'_=6 M2*-#[Y<<9QDX!^=]B^Z^]&US=HK"_M_4O^A1UK_O[9__ "11_P )1'#\M_I& MM6%J>UFF_)'LG@'7M4\<:"9[C7GM;JT812QV5O"KL<<.^\29!'0JJ M#(<8.!CJO^$:MY/GNM0U>XF/WI?[1EAW>GR1,B#CCA1ZG)R3YY\#M:T/4+74 MK>STR+3=5&QKA([B1TGC!;:R+([,-NXANW*G/.!Z[7/7PD\-4=*KNB*N)4YN M5%BZ=;7"9V2PVJ(ZY&#@@9'!(K3HHK%)+8PE*4G M>3N4;W1=*U&837VF6=U*J[0\\"NP'7&2.G)_.L;_ (0738+S[7IMYJFFSM)Y MDSVUXQ\]LY!D$FX-@YZ]=QSFNGHJ73C+5HKVL^7E;NNSU7XWM\K'S7X\LKBW M\9W\6HW:W]TOE[[DP+'O_=KCY1P,# _"M;X4P2CQ;++9V%G<7$=H[)]HD,03 MYE!96",*? /AN_OKO7M9U.YLE?9YLC7$<<28"H.67C.!U/4U M<\)^!]$\/W7]K:3>W-R+BWV([RH\;(Q5@RE5&>56$I)N"7+S.W-HF[.ZLTMNCO9FQ]H\1?\ 0+TO_P &4G_QBJUYJ/B>UA#P M^'K.\8MCRX-3PP'K\\2C'XYYK?HKT7%]W_7R/-BFG>]_7^D+ M_P#H1_\ RK0_X4?\)!XO_P"A'_\ *M#_ (5UM%'LY?S/\/\ (/:?W5]W_P!L M7(.&3_ $M]I[CCT5/LGW_!&BQ=5*RM_Y-_\F><; MY/\ H&:O_P"#76/_ (S1]JU.'_CQ35[//W_WU[<[O3_CXLY-N.?NXSGG.!CT M>BCV3_F'];J]H_=_]L>RS]W[?<1VN_UV^;8+NQWQG&1GJ* M/^$F\2)\L?B3P,R+PK3W;M(1V+%2JEO4A5&>@'2O1Z*/9R_F#ZW/K"#_ .W7 M_P#)'GUMXKUY+A&N];\"SP#.Z.*_DB8\<88[@._$.\M)A'%IVB7BE<^9;>(8 H]CYB MH<_ACGK5;_A9NH?] #3O_"BM/\:]'HJ7"I_,7'$65G2@_P#P+_Y(X_\ X3'4 M?^@&_P#WYO\ _P"1*XWXE^(;G4O#EO#;1%NU8.R7*Y.QQC,L$:]^Q)XZ= M2/3/^$5\._\ 0!TO_P X_\ "N3^(?@A=0\-+;>&] T\7K7"[GC1(62/#9(. M5!YP,'(P3QD C*K3J.#3?]?<;T<4E43C%4W_ #)RO'S6^WHSP6"Z$LSI[Y4^ MH_SS7UX.E?+ME\.O$UY=7$-C#9SW%H^R>.'4(':%LD8K_"P4445W'B!1110 4444 %%%% ! M1110 4444 %%%% !69X@U_3O#&B7&KZI,8K2 L0N223@ #N2>*TZ\P^.19/ M"FDRL2+>/5X&G;^$+\W+>V<4 ='X9^(.E^)M3ETL66IZ9J,<0F%IJ=MY,DD9 M_C49.1765Y=KC)/^T!X5%KAI(]-F>=]T;MVSY?O9QCMB@#C_ -G'_DGVH_\ 85D_]%15[!7C_P"S MC_R3[4/^PK)_Z*BKV"@ HHHH **** ,;Q9IVFZMX7OK#5H[J2RF4+(+6-Y)0 M=P*LJH"Q(8 ]"..1C-?.@^%,QUU[;[=J TM55A>'0+WS&)!RHB\OJ"!G+ 88 M$$G*CZDHKT\%F=7"1<8=?ZOMO_5B)04MSE]+\-:9_9EO)HUWKNG*B[(-]U<@ MQ*ORX\BXW*!@8 9.F",<&K?]E:_;?\>?B3S]WWO[3L8Y<>FSR3#COG=N[8QS MG=HKC=>;=WKZV?Z%6/!_C+XM\7:3/IFEB5].0JTQO-.GD1;HYVC^$%".24#N M!O7). :P?A#XR\3P^*(=+C_M#5]/: J]F'#F%$4[60R,JQ@':O4 @XP3MKZ MU[PSHOB>T%MK.G0WD:_<+@ATY!.UQAESM&<$9Q@U0\+> O#O@_<^D6.RYDB6 M*6YDW3S/"K NA*E[WHK>M]U_5M#)PES7N6/[0\2S M?O+?0+**(_=2^U(QS#_>6.*1![8<\8S@Y /M?BO_ * NB_\ @WE_^1JW:*\/ MVJ_D7X_YFMC"^U^*_P#H"Z+_ .#>7_Y&H\KQ9/\ O/MNBV6?^7?[)+=;/^VO MF1;L]?N#&<.22TT^PFBEF7.,8\V3> 2K;<#[N<_+@^IT5M0QE'VOQ7_ - 71?\ P;R__(U;M%>=[7O%?=_DT78P MOM?BO_H"Z+_X-Y?_ )&H_M77[;_C\\-^?N^[_9E]'+CUW^<(<=L;=W?..,[M M%'M(]8+\?\PL!OM_VG M^S9O*\K9]E^U2>7NSG?G._=V^]C';/->SEF/PF'4O;4]7MI?Y:[&S+WA MCQ'XL\0>&K#5?^$?TR+[3$&Q-J$L+-VW!/(;"MC*'^237=+2 M-N&:#2G60#N5+3LH;T)5AGJ#TK9@@AM;>.WMXDBAB4)''&H544# X [5) M7DSK1BWPP;O3YX8TD'.#\K#.,'( M)!MR>']*N--BTZ\LTO[6)MZ)J!-T0W/.Z4L2?F(R3P#CI6E16;K3?7[M/RL% MD4--T32='\W^R]+LK'S<>9]EMTBWXSC.T#.,G\S5^BBHE)R=Y.[&%%%%2!R> MH0>*[Z\TNX_LK14^P71N-O\ :LIWYADCQ_Q[\?ZS.>>F.^:W=-EU:7S?[4LK M*VQCR_LMV\^[KG.Z),=O7.3TQS?HK:=7FCR\JT_KN*P4445B,**** "O"_'O MPLNO$'BF\U32]+U.W\^5?-18[0Q.=P#RH?M"L,K\V&7);.2,\>Z45V8/&5,) M-SI[[$RBI*S/.OA_X TW2/#UQI>JZ"\[M.)Y)M4M[9A*V"JA5223 49^\>KL M1U('4?\ "$^%/^A8T7_P B_^)K=HJ:N+K5)N;DTWYO\ S!125C"_X1#2AQ$^ MIP1C[L4&K744:#LJHL@55'0* !P!1_PB\4/S6&KZU9RG@R?;WNI_-_7W#LC"_L#4O\ H;M:_P"_5G_\CT?8O%$?R1Z[ICQK MPK3Z4[2$=BQ6=5+>I"J,] .E;M%'MI=;/Y+_ "06/E_XV7&O'QG%::U-!)'! M:J;5K=&CC=&)W/L+OM;<"IYY"#VK5^!-WXE34-5ATJ*&ZTY(E>:"ZNC#&LK' M"L"$<[BJL. 0!D\+7T!J&EZ?JUNMOJ5A:WL*MO$=S"LBAL$9PP(S@GGWJ2R ML;33K1+2QM8+6VCSLA@C"(N3DX4<#DD_C7MRSB$L$L-[-7V\O6V]_F9^S][F MN9/VOQ7_ - 71?\ P;R__(U'VOQ7_P! 71?_ ;R_P#R-6[17B>U7\J_'_,T ML87VOQ7_ - 71?\ P;R__(U'VOQ7_P! 71?_ ;R_P#R-6[11[5?RK\?\PL8 M7VOQ7_T!=%_\&\O_ ,C4?:_%?_0%T7_P;R__ "-6[11[5?RK\?\ ,+&%]K\5 M_P#0%T7_ ,&\O_R-1]K\5_\ 0%T7_P &\O\ \C5NT4>U7\J_'_,+&%]K\5_] M 71?_!O+_P#(U'VOQ7_T!=%_\&\O_P C5NT4>U7\J_'_ #"QA?:_%?\ T!=% M_P#!O+_\C4?:_%?_ $!=%_\ !O+_ /(U;M%'M5_*OQ_S"QA?:_%?_0%T7_P; MR_\ R-1]K\5_] 71?_!O+_\ (U;M%'M5_*OQ_P PL87VOQ7_ - 71?\ P;R_ M_(U'VOQ7_P! 71?_ ;R_P#R-6[11[5?RK\?\PL87VOQ7_T!=%_\&\O_ ,C4 M?:_%?_0%T7_P;R__ "-6[11[5?RK\?\ ,+&%]K\5_P#0%T7_ ,&\O_R-7$_% M>?QM)X$NE@T^UM[?<#>/87SS2&#!W JT*$)G&X@YQG(V[L>IT5M0Q*I5(U.1 M.SOU_P Q.-U:Y\2:+]O_ +>T[^RO^0C]JB^R_=_UNX;/OQUX]:^V^U5+3 M2]/L+BYN+.PM;>:Z;?<20PJC3-DG+D#+')/)]35NNS-,R6.E%J-K?J3"'*%% M%%>.:!1110 4444 %%%% !1110 4444 %%%% !5;4-.L]6L)K'4+:*YM9EVR M12KN5A]*LT4 <]X:\#>&O"#3/H6E1VCSX$DF]Y&(]-SDD#V'%=#110!X9\ _ M$N@Z-X'O[?5-;TVQG;4Y'6.ZNDB8KY<0R Q!QD$9]C7J?_"=^#_^AKT/_P & M,/\ \55B^\)^&]3O)+R_\/Z5=W4F-\T]G'([8 RQ&3@ #\*K_\ "">#_P#H M5-#_ /!=#_\ $T '_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4 M?\()X/\ ^A4T/_P70_\ Q->>?&;X?6LO@F%_"OA6T%[%>QO+_9UDBRF+:ZG M0;F&YDR!GUZ#( /0_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ MBJ!X$\(8_P"14T/_ ,%T/_Q-'_"">#_^A4T/_P %T/\ \30 ?\)WX/\ ^AKT M/_P8P_\ Q5'_ G?@_\ Z&O0_P#P8P__ !5'_"">#_\ H5-#_P#!=#_\31_P M@G@__H5-#_\ !=#_ /$T '_"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ M\&,/_P 51_P@G@__ *%30_\ P70__$T?\()X/_Z%30__ 70_P#Q- !_PG?@ M_P#Z&O0__!C#_P#%5'!\0?!MS;Q3IXJT8)(@=1)>QHP!&>58@J?8@$=ZS/%G M@3PW_P (=KG]G^%-*^V_V?/]G^SZ='YGF>6VW9A<[LXQCG-8WPM\":/_ ,*Y MTK^W_"EC_:?[[SOM^G)YW^M?;NWKN^[C&>V* .P_X3OP?_T->A_^#&'_ .*H M_P"$[\'_ /0UZ'_X,8?_ (JC_A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ M (+H?_B: #_A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ/^$$\' M_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H /^$[\'_]#7H?_@QA_P#B MJ/\ A._!_P#T->A_^#&'_P"*H_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:' M_P""Z'_XF@ _X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (JO._AU M\/K9?%?C>?6_"MI_9SZD4TT7EDA78'E)\I6'";6CP0,'MG''HG_"">#_ /H5 M-#_\%T/_ ,30 ?\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 M'_"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$T '_ G?@_\ Z&O0 M_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\51_P@G@__H5-#_\ !=#_ /$T?\() MX/\ ^A4T/_P70_\ Q- !_P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ MP8P__%4?\()X/_Z%30__ 70_P#Q->=ZM\/K:7XZ:&]GX5M!X=BTUGO-MDBV MI?\ ?*-PQM9\M'QR<8/09 !Z)_PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__ M 8P_P#Q5'_"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 30 ?\ M)WX/_P"AKT/_ ,&,/_Q5<)I'Q+Y]-M/[0T^X-L(XV81.Q,85L') M 'FC*YYVGD9X[O\ X03P?_T*FA_^"Z'_ .)KA-(^$>I6/P@_$;PW?\ AW3+S4?$>AV]]/:Q2W$/ MVZ-/+D9 67:S9&"2,'D5H?\ "=^#_P#H:]#_ /!C#_\ %5GZ#\.?#=AX=TRS MU'PYH=Q?06L45Q-]AC?S)%0!FW,N3D@G)Y-:'_"">#_^A4T/_P %T/\ \30 M?\)WX/\ ^AKT/_P8P_\ Q5'_ G?@_\ Z&O0_P#P8P__ !5'_"">#_\ H5-# M_P#!=#_\31_P@G@__H5-#_\ !=#_ /$T '_"=^#_ /H:]#_\&,/_ ,51_P ) MWX/_ .AKT/\ \&,/_P 57F_Q(\"6?_"8>!?[$\*0?8O[0/\ :/V+3AY?E^9# M_KMJXVXW_>XQN]Z](_X03P?_ -"IH?\ X+H?_B: #_A._!__ $->A_\ @QA_ M^*H_X3OP?_T->A_^#&'_ .*H_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA M_P#@NA_^)H /^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\ XJC_ (03 MP?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XF@ _X3OP?_P!#7H?_ (,8 M?_BJ/^$[\'_]#7H?_@QA_P#BJ/\ A!/!_P#T*FA_^"Z'_P")KSCXU>!+/_A# M;3_A%_"D'V[^T$W_ -F:A_\ @QA_^*H'@3PAC_D5-#_\%T/_ ,31_P ()X/_ .A4 MT/\ \%T/_P 30 ?\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \51_ MP@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $T '_"=^#_\ H:]# M_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4?\()X/\ ^A4T/_P70_\ Q-'_ @G M@_\ Z%30_P#P70__ !- $<_Q!\&VUO+._BK1BD:%V$=[&[$ 9X522Q]@"3VJ M3_A._!__ $->A_\ @QB_^*KD/BCX$T?_ (5SJW]@^%+'^T_W/D_8-.3SO]:F M[;L7=]W.<=LUK^$O GAO_A#=#_M'PII7V[^SX/M'VC3H_,\SRUW;]RYW9SG/ M.: -C_A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*H_P"$$\'_ /0J M:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)H /^$[\'_\ 0UZ'_P"#&'_XJC_A M._!__0UZ'_X,8?\ XJC_ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z M'_XF@ _X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ/\ A!/!_P#T M*FA_^"Z'_P")K(\6>!/#?_"':Y_9_A32OMO]GS_9_L^G1^9YGEMMV87.[.,8 MYS0!IP?$'P;*M&"2('427L:, 1GE6(*GV(!'>I/^$[\'_]#7H?_@QA M_P#BJX_X6^!-'_X5SI7]O^%+'^T_WWG?;].3SO\ 6OMW;UW?=QC/;%=A_P ( M)X/_ .A4T/\ \%T/_P 30 ?\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P & M,/\ \51_P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $T '_"=^ M#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4?\()X/\ ^A4T/_P70_\ MQ-'_ @G@_\ Z%30_P#P70__ !- !_PG?@__ *&O0_\ P8P__%5'#\0?!LZ% MT\5:, '9/GO8T.58J>&(.,C@]",$9!!J3_A!/!__ $*FA_\ @NA_^)KS?X*^ M!+/_ (0^\_X2CPI!]M_M!_+_ +3TX>9Y?EQXQYBYVYW>VD?\)WX/_P"A MKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \51_P@G@_P#Z%30__!=#_P#$T?\ M"">#_P#H5-#_ /!=#_\ $T '_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ M!C#_ /%4?\()X/\ ^A4T/_P70_\ Q-'_ @G@_\ Z%30_P#P70__ !- !_PG M?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__ 8P_P#Q5'_"">#_ /H5-#_\%T/_ M ,31_P ()X/_ .A4T/\ \%T/_P 30!''\0?!LLDJ+XJT8&)]C;KV-03M#?*2 M<,,,.1D9R.H($G_"=^#_ /H:]#_\&,/_ ,57F_PX\"6?_"9^.O[:\*0?8?MX M_L[[;IP\OR_,F_U.Y<;<;/N\8V^U>D?\()X/_P"A4T/_ ,%T/_Q- &Q8W]GJ M=G'>6%W!=VLF=DT$@D1L$@X8<'!!'X58J.""&UMXK>WBCA@B0)''&H544# M X [5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q' MB3Q[>:;XC_X1_0/#LVNZE%;?:KE%N4@2&/.!\S Y8^GN.M=O7D=KJ=CX8^.W MB:;6[N"P@OK"&2VEN9!&D@4*" QXSD'CV- 'H'A'Q39>,?#T&KV*R1JY*20R M?>B<<,I_STQ6Y7FGP0AE'@V^OFB:."_U.>YMPPQF,X /Y@UZ70 4444 %%%% M '*^,_&J>$UT^V@TZ;4]5U*;R;*RB<)YC<9+.>% R.>>OIDB#PKXYFUO7+[0 M-8T271=;M(UF-L]PLZO$<8977 /)Y&.XYZXF\>^.]/\ >B"]NE\ZZF)2UM@ MVTRO[G^%1W-<]\-+6RGU>_U_4?$FE:MXIU&,&:&QNHY%M81C$:A23@?+D^PZ M]2(#TRBBB@ HHHH ***YWQRWB$>$[M/"UMY^JRXCC_>HA13]Y@6(&0.GO0!C M6_Q/L+_XF_\ "&V%M]HV(_G7JS?*DB@DH%P=V.A.1@Y':N[KYWTUM% M[1/!GV&6VT\P)9G4XI"\99M\QD QGEB1U)'O7T13Z!U"BBBD 4444 %><2_$ M_4;FYNY]!\&ZAK&BV=S]FGOH)U#EP0&\N'!:0#(Y&,^W6O19 6C91U((%?*] MII>A:=X"UV35-1EM?&.E7[+8Q?:V26)@RD>5'NY!.26 SWXQ0,^IXI!-"D@5 ME#J& =2I&?4'D'VI]9V@2WL_A[39=239?/:QM<*1C$A4;OUS6C0Q!1110 44 M44 %<;XK\=2Z'KMCX?TC1)M:UN[C,RVJ3K B1#.6:1@0.AP/;J.,]E7"?$7X MBV_@R&WL+;R)=;OOEMHYY D40)QYDK' "@^XSCMR0 :7@SQHOBM=0MKC3I=, MU;39O)O+*202>6><%7'# XZX'0]L$YMO\3["_P#B;_PAMA;?:-B/YUZLWRI( MH)*!<'=CH3D8.1VKF])TZ\TWP+K3>$-8L?$GB_4I5DU"ZM;R([&?.2O. %&[ M;G'/..PY;36US1_BUX7M$\&?89;;3S EF=3BD+QEFWS&0#&>6)'4D>]/J'0^ MB****0!1110!#=W=O8VTJ8)W;<#:<+TR:@^)5KXGU*?2[+2O#YU?1ED\^_@6]BMS,5.4C)? M^'/) !SC'%<3\/-7UR'5OB#(?# ;,DT\\)N5D$4P#8@V@9DSR,CCCWH&=+;? M&&Y9-/U2]\)75IX:U"Y^SV^IM=H[DDD*6A RH^4YY^F>,^IU\M6SZ58^$_"^ ML6.O'4]6_M-7'AN2??;1,S/PD .Y",C#$X.?>OJ0'*@D8/I3$+1112 *Q_$> MHZSIFGI-H>@_VSIIHVA7^J2#:SI_A"\O/#%G/Y4VIBZ1'P" S+"1D@9XY'OMYQH?!_37C\(-K]Z=^ MIZ[,U[(-/T?PU;./[1OKFY2*2\P M?]7"&(^7(Y;^G#/R ]EL;V#4M/M[ZU?S+>XC66-O56&0?UJQ573$LH]*M$TU MHFL5A1;VP99NP M'J20/QKC]#^)MU=ZUIFG>(/#4^AC5X_,TV9[I9EGXSAL %#@C //..*W/B'I MVGZIX"U>UU2Z>TLS!O>X2)I#%M(8-M7D@$ D>F:\9CN-7\2^*?A_9OKFAZJU MG.LD:Z0')CA0(3).6Y1R%QMVBA;AT/3M8^(NH1ZSJ.G>&?"ESKYTL#[?*ERL M(C8C(5 03(V <@#.?6NTTR^_M/3+:]^S7-KY\8[TZ.2Z:(%F#LLD:Y D?[HQ@U[+\,[O5+[X=:+YZX.,UVE>(=56TB%_+!#"]QMRY02J0N>PSV% UN;>O M>/+3P]X*M/$-U:2R/>)$+>SA.YI)9%RJ9Q]*O#LO MA^ZEMFN;9FNTN(Y44$MEE VD $XYZ'..,W6\4Z;X.^&6FZOJ;L(H[*%4C09: M5R@PJ^Y_3K7G5@D7C>/5_$FJZWI5QK]YID]OI&B6MY&[6L;1MP0#EI""<\<9 M/T5O=B70Z>S^+\DKV&H7OA>ZLO#6H7/V:UU5[E&+-D@%H@,J"0>0V_P!B1P9HV#MDE.H'OC'-?12 K&H/4 "@!U%% M%(#F_&/CG1/!&F&ZU6Y43.K?9[5>9)F Z =AVW'@9JSX0\0_\)5X5L-;^R_9 M?M:%_)\S?LP2/O8&>GI5/QOI-A/X=U;4YK2*2]M],N8X9G7+1JR'=M],^HYK MC?#3>(1^S_IB>%K;S]5EA,K-\J2*"2@7!W8Z$Y&#D=J7Q]\3K#P/=Z?8?9OMVH7C@?9UFV>7 M&3C>QP>_08YP?2O++>7Q%H7Q.\.V]IX&^SWEGI;Q0:[NM*M9[^R^Q7@:-K1C M.JZ387YBR(S=6R2[,]<;@<9P/RIFG>&M!T>X-QIFB:;8SLNPR6UHD3%?3*@' M' K4HH **** "BBB@ HHHH JOIEA)J,>HO8VS7T2&..Y:)3*BGJH;&0.3QGO M5JBB@ HHHH **** "L^?0='NM3CU*XTJQFOXL>7=26Z-*F.F'(R,?6M"B@ H MHHH **** "BBHYY?(MY9O+>3RT+;(QEFP,X [F@"2LK4?#.@:Q[\(>,+>:Y;9!'+IJHTK>B@OECR. ME;MCXZ^VQV;_ /"*^*+?[5=?9ML^G;#%P/WC_-\L?S?>]CZ4 ;NF:#H^B^9_ M96DV-AYN/,^RVZ1;\=,[0,XR?SJ9],L)-1CU%[&V:^B0QQW+1*944]5#8R!R M>,]ZM44 %%%% !116#X6\6V'BZVO;BPAN8TM+I[207"J"77&2,$\6Y?S)WAB5&E;^\Q ^8\]35JB@#,A\.:';ZH=3AT73H]09F8 MW26J"4D]3O SDY.>:TZ** "BBB@ J*YM;>]MI+:Z@BGMY5*R12H&5P>H(/!% M2T4 0P6MO:VD=K;V\4-M&@1(8T"HJCC X ]JQ?^$$\'_P#0J:'_ ."Z'_XF MN@HH CM[>&TMX[>VACA@B4)''&H544= . *DHHH **** $(#*00"#P0>]9^ MF:!HVBM(VE:186#2@"0VMLD1?'3.T#.,G\ZT:* ,_4-"T?5Y89=2TJQO9(?] M4]S;I(8^_P I8''0=*T*** "BBB@ J"]L;34;22TOK6"ZMI,;X9XPZ-SGE3P M>:GHH H7NA:1J5E#9WVE6-U:PX,4$]NCHF!@;5(P,#CBJUEX2\-Z;=I=V'A_ M2K6YCSLF@LHT=HOG?=I;H)6SUR^,G\Z MT*** "BBB@!DT,5S!)!/$DL,BE'C=0RLIX((/45'9V5KI]K':V5M#;6T8PD, M,81%'L!P*GHH JOIEA)J,>HO8VS7T2&..Y:)3*BGJH;&0.3QGO1?Z98:I"D. MH6-M=Q(XD5+B)9%5AT8 @X/O5JB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \N^)W_ "4#X>?]A%__ M &2CXK_\C5\/_P#L,+_-:[W4_#FDZSJ&G7]_:^=U;S&7RWXYPI /0<'(I]AGE$OAJP\5?'/Q5I^ MJ^?)8?8(7>VCG>-96"IM+;2,[>2 >]<39^'[>[^".I>(+NZOI]2TF[\K3I7N MY,6B*\8PBYVC/T],8Q7T9!X;TFV\07>O0VFW4[N-8IY_,<[U&,#:3M'0=!5& M+P)X:A\-7/AV/3<:5=2&2:W\^3YF)!SNW;AR!T-+H%]3Q2_?5O&OC>2TU'PU M+XE2UTNV>WL_[5%DL>^-&>89QN)8XX]L]L>K_#H:_HO@AH_&9-I+9R/MENKI M)"(!@@O(#CCD9..!5W6OAOX1\0QVB:IHL4_V2(0PN)9$<(!@*65@6 [9)[^I MJW-X6TVU\'W7A[2M,M([.6!H1;EFC1MPP2S+EB<=3U/KWIMB-JVN8+RVCN;6 M>.>"50\ ?'.IZE]IFEL[V[>UC^T.L<+JF=X0' M:6.0"2#P!7OV@:2F@^']/TF.0RI9VZ0!R,%MHQG%5++P?H.G:3J.EVMCY=EJ M+R/=1^A%*PTRA\-+RYO_AOH-S=SR3SO:C?)(V6;!(Y/ GRAPHIC 24 forms-4_013.jpg begin 644 forms-4_013.jpg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end GRAPHIC 25 forms-4_014.jpg begin 644 forms-4_014.jpg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forms-4_015.jpg begin 644 forms-4_015.jpg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end GRAPHIC 27 forms-4_016.jpg begin 644 forms-4_016.jpg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forms-4_017.jpg begin 644 forms-4_017.jpg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forms-4_018.jpg begin 644 forms-4_018.jpg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forms-4_019.jpg begin 644 forms-4_019.jpg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forms-4_020.jpg begin 644 forms-4_020.jpg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end GRAPHIC 32 forms-4_021.jpg begin 644 forms-4_021.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH %HH __]D! end GRAPHIC 33 annexd_001.jpg begin 644 annexd_001.jpg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�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�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end GRAPHIC 34 annexd_002.jpg begin 644 annexd_002.jpg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�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�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end GRAPHIC 35 annexd_003.jpg begin 644 annexd_003.jpg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�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

7F]OO55>Y^6K^(\G$U.>17FA^]7+ZVGWZW;F\KG-8 MN?EKV,)[I\CF4O=./O\ Y6K-W^6U7=2_?-64Z^6U?7T)>Z?E&)]VJ:]M>;-E M:R:DJ-7+PW/S5JV?SM71*1M0Q'V3HTU577[U2V&ZY;A^#-!6Y MM_-:O%Q>(]T^RRW#RQ%3EYBQH^FR_(U=K8)+##\U+#IJVWW:EFDV5\O7KGZE M@<++#_:+%%0PS583YJ\24N8^HI1]H/A3=3YDV+0C_P -9^I7GDUE*(5I>Q(9 MIJJH^]JKO<^=5J'[M$8GFRJ?37/\ MB&^9U^6K6JW^Q?EKG;R;[8O^[773I\QX.-Q)DO(SL]9MYM??6PZI'6)?5]!0 MCR'PF)KW2/B\3S#_FW;ZZC0;_8R*S5RZ/\ +5JSN=E1 M7I&N7UYPD>MZ:\4RI6]##L6N$\,:JOR;FKT*P=;F*OE\33Y)'ZQE=7VL2:P? M][70(E8EMM^T5N_PUY\:G++X3[BC'W2N[^6U=!IOSQ)6*]KOKK=!L/\ 1Z_1 MLCP,L15B<]>IR1-NSL]]O]VK$-M\OW:NPP^3%0Z?+7]!Y7@88?XCY3$U)3.: MUNPWQ/\ +7B/CFP9&?Y:]^O$^:O%/'7_ !]RUQ9][*%+X3YG&4/M'D[_ "2U M7OT_=5H.F]GJI>)^ZK\1KRC*7NG@5?>I'%:DGS5GUIZKN1JS*Q/C*_NR'R5# M3Y*9'6O,<4I?:!/OUK6G\-9E;&FURU)'I88V[-*TM_EK6;OVTS[0]>9(^LH5 M.4MW,WRTZP_TFJN_SEJ'[4ULU91]R7,=4JA;U*S^:J]F[)<;:O6US]I7[M5' MA:.XW5V\W.<_+S2.@MG:NHT>\\G9\URD>BV M&L;V^]6G]LKBM!O-[?-78)#\NZO"Q>.J_"?H&7Q]K[Q:^T[XJSYKGYJL?PUG MW+UXD<3[WO'MUIU5[Q/W5,2ZJEJ5_\M%D6F7DSI7D2ES'ULO=@9[KYDM/^QU7FF9&JQ;7GR_ M-793D>/(J:@BPQ?(U9\+_P!]JMZD_G54MK9]U=<8Q.27-$NV$WF?=K0A^26J ML,.RK"/\U='+R%4/B.@LWW[%K=L/D_BKG]-^=DK=ADV5I0K5:-7GA(^IH>_$ MZC3;_P G^*N@MM>BV[&:N%A>K'VS8NVOO\'Q)7A'D"6&.RFUZ+^]5=]569?E M:N/^V/NJW#>-7MT\YJUIMJZBYF?=1_8BWT5>K0Y:)\+CHRQ?N\IYE-;?+6[\-T_XJBW M_P"!5I:EX2\E7I_P]TKR?%$7_ JWQ&)C[(_/L=EKL=>]'$R,HTRZEU39KGY:K[?XJKS3;*=7, M/=.B- )KFLR\FWM3[E_EJC)7R>)Q/.=<8DT+U:1_FK/CJQ"]<-.IS2-9&Q:] MZO0UDVTU:$,U?5X'E//JFG"E2^34$+?+]ZITFKZNG*!S^\3>33/L>^KMLGG5 MH6MGO;;7;&G2F;07MI'/_P!FO_=J)]'9V^[7>V>A[_X=];OW:^/SG#0 MC'W3[7*\KE5//]*T1O-7Y:ZN'P]_LUU%GX>V,GRUM?V4J+NK\=QU.4JGNGZK ME>3\L?>//9M!5/X:SYM'5/X:](FL%>LF\L%A6O*^J5#W:N6TH0//;RS6%?NU MSE_MVO78:\JHK[:\_P!2F9):<<-,_/\ ,)1HF?>??K/FJZZ>=436?^U79&/( M?'RJC3YY&Q;(J+5M;EEK.MM]:=M;,_P##7!4Q-4^H MH8;W0>9FJ6VA^:K"::VW[M6(=-EKSJE24STZ6$D7K!5K:MKGRZQ[:V9*N^2W M]ZO(J1\;F&+Y8EI+_S*FA?< MU9EO'_%6G;/YG\-?H>!PGNGR5?%\QI6VVM!$6LJ&M"&:OJL)1C \_P!J:=KW MJZCUB)>;*L)?^96M:O&!Z6'JYUN5ZI7-XSU17<[5Q?VA5Q'PG+6E*)II?2S-4WDRS5#80_-7 M2V%G_?KU:,I2^,QC&4S%31V?Y]M78='_ -FNH2P7;3H;-=M=OL:_> MLJ2N@FL]]47L/FKHAB>0\^IAI%!/N56O/G6MC['L6LK4OD6M?K M8Q+E*I25;O)JS'?=7H4ZI\UB =*K^74LE1;6KKYCQ.20]$IR)47DO4J.U1&I M*$O=-O9%A/EK6L+RL3S*L0OY/\5?6Y?F$H'#7H'5PZE_M5:_M+_:KE4N?]JG M/>?[5?>T,YERG@5\-S'4?VE_M4?VE_M5R3W[1_Q5$^I-7=_;ONG)]3.KFU5= MOWJP;^\WUF27C-_%5=YJ^:QNA3PP^:;YJJ3/3W?=3)*^1KXN4ST(TRO) M1YE3>73/)KPI2YCHC$CW4W;N-3>33TAHY>8U*^SY:8B?-6AL^6J[P[*B42.4 MKR4^.CRZA+6MK['1]CKMCEO*9>U,5X6J%X:VWM:J36WS5C4R_E#VICNE0;/> MM6:SJC-#LKPZM#D+YB*.B2GHNVCRZ\Z4>4Z"&IJ9Y=%9%3LK2.!Y)![4 MHT58>&F[-M95L(7&H,\ZCS*/)HW[:\6I0Y#OC(ECJ)TH2:CSJYN4LKNGS4SR MZL.]-\RLI1(*_ETSRZL4>71$GE*_ET>75BF58JPFI1.U? M01Q="9Y\HR)?)2J5S;+5I[E=WRTV9]ZUSUO83",I0.X>E3D5&^Y31]VG.FVF[*^-YH\QZ$1E,I\E,\RN*M4B3RA1 M3/,H\RN0H****QY@"BBBK **** "BBBJA\0!13_+I_EUL?LBI_Q?C0O^!5_0!\/?^19M/^N2U^ O[(O_ "7;0O\ M@5?OW\/O^19L_P#KFM34C[(\:N=)_%3Z8OWFI]8Q. ****L HHHH **** "B MBB@ HHHH **** "BBB@!E#_ZNAJ'_P!71$B'Q"!MT=4[SY(:M1K574_]51(V MIQ_>GYK_ +;UGYWB#_@-?([Z;\WW:^T/VR-O_"3;6_NU\M7%FNZOCYL$N?X:Y(USVJV6Q//_L;; MON5=MK-O[M=1_P (]O:KO$^_5%/EKZ"'PGP]3W9FA:]ZWK"%:YRV1OO M5MZ;NW5PXB/+$]K+_?ERG2VT+5IVULVVF::Z^5\RUH)E3B=\9KJ-'U54^6OTCA^OR2]XRK5.8[!$J%T^:HK:_1UI MDTVSYJ_;OKE+V!X?LY3D%XZI'7):K,KUJZEJ7R[:Y#4KG?\ Q5^4Y_F7/[D3 MVJ,?=*-_;135R^I>'UFWMMK;FO-C5+#7,NO#!-_RSK/N;"#^[7)]>D>9+)HGE7]E3S?PTY/##.WS+7I"6<'\* MT][-47[M1]E&H6/XJL0I\M5[;YVK=L+;>R5RRER'I8>E[:1L>&-$^T M[&9:[NSMO)^5:S/#SI"NW;71HZ[MU?/XFH?IN483E')#Y:U-"^QJ'N5VU"DV M]J\SF/K(^Y(V[:;9LK5MKG?6%:]ZT(;GR:VIU>4]6A(Z"VFK=L-5\G8MMKG?\ -7T6"S*6%ES'H2Y9Q/0K;6%V_>I]SK$21?>KBOM+*GWJKR:DS_+O MK[6CQ-+V7+S'%+#1-+6-5\[^*N:N7J6;Y_FW5E37F^7;7QN:9E+%R",>0S-: M?>M84,+?>KH[^VWUDWDRV<5?/QE*9XV.E&B4KF\6VB?=7GGB'6-[/M:M/Q!X MB^^J+7!7UUYS-7L8:F?G&:9A[I7O+G>U9[OQ4LU4G?YJ]V/N'Y?6K\\I%C^& MHONTY'^6HM^]MM6FZ)>?;U3;7R^.I>Z?JN38WWCN]-=75*Z6U\IXJX); MEH6VUT%A?M7R52/),_8<#5C.)M/;*[57FME2G_:/EJO-<[ZQE*7,>I*, \ZJ ME^F]?EIZ34._\35KS2.64HQ&6/*0 MS/\ -5>::FW-S69A&B?/UL3[Q+-L>L?4H5VU--?[*S+R_P!ZUZM.GRGS M^.J<\3G-2_H:5J6^S^6OFL9\)^C9-5_> M'2IJ3>;]ZK=S<[UKFK:;][N9JU4N5FKY:M&1^I49>Z:%L]:<+_+6"EXL-6TU M):XN21Z%"OR2-M'7[U<_KDRNU,O-;V5A3:DUTU.,9F.+Q<#0A==M6H;E:Y_[ M3LI_VG8N[=7H4Z',>5]VW?6)->;VKJ^K'A8G M,#I;F;SH:QYODIJ:DOE;:KO=5UTZ!X]?%\Y7FF?=52Y7>M%Q_>W5F37^SY:] M.G$^?KU8E6\>LJ;[U6KF;?6>TU>U2B?)5Y;&KTOP]JO[K:S5X_83?9IDKKM'U+YDKPL7AI3D?;97F7)[IZK9 MOYDN^N@MIM^RN)T>\\Y4KJ[!_E3YJ\?V<:4O?/U? XGVL#I;9-^RN[T%%\BO M.K:_V;*[+1]55+?;7ZSP[C:$90B==;WCKID7RJKI]RF0WBS14R:\6&*OVJGC M*48Y3R6>L^9]_P M:M_#\SUBWG[FOSF-7G/BL31Y(\I@ZQ;+7/\ EUO:D_G5 MB.^VM8GPF+C[Q7DJ).]2N^ZHOX:UY3S9?"._BK6TUZQT>M739-]<54[<+(V- M^ZK<,.^JB/\ [-:%FK/7DU3ZVA[X](=E5[A$>MVVL]]O6?JK-?[_P"*O']G(]^6*C,NNZUFW\R[:A>\K,O[JN^-,^>KX@I7 M[+56V^]4-S-OJ6S^2O3^"F?-_'5.HT'=700VWS5BZ#_NUTL,F^OFJM3WC[3 MT"PEM\M4KFV^:M>'[M-FA6N?F/HY4/<.:N(5ID-MOJ[>(NZIK/;M^[71&1X_ ML#'N;/951$V-6W?I6?##O:NWVIYDJ!7W-3X?O5=>S_BJN\.RIE6"G3Y#=T=U MW)6W7'V=RT,J5T%G?^954ZA[>&ERQ-#SF2H?M[.U/?YJKHO[S[M>A3KGI&K; MNCUIP[:QH?NU<2;97T&&Q/O1,)4^8EN=CUA7\*HU:KS5F7[J]?8X:4IGS.81 MY#"U#;NK0TJY5(OF:L2_?9OK/>_9/NM7L\LCY7ZW0A(ZC4K^#RGW5G^!9HG\ M50[?]JN7N;]W5]S5L?#3;-XFBK@Q:G24VW_ (J=7.?<I4NJ]6..+C$VW?Y:HW7:J_VZFO=;ZRJ5^8U( M9*B=*L?>ICI7CRD=$8D2)3XZ M5 VDO/EJQ#-O:L='K3LTWUZ$KJ[:-;>O< M_M7E/HL'D_+(Z72K/Y:Z.&V^7[M%A1'I M;?[-2NG[JA)OE^\M-=_E^]7RTN3F/N(RC"'NE>:%47=7(Z]>+#OKIM2N56W? MYJ\O\3ZE^]?YJZ8TX'QN:9E*$3G->U+>S_-7)7C[FJ[J4SO*]9DWW:FI3CRG MY3B\7.M,BW[:KN],=VH3YJ\.43EB-W_-0[U+Y-#PU,8A*)41_FI_F4/#LIDE M;G/\)-YE7;:3\=59[=M:UA,J5R-G>5L6SM-]VN*4> M<^FPU<[.VF69:T(8:Y+37E1JVOMDJ;*GZNSZ*CB3;\E4JO<[$JNE^S5%-,SU MI]3.NIB^49-<[):B?4MBUGW\S*U9-S>?[53]1/'JY@:=QJOW_FK,FU+>U9LU MY_M51>\;=51P?*>54QQL33;UK*NGV4)>?+]ZJ]U,K_Q5Z=&GR2/'Q=;GB:%F M_P"ZK0A=4^:L2VN=B_>J;[9LB^]7WN#G"-,^?J2-C[8J4?VKL_BKG)K^JCWC M5EA).F3]6YR&PTWYJ MZ:PTW[E&FV?S?=KJ+"S7^[7U.&ES';2PD3/_ +/_ '-,2S^6NE>S7R::EG_L MU]!##2F:RI1@F?8]]=+-IO^S34L/F^[7;'+^S.!N;/8U4IK947=6AJURJ7#_,M85_JJI\J MM7R#6JQY)1,6YMJH_9WK; MNNU4JZHR/E:D>8H_9?>IH;.K2)6C;6V^JEB1TL)SF=#IN^A]*_V:Z:SL_O\ MRU8^P_[-7'$^Z=_]F\QQCZ:U1?8VKN/[*W_PU4?1/]FMJ>.Y#*IE)R7V=DIG MDO72OH[?W6JO-I3)_"U>Q0S/F]T\FIE+B<^\-1>36Q-IK)_#5*:V:NWZY(\B MI@G J>33'AJQY-#PM51JGT$94F4V.MJ(WSUCS0ONKL)K-:RKFS6O)Q>&Y MRXQY3GWA^6HO+K8FMJS)(]K5\55P?O'I4BI)44E6)*KR5X.)H\LBQE%%%C0I@,2'?4O MV7WJQ;)\M7DA_P!FOJ\OP/.>?4D>B_LG6WE_'#0F_P!ZOWR^'_\ R+-K_N+7 MX1?LKP[/C1HC;?[U?N[\/_\ D6;7_<6O'SBA[&1YE4Z-?O-3Z8OWFIZ?=KYZ M/PG*%%%%, HHHH **** "BBB@ HHHH **** "BBB@!E!_P!710?]71$C[8+_ M *NJ-]\\9JZ_^KJK/_J:)&E.7[T_-_\ ;7N/)\3I_N5\VPOYRI7T'^W.[?\ M"5)_NU\Z::[>4E?%9E']\?UEPA4_X3UZEB\AWQ5GPVS[JW=F^+YJB1%1J\_E M/T#XAD,*HOS+4V^+^&F7C[%KGYK^5)?EKGJ0D8^[2ES'41TQT:LJPOW?[U;" M/O6O/D>G3Q,9&?-5=T^6M"Y2J,WW:(D5H\QFWD-LQ]NZM._?[]8,TWS5]70^$_,\7[LC6A=46K$.I>2U8*7G^U M1]L^6M94NFZUO^5FKI;:\B==VZO(K:^9&^]72Z5JLNY/FKQZV M&/J\OS3G/2(;^M.V=GKA+"_9Y:[#3;G]TGS5X\J7(?=8;&<\3;2;93WNM]4I MON[JAAFI4ZGO'IRD:"3-6A9WC(U827/S5I6K[Z^APV*^KD1CSG9Z;K'R_-5A M]8WUS5L^RI7FV?Q5['^L%7EY#TXX8MW]SOKG-5N?)J6\U+;_ !UR^L:KO5/F MKR?K,\5+WSS,36]B/FO/FJW9WB_WZXR\U7YOO46VL-&R?-7%BZ?*>$\P]\]( M1U=:I7U9EAJOG?Q5JN_G+7SO*?3>WT,7[2T,NVK7VS>M-FA7=3/EK6,3DE6* M5X^_Y:HO;-MK8>%?O4UD7;6G+R')4_>G'ZE;5S^I6W[IZ[J^LU>N?O['[ZU[ MF%D?$YEA.<\MU6'8U9,R?+79ZQIOW_EKFKFS9?X6KZ6A5/RK'8&<)]&/VAEMO2K#S4?+MJ MO-6M(OFY"VEY6E;7GRI7.^95B&\V*E>A[/FB7&L=+]LWK1O^:L*&\^:M#[1\ MM<524H'I4ZG.6+F;8M9/_+7=1?WE4GO/W5:T_?..O4Y#0N9E2*O-_%NN;-ZJ MU6/$/B1H5=5>O.M6U1[N5J]/#4/>/SS.\=[I0OM2:9OO5G224Z;[WS5!<3;: M^HC3Y8GY#B,3*9#,[5$Z[J>K;J=_#5GCR(M^VG6R?-5=_OU8MVV-51,22;[U M.1ON4V;[U)'6O*=$#0C=J[CP;K'DS+N:N"AFK5L+CR?FW5XN)I\Y]=E>)Y)' MM#W\5Q+N6KMG>>77G^@ZEOMTW-786/H)8Z1V"7BU#>7GRURZ:DU$VI,]=L:!Q2QQIS7[5GS M7-5_M.]?O5GW-Y6WL/>.&IB?=+%S;DDH1Z]B/O1/E*E3DF:%C?^2U=]X;UO?%M9J\Q3[];%A?M;?Q5YF+H>Z?2Y M7F'LJA[ ]Y\ORUIZ5<^=\K-7!:#JOVQ=K-6U-JOV!?E:OGZF&/T_#9I[IU=X MZHWWJK_;T3^*N$N/$\LC?>I]MJK3?Q5E]6+_ +7Y)'2ZKJ6R+[]9]GK']ZLJ M\O-Z;=U5+9_F^]1'#'%6S#VAMS:W^]IDVO?+MW5CW,/R[JQYKG8WWJ[Z= \^ MICIJK]LK/FN?EIGVKVKT8T#YN6.E.1I_;*ZI4O-G\5: M^P-/K)KS3;UKG[^;YJL/?_+6?;Y:JR4QWHKOY3P/:\Y*GRT M_P RF1T^MHQ*)4?YJUM-N626LE$^:K<+[&J*D8G7A:DH3/4_#=YO5*[*SN:\ MR\,7Z_+\U=W9W-?(9A2]X_:LEK^X=+]IV5IV&L,G\5?[56+:;?6V"E+# MQ]I_*?4>T]X].L]>_=?>J6\UK?%]ZN$AO'1:T([EGAKZ^CQ!*5(U]E[Q8O[] MIDKF-2A\[?6ZZ;UJCY?YJQ'^_70W*?-6/,E>C3D?F6.C[Q4\NB9-BT^F3 M/\M=L9'CR^$KQUJZ765'6KI=16-A:/"LUNFZO%Q-?D/T;+\%&<8F+IOAY47YEJP^@J_ M\-;KHL,VVGPI\U>)]9ES'U/]FQY3C-5T'R5W;:XS4O\ 1I=M>L>(=J6]>5>( M4W;FKW\)5/B\XH>QAS0*JWF]:M6=RR5SZS-#_#3TU*O3]ESGQWUR5&1V"7[; M?O4)>;VKETU7_:JU9ZEN_CK*6&/6H9A(Z;Y76JEQ"M5$O_\ :ILUS_M5SG;4 MK>Z5YDVT6;_O=M5YIJ--???I75*/[H\W#2_>G>Z;#Y-NC5L6;_-44,*_8$:K M%LE?(U_=D?IN#^&)KVWW:6:H4?Y:-^ZN$]^7PF?>)\U%LGRU8N=M$*5U1/(^ MV9]RC/44-FR-6VEGOJPEC_LU?,:^P,E+;?39K/Y:V'AV4QX=]=5./.92H'+S M6S)4MG-+#70?8%F_AJ*;2MG\-= MC3+$/W:?YE,\ED6J\TWDUZ>&J;*EO-2V5S&JW^_\ MBK[W+\2? YM7YAEY?UDO=55O+EGJIYSU]5]8CRGYC7C*N*^"O M_)(?!/\ V!+'_P!)TKM?XJ\@_'JGQR'4444C,**** "BBB@ HHHH @N?^/=J M_%7_ (*%_P#)1)_^!?\ H=?M5<_\>[5^+'_!0O\ Y*)/_P "_P#0ZRD>KE_\ M0^1T^_0Z5)#]ZG.EG1T MU$W5*B5SU*G,;4X\I%L^:K2?(M1)"VZM6PL/.:N*IB8P/5H8:58;#"SUL:;" MR;*U=-T'>OW:T$TK9_#7G2QT3ZC#93(NZ:ZHM:?G+OJE;6=74L&K2GFY]'2P M,H&K87ZQUO0WZ[:Y>VL_FK5^6%?O5I4S;F/:HQ]D;":LJ5+)JJI7*MKS)8SVDST/K,84R]XAUZ+:_S5YOK&I+-WWJY&\F;S:^A MPU<_-\TQ/-(?(GNJ/.WU M7=*9OV+7D2I^RES&DJG-$M^=LH^U>U5/,IC[JWIU3DD7GFJN[U"CT_RZN5<< M8EVV2NCTI*Y^S_@6NMT>'?LKQZTN<^CP-'WC;TV'?71V%FSU4TJS^:NPT>PW M[*]/+P ML-E;MM#LIZ6ZK5B.O0EE,H'71Q,1_P!Y*EA2B%-U6]FVOJ\#@^6)SXJKS%=T MIGEU*[TWS*]"."Y9'F5*I7N8=]8-_9UT$SUBZE?JBUGBZ'+2.3ZP8[IY-<_K MVL+#"_S5:U7552)Z\]\0ZD\U?E^84XJF_P":GS/4/WJ\GV?NG)[7F]T'FIOWJ/)^:M"VL]]< M\HE1H\Y#;0[VK>L+-MWW:=8:571V>F[*\JMRGU>!P0RPLVVUH)IK/6G9V:HM M7885KS?;\ONGVM#+_=,=-*_V:?\ V#_L_K71HBU+M6NB//,[?J<#E_[%_P!F MHIM!W_PUV'V;?3DLUKJIQG&7,>&VV_*M<_>>%9_[M>P7$*HOW:Q M[C;NV[:[(USQ,3E"D>3OX9E3^&F_V#*G\->I?8XG_AJK:/H[?W:I7-ALKT"\LU3?\ +7.7\*U]1A(\Y\IF&&Y/=./FMJKO#71W-M\M M5/L&^O5E@953YCFY#*1*E\F6MB'2M]6/[':O0H91(Y)8GWCG_)EI_P!E;^*N M@_L=J9)I+)77_9$@^L'/_9?>F?9?>MY["J[V=<53*9!]8,G9MHJW-#LJH[U\ MYB:$J)W1JU:KONJ+R=[5RUOWQ/*9/V=Z?]C: MMC[+[T_[+[UST\&1*1B/;;*K[-M= ]GOJI-85K4PQES&>DU3)-4,UMLIL=<] M/]T*4>>1H(]%4?.I_P!J]JZOK?*7[(MTQWJO]J]J8\V^N66).?V7O%OS*/,J MEYU'G5<<3$VC$NO-5*Y>CSJKS/7G8FL:Q*\WWJ91)17S57WI'1$/X:93Z97. M 4445D 4444 'F4>93?,H\R@"7S*/,J+S*/,JRO:$S4W=4?F4Z@?M0IZ/3*; MYE5$.8M>944U'F4R@@FAJTC_ #52CJ5'KOHS V[/YZV(4V+7.6UYLK8AO]]? M787$^\)C[QV\PRBBBN(.4* M*** &35%4LE-\NH 94M-\NG4 %-;[PIU-;[PJX@.CI]11U+5 /J6.J]2PUZ% M&0&M9UL0IO6L&VFV5IPWE?>Y76C&!Y=2/O'MO[+L/_%XM$K]Q? /_(NVG_7- M:_#C]EJYW_%_1UK]Q_ /_(NVO_7)*\'.ZG/(\ZJ=!_RT>IJ8O^NI]?)Q.6(4 M444%!1110 4444 %%%% !1110 4444 %%%% #*;)]TTZFR?=-.(1^(1?NFJU MQ_J:LKU:JEU_JS65/XBH?Q$?G+^VK9_:?$R5\[V=ALB2OJ/]KJS\[Q1_P&OG MK[ WW:X\5E\JU3FB?UEPE+_8#'N4V154A;YMM;M_I3?9_NUE?8'AKEJ935A' MFY3[SF*]Y#O6L*YMOFKH+E_EK,F3YJ\FK*4/W4C+[14MH:V+;Y%JJB5+YVRO M"K1",O?+$U95T^RM#SM]9E]7#&)U5I>X9EY-OKG]5?Y:T[E_FK'U)_W3U[>% MB?&YA_#./U)_+9ZYRYN:V-5?YGK"DKZVA'W3\CS"I[Q%]J]J/M7M3)*B_BKK MA\1XNET34EW5Y[8.V MVMBPOVA;[U?-8F!^BX'$^Z>FM=+,M2PHM5JZP[;GKE[ZO:H2/SG-*CYBK?(U5X9OFK0N8=ZUD MO\C5STC:M3Y)=56:;8U,\RHIOG:NTY*DN8<[[JI7-OO6M"&'Y:9$YXR/)=2L'MF^[6)< M_/7INMZ/YRNVVN$O]-V2U]!0J'YKF6!<#FI*:%JZ]O\ ,]1.FVO5B?#RAR2( M:BDI_F44&4I GRT,U%'ET$1'Q]:TK--]4(EK7L$\NIE\)[&$C^\-BV^1:L)- M5+?\M.1_FW5YE<^HH>Y(ZO1YF2NHL'\YJX6PO]E;NFZWY,J5X-2F?=Y?B8Q. MPFW0TS[95=-8BN8OFJ+SE=J\^43Z6.+C(TDFWU-69;3;&2M"&9:R.N-3F!TJ M+?L^6KNY:S[G_6NU7$JI+W2Q#)LJ[]O5%K%^U>U133,ZUK&/.<].IR>\7YKG MSF^:L+6]52P7Y6JIJNL?8XG^;YZX74M>:\EVLU>G1H'RN[[:90Z4&0]'J5$^6JOW:L)-05$E1]M6X9M]9[?-5B&394\IZ-.M MR2.HTV\^SQI7<:#X@7Y%KRR&YK6TW4&MID;=7C8NES'W65YA&![*DGVE=U9E M_&R52\-^(5=D5FKH+F%;R+N^-3F]T\>I*4HA3HZ;3HZUE3B<].L3;-ZU4FAK3LTWTZ\MMD5W0D? XNER2&0I5C?L:JB/4V_^*NBI\)PTI^]RFKINI?9 MI*Z/^TOMBI7%;_XJTM'O]DR;J\^43ZC"8SV7NFK'ERR.H>Y_T>N1O+G_ $AZZ!_D MM:Y*Y;_2'KKI1,<=5+#S4(]4G?YJ$FV5Z7*>#[V'>73_ "Z/,IZ/71&ES$=S'16.?O)J MY36WWJ]=74^*S*AS^\>?W\?S/7.W+_,]=5JOR,UA&/O'RU4@CZUI6-9D=:%@_S5 MK(5#XCH[-ZU;9_FK'M9EW5T%A#O6O%K1/O, ='X>A^T7"5Z19V_DQI7GGA[] MS<)7HUGA9X MJX&_L_F^:O4+]%FKBO$E@T;/MKJI^Y(^5QV&YZ1PFL6>R+Y:Y7SMDNUJ] >' M?;OYM<5JFFLDSLM?582H?D698.<*IG.]6[:YV576W:A_W->C4I\YX\I.B:?V MZG?;JQWF^6F_:O:HIT#?Z][IL/=;ZT-'=OMJ5SGVG96GH]]_IB5SXF/+$[LO MQ//5/:+:9OL*46US6?:WG^@)1"]?)8CXC]:P]7FI1.@2ZJ7SJQ(9OFK33YUK MS)1/8IU_=(KF:BVF^:J]Y4-L]:Q,JE8ZBVFK13[E8-A)N:NELX=ZUD>_@OA* M[P[Z;]E]ZTOLOO4T-GOKT<-0JRE[I=:/O&>EK4J0UJQZ2SU;72FKZ2.5UZ\> M?E(IQ@87V7WIR0[*U9;';4'D[*\^O@ZN'.WEB5YD_=5R^L?)76M]RN?U6VWK M7DJ>GBJ7^SG[3_!O_DD'@K_L"67_ *)2NVKBO@S_ ,DA\%?] M@2S_ /1*5VM>VMC^;JO\27JQ]%%%(R"BBB@ HHHH **** (;C_4U^*__ 4. M?9\1'_X%7[47'^IK\5_^"B'_ "49O^!?^ATI;'JY?_$/DI'^:GN]0TUWKEY3 M[Z'P%A'J7^&J4+U;3[E;1B52$JPD/RU73[]:%M]]:].A3YC*J5_L>^K$-GLK M02%:MPPK7TE#":K+5Z\_=K7 M,W\WS5Z$8\QXV)J/']G]HJ)#5VVAJ9( M:L(FVOIL+3.:J0^7372K3I372OI:<8GFU(E3R4ICIMJW]VJTWW:NIR\IS_"9 MMS#5)TK0FJE)7R.,Y3MI$*??JPC[:KT]'KPHQ_>'=+X35AN6JVDU92/5A)J] MNA$Q]I(V(9JL/-\M9B34_P [?7H>R+]O()IOFJN[M4KO44E:\IC*OSE>2JDU M7G^Y52:O/KRY#+EYS/=*KNGS5:DJ)T^:OFL54YXG1&F1>70Z;JL>31Y-<,9! M[(J)#5M(:?[7WS[7 M!X8Z#1[;S&KK=-A5-E86E1KNKH[-UK]%R&O#F/=J4/=.@M]NVI=BI6?"]6'N M?EK]QP-2G*!\UB/W)*[TJ3*BUDW5YL_BK/FUA4_CI8VO2A$RH5_>.HMKGRVK M0^T[ZX>'7EW?>J[_ ,)"G]ZO'H9M&$CT*DN8Z:9U_O57FFV+7./K"_\ /6JE MYXA5%_UM>G6SF,3SZIL7VI;%_AKC]8UAGW_=K-U7Q"SM\K5R]SJ4LS?>KY_& MYW'E/.Y9%V_O)9E=:YJ_2KKS-_>JE8?6*GNE^S]WWC'F3?6?-\GR MUI352F3>U>/4ISF>?4C$S'^=JFA2I?)2C9MKSJF&D91E$>D/S5I6:JE9L/SM M6K;0UX]>G4@>WA91.@L$^Y71V<:USEFZILK=L[E=M>!4C5/NL#*,36CIV_;5 M=)EH\[?7'3H2G5/>^L\D30A^>M"VM_.7=5*PAWUU>E6&]:_2\TWYONU]A+A>7L_A,HY@<9<[O[M9LT*O76W^FUA M7-ML:OC,;DDJ,CMCBN>)D^2J4V9%VU:F^2LW4+K8M:X'"2/G\=7Y#"U7_6/7 M,WZ?-6W?W.]GK!O)M]?5X2GR2/SW,JD9F?-3[:&GU8MD6OL,-R\Q\)5+5M#5 MM;-7HAJPC[:^RH4X\IX4HRYB+[ NVJ[VR_Q5==ZKS/\ +77[*)'OE)[-6:H9 MK!:L(_S4]ON5Q5:4 ]\YR\L%K"N(51JZJ_\ N5S%_P#?KX3-J-*)ZM&14=Z/ M,J*CS*^"ER'L0+'F4[SGJKYE2H]<7-R'1$L>=3]^ZJ_F4;_FKJIXF1E(NPU; M3Y:HPO5[^&OH\/4YSDE$A&(^F24>91)7/ M[202B-\RF><]$E,H]N9<]-=]U%1/64JO.1RB4>9139*Y) 'F4>93*?42# MF#S*/,HHK(.8/,H9_EHHH 9YE'F444 %%%%62$=/ID=/H ****J(!3J;14E< MQ+3ZAIZ/71&0%A$I\-XT+5#O^6HM_P U>A3K\@9?EKY2O4YS;V?(144?-1\U<0!13Z* &4>73Y*9 M4&(>73*?3* "BBBB(!1111S %31U#4T==%.0%A)JL)-6?YE"35[=+%^RB<]2 M)[K^RC>-_P +IT1?]ZOW@^'O_(N6G_7):_ _]DN;?\<-!_X%7[W_ ]_Y%FS M_P"N:US8FO[8\>O$Z;;\U/I&I:\H\\****LL**** "BBB@ HHHH **** "BB MB@ HHHH 92O]RDHF^[0'VAFWY7JG?_ZAJO?\LZI:A_Q[FG0^(J/\:)\-_M16 M:W'B; 3/\U?J.6Y;2JT/:S/ZBX9KM.%_EJQ\KK7K?V70JTCZ^.)//-2TI49ZPKR'97H6I6>_>U M<5K$.QGK\=SW*?J]7F.J-4Q$FJ)YOFH_BIFS>U?GV)ICC+WB:&:F7[_+1"GS M4R_3]U7EX<[<-O:LS4D3[.[5;O'V,]8.JWG^CO7L86)\/F%?W3C=8? MYGK!\YZT+^9GE>LVOK:$?!Q9NVR+6G9_?K$MGK3MIJ\2O3/KL/5.B MMKEDHN7\Y:SX;FK:/NK@C[DCW^;G@<_JMG7):E"R5Z%>6WG5A7^E;_X:]>A7 MY#YC&X/G.*\MMU7;.V9]E:;Z.V[[M:5GI6W^&NSZV>)'+9:EL:N3V?.?1\6TA^6HIK;Y:TH8=ZTMS;;*/8'K1 MCS1,'R7K/NK/^*NC\FJEY;?NJP^ XZU#G.2OT_=;:XG6+/YJ]&O+:N7UBP_V M:]7#5#X7-,''E/,;Q=DCU5N8?EK6U2';(]9I7 M2H-M=)\_*F))5CRZBJ6.H*C$L6O>M.'Y*SX?DJPCU,OA/5H2Y#21ZL(_RUGH M]6$FKAE$]FG5+:7+0U;AO&W5F>93_,KBE3/8IXGD.@AU*7^&M6SU)OXJY*&Y MV+6A;7EM0QQUJ7]7;:_KEX9JO0W-<4J!]%2QAU"7B[:9-N1FFWS4^YO&D:JC_ -ZOHL/2/R;,L=+%2!YJJR4YWILE M>MR\A\]*IS#/,IGF42441DZ;:/,HDIE0 4>71Y=/\N@! M\=.\RFT59J6H7V-5Y'K)1ZMI-7)4CS'=0KR@:UAK$MG<*RUWN@^,V==LNVO+ MT?>U:ML[)]UJ\:MAO>/K94L=9OG58A MFK67.>7S1-BS?95JYF\Z&L=)FJ;[5[5/LY?$=_MX^RY#'U*W^9ZY^YAKK;GY MU>N?N8:]"A[I\ICH\YC[-M/W_+MH?Y&J%FKU_BB?*_!(F\[:NVG6URT+5!NI M*YY1*]I+F.CL[G?6K#NN:Y>P?RZZ/3;Q*YY1/IL%B.7XA\UA1;6VQJT))E:H M?)9VKSY1]X]VC[\N8FNIO]%VUR-Q_P ?#UU$T+1Q/NKDKR;_ $AZZZ43R,PD M1._S5"\U$SU%YE>ERGRTJ@.]'F4QWHCK:)RRJ$WF4ZHO,IZ/71$N,BTB58AA M62J\=7K7O7IX:GSE>U+%M;*E:"6WRTRS3Y:T$2OHJ6$]T/:F>]K6?AV>I-MJZE^VZN7TV9O*K8L)-S5\Q M5B?>X3%FLEXVZI7N=ZU$]M\NZJ,WR5P\I[$J_NEAW5FK-U6S6:%ZL6TR[GJ5 M]KUM2C[QY]?WZ1Y9K>FJDK_>KE[]-JUZ7XGMU_AKS?5?XJ^KP9^3YQ$YR:;> MU*GW*;)_K*7^&OI8_"?G%3XB+^*M"S7;6?\ Q5IV=5RFN'W-*V3]]\M=7IJ, MD-86FP_-\U=1;(NVO/J1/NL":NCS;)=M=QIKK\E<5HEMON*[VPL_N5\_B\-. M9^EY7]DV$177[U2^3O6B&S9%2K'DO7F1PDC[CF]TRIH63[M95Y9_:?O+74/# M52YME2N7V=:QHZK]W=7+W^E;X=M>FZE9^=6#-I2[ONUZ%"I[(^ M(QV7\YYE#_ (0_SMDM;4,W[JN8=V\V MMJ%F\I*\R43U8C+R9MU-MD=Z61])A/<@7;:V:;^&MVST=:-*MEVUT<,*JM?T!P]D5+$4HRFC[J_2*.2T*5/EY3RI8N7,8EQI*M7/W]AY+/MKN MWAWUB:K:KM>OB,[R.,8QS2G2,R_A5ZY36+;SEVUUTR;ZS+^SWUE0J\A\_C,-[IYT]LMM)5M/N5+K< M/DM5&VF^:O2]N?!2HSA\Y4KO?A[;[->M_\ MK'44451B%%%% !1110 4444 07'^K-?BQ_P4 M0_Y*,W_ O_0Z_:BX_P!37XJ_\%%_^2B/_P #_P#0Z4I6/5R_^(?)--=*(7J7 MS*=.G&1]QS>Z,A2K*?&S")W?V?/E')9[ZL)I3?W:UK"S_CK5^S+LKT( MXN$Y'JQR]\IS2:5L_AJU#H_\6VMC[+[UL6VFJ]ONKDQ?LIQ/3PV!G YJ.S_@ MV5JZ;I?W/EJVFF_O:V+.S\OY:_.LTC&,?YMF=JQPTI&MIS2-:U[UH)#699O6AYWRU]!AZGO&7V"W#"M2^36>ES\U6/.^6OJZ$HGF2B M/\NF.E"34/-7I>UC$Y^4BDJI,]2N]59JXJV,(E0*DSU4=*L3)45?-8G$\YM& MF5W2F1U;V;JB=-M>9&K[QU>S]T$>I4>J\E"/7L4L3$\^I&433\ZG(]9Z35,D MU>K'$Q,N21:=_FIOF57>:F>=4RQ(1I^\6W?Y:HS/0\U125X^)K2F=L8Q@1.] M$=$E,_BKPI%^T+";:E^]5=/FJVB4CHB")6A#MJE5V%-U<521Z.&CS'0::GW* MZ.S?96#I2[%2MN.O*D?L[_ /VJXR&;96G9WE?19;C/8R/3 ME+FB=K#?_+]ZA]2_VJYI-2JO-JWRU^I9;GO)%\Q\[C<-&9I:EK"I_%7.WFL? M[54=2U)I*Y^:Z9VJ,;G9J-S5\I+,*L9 M'7[:4CJTUMG_ .6M17E^TR_ZVL&&K=:5,TJ3+IQE5^(-\K_Q4SR6_O58AV[: M'VUY-3'5*WN'5]7IQ*6QM^RA[-F_AJQ\NZK"/7LY?E_MH\YXF-JQI2Y8F)-9 MM_=JJ^FL[?=KH)JK^97V5+*8\I\O6Q,C$_LU_P"[4/\ 9K?W:VW>HO,K*IE- M(XHXF7,9GV!T_AJQ#N3^&K?F57=Z^=Q>4TSV\/C)0)4NME:=G?\ ^U7-37-6 M+.Y^:OA<3A/92/LL#CI2.UAN=_\ %5N%]S5SEG3?[5<[J5S5VXO-ZUCW/SU\A_9L:4O=/G\3FDJW0Q+R9MSUCW, MU=!/G:TI5BIYU6+:Y_VJJ;-M-=V3^&IIXZ4)'F2PQT M4-XO]ZK'VE?[UF4_RZB4B^4?YE2I\U1>74L=81D7R MEA'VU8AF^:JD=/1_FKW<-B^0J5/W331ZL5F)-5M)J^JPN*/(J4RQ13$?=3_, MKW?;QY3F]D,JE>5;FFV+69Y37F'TRBBN>4B>8;3)***CF(&4V2I72F>71S!RD7\5/IWET>74ARC M:*=Y=%1(/9#:/+IU3>74UY#IIT"+S*9\U74L*F2PH]O(Z/JQF.C4Q M$:MC^S6IZ::U'UDVCA#'>&J\T+5T7]DOZU%-H[5SRKE2P/NG->2]'DUNOH\M M5WTJ5*B-21Y_U*9C^716B]BU0O9M71&43GEAN4I24RK#V[+430UE*7O'+[(9 M3*?Y=)MK4S]F-HHHJ.8GE"BG^71Y=7RARC*?3**UC$@?11'3Y*N0?$>O_LC_ M /)=-"_X'7[[?#W_ )%FT_ZY+7X#?LC_ /)=-"_X'7[]?#__ )%>S_ZYK1S' MA8OW3I)*?3/XJ?41//"BBBK **** "BBB@ HHHH **** "BBB@ HHHH 90WW M**&^Z*!?:#^&J&H?ZLU?7[C51OO]6WTJJ!4/XT3X=_:BF5?$'S-_!7@ORR-7 MK7[85_\ 9?$2?[E?/MGXA^Y\U?I66YDH4/92/Z7X?C_L1V&S8M".U9BZPOV> MJDVO*G\5?2_7J5*ES1D?50IFS>?ZEZ\VUIMDKUT=SXAWQ;=UN@O/GEK-O[#>M>QA(GPN94_B.!N$^_6;]S[U=!J5K ML:L&YA?=7U=#X3\LQU/WB*2H/XJG>%MM-5=M:\QY\8DM6(4:JD+5>A^]42-: M'-S&O8?O%JGV%&7NFG\KK5=U2.A)OEJCJ5YY.RJB14]\F=%J'?L_AJNEYOJPGS5 MMRG.5[Q_EKG;Q&>:NHFMJJ?V;OKTJ,N8\W%4I5OB,>P1U;YJU;F%IEI[VZVR M[FJ*'4HG;;7L4Z?.<-.,:/VAEMIOR_=K=TW3=B_=J*SF6;Y:ZBPL]\5>C0P, MZTCHC*G+WHE2VAV5--;;UW5JI9JBT?9_W=>_4R/DIZ?.9A0C*!X MKX@A\FZF_P!ZL&7[M=-XJ_X^I?\ >KF6^Y7UF%D?A^:>Y,J.GRU7DJVWW*KN MGS5W'RLAB)4T=$=%!'*6-RT(_P#M54=Z%:B1K&1II,M6$F7^]62CU8\ZN?E. MVG5-:%ZM(E8L-YLJPFI5'*>G&N:NU:?"^QJR?M_F5-#>;ZYY'52K^\=%#<_+ M5A+G_:K%AFJPEU7%+WCVZ>)D:3S4W>WR51^U>U/^T^7'NHC3-HUN4MWU^L-K M][YZX_4KIKGY:L:K?^8U8CW5=M.A$^9S3'2E[I%>;MU"/^ZIS_-5=_EKTXQY M#X^,O>(G^]11171\1R\P24RB2BE[,.8*?'3*?3("2B.BBH ?13/,I]6 ZHJ? M1Y=993_ #ODVUY\HGM4N:!JVUS\OWJ'F^:L]'JU#\]5&GS'HQK2 M#SJKS0[ZE?[]7K:VWUKR2C(B7OF5]C:I4M:TYK-DJHZNE=$H^Z8^P&/#\M5Y M-RU,^ZJ-R[5A$RE[@>=5*\VO]VHIIFJN\U7&)YE>L5+E:HO]^K=Q-56NJ,I' MSM;W@CJ7:U,CJ;S*LQB&YDJW:W?EM][%5'^Y44)^:HY3KC7Y#K;:_P#E3YJU M;>_7^.N/AN=E6$U*O/E3]X^EPV82C$ZN\O(GM7^:N%O&_P!(:MK[5YT585VN M)&KKC3.''5_:C)G^6H?,IK_6U.8WK:;R;?YJNZ5>?O:SYK/Y:--A9& MKY>J?>X7W9'9_;_D^]69?WFQ:9#56_3S*XN4]NI*48%'^U61JF?6%1?O5GNG MS5%-#O6NJG$\F6*J\I4U755FW_-7$ZJ_WJZ.\AKG+Q-^^O;PQ\!FDI3.=F_U MM.WKMHO$VM57[ZO7TM.7NGYS7YHS'?Q5K6'SLE9,-:FGMAZZ(FU ZJV^3[M; M&GN^[YJQ+/YU2NCL(?.9*RE3B?:Y;*4SK?#UAYUPGRUZAI>B,ZI\M<_X)T3? M+$VW^&O6M-TW97K9?E,L?[I^L9?'V48S,B'06V_=J&;2G1/NUW%G;+\ZTV\T MU'6O7EPIR'TL:_,>5B:?*!CB/B/';FS=/O+6?Y/S5Z%KVB*F]MM#I_NHF:Z?O:W;#;M2LR&V9VK8L+; M9]ZO/E4YCV*5,V(88FBJ)T\MONU;M]NVHIO]=4QJ'KQIQ$M46-JZ;2IE_O5S M^SYJU;!_+KUZ&)O4C*43IIQY3N]*==M=$FW;7"Z;?^3700ZJNVOW_AW-J5.E M&,CS,7A^^I+'_ !5^A1S3#PE&1H>=LK'U6Y7:_ MS5%RE")ZV&HF;J3^8SU@W*5IW+[ZJ25_.&95Y8C$ M\Q]%&/[LS?)JOU[$?A/A*^$]\O:/"WR?+7H7@9=NO6_P#NURNE6&S979>%8=FO M6_\ NU-'XS7$4.3!L_6GX._\DK\'_P#8(M?_ $2M=DO>N+^#O_)*_"'_ &"+ M7_T2M=HO>ON5\)_'>(_C3]7^8^BBBFEMO:NCTK3=^SY:\3&T948GT&6Q]M,--T?S&KHK;2?)6IK M"S\G^"M)]NVOC?KTX3/TNE@8^R*2?N5JW#)OJ%]M6[.&NV.;RB=$<'$8Z5H6 M]_L7;3?LS;JS]C)<54LWE,]6E@XQ-V'[VZMBS=:QX?\ 54+<>2U>'B\=SQ/6 MH1C Z7Y:/EK(MK]6:M+Y=M>#4E[8^EH2]T'=:9\M-3YVJM>3>3]VM*.#G/X3 M"O7B0:A=;%KGYOWS58O+S?\ Q4RSVR5[/U&<3Y:I7C*1$EM\M9]Y\E=!-Y4, M57V9B7B+\[5S]_-\M:=_J&S?MKFKFYWUZV'I\\3\_QM>/, M5)OG:J_W7I[S?-3-^]JU]GR'SM2I[Q=MIJO)-\M9,+U8W_+71&7(:QD7DF^: MK3S?+64C_-3WF\M:]BCB3*42Q]L^:C[962\S;J?N:NB6,,8Q-#SM]#_-5)'^ M:K2?-7E5,6=$:8WRZ9Y-6]JU"[UPRK\YU^P*^S;43_-4LE1.]'-[IE+W"NWW MZ94VS=3/+HCS')(**9YE/KT(RD<\OE#X 3[]:U@GF5GI#YC5NZ/ M;;Z\VO3D>K@S;L+7Y4K2>&BSME14^6KSP_+7B5*:%E:NNFL-]5/[ M'9V^1:Z8^UC\1YTL#&9S26S;JM)9M70)HFRIOL"K6,L7*)K' Q.?2P\NF30[ M*Z";:BUB7\RUE3KR)E3C I>?-5 MV&YK"1W2K"7FROT3+<5&E'E/C\7*4Y&P\U0N]4OMU/\ M/R_>K[.ECH\IXLH MR)7>J[O3'N?]JE\Y*Y:F-CS!&F.\RJ[O0\RU4>Y6O)Q.+C(ZHQD5YG^:BSF^ M:HG^=J?#L2OA\94C,]W#5.0Z"SF^:NHTV;Y4KC+"9=WS5NV=^J5\U[3DJAZ/?;*[O1+]?*^]7D-GJ2I_%706?B&*V7Y6K] R;._8GMRY>4]3^W+_ M 'ZJWFJJG\5>?-XM6/\ BK*O_%JLWWJ_6:&>TJM+E/EL74Y#I=;UCS-_S5Q5 M_J5YXA69OO51?4E>N:IF$)GS5>O(L>93:K_V@KU8A=IOX:BG*E,\R M4I \/RUDWEG6VZ54F2OG\;&-Y'JTH^ZK$Y)88@>;?4+_ #4UU\MJ'?;64L5,YY4"%]U5Y*F?=4,EZ5%M:N3F(#S*G^90FVG M.E5S2B:C?.J5)JKNE,\RO0H8F<#*I$TTNJ?]J]JST>G>97K1QTSDY2Q-<[UK M/F>K+_BGNC4 M;6KG+Y1GET>73]K4;6K(.4B=*/+ISI1Y= A=:S$^6GI,U8G51-J.ID3=_%63#-6A#,M<\CVXR@6 MTM:?]C6A)EJ5)JYYHD3Y MJNPI\M==.,Y#CR%1[9?[M57MEVUJO"SU7FA;^[75R3#V49F%,BU$D+-6A-9M MNJ>&S^6M>61Y4L,93JZ4Q-VZMC[+[T^&QWM7+4YH&M/#A M'+S$2S;^[3_LG^S72_85_N4?V:LG\-'MY?$=']GQ.7>S_P!FJ[Z;_LUUKZ:M M4GL]E:QQUIC6M7G2H:ZXGFRIE)HJ;MVU=\NF.BU',8RI> MZ5/+H\NIO+IGEU?,<4J9%Y=,\NI?+IM:\QSRB,I],_BHHYC6,3U_]D?_ )+I MH/\ P.OW[^'O_(KV?_7):_ ?]D?_ )+IH7_ Z_?CX??\BQ9_]3XC_ . U\KQZKLF^]7U!^W!M M_P"$E_X!7R/]F;[16%;&3I2]T_ISAV/^Q'9_VPWV7[U8]UK$KU%O_=[:J3?) M6,LTJGUD1_\ :4KM5A':;[S51A=7:K?F5Y5>O*<>+L=LKK]^HIH8D_ MBJH]RZ55>YW_ 'J\>I+F+E+WQTTV]MJT?V>SK\U16";[JNHN85AM?DKSY'9+ MWH'!7]MY,M9-_=D;Y:Y2Y25_O5[>$^&)\7CX^]*)BZE#YV^N?N86 MKI7^]M:HOL<3M7OTZA\#B<-SR.9>%MM571MU=A-IJ[?EK$O--;S:ZZ/%Q M6&]E3YC*A6KL*4W[,R-]ZITA;;6M21C0C*/O&QI25T"0_+7/Z5OW5V&FVWG+ M\U>%7D?;Y7^^,>\MME2VWW:V;_1VV[MM9*0LC;:\_P!J>O[+DD7;;[M:=G<[ M&K-3Y%J6%_FK&H>K0K;UK21*Y2VN=BUT%G>;_O5Y%:)]%AL3S&A5+4 MH?.V5=\RCR=ZUC$]6/OF?;6=:<,/RU%#\C?-5C?_ ':VYB1CI\U6$A7RJB?Y MJ=YS;=M=%*7+(TK5(SB8NO/Y<3[:Y2%W1J[/5;9IHOEK)MM'E=OF6OO1F4N6D>5>*D_TJ7_>KEIONUTFO7*S7 M#M7.7'W:^JPT3\&S27[TJMUIFVI:9]VO1/G)#:94OF57J#ED$E$=%%7$Y^;W M@\RG^=3**KE->8?YU/CDW5#Y=30I4\I?M)%M%W+4\-0(VQ:M(]KY1XFORQ(KAM[5GS58=Z MJ.E=M.)\IB:G.3(_RU%-\U,\RG(ZUL>?$BHH;[],K7F.B&PW_PU;>S; M;MKGE(]VAABO#-_#6G#;,\55;>QVR_-6HC[%VUQ5*GO'L1PWNF;L\MJ="F]J MFN4J6SVUT4X\X3\U:<,.Q:9Y.]OEK0AM6VUZM&,>:)MR^Z9[VWS5:MO MD6K"6;5,EG7=*A[:7N$>\0O-OJOY+/6G]@;R.?$Q.4FW55FK8F7?OK)N8:UY3Y?$9\U, M\RBN?E*C6-"WN=M0W$F^JZ/369JVB:RK\PS[U%/CIE4<$@HCHHCK:D0/CJ6. MHHZECKT( :<=:MC6/#6Q9U]%@=S61L6S_+5N.J,/W:L>97V$/@.4F=_EJ%T_ M=4UWISO\M95?>@:PE[Q@7'^NJ%_EJW>(NZL^9VKX3&1]X]6,A[/79>$K]8]D M3-7"?-6MI5T]M*G]ROC\73/J\MQ/)*)ZU#Y4R_?JQ9V<6[[U<58:Q\OWJZ#3 M;_>WWJ^0Q=/D/U#!UXSD=*\.RJ5XGRU=MG:YB>LV\\U(GW5X+SZ_!F)>;4BKG[S:Z M[6K>U#_4USSP^6#;JX/:GCU*!E:W MY3Q5Q_V-/.KJ-5MVVO7*.[0RU[%"1\%FT8PJFG9PJBO51W_>T^&\V*],AVNU M=%;X3A]I'W3L/#"--72_8:Y_PEM5JZMYME?,U_B/T?+>2I0B,AL%JW]F5*B2 M:H;F9G6N<]?EC$L/>*GRT(ZO\UK5TM]Z_-5\IR2K:I9JJ?Q5Y?-SS(J2Y8DWF4ZJ_EU8AAWUTTZ$IR)C+W3*UBVWUF0Z;\ MU==-8>=0FE?[-?54LMJRB>#5Y>8S[.SV;*W?#R>7KUO_ +M1?V>R*[-_#5CP M_P#\AR+=2^ISI3.3'\OU8_5KX.?\DK\'_P#8(M?_ $2M=HOW:XSX._\ )*_! M_P#V"+7_ -$K79)7T"^$_B7$_P :?J_S'T444SG"BBB@ HHHH **** *UU_J M37XX?M[0[_BE_P !:OV2N/\ 55^.O[>;J_Q2_P" M7T&3?QN4[<-*TCY4AA^ M9Z?Y=2HFQJ9Y=?J%:C^Z/6E4D-\FCRZEVM4L*+M^:N248^R.VA+G]TBMD_>U MW&B6:NJ5R5LG[VNZ\/;=J5^;9[+E@?I?#]&,Y&G]@V+5>2%G:MW8KK5>&S_> MU^*8BM*-4_;*>&C&D9\.E,]7K:S\FM6.%4IDR*_W:CVIM' _:(HT5UJD]JOF M[JT/NI52Z?951E(N5&,0WJB[:J3?/]VHGNJEMI-S5VRC&4?>.+_"/L$?S:Z! M'^6LQ-J5;MIM[5G0H1G5.J-7W30A3=5>\L6FK0LX=];MG9JZ_,M?MV19%2Q$ M3Y_&8N43S>\T%J;;:4R5Z+-H\4U,308MM?6XOAV/+[D3YVG7D>>W]ML6N)UA M]C/7L&O:4J+\M>6^)+/8SU\=7R*4)?"8YAC8PI?$/7I\AP>UYS0AFJPDU9L+ MU8CKDY3T*%0NI-\U/F?Y:J(]#OO6IIR.J4@\RGQU#3T>JJ2,HR+,/WJN0U3A M^]5R&N(]*AS%BJ3??J[5=TKG.[[)5DJ'9NJQLW5-;0_-\U:^T]TY(TI3J#(; M-GH>P^6MVSMEVU8>SK+ZR>A' \QQ_DT_:M;K::O]VHGTW_9KHCB3GJ9?+^4Q M'3YOEIZ)6PFFM_=H_LU_[M;>TB9?4I,B8X M*K_*8Z6;-5B'3=]=+;:5O_AK5L]!5OX:'O.K03P?O6NXT MWP\M=!;:)$GWJ]?#UK=FLU2L^Z397FU,OE+[)ZLJWL3*=-M,\ZGWC^6M9DTU M91RVI_*>97S*/\QJHZO5A$KGTOU6IO[4_P!JO?PF!Y/LGBULRY3==*(76&L' M^TF_O4KZDW]ZO5EEO/'X2(YM'^8VIKFLV:Y:JZ7GG4Z2OFL3E/\ =.V.91G] MHI7,WRUB7CL[5L7*5GO#\U>%+"RIQ'*OSF+,C5#M:M[[.E5WA6N#FY)G#4H2 MF93_ '*K>96G-"FVJGDKOKWV_VJ9Y.RN@?2EJ*;351:ZY4ZIE[(Y]TJ)X:W7L*B^QK7F5:KAL=5A(\_$ M^_$L/<_-]ZA+^L]_FH3Y:]..93/$J438AO-C5LV&J[*Y/SGJW;7+5]'A,RD9 M>SB=7-?J]5_M6]JS$FWU;AVUZG-*L1&IR2-.%Z<^VJL,R[JL*ZO7!*E_,>G3 MJG>2NRID2I73Y:CV<3MC'^8RKRV79]VN9O+;>U=G-#\M8MY"NZO*Q-. M7V8F4J<3CIK/YJJS6;5TLT/S?=JI-;5XDI2A\1PRI'-/"U5'1JZ::PJC-9UR M'GRI&+3*T)K-DJNZ;:/C^$Y:E,K_ ,56$AIB0^8U7DMFKUL-AJE7[)Q2Y8%= M[6H?LS(U:WETQT6O0^HU/Y3/VD?YBE#5A$IGRK3T>O-J8?E.F,ADR54=*O.E M0^76?LHQ"4BO3Z<_WZ?773IG.-J5$W5*MLS_ #5>AMEKVZ&!YX\QSU*GO&2\ M-1>76[-;;ZJO:U%3+0C4B9E,=ZMS0[*J.E>5B<)R1.B/*124SS*>Z4SRZ\24 M9&H45-M6C:M9!RE>2F58:/\ NTS:U!$HD3?M=$L"=].4>7XCF7TW?_!47V/^'971 MHBTS['O:M98.,3AE+F.A M&F'V-:E_LK>M6+;]\WRUMV=AO^]7V.7Y;+%RC'E"IRPB_\BS:?]7NG4:4GS[JV+ MR\7[/MK,L[9DM?-K*N=0WLZUA*//\)Z7M.2/O&9K=Y\U8_WXGJ74G9V>HK-& M=:]"A[D?>/E<3+VU27*8ES"S2TU+-D:NE32F>7[M/FTU4KT*ORU-#"W\5?.2J^\?;RPE.?PG*/9LC?WB8?V?+^4P8?DK6L:=_9NW^&FQHR-64BXT)43:MGK6AVNMQ0E$L7/R-44,WS4^\F7;5&'=NH.B4HFQ3:A1ZF3;7?[O-[H>S MB.AMO.^6M:STW9_!5>P^5JU4F^:OTGAZ/O1YCQ,7'E+T/^C+4J/YU9[S;V1: MNVO>OU+$58PY>0\2G'G'O#5>Y3Y:L3/6?,[5\?FV-CR_$?08;#%&YAK*F38U M:\WW:Q;QZ_**\N>1['P1(IIMBUYOXVD9V>N_F^[7G?C*;[^VKPT3Y+-ZG+2/ M--2W;JS+C[M:UYM=JS+C;MKZ>A$_!\PE+VI71ZBFIE$E=TCPI2&44^.F5!'Q M!111Y=7$)1"C^*CRZ>J-1S!&(>75B&CR7IZ)4MF7[M:'RNM<_;35IPW.^O/JGU^& MY32AA5VI[V=,L]VZM-$W5R?%(]RG3C[,Q'LZKQPLDU;%RC4R&V\ZO5H'GRI> M\%G#OK01&?8M6+"V5/O5MV>E;Y4^6NZE\9VT,-*+:B_QUV&FZ(J-\RU^H9!EL<1\85\-R'!0^"?X]M2S>'O)CKU.'2HT7YJS] M2TJ)(G:OLO-+_<\KU['XJLUVOMKR^\L_WKU^08W" M2P]64>4Y,3'F.9^S_?JE-9J]=!-;/NIJ:5O_ +U?.UIGR5#)4F M0^.BF1T^@@*(Z*(ZZ(@/CJ6.HHZEKMB!=A>M:S>L2&M6SF6O=P=3WBI&]"_R MU+YE4K:;Y:M(ZU]7&7N& ^C?\M1.].WKMHYO<-:?QF5>/\U4I*M7E9[O7Q^* M^(]7W1_F58CK/\RI?M.U:^7Q/Q'H8:?*=!9OL_BKJ-'F^:N'L[EJZ[09O[U? M*9A'^4^^RFO*4SU#PPF]7W4S6[5?L[[:KZ5>+#;T7E^KQ/NKY6,9TC. MD<)>0_,]9[PM6Q?5E35[5'X3XS%\OM1B0[ZJW]O\M2[V_AJ*\?Y:].D>)BZ< M>4Y'4H?FK-3Y:V-2?>U95>U2/@L33CSCO,JQ"]5*FA:NLQA([C07W1)7HNB( MJ*C5Y?H;[%2N]TK4EVHM<54_0\BJ7C/]ZNO/]5==[[*]_"R/SW.J<>8S'^1:L6:55?<]6+:3:M>C4 M^$^7E3Y91.R\-OY==!-<[ZXW0;S>U=1"_P WS5\WB8RYC]"RV7+2CRFA"[;: M+F:I84WQ54N4:LHQ/;YI94T\14Y3DYIR]\^0Q.,ESF@]LOV=ZJ:/;;-?ZLU^.W[=R;_BK_P%O_0Z_8J\YA-?CU^W.^WXJI_NM7U&04XRQ!UT MY>Z?,7V9M],\EZTTF6F/MK]FE1A[([8R,]TH3Y%J:9ZHS35X.+IQC3YCT,-+ M]X6(9MDU=AHM^L>RO/7N=C5L:3J6QDK\DSOWHGZ1D5?V54]=LW\ZM!+9JYSP MK?\ VG97=PHNVOQC'1]X_HG+^7%4C/\ )^6JDU;;P[ZKS6=>/&ORGKRI\L>4 MQ)G;;6;#C'G")T&F[=M=!;/7-6$RI716#JZU_1'"^)I M0@?.YE3YB7^*K'R[:BV?-4NSY:_4L-3AB#Y2,I0B86L(NVO,O$ENK,_RUZ;K MGR5YUKR+N>GBLLIN>O_N5\!F&&I0^$ M^:]Z9RMXNQJRIO\ 75M7B?-64\/S5^89A1CS'53IA#5N.F0PU8V?+7E4] M.,1E%%%<\:,3641M.CHI\=$J9=.)8AJVDVRJ\=0N^VL?8'1[?V7NFAYU1+-O M:J7G5:A2N65.,3HI5I3+T-MOK0L[/>U5[.NBTJVW[Z\^O*,(GOX2,IU(Q'V= MA6@EA5BVMJU8;.O!J5S[.A@3%32O]FG?V0O]VNH2V_V:?Y?M13Q9W2RTY1-' M6/\ AJ9-$\S^&NBV;V^[5ZVA5_X:]*A*5:1E_9L>4Y>'P]\W^JK2MO#:_P#/ M*NHALU_NUMZ;8;V^Y7V^!R^=8Q^J1@&/^F578=!V?PUZ!;:.NW[M%SIN MS^&O7KY)5A'FB>A0C&$CC[>S\G^&KJ)O^6KUS;LC?=JOL9/X:\2,*N'J>\>K M&G&8Q[.J\UG5M[K952;4E2OHZ57FC[QQ5Z,3*N;9TWUB7GR5T=S>*Z[JY?59 MM]?286G"J?!9A6E Q[Q]RUCWDVRK6I3>2M<_?7U>I4P4(1YC\[Q..E"1%2$C@ECI53J$O/]JG?:_P#:KGX9E_O5;AFW MU[M"4)1//E7D;$-^R58_M;YJQ9IMBTQ+K?7-7P]*9W4,;*!T3WZM3?.2L>&Y M6K'VA*^3Q>"ARGOT,PD79G6JCS+5*YO/F^6LR:^;=7P^+PT82/;IXZ4C8=UV MU%O7=68EYO:K/VA*\V/NS+E7YS=LW6MB%UVUQ\.I*E:5MJJ[4K[K+\3RGGU) M'1[EJO-L>L]-26A+]7?;7U%/$QG[IYE21*Z+5=]M3/' M?5*:VK3\RH?+KR:^!A(U]J8LUMLJ'9MK;FAWU2FMME?,8O"/)(]7VGN@[U%-\[5"\U"3;ZVH2.7F]X?Y='ET>916O,1(*EA>J M\E/A>O5PU?D.>5,V(7K0AK'MG^6KJ35]7AL<<_U8TXZL0UE0W/S;:NPR;ZJI MB^>1T4Z?(::/5A/FJO"FZM6SL_,KTZ%/VQZ'M/=*CP_+6;-9_,_RUUO]FTR; M2]B[MM>M'+93B<\I'!36;;ONUGW*,G\-=QZ>!B<,8GV%:KS6>S[JUT?V. MC["W]VOK:5#VQXM3#77I2PWNG/S&%/(>@,\NCRZ?17+&ESF MO-RD4E,DJQLW4QX:Z/JT@E4*]-JQY-.>&L:E"4#G*52QT.E/1*\V43HY0IG\ M534S9\U1RFL26&K:/5+[M2PO4'7$E?[]%%%:\O. ]?OU;AMM]58?O5M6">97 MTV6X3GDKR$*6%6/L;5IPPU;>'Y:^]I93S1/*EB^4R;:%DK3AJOY+U+#"R M5V_V7& 1QTB\CT[SGJOOVTU[Q:\JMAHP/8I8N1=2ZJ[#-7.I-4J7_EUPU.4] M"-8Z9)EW5I6R*]0V_EJI-1]I7;NJI-?K7P6 M.P4>8^OH8B,RW#3W?YJSX;]:E>;?\U?*^PC"J>E+$\L?=-O37^:NPL'55W5P M.GW6QJZNSN=ZU^T<.TXJB35-YR5^C_4HXB)P?69' M,ZQIJOO^6N2O-/\ )W_+7HMRZOOKE=:14WU^:9[E/(:>WD<#?VWWZYV_A^:N MJU)UKFK_ ._7YK*A[+W3S\3+F,*Y2J_EUH3)4/EU'PGS52/O%7RZ-K5:\NIH M;;?1[4Z(T^:)GONJI,C5N_V:U5;FS9*.8YZE.1B4^K#VVRH73;6W,>94C($2 MGNE,\RAW^6JB$?A/6/V3D_XOAHG_ *OWL\ ?\B[:?[JU^"?[)S_ /%\-$_X M%7[U^ _^19M/^N2UUQ/CLR^(Z7^*GTS^*GUT'@!1110 4444 %%%% !1110 M4444 %%%% !110WW* (I***=_!51,OMC:AOO]2:FJ"Z_U)^E3(WA_%/S+_;G M_P"1C_X#7R/#\[5]<_MT?\C%7RG9P[VKXS,JG+4/Z;X6CSX0FAA^6F/;+6JE MM\M5[F'Y:\B,N<_0/JGNE)Y%2*L>Y=49VJ6\=D:L^9&=:[:<3Y_$RY/<'I,M M7=-A6:6L)$;=76^&[#?3K_"/!_$=!_J;!U_V:XJ9O+N&KM=2^2WVUQ]S#\SU MPX?XSTL9'W#"N79Y:Z#0=-WK\U93P_O:ZW1$V15Z-:4N8\?"4.>1;MM*7^[5 M?5=*V?PUNV",[58O+.6;^&M*%27,?5_V?&=,\Z>P9&^[5VSTV5_FVUV=MX;E MF;[E;5GX59%V[:^HPV%JS]Z)\_+*^6KS'F[VE+WC6IA/=.%N=-\RI;.V:&MU[/90ELM<&+_>1]X\VCAO8R M(K:;^]6Q;0[UK*>SVMNK:TI_EKY&M3/HL.31P_WJE2V6AYEW4])E:O*^&1[\ M/?&/;1_W:S9K!=U:LE0NE='MS.6&YC"FL]E10NULU;3PK5*\ME?95QD>?4I\ MA7>ZWT^%ZHW+^33;:;?75&)Y\JW*:J757;::L5'JU#-77&/(=4:YT%L_RU;A MO%K$AO/EJ;>SU]AEN-]B95X\YT4-S%NJ]]IBC_BKD4F9:/M'^U7U%;./=.*G M0]XZ"YO%_O55^U_[59/G?[5->;97Q&.QWMCZ*G[D30N;SY:Q[RY^6H9KFJK3 M;UKP>;G.2I7]XKWE_L5Z\_\ %5SOW5TNL7FS?7!:W>;V:O;P<3\]SW%!^28Z7,5:910O:K/"C'W1Z)1MJ5$H\NK.BG$;'%NJ M=+6K%M#5O[+[UR2D>G3PWM?=,_['3_LOO6PEG\M,>UJ/:G7_ &?R&9Y-3?9? M>KODT_R:/:FOU;E,_P FG>36AY-#PUE*17U8S?)IGEU==*B=*KF,I1Y"*J\W MSU+)47\57S'+*/.0^33_ +/\M788:L/#\M7S"]A[IS]RFVJ3I6K?)5+9\U;? M$>1B8\I%L^6H:MR5%6IR#**?)3*#&04RGTR@D*5>M)2KUJBHCUIR4R.GU)MS M$J)5B-JKH]68UK$[:,?>+]FQ:MNS2L2S^_706TFU:\^N?88&)L6:5IHB)6/; M35:>9MM<49A3PW.7K.S7?^(;E M7WUQ5S;*[/75:E;,^^N?NK9D5Z_",VQWM<1*1/U24C"^QIYU;MAI2NOW:SX; M;_2*Z:P?R_X:_.L=BST,-E_/(HS:.J?PU5_LU/[M=$[;OX:$A^7[M?*RQ/O' MTO\ 9O[LY*\TWY?NUS6I:;\K_+7I%Y#\OW:Y^\AW_+MKT,-BCP<;EO+$\QOK M/RUKG[E/FKT'7K/8KUQ-XG[VOIZ%3G/RK,J')(S_ "Z95B2H'KTSY>5,ADIE M%%91.4?3***U#X@HCHI4K:)'*2QTZHHZEKHB'*6(:T(7^:L^&K<+_-7I827O M&O*;MG]RKT=9EF_RU;2:OLZ%3W3+E+#_ '*K[_EH>;Y:J.]*O5Y"XQ(K]_,K M/JU-)OJE)7RN+J_WK7A_5C[N.81Y2&YN6>L^9V> MK$SKNH^6NF-/EB>96J>VJ!\-B_=ES$52QU%)3HZV/*YO>.@TJYV5U>FWGS5P]G-L:NETV:N2J?<9 M76Y#T;0]57E[3G+(;]/*=:\YOWWRO75Z]O^>N2_P"6U>[A:9^=9M4_>C(;9GI[ MPNBU=MIE2B9U=:]6I'W3Q*TN;E)M!?9+77VTFYJY71+;S):ZA(?):O Q/NGV M>5Q_=G46NW[/5>:'?OIFGNWE58CKDYCZ2)A7-M\U0II_\5;SVN^H7AV4>U.. MI3((9OLU:5AJN]JQ[RC3?]96-;WCMPWN'9POO7=1)5>V?9%3'FK@C$]KVI*[ MTVJCW6RJDVI;*[XQ]TY95N4TWFV57FN:STO_ #J/.HIT_>.:I7":9JB\[?1, M_P M5]_S5]'AHGBUY&E9O71Z'_K:Y>P>NGT'_75^D9'&,9G%/X3H?NU4=?,E MJVWW*BA3YJ_;L/*7LCYBI\1=LTK3T]_^)I;_ .[6?#\BT[3YM^LQ?[M>%F4N M6E[QT8BG_LO,?J'\(_\ DE_A+_L$VO\ Z)6NQ':N-^$/_)+_ E_V";7_P!$ MK79#M7Y#4^-G\I8C^-/U?YCJ***@P"BBB@ HHHH **** *UY_JZ_'/\ ;PFV M?%7_ ("U?L7=?ZLU^./[>R?\75_X"U?1Y-+EKG52B?,\-Y\U.>ZK/1/FJ:OU M65>7LCKC$E>:HG^=:/+IWW:XJDI5J7*=;Y)M MU?"9IA.:)]7@:_)[QZ1X5UOR63YJ]5T?6%N8DKYJL]5EAEKT/POXJE54W/7Y M)F&!]X_8L@SWD]V1[5O5UIRI^[KF]*UM;F)&W5T%M,CK]ZOB*V&Y)'Z_A\;& MM&,ADR;VJN]FO]VM!U_BJ*N&/N'J\GYJ=]GWK7=#$R@<$<-[Q7MG:MZSU+R5K/2SICPM7W MF3Y[*B:QO_AK*N+S>M5Y MKG?51WKY*IF56?Q'BRI\I%=)OJND-6'FH3YJ^:Q-25:1T4J8):T[[.]6X4JQ MY/RUQ1IR/2C3,?[/\U3?9_EJUY/S4]T^6NVEAI3.>I'E*B6WRT;5J9]U0I"V MZO0_L^4SE]MRCW2J[I6A]F9UJ)[-J)9?*,0]I&91\FKUM;-0D-;%FB[4KY_$ MX.<#U<-*)#:PLK5T>E;D6LQ-J5>AO%AKYRK0D?68:I&'O'06TWS5M6URM%B:)]C@<7$Z"F25%#-5CS*\^-.1]1&O&8RWA9VK8MH=E4K.M MB%*^URN,?=.>J6K7O70:5#\U8MLGS5T>E)\U?N&24Z7*?/UY2.BMH?EJ6:VW MK3;9_EJ5]SK7Z1&A0]E[QRQE+F,*\LZS+FVV+6[>1M6/\O]C?-79ZDBNM>?ZVJHSU\;4C*D>9BZ\H%2\\0[%VUA7FO,]5 M+^\V,ZUA7EXU:X;'2HR/A<=7C,L7^L>=6#>7GF5% M,9R'S3;ZH[_FI[O45>#4Q,^8BG1C$NPS5IVU7OM*I%52S:1K]6B'VG94/V[_ &JS[F:L]YFW5Q2S"4PY>0WG MO-W\50^=65]J]J>DU>%B92F=M*K$V$=:=YE4H7^:I?,KS(Q/0]J3>91]O9/E MJN[K5=W^:O3I5.0YY2-5-2:K%KJ7S5A>94L,VQJ]6EBY1ES'++WSI4OZF2\K MG$NJE2ZKU8YE(Q]D=']LIGVRL+[8U'VR2IEF1?LC8>\JI-Y:HM[/7F5\ M7SQ.NE$N^=43O4*(U/>%J^4J2YYGJ\ONE2:A-U3.E0R5UTZ9Q2'U+'45/KKC M2YB)2'25-"E5ZG2ESCDA^:M" MV1J;##O:MBPLZUH2]\]*-#G+6FV;M75Z;IK?)\M1:)9K786UNJ1)7ZKDU#G. M?$T.2)D_8?\ 9I[V?R_=K=2%7IKVM?HU#!QY3SY1]TX^\TVN7U73=N^O2KFV MKDM;MJRQ&!ARGSN)ER'D^JP[&K$NGV5UWB2SV;]M<92J>WS2G$UK.\;Y*Z"S?G$J0ILJ6.C77YYBZ?O'JTAGDU,EG4MNN M]JU8;/Y:]#+\#[4RJ2Y3/AL*'TVMZVLUV_-5C[''7TO]E'GRQ)RGV#YJ)K.N ME>SBJE6)K3K'+S0[*KUIW\.RL^2OB,3AO9'JQESAYE,_BIF_YJ MFCKQY1.B(>73D2G^917%(Z(CZ=3?,IWF5U4S8DA^]6YIKK7/^96G87.ROLLK MK5;WKMK](HXGW3Q?9$OF4QYME57FV4SSM[5=2O[H1Y M8EMYOEK/N;FG3/\ +65_\ ]JL1[K943WE?)5Z\ MX2.N-0Z6WU#_ &JT[;553^*N)AO*F^W4OK,N4]"GB>0[K^V_EV[JJS:K\WWJ MX_\ M)MWWJ/MW^U7A5ZDIR/4H9A*)W%GJ7^U706UXLD25YC;:EL_BK;MM>V* MB[J\*MA)_0S*/VSO8;Q4:N@TW4EKR?\ X2'8WWJT[#Q)\WWJ^PR?%RP\ MHQ-ZF.I3IR/8(;QG_A6I7F;^ZM>>V'B=4_Y:K_WU5U_%"_\ /5?^^J_4L-FT M81/%^LQ.@N;]5W[JY?7M57:]8E_XG7//(Y:F,YR5[JF>=57S*/.2O.E3/,E7-#SJM M6=SLK*\Y*/M.RN65,ZJ.)C"1U"7*[:J7,RLKUE)>?+0]U5&G MO=5"\U7RG#*I$B\FF.E3>H7[E=! MX@4444 %%%% !1110 4444 %%%% !1110 4-]RBFO]R@!E*_W::M/;_5TXB_ MY>#%J*Z_U9J5:BN?]6:B1I'^(?F+^WA-Y/BI/]VOE33;Q?-KZ@_;_?R_$7_ M:^/+"_9):^.S*GS5#^C>&:_)A#T;SOW59]YJ'R[:SX=4_=?>JO-J45>;&F?? M_P!H1Y"I>3;VK/FFV+4MS?Q/6?,_G?=KMI'SV)J<\N8>DW[VNU\-S;%KA8?O M5V&@HVVJK_"=>7_$;NI3;UKG)D^:MNY3Y:S'3YJ\BA\1])B8_NC/\G]ZE=-I M5NVU*S(8?.F2NKTJS^5*[?:Q]IRG+@<-+XB[86WW*V$MM]16\*HM:%G"SUZ> M#Y9U3Z_EY(&[H>EJZ_=KH+?2EJ+08?W5:7W):_HO),MI>PYYG@5:G)(S[S1U M>N*\0Z#]^O0_,5V^]63J5FLU:YMD]+V7/ YXU/:RY3QJ\TWRY?NUF30[&KT# M6+#8S_+7&ZE;,DM?@N:4_95>0Z*V&]WF*+VV]:@W-;?QU=MG^;:U9VL?>KYF MI'F,>7D)H;G>U74F^6L5&\N*KL+_ "UY-2@;4ZYL0O3W=:S$NME/^V*]<7LC MTO;DLU5W2K:NKU#>?(J;:UB<]27.95_;;ZKVUM_LUK(OG-5V&P5*[8U#@EA. M_N M5AA>KC3]X\?$5_=E(Q?%5^JQ5YO?WF^MWQ%?^LWJ)&U"7 MO&Q9P_-6Q#9[U^[638/\U=!9S*BUY521]M@8^\-^QLE5WM:V-_RUGW+_ #5S M^U/V^:JDR?-6Q, MGRUFS(VZM>8\RI3*[PU7V+NJZZ-MJ)$^:M>8XO8%BSAJQ,GRU+9P_+12VVO,E$^EI2]XT+#2?FKIK" MPV*E9.FS?+700O\ ND:N*'Q'U-#X29$V-6Q9NJ;*Y&YO-DM:&FW_ />:OI<' M[GO'3[?WN0]0T&Z5-E=0ETKK7EMAK'DK]ZMBS\0L_P#%7[-DN>TL)2."M'GD M>@33+M^]7+ZW\_\ %3%U)I/XJJ7CLZUY.><31Q'N1/=PV7\\3FM2MJPIM-WK M747D-4714B>OR+$XSGD=%3 \AS4-BJ2U=2'95>YF56>JJ7[-7SF)]\RI\M&1 ML(BU82'Y:QTN6HFU7R?EW5X_L?>/2EBX1IEB\3_:K$FA^:F7.J[_ .*J7VSY MJZZ5/DD>-B<3&<#"\2?(KUYY?M^]>NX\3W.]7KS^X^]7UN#/R/.9>\,J":I9 M*ADKW?LGQ,I%=/OT_P NGHGS4[RZR.+E(O+H\NI?+H\NM9&W*1>73XZ=Y=&S M;1$.4***5:ZXARD\=6(ZKQT]'KHIRY"N4T(9FJVDW^U68CU82:O3IXWE+]D7 M?.J)YJJ/-37>BOC.D MWEM5VUN6_O5CU8AFKDJ1YC:A5Y#;^W[-E:27_P"Z^]7+N]:%M-^ZKSY4SVJ> M+D:WVQO[U'VZJ*3+MIKW*U/*>A'%>Z:']I4R:\^6L=[JGO<_+51BIKE]]5*[HGS5>MSC*FCJ&2GQUJ<48FG9_?K=MI-JUS]FZI6Q"Z.M<]4 M^EPDN4W=-O-DU=1#>>=LW-7#VWR-6]IMS\R5XF)^$^XR^O[QZ5H?_'N*VD_U M-N?N+76IMVU\;6E[Q^KX&7NE+>VZM"'YUJEL^:M"'Y*Y*T?=/;HR]XL; M/EJ%YM_RU8W^8M1)#^]KS.8]6,>8KW,.]:KNOEQ5NO;;UK/O(]D5==*1Q5Z9 MP^O.NUZXJY?][75^(=VYZY1X=]?4861^6YO_ !2+[3L6G0S,[5%-#\U2VZ>9R\_*=MX>M?EKHDMOF^:LKPW"VU*W;GB1.E5W2M+9NIKV=R,G['O^]3X85AJZ_P M M95Y<[*Z/B.*I[AIQWG\-#O7/I>-YU;$,V^&H]D13KC)KG965 MB;JVB<^(J>\6+::K7\-543;4J/71$RYA[[J$2G4(_P U=M*I[QSRB7K/Y*Z+ M09D\VN7MI-S5IV%SY,M?39?F'U>1K&ESQ.[V*]2I"M8EMJN^KW]I?)7ZU@^) MJ4*7O'G_ %'GD6IG\F)ZKZ)-OUR*L^\O]\-'AN;?K,5?.9EGL<1*7(5C\-[' M".)^L'P@_P"26>#_ /L$6G_HD5V@[UQ?P=_Y)3X/_P"P1:_^B5KLZ\26Y_&F M(_C3]7^8^BBBI, HHHH **** "BBB@"O>+OBK\;_ -O;Y/BE_P !:OV1F_U) MK\:/V_'\OXJ_\!:O=RN7)5.W#:RY3YBA?YJ*BMIEW/4OG5^F4Z\9P]X]B5/E M)8ZBF?YJ?N6F/MW4I5XQC[H0I\WQ$3[MM49H:TY*I;-TM>56C&M'WCTZ7- J M;&W5H6=^UM3_ +.E4;GY*^/QF7T9GK4,5*C\)VVB>+?LRIN:N]T?Q:MRJ*K5 MX#]I9&^]6]HFO-;2IN:OSS'Y7'WN0_17R MOO5S^L>)U1?O54<)5C\1WXC.<-3C[IUOV]=U7DNEVI7DZ>,/F^]72Z;XG694 MW-1+#2D<5/.J'-\1W'G*M,FOXH5KC[_Q4JK]^N=U+QG\OWJZZ&&E SQ>=4N7 MXCM=2UM85?YJX?6_$GG;]M93)*/XJ/;\WQ''4+")NJQ"FRJ M\-:=G#OJ>8Z:)=LX=]7OL?RU8L+6N@L]*\YD^6OK)E \W31&JVFFJGWJ[-]'_V:S+R MPV5[=3(J=*/NQ/G_ *Y+F,)H8H_X:KS0J_\ #5VZ39539\U>)6RTZ(XDI/;; M*9L:'YM]:#I52Y^[7R^+R^/*>G0KE6:\9*KS7[57O)MC5GO=5^>X[#S9\U?,UZ',?1X',N3XCUV&\5ZNI M=5P^E:QYW\5=1;7*O7BU*'*??X/,(53>MIJVK.;?7*I=;*TK._KMPU7V)[T: M\9Q.PLYE1DKJ]-D5Z\_MKRNET>\:OV+A_'4Y1]XY*D8R.VA^>K'W4K/LW^6K M%Q,J+7Z+4Q,?9')&,>8HW[_+7*ZA>;&>M#5-25=_S5P^MZK\K[6K\XS+&>:]JN]GVT_5=5;?]ZN?N;G?]ZOGXUI5OB/C^,1ZE2:JKOMJ+S#42C(UC(VH9%2F7+N]9\-Q5CSMZURR MIE^TD#O5>2IJADJ/=B$HQ&TY'IM(GWZ)2,HQB6T?Y:-S4W^&BN21U1D'G4Y' M7;5>GQT%ECY:9_N4^F5?, ]':I4=JKU8CK3VLBHDWG,E'VKVJ%WJ+S*GVDI& MW,:"3;Z?'5&%ZF2:N>4BJ,O>-*.K.S>M487K0W_+6$8GO1Y>4S[GY&J)-M6+ MRJ*/\U=]/FE[L3S*DHFA#;;ZF^PU8L(=ZUL)9[Z^[RW+8U8^\>/6J'/I9LU. M^PM740Z:M7DT=?[M?5T\GI_RGCRKR.,2P9:T+5-E=&^@[VIR>'ME<6-R'ECS M0B>M@\25;-%W)6U;;:KII7V;YJ?OVU\K3R^K1J^\?:4L3'E.HT=ZZN&;S(D6 MO/+/4O)K=MM;^5/FK]-R2O2HR]\Y<16]J=A"^Q:;->+'7.)KR_WJBN=8W+]Z MOOJ>.I6<3_=^2MJ\AK'O$VK7YSFU>,XG12H<]JD$D*HM,MD^:GO-OI]KWKSZE?D.OV?-\)T6CS5UVG_P"IKB=-FV-75V%Y M^ZKKP>92HR/?H8;VL/>-69EVUBW+KNJ[DK/N4JB^MU5FUO=7T^)S>$SX*.&Y!URC>;NIODLZUGS:Q3DUA=M>!+'4 MIR.V,"*\=H:K_:O:F7EYYU9[S5XN)QT8U/<.CV<382ZJVEXNVN<^T/4R7+44 M\RJ'/*C$VIKQ:SYIM]1>R MJ5I>\=?NQ(;"W^:N@MH?EJE9V>QJV(8?EK['+<-RGF5I%=X?FIZ0U:^R^]/\ MFOLXT?YCQY&>\-5V1=M:LR?+6;<_(M>3F%./*;TN8P;]5K N?O5M:E-6),_S M5^49I'0]ZA_>*M6/X:AJ9'KY21Z$9#/,IZ/3)*(Z\^1MS$OF45%3_,J_>#F) M8ZMPR;*SWFH2YKV,+7Y#GE[YNI=5+]N:L+[5[4?:'KZFAF4H?$<%2G$Z!+RC M[8M8/VAZ?]J]J[)9L<_L(FG->5F7-S0TV]:JN]>-7S*4S2-&)%--4.YJ?)46 MZO ]O*?Q'7RQ'[CZTY)JAI_F5KS&,I#_ #J/,J'S*?7%]KF+C4)EDS5A;EEJ MI3'?YJU]Z1?MY&@]XS4]+]JS/,H2:KC&, ]O,V(]29/XFH_M67^^U97G4>=7 M;&O(OV\C0?4FD_BJN]XU4?.--::N6O4E(QYRZ]XU5WF9JK^=NH\RO,YI$^UY M1_G4;FJ'S*/,H%[4F\XTGG/47F4>942B'M2QYST?:'JOYE'F5ERC]J6/.IOG M57\ZCSJOE#VI8W-3'FJ+SJ9YE'*9^UD>Q_LEO_Q?/0O^!5^^_P /?^19M/\ MKDM?@)^R/_R730O^!U^_?P]_Y%>S_P"N2UT1/FL=+FD='_%3U^Y3/XJ?6IY0 M4444 %%%% !1110 4444 %%%% !1110 4-]RBB@"%?EH;YDHHZBJB9&T_=5PEF_[VO0/#W^KKS<34/I\MB6[GYZS M)K9G:M.::JZ;7:O'C+DF?5U(\\ T>Q:1OO5V%A:[%K'TM%KI;9/EHARSK2D> MK@:<8TXCT2M6QJDFVI89ME>SA9;(FKZK,J]"&%D>9AJ M;VKG-0VR5_-.;8FE.O(^H]V4?>.5FVPRNU9F MI?.NZK>M?N?NUF>9YUO7RGVCY_%U.3X#/AOU1MM:=M?JR?=KE+]WAEW5+INI M?WJN5,^?CB995UX?EK/N4V;ZJ/OG14]SX M1_VE7J5/FK%MMVZMVSJ^6K$B-253X@\E7^\M5+RV7;6LR+MJOLW5T4ZG)\82 MHTSG+JV9U?;68^Z&NKFMEW;:I7FC^=]VO3C7ARGD8G#1^P;*I/?;&W;J MT]2T&5*Y^YT>?=1'$Q/GJ]+$0^$N_P!J^LFY^=JT;S_7O69KZ.A&,3\MQTN;XBNWW MJB;YJEDJ&O0/G)2(Y%Q25+1Y=8\TN8QERC:M0S;*K^73_,IRCS!0ERR-:SN/ MFK=LYM]_SM7CR MB?61Y1Z6?RT;U2G)-43I\U7&(2!TW4SR:FI[_3;MJ\[_ M #4Q(?WNZKYCDY2N]G51[;9+71PVWG52O+;RY7HYB:E&,8^Z,MD^6HKS]VM2 MI\M5[F3\9\E1[:GDJ&NO MWCPI#:***U("H:FJ&ID92"B2BB2H]XR&T444>^'+$L;]U/4[:ACJ6CWS>,N4 MMPW&VM2TO_+-8<=6(9MC5SRCSGMX;$\AW%G>;UJ)WE>7[U9.E7_S)6JERKM7 M%4IGU>$Q/.=-HCMM2N@FOOLT5K/N;E]U5/MFQJVY3Y*IBY-NJ;[9\M8_F-NJ7SGK:-,\Z5>7(9^MS;ZY*Y^=JZ757WUSDR?-7L8:/ M*?$9E[Y2;[],JPZ?-43I7JQD?*5(C$^_4U0Q_>JQ'6O*91B-HI_ETGEUSRD= MDJ8VF,FZI?+I=M7&1/LXD.W;3*FDJ&2M>8YY$T=.J*I8ZVYBR:.G>942/3_, MJ.8U'4_S*9YE-HYBQWF4VF>93T^Y4$$,E-ITE14$91'71RQ.N21[6$D::(S_ #5L:.C; MDK,MYE^[70:?MCKRL1RGVV7Q^&9V>ES*BI700W_RUQEG>5MV$U?*5Z<>;W3] M3R^O[IT"/\VZK'VQ4_AK/1_EJQ##YR[J\JOSSUS^S;71W/[[YJQ[B%:^BPY^=YA3C5ESF#>?.WRU;TV']ZE/>S:9JT--L]D MJ;JZZG+RGBX6,IU>61Z!X;L]ENC5L7]GYE0^'D5+=*UKE/EKQ*DHQD?JF$HQ MA2]XY_[/\U6ON[*>Z?-0[JE3RQF;?"6[9ZL.ZJM9D,U2ONKGE3.J-217N?G7 MY:Q;RV;=6Q,]5'F6JCRG!7,3[,\T]XF=&VTR'=4S_ '*A1_FHC(/>+>_Y:AW_ #4_ M^&J[_+7='W??"4O=-"PFV5H?[2UCV;_-6KO5%HC+F^([:-2/(7K:YV5JPS;U M^]7'W-_LJW8:QO\ XJZ929-/$QYS?F^Z]6_"4V_7HEK'^V;UJWX/N?\ BIHJ M*$_?Y3'.JT?JW,?KM\'/^25^#O\ L$6G_HI:[)>U<;\&_P#DE?@[_L#VG_HI M:[)>U?=Q^$_B/$?QI^K_ #'T444S$**** "BBB@ HHHH AN/]57XM?\ !02; M9\5?^ M_Z'7[2S?=K\4O^"B/R?$Y_P#@7_H==V&ER2/3P7Q'RO;7GS/5C[96 M*C_O:G1Z^B_M#DB?12C[IK?;*K*OO$,LW\587G5#]H^:N?ZG&9:5>;XCJ+CQ/+-_%52;56F7[U82_/[4_SME:QPD1ULRJR^T:K MS;Z?YWRUC_;*/ME=$:?(=3?,K/\ ME"757*01KFA3JI(]/\ ,KGY MI*OW3+Z=(^7QTC"N85^>L> M_MM]= _W*S+S[E>CBZ-/E/D)2ESG)7]LJ+62Z;&K6U2L&YFK\OS3$PP\N0]; M#1E./,$TFRL>\F^_\U%YE&40O'^:L^2K'WJ/+KX?%U M/;2/3I%&2GHSI3W2F>37FRHLYOFKE--U+?72V=RNVO,Q.7R@?H6&QT91.HL'^ MY70:;<[)*X>&\7;6M;:EY,7WZ]'*Y5JN]S\M?.5)2K2/*K9E[I:N7\YJS[E*L)-39I-]>Y@&H7AJ)2D43M MB5Z(ZE=*;'7.:\I+3)*FCH?YJGF+Y2&K$=-\NG51K&)$[U%YE2R5%)092#S* MEA>JE/CJ9'/&7O&W"]2O=5F0O5N&HB>W&I[I8?YUJO"F^6K#I\M11KYM@ M?XIPXGFY3HM*2N@A3Y:YW2IJZ*%]ZU^SY3&ER'SM7F+=LE:$=4H4JUYE?<4* M=,X2Y#]ZM)(?EK/LZU5^Y5RJ0G[AW4*?VC,O$^6LB;[U;M^GRUB3(U?,YA@X M_%$^BHR*\S[%IB7S+3YD;;5+YMU? XFO+"R]T]",3034FIW]IO\ WJI;&VU7 M=&I4\YJP+EANLFY>OG\7 MF7.='U(QWMOFJOJI,E?&UL3SR#ZMR&8D-7H;:J_D_-5U-M<G,_/J^&Y!CS?-3TFJ&BI]K M,\R);W_+46S=4,=3(]7RRF:R')#5M+.F0S582:O:P>&YSSZDAZ6M/2V_V:L0 MU=1*^PIX+W3S_:F?#;?-6G;6U"0_-6K;6U>GALMYS*6)(DM=E6H4JQY-3)#7 MU^%R_D.*5?F&)#\M5YODJ\Z[%K&O*O$_N2(RYRO-YN:_/\ MTQLHGJTHE74)M[5DS?.U7IGJI-7YEBZ_M3TX^Z1>71]VF24^.O'D7S#'FH1Z M'2F1UQ2->8L;_EIKO13)*UY0Y@\RBHI**B,N4CF)?,I_G57IU;2J2D3\182: MG[]U5ZE1]M+GF5&)-3)*/,J)FHY9%\H25#3W>F5<9&4I _WZ;3J;Y==$8RF< MDI!3J$2ID2NZGAI3,I2Y!D=,JQY='EUV_49D>U*]-D^[5KRZKS)\M<]3#2B7 M[4B\RF>93_+J+;7%*,H%Q?LD_P#)=-"_ MX%7[^_#[_D6+/_KDM?@'^R+_ ,EVT'_@5?OU\/?^19M/^N2UL>%C/B.E_BI] M,_BI]:GF!1110 4444 %%%% !1110 4444 %%%% !1110!%11151,OMC5Z5' M>?ZNI%Z5'>?ZNLI'1'^*?F/^W:F[Q4G^[7RK]@7[/NKZO_;G_P"1J3_N=BUB76F_-5O3?W M-IDUSL6F)<_-7G\I[_M(G0:;)LKH(9OEKDK"YV5T% MG-O6HC[M3F/5PE0TDNJF1ZJ(FZI:Z_:GO?%$O6USY;5L6VJ2HNU:Y??MIT-T MR-7U&7Y[5PAY52ESG8)JLNRLJ_U:5_EW5GO>-Y58MY>,[5]14XFEB*7)S'G^ MQC"1+?W[;JS+R\^6F37/RUS]_>?[5?'UX_6)]PS5+#<[&^:F^3L5ZSYMR-1]6Y# MS)5/>-J9%N5K*O+!4B^[5BVFJ*\=W;;7+[/WC2IRRBOAO%J.8/8%C37^6JFI?ZUZ>GRT?ZZ6HYB)4C/IDR?+6[]@^7=MJ ME?)LBJXR(Q-/]T??K-FJ_J7^LK/DKVJ!\+7^(KR5%5B2J\E>@>%(9)3:> MRT[RZ.8QE$BHISI11S&4HR&^73*?3*">4/+IGEU,E._AH#E(HZE_AJ/RZ=Y= M ^61*OWZ?Y=0^75Y(?W59'33C(EL_OUH0NVZJMA"WFUT5M9_+6,HGU6"C+D+ M&FHSUNI;>F[VKYO%^X?_AV5UMY7+ZQ-\KUZ%*ISGRN84^3WC">X\EJHW]YO6HKF9G9ZRKEV MKUZ1\)BZ\N8AN9OOUG^=O:K%1>77H71Y=.I]GQT%\Q8\RF4RBIYC7F&R5*OW*9 M3:@!TE14^BK#E&5+'13ZCF,AG\56(:KR5-#67,=5.):IKI5A$WK3O)K'F/6C M2YHF4R5%Y=:KPU$]G71&H<-2@9GETVKLUOLJNJUKS'%[(91_%3]OS5*B5E(N M-,>B5H6:541*NPURR/2H1Y#6L(=\J5TMM#\J5S5@_P M=1I3JGWJ\2M+WC[G M+_AB;%G;;8MU78;GR:KIZ>A3S+V,N8[#^U/]*^_5M]87=7$_:/.^:B&_WMY6^N3V!T?V MISG1WES]J:L^:&JB+N_BK3MK;Y:/8!SRK$3I^ZK'N7_>UUK[?*VUB7]LKM75 M&1$J?.5[!5K3AA7S4K*AMOF^6MW2K;YJTE[Y&$PW+5.ST2'_ $=*VIH?EJEH MZ?NDKI;:VWK7?E^4RS"4O[I][\%*)RLUM52:V:NPN;/_ &:I36'S?=KZ+_5V M5*)Y$JOO',PHR-5MW^6M.2PV?PU4FA_AKX['8.5&1Z=#WHF)MC[+[ MTR:'Y:\242*T3FM2MJQ$^26NCUB/[ZUR_EOYU5$^I7.>AREE/N56N?D6K=M#^]2HM8^ M26NJ,N"9G?Q-%7(/>?-]ZNM^&]RK^((J,-_%.+-9J_F4WSOFK7VW+$ZH_";]G-6PESO6N7MIJT(;_ .9*^@P.)C]H MSD;'F5,B52AN=]787K[*A4I5OA.&036V^L^YLZVD=:BFA5EJZF"YRXU>0YQX M=E5W2MNYL]]9DUMLKY+&9?*!UQQ$9&:Z57>M+:M1/;+7S_L)?9-^8S-S45;> MW7^]43IMKAJ4Y'+S2Y@2;94,TV^ATIM91C(UJ5.8**/+IWD_[592")%)3T>A MTVT>76)?,6H9OFJV[UE(^VK".TU7&)T4ZG\Q:1ZO6TVRLS[M"7FQJZ(R]X?M M3L--U+8R?-7:Z/K6S9\U>56U_6W9ZWLV+7Z!E>,C1Y>8TC7B>VV&O+M^_6G_ M &JKQ?>KQ_3_ !(U=!9^(=ZU^NY7G$?M2/-QKJKS;7,W**C/7YQ4K^\=TJ,8%?S*>C[UJH[T)-LKGE_,&S*K#XCIH=5_VJT/[6_<_?KCTF\E:/[5;;MV5Y4LKY M/LGU%//(\OQ'2W6H;U^]6.URN_[U9DVI-MK/FOV1:\:5&K"7O$RS:-7[1O/< MK3/.WM6%#>,]:%M-7K8'!2G(\S$XXTD>K")NJO"F]:O0_)7ZAE^$C"/O'RF) MKRF:5FB[4J\]LNVL^V?95I[G8M?7>PAR'F^U*MY"NVL>\A5UK0O)F>J^S=7S MV.P,9_"=M*IRG,WEA\U9\UML6NN>SK,N;"OBL7E,OBY3TZ=:,SE'3YJ;Y-:5 MS9[&JOLWM7R]3#1A+ED5(J_9M]._LVM:VME>M!+!=OWJ]O"9;[6/NG!*I&)S MB:;1]CKI?L*U$^FK_>KHJ9;+^4/6C$BH1/FJ5(6J9(:\R4CHB,2&CRZL(E& MS=61KRE?RZ95ATJN_P M',6-DJ&2K%1.E6<]2)7DID=/FH\NCXCA^&7O%B%Z MNVWSUFH]:%FZ_P!ZL9>Y\1Z=&4382'>M0S6WS58A9=M/?YUKNH5/Y3ME3YX# M+.;8U='87GW*Y3[KUH6UXRK7Z1E>91HQY9'BUZ!VT-RM2^C\1M]:PQK.FZL^:VWU8AO_ #OX:M?+MKY^I7E]H]&/+5^$QTLZ M:]G6D[_[--KS95S25")DOIM-33:VO)^6HD1D^]6,JTHEQPT>4I1Z2TE2I9M; M-MK8M=M$R+(VZI]I(UIX7D*7S;:HW/SJ]:N:FV[J^@H2D?GN._NE?S**=L3[U15[$>8^7ESCJ'R=E/\ROJZ7N>[(\F4C0M4WUJPI6/;35H)>?[-?48.5.)Q5(R-:%*L M>36?#?U=^V;Z^EIU*4_A.3FY?B&3)\M95Y#OK3FFJC--7)BZ5.<>4NG4]XY? M4K/Y7K N;;97:W,/G+6#?VRI7Y9FV D?04*T3E9DJI-6K7372I:BFKBY>FNBU<>8U*_F4ZF^73HZLY IZ)3- MGS5;MH=]>UA*?.<\I#X8=]6DLZFMH?FJZB+7V&%PGNGFU*D>8S_L='V/Y:T_ M+H\NO;^I^Z8^U,=[6J\UML6MIX:I7,/RUX]?"%QJ>\8[I5=TK0FAV52=*^:Q M-#D.WF*]%%%>%*,BPDIE/IE1[.07WN8*AO?]75BJ]RGRU,C6G\9^7_ M .WG<^3XHW?[-?)]GK'^U7U!_P %")MGB;_@-?&MAJ'S;:^7QU.4JA^^\-XV M,,-RQ/0+#4F>6KNJS*\25R^FWBPMNJWJNI;UKPI4Y'Z13QL91(9IE1JT[:\6 M2)*Y1[SSFJ:&_:'[M=$:B42XUHS^$T M&FWK42/Y;5+;6RNOWJ>]LNW[U8\IK^\@6+:\KH--OUKAWF:%JM6>JLC?=KGJ M4)M>?'FC+WCZZABZ;47[U7'XOE[21X6+E[7X3*=-M9.JO^Z>NFOX8X8MVZN4U M)U=7KHPU.4I'R^85(PI')7EX_FNM2Z;-OK/OT5+A_FI^FW6QJ^@]E[I\!&M^ M].EA3YJZC2]2^S,BUR]A-O:K#S;)4KQZD3['!XFG2/38;]9HJFMIM[5RFDW[ M/$JUTM@OR[J\R6&E(^TPF,C(U8?NT]W^6FKM1:EAA6;^*KC0Y3Z*,NKZC#9'5Q$.>G$(U(G-7,.Q:Q)OG:NVO--_AWU M@W.E^2V[=7)B?*-2(&/-<_PUE:E;K)#NV_/6[A&9R]YIOF+]VN9O]-7=7H=XG[K[M&K'QN882)QEY8?-6> M]G747,>YJB_LK>M>U&N?#U,#S2.2FM:I2Q5TMY8;*R;FVKNIU.<\'%X.4)&/ MY=%6YH=E5'^6NT^:J1Y)CXZECJ*%MU6/+J(Q]XN,N4FA^]72Z:Z^57.0I6[I MJ-MKEK1/I<#S&W9O6A##OK*MGV5JV/*)]GAI1D6TA;=5K9\M36:;ZT/ ML=M;^+;NK,UCY+>KIR]XY,;_". M"U+_ %E4G^Y5W4O]95)_N5]'0]V)^:XGXB&2F>74SI0\.RMY2/%C'WB%X=U/ M2%JMPVS?W:NI8-_=KGE4/2IX.4S$>&F^36T]G57[+[T1KF53"R,SR:;Y1J^] MLW]VC[.];>U,?JLBDL-/\FKJ6V^K"6?S5'MHEQPE0S_LOO3TM:TDM:F2SH]M M&1T?5)0^(S$L_N5L0V'^CT0VWS5IPOLBVT2D>A0PL2C9V&R:N@L[;Y:BTFS: M:X1=M=7;:/\ +7/[>/-R'U>#PONE'3;;YJ[;P]#L:L2PL6W?=KJ-*MFAKQ\; M_*?=Y7AHQD=GI6U%J6Y?YJS+.\:'^&KWG--\VVOD:E"7M3]4PE2,(\H.E0U- MYE0S2;*XJD>69-24N8S[]_EKE]5VNKUT&JW.Q:X_5;GY7KT\-&1\SF5:G*)B MWB+&U8]RZU+?7C;ZRIKG?7NTXR/S/$U(\_*2[EJ+S*8CT5UGG2Y9!YE,HVM1 M&C?Q5<>8(\I;AJ*\F6AYME5'1YFJ)2)JJ$WWJ].)XE4AJ6.HD3YJL1UKS'F74WDT>7FH-8QY_A&4^F[:DCH+]D1.E2PI3ZL0I64C MHIQ+%LE6/+H1/EI_S5Y]27O'NTH^Z0NE'RT^2J[[JN,I$5.4BN46J+I5YTW5 M"\-=$9>\>74HE7RZE1*?]E]ZE2&M9$1IR&>73Z?0Z;%KGD='+R&EH_SM74;/ M)BW5P]A>-;25MS:VTT.W;7GU*K<-S\M$J(HU8FW9WGEUJI?US2W*I_'6A9S+-_%7+*)Z]# M%\IT%L_G4Z:SWU%;0[%3:U:J0NZUYY]+0Y9Q,]+/R:UM-3YJHW/WMM:>E(NY M/FKTJ7*=%./O'9Z4GRI75V^W;7+:;)L6NFL7WK7W&12C&3C$]V7-[(EF2J_D MJ]6'^:JZ.V[[M?IGLN>'O'@5)>\,FLUVUA7D.QJZ=_\ 4UAWZ;]]?G^ M_(]_"5(\I@W,FUJI33?+5V\AK%O-T-?E5>F=LH^Z5[]?.K)>P7=5B:_V?>JN M]_6-*)\[B:E+FY2*9_LR[J+.\\RHKS]]$]0VW[EJUK1/-C[LN4Z.'YUIDUG^ M]2K&FIOCW5>2'>W^[7DRD?2T*,IQ*B0[&2L3Q)-L:N@?[]<;XPF^_77AO>E$ M\W'_ +FE*1REYJ7[U_FJO;7G[VLJ\F;[11YVSYJ^EC0YC\PQ&.E&1W6FZK\O MWJT$N?.KA]-OUW?>KJ]-??\ QUA6I\A[V$QL:L?='ONW/72_#2;_ (J.*L1K M;Y?F_BK;^'L*P^)HOFKDP_\ %YC/,Y5/JY^TGP>_Y)'X-_[ MG_Z)2NT%<1\ M&O\ DD'@O_L"6?\ Z(2NW%?>1^$_EBM_$EZL?1113,@HHHH **** "BBB@"& M3[IK\3?^"BB?\7.E_P"!?^AU^V4GW37XG_\ !1C_ )*=+_P/_P!#I2V/2P?Q M'Q[_ !_\!ID=2_\ +3_@-5ZP/IOL%B.CRZ;#5B2MI?"=$?A&(^VIH9FW+5:K M$*+7H4I+LK]-P-2-:,3RJI8FL(G7Y:Q[_2OEK>^T)52ZF5UKOQV7PG$RIU# MC+FS:-JJ.E=!>)\U94T-?FF+PG)+W#UZ=3F,J:J]:$T-473;7S]:A(VYB+RZ M94SI3/+KR91Y Y2OYE'F5+Y=1,M90[U,9 6T=TJ5+AEJDDU2H_P U>U1Q/(9&K;ZDR5K6VMLO\5=LKW M<)F4H$53K?[<9E^]47]I;_XJYG[7_M4?;O\ :KTZF<2Y3*G$Z9[^C^TOE^]7 M,_;_ )_O4?;*^:Q.+]M+F/8I5^2/*;%SJ&^LV:YWU4>X9JB\RO$E+WC65?F) M7?YJ(Z9YE"/5\WNG%]HMPO6A#-]VLI'JU"]>KA)1ZM0S5BI=5:AN?\ M:K[*A7.>1O)\ZTZJ5M>+M^]3_M7M7L4^3X@C(M57F3YJB^U>U1/\6+/=MK5MD^6LRP^Y6W;_=KH MP,HP+E&CJO"GRT[?MK[.AC(\IS2PTI&LCKMH=ZQ/MC[JT+5]]='] MJ&T<"2I#YC5-Y.RKMA;;ZE>UK6.+YSKCA#-\G?52:S5UK=2SWU;_ +$WK1*/ MMCHCA.0\_O--_P!FLQ[-4:O1KS0?]FL&\T%O[M>+6R;G]\XJGN'.PPJE:$,* MTR:P:%ONT)N1JBE"6',?8\Y=>UJ)[6G_ &S^]1]I7^]7?[>ES'/4HR*_V7WJ MO-;5H>SWU7>Q_V:V$DWM]VG3(NVOSW-,!2C+W#Z M;+ZDJM/WCFIH=E5]GS5L7G^[51$W5^=XNER2/?IT^8K^31M:M#R:/)KRN8[H MT#/\FJ\UM6QY-->V_P!FJIR"5 R42J]S'L6KSIMJC-)OKHE*)YE3W3-W_-3W M^Y3G3YJ'V[:VIQ/-J;D4=6D=XZKHE31U52ASD1JKC-[)_%0ERR-]ZOI<-G3RG3*O[QUL,T6VJ]_>*E85KJ6YWO5 M2B:RJ%A-2^:K<-YOKGW^1J?#>,E7&D<]3%R@=$[_ "UBZE>;%>J\VJ_+]ZL2 M\O\ >KUVTJ/O'BU\PERR(K^\WUCN_F-4MR^^JZ)7T=&F?)5:_,&YJ$^:K'DT M)#_LU[M"A*9Y,I$L*?-6M80U1MD^:MNPAKZ_+<#*1Y]:OR%V&VJWY/RU8MH? ME^[5CR:_5L#E_N'S5;$^\9CPU7>&M9X:9Y*O3Q&!Y#'VYF)\M6TFIES#LJOY ME1&/LXE\Q>2:K4,U97G+_?JQ;7-=6&Q,>8YZD35\RHIGIGG+M^]37>O.7E]XAF^[6+>?/6U-_JWK%FKY/,N6<3TJ$C$O(?EK$N4^:NFO-NVL2YA^:O MR7,J1]'2ES&91_#3YDVU7=Z^'Q,3THC_ #*8[[JC;-(OWC7#$N04R2GTR2K. M09)3:=)3: ):?3*EH ;1YE%%1S%\POFTOF4VF4^8OF'R4(],=Z$>MY'/S%A' MJQ;/6?YE2PS5[."JA>KJ/7/I=;/XJMPW]?=8/$QY3RJGQ&U3TVUF?; MJ>EXO]ZOH(XFD<_*:#[:KS(M,^TK_>J*:X7;]ZN2M.ERR*C\17O(UK*F^]5J MYN?,K/=VKX_$^^=T9#?+H\NG45X4J1U1&NE0^75C[U-=*B5,B7Q%?RZ/+J7R MZ9Y=<4J!8WRZ*=39*RE$L9)3*?)3*QY0"BB.BL@&/]^EIU%0$3V+]D?_ )+I MH/\ P.OW[^'W_(L6?_7):_ 3]D?_ )+IH/\ P.OW[^'W_(L6?_7):VB>%C/B M.F_BHH_BHK4\P**** "BBB@ HHHH **** "BBB@ HHHH **** &44458_LA4 M5Y\D=2K]TU7U+[E1(*7Q'Y7_ /!0N%G\0?+_ ':^'X894EK[P_;\3_BH/^ U M\:V\,6[YJ^;XOF:GWB*C?*M9$WWJX.7G/K M>:<"UYR5*CUE)N>6MB&'9#6_+R&49595!R/\U:UG\]8Z)\U;NFI7%5/;PWQ& M[#8-Y-1/"R?>K8TN3>OS4:E9[(G;;7G\W*?7QI<\3DKC_6U"C[:;(YJ->1>2_\NM*SU[8OWJYIW:F-,R?=KGEACJH9A*!Z-9ZKOB^ M]1)J47\35R-A>,D55;^\;^]67U<]6692Y3N/[;@1?O5S.L>)%W.JO7*OJ4_] MZLR:9G;Y)*TYG5VJ&%%1 MJ^ICAN>)\+[?EF=!H?WJVYM-9_FKE[.Z:%J[C3;^*945JYZF6GUF6XF$Y>^6 M-'LY4KJ[!6IFB0Q/6KY.R;Y5KY?$TI49'ZAE\:4X@Z-MJQ80MYJ5,B;UK2TV M%:C#TN=GN2C*/PG4:/;?>&L?2GK8=_EK]TR##1]@U==J5LJ35@WC*E?B^.P M?U6K*)Z]3WS*>'R5JOO^:B_O*J0S;Z^:K1.*4BQ-]VL>Y2ME_N51FA_V:\\F M4>>)DS?ZFN5U6'YJZ._=D:L&_P!TU>GACY3,*9S\,*R35I^3$BU$EGL;=44V M[^&O:/DI1]XJ:E:KM^6N7O(=C5ULR-MK$O(?FKKH2Y3Q\;2YCGWAK/F2MNY^ M2LB;[U>Q3D?#XFC[Q61*NP_=J*%-[5;V;:KF,8TA]G\TFVNEAMO)B2L71;?S MKM!7>7FF^3;I\E>;6J'V&7X;W3-L[;?6Q9V=&FVW^S706=@W]VO)E4/ML'@1 MEA:UMI#\M.L['Y?F6M![;Y:YX\TY'UL,-R1,J:']T]4G^Y6[]FW_ "[:B?3? M]FO5IT)S.2M[ARES,T-9DU\SL]=!K=AL6N7F79OK:6!Y?>/G\34Y MKG?+5? M7G_T>FJ^R6L_7KG_ $?[U84Z'O'A8NO^Z.9O/GEJO,GRT.^^6E?[E>YR^X?" M5??D5$1G:M"SL);EDJO;_>^[79>&[977TPF3''Z/HC)(GR MUU=GH\K_ ,-='9Z/$C;MM=1H^CH[?=HP,98C%'UN&RN,(G(Z;X9;^[70)X>9 M%^[7=VVCQ(OW:L/IJ[:^WQ&12F^8]BA0A1/.O[*9&^[4J0[*["\TU=OR+7+W MRM"U?$9ME<\++F/I:$HE?RZS[]_+K01ZS-1KXR5/FF*O\)RNJWC?-7+W]U\K MUNZQ_'7*7[_*]>Q3I\D3\[S*IR&%J$V]JSW?YJMS;G:J^SYJ]*G\)\)4]^7, M.CJ9(:$38M.\ZM@C$L(B1TV9%V[JA\RJ]S<[/EJ.8FI*,(C7^>6NET32EN=F MZN22;][73Z/JGV;8VZLI'91Y)Q'ZWX>BA5VKA;Y%A;;7>ZQKRS15PEY,LTKU MVT)G&1\E4B9O\5.HV?-3]K5J<7*/IU-HJ MP^$*ADI_F4R@)!1115&1%,E5*FF9JKT'GUB6.GT1T[RZ#6G\(VG1TVG1U,I< MH?;)&:I(?NTVF[C5>U.J4>8M(FZIH[1J2S7QA,,<^]FU0/ M"RUU[V:[:RKRV6IIU#HKX;E,1?N58A>F.FQJ(ZW/-C'D-.S?WAH\\2)X:8\.^M!X7;^&C[)_LUG[4[?JAE?8]]#V>RM5(=G\- M,O/N4>UY3*6&,?[-O:A[;96A;)OEJ]-:JZT>W(^K'..FVC^&M":S_P!FF);? M+5;5J.K?V.CR4K7F]TY(TN600Q_P 56DF9/NTU$7RJKS3;*Y91 M/0C4Y"U_:3+]YJ/M_F5E/-OJHUSL;[U7&F34QG)$Z/[G:)J7G;-U=E#- M%]GKR31[_9L^:NQL]8WK]ZO"E2/T' XR,S:O/WC5HZ4GS5B0S>=6UILVRB,3 MZ>C4CS'86'W*WK";Y:YFPN5=?O5T>F_.M?79)_'/9J5/<-.V^>I7VK5='VU$ M\S5^M2E+EB>!4]Z1:W[JS[R-:MVWSUGZK-L:OC\_J>X>QAH^Z8]_MKFM2>M7 M4KRN?O)M]?D54;YJJI+F-J9U&E/_H]7?M*HM8FGW7EQ?,U M5[S4MO\ '7F^R]X]J..Y(FM->*F^N)\3W/G5IS7_ ,OWJYS4IO._BKTL-3Y9 M1/G\PQ?/3D)\U5W>M6\C6LITKZND?F^("%_);=72Z+J3HU"_^P)9_^B$KMQ7%_![_ ))'X-_[ EG_ .B4KM!7VK'T444S(**** "BBB@ HHHH CF^[7XG?\%%O^2G/_P "_P#0Z_;&7[M? MB=_P46_Y*<__ +_ -#K*1Z6#^(^//X_^ U7J=O]9_P&JN[WKG/IOLEB%Z?) M4,-/DK7[)M'X26.GH]0*U.\RNKF]PHL>=5J&:LVK4-;8:7O!RFW9O\J5L6SU MSEL]='I^UZ_2,MJRCRGCUXF@C/)0Z-5NV1:=,BU^A1E*M \55RWG.CVG(6\AUTZYS[IMJO)6A M>0[*S71MU?!8RAR2/2C(9)3*L>743I7A'0124SRZE\NBL22*HJL/]RH:F42@ MIM.IM1RDR'1T^.F1T^B,N4Q+$=$E,CH=ZZ_:\IL%%1>915>UYPY26.GU%'16 M4BN7W26F4>947F5'*8G(M1U,CU7CJ6.NFE+E+D6$>I4FJK M3J^BPU8YY&G;7/RU+]O\NLI'V+3_ #*[I8F<2.4TO[2ILFI;ZS**YY8N9<8E MU[S?43S?-NJOYE/1ZX:E>1UT?U3E& M9VUG?Q5:?;-7'V=YL;[U=!9WBR+772S21[%.E"1IIIO\52I']F:K%M>+Y2+3 M9G5VKV*564R*D32L+S?\M:R?-7/V";6K=LZ^HPTB:<36L+#?716VE+69I3K7 M76<]"5/W3'N=#5UK'U#0?\ 9KO7A7;6?>0K7UM/#1G$\3$X4\LU M#P]_LUR]_8>2U>MZE:KM>N$UNP^9Z^?QV6\QXLJGLI'"WDRI_#5%[]5K8U*S M_P!FL*YMO]FORK%4ZM%G;*49A_:E,_M;YJI30U2W^6U<\<=5A$Y)4HG2V^I? M-OJ5[_S*Y])OW536SL]>/B'96LEOO6F?9/]FM:&&]L=LJ?)$RIE_V:9-_JJV)K;_9JE?P MLD7W:]#^RY1/-J2./5,F;Y*B\RG7GWZJL MU*E'D]T\:I\1:1ZF=ZHH]6/,K;VGO$RB:%F];UA-7.6;UMV;U]KELHG'*7(= M!:OOK8MOG7;7/VTRUL6UY\M?;T*$*L36GB2T]AO6J5S;>36A#)OK@QF! MB>K3Q)S]Q]ZJ[OMK5>S^6LRYAV5\;BA&7.-2:AWJ%/DEJ;[U?.2KRA( MZHQ!)JL)Y\[[U5YMU1;V2I^O53BJ4PF M3?0D-"?-4NUJX*E:K,NG3+$+U;\[Y:S$>AYJ\V7OGI4Y3;ZJ(F]JKS7/ MS4^&YV5CRG+*K[YM6UG5B1(DK-AU)46J]SJ7^U5QB=LL3RQ+5SY595S/-D2VT.^KR6'F46IR%>STJN@TW35IEM;5L M6$+5^HY;EL8Q/"KU>8MPV"[:8]G6@OW*9-]VOT"AAHP@>!4E[QBS6VRJCI6G M==JH^77EXFGS>Z5$S[E*RIODKH)D^6L*_P#DWU\KF'[F!Z=")1\ZIH;FL>:: MH4O/FKX#^T.2J>I[ ZM+RI?MEOE\9+GB>K&/(9\R55DJQ,]5W>OB ML7$[8C/,IE%-=Z\DN0>911Y=%68@Z4SRZ>[T4$C/+I]%0U<8\X$U'F5#YE%5 M[(B4A\E,\RBFTE,/8$OG4>94:U. MB5K&ISE2I\HY(=]3?9?>G1U-Y=>E3PW.AR&L98%%%% !1110 4444 %%%% !1110 M4444 %%%% "-1_#0U'\-6$MALE5=0_U=6JJ:E_JZ"Z'QGYB_MY?\AROC1(6W M5]K?MPP^=XBV_P"S7R)-YM='-"MS:UQUFDJ-73:;-N78U8RH'T M-"I[IR.MZ/Y,NY:P'W0M7I6N6>]=RUYYK$+)*_RU=#W?Q[/W3Y"5?ED;>_;3'D5U^:L^VN96^]5U'^6O/E\1ZE. MISE*;;6/>,J5T#IO7[M8E_#7H4#Q<89OVKVH2\H=*A\NO5B?/RD7H;FH;RYJ M)'IDU>CAJ'OG)B:_NE='\QJL0TU$IT=?;X2@?(5Z_O&A#6G;7GV?;6/#5V%- MU>W]3C.(4,9.$O=.XT3Q)MV?-770Z\DVSYJ\IAD\G[M:%AJK(WS-7QF892?I M639W*E[LSUZVO%FK:L[E:\UTW6%^3YJZBPU5'V?-7RLL-[$_5<+FT:T3T739 MO]JMO?O7[U<)INI+N^]746]XKK]ZOTCA_&_N3JQ7[XL3?ZW[U$=5WD5Y?O4; MU3^*OK/;\\)'C1C[&1E:\NQJXS4IJZK7KE=WWJY"_?S*_'>((_[0>U3K\T#G M[]ZHV=YLEVUK7,.^LQ+-4N-U?#UHGF2K>\=!"^]:>D.^J,-S$E:$-S%_>KYV MI[LCW,-[\3%U+2E9JQ+FQ6&NU?:]95_9J]53JG'B\,>?WC_,_P M9CO\_P!V MNFO+?]Z_RUDW-M_LU[%.L?%5Z'O&:C[JSK_[E:=RNQ?N5BWCM7HTY'S^)C[I MB7B?-6;<0^76E<[MU4KE&KVJ$CX3&?$%LE2NFZJ\.ZK";G:NN7PF%(W?#,/^ MF(U>@:DGG11+7%>'H=C(U=A\S[*\>M$_0LKI>Z:&E6?S5UNFV=8NE0UU6FPU MY4C]%R^@6/L_RU%]FWM6KY.^KUMI3-7T65X'ZQ(]6M[ACVVF[V2K#Z572VVE M;*>]GLK]4HY%&%+G/E<3(\Q\3Z/\KUYU?V>V9UKV7Q4FQ7KR^^7=98; MV,3Y_$QYXG+W,.Q:YK6I/W>VNUU*V_=/7#ZPGS5\E]L^:QWNQ,62A'ISI3?+ MKME+W#XS[9H:79_:;A*]2T'PVKVZ5YUH*?Z0FVO8-!W+:I7RF,D?H'#^&E,R MKSP[L9/EK5TK3?L:[JMS/O:H7O/X5KY653WC] G0Y)%+6X?M+5B7&FO(OW:Z MB&V\YJV&T>*2*NB-0ZI83VL#RUK#:U.^Q[/NUU&I::J7%36>B_:/FVUT?6>0 M\6IE?/(XQ]':9ONU=TW1&1D^6N^A\,_[-78=!\G^&N>6-/0H9%]LY>&VV?+6 MG8:;\VZKKZ;^]K5L[;8M:_63V(Y?$S7MOWM:5A#3YK/^*GV:;6K:G4YSTJ5" M,#=LX?N5V&@P_7V_O'=R\T#J$A^6F>34R?SU M_0%.-*<3PJG-S%1[;Y7KDM8TW]Z[5VK_ "-6/?P_?KXSB+ PG0D>AAI2YHG# MO;;&JE?V_P M;MYM26L^Y^=:_GS&TOJ\SW9>_$\\UZSV5Q6I0UZ1XDV5Y_JO MR-6M"ISQ/SS-J9CO9[UJI-;;*O377W*KN_RUW1ER^Z?%2IF>[[:K^=LJ6ZF7 MYZS_ +0E=$??/,J5.0L/>52N;GS&IDTU4G?YJZ(TSR<17]I'E+23?-5[[3LB MK,AJ7?\ +5>P'0KSI$TUXSU4=-U6(46GO#1[/D"IS8@J;-M135+-\E5'FKHB M>?4B-V?-1,GRT;_FI[_BG3-:^+YASOYGS41TW[J41UT'%&7.7;?[U;=G6%;O\U;6F_?KBKGO M8/\ E-VV3Y:M_8_EIEFGRU8W[:\653WC[&E3]TS;R'96)0^364C_ #_=KHK]/]FLU+/YONT>U//E0]XA_AJE,GS5M^3\NW;52:S; M=5QD92H&4]K69>0_-71O;?+69>0UZ5(\7$T/=,1$H_BJPZ;:KR5Z$3YFM'DD M6[:YV5H0S>=7/[_FJ];7.RLI1.NA5.ELYOFKJ-*F^Y7$V]XOR5T&FZLJ5Y53 M#'W&6XT[[3;GR]]:L-_L6N'AUA?[U:J7^^WKA]@?:TLPY3MM*UK][7=:#?[X MJ\2TJ\_TBO3?#%_O6O8RNI]7KGT>&Q?MHG?(^ZF257MKE:>]RM?HM3'1Y8G; M'WI$JS;%K"UBYW[ZNS7.RLRY_?5\!GV81/H*$?=,*YW352^S+OK5O-L*US]Y M?[&KX21PXB48R+OV-7I_]E+MJE87F]:VEF5XJ\^4@C2C./,_P [5%-;;UJ5[5D: MG^7713J'CU*9F3)3[.;R6JQ-#LK,F?:U=?-SG!\!TL.L;(OEKL_A=JK3>)HJ M\E69MKUWOP?N6?Q-%41I^\98S$_N#]V?@JV[X0^"3_U!+'_TG2NT'WFKB?@C M_P D=\#_ /8"L/\ TG2NV'WFKWH_"?AE3XY#Z***HS"BBB@ HHHH **** (9 MONU^)7_!11_^+G2_\"_]#K]M;C[M?B5_P44_Y*;-_P "_P#0ZB1Z&$W/CS=^ M\_X#452_\M/^ U%7.?1_9'QT]J9'0WWJV^R:QE[I+'3ZA1Z?51+YAZ/5J%ZS MZL0S5UT_<#F-.&;96Q87FRN<2:KUM-7TV#QAB83.3EE]HO3;'K/N(5=:L M>=3-^ZHJ^RK"]XYS4K!O[M84T.QOFKMKQU1:Y34OG:OS?-L/'F]V)[.'D9,E M158=*BKX"I$]49Y='EU+Y=-\NO/D;^S_+7V5#!1 M_E.250P7L_F^6A+6MA[;YJ/L;/6DL$1[4QW3;43[:U9M-:JLVG[*\RM@Y'7& MH9[O0CT30[*8OW*\25"4/B.CGB6$>K'G52W[:/M.RO,J4SHIU.0TDFV-]ZM" MVU+9_%7-)-OJW#O>G2B>A'$R_F.XL]2^5*UX;Q76N%MK[8J+6W9ZJNVOI*=7 MEB=L:_-\1V6FW*O)6]#FWB5UMC>+\M>5: M;K"UUNFZQ]ROT7*:\9%?6>7XCNWN5VU1FF6L]-2WK5>:\K]&PW+RGD8G%R^R M%^Z[:Y+4G^9ZW;R;>M<[?_,U>9CI'@R]^7O'.7ZK6)<0K6]?I6)>5^6YI*G& M)Z="F<_J2?-6$Z?-707Z>96(Z?-7Y9B\3[W+$]+V Q'_ (:O6?WZJ;/FJ[9I M\U>%5E[OO&F&I^^;UG6Q;6V^L^PA^6NETVW^5*X<-0]K5/NL-3Y8DMGIK/6A M#HF_^&MC3;-=E;"PJBU^O93E,9QC+E.'%U)?")Y+?P[+AUJCY.]JWM;MF2\>J,,-?.4Y2G'F/"Q='DJ%)TVU$ M[U=O*S_+KKC$\R4I%BVN62MBSN?EK"1-M6H9MBUZV&KRHR^(R]V1U%M>5K6U MS7'VUS6K;7FQDK[+!9A+^8QY3K8;FKR7*UR\.JK6E;7ZO7N2QD9_$==(TYG6 MLR\3?5[>KKNJC<.B5\[CI1F>W2^$RG3YJ(Z?--5=)J_.\7&7,>U0B:$-74?> MNVLR&:KT,U>/*4XGL4XC)K9:I30UI/,M4IIEJ/:2,*T8E=$J7RZB^TJE,^V+ M514KFF MUYL6J+WC3?Q54>;?357;71&G$\^IB92^T2R.W\-&]MOS4;]M13/O:NN,8G'* M7,$E.CJ*IH?O5UP,/=);9/FK0MOO;:I0_>K2LTWRU[>7RC.J9UY+4J M::F.]59GJ*F)YHBY0F M>J_F4UFI(Z^?KU2Q]%%%<], IDE/IDE60,DIM.H\NM8QB<\I#:=116O+_*$9 M#?,HW-1Y=&S;3]G(YY2"G>73?,H\RJ]D2%%%%_\BO:?]R5K[O*98:5?VOO2.[TJ\WJE;:.K+7/Z5#Y:I6U#7E5.64O=/OL-S#7MEW5 M:AL]_P##3[:'>U=!86&]:]7 X:4Y'=*-.7Q&(FC[_P"&HFL);-OEKL_LVRJ] M_9[X:^PEE<>3X3DE4C#X3F4O/.BVM7->(;!75W6MV\MFMIJRKRYWKM:OG99? M*%4Y<3*,Z1YU>6[)*]0I#LKIM2LUD5VKG)KE8:Z.7DB?!UHQYC0MDK06V;9] MVL>PU)=U;L.JQI:UY.(C'[)W4)1B-\O_ &:HWFF^=\FVK":VN[[M6$U6)ZY_ M>A\)VR]A./O1.2N=*:%JSYK;976ZE=1;?EKE;R;YJ]O+^:?Q'R>-C3C\!1_B MHV;J;\U.3=7VN#C[Q\GB_A!_D6HDF^:K'D^=\M'V/97W>'IQY3XVK*7,/A=J MU89DVUF)\M6X4KOIRY2XR_E+M"_[51)-LIDUY65>,9Q.NA7G"7Q&G;7[0M]Z MNETW7E38K-7"O-5?^TFA9/FKXK&82/\ *?;8',JL/M'LMMK:PM\K5T>F^)_[ MS5XC9^)-S5U&FZKOKYZ-66%]VG[I^B87-N?XI'KR>(8O[U,N?$B_WJ\\CO\ M8M/^W[Z[_P"U*L(?$>U]9A.)T=_K?G-6>]XK_>JBG[ZHKG="M?'8[$RQ%3F- MJ=>,8DLU^M9M]?[%W+5&:_V-5*YN?.KQY')4JQ'OK#;OO5I6&M[U^5OGKFKF MV^6I=-78U>?4IQY2*>+JPE[LCN[:ZWK\U/FDWUDV$WRUH(^ZO-E3Y3WHU^?X MS*N75&>JCI%,M3:K'L9VKF9M2:&7;7H88\?%\I8U6S5U^2N5O+9OGKJ$O/.6 MLR\3?OKTN;WCY'$QYCCWA_>_-45S#OK0N5V2O5=/FKZ"A+W3Y#$TX\QF>3L: MI84^:KTR+19P^=<)5U)>Z+;S?*_S5PKS-YFZOR3-*_.>55E'X0UC:EK MN6O.=2?S)GKN]8F_T6N"N7WRU\YRGQ^82*CI42+YC58?[E,7[]1(^7Y8\QK> M'4V72U[+HCJUFE>,Z:_ES)7I&@ZE^Z1:^9S:/+\)^E<.U.4V+_Y6JDB?-5NY MW/LVU"D+5X%&,>7WC[JMS2D:%L[I6PDR_9_O5CPHVVG[V1:X92]X]2G&7L#, MOY-]U74>&+;?%7-/#NEW5TOA^Y\FK.?!2_>_O3II+;8OW:KOM^[4MSJ2[:S) MM27=7FU(RYCZRK4I1C[I,\-$*;*9;7*O5W8KU?-(FG3YXALW15$D/S5=3:B[ M:?"B[J[Z$I$^P]X?9HR-75:/-LV5A0[$K0MKSR:^PRC&?5ZOO&]2ARQY8G<0 MS*R5*DVRN=MM87;5K^W$K]]P.>X3V7O'@5*'O&G7/EK3[AV=JI7/SU^(YE5YY'L?8.?U MN;?OKA-5_>5W>I6V]7KC-5MF3?7'@Y'P^;1DDV^HKYV>2F)NKV:5./*?&8BO+F)I*ACI\E$-$O<, MHR+$=/?[E$=0S/\ +6L2^8FAFV58^T)69YE,>:B42O;3?O7JI]ZHGF^: MG0O1RGFRJ2G(F\NG>71_#3T>K*B,\NJLR5==ZJ24!4B5:*92BZH+IU(R^(N.E1?Q4])O,6G1UC([?=^P36 M_P!ZN@TG[U85M]ZMW2?O5YM<]W+Y?S'10S;%^6IM[,M5_P"&F?;/EKR91/L. M;EA[I%,]9S_?K1A3SFITFE-\];1]PY9>_$ST=4JW"GG54N;9H6K0T[^"JYC* M%,?]CWU+#"V[;6FZI'3[/:\MQ2HG3Q)\OBLW;35:I] MD=M/%RA\,CK+/4OF^]746M_O@^]7G%O,VZNJTV9G5*X:D8Q/J\OQ-2M+WI'8 M:5][=7H'AN9HZ\\TIV397=Z)<_+7BXBOR2CRGZEE)WMG>?+3_MU85G,[U+YE M1+,*W\Q]W&G'E^$T'O-]1/=;*S_,JI>7.Q:\?$5Y5OC-8RY8#]5O-ZUQESM95(E4*TOAYBQ)-YTM17 M'^KHAA=VW57OGV+65.)KB8^X<_?_ #RU42%:??O\U,A?]U7NTH^Z?%RC[Y'- M]ZK]G"SK5!_]=6UIKKMJ:G,:1Y>;E,^YL&K/>VEKJG3SJKO9UC&4C>6$YSE[ ME/EK'N8?FKJ+RSV;ZYJ_W(U>M0D?-XO#2@54^17KNOA#_P C-%7GB.S[Z] ^ M#^[_ (2:*O2C*)\MC.;V1^[WP1_Y([X&_P"P%8_^DZ5VOK7%?!'_ )([X&_[ M 5C_ .DZ5VOK7IQV/R"I\4A]%%%! 4444 %%%% !1110!#-]VOQ*_P""B_R_ M$Z7_ (%_Z'7[;S??\ +3_@-14]/]9_ MP&BN<^BE\(42445M]DTC\(4[S*;10+F"G(]-HJN8.8L(]6(9F2JD=2H]==*I M*!9H0WC5>2__ -JL3SOEH\ZO>H8Z4#*43I;:_J]#>-7+PW-6H;S_ &J^DPF: M93JN7PA$E3[]:-KWK,1ZMPO7IX&7*953H+9ZT$^Y6#;7-:"7GRU^B8 M&O$\RI$T$=::\VRJ*75/W[J]&4HSD91C('N6J)]S_P -.J;RZYZD8FOOF9-; M5GS)L:MN:LFY3YJ^HJEF3YJ:Z?+7R5<[1D=6$F9:KT_P R MN>,C7F+27C5;AOV2L??\U6$>MO:FOM3I;#4FW5K)J35QB7+0U8AOVW?>KOH5 M^0Z8UST.PU)DKK=+U;[E>56=^VW[U;NFZJR-]ZOL,KS+V4C;XSV6WU+>M3;V M?YJX'2M8W[?FKJ+:\_=?>K]3R_,N>(O8&A-\ZUCWD+5H)-45RZO7I59B5F)>5,EY7@5^>9[M#$Q-B%*EW[%K*2_HNM2^6N'V$IGI?7H56QQ;>\_VJKOHIGH1Z9, M]'*S614KH_)6% M:P='N53971^RB?&XPB1Z'>K"HNVH9MM?3UN6#]P\R,?=(G>J[ MS-4KNM4IGKS:]?DB:QID4US51[JHKR:LR:\KY7$XX]"- NS3?+7.ZK^\JU-? M_+6/>7GF5\;F6*C.!ZU"F93I51_EJQ,]59J_(<3']Z>U$9YE'G5%3*\R4N61 M98\[Y:9YU-_AIE[M4._P#O4^F/]^IC*8#:*/+H9/EJ)>^ SS*?3/+I M]$8@%,DI]%=$8G/(913Z73_ ":L)#5I+6O3HX8RYN4STAI_ MV;?6A]E]Z?Y.RO1^IG/*1DO:U$\-:&F[/EKP*L> M4ZXE>BBCRZY"I!1YE'ETUJU(B)YE/W-3%[T4#)?.H\ZHJ*.8.8F^T^U.^U>U M5_,HK:G4(D2_:'J:&9JHTOF&O5IXDY)1->&:K".M8J7+5*EXU>E3QQ/*;'F4 MQW6L]+RFO>5URQGNF18F=:J.]1-<4S?NKPL37YXFX44>91YE>/*1844SS*?Y ME<\C4/XJ:U)107$]A_9(_P"2[:%_P*OWZ^'O_(LVG_7):_ 7]DC_ )+MH7_ MJ_?KX>_\BS:?]YJ^(QTN6N?U/P['GRZ)Q[ MZ/\ O=^VM/3["*%TW5I/"J5F7-XDH8&,Z1\_B:ASFJIYR_-7)7D/S5Z!?V?RUS5_8 M?-7RV99?&$I2.>-3GCRG&7B?*ZUR^I6"_P -=[?V>Q'K/2PBF7YJ_-<;+DD< M-3!\YY_;6VQJTWW)%M6MV\T18?F5:K_8_P!U\U>3S'+]6G$Y_P";=]VA[ED^ M[6F]GLJE-#L:NOW>4YY<\2H]RSK53[-O:K;I4L*5Z&!ER2/*J4Y3,][-:>EK M6FEMO:KJ:;\M?8861Y-?!\QS^S9]VHI*V+FSV5GS0[*^XPU3W3XW&83D*E6$ M?Y:KR4>977*1Y-./*6/,J*9*/,IDSU7V#48\WEK6?-<_-5BY>LJY>O'KQ-HU MY0+"7C(WRUNZ;XAEAKDMS5+#M2P^(6W5YXEY_M M58AOV_O5XE2A[I]70S<]1A\3>3%NJ&;Q4TRUY_\ VDWE_?HAO_\ :KQOJQZ< M7\NZN.I0.B.8W'$FG?S>8KUQ] M_#ODK5FO&>L^9&>G&GRG)7K\X^P1?G6F7**JO47G?9JHWEYO6NJG'WCRJM2/ MLS%U+=YM9_G;&JQ?S?-68[_-7O4X^Z?&8FO[Q;>ZK2T&%I+I&K"^^R5UOAN' M^*HJFN!]^J=Q;)LMTK3LYJROM/[I%K0TWYZ\7$'ZA@OA.@L_OUV&B)7#POL: MNET?4ME>UD\HPG[Q[=.7O'H%FZI6AO\ FKE["\WK6G]OV+7[C@<=2HTHG)5C M+VIM37&R+=7$>*M5V*_S5=O-;V*_S5Q^MS?;*\#.,Y@=WL_W1P^MWC32O6/L MW5JZK;,E9\*?+7YM7QG.?&5:9]\M==XD?[ZUR/_+:MZ53 MG/B\8Z6/ M^S45Y;*E=')"JK63JJ*BUQ4Y>\>M4IYOV\V MO?IT^>)\?4K^QJG8/JOG-]ZK<*J_S;JXRSO&D:N@MKS8M>?6I'H4L7[4VT^1 MJNPS-MK'L[GSFK6W[%KGE$]G#8OW2U]J]JL0S5SMUZWU4F=GICS57>:E4QTI1+]D%R_RUFS3?-6@_P U5)K:O$J5^9/"KM\U'V;97=7.@Q?W:Q[G1_EKVJ.)/B,3EL M^8Y*9&J)-R?>K8O+!DK*N(WC;YJZY5.<\F6&E1)TF7;5*YFH6;RZBF?>M=%( M\VO+D&><]-:9FZTRBNCE.'VH5+'3*?'5\H76,CKB/=Z) M*/+IE$2B)TIDE325#)6QQ51M%'ET>75JI_P MJT+9/F2N?F]T MTH1YI&[H\/\ >KKH=+\ZWW5B:);;UKL[.'9:[:^8Q=3DD?IV7X:,Z1RESIL6 MZLR\TW>NY5KKIK/YGJ6'2EFM_NU5#%^Z:XG+^<\OFL]C5GS(NZO0-5T1DW[5 MKDKFP9)/F6O8IXGF/B\7EA&H>#5HA3J$T,WS5NZ5,UQ@ZOOG4?:/EJO44+[UISI7BU(GVL:G- O:6^QOFK=WJZUREL[5MZ?NF1ZQ. MBE'F&7D*O4VFVV_[M.FLV>*HM-W6TU3([8Q]XW4T_P [[U3)IJPM5W3=LS5M MIIZLVZO*K2/J,#0YS/\ )EAM?NU#87C[MM='-#%Y?E5CS0Q6S;J\^1ZWLXPD M%RGG52>S;=\JU=AOXG9%K3?RDBW5$92+Y8F9*_ MRU1O+!9E=J[:=21YV)PT9Q/+[F'?\NVN=UJPV+]VNXU6V\FZ^[69?V:W-O7T M&$KGYKFF7GF\R?-3-FVMG5--\F2LFX7^&OI:53F/S?$X;DD1.]0I]^EIT=>A M+X3Q.67,6(7^:NMT&%I-GRUR4*?,E=WX>^14KPL3(^SR:,NKE[?[M;&FW/S5\OB9'[+EO[H[BV=46F.[52MKG>M2O-\U>5*H?:QE[A-\U M9EYOK53YUJK-;;ZRYC)'*7B-NI]LB[:NW]GLK,9_)KOYCY_$EA_D:IK9?.;Y M:R8[SSFVUT>CVV_YJRJ2+PD>:1H);>7;[FK"U)-_W:Z6\^2U>N?=7DKGC(]+ M%QER'):DFQJK6WW:V;ZP9Y:K_P!FRI7JTZA\;5I3,RX^]1;7C)5?4D:&LI+J M7=MKK^(\6I4E"J=K9W[/6AYV]:Y>V=DBW5;MKQG:N>4>0]_#8DNWD/RUS5_9 MK)71/-YWRU5FL-]$:G*<^+A[;X3EX;!?GKT#X2V>SQ';UCPZ/\WW:[OX::5L M\26_^[77"N?.XO+Y>P_Y*4__ O_ $.OVWF^Y7XD?\%&O^2G2_\ O\ T.HD>AA/B/CI/]9_P&BC M^/\ X#161]%+X0HHHJ^8O[ 4444$A1114 .CI_F57\RCHJ9TIE!$J9$W:EW4M-H(YN4EH\RHO,IWF58^8FH MJ&GQUK'W@YA_F5*CU%Y=2UT1C*(2+:/MJ[#-6?"FZM.&&OJ,#&K(Y)Z2W+UGS/3YIFJH[[J\3%XCW M3HIQY2N[_-3=_P M2NBU%)7SE3WS493/,I]15QJ]%646G?= M35F9&ID+_-1)6OM0C[AIVUXR5L6=S_MURZ/5V&YV5T4JLN;W3NC4.[TW4EA; M[U=AI6MJZ_>KR2WU#_:K;TW6-C?>K] RG,(P^(*E<]=34EVU4FU#?7-6>MJ\ M?WJMI=;_ .*OU3!UX5HGS]>O(EOYMZURE^C;JZB:'?%]ZL>_LUVO\UJVVL*B_>I[ZVNWY6KSJ'6&_O5:34O]JOT; YQ&C2Y3GK>_P"\='J& ML;V^_6%?WF^J,UYOJOOW5CB\[4X\IY_U7GD-F>H=GRU-M:F/N2OAZM7VL^8] M:-/D@9]S\E8EY6]>?,_RZKNE7?+ICPUT1/$JTS-\NG(E M6'AIOW:[:2LOJG* M7+&#T9Y*A=]M#HZ57?=7)5H&?M^97 M+RG5[2)8HJ)'IWF5CRR-H\H>71Y='F4?-5Q"0>71Y='S45K&1D-H1_FHIWEJ MJ[J[J9$HCX7^:M.SN?+EK)CJ]I\.]J^CR^4O:GE5X\YV&FW_ ,R?-72VVI+7 M'V=M6Q"FROVW*,;*$>4^9Q-,["VOT=:)KQ:Y]9MBT/>5]G'%^[[QQ1C[IJO, MM4KFY^6J7VRJ]S<_+7F8NM[IK'E*.I7FRL6:_JQJ3U@R5^=X^O+EERGH4Y1+ M%S?UGS7E-FW54KXC%XN<8'ITB5WJO)3?,ICO7Q\IRG([0DIE#O1'64H@/HHI ME ](RD+#]ZK2)1;HN^K M:(M?586F<4I D-6*9'3_ "Z]VE0.24AGF4SS*>Z57^[6TI1@9IG>J MDE>)7J1.J(QYOFIO\-,\NGQU\[4]\[HD-/J7R:?Y/^S41PDOB*YBO3)*L/#3 M?+KGJ49$E>.D?[]6?+JO,GS5S\D@E$937^Y24^HY3DE[I%11)11$L=2;:2BM MHF7M(CU7YJ=3/,IOF4O>YBI$OF45%YE/WUM[5F48\PQEV4?=IU-DKGE&17-] MD****@.8/,HHIE2;Q_LB_P#)=]!_X%7[^_#W_D6; M3_KDM?@%^R+_ ,EVT+_@5?O[\/?^19L_^N:UK$\3$^\=110OWFHJSSPHHHH M**** "BBB@ HHHH **** "BBB@ HHIK_ '* $:D7K21T1T:<3\V/VV]W_"1_\!KY4^S;Z^L/VWML?B-/]VOE M^P17KX?,H_ON8_JSA3WL"<_J5FZURE_N26O4[FP69:XS7M'9&?Y:YZ%:)[6. MPTI?"96FWFRNPT>;SF2N,MK!E:NKT1&A9*]CW9Q]TY\OYH2Y)G9[/W25H6#U MF/-_HZ5;TUVKWLHJ\E7E/;JG56T/RT3)1;3?+3;F:OZ P M_5/HO91I1]X;Y*NOS5DW\*HVU:T]_P M9EY_K*\R4OLG)*,#*>'?5*YMJVO) MJ)[7?5>W/(KX;G^$YQ[6IH;:MC[#_LTY+/9_!7=A:AYTL)(S8;;8U;%M#O6F M?9/]FK<*,E?:X.H<53#F?>6'F5B7EALKKYONUFWEMOK[7"R/E,=AN8XJ:V^: MJ_EUT%Q9MNK,>UKUO:1/BZN$E JHE$R4Z2HKI]E=L?>B<,H\I4F3Y:RKE*U9 MGK-N7KQ,3+D,C,FW57>9DJQ,]5W>ODZ\I5 ^$9]H>GIJNWWZB9MM<9<: MYJIJQ#-_M5B0S5>1UKDD=]&O*1M0WFS^*IOM?^U6#YU6+:;Y:XJD3UJ. M,.@MIM]:UG]^N9MIOFK>LYOEKQZT?=/I\-7YY1.@2;Y:J37GS5429O[U$R5P M1B?0^U-.&\5UI\TR;:P4F\MJ?-?_ "_>KJC3.>5>(^\N:SYIMZU4O+RL][QO M[U==.@?/XO%^]RC[EZS)G^:II+G=4+Q_+NKTHQY3YBI+WB6%]TJ5W'A[]W%7 M#VW\#5V>@NVU*X\1\)[F7Q][F.E\RM;39ME8Z)YFRM6V1DV5XTI1/TW!R]TZ M6V?SEJ];/Y,M<_#>>3_%5I+S_:HH5.21Z=.MRR.VL]2V+5B;6_EKCUO]B_,U M0S:E_M5]''-'R\IW2J1D;=YJ6]JKI-OK$>\_VJO6+Q$ZQK&H5-;1=M M8D*?NGK8U5]]8LTWDV[[:XX2Y_=/)Q=/W>U0ER'YKF$>>97J6%*;L^:KMLBU=3WSDI4^4NV"?O4KJ[--^RN7MI$5J MZO1Y-^RO$J^Z?6X'EYCLM$AV;*ZZ%U14KC+:\6%:T+;6%_O5\Q7IRG(_5,OQ M=*$3H[F9-MK!O+CYOO5S1HRYCIQ>+CR^Z4KQ=ZUA73JC5M7 M,W[JN=N49VKZ6A[L3\^QLO:2]TTM-VNU:TEK=2;Y?FK"M'F.S"2Y M(^\:>F_(U;KO^ZKE8;_RYOO5T5G,MRM>94]P^CP52,XF?>(S_P 597V5O,^] M75O8*ZU4_LU-U1$UJ4.>17TJV=)DKJ+--E9]G8;'W5L(BI%42K>\>GA]ULJO\ ;*S[FY^;[U5TF;=3YCH]MRFP]U4*3?-38?GJ5H_[M<\I';&7-[Q8 MA?Y:9,]-W[%JI--6)SU)%>Z[57^]5N;8]0QT^8Y?B*4T.]ONU2O(U1?NUM-_ MLUFWZ?+6].4CDKTH\IS\VUU?Y:QI(5>MZ9/E>LIX:]:A.1\?BZ4#*FL(GK!U MK1-[;E6NM=*JW,.^O=H5#YG$X3VL>6)Y?>6S0M5%]U=7KUAL9]M[ M0D?G&84_92Y"O13J;7JQB>)*/*.I\=,I]/E",B5/OU-5>.K$=<\HG7&0SRZ8 M]6*BDHC3Y3HYBO)1)3Y*AJCDE(/+I]%/K(B)7V?-5J%_F2HKA=B_+3+9_FJ/ MLEP_V>?O'?>&YOEKK8;G^&O.=$N727:K5Z#IL?G1(U?+YA'WC]3R:M&K NS0 M[XJMV",D7W:(86J["CH^W=7S_-(^RITBI1:AX>>&L&\L_)KU;5D7Y_EKC[_3?.;[M?04,3SG MYGF&6RYCA)H?FJ)D^6MW4M.\G^&L6;Y*]VG4YSXK$X;V0)]RG(]"_\>AAYM:;VS_>K"T5V?[U=Q#;JT25X M%<^]P?[V/NF-;0ONK9LY-BO4L.E_-6E#H_RUS3;UY5:C(^SPD? MJ\>:1BO-OEJI>?OEJWM5VIDEO_=KAE[ONE?Q:GNF.ELR-6FZ-]GJU#9KMW5G MS/*DNW=\E$:?,$J,H?:'V=M\VZK;[/GJOYRPK5J-%N8?O5G[2,"Z-/G.7U6P M6:6N:U*'[-7I$VCJB[JXS6]-WL]=]"O$^:5_LU]'0KGYUC,KES'!/;_-3$AK5O[-DE>J2)7M1K\Y\55PW),?;)\U=E MHGR*EKJ-$?>R5RXF/NGT&4QY9G56_W:T+--K5$D/[I-M:%M;-7RF)D? MJN&][EY35MIJO0S;ZJ6UM\M6_)V5XE4^HHR]TTH9OEHFF3;6?YVQ:B>Y;^]1 M$ZHU(Q"\^>NU>@:)#^ZKE='L_F^[7<6 M"+#%7/4D=>!H\DAEQ#O^6JL-FNZK[NK-36=4KDC(^DJ1A(Q[FP7S:8^E;U^[ M6@[J[5+"_P OS5UTJW*>54PD#SW7M*;Y_EKEWTUDDW5ZKJ5G]I_AKE+^S\MO MNU[5*O$^0Q>6^]SF1"G[K;3H86A:K\/T^'>U:'V7 MWJQ86'^S6E]D_P!FO*J5/9'TN&PWN^\5;.S5Z[7P';JGB"W_ -VN M"9&_X2"W_P!VM,+7]K4*S&A&.%?@[_R2OP?_ -@>T_\ 1*UV8Z"N,^#O M_)*_!_\ V![3_P!$K79"OTB/PG\;XC^-/U?YCZ***9@%%%% !1110 4444 1 MS?AA/B/CS_EI M_P !IM._B_X#3:R/H)?"%%%%0:_8"BCS*/,JR0HH\RCS* &4444 %/5J9MW4 M_P N@J,B7S*:#BF;6IU1*1M&1(NZI(ZBJ6.B,C7F'^913**B4BQZ/3ZACI]! MJ/DHH\RCS*RD7S!3G>F^93/,H"4@J)F^:G>9457$Q'^91YE,H7[]:F1+113_ M "Z"XC=E,\NI:905(BDIE34SRZ#BD,\NBG^73/+JXQ *?'3*>B5O#X@):?3/ M,H1ZZZ7QD6TSBJ2'[-M,=*>[_ #5*B;J^@E0Y MCE]J9[PU%Y+UL?9_EJ)[6N2M@36-0P9H:KNE;E&H9[I4 M7EU:DJ*2O"K4.0VYB+RZAJ:2F5X\BN4BHISI\U-J #?MJ5/FJO)3X6H L?=H M\RF?>J+S*UC+D)YN4M([5;AN62L])ME2^=N3Y:]+#XOV17Q'06&L,C?>KJ+/ M6%V_>KSJ'J_F5\Y4^+E.WVIK0WE6DO*PUDJU"]1*C$[Z6)Y3H(;E:NI=?W: MY^&9:MPW*UQ2J2A+E/1I8GGD;2/NJW"GRUB0WBUIPW-8U*DIGMTY1+ORU%,E M,2ZWT]WW5Q^^=7-&1GW2;ZS[FVK;V;JKS0UK'WSBK4X\QS[P[*ADK6FA^]63 M,C)7H4XGS^)B5Y*KNE3.E,1*[>21XDB)$JTB4)#5N&V?WAL#5JQ.>I+E* M_DU;MK;?5I+%FK3L[!DKZC Y-*4CS98GE,_[#3TL%_NUT'V.G)9K7U$SKI_L8/K)B?85JN]G\U;SV=0O:UA+)B)8DPIK:L^Y MAV5T=S#LK)NDWU\YCLMY#HIUS'=*;YE2W/R57DKX7$T^21Z$:@_S*/,J&CS* M\SE.CF)O,IWG57\RCS*RY3HC4+'G5-YE4?,I_G4U)?,I[O\M0^93_ #EV5VT@]J/1ZU=-?YJQZNV;^6U?08&7+(XI2.VL)E14 MK2\Y6KC[;4OX:V[-V=OO5^KY35B>)B8F["FZIEMU>G6R+MK0AVU^C4(^VB>% M4ERF:]FM,>S7;6G,\7]UJ9\M=-3!<\3'VIS5YIJO6/SK/N+9MSUY-;+^4[8U#*> M.BK#I47EU\U7I\II*)7DID=/^^VVC9Y;5Q?"8!13UA8KNI-FVJC4B1+#2C[Q M%)1YE/=?FVTSRZ)$T^;E#S*?YAIGDM1Y=9^\5*I[,?NS11LHJO?-/=G$**/+ MHJC/E'5%3_,IE "?Q4M)_%2U),OA/8_V1?\ DNVA?\"K]_/A[_R+-G_US6OP M#_9%_P"2[:%_P*OW\^'O_(LV?_7-:J)Y-KK]VKNFS12-4NH;9*^7]IR2/V-X:-:D<;-INS M^&K=A;;&2MI[576F)"B-7L4,3[IXOU3DJL)ME4;F%G7Y:?;0M_> MKW,OQ/[WF"M$ZV&\^6HKF;YJR8;GR?O59^TJ]?KU#.>2ER'B5*'.:%M-L5]U M5+^Y6JES>+#6;U6*8_RUYTI>\<0U(:L)"M0[_EJ9'WK4\P^6)*MFKT_P#LVG6T MVRM!)E:NB-?D-8X:,S*^P_[-136;)72I"M2OI7G+\M?2X'%F-7+SBID:HG3Y M:Z6\TW9_!6/F?Q4K+7+(P'*U3+- M5?;0ORUCR\YK[3D)_.J2.X:JWF41U,J9<:YL6]Y6[9W_ ,M<@NZK]K>?PUYE M2@>_A<=RR.NAO_FJ[]O7;7'I<_[52_;'VUSQPQ]!_:!L7-ROSM6;-+%\\B:27YJM3/\ Z/5!?O5) M--\NVKE$PE5]XMV_W5KL-'^2)*X^Q^?8M=WI2;;=:\G$?"?7Y7[TC=LWW-6K MOV*E95AM9JU9H=^S;7BR/TO#>[$'FJ6VF:J^]4;YJL0NKK\M$3:,O>+$TS57 M29MU$S_+55)OFJN8U]K[QL0_/5V%]BUF0O\ +1]O5/EK*I([:=0MWGSUS^JS M>2KK6Q]IWUS6L/NN'K+#2]XY\=+]T>3+MKGJ4^;_NUHVR>WEM)TULZ_P!ZKLSK MY56I;:'>U5?XJT+-/FHD$??D:4-M\M M/=-M/6;8M0S3?+7.>Q[L*15N9ME5/O/1<_.U$*4'GR]\?3/+JWY.RF25D1RE M39NJK?I\M:%5+Q=ZUT4CGJG/NE5'LZUGMFJ'Y8_O5Z%.1\_7H\YA7-MLJDZ; M%KHKF'>M8M^E>E2J>\>)7I>SCS'*:PB.KUP]_'MDKO;Q-[;:Y?6--=-[5]'A M:A^9YIAO?YSGZ5.].V?-1_%7T$9'QE7^493Z&^_171R\Y$1\=6(ZKQU8CJ)4 MI'1&0Z2HI*EJ*2IC&02D125#4TE0T2B<\I#Z?'3(Z?6,C:!+,F^HD3YJ/.W5 M8CKG-:GOR+6FOYM)\]=;J M3KMKE;_[]?0X<_/YC2TV;R:] T>99MGS5YE'^YDKL/#MXJR+]ZO"Q-,^\RJJ>D6UG%6G#Y M4+5B6+*,C]1PG+.)IZE;+-'\M5--TUD;[M;>FVS3*FZMVVT% MIONU[6#R^K6-?8>]S%2P7]U]VIKE&>*MVST1H4I]SI3)$_RUT8G)ZL?LGT%* M491Y#@7MI=U/2UEK=>S_ 'M/>VV15\U7P^<^]SY/RM6/ M)+EH6?;7&/?MYOWJ*-(^5QN,E"9U,UXKM\M6K.\\GY=U&H^VN@T2Y_TA*YI-^[;6KI3^7=)7;B M)>Z>+E-3]Z>MV>U[5*U;9ZPM*?S+5*V+#YFKXW%_$?N&7\O(;4/W:F3YUHAV M[:E1/EKS.8^GI4_=,V;=NIG\#U;F2J[I6L3"J5/X:B^^]77A_=52AA;S=]', M<7*;&FVRHM;#S>6M8]M-L6I?MBO64O?.^A[I82;][3)G:B%-U6TMM]1&F>A* M1GHC5;3[E$T.RF0_(WS5/*7\18AMM_WJY_6[#YJZ/S*HWZ;UK6-0X:U#GC(X MB:S;=5VSMME:%S9^3\S57^TK]U5KJ]J?.RPW)(U=-1:TWA^6L_28][5T#P_+ M7E8FISGU&&H>X9*)\U='X)3_ (J"W_W:QTAWM\M='X,MF37K?_=KKRV/OGGY MM3Y<*S]:O@[_ ,DK\'_]@>T_]%+79#I7'?![_DEOA#_L$6O_ **6NQ7I7ZI' MX3^)L1_&GZO\R2BBBF8!1110 4444 %%%% $945 M/7YJN,38=YE6$2JOW:E1ZRE$U+")3O+IJ/1YE4= R2BBBLI&4@IE/IE CU%'3O,H.B(^F24^F24%2&T445<3G"B2BG5J!$B4^B. MG25K$GE&T44+71#XQ?4B:2)YGS5>AAJI9 MOM6M.%Z^RPWOGF5 2&AX:L>917O_ %:$XG'[3E,R:VK/N;:MV9*I7*?+7D5\ M%$[*==OIGF5$K_+1YE95)>\91+'WDICI3%:AWK&H= UWJ5)J9 MLW4(E1[0RYBVDU6$NJSZ>CUS^PY_>.JG4Y?>-)+JK"7_ )=92/4J)71'#'=] M=D;T-_5V&\WUSB?+5ZVFJ)80]*AC9&ZDU,F>J7G4>=6$:'*>A[?GB/DK)N4K M3\RJ5RE>A3I'F5Y%6JF@ELM:%O"M9J/5V&:OL\'&,3PJDC0\E*>D*U"C_ "T] M'KZ6,8')S$OV97H^PK1O9*9]H>JE& HDN?FK&,82(E(S+^ MS^6N?O$V5U=^_P MJO7Y#C_ (CZ*G$* M93=U-9J\?E.CE$DH\RF45'*,?YE%,HHC$CF'^91YE,HK&1',/\ZG^=4--K:( MU6(;FLVG(]=4:G)(RYC>M;S8U=!INI?H6>I?+5Z&_KSFSUADK0AUZ7=7Z;@=OIGG5RD/B%J/[:_V MJ][^VERG+[$Z":9:S[EU>L>;6_\ :JE-K?\ M5X>)SCF]T[:=,T+EZY_4IEI M[ZEYU95]N>OS[-,9SGMT*9"[U%)3/,HK\_J^_([QC_?I\,.^H7^_5NSJZ%/] MX92+$.G[ZO)I52V_\%:")7WN!P49Q/,J5^0STTJA]-V5MHE.\FO:_LF$S@^L MR.:FL&6J4T+)77S6:NM95S9UX^+R?E.JG7.==*(ZT)K;9522OC<3@>21ZL:I M7DIZ/1)3/XJ\^,N0LMH]2^=5+S*/,KT(XGE)+OG57=ZB\RF>964L4$1[O3)* M/,IE"1L6O>K0HS)56:VWUI.E1.GRT8FA'D M'&1S4UM529-BUL7B5E3/7YKCJ7O'I1E[I415K0T?06U*?8M9LGS-\M=+X1O& ML[A-U?+XN7*=.#I^UJ\IHIX(?R\YK.UCPP]C_#7J5K-7EFULWW:I/\M>A>,+"VW.T6VO/;SY*].AB.<^5S? ^PEH"?.U/9 M:ALOO+]*T'2NR4O=.+#4_P!WS%>F;/FI\E/V?+643641GETQTI[O3/,KKB-"_X%7[_ /P]_P"19L_^N:U^ '[(/_)> M-"_X%7[_ /P]_P"19L_^N:U<3R:YU*_>:BA?O-15G$%%%% !1110 4444 %% M%% !1110 4444 %#?KR MT#N--U+9+]ZN@2Y\ZO/["9O-KJK";[E?%UZ?+(_;L+COV;%JE-]ZG/=4 MSS*(^[$]+FYH\P_?\M5WO_LU#S?PUE7ZM7KX21Y%>1:_MC>U:=KJ7RUR]LGS M5NV^WRJ]GZ],YZ?OEN:;SJK^2]/1ZL1UY.(Q9/*KG]2=-WRU?LO>/'K5>2GS%Y]2^6GV M=_O;;6#YVQ:L6%XNZNKV!Y\<7[QUL+UH6;US]M#K\YU5LB M^4E:$.W;65I\F]4K5A2O9P,3Z+EYXD5S8+-69I7 M]A\M4F1ZE1] MM5XZ?OVUR2^(UC+D+"S4[SGJKYE/W5?*=4:\I%IIMZU4?[]/IDE!,O>'QTR2 MF^91NJXQ.?[1+'3YOO5#'3_XJBJ=%/XS5TW_ %J5WVE?/;UP=A]Y*[G2G^5* M\3$?"?H&4Q-NV^2K3WE4F^Y53SOFKPI'W<:GNEYYO,:M*%]D582/\U:#W.R* MKB%.I[Q+2.H^W[%HMIO.EK"^T?+5 MJPN?WM95(GH4JYU#_)%7+ZE_Q\/6W-<_NJPKSY]]<]&/O%XJKSTS,=-[4?9? M>AW^:K"/\M=?,>#&/-(J30[*SYH:T[EZJ;-U=M.1RXF'*9\FY:J[V66M6YAV M+68Z?-6IY,8F]INI>3]ZMUYO.MZXJ%_F2NHL-07R]M<]2)ZV%F2PWGV9MM;= MA?HB[:PIH5F;=\M4GF^:NN,3S:I=L$_TBNHAN?)5*YW1_FN*Z":'Y:\^M\1[&$]R) M+-JORUGS:K\M4K]_+K)FF:JC2YHA7QDH2.KL-2\Q:UH;G?7':.[/746">97% M4I\AZ.!Q34/K*$C:=UVUGW-S\M17EYL6LQ M[C>U8'=*O[O*7M^ZI8:J6J;ZTX8?EH%2'^93*-FVF.]9&TA_RU7N-NVB9_F2 MHG^=:UB/E<;+W3"F3][63KT/\ H[UM_P#+:J6MP_Z.]?5X.)\GF%/] MUS'G\GRO4/\ RVJ]I$LEI],I]<4CMI#(ZL1U%'4M<\3HIDJ/MK0TV\:.6LU'^6I;9_WM<]:) MW8;$^RJGH>E:HVU%WU8FA:Y:N3?-57SOFJ6X^]53[KUTQB?-5^8KW[_+7 M.WGWZZ"\F^6N?O'^:O8PY\CF$C/V?-4L=,_BJ:.O2D?+P^(L MHR/0Y>4L._S5NZ#-ME2N<\RM;3;G9(E<]2/,>WEM?ED>I:3-YBI71V:;V2N2 M\-S;E2NMMOOK7CRI\DS]?RVMS1B=KHELKJE=7;0K"M7A,PES&1VB>;^)+!IF>N)DTW9<5['?Z>L MV^N4NM$B^T5\-&7)(\+,,#]HY*&V\FKOVG96M?Z5%"M<_>?N?E6M8_O3P)?[ M/$T(=8V?Q5L:5JN^X^;^[7G_ )S>96[HDS?:$KR,32]X[\)CI0D=;>:PELKU MR]S?KP\K;_#7E.L)LN':O0+F M%9JY+Q)8;%W5[N$/@)E*)W%J^^M!/N5S]A M-OV5M(_RU\_4]T_1L)+GB-F2J^SYJL3/5%W\MJR]J*M3]XUH;!7MZKO8>75B MVO/W5,\[?5\Q?U'[+D"VTWR5WU81-M: M=LBLNVJ]S#LKMY3JIQ]THNFZFI#5B.C^*K]D2,2&HIK;>M7:AF^[7)*GRFL? M>,B_M_EK$2S^:MV\>L^2L)'D5H^^7M-AV,E=%LW15S]L^S9700MOMZX91/

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�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�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�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�]%AL]#68 M:9;1:/I<<-JB:?:+#Z310!Y/K'P%^!GB&;XCW&O_ 7^$^N7'QCM+:P^+L^L M?#KP?JZ/._CBTM="\/Z#HMM;^)VU2=$TC38D6S MTVRAANZQ\%_@[XA\-^&_!VO_ G^&FN>$?!NG6FD>$/"NL>!/"^I^&_"NDZ? M:V5C8:7X;T.]TJ?3-#TZRL=-TZSM++3+6UMK:UL+*WAB2&U@2/TNB@#Q[5_V M>/@!X@\0^*?%VO? WX/:WXL\(?& ?P*=:O=$FU M+Q &^'Z)X&;^UKF[W>#D7PRD^!GP2FA\$6TOP=^%DMO\ #._DU3X< M02?#[PD\/P_U.77=+\42ZCX(B;2"GA2_D\3:'HOB*2[T%;"X?7='TO5VD.H: M?:7$/J=% 'BE]^S5^SGJ?A+XC> =2^ /P4U#P)\8?%U]\0/BWX*OOA7X%N_" M7Q2\>:GJ]CX@U+QM\1O#D^@R:/XW\7:AKVEZ9K=]XD\36>IZS=ZOIUCJ4][) M>6EO-'H:I\ /@1K>OS>*]:^"GPDU?Q1C2ZC+JOPU@\1^(8? &H/UF/P[-IR:I?"?UNB@#R6R^ 7 MP*TT1#3O@K\); 0?$5_C! ++X<>#K40_%J2\U74)/BC$(-&C$?Q%DO\ 7=:SJMRVIF;4;MYL[4_V=_@Y=?"J?X+Z'X \,> OAV-6T[Q+I'A_X MR\+>,-$\86/Q%\/>-_"MEX?L++3M$\8>'?B+I>E>/]&URWLFGM_&& MFV>MSI9[710!\SZU^R3\$]4MO$=SI?@_P />!O'?CG1M:\-?$+XQ?#G MP7\/O OQE\;^&?&^N>&]?^+>AZE\1_#_ (0L_$&D1_&:[\+:4/B#K'A2?P_X MF^U0VGB7P?KGA+QSX?\ "'BSPWW/@?X#_"CX;R>/SX)\"^%/#=O\4-1TK4O' M.FZ+X:T+1]&U^30?!'A[X;:);W^CZ/I^GZ9=VNE^ _"N@>$;?[;:W=V_AS2= M-T6YNY].TS3+>S]?HH \+\&_LY?"7P;9> ;=?"&@^*;_ .$FFR^'?A'XH\:^ M'_#_ (E\;?#/P:K6PTOP;X6\:7FE#Q/;Z+H=I8Z?IEA=7.J7/B"^LM,TZ7Q% MK6NZO!+JMQSWA;]E#X1^&_$'@/QQ>Z4WC/XG> /$WQ$\=V'Q9\:6'AS4_B9K M/Q#^*OART\&>.O&^N>+=/T'2+Y+[5O!-E:> [;PQX='A[X=:'X"TGP;X)T'P M5IGACX8?"K3/ _TK10!Y;XH^!OP4\;ZQK_B'QI\'OA;XOU_Q7X+7X;>*=<\4 M?#_PGX@UCQ+\.UDU>9? 6OZGJVD7=[K/@M9=?UZ4>%M1GN=#$FMZNXL=VI7A MFE\=?"#P#\0?APWPIUG0;2S\&01^%CH>G:%##HC>#]1\!:SHWB7X=Z_X*DL( MX5\+>(?AQXI\-^&O%7@'5M*C@G\*>(_#FAZMI0AN-,M2GIM% 'S=XO\ V5OA M+XSTWQ]#?:%I>E>)OC)HW@[PK\>OB3X:\)?#_P /_$SX]^!_"%DFD?\ ""?% M;QEIOA"'4M;\+:_X=?4?"NHVNF'1;_1/#.MZMIG@+4?!C2VMS9^H^*?A/\+O M''+NZ\/ZH-,:V.H:'<3Z3>M<64TL+^@44 >7W'P0^"UW\.]2^$-W\(?A?=?" M?69KNXUCX7W'@#PI-\.]5N+_ %H^);Z?4O!4FDMX:OIKWQ&3K]W+=:9*]SK1 M.JS,]\?/K.F_9Y^ -SK4GB2X^!OP>N/$4WCJ3XH3:_-\,_!WTB3Q:TYU]]+@AL&U VD21+[#10!RWA[P-X)\):EXPU MGPIX.\+>&-8^(7B*/Q?X^U;P]X>TG1=2\<>+8= T7PI%XH\87VFVEM=>)?$4 M7A?PUX=\-QZWK4M[J::!H&BZ.MR-.TJQMH/*M+_9/_9:T/PW;^#M%_9J^ &C M^$;3P=XK^'=IX5TOX.?#K3_#=K\/_'>N6GB?QQX%M]#M/#D.F0^#O&7B6PL? M$/BOPQ':KHGB'7+*TU;5[&\O[>&X3WZB@#QZV_9X^ %EKEIXGL_@;\'K3Q+8 M>)M$\:V/B&V^&?@J#7++QEX9\#Z9\,O#?BVTU:+1$O[?Q-X?^&VBZ/\ #[1- M>AN$U72? ^DZ9X3L+NWT&PM;"+G[?]DS]E>T\-^(O!MK^S/^S];>#_%_A"#X M?>+?"EO\&OAS#X;\4> ;;5=2UVV\$>(M"C\-KI>M^$+?7-8U?68/#6I6MSHL M6JZKJ6HQV2W=]=32_0-% 'CNH?L[_L_ZMXE\-^,]5^!GP=U/QAX-\+Z%X'\( M>*]0^&7@J\\2^%?!?A?Q%IOC#PSX0\-Z[(M*TW6]/M+?4[&UNHM?Q1\%_@[XXU/Q#K7C7X3_#3Q?K/B[P*/A=XKU; MQ1X$\+>(-3\3_#-=5O-=7X=^(;_5M*N[K6O HUO4=0U@>$=2EN?#XU6^O-0& MG_:[J>9_2Z* /G+X[_LQ?#WX\?!K3O@3J$EWX"\ Z5XY^"_CFSTSP'HO@>"R M27X%?%OP1\9_"/A>3P_XI\)>*?",O@O5?%7@#0M,\6Z _ATKJ_A.?6-%M+G2 MY;]-0MMSQ!^S/^SUXFM?#MOJ_P #?@Y>2^"M.33/ 5Y??"GX>ZK<> ;:#7M- M\662^#8]8\-ZA9Z FG>+M%T7Q;96ME:I8Q>)=%TG6GM)+VPMY4]QHH ^=?!/ M[,W@#0_ %MX(^);?\-&ZG+XWMOBCXI^(?QU\'?"K6_&7CKXHZ7>6,WAOXB^) M;'P;\// WP^@\5^"]-T7PQX8\#:AX8\">'?^$0\+>#O".BZ'':0:#:,.GA_9 MU_9]M].\1:1;_ KX.0:3XO\ "'BGX?>+-+A^&/@F+3O%'@'QSK&L>(?&W@CQ M%9)HBVVM^$/&.O\ B'7]<\4^&M2BN=%\0ZQKFL:GJUE=WNIWL\_L=% 'B=W^ MS3^SE?Z1-X?OO@!\$[W0;CP9X5^',^B7?PJ\"7.D3?#WP+J<>M>"/ U..._TBQL[I%E'3V_P@^$MIX>^('A&U^%WPZM MO"?Q9U/Q;K7Q4\,6_@GPU#X>^)>L>/[/^S_'>K?$#18],73?&6I^-;#_ $'Q M;?\ B.VU*Z\26?\ HVLRWL/R5Z+10!X,G[*W[,$=OK%I'^SA\!4M?$/A&_\ MA_K]LGP?^'JV^N> ]4'AL:GX)UB%?#HCU/PCJ(\'>$1?^&[U9]&NQX5\-BXL MI/[#TS[+L6/[//P!TSQC?_$33?@;\'M/^(&J6NBV6I^.K'X9^"[3QCJ-GX;\ M(ZG\/_#MI?\ B>WT2/6[RUT'P%K>L^"-%M[B^DBTOPCJ^I^&K%(-&O[NRE]A MHH \A\"?L^_ 3X6W'AF[^&7P0^$/PZNO!7@Z?X=^#;GP)\-?!GA&X\)?#^ZU MF;Q'<^!?#,WA_1=/DT'P=<^(;BXUZ?PQI36FB3:S/-JDEBU]*\[>O444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%<1\3/%NH^ ?AO\0/'>C^"_%/Q(U; MP5X)\5^+=+^'?@>'3[GQKX]U'PYH5_K%EX+\'V^K7VF:5/XI\4W-G%H7AZ'4 M]2T_3Y=7O[-+R]M;9I)T .WHK\2OV2O^"R?PG^.7P?\ #7QV^('B7X6Z)X*U M73_AAX!\<>#?AW-\5O&/[1OP:_;0^)?C*/P7+^Q/XP_99@^'=[\%_B=X1\,WMC\6]*\*?$#QO'\-OAA\/O \'BKQK]4Z[_ ,%2OV);!?$$ M.@_%?6?B'<:%\$V^/;S_ M^%_Q4\?\ AR_\$7'P2O/VD-"TK3_B1X>\&W7P MJC^)?BSX$6B?%GPI\)]5\=Z9\2=9^'VIZ)XS@\,#PSK.G:K< 'Z&45^0_P $ M_P#@KI\%/B+H?@;QWX^?3_A5X0\:_L)_LF_MDS>%-1T;X_\ B/XT:!>_M6?$ M34?ACX.\$:9X0TO]GBU\(_%/1?$?CR?PU\._A7K/PL\=>)/B+\3O'UQ?V&B_ M""/P]J7A3Q%K7KGC3_@K-^P=\/=(36_%?Q:\:65BOPR^+?QBU&*Q_9R_:"-5_; _:#_82T[Q MK)JNZ7XG M\#:5XHDFUSPY\1)+'X> 'Z]T5\+_ +.'[;_AC]H/]I/]L3]FI/!NO^"_%'[+ MNM_"_4/#>I:[/"]C\:_@S\5_!C77A[XR^"UCMX&;PZ_Q1\*?%WX?Q+83:W93 MZ/X0\)^+SK$3^.X-!T;COB;^UM^T/\,OVX/VKK]G3P7K?P#_ &AO$WQ M\$:1\5--^-=U-\:=+O/ /P,N_C)K_P 5K[X&Q_#$^'=-^!7AW7K.U^#.LZ_K M7Q._%'AZ]M_#D%GJG@?2OB2 ?HS17POX<_;A\+ZQ^WWXU_83O_!G MB'1=6T[]G71/CU\-_B9>RP/X4^*]QHWQ"UCP%\=/!'A@Q1FW.I?!>YUGX0?V MJ\6I7NHZCJGC+QCIEYHNA0_#W[?XBYS]OC]M;Q5^QGJ7[&4&A_"?2_B3I/[5 M?[]$\5^'/B;>7'CPZ=\0?%6J^&;;POXH^&WBKPIX:O_$%P--L=-\9ZUXW M^%$OC7X<_#I?%'ACX?\ C/Q+_P )?K^A2:EQVC?MK?MB3_MC?&K]DS4/V._A M]=7VA_L]WO[0GP,\2:%^TG>WFG:AH-W\?)O@1\.]*_:>U4_!*;3/@1?_ !4M M].\5_%[0;?P._P ;]6L_A[\-/B=I'A?1OBK\0?"&I>&H@#]7J*^+/V"_VF?B M!^U9\!]0^)'Q/^%ND?"OQMX6^,7QT^"'B"Q\'>,[KXB_"_QMJWP$^+/BSX1Z MO\3?@UXWU3PUX)U_Q)\*O'&K^$M0U+PC>^)/!?AG6TB6YLI;34K.VL=?U?RO MP+_P4Q^#VK_$#_@H9X7^)6D>(_A+X<_X)^Z)X=^*_B7QCK.GZGXCLOB/^S#K MWPENO'A_:(\%:-X5TG5-?UOPU;^*_ GQJ\*0:3X3L?&%YJ>B^"?"_B6RG_M+ MQY%X5T8 _2>BOR^B_P""R?\ P3SG\(^&?&A_ W]H368G\&:U^T#I7[*TE[XMO],^%-WIOPVU?PK^T/K6G?";XD M^$?B3>>$O&'PI\5320_$W0?"5G;75Y ?HK17Y;^(/\ @J_^RMX@T?2+OX%? M%?P?X[U:7XR_L1_#37;+Q5X:_:!\)V%GH'[=&OZ-)\$O%6CW.A_ ?QMJ&LP_ M%7P+=:CJGP<\13Z7I/PC\2>(5TW2_%GQ2\&V5Q)>KVFH_P#!5W]@+1_ -[\3 M;K]H*WO? -G8?&+5K+Q=HGPV^,/B/2/%NA?L^V_Q)NOC7XD^'4_A[X>ZJ?BA MX9^&%K\(OB'/XR\3_#E/%/A_2(_#CR3ZB%U/1?[1 /T4HK\X?V5OV[3^TQ^U M[^W7^SUHV@^%KKX@ZAHNKZQ!XFTC4+>^$5A*B17&'\-_P#@LA_P3E^+?AH^ M+?A_^T!J&M:1/\._#7Q7T&.Z^"'[0WA[7?'?@+QA\;;7]FWP[K/PL\*>)?A- MH_BKXN76H?'_ %'1_@W_ ,(_\,-&\6^)+/XCZ_X;\)W^D6NK>(]#M]0 /TZH MK\O]6_X*H? *Z^+7A;X8> ;+QQXN@\2_LL_M4?M/W/CB]^'?QC\.^%_!]A^R M=\3=*^#WC[X?^.=(@^$_B'XB^&?&^F_$9O&'ACQMX?U'P1%XH^'FL^#(_#>J M^%=3\9^-? WA37]SX-_\%2OV1_B#X;^&4?B3XR>#M,\;>)_V=/AW^T!X[U;P MUX=^-5Q\ / FE>,OV?(?VF+NUU?]H#Q_\)/AYX+\'W,/P8CO_B_I'@KXQ/\ M"WXSS?!T:7\0O$GPK\,Z;JL,2@'Z245\B^&?V[_V4O%?[/WCS]J.Q^+%KI'P M.^%FFMJOQ.\7>./"GCOX;ZG\.K7_ (0OPK\1[>/QQX!^(?A?PO\ $?PKJ&I> M /'7@?QKHFDZYX1L=4U[PMXS\)Z]HMG?Z9XBTFYNO'-0_P""M/[ VGR:5:+\ M9_$.KZOJ_P 2/VG?@[!X9\+? ;]HSQCXRL/BO^QMX4N?'?[2'PY\0^"?"?PD MUKQ=X5\9?#SP7:2^+(?#WB?1-(U+QMX>:#5_A[;^*[&YMII@#]':*_'SX_?\ M%>_@7X2N/V9;3]G;7=&^/5Y\=/VG?^"?OP>\1OIVA_$RW\,^#?AM^W_=QW_P MW\93^/K3P7<>"-(\?7'PYO=(^*VC?##Q5K>E>*YO!>L>&M2U_1=%L?'W@G4= M4Z;]I7_@I.OP"_;.TW]EFX\+^$M%\)>$OV0O%G[=7QR^./Q0UWQ[H'@SPA\" M?AK\9?!7PX^)&F: /"'PU\8K=>+=#\#^(O%/Q*T74-0O)=!\0>*/"/AOX+7Z M^&=4^*%GX[\(@'ZNT5^=/BC_ (*N_L+>"K;2)?%/Q2\\,_!2^T_XJ:7I7C7P MUX?O?'/@/4=-\2_#^'Q5IE_:3RY_CC_@KK_P3\^&NN_$CPSXY^-^M^'=<^$N MK?&_0?'>G7GP)_:+DETW7/V;OAKX-^,WQOT?2WM/A)<0^+-4^'WPA\>^'OBE MJNG^$9==NKOX=KXB\9Z1%J/AWP7XSU'0 #])J*PO"_B?P]XV\,^'?&?A#6M, M\2^$_%VA:3XG\+^(]$O(-1T;7_#NO6%OJNB:WI&H6SR6U]IFJZ9=VM_87EN[ MPW-K<131.R.K'=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ KSWXN?#JR^,'PH^)WPEU'Q+XQ M\&:?\4?A[XT^'5_XP^'>N#PS\0/"EEXV\-ZEX:NO$O@7Q(UIJ"^'_&.A0:F^ MJ>&-<:PO1I.MVMC?FTN1;^2_H5% 'XO_ ![_ ."'G[,?[3'Q0U+]H+XN?$7X MPZI^TRK_ +.]WX3^/N@6OP7\->(?#GB']F?Q'XMUWP/XY\0?#2P^$+?L_?&' MQOXDTWQEJ7@3Q[?_ !L^#_Q"\.7?P[T_0/"/@CPKX!L-)0S?0VG_ /!-+X5Z M'\1/VGO&7AGXL_'+PSX2_;$^%GAGX9?'[X,Z3JOPUE^%WBNX\(_!*]_9[T3Q M_H=EK'PPU7Q/\._&,'PR;P]IEQ!\-_%'A+P?J5YX)\)3ZIX4O;*PNM.OOT:H MH _&>Q_X(G? .STCP%I=Q\:_V@=9G^%7[*W[('[*7PWUK6)?@O+JOA7PY^PK M\>XOVB?V%_&47]@:^^IZ5=>&O&/@8MHVO\ AZZU6XU# M7[X\2?\ !$W]GSQ-I'Q#TR[^+WQSM;GXN_ 7]M3X$?$_6=/?X2VFH^+8/V_/ MCO:?M"?M"_$*2.+X5C3--\;S^,M-TG1_ BZ?I\/A7PAX.TJRT8^&M5NHO[4/ M[,44 ?#7[2/[#/AK]I3X9?LZ_#+7?BQ\2?!5K^S5\8?@/\>/!_B3P=9_#Z3Q M!K?Q(_9PU+2]>^&EYXE3Q5X+\2Z#+H:>(-+BU3Q'HNDZ+I7]L"22Q@O=-LB8 MFX#4O^"8/P/7XS^+OCWX)\5>/_AI\1-<^('QB^.WA*^\(_\ "%2:;\+_ -J+ MX[_ 7PG^S1\1/VE?".C>(_!^O:;JWC^Y^$GA&+3]+\+?$"V\:?"*+Q3XD\6^ M-]=^''B+Q'J&DWF@_I)10!^:*_\ !+3]GZV^/'P\^.>E:AX@T1/"_P"ROK7[ M&GQ'^$MGI7@G5?A'^T+\ ];F.I#P5\8/#_B_POXHUE['PQXC2'Q)X(?P!XB\ M"7FA7DFKZ-J%YKWA#Q'KWAJ_D'_!-'P;IG[3?P]_:'\$_M ?'WX9^%?A/X(T MGX;_ X_9<^',WPE\(_LY^%O NEZG;^+[WPMIVFZ1\*;?XJV.A^-?B;IWAWX MB?%+3-(^*VE67Q7O?!'P[\(_$2#Q)\//A_X0\):1^E5% 'YEZM_P3 ^&FJ^. M_P!DGXNI\6OBGI/QH_90\8?$[QA_PM;2;#X7Q:]\>G^.D4EM\?/#?QN\-7OP M]O\ X;W7A7XYQ7>HZE\1--^&O@?X;W5KXLNK7Q=\-]1^'>L:+H&_A[H6BZA\9/A M;>7VH>$'\2:9XB\(>)+"X\*O>ZGJ%QXETO1K;1-8UYWM@GB+31:_OOT9HH _ M-[3/^"-_&?QAU?]K;]JCQ%^T%JWPCUOX!_#3]H749?V=8_BA\"?@YXH M^*FG?%[Q5X/^'\=G^SS!\/O$]SXC\0Z#X5TB[\3_ !H\!_%3Q'HGA?PIIFG^ M"M0\*:EK'C?6/%V(/^":^JI\7_VH_C7;?MU?MGZ;XI_:AL?$=K=:?H6M_ GP MUH'PN_$GP_H.J>) MO$OQ:U70]>^-^KWGQ)E_3RB@#XA_9P_8LE_9@_9@U7]FCP'^TK^T!KV=&N/# M_@7XN^.I?A'K/CWX/:):^!?#GPZ\$:+\*/"VE_"G0?@CX4\._##PWX5TE_ G MA%/A+=>#;?6UO]9\1^'?$ESK.MKJ7Q/^U]_P22\-^*_ ?QK\??LTZ]XN\'?& M[6?^"9'[17_!/_1/ACH%_P""-%^%'QO\+_$?X9^+],^'/A[XKR^,_#WB'6- ML_ ?Q-U;1?%W@WQ!X \4>!-4\*A-=T>^OO$/A#Q#KOA?4?VVHH _F:\0?\$A M_C38^&?^"7_Q!\-76OZY^T)\(?CC_P $MM6_::N]<\0_":'1OA/\&/V'/V;O MC]\-+WP[\.XK'P]I5CXPET_XA_M >*]?UF9Y_$>O^,K34+I-)U'3+/P[X1TZ MW_27]F?_ ()5_!;]ESXQ>"OCEX"^)'QBU'QGX0_9E^,_[-CIXEOO ,UAKD?[ M0?[3M_\ M<_%CXM:G!HO@+1GMOB5X@^,.H3W>GVNDS6/PX\.>'6_X1_1? 5M M#%;7$'Z@44 ?BOX2_P""(GP6\,-J&H:E^TI^U1\0O%.N^.?V&OB+XI\;_$76 M_@WKGB[Q=XK_ & _B7\0/BO\)]8\5:SIGP8T*X\0ZUXX\7_$+4]0^-7BO6#? M>-OB3>Q3Z[J7B:#Q5K>O:_J.?XX_X(4_L\>.9?C43^T#^U+X(L_VDCXON/VA M-"^&6L_ [P-X.^-7B'QU\ OBQ^S]XI^(WC_X<:7\"F^%]W\6= /B'\4_&^N_'3X8_L?_ M\2V_Q(N/ EU8:7I7[&'P2;X%_#[6-%C\% M^!?!,J:YXO\ #TDFO?$)[Z6\TN[\2R%_"6E^$-#5-#7X<^&W_!OE^RQ\+](^ M#6F:)\:?VC-0NO@#^S[X9^ 'PMUG6[[X.7FH:!!X'_;IT/\ X*!^"?B--%#\ M'K73-0\STSQ#I'Q1CTG6_A\? I\'Z7H6C^'](\):OI_B+PZ-1L=1R_@S M_P $;_V??@GX4^*OPR\/_%C]H+6/@Q\?OV5?A3^R7^T!\&==\3^!9O!'Q>\( M?!_]FC_AD;PUXYU6_M/AW:>/? ?Q*U+X'V?AS0O%.K_!SQI\-M#U_6/"7A_7 M+GPZLMM<6]S^N-% 'P-X%_8"\+_#C]B#7/V'_!_QU^._AO1=9^'^H_#I/CWX M/N_A3\._V@M'TVZT33_"VGZYHGB+X:_"KP=X'T_QEH_A31](T&'QE#\/QXEU M,61\0:YJFI^,+NZ\1R_*7AC_ ((>?L[>#_%NF^--'^,W[0$NL:;\>/VT/VC8 MTOY?@I%IK?$3]N']FG2/V7?B5#%H_ASX,>&](TWPEX.\%:;-&\1_!'Q!K.F7^ MH^ ?!7@/PY\3-.^&FK_#W0_%_P#PA>DZI!INC:E>Z_/K/TG^U)_P2[^ '[7W MQ;^)_P 5OB_XA^(TS?%C]A3XB?L!>(/!^@ZAX4T_PYIOPS^)/Q,T3XLZE\0? M#\U[X1U/7+3XLZ%XN\,>&[GPMJNHZMJW@_38](C-WX)U*YN)[A_TEHH _,#P M=_P2Q^%'A;]H?X7?M27WQ8^+OBKXQ?#S]HOXY_M0:WK&KQ_#'3]*^)7Q*^.O M[-OAS]DW4H?%>C^&?AUH<>F^&/!7P8\+Z9IW@O1O!UQX;=?$GVOQ/XHO?$U] M?7L=SX=\9?\ @AG^SK\>+/C+\?[2Z^)_Q#_;C^)6MZ1HU]\+K;2K M'6_V]OV._#O[#WQ2M]):X^&-UJ<6G^#/@SX8TV_^&D5YJ%[-8^/6N=>\8S^- M=)E3PY%^V%% 'SS^S=^SZO[-_@73_ASIWQ6^)OQ)\*^'_"OPJ\'>#],^(LG@ M:6#P/H7PL^$/@3X30V7A=O!_@CPC=QV_C!_ Q^(?BNWUNZUN!?'OBGQ1=>&8 M_#GAZ\L_#MA]#444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 5GZMJFG:'I6IZUK&HZ?I&D:/ MI]YJFJ:MJUY!I^E:7INGV\EW?:CJ=_=20VUCI]E:PRW-Y>7$L<%M;123S.L: M,PT*\*_:C^"EG^TI^S-^T5^SGJ&N77ABP^/WP*^+GP3OO$MC#%=7@GNM)AUY[^WAF1XI9K=$D5D9@0#"\)?M*>%/%FD^&4D?0?! M?Q%^(N@:AXJ^%7P6^(7CGP5X;^*_CKPT;7Q#?>$M;'A*VUW5[_1[7QOIOA?6 M->T^T5-6U;P[X>@G?QAI^A^*-%\6^$?#7+^._P!L'P;X$_9#^*/[9$WA'QEK M_@GX-?#CXJ?$7XC^ =#F\"7'Q)\+O\"1XG@^-OP_NHW\<+X!N_B-\+]<\#>- M?!WB+1]/\?76@3^,?#&HZ5I/BF_M&MM4E^/_ !S^SE\=?C#\/?A5?^!/%.L^/['Q)\"H?CGI/Q:T"TO/A#=R-^T1#XW\+_ M !=TZY^ _B+Q#JWB_3OA9?\ @V[L/ _PPNO$7QA\>3Z3WVM?LH?$[XF?\$^_ MVMOV?TCT[P%\2/VT],_;&EO[#Q[J=K M+_A'X \$_%.N^$?$OQ#\/:]HGA3XH)X+U'1_%UL ?1'A']J:U\> M?M">)OV?O"7A&UU?6?A;I?A9_CO=+X_\%Q:]\(?$/COP-)X_\):5J'@==1FU M;Q/H#?B=\-OB,NO/\ M/?B!X)\>KX6URX\,>)V\%>*=#\5+X<\2V<<UXZ#?7XT?7;:*:*2XTC4 M/L^H0QRQO);JKJ3X7\%OA/\ %#P9\=?VC_BEXS;P'%X=^.O_ IW7=,T/PSK MOB/6M8\*^)? OPRT?P-XHTV]OM6\,>'=/UK1+Z\T\7.A:M;66CZA]FM1+J6D MB34UM-$^6_V1_P!@KXG_ 0TCXJ^'OB-\5/#L]G\1/V3OV=/V9[?7?@SI^K^ M ==\/:K\#]!^-WA/5/'_ ,.M%06_P\^!OAC4M.^)NCZS\+/@A\*?!FF> _@C M)Q8R^*/$P!]W/\ M$_L_P ?@OQ)\29/CG\'H_AUX-U2YT3Q?X_? MXF>"U\$>%-:L[&RU.[T?Q)XL;6AH.A:K:Z;J>G:C<:=JFH6MY#87]G>20K;W M,,CX6O\ [6/[+/A/Q1!X'\4_M+? #PUXTNDL)+;PAK_QD^'6C>*+B/58_#4V MF20>']1\1VVK3)J,/C/P?+8/':,MY'XK\-/;F1==TLW7Q3\/?V)OCWX!L?V= M/&%UX]_9KU_XN?L[^+?!]I

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�M7T3XL:]\8-'\?>+/A[HO@OXC_"'1;/Q1X%^$ MD&FWWQ5\6Z3XZ^)7Q"\!_#2>T\&V.JV3264WC.VN+^[DFRUEHFC^*?$'AP _ M*74/^"IW[1OB;2O&=E\/_B%^Q[X0\3_#3P)_P4H\7^+4^(7@N?XBSQW/[%=M M^S9XH\$>']8T[X2_MFVWA?PWJ^H>#/CPQ^)\^E_$7QGI*O;:3XM\/76@Z/?$*Z\#>*-2\) MWWA[XH?$S0/A[^RAXJ^%FG^#?'&K7VFP:SXJT'P/X^^+'B'PY!I-IJ4&L>"M M+\>Z]+X9O(;&UU_P=^Q'PP_:-^ WQD\*?#3QI\,/BY\/_&/ASXP^"4^(WPON M]*\2Z8+KQMX'^SQ7-QXDT+1KJXM]9N-/TQ)DAUT-I\<_AZ^6?3-=AT[4;:YM M8J_C;]I?]G[X>>"(_B1XP^,WPVT/P'-XZ\"_#*/QC<>*])NO#B^/OB5XB\.> M%O!/A:?5-/NKJUM]4US6/%WAU5CGEBCL--U.+7M4DL=!AN=2@ /QC\<_\%+? MCM\(E\7? R]^+?[!NE_$[3O%7@[P7\/?C_\ %H_$CX0?LQ>"+SXB?LA:=\;_ M (+>!?CTEM\3/B]K>C^)OB)XUM-?M/"GBR_^('P]T;XH>#-(UGP_X/TC3_B3 M;>&H?%_T?_P4<_:EC\%_!NP^%WCO4OAE\)?"?[3G[(O[65]?^-OC-H>O7W@B MY^*GAGP!\-+?P1^R]H<7C'5/@U/)\6?B[IWQ0\?^*O!/ASQ3IEEXY\0>'?@7 MX_L+7X6QZG;:U+X2^]?@[^TQ\/\ XN>'O&.O%V\ S^ _&WQQ\(>)/#_CK6?" M-CKVG:?\!/C#X^^"_BCX@7EMHOB77K*Q^'^L^(OAUKNJ:!K]WJ$<::.T,6N) MH^M6^HZ39='IG[1'P,USXE^&?@]H/Q=^'&N_$OQA\,F^,WAGP5H?BW2-9\0Z MS\*FU;^PK+X@V5EIES=!O">M:NFH67AS69)$M/$\OA_Q6?#KZI'X1\4R:, ? MSL?$7_@J1\3].^!?[17PQ^$_Q@^"_AZ7P!_P3)_;H^*?P8\<^$5T?6_B#H?Q M7_9 ^ G[*GC7P-8Z?<:]\2K^X\8ZWKWA#XP^._B1XAEU/X'^%_"<6C6/@O5_ MA?XE^*7@O0]6\?\ C?\ 2S]EC]N_QC^TA^U1XH^&F@^._P!E'5/AEX(M/B5H M'B;X>^'=<^(K_M37%YI:_#/6O@A^TIHOA:/3=8\"C]E#X^^!-4\7^._"/CE] M?U3PCK&C>/\ X$Z=X-^+'B;Q2WBOPYJ7VIX^_::^'_P\^-?PM^!NL2"?Q+\3 MM/\ '^KSZG::YX,CTSX=Z/X!\(WOC0ZG\0M.U'Q78>+=*TOQ5I6E:_'X9UK3 M_#.J:!]I\.:RNN:MHK#38]1VK/\ :9_9]U+XE>%?A#I7QI^&&K?$?QM\,]6^ M,OA;P?I/C31-4UO6_A5HVK0Z%>?$"Q@T^[N8I/"LFKR7-EIFKR316VMOHOBI M]$;4(O!WBJ32 #\!OB1^T?\ %72OVS/B]J6B_M&?L\3?'7]FU_\ @IYJGAS3 M_C)X)@\1S?#3X&>&OA'^QG\5?"/@?Q)X \$?&OX0^*+?P]=VD5OJND^++_7O M#]KJFB67B/QQJ5AXAU'55UJS^_OV4_\ @H+XW_:A_::G\":-J7[-6C?#O2?# M%[<>)?@[_P )C\0=7_:ST^#Q)\+O@M\5?A#\>=$TBP\(?\(-KG[,OC6Q\6^/ MM"MOB=/+I_@?Q+=ZU\*=.\._$&T^)>G>+?A9K?ZH>&O%?A?QIH5AXH\'>(]" M\6>&=5A>YTOQ%X9U:PU[0M3MXYI;>2?3M7TJXN]/OH8[B">W>2UN)42>&6%B M)(W5E:@EO?W[SPK:V\IE0, ?D'K'_!2GQQI^I_M$78\4?!*PG^! MOQ ^*O@7XE_ [6/ OC^/XM?LL_#WP7^V!\*/V??#W[7?[06OK\0K7PT_P!N_ MV>/%GB[]NR?3?$6F? _4_'OP(30[CX6>+-9\+>#_ (D?%"SY36/V^/VL-1^. MNO\ P1\!^/OV4)-*\*_##]M?XK:#\7;[X.>./'.@_M!>&OV9[#]A;Q?X7F^% MVB>%OVL?#EKH]KY?[6/Q2^ OQ"UM/$OCF"Y^+_[,'COQ=HVD>&=-O]3^&'@O M]0OCK^U3\+_@5\)-'^,E_J5KXW\->)[WP-;^"[+P3XC\#W&I>/['QYKWAS2K M#7/ D_B'Q9XVD!\1^&]%\3ZB_C6QU'P[;6OA2V\0)>Q MWVMWRS7D>AVRZ5J;7%]"T26-TT4UN0#\A_ 7_!1GXX7\WP]TGX@?$_\ 9-L_ M!_Q=/[,USHO[6/ASP3XATOX$?#+Q1^T;\&_VI?&*_L[^.-&U;]I3Q+::K\5_ M"'CCX$_"33=/\67/Q7\!V/CJV_:@^'/@F'X;>&?&4G@W4/B=S6A?\%(OVF]3 MT[XC>+M>\<_LE>%]%^&^D_L':3J_@%/AKXUO_&>I^+_VM?B%IW@(:MH_CJ]_ M:;T_PEX?T7XK0P?\)#^S38_%3PK\/?#L<'Q0^'*_%WXF:-HN@^)?$FJ?KE\. MO'OP!^'/PL\$^&M$^-W@'5?!/@CX6>&9M%\3:S\1? ]U]K^&N@FU\#Z1XTU' M6=/N=.T>YT.YU&RAT.7Q/;VUKHEUKH>PCF6^+M'T^Y?XH?$9-+N/!G@-K%KE[V/Q-K>EZSIWB1-+F MMXY;+P;)<^-=3^Q>$=/U#6K4 _#/PA_P59^)EQI^M?';7/B1\%O$&D:C^QG^ MRQXUT_X2Z)=6%GX#T'Q)J?[=?[0'[-'[7G[46GZSH'BGXA^,9/A!^R]X-TKP MA\1?VH%MM2^)/ASX1^!_"%D-5\7^$O[0U7Q/XP^\M2_;'^)OA7]C'X1?'3Q3 M\0?V7M?\:?$;XW^&_A:OQ$^$EUXK\1_L_P#B[0O%?QUUSP!X.U3X57_Q U[X M9:;J'B'Q_P"$+'P]IVAZEXX^*OA3X26WQ \17=]X9^(?Q.T&U\$Z-\2/TZTW M5]*UF&:YTC4K#5;>VO\ 4=*N9].NX+V&WU31[ZXTO5],GDMY)4AU#2M3M+K3 MM2L9&6ZL+ZVGM+N**XADC70(!!!&0>"#T(]#0!^#?[,/_!3OQI^UMIGPH\/: M=\9_V;_AC\5OB!\"/@QXV;X6Z=\/?&?C3QU\5(OB=^RKXF\>>./CQ^S??P?$ MC6_#][\,OA3^TS)+\&]7TO7?#WQ$\.>!-:_9O^-O@OXH_$A/$7Q-\ WO@/R3 M]FG_ (*0:I)I_P *]8\2?$C]E_Q#/XX_8T_X)'W?Q1_;'CT&PFO? ^J?M":K M^VYH?BJ#]HCQ'IGQ7^Q>)]#TOXN_"_PW\,?AAIZ:MX&TGX:_'7]K#4]<\06. MK:7KFH>'M1_H_HP/0?\ Z\9_D/R% '\^K_\ !3/]IW3-2\;ZCXF\8_LA>'O! MWP-N?V2'\>RZMX#\9Z8_Q@\(_'+_ (*3_M5_L0Z[\3/ 7BZ\_:670_A1X0\? M_"OX#^!_C]\)GUG1OB_9>&A\1;?2-4\0_$W0VT_7KGZ3_;W_ &[OBG^S!\0= M3\'>!-9^#(1?@O:^,]%L];\-ZI\6_']KX]U:T_: 7P[#\0_A)X>^,?P9\?Z) M\)?%^L?"S0=-\'?$[X6Z=\9[;2KC0/C5=_'72?@G\-O"FF_&*#]=_P"O6N#^ M*/P]T;XM_#;Q]\+/$EWJMEX;^)'@WQ+X$\17&ASVMIJZZ#XLT>[T+65TZ\O+ M+4(+2[ETV^NH8+IK.9[=Y!/$%FCC=0#\-_'G_!33]I#P)I[^&Y_B)^PG*/B. MGPZ;X1?ME^-1\0_AC^Q;X#^(7Q7^#7[0GCK2OV8_CGJVD?$WXR+:_%CP1XD^ M#_PTU2]\3W'Q1^&MA\3_ +^T)X/\,Z!X.\"?$7_ (08_%:]\9/^"COB#Q%\ M#?\ @H!*/V?OV:?VT]8^('[#GQE^$OQ6\3>-_#R?"[X:^'=9^%. MO?&E/$?B;P#%XN_9T_:1\-OXF\2V#>,/A;\&;?X@> OC;\*/!GA[48O''PX^ M)FE^._W4\(>'(/!_A3PSX2MM0U'5K;PQX?T7P[;ZGJYL#JNH0:)IEKID5]J1 MTJPTK3#?WB6JW-Z=/TS3[$W4LIM+&TMO*MHNB_S^72@#^>O2OBKX"3]M[X\? M$?6=8_9;^)WBZ/\ X*L_L^?LL_#/Q7XZ\.:/XF^(/PV^"_QL_P""<_[*?Q-' MA3X->,Y/B,EQX7OO$_Q<\)IXB\+"STS5=*U+QMH'Q9O--\-W>K^+99/!.S\) MO^"I/COX@Z7\,M5^-?CK]B[X9_#/X[^-/AOX-U#6&NOB'XQM/V9?%?C/X$_% M'Q;XX_9%_;'?Q3=_#;P+\-_VC;+XK^!K#X::)H>O^+= U5]0U76_A;X[^&OA MCXE3_"Z;XK?OT !T 'T&/7_$_F:6@#\(_P!FOXT:-\//^"3?_!%;6TOO@GJ^ MD>+_ E_P2\^%,H^*.E6?B73TU'Q'\-/!/AB\F^'MS+XP\.+X<^+O@K7[&36 MM UB3_A*;W0;OPKKVGR>&CJ#R:OH/LO[ 7[<'QA_:&\5?#GPM\8/&_[-7BVY M^,O['GAK]J7P=9_!'PKXD\#ZIX;@C^*>M?#3Q3::MI_B7X[?&N;QUX7UNXDT M.31M>TN'P='X-U31/$6AZI+XQGUFVG\,_KO10!_-O/\ M+:9^R?XZ^(7QL\) M^//"G[5&F:AH?[0.O6_Q4TSQK\0=/^)?PH\&:Y^U-\-K#XM:I_P4(^$VAZ3X MSB\6_"/]AOP_>7I^&/[2=D/"VM?#'X%^#?$'P&T#X9:#H^O7/CSQ?]+>%?\ M@HA\1+WQ%\#OA[XZ^//[$^@^(/BSI6K>,_AI\2/!7AWXO_$OX'_ME:)%^U,/"5WK?Q=\&?L\V_A^^^(&C^&;?XQPW_ ,5?C-X1\9^#;#5_ MA'\,_%^D^+_VRP,YQSTSWP,X'X9/YFB@#^;/P9_P42\<> O"G[('B[QGXW_9 MT^.?Q!UW]F?]I6Z^+_QVU[P=HMK\0_@)J'AK]O3_ ()^?!'XY>(?'&I^%_B9 MI>A>"/A!\(_ ?QF\8_&K]I[X8V-G\/-.L(?V4M+NM0UOX>Z-\/[FUT/LOV@? M^"F7[5_PH?X\Q^%_%W[(VN:5^SG^S+^W?^TX/&=]\-_&FJZ!^TGX5_9 G_8_ M\3^';;X92Z#^U':P> -*\9O^TG\0_P!DOQ=XONW^)]MX=_:8_9[\<>*=)T&_ MT^XE^#'A_P#H9P,YP,^N.>,XY]LG\SZF@ 8 '0#V';T[4 ?GK_P M4!\2>&-*\ _LN>+;CQI:Z!+/^W5^Q/I_@[5X/'-QX:L=?D\9_'SP5H6HZ3:" MRUK3=-\8Q^(O NI^)+7^Q;N+6;>\T6XU.\@LV6)[J'Y9U+XW:A\,OBOX;^*/ MQ7\6+X!\6^#/VU_VN%_:VO\ 5/\ 1K3X?_\ !/3X:_LZ_M9:[\ O$7B)KE+] M=#_9_F_L+]E'XA0>)M+O9?#4?[0/Q(U_28KS1/B)X_\ '7@,_MC@ 8 &,8QV MQZ8]*3 R3@9. 3@9(4D@$^Q)(]"21UH _%+X+?M.>.?@M^TUKWA'XI>!OB+- M?_MV?!CQ5^U5^S_\,-;^)W[.^M^-O'OQZ^"\&@:9\8_@;\%-9M_C_J'PKO=/ M7X >,/V9U^&>DWWCSP=X>OG^%WQE^)%WK4ND:SJFJZ/L_%_XO?LJ:O\ M,?L M[W7CWXX6_P"RU^V?>>,?@UXAN_A7\4?VH/AKHOQ?\#_#S6=0U/P]I_P!E^!O M@3XQ>._AU\1[/]HJ_NM4\/:_HGA^'QYHFGPZS+\;;SQEI?C+X3_!%]._97 Z M8X'0?3I^5% 'XA>&?VNU\+?M0_!']I'4;W7!^S!_P4&O/$'[.7PS\:Z[\3/@ M[J7PN\2>+?!>E>+?B9^PU<_!)M(^+6JOH$/[07@'PO\ M*ZGK\?C?1O!_B+Q M#\2?BE\&/ .NQ>'_ !'X9C\,2_KG\)_'?B7XC>#;7Q1XM^#GQ(^!&M7%Y?VL MWP[^*^I_"+5O&5A#9SF+N\^"'Q4^,G@$VFIH/M-C'9^.+O4(X"%U.PTZX MS;CTK '08ZG\23[T4 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %-8$J0IVDC ;&<>^.,_F/J.M.HH _,SPI^R=\2M/_ &8/B%^S M7\3/A/\ LX_'/P=\:/VC?VV/'7Q0\'^,_B=X]TGP?=?"']JC]I#X\_M):'IT M4EM\$--H/$6D7?Q&U&]\71V5SK-I);K?0:C^@ M=% 'Y37'[*W[5GA?1=&^"W@:3X%^(?@YKFO?%+XE?$'X@>+OB;\2O"OC73/C M7^TU\'/$ M!TSQ!XVU7Q!XC\*>#/$GA_Q'Q_\ L;?M*?'+X=?LQZ?I.F_"GP'XI^ /@3]G MSX<_%+1_B2FOVZZC\1?V5_VF/V9?C]I.J>#_ ![IGPWUW7OB?\"_'%Q\$;C6 M/!=SX3UOX'WL5[?^&-0^+.B^)?$%EK?PF^%7[CT4 ?E_KG[-7BW]I7]F[_@I M]X*^U:Q\,(O^"B$/Q@T7X*O&'P^N%TW5 M/#,6MZY\,-3^*^G^ M0O[7Q?;^"O$_A^'QQ8> OB+?>+? '@_P *^)/_ 3, M^(_C/QQXH^(&DV?P+T;P=\<9?BIX,_:"_8^M_&'QA\*_LYZUX"^+OPD_9P^& M%_\ $"]UGX5:;\.=2^,/Q7\*S?LXZ?<7N@>-?AYX1\'_ !/^&'CG5?@[?ZMX M"U/PWI?Q>U']M:* /QVUK]@W]H5_#WC_ ,.Z?>?LM^(=9T+]H#Q5\7_@=\:? M%W@J[N_C;=^%_B;_ ,%!_A+^WAK/@K7=?USP/XXT/X3ZA\(Y_ M_X%\$:Q8: M-\=?#OQ.\>>$O@/\=_%?@GP),-$_9@\0 M71\2_L9:GH%[TS]F3_@I?^UA^V-XQ6TU;Q!\&3?MJOQ*^!_[1 M>E?">\NH+BS>[UO0-=L-;N+SPGK*2Q_T&T4 ?B/\'?\ @F3\4?AUXQ^!#^(K MWX,>*OA/X(\-?![3M3^%0\4?&31_!OP3\:?LU_M7?'C]H[X6?$_X+>!/"_\ MPBOP]^(>O^+= ^-=G\/=3TOQYX;\!V_PCU7X9^ _&'AS4OB5HEA??#K4/J+Q M9^R'\0=<_;6C_:%N]2\&>/OAW'(O#NFV7[-=C!X\\)W'C[P! MK%U!\0=5TOP_XKB'A:VU?Q+W _8 ^+,)\&^(=)\&?LEV)\9>%OVJO ?[0OP% M\>S?%+X[_!MYOVLM;^!OC3Q5\:8/%OQ$T>#Q9\?_ !KHGCKX$)JOBSX<>-O" MOP=T+XSZ7\4M8LM0^(7PZUGP%;^(_B%^Q=% 'Y :+_P3L\8Z[XATKPS\9=,^ M#7C;X,W7C3_@K1I?C>&RU[Q3%XO\0?!+_@I!\9_$OQBL?#JZ=>^ #9?VM8P> M+;WP#X[T)/%=CHJ6VC6/C'2=;U^ZU!/"^@\OXP_X)L_&SQ=\/?V<]$\_''Q)8?";XW_"#]LZQ^).M_%GP7X3_:.U?XZK\ VC_:#\43_"O4=%U/XH>- M/@S;_LZ>$?!OA3X5_$.QL- \9_#+Q#J/@NV^)/PHB\+>&[YOVGHH ^./BYX2 M^-'[17[./[3GPMN_!WPT\#^,?$%[\2O /PFD\6ZK>_$'P'XP\,V,D2>!O&?C M/2=8^'VG2>&I?$,L$OC_IGBO0/V5/$GC#X@_!?_@H/X*^&7CO7]4\0ZQXJ\+_ !#_ &VO MVDH/CUH'C76M=G^!,4FG:E\)M3USQSXBBU[P%I_AV*]\4W]C8>#O!OP]L)Y] M9L?Z$Z* /RR^"O['O[0W@#]I;P9\1?&&N_!'6_AQ\//&G[?WB+1=>TB7Q='\ M5M>T+]O#XP>%?V@D\-ZIH]UX9@\.:-)\"_%/AV/X26^J6_BO74^,'@33/"WQ M N],^%FN:/-\/[WY^^(G_!*WQQXWN?'LF@67[.GPWUOXH?%[]O7Q=XK^).D: M9J6L>)KCP3^U'\.KGPIX&T'Q3HME\/?!E_\ $W2+S76T>\^-?P\U+XB^$M*U MGPWX?M]'T;QGJ&I7&E:WX8_)_$GB/Q;/X9LD\7?$ M>7X;:;J$?@31?AUX0M_!NI7'P[?6O%WY<:E_P26_:;\4^#_$WP_UGQO^SUX; MT?Q)^QU^T9^RU'K_ (>7Q)J%[HUW^T!^PY^SU^SA=^-SH5K\,O!=_P"*]>L? MB5\!=&U'Q'KOC7Q]KMWKWPTL/#6F>#],^&+:=>^%KW^B*B@#\)OC1_P3.^/_ M ,;_ O^VS#XRF^ .M_$']I[X)?M(^&?AGX\\2?$3XZ^)+[X':W^U9\!O!'P M>\:_!*PTO5-!E\(:C\*_A[X@^'?@OQUI?QDT/P?X5\4?%+3/!G@#P7JGP+^& ME]X)T_QU=_HK\:/@%XM\2:%^R[)\'-)^%W@/4_V?_CWX1^*\_@2:75-%^'LF M@7'@'XE?#+QQH>@7OA;PO%<)<:%IOQ8UGQIX9MG\)Z58^--:\,V7AG6+CP+! MXINO%_AC[$HH _"'P'_P3,^.?PP\9_LI>./ ^A?LOZ!K/P>T#7H_C!JNA:QJ M.B>+O'WB'Q%\2/B3XBGO?#?BV;]G37(;76+'P[\0=9@?XC^)/#>J>,+BR\<_ M%KPIX2M_AOXI\96/QPT#EOA7_P $F/BQX!^'WP:TK4]#_9:U/XH?"#X;?\$6 M_AUIWQ0L+SQ-:>(I8O\ @FS\3]-^(7QLU;3==N/@_<>)='?XK>&]!TGX2^%+ M%-6NO[7\,O/JGB^^T73K2U\"R?T#T4 ?)WC[X)>-O%G[6/P4^,L$GA2;X<>" M/V<_VIO@=XSM+[7-9L?&4US\?_&?[,'B_2=5\/:5;>%M1T74++1U_9UN-*U5 M-0\2:'"_V/ M/AE+H#77_%5>#_#DW@R[\6_%GQK!=Z3IJ:#XJ^(=Q\.? "67PWT:77]&^&\6 M@Z\\?Q"\>GQC%%X3^[Z* /PD\$_\$ZOVO_!VD_!'3+CQ?^S3XCU3]G/X9_"# MX)^'/'TZ>*1X\^+^A_!?]H+P1\4-,^.?C"Y\:_#+XF^&?A[\=/'7ARP\3ZSX MK2Y\,_'&QTKXNMK'C'0?%G]I?$RT\0?!F]^S!^Q]XA^&7Q(_92^$DKW,&N?L MS?L??#?X*_M1FP^#_P 9(_V;?C)IG[/?B>#QO^P0G@?XN_$W2=!T?Q)XX^#? MCSQ5\1_B)>VOPOU/QA?Z-<:UXPT3XMW>@3_\*YL]6_UC2_$'Q+\ >';N]_93\&_L\Z?:?%7Q MAXNT33_B[\8OAP+CP7H6F:7X>^,>N_&'XJ^#O@]HFC?"F;XZ^/?"&B>"O#W@ M:#]GW]B[]I'X5?M"^'/B_P"*=1^$NNZ1/\8_VGO'GC4Q_$3Q5J'C*72/C_\ M#']FK1H=96>S^!O@KPKXG\8Q>/O@SXIN=;TBRT+X:>$;7P]K.AW'AJ.Q,+^% M]+_7*B@#\+/V4O\ @FI^T)\#;;X'Z-\5]1^!7QO\/_!?X'_ ;PCX.L]:^(WQ MXC@^&_Q!_9Y_99UC]D*]M? WA.]TF\^&&I>"OVD/AYJ6K:]XGU[6? 6G^)?@ M8WQ0^.'@.#1/VB-.\>6/BWP_]&Z7^PWXZ\*_\$X/V:OV3?!Z?"+1?BO^ST_[ M ?BJXDTV35M!^%WCOQM^Q/\ &C]GCXP:M9W6O:3X*_X2/1-/^+DGP(?0)O%S M^ M=U?PM_P )+#JUQX:\5?V(-+U+]1J* /PN\5_\$R_C/>"Z\0>%M'_98L_B M5KGCW_@H#XQ\6>.-1MKZ:_\ $<'[4OQV\&?&?X96FIG4_@MXF'B"Y\/6OP_\ M(^%]6A\=Q>-?"O@^_P#"O@3Q"WA3XQ^'? MC\.=4]^_8_P#V-/V@/V>_BY9> M./%_B3X4ZSX9UB]_;=NO%MEHVM^,]4\1V$?[1W[:7CS]KOP$^E75_P"$?#FD M>(M96[^+'B;PU\0M7N;#PC8::?!^BW/A?P[J\'C2[A\!?JG10!^'_P 3O^"= M_P"U+XHF\=>'M'\3_LT^)?#-O\5?VX/BG\//&WQ*T_QIJ_C[Q9;?MGZ5X[UR MV^'WQ3\.WOA?Q1X0@TWX&>)O$&@?"SP?KTMW\2?#WBCX+>&?AX-9^%6F1?"A MOAW\3L5/^":?[5EQX=\=>'[7XO?"[P)>_$#0_P!OS3+GQ?H&N_$O6-?T6_\ MVL/VE/AU^U)X6U75$T#1?A1_PF/]K^,-#\:>!_C7I_AG4/@W8S^!]7@7X?Q: M7_:!T?P]^[5% 'Q!^R[X"^)WP6NE^&.H?"#X9^"? OB6U\?_ !J\8ZW\.OBY M\3?B#:^'?CG\2/B7+K?BCP='J'Q2\"Z#X@^)Y\>WFJ>+_BEXG^+MSJOAO6;C MQI>ZS!X@^%^BKXDT#7]9_/'6O^"6WQO\7_$G6M3\>)?'?A3QA8>)_$G MB_Q!XD^)7COQ1KFO_%_5_"VHPZ58_O;10!_/[IG_ 3 _:I\,:)\7?#7AKQ! M^S,?"WQGN_', ;;PC,/VG?BX MGQ%T3PI\ M!/VR/@Q^T=)I%T]O\)_&ZZ3X M27PS\,M7LM)URVU'5+^#Q;KT+'PC;VD4VM-^KM% 'X,?%3_@EE\=]?\ @GX[ M^%?PU\5_ /P[/XY^%'_!<#]GM8]8M/&4'AOPK\,?^"JO[3-M^TA\._$FB6&@ M>'[=I?$'PQ@\&^$?ACXL\"_9]/T#9XJUKX@Z%XMU=/A]IOPX^(_I6H?\$\_C ME8>*_B?XQ\!:E\#?"Q\4_'GX:_'.P\&7.J^.-?TCQ#K_ (/_ ."@&-0\3Q^-/A9HGBKXG? CQE\>/%NI_%SX7?##]F.;4?B M)9?%/]G:* .7\)6FL6>G7L>N:/X:T6\?Q!XEGBM_"EY=7NG7VG7&O:A/I>NW MC7FBZ'-:^(?$6GR6^M^)]-$.IPZ7K]_J.GV_B/Q-!;1:[?\ 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 24444 %%%% !1110 4444 ?_9 end GRAPHIC 38 annexd_006.jpg begin 644 annexd_006.jpg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�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annexd_007.jpg begin 644 annexd_007.jpg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�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�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end GRAPHIC 40 annexd_008.jpg begin 644 annexd_008.jpg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annexd_009.jpg begin 644 annexd_009.jpg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�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�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end EX-101.SCH 42 age-20230930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Operations Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization, Business Overview and Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Disposition and Deconsolidation of LifeMap Sciences link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Selected Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Warrant Liability link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders’ Deficit link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stock-Based Awards link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Convertible Note Receivable link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Stockholders’ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Disposition and Deconsolidation of LifeMap Sciences (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Selected Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Warrant Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stock-Based Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Organization, Business Overview and Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Disaggregated of Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Disaggregated Geographical Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Discontinued Operations (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Disposition and Deconsolidation of LifeMap Sciences (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Amortization Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Selected Balance Sheet Components (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Debt Issuance Costs and Debt Balances (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Schedule of Warrant Outstanding and Fair Values (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Warrant Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Stockholders’ Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Schedule of Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Stock-Based Awards (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Schedule of Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Schedule of Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Schedule of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Schedule of Debt Issuance Costs and Debt Balances (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Schedule of Warrant Outstanding and Fair Values (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Convertible Note Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Stockholders’ Equity (Deficit) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Schedule of Non-cash Investing and Financing Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 43 age-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 44 age-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 45 age-20230930_lab.xml XBRL LABEL FILE Entity Addresses, Address Type [Axis] Business Contact [Member] Related Party, Type [Axis] Related Party [Member] Class of Stock [Axis] Series B Preferred Stock [Member] Series A Preferred Stock [Member] Product and Service [Axis] Grant Revenues [Member] Other Revenues [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] AOCI Including Portion Attributable to Noncontrolling Interest [Member] Preferred Stock [Member] Legal Entity [Axis] Juvenescence Limited [Member] Consolidated Entities [Axis] Parent Company [Member] Investment, Name [Axis] AgeX [Member] LifeMap Sciences Inc [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Merger Agreement [Member] Juvenescence [Member] Loan Facility Agreement [Member] ReCyte Therapeutics Inc [Member] NeuroAirmid [Member] Debt Instrument [Axis] Convertible Promissory Note [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Subscription and Advertisement Revenues [Member] National Institutes of Health [Member] Lease Agreement [Member] Geographical [Axis] UNITED STATES Foreign [Member] Antidilutive Securities [Axis] Equity Option [Member] Warrant [Member] Restricted Stock Units (RSUs) [Member] Share-Based Payment Arrangement, Option [Member] Loan Agreements [Member] Asset Purchase Agreement [Member] Long-Lived Tangible Asset [Axis] Research and Development [Member] 2019 Loan Agreement [Member] 2020 Loan Agreement [Member] 2022 Secured Convertible Promissory Note and Security Agreement [Member] Secured Convertible Promissory Note [Member] Class of Warrant or Right [Axis] 2022 Warrants [Member] Security Agreement [Member] Reverse Ratio [Member] Registration Rights Agreements [Member] Twenty Twenty Loan Agreement [Member] Twenty Twenty Warrant [Member] Fourth Amendment [Member] Short-Term Debt, Type [Axis] Line of Credit [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Derivatives And Hedging [Member] 2022 Secured Note [Member] Secured Note [Member] Financial Instrument [Axis] Debt [Member] Ten Thousand Million Secured Note [Member] Total Debt Net [Member] Award Type [Axis] Inception Date [Member] Issuance Date [Member] Period Ending [Member] Award Date [Axis] Initial measurement date of 2/14/2022 [Member] 2/14/2022 [Member] 2/15/2022 [Member] 4/4/2022 [Member] 6/6/2022 [Member] 8/16/2022 [Member] 10/21/2022 [Member] 12/14/2022 [Member] 25 January 2023 [Member] 2 September 2023 [Member] 15 February 2023 [Member] 4 April 2023 [Member] Chardan Capital Markets LLC [Member] Plan Name [Axis] Two Thousand Seventeen Equity Incentive Plan [Member] Restricted Stock [Member] Stock Options [Member] Restricted Stock And Restricted Stock Units [Member] Stock Appreciation Rights (SARs) [Member] Equity Incentive Plan [Member] Sale of Stock [Axis] Employee Stock [Member] Income Statement Location [Axis] Research and Development Expense [Member] Operating Activities [Axis] Continuing Operations [Member] General and Administrative Expense [Member] Discontinued Operations [Member] Scenario [Axis] California Purposes [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] State and Local Jurisdiction [Member] Non-US [Member] GILTI [Member] Other Income Tax Matters [Member] Paycheck Protection Program [Member] Segment Continuing Operations One [Member] Segment Continuing Operations Two [Member] Origination Fee [Member] Convertible Note Purchase Agreement [Member] Subordination Agreement [Member] Issuance And Sale Of Warrants [Member] Revision of Prior Period [Axis] Revision of Prior Period, Adjustment [Member] Entity Addresses [Table] Entity Addresses [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Contact Personnel Name Statement [Table] Statement [Line Items] ASSETS Current assets: Cash and cash equivalents Accounts and grants receivable, net Related party receivables, net Prepaid expenses and other current assets Total current assets Restricted cash Intangible assets, net Convertible note receivable TOTAL ASSETS LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable and accrued liabilities Loans due to Juvenescence, net of debt issuance costs, current portion Related party payables, net Warrant liability Insurance premium liability and other current liabilities Total current liabilities Loans due to Juvenescence, net of debt issuance costs, net of current portion TOTAL LIABILITIES Commitments and contingencies (Note 11) Temporary equity preferred stock Stockholders’ deficit: Preferred stock, $0.0001 par value, 5,000 shares authorized Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total AgeX Therapeutics, Inc. stockholders’ deficit Noncontrolling interest Total stockholders’ deficit TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Temporary stock, par value Temporary stock, stated value Temporary stock, shares issued Temporary stock, shares outstanding REVENUES Total revenues Cost of sales Gross profit OPERATING EXPENSES Research and development General and administrative Total operating expenses Gain on deconsolidation of LifeMap Sciences (Note 3) Loss from operations OTHER EXPENSE, NET: Interest expense, net Change in fair value of warrants Other income, net Total other expense, net NET LOSS FROM CONTINUING OPERATIONS NET LOSS FROM DISCONTINUED OPERATIONS (Note 3) NET LOSS Net (income) loss attributable to noncontrolling interest Net loss attributable to noncontrolling interest from discontinued operations NET LOSS ATTRIBUTABLE TO AGEX NET LOSS PER COMMON SHARE: Continuing operations Discontinued operations BASIC DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC DILUTED AMOUNTS ATTRIBUTABLE TO AGEX: Loss from continuing operations Loss from discontinued operations Income Statement [Abstract] Other comprehensive expense, net of tax: Foreign currency translation adjustments from discontinued operations COMPREHENSIVE LOSS Less: Comprehensive loss attributable to noncontrolling interest from continuing operations Less: Comprehensive loss attributable to noncontrolling interest from discontinued operations COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX COMMON STOCKHOLDERS Balance Balance, shares Temporary equity balance, shares Temporary equity balance, value Issuance of preferred stock Issuance of common stock, shares Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares Issuance of warrants Stock-based compensation Transactions with noncontrolling interests – LifeMap Sciences Deconsolidation of LifeMap Sciences Fair value of liability classified warrants issued Net loss Temporary equity balance, shares Temporary equity balance, value Preferred stock issuance costs Temporary equity balance, value Temporary equity balance, value Balance Balance, shares Temporary equity balance, shares Temporary equity balance, value Statement of Cash Flows [Abstract] OPERATING ACTIVITIES: Net loss attributable to AgeX Net loss attributable to noncontrolling interest Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities: Gain on deconsolidation of LifeMap Sciences (Note 3) Gain on extinguishment of debt (Paycheck Protection Program loan) Change in fair value of warrants Amortization of intangible assets Amortization of debt issuance costs Stock-based compensation Changes in operating assets and liabilities: Accounts and grants receivable Prepaid expenses and other current assets Interest on convertible note receivable Accounts payable and accrued liabilities Related party payables, net Insurance premium liability Other current liabilities Net cash used in operating activities from continuing operations Net cash used in operating activities from discontinued operations (Note 3) Net cash used in operating activities INVESTING ACTIVITIES: Proceeds from the sale of LifeMap Sciences (Note 3) Partial collection on loan due from LifeMap Sciences Net cash provided by investing activities from continuing operations Deconsolidation of cash and cash equivalents from discontinued operations (Note 3) Cash advanced on convertible note receivable Net cash used in investing activities FINANCING ACTIVITIES: Drawdown on loan facilities from Juvenescence Proceeds from the issuance of common stock Net cash provided by financing activities from continuing operations Partial payment on loan due to AgeX from discontinued operations (Note 3) Net cash provided by financing activities NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH CASH, CASH EQUIVALENTS AND RESTRICTED CASH: At beginning of the period At end of the period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid during the year for interest SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES: Issuance of common stock upon vesting of restricted stock units (Note 8) Issuance of warrants for debt issuance under the 2020 Loan Agreement Issuance of warrants for debt issuance under the Secured Note (Note 6) Debt refinanced with new debt (Note 5) Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Business Overview and Liquidity Accounting Policies [Abstract] Basis of Presentation and Summary of Significant Accounting Policies Insurance [Abstract] Disposition and Deconsolidation of LifeMap Sciences Selected Balance Sheet Components Related Party Transactions [Abstract] Related Party Transactions Warrant Liability Warrant Liability Equity [Abstract] Stockholders’ Deficit Share-Based Payment Arrangement [Abstract] Stock-Based Awards Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Debt Disclosure [Abstract] Convertible Note Receivable Stockholders’ Equity (Deficit) Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Information Going Concern Assessment Fair value measurements of financial instruments Cash and Cash Equivalents Concentration of credit risk and other risks and uncertainties Cash, cash equivalents, and restricted cash Accounts Receivable, Net Long-lived intangible assets, net Impairment of long-lived assets Leases Accounting for warrants Stock-Based Compensation Income Taxes Revenue recognition Research and development General and administrative Foreign Currency Transaction Gains and Losses Segments Basic and diluted net loss per share attributable to common stockholders Recently adopted accounting pronouncements Recently Issued Accounting Pronouncements Not Yet Adopted CARES Act Principles of consolidation Use of estimates Reclassifications Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis Schedule of Cash, Cash Equivalents and Restricted Cash Schedule of Disaggregated of Revenues Schedule of Disaggregated Geographical Revenue Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Discontinued Operations Schedule of Intangible Assets, Net Schedule of Amortization Assets Schedule of Accounts Payable and Accrued Liabilities Schedule of Debt Issuance Costs and Debt Balances Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model Schedule of Warrant Outstanding and Fair Values Summary of Stock Option Activity Schedule of Stock Based Compensation Expense Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options Schedule of Components of Deferred Tax Assets and Liabilities Schedule of Income Tax Rate Reconciliation Schedule of Unrecognized Tax Benefits Schedule of Non-cash Investing and Financing Transactions Schedule of Condensed Consolidated Pro Forma Balance Sheets Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Sale of stock Sale of stock, percentage of ownership before transaction Sale of stock, percentage of ownership after transaction Number of common stock shares issued Retained shares of common stock Ownership interest Payment of merger consideration on pro rata portion Debt converted amount Paid in cash portion of indebtedness Accumulated deficit Cash and cash equivalents Line of credit facility, maximum borrowing capacity Secured debt Proceeds from convertible debt Long-Term Line of Credit Platform Operator, Crypto-Asset [Table] Platform Operator, Crypto-Asset [Line Items] Restricted cash Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows Schedule of Product Information [Table] Product Information [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Warrant to purchase shares of common stock Finite lived intangible asset useful life Office space Payments for rent Base rent Deductions Revenues, net Ownership, percentage Lessee operating lease description Net revenues Costs, operating and other expenses Loss from discontinued operations Net loss from discontinued operations attributable to noncontrolling interest Loss from discontinued operations Deconsolidation, gain (loss), amount Debt converted to equity Intangible assets Accumulated amortization Total intangible assets, net 2023 2024 2025 2026 2026 Thereafter Thereafter Total Accounts payable Accrued compensation Accrued vendors and other expenses Total accounts payable and accrued liabilities Payments to acquire businesses Number of shares issued for acquired, shares Value of common stock issued for acquisition Aggregate of acquisition cost Estimated useful life Royalty percentage Consulting fees and services Amortization expense of intangible assets Amortization of intangible assets for discontinued operations Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Drawdown of Funds Origination Fee Amount Refinanced Total Debt Debt Issuance Costs Amortization of Debt Issuance Costs Total Debt, Net Amount Refinanced Debt Exchanged for Preferred Stock Debt Issuance Costs Line of credit facility Line of credit, term Increase in line of credit Line of credit facility, current borrowing capacity Origination fee Common stock, shares Line of credit, current borrowing capacity Warrant purchase Line of credit, expiry date Line of credit facility, description Warrants exercise price, minimum Warrants exercise price, maximum Proceeds from sale of common stock Line of credit Warrants issued percentage Common stock held Indebtedness Reimbursement Accounts payable Extinguishment of debt Warrants outstanding Common stock, shares, outstanding Debt conversion description Proceeds from issuance of secured debt Debt instrument, indebtedness Accrued loan origination fees Convertiable promissoty note Proceeds from issuance of long term debt Origination fee description Common stock outstanding percentage Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Exercise Price Warrant Expiration Date Stock Price Interest Rate (annual) Volatility (annual) Time to Maturity (Years) Calculated fair value per share Fair value as of period beginning balance Fair value as of period beginning balance, shares Fair value as of period beginning balance, fair value per share Fair value as of period beginning balance, fair value Fair value as of period beginning balance Fair value as of period beginning balance, shares Fair value as of period beginning balance, fair value per share Fair value as of period beginning balance, fair value Fair value as of period beginning balance Fair value as of period beginning balance, shares Fair value as of period beginning balance, fair value per share Fair value as of period beginning balance, fair value Fair value as of period beginning balance Fair value as of period beginning balance, shares Fair value as of period beginning balance, fair value per share Fair value as of period beginning balance, fair value Loss on change in fair value of warrants Loan funds Loss on change in fair value of warrants Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Warrant to purchase share of common stock Proceeds from loans Payments for offering Proceeds from issuance costs Shares available for grant, beginning balance Number of options outstanding, beginning balance Number of RSUs outstanding, beginning balance Weighted average exercise price, outstanding, beginning balance Shares available for grant increase option pool Options grants increase option pool Number of shares outstanding increase option pool Weighted average exercise price increase option pool Shares available for grant, options granted Number of options outstanding, options granted Number of RSUs outstanding, options granted Weighted average exercise price, options granted Shares available for grant, options forfeited, cancelled or expired Number of options outstanding, options forfeited, cancelled or expired Number of RSUs outstanding, options forfeited, cancelled or expired Weighted average exercise price, options forfeited, cancelled or expired Shares available for grant, restricted stock units vested Number of options outstanding, restricted stock units vested Number of RSUs outstanding, restricted stock units vested Weighted average exercise price, restricted stock units vested Shares available for grant, ending balance Number of options outstanding, ending balance Number of RSUs outstanding, ending balance Weighted average exercise price, outstanding, ending balance Number of options outstanding, exercisable, ending balance Weighted average exercise price, exercisable, ending balance Shares available for grant, options granted Number of RSUs outstanding, options granted Weighted average exercise price, options granted Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock-based compensation expense Grant Price Expected life (in years) Risk-free interest rates Volatility Dividend yield Market price Number of common stock reserved Granted options description Options to purchase shares Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Fair market value of common stock Number of options exercised Options granted and outstanding exercised Total unrecognized compensation expense Recognized over weighted average period Intrinsic value outstanding Weighted-average estimated fair value of stock options granted Net operating loss carryforwards Capital loss carryforwards Research and development credit carryforwards Patents and fixed assets Stock-based compensation Capitalized Research Expenses Other, net Valuation allowance Total net deferred tax assets Computed tax benefit at federal statutory rate Research and development and other credits State tax benefit, net of effect on federal income taxes Permanent differences Stock Based Compensation Loss and deconsolidation of LifeMap Sciences Debt finance equity costs Return to provision & other adjustments Change in valuation allowance Income tax rate Balance at January 1 Additions for tax positions related to the current year Additions for tax positions related to prior years Reductions for tax positions related to prior years Reductions related to settlements Reductions related to a lapse of statute Balance at December 31 Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Net loss from operations Net operating losses Net operating loss, expiration date Deferred Tax Assets, Tax Credit Carryforwards, Research Tax Credit Carryforward, Description Deferred tax assets capital loss carry forwards Amortized over Period Income tax rate deduction Income tax provisions Income tax description Income tax provisions Loss Contingencies [Table] Loss Contingencies [Line Items] Lease and rental expense Loan obtained Interest rate Loan maturity date Notice of delisting Net loss Extinguishment of Debt, Amount Subsequent Event [Table] Subsequent Event [Line Items] Proceeds from Issuance of Secured Debt Warrant excercise price per share Principal amount Stockholder outstanding percentage Debt interest rate Other assets Line of Credit Facility, Increase (Decrease), Net Line of Credit, Current Equity, Attributable to Parent Secured note Lines of credit current Principal and interest outstanding Schedule of Stock by Class [Table] Class of Stock [Line Items] Subscriptions price Preferred stock closing price Conversion percentage, description Preferred stock voting rights Cash paid during the period for interest Issuance of preferred stock in exchange for debt Issuance of common stock upon vesting of restricted stock units (Note 8) Issuance of warrants for debt issuance under the 2020 Loan Agreement Fair value of liability classified warrants at debt inception date (Note 6) Debt refinanced with new debt (Note 5) Dividends Payable [Table] Dividends Payable [Line Items] LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) Loan due to Juvenescence, net of debt issuance costs, current portion Loan due to Juvenescence, net of debt issuance costs, net of current portion Commitments and contingencies Stockholders’ equity (deficit): Preferred stock, value Preferred Stock, Par or Stated Value Per Share Going concern policy [Text Block] Warrant Liability. Juvenescence [Member] 2020 Loan Agreement [Member] Chardan Capital Markets LLC [Member] AgeX [Member] Coronavirus Aid Relief And Economic Security Act [Policy Text Block] Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block] Loan Agreements [Member] National Institutes of Health [Member] Shares available for grant increase option pool. Share based compensation arrangement by share based payment award options grants increase option pool. Share based compensation arrangement by share based payment award equity instruments other than options grants increase option pool. Share based compensation arrangement by share based payment award options grants In period weighted average exercise price increase option pool. Shares Available For Grant Options Granted. Shares Available for Grant, Options forfeited, Cancelled or Expired. Shares available for grant, restricted stock units vested. Number of Options Outstanding, Restricted stock units granted. Weighted Average Exercise Price of Options, Restricted stock units granted. Other comprehensive income loss attributable to non controlling interest from discontinued operations. Payment of merger consideration on pro rata portion. LifeMap Sciences Inc [Member] Merger Agreement [Member] Paid in cash portion of Indebtedness. Warrant Liability [Text Block] Asset Purchase Agreement [Member] Royalty percentages. Research and Development [Member] 2019 Loan Agreement [Member] Summary of Debt Issuance Costs and Debt Balances [Table Text Block] 2022 Secured Note [Member] Registration Rights Agreements [Member] Indebtedness. Reverse Ratio [Member] Debt refinanced with new debt. 2022 Warrants [Member] 2022 Secured Convertible Promissory Note and Security Agreement [Member] Secured Convertible Promissory Note [Member] Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and fixed assets. Juvenescence Limited [Member] Deferred tax assets capitalized research expenses. Retained shares of common stock. Effective income tax rate reconciliation permanent differences. Effective income tax rate loss and deconsolidation. Security Agreement [Member] Effective income tax rate reconciliation return to provision other adjustments. Warrants issued percentage. Effective income tax rate reconciliation debt finance equity costs. Loan Facility Agreement [Member] California Purposes [Member] Net operating losses expiration date. ReCyte Therapeutics Inc [Member] Warrants Outstanding And Fair Values [Table Text Block] GILTI [Member]. Unrealized loss on change in fair value of warrants. Unrealized loss on change on other than options Unrealized loss on change in fair value of warrants per share Changes in fair value. Fourteen February Two Thousand and Twenty Two One [Member] Fifteen February Twenty Thousand And Twenty Two [Member] 4/4/2022 [Member] Six June Twenty Thousand And Twenty Two [Member] 8/16/2022 [Member] Warrants issued fair value. Fair value issued per share. Fair value of other than option issued. Other Income Tax Matters [Member] Fourteen December Two Thousand And Twenty Two [Member] Twenty First October Two Thousand And Twenty Two [Member] Lease Agreement [Member] Inception Date [Member] Issuance Date [Member] Period Ending [Member] Paycheck Protection Program [Member] Notice of Delisting. Insurance premium liability and other current liabilities. Accounting For Warrants [Policy Text Block] Two Thousand Seventeen Equity Incentive Plan [Member] Stock Options [Member] Restricted Stock And Restricted Stock Units [Member] Equity Incentive Plan [Member] Less comprehensive loss attributable to non controlling interest from continuing operations. Origination fee, description. Common stock outstanding percentage. Origination Fee [Member] Stockholder outstanding percentage. Weighted-average estimated fair value of stock options granted. Issuance of warrants for debt. Issuance of warrants for debt. NeuroAirmid [Member] Subscription and Advertisement Revenues [Member] Initial measurement date of 2/14/2022 [Member] Income tax reconciliation nondeductible expense research and development in years. Us [Member] Cash advanced on convertible note receivable. Finite lived intangible assets amortization expense after year three. Loan funds. Issuance of common stock upon vesting of restricted stock units. Comprehensive loss attributable to common stock holders. Cost of sales. Net loss attributable to noncontrolling interest. Grant Revenues [Member] Other Revenues [Member] Foreign [Member] Total Debt Net [Member] Twenty Twenty Loan Agreement [Member] Twenty Twenty Warrant [Member] 25 January 2023 [Member] 2 September 2023 [Member] 15 February 2023 [Member] 4 April 2023 [Member] Second Agreement [Member] Series A and B Preferred Stock [Member] Segment Continuing Operations One [Member] Segment Continuing Operations Two [Member] Serina Note [Member] Fourth Amendment [Member] Convertible Note Purchase Agreement [Member] Subordination Agreement [Member] Secured Note [Member] Ten Thousand Million Secured Note [Member] Convertible Promissory Note [Member] Assets, Current Assets Liabilities, Current Liabilities Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Cost of Revenue Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Comprehensive Income (Loss), Net of Tax, Attributable to Parent ComprehensiveLossAttributableToCommonStockholders Shares, Outstanding Noncontrolling Interest, Decrease from Deconsolidation Temporary Equity, Other Changes Temporary Equity, Net Income Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Accounts and Other Receivables Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Other Receivables Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Due to Related Parties Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations CashAdvancedOnConvertibleNoteReceivable Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations WarrantLiabilityTextBlock Income Tax, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Selling, General and Administrative Expenses, Policy [Policy Text Block] Cash Equivalents, at Carrying Value Restricted Cash Equivalents Restricted Cash and Cash Equivalents, Current Disposal Group, Including Discontinued Operation, Operating Expense Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Asset, Expected Amortization, Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree Finite-Lived Intangible Assets, Net Accounts Payable Warrants and Rights Outstanding Unrealized loss on change on other than options Unrealized loss on change in fair value of warrants per share Changes in fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesAvailableForGrant Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Unrecognized Tax Benefits Income Tax Expense (Benefit) IssuanceOfCommonStockUponVestingOfRestrictedStockUnits Proceeds from Issuance of Warrants Short-Term Debt, Refinanced, Amount EX-101.PRE 46 age-20230930_pre.xml XBRL PRESENTATION FILE XML 47 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
9 Months Ended
Sep. 30, 2023
Entity Addresses [Line Items]  
Document Type S-4/A
Amendment Flag true
Amendment Description AMENDMENT NO. 1
Entity Registrant Name AgeX Therapeutics, Inc.
Entity Central Index Key 0001708599
Entity Tax Identification Number 82-1436829
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1101 Marina Village Parkway, Suite 201
Entity Address, City or Town Alameda
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94501
City Area Code 510
Local Phone Number 671-8370
Entity Filer Category Non-accelerated Filer
Entity Small Business true
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
Business Contact [Member]  
Entity Addresses [Line Items]  
Entity Address, Address Line One 1101 Marina Village Parkway, Suite 201
Entity Address, City or Town Alameda
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94501
City Area Code 510
Local Phone Number 671-8370
Contact Personnel Name Andrea E. Park

XML 48 R2.htm IDEA: XBRL DOCUMENT v3.23.4
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Current assets:      
Cash and cash equivalents $ 397 $ 645 $ 584
Accounts and grants receivable, net 67 4 25
Related party receivables, net 4    
Prepaid expenses and other current assets 673 1,804 1,625
Total current assets 1,141 2,453 2,234
Restricted cash 50 50 50
Intangible assets, net 640 738 870
Convertible note receivable 10,379  
TOTAL ASSETS 12,210 3,241 3,154
Current liabilities:      
Accounts payable and accrued liabilities 1,671 1,034 771
Loans due to Juvenescence, net of debt issuance costs, current portion 1,526 7,646 7,140
Related party payables, net   141 70
Warrant liability 180
Insurance premium liability and other current liabilities 7 1,077 986
Total current liabilities 3,204 10,078 8,967
Loans due to Juvenescence, net of debt issuance costs, net of current portion 693 10,478 6,062
TOTAL LIABILITIES 3,897 20,556 15,029
Commitments and contingencies (Note 11)
Temporary equity preferred stock    
Stockholders’ deficit:      
Preferred stock, $0.0001 par value, 5,000 shares authorized
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively 4 4 4
Additional paid-in capital 100,017 98,994 93,912
Accumulated deficit (127,557) (116,210) (105,748)
Total AgeX Therapeutics, Inc. stockholders’ deficit (27,536) (17,212) (11,832)
Noncontrolling interest (109) (103) (43)
Total stockholders’ deficit (27,645) (17,315) (11,875)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT 12,210 3,241 3,154
Series B Preferred Stock [Member]      
Current liabilities:      
Temporary equity preferred stock 14,823
Series A Preferred Stock [Member]      
Current liabilities:      
Temporary equity preferred stock 21,135  
Related Party [Member]      
Current assets:      
Related party receivables, net 4
Current liabilities:      
Related party payables, net $ 141  
XML 49 R3.htm IDEA: XBRL DOCUMENT v3.23.4
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Preferred stock, par value $ 0.0001 $ 0.0001 $ 0.0001
Preferred stock, shares authorized 5,000,000 5,000,000 5,000,000
Preferred stock, shares issued   0 0
Preferred stock, shares outstanding   0 0
Common stock, par value $ 0.0001 $ 0.0001 $ 0.0001
Common stock, shares authorized 200,000,000 200,000,000 100,000,000
Common stock, shares issued 37,951,000 37,949,000 37,941,000
Common stock, shares outstanding 37,951,000 37,949,000 37,941,000
Series A Preferred Stock [Member]      
Temporary stock, par value $ 0 $ 0  
Temporary stock, stated value $ 100 $ 100  
Temporary stock, shares issued 212,000  
Temporary stock, shares outstanding 212,000  
Series B Preferred Stock [Member]      
Temporary stock, par value $ 0 $ 0  
Temporary stock, stated value $ 100 $ 100  
Temporary stock, shares issued 148,000  
Temporary stock, shares outstanding 148,000  
XML 50 R4.htm IDEA: XBRL DOCUMENT v3.23.4
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
REVENUES            
Total revenues $ 67,000 $ 9,000 $ 86,000 $ 26,000 $ 34,000 $ 144,000
Cost of sales (33,000) (5,000) (39,000) (12,000) (13,000) (19,000)
Gross profit 34,000 4,000 47,000 14,000 21,000 125,000
OPERATING EXPENSES            
Research and development 218,000 162,000 552,000 817,000 1,025,000 1,456,000
General and administrative 2,172,000 1,392,000 5,895,000 4,390,000 5,971,000 6,708,000
Total operating expenses 2,390,000 1,554,000 6,447,000 5,207,000 6,996,000 8,164,000
Gain on deconsolidation of LifeMap Sciences (Note 3)         106,000
Loss from operations (2,356,000) (1,550,000) (6,400,000) (5,193,000) (6,975,000) (7,933,000)
OTHER EXPENSE, NET:            
Interest expense, net (3,036,000) (923,000) (4,928,000) (2,357,000) (3,335,000) (1,097,000)
Change in fair value of warrants 35,000 (35,000) (220,000) (225,000)
Other income, net 3,000 2,000 10,000 9,000 13,000 448,000
Total other expense, net (3,033,000) (886,000) (4,953,000) (2,568,000) (3,547,000) (649,000)
NET LOSS FROM CONTINUING OPERATIONS         (10,522,000) (8,582,000)
NET LOSS FROM DISCONTINUED OPERATIONS (Note 3)         (103,000)
NET LOSS (5,389,000) (2,436,000) (11,353,000) (7,761,000) (10,522,000) (8,685,000)
Net (income) loss attributable to noncontrolling interest (12,000) 1,000 6,000 2,000 60,000 3,000
Net loss attributable to noncontrolling interest from discontinued operations         7,000
NET LOSS ATTRIBUTABLE TO AGEX $ (5,401,000) $ (2,435,000) $ (11,347,000) $ (7,759,000) $ (10,462,000) $ (8,675,000)
NET LOSS PER COMMON SHARE:            
Continuing operations         $ (0.28) $ (0.23)
Discontinued operations        
BASIC $ (0.14) $ (0.06) $ (0.30) $ (0.20) (0.28) (0.23)
DILUTED $ (0.14) $ (0.06) $ (0.30) $ (0.20) $ (0.28) $ (0.23)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:            
BASIC 37,951 37,946 37,951 37,944 37,945,000 37,886,000
DILUTED 37,951 37,946 37,951 37,944 37,945,000 37,886,000
AMOUNTS ATTRIBUTABLE TO AGEX:            
Loss from continuing operations         $ (10,462,000) $ (8,579,000)
Loss from discontinued operations         (96,000) [1]
Grant Revenues [Member]            
REVENUES            
Total revenues $ 21,000 $ 21,000 104,000
Other Revenues [Member]            
REVENUES            
Total revenues $ 46,000 $ 9,000 $ 65,000 $ 26,000 $ 34,000 $ 40,000
[1] Does not include $106,000 gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement. The gain on the sale of LifeMap Sciences is presented in the line item Gain on deconsolidation of LifeMap Sciences. There were no gains or losses resulting from the sale of businesses or assets that did not meet the criteria for a discontinued operation during the year ended December 31, 2021.
XML 51 R5.htm IDEA: XBRL DOCUMENT v3.23.4
Condensed Consolidated Statements of Operations Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
NET LOSS $ (10,522) $ (8,685)
Other comprehensive expense, net of tax:    
Foreign currency translation adjustments from discontinued operations (143)
COMPREHENSIVE LOSS (10,522) (8,828)
Less: Comprehensive loss attributable to noncontrolling interest from continuing operations 60 3
Less: Comprehensive loss attributable to noncontrolling interest from discontinued operations 7
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX COMMON STOCKHOLDERS $ (10,462) $ (8,818)
XML 52 R6.htm IDEA: XBRL DOCUMENT v3.23.4
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
AOCI Including Portion Attributable to Noncontrolling Interest [Member]
Total
Series A Preferred Stock [Member]
Series B Preferred Stock [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Balance at Dec. 31, 2020 $ 4 $ 91,810 $ (97,073) $ (280) $ 143 $ (5,396)        
Balance, shares at Dec. 31, 2020 37,691                  
Issuance of preferred stock 475 475        
Issuance of common stock, shares 242                  
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes (7) (7)        
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares 8                  
Issuance of warrants 757 757        
Stock-based compensation 1,003 1,003        
Transactions with noncontrolling interests – LifeMap Sciences (269) 269        
Deconsolidation of LifeMap Sciences 143 (22) (143) (22)        
Net loss (8,675) (10) (8,685)        
Balance at Dec. 31, 2021 $ 4 93,912 (105,748) (43) (11,875)        
Balance, shares at Dec. 31, 2021 37,941                  
Temporary equity balance, value at Dec. 31, 2021                  
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes (3)   (3)        
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares 6,000                  
Issuance of warrants 178   178        
Stock-based compensation 646   646        
Fair value of liability classified warrants issued 3,666   3,666        
Net loss (7,759) (2)   (7,761)        
Balance at Sep. 30, 2022 $ 4 98,399 (113,507) (45)   (15,149)        
Balance, shares at Sep. 30, 2022 37,947,000                  
Balance at Dec. 31, 2021 $ 4 93,912 (105,748) (43) (11,875)        
Balance, shares at Dec. 31, 2021 37,941                  
Temporary equity balance, value at Dec. 31, 2021                  
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes (4) (4)        
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares 8                  
Issuance of warrants 178 178        
Stock-based compensation 760 760        
Fair value of liability classified warrants issued 4,148 4,148        
Net loss (10,462) (60) (10,522)        
Balance at Dec. 31, 2022 $ 4 98,994 (116,210) (103) (17,315)        
Balance, shares at Dec. 31, 2022 37,949                  
Temporary equity balance, shares at Dec. 31, 2022            
Temporary equity balance, value at Dec. 31, 2022            
Balance at Jun. 30, 2022 $ 4 97,850 (111,072) (44)   (13,262)        
Balance, shares at Jun. 30, 2022 37,945,000                  
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes (1)   (1)        
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares 2,000                  
Stock-based compensation 209   209        
Fair value of liability classified warrants issued 341   341        
Net loss (2,435) (1)   (2,436)        
Balance at Sep. 30, 2022 $ 4 98,399 (113,507) (45)   (15,149)        
Balance, shares at Sep. 30, 2022 37,947,000                  
Balance at Dec. 31, 2022 $ 4 98,994 (116,210) (103) (17,315)        
Balance, shares at Dec. 31, 2022 37,949                  
Issuance of preferred stock          
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes (1)   (1)        
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares 2,000                  
Stock-based compensation 145   145        
Fair value of liability classified warrants issued 879   879        
Net loss (11,347) (6)   (11,353)        
Temporary equity balance, shares                 212,000 148,000
Temporary equity balance, value                 $ 21,160 $ 14,840
Preferred stock issuance costs          
Temporary equity balance, value                 (25) (17)
Temporary equity balance, value                
Balance at Sep. 30, 2023 $ 4 100,017 (127,557) (109)   (27,645)    
Balance, shares at Sep. 30, 2023 37,951,000                  
Temporary equity balance, shares at Sep. 30, 2023             212,000 148,000 212,000 148,000
Temporary equity balance, value at Sep. 30, 2023           $ 21,135 $ 14,823 $ 21,135 $ 14,823
Balance at Jun. 30, 2023 $ 4 99,977 (122,156) (121)   (22,296)    
Balance, shares at Jun. 30, 2023 37,951,000                  
Temporary equity balance, shares at Jun. 30, 2023                
Temporary equity balance, value at Jun. 30, 2023                
Issuance of preferred stock          
Stock-based compensation 40   40        
Net loss (5,401) 12   (5,389)    
Temporary equity balance, shares                 212,000 148,000
Temporary equity balance, value                 $ 21,160 $ 14,840
Preferred stock issuance costs          
Temporary equity balance, value                 (25) (17)
Temporary equity balance, value                
Balance at Sep. 30, 2023 $ 4 $ 100,017 $ (127,557) $ (109)   (27,645)    
Balance, shares at Sep. 30, 2023 37,951,000                  
Temporary equity balance, shares at Sep. 30, 2023             212,000 148,000 212,000 148,000
Temporary equity balance, value at Sep. 30, 2023           $ 21,135 $ 14,823 $ 21,135 $ 14,823
XML 53 R7.htm IDEA: XBRL DOCUMENT v3.23.4
Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
OPERATING ACTIVITIES:        
Net loss attributable to AgeX $ (11,347,000) $ (7,759,000) $ (10,462,000) $ (8,579,000)
Net loss attributable to noncontrolling interest (6,000) (2,000) (60,000) (3,000)
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:        
Gain on deconsolidation of LifeMap Sciences (Note 3)     (106,000)
Gain on extinguishment of debt (Paycheck Protection Program loan)     (437,000)
Change in fair value of warrants 35,000 220,000 225,000
Amortization of intangible assets 98,000 99,000 132,000 131,000
Amortization of debt issuance costs 5,170,000 2,221,000 3,137,000 1,114,000
Stock-based compensation 145,000 646,000 760,000 999,000
Changes in operating assets and liabilities:        
Accounts and grants receivable (63,000) 24,000 21,000 128,000
Prepaid expenses and other current assets 1,131,000 906,000 896,000 760,000
Interest on convertible note receivable (379,000)    
Accounts payable and accrued liabilities 571,000 (98,000) 144,000 (772,000)
Related party payables, net (33,000) 110,000 255,000
Insurance premium liability (1,075,000) (983,000) (983,000) (921,000)
Other current liabilities 5,000 (2,000) (4,000) (79,000)
Net cash used in operating activities from continuing operations     (5,939,000) (7,765,000)
Net cash used in operating activities from discontinued operations (Note 3)     (90,000)
Net cash used in operating activities (5,748,000) (4,618,000) (5,939,000) (7,855,000)
INVESTING ACTIVITIES:        
Proceeds from the sale of LifeMap Sciences (Note 3)     466,000
Partial collection on loan due from LifeMap Sciences     250,000
Net cash provided by investing activities from continuing operations     716,000
Deconsolidation of cash and cash equivalents from discontinued operations (Note 3)     (50,000)
Cash advanced on convertible note receivable (10,000,000)    
Net cash used in investing activities (10,000,000) 666,000
FINANCING ACTIVITIES:        
Drawdown on loan facilities from Juvenescence 15,500,000 4,500,000 6,000,000 7,000,000
Proceeds from the issuance of common stock     496,000
Net cash provided by financing activities from continuing operations     6,000,000 7,496,000
Partial payment on loan due to AgeX from discontinued operations (Note 3)     (250,000)
Net cash provided by financing activities 15,500,000 4,500,000 6,000,000 7,246,000
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (248,000) (118,000) 61,000 57,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:        
At beginning of the period 695,000 634,000 634,000 577,000
At end of the period 447,000 516,000 695,000 634,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:        
Cash paid during the year for interest $ 27,000 $ 14,000 14,000 13,000
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES:        
Issuance of common stock upon vesting of restricted stock units (Note 8)     8,000 16,000
Issuance of warrants for debt issuance under the 2020 Loan Agreement     178,000 757,000
Issuance of warrants for debt issuance under the Secured Note (Note 6)     4,148,000
Debt refinanced with new debt (Note 5)     $ 7,160,000
XML 54 R8.htm IDEA: XBRL DOCUMENT v3.23.4
Organization, Business Overview and Liquidity
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Organization, Business Overview and Liquidity

1. Organization, Business Overview and Liquidity

 

AgeX Therapeutics, Inc. (“AgeX”) was incorporated in January 2017 in the state of Delaware. AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions.

 

AgeX’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows AgeX to utilize telomerase-expressing regenerative pluripotent stem cells (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX’s main technology platforms and product candidates are:

 

  PureStem® PSC-derived clonal embryonic progenitor cell lines that may be capable of generating a broad range of cell types for use in cell-based therapies;
     
  UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells;
     
  AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes;
     
  AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and
     
  Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair.

 

Restructuring Plans and Merger Agreement

 

During March 2023, AgeX borrowed $10,000,000 from Juvenescence Limited (“Juvenescence”) under the terms of a Secured Convertible Promissory Note (the “$10 Million Secured Note”) and used the loan proceeds to make a $10,000,000 loan under the terms of a Convertible Promissory Note to Serina (the “Serina Note”), in order to provide financing to Serina Therapeutics, Inc. (“Serina”) in advance of corporate restructuring plans that include a potential merger between AgeX and Serina in which AgeX would be the surviving company.

 

On August 29, 2023, AgeX entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Serina and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“Merger Sub”). Serina currently has a pipeline of small molecule candidates targeting central nervous system (“CNS”) indications, enabled by the company’s proprietary POZ PlatformTM delivery technology. In addition to advancing Serina’s wholly owned pipeline assets, Serina is working with pharma partners currently advancing pre-clinical studies exploring POZ polymer lipid-nanoparticles (“LNPs”) in next generation LNP delivered RNA vaccines. In addition, Serina is advancing a lead drug candidate, SER-252 (POZ-apomorphine) for the treatment of advanced Parkinson’s Disease through pre-clinical studies towards the goal of an investigational new drug submission or “IND” to the Food and Drug Administration for the initiation of a Phase I clinical trial during the fourth quarter of 2024. Serina has two other pipeline assets that are positioned to enter IND enabling studies, SER-227 (POZ-buprenorphine) for certain post-operative pain indications, and SER-228 (POZ-cannabidiol) for treatment refractory epilepsy indications. Serina is also focused on expanding its LNP and anti-body drug conjugate partnering collaborations.

 

Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including that the Merger is approved by the stockholders of Serina and the issuance of AgeX common stock to Serina in the Merger is approved by the stockholders of AgeX, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the “Merger”). There is no assurance the necessary approvals by AgeX stockholders and Serina stockholders will be obtained or that the other conditions to the Merger as provided in the Merger Agreement will be met.

 

AgeX’s restructuring plans also include a potential spinoff of AgeX’s subsidiary Reverse Bioengineering, Inc. (“Reverse Bio”) through a distribution of some or all of the shares of capital stock of Reverse Bio held by AgeX to AgeX stockholders following a financing of Reverse Bio through the sale of shares of Reverse Bio common stock to private investors (the “Reverse Bio Financing”). If the Reverse Bio spinoff is completed, Reverse Bio would become a separate publicly traded company.

 

 

Definitive agreements regarding the Reverse Bio Financing and a Reverse Bio spinoff have not yet been executed, nor has AgeX’s board of directors approved the Reverse Bio spinoff. Accordingly, there is a risk that the Reverse Bio Financing and the Reverse Bio spinoff may never be consummated.

 

Emerging Growth Company

 

AgeX is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012.

 

Going Concern

 

AgeX primarily finances its operations through loans from its largest stockholder, Juvenescence Limited (“Juvenescence”). AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $127.6 million as of September 30, 2023. AgeX expects to continue to incur operating losses and negative cash flows.

 

Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have adopted operating plans and budgets to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those operating plans and budgets, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $0.4 million as of September 30, 2023 plus the loan facilities provided by Juvenescence to advance up to an additional $1 million to AgeX which was drawn in full in October 2023 and an additional $4.4 million line of credit made available to AgeX through an Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note with Juvenescence (the “Fifth Amendment”) on November 9, 2023 would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of these condensed consolidated interim financial statements. These conditions raise substantial doubt about AgeX’s ability to continue as a going concern. AgeX will need to obtain substantial additional funding in connection with its continuing operations. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should AgeX not continue as a going concern. See Note 12, Subsequent Events, for further details on the Fifth Amendment.

 

Liquidity and Impact of COVID-19

 

In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in out-licensing its technologies and development of its product candidates. Although AgeX has been able to reduce its operating expenses, with the exception of certain non-recurring expenses incurred related to the possible Merger between AgeX and Serina, by eliminating internal research and development activities and focusing instead on outsourcing research and development and seeking licensing arrangements for AgeX technologies, this approach has also made it more difficult for AgeX to make progress in developing its target product candidates and technologies, which in turn may make it more difficult for AgeX to raise capital. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its stockholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all.

 

1. Organization, Basis of Presentation and Liquidity

 

AgeX Therapeutics, Inc. (“AgeX,” “we,” “our,” or “us”) was incorporated in January 2017 in the state of Delaware as a subsidiary of Lineage Cell Therapeutics, Inc. (“Lineage,” formerly known as BioTime, Inc.), a publicly traded, clinical-stage biotechnology company.

 

AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions.

 

AgeX’s main technology platforms and product candidates are:

 

PureStem® PSC-derived clonal embryonic progenitor cell lines that may be capable of generating a broad range of cell types for use in cell-based therapies;

 

UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells;

 

AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes;

 

AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and

 

Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair.

 

AgeX is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012.

 

Lineage’s Sale of Significant Ownership Interest in AgeX to Juvenescence

 

On August 30, 2018, Lineage consummated the sale of 14,400,000 shares of common stock of AgeX owned by Lineage to Juvenescence Limited (“Juvenescence”). Prior to the transaction, Juvenescence owned 5.6% of AgeX’s issued and outstanding common stock. Upon completion of the transaction, Lineage’s ownership in AgeX was reduced from 80.4% to 40.2% of AgeX’s issued and outstanding shares of common stock, and Juvenescence’s ownership in AgeX was increased from 5.6% to 45.8% of AgeX’s issued and outstanding shares of common stock. AgeX did not receive any proceeds from the transaction. As a result of that transaction, AgeX ceased to be a subsidiary of Lineage because Lineage experienced a “loss of control” of a subsidiary, as defined by U.S. GAAP. Loss of control is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock in the subsidiary, lacks a controlling financial interest in the subsidiary and, is unable to unilaterally control the subsidiary through other means such as having, or being able to obtain, the power to elect a majority of the subsidiary’s Board of Directors based solely on contractual rights or ownership of shares holding a majority of the voting power of the subsidiary’s voting securities. All of these loss-of-control factors were present with respect to Lineage’s ownership interest in AgeX as of August 30, 2018. Accordingly, Lineage deconsolidated AgeX’s consolidated financial statements and results from its consolidated financial statements and results beginning on August 30, 2018.

 

On November 28, 2018 (the “Distribution Date”), Lineage distributed to its shareholders, on a pro rata basis, 12,697,028 shares of the AgeX common stock it then held (the “Distribution”). Immediately after the Distribution, Lineage retained 1,718,972 shares of AgeX common stock, representing approximately 4.8% of the common stock then issued and outstanding. Following the Distribution, AgeX common stock began publicly trading on the NYSE American under the symbol “AGE.”

 

Disposition and Deconsolidation of LifeMap Sciences

 

On March 6, 2021, AgeX and its then majority-owned subsidiary LifeMap Sciences, Inc. (“LifeMap Sciences”) entered into an Agreement and Plan of Merger (the “LifeMap Merger Agreement”) with Atlas Capital Partners Limited, a British Virgin Islands company limited by shares (“Atlas”), and GCLMS Acquisition Corporation (“GCLMS”), a Delaware corporation that was a wholly-owned subsidiary of Atlas. On March 15, 2021, the merger was completed pursuant to the terms of the LifeMap Merger Agreement. As a result of the merger, GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of a $500,000 cash payment for all shares of LifeMap Sciences common stock in the aggregate (the “LifeMap Merger Consideration”), with each LifeMap Sciences shareholder’s pro rata portion of the LifeMap Merger Consideration to be determined in accordance with the number of shares of LifeMap Sciences common stock owned by such shareholder as a percentage of shares of LifeMap Sciences common stock outstanding immediately before the effective date of the merger, and (b) the outstanding shares of GCLMS common stock were converted into shares of LifeMap Sciences common stock so that Atlas is now the sole shareholder of LifeMap Sciences.

 

 

AgeX received approximately $466,400 in cash as its pro rata share of the LifeMap Merger Consideration in the merger. Prior to and as a condition to the merger under the terms of the LifeMap Merger Agreement, $1,761,296 of LifeMap Sciences’ indebtedness to AgeX was converted into shares of LifeMap Sciences common stock. LifeMap Sciences also paid AgeX $250,000 in cash to pay off a portion of LifeMap Sciences’ indebtedness to AgeX that was not converted into shares of LifeMap Sciences common stock.

 

As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Accordingly, AgeX has deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from AgeX, effective March 15, 2021 (the “LifeMap Deconsolidation”), in accordance with Accounting Standards Codification (“ASC”) 810-10-40, Consolidation.

 

See Note 3, Disposition and Deconsolidation of LifeMap Sciences for additional information regarding the disposition and deconsolidation of LifeMap Sciences.

 

Going Concern

 

AgeX primarily finances its operations through loans from its largest stockholder Juvenescence. AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $116.2 million as of December 31, 2022. AgeX expects to continue to incur operating losses and negative cash flows.

 

Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have adopted operating plans and budgets to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those operating plans and budgets, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $0.6 million as of December 31, 2022 plus the loan facilities provided by Juvenescence to advance up to an additional $1.0 million for operating capital discussed in Note 11, Subsequent Events and the proceeds we may receive from the sale of additional shares of our common stock in “at-the-market” transactions through a Sales Agreement with Chardan Capital Markets, LLC (“Chardan”) as a sales agent, would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of these consolidated financial statements. These conditions raise substantial doubt about AgeX’s ability to continue as a going concern. AgeX will need to obtain substantial additional funding in connection with its continuing operations. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Principles of Consolidation

 

The consolidated financial statements of AgeX are presented in accordance with U.S. GAAP. AgeX’s consolidated financial statements include the accounts of its subsidiaries and certain research and development departments. AgeX consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of stockholders’ deficit on AgeX’s consolidated balance sheets.

 

AgeX’s consolidated balance sheets at December 31, 2022 and 2021 do not include LifeMap Sciences’ consolidated assets and liabilities due to the deconsolidation of LifeMap Sciences on March 15, 2021. LifeMap Sciences’ consolidated financial statements and consolidated results of operations include its wholly-owned and consolidated subsidiary, LifeMap Sciences, Ltd.

 

AgeX’s consolidated statements of operations for the year ended December 31, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the deconsolidation due to the conversion of $1,761,296 of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021 followed by the completion of the cash-out merger on the same day.

 

AgeX has three subsidiaries, Reverse Bioengineering, Inc. (“Reverse Bio”), ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTRTM research and development efforts. To the extent that such financing is obtained through the sale of capital stock or other equity securities to investors or other biopharma companies by Reverse Bio, AgeX’s equity interest in Reverse Bio and its iTRTM business would be diluted. ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 94.8% of the outstanding capital stock of ReCyte. NeuroAirmid is jointly owned by AgeX with the University of California – Irvine and certain researchers and was recently organized to pursue clinical development and commercialization of cell therapies, focusing initially on Huntington’s Disease. AgeX owns 50% of the outstanding capital stock of NeuroAirmid. AgeX consolidates NeuroAirmid despite not having majority ownership interest as it has the ability to influence decision making and financial results through contractual rights and obligations as per ASC 810, Consolidation.

 

All material intercompany accounts and transactions between AgeX and its subsidiaries have been eliminated in consolidation.

 

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, allocations and adjustments necessary for carve-out basis of presentation, including the separate return method for income taxes, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected. See Note 6, Warrant Liability for discussion on estimated change in fair value of warrant liability.

 

Transactions with Noncontrolling Interests of Subsidiaries

 

AgeX accounts for a change in ownership interests in its subsidiaries that does not result in a change of control of the subsidiary under the provisions of ASC 810-10-45-23, Consolidation – Other Presentation Matters, which prescribes the accounting for changes in ownership interest that do not result in a change in control of the subsidiary, as defined by U.S. GAAP, before and after the transaction. Under this guidance, changes in a controlling stockholder’s ownership interest that do not result in a change of control, as defined by U.S. GAAP, in the subsidiary are accounted for as equity transactions. Accordingly, if the controlling stockholder retains control, no gain or loss is recognized in the statements of operations of the controlling stockholder. Similarly, the controlling stockholder will not record any additional acquisition adjustments to reflect its subsequent purchases of additional shares in the subsidiary if there is no change of control. Only a proportional and immediate transfer of carrying value between the controlling and the noncontrolling stockholders occurs based on the respective ownership percentages.

 

Liquidity and Impact of COVID-19

 

In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in out-licensing its technologies and development of its product candidates. Although AgeX has been able to reduce its operating expenses by eliminating internal research and development activities and focusing instead on out-sourcing research and development and seeking licensing arrangements for AgeX technologies, this approach has also made it more difficult for AgeX to make progress in developing its target product candidates and technologies, which in turn may make it more difficult for AgeX to raise capital. The availability of financing also may be adversely impacted by the COVID-19 pandemic which disrupt aspects of AgeX’s operations. The extent to which the ongoing COVID-19 pandemic will ultimately impact AgeX’s business, results of operations, financial condition, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside AgeX’s control. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its stockholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all.

 

XML 55 R9.htm IDEA: XBRL DOCUMENT v3.23.4
Basis of Presentation and Summary of Significant Accounting Policies
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Basis of Presentation and Summary of Significant Accounting Policies

2. Basis of Presentation and Summary of Significant Accounting Policies

 

The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by U.S. GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

The accompanying condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of AgeX’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

Principles of consolidation

 

The consolidated financial statements include the accounts of AgeX and its subsidiaries in which AgeX has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which AgeX is the primary beneficiary (as described in more detail below). For consolidated entities where AgeX has less than 100% of ownership, AgeX records net loss attributable to noncontrolling interest on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. The noncontrolling interest is reflected as a separate element of stockholders’ equity (deficit) on AgeX’s consolidated balance sheets. Any material intercompany transactions and balances have been eliminated upon consolidation.

 

 

AgeX assesses whether it is the primary beneficiary of a variable interest entity (“VIE”) at the inception of the arrangement and at each reporting date. This assessment is based on its power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and AgeX’s obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. If the entity is within the scope of the variable interest model and meets the definition of a VIE, AgeX considers whether it must consolidate the VIE or provide additional disclosures regarding its involvement with the VIE. If AgeX determines that it is the primary beneficiary of the VIE, AgeX will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event. For entities AgeX holds as an equity investment that are not consolidated under the VIE model, AgeX will consider whether its investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.

 

AgeX has four subsidiaries, Reverse Bio, ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”), Canaria Transaction Corporation (“Merger Sub”), and has incorporated but not yet capitalized a fourth subsidiary UniverXome Bioengineering, Inc.(“UniverXome”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTRTM research and development efforts. AgeX is actively seeking equity financing for Reverse Bio and to the extent that such Reverse Bio Financing is obtained through the sale of capital stock or other equity securities by Reverse Bio, AgeX’s equity interest in Reverse Bio and its iTRTM business would be diluted. AgeX’s restructuring plans also include a potential spinoff of Reverse Bio through a distribution of some or all of the shares of capital stock of Reverse Bio held by AgeX to AgeX stockholders following the Reverse Bio Financing. ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 94.8% of the outstanding capital stock of ReCyte. NeuroAirmid is jointly owned by AgeX with the University of California – Irvine and certain researchers and was recently organized to pursue clinical development and commercialization of cell therapies, focusing initially on Huntington’s Disease. AgeX owns 50% of the outstanding capital stock of NeuroAirmid. AgeX consolidates NeuroAirmid despite not having majority ownership interest as it has the ability to influence decision making and financial results through contractual rights and obligations as per Accounting Standards Codification (“ASC”) 810, Consolidation. Merger Sub was incorporated for the purpose of merging with Serina to implement the Merger. UniverXome is expected, in connection with the planned Merger, to hold certain AgeX assets and assume AgeX indebtedness obligations to Juvenescence.

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of AgeX’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected.

 

See Note 6, Warrant Liability, for discussion on estimated change in fair value of warrant liability.

 

Concentration of credit risk and other risks and uncertainties

 

Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

 

AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, Convertible Note Receivable and 5, Related Party Transactions.

 

Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX.

 

 

Fair value measurements of financial instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.

 

The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. Fair values for AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.

 

To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures):

 

  Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
     
  Level 2 – Inputs to the valuation methodology include observable quoted prices (other than quoted market prices included within Level 1) for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.
     
  Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

 

In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. The discounted conversion prices triggered by certain qualified events in the Serina Note and the $10 Million Secured Note are Level 3 on the fair value hierarchy and subject to fair valuation at inception and remeasurement at each reporting period. The fair value of the discounted conversion prices under both notes were determined to have an immaterial value at inception and life to date of the notes, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period. For additional information regarding the convertible notes and derivatives, see Notes 4, Convertible Note Receivable, 5, Related Party Transactions, and 12, Subsequent Events.

 

The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.

 

The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations are discussed further in Note 6, Warrant Liability. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date. As of September 30, 2023, AgeX has utilized the full credit subject to warrants, and accordingly, the warrants were fully issued for each of the advances of loan funds under the Secured Note.

 

See Note 6, Warrant Liability, for additional information on accounting for liability classified warrants and certain Level 3 warrant valuation tables.

 

Cash, cash equivalents, and restricted cash

 

In accordance with Accounting Standards Update (“ASU”) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the condensed consolidated balance sheets to cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows for all periods presented is as follows (in thousands):

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Cash and cash equivalents  $397   $645 
Restricted cash (1)   50    50 
Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows  $447   $695 

 

(1) Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.

 

 

Long-lived intangible assets, net

 

Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 years. See Note 3, Selected Balance Sheet Components.

 

Impairment of long-lived assets

 

AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consists entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of September 30, 2023, there has been no impairment of long-lived assets.

 

Leases

 

AgeX accounts for leases in accordance with ASU 2016-02, Leases (Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX: (i) ASU 2018-10, Codification Improvements to Topic 842, Leases, and (ii) ASU 2018-11, Leases (Topic 842): Targeted Improvements, using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensed consolidated balance sheets.

 

ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.

 

AgeX leases office space in Alameda, California. For 2022 base monthly rent was $1,074 and for 2023 base monthly rent is $844 for slightly less space at the same building. AgeX has elected to not apply the recognition requirements under ASC 842 for the lease agreements and instead recognizes the lease payments as lease cost on a straight-line basis over the lease term as lease payments are not deemed material.

 

Accounting for warrants

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of September 30, 2023. See Notes 5, Related Party Transactions and 6, Warrant Liability, for additional information regarding warrants.

 

 

Revenue recognition

 

AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.

 

Grant revenues – AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements. At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.

 

In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, AgeX’s policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health (“NIH”) supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.

 

AgeX believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606.

 

In August 2023, AgeX was awarded a grant of up to approximately $341,000 from the NIH, National Heart, Lung and Blood Institute. The NIH grant will provide funding for continued development of AgeX’s technologies toward treating cardiovascular disease over a one year period starting September 1, 2023. Based on our evaluation under the accounting guidance aforementioned, this grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred. Accordingly, grant funds are made available by the NIH as allowable expenses are incurred. For the three and nine months ended September 30, 2023, AgeX incurred approximately $21,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues.

 

ESI BIO Research Products – AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP”. AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products have not been significant during the periods presented in the condensed consolidated interim financial statements included in this Report.

 

Arrangements with multiple performance obligations – AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of September 30, 2023 and December 31, 2022, AgeX did not have significant arrangements with multiple performance obligations.

 

 

Research and development

 

Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and contractors, sponsored research agreements with certain universities, and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations.

 

General and administrative

 

General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees.

 

Basic and diluted net loss per share attributable to common stockholders

 

Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.

 

For the three and nine months ended September 30, 2023 and 2022, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.

 

The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022   2023   2022 
Stock options   3,276    3,264    3,266    3,310 
Warrants (1)   12,132    10,616    12,716    8,947 
Restricted stock units   -    9    -    12 

 

(1) As of September 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 11,539,348 and 10,919,485 shares, respectively, of AgeX common stock as consideration for certain loan agreements discussed in Note 5, Related Party Transactions.

 

Reclassifications

 

Certain reclassifications have been made to the prior period’s condensed consolidated interim financial statements to conform to current year presentation. Additionally, certain financial information is presented on a rounded basis, which may cause minor differences.

 

Recently adopted accounting pronouncements

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.

 

 

In March 2022, the FASB issued ASU No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method, which clarifies the guidance in ASC 815 on fair value hedge accounting of interest rate risk for portfolios of financial assets. The ASU amends the guidance in ASU 2017-12 (released on August 28, 2017) that, among other things, established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible. ASU 2022-01 renames that method the “portfolio layer” method and addresses feedback from stakeholders regarding its application. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.

 

In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance became effective for AgeX on January 1, 2023 and includes interim periods. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. This ASU did not have a material impact on the condensed consolidated interim financial statements.

 

On July 14, 2023, the FASB issued ASU No. 2023-02, Presentation of Financial Statements (Topic 205), Income Statement – Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation, which amends or supersedes various SEC paragraphs within the codification to conform to past announcements and guidance issued by the SEC. Specifically, the ASU responds to (1) the issuance of SEC Staff Accounting Bulletin (SAB) 120; (2) the SEC staff announcement at the March 24, 2022, EITF meeting; and (3) SAB Topic 6.B, “Accounting Series Release No. 280 — General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.” This ASU is effective immediately and did not have a material impact on AgeX’s condensed consolidated interim financial statements.

 

2. Summary of Significant Accounting Policies

 

Going Concern Assessment

 

AgeX assesses going concern uncertainty for its consolidated financial statements to determine if AgeX has sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date the consolidated financial statements are issued or are available to be issued, which is referred to as the “look-forward period” as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to AgeX, AgeX will consider various scenarios, forecasts, projections, and estimates, and AgeX will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, AgeX makes certain assumptions concerning its ability to curtail or delay research and development programs and expenditures within the look-forward period in accordance with ASU No. 2014-15 (see Note 1, Organization, Basis of Presentation and Liquidity).

 

 

Fair Value Measurements of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.

 

The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. The credit facility is reported at fair value as it bears market rates of interest. Fair values for the AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.

 

To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures):

 

Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.

 

Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

 

The following table summarizes fair value measurements by level as of December 31, 2022 for liabilities measured at fair value on a recurring basis (in thousands):

 

   Level 1   Level 2   Level 3   Total 
Warrant liability  $-   $-   $180   $180 

 

There were no warrant liabilities as of December 31, 2021. See Note 6, Warrant Liability for additional information on accounting for liability classified warrants and level 3 rollforward table.

 

In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.

 

The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items.

 

The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.

 

The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations, are discussed further in Note 6, Warrant Liability. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date.

 

Cash and Cash Equivalents

 

AgeX considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2022 and 2021, AgeX’s cash balances totaled $0.6 million and $0.6 million, respectively, and consist entirely of bank account deposits and amounts held in money market funds.

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject AgeX to significant concentrations of credit risk consist primarily of cash and cash equivalents. AgeX limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, AgeX has not experienced any losses on such accounts.

 

 

Restricted Cash

 

In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands):

 

         
   December 31, 
   2022   2021 
Cash and cash equivalents  $645   $584 
Restricted cash (1)   50    50 
Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows  $695   $634 

 

 

(1)Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits in the consolidated balance sheets.

 

Accounts Receivable, Net

 

AgeX establishes an allowance for doubtful accounts based on the evaluation of the collectability of its receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. There were no amounts reserved for doubtful accounts as of December 31, 2022 and 2021.

 

Long-Lived Intangible Assets, Net

 

Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 years (see Note 4, Selected Balance Sheet Components).

 

Impairment of Long-Lived Assets

 

AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consist entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of December 31, 2022, there has been no impairment of long-lived assets.

 

Leases

 

AgeX accounts for leases in accordance with ASU 2016-02, Leases (Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX, which are: (i) ASU 2018-10, Codification Improvements to Topic 842, Leases, and (ii) ASU 2018-11, Leases (Topic 842): Targeted improvements, using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheets.

 

ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.

 

 

On November 3, 2020, AgeX entered into a one-year lease effective January 1, 2021 for 135 square feet of office space in a building in an office and research park in Alameda, California. Base monthly rent was $947 over the lease term. AgeX renewed this lease for 12 months effective January 1, 2022 for base monthly rent of $1,074. In October 2022, AgeX entered into a new 12 month lease for a slightly less space in the same building effective January 1, 2023 for base monthly rent of $844. AgeX elected to not apply the recognition requirements under ASC 842 and instead recognized the lease payments as lease costs on a straight-line basis over the lease term, as the amount of the lease payments were not deemed material.

 

Accounting for Warrants

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of December 31, 2022. See Notes 5, Related Party Transactions and 6, Warrant Liability for additional information regarding AgeX warrants.

 

Stock-Based Compensation

 

AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718, Compensation – Stock Compensation.

 

AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09.

 

AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under the Incentive Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.

 

Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations.

 

The Black-Scholes option pricing model requires AgeX to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 8, Stock-Based Awards).

 

The fair value of the shares of common stock underlying the stock options is determined in accordance with the Incentive Plan and is based on prevailing market prices on the NYSE American where AgeX common stock is traded.

 

The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. AgeX estimates the expected term of options granted using the “simplified method” provided under Staff Accounting

 

 

Bulletin, Topic 14, or SAB Topic 14.

 

Because AgeX’s common stock has public trading history of fewer than five years, AgeX has estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options, which may exceed five years. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage.

 

The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of AgeX’s stock options.

 

The dividend yield assumption is based on AgeX’s history and expectation of dividend payouts. AgeX has never declared or paid any cash dividends on its common stock, and AgeX does not anticipate paying any cash dividends in the foreseeable future.

 

All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.

 

Stock-based compensation expense for the years ended December 31, 2022 and 2021 consists of stock-based compensation under the AgeX 2017 Equity Incentive Plan (see Note 8, Stock-Based Awards).

 

Certain of AgeX’s consolidated subsidiaries have had their own share-based compensation plans; however, there are no awards granted and outstanding under those plans as of December 31, 2022 and 2021. For share-based compensation awards granted by privately held consolidated subsidiaries under their respective equity plans, AgeX determines the fair value of the options granted under those plans using similar methodologies and assumptions AgeX used for its stock options discussed above.

 

Although the fair value of stock options and restricted stock units is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.

 

Income Taxes

 

AgeX accounts for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. AgeX’s judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If AgeX’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on AgeX’s consolidated financial statements.

 

The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. AgeX recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No unrecognized tax benefits have been recorded and no amounts were accrued for the payment of interest and penalties as of December 31, 2022 and 2021. AgeX does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. AgeX is currently unaware of any tax issues under review.

 

Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2021, AgeX’s foreign entity operated at a loss; therefore, no GILTI was included in income. For the year ended December 31, 2022, there was no income or loss related to foreign activity as the entity deconsolidated from AgeX on March 15, 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.

 

 

Revenue Recognition

 

AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.

 

In the applicable paragraphs below, AgeX has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606.

 

Revenue recognition by source and geography – Revenues are recognized when control of the promised goods or services is transferred to customers, or in the case of governmental entities funding a grant, when allowable expenses are incurred, in an amount that reflects the consideration AgeX or a subsidiary, depending on which company has the customer or the grant, expects to be entitled to in exchange for those goods or services.

 

The following table presents AgeX’s consolidated revenues disaggregated by source for continuing operations (in thousands):

 

         
   Year Ended December 31, 
REVENUES:  2022   2021 
Grant revenues  $-   $104 
Other revenues   34    40 
Total revenues  $34   $144 

 

The following table presents consolidated revenues for continuing operations (in thousands), disaggregated by geography, based on the billing addresses of customers:

 

         
   Year Ended December 31, 
REVENUES:  2022   2021 
United States  $10   $107 
Foreign   24    37 
Total revenues  $34   $144 

 

Subscription and advertisement revenues – LifeMap Sciences sold subscription-based products, including research databases and software tools, for biomedical, gene, and disease research. LifeMap Sciences sold these subscriptions primarily through the internet to biotech and pharmaceutical companies worldwide. LifeMap Sciences’ principal subscription product was the GeneCards® Suite, which includes the GeneCards® human gene database, and the MalaCards™ human disease database. LifeMap Sciences’ performance obligations for subscriptions included a license of intellectual property related to its genetic information packages and premium genetic information tools. These licenses were deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue was recognized over a period of time, which was generally the subscription period. Payments were typically received at the beginning of a subscription period and revenue was recognized according to the type of subscription sold. For subscription contracts in which the subscription term commenced before a payment was due, LifeMap Sciences recorded an account receivable because the subscription was earned over time and billed the customer according to the contract terms. LifeMap Sciences deferred subscription revenues primarily represented subscriptions for which cash payment was received for the subscription term, but the subscription term was not completed as of the balance sheet date reported.

 

LifeMap Sciences licensed from third parties the databases and software it commercialized and had a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the consolidated statements of operations when the cash was received and the royalty obligation was incurred as the royalty payments did not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers.

 

LifeMap Sciences recognized $0.3 million in subscription and advertisement revenues for the year ended December 31, 2021, which is included in operating loss from discontinued operations, and is for revenues earned through March 15, 2021. As a result of the LifeMap Deconsolidation, AgeX does not expect to earn subscription and advertising revenues in subsequent accounting periods. See Note 3, Disposition and Deconsolidation of LifeMap Sciences for further information on the disposition and deconsolidation of LifeMap Sciences.

 

 

Grant revenues – AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements. At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.

 

In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.

 

On April 8, 2020, AgeX was awarded a grant of up to approximately $386,000 from the National Institutes of Health (“NIH”). The NIH grant provided funding for continued development of AgeX’s technologies for treating stroke. The grant funds were made available by the NIH to AgeX as allowable expenses were incurred. For the year ended December 31, 2021, AgeX incurred approximately $104,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. AgeX recognized no grant revenues for the year ended December 31, 2022 as AgeX had expended the full amount available under this grant as of December 31, 2021.

 

ESI BIO research products – AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP.” AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products are included in other revenues.

 

Arrangements with multiple performance obligations – AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of and for the years ended December 31, 2022 and 2021, AgeX did not have significant arrangements with multiple performance obligations.

 

Research and Development

 

Research and development expenses consist primarily of personnel costs and related benefits, stock-based compensation, amortization of intangible assets, and collaborative and contracted research and development fees. Research and development costs which have an alternative future use will be capitalized as intangible assets, and costs with no future benefit or alternative use will be expensed as incurred. Research and development expenses incurred and reimbursed by grants from third parties approximate the grant revenues recognized in the consolidated statements of operations.

 

General and Administrative

 

General and administrative expenses include employee and director compensation allocated to general and administrative expenses, consulting fees other than those paid for science-related consulting, license fees paid to third parties to acquire patents or licenses to use patents and other technology, professional fees to maintain patents and trademarks, minimum annual royalties stipulated under license and sublicense agreements with third parties, insurance costs allocated to general and administrative expenses, stock exchange-related costs, depreciation expense, marketing costs, legal and accounting costs, office rent, and other miscellaneous expenses which are allocated to general and administrative expense.

 

Foreign Currency Transaction Gains and Losses

 

For transactions denominated in other than the functional currency of AgeX or its subsidiaries, AgeX recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it.

 

 

Segments

 

AgeX’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, AgeX’s executive management team has viewed AgeX’s operations as one segment that includes the research and development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders, oncology, and neurological diseases and disorders, blood and vascular system diseases and disorders, and pluripotent cell technologies. As a result, the financial information disclosed materially represents all of the financial information related to AgeX’s sole operating segment.

 

Basic and Diluted Net Loss per Share Attributable to Common Stockholders

 

Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted-average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted-average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.

 

For the years ended December 31, 2022 and 2021, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.

 

The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):

 

   Year Ended December 31, 
   2022   2021 
Stock options   3,297    3,145 
Warrants (1)   9,558    3,492 
Restricted stock units        10         23 

 

 

(1)As of December 31, 2022 and 2021, AgeX issued Juvenescence warrants to purchase 12,129,260 and 3,512,098 shares, respectively, of AgeX common stock as consideration for the loan agreements discussed in Note 5, Related Party Transactions.

 

Recently Adopted Accounting Pronouncements

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The amendment in this update addresses how an issuer should account for modifications made to equity-classified written call options. The guidance in the standard requires the issuer to treat a modification of an equity-classified call option that does not cause the instrument to become liability-classified as an exchange of the original call option for a new call option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the call option or as termination of the original call option and issuance of a new call option. The Emerging Issues Task Force (EITF) concluded that the recognition of the modification depends on the nature of the transaction in which a warrant is modified. If there is more than one element in a transaction (for example, if the modification involves both a debt modification and an equity issuance), then the guidance requires the issuer to allocate the effect of the option modification to each element. Amendments in the new standard are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this ASU in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.

 

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity’s financial statements. The amendments are effective for all entities within their scope, which excludes not-for-profit entities and employee benefit plans, for financial statements issued for annual periods beginning after December 15, 2021. Early application of the amendment is permitted. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.

 

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. ASU 2016-13 is effective for AgeX beginning January 1, 2023 and is not expected to have a material impact on the consolidated financial statements.

 

In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance is effective for AgeX on January 1, 2023, including interim periods. Early adoption is permitted, and the amendment applied prospectively, except for the recognition and remeasurement of troubled debt restructurings. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. AgeX does not expect the adoption of this guidance to have a material impact on the consolidated financial statements.

 

CARES Act

 

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act but does not expect it to have a material impact to its tax provision or its consolidated financial statements. AgeX obtained a loan under the Paycheck Protection Program under the CARES Act, the repayment of which was forgiven in February 2021.

 

XML 56 R10.htm IDEA: XBRL DOCUMENT v3.23.4
Disposition and Deconsolidation of LifeMap Sciences
12 Months Ended
Dec. 31, 2022
Insurance [Abstract]  
Disposition and Deconsolidation of LifeMap Sciences

3. Disposition and Deconsolidation of LifeMap Sciences

 

Discontinued Operations

 

On March 6, 2021, AgeX and LifeMap Sciences entered into the LifeMap Merger Agreement with Atlas and GCLMS. On March 15, 2021, the merger was completed pursuant to the terms of the LifeMap Merger Agreement. As a result of the merger, GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of the $500,000 total LifeMap Merger Consideration, with each LifeMap Sciences shareholder’s pro rata portion of the LifeMap Merger Consideration determined in accordance with the number of shares of LifeMap Sciences common stock owned by such shareholder as a percentage of shares of LifeMap Sciences common stock outstanding immediately before the effective date of the merger, and (b) the outstanding shares of GCLMS common stock were converted into shares of LifeMap Sciences common stock so that Atlas is now the sole shareholder of LifeMap Sciences.

 

AgeX received approximately $466,400 in cash as its pro rata share of the LifeMap Merger Consideration in the merger. Prior to and as a condition to the merger under the terms of the LifeMap Merger Agreement, $1,761,296 of LifeMap Sciences’ indebtedness to AgeX was converted into shares of LifeMap Sciences common stock. LifeMap Sciences also paid AgeX $250,000 in cash to pay off a portion of LifeMap Sciences’ indebtedness to AgeX that was not converted into shares of LifeMap Sciences common stock.

 

The results of operations and cash flows for LifeMap Sciences are reported as discontinued operations under U.S. GAAP in accordance with ASC 205-20, Discontinued Operations, for all periods presented in our consolidated financial statements. AgeX will not have any continuing involvement in LifeMap Sciences subsequent to the consummation of the merger on March 15, 2021. The following table presents the operating results of LifeMap Sciences that have been treated as discontinued operations for the periods presented:

 

 

  

Year Ended

December 31, 2021

 
Net revenues  $277 
Costs, operating and other expenses   (380)
Loss from discontinued operations   (103)
Net loss from discontinued operations attributable to noncontrolling interest   7 
Loss from discontinued operations (1)  $(96)

 

 

(1)Does not include $106,000 gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement. The gain on the sale of LifeMap Sciences is presented in the line item Gain on deconsolidation of LifeMap Sciences. There were no gains or losses resulting from the sale of businesses or assets that did not meet the criteria for a discontinued operation during the year ended December 31, 2021.

 

 

Deconsolidation

 

As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Effective March 15, 2021, AgeX deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from those of AgeX under U.S. GAAP ASC 810-10-40-4, Deconsolidation of a Subsidiary or Derecognition of a Group of Assets, due to the disposition of LifeMap Sciences on that date.

 

AgeX’s consolidated balance sheets at December 31, 2022 and 2021 do not include LifeMap Sciences’ consolidated assets and liabilities due to the deconsolidation of LifeMap Sciences on March 15, 2021.

 

AgeX’s consolidated statement of operations for the year ended December 31, 2021 includes LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the LifeMap Deconsolidation due to the conversion of $1,761,296 of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021 followed by the completion of the cash-out merger on the same day.

 

AgeX recognized a gain of $106,000 from the LifeMap Deconsolidation. The sale of LifeMap Sciences was a taxable transaction to AgeX; however, no income tax is due as the transaction resulted in a taxable loss primarily due to AgeX’s tax basis in the subsidiary.

 

XML 57 R11.htm IDEA: XBRL DOCUMENT v3.23.4
Selected Balance Sheet Components
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Selected Balance Sheet Components

3. Selected Balance Sheet Components

 

Intangible assets, net

 

At September 30, 2023 and December 31, 2022, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands):

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Intangible assets  $1,312   $1,312 
Accumulated amortization   (672)   (574)
Total intangible assets, net  $640   $738 

 

AgeX recognized $33,000 and $98,000 in amortization expense of intangible assets, included in research and development expenses, for the three and nine months ended September 30, 2023, respectively and $33,000 and $99,000 for the same periods in 2022, respectively.

 

Amortization of intangible assets for periods subsequent to September 30, 2023 is as follows (in thousands):

 

Year Ending December 31, 

Amortization

Expense

 
2023  $33 
2024       131 
2025   131 
2026   132 
Thereafter   213 
Total  $640 

 

Accounts payable and accrued liabilities

 

At September 30, 2023 and December 31, 2022, accounts payable and accrued liabilities were comprised of the following (in thousands):

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Accounts payable  $1,172   $568 
Accrued compensation   206    193 
Accrued vendors and other expenses   293    273 
Total accounts payable and accrued liabilities  $1,671   $1,034 

 

 

4. Selected Balance Sheet Components

 

Intangible Assets, Net

 

On August 13, 2018, AgeX entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Escape Therapeutics, Inc. (“Escape”) pursuant to which AgeX acquired certain patents and patent applications related primarily to methods of modifying cells and tissues and certain pluripotent stem cell lines so as to reduce their risk of being rejected when transplanted. This technology is called “UniverCyte™.” AgeX paid Escape $1,072,436 in cash and issued 80,000 shares of AgeX common stock, with an approximate value of $240,000, for aggregate acquisition cost of $1.3 million for the UniverCyte™ assets. The Purchase Agreement was considered an asset acquisition rather than a business combination in accordance with ASC 805-50, Business Combinations.

 

ASC 730-10-25(c), Research and Development – Intangible Assets Purchased from Others, provides guidance for acquisition and capitalization of the cost of intangible assets purchased from others in an asset acquisition that have alternative future uses in other research and development projects. These intangible assets are referred to as acquired IPR&D with alternative future uses and are accounted for as intangible assets and amortized to research and development over their useful life. Acquired IPR&D in an asset acquisition that does not have any alternative future uses is expensed under the same guidance. As an initial focus, AgeX intends to use the UniverCyte™ technology in the development of its two lead products, AGEX-BAT1 and AGEX-VASC1 for the treatment of Type II diabetes and cardiovascular aging, respectively. Accordingly, AgeX recorded the UniverCyte™ technology acquired from Escape as IPR&D intangible assets with alternative future uses in accordance with ASC 730-10-25(c) and is amortizing those assets to research and development expense over their estimated 10-year useful life.

 

In addition to the purchase price, AgeX will pay Escape a royalty of less than 1% on net sales of products, processes and services under the acquired patents, if the assets are commercialized. Additional shares of AgeX common stock totaling up to $4.3 million of market value will also be issued to Escape upon the attainment of development and regulatory approval milestones by AgeX for each product covered by the acquired patents. Contingent consideration in an asset acquisition is generally recorded when probable and estimable in accordance with ASC 450, Contingencies. Accordingly, none of the milestone payments have been accrued since the attainment of any milestone in the Purchase Agreement was not probable as of December 31, 2022.

 

AgeX has also agreed to engage Escape’s chief executive officer as a consultant for a period of up to three years to assist AgeX in utilizing the acquired patents. AgeX paid $200,000 per year in consulting fees as services were performed, included in research and development expenses up until the agreement expired in August 2021.

 

 

AgeX estimated the future undiscounted cash flows expected to be received from the assets developed through the use of the UniverCyte™ technology when commercialized. The estimate of the future undiscounted cash flows considered AgeX’s financial condition and the royalties that may become payable to Escape.

 

At December 31, 2022 and 2021, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands):

 

         
   December 31, 
   2022   2021 
Intangible assets  $1,312   $1,312 
Accumulated amortization   (574)   (442)
Total intangible assets, net  $738   $870 

 

AgeX recognized $132,000 and $131,000 in amortization expense of intangible assets for continuing operations, included in research and development expenses, for the years ended December 31, 2022 and 2021, respectively.

 

Amortization expense of intangible assets for discontinued operations for the year ended December 31, 2021 amounted to $89,000. See Note 3, Disposition and Deconsolidation of LifeMap Sciences for discussion of discontinued operations.

 

Amortization of intangible assets for periods subsequent to December 31, 2022 is as follows (in thousands):

 

Year Ending December 31, 

Amortization

Expense

 
2023  $131 
2024   132 
2025   131 
2026   131 
Thereafter   213 
Total  $738 

 

Accounts Payable and Accrued Liabilities

 

At December 31, 2022 and 2021, accounts payable and accrued liabilities were comprised of the following (in thousands):

 

         
   December 31, 
   2022   2021 
Accounts payable  $568   $193 
Accrued compensation   193    212 
Accrued vendors and other expenses   273    366 
Total accounts payable and accrued liabilities  $1,034   $771 

 

XML 58 R12.htm IDEA: XBRL DOCUMENT v3.23.4
Related Party Transactions
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Related Party Transactions [Abstract]    
Related Party Transactions

5. Related Party Transactions

 

During July 2023, AgeX and Juvenescence entered into an Exchange Agreement pursuant to which AgeX issued shares of Series A Preferred Stock and Series B Preferred Stock to Juvenescence in exchange for the extinguishment of a total of $36 million of indebtedness under the 2020 Loan Agreement, the Secured Note, and the $10 Million Secured Note discussed below. The unused portion of the line of credit under the Secured Note remains available to AgeX subject to the terms and conditions of the Secured Note.

 

2019 Loan Agreement

 

On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence provided to AgeX a $2 million line of credit for a period of 18 months. On February 10, 2021, AgeX entered into an amendment (the “First Amendment”) to the 2019 Loan Agreement which extended the maturity date of loans under the 2019 Loan Agreement to February 14, 2022, and increased the amount of the loan facility by $4 million. On November 8, 2021, AgeX entered into Amendment No. 2 to the 2019 Loan Agreement which increased the amount of the loan facility by another $1 million. As of December 31, 2021, AgeX had borrowed all of the $7 million total line of credit under the 2019 Loan Agreement, as amended. On February 14, 2022, AgeX refinanced the $7 million outstanding principal amount of the loans and a $160,000 origination fee due under the 2019 Loan Agreement, as amended. See discussion regarding the 2022 Secured Convertible Promissory Note within this Note 5.

 

2020 Loan Agreement

 

On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence provided to AgeX an $8 million line of credit for a period of 18 months. Through September 30, 2023, AgeX had drawn the full $8 million line of credit. AgeX issued to Juvenescence 28,500 shares of AgeX common stock as an arrangement fee for the loan facility when AgeX borrowed an aggregate of $3 million under the 2020 Loan Agreement, and AgeX issued to Juvenescence warrants to purchase a total of 3,670,663 shares of AgeX common stock (“2020 Warrants”) as determined by the warrant formula described below of which 1,182,262 are outstanding as of September 30, 2023. On March 13, 2023, the 2020 Loan Agreement was amended to extend the maturity date to March 30, 2024. During July 2023, the full $8 million of 2020 Loan Agreement indebtedness was extinguished in exchange for shares of Series A Preferred Stock pursuant to the Exchange Agreement.

 

2020 Warrants — Under the terms of the 2020 Loan Agreement, each time AgeX received an advance of funds under the 2020 Loan Agreement, AgeX issued to Juvenescence a number of 2020 Warrants equal to 50% of the number determined by dividing the amount of the advance by the applicable Market Price. The Market Price set each 2020 Warrant when issued was the closing price per share of AgeX common stock on the NYSE American on the date of the applicable notice from AgeX requesting a draw of funds that triggered the obligation to issue the 2020 Warrant. The 2020 Warrants will expire at 5:00 p.m. New York time three years after the date of issue. AgeX had issued to Juvenescence 2020 Warrants to purchase a total of 3,670,663 shares of AgeX common stock of which 1,182,262 are outstanding as of September 30, 2023. The exercise prices of the 2020 Warrants issued through and that are still outstanding as of September 30, 2023 range from $0.81 per share to $1.895 per share representing the market closing price on the NYSE American of AgeX common stock on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

2022 Secured Convertible Promissory Note and Security Agreement

 

On February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence agreed to provide to AgeX a $13,160,000 line of credit for a period of 12 months. AgeX drew an initial $8,160,000 of the line of credit and used $7,160,000 to refinance the outstanding principal and the loan origination fees under the 2019 Loan Agreement with Juvenescence. On February 9, 2023, AgeX and Juvenescence entered into an Amended and Restated Secured Convertible Promissory Note which amends and restates the Secured Note and added $2 million to the line of credit available to be borrowed by AgeX under the Secured Note subject to Juvenescence’s discretion to approve each loan draw. On May 9, 2023, AgeX and Juvenescence entered into an Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (the “Second Amendment”) that increased the amount of the line of credit available to AgeX by $4,000,000, subject to the terms of the Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. On June 2, 2023, AgeX and Juvenescence entered into a Third Amendment to Amended and Restated Convertible Promissory Note (the “Third Amendment’), to provide that (i) AgeX may draw on the available portion of the line of credit under the Secured Note until the earlier of the date a Qualified Offering as defined in the Secured Note is consummated by AgeX or October 31, 2023 (subject to Juvenescence’s discretion to approve each loan draw as provided in the Secured Note), (ii) AgeX will not be obligated to issue additional common stock purchase warrants to Juvenescence in connection with the receipt of loan funds made available pursuant to the Second Amendment, and (iii) the definition of Reverse Financing Condition was amended to extend to June 20, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by Reverse Bioengineering, Inc. The date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.

 

 

On July 31, 2023, AgeX and Juvenescence entered into a Fourth Amendment (the “Fourth Amendment”) to the Secured Note to provide that (i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bio, and (ii) Juvenescence may convert the outstanding amount of the Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion. The 19.9% Cap is a provision of the Secured Note that limits the amount of common stock that Juvenescence may acquire through the conversion of Secured Note loans in order to comply with NYSE American requirements pertaining to the amount of shares that a listed company, such as AgeX, may sell at a price less than the market prices prevailing at the time the loans were made (the “Drawdown Market Prices”) without shareholder approval.

 

As of September 30, 2023, AgeX had borrowed a total of $18,160,000 under the Secured Note, of which $5,500,000 was borrowed during the nine months ended September 30, 2023. During July 2023, $17,992,800 of Secured Note indebtedness, comprised of $16,660,000 borrowing and $1,332,800 of accrued loan origination fees, was extinguished in exchange for shares of Series A Preferred Stock and Series B Preferred Stock pursuant to the Exchange Agreement. See Note 7, Stockholders’ Equity (Deficit).

 

As an arrangement fee for the Secured Note, AgeX will pay Juvenescence an origination fee in an amount equal to 4% of the amount each draw of loan funds, which will accrue as each draw is funded, and an additional 4% of all the total amount of funds drawn that will accrue following the end of the period during which funds may be drawn from the line of credit. The origination fee will become due and payable on the repayment date or in a pro rata amount with any prepayment of in whole or in part of the outstanding principal balance of the Secured Note.

 

2022 Warrants – Upon each drawdown of funds under the Secured Note prior to June 2, 2023 when the Third Amendment went into effect, AgeX issued to Juvenescence warrants to purchase shares of AgeX common stock (“2022 Warrants”). The 2022 Warrants are governed by the terms of a Warrant Agreement between AgeX and Juvenescence. The number of 2022 Warrants issued with respect to each draw of loan funds was equal to 50% of the number determined by dividing the amount of the applicable loan draw by the applicable Market Price. The Market Price was the last closing price per share of AgeX common stock on the NYSE American o preceding the delivery of the notice from AgeX requesting the draw of funds that triggered the obligation to issue 2022 Warrants. The exercise price of the 2022 Warrants is the applicable Market Price used to determine the number of Warrants issued. The 2022 Warrants will expire at 5:00 p.m. New York time three years after the date of issue.

 

As of September 30, 2023, AgeX had issued to Juvenescence 2022 Warrants to purchase a total of 10,357,086 shares of AgeX common stock, of which 2022 Warrants to purchase 1,898,489 shares of AgeX common stock were issued during the nine months ended September 30, 2023. The exercise prices of the 2022 Warrants issued through September 30, 2023 range from $0.59 per share to $0.88 per share representing the market closing price of AgeX common stock on the NYSE American on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

Conversion of Loan Amounts to Common Stock – In lieu of repayment of funds borrowed, AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock.

 

 

Default Provisions – The loan balance and origination fees may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the Secured Note include the following: (a) AgeX fails to pay any principal amount payable by it in the manner and at the time provided under and in accordance with the Secured Note; (b) AgeX fails to pay any other amount payable by it in the manner and at the time provided under and in accordance with the Secured Note or the Security Agreement described below or any other agreement executed in connection with the Secured Note (the “Loan Documents”) and the failure is not remedied within three business days; (c) AgeX fails to perform any of its covenants or obligations or fail to satisfy any of the conditions under the Secured Note or any other Loan Document and, such failure (if capable of remedy) remains unremedied to the satisfaction of Juvenescence (in its sole discretion) for 10 business days after the earlier of (i) notice requiring its remedy has been given by Juvenescence to AgeX and (ii) actual knowledge of the failure by senior officers of AgeX; (d) if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date; (e) AgeX stops payment of its debts generally or ceases or threatens to cease to carry on its business or is unable to pay its debts as they fall due or is deemed by a court of competent jurisdiction to be unable to pay its debts as they fall due, or enters into any arrangements with its creditors generally; (f) if (i) an involuntary proceeding (other than a proceeding instituted by Juvenescence or an affiliate of Juvenescence) shall be commenced or an involuntary petition shall be filed seeking liquidation, reorganization or other relief in respect of AgeX and any subsidiary, or of all or a substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) an involuntary appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for AgeX or a subsidiary or for a substantial part of its assets occurs (other than in a proceeding instituted by Juvenescence or an affiliate of Juvenescence), and, in any such case, such proceeding shall continue undismissed and unstayed for sixty (60) consecutive days without having been dismissed, bonded or discharged or an order of relief is entered in any such proceeding; (g) it becomes unlawful for AgeX to perform all or any of its obligations under the Secured Note or any authorization, approval, consent, license, exemption, filing, registration or other requirement of any governmental, judicial or public body or authority necessary to enable AgeX to comply with its obligations under the Secured Note or to carry on its business is not obtained or, having been obtained, is modified in a manner that precludes AgeX or its subsidiaries from conducting their business in any material respect, or is revoked, suspended, withdrawn or withheld or fails to remain in full force and effect; (h) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX or a subsidiary if such process is not released, vacated or fully bonded within 60 calendar days after its issue or levy; (i) any injunction, order, judgment or decision of any court is entered or issued which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX or a subsidiary to carry on its business or to pay amounts owed to Juvenescence under the Secured Note; (j) AgeX, whether in a single transaction or a series of related transactions, sells, leases, licenses, consigns, transfers or otherwise disposes of any material portion of its assets (with any such disposition with respect to any asset or assets with a fair value of at least $250,000 being deemed material), other than (i) certain permitted investments (ii) sales, transfers and dispositions of inventory in the ordinary course of business, (iii) any termination of a lease of real or personal property that is not necessary in the ordinary course of the AgeX’s business, could not reasonably be expected to have a material adverse effect and does not result from AgeX’s default, and (iv) any sale, lease, license, consignment, transfer or other disposition of assets that are no longer necessary in the ordinary course of business or which has been approved in writing by Juvenescence; (k) any of the following shall occur: (i) the security and/or liens created by the Security Agreement or any other Loan Document shall at any time cease to constitute valid and perfected security and/or liens on any material portion of the collateral intended to be covered thereby; (ii) except for expiration in accordance with its terms, the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall for whatever reason be terminated or shall cease to be in full force and effect; (iii) the enforceability of the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall be contested by AgeX or a subsidiary; (iv) AgeX shall assert that its obligations under the Secured Note or any other Loan Document shall be invalid or unenforceable; or (v) a loss, theft, damage or destruction occurs with respect to a material portion of the collateral; (l) there is any change in the financial condition of AgeX and its subsidiaries which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX to perform any of its obligations under the Secured Note; and (m) any representation, warranty or statement made, repeated or deemed made or repeated by AgeX in the Secured Note, or pursuant to the Loan Documents, is incomplete, untrue, incorrect or misleading in any material respect when made, repeated or deemed made.

 

Restrictive Covenants – The Secured Note includes certain covenants that among other matters such as financial reporting: (i) impose financial restrictions on AgeX while the Secured Note remains unpaid, including restrictions on the incurrence of additional indebtedness by AgeX and its subsidiaries, except that AgeX’s subsidiary Reverse Bio will be permitted to incur debt convertible into equity not guaranteed or secured by the assets of AgeX or any other AgeX subsidiary, (ii) require that AgeX use loan proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, for general working capital, and for repayment of all or a portion of AgeX’s indebtedness to Juvenescence; and (iii) prohibit AgeX from making additional investments in subsidiaries, unless AgeX obtains the written consent of Juvenescence to a transaction that otherwise would be prohibited or restricted.

 

Security Agreement – AgeX has entered into a Security Agreement granting Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral.

 

$10 Million Secured Convertible Promissory Note

 

On March 13, 2023, AgeX and Juvenescence entered into a $10 Million Secured Convertible Promissory Note (the “$10 Million Secured Note”) pursuant to which Juvenescence has loaned to AgeX $10,000,000. AgeX used the loan proceeds to finance the $10,000,000 loan to Serina under the Serina Note. See Note 4, Convertible Note Receivable, for further information on the Serina Note and the related Serina Note Purchase Agreement.

 

 

On July 31, 2023, AgeX and Juvenescence also entered into an amendment to the $10 Million Secured Note that mirrors the amendments of the Secured Note described above, and also creates an earlier time window, ending October 31, 2023, during which Juvenescence may elect to convert any amount outstanding under the $10 Million Secured Note into shares of AgeX common stock. After October 31, 2023, Juvenescence may convert outstanding amounts under the $10 Million Secured Note into AgeX common stock on any date more than ninety (90) days after the earlier of (a) the occurrence of a Qualified Merger as defined, and (b) March 13, 2024.

 

The outstanding principal balance of the $10 Million Secured Note was scheduled to become due and payable on March 13, 2026. In lieu of accrued interest, AgeX agreed to pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.

 

During July 2023, the $10 Million Secured Note indebtedness, plus a portion of the accrued loan origination fees, was exchanged for Series B Preferred Stock pursuant to the Exchange Agreement.

 

The $10 Million Secured Note includes a provision allowing AgeX to convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. If less than $25,000,000 is raised through the sale of common stock or units, the conversion price per share or units shall be the lowest price at which shares or units are sold. If at least $25,000,000 is raised, the conversion price per share shall be 85% of the “Market Price” of AgeX common stock determined as provided in the $10 Million Secured Note. AgeX evaluated the 15% discounted conversion feature of the $10 Million Secured Note under ASC 815-15, Derivatives and Hedging—Embedded Derivatives, and concluded that it was an embedded derivative which should be bifurcated from the $10 Million Secured Note and accounted for separately. The 15% discount was determined to have an immaterial value at inception and life to date of the $10 Million Secured Note, as the probability of a future financing event described above is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period and any adjustments will be included in Interest (income) expense, net in the Other (income) expense, net section of the condensed consolidated statements of operations.

 

The $10 Million Secured Note includes certain covenants that among other matters require financial reporting and impose certain restrictions on AgeX that are substantially the same as those under the Secured Note.

 

AgeX has entered into an Amended and Restated Security Agreement that amends the February 14, 2022 Security Agreement between AgeX and Juvenescence and adds the $10 Million Secured Note to the obligations secured by the Security Agreement. The Security Agreement grants Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default as defined in the $10 Million Secured Note occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral with respect to any accrued loan origination fees remaining unpaid under the $10 Million Secured Note.

 

Registration Rights

 

AgeX entered into certain Registration Rights Agreements, as amended, pursuant to which AgeX has agreed to register for sale under the Securities Act of 1933, as amended (the “Securities Act”) all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement and pursuant to the Secured Note, and shares that they may acquire through the conversion of those loans into AgeX common stock. AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of AgeX common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence. Juvenescence retains the right to require AgeX to register additional shares of common stock that Juvenescence may acquire through the exercise of warrants or the conversion of loans. AgeX is obligated to pay the fees and expenses of each registered offering under such registration rights agreement except for underwriting discounts and commissions. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.

 

AgeX and Juvenescence have entered into a second Registration Rights Agreement pursuant to which AgeX has agreed to use commercially reasonable efforts to register the for sale under the Securities Act the shares of common stock issuable upon conversion of Preferred Stock. A registration statement must be filed upon request of Juvenescence if Form S-3 is available to AgeX. Juvenescence will also have “piggy-back” registration rights if AgeX files a registration statement for the sale of shares for itself or other stockholders, subject to certain customary exceptions based on the nature of the registration statement. AgeX will bear the expenses of the registration statement but not underwriting or broker’s commissions related to the sale of the common stock. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.

 

 

Debt Issuance Costs

 

In accordance with ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, all debt issuance costs are recorded as a discount on the debt and amortized to interest expense over the term of the applicable loan agreement using the effective interest method. Direct debt issuance costs include but are not limited to legal fees, debt origination fees, estimated fair market value of common stock and warrants issued in connection with the loan agreement, and NYSE American additional listing fees for the underlying shares of warrants issued with each drawdown of funds.

 

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of September 30, 2023 (in thousands):

 

   Drawdown of Funds   Origination Fee   Debt Exchanged for Preferred Stock   Total Debt   Debt Issuance Costs  

Amortization

of Debt Issuance Costs

   Total Debt, Net 
Current                                   
2020 Loan Agreement  $8,000   $-   $(8,000)  $-   $(2,806)  $2,806   $- 
Secured Note   18,160    1,406    (17,993)   1,573    (6,044)   5,997    1,526 
 Total current, net   26,160    1,406    (25,993)   1,573    (8,850)   8,803    1,526 
Non-current                                   
 $10 Million Secured Note   10,000    700    (10,007)   693    (666)   666    693 
Total debt, net  $36,160   $2,106   $(36,000)  $2,266   $(9,516)  $9,469   $2,219 

 

Related Party Receivables/Payables, net

 

Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, is devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $280,000. AgeX reimburses Juvenescence for services provided by other Juvenescence employees on a work order basis under a shared services agreement effective January 1, 2023. As of September 30, 2023, AgeX had approximately $4,000 receivable from Juvenescence included in related party receivables, net, on the condensed consolidated balance sheet. As of December 31, 2022, AgeX had approximately $141,000 payable to Juvenescence included in related party payables, net, on the condensed consolidated balance sheet.

 

Indemnification Agreements

 

On March 13, 2023, AgeX executed that certain Letter of Indemnification in Lieu of or Supplemental to a Medallion Signature Guarantee (“Letter of Indemnification”), pursuant to which AgeX agreed to indemnify American Stock Transfer & Trust Company, LLC and its affiliates, successors and assigns (the “AST Indemnity”) from and against any and all claims, damages, liabilities or losses arising out of the transfer of all of the AgeX common stock held by Juvenescence to its wholly-owned subsidiary, Juvenescence US Corp. (the “Share Transfer”). In connection with AgeX’s execution of the Letter of Indemnification, AgeX and Juvenescence entered into that certain Transfer of Shares of AgeX Therapeutics, Inc. Common Stock – Indemnification Agreement, pursuant to which Juvenescence agreed to indemnify AgeX against any and all claims, damages, liabilities or losses arising out of the Share Transfer or AST Indemnity.

 

5. Related Party Transactions

 

2019 Loan Agreement

 

On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence provided to AgeX a $2.0 million line of credit for a period of 18 months. On February 10, 2021, AgeX entered into an amendment (the “First Amendment”) to the 2019 Loan Agreement which extended the maturity date of loans under the 2019 Loan Agreement to February 14, 2022 and increased the amount of the loan facility by $4.0 million. On November 8, 2021, AgeX entered into Amendment No. 2 to the 2019 Loan Agreement which increased the amount of the loan facility by another $1.0 million. As of December 31, 2021, AgeX had borrowed all of the $7.0 million total line of credit under the 2019 Loan Agreement, as amended. On February 14, 2022, AgeX refinanced the $7.0 million outstanding principal amount of the loans and a $160,000 origination fee due under the 2019 Loan Agreement, as amended. See discussion regarding 2022 Secured Convertible Promissory Note within this Note 5.

 

 

2020 Loan Agreement

 

On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence provided to AgeX an $8.0 million line of credit for a period of 18 months. Through December 31, 2022, AgeX had drawn the full $8.0 million line of credit. AgeX issued to Juvenescence 28,500 shares of AgeX common stock as an arrangement fee for the loan facility when AgeX borrowed an aggregate of $3.0 million under the 2020 Loan Agreement, and AgeX issued to Juvenescence warrants to purchase a total of 3,670,663 shares of AgeX common stock (“2020 Warrants”). The number of 2020 Warrants issued was determined by the warrant formula described below. The repayment date for the outstanding principal balance of the loan under the 2020 Loan Agreement will be March 30, 2024 (see Note 11, Subsequent Events).

 

Default Provisions – The loan balance may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the 2020 Loan Agreement include the following: (i) AgeX fails to pay any amount in the manner and at the time provided in the 2020 Loan Agreement and the failure to pay is not remedied within 10 business days; (ii) AgeX fails to perform any of its obligations under the 2020 Loan Agreement and if the failure can be remedied it is not remedied to the satisfaction of Juvenescence within 10 business days after notice to AgeX; (iii) other indebtedness for money borrowed in excess of $100,000 becomes due and payable or can be declared due and payable prior to its due date or if indebtedness for money borrowed in excess of $25,000 is not paid when due; (iv) AgeX stops payment of its debts generally or discontinues its business or becomes unable to pay its debts as they become due or enters into any arrangement with creditors generally; (v) AgeX becoming insolvent or in liquidation or administration or other insolvency procedures, or a receiver, trustee or similar officer is appointed in respect of all or any part of its assets and such appointment continues undischarged or unstayed for sixty days; (vi) it becomes illegal for AgeX to perform its obligations under the 2020 Loan Agreement or any governmental permit, license, consent, exemption or similar requirement for AgeX to perform its obligations under the 2020 Loan Agreement or to carry out its business is not obtained or ceases to remain in effect; (vii) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX if such process is not released, vacated or fully bonded within sixty calendar days after its issue or levy; (viii) any injunction, order or judgement of any court is entered or issued which in the opinion of Juvenescence materially and adversely affects the ability of AgeX to carry out its business or to pay amounts owed to Juvenescence under the 2020 Loan Agreement; (ix) there is a change in AgeX’s financial condition that in the opinion of Juvenescence materially and adversely affects, or is likely to so affect, its ability to perform any of its obligations under the 2020 Loan Agreement; (x) AgeX or a designated subsidiary sells, leases, licenses, consigns, transfers, or otherwise disposes of a material part of their assets other than inventory in the ordinary course of business or certain intercompany transactions, or certain other limited permitted transactions, unless Juvenescence approves; (xi) AgeX or a designated subsidiary contests the validity of its obligations under the 2020 Loan Agreement or other related agreement with Juvenescence; (xii) any representation, warranty, or other statement made by AgeX or a designated subsidiary under the 2020 Loan Agreement is incomplete, untrue, incorrect, or misleading: and (xiii) AgeX or a designated subsidiary suspends or ceases to carry on all or a material part of its business or threatens to do so.

 

2020 Warrants — Under the terms of the 2020 Loan Agreement, each time AgeX received an advance of funds under the 2020 Loan Agreement, AgeX issued to Juvenescence a number of 2020 Warrants equal to 50% of the number determined by dividing the amount of the advance by the applicable Market Price. The Market Price set each 2020 Warrant when issued was the closing price per share of AgeX common stock on the NYSE American on the date of the applicable notice from AgeX requesting a draw of funds that triggered the obligation to issue the 2020 Warrant. The exercise price of the 2020 Warrants is the applicable Market Price. The 2020 Warrants will expire at 5:00 p.m. New York time three years after the date of issue. As of December 31, 2022, AgeX had issued to Juvenescence 2020 Warrants to purchase 3,670,663 shares of AgeX common stock. The exercise prices of the 2020 Warrants issued through December 31, 2022 range from $0.70 per share to $1.895 per share representing the market closing price on the NYSE American of AgeX common stock on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

Conversion of Loan Amounts to Common Stock – In lieu of repayment of funds borrowed, AgeX may convert the loan balance into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock.

 

2022 Secured Convertible Promissory Note and Security Agreement

 

On February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence agreed to provide to AgeX a $13,160,000 line of credit for a period of 12 months. AgeX drew an initial $8,160,000 of the line of credit and used $7,160,000 to refinance the outstanding principal and the loan origination fees under the 2019 Loan Agreement with Juvenescence. During the year ended December 31, 2022, AgeX borrowed an additional $4.5 million under the Secured Note. During January 2023, AgeX borrowed an additional $500,000 under the Secured Note and during February 2023 the Secured Note was amended and restated to increase the total line of credit available by $2,000,000 and the date by which additional funds can be drawn was extended to May 9, 2023. The outstanding principal balance of the Secured Note, as amended will become due and payable on February 14, 2024. See Note 11, Subsequent Events for additional information on the amended and restated Secured Note.

 

 

As an arrangement fee for the Secured Note, AgeX will pay Juvenescence an origination fee in an amount equal to 4% of the amount each draw of loan funds, which will accrue as each draw is funded, and an additional 4% of all the total amount of funds drawn that will accrue following the end of the period during which funds may be drawn from the line of credit. The origination fee will become due and payable on the repayment date or in a pro rata amount with any prepayment of in whole or in part of the outstanding principal balance of the Secured Note.

 

2022 Warrants – Upon each drawdown of funds under the Secured Note, AgeX will issue to Juvenescence warrants to purchase shares of AgeX common stock (“2022 Warrants”). The 2022 Warrants will be governed by the terms of a Warrant Agreement between AgeX and Juvenescence. The number of 2022 Warrants to be issued will be equal to 50% of the number determined by dividing the amount of the applicable loan draw by the applicable Market Price. The Market Price will be the last closing price per share of AgeX common stock on the NYSE American or other national securities exchange preceding the delivery of the notice from AgeX requesting a draw of funds that triggers the obligation to issue 2022 Warrants; provided, however that if AgeX common stock is not traded on a national securities exchange the Market Price shall be determined with reference to closing prices quoted or bid and asked prices on an interdealer quotation system averaged over twenty consecutive trading days. The exercise price of the 2022 Warrants will be the applicable Market Price. The 2022 Warrants will expire at 5:00 p.m. New York time three years after the date of issue.

 

As of December 31, 2022, AgeX had issued to Juvenescence 2022 Warrants to purchase 8,458,597 shares of AgeX common stock. The exercise prices of the 2022 Warrants issued through December 31, 2022 range from $0.59 per share to $0.88 per share representing the market closing price of AgeX common stock on the NYSE American on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.

 

Conversion of Loan Amounts to Common Stock – In lieu of repayment of funds borrowed, AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock.

 

Default Provisions – The loan balance and origination fees may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the Secured Note include the following: (a) AgeX fails to pay any principal amount payable by it in the manner and at the time provided under and in accordance with the Secured Note; (b) AgeX fails to pay any other amount payable by it in the manner and at the time provided under and in accordance with the Secured Note or the Security Agreement described below or any other agreement executed in connection with the Secured Note (the “Loan Documents”) and the failure is not remedied within three business days; (c) AgeX fails to perform any of its covenants or obligations or fail to satisfy any of the conditions under the Secured Note or any other Loan Document and, such failure (if capable of remedy) remains unremedied to the satisfaction of Juvenescence (in its sole discretion) for 10 business days after the earlier of (i) notice requiring its remedy has been given by Juvenescence to AgeX and (ii) actual knowledge of the failure by senior officers of AgeX; (d) if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date; (e) AgeX stops payment of its debts generally or ceases or threatens to cease to carry on its business or is unable to pay its debts as they fall due or is deemed by a court of competent jurisdiction to be unable to pay its debts as they fall due, or enters into any arrangements with its creditors generally; (f) if (i) an involuntary proceeding (other than a proceeding instituted by Juvenescence or an affiliate of Juvenescence) shall be commenced or an involuntary petition shall be filed seeking liquidation, reorganization or other relief in respect of AgeX and any subsidiary, or of all or a substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) an involuntary appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for AgeX or a subsidiary or for a substantial part of its assets occurs (other than in a proceeding instituted by Juvenescence or an affiliate of Juvenescence), and, in any such case, such proceeding shall continue undismissed and unstayed for sixty (60) consecutive days without having been dismissed, bonded or discharged or an order of relief is entered in any such proceeding; (g) it becomes unlawful for AgeX to perform all or any of its obligations under the Secured Note or any authorization, approval, consent, license, exemption, filing, registration or other requirement of any governmental, judicial or public body or authority necessary to enable AgeX to comply with its obligations under the Secured Note or to carry on its business is not obtained or, having been obtained, is modified in a manner that precludes AgeX or its subsidiaries from conducting their business in any material respect, or is revoked, suspended, withdrawn or withheld or fails to remain in full force and effect; (h) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX or a subsidiary if such process is not released, vacated or fully bonded within 60 calendar days after its issue or levy; (i) any injunction, order, judgment or decision of any court is entered or issued which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX or a subsidiary to carry on its business or to pay amounts owed to Juvenescence under the Secured Note; (j) AgeX, whether in a single transaction or a series of related transactions, sells, leases, licenses, consigns, transfers or otherwise disposes of any material portion of its assets (with any such disposition with respect to any asset or assets with a fair value of at least $250,000 being deemed material), other than (i) certain permitted investments (ii) sales, transfers and dispositions of inventory in the ordinary course of business, (iii) any termination of a lease of real or personal property that is not necessary in the ordinary course of the AgeX’s business, could not reasonably be expected to have a material adverse effect and does not result from AgeX’s default, and (iv) any sale, lease, license, consignment, transfer or other disposition of assets that are no longer necessary in the ordinary course of business or which has been approved in writing by Juvenescence; (k) any of the following shall occur: (i) the security and/or liens created by the Security Agreement or any other Loan Document shall at any time cease to constitute valid and perfected security and/or liens on any material portion of the collateral intended to be covered thereby; (ii) except for expiration in accordance with its terms, the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall for whatever reason be terminated or shall cease to be in full force and effect; (iii) the enforceability of the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall be contested by AgeX or a subsidiary; (iv) AgeX shall assert that its obligations under the Secured Note or any other Loan Document shall be invalid or unenforceable; or (v) a loss, theft, damage or destruction occurs with respect to a material portion of the collateral; (l) there is any change in the financial condition of AgeX and its subsidiaries which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX to perform any of its obligations under the Secured Note; and (m) any representation, warranty or statement made, repeated or deemed made or repeated by AgeX in the Secured Note, or pursuant to the Loan Documents, is incomplete, untrue, incorrect or misleading in any material respect when made, repeated or deemed made.

 

 

Restrictive Covenants – The Secured Note includes certain covenants that among other matters such as financial reporting: (i) impose financial restrictions on AgeX while the Secured Note remains unpaid, including restrictions on the incurrence of additional indebtedness by AgeX and its subsidiaries, except that AgeX’s subsidiary Reverse Bio will be permitted to incur debt convertible into equity not guaranteed or secured by the assets of AgeX or any other AgeX subsidiary, and the restrictions on the incurrence of indebtedness applicable to Reverse Bio will end if it raises more than $15.0 million in debt or equity financing by May 15, 2023 (ii) require that AgeX use loan proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, for general working capital, and for repayment of all or a portion of AgeX’s indebtedness to Juvenescence; and (iii) prohibit AgeX from making additional investments in subsidiaries, unless AgeX obtains the written consent of Juvenescence to a transaction that otherwise would be prohibited or restricted.

 

Security Agreement – AgeX has entered into a Security Agreement granting Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral.

 

Registration Rights

 

AgeX entered into certain Registration Rights Agreements pursuant to which it has agreed to register for sale under the Securities Act all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement, and shares that they may acquire through the conversion of the loans into AgeX common stock. AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of our common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence. Juvenescence retains the right to require AgeX to register additional shares of common stock that Juvenescence may acquire through the exercise of warrants or the conversion of loans. AgeX is obligated to pay the fees and expenses of each registered offering under such registration rights agreement except for underwriting discounts and commissions. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.

 

AgeX entered into an amendment to its Registration Rights Agreement with Juvenescence to include the 2022 Warrants and underlying shares and any shares issuable upon the conversion of the Secured Note into common stock as registrable securities under the Registration Rights Agreement.

 

Debt Issuance Costs

 

In accordance with ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, all debt issuance costs are recorded as a discount on the debt and amortized to interest expense over the term of the loan agreement using the effective interest method. Direct debt issuance costs include but are not limited to legal fees, debt origination fees, estimated fair market value of common stock and warrants issued in connection with the loan agreements, and NYSE American additional listing fees for the underlying shares of warrants issued with each drawdown of funds.

 

 

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2022 (in thousands):

 

   Drawdown of Funds   Origination Fee   Amount Refinanced   Total Debt   Debt Issuance Costs   Amortization of Debt Issuance Costs   Total Debt, Net 
2019 Loan Agreement  $7,000   $160   $(7,160)  $-   $(494)  $494   $- 
2020 Loan Agreement   8,000    -    -    8,000    (2,805)   2,451    7,646 
2022 Secured Note   12,660    691    -    13,351    (4,720)   1,847    10,478 
   $27,660   $851   $(7,160)  $21,351   $(8,019)  $4,792   $18,124 

 

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2021 (in thousands):

 

   Drawdown of Funds   Origination Fee   Amount Refinanced   Total Debt   Debt Issuance Costs   Amortization of Debt Issuance Costs   Total Debt, Net 
2019 Loan Agreement  $7,000   $160   $     -   $7,160   $(494)  $474   $7,140 
2020 Loan Agreement   7,500    -    -    7,500    (2,620)   1,182    6,062 
   $14,500   $160   $-   $14,660   $(3,114)  $1,656   $13,202 

 

Related Party Payables

 

Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, has been devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $280,000. As of December 31, 2022 and 2021, AgeX had approximately $141,000 and $70,000, respectively, payable to Juvenescence for COO services rendered, included in related party payables, net of certain expenses owed by Juvenescence to AgeX, on the consolidated balance sheets.

 

XML 59 R13.htm IDEA: XBRL DOCUMENT v3.23.4
Warrant Liability
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Warrant Liability    
Warrant Liability

6. Warrant Liability

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, Distinguishing Liabilities from Equity, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP.

 

As a condition of each amount drawn up to $15,160,000 from the Secured Note, on receipt of each amount drawn AgeX granted to Juvenescence a number of warrants equal to 50% of the gross value of the relevant advance made. The gross value is the quotient of the drawdown amount and the exercise price. The exercise price was based on the market closing price of AgeX’s common stock on the NYSE American on the one day preceding the delivery of the relevant drawdown notice. See Note 5, Related Party Transactions.

 

 

AgeX has utilized the full credit available under the Secured Note that is subject to warrants and accordingly the warrants were issued for each of the advances of loan funds under the Secured Note. After all relevant assessments, AgeX determined that the warrants issued under the Secured Note require classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity. In accordance with the accounting guidance, for each reporting period prior to the full drawdown of the entire $15,160,000 of the Secured Note line of credit subject to warrants, the amount of warrant liability was determined and recognized on the balance sheet for the applicable reporting period based on the number of warrants that would have been issued if $15,160,000 of the Secured Note line of credit was drawn. The amount of warrant liability attributed to the expected future issuance of warrants upon subsequent loan draws was subsequently adjusted for the fair value of warrants actually issued upon each loan draw, and the number of warrants that could be issued for the remaining credit available was re-measured for the applicable reporting period with changes being recorded as a component of net other expense in the condensed consolidated statements of operations.

 

Under the Third Amendment, AgeX is not obligated to issue additional warrants to Juvenescence in connection with the receipt of loan funds up to $4 million made available pursuant to the Second Amendment. See Note 5, Related Party Transactions, for further details of the Second Amendment and the Third Amendment.

 

The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date, the date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:

 

Black-Scholes Assumptions 

Exercise

Price (1)

  

Warrant

Expiration

Date (2)

 

Stock

Price (3)

  

Interest

Rate

(annual) (4)

  

Volatility

(annual) (5)

  

Time to

Maturity (Years)

  

Calculated

Fair Value per Share

 
Inception Date: 2/14/2022  $0.780   2/13/2025  $0.691    1.80%   122.99%   3   $0.486 
Issuance Date: 2/14/2022  $0.780   2/13/2025  $0.691    1.80%   122.99%   3   $0.486 
Issuance Date: 2/15/2022  $0.780   2/14/2025  $0.747    1.80%   123.28%   3   $0.535 
Period Ended 3/31/2022  $0.940   3/30/2025  $0.854    2.45%   123.28%   3   $0.607 
Issuance Date: 4/4/2022  $0.880   4/3/2025  $0.819    2.61%   123.31%   3   $0.585 
Issuance Date: 6/6/2022  $0.711   6/5/2025  $0.800    2.94%   122.62%   3   $0.592 
Period Ended 6/30/2022  $0.600   6/29/2025  $0.576    2.99%   122.21%   3   $0.413 
Issuance Date: 8/16/2022  $0.670   8/15/2025  $0.640    3.19%   121.37%   3   $0.457 
Period Ended 9/30/2022  $0.610   9/29/2025  $0.562    4.25%   121.49%   3   $0.401 
Issuance Date: 10/21/2022  $0.690   10/20/2025  $0.620    4.52%   120.51%   3   $0.439 
Issuance Date: 12/14/2022  $0.590   12/13/2025  $0.540    3.94%   120.01%   3   $0.381 
Period Ended 12/31/2022  $0.550   12/30/2025  $0.552    4.22%   119.31%   3   $0.396 
Issuance Date: 1/25/2023  $0.735   1/24/2026  $0.751    3.84%   119.17%   3   $0.540 
Inception Date: 2/9/2023  $0.703   2/8/2026  $0.660    4.15%   118.94%   3   $0.466 
Issuance Date: 2/15/2023  $0.624   2/14/2026  $0.600    4.35%   118.93%   3   $0.426 
Period Ended 3/31/2023  $0.661   3/30/2026  $0.663    3.81%   113.43%   3   $0.459 
Issuance Date: 4/4/2023  $0.661   4/3/2026  $0.673    3.60%   113.01%   3   $0.466 

 

 

(1) Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit.
   
(2) Warrants are exercisable over a three-year period from each Issuance Date.
   
(3) Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.
   
(4) Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.
   
(5) Based on the historical daily volatility of AgeX common stock as of each date presented.

 

 

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

Warrant Liability 

Credit Line and

Draw Amounts

(in thousands)

   Warrants  

Fair Value

per Share

  

Fair Value

(in thousands)

 
Fair value as of January 1, 2022  $-    -   $-   $- 
Fair value at initial measurement date of 2/14/2022   13,160(1)   8,435,897(2)   0.4864    4,103 
Fair value of warrants issued on 2/14/2022   (7,160)(3)   (4,589,743)(4)   0.4864    (2,232)
Fair value of warrants issued on 2/15/2022   (1,000)(3)   (641,025)(4)   0.5349    (343)
Fair value of warrants issued on 4/4/2022   (1,000)(3)   (568,440)(4)   0.5854    (333)
Fair value of warrants issued on 6/6/2022   (1,000)(3)   (703,234)(4)   0.5924    (417)
Fair value of warrants issued on 8/16/2022   (1,000)(3)   (746,380)(4)   0.4569    (341)
Fair value of warrants issued on 10/21/2022   (500)(3)   (362,318)(4)   0.4386    (159)
Fair value of warrants issued on 12/14/2022   (1,000)(3)   (847,457)(4)   0.3810    (323)
Change in fair value of warrants   -    -    -    225 
Fair value as of December 31, 2022  $500(1)   454,545(2)  $0.3960   $180 
Fair value of warrants issued on 1/25/2023   (500)(3)   (340,136)(4)   0.5395    (184)
Fair value at initial measurement date of 2/9/2023   2,000(1)   1,422,879(2)   0.4657    663 
Fair value of warrants issued on 2/15/2023   (1,000)(3)   (801,924)(4)   0.4263    (342)
Fair value of warrants issued on 4/4/2023   (1,000)(3)   (756,429)(4)   0.4660    (352)
Change in fair value of warrants   -    -    -    35 
Fair value as of September 30, 2023  $-(1)   -(2)  $-   $- 

 

 

(1) Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit.
   
(2) Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.
   
(3) Amount of drawdown as of the date presented.
   
(4) Number of warrants issued upon receipt of amounts drawn against the Secured Note as of the date presented.

 

During the nine months ended September 30, 2023, AgeX recorded a loss on change in fair value of warrants of $35,000. During the three and nine months ended September 30, 2022, AgeX recorded a loss on change in fair value of warrants of $35,000 and $220,000, respectively.

 

The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and AgeX’s stock prices and historical volatility as inputs. None of the warrants issued have been exercised.

 

6. Warrant Liability

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, Distinguishing Liabilities from Equity, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or the warrants must or may require AgeX to issue a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP.

 

As a condition of each amount drawn from the Secured Note, on receipt of each amount drawn AgeX shall grant to Juvenescence a number of warrants equal to 50% of the gross value of the relevant advance made. The gross value is the quotient of the drawdown amount and the exercise price. The exercise price is based on the market closing price of AgeX’s common stock on the NYSE American on the one day preceding the delivery of the relevant drawdown notice (see Note 5, Related Party Transactions).

 

Given AgeX’s history, it is AgeX’s judgement that it is more likely than not that AgeX will utilize the full credit available under the Secured Note and accordingly warrants will be issued for each of the advances made within the credit availability period consisting of the 12 month period starting February 14, 2022. After all relevant assessments, AgeX determined that the warrants issued under the Secured Note require classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity. In accordance with the accounting guidance, the number of warrants that would have been issued if the amount of credit under the Secured Note was drawn in full is measured at the inception date at fair value and recognized as a warrant liability on the balance sheet, adjusted for the fair value of warrants actually issued upon each advance, and subsequently the number of warrants that may be issued for the remaining credit available is re-measured at each reporting period with changes being recorded as a component of net other expense in the consolidated statements of operations.

 

 

The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:

 

Black-Scholes Assumptions 

Exercise

Price (1)

   Warrant Expiration Date (2) 

Stock

Price (3)

   Interest Rate (annual) (4)   Volatility (annual) (5)   Time to Maturity (Years)   Calculated Fair Value per Share 
Inception Date: 2/14/2022  $0.780   13-Feb-25  $0.691    1.80%    122.99%    3   $0.486 
Issuance Date: 2/14/2022  $0.780   13-Feb-25  $0.691    1.80%    122.99%    3   $0.486 
Issuance Date: 2/15/2022  $0.780   14-Feb-25  $0.747    1.80%    123.28%    3   $0.535 
Period Ended 3/31/2022  $0.940   30-Mar-25  $0.854    2.45%    123.28%    3   $0.607 
Issuance Date: 4/4/2022  $0.880   3-Apr-25  $0.819    2.61%    123.31%    3   $0.585 
Issuance Date: 6/6/2022  $0.711   5-Jun-25  $0.800    2.94%    122.62%    3   $0.592 
Period Ended 6/30/2022  $0.600   29-Jun-25  $0.576    2.99%    122.21%    3   $0.413 
Issuance Date: 8/16/2022  $0.670   15-Aug-25  $0.640    3.19%    121.37%    3   $0.457 
Period Ended 9/30/2022  $0.610   29-Sep-25  $0.562    4.25%    121.49%    3   $0.401 
Issuance Date: 10/21/2022  $0.690   20-Oct-25  $0.620    4.52%    120.51%    3   $0.439 
Issuance Date: 12/14/2022  $0.590   13-Dec-25  $0.540    3.94%    120.01%    3   $0.381 
Period Ended 12/31/2022  $0.550   30-Dec-25  $0.552    4.22%    119.31%    3   $0.396 

 

 

(1)Based on the market closing price of AgeX’s common stock on the NYSE American on the one day prior to the debt inception date and each presented period ending date and also the market closing price of AgeX’s common stock on the NYSE American on the one trading day preceding the delivery of the relevant drawdown notice in accordance with terms per the Secured Note.

 

(2)Warrants are exercisable over a three-year period from each issuance date.

 

(3)Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.

 

(4)Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.

 

(5)Based on the historical daily volatility of AgeX common stock as of each date presented.

 

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

Warrant Liability 

Credit Line and Draw Amounts

(in thousands)

   Warrants  

Fair Value

per Share

  

Fair Value

(in thousands)

 
Fair value as of January 1, 2022  $               -                         -   $          -   $           - 
Fair value at initial measurement date of 2/14/2022   13,160(1)       8,435,897(2)    0.4864       4,103 
Fair value of warrants issued on 2/14/2022   (7,160)(3)    (4,589,743)(4)    0.4864    (2,232)
Fair value of warrants issued on 2/15/2022   (1,000)(3)       (641,025)(4)    0.5349       (343)
Fair value of warrants issued on 4/4/2022   (1,000)(3)       (568,440)(4)    0.5854       (333)
Fair value of warrants issued on 6/6/2022   (1,000)(3)       (703,234)(4)    0.5924       (417)
Fair value of warrants issued on 8/16/2022   (1,000)(3)       (746,380)(4)    0.4569       (341)
Fair value of warrants issued on 10/21/2022     (500)(3)       (362,318)(4)    0.4386       (159)
Fair value of warrants issued on 12/14/2022   (1,000)(3)       (847,457)(4)    0.3810       (323)
Change in fair value of warrant liability                  -                         -              -          225 
Fair value as of December 31, 2022  $     500(1)       454,545(2)   $0.3960   $     180 

 

 

(1)Amount of credit available under the Secured Note on date of inception and as of each period end date.

 

(2)Number of warrants issuable if the amount of credit available were drawn for measurement as of inception date and subsequently for remeasurement as of each period end date.

 

(3)Amount of drawdown as of each date presented.

 

(4)Number of warrants issued upon receipt of amounts drawn against the Secured Note as of each date presented.

 

During the year ended December 31, 2022, AgeX recorded a loss of $225,000 on changes in the fair value of warrant liability. There were no warrant liabilities or corresponding changes in valuation during the year ended December 31, 2021.

 

The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and AgeX’s stock prices and historical volatility as inputs. During the year ended December 31, 2022, none of the warrants issued were exercised.

 

 

 

XML 60 R14.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ Deficit
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Equity [Abstract]    
Stockholders’ Deficit

7. Stockholders’ Equity (Deficit)

 

Preferred Stock

 

On July 24, 2023, AgeX issued to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 million of indebtedness consisting of the outstanding principal amount of loans then outstanding under the 2020 Loan Agreement, the Secured Note, and the $10 Million Secured Note, plus the loan origination fees accrued with respect to the 2022 Secured Note and a portion of the loan origination fees accrued pursuant to the $10 Million Secured Note. The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to the Exchange Agreement between AgeX and Juvenescence. By completing the exchange of indebtedness for shares of Series A Preferred Stock and Series B Preferred Stock (collectively referred to as the “Preferred Stock”).

 

Classification of Preferred Stock

 

The deemed liquidation preference provisions of the preferred stock are considered contingent redemption provisions that are not solely within AgeX’s control. Accordingly, the preferred stock has been presented outside of permanent equity in the mezzanine section of the condensed consolidated balance sheet. Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values to the preferred stock would be made only when a deemed liquidation event becomes probable.

 

On November 7, 2023, certain terms of the Series A Preferred Stock and Series B Preferred Stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as adeemed liquidation if the applicable transaction is approved by the Board of Directors or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of Preferred Stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock. This amendment permits the classification of the Series A Preferred Stock and Series B Preferred Stock as permanent equity effective November 7, 2023. See Note 12, Subsequent Events, for illustration of the Preferred Stock presented in permanent equity in the condensed consolidated pro forma balance sheet.

 

 

Dividends – The Preferred Stock is not entitled to receive any payment or distribution of cash or other dividends.

 

Liquidation Preference – In the event of any voluntary or involuntary liquidation, dissolution or other winding up of the affairs of AgeX, subject to the preferences and other rights of any senior stock, before any assets of AgeX shall be distributed to holders of common stock or other junior stock, all of the assets of AgeX available for distribution to stockholders shall be distributed among the holders of Series A Preferred Stock and Series B Preferred Stock and any other “parity stock” that may be issued ranking parri passu with those series of Preferred Stock with respect to liquidation rights, in proportion to the number of shares of Series B Preferred Stock and parity stock held by each such holder as of the record date for the determination of holders of Series A Preferred Stock, Series B Preferred Stock, and parity stock entitled to receive such distribution, until AgeX shall have distributed to the holders of those shares an amount of assets having a value equal to the subscription price per share. If the assets of AgeX shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of Series A Preferred Stock, Series B Preferred Stock and parity stock shall be ratably distributed among such holders. The (i) acquisition of AgeX by another entity by means of any transaction or series of transactions (including, without limitation, any reorganization, merger or consolidation) in which the stockholders of AgeX immediately before such transaction or series of transactions do not own a majority of the outstanding stock of the surviving or acquiring corporation upon completion of such transaction or series of transactions or (ii) a sale of all or substantially all of the assets of AgeX in a single transaction or series of related transactions, shall be deemed a liquidation. On November 7, 2023, certain terms of the liquidation preference were amended. See Note 12 Subsequent Transactions.

 

Conversion of Preferred Stock into Common Stock – Each share of Preferred Stock shall be convertible into a number of shares of AgeX common stock determined by dividing (x) a number equal to the number of dollars and cents comprising the subscription price, by (y) a number equal to the number of dollars and cents comprising the conversion price. The subscription price per share of Preferred Stock is $100 which was paid through the exchange of indebtedness for shares of Preferred Stock. The conversion price per share of Series A Preferred Stock or Series B Preferred Stock is $0.72 which was the closing price of AgeX common stock on the NYSE American on the last trading day immediately preceding the execution of the Exchange Agreement.

 

Optional Conversion – Preferred Stock shall be convertible into common stock at the election of the holder of shares of Preferred Stock at any time and from time to time subject to the limitations on conversion of Series B Preferred Stock discussed below.

 

Automatic Conversion – The outstanding shares of Series A Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders (“Automatic Conversion”) upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina, or a subsidiary thereof; and (y) February 1, 2024. Further, if the holders of at least a majority of the outstanding shares of Series A Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, then the outstanding shares of Series A Preferred Stock shall be converted into common stock upon such approval or consent.

 

The outstanding shares of Series B Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina or a subsidiary thereof; and (y) February 1, 2024, provided that such conversion is not limited by the 19.9% Cap or the 50% Cap as described below; and if Automatic Conversion would then be limited by the 19.9% Cap or the 50% Cap, the Automatic Conversion shall take place on the tenth day after such stockholder approvals have been obtained as may be required to permit such Automatic Conversion without the limitations of the 19.9% Cap and the 50% Cap. Further, if the holders of at least a majority of the outstanding shares of Series B Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, and the conversion is not then limited by the 19.9% Cap or the 50% Cap, then the outstanding shares of Series B Preferred Stock shall be converted into common stock upon such approval or consent.

 

Certain Limitations on Conversion of Series B Preferred StockIf under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the “19.9% Cap” upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued upon conversion of all shares of Series B Preferred Stock shall be an amount equal to the 19.9% Cap. The 19.9% Cap means 7,550,302 shares of common stock, which is 19.9% of the shares of common stock outstanding on February 14, 2022 when the Secured Note, a portion of which has not been approved by AgeX stockholders for conversion into common stock without regard to the 19.9% Cap and 50% Cap, was issued.

 

 

If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the 50% Cap upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued to a holder of Series B Preferred Stock upon conversion of such shares shall be an amount that, when added to other shares of common stock owned by such holder immediately prior to such conversion would equal one share less than the 50% Cap.

 

Adjustment of conversion price and subscription price – If AgeX shall (a) declare a dividend or make a distribution on its common stock in shares of common stock, (b) subdivide or reclassify the outstanding common stock into a greater number of shares, or (c) combine or reclassify the outstanding common stock into a smaller number of shares, the conversion price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. If AgeX shall (i) declare a dividend or make a distribution on a series of Preferred Stock in shares of Preferred Stock, (ii) subdivide or reclassify the outstanding shares of a series of Preferred Stock into a greater number of shares, or (iii) combine or reclassify the outstanding shares of a series of Preferred Stock into a smaller number of shares, the subscription price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. Successive adjustments in the conversion price or subscription price, as applicable, shall be made whenever any event specified above shall occur.

 

No Fractional Shares – No fractional share of common stock or scrip shall be issued upon conversion of Preferred Stock. Instead of any fractional share of common stock which would otherwise be issuable upon conversion of any Preferred Stock, AgeX will pay a cash adjustment in respect of such fractional interest in an amount equal to that fractional interest at the then fair value determined in accordance with the terms of the Preferred Stock.

 

Voting Rights – The following matters shall require the approval of the holders of a majority of the shares of a series of Preferred Stock then outstanding, voting as a separate class: (i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock. Except as may otherwise be required by the Delaware General Corporation Law, as the same may be amended from time to time, the Preferred Stock will have no other voting rights.

 

Governing Law – The powers, designations, preferences, rights, qualifications, limitations, and restrictions of either series of Preferred Stock, the validity, authorization and issuance of such Preferred Stock, and the conversion of such Preferred Stock into common stock shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof, and all legal proceedings pursuant or with respect to or concerning such matters (a “Proceeding”), whether brought by or against a holder of Preferred Stock or AgeX or any of their respective directors, officers, stockholders, employees or agents, shall be commenced in the state and federal courts sitting in the State of Delaware (the “Delaware Courts”). The Preferred Stock provides that (a) AgeX and each holder of Preferred Stock irrevocably submits to the exclusive jurisdiction of the Delaware Courts for the adjudication of any Proceeding, and irrevocably waives, and agrees not to assert in any Proceeding any claim that they are not personally subject to the jurisdiction of such Delaware Courts, or such Delaware Courts are an improper or inconvenient venue for such Proceeding, and (b) AgeX and each holder of Preferred Stock irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to such party and agrees that such service shall constitute good and sufficient service of process and notice

 

Common Stock

 

AgeX has 200,000,000 shares of $0.0001 par value common stock authorized. At September 30, 2023 and December 31, 2022, there were 37,951,261 and 37,949,196 shares of AgeX common stock issued and outstanding, respectively.

 

Issuance and Sale of Warrants by AgeX

 

In connection with the $2,500,000 of drawdowns of loan funds from Juvenescence under the Secured Note during the nine months ended September 30, 2023, AgeX issued to Juvenescence 2022 Warrants to purchase 1,898,489 shares of AgeX common stock. See Note 6, Warrant Liability.

 

 

At-the-Market Offering Facility

 

On January 8, 2021, AgeX entered into a sales agreement with Chardan Capital Markets, LLC (“Chardan”) relating to the sale of shares of AgeX common stock, par value $0.0001 per share, through an at-the-market (“ATM”) offering as described in the prospectus supplement filed with the Form S-3 which was declared effective by the SEC on January 29, 2021. In accordance with the terms of the sales agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $12.6 million from time to time through Chardan, acting as the sales agent. The actual market value of shares of common stock that AgeX may sell through the ATM offering during any 12 month period will be limited to one-third of the aggregate market value of AgeX common stock held by stockholders that would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. During the nine months ended September 30, 2023 and 2022, no proceeds were raised through the sale of shares of common stock under the ATM.

 

7. Stockholders’ Deficit

 

Preferred Stock

 

AgeX is authorized to issue up to 5,000,000 shares of preferred stock, $0.0001 par value per share. At December 31, 2022 and 2021, there were no preferred shares issued and outstanding.

 

Common Stock

 

AgeX has 200,000,000 shares of common stock, $0.0001 par value per share, authorized. The holders of AgeX’s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of AgeX common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of AgeX outstanding preferred shares, if any.

 

The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of AgeX stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable.

 

As of December 31, 2022 and 2021, there were 37,949,196 and 37,941,220 shares of AgeX common stock issued and outstanding, respectively.

 

Issuance of Warrants by AgeX

 

In connection with the $12,660,000 of drawdowns of loan funds from Juvenescence under the Secured Note during the year ended December 31, 2022, AgeX has issued to Juvenescence 2022 Warrants to purchase 8,458,597 shares of AgeX common stock.

 

As consideration for $8.0 million in loans made to AgeX under the 2020 Loan Agreement, AgeX issued to Juvenescence warrants to purchase 3,670,663 shares of AgeX common stock.

 

See Notes 5, Related Party Transactions and 6, Warrant Liability for additional information on warrants issued to Juvenescence.

 

At-the-Market Offering Facility

 

On January 8, 2021, AgeX entered into a Sales Agreement with Chardan, relating to the sale of shares of AgeX common stock, in at-the-market transactions. In accordance with the terms of the Sales Agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $12.6 million from time to time through Chardan, acting as the sales agent. The actual market value of common shares that AgeX may sell through its Sales Agreement with Chardan during any 12 month period will be limited to one-third of aggregate market value of our common stock held by stockholders that would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. During the years ended December 31, 2022 and 2021, AgeX raised nil and $496,000, respectively, in gross proceeds through the sale of shares of common stock through the Sales Agreement with Chardan.

 

XML 61 R15.htm IDEA: XBRL DOCUMENT v3.23.4
Stock-Based Awards
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]    
Stock-Based Awards

8. Stock-Based Awards

 

Equity Incentive Plan Awards

 

AgeX has an Equity Incentive Plan (the “Plan”) under which a maximum of 8,500,000 shares of common stock are available for the grant of stock options, the sale of restricted stock, the settlement of restricted stock units, and the grant of stock appreciation rights. The Plan also permits AgeX to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine.

 

A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price):

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted-

Average

Exercise Price

 
Balance at December 31, 2022   5,139    3,261    3   $2.25 
Options granted   (26)   26    -    0.76 
Restricted stock units vested   -    -    (3)   - 
Balance at September 30, 2023   5,113    3,287          -   $       2.24 
Options exercisable at September 30, 2023        3,067        $2.32 

 

There have been no exercises of stock options to date.

 

Stock-based Compensation Expense

 

AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC 718, Compensation – Stock Compensation (“ASC 718”). AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09.

 

AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under AgeX’s 2017 Equity Incentive Plan (the “Incentive Plan”). The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.

 

Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations.

 

 

Operating expenses include stock-based compensation expense as follows (in thousands):

 

   2023   2022   2023   2022 
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022   2023   2022 
Research and development  $1   $8   $8   $25 
General and administrative   39    201    137    621 
Total stock-based compensation expense  $40   $209   $145   $646 

 

The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions including expected life, risk-free interest rates, volatility, and dividend yield. The assumptions that were used to calculate the grant date fair value of employee and non-employee stock option grants for the three and nine months ended September 30, 2022 were as follows:

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022(1)   2023   2022 
Grant price  $0.76   $-   $0.76   $0.79 
Market price  $0.76   $-   $0.76   $0.79 
Expected life (in years)   5.15    -    5.15    5.58 
Volatility   118.12%   -%   118.12%   130.71%
Risk-free interest rates   4.12%   -%   4.12%   1.74%
Dividend yield   -%   -%   -%   -%

 

(1)There were no stock options granted under the Plan during the three months ended September 30, 2022.

 

The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If AgeX had made different assumptions, its stock-based compensation expense and net loss for the nine months ended September 30, 2023 and 2022 may have been significantly different.

 

AgeX does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

 

8. Stock-Based Awards

 

Equity Incentive Plan

 

Under the 2017 Equity Incentive Plan, as amended (the “Incentive Plan”), AgeX has reserved 8,500,000 shares of common stock for the grant of stock options or the sale of restricted stock (“Restricted Stock”) or for the settlement of restricted stock units which are hypothetical units issued with reference to common stock (“Restricted Stock Units” or “RSUs”). AgeX may also grant stock appreciation rights (“SARs”) under the Incentive Plan. The Plan also permits AgeX to issue such other securities as its Board of Directors (the “Board”) or the Compensation Committee (the “Committee”) administering the Incentive Plan may determine. Awards of stock options, Restricted Stock, SARs, and RSUs (“Awards”) may be granted under the Incentive Plan to AgeX employees, directors, and consultants.

 

Awards may vest and thereby become exercisable or have restrictions on forfeiture lapse on the date of grant or in periodic installments or upon the attainment of performance goals, or upon the occurrence of specified events.

 

No person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than 1,000,000 shares in the aggregate, or any Awards of Restricted Stock or RSUs with respect to more than 500,000 shares in the aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual share limit.

 

No Awards may be granted under the Incentive Plan more than ten years after the date upon which the Incentive Plan was adopted by the Board, and no options or SARS granted under the Incentive Plan may be exercised after the expiration of ten years from the date of grant.

 

 

Stock Options

 

Options granted under the Incentive Plan may be either “incentive stock options” within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the “Code”), or “non-qualified” stock options that do not qualify incentive stock options. Incentive stock options may be granted only to AgeX employees and employees of subsidiaries. The exercise price of stock options granted under the Incentive Plan must be equal to the fair market of AgeX common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of AgeX stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $100,000.

 

The exercise price of an option may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board or Committee may approve.

 

Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter, but in the case of the termination of an employee, director, or consultant’s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option.

 

Restricted Stock and RSUs

 

In lieu of granting options, AgeX may enter into purchase agreements with employees under which they may purchase or otherwise acquire Restricted Stock or RSUs subject to such vesting, transfer, and repurchase terms, and other restrictions. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value. Employees or consultants, but not executive officers or directors, who purchase Restricted Stock may be permitted to pay for their shares by delivering a promissory note or an installment payment agreement that may be secured by a pledge of their Restricted Stock. Restricted Stock may also be issued for services actually performed by the recipient prior to the issuance of the Restricted Stock. Unvested Restricted Stock for which AgeX has not received payment may be forfeited, or AgeX may have the right to repurchase unvested shares upon the occurrence of specified events, such as termination of employment.

 

Subject to the restrictions set with respect to the particular Award, a recipient of Restricted Stock generally shall have the rights and privileges of a stockholder, including the right to vote the Restricted Stock and the right to receive dividends; provided that, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld for the recipient’s account, and interest may be credited on the amount of the cash dividends withheld. The cash dividends or stock dividends so withheld and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to the recipient in cash or, at the discretion of the Board or Committee, in shares of common stock having a fair market value equal to the amount of such dividends, if applicable, upon the release of restrictions on the Restricted Stock and, if the Restricted Stock is forfeited, the recipient shall have no right to the dividends.

 

The terms and conditions of a grant of RSUs shall be determined by the Board or Committee. No shares of common stock shall be issued at the time a RSU is granted. A recipient of RSUs shall have no voting rights with respect to the RSUs. Upon the expiration of the restrictions applicable to a RSU, AgeX will either issue to the recipient, without charge, one share of common stock per RSU or cash in an amount equal to the fair market value of one share of common stock.

 

At the discretion of the Board or Committee, each RSU (representing one share of common stock) may be credited with cash and stock dividends paid in respect of one share (“Dividend Equivalents”). Dividend Equivalents shall be withheld for the recipient’s account, and interest may be credited on the amount of cash Dividend Equivalents withheld. Dividend Equivalents credited to a recipient’s account and attributable to any particular RSU (and earnings thereon, if applicable) shall be distributed in cash or in shares of common stock having a fair market value equal to the amount of the Dividend Equivalents and earnings, if applicable, upon settlement of the RSU. If a RSU is forfeited, the recipient shall have no right to the related Dividend Equivalents.

 

SARs

 

A SAR is the right to receive, upon exercise, an amount payable in cash or shares, or a combination of shares and cash, equal to the number of shares subject to the SAR that is being exercised, multiplied by the excess of (a) the fair market value of a common stock on the date the SAR is exercised, over (b) the exercise price specified in the SAR Award agreement. SARs may be granted either as free standing SARs or in tandem with options. No SAR may be exercised later than 10 years after the date of grant.

 

 

The exercise price of a SAR shall not be less than 100% of the fair market value of one share of common stock on the date of grant. A SAR granted in conjunction with an option shall have the same exercise price as the related option, shall be transferable only upon the same terms and conditions as the related option, and shall be exercisable only to the same extent as the related option; provided, however, that the SAR by its terms shall be exercisable only when the fair market value per share exceeds the exercise price per share of the SAR or related option. Upon any exercise of a SAR granted in tandem with an option, the number of shares for which the related option shall be exercisable shall be reduced by the number of shares for which the SAR has been exercised. The number of shares for which a SAR issued in tandem with an option shall be exercisable shall be reduced by the number of shares for which the related option has been exercised.

 

Equity Incentive Plan Awards

 

A summary of the Incentive Plan activity and related information follows (in thousands except weighted-average exercise price):

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted-

Average

Exercise Price

 
Balance at January 1, 2021   1,046    2,854      28   $2.51 
Increase option pool      500            -         -         - 
Options granted   (568)        568         -    1.46 
Options forfeited, cancelled or expired        57       (57)         -    2.56 
Restricted stock units vested           -            -    (12)         - 
Balance at December 31, 2021   1,035    3,365      16   $2.32 
Increase option pool   4,000            -         -          - 
Options granted   (105)        105         -    0.79 
Options forfeited, cancelled or expired       209    (209)         -    2.82 
Restricted stock units vested           -            -    (13)         - 
Balance at December 31, 2022   5,139    3,261         3   $2.25 
Options exercisable at December 31, 2022        2,913        $2.37 

 

There were no exercises of stock options during the years ended December 31, 2022 and 2021. Total proceeds if all options granted and outstanding as of December 31, 2022 were exercised would be approximately $7.3 million.

 

At December 31, 2022, AgeX had approximately $0.3 million of total unrecognized compensation costs related to the stock options and unvested RSUs under the Incentive Plan that will be recognized as expense over a weighted-average period of approximately 2.02 years.

 

The aggregate intrinsic value of options outstanding was $1,700 and options exercisable was nil as of December 31, 2022.

 

Stock-Based Compensation Expense

 

AgeX recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021 (in thousands):

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Research and development – continuing operations  $32   $62 
General and administrative – continuing operations   728    937 
Total stock-based compensation expense – continuing operations   760    999 
General and administrative – discontinued operations   -    4 
Total stock-based compensation expense  $760   $1,003 

 

The weighted-average estimated fair value of stock options granted during the years ended December 31, 2022 and 2021 was $0.70 per share and $1.15 per share, respectively, using the Black-Scholes option pricing model with the following weighted-average assumptions:

 

   Year Ended December 31, 
   2022   2021 
Grant Price  $       0.79   $        1.46 
Expected life (in years)          5.58             5.71 
Risk-free interest rates       1.74%        0.99% 
Volatility   130.71%    102.34% 
Dividend yield            -%              -% 

 

 

The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If AgeX had made different assumptions, its stock-based compensation expense and net loss for the years ended December 31, 2022 and 2021 may have been significantly different. See Note 2, Summary of Significant Accounting Policies for a discussion of the factors used in determining these assumptions.

 

AgeX does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

 

XML 62 R16.htm IDEA: XBRL DOCUMENT v3.23.4
Income Taxes
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Income Taxes

9. Income Taxes

 

The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where AgeX conducts business.

 

For the three and nine months ended September 30, 2023 and 2022, AgeX experienced a loss; therefore, no income tax provision was recorded for the three and nine months ended September 30, 2023 and 2022.

 

Due to losses incurred for all periods presented, AgeX did not record a provision or benefit for income taxes. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all of its deferred tax assets for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

 

9. Income Taxes

 

Net loss from operations before income taxes as of December 31, 2022 and 2021 are approximately $10.5 million and $8.7 million, respectively.

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

 

The primary components of the net deferred tax assets and liabilities as of December 31, 2022 and 2021 were as follows (in thousands):

 

         
   December 31, 
Deferred tax assets/(liabilities):  2022   2021 
Net operating loss carryforwards  $12,408   $12,000 
Capital loss carryforwards   3,120    3,120 
Research and development credit carryforwards   1,138    1,426 
Patents and fixed assets   879    901 
Stock-based compensation   643    690 
Capitalized Research Expenses   211    - 
Other, net   62    80 
Valuation allowance   (18,461)   (18,217)
Total net deferred tax assets  $-   $- 

 

A valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

 

Income taxes differed from the amounts computed by applying the U.S. federal income tax rate indicated to pretax losses from operations as a result of the following:

 

   December 31, 
   2022   2021 
Computed tax benefit at federal statutory rate    21%      21% 
Research and development and other credits      1%        1% 
State tax benefit, net of effect on federal income taxes   (7)%      14% 
Permanent differences      -%     (1)% 
Stock Based Compensation   (2)%        -% 
Loss and deconsolidation of LifeMap Sciences       -%   (31)% 
Debt finance equity costs   (6)%        -% 
Return to provision & other adjustments   (5)%        -% 
Change in valuation allowance   (2)%     (4)% 
       -%         -% 

 

AgeX has established an accrual for uncertain tax positions related to its U.S. research and development credits. As of December 31, 2022 and 2021, there was no accrued interest related to uncertain tax positions. AgeX does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):

 

       
   December 31, 
   2022   2021 
Balance at January 1  $ -   $       - 
Additions for tax positions related to the current year   23    - 
Additions for tax positions related to prior years   356    - 
Reductions for tax positions related to prior years   -    - 
Reductions related to settlements   -    - 
Reductions related to a lapse of statute   -    - 
Balance at December 31  $379   $- 

 

 

AgeX monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2022, AgeX had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.

 

As of December 31, 2022, AgeX has net operating loss carryforwards of approximately $52.8 million for U.S. federal income tax purposes. In general, NOLs and other tax credit carryforwards generated by legal entities in a consolidated federal tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the consolidated federal tax group.

 

As of December 31, 2022, AgeX has net operating losses of approximately $14.9 million for California purposes. As AgeX and its subsidiaries have been included in the combined California tax return with Lineage, up to the date of deconsolidation on August 30, 2018, those state net operating losses will remain with AgeX. In general, NOLs and other tax credit carryforwards generated by legal entities in a combined state tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the combined state tax group. Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2042.

 

As of December 31, 2022, AgeX has research and development tax credit carryforwards for federal and state tax purposes of $0.9 million and $0.6 million, respectively. The federal tax credits expire between 2028 and 2042, while the state tax credits have no expiration date.

 

As of December 31, 2022, AgeX has capital loss carryforwards for federal and state tax purposes of $12.4 million and $5.9 million, respectively. The federal and California capital loss carryforwards will expire in 2026.

 

Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (“R&E”) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. We will continue to monitor this issue for future developments, but we does not expect R&E capitalization and amortization to require us to pay cash taxes now or in the near future.

 

Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. stockholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2021, AgeX’s foreign entity operated at an immaterial loss; therefore, no GILTI was included in income. For the year ended December 31, 2022, there was no income or loss related to foreign activity as the entity deconsolidated from AgeX on March 15, 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.

 

For the year ended December 31, 2022, we experienced a domestic loss from continuing operations; therefore, no income tax provision was recorded for the year ended December 31, 2022.

 

The sale of LifeMap Sciences resulted in a taxable loss primarily due to AgeX’s tax basis in the subsidiary.

 

Other Income Tax Matters

 

Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods.

 

AgeX and its subsidiaries may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. AgeX filed its first consolidated federal tax return in 2018. AgeX and its current subsidiaries are not subject to tax examination by federal tax authorities for tax years beginning before 2019 and for state tax authorities beginning before 2018. However, the tax authorities may still make adjustments to the net operating loss and credit carryforwards used in open years by AgeX or any of its subsidiaries. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.

 

 

XML 63 R17.htm IDEA: XBRL DOCUMENT v3.23.4
Commitments and Contingencies
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Commitments and Contingencies

11. Commitments and Contingencies

 

Office Lease Agreement

 

AgeX leases office space in Alameda, California. For 2022 base monthly rent was $1,074 and for 2023 base monthly rent is $844 for slightly less space at the same building. The lease also includes office furniture rental, janitorial services, utilities, and internet service.

 

ASC 842

 

For the office lease, AgeX has elected to not apply the recognition requirements under ASC 842 as lease cost on a straight-line basis over the lease term because the amount of the lease payments is not deemed material.

 

There were no future minimum lease commitments as of September 30, 2023.

 

Litigation – General

 

AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.

 

Tax Filings

 

AgeX tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes AgeX has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the unaudited condensed consolidated interim financial statements.

 

Employment Contracts

 

AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations.

 

Indemnification

 

In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s research and development programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s research and development. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property licensed from AgeX to third parties. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The sales agreement between AgeX and Chardan also includes indemnification provisions pursuant to which the parties have agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock through the ATM facility, including liabilities under the Securities Act. Similarly, the Registration Rights Agreement between Juvenescence and AgeX includes indemnification provisions pursuant to which the parties will indemnify each other from certain liabilities in connection with the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. AgeX has also agreed to provide the AST Indemnity pursuant to the Letter of Indemnification described in Note 5, Related Party Transactions. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular license, lease, or agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure and in the case of the AST Indemnity AgeX has received a cross-indemnity from Juvenescence against all claims, damages, liabilities or losses arising out of the AST Indemnity. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements to date.

 

 

Notice of Delisting 

 

On April 20, 2023, AgeX received a letter (the “2023 Deficiency Letter”) from the staff of the Exchange indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6,000,000 or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The 2023 Deficiency Letter states that as AgeX remains subject to the conditions set forth in prior letters from the Exchange with respect to AgeX’s deficiencies in stockholders equity, and if AgeX is not in compliance with all of the Exchange’s stockholders equity standards, or does not make progress consistent with AgeX’s Exchange approved plan to come into compliance with the Exchange’s continued listing standards, by May 17, 2023, the Exchange will initiate delisting proceedings as appropriate.

 

On May 17, 2023 AgeX received a notice from the staff of the Exchange indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange’s Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX did not meet the continued listing standards because it had stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6,000,000 or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years.

 

On May 24, 2023, AgeX filed a request for a review of the delisting determination by a Committee of the Board of Directors of the Exchange. On May 31, 2023, AgeX received a notice from the staff of the Exchange which scheduled a hearing for July 25, 2023. On July 24, 2023, AgeX issued shares of preferred stock to Juvenescence in exchange for the extinguishment of $36 million of indebtedness owed to Juvenescence for the purpose of remediating the deficiency in stockholders equity, and the hearing at the Exchange scheduled for July 25 was cancelled. See Note 7, Stockholders’ Equity (Deficit) and Note 12, Subsequent Events for further discussion on the classification of preferred stock and amendment to Section 3(b) of the terms of the Series A Preferred Stock and Series B Preferred Stock.

 

10. Commitments and Contingencies

 

Office Lease Agreement

 

Effective January 1, 2021, AgeX relocated its principal offices to a 135 square foot leased space in a building located in an office and research park in Alameda, California. Base monthly rent was $947 for the first year of the lease term. In September 2021, AgeX extended its office lease for another year, effective January 1, 2022, at a monthly rent of $1,074. In October 2022, AgeX entered into a new one-year lease that became effective January 1, 2023 for a different space, comprising of 101 square feet, in the same building, at a monthly rent of $844. The lease also includes office furniture rental, janitorial services, utilities, and internet service.

 

ASC 842

 

For the office lease, AgeX has elected to not apply the recognition requirements under ASC 842 and instead recognized the lease payments as lease costs on a straight-line basis over the lease term, as the amount of the lease payments is not deemed material.

 

There were no future minimum lease commitments as of December 31, 2022.

 

Litigation – General

 

AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.

 

Tax Filings

 

AgeX tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes AgeX has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the consolidated financial statements.

 

Employment Contracts

 

AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations.

 

Indemnification

 

In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s research and development programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s research and development. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property licensed from AgeX to third parties. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The sales agreement between AgeX and Chardan also includes indemnification provisions pursuant to which the parties have agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock through the ATM facility, including liabilities under the Securities Act. Similarly, the Registration Rights Agreement between Juvenescence and AgeX includes indemnification provisions pursuant to which the parties will indemnify each other from certain liabilities in connection with the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular license, lease, or agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements as of December 31, 2022 and 2021.

 

Paycheck Protection Program Loan

 

On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from a bank under the Paycheck Protection Program (the “PPP Loan”). The PPP Loan bore interest at a rate of 1% per annum. No payments were due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest became due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date was April 13, 2022. The principal amount of the PPP Loan was subject to forgiveness under the Paycheck Protection Program (the “Program”) to the extent of PPP Loan proceeds that were used to pay expense permitted by the Program, including payroll, rent, and utilities during the time frame permitted by the Program. On February 19, 2021, the PPP Loan was forgiven in full.

 

On December 27, 2020, the Consolidated Appropriations Act of 2021 was signed into law, retroactively allowing a federal deduction of the expenses that gave rise to the PPP Loan forgiveness. California does not allow a deduction for these expenses for publicly traded companies.

 

 

Notice of Delisting

 

On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders’ equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan.

 

On April 15, 2021, AgeX regained compliance with all of the Exchange’s continued listing standards set forth in Part 10 of the Exchange Company Guide. Specially, the Exchange has resolved the continued listing deficiency with respect to Section 1003(a)(i) of the Exchange Company Guide.

 

On November 17, 2021, AgeX received a second deficiency letter (“2021 Deficiency Letter”) from the staff of the Exchange indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX had stockholders equity of less than $2,000,000 and had incurred losses from continuing operations and/or net losses during the two most recent fiscal years, and that AgeX had stockholders equity of less than $4,000,000 and had incurred losses from continuing operations and/or net losses during three out of four of the most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the 2021 Deficiency Letter, AgeX provided the Exchange staff with an updated plan (the “2021 Plan”) during December 2021 advising the Exchange staff of action that AgeX had taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards. The Exchange staff accepted the 2021 Plan which was subsequently revised by AgeX in the course of the Exchange’s continued monitoring of AgeX’s progress to attain compliance with the continued listing standards. During November 2022, the Exchange sent AgeX a notification indicating that the Exchange has accepted the revised 2021 Plan and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide by increasing stockholders equity to not less than $4,000,000. The Exchange staff will periodically review AgeX’s adherence to the revised 2021 Plan milestones. If we are not in compliance with the continued listing standards by May 17, 2023, or if AgeX does not make progress consistent with the revised 2021 Plan during the plan period, the Exchange will initiate delisting proceedings as appropriate.

 

AgeX intends to make arrangements to have its common stock quoted on an interdealer quotation system if its common stock is delisted from the Exchange.

 

XML 64 R18.htm IDEA: XBRL DOCUMENT v3.23.4
Subsequent Events
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Subsequent Events [Abstract]    
Subsequent Events

12. Subsequent Events

 

Additional Loans Under Secured Note

 

On October 3, 2023, AgeX drew $500,000 of its credit available under the Secured Note. On October 31, 2023 AgeX drew the final $500,000 of the credit line available under the Secured Note.

 

Increase in Secured Note Line of Credit

 

On November 9, 2023, AgeX and Juvenescence entered into the Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note (the “Fifth Amendment”) that increases the amount of the line of credit available to AgeX by $4,400,000, subject to the terms of the Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. Concurrently with the execution of the Fifth Amendment, AgeX also entered into an additional Pledge Agreement to add shares of a subsidiary to the collateral under the Security Agreement, and AgeX’s subsidiaries ReCyte, Reverse Bio, and UniverXome each entered into a Guaranty Agreement and Joinder Agreement pursuant to which each of them agreed to guaranty AgeX’s obligations to Juvenescence pursuant to the Secured Note, as amended by the Fifth Amendment, and to grant Juvenescence a security interest in their respective assets pursuant to the Security Agreement to secure their obligations to Juvenescence.

 

Amendment to Preferred Stock and Remediation of Stock Exchange Listing Deficiency

 

On July 24, 2023, AgeX issued shares of AgeX Series A Preferred Stock and AgeX Series B Preferred Stock to Juvenescence in exchange for the extinguishment of $36 million of indebtedness owed to Juvenescence with the intent of adding $36 million to stockholders equity to eliminate a stockholders equity deficiency that caused AgeX to be out of compliance with the NYSE American continued listing standards. However, upon subsequent consideration in consultation with AgeX’s independent registered public accountants, AgeX determined that, in accordance with applicable guidance to GAAP, the deemed liquidation preference provisions of the Preferred Stock could be considered contingent redemption provisions that are not solely within AgeX’s control, requiring that the Preferred Stock be presented outside of permanent equity in the mezzanine section of the condensed consolidated balance sheet as of September 30, 2023. To comply with the NYSE American listing requirement by permitting the Preferred Stock to qualify now as permanent equity, on November 7, 2023, Section 3(b) of the terms of the Series A Preferred Stock and Series B Preferred Stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as a deemed liquidation if the applicable transaction is approved by the Board of Directors or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of Preferred Stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock. AgeX has informed the NYSE American of the accounting issue and the remedy that has been implemented and AgeX believes it is in compliance with NYSE American’s continued listing standards.

 

The following pro-forma condensed consolidated balance sheet illustrates the effect of the Preferred Stock in permanent equity.

 

 

Non-GAAP Financial Measures

 

The condensed consolidated interim financial statements include stockholders equity (deficit) prepared in accordance with accounting principles generally accepted in the United States (GAAP). The following pro-forma condensed consolidated balance sheet includes certain pro forma historical non-GAAP adjustments to the balance sheet. In particular, AgeX has provided a non-GAAP pro forma presentation of Series A Preferred Stock and Series B Preferred Stock classified as permanent equity, eliminating the stockholders deficit, based on a post-September 30, 2023 amendment to the liquidation provisions of the Preferred Stock. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable financial measures prepared in accordance with GAAP. However, AgeX believes the non-GAAP presentation of stockholders equity, when viewed in conjunction with our GAAP presentation, is helpful in understanding AgeX’s current capital structure.

 

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED PRO FORMA BALANCE SHEET

(in thousands, except par value amounts)

(unaudited)

   September 30, 2023   Adjustment   Adjusted Balance 
             
ASSETS               
Current assets:               
Cash and cash equivalents  $397   $-   $397 
Accounts and grants receivable, net   67    -    67 
Related party receivables, net   4    -    4 
Prepaid expenses and other current assets   673    -    673 
Total current assets   1,141    -    1,141 
                
Restricted cash   50    -    50 
Intangible assets, net   640    -    640 
Convertible note receivable   10,379    -    10,379 
TOTAL ASSETS  $12,210   $-   $12,210 
                
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)               
Current liabilities:               
Accounts payable and accrued liabilities  $1,671   $-   $1,671 
Loan due to Juvenescence, net of debt issuance costs, current portion   1,526    -    1,526 
Insurance premium liability and other current liabilities   7    -    7 
Total current liabilities   3,204    -    3,204 
                
Loan due to Juvenescence, net of debt issuance costs, net of current portion   693    -    693 
TOTAL LIABILITIES  3,897   -   3,897 
                
Commitments and contingencies   -     -     -  
                
Series A preferred stock; no par value; stated value $100 per share; 212 and nil shares issued and outstanding, respectively   21,135    (21,135)   - 
Series B preferred stock; no par value; stated value $100 per share; 148 and nil shares issued and outstanding, respectively   14,823    (14,823)   - 
               
Stockholders’ equity (deficit):              
Preferred stock, $0.0001 par value, 5,000 shares authorized; and                
Series A Preferred stock - 212 and nil shares issued and outstanding, respectively   -    -    - 
Series B Preferred stock - 148 and nil shares issued and outstanding, respectively   -    -    - 
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively   4    -    4 
Additional paid-in capital   100,017    35,958    135,975 
Accumulated deficit   (127,557)   -    (127,557)
Total AgeX Therapeutics, Inc. stockholders’ equity (deficit)   (27,536)   35,958    8,422 
Noncontrolling interest   (109)   -    (109)
Total stockholders’ equity (deficit)   (27,645)   35,958    8,313 
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)  $12,210   $-   $12,210 

11. Subsequent Events

 

2022 Secured Convertible Promissory Note

 

On January 25, 2023, AgeX borrowed an additional $500,000 under the Secured Note. In connection with that draw of loan funds under the Secured Note, AgeX issued to Juvenescence warrants to purchase 340,136 shares of AgeX common stock at an exercise price of $0.735 per share.

 

Amended and Restated Secured Convertible Promissory Note

 

On February 9, 2023, AgeX and Juvenescence entered into an Amended and Restated Secured Convertible Promissory Note which amends and restates the February 14, 2022 Secured Note and provides that AgeX may borrow up to an additional $2,000,000 from Juvenescence until May 9, 2023 subject to Juvenescence’s discretion to approve each loan draw. References to the Secured Note include the Amended and Restated Secured Note. AgeX may not draw more than $1 million in any single draw. The date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024, consistent with the original terms of the Secured Note.

 

The other material provisions of the Secured Note, including but not limited to those pertaining to loan origination fees, default provisions, provisions governing the rights of AgeX and Juvenescence to convert the loan balance and any accrued but unpaid origination fees into shares of AgeX common stock, and provisions requiring AgeX to issue common stock purchase warrants to Juvenescence in connection with borrowings remain in effect and will apply to any draw down of the additional $2,000,000 credit available under the Secured Note as amended.

 

AgeX’s obligations under the Secured Note, including with respect to any additional borrowings, will continue to be secured by the security interests in AgeX assets granted to Juvenescence pursuant to the Security Agreement.

 

On February 15, 2023, AgeX drew $1,000,000 of its available credit under the Secured Note. In connection with that draw of loan funds, AgeX issued to Juvenescence warrants to purchase 801,924 shares of AgeX common stock at an exercise price of $0.6235 per share, the closing price of AgeX common stock on the NYSE American on February 10, 2023, the trading day immediately preceding delivery of AgeX’s drawdown notice of loan funds.

 

 

2020 Loan Agreement

 

On March 13, 2023, the 2020 Loan Agreement was amended to extend the maturity date to March 30, 2024.

 

$10 Million Secured Convertible Promissory Note

 

On March 13, 2023, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “$10 Million Secured Note”) pursuant to which Juvenescence has loaned to AgeX $10,000,000. AgeX used the loan proceeds to finance the purchase of a Convertible Promissory Note (the “Serina Note”) issued by Serina Therapeutics Inc., an Alabama corporation (“Serina”) to AgeX on March 15, 2023, pursuant to the terms of a Convertible Note Purchase Agreement (the “Serina Note Purchase Agreement”)

 

The outstanding principal balance of the $10 Million Secured Note will become due and payable on March 13, 2026. In lieu of accrued interest, AgeX will pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.

 

If (a) AgeX and Serina have not entered into a definitive merger agreement by June 13, 2023; (b) a merger between AgeX and Serina is terminated or either party gives notice to terminate the merger agreement; or (c) the merger is not consummated by March 13, 2024, then AgeX may, after written notice to Juvenescence, pay and satisfy in full the principal balance and accrued origination fees under the $10 Million Secured Note by tendering to Juvenescence the Serina Note and shares of capital stock of Serina, if any, that may have been issued to AgeX upon conversion of the Serina Note in whole or in part.

 

AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. If less than $25,000,000 is raised through the sale of common stock or units, the conversion price per share or units shall be the lowest price at which shares or units are sold. If at least $25,000,000 is raised, the conversion price per share shall be 85% of the “Market Price” of AgeX common stock determined as provided in the $10 Million Secured Note.

 

Juvenescence may convert the outstanding principal amount of the $10 Million Secured Note plus the accrued origination fee into AgeX common stock at the market price per share of AgeX common stock. Juvenescence may not convert the $10 Million Secured Note to AgeX common stock before the earlier of (i) a merger between AgeX and Serina, and (ii) March 13, 2024. Any conversion of the $10 Million Secured Note into AgeX common stock is subject to certain restrictions to comply with applicable requirements of the NYSE American where AgeX common stock is listed.

 

The outstanding principal amount of the $10 Million Secured Note and the accrued origination fee may become immediately due and payable prior to the maturity date if an Event of Default as defined in the $10 Million Secured Note occurs. Events of Default under the $10 Million Secured Note are substantially the same events as those constituting an Event of Default under the Secured Note except that such events pertain to the $10 Million Secured Note and related loan documents.

 

The $10 Million Secured Note includes certain covenants that among other matters require financial reporting and impose certain restrictions on AgeX that are substantially the same as those under the Secured Note.

 

AgeX has entered into an Amended and Restated Security Agreement that amends the February 14, 2022 Security Agreement between AgeX and Juvenescence and adds the $10 Million Secured Note to the obligations secured by the Security Agreement. The Security Agreement grants Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral.

 

Serina Note

 

On March 15, 2023, AgeX and Serina entered into the Serina Note Purchase Agreement, pursuant to which AgeX has agreed to lend to Serina an aggregate principal amount of $10,000,000 as evidenced by the Serina Note. Interest on the principal amount under the Serina Note accrues on the unpaid principal amount at a simple interest rate equal to 7% per annum, computed on the basis of the 360-day year of twelve 30-day months. The outstanding principal balance of the Serina Note will become due and payable on March 15, 2026.

 

 

In connection with the issuance of the Serina Note, AgeX is entitled to elect one member to the board of directors of Serina and receive certain information and inspection rights as well as participation rights for subsequent equity issuances.

 

The principal balance of the Serina Note with accrued interest will automatically convert into Serina preferred stock if Serina raises at least $25,000,000 through the sale of shares of Serina preferred stock. The conversion price per share shall be the lower of (a) 80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by Serina’s then fully diluted capitalization. AgeX has the option to convert the Serina Note into Serina preferred stock after a sale of Serina preferred stock regardless of the amount sold by Serina.

 

AgeX may (i) at its election, upon a change of control (as defined in the Serina Note), convert the Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the Serina Note, plus interest, or (b) into the highest ranking shares of Serina then issued at a conversion price equal to the lowest price per share at which the most senior series of Serina shares has been sold in a single transaction or a series of related transactions through which Serina raised at least $5,000,000 or (ii) if the Serina Note remains outstanding as of the maturity date, AgeX may convert the Serina Note into the most senior shares of Serina issued at the time of conversion at a conversion price equal to the capped price.

 

Upon the consummation of a merger between AgeX and Serina, the Serina Note would remain outstanding and become an intercompany asset of AgeX and an intercompany liability of Serina.

 

The outstanding principal balance of the Serina Note with accrued interest may become immediately due and payable prior to the stated maturity date if an Event of Default as defined in the Serina Note occurs. In addition to this and any other remedy, both in equity and in law, upon the occurrence of an Event of Default, an interest rate of 10% per annum and computed on the basis of the 360-day year of twelve 30-day months, shall apply to the Convertible Amount until fully paid. Events of Default under the Serina Note include: (i) the commission of any act of bankruptcy by Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (ii) the execution by Serina of a general assignment for the benefit of creditors, (iii) the filing by or against Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) of a petition in bankruptcy or any petition for relief under the federal bankruptcy act (or, in each case, under any similar insolvency law) or the continuation of such petition without dismissal for a period of 60 calendar days or more, (iv) the appointment of a receiver or trustee to take possession of the property or assets of Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (v) failure of Serina to pay any amount due under the Serina Note when due, which failure to pay is not cured by Serina within 5 business days of written notice thereof, (vi) unless waived by AgeX, Serina’s material breach of any representation, warranty or covenant of Serina under the Serina Note Purchase Agreement, Serina Note or other agreements entered in connection therewith, which breach, if curable, is not cured by Serina within 10 business days of written notice by AgeX thereof, (vii) Serina or any subsidiary shall default on any of its obligations under any indebtedness which default causes the indebtedness thereunder to (x) become prematurely due and payable, (y) be placed on demand or (z) become capable of being declared by or on behalf of a creditor thereunder to be prematurely due and payable or being placed on demand, in each case, as a result of such default or any provision having a similar effect (howsoever prescribed), (viii) any monetary judgment, writ or similar final process shall be entered or filed against Serina, any subsidiary or any of their respective property or other assets for more than $250,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period of 45 calendar days, and (ix) Serina experiences a Material Adverse Effect (as defined in the Serina Note Purchase Agreement).

 

The Serina Note Purchase Agreement and Serina Note each includes certain covenants that among other matters require financial reporting and impose certain restrictions, including (i) restrictions on the incurrence of additional indebtedness by Serina and its subsidiaries; (ii) requiring that Serina use note proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, and for general working capital; and (iii) prohibiting Serina from entering into any material sale or transfer transactions outside of the ordinary course of business, other than in a merger between AgeX and Serina, without the consent of AgeX.

 

Subordination Agreement

 

In connection with the issuance of the Serina Note, Serina, each other holder of Serina indebtedness (each a “Serina Lender”), and AgeX entered into a Subordination Agreement, dated March 15, 2023, pursuant to which each Serina Lender agreed to subordinate to AgeX’s rights of repayment with respect to the obligations owed under the Serina Note Purchase Agreement and the Serina Note (i) all Serina indebtedness owed to such Serina Lender under certain convertible notes between each Serina Lender and Serina, which aggregate principal amount of all of such convertible notes equals $1,450,000, and (ii) any related security interests.

XML 65 R19.htm IDEA: XBRL DOCUMENT v3.23.4
Convertible Note Receivable
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Convertible Note Receivable

4. Convertible Note Receivable

 

On March 15, 2023, AgeX and Serina entered into a Convertible Note Purchase Agreement (the “Serina Note Purchase Agreement”), pursuant to which AgeX lent to Serina an aggregate principal amount of $10,000,000 as evidenced by the Serina Note on that date. Interest on the principal amount under the Serina Note accrues on the unpaid principal amount at a simple interest rate equal to 7% per annum, computed on the basis of the 360-day year of twelve 30-day months. The outstanding principal amount and accrued interest of $10,379,000 under the Serina Note will become due and payable on March 15, 2026.

 

In connection with the issuance of the Serina Note, AgeX is entitled to elect one member to the board of directors of Serina and receive certain information and inspection rights as well as participation rights for subsequent equity issuances.

 

The principal balance of the Serina Note with accrued interest will automatically convert into Serina preferred stock if Serina raises at least $25,000,000 through the sale of shares of Serina preferred stock (“qualifying event”). The conversion price per share shall be the lower of (a) 80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by Serina’s then fully diluted capitalization. AgeX has the option to convert the Serina Note into Serina preferred stock after a sale of Serina preferred stock regardless of the amount sold by Serina. AgeX evaluated the 20% discounted conversion feature of the Serina Note under ASC 815-15, Derivatives and Hedging—Embedded Derivatives, and concluded that it was an embedded derivative which should be bifurcated from the note and accounted for separately. The 20% discount was determined to have an immaterial value at inception and life to date of the Serina Note, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period and any adjustments will be included in Interest (income) expense, net in the Other (income) expense, net section of the condensed consolidated statements of operations.

 

AgeX may (i) at its election, upon a change of control (as defined in the Serina Note), convert the Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the Serina Note, plus interest, or (b) into the highest ranking shares of Serina then issued at a conversion price equal to the lowest price per share at which the most senior series of Serina shares has been sold in a single transaction or a series of related transactions through which Serina raised at least $5,000,000 or (ii) if the Serina Note remains outstanding as of the maturity date, AgeX may convert the Serina Note into the most senior shares of Serina issued at the time of conversion at a conversion price equal to the capped price.

 

If the Merger is consummated, the Serina Note will be canceled for no consideration.

 

The outstanding principal balance of the Serina Note with accrued interest may become immediately due and payable prior to the stated maturity date if an Event of Default as defined in the Serina Note occurs. In addition to this and any other remedy, both in equity and in law, upon the occurrence of an Event of Default, an interest rate of 10% per annum and computed on the basis of the 360-day year of twelve 30-day months, shall apply to the Convertible Amount until fully paid. Events of Default under the Serina Note include: (i) the commission of any act of bankruptcy by Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (ii) the execution by Serina of a general assignment for the benefit of creditors, (iii) the filing by or against Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) of a petition in bankruptcy or any petition for relief under the federal bankruptcy act (or, in each case, under any similar insolvency law) or the continuation of such petition without dismissal for a period of 60 calendar days or more, (iv) the appointment of a receiver or trustee to take possession of the property or assets of Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (v) failure of Serina to pay any amount due under the Serina Note when due, which failure to pay is not cured by Serina within 5 business days of written notice thereof, (vi) unless waived by AgeX, Serina’s material breach of any representation, warranty or covenant of Serina under the Serina Note Purchase Agreement, Serina Note or other agreements entered in connection therewith, which breach, if curable, is not cured by Serina within 10 business days of written notice by AgeX thereof, (vii) Serina or any subsidiary shall default on any of its obligations under any indebtedness which default causes the indebtedness thereunder to (x) become prematurely due and payable, (y) be placed on demand or (z) become capable of being declared by or on behalf of a creditor thereunder to be prematurely due and payable or being placed on demand, in each case, as a result of such default or any provision having a similar effect (howsoever prescribed), (viii) any monetary judgment, writ or similar final process shall be entered or filed against Serina, any subsidiary or any of their respective property or other assets for more than $250,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period of 45 calendar days, and (ix) Serina experiences a Material Adverse Effect (as defined in the Serina Note Purchase Agreement).

 

The Serina Note Purchase Agreement and Serina Note each includes certain covenants that among other matters require financial reporting and impose certain restrictions, including (i) restrictions on the incurrence of additional indebtedness by Serina and its subsidiaries; (ii) requiring that Serina use note proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, and for general working capital; and (iii) prohibiting Serina from entering into any material sale or transfer transactions outside of the ordinary course of business, other than in a merger between AgeX and Serina, without the consent of AgeX.

 

Subordination Agreement

 

In connection with the issuance of the Serina Note, Serina, each other holder of Serina indebtedness (each a “Serina Lender”), and AgeX entered into a Subordination Agreement, dated March 15, 2023, pursuant to which each Serina Lender agreed to subordinate to AgeX’s rights of repayment with respect to the obligations owed under the Serina Note Purchase Agreement and the Serina Note (i) all Serina indebtedness owed to such Serina Lender under certain convertible notes between each Serina Lender and Serina, which aggregate principal amount of all of such convertible notes equals $1,450,000, and (ii) any related security interests.

 

 

XML 66 R20.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ Equity (Deficit)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Equity [Abstract]    
Stockholders’ Equity (Deficit)

7. Stockholders’ Equity (Deficit)

 

Preferred Stock

 

On July 24, 2023, AgeX issued to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 million of indebtedness consisting of the outstanding principal amount of loans then outstanding under the 2020 Loan Agreement, the Secured Note, and the $10 Million Secured Note, plus the loan origination fees accrued with respect to the 2022 Secured Note and a portion of the loan origination fees accrued pursuant to the $10 Million Secured Note. The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to the Exchange Agreement between AgeX and Juvenescence. By completing the exchange of indebtedness for shares of Series A Preferred Stock and Series B Preferred Stock (collectively referred to as the “Preferred Stock”).

 

Classification of Preferred Stock

 

The deemed liquidation preference provisions of the preferred stock are considered contingent redemption provisions that are not solely within AgeX’s control. Accordingly, the preferred stock has been presented outside of permanent equity in the mezzanine section of the condensed consolidated balance sheet. Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values to the preferred stock would be made only when a deemed liquidation event becomes probable.

 

On November 7, 2023, certain terms of the Series A Preferred Stock and Series B Preferred Stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as adeemed liquidation if the applicable transaction is approved by the Board of Directors or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of Preferred Stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock. This amendment permits the classification of the Series A Preferred Stock and Series B Preferred Stock as permanent equity effective November 7, 2023. See Note 12, Subsequent Events, for illustration of the Preferred Stock presented in permanent equity in the condensed consolidated pro forma balance sheet.

 

 

Dividends – The Preferred Stock is not entitled to receive any payment or distribution of cash or other dividends.

 

Liquidation Preference – In the event of any voluntary or involuntary liquidation, dissolution or other winding up of the affairs of AgeX, subject to the preferences and other rights of any senior stock, before any assets of AgeX shall be distributed to holders of common stock or other junior stock, all of the assets of AgeX available for distribution to stockholders shall be distributed among the holders of Series A Preferred Stock and Series B Preferred Stock and any other “parity stock” that may be issued ranking parri passu with those series of Preferred Stock with respect to liquidation rights, in proportion to the number of shares of Series B Preferred Stock and parity stock held by each such holder as of the record date for the determination of holders of Series A Preferred Stock, Series B Preferred Stock, and parity stock entitled to receive such distribution, until AgeX shall have distributed to the holders of those shares an amount of assets having a value equal to the subscription price per share. If the assets of AgeX shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of Series A Preferred Stock, Series B Preferred Stock and parity stock shall be ratably distributed among such holders. The (i) acquisition of AgeX by another entity by means of any transaction or series of transactions (including, without limitation, any reorganization, merger or consolidation) in which the stockholders of AgeX immediately before such transaction or series of transactions do not own a majority of the outstanding stock of the surviving or acquiring corporation upon completion of such transaction or series of transactions or (ii) a sale of all or substantially all of the assets of AgeX in a single transaction or series of related transactions, shall be deemed a liquidation. On November 7, 2023, certain terms of the liquidation preference were amended. See Note 12 Subsequent Transactions.

 

Conversion of Preferred Stock into Common Stock – Each share of Preferred Stock shall be convertible into a number of shares of AgeX common stock determined by dividing (x) a number equal to the number of dollars and cents comprising the subscription price, by (y) a number equal to the number of dollars and cents comprising the conversion price. The subscription price per share of Preferred Stock is $100 which was paid through the exchange of indebtedness for shares of Preferred Stock. The conversion price per share of Series A Preferred Stock or Series B Preferred Stock is $0.72 which was the closing price of AgeX common stock on the NYSE American on the last trading day immediately preceding the execution of the Exchange Agreement.

 

Optional Conversion – Preferred Stock shall be convertible into common stock at the election of the holder of shares of Preferred Stock at any time and from time to time subject to the limitations on conversion of Series B Preferred Stock discussed below.

 

Automatic Conversion – The outstanding shares of Series A Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders (“Automatic Conversion”) upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina, or a subsidiary thereof; and (y) February 1, 2024. Further, if the holders of at least a majority of the outstanding shares of Series A Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, then the outstanding shares of Series A Preferred Stock shall be converted into common stock upon such approval or consent.

 

The outstanding shares of Series B Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina or a subsidiary thereof; and (y) February 1, 2024, provided that such conversion is not limited by the 19.9% Cap or the 50% Cap as described below; and if Automatic Conversion would then be limited by the 19.9% Cap or the 50% Cap, the Automatic Conversion shall take place on the tenth day after such stockholder approvals have been obtained as may be required to permit such Automatic Conversion without the limitations of the 19.9% Cap and the 50% Cap. Further, if the holders of at least a majority of the outstanding shares of Series B Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, and the conversion is not then limited by the 19.9% Cap or the 50% Cap, then the outstanding shares of Series B Preferred Stock shall be converted into common stock upon such approval or consent.

 

Certain Limitations on Conversion of Series B Preferred StockIf under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the “19.9% Cap” upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued upon conversion of all shares of Series B Preferred Stock shall be an amount equal to the 19.9% Cap. The 19.9% Cap means 7,550,302 shares of common stock, which is 19.9% of the shares of common stock outstanding on February 14, 2022 when the Secured Note, a portion of which has not been approved by AgeX stockholders for conversion into common stock without regard to the 19.9% Cap and 50% Cap, was issued.

 

 

If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the 50% Cap upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued to a holder of Series B Preferred Stock upon conversion of such shares shall be an amount that, when added to other shares of common stock owned by such holder immediately prior to such conversion would equal one share less than the 50% Cap.

 

Adjustment of conversion price and subscription price – If AgeX shall (a) declare a dividend or make a distribution on its common stock in shares of common stock, (b) subdivide or reclassify the outstanding common stock into a greater number of shares, or (c) combine or reclassify the outstanding common stock into a smaller number of shares, the conversion price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. If AgeX shall (i) declare a dividend or make a distribution on a series of Preferred Stock in shares of Preferred Stock, (ii) subdivide or reclassify the outstanding shares of a series of Preferred Stock into a greater number of shares, or (iii) combine or reclassify the outstanding shares of a series of Preferred Stock into a smaller number of shares, the subscription price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. Successive adjustments in the conversion price or subscription price, as applicable, shall be made whenever any event specified above shall occur.

 

No Fractional Shares – No fractional share of common stock or scrip shall be issued upon conversion of Preferred Stock. Instead of any fractional share of common stock which would otherwise be issuable upon conversion of any Preferred Stock, AgeX will pay a cash adjustment in respect of such fractional interest in an amount equal to that fractional interest at the then fair value determined in accordance with the terms of the Preferred Stock.

 

Voting Rights – The following matters shall require the approval of the holders of a majority of the shares of a series of Preferred Stock then outstanding, voting as a separate class: (i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock. Except as may otherwise be required by the Delaware General Corporation Law, as the same may be amended from time to time, the Preferred Stock will have no other voting rights.

 

Governing Law – The powers, designations, preferences, rights, qualifications, limitations, and restrictions of either series of Preferred Stock, the validity, authorization and issuance of such Preferred Stock, and the conversion of such Preferred Stock into common stock shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof, and all legal proceedings pursuant or with respect to or concerning such matters (a “Proceeding”), whether brought by or against a holder of Preferred Stock or AgeX or any of their respective directors, officers, stockholders, employees or agents, shall be commenced in the state and federal courts sitting in the State of Delaware (the “Delaware Courts”). The Preferred Stock provides that (a) AgeX and each holder of Preferred Stock irrevocably submits to the exclusive jurisdiction of the Delaware Courts for the adjudication of any Proceeding, and irrevocably waives, and agrees not to assert in any Proceeding any claim that they are not personally subject to the jurisdiction of such Delaware Courts, or such Delaware Courts are an improper or inconvenient venue for such Proceeding, and (b) AgeX and each holder of Preferred Stock irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to such party and agrees that such service shall constitute good and sufficient service of process and notice

 

Common Stock

 

AgeX has 200,000,000 shares of $0.0001 par value common stock authorized. At September 30, 2023 and December 31, 2022, there were 37,951,261 and 37,949,196 shares of AgeX common stock issued and outstanding, respectively.

 

Issuance and Sale of Warrants by AgeX

 

In connection with the $2,500,000 of drawdowns of loan funds from Juvenescence under the Secured Note during the nine months ended September 30, 2023, AgeX issued to Juvenescence 2022 Warrants to purchase 1,898,489 shares of AgeX common stock. See Note 6, Warrant Liability.

 

 

At-the-Market Offering Facility

 

On January 8, 2021, AgeX entered into a sales agreement with Chardan Capital Markets, LLC (“Chardan”) relating to the sale of shares of AgeX common stock, par value $0.0001 per share, through an at-the-market (“ATM”) offering as described in the prospectus supplement filed with the Form S-3 which was declared effective by the SEC on January 29, 2021. In accordance with the terms of the sales agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $12.6 million from time to time through Chardan, acting as the sales agent. The actual market value of shares of common stock that AgeX may sell through the ATM offering during any 12 month period will be limited to one-third of the aggregate market value of AgeX common stock held by stockholders that would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. During the nine months ended September 30, 2023 and 2022, no proceeds were raised through the sale of shares of common stock under the ATM.

 

7. Stockholders’ Deficit

 

Preferred Stock

 

AgeX is authorized to issue up to 5,000,000 shares of preferred stock, $0.0001 par value per share. At December 31, 2022 and 2021, there were no preferred shares issued and outstanding.

 

Common Stock

 

AgeX has 200,000,000 shares of common stock, $0.0001 par value per share, authorized. The holders of AgeX’s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of AgeX common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of AgeX outstanding preferred shares, if any.

 

The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of AgeX stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable.

 

As of December 31, 2022 and 2021, there were 37,949,196 and 37,941,220 shares of AgeX common stock issued and outstanding, respectively.

 

Issuance of Warrants by AgeX

 

In connection with the $12,660,000 of drawdowns of loan funds from Juvenescence under the Secured Note during the year ended December 31, 2022, AgeX has issued to Juvenescence 2022 Warrants to purchase 8,458,597 shares of AgeX common stock.

 

As consideration for $8.0 million in loans made to AgeX under the 2020 Loan Agreement, AgeX issued to Juvenescence warrants to purchase 3,670,663 shares of AgeX common stock.

 

See Notes 5, Related Party Transactions and 6, Warrant Liability for additional information on warrants issued to Juvenescence.

 

At-the-Market Offering Facility

 

On January 8, 2021, AgeX entered into a Sales Agreement with Chardan, relating to the sale of shares of AgeX common stock, in at-the-market transactions. In accordance with the terms of the Sales Agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $12.6 million from time to time through Chardan, acting as the sales agent. The actual market value of common shares that AgeX may sell through its Sales Agreement with Chardan during any 12 month period will be limited to one-third of aggregate market value of our common stock held by stockholders that would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. During the years ended December 31, 2022 and 2021, AgeX raised nil and $496,000, respectively, in gross proceeds through the sale of shares of common stock through the Sales Agreement with Chardan.

 

XML 67 R21.htm IDEA: XBRL DOCUMENT v3.23.4
Supplemental Cash Flow Information
9 Months Ended
Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information

10. Supplemental Cash Flow Information

 

Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022 are as follows (in thousands):

 

   2023   2022 
  

Nine Months Ended

September 30,

 
   2023   2022 
Cash paid during the period for interest  $27   $14 
Issuance of preferred stock in exchange for debt  $36,000   $- 
Issuance of common stock upon vesting of restricted stock units (Note 8)  $2   $6 
Issuance of warrants for debt issuance under the 2020 Loan Agreement  $-   $178 
Fair value of liability classified warrants at debt inception date (Note 6)  $663   $3,666 
Debt refinanced with new debt (Note 5)  $-   $7,160 

 

 

XML 68 R22.htm IDEA: XBRL DOCUMENT v3.23.4
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Going Concern Assessment  

Going Concern Assessment

 

AgeX assesses going concern uncertainty for its consolidated financial statements to determine if AgeX has sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date the consolidated financial statements are issued or are available to be issued, which is referred to as the “look-forward period” as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to AgeX, AgeX will consider various scenarios, forecasts, projections, and estimates, and AgeX will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, AgeX makes certain assumptions concerning its ability to curtail or delay research and development programs and expenditures within the look-forward period in accordance with ASU No. 2014-15 (see Note 1, Organization, Basis of Presentation and Liquidity).

 

 

Fair value measurements of financial instruments

Fair value measurements of financial instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.

 

The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. Fair values for AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.

 

To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures):

 

  Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
     
  Level 2 – Inputs to the valuation methodology include observable quoted prices (other than quoted market prices included within Level 1) for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.
     
  Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

 

In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. The discounted conversion prices triggered by certain qualified events in the Serina Note and the $10 Million Secured Note are Level 3 on the fair value hierarchy and subject to fair valuation at inception and remeasurement at each reporting period. The fair value of the discounted conversion prices under both notes were determined to have an immaterial value at inception and life to date of the notes, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period. For additional information regarding the convertible notes and derivatives, see Notes 4, Convertible Note Receivable, 5, Related Party Transactions, and 12, Subsequent Events.

 

The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.

 

The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations are discussed further in Note 6, Warrant Liability. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date. As of September 30, 2023, AgeX has utilized the full credit subject to warrants, and accordingly, the warrants were fully issued for each of the advances of loan funds under the Secured Note.

 

See Note 6, Warrant Liability, for additional information on accounting for liability classified warrants and certain Level 3 warrant valuation tables.

 

Fair Value Measurements of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.

 

The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. The credit facility is reported at fair value as it bears market rates of interest. Fair values for the AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.

 

To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures):

 

Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.

 

Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

 

The following table summarizes fair value measurements by level as of December 31, 2022 for liabilities measured at fair value on a recurring basis (in thousands):

 

   Level 1   Level 2   Level 3   Total 
Warrant liability  $-   $-   $180   $180 

 

There were no warrant liabilities as of December 31, 2021. See Note 6, Warrant Liability for additional information on accounting for liability classified warrants and level 3 rollforward table.

 

In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.

 

The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items.

 

The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.

 

The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations, are discussed further in Note 6, Warrant Liability. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date.

 

Cash and Cash Equivalents  

Cash and Cash Equivalents

 

AgeX considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2022 and 2021, AgeX’s cash balances totaled $0.6 million and $0.6 million, respectively, and consist entirely of bank account deposits and amounts held in money market funds.

 

Concentration of credit risk and other risks and uncertainties

Concentration of credit risk and other risks and uncertainties

 

Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

 

AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, Convertible Note Receivable and 5, Related Party Transactions.

 

Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX.

 

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject AgeX to significant concentrations of credit risk consist primarily of cash and cash equivalents. AgeX limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, AgeX has not experienced any losses on such accounts.

 

 

Cash, cash equivalents, and restricted cash

Cash, cash equivalents, and restricted cash

 

In accordance with Accounting Standards Update (“ASU”) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the condensed consolidated balance sheets to cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows for all periods presented is as follows (in thousands):

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Cash and cash equivalents  $397   $645 
Restricted cash (1)   50    50 
Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows  $447   $695 

 

(1) Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.

 

 

Restricted Cash

 

In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands):

 

         
   December 31, 
   2022   2021 
Cash and cash equivalents  $645   $584 
Restricted cash (1)   50    50 
Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows  $695   $634 

 

 

(1)Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits in the consolidated balance sheets.

 

Accounts Receivable, Net  

Accounts Receivable, Net

 

AgeX establishes an allowance for doubtful accounts based on the evaluation of the collectability of its receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. There were no amounts reserved for doubtful accounts as of December 31, 2022 and 2021.

 

Long-lived intangible assets, net

Long-lived intangible assets, net

 

Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 years. See Note 3, Selected Balance Sheet Components.

 

Long-Lived Intangible Assets, Net

 

Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 years (see Note 4, Selected Balance Sheet Components).

 

Impairment of long-lived assets

Impairment of long-lived assets

 

AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consists entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of September 30, 2023, there has been no impairment of long-lived assets.

 

Impairment of Long-Lived Assets

 

AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consist entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of December 31, 2022, there has been no impairment of long-lived assets.

 

Leases

Leases

 

AgeX accounts for leases in accordance with ASU 2016-02, Leases (Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX: (i) ASU 2018-10, Codification Improvements to Topic 842, Leases, and (ii) ASU 2018-11, Leases (Topic 842): Targeted Improvements, using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensed consolidated balance sheets.

 

ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.

 

AgeX leases office space in Alameda, California. For 2022 base monthly rent was $1,074 and for 2023 base monthly rent is $844 for slightly less space at the same building. AgeX has elected to not apply the recognition requirements under ASC 842 for the lease agreements and instead recognizes the lease payments as lease cost on a straight-line basis over the lease term as lease payments are not deemed material.

 

Leases

 

AgeX accounts for leases in accordance with ASU 2016-02, Leases (Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX, which are: (i) ASU 2018-10, Codification Improvements to Topic 842, Leases, and (ii) ASU 2018-11, Leases (Topic 842): Targeted improvements, using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheets.

 

ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.

 

 

On November 3, 2020, AgeX entered into a one-year lease effective January 1, 2021 for 135 square feet of office space in a building in an office and research park in Alameda, California. Base monthly rent was $947 over the lease term. AgeX renewed this lease for 12 months effective January 1, 2022 for base monthly rent of $1,074. In October 2022, AgeX entered into a new 12 month lease for a slightly less space in the same building effective January 1, 2023 for base monthly rent of $844. AgeX elected to not apply the recognition requirements under ASC 842 and instead recognized the lease payments as lease costs on a straight-line basis over the lease term, as the amount of the lease payments were not deemed material.

 

Accounting for warrants

Accounting for warrants

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of September 30, 2023. See Notes 5, Related Party Transactions and 6, Warrant Liability, for additional information regarding warrants.

 

 

Accounting for Warrants

 

AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of December 31, 2022. See Notes 5, Related Party Transactions and 6, Warrant Liability for additional information regarding AgeX warrants.

 

Stock-Based Compensation  

Stock-Based Compensation

 

AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718, Compensation – Stock Compensation.

 

AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09.

 

AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under the Incentive Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.

 

Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations.

 

The Black-Scholes option pricing model requires AgeX to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 8, Stock-Based Awards).

 

The fair value of the shares of common stock underlying the stock options is determined in accordance with the Incentive Plan and is based on prevailing market prices on the NYSE American where AgeX common stock is traded.

 

The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. AgeX estimates the expected term of options granted using the “simplified method” provided under Staff Accounting

 

 

Bulletin, Topic 14, or SAB Topic 14.

 

Because AgeX’s common stock has public trading history of fewer than five years, AgeX has estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options, which may exceed five years. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage.

 

The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of AgeX’s stock options.

 

The dividend yield assumption is based on AgeX’s history and expectation of dividend payouts. AgeX has never declared or paid any cash dividends on its common stock, and AgeX does not anticipate paying any cash dividends in the foreseeable future.

 

All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.

 

Stock-based compensation expense for the years ended December 31, 2022 and 2021 consists of stock-based compensation under the AgeX 2017 Equity Incentive Plan (see Note 8, Stock-Based Awards).

 

Certain of AgeX’s consolidated subsidiaries have had their own share-based compensation plans; however, there are no awards granted and outstanding under those plans as of December 31, 2022 and 2021. For share-based compensation awards granted by privately held consolidated subsidiaries under their respective equity plans, AgeX determines the fair value of the options granted under those plans using similar methodologies and assumptions AgeX used for its stock options discussed above.

 

Although the fair value of stock options and restricted stock units is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.

 

Income Taxes  

Income Taxes

 

AgeX accounts for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. AgeX’s judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If AgeX’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on AgeX’s consolidated financial statements.

 

The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. AgeX recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No unrecognized tax benefits have been recorded and no amounts were accrued for the payment of interest and penalties as of December 31, 2022 and 2021. AgeX does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. AgeX is currently unaware of any tax issues under review.

 

Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2021, AgeX’s foreign entity operated at a loss; therefore, no GILTI was included in income. For the year ended December 31, 2022, there was no income or loss related to foreign activity as the entity deconsolidated from AgeX on March 15, 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.

 

 

Revenue recognition

Revenue recognition

 

AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.

 

Grant revenues – AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements. At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.

 

In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, AgeX’s policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health (“NIH”) supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.

 

AgeX believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606.

 

In August 2023, AgeX was awarded a grant of up to approximately $341,000 from the NIH, National Heart, Lung and Blood Institute. The NIH grant will provide funding for continued development of AgeX’s technologies toward treating cardiovascular disease over a one year period starting September 1, 2023. Based on our evaluation under the accounting guidance aforementioned, this grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred. Accordingly, grant funds are made available by the NIH as allowable expenses are incurred. For the three and nine months ended September 30, 2023, AgeX incurred approximately $21,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues.

 

ESI BIO Research Products – AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP”. AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products have not been significant during the periods presented in the condensed consolidated interim financial statements included in this Report.

 

Arrangements with multiple performance obligations – AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of September 30, 2023 and December 31, 2022, AgeX did not have significant arrangements with multiple performance obligations.

 

 

Revenue Recognition

 

AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.

 

In the applicable paragraphs below, AgeX has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606.

 

Revenue recognition by source and geography – Revenues are recognized when control of the promised goods or services is transferred to customers, or in the case of governmental entities funding a grant, when allowable expenses are incurred, in an amount that reflects the consideration AgeX or a subsidiary, depending on which company has the customer or the grant, expects to be entitled to in exchange for those goods or services.

 

The following table presents AgeX’s consolidated revenues disaggregated by source for continuing operations (in thousands):

 

         
   Year Ended December 31, 
REVENUES:  2022   2021 
Grant revenues  $-   $104 
Other revenues   34    40 
Total revenues  $34   $144 

 

The following table presents consolidated revenues for continuing operations (in thousands), disaggregated by geography, based on the billing addresses of customers:

 

         
   Year Ended December 31, 
REVENUES:  2022   2021 
United States  $10   $107 
Foreign   24    37 
Total revenues  $34   $144 

 

Subscription and advertisement revenues – LifeMap Sciences sold subscription-based products, including research databases and software tools, for biomedical, gene, and disease research. LifeMap Sciences sold these subscriptions primarily through the internet to biotech and pharmaceutical companies worldwide. LifeMap Sciences’ principal subscription product was the GeneCards® Suite, which includes the GeneCards® human gene database, and the MalaCards™ human disease database. LifeMap Sciences’ performance obligations for subscriptions included a license of intellectual property related to its genetic information packages and premium genetic information tools. These licenses were deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue was recognized over a period of time, which was generally the subscription period. Payments were typically received at the beginning of a subscription period and revenue was recognized according to the type of subscription sold. For subscription contracts in which the subscription term commenced before a payment was due, LifeMap Sciences recorded an account receivable because the subscription was earned over time and billed the customer according to the contract terms. LifeMap Sciences deferred subscription revenues primarily represented subscriptions for which cash payment was received for the subscription term, but the subscription term was not completed as of the balance sheet date reported.

 

LifeMap Sciences licensed from third parties the databases and software it commercialized and had a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the consolidated statements of operations when the cash was received and the royalty obligation was incurred as the royalty payments did not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers.

 

LifeMap Sciences recognized $0.3 million in subscription and advertisement revenues for the year ended December 31, 2021, which is included in operating loss from discontinued operations, and is for revenues earned through March 15, 2021. As a result of the LifeMap Deconsolidation, AgeX does not expect to earn subscription and advertising revenues in subsequent accounting periods. See Note 3, Disposition and Deconsolidation of LifeMap Sciences for further information on the disposition and deconsolidation of LifeMap Sciences.

 

 

Grant revenues – AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements. At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.

 

In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.

 

On April 8, 2020, AgeX was awarded a grant of up to approximately $386,000 from the National Institutes of Health (“NIH”). The NIH grant provided funding for continued development of AgeX’s technologies for treating stroke. The grant funds were made available by the NIH to AgeX as allowable expenses were incurred. For the year ended December 31, 2021, AgeX incurred approximately $104,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. AgeX recognized no grant revenues for the year ended December 31, 2022 as AgeX had expended the full amount available under this grant as of December 31, 2021.

 

ESI BIO research products – AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP.” AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products are included in other revenues.

 

Arrangements with multiple performance obligations – AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of and for the years ended December 31, 2022 and 2021, AgeX did not have significant arrangements with multiple performance obligations.

 

Research and development

Research and development

 

Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and contractors, sponsored research agreements with certain universities, and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations.

 

Research and Development

 

Research and development expenses consist primarily of personnel costs and related benefits, stock-based compensation, amortization of intangible assets, and collaborative and contracted research and development fees. Research and development costs which have an alternative future use will be capitalized as intangible assets, and costs with no future benefit or alternative use will be expensed as incurred. Research and development expenses incurred and reimbursed by grants from third parties approximate the grant revenues recognized in the consolidated statements of operations.

 

General and administrative

General and administrative

 

General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees.

 

General and Administrative

 

General and administrative expenses include employee and director compensation allocated to general and administrative expenses, consulting fees other than those paid for science-related consulting, license fees paid to third parties to acquire patents or licenses to use patents and other technology, professional fees to maintain patents and trademarks, minimum annual royalties stipulated under license and sublicense agreements with third parties, insurance costs allocated to general and administrative expenses, stock exchange-related costs, depreciation expense, marketing costs, legal and accounting costs, office rent, and other miscellaneous expenses which are allocated to general and administrative expense.

 

Foreign Currency Transaction Gains and Losses  

Foreign Currency Transaction Gains and Losses

 

For transactions denominated in other than the functional currency of AgeX or its subsidiaries, AgeX recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it.

 

 

Segments  

Segments

 

AgeX’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, AgeX’s executive management team has viewed AgeX’s operations as one segment that includes the research and development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders, oncology, and neurological diseases and disorders, blood and vascular system diseases and disorders, and pluripotent cell technologies. As a result, the financial information disclosed materially represents all of the financial information related to AgeX’s sole operating segment.

 

Basic and diluted net loss per share attributable to common stockholders

Basic and diluted net loss per share attributable to common stockholders

 

Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.

 

For the three and nine months ended September 30, 2023 and 2022, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.

 

The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022   2023   2022 
Stock options   3,276    3,264    3,266    3,310 
Warrants (1)   12,132    10,616    12,716    8,947 
Restricted stock units   -    9    -    12 

 

(1) As of September 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 11,539,348 and 10,919,485 shares, respectively, of AgeX common stock as consideration for certain loan agreements discussed in Note 5, Related Party Transactions.

 

Basic and Diluted Net Loss per Share Attributable to Common Stockholders

 

Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted-average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted-average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.

 

For the years ended December 31, 2022 and 2021, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.

 

The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):

 

   Year Ended December 31, 
   2022   2021 
Stock options   3,297    3,145 
Warrants (1)   9,558    3,492 
Restricted stock units        10         23 

 

 

(1)As of December 31, 2022 and 2021, AgeX issued Juvenescence warrants to purchase 12,129,260 and 3,512,098 shares, respectively, of AgeX common stock as consideration for the loan agreements discussed in Note 5, Related Party Transactions.

 

Recently adopted accounting pronouncements

Recently adopted accounting pronouncements

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.

 

 

In March 2022, the FASB issued ASU No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method, which clarifies the guidance in ASC 815 on fair value hedge accounting of interest rate risk for portfolios of financial assets. The ASU amends the guidance in ASU 2017-12 (released on August 28, 2017) that, among other things, established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible. ASU 2022-01 renames that method the “portfolio layer” method and addresses feedback from stakeholders regarding its application. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.

 

In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance became effective for AgeX on January 1, 2023 and includes interim periods. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. This ASU did not have a material impact on the condensed consolidated interim financial statements.

 

On July 14, 2023, the FASB issued ASU No. 2023-02, Presentation of Financial Statements (Topic 205), Income Statement – Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation, which amends or supersedes various SEC paragraphs within the codification to conform to past announcements and guidance issued by the SEC. Specifically, the ASU responds to (1) the issuance of SEC Staff Accounting Bulletin (SAB) 120; (2) the SEC staff announcement at the March 24, 2022, EITF meeting; and (3) SAB Topic 6.B, “Accounting Series Release No. 280 — General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.” This ASU is effective immediately and did not have a material impact on AgeX’s condensed consolidated interim financial statements.

Recently Adopted Accounting Pronouncements

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The amendment in this update addresses how an issuer should account for modifications made to equity-classified written call options. The guidance in the standard requires the issuer to treat a modification of an equity-classified call option that does not cause the instrument to become liability-classified as an exchange of the original call option for a new call option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the call option or as termination of the original call option and issuance of a new call option. The Emerging Issues Task Force (EITF) concluded that the recognition of the modification depends on the nature of the transaction in which a warrant is modified. If there is more than one element in a transaction (for example, if the modification involves both a debt modification and an equity issuance), then the guidance requires the issuer to allocate the effect of the option modification to each element. Amendments in the new standard are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this ASU in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.

 

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity’s financial statements. The amendments are effective for all entities within their scope, which excludes not-for-profit entities and employee benefit plans, for financial statements issued for annual periods beginning after December 15, 2021. Early application of the amendment is permitted. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.

 

 

Recently Issued Accounting Pronouncements Not Yet Adopted  

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. ASU 2016-13 is effective for AgeX beginning January 1, 2023 and is not expected to have a material impact on the consolidated financial statements.

 

In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance is effective for AgeX on January 1, 2023, including interim periods. Early adoption is permitted, and the amendment applied prospectively, except for the recognition and remeasurement of troubled debt restructurings. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. AgeX does not expect the adoption of this guidance to have a material impact on the consolidated financial statements.

 

CARES Act  

CARES Act

 

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act but does not expect it to have a material impact to its tax provision or its consolidated financial statements. AgeX obtained a loan under the Paycheck Protection Program under the CARES Act, the repayment of which was forgiven in February 2021.

Principles of consolidation

Principles of consolidation

 

The consolidated financial statements include the accounts of AgeX and its subsidiaries in which AgeX has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which AgeX is the primary beneficiary (as described in more detail below). For consolidated entities where AgeX has less than 100% of ownership, AgeX records net loss attributable to noncontrolling interest on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. The noncontrolling interest is reflected as a separate element of stockholders’ equity (deficit) on AgeX’s consolidated balance sheets. Any material intercompany transactions and balances have been eliminated upon consolidation.

 

 

AgeX assesses whether it is the primary beneficiary of a variable interest entity (“VIE”) at the inception of the arrangement and at each reporting date. This assessment is based on its power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and AgeX’s obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. If the entity is within the scope of the variable interest model and meets the definition of a VIE, AgeX considers whether it must consolidate the VIE or provide additional disclosures regarding its involvement with the VIE. If AgeX determines that it is the primary beneficiary of the VIE, AgeX will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event. For entities AgeX holds as an equity investment that are not consolidated under the VIE model, AgeX will consider whether its investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.

 

AgeX has four subsidiaries, Reverse Bio, ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”), Canaria Transaction Corporation (“Merger Sub”), and has incorporated but not yet capitalized a fourth subsidiary UniverXome Bioengineering, Inc.(“UniverXome”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTRTM research and development efforts. AgeX is actively seeking equity financing for Reverse Bio and to the extent that such Reverse Bio Financing is obtained through the sale of capital stock or other equity securities by Reverse Bio, AgeX’s equity interest in Reverse Bio and its iTRTM business would be diluted. AgeX’s restructuring plans also include a potential spinoff of Reverse Bio through a distribution of some or all of the shares of capital stock of Reverse Bio held by AgeX to AgeX stockholders following the Reverse Bio Financing. ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 94.8% of the outstanding capital stock of ReCyte. NeuroAirmid is jointly owned by AgeX with the University of California – Irvine and certain researchers and was recently organized to pursue clinical development and commercialization of cell therapies, focusing initially on Huntington’s Disease. AgeX owns 50% of the outstanding capital stock of NeuroAirmid. AgeX consolidates NeuroAirmid despite not having majority ownership interest as it has the ability to influence decision making and financial results through contractual rights and obligations as per Accounting Standards Codification (“ASC”) 810, Consolidation. Merger Sub was incorporated for the purpose of merging with Serina to implement the Merger. UniverXome is expected, in connection with the planned Merger, to hold certain AgeX assets and assume AgeX indebtedness obligations to Juvenescence.

 

 
Use of estimates

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of AgeX’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected.

 

See Note 6, Warrant Liability, for discussion on estimated change in fair value of warrant liability.

 

 
Reclassifications

Reclassifications

 

Certain reclassifications have been made to the prior period’s condensed consolidated interim financial statements to conform to current year presentation. Additionally, certain financial information is presented on a rounded basis, which may cause minor differences.

 

 
XML 69 R23.htm IDEA: XBRL DOCUMENT v3.23.4
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis  

The following table summarizes fair value measurements by level as of December 31, 2022 for liabilities measured at fair value on a recurring basis (in thousands):

 

   Level 1   Level 2   Level 3   Total 
Warrant liability  $-   $-   $180   $180 
Schedule of Cash, Cash Equivalents and Restricted Cash

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Cash and cash equivalents  $397   $645 
Restricted cash (1)   50    50 
Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows  $447   $695 

 

(1) Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.

In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands):

 

         
   December 31, 
   2022   2021 
Cash and cash equivalents  $645   $584 
Restricted cash (1)   50    50 
Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows  $695   $634 

 

 

(1)Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits in the consolidated balance sheets.
Schedule of Disaggregated of Revenues  

The following table presents AgeX’s consolidated revenues disaggregated by source for continuing operations (in thousands):

 

         
   Year Ended December 31, 
REVENUES:  2022   2021 
Grant revenues  $-   $104 
Other revenues   34    40 
Total revenues  $34   $144 
Schedule of Disaggregated Geographical Revenue  

The following table presents consolidated revenues for continuing operations (in thousands), disaggregated by geography, based on the billing addresses of customers:

 

         
   Year Ended December 31, 
REVENUES:  2022   2021 
United States  $10   $107 
Foreign   24    37 
Total revenues  $34   $144 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022   2023   2022 
Stock options   3,276    3,264    3,266    3,310 
Warrants (1)   12,132    10,616    12,716    8,947 
Restricted stock units   -    9    -    12 

 

(1) As of September 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 11,539,348 and 10,919,485 shares, respectively, of AgeX common stock as consideration for certain loan agreements discussed in Note 5, Related Party Transactions.

The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):

 

   Year Ended December 31, 
   2022   2021 
Stock options   3,297    3,145 
Warrants (1)   9,558    3,492 
Restricted stock units        10         23 

 

 

(1)As of December 31, 2022 and 2021, AgeX issued Juvenescence warrants to purchase 12,129,260 and 3,512,098 shares, respectively, of AgeX common stock as consideration for the loan agreements discussed in Note 5, Related Party Transactions.
XML 70 R24.htm IDEA: XBRL DOCUMENT v3.23.4
Disposition and Deconsolidation of LifeMap Sciences (Tables)
12 Months Ended
Dec. 31, 2022
Insurance [Abstract]  
Schedule of Discontinued Operations

 

  

Year Ended

December 31, 2021

 
Net revenues  $277 
Costs, operating and other expenses   (380)
Loss from discontinued operations   (103)
Net loss from discontinued operations attributable to noncontrolling interest   7 
Loss from discontinued operations (1)  $(96)

 

 

(1)Does not include $106,000 gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement. The gain on the sale of LifeMap Sciences is presented in the line item Gain on deconsolidation of LifeMap Sciences. There were no gains or losses resulting from the sale of businesses or assets that did not meet the criteria for a discontinued operation during the year ended December 31, 2021.
XML 71 R25.htm IDEA: XBRL DOCUMENT v3.23.4
Selected Balance Sheet Components (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Schedule of Intangible Assets, Net

At September 30, 2023 and December 31, 2022, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands):

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Intangible assets  $1,312   $1,312 
Accumulated amortization   (672)   (574)
Total intangible assets, net  $640   $738 

At December 31, 2022 and 2021, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands):

 

         
   December 31, 
   2022   2021 
Intangible assets  $1,312   $1,312 
Accumulated amortization   (574)   (442)
Total intangible assets, net  $738   $870 
Schedule of Amortization Assets

Amortization of intangible assets for periods subsequent to September 30, 2023 is as follows (in thousands):

 

Year Ending December 31, 

Amortization

Expense

 
2023  $33 
2024       131 
2025   131 
2026   132 
Thereafter   213 
Total  $640 

Amortization of intangible assets for periods subsequent to December 31, 2022 is as follows (in thousands):

 

Year Ending December 31, 

Amortization

Expense

 
2023  $131 
2024   132 
2025   131 
2026   131 
Thereafter   213 
Total  $738 
Schedule of Accounts Payable and Accrued Liabilities

At September 30, 2023 and December 31, 2022, accounts payable and accrued liabilities were comprised of the following (in thousands):

 

  

September 30, 2023

(unaudited)

  

December 31, 2022

 
Accounts payable  $1,172   $568 
Accrued compensation   206    193 
Accrued vendors and other expenses   293    273 
Total accounts payable and accrued liabilities  $1,671   $1,034 

At December 31, 2022 and 2021, accounts payable and accrued liabilities were comprised of the following (in thousands):

 

         
   December 31, 
   2022   2021 
Accounts payable  $568   $193 
Accrued compensation   193    212 
Accrued vendors and other expenses   273    366 
Total accounts payable and accrued liabilities  $1,034   $771 
XML 72 R26.htm IDEA: XBRL DOCUMENT v3.23.4
Related Party Transactions (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Related Party Transactions [Abstract]    
Schedule of Debt Issuance Costs and Debt Balances

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of September 30, 2023 (in thousands):

 

   Drawdown of Funds   Origination Fee   Debt Exchanged for Preferred Stock   Total Debt   Debt Issuance Costs  

Amortization

of Debt Issuance Costs

   Total Debt, Net 
Current                                   
2020 Loan Agreement  $8,000   $-   $(8,000)  $-   $(2,806)  $2,806   $- 
Secured Note   18,160    1,406    (17,993)   1,573    (6,044)   5,997    1,526 
 Total current, net   26,160    1,406    (25,993)   1,573    (8,850)   8,803    1,526 
Non-current                                   
 $10 Million Secured Note   10,000    700    (10,007)   693    (666)   666    693 
Total debt, net  $36,160   $2,106   $(36,000)  $2,266   $(9,516)  $9,469   $2,219 

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2022 (in thousands):

 

   Drawdown of Funds   Origination Fee   Amount Refinanced   Total Debt   Debt Issuance Costs   Amortization of Debt Issuance Costs   Total Debt, Net 
2019 Loan Agreement  $7,000   $160   $(7,160)  $-   $(494)  $494   $- 
2020 Loan Agreement   8,000    -    -    8,000    (2,805)   2,451    7,646 
2022 Secured Note   12,660    691    -    13,351    (4,720)   1,847    10,478 
   $27,660   $851   $(7,160)  $21,351   $(8,019)  $4,792   $18,124 

 

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2021 (in thousands):

 

   Drawdown of Funds   Origination Fee   Amount Refinanced   Total Debt   Debt Issuance Costs   Amortization of Debt Issuance Costs   Total Debt, Net 
2019 Loan Agreement  $7,000   $160   $     -   $7,160   $(494)  $474   $7,140 
2020 Loan Agreement   7,500    -    -    7,500    (2,620)   1,182    6,062 
   $14,500   $160   $-   $14,660   $(3,114)  $1,656   $13,202 
XML 73 R27.htm IDEA: XBRL DOCUMENT v3.23.4
Warrant Liability (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Warrant Liability    
Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model

The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date, the date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:

 

Black-Scholes Assumptions 

Exercise

Price (1)

  

Warrant

Expiration

Date (2)

 

Stock

Price (3)

  

Interest

Rate

(annual) (4)

  

Volatility

(annual) (5)

  

Time to

Maturity (Years)

  

Calculated

Fair Value per Share

 
Inception Date: 2/14/2022  $0.780   2/13/2025  $0.691    1.80%   122.99%   3   $0.486 
Issuance Date: 2/14/2022  $0.780   2/13/2025  $0.691    1.80%   122.99%   3   $0.486 
Issuance Date: 2/15/2022  $0.780   2/14/2025  $0.747    1.80%   123.28%   3   $0.535 
Period Ended 3/31/2022  $0.940   3/30/2025  $0.854    2.45%   123.28%   3   $0.607 
Issuance Date: 4/4/2022  $0.880   4/3/2025  $0.819    2.61%   123.31%   3   $0.585 
Issuance Date: 6/6/2022  $0.711   6/5/2025  $0.800    2.94%   122.62%   3   $0.592 
Period Ended 6/30/2022  $0.600   6/29/2025  $0.576    2.99%   122.21%   3   $0.413 
Issuance Date: 8/16/2022  $0.670   8/15/2025  $0.640    3.19%   121.37%   3   $0.457 
Period Ended 9/30/2022  $0.610   9/29/2025  $0.562    4.25%   121.49%   3   $0.401 
Issuance Date: 10/21/2022  $0.690   10/20/2025  $0.620    4.52%   120.51%   3   $0.439 
Issuance Date: 12/14/2022  $0.590   12/13/2025  $0.540    3.94%   120.01%   3   $0.381 
Period Ended 12/31/2022  $0.550   12/30/2025  $0.552    4.22%   119.31%   3   $0.396 
Issuance Date: 1/25/2023  $0.735   1/24/2026  $0.751    3.84%   119.17%   3   $0.540 
Inception Date: 2/9/2023  $0.703   2/8/2026  $0.660    4.15%   118.94%   3   $0.466 
Issuance Date: 2/15/2023  $0.624   2/14/2026  $0.600    4.35%   118.93%   3   $0.426 
Period Ended 3/31/2023  $0.661   3/30/2026  $0.663    3.81%   113.43%   3   $0.459 
Issuance Date: 4/4/2023  $0.661   4/3/2026  $0.673    3.60%   113.01%   3   $0.466 

 

 

(1) Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit.
   
(2) Warrants are exercisable over a three-year period from each Issuance Date.
   
(3) Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.
   
(4) Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.
   
(5) Based on the historical daily volatility of AgeX common stock as of each date presented.

The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:

 

Black-Scholes Assumptions 

Exercise

Price (1)

   Warrant Expiration Date (2) 

Stock

Price (3)

   Interest Rate (annual) (4)   Volatility (annual) (5)   Time to Maturity (Years)   Calculated Fair Value per Share 
Inception Date: 2/14/2022  $0.780   13-Feb-25  $0.691    1.80%    122.99%    3   $0.486 
Issuance Date: 2/14/2022  $0.780   13-Feb-25  $0.691    1.80%    122.99%    3   $0.486 
Issuance Date: 2/15/2022  $0.780   14-Feb-25  $0.747    1.80%    123.28%    3   $0.535 
Period Ended 3/31/2022  $0.940   30-Mar-25  $0.854    2.45%    123.28%    3   $0.607 
Issuance Date: 4/4/2022  $0.880   3-Apr-25  $0.819    2.61%    123.31%    3   $0.585 
Issuance Date: 6/6/2022  $0.711   5-Jun-25  $0.800    2.94%    122.62%    3   $0.592 
Period Ended 6/30/2022  $0.600   29-Jun-25  $0.576    2.99%    122.21%    3   $0.413 
Issuance Date: 8/16/2022  $0.670   15-Aug-25  $0.640    3.19%    121.37%    3   $0.457 
Period Ended 9/30/2022  $0.610   29-Sep-25  $0.562    4.25%    121.49%    3   $0.401 
Issuance Date: 10/21/2022  $0.690   20-Oct-25  $0.620    4.52%    120.51%    3   $0.439 
Issuance Date: 12/14/2022  $0.590   13-Dec-25  $0.540    3.94%    120.01%    3   $0.381 
Period Ended 12/31/2022  $0.550   30-Dec-25  $0.552    4.22%    119.31%    3   $0.396 

 

 

(1)Based on the market closing price of AgeX’s common stock on the NYSE American on the one day prior to the debt inception date and each presented period ending date and also the market closing price of AgeX’s common stock on the NYSE American on the one trading day preceding the delivery of the relevant drawdown notice in accordance with terms per the Secured Note.

 

(2)Warrants are exercisable over a three-year period from each issuance date.

 

(3)Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.

 

(4)Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.

 

(5)Based on the historical daily volatility of AgeX common stock as of each date presented.
Schedule of Warrant Outstanding and Fair Values

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

Warrant Liability 

Credit Line and

Draw Amounts

(in thousands)

   Warrants  

Fair Value

per Share

  

Fair Value

(in thousands)

 
Fair value as of January 1, 2022  $-    -   $-   $- 
Fair value at initial measurement date of 2/14/2022   13,160(1)   8,435,897(2)   0.4864    4,103 
Fair value of warrants issued on 2/14/2022   (7,160)(3)   (4,589,743)(4)   0.4864    (2,232)
Fair value of warrants issued on 2/15/2022   (1,000)(3)   (641,025)(4)   0.5349    (343)
Fair value of warrants issued on 4/4/2022   (1,000)(3)   (568,440)(4)   0.5854    (333)
Fair value of warrants issued on 6/6/2022   (1,000)(3)   (703,234)(4)   0.5924    (417)
Fair value of warrants issued on 8/16/2022   (1,000)(3)   (746,380)(4)   0.4569    (341)
Fair value of warrants issued on 10/21/2022   (500)(3)   (362,318)(4)   0.4386    (159)
Fair value of warrants issued on 12/14/2022   (1,000)(3)   (847,457)(4)   0.3810    (323)
Change in fair value of warrants   -    -    -    225 
Fair value as of December 31, 2022  $500(1)   454,545(2)  $0.3960   $180 
Fair value of warrants issued on 1/25/2023   (500)(3)   (340,136)(4)   0.5395    (184)
Fair value at initial measurement date of 2/9/2023   2,000(1)   1,422,879(2)   0.4657    663 
Fair value of warrants issued on 2/15/2023   (1,000)(3)   (801,924)(4)   0.4263    (342)
Fair value of warrants issued on 4/4/2023   (1,000)(3)   (756,429)(4)   0.4660    (352)
Change in fair value of warrants   -    -    -    35 
Fair value as of September 30, 2023  $-(1)   -(2)  $-   $- 

 

 

(1) Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit.
   
(2) Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.
   
(3) Amount of drawdown as of the date presented.
   
(4) Number of warrants issued upon receipt of amounts drawn against the Secured Note as of the date presented.

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

Warrant Liability 

Credit Line and Draw Amounts

(in thousands)

   Warrants  

Fair Value

per Share

  

Fair Value

(in thousands)

 
Fair value as of January 1, 2022  $               -                         -   $          -   $           - 
Fair value at initial measurement date of 2/14/2022   13,160(1)       8,435,897(2)    0.4864       4,103 
Fair value of warrants issued on 2/14/2022   (7,160)(3)    (4,589,743)(4)    0.4864    (2,232)
Fair value of warrants issued on 2/15/2022   (1,000)(3)       (641,025)(4)    0.5349       (343)
Fair value of warrants issued on 4/4/2022   (1,000)(3)       (568,440)(4)    0.5854       (333)
Fair value of warrants issued on 6/6/2022   (1,000)(3)       (703,234)(4)    0.5924       (417)
Fair value of warrants issued on 8/16/2022   (1,000)(3)       (746,380)(4)    0.4569       (341)
Fair value of warrants issued on 10/21/2022     (500)(3)       (362,318)(4)    0.4386       (159)
Fair value of warrants issued on 12/14/2022   (1,000)(3)       (847,457)(4)    0.3810       (323)
Change in fair value of warrant liability                  -                         -              -          225 
Fair value as of December 31, 2022  $     500(1)       454,545(2)   $0.3960   $     180 

 

 

(1)Amount of credit available under the Secured Note on date of inception and as of each period end date.

 

(2)Number of warrants issuable if the amount of credit available were drawn for measurement as of inception date and subsequently for remeasurement as of each period end date.

 

(3)Amount of drawdown as of each date presented.

 

(4)Number of warrants issued upon receipt of amounts drawn against the Secured Note as of each date presented.
XML 74 R28.htm IDEA: XBRL DOCUMENT v3.23.4
Stock-Based Awards (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]    
Summary of Stock Option Activity

A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price):

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted-

Average

Exercise Price

 
Balance at December 31, 2022   5,139    3,261    3   $2.25 
Options granted   (26)   26    -    0.76 
Restricted stock units vested   -    -    (3)   - 
Balance at September 30, 2023   5,113    3,287          -   $       2.24 
Options exercisable at September 30, 2023        3,067        $2.32 

A summary of the Incentive Plan activity and related information follows (in thousands except weighted-average exercise price):

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted-

Average

Exercise Price

 
Balance at January 1, 2021   1,046    2,854      28   $2.51 
Increase option pool      500            -         -         - 
Options granted   (568)        568         -    1.46 
Options forfeited, cancelled or expired        57       (57)         -    2.56 
Restricted stock units vested           -            -    (12)         - 
Balance at December 31, 2021   1,035    3,365      16   $2.32 
Increase option pool   4,000            -         -          - 
Options granted   (105)        105         -    0.79 
Options forfeited, cancelled or expired       209    (209)         -    2.82 
Restricted stock units vested           -            -    (13)         - 
Balance at December 31, 2022   5,139    3,261         3   $2.25 
Options exercisable at December 31, 2022        2,913        $2.37 
Schedule of Stock Based Compensation Expense

Operating expenses include stock-based compensation expense as follows (in thousands):

 

   2023   2022   2023   2022 
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022   2023   2022 
Research and development  $1   $8   $8   $25 
General and administrative   39    201    137    621 
Total stock-based compensation expense  $40   $209   $145   $646 

AgeX recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021 (in thousands):

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Research and development – continuing operations  $32   $62 
General and administrative – continuing operations   728    937 
Total stock-based compensation expense – continuing operations   760    999 
General and administrative – discontinued operations   -    4 
Total stock-based compensation expense  $760   $1,003 
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2023   2022(1)   2023   2022 
Grant price  $0.76   $-   $0.76   $0.79 
Market price  $0.76   $-   $0.76   $0.79 
Expected life (in years)   5.15    -    5.15    5.58 
Volatility   118.12%   -%   118.12%   130.71%
Risk-free interest rates   4.12%   -%   4.12%   1.74%
Dividend yield   -%   -%   -%   -%

 

(1)There were no stock options granted under the Plan during the three months ended September 30, 2022.

 

   Year Ended December 31, 
   2022   2021 
Grant Price  $       0.79   $        1.46 
Expected life (in years)          5.58             5.71 
Risk-free interest rates       1.74%        0.99% 
Volatility   130.71%    102.34% 
Dividend yield            -%              -% 
XML 75 R29.htm IDEA: XBRL DOCUMENT v3.23.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Components of Deferred Tax Assets and Liabilities

The primary components of the net deferred tax assets and liabilities as of December 31, 2022 and 2021 were as follows (in thousands):

 

         
   December 31, 
Deferred tax assets/(liabilities):  2022   2021 
Net operating loss carryforwards  $12,408   $12,000 
Capital loss carryforwards   3,120    3,120 
Research and development credit carryforwards   1,138    1,426 
Patents and fixed assets   879    901 
Stock-based compensation   643    690 
Capitalized Research Expenses   211    - 
Other, net   62    80 
Valuation allowance   (18,461)   (18,217)
Total net deferred tax assets  $-   $- 
Schedule of Income Tax Rate Reconciliation

Income taxes differed from the amounts computed by applying the U.S. federal income tax rate indicated to pretax losses from operations as a result of the following:

 

   December 31, 
   2022   2021 
Computed tax benefit at federal statutory rate    21%      21% 
Research and development and other credits      1%        1% 
State tax benefit, net of effect on federal income taxes   (7)%      14% 
Permanent differences      -%     (1)% 
Stock Based Compensation   (2)%        -% 
Loss and deconsolidation of LifeMap Sciences       -%   (31)% 
Debt finance equity costs   (6)%        -% 
Return to provision & other adjustments   (5)%        -% 
Change in valuation allowance   (2)%     (4)% 
       -%         -% 
Schedule of Unrecognized Tax Benefits

 

       
   December 31, 
   2022   2021 
Balance at January 1  $ -   $       - 
Additions for tax positions related to the current year   23    - 
Additions for tax positions related to prior years   356    - 
Reductions for tax positions related to prior years   -    - 
Reductions related to settlements   -    - 
Reductions related to a lapse of statute   -    - 
Balance at December 31  $379   $- 
XML 76 R30.htm IDEA: XBRL DOCUMENT v3.23.4
Supplemental Cash Flow Information (Tables)
9 Months Ended
Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]  
Schedule of Non-cash Investing and Financing Transactions

Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022 are as follows (in thousands):

 

   2023   2022 
  

Nine Months Ended

September 30,

 
   2023   2022 
Cash paid during the period for interest  $27   $14 
Issuance of preferred stock in exchange for debt  $36,000   $- 
Issuance of common stock upon vesting of restricted stock units (Note 8)  $2   $6 
Issuance of warrants for debt issuance under the 2020 Loan Agreement  $-   $178 
Fair value of liability classified warrants at debt inception date (Note 6)  $663   $3,666 
Debt refinanced with new debt (Note 5)  $-   $7,160 
Schedule of Condensed Consolidated Pro Forma Balance Sheets

   September 30, 2023   Adjustment   Adjusted Balance 
             
ASSETS               
Current assets:               
Cash and cash equivalents  $397   $-   $397 
Accounts and grants receivable, net   67    -    67 
Related party receivables, net   4    -    4 
Prepaid expenses and other current assets   673    -    673 
Total current assets   1,141    -    1,141 
                
Restricted cash   50    -    50 
Intangible assets, net   640    -    640 
Convertible note receivable   10,379    -    10,379 
TOTAL ASSETS  $12,210   $-   $12,210 
                
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)               
Current liabilities:               
Accounts payable and accrued liabilities  $1,671   $-   $1,671 
Loan due to Juvenescence, net of debt issuance costs, current portion   1,526    -    1,526 
Insurance premium liability and other current liabilities   7    -    7 
Total current liabilities   3,204    -    3,204 
                
Loan due to Juvenescence, net of debt issuance costs, net of current portion   693    -    693 
TOTAL LIABILITIES  3,897   -   3,897 
                
Commitments and contingencies   -     -     -  
                
Series A preferred stock; no par value; stated value $100 per share; 212 and nil shares issued and outstanding, respectively   21,135    (21,135)   - 
Series B preferred stock; no par value; stated value $100 per share; 148 and nil shares issued and outstanding, respectively   14,823    (14,823)   - 
               
Stockholders’ equity (deficit):              
Preferred stock, $0.0001 par value, 5,000 shares authorized; and                
Series A Preferred stock - 212 and nil shares issued and outstanding, respectively   -    -    - 
Series B Preferred stock - 148 and nil shares issued and outstanding, respectively   -    -    - 
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively   4    -    4 
Additional paid-in capital   100,017    35,958    135,975 
Accumulated deficit   (127,557)   -    (127,557)
Total AgeX Therapeutics, Inc. stockholders’ equity (deficit)   (27,536)   35,958    8,422 
Noncontrolling interest   (109)   -    (109)
Total stockholders’ equity (deficit)   (27,645)   35,958    8,313 
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)  $12,210   $-   $12,210 
XML 77 R31.htm IDEA: XBRL DOCUMENT v3.23.4
Organization, Business Overview and Liquidity (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Mar. 15, 2021
Nov. 28, 2018
Aug. 30, 2018
Mar. 31, 2023
Dec. 31, 2021
Nov. 14, 2023
Nov. 09, 2023
Sep. 30, 2023
Jul. 31, 2023
Feb. 14, 2023
Dec. 31, 2022
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Sale of stock, percentage of ownership before transaction     80.40%                
Sale of stock, percentage of ownership after transaction     40.20%                
Accumulated deficit         $ 105,748,000     $ 127,557,000     $ 116,210,000
Cash and cash equivalents               400,000     600,000
Line of credit facility, maximum borrowing capacity                   7,160,000
Secured debt               10,000,000 $ 10,000,000 $ 10,000,000  
Long-Term Line of Credit         $ 14,500,000           27,660,000
Subsequent Event [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Accumulated deficit           $ 127,557,000          
Merger Agreement [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Payment of merger consideration on pro rata portion $ 466,400                    
Debt converted amount 1,761,296                    
Paid in cash portion of indebtedness 250,000                    
Common Stock [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Number of common stock shares issued         242            
Common Stock [Member] | AgeX [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Ownership interest   4.80%                  
Parent Company [Member] | Common Stock [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Number of common stock shares issued   12,697,028                  
Retained shares of common stock   1,718,972                  
Juvenescence Limited [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Sale of stock     14,400,000                
Sale of stock, percentage of ownership before transaction     5.60%                
Sale of stock, percentage of ownership after transaction     45.80%                
Secured debt                 10,000,000    
Juvenescence Limited [Member] | Convertible Promissory Note [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Secured debt       $ 10,000,000              
Proceeds from convertible debt       $ 10,000,000              
LifeMap Sciences Inc [Member] | Merger Agreement [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Payment of merger consideration on pro rata portion $ 500,000                    
Juvenescence [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Secured debt                 $ 10,000,000    
Juvenescence [Member] | Loan Facility Agreement [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Line of credit facility, maximum borrowing capacity               $ 1,000,000     $ 1,000,000.0
Juvenescence [Member] | Loan Facility Agreement [Member] | Subsequent Event [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Long-Term Line of Credit             $ 4,400,000        
ReCyte Therapeutics Inc [Member] | AgeX [Member] | Merger Agreement [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Ownership interest                     94.80%
NeuroAirmid [Member] | AgeX [Member] | Merger Agreement [Member]                      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                      
Ownership interest                     50.00%
XML 78 R32.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Platform Operator, Crypto-Asset [Line Items]      
Warrant liability $ 180
Fair Value, Inputs, Level 1 [Member]      
Platform Operator, Crypto-Asset [Line Items]      
Warrant liability    
Fair Value, Inputs, Level 2 [Member]      
Platform Operator, Crypto-Asset [Line Items]      
Warrant liability    
Fair Value, Inputs, Level 3 [Member]      
Platform Operator, Crypto-Asset [Line Items]      
Warrant liability   $ 180  
XML 79 R33.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Cash and cash equivalents $ 397 $ 645 $ 584
Restricted cash 50 [1] 50 [1],[2] 50 [2]
Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 447 $ 695 $ 634
[1] Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.
[2] Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits in the consolidated balance sheets.
XML 80 R34.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Disaggregated of Revenues (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Product Information [Line Items]            
Total revenues $ 67 $ 9 $ 86 $ 26 $ 34 $ 144
Grant Revenues [Member]            
Product Information [Line Items]            
Total revenues 21 21 104
Other Revenues [Member]            
Product Information [Line Items]            
Total revenues $ 46 $ 9 $ 65 $ 26 $ 34 $ 40
XML 81 R35.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Disaggregated Geographical Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Total revenues $ 67 $ 9 $ 86 $ 26 $ 34 $ 144
UNITED STATES            
Total revenues         10 107
Foreign [Member]            
Total revenues         $ 24 $ 37
XML 82 R36.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Equity Option [Member]            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Anti-dilutive securities         3,297 3,145
Warrant [Member]            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Anti-dilutive securities 12,132 [1] 10,616 [1] 12,716 [1] 8,947 [1] 9,558 [2] 3,492 [2]
Restricted Stock Units (RSUs) [Member]            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Anti-dilutive securities 9 12 10 23
Share-Based Payment Arrangement, Option [Member]            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Anti-dilutive securities 3,276 3,264 3,266 3,310    
[1] As of September 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 11,539,348 and 10,919,485 shares, respectively, of AgeX common stock as consideration for certain loan agreements discussed in Note 5, Related Party Transactions.
[2] As of December 31, 2022 and 2021, AgeX issued Juvenescence warrants to purchase 12,129,260 and 3,512,098 shares, respectively, of AgeX common stock as consideration for the loan agreements discussed in Note 5, Related Party Transactions.
XML 83 R37.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) (Parenthetical) - shares
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Warrant to purchase shares of common stock 1,898,489      
Loan Agreements [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Warrant to purchase shares of common stock 11,539,348,000 12,129,260 10,919,485,000 3,512,098
XML 84 R38.htm IDEA: XBRL DOCUMENT v3.23.4
Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 01, 2022
USD ($)
Jan. 01, 2021
USD ($)
ft²
Nov. 03, 2020
USD ($)
ft²
Apr. 08, 2020
USD ($)
Aug. 31, 2023
USD ($)
Oct. 31, 2022
USD ($)
ft²
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2018
Jul. 31, 2023
USD ($)
Feb. 14, 2023
USD ($)
Product Information [Line Items]                              
Cash and cash equivalents             $ 397,000   $ 397,000   $ 645,000 $ 584,000      
Finite lived intangible asset useful life             10 years   10 years   10 years        
Office space | ft²     135                        
Payments for rent $ 1,074   $ 947     $ 844                  
Base rent $ 1,074   $ 947     $ 844                  
Deductions                         50.00%    
Revenues, net             $ 67,000 $ 9,000 $ 86,000 $ 26,000 $ 34,000 144,000      
Secured debt             10,000,000   $ 10,000,000         $ 10,000,000 $ 10,000,000
Lessee operating lease description                 (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset            
Fair Value, Inputs, Level 3 [Member]                              
Product Information [Line Items]                              
Secured debt             $ 10,000,000   $ 10,000,000            
Lease Agreement [Member]                              
Product Information [Line Items]                              
Office space | ft²   135       101                  
Payments for rent   $ 947       $ 844     844 1,074 1,074        
Base rent   $ 947       $ 844     $ 844 $ 1,074 $ 1,074        
ReCyte Therapeutics Inc [Member]                              
Product Information [Line Items]                              
Ownership, percentage             100.00%   100.00%            
ReCyte Therapeutics Inc [Member] | Merger Agreement [Member]                              
Product Information [Line Items]                              
Ownership, percentage             50.00%   50.00%            
Merger Agreement [Member]                              
Product Information [Line Items]                              
Ownership, percentage             94.80%   94.80%            
National Institutes of Health [Member]                              
Product Information [Line Items]                              
Revenues, net       $ 386,000 $ 341,000   $ 21,000   $ 21,000     104,000      
Subscription and Advertisement Revenues [Member]                              
Product Information [Line Items]                              
Revenues, net                       $ 300,000      
XML 85 R39.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Discontinued Operations (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Insurance [Abstract]    
Net revenues   $ 277
Costs, operating and other expenses   (380)
Loss from discontinued operations (103)
Net loss from discontinued operations attributable to noncontrolling interest 7
Loss from discontinued operations $ (96) [1]
[1] Does not include $106,000 gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement. The gain on the sale of LifeMap Sciences is presented in the line item Gain on deconsolidation of LifeMap Sciences. There were no gains or losses resulting from the sale of businesses or assets that did not meet the criteria for a discontinued operation during the year ended December 31, 2021.
XML 86 R40.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Discontinued Operations (Details) (Parenthetical) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Insurance [Abstract]    
Deconsolidation, gain (loss), amount $ 106,000
XML 87 R41.htm IDEA: XBRL DOCUMENT v3.23.4
Disposition and Deconsolidation of LifeMap Sciences (Details Narrative) - USD ($)
12 Months Ended
Mar. 15, 2021
Dec. 31, 2022
Dec. 31, 2021
Deconsolidation, gain (loss), amount   $ 106,000
Merger Agreement [Member]      
Payment of merger consideration on pro rata portion $ 466,400    
Debt converted to equity 1,761,296    
Paid in cash portion of indebtedness 250,000    
LifeMap Sciences Inc [Member] | Merger Agreement [Member]      
Payment of merger consideration on pro rata portion $ 500,000    
XML 88 R42.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Intangible Assets, Net (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Intangible assets $ 1,312 $ 1,312 $ 1,312
Accumulated amortization (672) (574) (442)
Total intangible assets, net $ 640 $ 738 $ 870
XML 89 R43.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Amortization Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
2023 $ 33  
2024 131 $ 131
2025 131 132
2026 132 131
2026   131
Thereafter   213
Thereafter 213  
Total $ 640 $ 738
XML 90 R44.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Accounts payable $ 1,172 $ 568 $ 193
Accrued compensation 206 193 212
Accrued vendors and other expenses 293 273 366
Total accounts payable and accrued liabilities $ 1,671 $ 1,034 $ 771
XML 91 R45.htm IDEA: XBRL DOCUMENT v3.23.4
Selected Balance Sheet Components (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 13, 2018
Aug. 31, 2021
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Value of common stock issued for acquisition             $ 4,300,000  
Estimated useful life     10 years   10 years   10 years  
Royalty percentage             1.00%  
Amortization expense of intangible assets     $ 33,000 $ 33,000 $ 98,000 $ 99,000 $ 132,000 $ 131,000
Amortization of intangible assets for discontinued operations               $ 89,000
Research and Development [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Consulting fees and services   $ 200,000            
Asset Purchase Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Payments to acquire businesses $ 1,072,436              
Number of shares issued for acquired, shares 80,000              
Value of common stock issued for acquisition $ 240,000              
Aggregate of acquisition cost $ 1,300,000              
XML 92 R46.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Debt Issuance Costs and Debt Balances (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]      
Drawdown of Funds   $ 27,660 $ 14,500
Origination Fee   851 160
Amount Refinanced   (7,160)
Total Debt   21,351 14,660
Debt Issuance Costs   (8,019) (3,114)
Amortization of Debt Issuance Costs   4,792 1,656
Total Debt, Net   18,124 13,202
Amount Refinanced   7,160
Debt Issuance Costs   8,019 3,114
Debt [Member]      
Short-Term Debt [Line Items]      
Drawdown of Funds $ 26,160    
Origination Fee 1,406    
Total Debt 1,573    
Debt Issuance Costs (8,850)    
Amortization of Debt Issuance Costs 8,803    
Total Debt, Net 1,526    
Debt Exchanged for Preferred Stock (25,993)    
Debt Issuance Costs 8,850    
Total Debt Net [Member]      
Short-Term Debt [Line Items]      
Drawdown of Funds 36,160    
Origination Fee 2,106    
Total Debt 2,266    
Debt Issuance Costs (9,516)    
Amortization of Debt Issuance Costs 9,469    
Total Debt, Net 2,219    
Debt Exchanged for Preferred Stock (36,000)    
Debt Issuance Costs 9,516    
2019 Loan Agreement [Member]      
Short-Term Debt [Line Items]      
Drawdown of Funds   7,000 7,000
Origination Fee   160 160
Amount Refinanced   (7,160)
Total Debt   7,160
Debt Issuance Costs   (494) (494)
Amortization of Debt Issuance Costs   494 474
Total Debt, Net   7,140
Amount Refinanced   7,160
Debt Issuance Costs   494 494
2020 Loan Agreement [Member]      
Short-Term Debt [Line Items]      
Drawdown of Funds 8,000 8,000 7,500
Origination Fee
Amount Refinanced  
Total Debt 8,000 7,500
Debt Issuance Costs (2,806) (2,805) (2,620)
Amortization of Debt Issuance Costs 2,806 2,451 1,182
Total Debt, Net 7,646 6,062
Amount Refinanced  
Debt Exchanged for Preferred Stock (8,000)    
Debt Issuance Costs 2,806 2,805 $ 2,620
2022 Secured Note [Member]      
Short-Term Debt [Line Items]      
Drawdown of Funds   12,660  
Origination Fee   691  
Amount Refinanced    
Total Debt   13,351  
Debt Issuance Costs   (4,720)  
Amortization of Debt Issuance Costs   1,847  
Total Debt, Net   10,478  
Amount Refinanced    
Debt Issuance Costs   $ 4,720  
Secured Note [Member]      
Short-Term Debt [Line Items]      
Drawdown of Funds 18,160    
Origination Fee 1,406    
Total Debt 1,573    
Debt Issuance Costs (6,044)    
Amortization of Debt Issuance Costs 5,997    
Total Debt, Net 1,526    
Debt Exchanged for Preferred Stock (17,993)    
Debt Issuance Costs 6,044    
Ten Thousand Million Secured Note [Member]      
Short-Term Debt [Line Items]      
Drawdown of Funds 10,000    
Origination Fee 700    
Total Debt 693    
Debt Issuance Costs (666)    
Amortization of Debt Issuance Costs 666    
Total Debt, Net 693    
Debt Exchanged for Preferred Stock (10,007)    
Debt Issuance Costs $ 666    
XML 93 R47.htm IDEA: XBRL DOCUMENT v3.23.4
Related Party Transactions (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Nov. 09, 2023
Oct. 03, 2023
Jul. 31, 2023
Jul. 24, 2023
May 09, 2023
Mar. 13, 2023
Feb. 13, 2023
Feb. 09, 2023
Feb. 14, 2022
Nov. 08, 2021
Feb. 10, 2021
Mar. 30, 2020
Aug. 13, 2019
Jul. 31, 2023
Jan. 31, 2023
Jan. 25, 2023
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Mar. 15, 2023
Feb. 28, 2023
Feb. 15, 2023
Feb. 14, 2023
Line of credit facility, current borrowing capacity                                   $ 7,160,000        
Origination fee                                   851,000 160,000        
Warrant purchase                                 1,898,489            
Proceeds from sale of common stock     $ 25,000,000                             496,000        
Line of credit                                   27,660,000 14,500,000        
Common stock held                                 $ 250,000 250,000          
Extinguishment of debt                                   $ 437,000        
Secured debt     10,000,000                     $ 10,000,000     $ 10,000,000           $ 10,000,000
Warrants outstanding                                 [1] 454,545 [1],[2]        
Common stock, shares, outstanding                                 37,951,000 37,949,000 37,941,000        
Convertiable promissoty note                                       $ 105,000,000      
Line of Credit [Member]                                              
Accrued loan origination fees     $ 1,332,800                                        
2022 Warrants [Member]                                              
Warrants issued percentage                                   50.00%          
Subsequent Event [Member]                                              
Proceeds from sale of common stock           $ 25,000,000                                  
Proceeds from issuance of secured debt                               $ 500,000              
Convertiable promissoty note                                       105,000,000      
Secured Convertible Promissory Note [Member]                                              
Increase in line of credit         $ 4,000,000     $ 2,000,000                   $ 4,500,000          
Line of credit, expiry date                                   Feb. 14, 2024          
Secured debt                                 $ 18,160,000            
Proceeds from issuance of secured debt                           16,660,000     5,500,000            
Debt instrument, indebtedness                           17,992,800                  
Convertiable promissoty note                                       25,000,000      
Secured Convertible Promissory Note [Member] | Subsequent Event [Member]                                              
Increase in line of credit $ 4,400,000 $ 500,000                         $ 500,000                
Line of credit facility, current borrowing capacity               1,000,000                              
Line of credit, current borrowing capacity               $ 2,000,000                              
Convertiable promissoty note                                       25,000,000   $ 1,450,000  
Warrant [Member]                                              
Secured debt                                 15,160,000            
Common Stock [Member]                                              
Proceeds from sale of common stock                                 $ 10,000,000 $ 10,000,000          
Common stock, shares, outstanding                                 37,951,261 37,949,196 37,941,220        
2022 Warrants [Member]                                              
Warrant purchase                                   8,458,597          
Warrants exercise price, minimum                                 $ 0.59 $ 0.59          
Warrants exercise price, maximum                                 $ 0.88 $ 0.88          
2020 Loan Agreement [Member]                                              
Line of credit, term                       18 months                      
Line of credit facility, current borrowing capacity                       $ 8,000,000.0         $ 8,000,000 $ 8,000,000.0          
Common stock, shares                       28,500                      
Line of credit, current borrowing capacity                       $ 3,000,000.0                      
Warrant purchase                       3,670,663                      
Line of credit, expiry date                       Mar. 30, 2024                      
Line of credit facility, description                       other indebtedness for money borrowed in excess of $100,000 becomes due and payable or can be declared due and payable prior to its due date or if indebtedness for money borrowed in excess of $25,000 is not paid when due                      
Warrants outstanding                                 1,182,262            
2020 Loan Agreement [Member] | Warrant [Member]                                              
Warrant purchase                                 3,670,663 3,670,663          
Warrants exercise price, minimum                                   $ 0.70          
Warrants exercise price, maximum                                   $ 1.895          
Common stock, shares, outstanding                                 1,182,262            
2020 Loan Agreement [Member] | Twenty Twenty Warrant [Member]                                              
Warrants exercise price, minimum                                 $ 0.81            
Warrants exercise price, maximum                                 $ 1.895            
2022 Secured Convertible Promissory Note and Security Agreement [Member]                                              
Line of credit facility                 $ 8,160,000                            
Line of credit, term                 12 months                            
Line of credit facility, current borrowing capacity                 $ 7,160,000                            
Line of credit                 13,160,000                            
Secured Convertible Promissory Note [Member] | Subsequent Event [Member]                                              
Line of credit facility, current borrowing capacity                                         $ 2,000,000    
Security Agreement [Member]                                              
Line of credit facility, description                                 if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date; if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date          
Registration Rights Agreements [Member]                                              
Line of credit facility, description                                 AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of AgeX common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence. AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of our common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence          
Twenty Twenty Loan Agreement [Member]                                              
Extinguishment of debt                           8,000,000                  
Fourth Amendment [Member]                                              
Debt conversion description     (i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bio, and (ii) Juvenescence may convert the outstanding amount of the Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion. The 19.9% Cap is a provision of the Secured Note that limits the amount of common stock that Juvenescence may acquire through the conversion of Secured Note loans in order to comply with NYSE American requirements pertaining to the amount of shares that a listed company, such as AgeX, may sell at a price less than the market prices prevailing at the time the loans were made (the “Drawdown Market Prices”) without shareholder approval.                                        
Juvenescence [Member]                                              
Line of credit facility                                 $ 2,500,000 $ 12,660,000          
Warrant purchase                                 10,357,086 8,458,597          
Reimbursement                                 $ 280,000 $ 280,000          
Accounts payable                                 4,000 141,000,000 $ 70,000,000        
Secured debt     $ 10,000,000                     10,000,000                  
Juvenescence [Member] | Subsequent Event [Member]                                              
Line of credit, current borrowing capacity                                           $ 1,000,000  
Warrant purchase                               340,136           801,924  
Juvenescence [Member] | Secured Convertible Promissory Note [Member]                                              
Convertiable promissoty note     $ 10,000,000     10,000,000               10,000,000     $ 10,000,000            
Origination fee description     In lieu of accrued interest, AgeX agreed to pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.                                        
Juvenescence [Member] | Secured Convertible Promissory Note [Member] | Subsequent Event [Member]                                              
Convertiable promissoty note           10,000,000                           10,000,000      
Origination fee description             In lieu of accrued interest, AgeX will pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.                                
Juvenescence [Member] | 2019 Loan Agreement [Member]                                              
Line of credit facility                         $ 2,000,000.0                    
Line of credit, term                         18 months                    
Increase in line of credit                   $ 1,000,000.0 $ 4,000,000.0                        
Line of credit facility, current borrowing capacity                 7,000,000.0 $ 7,000,000.0                 $ 7,000,000        
Origination fee                 $ 160,000                            
Reverse Ratio [Member]                                              
Indebtedness                                   $ 15,000,000.0          
Juvenescence Limited [Member]                                              
Proceeds from sale of common stock     $ 10,000,000                                        
Extinguishment of debt     36,000,000 $ 36,000,000                                      
Secured debt     $ 10,000,000                     $ 10,000,000                  
Common stock outstanding percentage     85.00%                                        
Juvenescence Limited [Member] | Minimum [Member]                                              
Proceeds from sale of common stock     $ 10,000,000                                        
Juvenescence Limited [Member] | Maximum [Member]                                              
Proceeds from sale of common stock     $ 25,000,000                                        
Juvenescence Limited [Member] | Subsequent Event [Member]                                              
Proceeds from sale of common stock           $ 10,000,000                                  
Common stock outstanding percentage           85.00%                                  
Juvenescence Limited [Member] | Subsequent Event [Member] | Minimum [Member]                                              
Proceeds from sale of common stock           $ 10,000,000                                  
Juvenescence Limited [Member] | Subsequent Event [Member] | Maximum [Member]                                              
Proceeds from sale of common stock           25,000,000                                  
Juvenescence Limited [Member] | Secured Convertible Promissory Note [Member]                                              
Line of credit, current borrowing capacity           10,000,000                                  
Convertiable promissoty note                                       5,000,000      
Proceeds from issuance of long term debt           10,000,000                                  
Juvenescence Limited [Member] | Secured Convertible Promissory Note [Member] | Subsequent Event [Member]                                              
Line of credit, current borrowing capacity           $ 10,000,000                                  
Convertiable promissoty note                                       $ 5,000,000      
Juvenescence Limited [Member] | Derivatives And Hedging [Member]                                              
Common stock outstanding percentage     15.00%                                        
Juvenescence Limited [Member] | 2020 Loan Agreement [Member]                                              
Secured debt       $ 10,000,000                                      
[1] Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.
[2] Number of warrants issuable if the amount of credit available were drawn for measurement as of inception date and subsequently for remeasurement as of each period end date.
XML 94 R48.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) - $ / shares
2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 04, 2023
Mar. 31, 2023
Feb. 15, 2023
Feb. 09, 2023
Jan. 25, 2023
Dec. 31, 2022
Dec. 14, 2022
Oct. 21, 2022
Sep. 30, 2022
Aug. 16, 2022
Jun. 30, 2022
Jun. 06, 2022
Apr. 04, 2022
Feb. 15, 2022
Feb. 14, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Interest Rate (annual)                                 4.12% [1] 4.12% 1.74% 1.74% 0.99%
Volatility (annual)                                 118.12% [1] 118.12% 130.71% 130.71% 102.34%
Time to Maturity (Years)                                 5 years 1 month 24 days [1] 5 years 1 month 24 days 5 years 6 months 29 days 5 years 6 months 29 days 5 years 8 months 15 days
Inception Date [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Exercise Price [2]       $ 0.703                     $ 0.780 [3]              
Warrant Expiration Date [4]       Feb. 08, 2026                     Feb. 13, 2025 [5]              
Stock Price       $ 0.660 [6]                     $ 0.691 [7]              
Interest Rate (annual)       4.15% [8]                     1.80% [9]              
Volatility (annual)       118.94% [10]                     122.99% [11]              
Time to Maturity (Years)       3 years                     3 years              
Calculated fair value per share       $ 0.466                     $ 0.486              
Issuance Date [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Exercise Price [2] $ 0.661   $ 0.624   $ 0.735   $ 0.590 $ 0.690   $ 0.670 [3]   $ 0.711 [3] $ 0.880 [3] $ 0.780 [3] $ 0.780 [3]              
Warrant Expiration Date [4] Apr. 03, 2026   Feb. 14, 2026   Jan. 24, 2026   Dec. 13, 2025 Oct. 20, 2025   Aug. 15, 2025 [5]   Jun. 05, 2025 [5] Apr. 03, 2025 [5] Feb. 14, 2025 [5] Feb. 13, 2025 [5]              
Stock Price $ 0.673 [6]   $ 0.600 [6]   $ 0.751 [6]   $ 0.540 [6] $ 0.620 [6]   $ 0.640 [7]   $ 0.800 [7] $ 0.819 [7] $ 0.747 [7] $ 0.691 [7]              
Interest Rate (annual) 3.60% [8]   4.35% [8]   3.84% [8]   3.94% [8] 4.52% [8]   3.19% [9]   2.94% [9] 2.61% [9] 1.80% [9] 1.80% [9]              
Volatility (annual) 113.01% [10]   118.93% [10]   119.17% [10]   120.01% [10] 120.51% [10]   121.37% [11]   122.62% [11] 123.31% [11] 123.28% [11] 122.99% [11]              
Time to Maturity (Years) 3 years   3 years   3 years   3 years 3 years   3 years   3 years 3 years 3 years 3 years              
Calculated fair value per share $ 0.466   $ 0.426   $ 0.540   $ 0.381 $ 0.439   $ 0.457   $ 0.592 $ 0.585 $ 0.535 $ 0.486              
Period Ending [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Exercise Price   $ 0.661 [2]       $ 0.550 [2],[3] $ 0.590 [3] $ 0.690 [3] $ 0.610 [2],[3]   $ 0.600 [2],[3]         $ 0.940 [2],[3]   $ 0.610 [2],[3]   $ 0.610 [2],[3] $ 0.550 [2],[3]  
Warrant Expiration Date   Mar. 30, 2026 [4]       Dec. 30, 2025 [4],[5] Dec. 13, 2025 [5] Oct. 20, 2025 [5] Sep. 29, 2025 [4],[5]   Jun. 29, 2025 [4],[5]         Mar. 30, 2025 [4],[5]            
Stock Price   $ 0.663 [6]       $ 0.552 [7] $ 0.540 [7] $ 0.620 [7] $ 0.562 [7]   $ 0.576 [7]         $ 0.854 [7]   0.562 [7]   0.562 [7] 0.552 [7]  
Interest Rate (annual)   3.81% [8]       4.22% [9] 3.94% [9] 4.52% [9] 4.25% [9]   2.99% [9]         2.45% [9]            
Volatility (annual)   113.43% [10]       119.31% [11] 120.01% [11] 120.51% [11] 121.49% [11]   122.21% [11]         123.28% [11]            
Time to Maturity (Years)   3 years       3 years 3 years 3 years 3 years   3 years         3 years            
Calculated fair value per share   $ 0.459       $ 0.396 $ 0.381 $ 0.439 $ 0.401   $ 0.413         $ 0.607   $ 0.401   $ 0.401 $ 0.396  
[1] There were no stock options granted under the Plan during the three months ended September 30, 2022.
[2] Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit.
[3] Based on the market closing price of AgeX’s common stock on the NYSE American on the one day prior to the debt inception date and each presented period ending date and also the market closing price of AgeX’s common stock on the NYSE American on the one trading day preceding the delivery of the relevant drawdown notice in accordance with terms per the Secured Note.
[4] Warrants are exercisable over a three-year period from each Issuance Date.
[5] Warrants are exercisable over a three-year period from each issuance date.
[6] Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.
[7] Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.
[8] Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.
[9] Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.
[10] Based on the historical daily volatility of AgeX common stock as of each date presented.
[11] Based on the historical daily volatility of AgeX common stock as of each date presented.
XML 95 R49.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Warrant Outstanding and Fair Values (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance     $ 500,000 [1],[2]  
Fair value as of period beginning balance, shares     454,545 [3],[4]  
Fair value as of period beginning balance, fair value per share     $ 0.3960  
Fair value as of period beginning balance, fair value     $ 180,000  
Fair value as of period beginning balance $ (35,000) 35,000 $ 220,000 225,000
Fair value as of period beginning balance [4]       [3]  
Fair value as of period beginning balance, shares [5]       [6]  
Fair value as of period beginning balance, fair value per share        
Fair value as of period beginning balance, fair value     $ 35,000   $ 225,000  
Fair value as of period beginning balance [2]   [2]   $ 500,000 [1],[2]
Fair value as of period beginning balance, shares [4]   [4]   454,545 [3],[4]
Fair value as of period beginning balance, fair value per share     $ 0.3960
Fair value as of period beginning balance, fair value     $ 180,000
Initial measurement date of 2/14/2022 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [1],[2]         $ 13,160,000  
Fair value as of period beginning balance, shares [3],[4]         8,435,897  
Fair value as of period beginning balance, fair value per share         $ 0.4864  
Fair value as of period beginning balance, fair value         $ 4,103,000  
2/14/2022 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [7],[8]         $ (7,160,000)  
Fair value as of period beginning balance, shares [5],[6]         (4,589,743)  
Fair value as of period beginning balance, fair value per share         $ 0.4864  
Fair value as of period beginning balance, fair value         $ (2,232,000)  
2/15/2022 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [7],[8]         $ (1,000,000)  
Fair value as of period beginning balance, shares [5],[6]         (641,025)  
Fair value as of period beginning balance, fair value per share         $ 0.5349  
Fair value as of period beginning balance, fair value         $ (343,000)  
4/4/2022 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [7],[8]         $ (1,000,000)  
Fair value as of period beginning balance, shares [5],[6]         (568,440)  
Fair value as of period beginning balance, fair value per share         $ 0.5854  
Fair value as of period beginning balance, fair value         $ (333,000)  
6/6/2022 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [7],[8]         $ (1,000,000)  
Fair value as of period beginning balance, shares [5],[6]         (703,234)  
Fair value as of period beginning balance, fair value per share         $ 0.5924  
Fair value as of period beginning balance, fair value         $ (417,000)  
8/16/2022 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [7],[8]         $ (1,000,000)  
Fair value as of period beginning balance, shares [5],[6]         (746,380)  
Fair value as of period beginning balance, fair value per share         $ 0.4569  
Fair value as of period beginning balance, fair value         $ (341,000)  
10/21/2022 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [7],[8]         $ (500,000)  
Fair value as of period beginning balance, shares [5],[6]         (362,318)  
Fair value as of period beginning balance, fair value per share         $ 0.4386  
Fair value as of period beginning balance, fair value         $ (159,000)  
12/14/2022 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [7],[8]         $ (1,000,000)  
Fair value as of period beginning balance, shares [5],[6]         (847,457)  
Fair value as of period beginning balance, fair value per share         $ 0.3810  
Fair value as of period beginning balance, fair value         $ (323,000)  
25 January 2023 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [8]     $ (500,000)      
Fair value as of period beginning balance, shares [5]     (340,136)      
Fair value as of period beginning balance, fair value per share     $ 0.5395      
Fair value as of period beginning balance, fair value     $ (184,000)      
2 September 2023 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [2]     $ 2,000,000      
Fair value as of period beginning balance, shares [4]     1,422,879      
Fair value as of period beginning balance, fair value per share     $ 0.4657      
Fair value as of period beginning balance, fair value     $ 663,000      
15 February 2023 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [8]     $ (1,000,000)      
Fair value as of period beginning balance, shares [5]     (801,924)      
Fair value as of period beginning balance, fair value per share     $ 0.4263      
Fair value as of period beginning balance, fair value     $ (342,000)      
4 April 2023 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Fair value as of period beginning balance [8]     $ (1,000,000)      
Fair value as of period beginning balance, shares [5]     (756,429)      
Fair value as of period beginning balance, fair value per share     $ 0.4660      
Fair value as of period beginning balance, fair value     $ (352,000)      
[1] Amount of credit available under the Secured Note on date of inception and as of each period end date.
[2] Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit.
[3] Number of warrants issuable if the amount of credit available were drawn for measurement as of inception date and subsequently for remeasurement as of each period end date.
[4] Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.
[5] Number of warrants issued upon receipt of amounts drawn against the Secured Note as of the date presented.
[6] Number of warrants issued upon receipt of amounts drawn against the Secured Note as of each date presented.
[7] Amount of drawdown as of each date presented.
[8] Amount of drawdown as of the date presented.
XML 96 R50.htm IDEA: XBRL DOCUMENT v3.23.4
Warrant Liability (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Jul. 31, 2023
Feb. 14, 2023
Loss on change in fair value of warrants $ (35,000) $ 35,000 $ 220,000 $ 225,000    
Secured debt 10,000,000   10,000,000       $ 10,000,000 $ 10,000,000
Loss on change in fair value of warrants $ 35,000 (35,000) $ (220,000) $ (225,000)    
Juvenescence [Member]                
Secured debt             $ 10,000,000  
Loan funds 4,000,000   4,000,000          
Warrant [Member]                
Secured debt $ 15,160,000   $ 15,160,000          
XML 97 R51.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ Deficit (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Jul. 31, 2023
Jan. 08, 2021
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Mar. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Preferred stock, shares authorized     5,000,000   5,000,000 5,000,000  
Preferred stock, par value     $ 0.0001   $ 0.0001 $ 0.0001  
Preferred stock, shares issued         0 0  
Preferred stock, shares outstanding         0 0  
Common stock, shares authorized     200,000,000   200,000,000 100,000,000  
Common stock, par value     $ 0.0001   $ 0.0001 $ 0.0001  
Common stock, shares issued     37,951,000   37,949,000 37,941,000  
Common stock, shares outstanding     37,951,000   37,949,000 37,941,000  
Warrant to purchase share of common stock     1,898,489        
Proceeds from issuance costs $ 25,000,000       $ 496,000  
2020 Loan Agreement [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Warrant to purchase share of common stock             3,670,663
Juvenescence [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Line of credit facility     $ 2,500,000   $ 12,660,000    
Warrant to purchase share of common stock     10,357,086   8,458,597    
Chardan Capital Markets LLC [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Common stock, par value   $ 0.0001          
Payments for offering   $ 12,600,000          
Proceeds from issuance costs     $ 0 $ 0 $ 496,000  
Common Stock [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Common stock, shares issued     37,951,261   37,949,196 37,941,220  
Common stock, shares outstanding     37,951,261   37,949,196 37,941,220  
Proceeds from issuance costs     $ 10,000,000   $ 10,000,000    
Warrant [Member] | 2020 Loan Agreement [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Common stock, shares outstanding     1,182,262        
Warrant to purchase share of common stock     3,670,663   3,670,663    
Proceeds from loans         $ 8,000,000.0    
XML 98 R52.htm IDEA: XBRL DOCUMENT v3.23.4
Summary of Stock Option Activity (Details) - $ / shares
shares in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
[1]
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Weighted average exercise price, options granted $ 0.76 $ 0.76 [1] $ 0.79 $ 0.79 $ 1.46
Equity Incentive Plan [Member] | Employee Stock [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Shares available for grant, beginning balance     5,139 1,035 1,035 1,046
Number of options outstanding, beginning balance     3,261 3,365 3,365 2,854
Number of RSUs outstanding, beginning balance     3 16 16 28
Weighted average exercise price, outstanding, beginning balance     $ 2.25 $ 2.32 $ 2.32 $ 2.51
Shares available for grant increase option pool         4,000 500
Options grants increase option pool        
Number of shares outstanding increase option pool        
Weighted average exercise price increase option pool        
Shares available for grant, options granted         (105) (568)
Number of options outstanding, options granted     26   105 568
Number of RSUs outstanding, options granted      
Weighted average exercise price, options granted         $ 0.79 $ 1.46
Shares available for grant, options forfeited, cancelled or expired         209 57
Number of options outstanding, options forfeited, cancelled or expired         (209) (57)
Number of RSUs outstanding, options forfeited, cancelled or expired        
Weighted average exercise price, options forfeited, cancelled or expired         $ 2.82 $ 2.56
Shares available for grant, restricted stock units vested      
Number of options outstanding, restricted stock units vested      
Number of RSUs outstanding, restricted stock units vested     (3)   (13) (12)
Weighted average exercise price, restricted stock units vested      
Shares available for grant, ending balance 5,113   5,113   5,139 1,035
Number of options outstanding, ending balance 3,287   3,287   3,261 3,365
Number of RSUs outstanding, ending balance     3 16
Weighted average exercise price, outstanding, ending balance $ 2.24   $ 2.24   $ 2.25 $ 2.32
Number of options outstanding, exercisable, ending balance 3,067   3,067   2,913  
Weighted average exercise price, exercisable, ending balance $ 2.32   $ 2.32   $ 2.37  
Shares available for grant, options granted     (26)      
Number of RSUs outstanding, options granted      
Weighted average exercise price, options granted     $ 0.76      
[1] There were no stock options granted under the Plan during the three months ended September 30, 2022.
XML 99 R53.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Stock Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Total stock-based compensation expense $ 40 $ 209 $ 145 $ 646    
Continuing Operations [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Total stock-based compensation expense         $ 760 $ 999
Discontinued Operations [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Total stock-based compensation expense         760 1,003
Research and Development Expense [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Total stock-based compensation expense 1 8 8 25    
Research and Development Expense [Member] | Continuing Operations [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Total stock-based compensation expense         32 62
General and Administrative Expense [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Total stock-based compensation expense $ 39 $ 201 $ 137 $ 621    
General and Administrative Expense [Member] | Continuing Operations [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Total stock-based compensation expense         728 937
General and Administrative Expense [Member] | Discontinued Operations [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Total stock-based compensation expense         $ 4
XML 100 R54.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details) - $ / shares
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
[1]
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]            
Grant Price $ 0.76 $ 0.76 [1] $ 0.79 $ 0.79 $ 1.46
Expected life (in years) 5 years 1 month 24 days 5 years 1 month 24 days 5 years 6 months 29 days 5 years 6 months 29 days 5 years 8 months 15 days
Risk-free interest rates 4.12% 4.12% 1.74% 1.74% 0.99%
Volatility 118.12% 118.12% 130.71% 130.71% 102.34%
Dividend yield (0.00%) (0.00%)
Market price $ 0.76 $ 0.76 [1] $ 0.79    
[1] There were no stock options granted under the Plan during the three months ended September 30, 2022.
XML 101 R55.htm IDEA: XBRL DOCUMENT v3.23.4
Stock-Based Awards (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Number of common stock reserved 8,500,000 8,500,000  
Number of options exercised 0 0 0
Options granted and outstanding exercised   $ 7,300,000  
Total unrecognized compensation expense   $ 300,000  
Recognized over weighted average period   2 years 7 days  
Intrinsic value outstanding   $ 1,700  
Weighted-average estimated fair value of stock options granted   $ 0.70 $ 1.15
Share-Based Payment Arrangement, Option [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Granted options description   In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of AgeX stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years  
Stock Appreciation Rights (SARs) [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period   10 years  
Fair market value of common stock   100.00%  
Maximum [Member] | Restricted Stock And Restricted Stock Units [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Granted options description   they may purchase or otherwise acquire Restricted Stock or RSUs subject to such vesting, transfer, and repurchase terms, and other restrictions. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value  
Minimum [Member] | Stock Options [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Options exercisable   $ 100,000  
Two Thousand Seventeen Equity Incentive Plan [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Granted options description   No person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than 1,000,000 shares in the aggregate, or any Awards of Restricted Stock or RSUs with respect to more than 500,000 shares in the aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual share limit  
Two Thousand Seventeen Equity Incentive Plan [Member] | Maximum [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Options to purchase shares   1,000,000  
Two Thousand Seventeen Equity Incentive Plan [Member] | Maximum [Member] | Restricted Stock [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Options to purchase shares   500,000  
XML 102 R56.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards $ 12,408 $ 12,000
Capital loss carryforwards 3,120 3,120
Research and development credit carryforwards 1,138 1,426
Patents and fixed assets 879 901
Stock-based compensation 643 690
Capitalized Research Expenses 211
Other, net 62 80
Valuation allowance (18,461) (18,217)
Total net deferred tax assets
XML 103 R57.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Income Tax Rate Reconciliation (Details)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Computed tax benefit at federal statutory rate 21.00% 21.00%
Research and development and other credits 1.00% 1.00%
State tax benefit, net of effect on federal income taxes 7.00% 14.00%
Permanent differences 1.00%
Stock Based Compensation 2.00%
Loss and deconsolidation of LifeMap Sciences 31.00%
Debt finance equity costs 6.00%
Return to provision & other adjustments 5.00%
Change in valuation allowance 2.00% 4.00%
Income tax rate
XML 104 R58.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Balance at January 1
Additions for tax positions related to the current year 23
Additions for tax positions related to prior years 356
Reductions for tax positions related to prior years
Reductions related to settlements
Reductions related to a lapse of statute
Balance at December 31 $ 379
XML 105 R59.htm IDEA: XBRL DOCUMENT v3.23.4
Income Taxes (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2018
Operating Loss Carryforwards [Line Items]              
Net loss from operations         $ 10,500,000 $ 8,700,000  
Net operating losses         52,800,000    
Deferred Tax Assets, Tax Credit Carryforwards, Research         1,138,000 1,426,000  
Deferred tax assets capital loss carry forwards         3,120,000 $ 3,120,000  
Income tax rate deduction             50.00%
Income tax provisions         $ 0    
Income tax provisions $ 0 $ 0 $ 0 $ 0      
UNITED STATES              
Operating Loss Carryforwards [Line Items]              
Amortized over Period         5 years    
Non-US [Member]              
Operating Loss Carryforwards [Line Items]              
Amortized over Period         15 years    
Domestic Tax Authority [Member]              
Operating Loss Carryforwards [Line Items]              
Deferred Tax Assets, Tax Credit Carryforwards, Research         $ 900,000    
Tax Credit Carryforward, Description         The federal tax credits expire between 2028 and 2042, while the state tax credits have no expiration date    
Deferred tax assets capital loss carry forwards         $ 12,400,000    
State and Local Jurisdiction [Member]              
Operating Loss Carryforwards [Line Items]              
Deferred Tax Assets, Tax Credit Carryforwards, Research         600,000    
Deferred tax assets capital loss carry forwards         $ 5,900,000    
GILTI [Member]              
Operating Loss Carryforwards [Line Items]              
Income tax rate deduction         50.00%    
Other Income Tax Matters [Member]              
Operating Loss Carryforwards [Line Items]              
Income tax description         Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation    
California Purposes [Member]              
Operating Loss Carryforwards [Line Items]              
Net operating losses         $ 14,900,000    
Net operating loss, expiration date         Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2042    
XML 106 R60.htm IDEA: XBRL DOCUMENT v3.23.4
Commitments and Contingencies (Details Narrative)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 24, 2023
USD ($)
May 17, 2023
USD ($)
Apr. 20, 2023
USD ($)
Jan. 01, 2022
USD ($)
Nov. 17, 2021
USD ($)
Jan. 01, 2021
USD ($)
ft²
Nov. 03, 2020
USD ($)
ft²
Jun. 01, 2020
USD ($)
Apr. 13, 2020
USD ($)
Oct. 31, 2022
USD ($)
ft²
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Mar. 15, 2023
Loss Contingencies [Line Items]                                  
Office space | ft²             135                    
Lease and rental expense       $ 1,074     $ 947     $ 844              
Interest rate                                 10.00%
Notice of delisting               On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders’ equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan                  
Net loss               $ 2,000,000     $ (5,401,000) $ (2,435,000) $ (11,347,000) $ (7,759,000) $ (10,462,000) $ (8,675,000)  
Juvenescence Limited [Member]                                  
Loss Contingencies [Line Items]                                  
Extinguishment of Debt, Amount $ 36,000,000                                
Continuing Operations [Member]                                  
Loss Contingencies [Line Items]                                  
Net loss   $ 2,000,000 $ 2,000,000                            
Segment Continuing Operations One [Member]                                  
Loss Contingencies [Line Items]                                  
Net loss   4,000,000 4,000,000                            
Segment Continuing Operations Two [Member]                                  
Loss Contingencies [Line Items]                                  
Net loss   $ 6,000,000 $ 6,000,000                            
Minimum [Member]                                  
Loss Contingencies [Line Items]                                  
Net loss         $ 2,000,000                        
Maximum [Member]                                  
Loss Contingencies [Line Items]                                  
Net loss         $ 4,000,000                        
Paycheck Protection Program [Member]                                  
Loss Contingencies [Line Items]                                  
Loan obtained                 $ 432,952                
Interest rate                 1.00%                
Loan maturity date                 Apr. 13, 2022                
Lease Agreement [Member]                                  
Loss Contingencies [Line Items]                                  
Office space | ft²           135       101              
Lease and rental expense           $ 947       $ 844     $ 844 $ 1,074 $ 1,074    
XML 107 R61.htm IDEA: XBRL DOCUMENT v3.23.4
Subsequent Events (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Nov. 09, 2023
Oct. 03, 2023
Jul. 31, 2023
Jul. 24, 2023
May 09, 2023
Mar. 15, 2023
Mar. 15, 2023
Mar. 13, 2023
Feb. 13, 2023
Feb. 09, 2023
Jul. 31, 2023
Jan. 31, 2023
Jan. 25, 2023
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Nov. 14, 2023
Oct. 31, 2023
Feb. 15, 2023
Subsequent Event [Line Items]                                      
Warrant to purchase shares of common stock                           1,898,489          
Warrant excercise price per share                           $ 0.3960      
Line of credit facility, maximum borrowing capacity                             $ 7,160,000      
Principal amount           $ 105,000,000 $ 105,000,000                        
Proceeds from sale of common stock     $ 25,000,000                       496,000      
Debt interest rate           10.00% 10.00%                        
Other assets           $ 250,000 $ 250,000                        
Line of Credit, Current                           $ 2,000,000,000          
Equity, Attributable to Parent                           (27,536,000) (17,212,000) $ (11,832,000)      
Secured Convertible Promissory Note [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from Issuance of Secured Debt                     $ 16,660,000     $ 5,500,000          
Principal amount           $ 25,000,000 $ 25,000,000                        
Stockholder outstanding percentage             80.00%                        
Debt interest rate           20.00% 20.00%                        
Line of Credit Facility, Increase (Decrease), Net         $ 4,000,000         $ 2,000,000         $ 4,500,000        
Juvenescence [Member]                                      
Subsequent Event [Line Items]                                      
Warrant to purchase shares of common stock                           10,357,086 8,458,597        
Juvenescence [Member] | Secured Convertible Promissory Note [Member]                                      
Subsequent Event [Line Items]                                      
Principal amount     $ 10,000,000         $ 10,000,000     $ 10,000,000     $ 10,000,000          
Origination fee description     In lieu of accrued interest, AgeX agreed to pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.                                
Juvenescence Limited [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from sale of common stock     $ 10,000,000                                
Common stock outstanding percentage     85.00%                                
Extinguishment of Debt, Amount       $ 36,000,000                              
Equity, Attributable to Parent       $ 36,000,000                              
Juvenescence Limited [Member] | Minimum [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from sale of common stock     $ 10,000,000                                
Juvenescence Limited [Member] | Maximum [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from sale of common stock     $ 25,000,000                                
Juvenescence Limited [Member] | Secured Convertible Promissory Note [Member]                                      
Subsequent Event [Line Items]                                      
Line of credit, current borrowing capacity               10,000,000                      
Principal amount           $ 5,000,000 $ 5,000,000                        
Subsequent Event [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from Issuance of Secured Debt                         $ 500,000            
Principal amount           $ 105,000,000 $ 105,000,000                        
Proceeds from sale of common stock               25,000,000                      
Debt interest rate           10.00% 10.00%                        
Other assets           $ 250,000 $ 250,000                        
Equity, Attributable to Parent                                 $ 8,422,000    
Subsequent Event [Member] | Secured Convertible Promissory Note [Member]                                      
Subsequent Event [Line Items]                                      
Line of credit, current borrowing capacity                   2,000,000                  
Line of credit facility, maximum borrowing capacity                   $ 1,000,000                  
Principal amount           $ 25,000,000 25,000,000                       $ 1,450,000
Stockholder outstanding percentage           80.00%                          
Line of Credit Facility, Increase (Decrease), Net $ 4,400,000 $ 500,000                   $ 500,000              
Line of Credit, Current                                   $ 500,000  
Subsequent Event [Member] | Origination Fee [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from sale of common stock               10,000,000                      
Subsequent Event [Member] | Juvenescence [Member]                                      
Subsequent Event [Line Items]                                      
Warrant to purchase shares of common stock                         340,136           801,924
Warrant excercise price per share                         $ 0.735           $ 0.6235
Line of credit, current borrowing capacity                                     $ 1,000,000
Subsequent Event [Member] | Juvenescence [Member] | Secured Convertible Promissory Note [Member]                                      
Subsequent Event [Line Items]                                      
Principal amount           $ 10,000,000 10,000,000 10,000,000                      
Origination fee description                 In lieu of accrued interest, AgeX will pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.                    
Stockholder outstanding percentage           7.00%                          
Subsequent Event [Member] | Juvenescence Limited [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from sale of common stock               $ 10,000,000                      
Common stock outstanding percentage               85.00%                      
Subsequent Event [Member] | Juvenescence Limited [Member] | Minimum [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from sale of common stock               $ 10,000,000                      
Subsequent Event [Member] | Juvenescence Limited [Member] | Maximum [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from sale of common stock               25,000,000                      
Subsequent Event [Member] | Juvenescence Limited [Member] | Secured Convertible Promissory Note [Member]                                      
Subsequent Event [Line Items]                                      
Line of credit, current borrowing capacity               10,000,000                      
Principal amount           $ 5,000,000 $ 5,000,000                        
Subsequent Event [Member] | Juvenescence Limited [Member] | Origination Fee [Member]                                      
Subsequent Event [Line Items]                                      
Proceeds from sale of common stock               $ 10,000,000 $ 10,000,000                    
XML 108 R62.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Debt Issuance Costs and Debt Balances (Details) (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2023
Jul. 31, 2023
Feb. 14, 2023
Debt Disclosure [Abstract]      
Secured note $ 10 $ 10 $ 10
XML 109 R63.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) (Parenthetical)
$ in Thousands
Sep. 30, 2023
USD ($)
Debt Disclosure [Abstract]  
Lines of credit current $ 2,000,000
XML 110 R64.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Warrant Outstanding and Fair Values (Details) (Parenthetical)
$ in Thousands
Sep. 30, 2023
USD ($)
Debt Disclosure [Abstract]  
Lines of credit current $ 2,000,000
XML 111 R65.htm IDEA: XBRL DOCUMENT v3.23.4
Convertible Note Receivable (Details Narrative) - USD ($)
Mar. 15, 2023
Sep. 30, 2023
Jul. 31, 2023
Mar. 13, 2023
Short-Term Debt [Line Items]        
Principal amount $ 105,000,000      
Debt interest rate 10.00%      
Other assets $ 250,000      
Secured Convertible Promissory Note [Member]        
Short-Term Debt [Line Items]        
Principal amount $ 25,000,000      
Stockholder outstanding percentage 80.00%      
Debt interest rate 20.00%      
Subordination Agreement [Member] | Secured Convertible Promissory Note [Member]        
Short-Term Debt [Line Items]        
Principal amount $ 1,450,000      
Juvenescence [Member] | Secured Convertible Promissory Note [Member]        
Short-Term Debt [Line Items]        
Principal amount   $ 10,000,000 $ 10,000,000 $ 10,000,000
Juvenescence [Member] | Convertible Note Purchase Agreement [Member]        
Short-Term Debt [Line Items]        
Principal amount $ 10,000,000      
Stockholder outstanding percentage 7.00%      
Principal and interest outstanding $ 10,379,000      
Juvenescence Limited [Member] | Secured Convertible Promissory Note [Member]        
Short-Term Debt [Line Items]        
Principal amount $ 5,000,000      
XML 112 R66.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Jul. 31, 2023
Jul. 24, 2023
Jan. 08, 2021
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Feb. 14, 2023
Mar. 30, 2020
Class of Stock [Line Items]                  
Preferred stock, shares authorized       5,000,000   5,000,000 5,000,000    
Extinguishment of debt           $ 437,000    
Secured debt $ 10,000,000     $ 10,000,000       $ 10,000,000  
Conversion percentage, description   (y) February 1, 2024, provided that such conversion is not limited by the 19.9% Cap or the 50% Cap as described below; and if Automatic Conversion would then be limited by the 19.9% Cap or the 50% Cap, the Automatic Conversion shall take place on the tenth day after such stockholder approvals have been obtained as may be required to permit such Automatic Conversion without the limitations of the 19.9% Cap and the 50% Cap. Further, if the holders of at least a majority of the outstanding shares of Series B Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, and the conversion is not then limited by the 19.9% Cap or the 50% Cap, then the outstanding shares of Series B Preferred Stock shall be converted into common stock upon such approval or consent.              
Preferred stock voting rights       (i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock.          
Common stock, shares authorized       200,000,000   200,000,000 100,000,000    
Common stock, par value       $ 0.0001   $ 0.0001 $ 0.0001    
Common stock, shares outstanding       37,951,000   37,949,000 37,941,000    
Common stock, shares issued       37,951,000   37,949,000 37,941,000    
Warrant to purchase share of common stock       1,898,489          
Proceeds from issuance costs 25,000,000         $ 496,000    
Common Stock [Member]                  
Class of Stock [Line Items]                  
Common stock, shares outstanding       37,951,261   37,949,196 37,941,220    
Common stock, shares issued       37,951,261   37,949,196 37,941,220    
Proceeds from issuance costs       $ 10,000,000   $ 10,000,000      
2020 Loan Agreement [Member]                  
Class of Stock [Line Items]                  
Warrant to purchase share of common stock                 3,670,663
Series B Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Subscriptions price   $ 100,000              
Preferred stock closing price   $ 0.72              
Conversion percentage, description   If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the “19.9% Cap” upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued upon conversion of all shares of Series B Preferred Stock shall be an amount equal to the 19.9% Cap. The 19.9% Cap means 7,550,302 shares of common stock, which is 19.9% of the shares of common stock outstanding on February 14, 2022 when the Secured Note, a portion of which has not been approved by AgeX stockholders for conversion into common stock without regard to the 19.9% Cap and 50% Cap, was issued.              
Series B Preferred Stock [Member] | Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Conversion percentage, description   If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the 50% Cap upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued to a holder of Series B Preferred Stock upon conversion of such shares shall be an amount that, when added to other shares of common stock owned by such holder immediately prior to such conversion would equal one share less than the 50% Cap.              
Juvenescence Limited [Member]                  
Class of Stock [Line Items]                  
Extinguishment of debt 36,000,000 $ 36,000,000              
Secured debt 10,000,000                
Proceeds from issuance costs 10,000,000                
Juvenescence Limited [Member] | Origination Fee [Member]                  
Class of Stock [Line Items]                  
Secured debt   10,000,000              
Juvenescence Limited [Member] | 2020 Loan Agreement [Member]                  
Class of Stock [Line Items]                  
Secured debt   $ 10,000,000              
Juvenescence Limited [Member] | Series A Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Preferred stock, shares authorized   211,600              
Juvenescence Limited [Member] | Series B Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Preferred stock, shares authorized   148,400              
Juvenescence [Member]                  
Class of Stock [Line Items]                  
Secured debt $ 10,000,000                
Line of credit facility       $ 2,500,000   $ 12,660,000      
Warrant to purchase share of common stock       10,357,086   8,458,597      
Juvenescence [Member] | Issuance And Sale Of Warrants [Member]                  
Class of Stock [Line Items]                  
Warrant to purchase share of common stock       1,898,489          
Chardan Capital Markets LLC [Member]                  
Class of Stock [Line Items]                  
Common stock, par value     $ 0.0001            
Payments for offering     $ 12,600,000            
Proceeds from issuance costs       $ 0 $ 0 $ 496,000    
XML 113 R67.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Non-cash Investing and Financing Transactions (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]        
Cash paid during the period for interest $ 27 $ 14 $ 14 $ 13
Issuance of preferred stock in exchange for debt 36,000    
Issuance of common stock upon vesting of restricted stock units (Note 8) 2 6    
Issuance of warrants for debt issuance under the 2020 Loan Agreement 178    
Fair value of liability classified warrants at debt inception date (Note 6) 663 3,666    
Debt refinanced with new debt (Note 5) $ 7,160    
XML 114 R68.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) - USD ($)
shares in Thousands, $ in Thousands
Nov. 14, 2023
Sep. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Current assets:                
Cash and cash equivalents   $ 397   $ 645     $ 584  
Accounts and grants receivable, net   67   4     25  
Related party receivables, net   4            
Prepaid expenses and other current assets   673   1,804     1,625  
Total current assets   1,141   2,453     2,234  
Restricted cash   50   50     50  
Intangible assets, net   640   738     870  
Convertible note receivable   10,379          
TOTAL ASSETS   12,210   3,241     3,154  
Current liabilities:                
Accounts payable and accrued liabilities   1,671   1,034     771  
Loan due to Juvenescence, net of debt issuance costs, current portion   1,526   7,646     7,140  
Insurance premium liability and other current liabilities   7   1,077     986  
Total current liabilities   3,204   10,078     8,967  
Loan due to Juvenescence, net of debt issuance costs, net of current portion   693   10,478     6,062  
TOTAL LIABILITIES   3,897   20,556     15,029  
Commitments and contingencies          
Temporary equity preferred stock              
Stockholders’ equity (deficit):                
Preferred stock, shares authorized   5,000   5,000     5,000  
Preferred stock, value          
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively   4   4     4  
Additional paid-in capital   100,017   98,994     93,912  
Accumulated deficit   (127,557)   (116,210)     (105,748)  
Total AgeX Therapeutics, Inc. stockholders’ deficit   (27,536)   (17,212)     (11,832)  
Noncontrolling interest   (109)   (103)     (43)  
Total stockholders’ deficit   (27,645) $ (22,296) (17,315) $ (15,149) $ (13,262) (11,875) $ (5,396)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT   12,210   3,241     3,154  
Series A Preferred Stock [Member]                
Current liabilities:                
Temporary equity preferred stock   $ 21,135          
Temporary stock, shares issued   212          
Temporary stock, shares outstanding   212          
Series A Preferred Stock [Member] | Preferred Stock [Member]                
Current liabilities:                
Temporary equity preferred stock   $ 21,135        
Temporary stock, shares outstanding   212        
Stockholders’ equity (deficit):                
Preferred stock, value              
Total stockholders’ deficit            
Series B Preferred Stock [Member]                
Current liabilities:                
Temporary equity preferred stock   $ 14,823        
Temporary stock, shares issued   148          
Temporary stock, shares outstanding   148          
Series B Preferred Stock [Member] | Preferred Stock [Member]                
Current liabilities:                
Temporary equity preferred stock   $ 14,823        
Temporary stock, shares outstanding   148        
Stockholders’ equity (deficit):                
Preferred stock, value              
Total stockholders’ deficit            
Subsequent Event [Member]                
Current assets:                
Cash and cash equivalents $ 397              
Accounts and grants receivable, net 67              
Related party receivables, net 4              
Prepaid expenses and other current assets 673              
Total current assets 1,141              
Restricted cash 50              
Intangible assets, net 640              
Convertible note receivable 10,379              
TOTAL ASSETS 12,210              
Current liabilities:                
Accounts payable and accrued liabilities 1,671              
Loan due to Juvenescence, net of debt issuance costs, current portion 1,526              
Insurance premium liability and other current liabilities 7              
Total current liabilities 3,204              
Loan due to Juvenescence, net of debt issuance costs, net of current portion 693              
TOTAL LIABILITIES 3,897              
Commitments and contingencies              
Temporary equity preferred stock              
Stockholders’ equity (deficit):                
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively 4              
Additional paid-in capital 135,975              
Accumulated deficit (127,557)              
Total AgeX Therapeutics, Inc. stockholders’ deficit 8,422              
Noncontrolling interest (109)              
Total stockholders’ deficit 8,313              
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT 12,210              
Subsequent Event [Member] | Series A Preferred Stock [Member]                
Current liabilities:                
Temporary equity preferred stock              
Subsequent Event [Member] | Series A Preferred Stock [Member] | Preferred Stock [Member]                
Stockholders’ equity (deficit):                
Preferred stock, value              
Subsequent Event [Member] | Series B Preferred Stock [Member]                
Current liabilities:                
Temporary equity preferred stock              
Subsequent Event [Member] | Series B Preferred Stock [Member] | Preferred Stock [Member]                
Stockholders’ equity (deficit):                
Preferred stock, value              
Revision of Prior Period, Adjustment [Member]                
Current assets:                
Cash and cash equivalents              
Accounts and grants receivable, net              
Related party receivables, net              
Prepaid expenses and other current assets              
Total current assets              
Restricted cash              
Intangible assets, net              
Convertible note receivable              
TOTAL ASSETS              
Current liabilities:                
Accounts payable and accrued liabilities              
Loan due to Juvenescence, net of debt issuance costs, current portion              
Insurance premium liability and other current liabilities              
Total current liabilities              
Loan due to Juvenescence, net of debt issuance costs, net of current portion              
TOTAL LIABILITIES              
Commitments and contingencies              
Temporary equity preferred stock              
Stockholders’ equity (deficit):                
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively              
Additional paid-in capital   35,958            
Accumulated deficit              
Total AgeX Therapeutics, Inc. stockholders’ deficit   35,958            
Noncontrolling interest              
Total stockholders’ deficit   35,958            
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT              
Revision of Prior Period, Adjustment [Member] | Series A Preferred Stock [Member]                
Current liabilities:                
Temporary equity preferred stock   (21,135)            
Revision of Prior Period, Adjustment [Member] | Series A Preferred Stock [Member] | Preferred Stock [Member]                
Stockholders’ equity (deficit):                
Preferred stock, value              
Revision of Prior Period, Adjustment [Member] | Series B Preferred Stock [Member]                
Current liabilities:                
Temporary equity preferred stock   (14,823)            
Revision of Prior Period, Adjustment [Member] | Series B Preferred Stock [Member] | Preferred Stock [Member]                
Stockholders’ equity (deficit):                
Preferred stock, value              
XML 115 R69.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) (Parenthetical) - USD ($)
$ / shares in Units, $ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Dividends Payable [Line Items]        
Preferred Stock, Par or Stated Value Per Share $ 0.0001   $ 0.0001 $ 0.0001
Preferred stock, shares issued     0 0
Preferred stock, shares outstanding     0 0
Common stock, par value $ 0.0001   $ 0.0001 $ 0.0001
Common stock, shares authorized 200,000,000   200,000,000 100,000,000
Common stock, shares issued 37,951,000   37,949,000 37,941,000
Common stock, shares outstanding 37,951,000   37,949,000 37,941,000
Series A Preferred Stock [Member]        
Dividends Payable [Line Items]        
Temporary stock, par value $ 0   $ 0  
Temporary stock, stated value $ 100   $ 100  
Temporary stock, shares issued 212,000    
Temporary stock, shares outstanding 212,000    
Series A Preferred Stock [Member] | Preferred Stock [Member]        
Dividends Payable [Line Items]        
Temporary stock, shares outstanding 212,000  
Preferred stock, shares issued 212,000    
Preferred stock, shares outstanding 212,000    
Series B Preferred Stock [Member]        
Dividends Payable [Line Items]        
Temporary stock, par value $ 0   $ 0  
Temporary stock, stated value $ 100   $ 100  
Temporary stock, shares issued 148,000    
Temporary stock, shares outstanding 148,000    
Series B Preferred Stock [Member] | Preferred Stock [Member]        
Dividends Payable [Line Items]        
Temporary stock, shares outstanding 148,000  
Preferred stock, shares issued 148,000    
Preferred stock, shares outstanding 148,000    
XML 116 forms-4a_htm.xml IDEA: XBRL DOCUMENT 0001708599 2023-01-01 2023-09-30 0001708599 dei:BusinessContactMember 2023-01-01 2023-09-30 0001708599 2022-12-31 0001708599 2021-12-31 0001708599 us-gaap:RelatedPartyMember 2022-12-31 0001708599 us-gaap:RelatedPartyMember 2021-12-31 0001708599 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001708599 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001708599 2023-09-30 0001708599 us-gaap:RelatedPartyMember 2023-09-30 0001708599 us-gaap:SeriesAPreferredStockMember 2023-09-30 0001708599 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001708599 us-gaap:SeriesBPreferredStockMember 2023-09-30 0001708599 2022-01-01 2022-12-31 0001708599 2021-01-01 2021-12-31 0001708599 AGE:GrantRevenuesMember 2022-01-01 2022-12-31 0001708599 AGE:GrantRevenuesMember 2021-01-01 2021-12-31 0001708599 AGE:OtherRevenuesMember 2022-01-01 2022-12-31 0001708599 AGE:OtherRevenuesMember 2021-01-01 2021-12-31 0001708599 2023-07-01 2023-09-30 0001708599 2022-07-01 2022-09-30 0001708599 2022-01-01 2022-09-30 0001708599 AGE:GrantRevenuesMember 2023-07-01 2023-09-30 0001708599 AGE:GrantRevenuesMember 2022-07-01 2022-09-30 0001708599 AGE:GrantRevenuesMember 2023-01-01 2023-09-30 0001708599 AGE:GrantRevenuesMember 2022-01-01 2022-09-30 0001708599 AGE:OtherRevenuesMember 2023-07-01 2023-09-30 0001708599 AGE:OtherRevenuesMember 2022-07-01 2022-09-30 0001708599 AGE:OtherRevenuesMember 2023-01-01 2023-09-30 0001708599 AGE:OtherRevenuesMember 2022-01-01 2022-09-30 0001708599 us-gaap:CommonStockMember 2020-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001708599 us-gaap:RetainedEarningsMember 2020-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2020-12-31 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001708599 2020-12-31 0001708599 us-gaap:CommonStockMember 2021-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001708599 us-gaap:RetainedEarningsMember 2021-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2021-12-31 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001708599 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001708599 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001708599 us-gaap:CommonStockMember 2023-06-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001708599 us-gaap:RetainedEarningsMember 2023-06-30 0001708599 us-gaap:NoncontrollingInterestMember 2023-06-30 0001708599 2023-06-30 0001708599 us-gaap:CommonStockMember 2022-06-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001708599 us-gaap:RetainedEarningsMember 2022-06-30 0001708599 us-gaap:NoncontrollingInterestMember 2022-06-30 0001708599 2022-06-30 0001708599 us-gaap:CommonStockMember 2022-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001708599 us-gaap:RetainedEarningsMember 2022-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2022-12-31 0001708599 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001708599 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001708599 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001708599 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-12-31 0001708599 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001708599 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-12-31 0001708599 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001708599 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001708599 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001708599 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001708599 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001708599 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001708599 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001708599 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001708599 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0001708599 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0001708599 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001708599 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0001708599 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001708599 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001708599 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001708599 us-gaap:CommonStockMember 2023-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001708599 us-gaap:RetainedEarningsMember 2023-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2023-09-30 0001708599 us-gaap:CommonStockMember 2022-09-30 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001708599 us-gaap:RetainedEarningsMember 2022-09-30 0001708599 us-gaap:NoncontrollingInterestMember 2022-09-30 0001708599 2022-09-30 0001708599 AGE:JuvenescenceLimitedMember 2018-08-29 2018-08-30 0001708599 2018-08-29 2018-08-30 0001708599 srt:ParentCompanyMember us-gaap:CommonStockMember 2018-11-27 2018-11-28 0001708599 AGE:AgeXMember us-gaap:CommonStockMember 2018-11-28 0001708599 AGE:MergerAgreementMember AGE:LifeMapSciencesIncMember 2021-03-14 2021-03-15 0001708599 AGE:MergerAgreementMember 2021-03-14 2021-03-15 0001708599 AGE:LoanFacilityAgreementMember AGE:JuvenescenceMember 2022-12-31 0001708599 AGE:AgeXMember AGE:MergerAgreementMember AGE:ReCyteTherapeuticsIncMember 2022-12-31 0001708599 AGE:AgeXMember AGE:MergerAgreementMember AGE:NeuroAirmidMember 2022-12-31 0001708599 AGE:ConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-31 0001708599 AGE:ConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-01 2023-03-31 0001708599 AGE:LoanFacilityAgreementMember AGE:JuvenescenceMember 2023-09-30 0001708599 us-gaap:SubsequentEventMember AGE:LoanFacilityAgreementMember AGE:JuvenescenceMember 2023-11-09 0001708599 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001708599 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001708599 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001708599 2020-11-03 0001708599 2020-11-03 2020-11-03 0001708599 2022-01-01 2022-01-01 0001708599 2022-10-01 2022-10-31 0001708599 2018-01-01 2018-12-31 0001708599 AGE:SubscriptionAndAdvertisementRevenuesMember 2021-01-01 2021-12-31 0001708599 AGE:NationalInstitutesOfHealthMember 2020-04-07 2020-04-08 0001708599 AGE:NationalInstitutesOfHealthMember 2021-01-01 2021-12-31 0001708599 AGE:ReCyteTherapeuticsIncMember 2023-09-30 0001708599 AGE:MergerAgreementMember 2023-09-30 0001708599 AGE:ReCyteTherapeuticsIncMember AGE:MergerAgreementMember 2023-09-30 0001708599 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001708599 AGE:LeaseAgreementMember 2022-01-01 2022-09-30 0001708599 AGE:LeaseAgreementMember 2023-01-01 2023-09-30 0001708599 AGE:NationalInstitutesOfHealthMember 2023-08-01 2023-08-31 0001708599 AGE:NationalInstitutesOfHealthMember 2023-07-01 2023-09-30 0001708599 AGE:NationalInstitutesOfHealthMember 2023-01-01 2023-09-30 0001708599 country:US 2022-01-01 2022-12-31 0001708599 country:US 2021-01-01 2021-12-31 0001708599 AGE:ForeignMember 2022-01-01 2022-12-31 0001708599 AGE:ForeignMember 2021-01-01 2021-12-31 0001708599 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001708599 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001708599 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001708599 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001708599 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001708599 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001708599 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001708599 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001708599 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001708599 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001708599 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001708599 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001708599 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001708599 AGE:LoanAgreementsMember 2022-12-31 0001708599 AGE:LoanAgreementsMember 2021-12-31 0001708599 AGE:LoanAgreementsMember 2023-09-30 0001708599 AGE:LoanAgreementsMember 2022-09-30 0001708599 AGE:AssetPurchaseAgreementMember 2018-08-12 2018-08-13 0001708599 AGE:ResearchAndDevelopmentMember 2021-08-01 2021-08-31 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2019-08-12 2019-08-13 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2021-02-09 2021-02-10 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2021-11-07 2021-11-08 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2021-11-08 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2022-02-14 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2020-03-30 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2020-03-29 2020-03-30 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2022-12-31 0001708599 us-gaap:WarrantMember AGE:TwoThousandAndTwentyLoanAgreementMember 2022-12-31 0001708599 us-gaap:WarrantMember AGE:TwoThousandAndTwentyLoanAgreementMember 2022-01-01 2022-12-31 0001708599 AGE:TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember 2022-02-14 0001708599 AGE:TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember 2022-02-14 2022-02-14 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2022-01-01 2022-12-31 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-01-01 2023-01-31 0001708599 us-gaap:SubsequentEventMember AGE:SecuredConvertiblePromissoryNoteMember 2023-02-28 0001708599 AGE:TwoThousandTwentyTwoWarrantsMember 2022-01-01 2022-12-31 0001708599 AGE:TwoThousandTwentyTwoWarrantsMember 2022-12-31 0001708599 AGE:TwoThousandTwentyTwoWarrantsMember 2022-01-01 2022-12-31 0001708599 AGE:SecurityAgreementMember 2022-01-01 2022-12-31 0001708599 AGE:ReverseRatioMember 2022-12-31 0001708599 AGE:RegistrationRightsAgreementsMember 2022-01-01 2022-12-31 0001708599 AGE:JuvenescenceMember 2022-01-01 2022-12-31 0001708599 AGE:JuvenescenceMember 2022-12-31 0001708599 AGE:JuvenescenceMember 2021-12-31 0001708599 AGE:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 AGE:JuvenescenceLimitedMember 2023-07-31 0001708599 AGE:TwoThousandNineteenLoanAgreementMember AGE:JuvenescenceMember 2021-12-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2023-09-30 0001708599 AGE:TwentyTwentyLoanAgreementMember 2023-07-01 2023-07-31 0001708599 us-gaap:WarrantMember AGE:TwoThousandAndTwentyLoanAgreementMember 2023-09-30 0001708599 AGE:TwentyTwentyWarrantMember AGE:TwoThousandAndTwentyLoanAgreementMember 2023-01-01 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-02-08 2023-02-09 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-05-09 2023-05-09 0001708599 AGE:FourthAmendmentMember 2023-07-31 2023-07-31 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-01-01 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-07-01 2023-07-31 0001708599 us-gaap:LineOfCreditMember 2023-07-31 2023-07-31 0001708599 AGE:JuvenescenceMember 2023-09-30 0001708599 AGE:TwoThousandTwentyTwoWarrantsMember 2023-01-01 2023-09-30 0001708599 AGE:SecurityAgreementMember 2023-01-01 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-09-30 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-03-13 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-13 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-07-31 0001708599 AGE:JuvenescenceMember 2023-07-31 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceMember 2023-07-31 2023-07-31 0001708599 2023-07-31 0001708599 srt:MinimumMember AGE:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 srt:MaximumMember AGE:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 2023-07-31 2023-07-31 0001708599 AGE:DerivativesAndHedgingMember AGE:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 2023-02-14 0001708599 AGE:RegistrationRightsAgreementsMember 2023-01-01 2023-09-30 0001708599 AGE:JuvenescenceMember 2023-01-01 2023-09-30 0001708599 AGE:TwoThousandNineteenLoanAgreementMember 2022-12-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2022-12-31 0001708599 AGE:TwoThousandAndTwentyTwoSecuredNoteMember 2022-12-31 0001708599 AGE:TwoThousandNineteenLoanAgreementMember 2021-12-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2021-12-31 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember 2023-09-30 0001708599 AGE:SecuredNoteMember 2023-09-30 0001708599 us-gaap:DebtMember 2023-09-30 0001708599 AGE:TenThousandMillionSecuredNoteMember 2023-09-30 0001708599 AGE:TotalDebtNetMember 2023-09-30 0001708599 AGE:InceptionDateMember 2022-02-14 0001708599 AGE:InceptionDateMember 2022-02-14 2022-02-14 0001708599 AGE:IssuanceDateMember 2022-02-14 0001708599 AGE:IssuanceDateMember 2022-02-14 2022-02-14 0001708599 AGE:IssuanceDateMember 2022-02-15 0001708599 AGE:IssuanceDateMember 2022-02-15 2022-02-15 0001708599 AGE:PeriodEndingMember 2022-03-31 0001708599 AGE:PeriodEndingMember 2022-02-14 2022-03-31 0001708599 AGE:IssuanceDateMember 2022-04-04 0001708599 AGE:IssuanceDateMember 2022-04-04 2022-04-04 0001708599 AGE:IssuanceDateMember 2022-06-06 0001708599 AGE:IssuanceDateMember 2022-06-06 2022-06-06 0001708599 AGE:PeriodEndingMember 2022-06-30 0001708599 AGE:PeriodEndingMember 2022-06-30 2022-06-30 0001708599 AGE:IssuanceDateMember 2022-08-16 0001708599 AGE:IssuanceDateMember 2022-08-15 2022-08-16 0001708599 AGE:PeriodEndingMember 2022-09-30 0001708599 AGE:PeriodEndingMember 2022-09-29 2022-09-30 0001708599 AGE:PeriodEndingMember 2022-10-21 0001708599 AGE:PeriodEndingMember 2022-10-20 2022-10-21 0001708599 AGE:PeriodEndingMember 2022-12-14 0001708599 AGE:PeriodEndingMember 2022-12-13 2022-12-14 0001708599 AGE:PeriodEndingMember 2022-12-31 0001708599 AGE:PeriodEndingMember 2022-12-30 2022-12-31 0001708599 AGE:IssuanceDateMember 2022-10-21 0001708599 AGE:IssuanceDateMember 2022-10-20 2022-10-21 0001708599 AGE:IssuanceDateMember 2022-12-14 0001708599 AGE:IssuanceDateMember 2022-12-13 2022-12-14 0001708599 AGE:IssuanceDateMember 2023-01-25 0001708599 AGE:IssuanceDateMember 2023-01-24 2023-01-25 0001708599 AGE:InceptionDateMember 2023-02-09 0001708599 AGE:InceptionDateMember 2023-02-08 2023-02-09 0001708599 AGE:IssuanceDateMember 2023-02-15 0001708599 AGE:IssuanceDateMember 2023-02-14 2023-02-15 0001708599 AGE:PeriodEndingMember 2023-03-31 0001708599 AGE:PeriodEndingMember 2023-03-30 2023-03-31 0001708599 AGE:IssuanceDateMember 2023-04-04 0001708599 AGE:IssuanceDateMember 2023-04-03 2023-04-04 0001708599 AGE:InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:FourteenFebruaryTwoThousandAndTwentyTwoOneMember 2022-01-01 2022-12-31 0001708599 AGE:FifteenFebruaryTwentyThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:FourAprilTwentyThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:SixJuneTwentyThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:SixteenAugustTwentyThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:TwentyFirstOctoberTwoThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:FourteenDecemberTwoThousandAndTwentyTwoMember 2022-01-01 2022-12-31 0001708599 AGE:TwentyFiveJanuaryTwoThousandAndTwentyThreeMember 2023-01-01 2023-09-30 0001708599 AGE:TwoSeptemberTwoThousandAndTwentyThreeMember 2023-01-01 2023-09-30 0001708599 AGE:FifteenFebruaryTwentyThousandAndTwentyThreeMember 2023-01-01 2023-09-30 0001708599 AGE:FourthAprilTwentyThousandAndTwentyThreeMember 2023-01-01 2023-09-30 0001708599 us-gaap:WarrantMember 2023-09-30 0001708599 AGE:ChardanCapitalMarketsLLCMember 2021-01-07 2021-01-08 0001708599 AGE:ChardanCapitalMarketsLLCMember 2022-01-01 2022-12-31 0001708599 AGE:ChardanCapitalMarketsLLCMember 2021-01-01 2021-12-31 0001708599 AGE:TwoThousandSeventeenEquityIncentivePlanMember 2022-01-01 2022-12-31 0001708599 srt:MaximumMember AGE:TwoThousandSeventeenEquityIncentivePlanMember 2022-01-01 2022-12-31 0001708599 srt:MaximumMember us-gaap:RestrictedStockMember AGE:TwoThousandSeventeenEquityIncentivePlanMember 2022-01-01 2022-12-31 0001708599 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001708599 srt:MinimumMember AGE:StockOptionsMember 2022-12-31 0001708599 srt:MaximumMember AGE:RestrictedStockAndRestrictedStockUnitsMember 2022-01-01 2022-12-31 0001708599 us-gaap:StockAppreciationRightsSARSMember 2022-01-01 2022-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2020-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2021-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2022-12-31 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001708599 AGE:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2023-09-30 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentDiscontinuedOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-12-31 0001708599 us-gaap:SegmentDiscontinuedOperationsMember 2021-01-01 2021-12-31 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001708599 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001708599 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001708599 AGE:CaliforniaPurposesMember 2022-12-31 0001708599 AGE:CaliforniaPurposesMember 2022-01-01 2022-12-31 0001708599 us-gaap:DomesticCountryMember 2022-12-31 0001708599 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001708599 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0001708599 us-gaap:NonUsMember 2022-01-01 2022-12-31 0001708599 AGE:GILTIMember 2022-01-01 2022-12-31 0001708599 AGE:OtherIncomeTaxMattersMember 2022-01-01 2022-12-31 0001708599 AGE:LeaseAgreementMember 2021-01-01 0001708599 AGE:LeaseAgreementMember 2021-01-01 2021-01-01 0001708599 AGE:LeaseAgreementMember 2022-01-01 2022-12-31 0001708599 AGE:LeaseAgreementMember 2022-10-31 0001708599 AGE:LeaseAgreementMember 2022-10-01 2022-10-31 0001708599 AGE:PaycheckProtectionProgramMember 2020-04-13 0001708599 AGE:PaycheckProtectionProgramMember 2020-04-12 2020-04-13 0001708599 2020-06-01 2020-06-01 0001708599 srt:MinimumMember 2021-11-16 2021-11-17 0001708599 srt:MaximumMember 2021-11-16 2021-11-17 0001708599 us-gaap:SegmentContinuingOperationsMember 2023-04-19 2023-04-20 0001708599 AGE:SegmentContinuingOperationsOneMember 2023-04-19 2023-04-20 0001708599 AGE:SegmentContinuingOperationsTwoMember 2023-04-19 2023-04-20 0001708599 us-gaap:SegmentContinuingOperationsMember 2023-05-16 2023-05-17 0001708599 AGE:SegmentContinuingOperationsOneMember 2023-05-16 2023-05-17 0001708599 AGE:SegmentContinuingOperationsTwoMember 2023-05-16 2023-05-17 0001708599 AGE:JuvenescenceLimitedMember 2023-07-24 2023-07-24 0001708599 us-gaap:SubsequentEventMember 2023-01-01 2023-01-25 0001708599 us-gaap:SubsequentEventMember AGE:JuvenescenceMember 2023-01-25 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-02-09 0001708599 us-gaap:SubsequentEventMember AGE:JuvenescenceMember 2023-02-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember AGE:JuvenescenceMember 2023-03-13 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-03-13 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember AGE:JuvenescenceMember 2023-02-13 2023-02-13 0001708599 srt:MinimumMember us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 srt:MaximumMember us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 us-gaap:SubsequentEventMember 2023-03-13 2023-03-13 0001708599 us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 AGE:OriginationFeeMember us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 AGE:OriginationFeeMember us-gaap:SubsequentEventMember 2023-03-13 2023-03-13 0001708599 AGE:OriginationFeeMember us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-02-13 2023-02-13 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember AGE:JuvenescenceMember 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember AGE:JuvenescenceMember 2023-03-13 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-03-13 2023-03-15 0001708599 us-gaap:SubsequentEventMember 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember AGE:JuvenescenceLimitedMember 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-02-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-10-03 2023-10-03 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-10-31 0001708599 AGE:SecuredConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2023-11-09 2023-11-09 0001708599 AGE:JuvenescenceLimitedMember 2023-07-24 0001708599 AGE:ConvertibleNotePurchaseAgreementMember AGE:JuvenescenceMember 2023-03-15 0001708599 AGE:ConvertibleNotePurchaseAgreementMember AGE:JuvenescenceMember 2023-03-15 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember 2023-03-15 2023-03-15 0001708599 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:JuvenescenceLimitedMember 2023-03-15 0001708599 AGE:SecuredConvertiblePromissoryNoteMember AGE:SubordinationAgreementMember 2023-03-15 0001708599 us-gaap:SeriesAPreferredStockMember AGE:JuvenescenceLimitedMember 2023-07-24 0001708599 us-gaap:SeriesBPreferredStockMember AGE:JuvenescenceLimitedMember 2023-07-24 0001708599 AGE:JuvenescenceLimitedMember 2023-07-23 2023-07-24 0001708599 AGE:TwoThousandAndTwentyLoanAgreementMember AGE:JuvenescenceLimitedMember 2023-07-24 0001708599 AGE:OriginationFeeMember AGE:JuvenescenceLimitedMember 2023-07-24 0001708599 us-gaap:SeriesBPreferredStockMember 2023-07-24 0001708599 2023-07-23 2023-07-24 0001708599 us-gaap:SeriesBPreferredStockMember 2023-07-23 2023-07-24 0001708599 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-07-23 2023-07-24 0001708599 AGE:IssuanceAndSaleOfWarrantsMember AGE:JuvenescenceMember 2023-09-30 0001708599 AGE:ChardanCapitalMarketsLLCMember 2021-01-08 0001708599 AGE:ChardanCapitalMarketsLLCMember 2023-01-01 2023-09-30 0001708599 AGE:ChardanCapitalMarketsLLCMember 2022-01-01 2022-09-30 0001708599 srt:RestatementAdjustmentMember 2023-09-30 0001708599 us-gaap:SubsequentEventMember 2023-11-14 0001708599 srt:RestatementAdjustmentMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001708599 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2023-11-14 0001708599 srt:RestatementAdjustmentMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001708599 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2023-11-14 0001708599 srt:RestatementAdjustmentMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001708599 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember us-gaap:SubsequentEventMember 2023-11-14 0001708599 srt:RestatementAdjustmentMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001708599 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember us-gaap:SubsequentEventMember 2023-11-14 iso4217:USD shares iso4217:USD shares pure AGE:Integer utr:sqft true 0001708599 S-4/A 0001708599 AMENDMENT NO. 1 AgeX Therapeutics, Inc. DE 82-1436829 1101 Marina Village Parkway, Suite 201 Alameda CA 94501 510 671-8370 Andrea E. Park 1101 Marina Village Parkway, Suite 201 Alameda CA 94501 510 671-8370 Non-accelerated Filer true true true 645000 584000 4000 25000 1804000 1625000 2453000 2234000 50000 50000 738000 870000 3241000 3154000 1034000 771000 7646000 7140000 141000 70000 180000 1077000 986000 10078000 8967000 10478000 6062000 20556000 15029000 0.0001 0.0001 5000000 5000000 0 0 0 0 0.0001 0.0001 200000000 100000000 37949000 37949000 37941000 37941000 4000 4000 98994000 93912000 -116210000 -105748000 -17212000 -11832000 -103000 -43000 -17315000 -11875000 3241000 3154000 104000 34000 40000 34000 144000 13000 19000 21000 125000 1025000 1456000 5971000 6708000 6996000 8164000 106000 -6975000 -7933000 3335000 1097000 225000 13000 448000 -3547000 -649000 -10522000 -8582000 -103000 -10522000 -8685000 -60000 -3000 -7000 -10462000 -8675000 -0.28 -0.23 -0.28 -0.28 -0.23 -0.23 37945000 37945000 37886000 37886000 -10462000 -8579000 -96000 -10462000 -8675000 -10522000 -8685000 -143000 -10522000 -8828000 60000 3000 7000 -10462000 -8818000 37691 4000 91810000 -97073000 -280000 143000 -5396000 242 475000 475000 8 -7000 -7000 757000 757000 1003000 1003000 -269000 269000 -143000 22000 143000 22000 -8675000 -10000 -8685000 37941 4000 93912000 -105748000 -43000 -11875000 37941 4000 93912000 -105748000 -43000 -11875000 8 -4000 -4000 178000 178000 4148000 4148000 760000 760000 -10462000 -60000 -10522000 37949 4000 98994000 -116210000 -103000 -17315000 37949 4000 98994000 -116210000 -103000 -17315000 -10462000 -8579000 -60000 -3000 106000 437000 225000 132000 131000 3137000 1114000 760000 999000 -21000 -128000 -896000 -760000 144000 -772000 255000 -983000 -921000 -4000 -79000 -5939000 -7765000 -90000 -5939000 -7855000 466000 250000 716000 -50000 666000 6000000 7000000 496000 6000000 7496000 -250000 6000000 7246000 61000 57000 634000 577000 695000 634000 14000 13000 8000 16000 178000 757000 4148000 7160000 <p id="xdx_80E_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zY3Jctt6W2f8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span>Organization, Basis of Presentation and Liquidity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_824_zKK7mNFf8mDl" style="display: none">Organization, Business Overview and Liquidity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX Therapeutics, Inc. (“AgeX,” “we,” “our,” or “us”) was incorporated in January 2017 in the state of Delaware as a subsidiary of Lineage Cell Therapeutics, Inc. (“Lineage,” formerly known as BioTime, Inc.), a publicly traded, clinical-stage biotechnology company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s main technology platforms and product candidates are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PureStem<i><sup>® </sup></i>PSC-derived clonal embryonic progenitor cell lines that may be capable of generating a broad range of cell types for use in cell-based therapies;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lineage’s Sale of Significant Ownership Interest in AgeX to Juvenescence</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 30, 2018, Lineage consummated the sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20180829__20180830__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z14HWviCK898" title="Sale of stock">14,400,000</span> shares of common stock of AgeX owned by Lineage to Juvenescence Limited (“Juvenescence”). Prior to the transaction, Juvenescence owned <span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20180829__20180830__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zLkMwcF2gLr2" title="Sale of stock, percentage of ownership before transaction">5.6</span>% of AgeX’s issued and outstanding common stock. Upon completion of the transaction, Lineage’s ownership in AgeX was reduced from <span id="xdx_904_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20180829__20180830_zYHJ4Bbqm2Qk" title="Sale of stock, percentage of ownership before transaction">80.4</span>% to <span id="xdx_90E_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20180829__20180830_z6FHiuejdCl7" title="Sale of stock, percentage of ownership after transaction">40.2</span>% of AgeX’s issued and outstanding shares of common stock, and Juvenescence’s ownership in AgeX was increased from <span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20180829__20180830__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zrieMB28Pgv7" title="Sale of stock, percentage of ownership before transaction">5.6</span>% to <span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20180829__20180830__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zXphmbOaNkYk" title="Sale of stock, percentage of ownership after transaction">45.8</span>% of AgeX’s issued and outstanding shares of common stock. AgeX did not receive any proceeds from the transaction. As a result of that transaction, AgeX ceased to be a subsidiary of Lineage because Lineage experienced a “loss of control” of a subsidiary, as defined by U.S. GAAP. Loss of control is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock in the subsidiary, lacks a controlling financial interest in the subsidiary and, is unable to unilaterally control the subsidiary through other means such as having, or being able to obtain, the power to elect a majority of the subsidiary’s Board of Directors based solely on contractual rights or ownership of shares holding a majority of the voting power of the subsidiary’s voting securities. All of these loss-of-control factors were present with respect to Lineage’s ownership interest in AgeX as of August 30, 2018. Accordingly, Lineage deconsolidated AgeX’s consolidated financial statements and results from its consolidated financial statements and results beginning on August 30, 2018.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 28, 2018 (the “Distribution Date”), Lineage distributed to its shareholders, on a pro rata basis, <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181127__20181128__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDR3Szclpprg" title="Number of common stock shares issued">12,697,028</span> shares of the AgeX common stock it then held (the “Distribution”). Immediately after the Distribution, Lineage retained <span id="xdx_902_ecustom--RetainedSharesOfCommonStock_c20181127__20181128__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zvl0kIJ7cfh1" title="Retained shares of common stock">1,718,972</span> shares of AgeX common stock, representing approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20181128__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgeXMember_zWZfx2YUP14a" title="Ownership interest">4.8</span>% of the common stock then issued and outstanding. Following the Distribution, AgeX common stock began publicly trading on the NYSE American under the symbol “AGE.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disposition and Deconsolidation of LifeMap Sciences</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2021, AgeX and its then majority-owned subsidiary LifeMap Sciences, Inc. (“LifeMap Sciences”) entered into an Agreement and Plan of Merger (the “LifeMap Merger Agreement”) with Atlas Capital Partners Limited, a British Virgin Islands company limited by shares (“Atlas”), and GCLMS Acquisition Corporation (“GCLMS”), a Delaware corporation that was a wholly-owned subsidiary of Atlas. On March 15, 2021, the merger was completed pursuant to the terms of the LifeMap Merger Agreement. As a result of the merger, GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of a $<span id="xdx_906_ecustom--PaymentOfMergerConsiderationOnProRataPortion_c20210314__20210315__dei--LegalEntityAxis__custom--LifeMapSciencesIncMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zeHIwfZxkR71" title="Payment of merger consideration on pro rata portion">500,000</span> cash payment for all shares of LifeMap Sciences common stock in the aggregate (the “LifeMap Merger Consideration”), with each LifeMap Sciences shareholder’s pro rata portion of the LifeMap Merger Consideration to be determined in accordance with the number of shares of LifeMap Sciences common stock owned by such shareholder as a percentage of shares of LifeMap Sciences common stock outstanding immediately before the effective date of the merger, and (b) the outstanding shares of GCLMS common stock were converted into shares of LifeMap Sciences common stock so that Atlas is now the sole shareholder of LifeMap Sciences.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX received approximately $<span id="xdx_902_ecustom--PaymentOfMergerConsiderationOnProRataPortion_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zkt6kSOqAeYe" title="Payment of merger consideration on pro rata portion">466,400</span> in cash as its pro rata share of the LifeMap Merger Consideration in the merger. Prior to and as a condition to the merger under the terms of the LifeMap Merger Agreement, $<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zOlQGqoUjPWd" title="Debt converted to equity">1,761,296</span> of LifeMap Sciences’ indebtedness to AgeX was converted into shares of LifeMap Sciences common stock. LifeMap Sciences also paid AgeX $<span id="xdx_906_ecustom--PaidInCashPortionOfIndebtedness_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zhcT4eaGfCM8" title="Paid in cash portion of indebtedness">250,000</span> in cash to pay off a portion of LifeMap Sciences’ indebtedness to AgeX that was not converted into shares of LifeMap Sciences common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Accordingly, AgeX has deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from AgeX, effective March 15, 2021 (the “LifeMap Deconsolidation”), in accordance with Accounting Standards Codification (“ASC”) 810-10-40, <i>Consolidation</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 3, <i>Disposition and Deconsolidation of LifeMap Sciences</i> for additional information regarding the disposition and deconsolidation of LifeMap Sciences.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going Concern</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX primarily finances its operations through loans from its largest stockholder Juvenescence. AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $<span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_zSsKZsptDHA3" title="Accumulated deficit">116.2</span> million as of December 31, 2022. AgeX expects to continue to incur operating losses and negative cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have adopted operating plans and budgets to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those operating plans and budgets, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $<span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zHoPNrbkMS4b" title="Cash and cash equivalents">0.6</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of December 31, 2022 plus the loan facilities provided by Juvenescence to advance up to an additional $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20221231__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--LoanFacilityAgreementMember_zk6MZWrfRHTc" title="Line of credit facility, maximum borrowing capacity">1.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for operating capital discussed in Note 11, <i>Subsequent Events</i> and the proceeds we may receive from the sale of additional shares of our common stock in “at-the-market” transactions through a Sales Agreement with Chardan Capital Markets, LLC (“Chardan”) as a sales agent, would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of these consolidated financial statements. These conditions raise substantial doubt about AgeX’s ability to continue as a going concern. AgeX will need to obtain substantial additional funding in connection with its continuing operations. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Principles of Consolidation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements of AgeX are presented in accordance with U.S. GAAP. AgeX’s consolidated financial statements include the accounts of its subsidiaries and certain research and development departments. AgeX consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of stockholders’ deficit on AgeX’s consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s consolidated balance sheets at December 31, 2022 and 2021 do not include LifeMap Sciences’ consolidated assets and liabilities due to the deconsolidation of LifeMap Sciences on March 15, 2021. LifeMap Sciences’ consolidated financial statements and consolidated results of operations include its wholly-owned and consolidated subsidiary, LifeMap Sciences, Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s consolidated statements of operations for the year ended December 31, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the deconsolidation due to the conversion of $<span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zDMTmMPX7gI2" title="Debt converted amount">1,761,296</span> of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021 followed by the completion of the cash-out merger on the same day.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has three subsidiaries, Reverse Bioengineering, Inc. (“Reverse Bio”), ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTR<sup>TM</sup> research and development efforts. To the extent that such financing is obtained through the sale of capital stock or other equity securities to investors or other biopharma companies by Reverse Bio, AgeX’s equity interest in Reverse Bio and its iTR<sup>TM</sup> business would be diluted. ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ReCyteTherapeuticsIncMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgeXMember_zSEBGl20rQZ3" title="Ownership interest">94.8</span>% of the outstanding capital stock of ReCyte. NeuroAirmid is jointly owned by AgeX with the University of California – Irvine and certain researchers and was recently organized to pursue clinical development and commercialization of cell therapies, focusing initially on Huntington’s Disease. AgeX owns <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--NeuroAirmidMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgeXMember_zCBvKGgB27S5" title="Ownership interest">50</span>% of the outstanding capital stock of NeuroAirmid. AgeX consolidates NeuroAirmid despite not having majority ownership interest as it has the ability to influence decision making and financial results through contractual rights and obligations as per ASC 810, <i>Consolidation</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">All material intercompany accounts and transactions between AgeX and its subsidiaries have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, allocations and adjustments necessary for carve-out basis of presentation, including the separate return method for income taxes, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected. See Note 6, <i>Warrant Liability</i> for discussion on estimated change in fair value of warrant liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions with Noncontrolling Interests of Subsidiaries</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX accounts for a change in ownership interests in its subsidiaries that does not result in a change of control of the subsidiary under the provisions of ASC 810-10-45-23, <i>Consolidation – Other Presentation Matters, </i>which prescribes the accounting for changes in ownership interest that do not result in a change in control of the subsidiary, as defined by U.S. GAAP, before and after the transaction. Under this guidance, changes in a controlling stockholder’s ownership interest that do not result in a change of control, as defined by U.S. GAAP, in the subsidiary are accounted for as equity transactions. Accordingly, if the controlling stockholder retains control, no gain or loss is recognized in the statements of operations of the controlling stockholder. Similarly, the controlling stockholder will not record any additional acquisition adjustments to reflect its subsequent purchases of additional shares in the subsidiary if there is no change of control. Only a proportional and immediate transfer of carrying value between the controlling and the noncontrolling stockholders occurs based on the respective ownership percentages.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity and Impact of COVID-19</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in out-licensing its technologies and development of its product candidates. Although AgeX has been able to reduce its operating expenses by eliminating internal research and development activities and focusing instead on out-sourcing research and development and seeking licensing arrangements for AgeX technologies, this approach has also made it more difficult for AgeX to make progress in developing its target product candidates and technologies, which in turn may make it more difficult for AgeX to raise capital. The availability of financing also may be adversely impacted by the COVID-19 pandemic which disrupt aspects of AgeX’s operations. The extent to which the ongoing COVID-19 pandemic will ultimately impact AgeX’s business, results of operations, financial condition, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside AgeX’s control. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its stockholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 14400000 0.056 0.804 0.402 0.056 0.458 12697028 1718972 0.048 500000 466400 1761296 250000 -116200000 600000 1000000.0 1761296 0.948 0.50 <p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zS3ef9QLOOKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span>Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_82D_z1jTZJcrpEc4" style="display: none">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--GoingConcernPolicyTextBlock_zcPgpAxkKhy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zPxafZTpU33g">Going Concern Assessment</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX assesses going concern uncertainty for its consolidated financial statements to determine if AgeX has sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date the consolidated financial statements are issued or are available to be issued, which is referred to as the “look-forward period” as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to AgeX, AgeX will consider various scenarios, forecasts, projections, and estimates, and AgeX will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, AgeX makes certain assumptions concerning its ability to curtail or delay research and development programs and expenditures within the look-forward period in accordance with ASU No. 2014-15 (see Note 1, <i>Organization, Basis of Presentation and Liquidity</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGEJlhvHs4vc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zq0d59PFUu14">Fair Value Measurements of Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. The credit facility is reported at fair value as it bears market rates of interest. Fair values for the AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, <i>Fair Value Measurements and Disclosures</i>):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zRIZekx76Tr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes fair value measurements by level as of December 31, 2022 for liabilities measured at fair value on a recurring basis (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span id="xdx_8B6_zmt8k9doNKD2" style="display: none">Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WarrantLiability_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zW3VWQoRnzhf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--WarrantLiability_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTH6K6Bb2Cca" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--WarrantLiability_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCge5bYEJMtf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif">180</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--WarrantLiability_iI_pn3n3_c20221231_zi3ZE0vjcfaa" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif">180</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zzBg9O1CPltb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no warrant liabilities as of December 31, 2021. See Note 6, <i>Warrant Liability</i> for additional information on accounting for liability classified warrants and level 3 rollforward table.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations, are discussed further in Note 6, <i>Warrant Liability</i>. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zlBSq145qsg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z7fi2ru4E4zh">Cash and Cash Equivalents</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2022 and 2021, AgeX’s cash balances totaled $<span id="xdx_904_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_znZQR5bQnf61" title="Cash and cash equivalents">0.6</span> million and $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zdCQBkpasW8h" title="Cash and cash equivalents">0.6</span> million, respectively, and consist entirely of bank account deposits and amounts held in money market funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zQY2jqcJHDi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span>Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span id="xdx_86B_zDtyaF99nuMg" style="display: none">Concentration of credit risk and other risks and uncertainties</span></i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject AgeX to significant concentrations of credit risk consist primarily of cash and cash equivalents. AgeX limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, AgeX has not experienced any losses on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84C_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zV7la1cqwXq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span>Restricted Cash</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zkQKxafKRnGb" style="display: none">Cash, cash equivalents, and restricted cash</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_zcCitR0cbav" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASU 2016-18, <i>Statement of Cash Flows (Topic 230): Restricted Cash</i>, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zfJtsJEb6N35" style="display: none">Schedule of Cash, Cash Equivalents and Restricted Cash</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_z8HkyuynDur2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zs3RtrJ11yx" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzuPR_zPzAjQ8YEBa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">645</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">584</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RestrictedCashEquivalents_iI_pn3n3_maRCACEzuPR_zAw57Rzsj6Sc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash <sup id="xdx_F4C_z880CvNcgJff">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtRCACEzuPR_zrWLCt0Zwro3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">634</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_zYS4pFtKiC03" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zNqnS89olFLe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits in the consolidated balance sheets.</span></td></tr></table> <p id="xdx_8A2_zy1ckd4DiTna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z1P5F20iQ8z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zJrySDnnpAXh">Accounts Receivable, Net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX establishes an allowance for doubtful accounts based on the evaluation of the collectability of its receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. There were no amounts reserved for doubtful accounts as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zUUsM6aqCSTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z20eRuxDXKjh">Long-Lived Intangible Assets, Net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&amp;D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231_zFlewtAIOT7l" title="Finite lived intangible asset useful life">10</span> years (see Note 4, <i>Selected Balance Sheet Components</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z13FaCWV0q4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_znrOZ89Rgo23">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consist entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of December 31, 2022, there has been no impairment of long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zuTcNo8kgyn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zxGukLrPcQze">Leases</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX accounts for leases in accordance with ASU 2016-02, <i>Leases </i>(Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX, which are: (i) ASU 2018-10, <i>Codification Improvements to Topic 842, Leases,</i> and (ii) ASU 2018-11, <i>Leases (Topic 842): Targeted improvements, </i>using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 3, 2020, AgeX entered into a one-year lease effective January 1, 2021 for <span id="xdx_90A_eus-gaap--NetRentableArea_iI_uSqft_c20201103_zuhDu5Sjd7Ee" title="Office space">135</span> square feet of office space in a building in an office and research park in Alameda, California. Base monthly rent was $<span id="xdx_901_eus-gaap--PaymentsForRent_iT_pp0p0_c20201103__20201103_zlzm4SF0Htfg" title="Payments for rent">947</span> over the lease term. AgeX renewed this lease for 12 months effective January 1, 2022 for base monthly rent of $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20220101__20220101_zrORSjHVTHFj" title="Payments for rent">1,074</span>. In October 2022, AgeX entered into a new 12 month lease for a slightly less space in the same building effective January 1, 2023 for base monthly rent of $<span id="xdx_90D_eus-gaap--PaymentsForRent_pp0p0_c20221001__20221031_zMF2T6JeFuLg" title="Payments for rent">844</span>. AgeX elected to not apply the recognition requirements under ASC 842 and instead recognized the lease payments as lease costs on a straight-line basis over the lease term, as the amount of the lease payments were not deemed material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--AccountingForWarrantsPolicyTextBlock_zzf4todlLdZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zytsy6HR1XB">Accounting for Warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</i>, then in accordance with ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</i>. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of December 31, 2022. See Notes 5, <i>Related Party Transactions</i> and 6, <i>Warrant Liability</i> for additional information regarding AgeX warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zbGsa6JHynFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_z0WMraFADS97">Stock-Based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718, <i>Compensation – Stock Compensation</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under the Incentive Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Black-Scholes option pricing model requires AgeX to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 8, <i>Stock-Based Awards</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the shares of common stock underlying the stock options is determined in accordance with the Incentive Plan and is based on prevailing market prices on the NYSE American where AgeX common stock is traded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. AgeX estimates the expected term of options granted using the “simplified method” provided under <i>Staff Accounting </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bulletin, Topic 14,</i> or SAB Topic 14.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because AgeX’s common stock has public trading history of fewer than five years, AgeX has estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options, which may exceed five years. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of AgeX’s stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dividend yield assumption is based on AgeX’s history and expectation of dividend payouts. AgeX has never declared or paid any cash dividends on its common stock, and AgeX does not anticipate paying any cash dividends in the foreseeable future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense for the years ended December 31, 2022 and 2021 consists of stock-based compensation under the AgeX 2017 Equity Incentive Plan (see Note 8, <i>Stock-Based Awards</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of AgeX’s consolidated subsidiaries have had their own share-based compensation plans; however, there are no awards granted and outstanding under those plans as of December 31, 2022 and 2021. For share-based compensation awards granted by privately held consolidated subsidiaries under their respective equity plans, AgeX determines the fair value of the options granted under those plans using similar methodologies and assumptions AgeX used for its stock options discussed above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although the fair value of stock options and restricted stock units is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zSuDSkgEN2ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zjEAQdzuXTh7">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX accounts for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. AgeX’s judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If AgeX’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on AgeX’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. AgeX recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No unrecognized tax benefits have been recorded and no amounts were accrued for the payment of interest and penalties as of December 31, 2022 and 2021. AgeX does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. AgeX is currently unaware of any tax issues under review.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductions_pid_dp_uPure_c20180101__20181231_zEQU92Rll1G2" title="Deductions">50</span>% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2021, AgeX’s foreign entity operated at a loss; therefore, no GILTI was included in income. For the year ended December 31, 2022, there was no income or loss related to foreign activity as the entity deconsolidated from AgeX on March 15, 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zhyw8m7318Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zufL7CehbtA4">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the applicable paragraphs below, AgeX has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue recognition by source and geography </i>– Revenues are recognized when control of the promised goods or services is transferred to customers, or in the case of governmental entities funding a grant, when allowable expenses are incurred, in an amount that reflects the consideration AgeX or a subsidiary, depending on which company has the customer or the grant, expects to be entitled to in exchange for those goods or services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--DisaggregationOfRevenueTableTextBlock_zRx332HlFOI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents AgeX’s consolidated revenues disaggregated by source for continuing operations (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zntZ7wl1t907" style="display: none">Schedule of Disaggregated of Revenues</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zqpeVkKEuROd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210101__20211231_zSZXWf91r6Q6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">REVENUES:</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--GrantRevenuesMember_zVIRNC3PRrB9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Grant revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0687">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_z0hkuNAJ5Fia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPzynjN2nuSf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AF_z5wOfk6LNZra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zZ2xQiwsoVbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents consolidated revenues for continuing operations (in thousands), disaggregated by geography, based on the billing addresses of customers:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zmEIZKgaAZ87" style="display: none">Schedule of Disaggregated Geographical Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_z3TW51OQI0Ta" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20211231_zXUMuC514Inf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">REVENUES:</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zryMdVOyDK1d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">United States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">107</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--ForeignMember_zXAqlcWQEbg1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqGPIHh64ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AF_z8y7fXOAWSse" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription and advertisement revenues</i> – LifeMap Sciences sold subscription-based products, including research databases and software tools, for biomedical, gene, and disease research. LifeMap Sciences sold these subscriptions primarily through the internet to biotech and pharmaceutical companies worldwide. LifeMap Sciences’ principal subscription product was the GeneCards<sup>® </sup>Suite, which includes the GeneCards<sup>®</sup> human gene database, and the MalaCards™ human disease database. LifeMap Sciences’ performance obligations for subscriptions included a license of intellectual property related to its genetic information packages and premium genetic information tools. These licenses were deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue was recognized over a period of time, which was generally the subscription period. Payments were typically received at the beginning of a subscription period and revenue was recognized according to the type of subscription sold. For subscription contracts in which the subscription term commenced before a payment was due, LifeMap Sciences recorded an account receivable because the subscription was earned over time and billed the customer according to the contract terms. LifeMap Sciences deferred subscription revenues primarily represented subscriptions for which cash payment was received for the subscription term, but the subscription term was not completed as of the balance sheet date reported.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMap Sciences licensed from third parties the databases and software it commercialized and had a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the consolidated statements of operations when the cash was received and the royalty obligation was incurred as the royalty payments did not qualify for capitalization of costs to fulfill a contract under ASC 340-40, <i>Other Assets and Deferred Costs - Contracts with Customers</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMap Sciences recognized $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210101__20211231__srt--ProductOrServiceAxis__custom--SubscriptionAndAdvertisementRevenuesMember_zvzLB73ku6Hc" title="Revenues recognized">0.3</span> million in subscription and advertisement revenues for the year ended December 31, 2021, which is included in operating loss from discontinued operations, and is for revenues earned through March 15, 2021. As a result of the LifeMap Deconsolidation, AgeX does not expect to earn subscription and advertising revenues in subsequent accounting periods. See Note 3, <i>Disposition and Deconsolidation of LifeMap Sciences</i> for further information on the disposition and deconsolidation of LifeMap Sciences.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant revenues –</i> AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, <i>Research and Development Arrangements.</i> At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 8, 2020, AgeX was awarded a grant of up to approximately $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200407__20200408__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zD3ecDluBxrg" title="Revenues">386,000</span> from the National Institutes of Health (“NIH”). The NIH grant provided funding for continued development of AgeX’s technologies for treating stroke. The grant funds were made available by the NIH to AgeX as allowable expenses were incurred. For the year ended December 31, 2021, AgeX incurred approximately $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20211231__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zuK18Kqo8FYa" title="Revenues, net">104,000</span> of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. AgeX recognized no grant revenues for the year ended December 31, 2022 as AgeX had expended the full amount available under this grant as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ESI BIO research products –</i> AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP.” AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products are included in other revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Arrangements with multiple performance obligations –</i> AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of and for the years ended December 31, 2022 and 2021, AgeX did not have significant arrangements with multiple performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvq6dLyXS4j2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zoHW1LD5xODc">Research and Development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses consist primarily of personnel costs and related benefits, stock-based compensation, amortization of intangible assets, and collaborative and contracted research and development fees. Research and development costs which have an alternative future use will be capitalized as intangible assets, and costs with no future benefit or alternative use will be expensed as incurred. Research and development expenses incurred and reimbursed by grants from third parties approximate the grant revenues recognized in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z0jen9CxGb5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zQcJYhcZ1w06">General and Administrative</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses include employee and director compensation allocated to general and administrative expenses, consulting fees other than those paid for science-related consulting, license fees paid to third parties to acquire patents or licenses to use patents and other technology, professional fees to maintain patents and trademarks, minimum annual royalties stipulated under license and sublicense agreements with third parties, insurance costs allocated to general and administrative expenses, stock exchange-related costs, depreciation expense, marketing costs, legal and accounting costs, office rent, and other miscellaneous expenses which are allocated to general and administrative expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zYe7F13Hm1C9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zrsW7PtvQDz4">Foreign Currency Transaction Gains and Losses</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For transactions denominated in other than the functional currency of AgeX or its subsidiaries, AgeX recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zzicS94Z6qmh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zjGgHig1Wjh6">Segments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, AgeX’s executive management team has viewed AgeX’s operations as one segment that includes the research and development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders, oncology, and neurological diseases and disorders, blood and vascular system diseases and disorders, and pluripotent cell technologies. As a result, the financial information disclosed materially represents all of the financial information related to AgeX’s sole operating segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_z8qwfldQ9Jx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zSqeKGutb4mh">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted-average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted-average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2022 and 2021, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zOeM1Hnhwt92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_z2JQ3uZdNv1b" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zm5tzZACJIci" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">3,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z2ZLeTL6QUu1" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">3,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants <sup id="xdx_F4B_zPlB9Sk2S7Ql">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_z0CxZoOeFCQb" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">9,558</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_z3oEkWwGZqr7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">3,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zlfeJdJHs61b" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities">     <span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUSOcWpEipk" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities">     <span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0F_z0x9tIth02D4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_z5JMf5tc41m5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, AgeX issued Juvenescence warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_z5DbNJqM4HBi" title="Warrant to purchase share of common stock">12,129,260</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zrsanWlYtOr8" title="Warrant to purchase share of common stock">3,512,098</span> shares, respectively, of AgeX common stock as consideration for the loan agreements discussed in Note 5, <i>Related Party Transactions</i>.</span></td></tr></table> <p id="xdx_8A2_zNtxNdw0XXlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zf7INKK11lRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zIfA30nPnpPl">Recently Adopted Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)</i>. The amendment in this update addresses how an issuer should account for modifications made to equity-classified written call options. The guidance in the standard requires the issuer to treat a modification of an equity-classified call option that does not cause the instrument to become liability-classified as an exchange of the original call option for a new call option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the call option or as termination of the original call option and issuance of a new call option. The Emerging Issues Task Force (EITF) concluded that the recognition of the modification depends on the nature of the transaction in which a warrant is modified. If there is more than one element in a transaction (for example, if the modification involves both a debt modification and an equity issuance), then the guidance requires the issuer to allocate the effect of the option modification to each element. Amendments in the new standard are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this ASU in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</i>. The amendments in this update require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity’s financial statements. The amendments are effective for all entities within their scope, which excludes not-for-profit entities and employee benefit plans, for financial statements issued for annual periods beginning after December 15, 2021. Early application of the amendment is permitted. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_843_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zfDiI8MhKFT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_znuM2qnz4B95">Recently Issued Accounting Pronouncements Not Yet Adopted</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, </i>and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. ASU 2016-13 is effective for AgeX beginning January 1, 2023 and is not expected to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the FASB issued ASU 2022-02, <i>Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures</i>, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance is effective for AgeX on January 1, 2023, including interim periods. Early adoption is permitted, and the amendment applied prospectively, except for the recognition and remeasurement of troubled debt restructurings. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. AgeX does not expect the adoption of this guidance to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--CoronavirusAidReliefAndEconomicSecurityActPolicyTextBlock_zYPiZQzsVfSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_ziUQyBJwMoJ8">CARES Act</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act but does not expect it to have a material impact to its tax provision or its consolidated financial statements. AgeX obtained a loan under the Paycheck Protection Program under the CARES Act, the repayment of which was forgiven in February 2021.</span></p> <p id="xdx_85E_zE1ie4eCyQ3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--GoingConcernPolicyTextBlock_zcPgpAxkKhy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zPxafZTpU33g">Going Concern Assessment</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX assesses going concern uncertainty for its consolidated financial statements to determine if AgeX has sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date the consolidated financial statements are issued or are available to be issued, which is referred to as the “look-forward period” as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to AgeX, AgeX will consider various scenarios, forecasts, projections, and estimates, and AgeX will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, AgeX makes certain assumptions concerning its ability to curtail or delay research and development programs and expenditures within the look-forward period in accordance with ASU No. 2014-15 (see Note 1, <i>Organization, Basis of Presentation and Liquidity</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGEJlhvHs4vc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zq0d59PFUu14">Fair Value Measurements of Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. The credit facility is reported at fair value as it bears market rates of interest. Fair values for the AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, <i>Fair Value Measurements and Disclosures</i>):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zRIZekx76Tr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes fair value measurements by level as of December 31, 2022 for liabilities measured at fair value on a recurring basis (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span id="xdx_8B6_zmt8k9doNKD2" style="display: none">Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WarrantLiability_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zW3VWQoRnzhf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--WarrantLiability_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTH6K6Bb2Cca" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--WarrantLiability_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCge5bYEJMtf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif">180</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--WarrantLiability_iI_pn3n3_c20221231_zi3ZE0vjcfaa" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif">180</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zzBg9O1CPltb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no warrant liabilities as of December 31, 2021. See Note 6, <i>Warrant Liability</i> for additional information on accounting for liability classified warrants and level 3 rollforward table.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations, are discussed further in Note 6, <i>Warrant Liability</i>. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zRIZekx76Tr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes fair value measurements by level as of December 31, 2022 for liabilities measured at fair value on a recurring basis (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span id="xdx_8B6_zmt8k9doNKD2" style="display: none">Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WarrantLiability_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zW3VWQoRnzhf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--WarrantLiability_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTH6K6Bb2Cca" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--WarrantLiability_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCge5bYEJMtf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif">180</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--WarrantLiability_iI_pn3n3_c20221231_zi3ZE0vjcfaa" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrant liability"><span style="font-family: Times New Roman, Times, Serif">180</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 180000 180000 <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zlBSq145qsg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z7fi2ru4E4zh">Cash and Cash Equivalents</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2022 and 2021, AgeX’s cash balances totaled $<span id="xdx_904_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_znZQR5bQnf61" title="Cash and cash equivalents">0.6</span> million and $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zdCQBkpasW8h" title="Cash and cash equivalents">0.6</span> million, respectively, and consist entirely of bank account deposits and amounts held in money market funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 600000 600000 <p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zQY2jqcJHDi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span>Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span id="xdx_86B_zDtyaF99nuMg" style="display: none">Concentration of credit risk and other risks and uncertainties</span></i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject AgeX to significant concentrations of credit risk consist primarily of cash and cash equivalents. AgeX limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, AgeX has not experienced any losses on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84C_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zV7la1cqwXq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span>Restricted Cash</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zkQKxafKRnGb" style="display: none">Cash, cash equivalents, and restricted cash</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_zcCitR0cbav" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASU 2016-18, <i>Statement of Cash Flows (Topic 230): Restricted Cash</i>, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zfJtsJEb6N35" style="display: none">Schedule of Cash, Cash Equivalents and Restricted Cash</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_z8HkyuynDur2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zs3RtrJ11yx" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzuPR_zPzAjQ8YEBa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">645</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">584</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RestrictedCashEquivalents_iI_pn3n3_maRCACEzuPR_zAw57Rzsj6Sc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash <sup id="xdx_F4C_z880CvNcgJff">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtRCACEzuPR_zrWLCt0Zwro3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">634</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_zYS4pFtKiC03" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zNqnS89olFLe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits in the consolidated balance sheets.</span></td></tr></table> <p id="xdx_8A2_zy1ckd4DiTna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_zcCitR0cbav" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASU 2016-18, <i>Statement of Cash Flows (Topic 230): Restricted Cash</i>, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zfJtsJEb6N35" style="display: none">Schedule of Cash, Cash Equivalents and Restricted Cash</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_z8HkyuynDur2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zs3RtrJ11yx" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzuPR_zPzAjQ8YEBa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">645</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">584</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RestrictedCashEquivalents_iI_pn3n3_maRCACEzuPR_zAw57Rzsj6Sc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash <sup id="xdx_F4C_z880CvNcgJff">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtRCACEzuPR_zrWLCt0Zwro3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">634</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_zYS4pFtKiC03" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zNqnS89olFLe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits in the consolidated balance sheets.</span></td></tr></table> 645000 584000 50000 50000 695000 634000 <p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z1P5F20iQ8z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zJrySDnnpAXh">Accounts Receivable, Net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX establishes an allowance for doubtful accounts based on the evaluation of the collectability of its receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. There were no amounts reserved for doubtful accounts as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zUUsM6aqCSTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z20eRuxDXKjh">Long-Lived Intangible Assets, Net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&amp;D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231_zFlewtAIOT7l" title="Finite lived intangible asset useful life">10</span> years (see Note 4, <i>Selected Balance Sheet Components</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P10Y <p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z13FaCWV0q4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_znrOZ89Rgo23">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consist entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of December 31, 2022, there has been no impairment of long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zuTcNo8kgyn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zxGukLrPcQze">Leases</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX accounts for leases in accordance with ASU 2016-02, <i>Leases </i>(Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX, which are: (i) ASU 2018-10, <i>Codification Improvements to Topic 842, Leases,</i> and (ii) ASU 2018-11, <i>Leases (Topic 842): Targeted improvements, </i>using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 3, 2020, AgeX entered into a one-year lease effective January 1, 2021 for <span id="xdx_90A_eus-gaap--NetRentableArea_iI_uSqft_c20201103_zuhDu5Sjd7Ee" title="Office space">135</span> square feet of office space in a building in an office and research park in Alameda, California. Base monthly rent was $<span id="xdx_901_eus-gaap--PaymentsForRent_iT_pp0p0_c20201103__20201103_zlzm4SF0Htfg" title="Payments for rent">947</span> over the lease term. AgeX renewed this lease for 12 months effective January 1, 2022 for base monthly rent of $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20220101__20220101_zrORSjHVTHFj" title="Payments for rent">1,074</span>. In October 2022, AgeX entered into a new 12 month lease for a slightly less space in the same building effective January 1, 2023 for base monthly rent of $<span id="xdx_90D_eus-gaap--PaymentsForRent_pp0p0_c20221001__20221031_zMF2T6JeFuLg" title="Payments for rent">844</span>. AgeX elected to not apply the recognition requirements under ASC 842 and instead recognized the lease payments as lease costs on a straight-line basis over the lease term, as the amount of the lease payments were not deemed material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 135 947 1074 844 <p id="xdx_84E_ecustom--AccountingForWarrantsPolicyTextBlock_zzf4todlLdZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zytsy6HR1XB">Accounting for Warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</i>, then in accordance with ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</i>. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of December 31, 2022. See Notes 5, <i>Related Party Transactions</i> and 6, <i>Warrant Liability</i> for additional information regarding AgeX warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zbGsa6JHynFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_z0WMraFADS97">Stock-Based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718, <i>Compensation – Stock Compensation</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under the Incentive Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Black-Scholes option pricing model requires AgeX to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 8, <i>Stock-Based Awards</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the shares of common stock underlying the stock options is determined in accordance with the Incentive Plan and is based on prevailing market prices on the NYSE American where AgeX common stock is traded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. AgeX estimates the expected term of options granted using the “simplified method” provided under <i>Staff Accounting </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bulletin, Topic 14,</i> or SAB Topic 14.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because AgeX’s common stock has public trading history of fewer than five years, AgeX has estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options, which may exceed five years. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of AgeX’s stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dividend yield assumption is based on AgeX’s history and expectation of dividend payouts. AgeX has never declared or paid any cash dividends on its common stock, and AgeX does not anticipate paying any cash dividends in the foreseeable future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense for the years ended December 31, 2022 and 2021 consists of stock-based compensation under the AgeX 2017 Equity Incentive Plan (see Note 8, <i>Stock-Based Awards</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of AgeX’s consolidated subsidiaries have had their own share-based compensation plans; however, there are no awards granted and outstanding under those plans as of December 31, 2022 and 2021. For share-based compensation awards granted by privately held consolidated subsidiaries under their respective equity plans, AgeX determines the fair value of the options granted under those plans using similar methodologies and assumptions AgeX used for its stock options discussed above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although the fair value of stock options and restricted stock units is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zSuDSkgEN2ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zjEAQdzuXTh7">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX accounts for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. AgeX’s judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If AgeX’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on AgeX’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. AgeX recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No unrecognized tax benefits have been recorded and no amounts were accrued for the payment of interest and penalties as of December 31, 2022 and 2021. AgeX does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. AgeX is currently unaware of any tax issues under review.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductions_pid_dp_uPure_c20180101__20181231_zEQU92Rll1G2" title="Deductions">50</span>% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2021, AgeX’s foreign entity operated at a loss; therefore, no GILTI was included in income. For the year ended December 31, 2022, there was no income or loss related to foreign activity as the entity deconsolidated from AgeX on March 15, 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> 0.50 <p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zhyw8m7318Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zufL7CehbtA4">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the applicable paragraphs below, AgeX has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue recognition by source and geography </i>– Revenues are recognized when control of the promised goods or services is transferred to customers, or in the case of governmental entities funding a grant, when allowable expenses are incurred, in an amount that reflects the consideration AgeX or a subsidiary, depending on which company has the customer or the grant, expects to be entitled to in exchange for those goods or services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--DisaggregationOfRevenueTableTextBlock_zRx332HlFOI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents AgeX’s consolidated revenues disaggregated by source for continuing operations (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zntZ7wl1t907" style="display: none">Schedule of Disaggregated of Revenues</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zqpeVkKEuROd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210101__20211231_zSZXWf91r6Q6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">REVENUES:</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--GrantRevenuesMember_zVIRNC3PRrB9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Grant revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0687">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_z0hkuNAJ5Fia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPzynjN2nuSf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AF_z5wOfk6LNZra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zZ2xQiwsoVbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents consolidated revenues for continuing operations (in thousands), disaggregated by geography, based on the billing addresses of customers:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zmEIZKgaAZ87" style="display: none">Schedule of Disaggregated Geographical Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_z3TW51OQI0Ta" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20211231_zXUMuC514Inf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">REVENUES:</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zryMdVOyDK1d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">United States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">107</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--ForeignMember_zXAqlcWQEbg1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqGPIHh64ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AF_z8y7fXOAWSse" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription and advertisement revenues</i> – LifeMap Sciences sold subscription-based products, including research databases and software tools, for biomedical, gene, and disease research. LifeMap Sciences sold these subscriptions primarily through the internet to biotech and pharmaceutical companies worldwide. LifeMap Sciences’ principal subscription product was the GeneCards<sup>® </sup>Suite, which includes the GeneCards<sup>®</sup> human gene database, and the MalaCards™ human disease database. LifeMap Sciences’ performance obligations for subscriptions included a license of intellectual property related to its genetic information packages and premium genetic information tools. These licenses were deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue was recognized over a period of time, which was generally the subscription period. Payments were typically received at the beginning of a subscription period and revenue was recognized according to the type of subscription sold. For subscription contracts in which the subscription term commenced before a payment was due, LifeMap Sciences recorded an account receivable because the subscription was earned over time and billed the customer according to the contract terms. LifeMap Sciences deferred subscription revenues primarily represented subscriptions for which cash payment was received for the subscription term, but the subscription term was not completed as of the balance sheet date reported.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMap Sciences licensed from third parties the databases and software it commercialized and had a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the consolidated statements of operations when the cash was received and the royalty obligation was incurred as the royalty payments did not qualify for capitalization of costs to fulfill a contract under ASC 340-40, <i>Other Assets and Deferred Costs - Contracts with Customers</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMap Sciences recognized $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210101__20211231__srt--ProductOrServiceAxis__custom--SubscriptionAndAdvertisementRevenuesMember_zvzLB73ku6Hc" title="Revenues recognized">0.3</span> million in subscription and advertisement revenues for the year ended December 31, 2021, which is included in operating loss from discontinued operations, and is for revenues earned through March 15, 2021. As a result of the LifeMap Deconsolidation, AgeX does not expect to earn subscription and advertising revenues in subsequent accounting periods. See Note 3, <i>Disposition and Deconsolidation of LifeMap Sciences</i> for further information on the disposition and deconsolidation of LifeMap Sciences.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant revenues –</i> AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, <i>Research and Development Arrangements.</i> At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 8, 2020, AgeX was awarded a grant of up to approximately $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200407__20200408__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zD3ecDluBxrg" title="Revenues">386,000</span> from the National Institutes of Health (“NIH”). The NIH grant provided funding for continued development of AgeX’s technologies for treating stroke. The grant funds were made available by the NIH to AgeX as allowable expenses were incurred. For the year ended December 31, 2021, AgeX incurred approximately $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20211231__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zuK18Kqo8FYa" title="Revenues, net">104,000</span> of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. AgeX recognized no grant revenues for the year ended December 31, 2022 as AgeX had expended the full amount available under this grant as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ESI BIO research products –</i> AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP.” AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products are included in other revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Arrangements with multiple performance obligations –</i> AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of and for the years ended December 31, 2022 and 2021, AgeX did not have significant arrangements with multiple performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--DisaggregationOfRevenueTableTextBlock_zRx332HlFOI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents AgeX’s consolidated revenues disaggregated by source for continuing operations (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zntZ7wl1t907" style="display: none">Schedule of Disaggregated of Revenues</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zqpeVkKEuROd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210101__20211231_zSZXWf91r6Q6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">REVENUES:</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--GrantRevenuesMember_zVIRNC3PRrB9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Grant revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0687">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_z0hkuNAJ5Fia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPzynjN2nuSf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 104000 34000 40000 34000 144000 <p id="xdx_89B_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zZ2xQiwsoVbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents consolidated revenues for continuing operations (in thousands), disaggregated by geography, based on the billing addresses of customers:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zmEIZKgaAZ87" style="display: none">Schedule of Disaggregated Geographical Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_z3TW51OQI0Ta" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20211231_zXUMuC514Inf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">REVENUES:</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zryMdVOyDK1d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">United States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">107</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--ForeignMember_zXAqlcWQEbg1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqGPIHh64ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 10000 107000 24000 37000 34000 144000 300000 386000 104000 <p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvq6dLyXS4j2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zoHW1LD5xODc">Research and Development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses consist primarily of personnel costs and related benefits, stock-based compensation, amortization of intangible assets, and collaborative and contracted research and development fees. Research and development costs which have an alternative future use will be capitalized as intangible assets, and costs with no future benefit or alternative use will be expensed as incurred. Research and development expenses incurred and reimbursed by grants from third parties approximate the grant revenues recognized in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z0jen9CxGb5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zQcJYhcZ1w06">General and Administrative</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses include employee and director compensation allocated to general and administrative expenses, consulting fees other than those paid for science-related consulting, license fees paid to third parties to acquire patents or licenses to use patents and other technology, professional fees to maintain patents and trademarks, minimum annual royalties stipulated under license and sublicense agreements with third parties, insurance costs allocated to general and administrative expenses, stock exchange-related costs, depreciation expense, marketing costs, legal and accounting costs, office rent, and other miscellaneous expenses which are allocated to general and administrative expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zYe7F13Hm1C9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zrsW7PtvQDz4">Foreign Currency Transaction Gains and Losses</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For transactions denominated in other than the functional currency of AgeX or its subsidiaries, AgeX recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zzicS94Z6qmh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zjGgHig1Wjh6">Segments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, AgeX’s executive management team has viewed AgeX’s operations as one segment that includes the research and development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders, oncology, and neurological diseases and disorders, blood and vascular system diseases and disorders, and pluripotent cell technologies. As a result, the financial information disclosed materially represents all of the financial information related to AgeX’s sole operating segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_z8qwfldQ9Jx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zSqeKGutb4mh">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted-average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted-average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2022 and 2021, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zOeM1Hnhwt92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_z2JQ3uZdNv1b" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zm5tzZACJIci" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">3,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z2ZLeTL6QUu1" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">3,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants <sup id="xdx_F4B_zPlB9Sk2S7Ql">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_z0CxZoOeFCQb" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">9,558</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_z3oEkWwGZqr7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">3,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zlfeJdJHs61b" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities">     <span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUSOcWpEipk" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities">     <span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0F_z0x9tIth02D4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_z5JMf5tc41m5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, AgeX issued Juvenescence warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_z5DbNJqM4HBi" title="Warrant to purchase share of common stock">12,129,260</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zrsanWlYtOr8" title="Warrant to purchase share of common stock">3,512,098</span> shares, respectively, of AgeX common stock as consideration for the loan agreements discussed in Note 5, <i>Related Party Transactions</i>.</span></td></tr></table> <p id="xdx_8A2_zNtxNdw0XXlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zOeM1Hnhwt92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_z2JQ3uZdNv1b" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zm5tzZACJIci" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">3,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z2ZLeTL6QUu1" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">3,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants <sup id="xdx_F4B_zPlB9Sk2S7Ql">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_z0CxZoOeFCQb" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">9,558</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_z3oEkWwGZqr7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif">3,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zlfeJdJHs61b" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities">     <span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUSOcWpEipk" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Anti-dilutive securities">     <span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0F_z0x9tIth02D4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_z5JMf5tc41m5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, AgeX issued Juvenescence warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_z5DbNJqM4HBi" title="Warrant to purchase share of common stock">12,129,260</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zrsanWlYtOr8" title="Warrant to purchase share of common stock">3,512,098</span> shares, respectively, of AgeX common stock as consideration for the loan agreements discussed in Note 5, <i>Related Party Transactions</i>.</span></td></tr></table> 3297000 3145000 9558000 3492000 10000 23000 12129260 3512098 <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zf7INKK11lRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zIfA30nPnpPl">Recently Adopted Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)</i>. The amendment in this update addresses how an issuer should account for modifications made to equity-classified written call options. The guidance in the standard requires the issuer to treat a modification of an equity-classified call option that does not cause the instrument to become liability-classified as an exchange of the original call option for a new call option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the call option or as termination of the original call option and issuance of a new call option. The Emerging Issues Task Force (EITF) concluded that the recognition of the modification depends on the nature of the transaction in which a warrant is modified. If there is more than one element in a transaction (for example, if the modification involves both a debt modification and an equity issuance), then the guidance requires the issuer to allocate the effect of the option modification to each element. Amendments in the new standard are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this ASU in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</i>. The amendments in this update require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity’s financial statements. The amendments are effective for all entities within their scope, which excludes not-for-profit entities and employee benefit plans, for financial statements issued for annual periods beginning after December 15, 2021. Early application of the amendment is permitted. AgeX adopted this standard as of January 1, 2022, and it did not have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_843_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zfDiI8MhKFT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_znuM2qnz4B95">Recently Issued Accounting Pronouncements Not Yet Adopted</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, </i>and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. ASU 2016-13 is effective for AgeX beginning January 1, 2023 and is not expected to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the FASB issued ASU 2022-02, <i>Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures</i>, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance is effective for AgeX on January 1, 2023, including interim periods. Early adoption is permitted, and the amendment applied prospectively, except for the recognition and remeasurement of troubled debt restructurings. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. AgeX does not expect the adoption of this guidance to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--CoronavirusAidReliefAndEconomicSecurityActPolicyTextBlock_zYPiZQzsVfSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_ziUQyBJwMoJ8">CARES Act</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act but does not expect it to have a material impact to its tax provision or its consolidated financial statements. AgeX obtained a loan under the Paycheck Protection Program under the CARES Act, the repayment of which was forgiven in February 2021.</span></p> <p id="xdx_807_eus-gaap--ClosedBlockDisclosureTextBlock_zAyqDjxeBH0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_82D_zpNSYSVg8Gk2">Disposition and Deconsolidation of LifeMap Sciences</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Discontinued Operations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2021, AgeX and LifeMap Sciences entered into the LifeMap Merger Agreement with Atlas and GCLMS. On March 15, 2021, the merger was completed pursuant to the terms of the LifeMap Merger Agreement. As a result of the merger, GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of the $<span id="xdx_90B_ecustom--PaymentOfMergerConsiderationOnProRataPortion_c20210314__20210315__dei--LegalEntityAxis__custom--LifeMapSciencesIncMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zFLjMC6UqjCg" title="Payment of merger consideration on pro rata portion">500,000</span> total LifeMap Merger Consideration, with each LifeMap Sciences shareholder’s pro rata portion of the LifeMap Merger Consideration determined in accordance with the number of shares of LifeMap Sciences common stock owned by such shareholder as a percentage of shares of LifeMap Sciences common stock outstanding immediately before the effective date of the merger, and (b) the outstanding shares of GCLMS common stock were converted into shares of LifeMap Sciences common stock so that Atlas is now the sole shareholder of LifeMap Sciences.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX received approximately $<span id="xdx_90C_ecustom--PaymentOfMergerConsiderationOnProRataPortion_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_znmi4JRlyBKk" title="Payment of merger consideration on pro rata portion">466,400</span> in cash as its pro rata share of the LifeMap Merger Consideration in the merger. Prior to and as a condition to the merger under the terms of the LifeMap Merger Agreement, $<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z9ufetsxmcLf" title="Debt converted to equity">1,761,296</span> of LifeMap Sciences’ indebtedness to AgeX was converted into shares of LifeMap Sciences common stock. LifeMap Sciences also paid AgeX $<span id="xdx_90E_ecustom--PaidInCashPortionOfIndebtedness_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zSHM7VTgq3Kj" title="Paid in cash portion of indebtedness">250,000</span> in cash to pay off a portion of LifeMap Sciences’ indebtedness to AgeX that was not converted into shares of LifeMap Sciences common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results of operations and cash flows for LifeMap Sciences are reported as discontinued operations under U.S. GAAP in accordance with ASC 205-20, <i>Discontinued Operations</i>, for all periods presented in our consolidated financial statements. AgeX will not have any continuing involvement in LifeMap Sciences subsequent to the consummation of the merger on March 15, 2021. The following table presents the operating results of LifeMap Sciences that have been treated as discontinued operations for the periods presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zTMVt4K8aupd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zazUlluNsoIk" style="display: none">Schedule of Discontinued Operations</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20210101__20211231_z2wnwRbOdidk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_maILFDOzMfN_zf2o2SKiVpm6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">277</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_iN_pn3n3_di_msILFDOzMfN_zqt9vFJb7HNg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Costs, operating and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(380)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_mtILFDOzMfN_maILFDOz37X_zDLgWxIaS2J3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss from discontinued operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(103)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_iN_pn3n3_di_msILFDOz37X_zAHYYtPUrI53" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss from discontinued operations attributable to noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_iT_pn3n3_mtILFDOz37X_zHTSYOKto3k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from discontinued operations <sup id="xdx_F45_zOi3rb4tStPb">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(96)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zFToMGmsd6n2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zZwWIJKvT6j3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not include $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIERpc2NvbnRpbnVlZCBPcGVyYXRpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--DeconsolidationGainOrLossAmount_pp0p0_c20210101__20211231_zNXsc0zcYCw2" title="Deconsolidation, gain (loss), amount">106,000</span> gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement. The gain on the sale of LifeMap Sciences is presented in the line item <i>Gain on deconsolidation of LifeMap Sciences</i>. There were no gains or losses resulting from the sale of businesses or assets that did not meet the criteria for a discontinued operation during the year ended December 31, 2021.</span></td></tr></table> <p id="xdx_8AC_zRX4eeebfAmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deconsolidation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Effective March 15, 2021, AgeX deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from those of AgeX under U.S. GAAP ASC 810-10-40-4, <i>Deconsolidation of a Subsidiary or Derecognition of a Group of Assets</i>, due to the disposition of LifeMap Sciences on that date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s consolidated balance sheets at December 31, 2022 and 2021 do not include LifeMap Sciences’ consolidated assets and liabilities due to the deconsolidation of LifeMap Sciences on March 15, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s consolidated statement of operations for the year ended December 31, 2021 includes LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the LifeMap Deconsolidation due to the conversion of $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zuB3TWp2JeU8" title="Debt converted to equity">1,761,296</span> of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021 followed by the completion of the cash-out merger on the same day.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognized a gain of $<span id="xdx_90A_eus-gaap--DeconsolidationGainOrLossAmount_c20210101__20211231_zRiG3eLtg6Pa" title="Deconsolidation, gain (loss), amount">106,000</span> from the LifeMap Deconsolidation. The sale of LifeMap Sciences was a taxable transaction to AgeX; however, no income tax is due as the transaction resulted in a taxable loss primarily due to AgeX’s tax basis in the subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 500000 466400 1761296 250000 <p id="xdx_890_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zTMVt4K8aupd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zazUlluNsoIk" style="display: none">Schedule of Discontinued Operations</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20210101__20211231_z2wnwRbOdidk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_maILFDOzMfN_zf2o2SKiVpm6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">277</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_iN_pn3n3_di_msILFDOzMfN_zqt9vFJb7HNg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Costs, operating and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(380)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_mtILFDOzMfN_maILFDOz37X_zDLgWxIaS2J3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss from discontinued operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(103)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_iN_pn3n3_di_msILFDOz37X_zAHYYtPUrI53" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss from discontinued operations attributable to noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_iT_pn3n3_mtILFDOz37X_zHTSYOKto3k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from discontinued operations <sup id="xdx_F45_zOi3rb4tStPb">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(96)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zFToMGmsd6n2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zZwWIJKvT6j3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not include $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIERpc2NvbnRpbnVlZCBPcGVyYXRpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--DeconsolidationGainOrLossAmount_pp0p0_c20210101__20211231_zNXsc0zcYCw2" title="Deconsolidation, gain (loss), amount">106,000</span> gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement. The gain on the sale of LifeMap Sciences is presented in the line item <i>Gain on deconsolidation of LifeMap Sciences</i>. There were no gains or losses resulting from the sale of businesses or assets that did not meet the criteria for a discontinued operation during the year ended December 31, 2021.</span></td></tr></table> 277000 380000 -103000 -7000 -96000 106000 1761296 106000 <p id="xdx_80C_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zk060BFrFbZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_823_z7CTr5VnkeUe">Selected Balance Sheet Components</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intangible Assets, Net</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 13, 2018, AgeX entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Escape Therapeutics, Inc. (“Escape”) pursuant to which AgeX acquired certain patents and patent applications related primarily to methods of modifying cells and tissues and certain pluripotent stem cell lines so as to reduce their risk of being rejected when transplanted. This technology is called “UniverCyte™.” AgeX paid Escape $<span id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_c20180812__20180813__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zk9yQdDBm5la" title="Payments to acquire businesses">1,072,436</span> in cash and issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20180812__20180813__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zB4NWYUZqyA1" title="Number of shares issued for acquired, shares">80,000</span> shares of AgeX common stock, with an approximate value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20180812__20180813__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zXjx5EhRdUm2" title="Number of shares issued for aquired">240,000</span>, for aggregate acquisition cost of $<span id="xdx_906_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20180812__20180813__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zQ6Na9YS0PPl" title="Aggregate of acquisition cost">1.3</span> million for the UniverCyte™ assets. The Purchase Agreement was considered an asset acquisition rather than a business combination in accordance with ASC 805-50, <i>Business Combinations</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 730-10-25(c), <i>Research and Development – Intangible Assets Purchased from Others</i>, provides guidance for acquisition and capitalization of the cost of intangible assets purchased from others in an asset acquisition that have alternative future uses in other research and development projects. These intangible assets are referred to as acquired IPR&amp;D with alternative future uses and are accounted for as intangible assets and amortized to research and development over their useful life. Acquired IPR&amp;D in an asset acquisition that does not have any alternative future uses is expensed under the same guidance. As an initial focus, AgeX intends to use the UniverCyte™ technology in the development of its two lead products, AGEX-BAT1 and AGEX-VASC1 for the treatment of Type II diabetes and cardiovascular aging, respectively. Accordingly, AgeX recorded the UniverCyte™ technology acquired from Escape as IPR&amp;D intangible assets with alternative future uses in accordance with ASC 730-10-25(c) and is amortizing those assets to research and development expense over their estimated <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231_znEUsmBikGA1" title="Estimated useful life">10</span>-year useful life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the purchase price, AgeX will pay Escape a royalty of less than <span id="xdx_90B_ecustom--RoyaltyPercentages_pid_dp_uPure_c20220101__20221231_zU01L5QxIAwg" title="Royalty percentage">1</span>% on net sales of products, processes and services under the acquired patents, if the assets are commercialized. Additional shares of AgeX common stock totaling up to $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220101__20221231_z29mlDGMGJhb" title="Value of common stock issued for acquisition">4.3</span> million of market value will also be issued to Escape upon the attainment of development and regulatory approval milestones by AgeX for each product covered by the acquired patents. Contingent consideration in an asset acquisition is generally recorded when probable and estimable in accordance with ASC 450, <i>Contingencies</i>. Accordingly, none of the milestone payments have been accrued since the attainment of any milestone in the Purchase Agreement was not probable as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has also agreed to engage Escape’s chief executive officer as a consultant for a period of up to three years to assist AgeX in utilizing the acquired patents. AgeX paid $<span id="xdx_90F_eus-gaap--ProfessionalFees_c20210801__20210831__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchAndDevelopmentMember_zMp9LBWZjJ56" title="Consulting fees and services">200,000</span> per year in consulting fees as services were performed, included in research and development expenses up until the agreement expired in August 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX estimated the future undiscounted cash flows expected to be received from the assets developed through the use of the UniverCyte™ technology when commercialized. The estimate of the future undiscounted cash flows considered AgeX’s financial condition and the royalties that may become payable to Escape.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zAewhbfF8nk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022 and 2021, intangible assets, primarily consisting of acquired IPR&amp;D and patents, and accumulated amortization were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zgpYLNEKpRf7" style="display: none">Schedule of Intangible Assets, Net</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zWNA8og1aG91" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20211231_zoGdQqRlSp0k" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANz8a7_zBG8Um2emDB6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,312</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,312</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANz8a7_z8okWIAMfCJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(574)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(442)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr id="xdx_400_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_pn3n3_mtFLIANz8a7_z8KJc8T30vd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">870</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zAo24s0VFkqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognized $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_z5TByi6HQ0Zc" title="Amortization expense of intangible assets">132,000</span> and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231_zQjWVr0WfgLa" title="Amortization expense of intangible assets">131,000</span> in amortization expense of intangible assets for continuing operations, included in research and development expenses, for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense of intangible assets for discontinued operations for the year ended December 31, 2021 amounted to $<span id="xdx_904_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20210101__20211231_zvhSHXwUqfN2" title="Amortization of intangible assets for discontinued operations">89,000</span>. See Note 3, <i>Disposition and Deconsolidation of LifeMap Sciences</i> for discussion of discontinued operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zQOHIyUKESol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of intangible assets for periods subsequent to December 31, 2022 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zgPJRkoCgw35" style="display: none">Schedule of Amortization Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20221231_zh6jW5qxZ286" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzFZe_zohWVtxNnkN5" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzFZe_zJ42UOyBlST9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzFZe_z0Pl8zSgjMy9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">132</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzFZe_zxpPIutPAqOa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzFZe_zPujHuQTwbnf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzFZe_zmBSJSOu7Ksb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">213</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree_iI_pn3n3_maFLIANzFZe_zIvYBqUFyyv6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzFZe_zyNaVfr5CsL2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zljQtGu9CSeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts Payable and Accrued Liabilities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zZx70Lr1vxjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022 and 2021, accounts payable and accrued liabilities were comprised of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zn3f5X6uGjnh" style="display: none">Schedule of Accounts Payable and Accrued Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231_zigaD4No5q85" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231_zNzT2pydOHMi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maAPAALzgAT_z0F1fFYT6mE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">568</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AccruedBonusesCurrent_iI_pn3n3_maAPAALzgAT_zVF5RByBLPue" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">212</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzgAT_zGY8j3oKeoA6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued vendors and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">273</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">366</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzgAT_zdbu1qNpZ0of" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable and accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">771</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A7_zXlVhFIGiWN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1072436 80000 240000 1300000 P10Y 0.01 4300000 200000 <p id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zAewhbfF8nk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022 and 2021, intangible assets, primarily consisting of acquired IPR&amp;D and patents, and accumulated amortization were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zgpYLNEKpRf7" style="display: none">Schedule of Intangible Assets, Net</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zWNA8og1aG91" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20211231_zoGdQqRlSp0k" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANz8a7_zBG8Um2emDB6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,312</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,312</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANz8a7_z8okWIAMfCJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(574)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(442)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr id="xdx_400_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_pn3n3_mtFLIANz8a7_z8KJc8T30vd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">870</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1312000 1312000 574000 442000 738000 870000 132000 131000 89000 <p id="xdx_893_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zQOHIyUKESol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of intangible assets for periods subsequent to December 31, 2022 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zgPJRkoCgw35" style="display: none">Schedule of Amortization Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20221231_zh6jW5qxZ286" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzFZe_zohWVtxNnkN5" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzFZe_zJ42UOyBlST9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzFZe_z0Pl8zSgjMy9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">132</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzFZe_zxpPIutPAqOa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzFZe_zPujHuQTwbnf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzFZe_zmBSJSOu7Ksb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">213</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree_iI_pn3n3_maFLIANzFZe_zIvYBqUFyyv6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzFZe_zyNaVfr5CsL2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 131000 132000 131000 131000 213000 738000 <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zZx70Lr1vxjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022 and 2021, accounts payable and accrued liabilities were comprised of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zn3f5X6uGjnh" style="display: none">Schedule of Accounts Payable and Accrued Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231_zigaD4No5q85" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231_zNzT2pydOHMi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maAPAALzgAT_z0F1fFYT6mE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">568</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AccruedBonusesCurrent_iI_pn3n3_maAPAALzgAT_zVF5RByBLPue" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">212</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzgAT_zGY8j3oKeoA6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued vendors and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">273</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">366</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzgAT_zdbu1qNpZ0of" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable and accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">771</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 568000 193000 193000 212000 273000 366000 1034000 771000 <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zqhGNoi91W12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_82A_ziy06VzfZzL7">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2019 Loan Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence provided to AgeX a $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn5n6_c20190812__20190813__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember_zdrxVpQi8dt6" title="Line of credit facility">2.0</span> million line of credit for a period of <span id="xdx_907_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20190812__20190813__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember_zrev1EUh38r6" title="Line of credit, term">18</span> months. On February 10, 2021, AgeX entered into an amendment (the “First Amendment”) to the 2019 Loan Agreement which extended the maturity date of loans under the 2019 Loan Agreement to February 14, 2022 and increased the amount of the loan facility by $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn5n6_c20210209__20210210__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember_zIXiupnYtgSb" title="Increase in line of credit">4.0</span> million. On November 8, 2021, AgeX entered into Amendment No. 2 to the 2019 Loan Agreement which increased the amount of the loan facility by another $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn6n6_c20211107__20211108__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zvJqZCEgQff4" title="Increase in line of credit">1.0</span> million. As of December 31, 2021, AgeX had borrowed all of the $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20211108__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zA8iMwkDhjs1" title="Line of credit facility">7.0</span> million total line of credit under the 2019 Loan Agreement, as amended. On February 14, 2022, AgeX refinanced the $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zznrObE6tpJc" title="Line of credit facility">7.0</span> million outstanding principal amount of the loans and a $<span id="xdx_90C_eus-gaap--DebtInstrumentFeeAmount_iI_pn3p0_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_znGjBQKvGfSk" title="Origination Fee">160,000</span> origination fee due under the 2019 Loan Agreement, as amended. See discussion regarding 2022 Secured Convertible Promissory Note within this Note 5.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>2020 Loa<span style="font-size: 10pt">n Agreement</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence provided to AgeX an $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zswBNCfU3Hji">8.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million line of credit for a period of <span id="xdx_907_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20200329__20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zIWnOeO2KlJj">18</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">months. Through December 31, 2022, AgeX had drawn the full $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zuv6F4cxDpld">8.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million line of credit. AgeX issued to Juvenescence <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200329__20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zKM9B9D2bIca">28,500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of AgeX common stock as an arrangement fee for the loan facility when AgeX borrowed an aggregate of $<span id="xdx_904_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn5n6_c20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_z5VHD46bBmQd">3.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million under the 2020 Loan Agreement, and AgeX issued to Juvenescence warrants to purchase a total of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zMcLh0yWDU1l">3,670,663 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of AgeX common stock (“2020 Warrants”). The number of 2020 Warrants issued was determined by the warrant formula described below. The repayment date for the outstanding principal balance of the loan under the 2020 Loan Agreement will be <span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20200329__20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zBG1JgQJHLY2">March 30, 2024</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(see Note 11, <i>Subsequent Events</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Default Provisions –</i> The loan balance may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the 2020 Loan Agreement include the following: (i) AgeX fails to pay any amount in the manner and at the time provided in the 2020 Loan Agreement and the failure to pay is not remedied within 10 business days; (ii) AgeX fails to perform any of its obligations under the 2020 Loan Agreement and if the failure can be remedied it is not remedied to the satisfaction of Juvenescence within 10 business days after notice to AgeX; (iii) <span id="xdx_90B_eus-gaap--LineOfCreditFacilityDescription_c20200329__20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zQlLKXPDTA49" title="Line of credit facility, description">other indebtedness for money borrowed in excess of $100,000 becomes due and payable or can be declared due and payable prior to its due date or if indebtedness for money borrowed in excess of $25,000 is not paid when due</span>; (iv) AgeX stops payment of its debts generally or discontinues its business or becomes unable to pay its debts as they become due or enters into any arrangement with creditors generally; (v) AgeX becoming insolvent or in liquidation or administration or other insolvency procedures, or a receiver, trustee or similar officer is appointed in respect of all or any part of its assets and such appointment continues undischarged or unstayed for sixty days; (vi) it becomes illegal for AgeX to perform its obligations under the 2020 Loan Agreement or any governmental permit, license, consent, exemption or similar requirement for AgeX to perform its obligations under the 2020 Loan Agreement or to carry out its business is not obtained or ceases to remain in effect; (vii) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX if such process is not released, vacated or fully bonded within sixty calendar days after its issue or levy; (viii) any injunction, order or judgement of any court is entered or issued which in the opinion of Juvenescence materially and adversely affects the ability of AgeX to carry out its business or to pay amounts owed to Juvenescence under the 2020 Loan Agreement; (ix) there is a change in AgeX’s financial condition that in the opinion of Juvenescence materially and adversely affects, or is likely to so affect, its ability to perform any of its obligations under the 2020 Loan Agreement; (x) AgeX or a designated subsidiary sells, leases, licenses, consigns, transfers, or otherwise disposes of a material part of their assets other than inventory in the ordinary course of business or certain intercompany transactions, or certain other limited permitted transactions, unless Juvenescence approves; (xi) AgeX or a designated subsidiary contests the validity of its obligations under the 2020 Loan Agreement or other related agreement with Juvenescence; (xii) any representation, warranty, or other statement made by AgeX or a designated subsidiary under the 2020 Loan Agreement is incomplete, untrue, incorrect, or misleading: and (xiii) AgeX or a designated subsidiary suspends or ceases to carry on all or a material part of its business or threatens to do so.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020 Warrants —</i> Under the terms of the 2020 Loan Agreement, each time AgeX received an advance of funds under the 2020 Loan Agreement, AgeX issued to Juvenescence a number of 2020 Warrants equal to 50% of the number determined by dividing the amount of the advance by the applicable Market Price. The Market Price set each 2020 Warrant when issued was the closing price per share of AgeX common stock on the NYSE American on the date of the applicable notice from AgeX requesting a draw of funds that triggered the obligation to issue the 2020 Warrant. The exercise price of the 2020 Warrants is the applicable Market Price. The 2020 Warrants will expire at 5:00 p.m. New York time three years after the date of issue. As of December 31, 2022, AgeX had issued to Juvenescence 2020 Warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgMLd8W9kZJi" title="Sale of warrants purchase of common stock">3,670,663</span> shares of AgeX common stock. The exercise prices of the 2020 Warrants issued through December 31, 2022 range from $<span id="xdx_90E_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zkouEfxxXlUa" title="Warrants exercise price, minimum">0.70</span> per share to $<span id="xdx_908_eus-gaap--WarrantExercisePriceIncrease_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zUSJUlYwblJa" title="Warrants exercise price, maximum">1.895</span> per share representing the market closing price on the NYSE American of AgeX common stock on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion of Loan Amounts to Common Stock –</i> In lieu of repayment of funds borrowed, AgeX may convert the loan balance into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z52U7sXgfR6h" title="Proceeds from issuance costs">10,000,000</span>. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022 Secured Convertible Promissory Note and Security Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence agreed to provide to AgeX a $<span id="xdx_902_eus-gaap--LineOfCredit_iI_pn3d_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zrZKtMSm79P1" title="Line of credit facility">13,160,000</span> line of credit for a period of <span id="xdx_902_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20220214__20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zMW5T1ZLC1a6" title="Line of credit, term">12</span> months. AgeX drew an initial $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3p0_c20220214__20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zr9oSSRkQOKj" title="Line of credit facility">8,160,000</span> of the line of credit and used $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3p0_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zghlEd52UFd8" title="Line of credit facility">7,160,000</span> to refinance the outstanding principal and the loan origination fees under the 2019 Loan Agreement with Juvenescence. During the year ended December 31, 2022, AgeX borrowed an additional $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn5n6_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zt8sf7A7ptVf" title="Increase in line of credit">4.5</span> million under the Secured Note. During January 2023, AgeX borrowed an additional $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20230101__20230131__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBdwOSsNiis4" title="Increase in line of credit">500,000</span> under the Secured Note and during February 2023 the Secured Note was amended and restated to increase the total line of credit available by $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3p0_c20230228__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTAxFyeSeINl" title="Line of credit facility">2,000,000</span> and the date by which additional funds can be drawn was extended to May 9, 2023. The outstanding principal balance of the Secured Note, as amended will become due and payable on <span id="xdx_90C_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zSF5TQuDVCM2" title="Line of credit, expiry date">February 14, 2024</span>. See Note 11, <i>Subsequent Events</i> for additional information on the amended and restated Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As an arrangement fee for the Secured Note, AgeX will pay Juvenescence an origination fee in an amount equal to 4% of the amount each draw of loan funds, which will accrue as each draw is funded, and an additional 4% of all the total amount of funds drawn that will accrue following the end of the period during which funds may be drawn from the line of credit. The origination fee will become due and payable on the repayment date or in a pro rata amount with any prepayment of in whole or in part of the outstanding principal balance of the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022 Warrants – </i>Upon each drawdown of funds under the Secured Note, AgeX will issue to Juvenescence warrants to purchase shares of AgeX common stock (“2022 Warrants”). The 2022 Warrants will be governed by the terms of a Warrant Agreement between AgeX and Juvenescence. The number of 2022 Warrants to be issued will be equal to <span id="xdx_909_ecustom--WarrantsIssuedPercentage_pid_dp_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoWarrantsMember_zRLX3SK7a995" title="Warrants issued percentage">50</span>% of the number determined by dividing the amount of the applicable loan draw by the applicable Market Price. The Market Price will be the last closing price per share of AgeX common stock on the NYSE American or other national securities exchange preceding the delivery of the notice from AgeX requesting a draw of funds that triggers the obligation to issue 2022 Warrants; provided, however that if AgeX common stock is not traded on a national securities exchange the Market Price shall be determined with reference to closing prices quoted or bid and asked prices on an interdealer quotation system averaged over twenty consecutive trading days. The exercise price of the 2022 Warrants will be the applicable Market Price. The 2022 Warrants will expire at 5:00 p.m. New York time three years after the date of issue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, AgeX had issued to Juvenescence 2022 Warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoWarrantsMember_z8TXglW8vRt5" title="Warrant to purchase share of common stock">8,458,597</span> shares of AgeX common stock. The exercise prices of the 2022 Warrants issued through December 31, 2022 range from $<span id="xdx_90A_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoWarrantsMember_zxSFViwajy8d" title="Warrants exercise price, minimum">0.59</span> per share to $<span id="xdx_909_eus-gaap--WarrantExercisePriceIncrease_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoWarrantsMember_z2O3C3IXU0nj" title="Warrants exercise price, maximum">0.88</span> per share representing the market closing price of AgeX common stock on the NYSE American on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion of Loan Amounts to Common Stock –</i> In lieu of repayment of funds borrowed, AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3GzbWd9CG2e">10,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Default Provisions –</i> The loan balance and origination fees may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the Secured Note include the following: (a) AgeX fails to pay any principal amount payable by it in the manner and at the time provided under and in accordance with the Secured Note; (b) AgeX fails to pay any other amount payable by it in the manner and at the time provided under and in accordance with the Secured Note or the Security Agreement described below or any other agreement executed in connection with the Secured Note (the “Loan Documents”) and the failure is not remedied within three business days; (c) AgeX fails to perform any of its covenants or obligations or fail to satisfy any of the conditions under the Secured Note or any other Loan Document and, such failure (if capable of remedy) remains unremedied to the satisfaction of Juvenescence (in its sole discretion) for 10 business days after the earlier of (i) notice requiring its remedy has been given by Juvenescence to AgeX and (ii) actual knowledge of the failure by senior officers of AgeX; (d) <span id="xdx_908_eus-gaap--LineOfCreditFacilityDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zbx8ETjbBVJ3" title="Line of credit facility, description">if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date</span>; (e) AgeX stops payment of its debts generally or ceases or threatens to cease to carry on its business or is unable to pay its debts as they fall due or is deemed by a court of competent jurisdiction to be unable to pay its debts as they fall due, or enters into any arrangements with its creditors generally; (f) if (i) an involuntary proceeding (other than a proceeding instituted by Juvenescence or an affiliate of Juvenescence) shall be commenced or an involuntary petition shall be filed seeking liquidation, reorganization or other relief in respect of AgeX and any subsidiary, or of all or a substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) an involuntary appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for AgeX or a subsidiary or for a substantial part of its assets occurs (other than in a proceeding instituted by Juvenescence or an affiliate of Juvenescence), and, in any such case, such proceeding shall continue undismissed and unstayed for sixty (60) consecutive days without having been dismissed, bonded or discharged or an order of relief is entered in any such proceeding; (g) it becomes unlawful for AgeX to perform all or any of its obligations under the Secured Note or any authorization, approval, consent, license, exemption, filing, registration or other requirement of any governmental, judicial or public body or authority necessary to enable AgeX to comply with its obligations under the Secured Note or to carry on its business is not obtained or, having been obtained, is modified in a manner that precludes AgeX or its subsidiaries from conducting their business in any material respect, or is revoked, suspended, withdrawn or withheld or fails to remain in full force and effect; (h) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX or a subsidiary if such process is not released, vacated or fully bonded within 60 calendar days after its issue or levy; (i) any injunction, order, judgment or decision of any court is entered or issued which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX or a subsidiary to carry on its business or to pay amounts owed to Juvenescence under the Secured Note; (j) AgeX, whether in a single transaction or a series of related transactions, sells, leases, licenses, consigns, transfers or otherwise disposes of any material portion of its assets (with any such disposition with respect to any asset or assets with a fair value of at least $<span id="xdx_90E_eus-gaap--CommonStockHeldBySubsidiary_iI_c20221231_z2hEfq1k2Q24" title="Common stock held">250,000</span> being deemed material), other than (i) certain permitted investments (ii) sales, transfers and dispositions of inventory in the ordinary course of business, (iii) any termination of a lease of real or personal property that is not necessary in the ordinary course of the AgeX’s business, could not reasonably be expected to have a material adverse effect and does not result from AgeX’s default, and (iv) any sale, lease, license, consignment, transfer or other disposition of assets that are no longer necessary in the ordinary course of business or which has been approved in writing by Juvenescence; (k) any of the following shall occur: (i) the security and/or liens created by the Security Agreement or any other Loan Document shall at any time cease to constitute valid and perfected security and/or liens on any material portion of the collateral intended to be covered thereby; (ii) except for expiration in accordance with its terms, the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall for whatever reason be terminated or shall cease to be in full force and effect; (iii) the enforceability of the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall be contested by AgeX or a subsidiary; (iv) AgeX shall assert that its obligations under the Secured Note or any other Loan Document shall be invalid or unenforceable; or (v) a loss, theft, damage or destruction occurs with respect to a material portion of the collateral; (l) there is any change in the financial condition of AgeX and its subsidiaries which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX to perform any of its obligations under the Secured Note; and (m) any representation, warranty or statement made, repeated or deemed made or repeated by AgeX in the Secured Note, or pursuant to the Loan Documents, is incomplete, untrue, incorrect or misleading in any material respect when made, repeated or deemed made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restrictive Covenants – </i>The Secured Note includes certain covenants that among other matters such as financial reporting: (i) impose financial restrictions on AgeX while the Secured Note remains unpaid, including restrictions on the incurrence of additional indebtedness by AgeX and its subsidiaries, except that AgeX’s subsidiary Reverse Bio will be permitted to incur debt convertible into equity not guaranteed or secured by the assets of AgeX or any other AgeX subsidiary, and the restrictions on the incurrence of indebtedness applicable to Reverse Bio will end if it raises more than $<span id="xdx_90D_ecustom--Indebtedness_iI_pn6n6_c20221231__dei--LegalEntityAxis__custom--ReverseRatioMember_zZGzck9enbCb" title="Indebtedness">15.0</span> million in debt or equity financing by May 15, 2023 (ii) require that AgeX use loan proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, for general working capital, and for repayment of all or a portion of AgeX’s indebtedness to Juvenescence; and (iii) prohibit AgeX from making additional investments in subsidiaries, unless AgeX obtains the written consent of Juvenescence to a transaction that otherwise would be prohibited or restricted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Security Agreement – </i>AgeX has entered into a Security Agreement granting Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registration Rights</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX entered into certain Registration Rights Agreements pursuant to which it has agreed to register for sale under the Securities Act all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement, and shares that they may acquire through the conversion of the loans into AgeX common stock. <span id="xdx_903_eus-gaap--LineOfCreditFacilityDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementsMember_zjRoVPVUY5ol" title="Line of credit facility, description">AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of our common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence</span>. Juvenescence retains the right to require AgeX to register additional shares of common stock that Juvenescence may acquire through the exercise of warrants or the conversion of loans. AgeX is obligated to pay the fees and expenses of each registered offering under such registration rights agreement except for underwriting discounts and commissions. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX entered into an amendment to its Registration Rights Agreement with Juvenescence to include the 2022 Warrants and underlying shares and any shares issuable upon the conversion of the Secured Note into common stock as registrable securities under the Registration Rights Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt Issuance Costs</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASU 2015-03, <i>Simplifying the Presentation of Debt Issuance Costs, </i>all debt issuance costs are recorded as a discount on the debt and amortized to interest expense over the term of the loan agreement using the effective interest method. Direct debt issuance costs include but are not limited to legal fees, debt origination fees, estimated fair market value of common stock and warrants issued in connection with the loan agreements, and NYSE American additional listing fees for the underlying shares of warrants issued with each drawdown of funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock_zxLBP9nQnPZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2022 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zRh3wrr0EZl5" style="display: none">Schedule of Debt Issuance Costs and Debt Balances</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_488_eus-gaap--LineOfCredit_iI_zgjeSHWcVmLj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Drawdown of Funds</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_48D_eus-gaap--DebtInstrumentFeeAmount_iI_zburp6h9fnU5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Origination Fee</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_489_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iNI_di_zV1IREX6Gp2j" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount Refinanced</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_48C_eus-gaap--DebtInstrumentCarryingAmount_iI_ztCpbwODWBD4" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total Debt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_481_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_zWN1jG3xYqgh" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Debt Issuance Costs</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_489_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_zlzn3qOYJnG5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortization of Debt Issuance Costs</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_488_eus-gaap--LongTermDebt_iI_zDqJOKoQ7qY" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total Debt, Net</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_41A_20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandNineteenLoanAgreementMember_z4WaWf0HlIH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2019 Loan Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">160</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,160)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(494)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">494</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_41B_20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyLoanAgreementMember_z1Eru5li5z4e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2020 Loan Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,805)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,646</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_419_20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyTwoSecuredNoteMember_z1n6T3OcFQP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2022 Secured Note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,660</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">691</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,720)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,847</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,478</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--LineOfCredit_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Drawdown of Funds"><span style="font-family: Times New Roman, Times, Serif">27,660</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--DebtInstrumentFeeAmount_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Origination Fee"><span style="font-family: Times New Roman, Times, Serif">851</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iNI_pn3n3_di_c20221231_zfzZU13zkovf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount Refinanced"><span style="font-family: Times New Roman, Times, Serif">(7,160)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--DebtInstrumentCarryingAmount_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Debt"><span style="font-family: Times New Roman, Times, Serif">21,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_pn3n3_di_c20221231_zzYLaXKsDQvc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Issuance Costs"><span style="font-family: Times New Roman, Times, Serif">(8,019)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization of Debt Issuance Costs"><span style="font-family: Times New Roman, Times, Serif">4,792</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--LongTermDebt_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Debt, Net"><span style="font-family: Times New Roman, Times, Serif">18,124</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2021 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_488_eus-gaap--LineOfCredit_iI_zj5pXWxqoU72" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Drawdown of Funds</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48D_eus-gaap--DebtInstrumentFeeAmount_iI_zF2CZEuR2p7d" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Origination Fee</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_489_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iNI_di_zFdcJfLzvLed" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount Refinanced</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48C_eus-gaap--DebtInstrumentCarryingAmount_iI_zfjJN1BpFfTl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Debt</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_481_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_zMiFYdCxRHd7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Debt Issuance Costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_489_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_zvCfPfbd4vP3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amortization of Debt Issuance Costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_488_eus-gaap--LongTermDebt_iI_zbi4Ro28fQPf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Debt, Net</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_413_20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandNineteenLoanAgreementMember_zCsfUu9Sstt6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left">2019 Loan Agreement</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">7,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">160</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">7,160</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">(494)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">474</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">7,140</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_41D_20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zijcrjKCf8T5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">2020 Loan Agreement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0954">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,620)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,182</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,062</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--LineOfCredit_iI_pn3n3_c20211231_z2OVA97zLxQe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Drawdown of Funds">14,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentFeeAmount_iI_pn3n3_c20211231_zFvGwBBTzS65" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Origination Fee">160</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231_zl3tJc2GS7mj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount Refinanced"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20211231_z4GpHBwSllsh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Debt">14,660</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_pn3n3_di_c20211231_zn61W250aHsl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Issuance Costs">(3,114)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_pn3n3_c20211231_zdSPlalPyTx2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization of Debt Issuance Costs">1,656</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--LongTermDebt_iI_pn3n3_c20211231_zbUnEfPvub8f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Debt, Net">13,202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zDHN8wyJ2QQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Related Party Payables</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, has been devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $<span id="xdx_903_eus-gaap--ReimbursementFromLimitedPartnershipInvestment_c20220101__20221231__dei--LegalEntityAxis__custom--JuvenescenceMember_z4pvDoo8ECci" title="Reimbursement">280,000</span>. As of December 31, 2022 and 2021, AgeX had approximately $<span id="xdx_90D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_c20221231__dei--LegalEntityAxis__custom--JuvenescenceMember_zHSEIYKFfEg9" title="Accounts payable">141,000</span> and $<span id="xdx_90B_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_c20211231__dei--LegalEntityAxis__custom--JuvenescenceMember_z0ccfVENcwVd" title="Accounts payable">70,000</span>, respectively, payable to Juvenescence for COO services rendered, included in related party payables, net of certain expenses owed by Juvenescence to AgeX, on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2000000.0 P18M 4000000.0 1000000.0 7000000.0 7000000.0 160000 8000000.0 P18M 8000000.0 28500 3000000.0 3670663 2024-03-30 other indebtedness for money borrowed in excess of $100,000 becomes due and payable or can be declared due and payable prior to its due date or if indebtedness for money borrowed in excess of $25,000 is not paid when due 3670663 0.70 1.895 10000000 13160000 P12M 8160000 7160000 4500000 500000 2000000 2024-02-14 0.50 8458597 0.59 0.88 10000000 if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date 250000 15000000.0 AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of our common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence <p id="xdx_89F_ecustom--SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock_zxLBP9nQnPZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2022 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zRh3wrr0EZl5" style="display: none">Schedule of Debt Issuance Costs and Debt Balances</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_488_eus-gaap--LineOfCredit_iI_zgjeSHWcVmLj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Drawdown of Funds</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_48D_eus-gaap--DebtInstrumentFeeAmount_iI_zburp6h9fnU5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Origination Fee</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_489_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iNI_di_zV1IREX6Gp2j" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount Refinanced</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_48C_eus-gaap--DebtInstrumentCarryingAmount_iI_ztCpbwODWBD4" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total Debt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_481_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_zWN1jG3xYqgh" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Debt Issuance Costs</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_489_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_zlzn3qOYJnG5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortization of Debt Issuance Costs</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_488_eus-gaap--LongTermDebt_iI_zDqJOKoQ7qY" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total Debt, Net</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_41A_20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandNineteenLoanAgreementMember_z4WaWf0HlIH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2019 Loan Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">160</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,160)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(494)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">494</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_41B_20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyLoanAgreementMember_z1Eru5li5z4e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2020 Loan Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,805)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,646</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_419_20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyTwoSecuredNoteMember_z1n6T3OcFQP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2022 Secured Note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,660</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">691</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,720)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,847</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,478</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--LineOfCredit_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Drawdown of Funds"><span style="font-family: Times New Roman, Times, Serif">27,660</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--DebtInstrumentFeeAmount_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Origination Fee"><span style="font-family: Times New Roman, Times, Serif">851</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iNI_pn3n3_di_c20221231_zfzZU13zkovf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount Refinanced"><span style="font-family: Times New Roman, Times, Serif">(7,160)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--DebtInstrumentCarryingAmount_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Debt"><span style="font-family: Times New Roman, Times, Serif">21,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_pn3n3_di_c20221231_zzYLaXKsDQvc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Issuance Costs"><span style="font-family: Times New Roman, Times, Serif">(8,019)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization of Debt Issuance Costs"><span style="font-family: Times New Roman, Times, Serif">4,792</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--LongTermDebt_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Debt, Net"><span style="font-family: Times New Roman, Times, Serif">18,124</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2021 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_488_eus-gaap--LineOfCredit_iI_zj5pXWxqoU72" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Drawdown of Funds</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48D_eus-gaap--DebtInstrumentFeeAmount_iI_zF2CZEuR2p7d" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Origination Fee</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_489_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iNI_di_zFdcJfLzvLed" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount Refinanced</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48C_eus-gaap--DebtInstrumentCarryingAmount_iI_zfjJN1BpFfTl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Debt</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_481_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_zMiFYdCxRHd7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Debt Issuance Costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_489_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_zvCfPfbd4vP3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amortization of Debt Issuance Costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_488_eus-gaap--LongTermDebt_iI_zbi4Ro28fQPf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Debt, Net</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_413_20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandNineteenLoanAgreementMember_zCsfUu9Sstt6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left">2019 Loan Agreement</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">7,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">160</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">7,160</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">(494)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">474</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">7,140</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_41D_20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zijcrjKCf8T5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">2020 Loan Agreement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0954">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,620)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,182</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,062</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--LineOfCredit_iI_pn3n3_c20211231_z2OVA97zLxQe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Drawdown of Funds">14,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentFeeAmount_iI_pn3n3_c20211231_zFvGwBBTzS65" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Origination Fee">160</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231_zl3tJc2GS7mj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount Refinanced"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20211231_z4GpHBwSllsh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Debt">14,660</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_pn3n3_di_c20211231_zn61W250aHsl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Issuance Costs">(3,114)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_pn3n3_c20211231_zdSPlalPyTx2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization of Debt Issuance Costs">1,656</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--LongTermDebt_iI_pn3n3_c20211231_zbUnEfPvub8f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Debt, Net">13,202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 7000000 160000 7160000 494000 494000 8000000 8000000 2805000 2451000 7646000 12660000 691000 13351000 4720000 1847000 10478000 27660000 851000 7160000 21351000 8019000 4792000 18124000 7000000 160000 7160000 494000 474000 7140000 7500000 7500000 2620000 1182000 6062000 14500000 160000 14660000 3114000 1656000 13202000 280000 141000000 70000000 <p id="xdx_80C_ecustom--WarrantLiabilityTextBlock_zc5x93VtloU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_823_z3DQMzwmYPWj">Warrant Liability</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</i>, then in accordance with ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</i>. Under ASC 480, <i>Distinguishing Liabilities from Equity, </i>warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or the warrants must or may require AgeX to issue a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a condition of each amount drawn from the Secured Note, on receipt of each amount drawn AgeX shall grant to Juvenescence a number of warrants equal to 50% of the gross value of the relevant advance made. The gross value is the quotient of the drawdown amount and the exercise price. The exercise price is based on the market closing price of AgeX’s common stock on the NYSE American on the one day preceding the delivery of the relevant drawdown notice (see Note 5, <i>Related Party Transactions</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given AgeX’s history, it is AgeX’s judgement that it is more likely than not that AgeX will utilize the full credit available under the Secured Note and accordingly warrants will be issued for each of the advances made within the credit availability period consisting of the 12 month period starting February 14, 2022. After all relevant assessments, AgeX determined that the warrants issued under the Secured Note require classification as a liability pursuant to ASC 480, <i>Distinguishing Liabilities from Equity</i>. In accordance with the accounting guidance, the number of warrants that would have been issued if the amount of credit under the Secured Note was drawn in full is measured at the inception date at fair value and recognized as a warrant liability on the balance sheet, adjusted for the fair value of warrants actually issued upon each advance, and subsequently the number of warrants that may be issued for the remaining credit available is re-measured at each reporting period with changes being recorded as a component of net other expense in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfRegulatoryLiabilitiesTextBlock_z1vgZbjFzp7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zHPsoEmQaSsa" style="display: none">Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: italic bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Black-Scholes Assumptions</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price <sup id="xdx_F5B_z0rmSfWLPyB3">(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant Expiration Date <sup id="xdx_F5D_zRPILoIGOdCj">(2)</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price <sup id="xdx_F52_zjaF41kn7Gs6">(3)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest Rate (annual) <sup id="xdx_F58_zbDmqt1XbhD7">(4)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Volatility (annual) <sup id="xdx_F54_zmnCnvxKQpAl">(5)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Time to Maturity (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Calculated Fair Value per Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Inception Date: 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_zjob4wXQjq96" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_zOI0k6loYBvh" title="Warrant Expiration Date">13-Feb-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zCbq0Gr8i7R8" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">0.691</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_zk2lgpvByzJh" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif">1.80%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zRuAAqeQkm98" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif">122.99%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zCR5jAWfTWP4" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_z1Ecz6gOjcr" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.486</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zVJElTVmPqH5" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zpfqa7NmydNl" title="Warrant Expiration Date">13-Feb-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zx0EFIdfa7Vd" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.691</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zvFoltBL9ryc" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1.80</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_ze5rcCyToLa3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">122.99</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zEmkbFfEct16" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z7tfvQkntIki" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.486</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 2/15/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zjdb93ZAyXl6" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zam6jnZhPiIi">14-Feb-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zR58Aq4EsuA6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zd8I5Joj7AU8" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1.80</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zgjE0ARWVHC4" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">123.28</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zq1DUAAQmNU8" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zCdv81seVUv8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.535</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Period Ended 3/31/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zJhJH50z6x7g" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">0.940</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zWgq1l7jFjoh">30-Mar-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_znVYzClmVVT" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.854</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zQvZY2FxfYU5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.45</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zl6dCjDvVCC2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">123.28</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zqqftA1KBPqj" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zkvpnqHd8Om2" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.607</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 4/4/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zpXbqnQwSvuc" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.880</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zowjXlxLrHu7">3-Apr-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zRzYwvEfoYNg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.819</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zw0upK9Xzbf6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.61</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zGgrCxAvItB3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">123.31</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zZ2E31Pbemsb" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zkU0k4Q5jgE4" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.585</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 6/6/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zBZ7WbcsUiA5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.711</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zgQWPfDraGS">5-Jun-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z9mznknP8jlb" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.800</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zh38cWzv6Aud" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.94</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zv0qqftRgrVh" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">122.62</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z9M8OiXLy0N" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z1l9HoYm5s5f" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.592</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Period Ended 6/30/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zX7hO0FdiAf8" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zrQFqUh31Aae">29-Jun-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zAYIJSvJX5T5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.576</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zBPKkWC70S1k" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.99</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zcgIQpPMixNl" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">122.21</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z2ivrGmOJKJc" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z73slwL0jnaj" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.413</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 8/16/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z9gzYuVtxfC2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.670</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zv0m3xxwIQFf">15-Aug-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zDKDYDStV7b8" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.640</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_ziwg3lOv7R5e" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.19</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_z5ZWFHONpivk" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">121.37</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zHlcqYvYI7x2" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zh7wpaF2U0f1" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.457</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Period Ended 9/30/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zVIopsxn2LTl" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.610</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_z8CMuZxyidl1">29-Sep-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_z9XhbSV3Vz0d" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.562</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zcoA3SSKUT38" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.25</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zEUP1D4ZZt52" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">121.49</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zQaMjJk3GHGk" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zY1PJn96lEql" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.401</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 10/21/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_ziDYvaX3tDcd" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.690</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221020__20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zTjk3XwwOQmd">20-Oct-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zoKNBWzpPNXd" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zc8sV55glXGh" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.52</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zn2U0BqrUGhb" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">120.51</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221020__20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zDDh3MzfZCZ4" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z4KhdJS1qMAb" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.439</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 12/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zCSwqmYEcIAe" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.590</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221213__20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zREfrQuHQ0Pi">13-Dec-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--SharePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zjYuuJ39XQ6i" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.540</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zjOhVfrcNtL4" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.94</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zNwlluN3zyse" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">120.01</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221213__20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zwwmxkVIHbPa" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zP1ic0xXZ3Mc" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.381</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Period Ended 12/31/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zn4Xb86fxgia" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.550</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zzb8pEDPQleb">30-Dec-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zZndQxjAltAa" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.552</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zPDuPfqvUx1d" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.22</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zJcZBdT5O6h3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">119.31</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zy8LqEle8IVl" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zv9XMLLA8zN4" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.396</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zYcmOCnUzH86" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zqsCqPEYXKu1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the market closing price of AgeX’s common stock on the NYSE American on the one day prior to the debt inception date and each presented period ending date and also the market closing price of AgeX’s common stock on the NYSE American on the one trading day preceding the delivery of the relevant drawdown notice in accordance with terms per the Secured Note.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zXCRrYUorred" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zGgBYruslO15" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants are exercisable over a three-year period from each issuance date.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zWsXm6tftVOe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_z4LsOXlnHzb7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_z7kepTSQbm35" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zBrj3JtKVcfk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_z6RUUrQKHIoc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zs7dJU7kqCHb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the historical daily volatility of AgeX common stock as of each date presented.</span></td></tr></table> <p id="xdx_8A3_zvwGfKkSsscj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--WarrantsOutstandingAndFairValuesTableTextBlock_zMFWLr0ymHf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants outstanding and fair values at each of the respective valuation dates are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zr2vJaDCTiGg" style="display: none">Schedule of Warrant Outstanding and Fair Values</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrant Liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit Line and Draw Amounts</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Fair value as of January 1, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20220101__20221231_zXb2eOVgaLCc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">               <span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20220101__20221231_ztoLXHsRGOze" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">                     <span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zUtlBX0oSDI6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share">          <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--WarrantLiability_iS_pid_c20220101__20221231_zT31ZdpIqLif" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value">           <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value at initial measurement date of 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDEp_zqjzSu9QP3eh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">13,160<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDIp_zuVMlUiG5A8k" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   8,435,897<sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zfu0PT8cz7Ek" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.4864</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zsctLcbsUdJ7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   4,103</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDMp_zdp2jSyLP7b8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(7,160)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDQp_zgF1h77RkUab" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">(4,589,743)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zQBumssSr89b" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.4864</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zoKvTjKPPiek" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">(2,232)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 2/15/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDMp_z9EwkCknUzPa" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDQp_zcZH9GReRFD3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (641,025)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_z75TCXlSzZXa" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.5349</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zpkLWhyzVqBj" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   (343</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 4/4/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDMp_z3ua5Q7p60ql" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDQp_zL6EHxgCH2Hh" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares">   <span style="font-family: Times New Roman, Times, Serif">(568,440)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zZXuefzx9KT7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.5854</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_z90aFCXddik8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   (333</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 6/6/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDMp_z39301gZLt1k" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDQp_z10ythmov1nl" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (703,234)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_zF6q73yKQRO3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.5924</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_zGT9vBLqQbZ5" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   (417</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 8/16/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDMp_zMi5Ogg7973i" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDQp_zZ3YNxAQKNY9" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (746,380)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_zLb7uHyXZ4C5" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.4569</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_z7MHszDZuqNl" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   (341</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 10/21/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDMp_z3vzefIMRxAk" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">  (500)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDQp_zP3ayp4s9CF2" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (362,318)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_zPmohrzBt5Jj" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.4386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_zY1WEMfk4iJ8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value">   <span style="font-family: Times New Roman, Times, Serif">(159</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 12/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDMp_zMkKwtY5Aimg" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDQp_zXX1fPDatj8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (847,457)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_zYsD9p9d77Ul" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.3810</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_zvxRdopCJk0f" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value">   <span style="font-family: Times New Roman, Times, Serif">(323</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change </span><span style="font-family: Times New Roman, Times, Serif">in fair value of warrant liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20220101__20221231_fKDIp_zyBidy5Nwivk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">               <span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20220101__20221231_fKDQp_zmj4A0PnQ9Fa" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">                     <span style="-sec-ix-hidden: xdx2ixbrl1183">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20220101__20221231_zQAuKQdIU6f2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">          <span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ChangesInFairValue_pn3n3_c20220101__20221231_zk2nXJEWviF3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">      225</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Fair value as of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20220101__20221231_fKDEp_z4lILzqyNcr1" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">     500<sup>(1)</sup></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20220101__20221231_fKDIp_z5eIkSr7Etn" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   454,545<sup>(2)</sup></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20220101__20221231_ztDokg4KJMq" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.3960</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--WarrantLiability_iE_pn3n3_c20220101__20221231_zTXoNB890YQd" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value">     <span style="font-family: Times New Roman, Times, Serif">180</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zjeoky7dv7X9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_zB3gxMfXGoIk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of credit available under the Secured Note on date of inception and as of each period end date.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zlev8zxJWDi1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zhLPu9kMzi3h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of warrants issuable if the amount of credit available were drawn for measurement as of inception date and subsequently for remeasurement as of each period end date.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F07_zblvSNqkQZi3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zJUeaMFDwCNj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of drawdown as of each date presented.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zXej803gonI2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zm10Q6NtmVMe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of warrants issued upon receipt of amounts drawn against the Secured Note as of each date presented.</span></td></tr></table> <p id="xdx_8A1_zisoVOuposQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, AgeX recorded a loss of $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20220101__20221231_zjYGCefccHH2" title="Fair value of warrant liability">225,000</span> on changes in the fair value of warrant liability. There were no warrant liabilities or corresponding changes in valuation during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and AgeX’s stock prices and historical volatility as inputs. During the year ended December 31, 2022, none of the warrants issued were exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfRegulatoryLiabilitiesTextBlock_z1vgZbjFzp7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zHPsoEmQaSsa" style="display: none">Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: italic bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Black-Scholes Assumptions</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price <sup id="xdx_F5B_z0rmSfWLPyB3">(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant Expiration Date <sup id="xdx_F5D_zRPILoIGOdCj">(2)</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price <sup id="xdx_F52_zjaF41kn7Gs6">(3)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest Rate (annual) <sup id="xdx_F58_zbDmqt1XbhD7">(4)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Volatility (annual) <sup id="xdx_F54_zmnCnvxKQpAl">(5)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Time to Maturity (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Calculated Fair Value per Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Inception Date: 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_zjob4wXQjq96" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_zOI0k6loYBvh" title="Warrant Expiration Date">13-Feb-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zCbq0Gr8i7R8" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">0.691</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_zk2lgpvByzJh" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif">1.80%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zRuAAqeQkm98" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif">122.99%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zCR5jAWfTWP4" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_z1Ecz6gOjcr" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.486</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zVJElTVmPqH5" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zpfqa7NmydNl" title="Warrant Expiration Date">13-Feb-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zx0EFIdfa7Vd" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.691</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zvFoltBL9ryc" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1.80</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_ze5rcCyToLa3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">122.99</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zEmkbFfEct16" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z7tfvQkntIki" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.486</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 2/15/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zjdb93ZAyXl6" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zam6jnZhPiIi">14-Feb-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zR58Aq4EsuA6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zd8I5Joj7AU8" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1.80</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zgjE0ARWVHC4" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">123.28</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zq1DUAAQmNU8" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zCdv81seVUv8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.535</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Period Ended 3/31/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zJhJH50z6x7g" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">0.940</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zWgq1l7jFjoh">30-Mar-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_znVYzClmVVT" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.854</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zQvZY2FxfYU5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.45</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zl6dCjDvVCC2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">123.28</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zqqftA1KBPqj" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zkvpnqHd8Om2" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.607</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 4/4/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zpXbqnQwSvuc" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.880</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zowjXlxLrHu7">3-Apr-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zRzYwvEfoYNg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.819</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zw0upK9Xzbf6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.61</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zGgrCxAvItB3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">123.31</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zZ2E31Pbemsb" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zkU0k4Q5jgE4" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.585</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 6/6/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zBZ7WbcsUiA5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.711</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zgQWPfDraGS">5-Jun-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z9mznknP8jlb" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.800</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zh38cWzv6Aud" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.94</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zv0qqftRgrVh" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">122.62</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z9M8OiXLy0N" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z1l9HoYm5s5f" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.592</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Period Ended 6/30/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zX7hO0FdiAf8" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zrQFqUh31Aae">29-Jun-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zAYIJSvJX5T5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.576</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zBPKkWC70S1k" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.99</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zcgIQpPMixNl" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">122.21</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z2ivrGmOJKJc" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z73slwL0jnaj" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.413</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 8/16/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z9gzYuVtxfC2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.670</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zv0m3xxwIQFf">15-Aug-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zDKDYDStV7b8" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.640</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_ziwg3lOv7R5e" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.19</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_z5ZWFHONpivk" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">121.37</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zHlcqYvYI7x2" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zh7wpaF2U0f1" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.457</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Period Ended 9/30/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zVIopsxn2LTl" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.610</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_z8CMuZxyidl1">29-Sep-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_z9XhbSV3Vz0d" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.562</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zcoA3SSKUT38" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.25</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zEUP1D4ZZt52" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">121.49</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zQaMjJk3GHGk" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zY1PJn96lEql" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.401</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 10/21/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_ziDYvaX3tDcd" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.690</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221020__20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zTjk3XwwOQmd">20-Oct-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zoKNBWzpPNXd" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zc8sV55glXGh" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.52</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zn2U0BqrUGhb" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">120.51</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221020__20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zDDh3MzfZCZ4" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z4KhdJS1qMAb" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.439</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance Date: 12/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zCSwqmYEcIAe" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.590</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221213__20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zREfrQuHQ0Pi">13-Dec-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--SharePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zjYuuJ39XQ6i" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.540</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zjOhVfrcNtL4" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.94</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zNwlluN3zyse" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">120.01</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221213__20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zwwmxkVIHbPa" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zP1ic0xXZ3Mc" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.381</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Period Ended 12/31/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zn4Xb86fxgia" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.550</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zzb8pEDPQleb">30-Dec-25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zZndQxjAltAa" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0.552</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zPDuPfqvUx1d" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.22</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zJcZBdT5O6h3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">119.31</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zy8LqEle8IVl" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zv9XMLLA8zN4" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.396</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zYcmOCnUzH86" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zqsCqPEYXKu1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the market closing price of AgeX’s common stock on the NYSE American on the one day prior to the debt inception date and each presented period ending date and also the market closing price of AgeX’s common stock on the NYSE American on the one trading day preceding the delivery of the relevant drawdown notice in accordance with terms per the Secured Note.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zXCRrYUorred" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zGgBYruslO15" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants are exercisable over a three-year period from each issuance date.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zWsXm6tftVOe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_z4LsOXlnHzb7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_z7kepTSQbm35" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zBrj3JtKVcfk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_z6RUUrQKHIoc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zs7dJU7kqCHb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the historical daily volatility of AgeX common stock as of each date presented.</span></td></tr></table> 0.780 2025-02-13 0.691 0.0180 1.2299 P3Y 0.486 0.780 2025-02-13 0.691 0.0180 1.2299 P3Y 0.486 0.780 2025-02-14 0.747 0.0180 1.2328 P3Y 0.535 0.940 2025-03-30 0.854 0.0245 1.2328 P3Y 0.607 0.880 2025-04-03 0.819 0.0261 1.2331 P3Y 0.585 0.711 2025-06-05 0.800 0.0294 1.2262 P3Y 0.592 0.600 2025-06-29 0.576 0.0299 1.2221 P3Y 0.413 0.670 2025-08-15 0.640 0.0319 1.2137 P3Y 0.457 0.610 2025-09-29 0.562 0.0425 1.2149 P3Y 0.401 0.690 2025-10-20 0.620 0.0452 1.2051 P3Y 0.439 0.590 2025-12-13 0.540 0.0394 1.2001 P3Y 0.381 0.550 2025-12-30 0.552 0.0422 1.1931 P3Y 0.396 <p id="xdx_89B_ecustom--WarrantsOutstandingAndFairValuesTableTextBlock_zMFWLr0ymHf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants outstanding and fair values at each of the respective valuation dates are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zr2vJaDCTiGg" style="display: none">Schedule of Warrant Outstanding and Fair Values</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrant Liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit Line and Draw Amounts</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Fair value as of January 1, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20220101__20221231_zXb2eOVgaLCc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">               <span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20220101__20221231_ztoLXHsRGOze" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">                     <span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zUtlBX0oSDI6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share">          <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--WarrantLiability_iS_pid_c20220101__20221231_zT31ZdpIqLif" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value">           <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value at initial measurement date of 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDEp_zqjzSu9QP3eh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">13,160<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDIp_zuVMlUiG5A8k" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   8,435,897<sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zfu0PT8cz7Ek" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.4864</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zsctLcbsUdJ7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   4,103</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDMp_zdp2jSyLP7b8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(7,160)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDQp_zgF1h77RkUab" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">(4,589,743)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zQBumssSr89b" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.4864</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zoKvTjKPPiek" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">(2,232)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 2/15/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDMp_z9EwkCknUzPa" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDQp_zcZH9GReRFD3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (641,025)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_z75TCXlSzZXa" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.5349</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zpkLWhyzVqBj" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   (343</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 4/4/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDMp_z3ua5Q7p60ql" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDQp_zL6EHxgCH2Hh" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares">   <span style="font-family: Times New Roman, Times, Serif">(568,440)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zZXuefzx9KT7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.5854</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_z90aFCXddik8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   (333</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 6/6/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDMp_z39301gZLt1k" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDQp_z10ythmov1nl" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (703,234)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_zF6q73yKQRO3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.5924</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_zGT9vBLqQbZ5" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   (417</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 8/16/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDMp_zMi5Ogg7973i" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDQp_zZ3YNxAQKNY9" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (746,380)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_zLb7uHyXZ4C5" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.4569</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_z7MHszDZuqNl" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">   (341</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 10/21/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDMp_z3vzefIMRxAk" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">  (500)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDQp_zP3ayp4s9CF2" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (362,318)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_zPmohrzBt5Jj" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.4386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_zY1WEMfk4iJ8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value">   <span style="font-family: Times New Roman, Times, Serif">(159</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants issued on 12/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDMp_zMkKwtY5Aimg" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">(1,000)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDQp_zXX1fPDatj8" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   (847,457)<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_zYsD9p9d77Ul" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.3810</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_zvxRdopCJk0f" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value">   <span style="font-family: Times New Roman, Times, Serif">(323</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change </span><span style="font-family: Times New Roman, Times, Serif">in fair value of warrant liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20220101__20221231_fKDIp_zyBidy5Nwivk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">               <span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20220101__20221231_fKDQp_zmj4A0PnQ9Fa" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">                     <span style="-sec-ix-hidden: xdx2ixbrl1183">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20220101__20221231_zQAuKQdIU6f2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">          <span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ChangesInFairValue_pn3n3_c20220101__20221231_zk2nXJEWviF3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value"><span style="font-family: Times New Roman, Times, Serif">      225</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Fair value as of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20220101__20221231_fKDEp_z4lILzqyNcr1" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance"><span style="font-family: Times New Roman, Times, Serif">     500<sup>(1)</sup></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20220101__20221231_fKDIp_z5eIkSr7Etn" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center" title="Fair value as of period beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">   454,545<sup>(2)</sup></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20220101__20221231_ztDokg4KJMq" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center" title="Fair value as of period beginning balance, fair value per share"><span style="font-family: Times New Roman, Times, Serif">0.3960</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--WarrantLiability_iE_pn3n3_c20220101__20221231_zTXoNB890YQd" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: center" title="Fair value as of period beginning balance, fair value">     <span style="font-family: Times New Roman, Times, Serif">180</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <div style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zjeoky7dv7X9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_zB3gxMfXGoIk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of credit available under the Secured Note on date of inception and as of each period end date.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zlev8zxJWDi1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zhLPu9kMzi3h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of warrants issuable if the amount of credit available were drawn for measurement as of inception date and subsequently for remeasurement as of each period end date.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F07_zblvSNqkQZi3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zJUeaMFDwCNj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of drawdown as of each date presented.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zXej803gonI2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zm10Q6NtmVMe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of warrants issued upon receipt of amounts drawn against the Secured Note as of each date presented.</span></td></tr></table> 13160000 8435897 0.4864 4103000 -7160000 -4589743 0.4864 -2232000 -1000000 -641025 0.5349 -343000 -1000000 -568440 0.5854 -333000 -1000000 -703234 0.5924 -417000 -1000000 -746380 0.4569 -341000 -500000 -362318 0.4386 -159000 -1000000 -847457 0.3810 -323000 225000 500000 454545 0.3960 180000 225000 <p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyZK6PCA6G73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_823_zzgR3XHzNKEe">Stockholders’ Deficit</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX is authorized to issue up to <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pn3d_c20221231_zRa46vBTpko2" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pn3d_c20211231_zC2tVtGbExI1" title="Preferred stock, shares authorized">5,000,000</span></span> shares of preferred stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20221231_zIfW1jeFHkK8" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20211231_zhDQ2mW3VsLf" title="Preferred stock, par value">0.0001</span></span> par value per share. At December 31, 2022 and 2021, there were <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20221231_zzTyLKHFq1o3" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231_zzuvHPxKNe37" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20221231_zM11X5waZIh1" title="Preferred stock, shares outstanding"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20221231_zjutz5zyGrjb" title="Preferred stock, shares outstanding">no</span></span></span></span> preferred shares issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zarQpUkssR54" title="Common stock, shares authorized">200,000,000</span> shares of common stock, $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zfvawBg1x9s5" title="Common stock, par value">0.0001</span> par value per share, authorized. The holders of AgeX’s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of AgeX common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of AgeX outstanding preferred shares, if any.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of AgeX stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, there were <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7aJjZyr4kO2" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhBedyftlUR5" title="Common stock, shares outstanding">37,949,196</span></span> and <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsbL3aefNbjd" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSv1ZWhRWDX5" title="Common stock, shares outstanding">37,941,220</span></span> shares of AgeX common stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance of Warrants by AgeX</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pp0p0_c20220101__20221231__dei--LegalEntityAxis__custom--JuvenescenceMember_zkcLz2yMda9a" title="Line of credit facility">12,660,000</span> of drawdowns of loan funds from Juvenescence under the Secured Note during the year ended December 31, 2022, AgeX has issued to Juvenescence 2022 Warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__dei--LegalEntityAxis__custom--JuvenescenceMember_zlU25IWQiYMa" title="Warrant to purchase share of common stock">8,458,597</span> shares of AgeX common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As consideration for $<span id="xdx_90E_eus-gaap--ProceedsFromLoans_pn5n6_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zuDOalHv7Vh5" title="Proceeds from loans">8.0</span> million in loans made to AgeX under the 2020 Loan Agreement, AgeX issued to Juvenescence warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zFurKoenyLRk" title="Warrant to purchase share of common stock">3,670,663</span> shares of AgeX common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Notes 5, <i>Related Party Transactions</i> and 6, <i>Warrant Liability</i> for additional information on warrants issued to Juvenescence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>At-the-Market Offering Facility</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2021, AgeX entered into a Sales Agreement with Chardan, relating to the sale of shares of AgeX common stock, in at-the-market transactions. In accordance with the terms of the Sales Agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $<span id="xdx_90B_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_pn5n6_c20210107__20210108__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zjoV4BZn4OX8" title="Payments for offering">12.6</span> million from time to time through Chardan, acting as the sales agent. The actual market value of common shares that AgeX may sell through its Sales Agreement with Chardan during any 12 month period will be limited to one-third of aggregate market value of our common stock held by stockholders that would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. During the years ended December 31, 2022 and 2021, AgeX raised <span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_dxL_c20220101__20221231__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zQibqMkgsone" title="Proceeds from issuance costs::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1243">nil</span></span> and $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_ztE4jYTExcnc" title="Proceeds from issuance costs">496,000</span>, respectively, in gross proceeds through the sale of shares of common stock through the Sales Agreement with Chardan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5000000 5000000 0.0001 0.0001 0 0 0 0 200000000 0.0001 37949196 37949196 37941220 37941220 12660000 8458597 8000000.0 3670663 12600000 496000 <p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zFzgCResVcek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_82E_z6kOUqSAvIBl">Stock-Based Awards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity Incentive Plan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the 2017 Equity Incentive Plan, as amended (the “Incentive Plan”), AgeX has reserved <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231_zGZ1ufbRGwpe" title="Number of common stock reserved">8,500,000</span> shares of common stock for the grant of stock options or the sale of restricted stock (“Restricted Stock”) or for the settlement of restricted stock units which are hypothetical units issued with reference to common stock (“Restricted Stock Units” or “RSUs”). AgeX may also grant stock appreciation rights (“SARs”) under the Incentive Plan. The Plan also permits AgeX to issue such other securities as its Board of Directors (the “Board”) or the Compensation Committee (the “Committee”) administering the Incentive Plan may determine. Awards of stock options, Restricted Stock, SARs, and RSUs (“Awards”) may be granted under the Incentive Plan to AgeX employees, directors, and consultants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards may vest and thereby become exercisable or have restrictions on forfeiture lapse on the date of grant or in periodic installments or upon the attainment of performance goals, or upon the occurrence of specified events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zmeIcVu4KQN9" title="Granted options description">No person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zF3k42MkJo4b" title="Options to purchase shares">1,000,000</span> shares in the aggregate, or any Awards of Restricted Stock or RSUs with respect to more than <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--RangeAxis__srt--MaximumMember_zTbKEsGN6W5l" title="Options to purchase shares">500,000</span> shares in the aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual share limit</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Awards may be granted under the Incentive Plan more than ten years after the date upon which the Incentive Plan was adopted by the Board, and no options or SARS granted under the Incentive Plan may be exercised after the expiration of ten years from the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted under the Incentive Plan may be either “incentive stock options” within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the “Code”), or “non-qualified” stock options that do not qualify incentive stock options. Incentive stock options may be granted only to AgeX employees and employees of subsidiaries. The exercise price of stock options granted under the Incentive Plan must be equal to the fair market of AgeX common stock on the date the option is granted. <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zTVS6QTBbTf2" title="Granted options description">In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of AgeX stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years</span>. The aggregate fair market value of common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember__srt--RangeAxis__srt--MinimumMember_z97lZyT0Qgyf" title="Options exercisable">100,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise price of an option may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board or Committee may approve.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter, but in the case of the termination of an employee, director, or consultant’s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted Stock and RSUs</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In lieu of granting options, AgeX may enter into purchase agreements with employees under which <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAndRestrictedStockUnitsMember__srt--RangeAxis__srt--MaximumMember_zPSCKesi2A7g" title="Granted options description">they may purchase or otherwise acquire Restricted Stock or RSUs subject to such vesting, transfer, and repurchase terms, and other restrictions. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value</span>. Employees or consultants, but not executive officers or directors, who purchase Restricted Stock may be permitted to pay for their shares by delivering a promissory note or an installment payment agreement that may be secured by a pledge of their Restricted Stock. Restricted Stock may also be issued for services actually performed by the recipient prior to the issuance of the Restricted Stock. Unvested Restricted Stock for which AgeX has not received payment may be forfeited, or AgeX may have the right to repurchase unvested shares upon the occurrence of specified events, such as termination of employment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the restrictions set with respect to the particular Award, a recipient of Restricted Stock generally shall have the rights and privileges of a stockholder, including the right to vote the Restricted Stock and the right to receive dividends; provided that, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld for the recipient’s account, and interest may be credited on the amount of the cash dividends withheld. The cash dividends or stock dividends so withheld and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to the recipient in cash or, at the discretion of the Board or Committee, in shares of common stock having a fair market value equal to the amount of such dividends, if applicable, upon the release of restrictions on the Restricted Stock and, if the Restricted Stock is forfeited, the recipient shall have no right to the dividends.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The terms and conditions of a grant of RSUs shall be determined by the Board or Committee. No shares of common stock shall be issued at the time a RSU is granted. A recipient of RSUs shall have no voting rights with respect to the RSUs. Upon the expiration of the restrictions applicable to a RSU, AgeX will either issue to the recipient, without charge, one share of common stock per RSU or cash in an amount equal to the fair market value of one share of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the discretion of the Board or Committee, each RSU (representing one share of common stock) may be credited with cash and stock dividends paid in respect of one share (“Dividend Equivalents”). Dividend Equivalents shall be withheld for the recipient’s account, and interest may be credited on the amount of cash Dividend Equivalents withheld. Dividend Equivalents credited to a recipient’s account and attributable to any particular RSU (and earnings thereon, if applicable) shall be distributed in cash or in shares of common stock having a fair market value equal to the amount of the Dividend Equivalents and earnings, if applicable, upon settlement of the RSU. If a RSU is forfeited, the recipient shall have no right to the related Dividend Equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SARs</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A SAR is the right to receive, upon exercise, an amount payable in cash or shares, or a combination of shares and cash, equal to the number of shares subject to the SAR that is being exercised, multiplied by the excess of (a) the fair market value of a common stock on the date the SAR is exercised, over (b) the exercise price specified in the SAR Award agreement. SARs may be granted either as free standing SARs or in tandem with options. No SAR may be exercised later than <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockAppreciationRightsSARSMember_z9Osp58723K5">10</span> years after the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise price of a SAR shall not be less than <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockAppreciationRightsSARSMember_zzDpRyKi62S8" title="Fair market value of common stock">100</span>% of the fair market value of one share of common stock on the date of grant. A SAR granted in conjunction with an option shall have the same exercise price as the related option, shall be transferable only upon the same terms and conditions as the related option, and shall be exercisable only to the same extent as the related option; provided, however, that the SAR by its terms shall be exercisable only when the fair market value per share exceeds the exercise price per share of the SAR or related option. Upon any exercise of a SAR granted in tandem with an option, the number of shares for which the related option shall be exercisable shall be reduced by the number of shares for which the SAR has been exercised. The number of shares for which a SAR issued in tandem with an option shall be exercisable shall be reduced by the number of shares for which the related option has been exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity Incentive Plan Awards</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zHddieLmFYm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Incentive Plan activity and related information follows (in thousands except weighted-average exercise price):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zAhiYf83TTQb" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for Grant</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of RSUs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at January 1, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zvzuAK26c362" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center" title="Shares available for grant, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,046</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z8jSFnTnJy5k" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center" title="Number of options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,854</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zNdZ27NZBCvg" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center" title="Number of RSUs outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  28</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zgSAxZx8vsbb" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.51</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase option pool</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--SharesAvailableForGrantIncreaseOptionPool_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYTEx23gipmd" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant increase option pool">  <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsIncreaseOptionPool_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw2eH9itrNGg" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Options grants increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodOptionPool_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWUH4zIsfCoe" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of shares outstanding increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1280">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceIncreaseOptionPool_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zMZh2wUWAGx" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price increase option pool">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1282">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--SharesAvailableForGrantOptionsGranted_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zTfxcwJwYz4e" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(568</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zRF8RXVZQFql" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    568</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zXBmzZfr47Si" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1288">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zeQb57915t41" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options forfeited, cancelled or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--SharesAvailableForGrantOptionsForfeitedCancelledOrExpired_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zEcw1vqU1HS4" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, options forfeited, cancelled or expired">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJJekqhUpyP9" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">   (57)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYWXavMMO0c6" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1296">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zapmbQ8ldpaa" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.56</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units vested</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zVvZrNjSW5Bi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zlJEDWRyYgFd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zpAoV6LI62dh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zirbYK8MF0xh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zFdalfJLjekf" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,035</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOBPEqQhOoW3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,365</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zXS51mcGgdn1" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zn92PcgGB838" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase option pool</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--SharesAvailableForGrantIncreaseOptionPool_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zeJOh0szZacj" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsIncreaseOptionPool_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zyyUhDAhyhkh" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Options grants increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodOptionPool_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zvpPB1nPVjI3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of shares outstanding increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceIncreaseOptionPool_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zHlQXsOzcb1a" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price increase option pool">      <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--SharesAvailableForGrantOptionsGranted_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z0Zcg0Zjwlc3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(105)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zEhU1pmT3Zk9" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    105</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zGHyNTygMIq2" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1328">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zjF5xbDe3dof" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options forfeited, cancelled or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--SharesAvailableForGrantOptionsForfeitedCancelledOrExpired_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zNkGxUyeTyLh" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    209</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOih8a3Acbec" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(209)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zSixkhhMBffb" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zPXyiqknMNzk" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.82</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units vested</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zmaDVrNSxdz8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zjf7KUOkb593" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1342">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zyDtiB355tT1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYHyFkSv2nid" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1346">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJk4ibVxgwTh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,139</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zhJWOkxyZQra" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,261</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDUpKIbeJpTl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJGd0ify7dU6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJJs9fEp82wk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOGcnbLJTn6h" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_zqXIhXqFdzte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_do_c20210101__20211231_zaE34YeSOCTc" title="Number of options exercised"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_do_c20220101__20221231_zZY5bO3aEiVi" title="Number of options exercised">no</span></span> exercises of stock options during the years ended December 31, 2022 and 2021. Total proceeds if all options granted and outstanding as of December 31, 2022 were exercised would be approximately $<span id="xdx_90C_eus-gaap--ProceedsFromStockOptionsExercised_pn5n6_c20220101__20221231_zlPmJybg2xre" title="Options granted and outstanding exercised">7.3</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, AgeX had approximately $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231_zbVzU6Ot38Bg" title="Total unrecognized compensation expense">0.3</span> million of total unrecognized compensation costs related to the stock options and unvested RSUs under the Incentive Plan that will be recognized as expense over a weighted-average period of approximately <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231_zUJxtQV7e5J4" title="Recognized over weighted average period">2.02</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate intrinsic value of options outstanding was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231_zKPz7rBh6Zul" title="Intrinsic value outstanding">1,700</span> and options exercisable was nil as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based Compensation Expense</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zVE5b8fZR8X8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zA52KpbPNKz9" style="display: none">Schedule of Stock Based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20220101__20221231_zlMNFzyDI4hi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20210101__20211231_zYJdLiDl5Ndg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zwqP2GK1kkik" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development – continuing operations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_z69UcTR8CG58" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative – continuing operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">728</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">937</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zUzhcDek19z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense – continuing operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">999</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zFs2u7gc31h4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative – discontinued operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1383">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_z0rs2vNSXfm2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,003</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zHR3Lk6wN1U2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average estimated fair value of stock options granted during the years ended December 31, 2022 and 2021 was $<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageFairValue_pid_c20220101__20221231_zZklcBNpsisl" title="Weighted-average estimated fair value of stock options granted">0.70</span> per share and $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageFairValue_pid_c20210101__20211231_zCPie8Qmln7k" title="Weighted-average estimated fair value of stock options granted">1.15</span> per share, respectively, using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></p> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDleIO1YHYM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B2_zJCfKZ2fph3" style="display: none">Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zR5yRkQS6yY1" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       0.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_z3gF8xVJFIMc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        1.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zewx2Qu2lqm4" title="Expected life (in years)">5.58</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zySplEvAFN69" title="Expected life (in years)">5.71</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_z0Rfc6iUOf0f" title="Risk-free interest rates">1.74%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zzi0VsbDRkl7" title="Risk-free interest rates">0.99%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zIkZD0l19fDi" title="Volatility">130.71%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zmqXqlbmO2pk" title="Volatility">102.34%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_z1Xp9TN0euDh" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         -</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zILRtmaBk9I3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          -</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zwLwEvZYN4sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If AgeX had made different assumptions, its stock-based compensation expense and net loss for the years ended December 31, 2022 and 2021 may have been significantly different. See Note 2, <i>Summary of Significant Accounting Policies</i> for a discussion of the factors used in determining these assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 8500000 No person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than 1,000,000 shares in the aggregate, or any Awards of Restricted Stock or RSUs with respect to more than 500,000 shares in the aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual share limit 1000000 500000 In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of AgeX stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years 100000 they may purchase or otherwise acquire Restricted Stock or RSUs subject to such vesting, transfer, and repurchase terms, and other restrictions. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value P10Y 1 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zHddieLmFYm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Incentive Plan activity and related information follows (in thousands except weighted-average exercise price):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zAhiYf83TTQb" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for Grant</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of RSUs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at January 1, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zvzuAK26c362" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center" title="Shares available for grant, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,046</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z8jSFnTnJy5k" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center" title="Number of options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,854</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zNdZ27NZBCvg" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center" title="Number of RSUs outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  28</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zgSAxZx8vsbb" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.51</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase option pool</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--SharesAvailableForGrantIncreaseOptionPool_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYTEx23gipmd" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant increase option pool">  <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsIncreaseOptionPool_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw2eH9itrNGg" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Options grants increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodOptionPool_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWUH4zIsfCoe" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of shares outstanding increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1280">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceIncreaseOptionPool_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zMZh2wUWAGx" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price increase option pool">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1282">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--SharesAvailableForGrantOptionsGranted_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zTfxcwJwYz4e" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(568</span>)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zRF8RXVZQFql" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    568</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zXBmzZfr47Si" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1288">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zeQb57915t41" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options forfeited, cancelled or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--SharesAvailableForGrantOptionsForfeitedCancelledOrExpired_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zEcw1vqU1HS4" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, options forfeited, cancelled or expired">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJJekqhUpyP9" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">   (57)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYWXavMMO0c6" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1296">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zapmbQ8ldpaa" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.56</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units vested</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zVvZrNjSW5Bi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zlJEDWRyYgFd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zpAoV6LI62dh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zirbYK8MF0xh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zFdalfJLjekf" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,035</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOBPEqQhOoW3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,365</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zXS51mcGgdn1" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zn92PcgGB838" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase option pool</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--SharesAvailableForGrantIncreaseOptionPool_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zeJOh0szZacj" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsIncreaseOptionPool_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zyyUhDAhyhkh" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Options grants increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodOptionPool_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zvpPB1nPVjI3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of shares outstanding increase option pool"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceIncreaseOptionPool_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zHlQXsOzcb1a" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price increase option pool">      <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--SharesAvailableForGrantOptionsGranted_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z0Zcg0Zjwlc3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(105)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zEhU1pmT3Zk9" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    105</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zGHyNTygMIq2" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1328">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zjF5xbDe3dof" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options forfeited, cancelled or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--SharesAvailableForGrantOptionsForfeitedCancelledOrExpired_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zNkGxUyeTyLh" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    209</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOih8a3Acbec" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(209)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zSixkhhMBffb" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zPXyiqknMNzk" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, options forfeited, cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.82</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units vested</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zmaDVrNSxdz8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zjf7KUOkb593" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1342">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zyDtiB355tT1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYHyFkSv2nid" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl1346">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJk4ibVxgwTh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Shares available for grant, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,139</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zhJWOkxyZQra" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,261</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDUpKIbeJpTl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of RSUs outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJGd0ify7dU6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJJs9fEp82wk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Number of options outstanding, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOGcnbLJTn6h" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center" title="Weighted average exercise price, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1046000 2854000 28000 2.51 500000 -568000 568000 1.46 57000 57000 2.56 12000 1035000 3365000 16000 2.32 4000000 -105000 105000 0.79 209000 209000 2.82 13000 5139000 3261000 3000 2.25 2913000 2.37 0 0 7300000 300000 P2Y7D 1700 <p id="xdx_89F_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zVE5b8fZR8X8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zA52KpbPNKz9" style="display: none">Schedule of Stock Based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20220101__20221231_zlMNFzyDI4hi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20210101__20211231_zYJdLiDl5Ndg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zwqP2GK1kkik" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development – continuing operations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_z69UcTR8CG58" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative – continuing operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">728</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">937</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zUzhcDek19z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense – continuing operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">999</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zFs2u7gc31h4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative – discontinued operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1383">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_z0rs2vNSXfm2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,003</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 32000 62000 728000 937000 760000 999000 4000 760000 1003000 0.70 1.15 <p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDleIO1YHYM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B2_zJCfKZ2fph3" style="display: none">Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zR5yRkQS6yY1" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       0.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_z3gF8xVJFIMc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        1.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zewx2Qu2lqm4" title="Expected life (in years)">5.58</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zySplEvAFN69" title="Expected life (in years)">5.71</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_z0Rfc6iUOf0f" title="Risk-free interest rates">1.74%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zzi0VsbDRkl7" title="Risk-free interest rates">0.99%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zIkZD0l19fDi" title="Volatility">130.71%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zmqXqlbmO2pk" title="Volatility">102.34%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_z1Xp9TN0euDh" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         -</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zILRtmaBk9I3" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          -</span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> 0.79 1.46 P5Y6M29D P5Y8M15D 0.0174 0.0099 1.3071 1.0234 -0 -0 <p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_znI7xvEnmVUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. <span id="xdx_82E_zmdjXtDZBHU3">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss from operations before income taxes as of December 31, 2022 and 2021 are approximately $<span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn5n6_c20220101__20221231_zjOgcttobyO3" title="Net loss from operations">10.5</span> million and $<span id="xdx_906_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn5n6_c20210101__20211231_zEHhFAzUnmlk" title="Net loss from operations">8.7</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxPvSEjOgmr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The primary components of the net deferred tax assets and liabilities as of December 31, 2022 and 2021 were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BE_zy6ASnelxIVa" style="display: none">Schedule of Components of Deferred Tax Assets and Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20221231_zWITA8rZd30f" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_496_20211231_ze4N74SXk0t6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets/(liabilities):</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzon4_zFoMs9N53Hk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_maDTANzon4_zn8EtZBw7jYe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital loss carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,120</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,120</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTANzon4_z0j0T5smnPHb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development credit carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,138</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,426</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsPatentsAndFixedAssets_iI_pn3n3_maDTANzon4_znTZ37zlm0Yk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents and fixed assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">879</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">901</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTANzon4_zPZzkW048ZO3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">643</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchExpenses_iI_pn3n3_maDTANzon4_zWso7eQZDbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized Research Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">211</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1439">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTANzon4_zF59KbLgmkVg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzon4_zquLeR9gkBz8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,461)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,217)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzon4_zYz2A6pgwZ0j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1447">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zQDRWZMGppph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zHjuwqZOBiJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes differed from the amounts computed by applying the U.S. federal income tax rate indicated to pretax losses from operations as a result of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B3_zz2nmtHZ65Hl" style="display: none">Schedule of Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed tax benefit at federal statutory rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zIam4NKjyuvg" title="Computed tax benefit at federal statutory rate">21</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">   <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zyNI4QF3TfL6" title="Computed tax benefit at federal statutory rate">21</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development and other credits</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231_zGvU2UXrq4K4" title="Research and development and other credits">1</span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20210101__20211231_zKszhOFBmF9j" title="Research and development and other credits">1</span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State tax benefit, net of effect on federal income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zQVAy24FlGG" title="State tax benefit, net of effect on federal income taxes">7</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231_zyRxghXRExcd" title="State tax benefit, net of effect on federal income taxes">14</span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">   <span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_c20220101__20221231_zvIWK8AzSlTb" title="Permanent differences"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  (<span id="xdx_900_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_c20210101__20211231_zd1tAsQ8lKx6" title="Permanent differences">1</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Based Compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_c20220101__20221231_zTiaswxRpMvf" title="Stock Based Compensation">2</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_c20210101__20211231_zOibnPgfaNS2" title="Stock Based Compensation"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss and deconsolidation of LifeMap Sciences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--EffectiveIncomeTaxRateLossAndDeconsolidation_pid_dp_uPure_c20220101__20221231_zZgDxjn7IlG6" title="Loss and deconsolidation of LifeMap Sciences"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_906_ecustom--EffectiveIncomeTaxRateLossAndDeconsolidation_pid_dp_uPure_c20210101__20211231_zE4aWEXc2Umc" title="Loss and deconsolidation of LifeMap Sciences">31</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt finance equity costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_909_ecustom--EffectiveIncomeTaxRateReconciliationDebtFinanceEquityCosts_pid_dp_uPure_c20220101__20221231_zsvKVSbkwvVk" title="Debt finance equity costs">6</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--EffectiveIncomeTaxRateReconciliationDebtFinanceEquityCosts_pid_dp_uPure_c20210101__20211231_zSfRVCjJ9Oda" title="Debt finance equity costs"><span style="-sec-ix-hidden: xdx2ixbrl1478">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return to provision &amp; other adjustments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionOtherAdjustments_pid_dp_uPure_c20220101__20221231_zvPNYMmhAcZc" title="Return to provision &amp; other adjustments">5</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionOtherAdjustments_pid_dp_uPure_c20210101__20211231_zx30dOKocPyj" title="Return to provision &amp; other adjustments"><span style="-sec-ix-hidden: xdx2ixbrl1482">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20220101__20221231_z3zxCyRpf7ba" title="Change in valuation allowance">2</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  (<span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20210101__20211231_zGwaVZCrPSBc" title="Change in valuation allowance">4</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zoiilRyLtR3g" title="Income tax rate"><span style="-sec-ix-hidden: xdx2ixbrl1488">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">      <span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zT1FHlFVLh4e" title="Income tax rate"><span style="-sec-ix-hidden: xdx2ixbrl1490">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z7rFQrccH7l8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has established an accrual for uncertain tax positions related to its U.S. research and development credits. As of December 31, 2022 and 2021, there was no accrued interest related to uncertain tax positions. AgeX does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span></p> <p id="xdx_898_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zP60ax46DOyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zDusI43XVhD3" style="display: none">Schedule of Unrecognized Tax Benefits</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zmlDzgvKErp8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20210101__20211231_zJ1h0fu9HIua" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefits_iS_zrozfUv3fRP3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance at January 1</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1494">-</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl1495">-</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zTMcSFbIgYm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Additions for tax positions related to the current year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">23</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1498">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zkoHuoik27je" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additions for tax positions related to prior years</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">356</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1501">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_zO4pkYxcnApg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reductions for tax positions related to prior years</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1504">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_zpApPfV9CSn1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reductions related to settlements</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1506">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1507">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_zzzHUldgOa7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reductions related to a lapse of statute</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1509">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1510">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--UnrecognizedTaxBenefits_iE_znd10ZXiTpA4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">Balance at December 31</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">379</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z2bbuLV55ng4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2022, AgeX had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, AgeX has net operating loss carryforwards of approximately $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20221231_zxVVDaaLKYT3">52.8 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for U.S. federal income tax purposes. In general, NOLs and other tax credit carryforwards generated by legal entities in a consolidated federal tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the consolidated federal tax group.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, AgeX has net operating losses of approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20221231__srt--StatementScenarioAxis__custom--CaliforniaPurposesMember_zyoZfSeh0FPe" title="Net operating losses">14.9</span> million for California purposes. As AgeX and its subsidiaries have been included in the combined California tax return with Lineage, up to the date of deconsolidation on August 30, 2018, those state net operating losses will remain with AgeX. In general, NOLs and other tax credit carryforwards generated by legal entities in a combined state tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the combined state tax group. <span id="xdx_906_ecustom--NetOperatingLossesExpirationDate_c20220101__20221231__srt--StatementScenarioAxis__custom--CaliforniaPurposesMember_zztdFiYiq37d" title="Net operating loss, expiration date">Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2042</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, AgeX has research and development tax credit carryforwards for federal and state tax purposes of $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z0A59FKyh6s3">0.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zJuwdYcjmgac">0.6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> respectively. <span id="xdx_903_eus-gaap--TaxCreditCarryforwardDescription_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z83oZZfMJws1">The federal tax credits expire between 2028 and 2042, while the state tax credits have no expiration date</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, AgeX has capital loss carryforwards for federal and state tax purposes of $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zX4wOKJsjSm1" title="Deferred tax assets capital loss carry forwards">12.4</span> million and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zIC07dWed7Mi" title="Deferred tax assets capital loss carry forwards">5.9</span> million, respectively. The federal and California capital loss carryforwards will expire in 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (“R&amp;E”) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a <span id="xdx_90A_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears_dtY_c20220101__20221231__srt--StatementGeographicalAxis__country--US_z7lWlUYfq7L2" title="Amortized over Period">5</span>-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a <span id="xdx_90F_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears_dtY_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zX1ZIGJE5Kyi" title="Amortized over Period">15</span>-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. We will continue to monitor this issue for future developments, but we does not expect R&amp;E capitalization and amortization to require us to pay cash taxes now or in the near future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. stockholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductions_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--GILTIMember_zH5YOvzBh58" title="Income tax rate deduction">50</span>% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2021, AgeX’s foreign entity operated at an immaterial loss; therefore, no GILTI was included in income. For the year ended December 31, 2022, there was no income or loss related to foreign activity as the entity deconsolidated from AgeX on March 15, 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2022, we experienced a domestic loss from continuing operations; therefore, <span id="xdx_90A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_do_c20221231_z42KAmU9JKs" title="Income tax provisions">no</span> income tax provision was recorded for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The sale of LifeMap Sciences resulted in a taxable loss primarily due to AgeX’s tax basis in the subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Income Tax Matters</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--OtherIncomeTaxMattersMember_z1MiHLbvv8Td" title="Income tax description">Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation</span>. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX and its subsidiaries may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. AgeX filed its first consolidated federal tax return in 2018. AgeX and its current subsidiaries are not subject to tax examination by federal tax authorities for tax years beginning before 2019 and for state tax authorities beginning before 2018. However, the tax authorities may still make adjustments to the net operating loss and credit carryforwards used in open years by AgeX or any of its subsidiaries. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 10500000 8700000 <p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxPvSEjOgmr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The primary components of the net deferred tax assets and liabilities as of December 31, 2022 and 2021 were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BE_zy6ASnelxIVa" style="display: none">Schedule of Components of Deferred Tax Assets and Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20221231_zWITA8rZd30f" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_496_20211231_ze4N74SXk0t6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets/(liabilities):</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzon4_zFoMs9N53Hk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_maDTANzon4_zn8EtZBw7jYe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital loss carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,120</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,120</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTANzon4_z0j0T5smnPHb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development credit carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,138</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,426</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsPatentsAndFixedAssets_iI_pn3n3_maDTANzon4_znTZ37zlm0Yk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents and fixed assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">879</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">901</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTANzon4_zPZzkW048ZO3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">643</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchExpenses_iI_pn3n3_maDTANzon4_zWso7eQZDbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized Research Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">211</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1439">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTANzon4_zF59KbLgmkVg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzon4_zquLeR9gkBz8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,461)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,217)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzon4_zYz2A6pgwZ0j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1447">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 12408000 12000000 3120000 3120000 1138000 1426000 879000 901000 643000 690000 211000 62000 80000 18461000 18217000 <p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zHjuwqZOBiJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes differed from the amounts computed by applying the U.S. federal income tax rate indicated to pretax losses from operations as a result of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B3_zz2nmtHZ65Hl" style="display: none">Schedule of Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed tax benefit at federal statutory rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zIam4NKjyuvg" title="Computed tax benefit at federal statutory rate">21</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">   <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zyNI4QF3TfL6" title="Computed tax benefit at federal statutory rate">21</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development and other credits</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231_zGvU2UXrq4K4" title="Research and development and other credits">1</span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20210101__20211231_zKszhOFBmF9j" title="Research and development and other credits">1</span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State tax benefit, net of effect on federal income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zQVAy24FlGG" title="State tax benefit, net of effect on federal income taxes">7</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231_zyRxghXRExcd" title="State tax benefit, net of effect on federal income taxes">14</span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">   <span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_c20220101__20221231_zvIWK8AzSlTb" title="Permanent differences"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  (<span id="xdx_900_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_c20210101__20211231_zd1tAsQ8lKx6" title="Permanent differences">1</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Based Compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_c20220101__20221231_zTiaswxRpMvf" title="Stock Based Compensation">2</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     <span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_c20210101__20211231_zOibnPgfaNS2" title="Stock Based Compensation"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss and deconsolidation of LifeMap Sciences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--EffectiveIncomeTaxRateLossAndDeconsolidation_pid_dp_uPure_c20220101__20221231_zZgDxjn7IlG6" title="Loss and deconsolidation of LifeMap Sciences"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_906_ecustom--EffectiveIncomeTaxRateLossAndDeconsolidation_pid_dp_uPure_c20210101__20211231_zE4aWEXc2Umc" title="Loss and deconsolidation of LifeMap Sciences">31</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt finance equity costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_909_ecustom--EffectiveIncomeTaxRateReconciliationDebtFinanceEquityCosts_pid_dp_uPure_c20220101__20221231_zsvKVSbkwvVk" title="Debt finance equity costs">6</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--EffectiveIncomeTaxRateReconciliationDebtFinanceEquityCosts_pid_dp_uPure_c20210101__20211231_zSfRVCjJ9Oda" title="Debt finance equity costs"><span style="-sec-ix-hidden: xdx2ixbrl1478">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return to provision &amp; other adjustments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionOtherAdjustments_pid_dp_uPure_c20220101__20221231_zvPNYMmhAcZc" title="Return to provision &amp; other adjustments">5</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionOtherAdjustments_pid_dp_uPure_c20210101__20211231_zx30dOKocPyj" title="Return to provision &amp; other adjustments"><span style="-sec-ix-hidden: xdx2ixbrl1482">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20220101__20221231_z3zxCyRpf7ba" title="Change in valuation allowance">2</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  (<span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20210101__20211231_zGwaVZCrPSBc" title="Change in valuation allowance">4</span></span>)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zoiilRyLtR3g" title="Income tax rate"><span style="-sec-ix-hidden: xdx2ixbrl1488">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">      <span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zT1FHlFVLh4e" title="Income tax rate"><span style="-sec-ix-hidden: xdx2ixbrl1490">-</span></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.21 0.21 0.01 0.01 0.07 0.14 0.01 0.02 0.31 0.06 0.05 0.02 0.04 <p id="xdx_898_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zP60ax46DOyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zDusI43XVhD3" style="display: none">Schedule of Unrecognized Tax Benefits</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zmlDzgvKErp8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20210101__20211231_zJ1h0fu9HIua" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefits_iS_zrozfUv3fRP3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance at January 1</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1494">-</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl1495">-</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zTMcSFbIgYm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Additions for tax positions related to the current year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">23</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1498">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zkoHuoik27je" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additions for tax positions related to prior years</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">356</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1501">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_zO4pkYxcnApg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reductions for tax positions related to prior years</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1504">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_zpApPfV9CSn1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reductions related to settlements</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1506">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1507">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_zzzHUldgOa7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reductions related to a lapse of statute</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1509">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1510">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--UnrecognizedTaxBenefits_iE_znd10ZXiTpA4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">Balance at December 31</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">379</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> 23000 356000 379000 52800000 14900000 Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2042 900000 600000 The federal tax credits expire between 2028 and 2042, while the state tax credits have no expiration date 12400000 5900000 P5Y P15Y 0.50 0 Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation <p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zeMpyKQSDVhf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span id="xdx_821_z6mG8jZRXHW7">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Office Lease Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 1, 2021, AgeX relocated its principal offices to a <span id="xdx_902_eus-gaap--NetRentableArea_iI_pid_uSqft_c20210101__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zybaerChjJsj" title="Office space">135</span> square foot leased space in a building located in an office and research park in Alameda, California. Base monthly rent was $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20210101__20210101__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_znXTst9LaGl4" title="Base rent">947</span> for the first year of the lease term. In September 2021, AgeX extended its office lease for another year, effective January 1, 2022, at a monthly rent of $<span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zdyxtIsiy9Dj" title="Lease and rental expense">1,074</span>. In October 2022, AgeX entered into a new one-year lease that became effective January 1, 2023 for a different space, comprising of <span id="xdx_900_eus-gaap--NetRentableArea_iI_pid_uSqft_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zSvdkrJTEDPf" title="Office space">101</span> square feet, in the same building, at a monthly rent of $<span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20221001__20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zD7OjdO34Tvj" title="Lease and rental expense">844</span>. The lease also includes office furniture rental, janitorial services, utilities, and internet service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ASC 842</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the office lease, AgeX has elected to not apply the recognition requirements under ASC 842 and instead recognized the lease payments as lease costs on a straight-line basis over the lease term, as the amount of the lease payments is not deemed material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no future minimum lease commitments as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigation – General</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax Filings</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes AgeX has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment Contracts</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s research and development programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s research and development. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property licensed from AgeX to third parties. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The sales agreement between AgeX and Chardan also includes indemnification provisions pursuant to which the parties have agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock through the ATM facility, including liabilities under the Securities Act. Similarly, the Registration Rights Agreement between Juvenescence and AgeX includes indemnification provisions pursuant to which the parties will indemnify each other from certain liabilities in connection with the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular license, lease, or agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Paycheck Protection Program Loan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2020, AgeX obtained a loan in the amount of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_pp0p0_c20200413__us-gaap--PlanNameAxis__custom--PaycheckProtectionProgramMember_z7wMXoEjiOV" title="Loan obtained">432,952</span> from a bank under the Paycheck Protection Program (the “PPP Loan”). The PPP Loan bore interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200413__us-gaap--PlanNameAxis__custom--PaycheckProtectionProgramMember_ztY67gTnCOF2" title="Interest rate">1</span>% per annum. No payments were due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest became due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date was <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200412__20200413__us-gaap--PlanNameAxis__custom--PaycheckProtectionProgramMember_z5lemzR66Gfa" title="Loan maturity date">April 13, 2022</span>. The principal amount of the PPP Loan was subject to forgiveness under the Paycheck Protection Program (the “Program”) to the extent of PPP Loan proceeds that were used to pay expense permitted by the Program, including payroll, rent, and utilities during the time frame permitted by the Program. On February 19, 2021, the PPP Loan was forgiven in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 27, 2020, the Consolidated Appropriations Act of 2021 was signed into law, retroactively allowing a federal deduction of the expenses that gave rise to the PPP Loan forgiveness. California does not allow a deduction for these expenses for publicly traded companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notice of Delisting</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--LossContingencyDescription_c20200601__20200601_zE7qQDFQDQo2" title="Notice of delisting">On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders’ equity of less than $<span id="xdx_90C_eus-gaap--NetIncomeLoss_c20200601__20200601_ziyFKajAoEs6" title="Net loss">2,000,000</span> and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 15, 2021, AgeX regained compliance with all of the Exchange’s continued listing standards set forth in Part 10 of the Exchange Company Guide. Specially, the Exchange has resolved the continued listing deficiency with respect to Section 1003(a)(i) of the Exchange Company Guide.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2021, AgeX received a second deficiency letter (“2021 Deficiency Letter”) from the staff of the Exchange indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX had stockholders equity of less than $<span id="xdx_904_eus-gaap--NetIncomeLoss_c20211116__20211117__srt--RangeAxis__srt--MinimumMember_zTqAqRpQD4Ef" title="Net loss">2,000,000</span> and had incurred losses from continuing operations and/or net losses during the two most recent fiscal years, and that AgeX had stockholders equity of less than $<span id="xdx_906_eus-gaap--NetIncomeLoss_c20211116__20211117__srt--RangeAxis__srt--MaximumMember_z0fRbOklNH8f" title="Net loss">4,000,000</span> and had incurred losses from continuing operations and/or net losses during three out of four of the most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the 2021 Deficiency Letter, AgeX provided the Exchange staff with an updated plan (the “2021 Plan”) during December 2021 advising the Exchange staff of action that AgeX had taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards. The Exchange staff accepted the 2021 Plan which was subsequently revised by AgeX in the course of the Exchange’s continued monitoring of AgeX’s progress to attain compliance with the continued listing standards. During <span style="background-color: white">November 2022, the Exchange sent AgeX a notification indicating that the Exchange has accepted the revised 2021 Plan and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide by increasing stockholders equity to not less than $<span id="xdx_906_eus-gaap--NetIncomeLoss_c20211116__20211117__srt--RangeAxis__srt--MaximumMember_z8WHzm0WNipd" title="Net loss">4,000,000</span>. The Exchange staff will periodically review AgeX’s adherence to the revised 2021 Plan milestones. If we are not in compliance with the continued listing standards by May 17, 2023, or if AgeX does not make progress consistent with the revised 2021 Plan during the plan period, the Exchange will initiate delisting proceedings as appropriate.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX intends to make arrangements to have its common stock quoted on an interdealer quotation system if its common stock is delisted from the Exchange.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 135 947 1074 101 844 432952 0.01 2022-04-13 On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders’ equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan 2000000 2000000 4000000 4000000 <p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zE7Ja2GvqEW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span id="xdx_823_zlwiTQ7tSwa8">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022 Secured Convertible Promissory Note</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 25, 2023, AgeX borrowed an additional $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_c20230101__20230125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zW1sgBQorTd5">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under the Secured Note. In connection with that draw of loan funds under the Secured Note, AgeX issued to Juvenescence warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230125__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5D2FXd9Rdi3" title="Number of warrants, shares">340,136 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of AgeX common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceMember_z7dOJl8KI0Ie">0.735 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amended and Restated Secured Convertible Promissory Note</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 9, 2023, AgeX and Juvenescence entered into an Amended and Restated Secured Convertible Promissory Note which amends and restates the February 14, 2022 Secured Note and provides that AgeX may borrow up to an additional $<span id="xdx_900_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20230209__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSineBSbEful" title="Line of credit, current borrowing capacity">2,000,000</span> from Juvenescence until May 9, 2023 subject to Juvenescence’s discretion to approve each loan draw. References to the Secured Note include the Amended and Restated Secured Note. AgeX may not draw more than $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230209__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQBTD5B2pw28" title="Maximum borrowing capacity">1</span> million in any single draw. The date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024, consistent with the original terms of the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The other material provisions of the Secured Note, including but not limited to those pertaining to loan origination fees, default provisions, provisions governing the rights of AgeX and Juvenescence to convert the loan balance and any accrued but unpaid origination fees into shares of AgeX common stock, and provisions requiring AgeX to issue common stock purchase warrants to Juvenescence in connection with borrowings remain in effect and will apply to any draw down of the additional $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20230209__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFwV2Xu6Xu9l" title="Line of credit, current borrowing capacity">2,000,000</span> credit available under the Secured Note as amended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s obligations under the Secured Note, including with respect to any additional borrowings, will continue to be secured by the security interests in AgeX assets granted to Juvenescence pursuant to the Security Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 15, 2023, AgeX drew $<span id="xdx_903_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20230215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zBBugSEWN1X3" title="Line of credit, current borrowing capacity">1,000,000</span> of its available credit under the Secured Note. In connection with that draw of loan funds, AgeX issued to Juvenescence warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230215__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrfaM2zhKOG4" title="Warrant to purchase shares of common stock">801,924</span> shares of AgeX common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zxgGpi2Z84Bf" title="Warrant excercise price per share">0.6235</span> per share, the closing price of AgeX common stock on the NYSE American on February 10, 2023, the trading day immediately preceding delivery of AgeX’s drawdown notice of loan funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020 Loan Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, the 2020 Loan Agreement was amended to extend the maturity date to March 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>$<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zHUIarfxs0jj" title="Convertiable promissoty note">10</span> Million Secured Convertible Promissory Note</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “$<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zsShLgTbris4" title="Convertiable promissoty note">10</span> Million Secured Note”) pursuant to which Juvenescence has loaned to AgeX $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zJx5AA2k9UB7" title="Line of credit, current borrowing capacity">10,000,000</span>. AgeX used the loan proceeds to finance the purchase of a Convertible Promissory Note (the “Serina Note”) issued by Serina Therapeutics Inc., an Alabama corporation (“Serina”) to AgeX on March 15, 2023, pursuant to the terms of a Convertible Note Purchase Agreement (the “Serina Note Purchase Agreement”)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outstanding principal balance of the $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zCwvFhlHvMZ8" title="Convertiable promissoty note">10</span> Million Secured Note will become due and payable on March 13, 2026. <span id="xdx_903_ecustom--OriginationFeeDescription_c20230213__20230213__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIiIqPSDVik2">In lieu of accrued interest, AgeX will pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If (a) AgeX and Serina have not entered into a definitive merger agreement by June 13, 2023; (b) a merger between AgeX and Serina is terminated or either party gives notice to terminate the merger agreement; or (c) the merger is not consummated by March 13, 2024, then AgeX may, after written notice to Juvenescence, pay and satisfy in full the principal balance and accrued origination fees under the $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zsA42BQeyRW8" title="Convertiable promissoty note">10</span> Million Secured Note by tendering to Juvenescence the Serina Note and shares of capital stock of Serina, if any, that may have been issued to AgeX upon conversion of the Serina Note in whole or in part.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.9pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230313__20230313__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z70PKaKTDSii">10,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If less than $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230313__20230313__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zYNlZkA5M3U1">25,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is raised through the sale of common stock or units, the conversion price per share or units shall be the lowest price at which shares or units are sold. If at least $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8jfml989fgc">25,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is raised, the conversion price per share shall be <span id="xdx_903_ecustom--CommonStockOutstandingPercentage_pid_dp_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z78KTOzjqt36">85</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the “Market Price” of AgeX common stock determined as provided in the $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z6CrViJ7NZ84" title="Proceeds from sale of common stock">10</span> Million Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Juvenescence may convert the outstanding principal amount of the $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zCBlU97XONm7" title="Proceeds from sale of common stock">10</span> Million Secured Note plus the accrued origination fee into AgeX common stock at the market price per share of AgeX common stock. Juvenescence may not convert the $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z6zE95EEpJ6" title="Proceeds from sale of common stock">10</span> Million Secured Note to AgeX common stock before the earlier of (i) a merger between AgeX and Serina, and (ii) March 13, 2024. Any conversion of the $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zDWZe4GANps" title="Proceeds from sale of common stock">10</span> Million Secured Note into AgeX common stock is subject to certain restrictions to comply with applicable requirements of the NYSE American where AgeX common stock is listed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outstanding principal amount of the $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--OriginationFeeMember_zwkm1k0mVvTi" title="Proceeds from sale of common stock">10</span> Million Secured Note and the accrued origination fee may become immediately due and payable prior to the maturity date if an Event of Default as defined in the $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--OriginationFeeMember_zYViIp4Qyoz5" title="Proceeds from sale of common stock">10</span> Million Secured Note occurs. Events of Default under the $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--OriginationFeeMember_zgt493HE37Q5" title="Proceeds from sale of common stock">10</span> Million Secured Note are substantially the same events as those constituting an Event of Default under the Secured Note except that such events pertain to the $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--OriginationFeeMember_zbbkS2RTZ5x1" title="Proceeds from sale of common stock">10</span> Million Secured Note and related loan documents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230313__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--OriginationFeeMember_z3uMtL3MB0X3" title="Proceeds from sale of common stock">10</span> Million Secured Note includes certain covenants that among other matters require financial reporting and impose certain restrictions on AgeX that are substantially the same as those under the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has entered into an Amended and Restated Security Agreement that amends the February 14, 2022 Security Agreement between AgeX and Juvenescence and adds the $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230213__20230213__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--OriginationFeeMember_zpjZbw06Ayoi" title="Proceeds from sale of common stock">10</span> Million Secured Note to the obligations secured by the Security Agreement. The Security Agreement grants Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Serina Note</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 15, 2023, AgeX and Serina entered into the Serina Note Purchase Agreement, pursuant to which AgeX has agreed to lend to Serina an aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zSKqOUID5ic7" title="Convertiable promissoty note">10,000,000</span> as evidenced by the Serina Note. Interest on the principal amount under the Serina Note accrues on the unpaid principal amount at a simple interest rate equal to <span id="xdx_90F_ecustom--StockholderOutstandingPercentage_pid_dp_c20230313__20230315__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zslWkGG4dCr8" title="Stockholder outstanding percentage">7</span>% per annum, computed on the basis of the 360-day year of twelve 30-day months. The outstanding principal balance of the Serina Note will become due and payable on March 15, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the issuance of the Serina Note, AgeX is entitled to elect one member to the board of directors of Serina and receive certain information and inspection rights as well as participation rights for subsequent equity issuances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.9pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The principal balance of the Serina Note with accrued interest will automatically convert into Serina preferred stock if Serina raises at least $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zLcPFjz8Se9b" title="Convertiable promissoty note">25,000,000</span> through the sale of shares of Serina preferred stock. The conversion price per share shall be the lower of (a) <span id="xdx_909_ecustom--StockholderOutstandingPercentage_pid_dp_c20230313__20230315__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zWDVKQUitfq9" title="Stockholder outstanding percentage">80</span>% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsosAufXHvFa" title="Convertiable promissoty note">105,000,000</span> divided by Serina’s then fully diluted capitalization. AgeX has the option to convert the Serina Note into Serina preferred stock after a sale of Serina preferred stock regardless of the amount sold by Serina.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.9pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX may (i) at its election, upon a change of control (as defined in the Serina Note), convert the Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the Serina Note, plus interest, or (b) into the highest ranking shares of Serina then issued at a conversion price equal to the lowest price per share at which the most senior series of Serina shares has been sold in a single transaction or a series of related transactions through which Serina raised at least $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zYz9BD2D3fih" title="Principal amount">5,000,000</span> or (ii) if the Serina Note remains outstanding as of the maturity date, AgeX may convert the Serina Note into the most senior shares of Serina issued at the time of conversion at a conversion price equal to the capped price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the consummation of a merger between AgeX and Serina, the Serina Note would remain outstanding and become an intercompany asset of AgeX and an intercompany liability of Serina.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.9pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outstanding principal balance of the Serina Note with accrued interest may become immediately due and payable prior to the stated maturity date if an Event of Default as defined in the Serina Note occurs. In addition to this and any other remedy, both in equity and in law, upon the occurrence of an Event of Default, an interest rate of<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230315__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4LK1Sg4kOSg" title="Debt interest rate"> 10%</span> per annum and computed on the basis of the 360-day year of twelve 30-day months, shall apply to the Convertible Amount until fully paid. Events of Default under the Serina Note include: (i) the commission of any act of bankruptcy by Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (ii) the execution by Serina of a general assignment for the benefit of creditors, (iii) the filing by or against Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) of a petition in bankruptcy or any petition for relief under the federal bankruptcy act (or, in each case, under any similar insolvency law) or the continuation of such petition without dismissal for a period of 60 calendar days or more, (iv) the appointment of a receiver or trustee to take possession of the property or assets of Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (v) failure of Serina to pay any amount due under the Serina Note when due, which failure to pay is not cured by Serina within 5 business days of written notice thereof, (vi) unless waived by AgeX, Serina’s material breach of any representation, warranty or covenant of Serina under the Serina Note Purchase Agreement, Serina Note or other agreements entered in connection therewith, which breach, if curable, is not cured by Serina within 10 business days of written notice by AgeX thereof, (vii) Serina or any subsidiary shall default on any of its obligations under any indebtedness which default causes the indebtedness thereunder to (x) become prematurely due and payable, (y) be placed on demand or (z) become capable of being declared by or on behalf of a creditor thereunder to be prematurely due and payable or being placed on demand, in each case, as a result of such default or any provision having a similar effect (howsoever prescribed), (viii) any monetary judgment, writ or similar final process shall be entered or filed against Serina, any subsidiary or any of their respective property or other assets for more than $<span id="xdx_909_eus-gaap--OtherAssets_iI_c20230315__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5jwFF2ME672" title="Other assets">250,000</span>, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period of 45 calendar days, and (ix) Serina experiences a Material Adverse Effect (as defined in the Serina Note Purchase Agreement).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.9pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Serina Note Purchase Agreement and Serina Note each includes certain covenants that among other matters require financial reporting and impose certain restrictions, including (i) restrictions on the incurrence of additional indebtedness by Serina and its subsidiaries; (ii) requiring that Serina use note proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, and for general working capital; and (iii) prohibiting Serina from entering into any material sale or transfer transactions outside of the ordinary course of business, other than in a merger between AgeX and Serina, without the consent of AgeX.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subordination Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the issuance of the Serina Note, Serina, each other holder of Serina indebtedness (each a “Serina Lender”), and AgeX entered into a Subordination Agreement, dated March 15, 2023, pursuant to which each Serina Lender agreed to subordinate to AgeX’s rights of repayment with respect to the obligations owed under the Serina Note Purchase Agreement and the Serina Note (i) all Serina indebtedness owed to such Serina Lender under certain convertible notes between each Serina Lender and Serina, which aggregate principal amount of all of such convertible notes equals $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_z3UHc1WV6DD4" title="Principal amount">1,450,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and (ii) any related security interests.</span></p> 500000 340136 0.735 2000000 1000000 2000000 1000000 801924 0.6235 10000000 10000000 10000000 10000000 In lieu of accrued interest, AgeX will pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note. 10000000 10000000 25000000 25000000 0.85 10000000 10000000 10000000 10000000 10000000 10000000 10000000 10000000 10000000 10000000 10000000 0.07 25000000 0.80 105000000 5000000 0.10 250000 1450000 397000 645000 67000 4000 4000 673000 1804000 1141000 2453000 50000 50000 640000 738000 10379000 12210000 3241000 1671000 1034000 1526000 7646000 141000 180000 7000 1077000 3204000 10078000 693000 10478000 3897000 20556000 0 0 100000 100000 212000 212000 21135000 0 0 100000 100000 148000 148000 14823000 14823000 0.0001 0.0001 5000000 5000000 0.0001 0.0001 200000000 200000000 37951000 37951000 37949000 37949000 4000 4000 100017000 98994000 -127557000 -116210000 -27536000 -17212000 -109000 -103000 -27645000 -17315000 12210000 3241000 21000 21000 46000 9000 65000 26000 67000 9000 86000 26000 33000 5000 39000 12000 34000 4000 47000 14000 218000 162000 552000 817000 2172000 1392000 5895000 4390000 2390000 1554000 6447000 5207000 -2356000 -1550000 -6400000 -5193000 3036000 923000 4928000 2357000 -35000 35000 220000 3000 2000 10000 9000 -3033000 -886000 -4953000 -2568000 -5389000 -2436000 -11353000 -7761000 12000 -1000 -6000 -2000 -5401000 -2435000 -11347000 -7759000 -0.14 -0.14 -0.06 -0.06 -0.30 -0.30 -0.20 -0.20 37951 37951 37946 37946 37951 37951 37944 37944 37951000 4000 99977000 -122156000 -121000 -22296000 212000 21160000 148000 14840000 -25000 -17000 40000 40000 -5401000 12000 -5389000 212000 21135000 148000 14823000 37951000 4000 100017000 -127557000 -109000 -27645000 37945000 4000 97850000 -111072000 -44000 -13262000 2000 -1000 -1000 341000 341000 209000 209000 -2435000 -1000 -2436000 37947000 4000 98399000 -113507000 -45000 -15149000 37949 4000 98994000 -116210000 -103000 -17315000 212000 21160000 148000 14840000 -25000 -17000 2000 -1000 -1000 879000 879000 145000 145000 -11347000 -6000 -11353000 212000 21135000 148000 14823000 37951000 4000 100017000 -127557000 -109000 -27645000 37941 4000 93912000 -105748000 -43000 -11875000 37941 4000 93912000 -105748000 -43000 -11875000 6000 -3000 -3000 178000 178000 3666000 3666000 646000 646000 -7759000 -2000 -7761000 37947000 4000 98399000 -113507000 -45000 -15149000 37947000 4000 98399000 -113507000 -45000 -15149000 -11347000 -7759000 -6000 -2000 35000 220000 98000 99000 5170000 2221000 145000 646000 63000 -24000 -1131000 -906000 379000 571000 -98000 -33000 110000 -1075000 -983000 5000 -2000 -5748000 -4618000 10000000 -10000000 15500000 4500000 15500000 4500000 -248000 -118000 695000 634000 447000 516000 <p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zVlE5ixQT88d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_826_zQpbxQDh67A4">Organization, Business Overview and Liquidity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX Therapeutics, Inc. (“AgeX”) was incorporated in January 2017 in the state of Delaware. AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows AgeX to utilize telomerase-expressing regenerative pluripotent stem cells (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX’s main technology platforms and product candidates are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PureStem<i><sup>® </sup></i>PSC-derived clonal embryonic progenitor cell lines that may be capable of generating a broad range of cell types for use in cell-based therapies;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restructuring Plans and Merger Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During March 2023, AgeX borrowed $<span id="xdx_90D_eus-gaap--SecuredDebt_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z9kzrJgKNVa5" title="Secured debt">10,000,000</span> from Juvenescence Limited (“Juvenescence”) under the terms of a Secured Convertible Promissory Note (the “$<span id="xdx_901_eus-gaap--SecuredDebt_iI_pn6n6_c20230331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zpn4NLS8jZsi" title="Secured debt">10</span> Million Secured Note”) and used the loan proceeds to make a $<span id="xdx_906_eus-gaap--ProceedsFromConvertibleDebt_c20230301__20230331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zsty2ihefyq" title="Proceeds from convertible debt">10,000,000</span> loan under the terms of a Convertible Promissory Note to Serina (the “Serina Note”), in order to provide financing to Serina Therapeutics, Inc. (“Serina”) in advance of corporate restructuring plans that include a potential merger between AgeX and Serina in which AgeX would be the surviving company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 29, 2023, AgeX entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Serina and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“Merger Sub”). Serina currently has a pipeline of small molecule candidates targeting central nervous system (“CNS”) indications, enabled by the company’s proprietary POZ Platform<sup>TM</sup> delivery technology. In addition to advancing Serina’s wholly owned pipeline assets, Serina is working with pharma partners currently advancing pre-clinical studies exploring POZ polymer lipid-nanoparticles (“LNPs”) in next generation LNP delivered RNA vaccines. In addition, Serina is advancing a lead drug candidate, SER-252 (POZ-apomorphine) for the treatment of advanced Parkinson’s Disease through pre-clinical studies towards the goal of an investigational new drug submission or “IND” to the Food and Drug Administration for the initiation of a Phase I clinical trial during the fourth quarter of 2024. Serina has two other pipeline assets that are positioned to enter IND enabling studies, SER-227 (POZ-buprenorphine) for certain post-operative pain indications, and SER-228 (POZ-cannabidiol) for treatment refractory epilepsy indications. Serina is also focused on expanding its LNP and anti-body drug conjugate partnering collaborations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including that the Merger is approved by the stockholders of Serina and the issuance of AgeX common stock to Serina in the Merger is approved by the stockholders of AgeX, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the “Merger”). There is no assurance the necessary approvals by AgeX stockholders and Serina stockholders will be obtained or that the other conditions to the Merger as provided in the Merger Agreement will be met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX’s restructuring plans also include a potential spinoff of AgeX’s subsidiary Reverse Bioengineering, Inc. (“Reverse Bio”) through a distribution of some or all of the shares of capital stock of Reverse Bio held by AgeX to AgeX stockholders following a financing of Reverse Bio through the sale of shares of Reverse Bio common stock to private investors (the “Reverse Bio Financing”). If the Reverse Bio spinoff is completed, Reverse Bio would become a separate publicly traded company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive agreements regarding the Reverse Bio Financing and a Reverse Bio spinoff have not yet been executed, nor has AgeX’s board of directors approved the Reverse Bio spinoff. Accordingly, there is a risk that the Reverse Bio Financing and the Reverse Bio spinoff may never be consummated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Emerging Growth Company</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going Concern</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX primarily finances its operations through loans from its largest stockholder, Juvenescence Limited (“Juvenescence”). AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $<span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230930_zMNIz2hJXSge" title="Accumulated deficit">127.6</span> million as of September 30, 2023. AgeX expects to continue to incur operating losses and negative cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have adopted operating plans and budgets to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those operating plans and budgets, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $<span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20230930_zDuvfZfeKEP5">0.4</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of September 30, 2023 plus the loan facilities provided by Juvenescence to advance up to an additional $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230930__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--LoanFacilityAgreementMember_zXDovEpteiZ">1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to AgeX which was drawn in full in October 2023 and an additional $<span id="xdx_90E_eus-gaap--LineOfCredit_iI_pn5n6_c20231109__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--LoanFacilityAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrMGiJod65Qk">4.4 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million line of credit made available to AgeX through an Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note with Juvenescence (the “Fifth Amendment”) on November 9, 2023 would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of these condensed consolidated interim financial statements. These conditions raise substantial doubt about AgeX’s ability to continue as a going concern. AgeX will need to obtain substantial additional funding in connection with its continuing operations. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should AgeX not continue as a going concern. See Note 12, <i>Subsequent Events</i>, for further details on the Fifth Amendment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity and Impact of COVID-19</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in out-licensing its technologies and development of its product candidates. Although AgeX has been able to reduce its operating expenses, with the exception of certain non-recurring expenses incurred related to the possible Merger between AgeX and Serina, by eliminating internal research and development activities and focusing instead on outsourcing research and development and seeking licensing arrangements for AgeX technologies, this approach has also made it more difficult for AgeX to make progress in developing its target product candidates and technologies, which in turn may make it more difficult for AgeX to raise capital. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its stockholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000000 10000000 10000000 -127600000 400000 1000000 4400000 <p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zxvlKMXL9g74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_82F_z3rejLik1Wgf">Basis of Presentation and Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by U.S. GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of AgeX’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zbhpCdubb5b1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zjzf02JiGb03">Principles of consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of AgeX and its subsidiaries in which AgeX has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which AgeX is the primary beneficiary (as described in more detail below). For consolidated entities where AgeX has less than <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ReCyteTherapeuticsIncMember_zHIuzldrLlda" title="Ownership, percentage">100</span>% of ownership, AgeX records net loss attributable to noncontrolling interest on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. The noncontrolling interest is reflected as a separate element of stockholders’ equity (deficit) on AgeX’s consolidated balance sheets. Any material intercompany transactions and balances have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX assesses whether it is the primary beneficiary of a variable interest entity (“VIE”) at the inception of the arrangement and at each reporting date. This assessment is based on its power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and AgeX’s obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. If the entity is within the scope of the variable interest model and meets the definition of a VIE, AgeX considers whether it must consolidate the VIE or provide additional disclosures regarding its involvement with the VIE. If AgeX determines that it is the primary beneficiary of the VIE, AgeX will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event. For entities AgeX holds as an equity investment that are not consolidated under the VIE model, AgeX will consider whether its investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has four subsidiaries, Reverse Bio, ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”), Canaria Transaction Corporation (“Merger Sub”), and has incorporated but not yet capitalized a fourth subsidiary UniverXome Bioengineering, Inc.(“UniverXome”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTR<sup>TM</sup> research and development efforts. AgeX is actively seeking equity financing for Reverse Bio and to the extent that such Reverse Bio Financing is obtained through the sale of capital stock or other equity securities by Reverse Bio, AgeX’s equity interest in Reverse Bio and its iTR<sup>TM</sup> business would be diluted. AgeX’s restructuring plans also include a potential spinoff of Reverse Bio through a distribution of some or all of the shares of capital stock of Reverse Bio held by AgeX to AgeX stockholders following the Reverse Bio Financing. ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MergerAgreementMember_zICZipN9a5L2" title="Ownership, percentage">94.8</span>% of the outstanding capital stock of ReCyte. NeuroAirmid is jointly owned by AgeX with the University of California – Irvine and certain researchers and was recently organized to pursue clinical development and commercialization of cell therapies, focusing initially on Huntington’s Disease. AgeX owns <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ReCyteTherapeuticsIncMember_zPBDnFjbf3Aj" title="Ownership, percentage">50</span>% of the outstanding capital stock of NeuroAirmid. AgeX consolidates NeuroAirmid despite not having majority ownership interest as it has the ability to influence decision making and financial results through contractual rights and obligations as per Accounting Standards Codification (“ASC”) 810, <i>Consolidation</i>. Merger Sub was incorporated for the purpose of merging with Serina to implement the Merger. UniverXome is expected, in connection with the planned Merger, to hold certain AgeX assets and assume AgeX indebtedness obligations to Juvenescence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--UseOfEstimates_zfjZlstztv2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_z451xNrweXZf">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of AgeX’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 6, <i>Warrant Liability</i>, for discussion on estimated change in fair value of warrant liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_znIp9jufHwlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zRcpNuonImJi">Concentration of credit risk and other risks and uncertainties</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, <i>Convertible Note Receivable </i>and 5, <i>Related Party Transactions</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zRxt746O11Li" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zQyAjFJKiIZc">Fair value measurements of financial instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. Fair values for AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, <i>Fair Value Measurements and Disclosures</i>):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Inputs to the valuation methodology include observable quoted prices (other than quoted market prices included within Level 1) for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. The discounted conversion prices triggered by certain qualified events in the Serina Note and the $<span id="xdx_901_eus-gaap--SecuredDebt_iI_pn6n6_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRzdsffVj2j1" title="Secured debt">10</span> Million Secured Note are Level 3 on the fair value hierarchy and subject to fair valuation at inception and remeasurement at each reporting period. The fair value of the discounted conversion prices under both notes were determined to have an immaterial value at inception and life to date of the notes, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period. For additional information regarding the convertible notes and derivatives, see Notes 4, <i>Convertible Note Receivable</i>, 5, <i>Related Party Transactions</i>, and 12, <i>Subsequent Events</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations are discussed further in Note 6, <i>Warrant Liability</i>. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date. As of September 30, 2023, AgeX has utilized the full credit subject to warrants, and accordingly, the warrants were fully issued for each of the advances of loan funds under the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 6, <i>Warrant Liability</i>, for additional information on accounting for liability classified warrants and certain Level 3 warrant valuation tables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zkB9TT0ILjM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zlqC54PEjDD1">Cash, cash equivalents, and restricted cash</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Accounting Standards Update (“ASU”) 2016-18, <i>Statement of Cash Flows (Topic 230): Restricted Cash</i>, a reconciliation of AgeX’s cash and cash equivalents in the condensed consolidated balance sheets to cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows for all periods presented is as follows (in thousands):</span></p> <p id="xdx_89C_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_zTp69gCodGfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zzgpgcTv6lba" style="display: none">Schedule of Cash, Cash Equivalents and Restricted Cash</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20230930_zxQLxqVesFo9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20221231_z2poUcgmklVf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzJLb_ztZzlelZ2Z07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">397</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">645</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--RestrictedCashEquivalents_iI_pn3n3_maRCACEzJLb_zirgDAZOgtu3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash <sup id="xdx_F42_zuc9Ru1osro">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtRCACEzJLb_zD3BGxiRUmGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">447</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zRUc3oeIgh5e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zxkFxQEz6vIj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.</span></td></tr> </table> <p id="xdx_8A5_zDjbwQXv7bxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zF4esAdbGWje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zw5OQlSDBSV4">Long-lived intangible assets, net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&amp;D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230930_zgUu0iqxb7Nl" title="Finite lived intangible asset useful life">10</span> years. See Note 3, <i>Selected Balance Sheet Components</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8010MkyZxCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z0jCCQNaJkCj">Impairment of long-lived assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consists entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of September 30, 2023, there has been no impairment of long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zo2q3KAsHNtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z2zUmuAG5DD5">Leases</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX accounts for leases in accordance with ASU 2016-02, <i>Leases </i>(Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX: (i) ASU 2018-10, <i>Codification Improvements to Topic 842, Leases,</i> and (ii) ASU 2018-11, <i>Leases (Topic 842): Targeted Improvements, </i>using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20230930_z5KeqI13deLa" title="Lessee operating lease description">(i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset</span>. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX leases office space in Alameda, California. For 2022 base monthly rent was $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zxVfg03GJpLa" title="Base rent">1,074</span> and for 2023 base monthly rent is $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zZCt9lkSxrkl" title="Base rent">844</span> for slightly less space at the same building. AgeX has elected to not apply the recognition requirements under ASC 842 for the lease agreements and instead recognizes the lease payments as lease cost on a straight-line basis over the lease term as lease payments are not deemed material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--AccountingForWarrantsPolicyTextBlock_zf3lJfRb0B0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_z8sTWEZ35oIh">Accounting for warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</i>, then in accordance with ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</i>. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of September 30, 2023. See Notes 5, <i>Related Party Transactions</i> and 6, <i>Warrant Liability</i>, for additional information regarding warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zNLp97jxqO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zHqX1RTNqAl9">Revenue recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant revenues –</i> AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, <i>Research and Development Arrangements.</i> At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, AgeX’s policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health (“NIH”) supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2023, AgeX was awarded a grant of up to approximately $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230801__20230831__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zHyvQhPMTIoh">341,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the NIH, National Heart, Lung and Blood Institute. The NIH grant will provide funding for continued development of AgeX’s technologies toward treating cardiovascular disease over a one year period starting September 1, 2023. Based on our evaluation under the accounting guidance aforementioned, this grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred. Accordingly, grant funds are made available by the NIH as allowable expenses are incurred. For the three and nine months ended September 30, 2023, AgeX incurred approximately $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zBRAjIvCQLKk"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zMqAfgTotzo8">21,000</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ESI BIO Research Products –</i> AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP”. AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products have not been significant during the periods presented in the condensed consolidated interim financial statements included in this Report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Arrangements with multiple performance obligations –</i> AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of September 30, 2023 and December 31, 2022, AgeX did not have significant arrangements with multiple performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZHM5miZ27Fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zS6Ob5ZXIdRf">Research and development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and contractors, sponsored research agreements with certain universities, and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXcQeS5emrma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zEcGv4Zwk5Gb">General and administrative</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zresklRwqtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zN6BVq0wtEVj">Basic and diluted net loss per share attributable to common stockholders</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and nine months ended September 30, 2023 and 2022, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgaeMKo6paqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zCXyPUYhKdKk" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zXDeXTtb3oO5" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,276</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zpQYtVvJYLD3" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,264</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrygeAra29e9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,266</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zKdriq7JNTEi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,310</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants <sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_z0QqncTBy81f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,132</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zs17suWTky83" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,616</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zBsGh5fNdVe8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,716</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zdl6ewoDXUw9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,947</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zv18H3uVl0Ja" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2378">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zSMCsahdoHa9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z3HSTbjjfGPb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2382">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zBphJNdlkAea" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0F_zGzhb7jstfef" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zelhY1vQUrG4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_z6UFBVmaRth4" title="Warrant to purchase shares of common stock">11,539,348</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zhBS5VUqdkM7" title="Warrant to purchase shares of common stock">10,919,485</span> shares, respectively, of AgeX common stock as consideration for certain loan agreements discussed in Note 5, <i>Related Party Transactions</i>.</span></td></tr> </table> <p id="xdx_8A6_zrj3iRRAK1Y9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPseKEORcoSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zuL7aRIYJN92">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the prior period’s condensed consolidated interim financial statements to conform to current year presentation. Additionally, certain financial information is presented on a rounded basis, which may cause minor differences.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z4l9ZMKfdKFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zKAdKdykLclj">Recently adopted accounting pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, <i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the FASB issued ASU No. 2022-01, <i>Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method</i>, which clarifies the guidance in ASC 815 on fair value hedge accounting of interest rate risk for portfolios of financial assets. The ASU amends the guidance in ASU 2017-12 (released on August 28, 2017) that, among other things, established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible. ASU 2022-01 renames that method the “portfolio layer” method and addresses feedback from stakeholders regarding its application. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the FASB issued ASU No. 2022-02, <i>Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures</i>, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance became effective for AgeX on January 1, 2023 and includes interim periods. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. This ASU did not have a material impact on the condensed consolidated interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2023, the FASB issued ASU No. 2023-02, P<i>resentation of Financial Statements (Topic 205), Income Statement – Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation</i>, which amends or supersedes various SEC paragraphs within the codification to conform to past announcements and guidance issued by the SEC. Specifically, the ASU responds to (1) the issuance of SEC Staff Accounting Bulletin (SAB) 120; (2) the SEC staff announcement at the March 24, 2022, EITF meeting; and (3) SAB Topic 6.B, “Accounting Series Release No. 280 — General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.” This ASU is effective immediately and did not have a material impact on AgeX’s condensed consolidated interim financial statements.</span></p> <p id="xdx_854_zfAmlmBNs0I2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zbhpCdubb5b1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zjzf02JiGb03">Principles of consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of AgeX and its subsidiaries in which AgeX has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which AgeX is the primary beneficiary (as described in more detail below). For consolidated entities where AgeX has less than <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ReCyteTherapeuticsIncMember_zHIuzldrLlda" title="Ownership, percentage">100</span>% of ownership, AgeX records net loss attributable to noncontrolling interest on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. The noncontrolling interest is reflected as a separate element of stockholders’ equity (deficit) on AgeX’s consolidated balance sheets. Any material intercompany transactions and balances have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX assesses whether it is the primary beneficiary of a variable interest entity (“VIE”) at the inception of the arrangement and at each reporting date. This assessment is based on its power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and AgeX’s obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. If the entity is within the scope of the variable interest model and meets the definition of a VIE, AgeX considers whether it must consolidate the VIE or provide additional disclosures regarding its involvement with the VIE. If AgeX determines that it is the primary beneficiary of the VIE, AgeX will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event. For entities AgeX holds as an equity investment that are not consolidated under the VIE model, AgeX will consider whether its investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has four subsidiaries, Reverse Bio, ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”), Canaria Transaction Corporation (“Merger Sub”), and has incorporated but not yet capitalized a fourth subsidiary UniverXome Bioengineering, Inc.(“UniverXome”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTR<sup>TM</sup> research and development efforts. AgeX is actively seeking equity financing for Reverse Bio and to the extent that such Reverse Bio Financing is obtained through the sale of capital stock or other equity securities by Reverse Bio, AgeX’s equity interest in Reverse Bio and its iTR<sup>TM</sup> business would be diluted. AgeX’s restructuring plans also include a potential spinoff of Reverse Bio through a distribution of some or all of the shares of capital stock of Reverse Bio held by AgeX to AgeX stockholders following the Reverse Bio Financing. ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MergerAgreementMember_zICZipN9a5L2" title="Ownership, percentage">94.8</span>% of the outstanding capital stock of ReCyte. NeuroAirmid is jointly owned by AgeX with the University of California – Irvine and certain researchers and was recently organized to pursue clinical development and commercialization of cell therapies, focusing initially on Huntington’s Disease. AgeX owns <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ReCyteTherapeuticsIncMember_zPBDnFjbf3Aj" title="Ownership, percentage">50</span>% of the outstanding capital stock of NeuroAirmid. AgeX consolidates NeuroAirmid despite not having majority ownership interest as it has the ability to influence decision making and financial results through contractual rights and obligations as per Accounting Standards Codification (“ASC”) 810, <i>Consolidation</i>. Merger Sub was incorporated for the purpose of merging with Serina to implement the Merger. UniverXome is expected, in connection with the planned Merger, to hold certain AgeX assets and assume AgeX indebtedness obligations to Juvenescence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 0.948 0.50 <p id="xdx_84E_eus-gaap--UseOfEstimates_zfjZlstztv2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_z451xNrweXZf">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of AgeX’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 6, <i>Warrant Liability</i>, for discussion on estimated change in fair value of warrant liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_znIp9jufHwlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zRcpNuonImJi">Concentration of credit risk and other risks and uncertainties</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, <i>Convertible Note Receivable </i>and 5, <i>Related Party Transactions</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zRxt746O11Li" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zQyAjFJKiIZc">Fair value measurements of financial instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. Fair values for AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, <i>Fair Value Measurements and Disclosures</i>):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Inputs to the valuation methodology include observable quoted prices (other than quoted market prices included within Level 1) for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. The discounted conversion prices triggered by certain qualified events in the Serina Note and the $<span id="xdx_901_eus-gaap--SecuredDebt_iI_pn6n6_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRzdsffVj2j1" title="Secured debt">10</span> Million Secured Note are Level 3 on the fair value hierarchy and subject to fair valuation at inception and remeasurement at each reporting period. The fair value of the discounted conversion prices under both notes were determined to have an immaterial value at inception and life to date of the notes, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period. For additional information regarding the convertible notes and derivatives, see Notes 4, <i>Convertible Note Receivable</i>, 5, <i>Related Party Transactions</i>, and 12, <i>Subsequent Events</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations are discussed further in Note 6, <i>Warrant Liability</i>. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date. As of September 30, 2023, AgeX has utilized the full credit subject to warrants, and accordingly, the warrants were fully issued for each of the advances of loan funds under the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 6, <i>Warrant Liability</i>, for additional information on accounting for liability classified warrants and certain Level 3 warrant valuation tables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000000 <p id="xdx_843_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zkB9TT0ILjM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zlqC54PEjDD1">Cash, cash equivalents, and restricted cash</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Accounting Standards Update (“ASU”) 2016-18, <i>Statement of Cash Flows (Topic 230): Restricted Cash</i>, a reconciliation of AgeX’s cash and cash equivalents in the condensed consolidated balance sheets to cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows for all periods presented is as follows (in thousands):</span></p> <p id="xdx_89C_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_zTp69gCodGfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zzgpgcTv6lba" style="display: none">Schedule of Cash, Cash Equivalents and Restricted Cash</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20230930_zxQLxqVesFo9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20221231_z2poUcgmklVf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzJLb_ztZzlelZ2Z07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">397</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">645</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--RestrictedCashEquivalents_iI_pn3n3_maRCACEzJLb_zirgDAZOgtu3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash <sup id="xdx_F42_zuc9Ru1osro">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtRCACEzJLb_zD3BGxiRUmGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">447</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zRUc3oeIgh5e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zxkFxQEz6vIj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.</span></td></tr> </table> <p id="xdx_8A5_zDjbwQXv7bxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_zTp69gCodGfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zzgpgcTv6lba" style="display: none">Schedule of Cash, Cash Equivalents and Restricted Cash</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20230930_zxQLxqVesFo9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20221231_z2poUcgmklVf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzJLb_ztZzlelZ2Z07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">397</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">645</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--RestrictedCashEquivalents_iI_pn3n3_maRCACEzJLb_zirgDAZOgtu3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash <sup id="xdx_F42_zuc9Ru1osro">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtRCACEzJLb_zD3BGxiRUmGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">447</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zRUc3oeIgh5e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zxkFxQEz6vIj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.</span></td></tr> </table> 397000 645000 50000 50000 447000 695000 <p id="xdx_849_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zF4esAdbGWje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zw5OQlSDBSV4">Long-lived intangible assets, net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&amp;D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230930_zgUu0iqxb7Nl" title="Finite lived intangible asset useful life">10</span> years. See Note 3, <i>Selected Balance Sheet Components</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P10Y <p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8010MkyZxCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z0jCCQNaJkCj">Impairment of long-lived assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consists entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of September 30, 2023, there has been no impairment of long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zo2q3KAsHNtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z2zUmuAG5DD5">Leases</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX accounts for leases in accordance with ASU 2016-02, <i>Leases </i>(Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX: (i) ASU 2018-10, <i>Codification Improvements to Topic 842, Leases,</i> and (ii) ASU 2018-11, <i>Leases (Topic 842): Targeted Improvements, </i>using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20230930_z5KeqI13deLa" title="Lessee operating lease description">(i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset</span>. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX leases office space in Alameda, California. For 2022 base monthly rent was $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zxVfg03GJpLa" title="Base rent">1,074</span> and for 2023 base monthly rent is $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zZCt9lkSxrkl" title="Base rent">844</span> for slightly less space at the same building. AgeX has elected to not apply the recognition requirements under ASC 842 for the lease agreements and instead recognizes the lease payments as lease cost on a straight-line basis over the lease term as lease payments are not deemed material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset 1074 844 <p id="xdx_844_ecustom--AccountingForWarrantsPolicyTextBlock_zf3lJfRb0B0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_z8sTWEZ35oIh">Accounting for warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</i>, then in accordance with ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</i>. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of September 30, 2023. See Notes 5, <i>Related Party Transactions</i> and 6, <i>Warrant Liability</i>, for additional information regarding warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zNLp97jxqO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zHqX1RTNqAl9">Revenue recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant revenues –</i> AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, <i>Research and Development Arrangements.</i> At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, AgeX’s policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health (“NIH”) supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2023, AgeX was awarded a grant of up to approximately $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230801__20230831__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zHyvQhPMTIoh">341,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the NIH, National Heart, Lung and Blood Institute. The NIH grant will provide funding for continued development of AgeX’s technologies toward treating cardiovascular disease over a one year period starting September 1, 2023. Based on our evaluation under the accounting guidance aforementioned, this grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred. Accordingly, grant funds are made available by the NIH as allowable expenses are incurred. For the three and nine months ended September 30, 2023, AgeX incurred approximately $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zBRAjIvCQLKk"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zMqAfgTotzo8">21,000</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ESI BIO Research Products –</i> AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP”. AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products have not been significant during the periods presented in the condensed consolidated interim financial statements included in this Report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Arrangements with multiple performance obligations –</i> AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of September 30, 2023 and December 31, 2022, AgeX did not have significant arrangements with multiple performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 341000 21000 21000 <p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZHM5miZ27Fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zS6Ob5ZXIdRf">Research and development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and contractors, sponsored research agreements with certain universities, and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXcQeS5emrma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zEcGv4Zwk5Gb">General and administrative</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zresklRwqtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zN6BVq0wtEVj">Basic and diluted net loss per share attributable to common stockholders</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and nine months ended September 30, 2023 and 2022, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgaeMKo6paqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zCXyPUYhKdKk" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zXDeXTtb3oO5" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,276</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zpQYtVvJYLD3" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,264</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrygeAra29e9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,266</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zKdriq7JNTEi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,310</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants <sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_z0QqncTBy81f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,132</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zs17suWTky83" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,616</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zBsGh5fNdVe8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,716</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zdl6ewoDXUw9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,947</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zv18H3uVl0Ja" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2378">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zSMCsahdoHa9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z3HSTbjjfGPb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2382">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zBphJNdlkAea" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0F_zGzhb7jstfef" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zelhY1vQUrG4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_z6UFBVmaRth4" title="Warrant to purchase shares of common stock">11,539,348</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zhBS5VUqdkM7" title="Warrant to purchase shares of common stock">10,919,485</span> shares, respectively, of AgeX common stock as consideration for certain loan agreements discussed in Note 5, <i>Related Party Transactions</i>.</span></td></tr> </table> <p id="xdx_8A6_zrj3iRRAK1Y9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgaeMKo6paqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zCXyPUYhKdKk" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zXDeXTtb3oO5" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,276</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zpQYtVvJYLD3" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,264</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrygeAra29e9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,266</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zKdriq7JNTEi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,310</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants <sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_z0QqncTBy81f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,132</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zs17suWTky83" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,616</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zBsGh5fNdVe8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,716</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zdl6ewoDXUw9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,947</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zv18H3uVl0Ja" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2378">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zSMCsahdoHa9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z3HSTbjjfGPb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2382">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zBphJNdlkAea" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0F_zGzhb7jstfef" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zelhY1vQUrG4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_z6UFBVmaRth4" title="Warrant to purchase shares of common stock">11,539,348</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zhBS5VUqdkM7" title="Warrant to purchase shares of common stock">10,919,485</span> shares, respectively, of AgeX common stock as consideration for certain loan agreements discussed in Note 5, <i>Related Party Transactions</i>.</span></td></tr> </table> 3276000 3264000 3266000 3310000 12132000 10616000 12716000 8947000 9000 12000 11539348000 10919485000 <p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPseKEORcoSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zuL7aRIYJN92">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the prior period’s condensed consolidated interim financial statements to conform to current year presentation. Additionally, certain financial information is presented on a rounded basis, which may cause minor differences.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z4l9ZMKfdKFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zKAdKdykLclj">Recently adopted accounting pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, <i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the FASB issued ASU No. 2022-01, <i>Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method</i>, which clarifies the guidance in ASC 815 on fair value hedge accounting of interest rate risk for portfolios of financial assets. The ASU amends the guidance in ASU 2017-12 (released on August 28, 2017) that, among other things, established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible. ASU 2022-01 renames that method the “portfolio layer” method and addresses feedback from stakeholders regarding its application. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the condensed consolidated interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the FASB issued ASU No. 2022-02, <i>Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures</i>, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance became effective for AgeX on January 1, 2023 and includes interim periods. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. This ASU did not have a material impact on the condensed consolidated interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2023, the FASB issued ASU No. 2023-02, P<i>resentation of Financial Statements (Topic 205), Income Statement – Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation</i>, which amends or supersedes various SEC paragraphs within the codification to conform to past announcements and guidance issued by the SEC. Specifically, the ASU responds to (1) the issuance of SEC Staff Accounting Bulletin (SAB) 120; (2) the SEC staff announcement at the March 24, 2022, EITF meeting; and (3) SAB Topic 6.B, “Accounting Series Release No. 280 — General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.” This ASU is effective immediately and did not have a material impact on AgeX’s condensed consolidated interim financial statements.</span></p> <p id="xdx_80C_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zqckxR3ZqFMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_82D_zSbx2FuCk9d1">Selected Balance Sheet Components</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intangible assets, net</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zC4XfTUZAdY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September 30, 2023 and December 31, 2022, intangible assets, primarily consisting of acquired IPR&amp;D and patents, and accumulated amortization were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B9_zZNfuN0bQoT1" style="display: none">Schedule of Intangible Assets, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20230930_zAm3yRbLcgG5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20221231_zbtGdC7xacs7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANz8a7_zvDz6SundAc4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,312</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,312</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANz8a7_zZH2jP3kgRE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(672</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(574</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_pn3n3_mtFLIANz8a7_zMhrjCEyQlB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">640</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A0_zojpTU4T2Kmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognized $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3d_c20230701__20230930_zu4JJS2ocK59" title="Amortization expense of intangible assets">33,000</span> and $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pn3d_c20230101__20230930_zkb9q01Rw4oh" title="Amortization expense of intangible assets">98,000</span> in amortization expense of intangible assets, included in research and development expenses, for the three and nine months ended September 30, 2023, respectively and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pn3d_c20220701__20220930_z1rC6T3B3lKh" title="Amortization expense of intangible assets">33,000</span> and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pn3d_c20220101__20220930_zIRgVHd74Kdb" title="Amortization expense of intangible assets"><span>99,000</span></span> for the same periods in 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zdtlpYl8YNS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of intangible assets for periods subsequent to September 30, 2023 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zGGOwTsSwYBg" style="display: none">Schedule of Amortization Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ending December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20230930_ztNHRSN7mzXa" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzFZe_zvwFabuPWzb2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzFZe_zpqHt3jMXIJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    131</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzFZe_zpJmBCa0KE6b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzFZe_zl9S7rGm27Cf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree_iI_pn3n3_maFLIANzFZe_zf9pDsWEZKKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">213</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzFZe_zHp8GVBHwoI" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">640</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A2_zdv42sboULg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts payable and accrued liabilities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ziUKN1QKyoK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September 30, 2023 and December 31, 2022, accounts payable and accrued liabilities were comprised of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_ziNRJ8wDiIf9" style="display: none">Schedule of Accounts Payable and Accrued Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20230930_z1FEcIwiFSE9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20221231_zxbp9G30Dsd2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maAPAALzW5b_zDhfMKMw0BHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,172</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">568</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccruedBonusesCurrent_iI_pn3n3_maAPAALzW5b_zRYELVEGe585" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">206</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzW5b_zyvkPNSbQc62" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued vendors and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">293</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">273</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzW5b_zL1ZVN8q9d05" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accounts payable and accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,671</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zerrXwAd3Hi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zC4XfTUZAdY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September 30, 2023 and December 31, 2022, intangible assets, primarily consisting of acquired IPR&amp;D and patents, and accumulated amortization were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B9_zZNfuN0bQoT1" style="display: none">Schedule of Intangible Assets, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20230930_zAm3yRbLcgG5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20221231_zbtGdC7xacs7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANz8a7_zvDz6SundAc4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,312</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,312</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANz8a7_zZH2jP3kgRE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(672</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(574</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_pn3n3_mtFLIANz8a7_zMhrjCEyQlB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">640</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1312000 1312000 672000 574000 640000 738000 33000 98000 33000 99000 <p id="xdx_893_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zdtlpYl8YNS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of intangible assets for periods subsequent to September 30, 2023 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zGGOwTsSwYBg" style="display: none">Schedule of Amortization Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ending December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20230930_ztNHRSN7mzXa" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzFZe_zvwFabuPWzb2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzFZe_zpqHt3jMXIJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    131</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzFZe_zpJmBCa0KE6b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzFZe_zl9S7rGm27Cf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree_iI_pn3n3_maFLIANzFZe_zf9pDsWEZKKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">213</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzFZe_zHp8GVBHwoI" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">640</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 33000 131000 131000 132000 213000 640000 <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ziUKN1QKyoK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September 30, 2023 and December 31, 2022, accounts payable and accrued liabilities were comprised of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_ziNRJ8wDiIf9" style="display: none">Schedule of Accounts Payable and Accrued Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20230930_z1FEcIwiFSE9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20221231_zxbp9G30Dsd2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maAPAALzW5b_zDhfMKMw0BHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,172</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">568</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccruedBonusesCurrent_iI_pn3n3_maAPAALzW5b_zRYELVEGe585" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">206</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzW5b_zyvkPNSbQc62" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued vendors and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">293</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">273</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzW5b_zL1ZVN8q9d05" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accounts payable and accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,671</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1172000 568000 206000 193000 293000 273000 1671000 1034000 <p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zW49mGoZO8Ng" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_826_zhSvMWqJCQf4">Convertible Note Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 15, 2023, AgeX and Serina entered into a Convertible Note Purchase Agreement (the “Serina Note Purchase Agreement”), pursuant to which AgeX lent to Serina an aggregate principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zSAPyuEpro59">10,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as evidenced by the Serina Note on that date. Interest on the principal amount under the Serina Note accrues on the unpaid principal amount at a simple interest rate equal to <span id="xdx_904_ecustom--StockholderOutstandingPercentage_pid_dp_uPure_c20230315__20230315__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zd5aZPzeKQ4e">7</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% per annum, computed on the basis of the 360-day year of twelve 30-day months. The outstanding principal amount and accrued interest of $<span id="xdx_906_ecustom--DebtInstrumentFaceAndInterestOutstanding_iI_c20230315__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zlBgXZml9lkd" title="Principal and interest outstanding">10,379,000</span> under the Serina Note will become due and payable on March 15, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the issuance of the Serina Note, AgeX is entitled to elect one member to the board of directors of Serina and receive certain information and inspection rights as well as participation rights for subsequent equity issuances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The principal balance of the Serina Note with accrued interest will automatically convert into Serina preferred stock if Serina raises at least $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zPZtRqyTjSob" title="Convertiable promissoty note">25,000,000</span> through the sale of shares of Serina preferred stock (“qualifying event”). The conversion price per share shall be the lower of (a) <span id="xdx_903_ecustom--StockholderOutstandingPercentage_pid_dp_c20230315__20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zUPyiES7Raa" title="Stockholder outstanding percentage">80</span>% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315_zxm6zgcD7r2a" title="Convertiable promissoty note">105,000,000</span> divided by Serina’s then fully diluted capitalization. AgeX has the option to convert the Serina Note into Serina preferred stock after a sale of Serina preferred stock regardless of the amount sold by Serina. AgeX evaluated the <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zN6L1gopEx47" title="Discounted conversion price">20</span>% discounted conversion feature of the Serina Note under ASC 815-15, <i>Derivatives and Hedging—Embedded Derivatives</i>, and concluded that it was an embedded derivative which should be bifurcated from the note and accounted for separately. The <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zIn60qnSCMEk" title="Discounted conversion price">20</span>% discount was determined to have an immaterial value at inception and life to date of the Serina Note, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period and any adjustments will be included in <i>Interest (income) expense, net</i> in the <i>Other (income) expense, net</i> section of the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX may (i) at its election, upon a change of control (as defined in the Serina Note), convert the Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the Serina Note, plus interest, or (b) into the highest ranking shares of Serina then issued at a conversion price equal to the lowest price per share at which the most senior series of Serina shares has been sold in a single transaction or a series of related transactions through which Serina raised at least $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zD5I8hF0D8sl" title="Principal amount">5,000,000</span> or (ii) if the Serina Note remains outstanding as of the maturity date, AgeX may convert the Serina Note into the most senior shares of Serina issued at the time of conversion at a conversion price equal to the capped price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Merger is consummated, the Serina Note will be canceled for no consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outstanding principal balance of the Serina Note with accrued interest may become immediately due and payable prior to the stated maturity date if an Event of Default as defined in the Serina Note occurs. In addition to this and any other remedy, both in equity and in law, upon the occurrence of an Event of Default, an interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230315_zNyGsj132KSh" title="Debt interest rate">10</span>% per annum and computed on the basis of the 360-day year of twelve 30-day months, shall apply to the Convertible Amount until fully paid. Events of Default under the Serina Note include: (i) the commission of any act of bankruptcy by Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (ii) the execution by Serina of a general assignment for the benefit of creditors, (iii) the filing by or against Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) of a petition in bankruptcy or any petition for relief under the federal bankruptcy act (or, in each case, under any similar insolvency law) or the continuation of such petition without dismissal for a period of 60 calendar days or more, (iv) the appointment of a receiver or trustee to take possession of the property or assets of Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (v) failure of Serina to pay any amount due under the Serina Note when due, which failure to pay is not cured by Serina within 5 business days of written notice thereof, (vi) unless waived by AgeX, Serina’s material breach of any representation, warranty or covenant of Serina under the Serina Note Purchase Agreement, Serina Note or other agreements entered in connection therewith, which breach, if curable, is not cured by Serina within 10 business days of written notice by AgeX thereof, (vii) Serina or any subsidiary shall default on any of its obligations under any indebtedness which default causes the indebtedness thereunder to (x) become prematurely due and payable, (y) be placed on demand or (z) become capable of being declared by or on behalf of a creditor thereunder to be prematurely due and payable or being placed on demand, in each case, as a result of such default or any provision having a similar effect (howsoever prescribed), (viii) any monetary judgment, writ or similar final process shall be entered or filed against Serina, any subsidiary or any of their respective property or other assets for more than $<span id="xdx_908_eus-gaap--OtherAssets_iI_c20230315_zB6bXXoOK7Wf" title="Other assets">250,000</span>, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period of 45 calendar days, and (ix) Serina experiences a Material Adverse Effect (as defined in the Serina Note Purchase Agreement).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Serina Note Purchase Agreement and Serina Note each includes certain covenants that among other matters require financial reporting and impose certain restrictions, including (i) restrictions on the incurrence of additional indebtedness by Serina and its subsidiaries; (ii) requiring that Serina use note proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, and for general working capital; and (iii) prohibiting Serina from entering into any material sale or transfer transactions outside of the ordinary course of business, other than in a merger between AgeX and Serina, without the consent of AgeX.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subordination Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the issuance of the Serina Note, Serina, each other holder of Serina indebtedness (each a “Serina Lender”), and AgeX entered into a Subordination Agreement, dated March 15, 2023, pursuant to which each Serina Lender agreed to subordinate to AgeX’s rights of repayment with respect to the obligations owed under the Serina Note Purchase Agreement and the Serina Note (i) all Serina indebtedness owed to such Serina Lender under certain convertible notes between each Serina Lender and Serina, which aggregate principal amount of all of such convertible notes equals $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SubordinationAgreementMember_zoRz5ozZvIH" title="Principal amount">1,450,000</span>, and (ii) any related security interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000000 0.07 10379000 25000000 0.80 105000000 0.20 0.20 5000000 0.10 250000 1450000 <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zwTxBhVTJhS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_820_zJcHv9iNMqg1">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During July 2023, AgeX and Juvenescence entered into an Exchange Agreement pursuant to which AgeX issued shares of Series A Preferred Stock and Series B Preferred Stock to Juvenescence in exchange for the extinguishment of a total of $<span id="xdx_902_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn6n6_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zkmZB4EH4HY5" title="Extinguishment of debt">36</span> million of indebtedness under the 2020 Loan Agreement, the Secured Note, and the $<span id="xdx_909_eus-gaap--SecuredDebt_iI_pn6n6_c20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_ztJJNTla9xH" title="Secured debt">10</span> Million Secured Note discussed below. The unused portion of the line of credit under the Secured Note remains available to AgeX subject to the terms and conditions of the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2019 Loan Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence provided to AgeX a $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn6n6_c20190812__20190813__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember_zUcti9ArtGnk" title="Line of credit facility">2</span> million line of credit for a period of <span id="xdx_908_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20190812__20190813__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember_zqccoV6u955d" title="Line of credit, term">18</span> months. On February 10, 2021, AgeX entered into an amendment (the “First Amendment”) to the 2019 Loan Agreement which extended the maturity date of loans under the 2019 Loan Agreement to February 14, 2022, and increased the amount of the loan facility by $<span id="xdx_902_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn6n6_c20210209__20210210__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember_z91ZWOcflEfi" title="Increase in line of credit">4</span> million. On November 8, 2021, AgeX entered into Amendment No. 2 to the 2019 Loan Agreement which increased the amount of the loan facility by another $<span id="xdx_905_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn6n6_c20211107__20211108__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_z59Tq9jMAiSg" title="Increase in line of credit">1</span> million. As of December 31, 2021, AgeX had borrowed all of the $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zDhONTifTIah" title="Line of credit facility">7</span> million total line of credit under the 2019 Loan Agreement, as amended. On February 14, 2022, AgeX refinanced the $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_z47uMlkZolAh" title="Line of credit facility">7</span> million outstanding principal amount of the loans and a $<span id="xdx_90A_eus-gaap--DebtInstrumentFeeAmount_iI_pn3p0_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_z9BvJtHa3dui" title="Origination fee">160,000</span> origination fee due under the 2019 Loan Agreement, as amended. See discussion regarding the 2022 Secured Convertible Promissory Note within this Note 5.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020 Loan Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence provided to AgeX an $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zQDG6fELFEOd" title="Line of credit facility">8</span> million line of credit for a period of <span id="xdx_909_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20200329__20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zkMaFKBtIZ4e" title="Line of credit, term">18</span> months. Through September 30, 2023, AgeX had drawn the full $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_z5TQ5vLuTRQi" title="Line of credit facility, current borrowing capacity">8</span> million line of credit. AgeX issued to Juvenescence <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200329__20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_ztPcT6QNbCTf" title="Common stock, shares">28,500</span> shares of AgeX common stock as an arrangement fee for the loan facility when AgeX borrowed an aggregate of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn6n6_c20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zLIBr4koO8Qk" title="Line of credit facility">3</span> million under the 2020 Loan Agreement, and AgeX issued to Juvenescence warrants to purchase a total of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zKE2rbiW0uO3" title="Total warrants to purchase">3,670,663</span> shares of AgeX common stock (“2020 Warrants”) as determined by the warrant formula described below of which <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zm5ato6ohxZj" title="Warrants outstanding">1,182,262</span> are outstanding as of September 30, 2023. On March 13, 2023, the 2020 Loan Agreement was amended to extend the maturity date to March 30, 2024. During July 2023, the full $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn6n6_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyLoanAgreementMember_zCtRRffS7uhe" title="Extinguishment of debt">8</span> million of 2020 Loan Agreement indebtedness was extinguished in exchange for shares of Series A Preferred Stock pursuant to the Exchange Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020 Warrants —</i> Under the terms of the 2020 Loan Agreement, each time AgeX received an advance of funds under the 2020 Loan Agreement, AgeX issued to Juvenescence a number of 2020 Warrants equal to 50% of the number determined by dividing the amount of the advance by the applicable Market Price. The Market Price set each 2020 Warrant when issued was the closing price per share of AgeX common stock on the NYSE American on the date of the applicable notice from AgeX requesting a draw of funds that triggered the obligation to issue the 2020 Warrant. The 2020 Warrants will expire at 5:00 p.m. New York time three years after the date of issue. AgeX had issued to Juvenescence 2020 Warrants to purchase a total of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX857fIdeWlg" title="Sale of warrants purchase of common stock">3,670,663</span> shares of AgeX common stock of which <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFfqRXZLDcWc" title="Common stock, shares, outstanding">1,182,262</span> are outstanding as of September 30, 2023. The exercise prices of the 2020 Warrants issued through and that are still outstanding as of September 30, 2023 range from $<span id="xdx_906_eus-gaap--WarrantExercisePriceDecrease_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyWarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zuLpbOktlYU7" title="Warrants exercise price, minimum">0.81</span> per share to $<span id="xdx_908_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyWarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_z90q0JehUKAb" title="Warrants exercise price, maximum">1.895</span> per share representing the market closing price on the NYSE American of AgeX common stock on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022 Secured Convertible Promissory Note and Security Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence agreed to provide to AgeX a $<span id="xdx_90F_eus-gaap--LineOfCredit_iI_pn3d_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zoG8HkQsAWTj" title="Line of credit">13,160,000</span> line of credit for a period of <span id="xdx_902_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20220214__20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zQekGRurIJF9" title="Line of credit, term">12</span> months. AgeX drew an initial $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3p0_c20220214__20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zkKQqZtJmR7h" title="Line of credit facility">8,160,000</span> of the line of credit and used $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3p0_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zHc4uL9A678d" title="Line of credit facility, current borrowing capacity">7,160,000</span> to refinance the outstanding principal and the loan origination fees under the 2019 Loan Agreement with Juvenescence. On February 9, 2023, AgeX and Juvenescence entered into an Amended and Restated Secured Convertible Promissory Note which amends and restates the Secured Note and added $<span id="xdx_905_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn6n6_c20230208__20230209__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_z8sD5Q2So4M7">2</span> million to the line of credit available to be borrowed by AgeX under the Secured Note subject to Juvenescence’s discretion to approve each loan draw. On May 9, 2023, AgeX and Juvenescence entered into an Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (the “Second Amendment”) that increased the amount of the line of credit available to AgeX by $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn3p0_c20230509__20230509__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_z3E6SVZnFpi4">4,000,000</span>, subject to the terms of the Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. On June 2, 2023, AgeX and Juvenescence entered into a Third Amendment to Amended and Restated Convertible Promissory Note (the “Third Amendment’), to provide that (i) AgeX may draw on the available portion of the line of credit under the Secured Note until the earlier of the date a Qualified Offering as defined in the Secured Note is consummated by AgeX or October 31, 2023 (subject to Juvenescence’s discretion to approve each loan draw as provided in the Secured Note), (ii) AgeX will not be obligated to issue additional common stock purchase warrants to Juvenescence in connection with the receipt of loan funds made available pursuant to the Second Amendment, and (iii) the definition of Reverse Financing Condition was amended to extend to June 20, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by Reverse Bioengineering, Inc. The date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2023, AgeX and Juvenescence entered into a Fourth Amendment (the “Fourth Amendment”) to the Secured Note to provide that <span id="xdx_909_eus-gaap--DebtConversionDescription_c20230731__20230731__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember_zBuOsTjs9UN4" title="Debt conversion description">(i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bio, and (ii) Juvenescence may convert the outstanding amount of the Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion. The 19.9% Cap is a provision of the Secured Note that limits the amount of common stock that Juvenescence may acquire through the conversion of Secured Note loans in order to comply with NYSE American requirements pertaining to the amount of shares that a listed company, such as AgeX, may sell at a price less than the market prices prevailing at the time the loans were made (the “Drawdown Market Prices”) without shareholder approval.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, AgeX had borrowed a total of $<span id="xdx_900_eus-gaap--SecuredDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zPV4hI7U4ZQc" title="Secured debt">18,160,000</span> under the Secured Note, of which $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_c20230101__20230930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zT6cy71JsLxl" title="Proceeds from issuance of secured debt">5,500,000</span> was borrowed during the nine months ended September 30, 2023. During July 2023, $<span id="xdx_90D_eus-gaap--DebtInstrumentDecreaseForgiveness_c20230701__20230731__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zvZpdf9gQBP2" title="Debt instrument, indebtedness">17,992,800</span> of Secured Note indebtedness, comprised of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_c20230701__20230731__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_z0YWuUxmVMtk" title="Proceeds from issuance of secured debt">16,660,000</span> borrowing and $<span id="xdx_90C_ecustom--AccruedLoanOriginationFees_iI_c20230731__20230731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LineOfCreditMember_zE0gVfs6wVxi" title="Accrued loan origination fees">1,332,800</span> of accrued loan origination fees, was extinguished in exchange for shares of Series A Preferred Stock and Series B Preferred Stock pursuant to the Exchange Agreement. See Note 7, <i>Stockholders’ Equity (Deficit)</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As an arrangement fee for the Secured Note, AgeX will pay Juvenescence an origination fee in an amount equal to 4% of the amount each draw of loan funds, which will accrue as each draw is funded, and an additional 4% of all the total amount of funds drawn that will accrue following the end of the period during which funds may be drawn from the line of credit. The origination fee will become due and payable on the repayment date or in a pro rata amount with any prepayment of in whole or in part of the outstanding principal balance of the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022 Warrants – </i>Upon each drawdown of funds under the Secured Note prior to June 2, 2023 when the Third Amendment went into effect, AgeX issued to Juvenescence warrants to purchase shares of AgeX common stock (“2022 Warrants”). The 2022 Warrants are governed by the terms of a Warrant Agreement between AgeX and Juvenescence. The number of 2022 Warrants issued with respect to each draw of loan funds was equal to 50% of the number determined by dividing the amount of the applicable loan draw by the applicable Market Price. The Market Price was the last closing price per share of AgeX common stock on the NYSE American o preceding the delivery of the notice from AgeX requesting the draw of funds that triggered the obligation to issue 2022 Warrants. The exercise price of the 2022 Warrants is the applicable Market Price used to determine the number of Warrants issued. The 2022 Warrants will expire at 5:00 p.m. New York time three years after the date of issue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, AgeX had issued to Juvenescence 2022 Warrants to purchase a total of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930__dei--LegalEntityAxis__custom--JuvenescenceMember_zL2G1mBz8A1k" title="Warrant to purchase share of common stock">10,357,086</span> shares of AgeX common stock, of which 2022 Warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930_zS1yKoix5LAg" title="Warrant purchase">1,898,489</span> shares of AgeX common stock were issued during the nine months ended September 30, 2023. The exercise prices of the 2022 Warrants issued through September 30, 2023 range from $<span id="xdx_90F_eus-gaap--WarrantExercisePriceDecrease_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoWarrantsMember_z2mW7MYwc9Eh" title="Warrants exercise price, minimum">0.59</span> per share to $<span id="xdx_905_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoWarrantsMember_zcF4L8ZzcJl1" title="Warrants exercise price, maximum">0.88</span> per share representing the market closing price of AgeX common stock on the NYSE American on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion of Loan Amounts to Common Stock –</i> In lieu of repayment of funds borrowed, AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvcdvAtuB2X7" title="Proceeds from issuance costs">10,000,000</span>. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Default Provisions –</i> The loan balance and origination fees may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the Secured Note include the following: (a) AgeX fails to pay any principal amount payable by it in the manner and at the time provided under and in accordance with the Secured Note; (b) AgeX fails to pay any other amount payable by it in the manner and at the time provided under and in accordance with the Secured Note or the Security Agreement described below or any other agreement executed in connection with the Secured Note (the “Loan Documents”) and the failure is not remedied within three business days; (c) AgeX fails to perform any of its covenants or obligations or fail to satisfy any of the conditions under the Secured Note or any other Loan Document and, such failure (if capable of remedy) remains unremedied to the satisfaction of Juvenescence (in its sole discretion) for 10 business days after the earlier of (i) notice requiring its remedy has been given by Juvenescence to AgeX and (ii) actual knowledge of the failure by senior officers of AgeX; (d) <span id="xdx_90B_eus-gaap--LineOfCreditFacilityDescription_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zvBVGFm53SQ4" title="Line of credit facility, description">if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date;</span> (e) AgeX stops payment of its debts generally or ceases or threatens to cease to carry on its business or is unable to pay its debts as they fall due or is deemed by a court of competent jurisdiction to be unable to pay its debts as they fall due, or enters into any arrangements with its creditors generally; (f) if (i) an involuntary proceeding (other than a proceeding instituted by Juvenescence or an affiliate of Juvenescence) shall be commenced or an involuntary petition shall be filed seeking liquidation, reorganization or other relief in respect of AgeX and any subsidiary, or of all or a substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) an involuntary appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for AgeX or a subsidiary or for a substantial part of its assets occurs (other than in a proceeding instituted by Juvenescence or an affiliate of Juvenescence), and, in any such case, such proceeding shall continue undismissed and unstayed for sixty (60) consecutive days without having been dismissed, bonded or discharged or an order of relief is entered in any such proceeding; (g) it becomes unlawful for AgeX to perform all or any of its obligations under the Secured Note or any authorization, approval, consent, license, exemption, filing, registration or other requirement of any governmental, judicial or public body or authority necessary to enable AgeX to comply with its obligations under the Secured Note or to carry on its business is not obtained or, having been obtained, is modified in a manner that precludes AgeX or its subsidiaries from conducting their business in any material respect, or is revoked, suspended, withdrawn or withheld or fails to remain in full force and effect; (h) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX or a subsidiary if such process is not released, vacated or fully bonded within 60 calendar days after its issue or levy; (i) any injunction, order, judgment or decision of any court is entered or issued which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX or a subsidiary to carry on its business or to pay amounts owed to Juvenescence under the Secured Note; (j) AgeX, whether in a single transaction or a series of related transactions, sells, leases, licenses, consigns, transfers or otherwise disposes of any material portion of its assets (with any such disposition with respect to any asset or assets with a fair value of at least $<span id="xdx_907_eus-gaap--CommonStockHeldBySubsidiary_iI_c20230930_zC9WhAFH712l" title="Common stock held">250,000</span> being deemed material), other than (i) certain permitted investments (ii) sales, transfers and dispositions of inventory in the ordinary course of business, (iii) any termination of a lease of real or personal property that is not necessary in the ordinary course of the AgeX’s business, could not reasonably be expected to have a material adverse effect and does not result from AgeX’s default, and (iv) any sale, lease, license, consignment, transfer or other disposition of assets that are no longer necessary in the ordinary course of business or which has been approved in writing by Juvenescence; (k) any of the following shall occur: (i) the security and/or liens created by the Security Agreement or any other Loan Document shall at any time cease to constitute valid and perfected security and/or liens on any material portion of the collateral intended to be covered thereby; (ii) except for expiration in accordance with its terms, the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall for whatever reason be terminated or shall cease to be in full force and effect; (iii) the enforceability of the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall be contested by AgeX or a subsidiary; (iv) AgeX shall assert that its obligations under the Secured Note or any other Loan Document shall be invalid or unenforceable; or (v) a loss, theft, damage or destruction occurs with respect to a material portion of the collateral; (l) there is any change in the financial condition of AgeX and its subsidiaries which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX to perform any of its obligations under the Secured Note; and (m) any representation, warranty or statement made, repeated or deemed made or repeated by AgeX in the Secured Note, or pursuant to the Loan Documents, is incomplete, untrue, incorrect or misleading in any material respect when made, repeated or deemed made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restrictive Covenants – </i>The Secured Note includes certain covenants that among other matters such as financial reporting: (i) impose financial restrictions on AgeX while the Secured Note remains unpaid, including restrictions on the incurrence of additional indebtedness by AgeX and its subsidiaries, except that AgeX’s subsidiary Reverse Bio will be permitted to incur debt convertible into equity not guaranteed or secured by the assets of AgeX or any other AgeX subsidiary, (ii) require that AgeX use loan proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, for general working capital, and for repayment of all or a portion of AgeX’s indebtedness to Juvenescence; and (iii) prohibit AgeX from making additional investments in subsidiaries, unless AgeX obtains the written consent of Juvenescence to a transaction that otherwise would be prohibited or restricted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Security Agreement – </i>AgeX has entered into a Security Agreement granting Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>$<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zB052XwpJv9g" title="Convertiable promissoty note">10</span> Million Secured Convertible Promissory Note</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, AgeX and Juvenescence entered into a $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230313__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zR16QtXTB0L5" title="Convertiable promissoty note">10</span> Million Secured Convertible Promissory Note (the “$<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230313__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zXYWWcnpoOfh" title="Convertiable promissoty note">10</span> Million Secured Note”) pursuant to which Juvenescence has loaned to AgeX $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20230313__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zHkm3z3HwbUh" title="Line of credit, current borrowing capacity">10,000,000</span>. AgeX used the loan proceeds to finance the $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_c20230313__20230313__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zhSuKBKwiQ64" title="Proceeds from issuance of long term debt">10,000,000</span> loan to Serina under the Serina Note. See Note 4, <i>Convertible Note Receivable</i>, for further information on the Serina Note and the related Serina Note Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2023, AgeX and Juvenescence also entered into an amendment to the $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230731__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zQJBPjZkeQn4" title="Convertiable promissoty note">10</span> Million Secured Note that mirrors the amendments of the Secured Note described above, and also creates an earlier time window, ending October 31, 2023, during which Juvenescence may elect to convert any amount outstanding under the $<span id="xdx_909_eus-gaap--SecuredDebt_iI_pn6n6_c20230731__dei--LegalEntityAxis__custom--JuvenescenceMember_zAXbXoua5EHj" title="Secured note">10</span> Million Secured Note into shares of AgeX common stock. After October 31, 2023, Juvenescence may convert outstanding amounts under the $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230731__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zhIXuLsS6Xlc" title="Convertiable promissoty note">10</span> Million Secured Note into AgeX common stock on any date more than ninety (90) days after the earlier of (a) the occurrence of a Qualified Merger as defined, and (b) March 13, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outstanding principal balance of the $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230731__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_z1s9e93Wn8L6" title="Convertiable promissoty note">10</span> Million Secured Note was scheduled to become due and payable on March 13, 2026. <span id="xdx_909_ecustom--OriginationFeeDescription_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_znn3Sq1OKyh3" title="Origination fee description">In lieu of accrued interest, AgeX agreed to pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During July 2023, the $<span id="xdx_90B_eus-gaap--SecuredDebt_iI_pn6n6_c20230731_zn8zZ7zGgW69" title="Secured debt">10</span> Million Secured Note indebtedness, plus a portion of the accrued loan origination fees, was exchanged for Series B Preferred Stock pursuant to the Exchange Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The $<span id="xdx_905_eus-gaap--SecuredDebt_iI_pn6n6_c20230731_zkTpYUCV4FCa" title="Secured debt">10</span> Million Secured Note includes a provision allowing AgeX to convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230731__20230731__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z22Dn7h66rd5">10,000,000</span>. If less than $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230731__20230731__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zSe7RDlKm10j">25,000,000</span> is raised through the sale of common stock or units, the conversion price per share or units shall be the lowest price at which shares or units are sold. If at least $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230731__20230731_zKinHABQLlS5">25,000,000</span> is raised, the conversion price per share shall be <span id="xdx_903_ecustom--CommonStockOutstandingPercentage_pid_dp_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zzQWCpaZayE7">85</span>% of the “Market Price” of AgeX common stock determined as provided in the $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zQhz31hDPwn6" title="Proceeds from sale of common stock">10</span> Million Secured Note. AgeX evaluated the <span id="xdx_903_ecustom--CommonStockOutstandingPercentage_pid_dp_uPure_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--DerivativesAndHedgingMember_zPrN1AVXNENa" title="Common stock outstanding percentage">15</span>% discounted conversion feature of the $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zRbNatwjKOud" title="Proceeds from sale of common stock">10</span> Million Secured Note under ASC 815-15, <i>Derivatives and Hedging—Embedded Derivatives</i>, and concluded that it was an embedded derivative which should be bifurcated from the $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z04uKyR8ys3k" title="Proceeds from sale of common stock">10</span> Million Secured Note and accounted for separately. The <span id="xdx_901_ecustom--CommonStockOutstandingPercentage_pid_dp_uPure_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--DerivativesAndHedgingMember_ztIAT1RU4452" title="Common stock outstanding percentage">15</span>% discount was determined to have an immaterial value at inception and life to date of the $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zYmGiELZk6wb" title="Proceeds from sale of common stock">10</span> Million Secured Note, as the probability of a future financing event described above is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period and any adjustments will be included in <i>Interest (income) expense, net</i> in the <i>Other (income) expense, net</i> section of the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The $<span id="xdx_905_eus-gaap--SecuredDebt_iI_pn6n6_c20230731_zxLe0jYPZR47" title="Secured debt">10</span> Million Secured Note includes certain covenants that among other matters require financial reporting and impose certain restrictions on AgeX that are substantially the same as those under the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has entered into an Amended and Restated Security Agreement that amends the February 14, 2022 Security Agreement between AgeX and Juvenescence and adds the $<span id="xdx_901_eus-gaap--SecuredDebt_iI_pn6n6_c20230214_zlu6xt0RemAb" title="Secured debt">10</span> Million Secured Note to the obligations secured by the Security Agreement. The Security Agreement grants Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default as defined in the $<span id="xdx_901_eus-gaap--SecuredDebt_iI_pn6n6_c20230214_zST8U1Xgoxld" title="Secured debt">10</span> Million Secured Note occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral with respect to any accrued loan origination fees remaining unpaid under the $<span id="xdx_90F_eus-gaap--SecuredDebt_iI_pn6n6_c20230731_zyQzcfRJcZSk" title="Secured debt">10</span> Million Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registration Rights</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX entered into certain Registration Rights Agreements, as amended, pursuant to which AgeX has agreed to register for sale under the Securities Act of 1933, as amended (the “Securities Act”) all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement and pursuant to the Secured Note, and shares that they may acquire through the conversion of those loans into AgeX common stock. <span id="xdx_90D_eus-gaap--LineOfCreditFacilityDescription_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementsMember_zPWGJk2uq8mj" title="Line of credit facility, description">AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of AgeX common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence.</span> Juvenescence retains the right to require AgeX to register additional shares of common stock that Juvenescence may acquire through the exercise of warrants or the conversion of loans. AgeX is obligated to pay the fees and expenses of each registered offering under such registration rights agreement except for underwriting discounts and commissions. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX and Juvenescence have entered into a second Registration Rights Agreement pursuant to which AgeX has agreed to use commercially reasonable efforts to register the for sale under the Securities Act the shares of common stock issuable upon conversion of Preferred Stock. A registration statement must be filed upon request of Juvenescence if Form S-3 is available to AgeX. Juvenescence will also have “piggy-back” registration rights if AgeX files a registration statement for the sale of shares for itself or other stockholders, subject to certain customary exceptions based on the nature of the registration statement. AgeX will bear the expenses of the registration statement but not underwriting or broker’s commissions related to the sale of the common stock. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt Issuance Costs</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASU 2015-03, <i>Simplifying the Presentation of Debt Issuance Costs, </i>all debt issuance costs are recorded as a discount on the debt and amortized to interest expense over the term of the applicable loan agreement using the effective interest method. Direct debt issuance costs include but are not limited to legal fees, debt origination fees, estimated fair market value of common stock and warrants issued in connection with the loan agreement, and NYSE American additional listing fees for the underlying shares of warrants issued with each drawdown of funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock_zdPbW4YkHsf2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of September 30, 2023 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zF4LIKn3rYw8" style="display: none">Schedule of Debt Issuance Costs and Debt Balances</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_484_eus-gaap--LineOfCredit_iI_z12sdK4wHI48" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_91A_eus-gaap--LineOfCredit_zCTo7c3AQPQ6">Drawdown of Funds</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_48D_eus-gaap--DebtInstrumentFeeAmount_iI_zKAtn2obzDL9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_919_eus-gaap--DebtInstrumentFeeAmount_zgY0s54FQs6l">Origination Fee</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_48A_ecustom--DebtExchangedForPreferredStock_iI_zttszsfV4rTf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_912_ecustom--DebtExchangedForPreferredStock_zfLjjcYkN0w9">Debt Exchanged for Preferred Stock</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_48C_eus-gaap--DebtInstrumentCarryingAmount_iI_ziRZwEA8GaV1" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_91A_eus-gaap--DebtInstrumentCarryingAmount_zF93XC5NuYCe">Total Debt</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_480_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_zimLbhUP3iI3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_91D_eus-gaap--DeferredFinanceCostsNoncurrentGross_zq4V8gVXqj37">Debt Issuance Costs</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_48B_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_z4U63stL0dv7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Debt Issuance Costs</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_485_eus-gaap--LongTermDebt_iI_zXm2i9cnx4C9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_914_eus-gaap--LongTermDebt_zx4WxWzvd7Y9">Total Debt, Net</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_416_20230930__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zsy5RDP3mE4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left; text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020 Loan Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2606">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2608">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2611">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_415_20230930__us-gaap--DebtInstrumentAxis__custom--SecuredNoteMember_zcSVO9LW3e8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secured Note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,406</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,993</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,044</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,997</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_41A_20230930__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zB4i5AmvsWOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total current, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,406</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,993</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,850</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,803</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_412_20230930__us-gaap--DebtInstrumentAxis__custom--TenThousandMillionSecuredNoteMember_zRYxhFAXLD1c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIERlYnQgSXNzdWFuY2UgQ29zdHMgYW5kIERlYnQgQmFsYW5jZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--SecuredDebt_iI_pn6n6_c20230930_zLOuvUw10ybl" title="Secured note">10</span> Million Secured Note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">700</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,007</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(666</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">666</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_41E_20230930__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zWkTNKRD5b2i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total debt, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,106</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(36,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,266</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,516</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,469</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,219</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AB_z1OxL4LTgcp7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Related Party Receivables/Payables, net</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, is devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $<span id="xdx_907_eus-gaap--ReimbursementFromLimitedPartnershipInvestment_c20230101__20230930__dei--LegalEntityAxis__custom--JuvenescenceMember_zsSbP70GgIcj" title="Reimbursement">280,000</span>. AgeX reimburses Juvenescence for services provided by other Juvenescence employees on a work order basis under a shared services agreement effective January 1, 2023. As of September 30, 2023, AgeX had approximately $<span id="xdx_902_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20230930__dei--LegalEntityAxis__custom--JuvenescenceMember_z4vF8MZDlzG8" title="Accounts payable">4,000</span> receivable from Juvenescence included in related party receivables, net, on the condensed consolidated balance sheet. As of December 31, 2022, AgeX had approximately $<span id="xdx_90C_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_c20221231__dei--LegalEntityAxis__custom--JuvenescenceMember_zoNi5IEOHrm" title="Accounts payable">141,000</span> payable to Juvenescence included in related party payables, net, on the condensed consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification Agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, AgeX executed that certain Letter of Indemnification in Lieu of or Supplemental to a Medallion Signature Guarantee (“Letter of Indemnification”), pursuant to which AgeX agreed to indemnify American Stock Transfer &amp; Trust Company, LLC and its affiliates, successors and assigns (the “AST Indemnity”) from and against any and all claims, damages, liabilities or losses arising out of the transfer of all of the AgeX common stock held by Juvenescence to its wholly-owned subsidiary, Juvenescence US Corp. (the “Share Transfer”). In connection with AgeX’s execution of the Letter of Indemnification, AgeX and Juvenescence entered into that certain Transfer of Shares of AgeX Therapeutics, Inc. Common Stock – Indemnification Agreement, pursuant to which Juvenescence agreed to indemnify AgeX against any and all claims, damages, liabilities or losses arising out of the Share Transfer or AST Indemnity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 36000000 10000000 2000000 P18M 4000000 1000000 7000000 7000000 160000 8000000 P18M 8000000 28500 3000000 3670663 1182262 8000000 3670663 1182262 0.81 1.895 13160000 P12M 8160000 7160000 2000000 4000000 (i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bio, and (ii) Juvenescence may convert the outstanding amount of the Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion. The 19.9% Cap is a provision of the Secured Note that limits the amount of common stock that Juvenescence may acquire through the conversion of Secured Note loans in order to comply with NYSE American requirements pertaining to the amount of shares that a listed company, such as AgeX, may sell at a price less than the market prices prevailing at the time the loans were made (the “Drawdown Market Prices”) without shareholder approval. 18160000 5500000 17992800 16660000 1332800 10357086 1898489 0.59 0.88 10000000 if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date; 250000 10000000 10000000 10000000 10000000 10000000 10000000 10000000 10000000 10000000 In lieu of accrued interest, AgeX agreed to pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note. 10000000 10000000 10000000 25000000 25000000 0.85 10000000 0.15 10000000 10000000 0.15 10000000 10000000 10000000 10000000 10000000 AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of AgeX common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence. <p id="xdx_89F_ecustom--SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock_zdPbW4YkHsf2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of September 30, 2023 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zF4LIKn3rYw8" style="display: none">Schedule of Debt Issuance Costs and Debt Balances</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_484_eus-gaap--LineOfCredit_iI_z12sdK4wHI48" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_91A_eus-gaap--LineOfCredit_zCTo7c3AQPQ6">Drawdown of Funds</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_48D_eus-gaap--DebtInstrumentFeeAmount_iI_zKAtn2obzDL9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_919_eus-gaap--DebtInstrumentFeeAmount_zgY0s54FQs6l">Origination Fee</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_48A_ecustom--DebtExchangedForPreferredStock_iI_zttszsfV4rTf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_912_ecustom--DebtExchangedForPreferredStock_zfLjjcYkN0w9">Debt Exchanged for Preferred Stock</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_48C_eus-gaap--DebtInstrumentCarryingAmount_iI_ziRZwEA8GaV1" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_91A_eus-gaap--DebtInstrumentCarryingAmount_zF93XC5NuYCe">Total Debt</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_480_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_zimLbhUP3iI3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_91D_eus-gaap--DeferredFinanceCostsNoncurrentGross_zq4V8gVXqj37">Debt Issuance Costs</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_48B_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_z4U63stL0dv7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Debt Issuance Costs</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_485_eus-gaap--LongTermDebt_iI_zXm2i9cnx4C9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_914_eus-gaap--LongTermDebt_zx4WxWzvd7Y9">Total Debt, Net</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_416_20230930__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zsy5RDP3mE4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left; text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020 Loan Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2606">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2608">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2611">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_415_20230930__us-gaap--DebtInstrumentAxis__custom--SecuredNoteMember_zcSVO9LW3e8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secured Note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,406</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,993</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,044</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,997</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_41A_20230930__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zB4i5AmvsWOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total current, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,406</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,993</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,850</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,803</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_412_20230930__us-gaap--DebtInstrumentAxis__custom--TenThousandMillionSecuredNoteMember_zRYxhFAXLD1c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIERlYnQgSXNzdWFuY2UgQ29zdHMgYW5kIERlYnQgQmFsYW5jZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--SecuredDebt_iI_pn6n6_c20230930_zLOuvUw10ybl" title="Secured note">10</span> Million Secured Note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">700</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,007</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(666</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">666</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_41E_20230930__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zWkTNKRD5b2i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total debt, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,106</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(36,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,266</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,516</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,469</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,219</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 8000000 -8000000 2806000 2806000 18160000 1406000 -17993000 1573000 6044000 5997000 1526000 26160000 1406000 -25993000 1573000 8850000 8803000 1526000 10000000 10000000 700000 -10007000 693000 666000 666000 693000 36160000 2106000 -36000000 2266000 9516000 9469000 2219000 280000 4000 141000000 <p id="xdx_804_ecustom--WarrantLiabilityTextBlock_zihYqHuecHn4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_82F_z5Lh6SYoNqAk">Warrant Liability</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</i>, then in accordance with ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</i>. Under ASC 480, <i>Distinguishing Liabilities from Equity, </i>warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a condition of each amount drawn up to $<span id="xdx_90D_eus-gaap--SecuredDebt_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQXTEyBrLU02" title="Secured debt">15,160,000</span> from the Secured Note, on receipt of each amount drawn AgeX granted to Juvenescence a number of warrants equal to 50% of the gross value of the relevant advance made. The gross value is the quotient of the drawdown amount and the exercise price. The exercise price was based on the market closing price of AgeX’s common stock on the NYSE American on the one day preceding the delivery of the relevant drawdown notice. See Note 5, <i>Related Party Transactions</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has utilized the full credit available under the Secured Note that is subject to warrants and accordingly the warrants were issued for each of the advances of loan funds under the Secured Note. After all relevant assessments, AgeX determined that the warrants issued under the Secured Note require classification as a liability pursuant to ASC 480, <i>Distinguishing Liabilities from Equity</i>. In accordance with the accounting guidance, for each reporting period prior to the full drawdown of the entire $<span id="xdx_90F_eus-gaap--SecuredDebt_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBRARj9JHUZi" title="Secured debt">15,160,000</span> of the Secured Note line of credit subject to warrants, the amount of warrant liability was determined and recognized on the balance sheet for the applicable reporting period based on the number of warrants that would have been issued if $<span id="xdx_905_eus-gaap--SecuredDebt_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zauCKOIP0nYb" title="Secured debt">15,160,000</span> of the Secured Note line of credit was drawn. The amount of warrant liability attributed to the expected future issuance of warrants upon subsequent loan draws was subsequently adjusted for the fair value of warrants actually issued upon each loan draw, and the number of warrants that could be issued for the remaining credit available was re-measured for the applicable reporting period with changes being recorded as a component of net other expense in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Third Amendment, AgeX is not obligated to issue additional warrants to Juvenescence in connection with the receipt of loan funds up to $<span id="xdx_90D_ecustom--LoanFunds_iI_pn6n6_c20230930__dei--LegalEntityAxis__custom--JuvenescenceMember_z8FKePWggz67" title="Loan funds">4</span> million made available pursuant to the Second Amendment. See Note 5, <i>Related Party Transactions,</i> for further details of the Second Amendment and the Third Amendment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfRegulatoryLiabilitiesTextBlock_z2GcxiKrf1u4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date, the date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zw2QQ6saxTs6" style="display: none">Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Black-Scholes Assumptions</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price <sup id="xdx_F4C_zHuoUq0VPEBe">(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date <sup id="xdx_F5D_zQWxI9zocCM6">(2)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price <sup id="xdx_F5D_zUGK0X4CEZO9">(3)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(annual) <sup id="xdx_F57_zH43klumLauh">(4)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Volatility</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(annual) <sup id="xdx_F5D_z89p7UeFUJt5">(5)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Time to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturity (Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Calculated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value per Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inception Date: 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_z9BzORQtDJpc" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_z0bV2kaRKyZe" title="Warrant Expiration Date">2/13/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zACGRla6mSo8" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.691</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_z4k2C6fLHOWg" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zeojZ1bb9M1b" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zqMMhDdFcQC3" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zWOcaNB0dOo4" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.486</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zfF2aN7zi833" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_z0TowKtJICKl" title="Warrant Expiration Date">2/13/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zMIooITVLcDe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.691</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zs6vUWiqeKdk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_z34WNUBI3pwc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zxkFFcyglDj1" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zHQpYwncfXG" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.486</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 2/15/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zNR1anuvvqh7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zP9urdCMTqqe" title="Warrant Expiration Date">2/14/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--SharePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zo5rH6wv50Xi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zPX5N50cQsg1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zg3FpSsv70P1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123.28</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zVOjBmWPCi2a" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zOOxH3LnCNN8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.535</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 3/31/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zOp9sDkRfWC" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.940</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zJsSrZ4KPfG8" title="Warrant Expiration Date">3/30/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zhHGACPn38W2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.854</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zlHKXCPCSBV" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.45</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zO52XnYdPc5f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123.28</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z4txJIhra84f" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zhiP7zkgZbVa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.607</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 4/4/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zdVBQmty8mdf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.880</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zltSF2wnEjwe" title="Warrant Expiration Date">4/3/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_ziJSTjnyoX86" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.819</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z9dk96Gl4BZ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.61</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zSHcNol77K1h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123.31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zkUBEcpNM1J" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zq0mSI5PbUG6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.585</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 6/6/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zRBcNRkfzS53" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.711</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zLp7JLufavE" title="Warrant Expiration Date">6/5/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zBAGrSnQMXEd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.800</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zxacQhvXLha7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zKPoE8D4fPm1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.62</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zMCZoZeCJDA7" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zS8j2gyepkX1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.592</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 6/30/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zn1uXv4W2gBg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_z0omsK88LKQh" title="Warrant Expiration Date">6/29/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zkqxmyCSjGO4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.576</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zg8pAayspqWi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zJKRSWDVBCV2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zwpZ0jhxGV37" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zqnqv2ZXzu7l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.413</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 8/16/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z7cWvgwIIcw4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.670</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zSyYOorAGrK8" title="Warrant Expiration Date">8/15/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z3bDVTCvwLDe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.640</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zZSWTQscsrqe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zkCzpEAkxn99" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zoxx3kBJSzPi" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zZHU2MRfbKkk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.457</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 9/30/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zCq7830EasZf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.610</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_z8TNe8ePOZA" title="Warrant Expiration Date">9/29/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zXZyPyf0FWId" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.562</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zjr85MhZW775" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_z4cwGErjKv74" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121.49</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zBhrneleGQg7" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zuYRPmNvaDZ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.401</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 10/21/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zquQtoIrn1u8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.690</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zyv8R8R8zSzb" title="Warrant Expiration Date">10/20/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zZwhAmA6hrOj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z45YiG7WNqMf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zXuGNvudfoH7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120.51</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z882Taqn4mNj" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zOP4mH7qoXd4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.439</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 12/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zVnalGo9XER3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.590</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zGBwCss5TSx3" title="Warrant Expiration Date">12/13/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zDhDntPTK6zd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.540</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zL2zP1idEEPf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zV93sHSBaNW1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zhgYe21F0DK6" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zBFeNoC7zO1c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.381</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 12/31/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zGE8jyFaEWg3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.550</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zvK9SuxaJlk3" title="Warrant Expiration Date">12/30/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zgpIRueS7jo5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.552</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zzACG8WAoeTi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_z9TwgzMg9LD9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119.31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zNp2oj9bIbR1" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zLlxtlkjDYE3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.396</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 1/25/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z4oiLyLvcBH6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.735</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_z9EJwZW0zYC6" title="Warrant Expiration Date">1/24/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zVrRPQK5O2Nf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.751</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zHprLK2k1sbh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.84</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zwmaISQcJsQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zoEHNuCa0BS4" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zuQrY2qe3Uu4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.540</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inception Date: 2/9/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_z6NLwEO02U69" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.703</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_zBKn1SJSZh79" title="Warrant Expiration Date">2/8/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zCYDPdTJYCcg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_znirqFswjNO7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zkX5xp8UMSCg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118.94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zIMP7Hx7a74c" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zzUitvhQkkBa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.466</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 2/15/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zbtGWL7MhQqd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.624</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zSmpKUuFB0oe" title="Warrant Expiration Date">2/14/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z2jjTTEfeexa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zeKwy9vJHK53" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.35</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zSC86DtX567b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zamgZi5w6FKb" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zybqpnorgjL4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.426</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 3/31/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zgK683Xwhp77" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.661</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zJThMbc5Kkdl" title="Warrant Expiration Date">3/30/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zV8EM8qm2Mo6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.663</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zzHHhO5WCFk2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.81</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zoiJsyQJicQ5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113.43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zQAolwfAEMU6" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zTmAKIFy2rOg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.459</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 4/4/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zvHAFdqfuIPb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.661</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_znaDjAmWAUJ2" title="Warrant Expiration Date">4/3/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zOE0lrvCuJ3h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.673</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zrdMG48o5bS2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zQBTZNK6Hch9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zQK3ube8upya" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zZEJNeuVHOv9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.466</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0E_zVl5EWxB0Phc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zU16xDfIx2fb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIExpYWJpbGl0aWVzIEFuZCBTdG9jayBPcHRpb24gQXdhcmRzIHVzaW5nIGEgQmxhY2stU2Nob2xlcyBPcHRpb24tUHJpY2luZyBNb2RlbCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--LinesOfCreditCurrent_iI_c20230930_z6MDA7K8WREh" title="Lines of credit current">2,000,000</span> was treated as a new Inception Date for that portion of the line of credit.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zZPWjizx9f1l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zf7kWJMwAu3a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants are exercisable over a three-year period from each Issuance Date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0B_zyOtGwIWEQB" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_z5V7lXmeVkA7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0F_zNTqC69vCmJd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zi2x9E3jpv0b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F00_zJj8ZC9jVGZd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zjXcFVWduVX" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the historical daily volatility of AgeX common stock as of each date presented.</span></td></tr> </table> <p id="xdx_8AE_zM9gAEybgTzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--WarrantsOutstandingAndFairValuesTableTextBlock_zXWhGVClUjLj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants outstanding and fair values at each of the respective valuation dates are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zvSTheelmzW9" style="display: none">Schedule of Warrant Outstanding and Fair Values</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Warrant Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit Line and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Draw Amounts</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair value as of January 1, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20220101__20221231_zYHmiBCfBV12" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl2908">-</span></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20220101__20221231_zwfn94rSg3j6" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl2910">-</span></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zmvtkyeTruX1" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value per share"><span style="-sec-ix-hidden: xdx2ixbrl2912">-</span></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantLiability_iS_pid_c20220101__20221231_zRU8ZojU0gLl" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2914">-</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left">Fair value at initial measurement date of 2/14/2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDEp_zhRX1Sqt7Kg4" style="width: 10%; text-align: right" title="Fair value as of period beginning balance">13,160</td><td style="width: 4%; text-align: left"><sup>(1)</sup></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDIp_zyKx40evd6Ph" style="width: 10%; text-align: right" title="Fair value as of period beginning balance, shares">8,435,897</td><td style="width: 4%; text-align: left"><sup>(2)</sup></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_z4cFeMCxQh8e" style="width: 10%; text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4864</td><td style="width: 3%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zkYkixafO8Kj" style="width: 10%; text-align: right" title="Fair value as of period beginning balance, fair value">4,103</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 2/14/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDMp_zhn5aeKFklzk" style="text-align: right" title="Fair value as of period beginning balance">(7,160</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDQp_zpGiipcFqK58" style="text-align: right" title="Fair value as of period beginning balance, shares">(4,589,743</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zLvyKPTY0bJk" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4864</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zKOl61DDVFN3" style="text-align: right" title="Fair value as of period beginning balance, fair value">(2,232</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 2/15/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDMp_zI9tPi1GsaFi" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDQp_zsmgtJxyo4ei" style="text-align: right" title="Fair value as of period beginning balance, shares">(641,025</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zMGBhLlV1q8f" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.5349</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zF4l3PVdSTC7" style="text-align: right" title="Fair value as of period beginning balance, fair value">(343</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 4/4/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDMp_z4Dq1c69XVZb" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDQp_zF3Ji5tfGT5" style="text-align: right" title="Fair value as of period beginning balance, shares">(568,440</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zEFZxKCZrNgj" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.5854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zzPoDTBKIVL9" style="text-align: right" title="Fair value as of period beginning balance, fair value">(333</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 6/6/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDMp_zfJ0MlBRB5x7" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDQp_zuaPczWKUF62" style="text-align: right" title="Fair value as of period beginning balance, shares">(703,234</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_z2xDNvX69jcg" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.5924</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_zyLKdUfTxnEf" style="text-align: right" title="Fair value as of period beginning balance, fair value">(417</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 8/16/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDMp_zWHZlm2TwXx6" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDQp_zZfSvEOjeN56" style="text-align: right" title="Fair value as of period beginning balance, shares">(746,380</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_zsbMVPINZNi6" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_ztj943KVlO4g" style="text-align: right" title="Fair value as of period beginning balance, fair value">(341</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 10/21/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDMp_z9nYNyP2OGKi" style="text-align: right" title="Fair value as of period beginning balance">(500</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDQp_ziPCVVtpzukd" style="text-align: right" title="Fair value as of period beginning balance, shares">(362,318</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_znkVwTqbLQT1" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4386</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_zt9zjJ8BpaEb" style="text-align: right" title="Fair value as of period beginning balance, fair value">(159</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 12/14/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDMp_zUYXwtsxQJ3h" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDQp_zoSyVInAf5A9" style="text-align: right" title="Fair value as of period beginning balance, shares">(847,457</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_zC085kRBT1Gb" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.3810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_znqygaWWAMcf" style="text-align: right" title="Fair value as of period beginning balance, fair value">(323</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20220101__20221231_fKDIp_zzNLY1PH2V8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value as of period beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl2980">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20220101__20221231_fKDQp_z1rEnCXVmcZf" style="padding-bottom: 1.5pt; text-align: right" title="Fair value as of period beginning balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl2982">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20220101__20221231_zfHap1ffykA6" style="padding-bottom: 1.5pt; text-align: right" title="Fair value as of period beginning balance, fair value per share"><span style="-sec-ix-hidden: xdx2ixbrl2984">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ChangesInFairValue_pn3n3_c20220101__20221231_zA1E3lKYcYMd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value as of period beginning balance, fair value">225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair value as of December 31, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20230101__20230930_fKDEp_ztnGps2NOuae" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance">500</td><td style="font-weight: bold; text-align: left"><sup>(1)</sup></td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20230101__20230930_fKDIp_zlK3V0MONBt4" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, shares">454,545</td><td style="font-weight: bold; text-align: left"><sup>(2)</sup></td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20230101__20230930_zn7fecpqujqj" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value per share">0.3960</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_985_ecustom--WarrantLiability_iS_pn3n3_c20230101__20230930_ztfE3H7LwqAk" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value">180</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 1/25/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_fKDMp_zZSKehOBYpoc" style="text-align: right" title="Fair value as of period beginning balance">(500</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_fKDQp_zUHhbXLSxktk" style="text-align: right" title="Fair value as of period beginning balance, shares">(340,136</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_zwCLXJNtfCbc" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.5395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_zZwzhl8gQxVg" style="text-align: right" title="Fair value as of period beginning balance, fair value">(184</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value at initial measurement date of 2/9/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwoSeptemberTwoThousandAndTwentyThreeMember_fKDEp_z3MSBqfGQ5Ge" style="text-align: right" title="Fair value as of period beginning balance">2,000</td><td style="text-align: left"><sup>(1)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwoSeptemberTwoThousandAndTwentyThreeMember_fKDIp_z9jIMJEqnga5" style="text-align: right" title="Fair value as of period beginning balance, shares">1,422,879</td><td style="text-align: left"><sup>(2)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueIssuedPerShare_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwoSeptemberTwoThousandAndTwentyThreeMember_z3JHSsqLER36" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwoSeptemberTwoThousandAndTwentyThreeMember_zMjhOp6XDBeb" style="text-align: right" title="Fair value as of period beginning balance, fair value">663</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 2/15/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_fKDMp_z6lnW9D3Tvri" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_fKDQp_zb07ozqsm2Oe" style="text-align: right" title="Fair value as of period beginning balance, shares">(801,924</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueIssuedPerShare_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_z26bqSLHtYVl" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_zzEskgk94Cbk" style="text-align: right" title="Fair value as of period beginning balance, fair value">(342</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 4/4/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_fKDMp_zFQDvfMWB1Va" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_fKDQp_zSM7RfgtCSId" style="text-align: right" title="Fair value as of period beginning balance, shares">(756,429</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueIssuedPerShare_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_zPwZezmJGR0d" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_zglDLLBdhv1l" style="text-align: right" title="Fair value as of period beginning balance, fair value">(352</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20230101__20230930_fKDIp_zohIdCPywvKf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value as of period beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl3028">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20230101__20230930_fKDQp_z1x4gNJErgCi" style="padding-bottom: 1.5pt; text-align: right" title="Fair value as of period beginning balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl3030">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_981_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20230101__20230930_zxhsc8d7Poy6" style="padding-bottom: 1.5pt; text-align: right" title="Fair value as of period beginning balance, fair value per share"><span style="-sec-ix-hidden: xdx2ixbrl3032">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ChangesInFairValue_pn3n3_c20230101__20230930_zKNbdA95sRoc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value as of period beginning balance, fair value">35</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Fair value as of September 30, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20230101__20230930_fKDEp_z2ztt7PXqc9b" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value as of period beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl3036">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><sup>(1)</sup></td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20230101__20230930_fKDIp_zdOp4oZaqz1a" style="padding-bottom: 2.5pt; font-weight: bold; text-align: right" title="Fair value as of period beginning balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl3038">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><sup>(2)</sup></td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20230101__20230930_zsMiZjkWp3L1" style="padding-bottom: 2.5pt; font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value per share"><span style="-sec-ix-hidden: xdx2ixbrl3040">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--WarrantLiability_iE_pn3n3_c20230101__20230930_zbG0CtUgX5K1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value"><span style="-sec-ix-hidden: xdx2ixbrl3042">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zlFGWKX8xgW4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_ziszoUkcFXZ7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgT3V0c3RhbmRpbmcgYW5kIEZhaXIgVmFsdWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--LinesOfCreditCurrent_iI_c20230930_zqVOhmILQVF5" title="Lines of credit current">2,000,000</span> was treated as a new Inception Date for that portion of the line of credit.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0C_zo6T4Jo46G6d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zUjxmYIwlA57" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F01_zH2slpKxOF14" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zQXsjqFVzG34" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of drawdown as of the date presented.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F05_zKPGCAOomVMl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zi2Znp6ufeOc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of warrants issued upon receipt of amounts drawn against the Secured Note as of the date presented.</span></td></tr> </table> <p id="xdx_8A6_zJuguL428Qv2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, AgeX recorded a loss on change in fair value of warrants of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn3p0_c20230101__20230930_z1zL1RkYYi92" title="Loss on change in fair value of warrants">35,000</span>. During the three and nine months ended September 30, 2022, AgeX recorded a loss on change in fair value of warrants of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_iN_pn3d_di_c20220701__20220930_z9YR9tkxWUOk" title="Loss on change in fair value of warrants">35,000</span> and $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn3p0_c20220101__20220930_zQpK0Rq46kU3" title="Loss on change in fair value of warrants">220,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and AgeX’s stock prices and historical volatility as inputs. None of the warrants issued have been exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 15160000 15160000 15160000 4000000 <p id="xdx_893_eus-gaap--ScheduleOfRegulatoryLiabilitiesTextBlock_z2GcxiKrf1u4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date, the date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zw2QQ6saxTs6" style="display: none">Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Black-Scholes Assumptions</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price <sup id="xdx_F4C_zHuoUq0VPEBe">(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date <sup id="xdx_F5D_zQWxI9zocCM6">(2)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price <sup id="xdx_F5D_zUGK0X4CEZO9">(3)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(annual) <sup id="xdx_F57_zH43klumLauh">(4)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Volatility</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(annual) <sup id="xdx_F5D_z89p7UeFUJt5">(5)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Time to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturity (Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Calculated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value per Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inception Date: 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_z9BzORQtDJpc" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_z0bV2kaRKyZe" title="Warrant Expiration Date">2/13/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zACGRla6mSo8" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.691</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_z4k2C6fLHOWg" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zeojZ1bb9M1b" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zqMMhDdFcQC3" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zWOcaNB0dOo4" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.486</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 2/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zfF2aN7zi833" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_z0TowKtJICKl" title="Warrant Expiration Date">2/13/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zMIooITVLcDe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.691</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zs6vUWiqeKdk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_z34WNUBI3pwc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zxkFFcyglDj1" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zHQpYwncfXG" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.486</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 2/15/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zNR1anuvvqh7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zP9urdCMTqqe" title="Warrant Expiration Date">2/14/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--SharePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zo5rH6wv50Xi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zPX5N50cQsg1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zg3FpSsv70P1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123.28</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zVOjBmWPCi2a" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zOOxH3LnCNN8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.535</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 3/31/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zOp9sDkRfWC" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.940</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zJsSrZ4KPfG8" title="Warrant Expiration Date">3/30/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zhHGACPn38W2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.854</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zlHKXCPCSBV" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.45</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zO52XnYdPc5f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123.28</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z4txJIhra84f" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zhiP7zkgZbVa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.607</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 4/4/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zdVBQmty8mdf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.880</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zltSF2wnEjwe" title="Warrant Expiration Date">4/3/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_ziJSTjnyoX86" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.819</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z9dk96Gl4BZ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.61</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zSHcNol77K1h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123.31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zkUBEcpNM1J" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zq0mSI5PbUG6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.585</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 6/6/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zRBcNRkfzS53" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.711</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zLp7JLufavE" title="Warrant Expiration Date">6/5/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zBAGrSnQMXEd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.800</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zxacQhvXLha7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zKPoE8D4fPm1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.62</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zMCZoZeCJDA7" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zS8j2gyepkX1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.592</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 6/30/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zn1uXv4W2gBg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_z0omsK88LKQh" title="Warrant Expiration Date">6/29/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zkqxmyCSjGO4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.576</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zg8pAayspqWi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zJKRSWDVBCV2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zwpZ0jhxGV37" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zqnqv2ZXzu7l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.413</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 8/16/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z7cWvgwIIcw4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.670</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zSyYOorAGrK8" title="Warrant Expiration Date">8/15/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z3bDVTCvwLDe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.640</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zZSWTQscsrqe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zkCzpEAkxn99" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zoxx3kBJSzPi" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zZHU2MRfbKkk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.457</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 9/30/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zCq7830EasZf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.610</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_z8TNe8ePOZA" title="Warrant Expiration Date">9/29/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zXZyPyf0FWId" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.562</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zjr85MhZW775" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_z4cwGErjKv74" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121.49</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zBhrneleGQg7" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zuYRPmNvaDZ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.401</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 10/21/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zquQtoIrn1u8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.690</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zyv8R8R8zSzb" title="Warrant Expiration Date">10/20/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zZwhAmA6hrOj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z45YiG7WNqMf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zXuGNvudfoH7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120.51</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z882Taqn4mNj" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zOP4mH7qoXd4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.439</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 12/14/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zVnalGo9XER3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.590</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zGBwCss5TSx3" title="Warrant Expiration Date">12/13/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zDhDntPTK6zd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.540</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zL2zP1idEEPf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zV93sHSBaNW1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zhgYe21F0DK6" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zBFeNoC7zO1c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.381</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 12/31/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zGE8jyFaEWg3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.550</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zvK9SuxaJlk3" title="Warrant Expiration Date">12/30/2025</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zgpIRueS7jo5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.552</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zzACG8WAoeTi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_z9TwgzMg9LD9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119.31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zNp2oj9bIbR1" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zLlxtlkjDYE3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.396</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 1/25/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z4oiLyLvcBH6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.735</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_z9EJwZW0zYC6" title="Warrant Expiration Date">1/24/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zVrRPQK5O2Nf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.751</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zHprLK2k1sbh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.84</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zwmaISQcJsQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zoEHNuCa0BS4" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zuQrY2qe3Uu4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.540</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inception Date: 2/9/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_z6NLwEO02U69" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.703</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_zBKn1SJSZh79" title="Warrant Expiration Date">2/8/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zCYDPdTJYCcg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_znirqFswjNO7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zkX5xp8UMSCg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118.94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zIMP7Hx7a74c" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zzUitvhQkkBa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.466</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 2/15/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zbtGWL7MhQqd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.624</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zSmpKUuFB0oe" title="Warrant Expiration Date">2/14/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z2jjTTEfeexa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zeKwy9vJHK53" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.35</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zSC86DtX567b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zamgZi5w6FKb" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zybqpnorgjL4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.426</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ended 3/31/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zgK683Xwhp77" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.661</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zJThMbc5Kkdl" title="Warrant Expiration Date">3/30/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zV8EM8qm2Mo6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.663</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zzHHhO5WCFk2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.81</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zoiJsyQJicQ5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113.43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zQAolwfAEMU6" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zTmAKIFy2rOg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.459</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: 4/4/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zvHAFdqfuIPb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.661</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_znaDjAmWAUJ2" title="Warrant Expiration Date">4/3/2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zOE0lrvCuJ3h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.673</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zrdMG48o5bS2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Rate (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zQBTZNK6Hch9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility (annual)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zQK3ube8upya" title="Time to Maturity (Years)">3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zZEJNeuVHOv9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Calculated fair value per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.466</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0E_zVl5EWxB0Phc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zU16xDfIx2fb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIExpYWJpbGl0aWVzIEFuZCBTdG9jayBPcHRpb24gQXdhcmRzIHVzaW5nIGEgQmxhY2stU2Nob2xlcyBPcHRpb24tUHJpY2luZyBNb2RlbCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--LinesOfCreditCurrent_iI_c20230930_z6MDA7K8WREh" title="Lines of credit current">2,000,000</span> was treated as a new Inception Date for that portion of the line of credit.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zZPWjizx9f1l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zf7kWJMwAu3a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants are exercisable over a three-year period from each Issuance Date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0B_zyOtGwIWEQB" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_z5V7lXmeVkA7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0F_zNTqC69vCmJd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zi2x9E3jpv0b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F00_zJj8ZC9jVGZd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zjXcFVWduVX" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the historical daily volatility of AgeX common stock as of each date presented.</span></td></tr> </table> 0.780 2025-02-13 0.691 0.0180 1.2299 P3Y 0.486 0.780 2025-02-13 0.691 0.0180 1.2299 P3Y 0.486 0.780 2025-02-14 0.747 0.0180 1.2328 P3Y 0.535 0.940 2025-03-30 0.854 0.0245 1.2328 P3Y 0.607 0.880 2025-04-03 0.819 0.0261 1.2331 P3Y 0.585 0.711 2025-06-05 0.800 0.0294 1.2262 P3Y 0.592 0.600 2025-06-29 0.576 0.0299 1.2221 P3Y 0.413 0.670 2025-08-15 0.640 0.0319 1.2137 P3Y 0.457 0.610 2025-09-29 0.562 0.0425 1.2149 P3Y 0.401 0.690 2025-10-20 0.620 0.0452 1.2051 P3Y 0.439 0.590 2025-12-13 0.540 0.0394 1.2001 P3Y 0.381 0.550 2025-12-30 0.552 0.0422 1.1931 P3Y 0.396 0.735 2026-01-24 0.751 0.0384 1.1917 P3Y 0.540 0.703 2026-02-08 0.660 0.0415 1.1894 P3Y 0.466 0.624 2026-02-14 0.600 0.0435 1.1893 P3Y 0.426 0.661 2026-03-30 0.663 0.0381 1.1343 P3Y 0.459 0.661 2026-04-03 0.673 0.0360 1.1301 P3Y 0.466 2000000000 <p id="xdx_89E_ecustom--WarrantsOutstandingAndFairValuesTableTextBlock_zXWhGVClUjLj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants outstanding and fair values at each of the respective valuation dates are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zvSTheelmzW9" style="display: none">Schedule of Warrant Outstanding and Fair Values</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Warrant Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit Line and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Draw Amounts</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair value as of January 1, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20220101__20221231_zYHmiBCfBV12" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl2908">-</span></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20220101__20221231_zwfn94rSg3j6" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl2910">-</span></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zmvtkyeTruX1" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value per share"><span style="-sec-ix-hidden: xdx2ixbrl2912">-</span></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantLiability_iS_pid_c20220101__20221231_zRU8ZojU0gLl" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2914">-</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left">Fair value at initial measurement date of 2/14/2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDEp_zhRX1Sqt7Kg4" style="width: 10%; text-align: right" title="Fair value as of period beginning balance">13,160</td><td style="width: 4%; text-align: left"><sup>(1)</sup></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDIp_zyKx40evd6Ph" style="width: 10%; text-align: right" title="Fair value as of period beginning balance, shares">8,435,897</td><td style="width: 4%; text-align: left"><sup>(2)</sup></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_z4cFeMCxQh8e" style="width: 10%; text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4864</td><td style="width: 3%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zkYkixafO8Kj" style="width: 10%; text-align: right" title="Fair value as of period beginning balance, fair value">4,103</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 2/14/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDMp_zhn5aeKFklzk" style="text-align: right" title="Fair value as of period beginning balance">(7,160</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDQp_zpGiipcFqK58" style="text-align: right" title="Fair value as of period beginning balance, shares">(4,589,743</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zLvyKPTY0bJk" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4864</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zKOl61DDVFN3" style="text-align: right" title="Fair value as of period beginning balance, fair value">(2,232</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 2/15/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDMp_zI9tPi1GsaFi" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDQp_zsmgtJxyo4ei" style="text-align: right" title="Fair value as of period beginning balance, shares">(641,025</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zMGBhLlV1q8f" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.5349</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zF4l3PVdSTC7" style="text-align: right" title="Fair value as of period beginning balance, fair value">(343</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 4/4/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDMp_z4Dq1c69XVZb" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDQp_zF3Ji5tfGT5" style="text-align: right" title="Fair value as of period beginning balance, shares">(568,440</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zEFZxKCZrNgj" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.5854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zzPoDTBKIVL9" style="text-align: right" title="Fair value as of period beginning balance, fair value">(333</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 6/6/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDMp_zfJ0MlBRB5x7" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDQp_zuaPczWKUF62" style="text-align: right" title="Fair value as of period beginning balance, shares">(703,234</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_z2xDNvX69jcg" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.5924</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_zyLKdUfTxnEf" style="text-align: right" title="Fair value as of period beginning balance, fair value">(417</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 8/16/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDMp_zWHZlm2TwXx6" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDQp_zZfSvEOjeN56" style="text-align: right" title="Fair value as of period beginning balance, shares">(746,380</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_zsbMVPINZNi6" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_ztj943KVlO4g" style="text-align: right" title="Fair value as of period beginning balance, fair value">(341</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 10/21/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDMp_z9nYNyP2OGKi" style="text-align: right" title="Fair value as of period beginning balance">(500</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDQp_ziPCVVtpzukd" style="text-align: right" title="Fair value as of period beginning balance, shares">(362,318</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_znkVwTqbLQT1" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4386</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_zt9zjJ8BpaEb" style="text-align: right" title="Fair value as of period beginning balance, fair value">(159</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 12/14/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDMp_zUYXwtsxQJ3h" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDQp_zoSyVInAf5A9" style="text-align: right" title="Fair value as of period beginning balance, shares">(847,457</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_zC085kRBT1Gb" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.3810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_znqygaWWAMcf" style="text-align: right" title="Fair value as of period beginning balance, fair value">(323</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20220101__20221231_fKDIp_zzNLY1PH2V8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value as of period beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl2980">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20220101__20221231_fKDQp_z1rEnCXVmcZf" style="padding-bottom: 1.5pt; text-align: right" title="Fair value as of period beginning balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl2982">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20220101__20221231_zfHap1ffykA6" style="padding-bottom: 1.5pt; text-align: right" title="Fair value as of period beginning balance, fair value per share"><span style="-sec-ix-hidden: xdx2ixbrl2984">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ChangesInFairValue_pn3n3_c20220101__20221231_zA1E3lKYcYMd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value as of period beginning balance, fair value">225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair value as of December 31, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20230101__20230930_fKDEp_ztnGps2NOuae" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance">500</td><td style="font-weight: bold; text-align: left"><sup>(1)</sup></td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20230101__20230930_fKDIp_zlK3V0MONBt4" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, shares">454,545</td><td style="font-weight: bold; text-align: left"><sup>(2)</sup></td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20230101__20230930_zn7fecpqujqj" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value per share">0.3960</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_985_ecustom--WarrantLiability_iS_pn3n3_c20230101__20230930_ztfE3H7LwqAk" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value">180</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 1/25/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_fKDMp_zZSKehOBYpoc" style="text-align: right" title="Fair value as of period beginning balance">(500</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_fKDQp_zUHhbXLSxktk" style="text-align: right" title="Fair value as of period beginning balance, shares">(340,136</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_zwCLXJNtfCbc" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.5395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_zZwzhl8gQxVg" style="text-align: right" title="Fair value as of period beginning balance, fair value">(184</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value at initial measurement date of 2/9/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwoSeptemberTwoThousandAndTwentyThreeMember_fKDEp_z3MSBqfGQ5Ge" style="text-align: right" title="Fair value as of period beginning balance">2,000</td><td style="text-align: left"><sup>(1)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwoSeptemberTwoThousandAndTwentyThreeMember_fKDIp_z9jIMJEqnga5" style="text-align: right" title="Fair value as of period beginning balance, shares">1,422,879</td><td style="text-align: left"><sup>(2)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueIssuedPerShare_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwoSeptemberTwoThousandAndTwentyThreeMember_z3JHSsqLER36" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--TwoSeptemberTwoThousandAndTwentyThreeMember_zMjhOp6XDBeb" style="text-align: right" title="Fair value as of period beginning balance, fair value">663</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 2/15/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_fKDMp_z6lnW9D3Tvri" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_fKDQp_zb07ozqsm2Oe" style="text-align: right" title="Fair value as of period beginning balance, shares">(801,924</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueIssuedPerShare_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_z26bqSLHtYVl" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_zzEskgk94Cbk" style="text-align: right" title="Fair value as of period beginning balance, fair value">(342</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 4/4/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_fKDMp_zFQDvfMWB1Va" style="text-align: right" title="Fair value as of period beginning balance">(1,000</td><td style="text-align: left">)<sup>(3)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_fKDQp_zSM7RfgtCSId" style="text-align: right" title="Fair value as of period beginning balance, shares">(756,429</td><td style="text-align: left">)<sup>(4)</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueIssuedPerShare_pid_c20230101__20230930__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_zPwZezmJGR0d" style="text-align: right" title="Fair value as of period beginning balance, fair value per share">0.4660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20230930__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_zglDLLBdhv1l" style="text-align: right" title="Fair value as of period beginning balance, fair value">(352</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20230101__20230930_fKDIp_zohIdCPywvKf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value as of period beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl3028">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20230101__20230930_fKDQp_z1x4gNJErgCi" style="padding-bottom: 1.5pt; text-align: right" title="Fair value as of period beginning balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl3030">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_981_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20230101__20230930_zxhsc8d7Poy6" style="padding-bottom: 1.5pt; text-align: right" title="Fair value as of period beginning balance, fair value per share"><span style="-sec-ix-hidden: xdx2ixbrl3032">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ChangesInFairValue_pn3n3_c20230101__20230930_zKNbdA95sRoc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value as of period beginning balance, fair value">35</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Fair value as of September 30, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20230101__20230930_fKDEp_z2ztt7PXqc9b" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value as of period beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl3036">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><sup>(1)</sup></td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20230101__20230930_fKDIp_zdOp4oZaqz1a" style="padding-bottom: 2.5pt; font-weight: bold; text-align: right" title="Fair value as of period beginning balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl3038">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><sup>(2)</sup></td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20230101__20230930_zsMiZjkWp3L1" style="padding-bottom: 2.5pt; font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value per share"><span style="-sec-ix-hidden: xdx2ixbrl3040">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--WarrantLiability_iE_pn3n3_c20230101__20230930_zbG0CtUgX5K1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value"><span style="-sec-ix-hidden: xdx2ixbrl3042">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zlFGWKX8xgW4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_ziszoUkcFXZ7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgT3V0c3RhbmRpbmcgYW5kIEZhaXIgVmFsdWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--LinesOfCreditCurrent_iI_c20230930_zqVOhmILQVF5" title="Lines of credit current">2,000,000</span> was treated as a new Inception Date for that portion of the line of credit.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0C_zo6T4Jo46G6d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zUjxmYIwlA57" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F01_zH2slpKxOF14" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zQXsjqFVzG34" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of drawdown as of the date presented.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F05_zKPGCAOomVMl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zi2Znp6ufeOc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of warrants issued upon receipt of amounts drawn against the Secured Note as of the date presented.</span></td></tr> </table> 13160000 8435897 0.4864 4103000 -7160000 -4589743 0.4864 -2232000 -1000000 -641025 0.5349 -343000 -1000000 -568440 0.5854 -333000 -1000000 -703234 0.5924 -417000 -1000000 -746380 0.4569 -341000 -500000 -362318 0.4386 -159000 -1000000 -847457 0.3810 -323000 225000 500000 454545 0.3960 180000 -500000 -340136 0.5395 -184000 2000000 1422879 0.4657 663000 -1000000 -801924 0.4263 -342000 -1000000 -756429 0.4660 -352000 35000 2000000000 35000 -35000 220000 <p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z4rJlcIhx6ie" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_82C_zf4mjYJIOm35">Stockholders’ Equity (Deficit)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2023, AgeX issued to Juvenescence <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwnxwTJB5w9k" title="Preferred stock, shares authorized">211,600</span> shares of a newly authorized Series A Preferred Stock and <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgg01d8przs6" title="Preferred stock, shares authorized">148,400</span> shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn6n6_c20230723__20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zyrjb91RkCD4" title="Extinguishment of debt">36</span> million of indebtedness consisting of the outstanding principal amount of loans then outstanding under the 2020 Loan Agreement, the Secured Note, and the $<span id="xdx_90A_eus-gaap--SecuredDebt_iI_pn6n6_c20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zI4874VzrbUf" title="Secured debt">10</span> Million Secured Note, plus the loan origination fees accrued with respect to the 2022 Secured Note and a portion of the loan origination fees accrued pursuant to the $<span id="xdx_901_eus-gaap--SecuredDebt_iI_pn6n6_c20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--OriginationFeeMember_zuY5ZP34yNka" title="Secured debt">10</span> Million Secured Note. The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to the Exchange Agreement between AgeX and Juvenescence. By completing the exchange of indebtedness for shares of Series A Preferred Stock and Series B Preferred Stock (collectively referred to as the “Preferred Stock”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Classification of Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The deemed liquidation preference provisions of the preferred stock are considered contingent redemption provisions that are not solely within AgeX’s control. Accordingly, the preferred stock has been presented outside of permanent equity in the mezzanine section of the condensed consolidated balance sheet. Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values to the preferred stock would be made only when a deemed liquidation event becomes probable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 7, 2023, certain terms of the Series A Preferred Stock and Series B Preferred Stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as adeemed liquidation if the applicable transaction is approved by the Board of Directors or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of Preferred Stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock. This amendment permits the classification of the Series A Preferred Stock and Series B Preferred Stock as permanent equity effective November 7, 2023. See Note 12, <i>Subsequent Events,</i> for illustration of the Preferred Stock presented in permanent equity in the condensed consolidated pro forma balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends </i>– The Preferred Stock is not entitled to receive any payment or distribution of cash or other dividends.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation Preference</i> – In the event of any voluntary or involuntary liquidation, dissolution or other winding up of the affairs of AgeX, subject to the preferences and other rights of any senior stock, before any assets of AgeX shall be distributed to holders of common stock or other junior stock, all of the assets of AgeX available for distribution to stockholders shall be distributed among the holders of Series A Preferred Stock and Series B Preferred Stock and any other “parity stock” that may be issued ranking <i>parri passu</i> with those series of Preferred Stock with respect to liquidation rights, in proportion to the number of shares of Series B Preferred Stock and parity stock held by each such holder as of the record date for the determination of holders of Series A Preferred Stock, Series B Preferred Stock, and parity stock entitled to receive such distribution, until AgeX shall have distributed to the holders of those shares an amount of assets having a value equal to the subscription price per share. If the assets of AgeX shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of Series A Preferred Stock, Series B Preferred Stock and parity stock shall be ratably distributed among such holders. The (i) acquisition of AgeX by another entity by means of any transaction or series of transactions (including, without limitation, any reorganization, merger or consolidation) in which the stockholders of AgeX immediately before such transaction or series of transactions do not own a majority of the outstanding stock of the surviving or acquiring corporation upon completion of such transaction or series of transactions or (ii) a sale of all or substantially all of the assets of AgeX in a single transaction or series of related transactions, shall be deemed a liquidation. On November 7, 2023, certain terms of the liquidation preference were amended. See Note 12 <i>Subsequent Transactions.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion of Preferred Stock into Common Stock</i> – Each share of Preferred Stock shall be convertible into a number of shares of AgeX common stock determined by dividing (x) a number equal to the number of dollars and cents comprising the subscription price, by (y) a number equal to the number of dollars and cents comprising the conversion price. The subscription price per share of Preferred Stock is $<span id="xdx_901_eus-gaap--CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_iI_pn3n3_c20230724__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zxEIIXDEkxY2" title="Subscriptions price">100</span> which was paid through the exchange of indebtedness for shares of Preferred Stock. The conversion price per share of Series A Preferred Stock or Series B Preferred Stock is $<span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20230724__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLiMj0Cgvcx1" title="Preferred stock closing price">0.72</span> which was the closing price of AgeX common stock on the NYSE American on the last trading day immediately preceding the execution of the Exchange Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Optional Conversion</i> – Preferred Stock shall be convertible into common stock at the election of the holder of shares of Preferred Stock at any time and from time to time subject to the limitations on conversion of Series B Preferred Stock discussed below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Automatic Conversion</i> – The outstanding shares of Series A Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders (“Automatic Conversion”) upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina, or a subsidiary thereof; and (y) February 1, 2024. Further, if the holders of at least a majority of the outstanding shares of Series A Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, then the outstanding shares of Series A Preferred Stock shall be converted into common stock upon such approval or consent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outstanding shares of Series B Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina or a subsidiary thereof; and <span id="xdx_907_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230723__20230724_zPobSY1qW7yg" title="Conversion percentage, description">(y) February 1, 2024, provided that such conversion is not limited by the 19.9% Cap or the 50% Cap as described below; and if Automatic Conversion would then be limited by the 19.9% Cap or the 50% Cap, the Automatic Conversion shall take place on the tenth day after such stockholder approvals have been obtained as may be required to permit such Automatic Conversion without the limitations of the 19.9% Cap and the 50% Cap. Further, if the holders of at least a majority of the outstanding shares of Series B Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, and the conversion is not then limited by the 19.9% Cap or the 50% Cap, then the outstanding shares of Series B Preferred Stock shall be converted into common stock upon such approval or consent.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain Limitations on Conversion of Series B Preferred Stock</i> – <span id="xdx_90D_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230723__20230724__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUJu2A5COmJl" title="Conversion percentage, description">If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the “19.9% Cap” upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued upon conversion of all shares of Series B Preferred Stock shall be an amount equal to the 19.9% Cap. The 19.9% Cap means 7,550,302 shares of common stock, which is 19.9% of the shares of common stock outstanding on February 14, 2022 when the Secured Note, a portion of which has not been approved by AgeX stockholders for conversion into common stock without regard to the 19.9% Cap and 50% Cap, was issued.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230723__20230724__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLafAjWZn3oc" title="Conversion percentage, description">If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the 50% Cap upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued to a holder of Series B Preferred Stock upon conversion of such shares shall be an amount that, when added to other shares of common stock owned by such holder immediately prior to such conversion would equal one share less than the 50% Cap.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Adjustment of conversion price and subscription price</i> – If AgeX shall (a) declare a dividend or make a distribution on its common stock in shares of common stock, (b) subdivide or reclassify the outstanding common stock into a greater number of shares, or (c) combine or reclassify the outstanding common stock into a smaller number of shares, the conversion price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. If AgeX shall (i) declare a dividend or make a distribution on a series of Preferred Stock in shares of Preferred Stock, (ii) subdivide or reclassify the outstanding shares of a series of Preferred Stock into a greater number of shares, or (iii) combine or reclassify the outstanding shares of a series of Preferred Stock into a smaller number of shares, the subscription price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. Successive adjustments in the conversion price or subscription price, as applicable, shall be made whenever any event specified above shall occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No Fractional Shares</i> – No fractional share of common stock or scrip shall be issued upon conversion of Preferred Stock. Instead of any fractional share of common stock which would otherwise be issuable upon conversion of any Preferred Stock, AgeX will pay a cash adjustment in respect of such fractional interest in an amount equal to that fractional interest at the then fair value determined in accordance with the terms of the Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Rights</i> – The following matters shall require the approval of the holders of a majority of the shares of a series of Preferred Stock then outstanding, voting as a separate class: <span id="xdx_90F_eus-gaap--PreferredStockVotingRights_c20230101__20230930_zAfUxcQLMepf" title="Preferred stock voting rights">(i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock.</span> Except as may otherwise be required by the Delaware General Corporation Law, as the same may be amended from time to time, the Preferred Stock will have no other voting rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governing Law</i> – The powers, designations, preferences, rights, qualifications, limitations, and restrictions of either series of Preferred Stock, the validity, authorization and issuance of such Preferred Stock, and the conversion of such Preferred Stock into common stock shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof, and all legal proceedings pursuant or with respect to or concerning such matters (a “Proceeding”), whether brought by or against a holder of Preferred Stock or AgeX or any of their respective directors, officers, stockholders, employees or agents, shall be commenced in the state and federal courts sitting in the State of Delaware (the “Delaware Courts”). The Preferred Stock provides that (a) AgeX and each holder of Preferred Stock irrevocably submits to the exclusive jurisdiction of the Delaware Courts for the adjudication of any Proceeding, and irrevocably waives, and agrees not to assert in any Proceeding any claim that they are not personally subject to the jurisdiction of such Delaware Courts, or such Delaware Courts are an improper or inconvenient venue for such Proceeding, and (b) AgeX and each holder of Preferred Stock irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to such party and agrees that such service shall constitute good and sufficient service of process and notice</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230930_zeOu07jAG8Be" title="Common stock, shares authorized"><span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zVTWE2i69kl3" title="Common stock, shares authorized">200,000,000</span></span> shares of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230930_zjiqoDGdQ7A1" title="Common stock, par value"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zFSlosZB5Tyi" title="Common stock, par value">0.0001</span></span> par value common stock authorized. At September 30, 2023 and December 31, 2022, there were <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG3LtfE1CTEl" title="Common stock, shares outstanding"><span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zojZ5bCsxT2a" title="Common stock, shares issued">37,951,261</span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNIbBT6TU004" title="Common stock, shares outstanding"><span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdAlY1lOJRJ9" title="Common stock, shares issued">37,949,196</span></span> shares of AgeX common stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance and Sale of Warrants by AgeX</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--JuvenescenceMember_zZaWJC7qPE2e" title="Line of credit facility">2,500,000</span> of drawdowns of loan funds from Juvenescence under the Secured Note during the nine months ended September 30, 2023, AgeX issued to Juvenescence 2022 Warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--DebtInstrumentAxis__custom--IssuanceAndSaleOfWarrantsMember_zqyYa9yZhpfb" title="Warrant to purchase share of common stock">1,898,489</span> shares of AgeX common stock. See Note 6, <i>Warrant Liability</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>At-the-Market Offering Facility</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2021, AgeX entered into a sales agreement with Chardan Capital Markets, LLC (“Chardan”) relating to the sale of shares of AgeX common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210108__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zSCiSS7Xvi1" title="Common stock, par value">0.0001</span> per share, through an at-the-market (“ATM”) offering as described in the prospectus supplement filed with the Form S-3 which was declared effective by the SEC on January 29, 2021. In accordance with the terms of the sales agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $<span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_pn5n6_c20210107__20210108__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_znlbYdpshHQd" title="Payments for offering">12.6</span> million from time to time through Chardan, acting as the sales agent. The actual market value of shares of common stock that AgeX may sell through the ATM offering during any 12 month period will be limited to one-third of the aggregate market value of AgeX common stock held by stockholders that would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. During the nine months ended September 30, 2023 and 2022, <span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_do_c20230101__20230930__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_z4Zvn1ZOss0k" title="Proceeds from issuance costs"><span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_do_c20220101__20220930__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_z1OJJ3xV67rj" title="Proceeds from issuance costs">no</span></span> proceeds were raised through the sale of shares of common stock under the ATM.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 211600 148400 36000000 10000000 10000000 100000 0.72 (y) February 1, 2024, provided that such conversion is not limited by the 19.9% Cap or the 50% Cap as described below; and if Automatic Conversion would then be limited by the 19.9% Cap or the 50% Cap, the Automatic Conversion shall take place on the tenth day after such stockholder approvals have been obtained as may be required to permit such Automatic Conversion without the limitations of the 19.9% Cap and the 50% Cap. Further, if the holders of at least a majority of the outstanding shares of Series B Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, and the conversion is not then limited by the 19.9% Cap or the 50% Cap, then the outstanding shares of Series B Preferred Stock shall be converted into common stock upon such approval or consent. If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the “19.9% Cap” upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued upon conversion of all shares of Series B Preferred Stock shall be an amount equal to the 19.9% Cap. The 19.9% Cap means 7,550,302 shares of common stock, which is 19.9% of the shares of common stock outstanding on February 14, 2022 when the Secured Note, a portion of which has not been approved by AgeX stockholders for conversion into common stock without regard to the 19.9% Cap and 50% Cap, was issued. If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the 50% Cap upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued to a holder of Series B Preferred Stock upon conversion of such shares shall be an amount that, when added to other shares of common stock owned by such holder immediately prior to such conversion would equal one share less than the 50% Cap. (i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock. 200000000 200000000 0.0001 0.0001 37951261 37951261 37949196 37949196 2500000 1898489 0.0001 12600000 0 0 <p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zTaPrhJHP736" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_828_zZlbZC67gj6b">Stock-Based Awards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity Incentive Plan Awards</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has an Equity Incentive Plan (the “Plan”) under which a maximum of <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230930_zZuUaCzV9Ut6" title="Number of common stock reserved">8,500,000</span> shares of common stock are available for the grant of stock options, the sale of restricted stock, the settlement of restricted stock units, and the grant of stock appreciation rights. The Plan also permits AgeX to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zJERWtj0VpY6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zPPpV49QXhC" style="display: none">Summary of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for Grant</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of RSUs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zEgMEdbhJkU5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Shares available for grant, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,139</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zbCUqTD17Di2" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,261</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw6TBVgIxSl8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of RSUs outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zsNE22LOXTK7" title="Weighted average exercise price, outstanding, beginning balance">2.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesAvailableForGrant_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zs72XlLiOxq1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares available for grant, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zGlzfVL14q82" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zcFZTnR61Tc1" title="Number of RSUs outstanding, options granted"><span style="-sec-ix-hidden: xdx2ixbrl3126">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zv92n2ygNnrj" title="Weighted average exercise price, options granted">0.76</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units vested</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zd3V7naa72ja" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares available for grant, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3130">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zMrsP2Temi74" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3132">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zhdADhbePlR4" title="Number of RSUs outstanding, restricted stock units vested">(3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zuRgHZPZwWSj" title="Weighted average exercise price, restricted stock units vested"><span style="-sec-ix-hidden: xdx2ixbrl3136">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z3JHqpxiHkhf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares available for grant, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,113</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z9KAI8Q1VEs6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,287</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z5vYSCXoowA1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">      <span style="-sec-ix-hidden: xdx2ixbrl3142">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYmawL9hx379" title="Weighted average exercise price, outstanding, ending balance">2.24</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options exercisable at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zBHTkzDHiEFe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,067</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zMip3VGBQARe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AE_z2pdtrIH4bd1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230101__20230930_zKfaTEYCK5Sf" title="Number of options exercised">no</span> exercises of stock options to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based Compensation Expense</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC 718, <i>Compensation – Stock Compensation</i> (“ASC 718”). AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under AgeX’s 2017 Equity Incentive Plan (the “Incentive Plan”). The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zG98jPuMGsOb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses include stock-based compensation expense as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zizrqk6whfHe" style="display: none">Schedule of Stock Based Compensation Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20230701__20230930_z4oQpgYLtmYh" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220701__20220930_zoDThYBsoTy5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20230101__20230930_zXWUlvaBTvc3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20220101__20220930_zwDXQU9knjcg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXCXKVlwNE5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBDJfsgiHaKh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">621</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zn1RoudE0db7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">209</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">646</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A5_zUmekgXR9zf6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions including expected life, risk-free interest rates, volatility, and dividend yield. The assumptions that were used to calculate the grant date fair value of employee and non-employee stock option grants for the three and nine months ended September 30, 2022 were as follows:</span></p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDEb0Igckr51" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zrfAnoEmwPB6" style="display: none">Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022<sup id="xdx_F58_zGG75Zw3QUt6">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant price</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230701__20230930_zfclkE9OnICk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.76</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220701__20220930_fKDEp_zWyXBaGWWj26" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3173">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230930_fKDEp_zmk0TP1StrE3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.76</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220930_z5SMeKEXLne3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market price</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_pid_c20230701__20230930_z3C2p5X30L2g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Market price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_pid_c20220701__20220930_fKDEp_zqrzjAD6gefj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Market price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3181">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_pid_c20230101__20230930_fKDEp_zb5zUuwCCgDf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Market price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_pid_c20220101__20220930_zs6pW2yTsTJi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Market price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20230930_zAWDCf7ZjQNh" title="Expected life (in years)">5.15</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220701__20220930_fKDEp_zgEQqlj1gBva" title="Expected life (in years)"><span style="-sec-ix-hidden: xdx2ixbrl3189">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zIirEZFrcYba" title="Expected life (in years)">5.15</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_zgtFOzmgodMh" title="Expected life (in years)">5.58</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230701__20230930_zxA41N31zRXa" title="Volatility">118.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220701__20220930_fKDEp_zLAyV0BG4t18" title="Volatility"><span style="-sec-ix-hidden: xdx2ixbrl3197">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930_zdCeCxc0rqj7" title="Volatility">118.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930_zCeBEsI8941j" title="Volatility">130.71</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230701__20230930_zqBxhq7vmYih" title="Risk-free interest rates">4.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220701__20220930_fKDEp_zptFu7AwzOCd" title="Risk-free interest rates"><span style="-sec-ix-hidden: xdx2ixbrl3205">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930_zBMZjTc4VST8" title="Risk-free interest rates">4.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930_z1yLUsSfTh6g" title="Risk-free interest rates">1.74</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230701__20230930_zKq1eyvpIFg2" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl3211">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220701__20220930_fKDEp_zTZFrjFk5pK2" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl3213">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_z45yXXdsOEza" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl3215">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930_zYTZMwenHZjk" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl3217">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><span id="xdx_F0F_zvnlHECALPW" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zCbj0kzylSK4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no stock options granted under the Plan during the three months ended September 30, 2022.</span></td></tr></table> <p id="xdx_8AE_zjyt7oFlnbpb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If AgeX had made different assumptions, its stock-based compensation expense and net loss for the nine months ended September 30, 2023 and 2022 may have been significantly different.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 8500000 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zJERWtj0VpY6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zPPpV49QXhC" style="display: none">Summary of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for Grant</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of RSUs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zEgMEdbhJkU5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Shares available for grant, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,139</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zbCUqTD17Di2" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,261</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw6TBVgIxSl8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of RSUs outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zsNE22LOXTK7" title="Weighted average exercise price, outstanding, beginning balance">2.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesAvailableForGrant_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zs72XlLiOxq1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares available for grant, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zGlzfVL14q82" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding, options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zcFZTnR61Tc1" title="Number of RSUs outstanding, options granted"><span style="-sec-ix-hidden: xdx2ixbrl3126">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zv92n2ygNnrj" title="Weighted average exercise price, options granted">0.76</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units vested</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zd3V7naa72ja" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares available for grant, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3130">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zMrsP2Temi74" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding, restricted stock units vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3132">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zhdADhbePlR4" title="Number of RSUs outstanding, restricted stock units vested">(3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zuRgHZPZwWSj" title="Weighted average exercise price, restricted stock units vested"><span style="-sec-ix-hidden: xdx2ixbrl3136">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z3JHqpxiHkhf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares available for grant, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,113</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z9KAI8Q1VEs6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,287</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z5vYSCXoowA1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">      <span style="-sec-ix-hidden: xdx2ixbrl3142">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYmawL9hx379" title="Weighted average exercise price, outstanding, ending balance">2.24</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options exercisable at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zBHTkzDHiEFe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,067</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zMip3VGBQARe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 5139000 3261000 3000 2.25 26000 26000 0.76 3000 5113000 3287000 2.24 3067000 2.32 0 <p id="xdx_892_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zG98jPuMGsOb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses include stock-based compensation expense as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zizrqk6whfHe" style="display: none">Schedule of Stock Based Compensation Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20230701__20230930_z4oQpgYLtmYh" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220701__20220930_zoDThYBsoTy5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20230101__20230930_zXWUlvaBTvc3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20220101__20220930_zwDXQU9knjcg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXCXKVlwNE5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBDJfsgiHaKh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">621</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zn1RoudE0db7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">209</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">646</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1000 8000 8000 25000 39000 201000 137000 621000 40000 209000 145000 646000 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDEb0Igckr51" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zrfAnoEmwPB6" style="display: none">Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022<sup id="xdx_F58_zGG75Zw3QUt6">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant price</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230701__20230930_zfclkE9OnICk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.76</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220701__20220930_fKDEp_zWyXBaGWWj26" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3173">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230930_fKDEp_zmk0TP1StrE3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.76</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220930_z5SMeKEXLne3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Grant Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market price</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_pid_c20230701__20230930_z3C2p5X30L2g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Market price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_pid_c20220701__20220930_fKDEp_zqrzjAD6gefj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Market price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3181">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_pid_c20230101__20230930_fKDEp_zb5zUuwCCgDf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Market price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_pid_c20220101__20220930_zs6pW2yTsTJi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Market price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20230930_zAWDCf7ZjQNh" title="Expected life (in years)">5.15</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220701__20220930_fKDEp_zgEQqlj1gBva" title="Expected life (in years)"><span style="-sec-ix-hidden: xdx2ixbrl3189">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zIirEZFrcYba" title="Expected life (in years)">5.15</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_zgtFOzmgodMh" title="Expected life (in years)">5.58</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230701__20230930_zxA41N31zRXa" title="Volatility">118.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220701__20220930_fKDEp_zLAyV0BG4t18" title="Volatility"><span style="-sec-ix-hidden: xdx2ixbrl3197">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930_zdCeCxc0rqj7" title="Volatility">118.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930_zCeBEsI8941j" title="Volatility">130.71</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230701__20230930_zqBxhq7vmYih" title="Risk-free interest rates">4.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220701__20220930_fKDEp_zptFu7AwzOCd" title="Risk-free interest rates"><span style="-sec-ix-hidden: xdx2ixbrl3205">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930_zBMZjTc4VST8" title="Risk-free interest rates">4.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930_z1yLUsSfTh6g" title="Risk-free interest rates">1.74</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -6.45pt; padding-left: 6.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230701__20230930_zKq1eyvpIFg2" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl3211">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220701__20220930_fKDEp_zTZFrjFk5pK2" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl3213">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_z45yXXdsOEza" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl3215">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930_zYTZMwenHZjk" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl3217">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><span id="xdx_F0F_zvnlHECALPW" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zCbj0kzylSK4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no stock options granted under the Plan during the three months ended September 30, 2022.</span></td></tr></table> 0.76 0.76 0.79 0.76 0.76 0.79 P5Y1M24D P5Y1M24D P5Y6M29D 1.1812 1.1812 1.3071 0.0412 0.0412 0.0174 <p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zuuPucREOvbc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. <span id="xdx_820_zm2Y8j5GYcwh">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270<i>, Income Taxes, Interim Reporting</i>. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where AgeX conducts business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and nine months ended September 30, 2023 and 2022, AgeX experienced a loss; therefore, <span id="xdx_90E_eus-gaap--IncomeTaxExpenseBenefit_do_c20230101__20230930_zvRF3MMNMrUc" title="Income tax provisions"><span id="xdx_90A_eus-gaap--IncomeTaxExpenseBenefit_do_c20220101__20220930_z6zS2nHAN299" title="Income tax provisions"><span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_do_c20230701__20230930_zTaSyl48dDsg" title="Income tax provisions"><span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_do_c20220701__20220930_zqeKAHq8R5mk" title="Income tax provisions">no</span></span></span></span> income tax provision was recorded for the three and nine months ended September 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to losses incurred for all periods presented, AgeX did not record a provision or benefit for income taxes. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all of its deferred tax assets for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 0 0 <p id="xdx_80B_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_z8GLrTQttti5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span id="xdx_828_z0IWpANvlvi8">Supplemental Cash Flow Information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zgZZE82fTKId" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zuCRpY8z0hQe" style="display: none">Schedule of Non-cash Investing and Financing Transactions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20230101__20230930_zJ7sQw6cqwy3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20220101__20220930_zXLfl2UfuFT8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--InterestPaidNet_i01_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid during the period for interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--IssuanceOfPreferredStockInExchangeForDebt_i01_pn3n3_zwheNhXISOEe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of preferred stock in exchange for debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3238">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--IssuanceOfCommonStockUponVestingOfRestrictedStockUnits_i01_pn3n3_zSoGVaEeP7cl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock upon vesting of restricted stock units (Note 8)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of warrants for debt issuance under the 2020 Loan Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3243">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">178</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AssetsFairValueAdjustment_i01_pn3n3_zqmq1MBImc8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of liability classified warrants at debt inception date (Note 6)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">663</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--ShortTermDebtRefinancedAmount_i01_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt refinanced with new debt (Note 5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3249">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AB_z4ZetzPDCp9d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zgZZE82fTKId" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zuCRpY8z0hQe" style="display: none">Schedule of Non-cash Investing and Financing Transactions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20230101__20230930_zJ7sQw6cqwy3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20220101__20220930_zXLfl2UfuFT8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--InterestPaidNet_i01_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid during the period for interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--IssuanceOfPreferredStockInExchangeForDebt_i01_pn3n3_zwheNhXISOEe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of preferred stock in exchange for debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3238">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--IssuanceOfCommonStockUponVestingOfRestrictedStockUnits_i01_pn3n3_zSoGVaEeP7cl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock upon vesting of restricted stock units (Note 8)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of warrants for debt issuance under the 2020 Loan Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3243">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">178</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AssetsFairValueAdjustment_i01_pn3n3_zqmq1MBImc8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of liability classified warrants at debt inception date (Note 6)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">663</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--ShortTermDebtRefinancedAmount_i01_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt refinanced with new debt (Note 5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3249">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 27000 14000 36000000 2000 6000 178000 663000 3666000 7160000 <p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMJW8NPDWjI2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span id="xdx_823_zQdvp0Mte3b">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Office Lease Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX leases office space in Alameda, California. For 2022 base monthly rent was $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zv664yofB7N5" title="Lease and rental expense">1,074</span> and for 2023 base monthly rent is $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zHaw8fZpufki" title="Lease and rental expense">844</span> for slightly less space at the same building. The lease also includes office furniture rental, janitorial services, utilities, and internet service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ASC 842</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the office lease, AgeX has elected to not apply the recognition requirements under ASC 842 as lease cost on a straight-line basis over the lease term because the amount of the lease payments is not deemed material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no future minimum lease commitments as of September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigation – General</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax Filings</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes AgeX has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the unaudited condensed consolidated interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment Contracts</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s research and development programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s research and development. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property licensed from AgeX to third parties. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The sales agreement between AgeX and Chardan also includes indemnification provisions pursuant to which the parties have agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock through the ATM facility, including liabilities under the Securities Act. Similarly, the Registration Rights Agreement between Juvenescence and AgeX includes indemnification provisions pursuant to which the parties will indemnify each other from certain liabilities in connection with the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. AgeX has also agreed to provide the AST Indemnity pursuant to the Letter of Indemnification described in Note 5, <i>Related Party Transactions</i>. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular license, lease, or agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure and in the case of the AST Indemnity AgeX has received a cross-indemnity from Juvenescence against all claims, damages, liabilities or losses arising out of the AST Indemnity. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notice of Delisting</i> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 20, 2023, AgeX received a letter (the “2023 Deficiency Letter”) from the staff of the Exchange indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $<span id="xdx_908_eus-gaap--NetIncomeLoss_c20230419__20230420__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zRjxi0pCRlQg" title="Net loss">2,000,000</span> and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $<span id="xdx_90B_eus-gaap--NetIncomeLoss_c20230419__20230420__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--SegmentContinuingOperationsOneMember_zgy0PpZvJBml" title="Net loss">4,000,000</span> and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $<span id="xdx_90A_eus-gaap--NetIncomeLoss_c20230419__20230420__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--SegmentContinuingOperationsTwoMember_zV2oOVfAt0Cb" title="Net loss">6,000,000</span> or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The 2023 Deficiency Letter states that as AgeX remains subject to the conditions set forth in prior letters from the Exchange with respect to AgeX’s deficiencies in stockholders equity, and if AgeX is not in compliance with all of the Exchange’s stockholders equity standards, or does not make progress consistent with AgeX’s Exchange approved plan to come into compliance with the Exchange’s continued listing standards, by May 17, 2023, the Exchange will initiate delisting proceedings as appropriate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 17, 2023 AgeX received a notice from the staff of the Exchange indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange’s Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX did not meet the continued listing standards because it had stockholders equity of less than (A) $<span id="xdx_900_eus-gaap--NetIncomeLoss_c20230516__20230517__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_z635NUiuPEVg" title="Net loss">2,000,000</span> and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $<span id="xdx_906_eus-gaap--NetIncomeLoss_c20230516__20230517__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--SegmentContinuingOperationsOneMember_z9LHqxpYmhi8" title="Net loss">4,000,000</span> and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $<span id="xdx_90F_eus-gaap--NetIncomeLoss_c20230516__20230517__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--SegmentContinuingOperationsTwoMember_zqFAvXWTOVjd" title="Net loss">6,000,000</span> or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 24, 2023, AgeX filed a request for a review of the delisting determination by a Committee of the Board of Directors of the Exchange. On May 31, 2023, AgeX received a notice from the staff of the Exchange which scheduled a hearing for July 25, 2023. On July 24, 2023, AgeX issued shares of preferred stock to Juvenescence in exchange for the extinguishment of $<span id="xdx_900_eus-gaap--ExtinguishmentOfDebtAmount_pn6n6_c20230724__20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zL63dHurPkJb">36 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of indebtedness owed to Juvenescence for the purpose of remediating the deficiency in stockholders equity, and the hearing at the Exchange scheduled for July 25 was cancelled. See Note 7, <i>Stockholders’ Equity (Deficit)</i> and Note 12, <i>Subsequent Events</i> for further discussion on the classification of preferred stock and amendment to Section 3(b) of the terms of the Series A Preferred Stock and Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1074 844 2000000 4000000 6000000 2000000 4000000 6000000 36000000 <p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zXYOlW3mcVwb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span id="xdx_821_zzapmhmzKQLg">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional Loans Under Secured Note</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 3, 2023, AgeX drew $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn3p0_c20231003__20231003__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdQOjtusOgGl">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">of its credit available under the Secured Note. On October 31, 2023 AgeX drew the final $<span id="xdx_900_eus-gaap--LinesOfCreditCurrent_iI_pn3p0_c20231031__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoXsjmERDUW">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">of the credit line available under the Secured Note</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increase in Secured Note Line of Credit</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 9, 2023, AgeX and Juvenescence entered into the Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note (the “Fifth Amendment”) that increases the amount of the line of credit available to AgeX by $<span id="xdx_901_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn3p0_c20231109__20231109__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0kaIlVOjK86">4,400,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, subject to the terms of the Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. Concurrently with the execution of the Fifth Amendment, AgeX also entered into an additional Pledge Agreement to add shares of a subsidiary to the collateral under the Security Agreement, and AgeX’s subsidiaries ReCyte, Reverse Bio, and UniverXome each entered into a Guaranty Agreement and Joinder Agreement pursuant to which each of them agreed to guaranty AgeX’s obligations to Juvenescence pursuant to the Secured Note, as amended by the Fifth Amendment, and to grant Juvenescence a security interest in their respective assets pursuant to the Security Agreement to secure their obligations to Juvenescence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment to Preferred Stock and Remediation of Stock Exchange Listing Deficiency</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2023, AgeX issued shares of AgeX Series A Preferred Stock and AgeX Series B Preferred Stock to Juvenescence in exchange for the extinguishment of $<span id="xdx_906_eus-gaap--ExtinguishmentOfDebtAmount_pn6n6_c20230724__20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zGkDwR6nMSSj">36 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of indebtedness owed to Juvenescence with the intent of adding $<span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn6n6_c20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zial9ame2Jc6">36 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to stockholders equity to eliminate a stockholders equity deficiency that caused AgeX to be out of compliance with the NYSE American continued listing standards. However, upon subsequent consideration in consultation with AgeX’s independent registered public accountants, AgeX determined that, in accordance with applicable guidance to GAAP, the deemed liquidation preference provisions of the Preferred Stock could be considered contingent redemption provisions that are not solely within AgeX’s control, requiring that the Preferred Stock be presented outside of permanent equity in the mezzanine section of the condensed consolidated balance sheet as of September 30, 2023. To comply with the NYSE American listing requirement by permitting the Preferred Stock to qualify now as permanent equity, on November 7, 2023, Section 3(b) of the terms of the Series A Preferred Stock and Series B Preferred Stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as a deemed liquidation if the applicable transaction is approved by the Board of Directors or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of Preferred Stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock. AgeX has informed the NYSE American of the accounting issue and the remedy that has been implemented and AgeX believes it is in compliance with NYSE American’s continued listing standards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following pro-forma condensed consolidated balance sheet illustrates the effect of the Preferred Stock in permanent equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-GAAP Financial Measures</b></span></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-size: 10pt">The condensed consolidated interim financial statements include stockholders equity (deficit) prepared in accordance with accounting principles generally accepted in the United States (GAAP). The following pro-forma condensed consolidated balance sheet includes certain pro forma historical non-GAAP adjustments to the balance sheet. In particular, AgeX has provided a non-GAAP pro forma presentation of Series A Preferred Stock and Series B Preferred Stock classified as permanent equity, eliminating the stockholders deficit, based on a post-September 30, 2023 amendment to the liquidation provisions of the Preferred Stock. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable financial measures prepared in accordance with GAAP. However, AgeX believes the non-GAAP presentation of stockholders equity, when viewed in conjunction with our GAAP presentation, is helpful in understanding AgeX’s current capital structure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGEX THERAPEUTICS, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>CONDENSED CONSOLIDATED PRO FORMA BALANCE SHEET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in thousands, except par value amounts)</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(unaudited)</i></b></span></p> <p id="xdx_892_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_z1qD5IaMOUP3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8BA_zmMm7Ad4joKj" style="display: none">Schedule of Condensed Consolidated Pro Forma Balance Sheets</span></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20230930_zzlh6ggmZLCk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20230930__srt--RestatementAxis__srt--RestatementAdjustmentMember_zpHsWSy18nC9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20231114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlPOp5YYnejc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted Balance</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zOahMCLJzGba" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zmgKozUBZRN1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current </span>assets:</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzK6v_zAdtDtMqQASk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">397</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3289">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">397</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccountsReceivableNetCurrent_i02I_pn3n3_maACzK6v_zsE9V8DhDDpb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts and grants receivable, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3293">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--AccountsAndOtherReceivablesNetCurrent_i02I_pn3n3_maACzK6v_ztmIitq6q31d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party receivables, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3297">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzK6v_zAMTgXkuiAC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">673</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3301">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">673</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzK6v_maAzTOG_zXs1xqTclih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,141</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3305">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,141</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--RestrictedCashNoncurrent_i01I_pn3n3_maAzTOG_zFpDWqBU54id" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3309">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_pn3n3_maAzTOG_zgcCAQaX2xp" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">640</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3313">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">640</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--NotesAndLoansReceivableGrossNoncurrent_i01I_pn3n3_maAzTOG_zQgydxF1q5Qb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible note receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,379</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3317">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,379</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--Assets_i01TI_pn3n3_mtAzTOG_zEeMpex7dBI8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3321">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zzxrWphZIrgc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES, CONVERTIBLE PREFERRED STOCK</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> AND STOCKHOLDERS’ EQUITY (DEFICIT)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--LiabilitiesCurrentAbstract_i01B_znDuHEAV5ye2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pn3n3_maLCzcF6_znAOL2qTSlp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,671</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3333">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,671</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--LoansPayableCurrent_i02I_pn3n3_maLCzcF6_zycVaE3PKC1c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan due to Juvenescence, net of debt issuance costs, current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3337">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_ecustom--InsurancePremiumLiabilityAndOtherCurrentLiabilities_i02I_pn3n3_maLCzcF6_zLdhr7qxfdN9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance premium liability and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3341">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzcF6_maLzvGy_zBaAzc1VabRg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3345">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LongTermLoansPayable_i01I_maLzvGy_z1aclWwRc236" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan due to Juvenescence, net of debt issuance costs, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3349">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--Liabilities_i01TI_pn3n3_mtLzvGy_maLASEzD07_z5TviAn2ORV8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,897</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3353">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,897</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--CommitmentsAndContingencies_i01I_pn3n3_maLASEzD07_zP96DhPsR5r1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and contingencies</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3356">-</span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3357">-</span><span style="font-size: 10pt"> </span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3358">-</span><span style="font-size: 10pt"> </span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4ap1PqYY9Ql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A preferred stock; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfTyfjLTUnf1" title="Temporary stock, par value">no</span> par value; stated value $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhbcIqurZ5Rl" title="Temporary stock, stated value">100</span> per share; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--TemporaryEquitySharesIssued_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztSXLwn2UScc" title="Temporary stock, shares issued"><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJwpRvrvDIU5" title="Temporary stock, shares outstanding">212</span></span></span> and <span title="Temporary stock, shares issued"><span id="xdx_903_eus-gaap--TemporaryEquitySharesIssued_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOJtQOXxN149" title="Temporary stock, shares issued::XDX::-"><span id="xdx_903_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4xWzxotl65" title="Temporary stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3372"><span style="-sec-ix-hidden: xdx2ixbrl3374">nil</span></span></span></span></span> shares issued and outstanding, respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3362">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWt0mZUPKL5c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B preferred stock; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zq2eQx5O2L86" title="Temporary stock, par value">no</span> par value; stated value $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zOr73mBoozZ2" title="Temporary stock, stated value">100</span> per share; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--TemporaryEquitySharesIssued_iI_pn3n3_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zu4arN29aay1" title="Temporary stock, shares issued"><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_pn3n3_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZuocRqs6G5a" title="Temporary stock, shares outstanding">148</span></span></span> and <span title="Temporary stock, shares issued::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--TemporaryEquitySharesIssued_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaVRwwaTb1e1" title="Temporary stock, shares issued::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFiU4p5PxgM7" title="Temporary stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3388"><span style="-sec-ix-hidden: xdx2ixbrl3390">nil</span></span></span></span></span> shares issued and outstanding, respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,823</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,823</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3378">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_maLASEzD07_zOVx1oCg7c44" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Temporary equity preferred stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3392">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3393">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3394">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_i01B_zzkTq9tUUdY4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders’ equity (deficit):</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930_zgIMnqLEtXng">0.0001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">par value, <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_c20230930_zhdlR8fAPGqg" title="Preferred stock, shares authorized">5,000</span> shares authorized; and </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_maSEzysv_zznJNoGAPf27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Series A Preferred stock - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zreEuGwCBUM6"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQB1RTv1woh7">212</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zneD4VFMFWp1" title="::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQfgHuRrqhP" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3408"><span style="-sec-ix-hidden: xdx2ixbrl3409">nil </span></span></span></span></span>shares issued and outstanding, respectively</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3403">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3404">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3405">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_maSEzysv_z5vpHWjBnWD1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Series B Preferred stock - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pn3n3_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_za32Wq5bYSs5" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pn3n3_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zcpwZl3AWnw4" title="Preferred stock, shares outstanding">148</span></span> and <span title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDoMjfrtlzqa" title="Preferred stock, shares issued::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z79ESPoqLrx5" title="Preferred stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3419"><span style="-sec-ix-hidden: xdx2ixbrl3421">nil</span></span></span></span></span> shares issued and outstanding, respectively</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3411">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3412">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3413">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_maSEzysv_zqrLa4QE4aJ6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Preferred stock, value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3423">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3424">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3425">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CommonStockValue_i02I_pn3n3_maSEzysv_zeo45gFAKTfa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230930_z70CFIKrj7e8" title="Common stock, par value">0.0001</span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20230930_zXjvLZco8ah2" title="Common stock, shares authorized">200,000</span> shares authorized; <span>and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20230930_z1Jj9KCptbO" title="Common stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20230930_zorLXg1iTKXd" title="Common stock, shares outstanding">37,951</span></span></span> and <span title="Common stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20221231_z6VAmuLqYcak" title="Common stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20221231_zd0ruEflnpv" title="Common stock, shares outstanding">37,949</span></span></span> shares issued and outstanding, respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3428">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_maSEzysv_zLtWnDr8Ow5k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,017</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,975</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzysv_zd1HOmrbeRlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(127,557</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3448">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(127,557</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEzysv_maSEIPAzF6H_z84ofmLdwjo5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total AgeX Therapeutics, Inc. stockholders’ equity (deficit)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,536</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,422</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--MinorityInterest_i02I_pn3n3_maSEIPAzF6H_znmTdlrd193d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3456">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_405_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_mtSEIPAzF6H_maLASEzD07_z3PiXjLzCYLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stockholders’ equity (deficit)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,645</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,313</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzD07_zeilFBoVVaP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3464">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 500000 500000 4400000 36000000 36000000 <p id="xdx_892_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_z1qD5IaMOUP3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8BA_zmMm7Ad4joKj" style="display: none">Schedule of Condensed Consolidated Pro Forma Balance Sheets</span></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20230930_zzlh6ggmZLCk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20230930__srt--RestatementAxis__srt--RestatementAdjustmentMember_zpHsWSy18nC9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20231114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlPOp5YYnejc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted Balance</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zOahMCLJzGba" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zmgKozUBZRN1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current </span>assets:</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzK6v_zAdtDtMqQASk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">397</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3289">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">397</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccountsReceivableNetCurrent_i02I_pn3n3_maACzK6v_zsE9V8DhDDpb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts and grants receivable, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3293">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--AccountsAndOtherReceivablesNetCurrent_i02I_pn3n3_maACzK6v_ztmIitq6q31d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party receivables, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3297">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzK6v_zAMTgXkuiAC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">673</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3301">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">673</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzK6v_maAzTOG_zXs1xqTclih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,141</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3305">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,141</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--RestrictedCashNoncurrent_i01I_pn3n3_maAzTOG_zFpDWqBU54id" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3309">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_pn3n3_maAzTOG_zgcCAQaX2xp" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">640</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3313">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">640</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--NotesAndLoansReceivableGrossNoncurrent_i01I_pn3n3_maAzTOG_zQgydxF1q5Qb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible note receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,379</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3317">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,379</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--Assets_i01TI_pn3n3_mtAzTOG_zEeMpex7dBI8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3321">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zzxrWphZIrgc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES, CONVERTIBLE PREFERRED STOCK</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> AND STOCKHOLDERS’ EQUITY (DEFICIT)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--LiabilitiesCurrentAbstract_i01B_znDuHEAV5ye2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pn3n3_maLCzcF6_znAOL2qTSlp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,671</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3333">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,671</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--LoansPayableCurrent_i02I_pn3n3_maLCzcF6_zycVaE3PKC1c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan due to Juvenescence, net of debt issuance costs, current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3337">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_ecustom--InsurancePremiumLiabilityAndOtherCurrentLiabilities_i02I_pn3n3_maLCzcF6_zLdhr7qxfdN9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance premium liability and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3341">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzcF6_maLzvGy_zBaAzc1VabRg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3345">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LongTermLoansPayable_i01I_maLzvGy_z1aclWwRc236" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan due to Juvenescence, net of debt issuance costs, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3349">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--Liabilities_i01TI_pn3n3_mtLzvGy_maLASEzD07_z5TviAn2ORV8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,897</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3353">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,897</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--CommitmentsAndContingencies_i01I_pn3n3_maLASEzD07_zP96DhPsR5r1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and contingencies</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3356">-</span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3357">-</span><span style="font-size: 10pt"> </span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3358">-</span><span style="font-size: 10pt"> </span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4ap1PqYY9Ql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A preferred stock; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfTyfjLTUnf1" title="Temporary stock, par value">no</span> par value; stated value $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhbcIqurZ5Rl" title="Temporary stock, stated value">100</span> per share; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--TemporaryEquitySharesIssued_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztSXLwn2UScc" title="Temporary stock, shares issued"><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJwpRvrvDIU5" title="Temporary stock, shares outstanding">212</span></span></span> and <span title="Temporary stock, shares issued"><span id="xdx_903_eus-gaap--TemporaryEquitySharesIssued_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOJtQOXxN149" title="Temporary stock, shares issued::XDX::-"><span id="xdx_903_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4xWzxotl65" title="Temporary stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3372"><span style="-sec-ix-hidden: xdx2ixbrl3374">nil</span></span></span></span></span> shares issued and outstanding, respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3362">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWt0mZUPKL5c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B preferred stock; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zq2eQx5O2L86" title="Temporary stock, par value">no</span> par value; stated value $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zOr73mBoozZ2" title="Temporary stock, stated value">100</span> per share; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--TemporaryEquitySharesIssued_iI_pn3n3_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zu4arN29aay1" title="Temporary stock, shares issued"><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_pn3n3_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZuocRqs6G5a" title="Temporary stock, shares outstanding">148</span></span></span> and <span title="Temporary stock, shares issued::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--TemporaryEquitySharesIssued_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaVRwwaTb1e1" title="Temporary stock, shares issued::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFiU4p5PxgM7" title="Temporary stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3388"><span style="-sec-ix-hidden: xdx2ixbrl3390">nil</span></span></span></span></span> shares issued and outstanding, respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,823</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,823</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3378">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_maLASEzD07_zOVx1oCg7c44" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Temporary equity preferred stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3392">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3393">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3394">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_i01B_zzkTq9tUUdY4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders’ equity (deficit):</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930_zgIMnqLEtXng">0.0001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">par value, <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_c20230930_zhdlR8fAPGqg" title="Preferred stock, shares authorized">5,000</span> shares authorized; and </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_maSEzysv_zznJNoGAPf27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Series A Preferred stock - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zreEuGwCBUM6"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pn3n3_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQB1RTv1woh7">212</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zneD4VFMFWp1" title="::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQfgHuRrqhP" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3408"><span style="-sec-ix-hidden: xdx2ixbrl3409">nil </span></span></span></span></span>shares issued and outstanding, respectively</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3403">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3404">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3405">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_maSEzysv_z5vpHWjBnWD1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Series B Preferred stock - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pn3n3_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_za32Wq5bYSs5" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pn3n3_do_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zcpwZl3AWnw4" title="Preferred stock, shares outstanding">148</span></span> and <span title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDoMjfrtlzqa" title="Preferred stock, shares issued::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z79ESPoqLrx5" title="Preferred stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3419"><span style="-sec-ix-hidden: xdx2ixbrl3421">nil</span></span></span></span></span> shares issued and outstanding, respectively</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3411">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3412">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3413">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_maSEzysv_zqrLa4QE4aJ6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Preferred stock, value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3423">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3424">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3425">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CommonStockValue_i02I_pn3n3_maSEzysv_zeo45gFAKTfa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230930_z70CFIKrj7e8" title="Common stock, par value">0.0001</span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20230930_zXjvLZco8ah2" title="Common stock, shares authorized">200,000</span> shares authorized; <span>and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20230930_z1Jj9KCptbO" title="Common stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20230930_zorLXg1iTKXd" title="Common stock, shares outstanding">37,951</span></span></span> and <span title="Common stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20221231_z6VAmuLqYcak" title="Common stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbmRlbnNlZCBDb25zb2xpZGF0ZWQgUHJvIEZvcm1hIEJhbGFuY2UgU2hlZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20221231_zd0ruEflnpv" title="Common stock, shares outstanding">37,949</span></span></span> shares issued and outstanding, respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3428">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_maSEzysv_zLtWnDr8Ow5k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,017</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,975</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzysv_zd1HOmrbeRlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(127,557</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3448">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(127,557</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEzysv_maSEIPAzF6H_z84ofmLdwjo5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total AgeX Therapeutics, Inc. stockholders’ equity (deficit)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,536</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,422</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--MinorityInterest_i02I_pn3n3_maSEIPAzF6H_znmTdlrd193d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3456">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_405_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_mtSEIPAzF6H_maLASEzD07_z3PiXjLzCYLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stockholders’ equity (deficit)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,645</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,313</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzD07_zeilFBoVVaP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3464">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 397000 397000 67000 67000 4000 4000 673000 673000 1141000 1141000 50000 50000 640000 640000 10379000 10379000 12210000 12210000 1671000 1671000 1526000 1526000 7000 7000 3204000 3204000 693000 693000 3897000 3897000 0 100000 212000 212000 21135000 -21135000 0 100000 148000 148000 14823000 -14823000 0.0001 5000000 212000 212000 148000 148000 0.0001 200000000 37951000 37951000 37949000 37949000 4000 4000 100017000 35958000 135975000 -127557000 -127557000 -27536000 35958000 8422000 -109000 -109000 -27645000 35958000 8313000 12210000 12210000 Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits in the consolidated balance sheets. As of December 31, 2022 and 2021, AgeX issued Juvenescence warrants to purchase 12,129,260 and 3,512,098 shares, respectively, of AgeX common stock as consideration for the loan agreements discussed in Note 5, Related Party Transactions. Does not include $106,000 gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement. The gain on the sale of LifeMap Sciences is presented in the line item Gain on deconsolidation of LifeMap Sciences. There were no gains or losses resulting from the sale of businesses or assets that did not meet the criteria for a discontinued operation during the year ended December 31, 2021. Based on the market closing price of AgeX’s common stock on the NYSE American on the one day prior to the debt inception date and each presented period ending date and also the market closing price of AgeX’s common stock on the NYSE American on the one trading day preceding the delivery of the relevant drawdown notice in accordance with terms per the Secured Note. Warrants are exercisable over a three-year period from each issuance date. Based on the market price of AgeX’s common stock on the NYSE American as of each date presented. Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve. Based on the historical daily volatility of AgeX common stock as of each date presented. Amount of credit available under the Secured Note on date of inception and as of each period end date. Number of warrants issuable if the amount of credit available were drawn for measurement as of inception date and subsequently for remeasurement as of each period end date. Amount of drawdown as of each date presented. Number of warrants issued upon receipt of amounts drawn against the Secured Note as of each date presented. Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. As of September 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 11,539,348 and 10,919,485 shares, respectively, of AgeX common stock as consideration for certain loan agreements discussed in Note 5, Related Party Transactions. Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit. Warrants are exercisable over a three-year period from each Issuance Date. Based on the market price of AgeX’s common stock on the NYSE American as of each date presented. Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve. Based on the historical daily volatility of AgeX common stock as of each date presented. Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit. Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date. Amount of drawdown as of the date presented. Number of warrants issued upon receipt of amounts drawn against the Secured Note as of the date presented. There were no stock options granted under the Plan during the three months ended September 30, 2022. EXCEL 117 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %A),%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !823!8[0GG"NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$Y+#R;-I6.G#08K;.QF9+4UBV-C:R1]^R59FS*V!]C1TN]/ MGT U1HTAT7,*D1([RG>#;[NL,6[%B3EJ@(PG\B:78Z(;FX>0O.'QF8X0#7Z8 M(T$EY08\L;&S (BY$T=06-28R'-(%;W'!Q\_4SC"+0"UYZCB#*A6(9IH8 MST-;PPTPP9B2S]\%L@MQKOZ)G3L@+LDANR75]WW9K^;/ MC:^"30V_[J+Y E!+ P04 " !823!8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M %A),%CO K7DJ 0 .@3 8 >&PO=V]R:W-H965T&UL MK9A=<^(V%(;O\RLT[DRO$FR)\)4",X20-M,-RP1VV^E.+Q3[ )K8EE<2(?GW M/3)@IZV12=J+!,O6>?WHZ[RR^ENIGO0:P)"7)$[UP%L;DUWYO@[7D'#=D!FD M^&0I5<(-%M7*UYD"'N5!2>RS(&C["1>I-^SG]V9JV)<;$XL49HKH39)P]7H- ML=P./.H=;CR(U=K8&_ZPG_$5S,%\R68*2WZA$HD$4BUD2A0L!]Z(7EVSG@W( M:WP5L-5OKHEMRJ.43[9P%PV\P!)!#*&Q$AQ_GF$,<6R5D./[7M0KWFD#WUX? MU&_SQF-C'KF&L8Q_$Y%9#[RN1R)8\DUL'N3V%]@WJ&7U0AGK_#_9[NJV H^$ M&VUDL@]&@D2DNU_^LN^(-P'-WI$ M@]@.??N13GE#3=\V%=R2Y2MC6KV(F]J M'HUP(K6C,C<*GPJ,,\.Q? ;5]PU*V1M^N ^[WH6Q(V$] M1X2"@QTXKIE3< Y9@S2#<\("UG3H-8MV-7.]YA&]26J$>26C*%*@-6CR[1/6 M('<&$OUG57MW"/# M#+-2B>P<:(4)^3NS1L. B[!6'W%,(Q=I[B,:I&\$)^A=;I)'JOSCUNQRR[H9;/=92X\&I1) M,#@%$$=!JDRJG.VHWTQB SKIZV_!6;OQ'8?!:XE@YE)3U[%_W8 MEK!O%W);N;AKY$8Q+KV(N]!*JZ#.Y/XOM&+<9TH^BS2L[EFWYMB5D&EI#-2= MVO^)-I/:X,+^0V3')Z-;L7?9[S$1SA5O XBEN@10,72.D7U)WI M/\D0^V2VEK@.CB>4&I%VAUYTFQTG46D4]"2GN!4Q8/; V;22JC()U^A,97K! MPQ#WL)B3(-H)N@A+HZ G.<4\X7%,KC<:'VM=2>C6J?%\6EH$/4<=;&D2S)W1#T.)'9<:_.0AW^[!KHC*/:];ZX.;7E9: M F/_[QZ=.3WAH[RE3[#W^<0I!EPC:0V8_!<#9J65L/=929T!U\C5&S KG82Y MC>!#!ERCZ31@5GH+<]O"!PRX1K'.@%GI,LSM#O4&7"/@-F!6F@ESF\!I!EPC M>GTT:^;*L8O/?'+Y8\\J/F#0) M[3?#[ARFN%L<8XUVAS=E]=T9&"8"]#Y-8EAB:-#HX!17NV.E7<'(+#_*>93& MR"2_7 ./0-D*^'PII3D4[ N*P[WA7U!+ P04 " !823!876HC-AWX_"]Q]\[T-Z^3]6P>OR& M_JD@+\D\DHQ.6?Q'M!3KZ]ZP!Y;TB>2Q>& O/]$=(4_AA2S.BK_@91?K]$"8 M9X(EN\;R#I(HW?XGWW9"5!I MZ4!VC5 QS; NP;XV ;NKH%;*+.E4N@0$$'& M5YR] *ZB)9HZ*,0L6DOZ4:K&?2ZXO!K)=F(\9>E2CB)= GF4L3A:$B%/;DA, MTI""N0+.P'OPVSP /[S[$;P#40H6:Y9G)%UF5WTA[T$A]<-=?S?;_E!+?W.Z MN038N0#(0=C0?&IO'M!0-H=%_707CU4X.$V]7+.:2H MR3(ITP>3'%L UPR@5O6';$-">MV3RS:C_)GVQM]_!P?.1Y,X78(%'8'5A,-[ MX; -?3PEV1K(&01"=4#_SJ-G$DLEC3-J"^454"J//8_QR+_J/U>5T6,&KE>/ M"?08;^CN8VH\W#T/U\IC$H8LE[==<%EQH@XY#:FD\QC3"Y!286*T!1U4[[9) M2 ]Q&W3T".29V7A[-IZ5S0.-B]6_(5R\5GADK42\0W;J:!DPZ#0P#CAM*Z3%PZ#0'W1 T:!MV M?\_,MS);,$'B(TCX>M_0A0T6>A!RO0;5P!"$<,M2'.Y9# ],WDSP*%3S5R45 M$X&AUJWG-&[_<$A@#:G=^FA_ZR/KK<]20=)5)%?:3OW6]3;2YY';I*#'^'C8 MX*#'#/T6$M IK81C3^HL?:9<%#Q2)F@E@QB-@J//)P?[HP8=>Z?F10^,UN , MH(/9 U:,%K2OLB^+R1V8S.>WB[E1#JC+@1!LCJXA#*/F*@Q,4=!K66&PM#OP M.+\31^0QBB,14;/I@9VZGD[1@J[0ZA*6Q@?:G<_>,6S(*RE6O'R,D##DN4Q< M%5V-LF)#]O>;&=@4Y>#F@\00Y5>@ZNQ*.P3M?NB.D30#RYP"P<#/^3--:192 MN9,H,AI@3W)/]BA E&5YL;\(6::RW=NS9\.XV@T:N>MV!WIHT.2N1_D#=]#D M;HB";EO^*]T3/,4^[<:W/9?;T4Y>)+H5TQ[.@2&H->V7O@C:C=$?A"OCNY^\ MKT:R5HSCL_@4&FU2D^=_[ZTN1FFEH-U+S=(LY\74ELA)E">E+ ;#>&B]ZSZI MN4TPA$#']YMZZ%&CX:!EX$O#!>V.J^X;#W'1;1-&37L[-41!Q_&;]L40-AQ5 MME!U0J4-@W8?=F;VVET[)HD9_-NHN0\P!$''U34P8#D#9-8 E28.V4W%"=L,U94D2B82^ M;<]#EHHH7$$3.:,) M?RW*-.K!QND3E5-]"3+!PJ]&_<[P6&;]NJUX_3^L'RJM'\)6]SQ75^?@Q?@G7/I. Y4 MW@L\DSB7*=N[D+^ ;$VX*M;D8LUX] ]=&I6V]G;*?.T(*.@ J"YMZ6*1W<6J MM,E2BZ[(<\D;-[>BICCHH\H [6B;XN 0MPUDZ6:1WE> M4DK?K,29HYJU75.4B\UD<&E+\0%;6@SAB4.%=6:<E>\8%WV>K MUR5:T!5:_:.ITLV[=C=_^H=&KFZ]FT4 >Y\GK,\.@.JZE/L %W;R '#/J :W M3ZU.T8*NT.H2EIL(U[Z)./$EK!WMA,K?#JCZ=:'^_O6/_U^?A?4$L#!!0 ( %A),%A1ND'-_@, /85 8 >&PO=V]R:W-H M965T&ULK9A=CYLX%(;_BL56JU9J!TR^9Y-(G:!5]Z)2U+3= MB]5>>. DH ',VD[2W5^_-F$@*<9\*',QP>2LH0(.60'FV<,2) G);'M.L[43DB46NME?F_+ MUDMZ%'&4PI8A?DP2POY]@IB>5Q:V7F]\B0ZA4#?L]3(C!]B!^)9MF1S9I4H0 M)9#RB*:(P7YE?<2/'EZHA#SB>P1G?G6-%,HSI2]J\$>PLARU(HC!%TJ"R(\3 M;"".E9)OX$ M!=!$Z?DTYOE_=+[$SA86\H]$<9$PSBMS0H.B M%'T-Z9&3-.!+6\@U*67;+^9_NLSO-LR_@^P!C9SWR'7E>]W1\FV[+0I;5=,MJNKG>N$%O*U]:8$P64#XX_^4]R@A#)Q(?05>9B]8L MUU+[\[1V'AS'D0LY75>@6YC7&G9#-"J)1OV(>"A?!8[(48241?]!H".[:$ZO MUC)Q\K^?T#K&>>UQ-W#C$FX\""[B_*@',^JI'OW(,^+#RI)-F ,[@;7^]1<\ M=7[3O=KC&M7/W*:(&^))23P91"Q_$;B0.SA*#SILHVA?[$DKMBGB!GM:8D^- MV!N:)/)'ILNFG';;E-W"O-:P&YQ9B3/K@=-I1\YJ)74=1[LG.T=Z]4A&[>KR[JGGW4KNM9V4>L=D] M]NS"T_8NW!KBF94E^+).T M..\]E^7JM-\OYL]\&17?LA5/Q2>/6;Z,2O$V?^H7JYQ'BXW1,NE33;/[RRA. M>Q=GFV-W^<59MBZ3..5W.2G6RV64_^^2)]GK>4_OO1V8Q$_/976@?W&VBI[X ME)?WJ[MF72RF"#^![SU^+=:U*=RD.6_5.] MN5Z<][3J&_&$S\N*(A+_7OB0)TG%)+['OS5I;S=F9?C^]1M[L#EY<3(/4<&' M6?)'O"B?SWMNCRSX8[1.RDGV>L7K$[(JOGF6%)N_Y'6+=01XOB[*;%D;BV^P MC-/M_^A'[8AW!H('-J"U =TW,#L,C-K .'0$LS8P#QW!J@VL?0.[P\"N#>Q# M1W!J V??P.@P<&L#=S.[V^G8S*4?E='%69Z]DKQ""[;JQ28@-M9B"N.TBMUI MF8M/8V%77@RS="$BD2^(>%5D2;R(2O%F6HI_(D3+@F2/9+SB>52%6D%.R/W4 M)U]^_>VL7XKA*Y+^O![J._B MO[_HMO8[-*689#XF&<,D"S#)0B2R5F"8N\ P5>P7LZR,$K'+OO!TS0LH/+;V MUL:^VNI?+FQ'T[2S_LO[>9=1G@3R99!K2R@FHZB,"F2484JH4$;I9@O6^8>W[')8'8]"@G[\XZ-IG .=S!S.":9CTG&,,D"3+(0B:P5 M(NXN1%SEJIH(QBB?/Y,H78C&Y$5T7*NJ.(4"Q05"V967F S3;3F9^#+,LF08 MDV&N+B_& !A4HW)"# &<:=F=*\W;N=%3)R>>BCH^V7@Q6HAF(B[*JJY_X9 C M/<"1CGSN0QFG&Q[@2AEGN9Y\\DS&F9O=8-^9 )_G %E+QHGMW>UTIJXUG9-V M0&61;7NC](GP'ZNJDP+WRYJJY4WHK(8 4+4&^ MC+*2$P-N1)7#'+M=H++YJ&P,E2WX#!N!=HN:J)WJNC.83IL(H.VJN^W4IG?6U';%)F_EUUHC30JFX_*QE#9 E2V$(NM'2M- M.ZVK^^GKM.2"MWS;[KZ2E(.%6,W3;NLT UJ! -*C\F+Q(:#I4;F\8Q!2+']H MUX.^IF% "Q! ZIKG="_ IMW6/^BWGZ/TB1.Q^3U&<4Y>HF3-JTWO-D/#Q7#W6Y%09.WP=@)P".03A*@0(.!D*.__DS;<]+T\WKZG9^7#[S7$S+ M/%LJ AUHZH$@!WILP,E CPWM+S),%DP"B Q00@"8:2H*Y*:QUY5-X5N!O/'A MA]G" ;,%Y$@ Z0(RFP\!3<^2*1F$I)8MYY4 _)H64':'$-(VNQ4FO6F&=74W M++9G3DDP&=^2X7@TNQ[=5_I)K:2,1Z""HF8]>O?&9/-1V1@J6Z#+W;A( M^Q:55V\(05W+I=V3WK3NNKIW;T^Z?SVMYYWY[Z9=W1,I!SAZ_C'9?%0VALH6 M?(8-[HED)4($4G?]3ALE@JJ5B+?@@*:=RLWZB66X\G8QA)#4! HV'T+JN@&E M5@CJ.+:LTP0@*;S.(*AKN]U:-&T4"*I6($:\)%^V&_YO)*F:S:@L\_AA748/ M"2=E1M),?)J6>98DE>H3U_4PZ'NY"X9^LA@".-E!/H "?EP"4,"/)!UFR:>JIOXRLG'^';;\"_BHOHP3M=\\4'WKQ[_V%R'RN:CLC%4MN S;&"N MH[)8T=TGT4:HH,KFMMD%![/9Y/KR?C:XO&%D-B:#D/T)!H(A_3YZ8IF:O+J& M$%)D/Z 1@I B^T':*P1U' NHU4%2S01^DP@AJ&L[BNS7-/?45 I!._^*DD)4 MEK>WXQ&97@TF#-2#J%(I.'J58;+YJ&P,E2U 90NQV-HATT@7]*-+!38IN4K7 M'^3D3W3QBFC!9/-1V1@J6U"SN>^7N_:-NOM9 889'2FAD4"H6@+QC]AUE4Q' MSS FFX_*QE#9@L^PP;ONSQ.UHZ21>JA:ZKD<3*^'8$PX4%CJYO[N"\(T>W_K M!6'&_JX+HNC^CKM%>1^M*QC6M:X:%8>J51S_^N9^QGS09^YA/@-ALL] F.0S M$"7Y#$9)/H-A73YK1!#J*"6<1@;?V424?&1T?WLI*I5QT"I6IF1\ M/YO.!B/_>A3"E0NJ%H+*YJ.R,52V )4MQ&)K7S#^L/AIG[Z^\P-M;!MK?H@PX8\*L)B-P3RMN>:T020RV2*'*7 2@&D.] F.R[ M@]A8!YOD.Q@&^0Y"*GW7:!\&5>:PP>WX?C2#.U@P5QFH6@8JFX_*QE#9 E2V M$(NM'37O[FY0"Q_-92_S0_LM->/1<8-[WP/NC0^X=SX^D+]N^?*!YW^#H8.JSJ"R^:AL#)4M0&4+L=C:\=)H/8:M MK$V4-]&ABCNH;#XJ&T-E"U#90BRV=H T,H]QR!4]JIOI:H+6S6W KRWJ<0[/ MN/YAXS&L\0(LHM"0KP\2549WY= (2X9:6-I>LW98TD>]) B5S4=E8ZAL 2I; MB,76CI=&5#/4HIHRZ:/J9*AL/BH;0V4+4-E"++;V_=.-3F8>0?P#LWKB#60A_/?V+)Q^ M^N9YY]GIGQ,/T] M%]]D1*F"QS1A"+S7]B7MI8!P58JGI;.R""-6?$DCV4@#AQL]XR#4SHX MIP[M,PZMTJ&5"RV8Y;*NB")^7_ ]"&V-:'J1QR;W1C4QTVE<*(%O8_13_IBS M$)-"0\"5Y$D<$H6;A<('9DM)X&N89500'76)5BF62Z3SN*,PY5+"!WA87,$? M[_Z$=Q S6$9\*PD+9=]42%!?8P8EF5%!QCE#QG;@EC,529@@J_ 8P$1EE3SG M2=[(:42\HL$%M.SWX%B.4T-H_//N=@.=5A7M5H[7.H-WPP*>TN?HPC_#E50" M:_G?NF@58.UZ,/V!]V1& CHP,"62BATU_-]_LUWK8YW2-P([TMVN=+>;T/V[ MR1*FL\6B3F3AV>W6\.V^9G#<".PJ"6P7!;4P.MD-L=@R[C1"4!3\ M"Y+)A!1M-OP/FU#1"=:"IQ#&,L!O-&9;;!.\:@QU$6J\MEX4U 6GP'&/*J3= MJL]\MQ+=;10]GMW>SR?7D[O%S9?)V=KLUMQ<4YLU9I[G>/4,O8JAU\AP2J7L MG?3;1/=;HI2(5UM%5@D%Q8%QIC,B>((0&VS!BF(\59&N,E?Z17.RO!<:7.M$ MYDN3,TFXK"1>_@*)KZC(1CJOJ,C+%Y'HUD?"MI[_AZU7%B0,E\OYS>AA.1Q- M)["6[GE;2=MM>V>EFZ=G>?9I[5K'DP8 M*16;?/"26%U;IHI_X^JT&NZ&^4AS,A*X1TKKH M(B=1#&'%1O$LGV-67.%4E"\C'%RIT ;X?LVY>MKH"ZI1V/\?4$L#!!0 ( M %A),%BHV@Z]61( ,7W 8 >&PO=V]R:W-H965T&UL MU9U=@XV?*NDXM4+M@16E$>#6- *^^_ M#XQ&0MV<.0/LF\2^L:55]W,:YKPT\)[N>?505K_4MWG>&+_=;;;UZ[/;IME] M>W%1KV_SNZS^IMSEV_8O-V5UES7MK]6'BWI7Y=GUOM/=YL):++R+NZS8GEV^ MVO_;F^KR57G?;(IM_J8RZON[NZSZ]$.^*1]>GYEG3__P4_'AMNG^X>+RU2[[ MD+_-FY]W;ZKVMXMGRG5QEV_KHMP:57[S^NQ[\UOI+[L.^Q;_*/*'^L7/1GP/ MOCV8]UF=7Y6;?Q;7S>WKL^69<9W?9/>;YJ?R(]\,^3_?]V\PJMIVD MWC95^]>B[==<7I7;ZU8@^;71_E27F^(Z:]I?WC;M_UKE-+51WG1_^IA73?%^ MDQMOVI3/JVK?IES_8F3;PT^WY>8ZK^JOC""_*=9%8YP;/[\-C#__Z2_&GXQB M:[R[+>_KMG7]ZJ)I!]Z%OU@?!OG#XR"MHX.\NVOE]QCP7S_F=^_SZM\$YHK' M?']]770ZSC;&FZRX/F\'=97MBJ;]G8$&//2GO&DO7.WI"+-J6VP_U!PKY%E_ M*[?K'_? M9-TGVI3&C, 1'_A=V9Y6HEO,=WN;5T5>&]\/THP923(*^<,49,HCCY&,.<.7 MGQ=K['%=M!>&YZN#]7QUL/;!G2/!?\@VV7:=&UG3JGK]C6&;7QO6PEI0$GXD MN7M2-Y%_O'1>77Q\JIN^_YMMYEZ_SU67MC4^?5Q_SL\LLO3&_Q'96P2%B*A$D03$DV M^SG9[#')]K51WV8M?532/1*]%Q^>[7LK4TL\-N[$4Q0@82$2)I"P" F+D; $ M"4N1, F"*>IQGM7CL.I)ZOI^?ZUN[]=VSS-"W)A$I_ M=_#168ZES1ILU*FS!A(6(F$""8N0L!@)2Y"P% F3()BB'>]9.]XL[1CWN_;' MC^TS8/<\V/ZQ>QRLBG7S-*<8]]NBJ;\VMGG3_?EPRU;E3=%-.^TCY2[[9.1W MNTWY*<^__&)IF?YWM=%DO]%Z9$R13)S@D+$3"!!(6(6$Q M$I8@82D2)D$P18_+9STN1^OQ(:NJ;-N0:F$I$R:@Y4!UOJO/0*!8(8@C0)QH MQ+'',V(=3WDD+$7") BFI/SJ.>57;,KOWP*?=S[C=3<%[?)MG75O_:FT9TD3 MTGXU^.C-Q4)[TQJ @H4@C@!QHC$''\\(=CSQD; 4"9,@F)+XYJ(W,Q=LZK]K MK^]UMC?K:^.A:&Z-K>IL%0=GJS;VSR3F=\9?BYO\QVQGO%T7>3M/T.XD&W6" M3 X@Y2;=\E::3E#A0B+<()I 18M0H'@.Z+A6H+042I,HFBJ7%]Z_R6I:N!:#3T#,>@XCD#9](824NA M-(FBJ6GN MW^5WN[+*JD]&_NM]T7PRWC])ZV.VN1]Y_4>ZD5=06@"EA5":@-(B*"V&TI(Y M-&HF3J'#DBB:JKW>^C;_&-XW/\PICRB$!3QXFD;9WRB0F -B9'CZ',30B F4 MED)I$D53%=9[X>8?Q0PWAVZXMU@L])M/J",.I850FH#2(B@MAM(2*"V%TB2* MILJSM\9-C#?.8Z9,4$.'V/27^@R%LL=1(#$'Q(AEQ$F(H2$3*"V%TB2*IFJ@ M]\I-G%G.HZ;H8.@8>XZGZP!EEZ- 8@Z(T<&(DQ!#0R906@JE211-7>?7.^<6 M[YR+K*@.[QS:V6!39.^+3?<^8KW)ZKJX*5IY/$T11M'.&_DUI1 ^R 2%6$/G MVO8\72*H<"$*).: CDMDU%F(H3$3*"V%TB2*IFJDM\LMWB[G?$:^ZY3,!X$" MB_"H?=_5RC]"JIENBL\9$Y/5Y, \4T]KJ'T.I:50FD31U+3N[7-K]"+OM_GN M&\->[-\U6V2:CUCE/;225TM[I1H$1#Q]4S%&G^1N387--9 MZ2F*716.71:.71?^W[##K=X.MR8O#3^=JM3:\)7C#U_[\,&GOO:!TD(H34!I M$9060VD)E)9":1)%4\74N_?6*/=^E+=X0+'7^Z&Q3]66$,WHVA*JX:"VA#_$ M";4EY+"(VI(Y 9GLA#KB4)I$T=3L[!UQBW?$Y]266,/EW%1M"1]Y\G4>:FU# M:0)*BZ"T&$I+H+042I,HFJJDWM^V>'\;45O"AYA:6P*E!5!:"*4)*"V"TF(H M+9E#(VM+H,.2*)JJO=[YMGX/SO?IVA)^F%->2PT-]'-'O\4#!0M1(($"12,. M/YX3C-$5U+>&TB2*IHJK]ZVM\;[U_[>LQ!IZN?HF"_RQ3)[SD+002A-06@2E MQ5!: J6E4)I$T51M]GZZQ?OI8VM*>,R4B8E8?3VH*4%%"U$@@0)%8XX_GA.- M27^HC0ZE211-W<&TM]%MWD:?4D["HR9(P![:Q+ZG;ZN+BA:B0 (%BL8K?=GK]8G>\Z)>E1B]5MKV\1R]>5JI;]O(IJ=FZ9G MZ=LDA&1#?8\?;'N5X'_,4 MZ30=&L.=I[C24Q7IO0906@BE"2@M@M)B*"V!TE(H3:)HJI)Z=]Z>NUY]BK2@ M"]:AM !*"Z$T :5%4%H\AT9-G@D*E*) $@!2U=8[^#;4P:?%!G7PH;0 2@NA M- &E15!:/(=&BPUEWJ- $@!2Q=9;]C9OV;]XADGOMWQM\0'%/L,,'>.5OW0' MKV4)8]DTS84_>,*F'&A'?X2!+NLFQV9;^L-_#(V:0&DIE"91-#5%>^/;YHUO MXCGF=*H.+>KN.<8=EL'SP2=?VZ%.-90FH+0(2HNAM 1*2Z$TB:*I8NJ=:GN\ M4_W_+-'BASGEI>_0"3XW]>D&982C0&(.B-'BZ7,00R,F4%H*I4D43?U"PMX, M=W@S_/=3I^40&Z$/)T#^<*9.@%!:"*4)*"V"TF(H+8'24BA-HFBJ/'NCWN&- M^BFU*CQJPB3E#-UH:Z&O#49%"U$@,0?$"&;$28BA(1,H+872)(JFZJ!WY!W> MD<<4K/!!IBAD:&[;^E*V !4M1('$'!"CD!$G(8:&3*"T%$J3*)JJD-[>=WA[ MGZM9X;M.R7L0*' (^]UR;/T+%JAF6H:).6-BDIH>F+Z?#S1H J6E4)I$T=2T M?O&-Z:/* D;M)G% <6]\G6'% +7Q"=&,WOB$:CC8^(0_Q,D92HV-V/@$&C6! MTE(H3:)H:HKV?KLS>37\Z52E5\,3&Y_PP2<_\$*MO0'MC#*@)Y52.4.+EJI2Y"-/OM!#-S:'T@24%D%I,926 M0&DIE"91-%5)O4_NC%\@W@:XR:OJR5H@183:WQP%"E"@$ 42&6HX*%*)"8 V)D.,(MAT9,H+042I,H MFJ(PMW?+W3^*6^Z.H"*%J) 8@Z($< M#S)%(4.C>.GKE@LJ6H@"B3D@1B$C3D(,#9E :2F4)E$T52&]6^[.=\OYKE/R M'N66N^0B>MO1W4BJG>9 MAG=Y&_Z-ZLCLGQ+V+[[694UO%LH#I]PU@4 !"A2B0&(.B!$#:%@Q=%@)E)9" M:1)%4U755P^X?/7 G'D'Z?E>06D!E!9":0)*BZ"T&$I+H+34)?83L%Q]UJ$V M'?"/S#E]18#+5P3,40?2OKV"T@(H+832!)0606DQE)9 :>D<&KF%"@"DJJPO M$G#Y(H$C!?4V*:_5X.Y2+[!TB:W-VR'TM(Y-#HU/Q^DI*;7N^L>[ZZ?**0G4]0COG[;7[GFT OG M@T^]ND-I(90FH+0(2HNAM 1*2Z$TB:*I8NJ]<(_WPL?L GE:74A7] I*"Z"T M$$H34%H$I<4>L;"=>/N:$.VTMZ\'U8SCR=,\-=-[M]OCW>X1.S">3G2DN7D% MI0506@BE"2@MFD,CWV@=0-K;4WUY<4(T:U/2LO4,'T63)VEJ?O=>M3=ZX_:7 M.\G1>7QZXW:/V+A]M?+U&W:B67O#;IFN9BB'=$-]E39_C),3A5JE;5DK?9DV M-&H"I:5S:.0-.P"D9F9O-GN\V7QBKT,Z0X>FWK$;=JB1#*6%4)J TB(H+8;2 M$B@MA=(DBJ:*J3>EO<_?MOVTNJ V-9060&DAE":@M A*BZ&T!$I+Y]#H20R\ M@;O76]W>9V_@?EIVT W@0 $*%*) 8@Z(41-H6#%T6 F4ED)I$D53)=4;Z!YOH$]9 M_L2CINAIN'>]HW^! BI8B *).2!&*J?/00R-F$!I*90F4315!;W![?$&-[>T M@^\Z)>M!H, CK&?769CZ2S;"9K?T5VQ03YPSL$#)]PIH4 !"A2B0&(.B!$#ROR&#BN!TE(H3:)HJJIZ8][GC?DY\P[2 M0KZ"T@(H+832!)0606DQE)9 ::E/%4KHA2M4HV/+.?R^.,#GBP/FJ /IYUY! M:0&4%D)I DJ+H+082DN@M'0.C7Q! "I*NNK!OQ1F\^/*G+TAXN%]>(PH@FY MG(-H1R_G(!L.EG/P!SDY@8>;ZY/+.:!1$R@MG4.C4Q-LK/N]L>Z/VLI]4L&Y M/]SP_$AU&!]\\M4=:I)#:0)*BZ"T&$I+H+042I,HFBJFWB[WYRX=GZ(NZ&)R M*"V TD(H34!I$906^\.UV.1R#J(=N9QC)$^>YJF9WKO8_FSI8SD$THY9SC*/)D[3'_+ZH;_.\";(FNWRURS[D M/V;5AV);&YO\INVW^*:[_ZJ*#[?/OS3E[O69>6:\+YNFO-O_>)MGUWG5-6C_ M?E.6S=,O%RW_H:Q^V<>X_ ]02P,$% @ 6$DP6&$E+S*@"@ FT$ !@ M !X;"]W;W)KG.],6) L, MV20S%#LM.RG)AJ1O_U5L =Z"S9-M:/;3KV0[&*)K!:CVS9N&'U='UKE75_=8 M,I?;1/Q,%YQGZ-=J&:=7K466K2_:[318\!5+/R=K'LMO9HE8L4R^%?-VNA:< MA46CU;)-.IU>>\6BN'5]67QV+ZXODSQ;1C&_%RC-5RLF7K[P9;*]:N'6ZP4Y27ZJ-^/PJM515\27/,@4!)-_-GS$ETN%)*_CSPJTM>M3-=Q__8I^ M4PQ>#N:9I7R4+/^(PFQQU>JW4,AG+%]F#\GV&Z\&U%5X0;),BW_1MK+MM%"0 MIUFRJAK+*UA% &I&I WC:@#0V^A6 M#8JAM\NQ%\1Y+&/7ER+9(J&L)9IZ4;!?M)9\1;$*E&DFY+>1;)==CY(XE&[G M(9*OTF09A2R3;Z:9_"/C(4M1,D,CEB[0C8RI%'U"3U,/??CKWR_;F>Q>@;2# MJJLO95>DH:L!^I[$V2)%ONPR!-I[YO:8& #:R!5BF:0I8EDFHN<\8\]+CK($#>?\WY!/2KAN :?6ALWU M)XP=ZG8ZG_K7U=%( *WV<7@/66SH ,Z>1B]Z.BYYQ=@[# M_\C%H,S(D@'!)0%!).F(3:%2D"4- I7 3G6533#O## $>T(,[=;7>,1(T7"4BB_Z[2Q)RZ9.,12KELS3E,$,5 MYOZH!GV=(L@,J L ,^P 50%HAQM#!.\I%GP2!\5$C=(T9S)-HB!)&UC VO5T ML:O'P @P)(1@@ G=T,&.7G/Y@"'&F#9S06HNB)&+:98$/S\II1S*D:_64LH5 MO( $$/TJ*#!5 +L>U8LF#[!SH7H(L!L,FJM#7 L6;%8L9;9(W]0TQ31 + [1 M,F+/T;*YOL%6E8Q5-,\JFF\+[=!1M9K!9CDS#((DCRNOS(M,KBI8'FU4L0JZ MA@*UM@/$JFY'*!"J@)D^H7W #)-^L>S=L,#[##5)Z\/X;DN:8[#NO;' MYN+_@2^+NYUK)K*75TK2CTHR@P0 5:\#)27=#F.@V 3L2!>H-LVC.*/T*-(FP\^>%/C]DV(D:-<'+@V43SK*+Y MMM ./5*+#?*>V$@"SL,J1\C%"Z5LR4^^I6SNY61_V43SSD&#$X4N<6BO^:XR MJ24.,4N<>UE21FPIU\7EZYD(^;^Z8XS"G)>N>>L.T M6-V&LHGGGH,%>T$5= M<=>UR0NUW"%FN;-+UVN1;*)0INSG%YFU-U)[_EX18W6_Q2J:=PX:[!5==[G8 M,#=JV47,LLO3-[L*)RDM6KS@?^;11N8L)53/+W2L[L)81?/.08-]!$A2T\RI ME1]Y9R>F<$BX4>(O/.,^#0&E8/G?VX+G]W=3*E;/ #*LXI;0#@_CU*K3,:M. MK=*$TA9X/ =0@PW,FR_A!.9M ?G Q?<,Z[%32UD'&\O4F_%D.!D=<[K)JCZU MBN991?-MH1UZI-:YCEGG>H)MPV1;UT4S%E0W5LJD_\]\PV.>!JHV CT%[&<5 MDD:/<]V20H8>8-B#9HX/&+IO# ]IV3N%9U:8>O6^V]I4ZV2R6DF^4K7M!W)B M]W">W=-Y9Z#!24)7LW1@2!*UEG7>/W:GE8NS*);L_U:Y:.[V9*]8E;Z.ON?5 M$/*ZH6NDO1:LSCN"M=)*:_92'K[9$TJO!]G.+@/-?9_,O549>PX:/".@ XR& M.M"I=:QCUK%'3PF0>UW7-65HW;(A0^N&#>&J&[J$&L*U%I7..Z+2?T2C;\/) M5Q^-)V@TG'[[6/R+_'\]C7\,;_W)XQ0-)QYZ\*>/#^/1H^\5WX,, 7M;!+HK M"!EBZ*8@8-@#MKH!LV[S^2VGUG9.WWPFXV@ZX.K+JFBSBN991?-MH1WZJ=9W MCEG?#3/TS.=1'!>KUZPH-&1"C1+HP8POCJ[F>@-@7PNRL+9P+-$F%\[J$"WG\H@T!Q MJYMA8+Y2Z.@@$+6 6?.C#[361-1\T.\@:*>C;[[W=%N$[.1N4D9MK>[E0G/T MEA2UJI:LHGE6T7Q;:(<.W'NN3G6A57%%=,^DEFP]8&>ZSTUI74;.NVF?]]01]D3@.3TSG<P[G@Q?.?(.-6)955-(\"AR5=B'/@;*.A *:U8*+OG&T\E?0I M#W(AX[T(\3+0>W"@6]T*M(KF44"_84#'^.=T:SK+1FO91LVRS5/\"UYJ5\GW M-LH6*.;;ZD&?@O@N3+S5W3ZK:%Z%MK^ EYMT&O&_ORU8$M_>>]A\Q<6\>,H_ M1<6YTO)IX]VGNU\2&!;/S[_Y_ N^&&'@S1'JY>J,ZV/T>P_7_ M %!+ P04 " !823!8YA)I3"D5 #*1 & 'AL+W=OBA*EC=.'@X".!$Y[$MU7;^J:O+)I3:?[$:I M3GRNJ\8^W=MT7?OSP8'--ZJ6=JI;U>"3E3:U[/#6K ]L:Y0L>%)='

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�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®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�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

!W_$I17"6I@;3O'!8I"=9WC\2;=1>;&6B!J%[K]@ETM MKQ/L^/*?F%C+!>$:06D\&J4V> J?ZA,OLB($(J[E^\N:.9)[.NW\Z9G38LRF M7?F07* (%;1VZ!.F52)':/?34Q)G?#,FRQS>QCC/K:MW4 M'$G]V!_YT"YK_B&7S'2&N+MDZ/1F'O@BQ%NY5/Q]C;/'6L"Y:]"FRW! 3PZ3<>M0\HE45A"V MK@;;Y@YK+TQ([)+UDZ]+F"=.'H'YMEMDJ;$#IT\*8_'8_SO42K<9L&^ 0RJ$ MKH\[P")!(DM9G=P/'5)5+@*12(*WAM<@U=(=<7[?'"EIB)\O7:I@9^? C9)V MMA<> ;)J0>;[CA:.NJ>0ZOW\U":38>$;X08LHE(,5WB;R07*AX]U)>Q$I5AI MW\ IF#'D"5=#ZS!ZI[*@<@G0IL,6-J_U.6LCP;6!Y:9E>#)!@+T\P>DA;1A# M38COX$@/5JJ:XJY$[[< ME7VRLT79(7+'75&1AK8 CT.;6N\+F@]BVB)F+):5 +9+ES3P\JA4--W:F(4< MF$P(U ^KMO>&I&5U-7-7$P[NBUQH34]I92%6\YE-@'<5)-7;]0G1+"]X)P=!2QTU1\ MRKD?F2Y"^]JM =CS:OGP,G2J]HX>'\0;@3XI"6N@<]5@K3[5-:HBX& MMSGW?=& ):KY^2SJ+Y@A5RY"K#[$DNY^^89-5K@*7%FLP9\4'L(_-@A_CQ&4 M=$]E@>S#)[ @>&O!+!O:"5R-,K%TN=POL%6$&DSB#K[#(2B*[1% P-EW*%]M M7G)0,+NIN0V%AAV;,+NBU;K/V3N"E7H[X[MZH[WBP[?6L&?5:$AS?C6Z;^!! M<$93[/Y*=D[71NC3L'E#E3!R0M*^LWT%[B^'F>PB$%> M>!%Z04X7B[Z=(PUF:!2!*(WP^TY0$EK2;)HC%9RF#-^!R1\D_YWB10UM[<,# M$(,KQ,**!Q[ :WYFK42_%W@A] OX-G1(VXU8PC==;I>Z3A3*2(*V8)[7/W'! ME>S$6=<4BFALE(]^K3(Q\D\194\0:3I6@ T9#06Z2*6.Z85F'4(YZFQ_9/X^ M8I[0 V28.!10K_;BU5OSR]CX*IW((9US,::G2N"G9OFBA@[)4GQI;[#L0DMB M9YHRA_V06HV*3:^4V!_0%V)U+(N!9DC&\(SK[)S 4U>?6U?A7X [9'4"1Z,/ MO$XKF?0)4K&(CVX+U_;P4H=_?'Y?#"#>Y;&MQ]> P3U"J MV?\]=!@$.>G.0R'.,I-_JJ28;9OV^ND1*:)3_8IO@[ET(BX*A+^V\"X<;Y21 MK;T\VYJ!XU9[4&A2B@/DD4CVCEV],#AS(XGF-OD1E&7ZIZ&8?$@'V:'O(Y]; MW04&E3 ,RQ (GZI$OBBUS'!!F62PW82E M=K)6]"J3S"_NSI&FM@U\RUR+>NU"FPJ,Q9&Q&$=K<#<(WG=05Q!N2UTSECSH#^8[_D;][X#U0ZRQ3:>6B)L A\DY#5G>!VX];Y1YI_#<(67>#.U\0ZREAIQ8]+LT)CO#> M@_E,5I:S.V.5:/10 *=+Z0WMN0.:X="V:BA[@!EA4E)!5I?T88V*G<_),@U" M_NA\1QD/:,.,09)N)12,!W*E-E%0SD M04:#T\RX^P6[48W5BC":<7&9RL08(1IU0DX(D8*2?3 M@%1SM=)I@!EN(GNG#*_!I)W>] 4"K9I=/UQQC4"BXVU8>#0(9Y6FIV$2JU?@ MN1LX[R'IO'FJKP\_B=4;&9WDP:'MO4*_+=C)]N'/ !'2IH3+"%W,7$H$TWSK M'0TZ"I,U$@=Z_BEZ7B7]8:\U1!#Z6C,<5#8-*R5LV%WY5+@:9S0".N:CH(U* M73_&]QB'6Q'=N&$V!%J>MQ;S*FH4N8T48^QVFCW[9]8*$*[AN4S^P^28S"54 M)\M_KRL:^^3^-T?L8E "PC\1F+:#,Z;BK"^S1MG.T.>-SQ5>CU]#^QX0(D7A M1L)18ZFUN#^P&,W%%+ZZVV&<$3U_X/QADW3),,[Z1;(;RRA1IM)**EV!Q<3W M>,-=FX/X'@3^*JXG1CM_BN,D\.\X"79H2E'P%4_B+M"I%7X*D=N6_[%=V<;R M%FF1/!;S[HHC:WV-T9PNMKMB.7ZTZ:F<@=[7[00G$$[!',ENWHCGTAI?JZ0^ MT$EPDI@I*CBIXBV%3L(?"AT$'&. 3*VTCX;6"*.15W0W\(VSMU5*,'/^,&9)E:J&- MZU#3(>)_LIV3I\NVUJ.7HT$,JNIJ(1.CX2 ]RPET [DFI42T5)18)S*^NXY6 MJ:Q+Y%B@V$1?*)B%;RJ6Z1K8C2FLC43<%GEIK%Y8SP6FUVV!U_XH-.&(U5X4 MV(P:VA6DTJE<+/WF'*F^L59O_;4R\"'JE;>*$,56']K454NE*$4F#J-K;L?' M9'N9%!)T6DM[:.BDB^]>I7 Z$_A=2MLT*/X&T*G## 13>-1T!03]C'F-K<5. M)H#W1H[^A"C%MAGHB$%T9)+%P17?XNL'QIEK1>E^&EJ^]1.0 UM$[=3E8 B6 M.(-6HR%?;H>E:GB.D*N1[*U%.%0HY+)*Y"#T\^OB>T#1Z.E',H'19I1?P&MD MM\LN4-%<%Y1'H]Q";(EI:S-:6BR/S/"[ &W!W'<"SHV1T[XJZHJ! M&_VOE4!<]\;J)8GJ^Z95Y]OV_-3;UWU?_]S6U'KY=5J0=8DOND>9PJ8)GPQ_ MB$G.,VDU24(?0)$ZXXEU0!+31U?X0KM ]>PF8;^HGEUH]8F"BT^JPCYYZV3D M%='J%86H>2?&#!NHAPV>@O=(:0[N&X$,2-^>V8_9=0I;"Q/(SIW BF M]S\/_G*"9PLE@@1D?^^W:3?+-=+Y%SBCOA2KJ6ZI!3+?UJ?E6X$*?6VD:2-H ML7V)+7*.&^Z&6@O">JI'9JHZ_L=:36CW&8'T8+FFY0XU%&4Y" 9')F*CDTHW?R@4/4^B1 #S@?0)^#C$;9M"G7MJSG2D3G24"+<,QX+QV?%9V>TQS&Z+$%1S]-%^4I;_".3&FLS MG_OZF745T,*MO[<\'LB%X\>/=4";C-T6EO4O/*C:D!1WLVDF-G^BPGVW_$&] MM&M^NX5M7071L+]*U>0/A'V44O%D&E_+:^BJQO8.],&AET[> GUP\[C/+ ^* MM-23:54IKA# MY")W?R.J-XPE(Z)SUE 0@3R.1)HNF[S9N>P/K$&X3QJU#ZZ8(^76Z&2*(/PX M:NX*B-6XI)3R/.2QSN(C57X7F)_!=0P5ISI%YZ[UO%/+%?QD'3Q\\TT[]1%L MT'<;-9I;5]CYPO502 G/#>)@9A7=B0-+77BCF3ZOFF&)?K5Y*J5W(B$J[E'O MQ&B"K\9+ZGD4G>Z,V#5@J9O8)@P=&4<-G7&O+\K^UQ>83KX!L1$?/TW8UZ.4 MM>KFN)/#(RV9G("*\9R0X8*[PV_*OG?(WCP\,/H-I;+BS,*3/W[A=4)=>GKO MGP\7I4H*1$LF> 6A/#>^?!OMO'!E"J,;+44R+H3\(X]&)4BLRH>QE>H/HK-, M/K[;L>B:MQGB 'Q36DVPT*^_H8VWGS%S[]9L5&^@/.)?IP8G=PQ.A&^LYJ8. MKZT(G*AS3@C?WB][(EL3-U!]-*,N?C )37%]T_)OVTF//9\O^O_TLR]^J#N- M]>2==>K5\.]/?M=GM;9V/[K1W-#0V%1PZY='CRJ35^#917?]_SK#3E&2MZ!]5B^FTMFZK@/]4? UF<8HJ?D9W1Y7HTJ5N$37 M$!GR6WFG%)72"CP5KDUHT1[H0!M#N%BL#I4ZRU8GXZS*3QO[Y:Z)$VD]!K9.JW]54N"YJW'...QFTM:^JYDW*:\AW7\.+M:?[MA,AO2C-OU:P?>JM/ MJWW)W''B-N_0)T/Z@YNYKY#O5EWT*_WK;NQP 'K_Q_20?OF.:\F/;T351-^K MLSZH&6RZY"S;V/SLZ'-/! FJT=P]]%'.KN_'-I?VD=<_K[[\US7G\Q=?&S0* MSR+U&FQ=SG(IE\B5_>2@V+Z^)]C6-6RT^ NNT9[Y^<)/+M^XE;YR]7_*=[O^ M_%8> Y>?.7+>I*8$R)]Q]X_!92W;EU0=L6 5LB9 L2X6F-\CS-+B2 EM OWX*9U-0 ]+4X MQ(?"7_*X&GP]W2EREB=B$7Y88]YUI"*H*S23?Y$9@;[ONLKR>BYGP!R/Y,NI M,ROTIQ^E7U^KN:+1R0Z!RZJ!$R/?#Z>6;;D9M_91ZT#UH_ZTE9*HAO@3IX]/ MQE[])B%,-U94NOD5JEK0=.J_7WY]ZKL%C5L.\T"5*F[WV9'*54\G>M-K1N+: M'O2'Q#NL.GGSS<#3X9&9:B)J5K$JJ@_^.?1R)+:7W_B@J7+YN^J+'[D6?H/Q M6_.':Y]QH'N>+/M^TCR;_NKS[]"\.WQ1?UZYK*/[N:Z>;4>MN MWAS<^OZVK64IG"D:=T?;H*.)J*Z+NNZI< 7.>3YAN,A=_U3H+=!J% MYRPB0 M8GG@7^; !$AN'NA1L0*PB LLQX')@-C.F:;\F;RJHXA_!$,3Q[UBHI$%.[1Q M_"*F%\S;7ZIA+3\78G\,;WQ\?/IT]R>^A[Z@:17KA$^Y;H"'!4T)P;Y[ MR3/#-0A;'XYP\A5>("S:49 YHE/-O!8K[(@*^'6:VIMO8Z=FTHK'9MK^8R?O/> BD*F\0J]F#%A]G][_N-'> MVGTDBU][(#KQS*F0^+2%0_I#FG^CAW:%#'5'>*@\)"N?FP.".Y5I+>?M6=]A MDO$,0C:E'HV2"U<5-'#.1'8!45Q A@WYT\(EZ//*1\FH8G3J1^Q[@;OQ28W) M:75:UDZL6I?'W(8L.)W.\10$=59^C/;D!!?3N3J(7POXVU!=_OV)G\FU']Y; MCA/A?R"DMESF\N;JP+!W.!1U@E5[Q)%*.\)W>I%P/-GOP,35T&:7A$7*U._2 MJDN,-NYV3 <\!0VPUIMX#@+_?3\3MI&=Q_T,M3LK]!,$=5A7HEE @_488N8 M/K4'#@DZ=6JN'_K7_5+/*T;IBB21:XC36GX@,_ZN8/.K/P%#Q?7'UM7"9J?1 MSZF/MARIR3^U/+#1>]ED78"YH; XM&__P_C9_?)G[R:OG)O(BM[>OSWQ0.E'WF&#%UOZ).O^]"L7#YB,U]I-9_A^5?=E3<;AM0/W9;/)>/ SEB^P M:??] BNIJ<*W@/>FGL'Z*/#H5H?1A)9H$5FG^1QON94%1?4UDEU2J)_U30ZU MT=K+Z.V\? ,9.BP39*@H[R[!LF)*8 VJ.MA6KX,"3+?0VW8OOHI]P@JQU BI M$*,-7+DEF)Y-[=0WJRJ\5:Q5C;WFB:'4XABD1&)*V]O3R5TBRKF:N;_VS@[3 M',E%T(QD3RH['MO ?WVOQW?*0=5M 4?5)P@=Z$,2.^MBMY)W@M&30S5 M8I87'M<*)&BX4=9!+[&N1_?EB6&GJ(,#\K68(09HJP2\;>A.O4AROT'D(6C^ M8H!E VU[QHRNTH_\9TA1=>N "HZ(TB1^];,7B;:GE[OY,F/@'B>< MW?8+]I-7#_?WU02.U(')ZYJ*@E>*:Y8E"H9]M.LA?@7X&?JKN15,(K0?;@T7U\ M#=#="#^?NB?<=3&6OQ+;$G*S*V**>F%TW,DLOR@<8Y4> F,J@Q#3=.\ MQ?B>F_CFQ@?EGX==T/_;;F!B_ZXZV9O,1;E/:N^/S!POJ!X,MC]S-V6Z:>98 M>8HNUO7@4(#&,O:?N,W' U_G/5NPYO=C+5?#!=,[1_)$XPE!X[6W?#;_FL+Q M^>.WFO(?M[S7)%JD4[_M_4.IIX3SQK/]Q@-]_4G/@_L^VI.=^NHL[X;BX_XY M4IK(44*X^7:A(]B"748.589B=H19<138J!5D,;Q4G N=O =YY;HC$(NJQ.:W MM&U2V$=013VU&E:.UQWYLGKBG_^N\65?2ARYJ^>"WI # M;8;VH;/JEM.2VR,SQW),$8GM;H*>'816'AMM/TO;WGL@0^&'OBH_>>;H[=29 MD-Q7%54)@I*99],Q]8TM]>CDY8;8LLG'\O=KGKYIJO>//'GWU\+#"W_'MH7] M>J_J+WZ>J&FZ0YI/L\6=L%'>+W(0A*H04F^,)SL*S":)RNR1Q'9)1&]5('3'$<)0 MSK?>O2@BR4_<216A14"F&:8VH\]?%[/(@B=S)%78!&M5I2X&?=G F-Y1PXNZ M_?8JP:SFXLH/P$ZA+KXOY$BVYJ/]?IOFB//(:X*KV#8R1(HY?Q QY M(DHP.;\EX>5?PX6(3$SIJC E\.#YEO&*#Y/W5[ICWW _>9JV6MD?W.KO\3P] M(5R]__*+G2WWS\E S'Z=G(&,DS2(S#Z58LZE-SS^;H[4*R[ 0Q-3]R!.'G_> M)RYUL2G>:>^O?Y)=+&='JC[?8(\;QJNJ<^XX^2<.#7'F2#L]7PU-_[#@T99_ ML]: @JJD8?* //9:%U.4?@3./JD>IJ$U%T+F2 M5]\%X0YK_GGZXE^EW&W1K MA"[HY_WII7V!P>/A>[&H(F80[!W>IJ.NQE@Y-^-2PJI+_:Y!&2BM>/+,A#0O MLZL4BSY%+V3Y 3I&WH>2\^7+[[P5+<%/&,U+P&4U=VT?GC0CN3A1/CM408Y[ M&F!=D9II=W:,F6P*L$&#/R]Y>Z+WSQF!JX0])G2\H7;6M5-?>5/:3=3=&%Y4N^VEU<4/]WF MG/0XX=97;Y\L@0^=6R+;^2J+U;CKX< MS6151%RY556;W.2569B@K1GB#@\=[!&MDR:&5@FO;OBS>T5I]-&:H4.\EQ\[ MK&I^D+?C4=-0U?;/>"0H!O"QV':6-ZA!#5KJ,JQ9)5HFR.S15'IAVKS)K(@8 M%<6O?LV@;Y:?A"Z_&UG=F=0R]GP$?]7DOPY4J/7 M><@>\X7M.B/,%K44E:M'%H!$% M$S.?E4=DP;P%C*X>&U#XU3.<42O(T2I6H<_ ^>EVJ@-VY55N=HV&4:1,X>VE'H;=DV,./M0KZ9)"L.X0P%1?[\3+BJ6MPA ME52N :7HD^Y.[DJ,W,XA"_PZIWG+OT'))>/ILV8[/+J^E\]:^4(01[NS%AI:,#+?[8TJ*.R(XQ _PZ/_3I&^^6ZM888^$W1O:/'TR(=!&1:N_)UVX2(>VSI 0W=Q) :W.=(W/>>D]2(5V0-?BX6V MHMU3)# YNW)4P08$?'L(>''/F261KH-6PYW-:^1RIJ69,@XE-V@*KLZ"F MH\QOS(1%=>IC55(]S2C5R,[1&IV:BP*%[BD4]CBM"F(\NP4&K]-S\8U(88\; M,!NG*M!9#=6V3TA)B6.?=T=D*G+)',F3N<'@PW+Z[3N=_G4/-VB.=/[(J-2[ M@5_ =E#04WCD"?IB0=X<:>JOOE.&$I'S2[.""7V.QHZ+D;0,A'XAF$\3\-4B MIWM0$.PP1QJ<1NP*Y!&(TCDA61$!+JJ 578>^-TY\M(4\^X'>9N MU&DEGM8^$3E=FJ,_]I-)E#\]1[)5? +Y#T2IR!>&0WEY%$F!?*,I@K%/;%)V MF%W!$@\L]ER*%-U.+W@HH*A4*/":2GC>(*7B\]LNQ5)]D%%.%$4PEPOS@ MV/&ZV1A!CDG:(2TH$Q.$Y"?'"IHLGI/JH+M8"2Y7"!4]$:W!_C@_@G*/3]+.9M:4L&CX M>G"F+A(3OM^):=LYQ/23Q^BGV'EZF^+\Q3A?G D7: M7N&^2X$IJC&[O4!DHN<;O%:V $TV32.[$/=73>XJH(-Y>;NAXY8?\+4FOICM MO+(-7()Y-H(>8K)2>TH4B\!'V Z5:,$$F"!*M4AM^#/L0QNLOI.&B23HQ*Q(H*0YBL@W*BLQ+WGBZ_E M&KX-2YSB8+'CRXGT\<6(TG6^DFKYGKD<<^^(U A9V+BT8((W6#KU+;$ZN=:> MOM$!+A6;'GN9>DU0&*^;Y.E-<*GZ)7F;;BTZ7B,FGZ&8WPE@F.J&9V$=ZE*VYK*3M/"=OU-[Y0 MK!(P>-@/8?NTXONL^_66'UB^T#'B:X]!)X$/QE"7V>'!LO&*V2#\2[2YBUV8 MJ54UH45E!@WGHG+!96-/+I2&D>&_SIU/8'!1SKF)'C'5&Z.)[QW@? VYZ-.J MU9<[Z4E;U7\JE>YC[::,F_,5JX:2]-2Z MVP(_M7[_';)J,/U+OMS',Z-POD,((3J2X@FR UAG0NCM,CN#RB1QP79 M$29.09EDW,;(=H.^)"[S*SQY?C<3%$8_G3AH]7CS (]6@ #, ?$3"S_&_<&E MN_@!D' ;F-M; J5&MHL@"&[.AP+()= ^BRVQ+A=%]6;Q!"2(C(K68 M2P$YU4D&6XA1AW\*BM'6@R!R=NN;2G]P#J;IO6%IYV/Z5^AQ)58+AU;?$O Z M"F[B!U&ZIMQ,3M5O,:LXRZ%M?8KE(QL$I=&8'\&&2$!,1Z;S?PU5/^RV,[XC MYF\A9JEE>J6O#R^/Y0!^9/FKL*9!2E,F$KW.ROE3:RY>:R'H_ M0D7QH-DODX2K49&:1Q;^,

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®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
  •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

    VM0_*(' MIJ-FUP$H;\_S[^!UU\'V>C,#2'3VP54$[3S;!S.1/CMG7; )LZ&W7EC&[/53 M,P/MS77/:^H4185R_+5D)L'Y5$9##@_7U+57&TM\]+GW2&Z':CG(UEGW--?Z MB=8]?_VV/_P9^6%:WD''W^>]#=%S^Q$J^X7E$ $F3*C/VJ UH&O$6&@V%OK/ M(ZD?F"9M[C$HLZA!'4#NNI::J?+'7]7>? FFM.9W%..C>_L7])R*G8*F R1"PH&*47.I>!)M,WY5;78O86+"ONB^ZW:I^7H/I+@B6% MXV\]M6S9T"HRXW'VSQ[AZ>,1MT2_#4:8R+23E<$@^ &Y$9S!_,F#AZS,H/W] M4+^F7$6G"H)7/&THI$H;?&53,4#NU[4X*Y^=A2D6<6Y50]FMSH FPNMB-CM[ M_\<+<_/50FZO:QQ8APF#9ETT>MQ6H'P/CXGOK%.7< *ZE"'6P#AI84\/XO$O M<%E@Y\[?#WW)]7F*=YK15,D]\E-<*B6CT6JU.&!*(Z5E[6[NME; MZ&?J:$M/56WO^ O1**Z_BAPH_[TSG+9H(),19F(=IP#GR$EGXVTRP2H%:P[_ M9*6R+A1HY98X-UR1]06W5.1J:>]0,.2]&B18KN:V1%)_H*)#0BNKX#BO:%K6 MB@3RH<:MS;]<%G'A.%#(+.4?0);VP?QF?/"1;R?,P@&(/#4Y)>4>FN$QP(Q% M41+!7!H&PE"AAG=^UF5ACNW=S(#M^C:YU>A&'I[+,]R[[9'GPV4^T _*L'L9 M52TG/Z\YEH$.[#EJ??(<:Y#&_2KC=8>?]@Q=8-? >1'F"WKD2',LBQ-J*] +2+0/]E3QF;1NKC*@! MS$\)OS,83>P792RM2]D]HW$R31'QFU6%,^FB/SAKN\*STK2(S_V<)S1=17G+ M!&NKJ4[H"8Q?/ZO/X&9D+>S2\5W>;HE,:L#_J-AC+E*MWY?IYR?R)N#$>#3: MMC0U"42\_5F9F.U5$O('8SZ%&M_SR54@%X^+P;D&F4^KU=Q;I9_>T8C7MEUB MNHG<1Q0*$/@9.(89\W-%"\$5U#/L"]PLAK.MK$#R0T)TT[D&W,VZ!VC?-,]] MUI/8=L*O,A!?<[D&7F\B0^P9U!&.P7$2.^+XB8M&@(L$S9(N92_#>4XW0QJ1 M:U'=0J5GU4LF1YSA2"NW[*=CU]OO0NV:\J;Q,,!MBSSY;1*0Q^&NI775DN%P M[J(QQ@J"=N;F+\10 ;EWWA1=2^N_:,\E&G["A^+Y)0%T"9R-F<_(%HJB#\BU MPOEDH@D.S;:8RU*7=[]5% V&/K-)SSY(?X3;]*7;M)SW.E7>(Y6K*[1ZU6;3 M> W;^]9(E%CZ.K3.O2S:.D3Z+D C3\^Z'#8O)2'P"7*-3'U>9W.G:+,R )>5 M6P<^^$HUGYA[((JS,AFRQ[NWI(80-,T5VSM _07!.QN1QRP1,?#SFQ%?,CH7 M[]%I^G@MU4U3C@H1$\KG ?ZU M?:.#_MU#(>!8'I%K/X;T-EIQ'-&H M"[\&0LRUL([+@/>!1[AA-QZ3_^_.LI_P2V_01*DS"D[LFHS.74:&$$^ R_09SG=B%(RBW3>H)>Q!_5&Z8XPU>OME;]/%6K%VQ M #PD/^I2TG&SOG(!?JE>>(_\0AHC7*3'!*4"C%'J*2VZ_GQ33O&M*S%UW1/' M!V(,7,]QY;<50Q/1> 7O-#] ] F4VQ;%N(Q*\ZGDZ?:DBTRXUFL^)ZS O19,;5$Y3^&>,*>F-%KF%Y)QZ?R(]JOL/SC"9G] M.T>5TP?>]9BQ\>'SXQ8A7J$HNJO.,WT[X7J&%!X2W@,Q;:*@[N-! MNS'?;H(_+A!@TM/FAG)-S38#_UM"//'\H/6N:C,9UT6&'^P<)V.M2.]0"_?Q M9)/I+/QN+B9Y=&U$M )LP[6M44=+;HQR6#VKHU3GINW-]P6Y)R_=+E_)N(C1 M^OKM1_'IW1^]UCE)[\2ZI&JNDN=)FWJ>PZY*@(8 MT%=W,<6"N=T]$PO@Q"Q4YCBRW1Q0*.MBQQ"DX C.>Y>,2 M:*DJWQ?T;O!UJWD,QHGJIH*_AMH6)0$Q[*0@BF#O 98SF!HUM^[5# MY2GX:!A95N]Y-"BN]2');9:VB + K:"A$E-;THDSG"O7S&08(2Y4(C>A>U^H M47\*I!Z,B%9UUDN>!HQNT X%R"9^G]ETQ!1U].H]:"BACO"J)9;.H)LO6DQ@ M/_&#&L*]%:$[?:$KEG0)>_L-* PU:T)% M-E1>S&%F\MTKTA^!O.N](%-84CY([[9%(,OASZ_LX.(_0GW30[N[X$]09-%^ MD-V2&B2_Y6QCK$=*F>\B1[C%S!6!!KZ?;C"6N/L[8/1=G"Y5A M^%"LRW1:FZPNLI4F3OVH@=)U&$$57D U%-\1T5[*^$_&P&1*L&Y:7!*N=LMT MAJKJZG_I8M/E@"+T5@97W%H^R%(]FU FB8+@'5>TV9E_([G$_2;75[:)6*NQ M-PX3ZRCX&FL[R1\WX73[>8J::*5\.O>O3'JFV5_YR0/@3E768C@&-]H_=-SD M9B$>\&;")"83\.K=1 $GR,337F7NDL00"O&FC>'1_3O()P74(5$YBD*3B;W@$/9MR%7C6HM$**T(L1_8XUS MP\A_:3/O@":AN\@XG64SA/I\322V&,_SEZ@V-Q9?M-#.P,'7@+:-$^;X2?2! MZ'>_;Z=:^.X1LR[BI#4E\FT6XWG5:F+H/*[H!83M4_0=N$A9Y9J4?O/ M\\8XOHZ'\+H<7&(/(H9*X0U8-&V9Z*4?DQ9N?F>80<,;SRFS;T*(H7*S0P8G MSGQZ8,09W%.WQ7WW+\_(T%L :>6LJ;NBK[A=^??^^]ZC)__AUQ??4(O<_IOZ M<2/IZV,Q4$N;SV$0#>K[5/Q%?*Z!# LMB(P%Z>@%*\V_4;R:NASQO):3J1>XIP#]QVZ(_MGS'%\@O34 !29VU D##"'B@V,QX[FYZ7BN M?3405L%[NR>%2YVZBBEM5EJKZI-:_$3A#ZZ2;_'$%@7#^;3IW[)B.*3&/+JW M)U]G=A>%0$\FCDXZ_OH4-09<==7MHFQA#H@BA#_G(&#UE@=/+.H"D7>W*MSM M, C$A2ARFL,8?0.O[:C?5T68-"P)3N[!U:7L7:AQ*=25B@^5D,L>[-O*U4J9 M).M)5]HO)O;JFK'*]UE]%VZ::)P)@=J$8KN*#M3HU>]Y)4V1A3DR#\]( M'K$"[^^#/Z42&KG,4AK=%KG@LV2D2+6&4)0Y \C/01;*6PC'7-2(0HD0G4(\ M& XRJH;+59_@EK /NA ] M8@RC&X(2$\$Q=("Y]YDR%'_5CQ4VZO+418S@G]A<#/$=41^RT1NR[2KE.,QRJT3:^/:947F%>&OGG&6#0^& MJ7%/YT4BX0"!:%DTX,==81YMV#O]^DS:_^Y46YTW_%9@].0?Z?O;0R"TMK;@'N3IREDYN./[(P5X WJ+A,UM9W M?-"C""GJ "%8NI:_G&03Q\W>/IK?45G0BY%!WYX* Y]@%7T7(2NE0J/E'WM% MJT"*Q598&0X7X-1/LWT@I==/S#Z]59"H$$".1Y@L,^HGS)[ MUXVE("A=2K(RJ@=&DFH:U"BO9(=V6Q><>$TAGB#CJZ#V,=99YN,'C7@Y5E^N M]XS#-A5BZY(MA]2:E#2MB@GV5)&1SY(3Q=A>-4'YO*8IL4@9N[D097GT(9J8 M']"G&UK3/NO).2CO'9DV%(M60N7Z,"#>3[BX7H6_==RCSKLR2EIZLT.U&:IJ M23))U(?Y?M"4P:^$.FWQX$>FC>0\(L8B/!W*V0#^-&NC"E0>3W![#3%WKT+U M&%)ZB>&*/QVL)39WH:K+QXAJ;2H#60SVVO1-B76@UO[4<46Y#/N%PQ0XHYOY M 8/0?XQHV46+(["%Z\-.P$(10Y18.X^XT:YU+N]0AEJ>9L[H?0[ ZY/-*ZB3 M_RTG/FS&)X;PT,P\Q0?5%&M4.+6J]QW7V =G!!E(7:CB/.F.IU.HNI68DWZ/ MNM(U-O1?C'6$J,2J %29YL^Z?*M8 KVF^0VGLHCQ)&%!\O8>3LC^A.V/ M"E?L X_;M8/K",]NI_]%YY+UDUSQK,M#;AD92HA;^ '*_3-?C)W]+>A7>8V/&G!/>3 MP6LG=]F(DW'QB^[P 2]38L?;9[0;[+"9P\X_*B/*M8_ !FR[XKQ1TL_G+^*A M3'=H2.^G8C&80'B(0)SKHB=HFKY"64F7GN_&&N>L)L.B@O33< KNVX3>J1,AR5J(UUL@:AL^:OB+\V,I%RO<( M^W_LIF2^5U#D+N)=<$F7C MKJ3/E[RB'C-M"!=.^%A9B\;,GJK5^Z$I[1LH$!5K;#28TW7["?"VTDZ;?=XR M/4FOBU_T<&CPA\10VW+X6 WY+3$QI:$M)+> [7=AJ*%+]5Y(B[$6Y&,-9XBX MWX[;0+"N(97V#/95UT>>SWGBKF76.AMGV" 3609OQNVU-4=$KH3K.!=EO3!\ MTU%WI1U9FA%PHA#-S[$TT\KL%;3"XZ<6OI[!=C1B$L0/7-3W!9G$/EH7YO=0 MFAUW_$SF$=%4F2+BRM4FSGL47F^JMV8M_M/62H4Z^(=JD*X=:G$NP.DZ06EB M&V<5(T <0[$..]FB.(=X*>-PDVZZ\)\@%\LMA/=D8<;YF4T4MWZ7D_6MX0&_ MSVS1 )N5KQV;(BI_JB'=B-S3Y#Q,4AJ#-DK[>03WO.I]*NV#$E3M3FYJ?HP/ MO(&_,1W"3>?")25UW'D&Q=B2/TU4\:3_]^2><1S\>6'&:ZPI=V)+E:A3C3>S M5G:'/XW[+%*TO-/)&/F@?XP3V A8U\@-1**8E7,J5^<,J1A0QE=#D:VJM74] M=4^C*,'\M',ED5O8D;,E3E<1Q@U":>9A3>A3][3@JSLF^/?2AP+JS% M[P]^@&L!HC/C%X^558$'+WMI!,A&//%U#IA"ARF TBX/XC$Y+"\EU-XOEYZ;_ M?&:.P[*6+YB,1GD3-%QH+947*9S+H+\#[5>$M%5=:*YS+8J(XWE"S3L[WLH* M9(%<=#77 T[.JA94!G5._@&I6(O CZ^[MOXXPMXEE.]#,D8K@GXJ?/N3WLC, MFDES/HTJZ;G6J5JI?R"("N][?QL:[Z-A1)O('[!^X=*169:5.WV%&&"X^?YQ;*/.),'L(3C9:@;_%1JU00@^EX1MX2I 7 M.G6VKL8=E1=MNC\)8+K%[ L-M52^:U+ ,:C:!1IKXW@^[H"WWH6D6AH(R3TG M\H98]A.XHD"=20LR\V:">"C-4]1NU9MIHJ#105]B4(3Y2UV33#*2W) 4ISJXRP:=. M836!&L:JGBM:CF=7A-EWN.+PSSFLI4>:MO^?/=&';+R.M$;>P+^CGTS,IZ1? M?SV>$%+Y\7[,.9@F5$"2K]6.G]G\;"(DX53V-QW*0VC0PB$=XL]9D_(2JM5- M-^2C/')-AEG4WF,(?@5LVP[2JDD6D=".FOU@?]S8P@T:Y=<.7D5W M(=<% >EGOINLR=8PWL/%9759"W1)'[LV@3P[Z?B[P?,A,L56H72YR!X$[NU_# M N(P!7S?9U#LN@7;PM,Z0^HZCI,1,ZFP)[%*M>[YI+2$XT/PBC;6J0LJ9$4U M<% 5U*]+C33%Z,WO9C*7P(P*7N&DC,;/'(QL(J3YXVIT+7[[,CX5:ZK/..[) M2E4]_VY"_7B37GV).Q[L:::HXHAZGJ R"E>?AT.(J39N[53IIN,\)KD(I%OC MY],!':7EJ]R4>&.ITOW^9:<_U*R1+3W..\L);#!M5+YG$18FR<_N?(*E;$,W M-UM21.VHO1&?^:.."=90;SKR 0AKZT'JY*41QA*N&YDPPP7]:(R.R8"^?X.% M%(]3Q2Q N6W(F<%UO',G%9379%;8]!-T3*'A]05CMM,1;F_C!9\",3K VO=, MN9VN.Y6.\<0^AND[KAU]R,383-"H:!7.+1BGN"_^K:TD*E<3GZC9JSB$1>]C MU1FE%6))."V?7G&[.N=:_PC#7XSQSRL#%7 X?A&J_KH#J7.RD+^2#*E0SUP* M"311ZB[1!T1Z$;S@6@J0Z7UBTZKV_R[O;P^]??GN6*(I' M+R5=:GP@2!K\]>Y(T^;\ZT>:CEZ_-SK]Q''[ZNW]!\P'6CUDE]MG7=YI[JSK MMS$/0 )LXG6%B@.D,TSRF^>KGRMI"^MSLJW"7H%]&IAF7=Y=1S"+]#IV MV?9YG92/&1<(>KB MUZ:?Y03 IXC&HE#G1U!T6ZHKD-^&/\,3SXQ'\-Y-(F- !C9%, M">E3^H.=- M8HA>N?_WF!61+N2-?3.6[=JJ#16I"V'[^V<.KLK,O169?> M.&R[J7"CB!*]\K8I3E2^I9""42O>2%GMN23<-,GOBXPE[,VX6'_I^PR1:[/4 MN83OO1]>"VXT&:1!AGSE@KOD9L(I)GR2\RE\NDEXX][SS MW1$GG7 M) ]:U PX^;F*27[5G55N0/!*D*QII#S4-!$YLXU<#2[@:E1TU1*Z M3:=>06&*:LK^'<$M$/D"(]HWQO$%\M4/'JH7L42K1I-2:P37CV8B#TW%MK=S M3W.&/0;6[.O BBY4W^B#%NCZYF+9XHQ7K+.5*VL[9EW0&^IT];+AI)V/;H/L M_2![9JN@"2*"'*K\V]!.GKA)*N;XI(+=GT38"A@^IK'+((6ZL@Y*<3VC[3OP M-Z(NYP?$5"'WV]*C;L[%1T11.*UHTQI& "X>[YK9ZFQ'%M>9EV<.KNAA1^1B M/-\1T7S']9Q FT04WG^0I3^5AIJT(W6A@>A!L9Z'M="R>A#AK,L+X[9G;Q4^ M*>0I/'0HGQUMV6 K22HOJW-]3B7^-TYO 2W?3UU7^JR+LQ+BQ_:PZ0^@:Z(_ MFXID,Y_J+:$^*=WL4\=P[JXN9V@R=)CO8DX"9_?7<_O5]L\[V6%6%GV0_"L^ M_,S)R&1$/"::DS(8&[OK$0_**;W8$1;C"FBH+:FQZ+C-*P6ZU$_9/3R/"$;E MNJLQ6&]G(/H]_!&XB ]AGXL^0-Z!;)H >^U_U7=G75J7%E7C="V_]JUM@H=) MS!Y0LB5KJ"74)ZE;11^ID!:',Q>8D=;H'#,(V?/Z IJ=;;56 ?YV-7Y)+B#: M=W75E:Z/=@BM:6-3JO=,$?QW7LYMUT:;$/7Q'PU-T+GZ&6,QUY,=8J65B@+ M@%58S%@%KF3@5SX'O&M CLX B<5UG)CYA%L0\92+R2?.S&Q*A6R61JG2![_T M1L<)[3K.+0W-D$/:'9UT/3)/%3; AR,(P_CHO.E'#^R5S)_7"C%X2T5925WX JAN+%FCYQZ7>P*R:DD9_] M"KZO^!V.<^F1&0+]!I>>M!"OUE)\N8WJP[N%( M)8-BZXB1<+[[B](X?>K*?(W3K8,=BY5,TA:/_!B#8(HEVIL<*=H>?26N]'MG MVX;V]'*+>IY(RZ6K@C+GAG1&04R,IU70G,_X="73@@2 BY]>05F%.:Q"9X#C M3CC2V]R"U$J+,!N__4@.>]<]O_AUEY)_.60AYV,H&DLQ:\P2YB)X'9&-EI.K-G.6=5!I#92C MB88C*@:?C,5O.I<30=U_&SDI)T.8KB(O*,FR'64IHS&F^$33ID8YU-Q2 MN9J0%9!?SNN!%M@O@'5$HF$P J3C8_IM;1P6^)M=8OVF X[$QJ0>0#2V"Y\; M:+0BPR\!.)1;F*?ESR.,[\![ &)ETD9.,%8WS4WJ< >7:$N&+S5.;[]]ZU2& M5>W#%1I[)6A%O-]UC+<$2!(D;68WV#OK%A2"FLO(77<$Y4PZAPOB[!E=];;Y M5UB>@;02$1U'](KEPR(ZN%!-;GY"9*G/YER-^1SO:5S!V$0@9^%H+)G[B#\N M0(4OY%O!=0M//$WVB>=V$*E"CU9;%!XI(XG/4J@U5;>J*2T7.2ZPO=&%!.,6 MABSA ]U67&L7@%-W,E-7=K__4-VM3#F%/=G]A>5A]^33P,__.^LRIX1_.=(D M/Z.B0R%..NMQV_L&L1ZB%$:LVUPNN M"PAI'"XL4:>I3R/N&]E;3ZJ\B#(%+M8D_AU4IYJ<&\ 5G9H>\2GM*T<%5R@K M8BX/MP4.,[8\9Z^S",\/S@D'(/\Z%!-#1!I.Q;^&@^^(3*I-CWN^HU;MVV0IV*^NYY&^P98ITO=>>YOZ MA2J8<"UA!^?>)-> 69<9+KFAZ[AT'KBHK0S!ATKA>5E6FB?0L[CHAH8GN,FD MKC6/7[D+>P*UE77N#;FM"_YJ< OPP1%+3R-:$XF*Q2KF2-0AHX9UCEN'Z)]$ MI^ UC84YK3>/G%SVZLG,+GC;LVOX_S7YR2DM/^6#DI&#+!,[]A;4K$_]V&4F M=N>_][9%KOUX\K<_N8N3UEZ;?^[_\U)>L9I+-WU]@<" M>^KR9XJWS4\"=TAU?0:Q\I,UU7=;TU975E8XG]P8?IH;'ISP_+N-YTV[7$3O M4<&PT:1G%OA5A.B,YT4?.8IS>,N@*_9X1RDG?%3F6\0V=$Q6;/8)ESZ"(,,]\.8+ M_/;5-T:JV++,DNGP/N'$73GYI4.B3",B+6K29\BY.)<0Z/]#JD4,(-R%M5 <2:)X([9FCWEH0X(L(L#K_*1XT2*T$O?+LE]7775]UL M[MWV33]KGW/H$!U-U&Z] X=ULN-#),H?5JMD5E[0(#2D/U') H^P_IK8C77N M/ 9XF?);T]G^T2Q4$!2\S:]BA\12XV725B"%Y+*J(P%T<5V-STX7$@>[9C+ M5"O_8>)$\LQ68#90^#-E5?2VVZ\X?B47*%*&D[8/RM(L3#L LL.?6L-J'3-MTH:I50;G].W4S,0\@ M]DU&+$93+?5\0<5]D&_)@(-.;7R6D1KRB$#$@=J @IZ*EPS?7R6\GK]T[[R8 M&\Y8=ZLG3['7Z_NKX:36>>TZ=I2XSNSN#1\V+X:@*=:F0C*YR]C#GBY8/ M5T9UA9J0WOY4<,C* M]!^ PH;B$+ VL8VW /*Q'R>"AG2R7B9F-&Q)MB@FI!D*\B_$E/:_@?I4%U!H MH7ZSG/1Y8\F5<)9D?@]%6XO*G+1.Y5945D:?XG! ^JV71\(RG)L!#R_?\TOG MJBX.4YW_EC_\)NX7/&?BE;QJV)3*_$6-M]W;^+:4]=656$K5IT>'3VZZ?ZGI MI\*[82-1#W%SB3+ZWO:@[LU3DNM0_G:5).#$H[10H]$<-.N2H3@M>T?)4(42 M.YK1()%=*!E<#/RKAC>GOH]O//D/L[]HI6!SWPFQ)6\B3A?PZF(5Q-]?Y)EJ MT_7AIIQXSM27N"Z@K6ZC[?57>^D6YH],/ZZEFD]W^G'/J>B"N7E3!T^Y6R/S MV?R9G5#(3D)\_JGMK"B $J?R%GX)S7^W# ^Q9'CC=;M/:5W MJ%Y%Z,YUX&B_(=6W1QE_9V30_POV)[BB39:!M'[.S>!Y.__H)%<1FPI#*$/) MP?)QA?T9(1?7LR0JSR>FB%.!;7.;(A^2^L.[GU%M/"]U/_DUOE=^ V3&*;Q> M#C-]P_,"KSQ-UE5Z$>%)6>I2):.G:";1.DDE#1]'-2=

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

    F-_82,&2;-SC1%']_W0)BZQQ$C: MEH*--I> $!OR4O/@#-<_7]YQJKC@#@')\P%\2YU(/'8W%<1DQ)+62G0[P:V( MN]%,W M-I+15?VBHX]47K&.%@[,<,AD;VC' JI G'9Z%]AB MU"^K&6P!AOV>2F69_!(N+*]6VS_14E6[P4AQ MJ>H]P7@C5OL-N90P5\4=OTF<"4]R:4TF;A5T*UJI6X2FVR)X^UQJ-,7YINP^ MXTYU:W41)QT3F/Z&9J/LM]2=Y[SOD.-]D/_+U@V?D'^T?D9^^

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�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�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

      ^Q/^'7A?Y9&)KTV> M'LGTL%[U?_Q?AW;Y*F0N9?=T@,(E85_E+Q^NIO)5[ESP[ND@)8$5.>P>V5>Y M28GN>_+Y&OZDY,H:7_FHZ(6-X&TEF;30'B5"GNT$-P=)]8#*V&8U*",'(_M4 M20Z'6)& &)W!C4;8)/Q]]KZ*T&7GZ/$K#E&#SCUEH$M@O=@4S@<8D_W ! M< R+: >G4(S(7G;-W"'YH#Y>ZOKL%!)[=#2N M:J3'T-?]; U=N M2>_%%PR.(S9X_J6E^7XM"'1[0WI%;-<4+-KEWC;FE(7UBZ"Q6DACEL"@A[=% M,YV&L;2&[@U7W%R*W[7(+.U,V/I$NZO+1=_!O!NX*V'#.Z_Y/D^(,74%QHLZP<[ M ;^\9-^BE_%5OG7990H/"0D9/Z7CNJ_R!9E2^C9K<7&VQ>#E]F.*+6?'EM86CO-DR^]Z-T])WDEV@:U)]7'"7W\K!"'2$.]%R<@BW M5XAXBU5_6=KIUA+%D3M+IRCF@WS.@V,?[:("W&'T;[[2?R,TXF@'_ M1@="4W(FB7*DMTS,'.!(/RP?C?Q4T4J*?SX@R!GPEP;$0)>(%8TB<#&N18;-)./ VZ, D9 MD-!\RMWALEV/8&_-+7WNC4"AMXZ]"WV\G^8_"Y>EK6]AH*:7JE2%1.^SQ")U MJ8YVM?8I)0!XF>L\P"FDZ@?WU8)S7!J5L>3"FT=%544-/A[82+M;V/E:Y3.M 2L?A=E'^[?LJ:4VEC'7-"C7'#[=2*#T\7],"*D-/EF0XA72XEFD'V83YY3"@]X*$"-%F76Z/U\,5"ZU ) M>8H?TS"T$C'=ALS@I"4M[#K/0+O5!\O)]@CD1H@R8#EY <:S_%=LZ48'ZT-387=*!V@UT_MBC?J='P83KSVCFB?K8)[%IG\ M4"P'G1(X/R2%>)%6TH2UO';F+_=?9*4_5BP&]U=7--EO.,%>HS"EI5;7YN4; M %-5(7E\/)V5UV5K$6XF,$D,T0;_?A=..XYC\5TF20;OLG7:8J$.[M_C1$9\9Z$M"*,\=>@BE&,AT/NXS=\^GX%&4 M=P,*@#^V%R2/V-F!)NE[SEI;,[(N/M7M\X<\6:-8UY+,W0.?M?N(-+T7Q[8> M!WNWR& OC9%T""+AQ'/:K^@88G!)Q(=#6C_<:/7P#2,]]:6P?6-ZI1!A*OM" M#OG4B^+MA<1JFT_P]!Q'("J1ZU)2C?N=@1K(]CFH09KRVX_?OI5YYD29JQ#W MRZ&H6E2Q+W/!L03O!?3N#I0(+1_NY)+2$-6M*A5 #]#:4NFQC8+>%B@K\-A*>_O4Z )%(.54WX5!@*#WS#^2%= MI[U@IVLNO7()MR_S6IZ_,*S,5TU:%C>4-!IC_//1:KQ@U."6X"")";[;5\DJ M]T"S7)N;OJWLD6LKN6;27Q14^E]<4XC?.9;UA>(=2Q)DH;5])DNQ^Y=_UX%/ M5TQJZM##!>Z:G7W9KL_.F+3ZO]M4_L_#R M1>]&"O955D0)\]LU*7* )+.R2<')_&%?Y:MORR-S6?\&K%.RJZ1(:FD/J)BD MQ?S$M[S6'?_Z\Y%CMRNA':1^ZBF(22W_JE$[1=Q>LD$][#.?5>AY7LTQ.QJK MWKI"/7NKB 'LE.)JL_>JY+1A]7AK02[&=&2J?:5A8%\% %:,1!+ORA:*71]% M#@"&57]?5O"+G8/2I:__THWS^+SW(/+_D.,W4,CQRTHKBC1,)IX.&L0ZM"'U<'%HR[CXPN%%U14JB",>"NR!:^5.V)%KH M%X3^&:/0J1J[ -QZ=*[Z *RTM7 V1+"2I:H_B@P3'_B%X13?S>8GBP4 70BD ML0!@[0+L$Y[1/JPD-JD*!,6U=H#9LC;L/:N 9Y4G-9$7[$K;,_Z.R/J\>-<3 MU_[(Q%MN?HEK[,ZW0ON>;W+I;GS_$C4>1$-%MM'B/=!A,+@]_<"^SPST:4'&I-M2 H3 MFE5>?77F3="I*''^%EE\;4(CT-%Z\;6VMRX@X?B;AMO,Y,9)J;M"8^/7!(+, MJ",I/B2^TUEK&:N?L'O%Y*G_UJ;X4="7)*"?S5,E(9I)"^SY>\U:^FO?CN@M MATNK]UM,K5(F84<=NR&S)B[][/?0OSR^!4;B:-!?8P M2";+E"78& )_ O3E@'81;ISH>B:QK>2\X17A9 =Q3&1[ 7;\3B%&,.PKS GW M09=T>.*(FK+R@1C@\6VUPU1M]9#M5(?S$Y[WH)2NF-FILG$'V>F M&U$^=@:IUFZO4Z.9[DB["K#* MNCTE<'% '/E0I-0G/:KT@LY-AV7FY\\TRF4:L6@0@U33T/(IMM]_ME^.N73ZE;KX)YGVNR [.K.LB@4'0P$ MEI%T+L'CBQL[P%IS9"Y>MP]L'[S&1>J[ !_ +H,RL'AS#KF4I)HI_CR7BKT% M]Q-?]L0U *%2S4@]+\^:W@8=U=_"3Q_,9&_!\[];!,^33W-=6HJ\#+QN[K8. MF=%L)])9_]@Y<&W[NA!S3:S?L3AVCGT:M-N>IG.!L.MP\H22:8-0%BA4/: MI3A9O!,[661S9-/1 WM5WY/\#T*X=O5SU[.]OK;M)^VAZ %8YNWTG@X7^\4C M!"TC>Y=&.>FC_DE0<9[@;'T[6.3..=(==+*T$Y6DA\UHQY[";P:G82]2PARC MWT66>M:]7VQ"5 *!)A<)-;LK0&C)^,*3_;CCC' MIVVIG:Y1^_[U5OC S,F1D=JOQ\II.Y'-HIS.U#,Z:T=Q \GC9^:O MJ[>G[*N _%(669E9Z.>"SLI=#/J0MVWML?YR*-'=J@\2=[$A8. ]5P!>K&C& MM$-8P3;-L#]3P+G4S4QQX];&(SW\]5RB:WEQ7J3<;+5Z4-I?3W7(5!VSG&' MQUL]+>V7&1Z/M2JBG_HK-@S>XLH_3D.*-%84*RBSPL^M>NQ[!I>OJQFJOGX: M U_06N.>_WB(N90A'+/$ MPAK3;_K=HC,PJ5;,,N%3_LZ0DG-&X[@I_$:J>^:^2H^?;]V[] ]N,?">:4UY MFUTBZ]B5?96\QP:O$7&E0H4!;SO]ZRW.#RI<3?'%%\\Q[K5VP%>!KDJ@J=AS$MY9 M ZG]#:DQ0G#-AKYXZE.O/.=TGWNVVZ/@DSV0=8B[TX2>SMWXJ*_[- M"4113$4$=WFAH^,4!L(LKH*C=3!HVV53]IKA1GR]6*G K)B4KD',-_=5\&M> MFVQ9@X<)S_79ICYD'J/?E% ?US!Q,'3]>T1])WM=QR1U'"S+#5+ M94P5YLC M3:\[-VGT:J/JZ$QR"KPQ2T^D'QGP(^8Y%O%4+X7D_T@H=)9DK'D M0?+EYK>M@12<%=@;>\^'VI/X*C*,Z11?C*M^-FVG,O9X/'$%W0&I( MG^KZ/&;HS,%L,]LZBY% /?Y93+] M+$\,H5%"\T4V'^^;9U1L>", 292QEAG??94F*\HI#-U&^_Z\K4)Z4"QMT1SP M(@]3+;0V$5]+?XA;Y>8'7!%M#1I4S@YV'R9$W3P\>N5E5,#J^_)"DOX-OP2M MT,&@=&CN2O2^2HQB0RLZ> V";B/T)XS57&)-9(H[QSE5(IT;4J-DG[H;-/,\ ML^='N2TS8'[/'N[#;:NVZ3JW?#K+;N#:Z1J3GW9BF"](HUN/X5')X$P\( :& M[@"?M(*(4ML#B^QV$F5Y"O?ST%9;G"U.PGB\\-Y\%T<%T&)0%MP#"T+2\U]\ MCA:[4!,TWY 'R^$%(W&-N2ZZ9:!I\Y3=L2UYL<@3E\.CT^M4!XB,TTG1&A]) M"UB+)+!>0J'Z\UKL\\&-+H3F1L-Y&WY+VL:!8/3:8Y/EQTH(8-4[ 7U9W3YZ MI05E+^:VN![Z_MS 8,B !,S[IM:N'#1+GPB"35).96*LW_M/D0PR.&V11*<] M\4>K9O290_'O9M*8I<U<,%D=58QPG;'YJ%J+&[P,_9/EOB3AY'8Z MJ5)"9I;@2U#.FSN"0VI6BRV9=VWY@;0TB3QK7P77G+)6PM35, "=LIAE?. 0 MD G,IKLN(W29H?0H$+3T4[/ 8GJ MRK@3(H:4GQ%W3E+[MLBG)/LJ:5W)(S5KFD89KP*;+[$Z9_Q6%:$^;29,+@V PO=_9-1KTS\*(O+#LOIQ6",A@YT76 MHOJ4?\R@I:GB*H=4@6#K882-G7S-R!%2>Q,,@,,CI:9EP$^C0G=:$)^II:HZ\G!?Q>S96GM-S(@)']!] M:OYTK_[G7H/!'XI T2.@J"^@F6:$W[X>%GHY 4TS7LE:F>&699[/F'%ODHM;%^'?UNT[I M[\:;:^4?0S/:]<:=PWJ/\]Y][3!#J/.Z<](N__]M ML_5??EJ(3ZK_^_6HRK/FEW(8!>]BPQ^0EOAQ^4)XYIR!%9M6:,5O/ Y+6$+5?<%]CC6P M"[\B*J%?S D#L$PN%H?[@K_1WN50(J7C-KH# >UPR!D0KSO#>=GRV/R8YQ%= M/N61L?N2U(OHOYS+0Z)VI^JX;TMM/5P^[B%O8.CE\?LJBR?NR+ +WEN+6KH/ MA34PIWF69,EE"/:!E<:H2ZZUZ,&$]KW&9NG()[H54AVG=3 M>\^ 69UQ:[[!$#O_"&_!=S-A)L>G+/)9"ZXJE$SSUQ/RXB>6H ]N"" MJ?3W3C;PARM=TDQQQ_$VB3+2I.QR#-R5-S9"LVWQ*[\G9/3:B(9ERG6%4&D[[R\R.+0;%'N)^9,2>0/ M57MB7KE[I(Q!>UX9*G0QYXA5]9",R,"L1K)I6??@ZX?M?:Y#DL_]HPV'-KFQ0C"S/U'>/B"(9>FR'0V-1 MFS/Q;97J/2.5= T%=&_TG]W #Q<^Y*9?.DOW;0ARZ190_(T[Z3RO0(4L.D(M MSC8L?K8I8_3[\Y^1/(3FW% Z)(@88.#N9U5 #,[_^!(-)NM5=GEFL%,SL"2Y M FZR9O#"/(Z*HZCF>5]UWT)H"@S#%0(OG#*##5WQ$N4^M=K!"9+\LN +:].% MY*_W51(YB[.8XG[]Y[O7&I[ZXI^>,G(L23^?Y&2Y-DN-DND#^09P7W*;H!$F MT7@4%/..AU#& 5S[@FOQ^GHKXW'F;(.LB+Z:Y?*N? W2Y %48D#YFS"7CA/3 M]57N*[Z;2)+0]-'%3;1%.8*0S>O--3SGU"9M? ]!*0FZY:($4@ZMVE3+.C]M M'K/2-OZFHD(=V28'O/?_8+6%Z,7>7'F9>K+D+(W^9+=UZ;I6J1#Z/CVNA/%Q MP%HKX*C593=BU=XH1U>.[=A$*IG2?WJ8<.IN)%@;IN?H)YC?]'\:;-["_8'R M(08J$ :5+T7_B,K\*%H'6'\Q*+"S/(;JY#+59]0<>QE_@F S#'IDC^<%\H M^Z=2>\W,F>26*\.6KK#\AAOT 3_(0U86J?*RZ+7@7F[NWB^LR&E_:BW)G/NO M+7P[S\=+C9<\^5D[\!/I1]E1?THG[F).9E1PM_G;R\MHN@/,AJOR\,*^=IV%@ MLCI:5^D.TJC$G+)]G$@L.3&,5OL=_3,IR1V*$CQJ&+42XZ:..6M9D^RM_3^L<0'W4\ M<2'43\\;R:DS@/BMK6##\=6FW21V,(N]L0RJZU65=K+K+CZH=^\BV\T(R0FQ MR23Y 57;U7WELR7HM[$INUBE&C+:*?Z@?>K5):![V;E8<4X_:W)G)J?Z01#Y =/I 9V; MWH#HLP"_@KFUN&SP;@3689\YFYHK=L#^5>15O%6?EQMV\2VPUR>W?-=';)DQ MMD>!/@^L61R;-.B>/9SM@BYS^^WR:2\GK\+3O6"#Z#)2US=XOQ*;S).CG>W' MHG>UHX='HX?'V(%5F[UJI%M9*Y;EOW/2020OH=&E6&)-*]P5,,5Y'Q!@2+GG M4Y_^G9OI4%>YSXDC1DEK$1U*HC8!CQZS,9QEN#G)L2'G:FUBX-J4(4O3>8OE MF03P6$YF>,#U6$J^0^7O\ Q@6S;&]E:E>F@WLU7S7-QLS3)^>3QK;&6G"KMI M]]FNDLVYE8P^9B9=]5I!N1&R314#7?7I2&Q53+F / HE4S2G,.0+'VLG';); MKQQ4A9^5S!A!3(>\?WZRP$="'U/V'F-T#&%QB?./C/W_;KJO<@9ZN\Q^!7 R M@T2UX!F6>-E].S9OA(XVVQ/6K"C"PVUYXIK Y;@NB'K8V-MXQP7%%,T #N[; MH^Z1?)A[*XCEXZE"H!- CDZC?( _VA.+1N*N;Y/&S&(:79Z%?N@6?E,7A2NM M:$E*OC-P;F*IUR)]K]P>OARS\6AIB_P*J_WYPG$S"8*R-A+3X@9I&Q.ZZT,1!,^?1NDR,622 M%J2%=)0"LFCZKB6Z/X/XA8@L\5#G(_ATVY#_3@-/G>G@0%S5?*MNOXA!TQF4 MVTL0[\[&+ ER0W;&B]U:I7IX7V5MW(U[])%DG+;7]6?+]KBY&)=OX)/$KR1 M B"=8TKXKH%B]O'MZC\R+B'<4XG,W_&J4S).'6!?10DJGX_52EEY750$,ETX2D4 *4 *?"4+RH53[WQ3E)0%)BN_&+!4XO"ME.;T5WTK*O MX*U'?R&^2SF1.FH 7[:$JUK=,4_:6\G)#LN/"* MX4S:5XF4(5*6X9_M'J# \?R$FLGX"UT#M,@!9%#0P(.(P ^6D[)=6,"[I-'& MA-5R>">V"G66!G-?[N#;)M+^VK;KJ<5TT^ ML66@7N;X6^THD7;AQ;O$Q.W%PM&% H:;Z\EA'3,;C27JI*3\JS/GRIP@--%Q M;[_%C=.)OMZ&I=,ZM4K>#PL'ZN>8&MG;4(6@C[_QG^=[C;W;@-F4V"P2C+WG M_8!$;SC9@UK=[6L]'\T+W*69\';;V< /K4JDW4'(?7Y+8,%J)3;# Y;,\D0E MQN%O=;B=,UZV,Y9BY>L-+V434!J)F;WJOES[H!C_F=V#SNR775!@HR=%HLFQ M=HY$1J+/0#-;(%J1J";F1N+9E/Q+W*"K(\ FC^++T;7ENV #X&8$^2PW7W!I M-"(IF1J"]7?+*[1H,+':I37@ 0F;AVCDY$%FS;%+T:_'7[Z<"3I#+Z:5$6RX M09$GIJB4/X#//^MX3INN)@*2&C)O'LQ9=W ?)(]GSAL&!W@>4WN];OH]J ]P MX@2Z);!K+Z>(LY2&):VDS0(Z3I0MB=8GXDSGV'7-A:_X;L1=@-,:!Q'J?1"7 M7C8B61-4=I./>#@RAJ"6LTDPEP<(2:";/FTR9.!Z#_B^QVWOW!&>.-AR![NV MRU8&EFF?\<$AF+VNF2*TXY F"#R3Y(I$=GD1Z>_7*'IWJ0]?SV6V#C5W@\YO MHDNJ4I-]FP/6H)$3#A.4J+M=33R#C$*SVN#-Z*=H$B67PIH@03XU.VTAWBOZ MBCTM7SR.%VR-9_1"56_(20WOFXWN^;QR^0;CTUL^7]_)3A+-D!K&B,"GT[9P M_,EHS=H4DMY&:#^EJZ[3K3K*ORO.SSU04#X^7CU=>;MT\/TX,Y*$ 5<<&G%++EWY5^SE7//KZ^5X/ MG[0J1X"7%=!^1DYX1JSN"8/(*K6$1[?K4^I!\R5*]B,MHNK=$A?\<(5\*'[L M=4ZFW6PBE.W7VS-[/?1?"7P )!U_?0V,:O,)F##(ZO*9([I=W!XX!0IEC&/2MC&0PX";0OWSHI>MRS/FO0T#'2>-H >&'ZI<^;83IW@W MF52=G#*GYP[Q](O9S"VC/Z25[FG/'Z3;&;0?LW*'AM-H,7XW.#N/ TK>FMH: M;*#R?_I@/!DZ,?[+'CML)IGUKZKL@G\>7*_]KB4@AO086Y9GQ3 MYJ09=";BGXMNDL75SW=N#1GCG6Y"OI/^#- ,ORGT B\_+,[I=9/JU0ZSP_N5 MD"/P84%VYF1:EVG) ^AXA<>_"@WL_&Z3J*6>5 \LZ@)SZ'G[4Y"F5$CJP!!T M$H$:WV.7C\S$U*Q<%Q/LF"O(C44WNY]-*H!E7A2/7.C;.FOO.K;UQ1E09BF_ M0L-=P"5X'AN,9]?I@Y9Y^H^QZ0?^5_&O3JZX'10GYCEK5YY]XNJXJ;7"3W>V M/U#L!2367Y%SYKA5[Q!J"4^&G<[,LW7_Q=:K_OW%WQR+MQ?JOZUD_%5B3GR/ M_G>2?.O_Z7(^*=?YK^;G)/G:_[WT%0$JYTI_U(U3K^&:NM=#?'\*/C@S;(Y$S;4?N4AW_-W5X* MY%T%2)X-?<0/9YA_MW=3&&%'WR!1:];@[P/>.)/I"8XK@;M3.2-RO4%GFZCK M]DB:X2)MHAMYNL\K<)&\"Q@RV%<)6R/\1\%C+XO)]RTYO616I(RX%L&YM_4. M>R+\$K\\E8],3+C19DGK\7]1SQF-;HD->N3'_OFSA4%ZG39E0>'64?)2*]$( MAFWT7POJ@Z$:;O0:[M(2[69^6C<=QEC4>J/:1F?W56);- 6%]?)0]+%TS:%I M^QM@61ARC>>&.L,5-L@190%KX#%T2:YNXX Z_TD_< MJG^MW\N.F^RJ=V5K&&@9=_GA'?3/53'JXXSAE]/". NS]>FB*U=8[1"@5+WA MIKMC'3 X[OYO&0_2%.M5QZ)YL$P\,K0;=L[+G8?[PSEN/4UL>'QW7KTSC M 4GOEWHMAW"=M6JV>"7%4"=K9PP$JST+UUWTMTPQ@"T/P>B=_F3XH QD#A] M-\L3UYY_#*P5.1!L>-6JR0'\2CA,41U.G&!-4KKDW#7(H5JQZ__BZUV@V4S7 MOW_[-WMF=CL]3*NJU99IU;FJ#JDZ[QY0%"4B!,E4'2H1IHX-B>SIM)06=8@S MJ3.))%1#'3-36I4(1>*4BJ$2A% )(N+PC]G_]_?NW[O>]:Z59X4K:SWK6<]S MW]?U_3SW=5]7VPK8+?P1F19'NSV]';[L4@=>>:Z()/< MT%PDPK>KL_$XT_U+--KJ04D ,;[G^@\KD+B;G35=D<<]GY@:8N,Z8ZK;U#]W MQ:\:1NOK>!./\]_?([,W.@)AXT0VD/!PYFL/GFNS7Q06-:$0PLE\;P M-MUOZ-[@TK *FH__ +<6]--DN.J(-N5E3_TOU#B36?2NIO5"LERB!7V^R1O! M]0O9CCR5#L)Q:\73J]^^]B 7$MHM"._"8L@M:,T3J5.'NG;S4J&_UFH5GW#R M!2>5CGUDCZ$'7K?'#=KOQ '0NQQIQ;KG[?>:3N,A*4P9YW.FSM;&P0,4//Q%V MO,/I^M>)CE9P\0.=W9>%B#&3N2J(C[28UF?(=CXI<7 F4W<^]2;! MRQ7Q#0/2A0!V]C0NC[K5AA!RE0 ESS?2"Y%1F."7J_! M.A:S^!$D(P:ZSQX M^K0U9*7TZX ,$'/N^]Y=E;DM98&DP1(*3%0SQ_'.8W[NIB]GM6%+M$#E7>N&(:.BW#C3VXLD.?K9M:!ON\ MHGVFO)WFPL)7SGUN_V3^)(E7A0(88>CGG9?6=_[F8E*M^*Z6V><1'XY;S!PQ MF>*V@>%["NJ>5MLV"9W&S^JO%!]0351QYR=W=31](( WY.,JC(MT0%C/S4%V MT1^&MMH'8J#;KI:C=1M@I=J;T(P99]S<%N4CFW2P:-7&DEF;MQ+< :\8X>BN MC<(BB/M[+$]'R*K?.^:7K#01I1Q=G]K9_7 4Y4$.0W^H M<@:XQTJ)928#6L=@$_;9;[+0['BAQ86ZCW"__>++]><.BBN< 5^L/*(F/<_; M5K>;Q%O_LY;Y3#>4X^;LSA2![ M:+Z#6+Y@&,V_UB@9I_&K:9U*Z37;EMD>F M!]>5>;<7DG$W)46;:'9C/UWV0!:/4.+GDR^@Y5]_ZN\%Y-6B6Y-5*^U?S5=^ M/88"7+HRN U"'G^=T6&.'M)K!YR<*B#WRJ._F4M*R9\RTW&?DZ-R?;DL"UF( M?-VBH4@YG#QKGD3SHZ:C4'R0=<6;$Q9+/S7O^N_(*BIEJS[?V^/Q'8 M[]>\W[_-RW-%+,=!R6)*R\K/>PK9DTVN.:2==%Z5=S7#TU1(.2D?T/8]_5<=W M52J-T.SFV>VV&+9#'2?:-R!0]SO@Q$C@K T@*APIDO\!6'"W]'4^&M5]JWR3 MT%4U0=&(.V8=] 9UT:>I91SR(W,.;$/C$T=&+?1T;BV6>BR$\J7$FJ$J&:Z; MPS7H]?NND*@+Q@$/83[XI%H(K\XQIB#U4TN0Z>D191F;D"L3+B:-J2&?2]AJ _33^UIVUM'?8?)N;1T\)KFC5SP,,FB\ MO,5NYQPG.@HR#L4?=&[_EU]SZW ?A2HX]V9PH'7[WVW)W*DJA2$(C:F M9-ZHK7E2NGM^OA%PB2^"U#D?H??E;U"CQ9%%:G\;ZJH+?B*0/E-';&T[Y>]MYV5;H7(/GCUN2X?G<0_)K5-'WWLNG/]$G:M6.^- M&HJ8O"D7+Q=C?]]3V/BO^CV%H2CR&(9/B;,YL!GHFG9SOBRE_,I_;BH^W2E, MT,#^8:NV>SF*]M5@YP@-&6;];Y/-;!7SWQ@LN!AWRGD@W31!O/N-FP=--"S_ M INM80/041M5]CJ>-!Q:5(YNP;:*.@V!OO9_&*6>BU( M/DV4"_6*' CK;]AK8Y:^Y1MICAE\\['P/84VSZ%%3&3.<"B\-1>TI?K]611( MI_ 3$XSFC?ON4)E^#L2%>?][QEDYL <=5WOJ9,] (W4H%E-&T)7IOI.D1;K7 MAR^/G/BT%%[0ANCQ@/ !L5$,9IS5#4\1JLQ*2-+P];SG*[NYL$,*[<2/U4_ M)]XPNE4\BZ3?U+#EL=,OYRUX?TR^1;&U3K],&C22Y/4^&L*^R5QFWJAL<5MUU@)NB0LGS:08Z/-*ER^.5+ MH>L5];?B@>>&D;=D"$\D@% WD4 7Z_T\&_VAM&3EAI7BS==YM(AVA[O9UNKE M)1I/XAKF0/JR!S(7NE@7:*[#FC7)1*9*B#05#:*$'T@V_^*N5;K0G.R'3)W9IO(@8?74D876GL^4P8B"U0R8-V\S3;@, M1KH5!-:ML9I)X (1S:XK0E1BIZ5L\%IYN0V1R<+SXR;;"^-&+;!B "IO0?50 MAS2^QRR!Z)7[(RD<5ND/!?-:*FH_:%7?R!\0.(@]%:N9?M]NH7#/%L1@7EZ[ M:P=#<6CCFV-["HD4[YVMVD8^L2E$#'[J"5UI#TFL7BDKKR?H)W1D\PR+[E\&)BF[ MPP[T.I<*='*G.IZ/3U2([68:*:V!3GU$*YT MP6.LB?Z HX7,^&07[;+=;0.:E/]M;S[Y_CU5UTIL)/-^G' MC<%%Y0;/&),9+!^H)Y7*?+@Q"B B40V9G8QO\YRD+U N36<*VG/U?-O-"2,X MZE9'?.8'.^RQT=O#^2.-!HH8*)?<1DCM*@/W?ZD\73)I\(0>):U)PYNP_30I M_:L/^YW[HW%""VZMSZCV.")U-?Y7LX('5=ZI+M4/V3A M<,*OB:4?'U%U(T\.+J0WY3MG=B2$1TWK,9L(YOI>!<2V41S$;3.M!!95&2G2 MC]BJXYB..CV2RX>'6SVKHW_, 2 M5_+@>;9F'(4/]*Y5I^ I'@UK;K:1PPI5#JY5#I[_[-5Y([!L'3%,'M Y7.UF MBV!LEYX^+-;^S$)%A7)US[0WK;N!O:%@PB"\ZOOR<1K$''=/U6APK==>R?)[@YYC& MA@FAK+5\Q,(#<#+?(]D_7^/(VI11J[2EPMZ@]82Y_@F+[3<>FW=2LBZP=;+X MQ$8K]X).A%+#Z/'V;/K%\DW$G*! _.T)-R@Z]69?Z7C-KBZ"I:PX1@M(VE-X M+ORK5_3B?U>3_GIT0ZXE,O]MGI.;4S;VS7)N>[&95KA9N_9>-N!*M/SZ_UHY M/EEXFV4 ^16343<6"HI_/W78*VM%)5&\XS3R>O.&]=(7>D+(+B>L=L9*3B\] M!9-;%: --6'ST>(9*_S2Z(>M]<2/Q%G#B!WI#B +N*?PA/8+#RJ34!/>B?DR M]G,3"PV2_M5S2SA*&STP$8=%K-Q>7B,R!;BFM#KJP,)=*1Q'/8P"F04:1,F6 M3*^,-OFQX6>L]A2Z7)N2XL'7[]WK0+!_GZXT.S>4:H:VN_! )O='98@#H1QY M1%[BZ';LE&PBEC1P/5G39AKN5S9= @TLYYNHD=#S]6!P-(G#"&HJ>$VY'$L> MH13GP+1!9@^-7BRH1J/">O58.D?H"U0]0(8?L:B =X^E5-*S7UVO:W M:C/E08)PIHLS>^/M-5E/[\SNC]@,^,5"/E'5M5@TN&&%DSR*>\BSOEI7V6>M M#&QW[6R8S*%4/KMG&O+D T1G8^PLO!"/K=1=7>F >*IPUZ4^=8U:KN.C."=]"EM.6)Q;AMEK1BRONJ(IKZ*KVU?1S(LYH?G=OL(^9Z!!/2 M,NY0KQ)5/\20@Y .I;G(N%/W>]Z+<@ ^@&BI'JZ]*;RD]4F[.$?NGQ.VUEHZ MOLP^-.1?DR1): #;R"-;GUK\,CO K@6=CY]T#,\:FGSI"T)9J%0^M89W&.F? M_$4Z>@#L#EU@.CY!]1.O-^Z,".8O30?'/;_5-!Z&&QKG7)X0"U@2U\'7$V<; M-(?=6TGF]77GR;F.27PR&F!3=T?V0JL5.=XUY^1WKKB)7E[IXRFZ4 X6GO[. MYY2=OCQLDV,XRH:LM Y176;6F"EUB%>\XYUPG**#.G%H!? M+%!X?;@%E2.5L@J(M&C"DG9@"WR$Q;MJL.M)N(T'^+1\EEUEZ?P _M7.D"=) M;R4Q=51.]B_X'##:P:]X6FIS0F3C)]\&&CQ:U_D _;V/EH5A1ZN>:II2BG0] MLA +=IJ6X37KYOYPDM ZS$/TFPPF"2O-RZQF\TQA72]58Q**O,W(VZ)3=>RL M%XR[;NF\SD=&4, Q>FSQ[8(HZ:MI"O9,9UEUZ5>9N*='NDD_( 8T.[NT/V"@E/9P]Z1+*/_8'_OJ<+K.KULXR'LQ;(JP MFS+UB]FRXGA\SZ_N2>TAG_NHZ=B(-KA>,1)Q?$\!),Y%HD>BBX9(+FZ_D@Y& MO$@!B_48WJ:YUI#AY7/%!-S .P9'X2:C5?[>6Z]I7F%K C:X<7&X9K6X[X M?(*H^)0B$1=%:6&GPG4OM5#:Y&MEV2% MUU"*2QS]PRA!N&LB_.EGE,O^(;JG%D1NAX]+#I5?Z(Z2R++M[^Z_+4(U^I\+&14HZ*PAZU4 MZVI>B 1UO6 _047VM[=Q#ZK-@0BODM#'*=KDMWDO^];]=+NZG Y3SP[RS*2! M.FF)DU4RZCVA]\DW)FUJAG*EJQ8WFNQ.NY1>7OK;W*^,LJN"AG,^AEAKQ5.IF4N:U%H!%_I* M(J18P\&;5]]+X<@E!DCNS_,W!G+:\V_)CH1YQ5< K8)MIDBG@/WPJ (@>OT- MIBL'NGUG+=JQ^2"*[K.Q+R0E!LF&$X<]T,D@@:@)=_A)Y+?.5*">XX$P@W2#%L6DEB'?/*+W: M(GQMH%9\,$J.?Y->GI$6K,[ 6XT'I_HPGT-ZEAKJD^?^3I;JEHQ)HI],*;0FNK[P&0F.H 4#\'C4/T M_C93L*5A2W8!+0\E-Z*]BU?R6!*"#M%EQ8]U':BD2'D-C@\4L4^MS![H*4>/A ?@B!$ MB0EMXR.&V:F\)W-F\=E2A"I?K:#U.<.J<+& ]CD52CV@9OJ\R_%;#ZG28NOF MS3T%=1/0W+,EV>(GZZ/+_\;D^A7BE]-ZLR MII/Z'BVGE4R+/\-E?_/:4U@P!R,6H44Q-C_5KM[&G'"[_C?;$W?_U_%W8\S$ MMN.>PN/GVS3%_Y4P'F[ZF=*=OJDMV6;/_['N?SI?MR):URIZJ%;[ MY(.;C]@H@SV%B3I7"UYY/R4NT?RN4;9+SL0N1?X+HRO2L[1]/_4YZT!!Q%F< M=C'DSH"K6 \O5U^$2(&/35J'.:IA8/T^9&X.,KJ4L'9@<:.:*SZ6(-]0?=X;EW1 ((\F_T&PO.(H&W M3HG?WQW5'Y2E'&JQ)5HLJ?!'K.1G^7BB>QN( M8?#>%GGHC3SC8I@\;#]C/"G0S0F0UI+Q^FA4TU\\EE M$V()+(X&9(@O/WH^IJ*(7O22O*0^N,A68A!'*SU]^48O?HK8RH[7*VB/)C=[ M<:B++SH#[2A]QA.*O*M=GLF. 5QJWM=M=EP(X<4H0/JM8\13V*.-G0J4G32Z M]-Y1IK=U] ,O9S%8]:>IP]KB<]&/+T\(WM2 <"IO.0Y),=@ XAP MT&"^_Y>E]&\X,AX*X-GTE@#>XMQAYZ.P'26-_!;*W#:_FDK 6!WSYQ!0/""AG?5P?O%'Q*LK.;G0C20*?;"+T>CGL5WP:2=.T M:_^NST?D!K5($R!]!;Q,8L>.>X$8XO!R[C M^7<7Y..]S[Z-9)2^WW,B6?T+\4 3<3AC%RY(ZKX>:#/J22[ =]358$<]1W"[ M39V->N5J",4L1?6W@TLCMH[SV[BGB._M6SS&_=2*R-0=C0Q@Y5(9.NQ*LFI2 M7'U-&_QTT^CP".\WR5$C0\GM8D%;'UNOE:U3TCZQ+KV 4 D ^K+M6VLHFG6] M%#W>PVM?/J7^U](PFMHOH+43@;#MO]Y#@S_PO6KZOR?=R,]> *GQB(I6H +: M^>X>237U6$F@:K3M'8J1.R\C,-V"5X5B34U7@2]6_J2ZS#ZRI[ "7$B7".[K M_&M"6S0?((5KK/QKP A_1[2P9O?3?MHT^)9_Y,? $UL1&C$?DLP&=(ZAHO84 M-.LN D+T$21I'+.PZT)?2ZB*I-LY3;!<#X?TX?R&W@H^ M\0#)>)<)]KWIJB4IXG>B*I"L$:==SB#?J#B!RD9%C9!N/RL)M(D$*G><.)3; M7]Y?4U.>9Y;<.2QTD3,Y6*Q-JF5=N$5[$%=PNJ!F2)K8 7F4E>D&F"ZH4R?Y M5S(\:A^Q%X ]BO105'9/=-U:>U4'+YIQ>CG_I&8T(6U=T1=HNDSY01%6HCEM MJQJH&OA(E''/UKBO6HH;4+\KAV!WM^L/K9+^ W?_@X*5_V]F>!EZUW3&'/8E M#G,"5/+H_[4>W*OS/=?DM?O1=GB P6N[J83\Z%V2P-MZ=;_14D>(P1/KST>9 M%([#F=WCX9N'TP+L,2R^O0CO!XI8@OW6.Z98YLWXH\M6EVZD)\ WQX]<]GA+. * M>@[/\0F%#V-Z3[))'.:Q>U(Q 'IKM*13&3I8N>UL+0SI* MZ)4F%BJM.UQ@B>^JKA7#G.W:& YO6G!_AYO_.;!7G5[K C3F,D,6$) 09 =! M$$+3QR2>M,^"?=\7*;N*F4AQ'&MI'/<6WWS=^>4P<-+:]/2365W0$VP.L=<^ MWR\B8W8X7>=^7TV5HR4]8 "T<=C.D@L908_: +Q:XN@M<:N+W1, WG^]@QJ9 M,GQ:PY\%)K;H,]V[(MBBM^V6KHC#>8Y:Y3=G,(ON73,G)Z&/R-@S M'J7+>/!-4RL[-46485A-T"KP#G5.'J*=>3M;YVGR:-P>3E0MBHQLE-V_,Q53 MA$]HX2 &-@@]&[FYHF6R>?:19_RS?/87"D[$CC=K:II@[@Y-V5(95N]_H>=S MG!17SCTM8C:].=\20([@BOW9Z4)]7*]NM X( MKE9!5VO$;7]9.I807>5;1NBPG<,4U'"AX1!!M=HC$8&5WF@8K<]%!DLY*G4P MIMCS/HT)7;\FJ_[@CY"];VXEZ7]W,G-!I;Y3IA'=>29IDZ!;\"=FJ_IA:*'^ MT)LE?AWES>Z"7.Q/E;3[7M]*_&':_ <;FE_B,US7.YE*JY^:^SATQ%7[7<*J M<#BW/>[;0H)GXIY"04O\#\Q%"#9\C"I+^_Z<8ZIV$>Z^ 1SI_/"U/KO[$1$T M1A&#.,QP?SF3)C2;BYO!MI9%Y8R.C,'),_[DEW-"83V@ I>@#8P*/R++SJ(A3S7YN @/X M(0'8-N]=56S&R5;64S_WSAL5+4='ZEF8YO;[E>DR@!+O=654Q T"-8M05C:J M9!;?0W+/U5 OSH(#S]/BO;%CA%P1$M[30@N_VK$E)T\TQG'W0^V8-7'.E$O\ MA4!CMKYE6'S((+YJ:A^CSHU4Q)UH2&!Q7#,(2\97)WH:6\0%U.8ER%RV:_#A MYQ(G&'R#^"/35\AF:*V";K&]SZQXODG52)O-F*QD>SD1OBRM:\;(V-3@1P-^ M@[GG!"?.))Z^[!P566;#]^)?"< MSBU:@+*!:"1T&,U^M:< \"B8:'?$23]FY$?(%@_N#L2-VAOINQ4H!9)3E%"N MQ>\_S5E*O!I%"8)1M=JP26@#-H@B$I(COEP'(SF(L>IDZS-GP]?)KO-M;4X*YU,';8@3C97#1VDA^(WE/(P?.!BBN#O!$C\QDK;K*V:"'[5IF68P#.!'<(U_#> WD"%86*]OUP MTR:%Q-D1U,JU-O'&N'4 .2$\:N@)JB)L_NL^0\Y'TW#L60>9+&J45I2F>3H3=H5@@[!6A')#.F M0<' ?4_TQS;B)X#?L:P$-MF1_T>F:_[^[>!;&RCCZ)JN6.B+J$XT'M&R1GPK+HP8(I&K>X-\>YUY8(WSH2E V (0 M$)DL60QW+@S\922]/?Z4>:>4A2GG$=9/&'2$].-F6,D;#;7,_]K(D9WADR8% MB[Z5C53D@JS*OLXEQ8U_&G6PP[F*$RY[LU W/E/S9G)DV..C\ 7F2[3)GH+% MBD=O59T^.&JR$8"L*JGC$.DD=<$5$[,^>6SW0B8(;]Y[)&L:M33);VZ6JS8TO+BKKS(&T&I%3NNRQ\)D86Y*I*%.??2S[.2\Y/[*2Z+TS,4-9 M4CD9S8'^>FZ&QO (OW0R,(8\$7T1-59D$JS(6+XW)1\SL9#Z,5I,6ZHGI[=5 M1LW'!C5?75\[Y3C';ZF"HMI[Q<"K2%(QT%D44%?X=%=E"P(R2V>N7@MS.&;! MTI$LA R.EAH\634+[/-ZN@M?C#H%<<;K1]RM[L--;L;/>LACO?J2Z &C:#'T MO-=(:ZHB?$? $^X*0T.:;0#H3DW[I9;PY;291)X:7ZK[@-5LDZ;CNW/49N$% MXVB^%*%I,6 FOT_EG' I43?3X(!JB,H!)(^S#'_'RL).DG/$L]2XN4FHX]R+ M="?ETQ%G0A =)QBN02,A0./+UNLG1U_@8.YVB:\S M!7X3N/G-AMD?[*71]4D M[ :A.M_5OJSD@EU[!05@+ =GW@B(2+>-2!-K5TFS!1] +<\/:F<6^OKVW/(W M3T$ZV5^YG9)RL&X? 1JH&LERI&G'5S0; M>(NMK$,*"!;+%$7E9Q*7E(<\O;9MUJ3<33G.4T_@Q#@KL5NV7(F[@94OE;D: MZMHP7.T):Z!L2.RDLW>^2OX/VRP'B.QN^ML0#M3(\WWQ@"R:4"XL!V^J^ MYDM1,3Z1DWT8Z-(U6.["G,4-A7HJN2ABDF+2QQW M3Z$]*BZQH:-SYQZ,&TXPAH839!+/:^U"%\MJ_#H4=3A?< ZO[TRM36_1FQ:P M-QKY5@^&9W_%1XH\-7CA4 R]I\5Q+KOC2P]%[=& 2-!6Z2=:2#\<=6M5=]@8 MW1JAX?4H1.ZE0GJDZ=85F,&/V7L*E_/2@=C#L1$9:E&Z7@+="#1[T&GJ,G35 MR,JBOZ83CF7NT.>WWL:[W("9X^<\3+"_(V"U!3W'O>0<8PM@ "WIR>S9NLY: MNF_#;X,ECD^GD$?2<'X2L ;DNX2IHL+^:G4V!*?:WGMK"/!#0J!Q@F!_1S[8 M0(OI=UKKX_):LB]E$=^7,\ M BR4(#&UT4?EM7(7ZE".YC@^_7W!;AWP;"=ETW4\@'<5 MR7;O5%=^7O1S7%2RGZ ]>\HH;P6FID./L+CA&'ADS=[;\2?K%)WL[Z]L:5>'HUSB[6R?LA7B@^#\^^(=99QL.61H>R? ^E'UMVX5;&$3' RM,*E MY@6J$Q[^==BR%1TMIEJ)6R^:;.7V5DMMEECV!PR>D?T[C!SKO\J)?Z[6[A;N M2P66YHG>+[','NC]*=L."%MV!PK,7!SB*SS<-$[<:F 5AFB3R@*%%ZS _&KY M,PW/=^+R=6]U!BHIY[M.^<1[!IX2'PH[_,^C8$\AXE_':I5)%Z/L[75L)D]K;?54^6)[VG'W M4VIK3)=W(1H&44.&_")79CHG/';[(O:KBA2XQ%E+*_@RE) M?>6RY?M;C4^ME@X,"#S#J'38L@."M1QZ,I!L#!T*PT@')_L@@SC#?@/VG1C(FWB<*5_KR>)\:65_H, M^Q&Y=%T1B&?56@U"'F7 \QW9(?;< M,[-$"M/;]"OA*IMDM9\N"\7648S<95H7R[_1F9[R(".)B-Z:DE$,N-DR93,, M^V1.=:0J<:+)NFN7:79I _MM[#VX:E1]IO&]IC%V _+(>A4F:Z>@^: 1>.)/ MP5G0%3Z&EY3OE9MS1H]2N#R"Y#5MR7POI6?WW&M)TT6$%Q"ET9]\O9L$??&0 M]8X*U^?$)]D':[+O9"_HZE6/^S5(RGZA6U8Z9/'JB-DD[Y+&,&C[G3LMAU[T M-H-B\S/K[JS[<3M=VBOO6A_#/XB+\VV6$-HP6\F%R(>Y*GS"_K_=QEBJUTLF M.&.DY6+L($7GS%UNZ*YNH1 K]#Q:[*E?)46D5+A"TJ[,ZU=-04:P"2V%(9UP M;F,ACZ+Z!C.\\)4MY2F^M. M%#+@Z-$]!0,NN6;8C =57[F\WXR,Y-'>7B=I#U\!^YE_/S"SFB#1EN76]>+Y MM14MDW?;L9<%:^6J0+ZN$U?CJ<01]_E1O.0A^"AR^[!?R6,A52_]V-<2/DPM M/F\!31\9#AKWFB\)HK.;[)QQ7QS=;)S_8$R:^P2+BP$WKU;NLC%G(^T9]%C'B@ D%^XS M0:S@+!Y;L9D@CD2BJ=,SJXIU")6GSDAEI/\-?&O<&!N&\6>:9H7)$&G'YR2N M6LJNDW/7L,=,MX"DR&5\!XD$:IZT"C1/D$3'>VA\3$#DV9<$QN6H2-!V,UJE2QO"7_ZJA9K2_5)UXHC\O?B;[P96RF MBA'?_.&CMR)9I=Y[+O5IE"#5!RR/ "V<[&#X%D1UR76@X?5&IL19WQ1!13CX M\GY[HR\A1FM*$^#OWJ#2^BZVJ*^HQ(5_9+>NR B\>S21_)R#WGW->M! UU^V M+)5N]VMB9HSW%)0",;CV@0X_GS$]DL*;+J ,ZYQIR3=OEDAP2,. \U0"O&/;4LG)06FX#83L\^6/KAZ*D:;!G ME286G&6VWD>V\O+(,+;1NWE!-++&4\_LT!85;7/\8+RZD/-@TD(6+X[^"#%2 M:J:F]KSR&UW$/TKJHTF*\6$@,G6(\+FKLV-"Z6A^][15'$UWF#;2L!@ MBE=H,,>7U=NX FZ[83]W^JE-X.4;'2<$R+B&Y!E'R_+:U6&=->D-(PU7&A#T M2- =/:!=_/#EP.6\=?^RS&?#/'.S%)&;AK5C8LUL]F^,ZD'7NF?)L&"F9RDV M7U?OZ1A-WVA\%Y[^VM=F?&[EG"11+O])B7.;B/XHIUR'&"+XU4*#=% =S. ? MDZ2S1/!!XG\M?5I)(8VI7X3%/+L';SMH;CW)%F\/6=.++U0R"SY73Y(1H*_< M#3D>?].[,\KPEEQE-D>"_0[!=$JT#%[\B3I9.CV76!]^:;M@'>FM/"8N/%/?$11 M^HT=NF7KHN5F)KLMI G@+M9I: LC.^Y*VN-.H2(\S&7*7&K5QH"$^(-M#+;# MK_NJ8%#CD=) QQ^[&]8+J<@?EDF%9E?U6/4+6$#(3;F*8_9A (=.I#B8YE&! MNSZ>Q2,%(RP?;RE3 M]5]QK,-=4I??6NG^CW1.>U/AM?%N(C?\B+U5GA4!#< MR'K@@!JQI\!.CREW/"@9CQ@/FLC7H$D0B="55O J/+[*W,<($-)J.BY@744T M1P?WB2K:8M'9=O@KCB]*-Y+&.6@.@;,D%="*ZDF0U)-\M0YOV>W?6TVD_3!0 MO7&>M,1>4'P@>-[ZEAGNS!WP6]/KEO8Q?NC_90M'*_85OG\>1MY FAM MWI("L RP%J6'+[YOU!)Y5I&SS>I.I(8OC6O$521#60@Q7@E\N-=PHU<,#BQ# MI^#HG!V!P,2>V^O[-D]6_2G0D)?/]MF9^-3H3'*[:-/J3"U%AK)%>?EJA.F. M92C0<8@CJ*0V,SRWBW$S(.NR%QW#CJ<[(9KY5T>PQ0UPK9;P%3=% D#] MQW;I8A$;[#\B9G8VK&M,^=Q:1?04]0Y/<]GS*O)3D\'V^WG=_UB M])\/1+<#NRUV(<3#!M1I]4R7=A?"FG .RHN/(E<$;^&FR^^X ([P-RM9=M;ZI MG"/[S+^E(R.]F;_W $+JI>KZ/$"O=(!U(E4#0N*[UC9CJ0\PN=PZ+R]L(P06 M($?7=@+.*F/M;:AIVXI2Z!)[D?KU7&OU,_T]A4ERQ*D80+3J@0S:]$_->PHQ M;]Z-;E /]CVPNP967Y_[:?Q4D]\)C\UW W5W8_/M\^^4)NS M YQL]]..'\^8!AHS:D.RE2[HZ. QHQ7,W+ODX+=7T_]\N-!=!0]3B/\Z+,# M(6L#1D_B%BM7,_H0/AIPCA;#VS.:BA3I8[@^=V9JS\NN#I_36=Y3 #@FMW8^ M]C!+@\&#VP'*F>L-3B8*1='!=U_SL:YU02W M>D#]()EEF>VZ++/#^^6_$JLR\Z&6*;P+944+8B!:=2X3(R6+>!3A/;M_G>-13OE77X/U1'#YS<\:8.D#<1/0 M="E90,N'F0%G>!:86M)A'L2)WN6MRS)PTS6T6/!'N3P^@R/61N],S$WGPS^; MZOFZUVH[9:^%^*-FD>K+Q%^J&5XON?HA79%>K%J=DDFS6VTB%E##\'+S\*0$ MK-89'6EGAQD*E\\E<@\C%!#SY!<+'NLOR[5!)!"2F7L+",C<*F+UL", M/SB3V.K1G]WM*)S-F+F=?)QTX>Y+]ELD/@+\L@XBX ,M28%1L5>6Z@HK MIF!F:0S4D93HOEC'\'SWS]LXJ..FK[.U@^H3^-']X:UB21>;N:3YAQL5SX&P M*RFN6("7(U*DD7L4090@Y5H:FHNZ;16^43'1;^^//$I"9F0>L-Z0NNINV\58IQDN#2*#.E;Q4;7 MXO6C6']$=O=,%+'Y!10OB;DG?:G*MH[#;$/,KN;[NK1&']$4#3#J:DO'_9#; M%KO"2,G+I2E8(3_OU.\2;0]#^&G=KBXW<_"]='D$]GS\YF%?$]#R<<, M_6.?TEOQO%'?7X;R(K_/O9-9*9H702F"H63HT$6H')WW<_KK>*[9":R *'/@ MKE MKB60?G?@O0>F:G:-,<#4]1/NO,N,R85-JB0]8 M^=W/)X C)_5:LX(F:EC)Q[L6+7F?L)P?\7,[P,!>BO3!"[W=CAE]7-_&=C@O]QG%EVNXFA*SP->5!M MX%BS%+CQP11.PNQ6L ?^)#2GRPKH=E]W=:1X6V>>[!>8@G\*SPUGPLX48'_\/N;8^HGG,UO8IVN0> M9R\>: *=R?,>Y55S;DQQ*9$&W;N2/+U;B_?:I7 ]N1?O39SKE;&#A;KK6^N' MYC)SS\]XE/8_\'%N@$5[T%H@M9&/ZD>0S#V%8IA!?E#1JOE7EMEWOE+VC2E.I59<. 1E6NG+WIKE+_DG23QJO-D)!< MKTC]'9O@:WL*2Q/1;SAZUS4]R<]&9P%I*L9&G7(BM044:D35'F11*E$,T>C0 MGP^# !'BE'R5LB@IHK)]. ;[[?W/XZ_!"Z?,=Q=6O1._L[LXPME32&Q8#N7( M-2,Y<0 #;M\O5M !"T,C?0_-HG;Z+N'PD9VMG)VK+0S&U5V5Q32C*\GBS:)# MK_PG8^H*UROW."Q)?>1N^#)MO[]D1\7"RE20DKG%'DPX7(7;;31@_'=[5+[?K.JU#?SY1^ M=F$D%K0<;A/M)?9#LP=5OO\V]..G AZAS1DTA%Q#X09/E9@TH$6:F; "TIT] MA?GUZPGK#B93ER=:;KT#868F:9.0)1-LYD6R=<_<&'5RP:%I$M';C=8:Y26L MI7),/[.)-/_*0"]D$,F[=*H1^>BUC5-7?,/W!95-^83.=3LIH?LRF:9_[.J+ MCIGN80#8H3!:T88!S?=[HA.Q#MXV5W],-_: ;\NFK%NXA1>AF6H2P]+GH M]0%!(TIWT4R;JEZ)!6&U>*0?F&0J>!,Q]B+] M7R37@D#EQ*JDV?TMB5/(J,A3=,LGC3:?29/?[2GX;[,'=M:J.5"4D9 [CIBJ>'L0F]$.Z1Z)401%&M5%RL'_M2WT23)JR#6@HQ M 1QHN(Q:'EH2L4S6 5K-SV#>./8+04%1(&(D1M!+B]E56:IXM-YY_NMG L!/ M%LSPNIVY(XADBMB.6I8(4<& <9@44?9U_4L8QQ?SA!N))'?9)_6.L=^G5*^H M1T VT&O@22,W%.",*FO+DTS"^[KI9@EWUU2M]J&&D5 M-$8]M)_?$J^ZI*,4%C0.LA8/1HJI/U9^CS= 8XP9Q 07>@ NXVRE!(O?44>JNT'1LO[[_ER0@DNA2=;]?)B2?Y3 ME7%R/]B3#,UM3#>D(_Z11O&UVHX/(&^LFC9-\-93 PL=[6]..>>55N91$65WLZ*FHA:N MHWO_]-\K;#5N AWN#FH7B5YNH:,^+JR_2'WE9!1>DV$-MQ2R_-J4FN<7^ M(NWV(O@$H,WMRN07+FGO%N.&5S3]VO3P]33N&YEL9=+3[544Z'U/=FWM19A5 M9.[E&A9,<$?HO1LS)R5.E*K>G#%D?S&V 2$7?7$SZ/41@4L; D>3K:]=BQ1_ M_EB7[BK6KSH\USJV?9!BU*#^+RAX2 1XI,) M*@>)!Z"RL2V9;4>/<'4_RA7?)6?C%2-"=86/]WO(+]*[5'_O/OF-07*R A^] M?I'.^J6H,;FZUN?2X#85Z#SL?69YA%L8.JP;1N(@OZV2484_B[:HJ9BDCCZ/ M>M@D9J* =WJ&Q+$Z5NJ(Z<_N5=RF#B;W"GJ6\-<=W;)11[X55DZZ.GDCHN5Q M,]XU'ID!9H+_H*L=BZCN72F2?9;:Z'E:,;>A2-6++0^\-T9/283\'8'VD#7X MS(MLS6ACJ)ZBL9,,2 4"89/DQ)-?O]B]:7,Z7V+7QM!K_BR MEA_[9"%/BTLZ3)<'G[<)WW"K7:[]]MVLS;>S&3F[IW XSCYK3O]AY_FG MT& _ZKB3HOH?S"N&R7SS;GUQT\26,-,U,L2KP,M%5-M2/B"*V]2(V9&8[GD,A HJ2:-"^,]2#[!=?HZ MVPP/TO.C^<0O#[''9(DPQD?D30D\0#KR+$98ZV8-$9NE5U>Z3AH'3;;F;Q_U MY#N2%R#=[VJ!FW"#SO7HZ1VV>^))<>Q@W\.(0A7DZ[*1+B:/=)_CW "'->F- MN$OZMU07[FGN"(V"X>>=V4C]9I9=_KRC79PZZ(TLV_D(/&"?4D( 1Q M F]QR?1BJA_@Y!NN6D[C6IZ$&G7T* /JJ5EMMGX*KCJ=F2P&V_\I%YDICZ=V M)GINQS8S_-1^T\\'+&(E"(I^>B=*2K7VU;.!=![94^C5^XK]JT62^VB .?C< MU_A=A_ G-DO'$'L*93EM2@LP@OVT37*#V@<\<;M7NRPEZ'\DY$9B)O[BPA=R M+LS=E2-FZ:BP&Q_YE=*-W]0>WP.[WU'6W.J36C8[^*R'79*)A&_M5A6+: MZX[YYB#"W=XU\S5 IBX_\P&YF/E5#J#77QI,54NSZ=J7,.9EWP_['WGE%-I>^[<-2QZZ#2K.1G0>D( M"*@(L0$**$* 2 0R(@@$@1$$I"4Z%@0$!J0(*!$00@NA(S6C-&D&A(#4#%UJ M()0D)-DY>P><==:[UOOA_; ).WG:W:[[NI^=[&U$;# *JSI.0CQ< MO/$TR3S6NJ3 !/E;%T#*/]3@[A MX7A4B)/ZF;'TC$B+0JQA5.?E :\5AS@3>5ZA3W3T5;\Z$X6 D;2S2/%T[VSL MH0W6DV;Q<06>6Z*E6IM>%[\R?UJ6O>*K[<']&?]PDHB,'3@5.9DM+8#%6EY9 MDI-^H+_#.\!+;U%SR>M R]*7$TTH4EIZS*[%]#MVKN\[&A(S?#I\:$\=W1,# M2\9?<.2/C\H;-V>B9&V>G=6/L[$:\TN]&&31KX,./KN8;LH*ER@IE[*E%:J3 M7.Y1I._>TL;V7EN0QCV.;0^7';3(=)3.[WQ6(6^9ON2U+VMZ[OY+XVWO0T6D M92>V=<">2 #+]1?M_N9L07 M(H>V4Z/XA8=$%6W&XG!I=H^[MJ<>\=C+TM"I6RVAUIL2,@(:AVXGC)&VN,;) MS[A7/'CGT1$T*>$;VX1*HI#/%'3ND[]XR->:MN*Z^?1(T)!%*N,0ZVU5W#A* M5N0%.GR&O)PU /18$97SSFY-0U-+/7WK$VX)8-B,:R0!K,A&ZL3I,=;UG@*%S8>S)N:JJY+P M%(OIR>](_F!4R*X)[B33R5R1,F?QFW3 [.:-^VH6Y% C:NT&28O]T<5@W#CW M U/OXAD?QY+R[7/1%YLL/;OQ$Y9HC0\AX>8.&3F6X^W#Y+/ML;WVIM%5FF* M/AZ)F*S+L#'PU=Z#1 17L)M^S^_1-APW5P8+W\HM0SY7E3@TZX%DZ+GO]@HW M+OM50D]BM7P."!NH(/UVA,=JG[V]-G<9UDV>3$+7CE,]DS=ZI%[O#4)RU*5-1S)AOGCZD8 MM:$>+P5YP%,,95+E#M9'ZT3U5LT8_OQ$'B38&F1S8Q'+:M?(?'*+A6+V SZE M^E;]7JI$S+6M4NH^=SM;6-A7O*+O-B=SB_MF)'H6>JF1E6?WAGF,>OB+Y,8\ M(F@AN[$'E"LH!JT/4V>*@@__]#*\VG\5Y9H$ORG [L_>: M\_!8 :P$^,:[)H"M([]:]'L;O03GB6T;!^2@+]2&IX$*;A[.6&AZS5]X-LEL MU0K5-.U6'LAYK.0_N<#=FM"2D_G)K10C:4-0"._-_<#PB!KHSL-&T7W?L,RH MJB^X>=I*KHX+(G0FS9O"51?1G.LT7RGR95^5TO61H!1K%CGU3&(4W9<;%BQF MJNARE02RT3B1$3.6\"43,&QOFZSQ'!E2<7\3;O!63752HM>2=*_I5@FA'#T^ MZXKQ% M8:*S;53Z3N8"]$F(A9 MEU\XO1+9-VV4)B>7-Q,.8BH\PU8^6"<[ZXQ]*N]]J^D "O@EP?IKSD/3QB$?/I# [)+.ONFC/HE:ABNZ ME^4DC*/BD/N.CN5UWS-6H 3>7?E4D3-UL]W++4?3M/@;%;G#^ RG2FMKP]%- MV"QI='PF@IX3!(??=!$SL8H\\RG.^'TOLAFE?+K'_T&CO(VMS]6(2;. (INS M.'Y1@_*+3M41!84.QIE)<[EGXEC!K,J\"WKFQ" MBKKVCF09^Y@ES)H;:XV1M^GWUQ'+;'PJZD@R&#OSI^$+%D_ZIH-S#E\G5AAZ M^#!G,F_T N.&Q7U,A;_,"521UZGF-QPI>8W*HV)BUK.V&@T_R( MKUC6VTN\")1R!KZ^NK.O"U&6+4\E!'BTA5?8R)&UU53:_4R6,;Z' &QN.+,+ MH_)GW;FOBG?/^M,R1NJ. M+R=D^"!\2VS,&4PJJ&]D+G=I7TDLEK#+'0B(*^[L?[9R9"9;-LDR MP;T]R>NJ5U><#$'7@"S;JI5E+O_9NY5A5(KO-Q%--AV7?X]0-'O R:Q_RZ2= M2!B#;EJ C;TGRC]2]L+5/]I@_ $^?JAL:Q+'F4J:EZH3[0M2Z"$W62Y@*8JF M%+Q2_MVXS!3#^,.8?3)7)J?5E56+M4[SE*M=7_SB:XU)1S^_N=]#Y*H MY7&2HGI)T5T.0M'QIG]F]$B'3O[34*)GKR7TG1%='Y\\9Y59S:)?O THY8TV M]++4YYGHM)7VY_"8QZ;P,:1,=_%KAN6!*_@F\UF-F60'3F0R_JWSS3>1Z$T3,=[+(CY!VRU'M#:6*[[%+MT>+? M/X,@(.:IZ%'S/@,ZG]>PY4C)DV@4UQTZ1;' MG^6@2ULTW*+EDW/C$JO<*Y4?\K=OM3%/OO4<+HVMY%-G,YT3TGHM8\-+'4/5 ME>1 +$. +M\-@WU5@_.^5HZ^BH@A:/5OZNI=@LQZ.9 MY*(Q;A=DM72TV<_'!65,R=LCF7P33BXQ5) M+7O?Y@3=R\FPMBZ4W]9U9I#RUK3,@>.\=/U M5[>=%=&PWK:FZ:2L8RTB.,A M6-KEGGED-L!JP>"#&R?<_4_$/FV6;K:S^N;_A49P)Y3Y3A;M+'=^^Z&WC")" M/9F7@M;OO1%;'#0&',MUBIL*>G6M^[Y-/9Z8W3L55=9VA*OK?\J^X>BGYI,( MQY&D8B:6T>-E401$B\E;\<=G<>:D.]SV/V*YYZYM\0PEU-[:;Y%5-3P&S/@( M8&\&[%V_O]+LV5/Q\IKR0\:G.ZE;#[F,Y<8T+C7UT4DM=9.=%04+R?TW7UER MY'6W;;ZN+#J3C+C9D>PG(N\VUQ4UM35_L*=R_9AX?*GRGIOWK&FS@R*/OQRE M;HBBY[',6W3PC*ES$0^PB<3D2T@MBP$ M;!K,*FAWO>7I7ZP4MS*+"HI*]I8@5Q6*SJ(0MS7XT84@;%"A'X7G1HZ_Z([, MFN9DUE#-K'G%V97I64A6J.,]\9G)\F\^GK8]"V#&T@K J.!1*(O_ MG?;B.R!'L;M2\SPYOM>7UO/\U!L>(]9^S! MBKW.;RF[B/K7B&:2C7N0PVDF%@??#]AK-:=K(DO\NA"R9%E%#0.9E*C>U1L, M!8>9^!V.6I')@A=LD_4V*2N2+ @ZZ*GP@*Z4&D:.2KR13-!U;CSX7M4$>18I M?[/&/V\?='LB<($KOZ]!3F5G1CJJ]HW(_ M;@J9K.J0GNZ=YA,]SXY_\U5[2SOE5-Y^)F9QWK[G,75+7O1[VV#T\ MF7!(JR'KI7[3[L*9A S@FN$.A+JO6?I"2.SO(4U$3O2=!F) 6'',IHS8(GE. M]"GEZ]P#YB'.F\B7=L;2CDY9/6GW(*F-]:-SO_$*Z7D\V@3>[G//Z6'$6)K. M9*??V6?3H)T=#'X*\'C=F-)$0N2V2[50RB^[Z]4Z$FSG$ M&G,L0A, K%V#34EN:M.7^SL7(K.L^J;3*+, E@KB*OEMO47HT>*G%YWYA%IS M1!&B)[NIH0J;.H:J[FQ&5/GM3OJ"[9LTFF)E23F5@&E+?2S=CKQ!-&3\[-&+ M)X_$9S58C*1;RX]E^HTG29F25%/3RE [@D8/)Q.,B;^\K<6"FQJ,L@2:JY]2JE)\-TG)])79!9D.\@ MOGB#:Y/ZX#;$9!*J: 1QDS&49C.<=[P\@W%J62L,;"_YHR^>;G-TE4YD*21MKI_ M-@TJO[?DHH3..US:C3R>BO%\6E>W^]Q*U)DOCY4RP!+_TS6#5*"3X_R-&'?Y MSYA=G3[QT$T!$U=J+_&SJG+)K_7NJQ.?*UA[97?Y>K:,K60NN)'#:KO&([[K MO:CC+C8>FBA:R(_H;92R/YL,^D73T>LWP]+:O9%9N[DGDX/EZJ<;[F28R,E@ M>Z1]Q29"HFRE$4U95W<:Q11-?OVT3PSEKNYL^7N9;PH^A> ME:>K?_]._*S36^U+X#%)6_Q5TO%4N2)XS7,+7=#\8;3ON&/W #C/JS!,J1+N M%?>]_>-@5GU\QA./0>M+@ \2^0D=& UDEH6S+;<)8-50#V]V1%X5 ]"R5B_8 M8?P?2G[N.;KDD'NLCD@'8CRRTYSZ9$F$\V=13[__%0','L^(IR8,Z;]:\*>P M6OPW:>T+&M.6&65OT1\^77KN0#KK$?+V7&(:Q?VHM0?O.F:6S%_0YRG4 B#8 MT=47:,Z=A.XM@[]BOG@0NM%C_5GEP JQ^MU40HG&N #FD_5. 'OV.Z4?PQTC M"&#;E?G1 EB5(7/GE-.F 'L'%9C3B>%L"0^@/_D4P!8XH>+Q A[ M:(C12$A5;WW5JR?9(F.GYQI@.]SJ'Q]G$E MYLCP<@;\3$BT3*/)XTE*OAR^=OD?W[%5AKYZNY4K3>1A0K<#&S$4B@A^Q!(L M\W,,S?P]\2\F8AGJPB_?7O_U?_G(G!69=\?4@5&+"DP_+4CN /6#HUP<1PMZ MG&Q HASTY5IK6?$9%JH#,V>"?U5#8[H^\:BBNTXR\^XC;@_&Z7>_E8B6XI(K MK6V6GLL-+Q*[/+-:DWC6B]&X+U(;ASG^,";&(8Y?49QRMS45.X95B\>T8+^M;G*W&/96VOJ MTHR61 4=_WI)FUP^NVL2A9#OTEHF8ULII?2JO*GB-^\?WHS;T]?'*WKFH[%, MVDXMO1FKO(!*,HXWU7$6E77_S;]# /NPM$,9:22 *7ISU>I?IC9C)PKP1=8; M"WA%]=U]T]B)!]TE)$R^SI/--B9G9V2!&:_]][264:*IB.;H[_N/!#2R5-]H M,HS)H9A?!W)S4<#^5H!JABDW[9ZY4F(>"*)Q[Z^E+G*%0=%W"!6YF-E.Z=I MKGJ74<*4*O-0".;,&WNING-MZJDR7VSFZPV$(DEK)!]AZYM<2VDF71V3#B/PU'?"JTU1)U=D$^VE[-XX;5WG+%^>A?#+!KN>,8GZ ZQWD3>;(XL;JXCFB)B/*!>2*^(_G93,R;# MRO4M*[*L%U%JL]&1\,X^?R3*SD6;.INE/<;)E$WC8(\%S%CI?%X))UUIO9KQ MRL:?XOLT<#0[J]X.JQU1B]Q]!%7*R3Q1EHX<2_I:-@Q_,#H^%JOB^V7T;1:6 M.I+C11W%?E0T(BVZ:2WR*Q)"JE'LOB-]172(LK"6I6-&],8[1GJ&$5&O*7+CX MO3?KTFRE^O)G6K:M3U$I)]#Q%3X5]1HSE7KRS/G0YR MCR+/].+[LV.+7:!;*0<:%_)[X@_M?IN5:!I!EX.C(YXXW*/WYY -PNTPZ@;Q MQVNSO#K])"HR:=+-?@_O[:\C? N-STFU5VDT5_EXM]LQ?O_IB:_^BSS(ZSD9T261IUOLV&RWI9IU.# M1K0P9]#Q$S>7-6GEVSE-5K0S88WBVGF&#?3K8>1CZMNK%RRLOHYJ!;S5<7OH M>WPI6]&6.IH3#"\W9RCP1HD&IF,J-5]3&WTJ1Q1"65DZ!A-%63L3IF+Q,=;1 MBZ^O>ESA C UM-PGE[D]]6S_L6WFZ;#5/D"F)^Y M"?C'% N?ROS).+ZJ8!O.,NAE0(8;PZRXE==QQ+S<$5W5KORQ/N'U?%;'*<4D M#G:JFIL9W*V#+=+L)U>&[3D8&")7-1^.(RAZL*RS4BCXF-*L6'),<[K>9O.S MJ;XAWBW7TRG!57*5:JW$&]%2J6%9]U?4,T65U[0U=%F=S6;++1.1ZWO'=__LN ]HL. M 73?!-ZIFH 9U.UG&ET1S][J3] 7LK+VFZ.CR^?D-)3 M4AT]T\3B9,EA:: ;)JC[=H0'U2)!\BBN\$"5UX$R&7*/[&CKV%UT%26:$ML/ M1Z-1 P:-"_(7/P+83,+6ML=612*ZK9A9U/W;"]-DS597G!WY?-L8>?-NT:6^ M')-8A>O4RW&19IRL GWZGJY$R[YINYPOG\:;@^2G/WCOF[8+\#1P'U6?J9JY M0IC*4 !&M=O'R'V#IJ>#]5O\MGK$'!? PGW'&8(>9=%#]5640T-7 MZE2CC(L^^D4-V0WHU/J.N[KB_=#H9V/\)6K+0A,F!$54NM.:H?Q N2TMN#0K M85/.QV6.>>*$*.F.?OR;TG "Z=*4U$2#]!,?BE>)2Q+S-K<;8Q.;L[V* MXG(>;X#J;U%W*^RX+28V-I>7!3#? O40 6RV\U)?81M_\GM2L\_I-ZC_A'KD M#P+8>PWBPR<26'(O/[?R6J[YU<8K%O4;O F/ST#KW[I])XD?RRKW[LBZ#7*2 MGWN8)-.K=]QB]#)_';":%< LK?.):HUASOO5<2)_L [)55_I9^9W&3K<)D*- MY_HW,5%N2R3KV?!3E!,,Y_&\PC' M)Y/1*\FE#3:JZ2SL#,EH:AUX\%M6Q4D+7RN00HC_/%7"0$E2OG@;BB)F$R1: M>UV2OO;D[08PE2;G7LZPLCJ(S;>1^UTYO^)]2=V]%\I*/WN[<&EY[S]]H2V> M-BJ9VB0V'VCBXB!!C2'P$\;-^T_H.YCE_$;7)YMKI=1WE5)C<%7/L^R;)>8NF.D;0?K9A'7RH[G_:[F4*@%L*),!+$$7R>5(KG 5TJK6_3%?ORRS]_Q9DZ1%"8.=#++>)J(PFBO1Y,Y]LAH,3)SSS<:ZPBS0]G\QMQ!&;#D.\$&F?]E%C3O'LJ['AG)KC2\#GZN1@#;#^H)&NJ3 M&7A*/X#XGCA)835V+1[67;&3P.OEI4J(H 4!5B^&HQ?S ))?N! M)ULQK2YBF[LRA9,)A>XAKDY&@"9;6ITLI2E]5)Y[,8FW0IY&@6I:DU@+V$L> M=N"+\B&E 8^]2%+6!U/QCJ *R&Q;.MC_/Y":(.(=@CLE@+4A: A&-/G[YE^( MT\8&TGLHA7($*IVGXE9'6#FQ DU+_4QI] %774S<#GZ$D< S4@RVX7P"YN@I9(@L_54O:#]IHD0'K=7.38 M4V3U"6C-Q*W#5TOPG$##'!$V3/U70T97$[_1.)+\&@$N\1%^]:-+X.JC4H"] M)OJ"P4<(%"&!)(JL.B0/0.FCM=$A]Z_#_5%@& P2JG@,*"&!L-Q*OC6H P\79U;,N)GZJ-#(R]7WO?SF(L%]K*@ M8>)CP676\\,!567>9S2XYB+NQR)'YH0 =@^ENDS\,YHZ[3.?:,SY'3*$W"M< M'7Z_W=\1AJLHDSB5@XZ+1K>-1MPG?X94+B:46-C XK4 EH<"W5MH1C!X>ZJB MRBT^V-N8:JQ,4\?I:[XU _D6 M2'N@#6^AB*9$RK$BT%VZE'Z!$W'I_Z=[-@ M0 /?I@,9BOQ=$MM6Y'B">S&#Q__OD0 #.?J*,+I_@0>(72!M8AL M.0K\?0+ZHDBA+]*+=%[HW.%0G.?JIQ[0 M3[T)5-X <&NR(=:<\)]QMQQNH!%NL'EI,G!A_M]#:"- >%01P)K7%'>\;4*O M;>)\@&\2>QW8$C-/7$.\7$)>8%T 1?.1T!:L86R[!LG*OA$40^2/1?Y+'55\ MZS-PB%/@_P#H-"%"I^D=3=7$=MFI1*8R0%]4F[N/N./V$KYX9!)TQ9O&H%]N MYF\I@SRQW.9*BJTO"K7&C-15IC.3 M@5%/?#:M89DXR."I*M=25G8O*7.'0-?*UU\[&:/<]T^GE!HSV[E%;SY$EMKT M\<#0>GZ)70+&PG4H%I#M8&3DTA>.00O'#7.N\GN<+T?#>VDCJ$Z1ZD#0_W], MJRX"3?(-8#SVA ;VL% '9A#8=H!>\T>0.6(;8?D*^S/%XP](:--JK@S/+ISQ M5WH\9F'"%Q&L3^6 )>M04-1541HI%@G'K M*8"1/@S8('5N$@)C$?G>=9M#1N>$H9MJ;P5\INR# W:*H.G(_>'2CDS3BI4X MX'A)G=L^=_AOFH@\ :S.^Z](3 ;%U6"W_$ 011SGU(-1[9@GWU7_ M3S D"!!@@;EE4!8_^!(XM19L6S%5?7BOE]+V2PV;NX[A0%I0O>_O$-Z3 HZL M_#?:IN+X,VCCR)2I/2= P($A_HEB:?\.?LH[ZY")JWD!\LJNF"X[/$*9*\IS M_O&I:=R_TC'PV[G"Q90F8P/M]*K2HQS6CYRW-JDFL)< A5D_$F"#;2L*%U.9 M]:GZ)P/<]1R#(OD-B\UP*$DB8"B&&0&X

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�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

      #=X@V5V7+,YOR"09%L#:SNI+G7I^-L^%N\FMP95\O=,:[OJ#*2X!& M-B'^8=HOP>=P-C2!4K0 3? MK19INFUC5%;S6A $L7] [K).3,PRU')]SB19(N>>"];"5X&,1PHJ_#8P&[ M#$RB_C7GM M5,,?RG(%936W4"%R]J(X3I9L 4)DSN\DFIR-A\*,Y7APW3MQG@@-Y"C]VEDF MQITX T2CZ;J=Z E>CVR9+%Z;5>(&]B-BY6[=37!'S;\N6\>/XPM$YEXN5%T. M.(==NM;C%PCP R<:CX/@4JDL[MD.O"9AG M'B;Q-H([QM6EB"A;5NM>('7#PP!9[PQ] G6]+ MB-:@1=)5U?-B;NB)7EJ WEO%33W=A(D4S P'GA\VNY!Y,1[?,^Z,%1[44!Q? MD]>\YGV/>P R%CFAD6404H\)0E"Q)K2#2 RMVK!RHN-'XGX30@IKX*Q_2017 M!I;. I[!O$0V;Q=)YYJ<#+)O(JYTV.L(12KJ"&,L3?VS8>$A/9*=6'JKZW;, MH:/*'1XF<#G5P Z^=N-\P<]SPJ,DP-*Y Q.,K?L.5=Q8VFI4P&>EMD.T5#%7 M(5=J,]ZGGL&AA!GQ&GQ7C]===^1;HQ-P1$-:9-;0J:(4RHU[#%L"!5=S'2)< M5_31UW'Y'<4![>3L9URMQB?'EVD&.8/2>\;1I?,K(IE(3R6QH_M\@LDZ&)WA])8_E&) M]0"5ZG6Z,*3N1?KLT8]-_FGN8:AO\EUI%C#Y6IA/)IUB?&E#%)DNP7!;LEH? M"NWJ-WX*A8-PF#I*11Q:J2MY_11S6AJ! +FN?@1R^HESWM(VW!;5?EZ$E3>+ MUD)'8*$3MWQIH&3$9EB0S7.(*7'!+BZ2;&@>L-CQ+(PA2'K.WXE7OX3I:IL9>RO(Z5&1JYYKOS M1XBW0Z>A=87AJ$^62J.]3I!LD>X)JLVD[YX1K:'MQEJG]2T,LL0!IMH2ADF5 M;?3F)A^4]3/N+P&<"?@Q](,^!-0$]"&@BE_VIS(, MNF"X*36%-J.5I@'@![T+Y D2'_TY0W&D4X J'!N3I>,6\%WW?>A$MB>-71X& M%CK"JIO@.IW6E2?G?0($>G]^BZ]Q:0_&AN6-(J$6HR+1PD3_8S-M M)?Z#GMZ,= O,M$5J UY) N;,B"]I!"(LD"@&:\P/[BJ:-: *I*B#H:SH8%E! M9/VAJ>*".D*@P=06 H?0P @?W;KA.G_GX'ZC=?Z!&61E'I8USLE[!NUZ@4EO MJ65.,4-#N]A\FUJ6%>5Y.&^R=Q_ECM34\",MJA10=,_&T&XUN94M5(:H.5FT M-:H:AIQJJP+INH1Z4/X(\L$6,B4LS",,\^YN%@N*KHSCS/3V\94@$-'WHJ'' M2V;@:.(7]K,:^K3O@XYIFZ7K\4%#!?\;EU0=&WCJMX )>*)5.")O">/,3NCW M$M9%V&9ATD)!:[PHI@2!.]+"]00KM^PV>@56@BZI.:\S>Z M>(=FRG+^!9; WIY?P\'7=K:R:MX;ZY#N;)](:U0P=U ? R4 ;VQ&73]GJF>0 MK7@=E%62<'0&)C??#9>'#8I:&)2IDF7]O(TXO1J1^LR( MRE!>.\/Z/77$U+C&6;\[+H720C:?5M71:_1L%K072TJOG$GY7]:OC+B7] V@ MM/D/?)+QE*G]>B.%V ,YN32:6C K$J=*K; 4]"BI=%\[^#D EH 0LWA MDW$WZFQ[-,I2L)X7";)*]73HL[[WBZ0,^X8W>><>3$:Z%0:C^:(TJ5.GS9*&K!7 @3(TYUP%942YOP6"( M7\E5O;] 2,QC$K -ZD/@@PN5_&7$2Y;N@MD=SZ M<:S3CHI41+0::H')8"LK76K"ZUPDU5D9Q$8G7E?)1UA1/NZ "II%*WE>O#^, MJS#*G 66VF+T1O?DPVQF5K$H7;+MBMZ/\&U9#Y&@S1JA7);!L(*6H0^/T'?W M2-B(B R26\^,>Z"B7,@-VQP J/K-7 9R M@X\&B_-8M=H"6B+L/-OO3S/V&$E7LJ(;29]32)-FI)X:PEM5C_[;.DP@.$I M?15W1GWA=_'2KOKGO\!"@8C",X&^Q7;DJ*FYQMVI;#/&TC@+NI1F5,BL:\G+ M)V?TGMQ/_ ]TM_(V@TRU(]WA+-">'<23E]KG2=?_SLFCV'I*KI2%CW,%"QZM M-=R2"7DDY7>L^I<',26?_M[K=4=H%U/BB*U8R(/V/@ %\71ET)4C1"GGOF>: M'8/2<\KC\Y-A2;EXP&IW!>5^QJNJ]A\P,\%)_\4 .Y@[S6^%]1[7 6([KJ["2%(@D@ M"BZZAV?*KDBU_%E)[; X#RMRO(A8I/PV4.W)^;K_U1U-8+X-&MD=G6QQ7]#] MXU!"_H/OR%^@LC;9"JY*7N1*12,;XQ&M>?@8^T5@-?<;O_Q4IJP1?74_^=', MKS%7IKX;(UN_$%6<9DV9C[LZ/3C+M@]-";IS=MJ^/]S=[RF>"KP?0)M$&ETY MYM$RI/HH'OJ$EIR(17@W^HE)2K ^S.( QW&,6]+UUJN1M?KTU/BE\@KNCV^X M"?F4+^N:!NH"&P.=/2JR^7OF$"#&J+I;!A'M(/H#SW=*].Q5.G%C"$_+: Z* MUJ6!0E33*EOEI1>;QU'6T5;K_S_&SOVOB2O__U$4%(2("%$0XATM:JJ"5 B9 MJK6HE*;6*@I":JER23%M!1EE3(H(X2)F6[?RJ12BHE!$B B((B20ZUJ71NX2 M*LE,=HOY'U]EJVF]G-9D\\ MVH/AC *Y[PO 4_EFYK2>J([$9/,[JT!,+-A%98+KXLN?!FJ@A90U4Z@S;Y+2 M'5DRM/#MN+& XV^O>BL=8NZV7V%#IL=O)[_B>KZ8/9)1289'U3K;X],OX7IJ MKQDJ1\Q,]04GC:'\<28:)W$&XU'$T'@+E".HO9?^);V/.Y]ZUQG"ZQA!%[-7 M8441,>H$K_O/,WA>\-FH+#M+[>OS,U8D6_P"\ _W-D9\UABV<7[ EO>C5C2=$)):4+7>CA,*BL10X5CW$2U2BO(#%!%V" M9&$US_BV)RQW&%*>/]S?C$4(WQFC&N6] ;K([DUU4VZJE*3O-IWM_\\_5G^9 MIU@E9\.95AD5C@DGE&[IFDQQRT!9.[I@Q+UEP,6 M]2XFIH;E-UOJ3\<2.^8.I'W=12;B(8V"8D6C3BQ<#61JQUH0@1=A MY048)!5N1+;;GPAW")^)'BIR.&M)?WLU70L5*.I96MXYDZF M.7)B'2J:!T>AY=7X6;TV84/W6YEA392]BI'00V;<32E?AI\MO36>I$OX0&1P MYF8/KZ=\T++X!]''-_[U]>6,?_SC ]TC[$;H9VXW3_[U\6GDQV]/+-&,+'!K M_"K18X;VP4=?[V%>3_0L^>^>:S%N_\V\!5RL.<]GBP%V['7X@"#EH M$BP&T^@_ ^9UKY5^!/;?([?@X4C@$WQ:^\Y%R1J2* />(T;4XZQ&03N&'L- R%VQDTJD2EJ&01F((M0:# MBHKCPJ?R %!0QZ>T>TXML.T!:;.MYJ+V$BY*:!D9_27]U>>M 3W6Z\#_ JY7 M,9=-LD65G7@/A<^X5&E9!.J_:;I3W\<6F:5%YT7M(E?X>-S3.Y452=5\:%E( M%)/V88A;4!2<\>Q2W.#D-V_2H2U)5 A)&A7YI#4FMX;:8L!5:V(_F4$DQ=I_ M#>&Y"+L((#('*C<+9UN@:(3.O5!JV2%,H7;/4B>$@]![Y*XN4:K $V9^2-QC M^NI4EIR$M5U"#_)CX/G;V+20!E)09CD[!(>L-_KE7G #JI!P/,C,KI#H0]9' M]G+Y*L2GG_3$I+ZCY=Y=HJ0G A#$$"N29V@%,9PMX.!OL.H(.&.2&L)1W:76 MK9BLZ$>$^Z0KPWWVZ]5%[%WX4(>#T7NO]>1)C)=C^-;E;9[?!K]EO^=U?*!; MWA'H1(2@T\9&:8=[J$FOEAI\;+IW:'H59YL!+"KY4$K &CY^A349CQ6>P?Y<4 M<\*0^02C7> G_/W\-2E=&\; #3'@/H:T!QM;VX--V]PA(/U77XH7>?NM O0 M,>E@5KQ=+I]'[L/;C"J]&\D!%]GG4#UU+RA__LH]4*MPY;":Q1.MC#N@1',= MTGW05"2Y$D3XF5CY(?0ZQ3?ZB]#BJ3(OZTX0CY<>M5?6D@M143[D2<6VS!AP MDK"9^[.)N693I=3F*>SA>.+Q>HG\_63CDF\X&^$A]4_"KF9F0]J_)46M^\T4 M+1WH9<=[@9[#_8'=)I!;>\-E5/,M9S.X:1(XP5?1JDO(85G';5AB9A1-\6CD MMNZ_FN77N Q8]Q$X9Q84^=9E)T8TW>L_.]"O\'"L &8-1&Q[]" OB^X^YCD4 M%6+*,_ Z_/W03,HGF!TO>1_WG19]\S)*F\ AQ!VR?,ZZ?H$C>'P\$[4$ )5C M89=YGW#K7I]2U)(O="<22O&'XU9E#Q*"/F->Y,WAK$>P3Q##"I5%_.Q)*6L4.HI7$^& M]T))(J>CR"[J=\.%W2(G!],(+&C=+T3HH9ZW,[0 V,O:"4I\I(2UYP"(-W?& M8EDSM,5 W.Y8342JN$O@<)7/#\SN#W?2WE$S]BM62&H '[5<,<1,<&TQ1CA) M*7K8)M-(E\-\,[-0[HZ\#R:)(5.;99*!&GU3F?.#RZ#=X!Q>A77VZ:C%*A;1 MOZ%4,27E^B^XAX*(.@SJ42D='C\ZP([W^3FTXUCKI'$6B0#E^0+?>%(ZX^$9>(IX6/3EH?@TY+-K1MO")^5NX)BDV4I[*0> MW@9ZB"BSAZ22$J!UBN*/?$5:0?["+.M01-SN?C9TD]S^TT!'[)>=3: MW)25_->UX)^L9Q\V%O^[,/3QHSA^D39OWH]]53^GI9T^[?O!1U>N6=_\&79O M 9)Z_L-/GG4RW.4M3_EX/>MM^)*%/[DH&/9_@K(5=,!Z0C((U:\@D2XJDDD7)LN=[3=F:*# M0"Z8V\AA$I-Y3)*Y]93KW-?O+5S[@_/W7*>U M/R0VM5RT&MR>';M5;AA;]GKS2-Y'UQ>:?IGW8_2BKH:]P=NTS]8>^LBRM/[! M4[^6;?5D+[6Z1-3&_I7*,%_SEE$#FL:BC2J? 44B:P&R2W#%P28>_D)(T.:) M:;.""9]76<4#9\RU!]-%AB0=5Q9MDAA<-+7\2ACKP<3*"ZFJC_LFD55\M#29 MXV8O<[@)_^2XVDNHP4#9)0$T^QWAD(MRBXQI([O/'Y6];26&#L, RT*_)FSU72\9H/ M\2IUYR'4DBU?11.^03X"528HUS>AM);<17A+\])K>9H$9_S3LG-PR78WQ5+D M #&2*UP&,_=?<5NVY74.R,%2'Q!MQ0^S M\='_=5_:2QGA=X2C]BZ\YSC(/I&8B*5M1_\>.U#(#L0B_-#FPJGB S;5?V)# M5)SX$Y?J:I<\PP**?H/7 M6!\] &6XUFC].V'4ZGWXPR&@F0I%U%*]4+(73P\;KJ\DTXE["?-PBY9%@XN4 M#(47$HD7#AVFV5_?4BR#4A6+R*_ SS8>%>==.F9H^U2_RE)L>)AB9A>S-D!^_ 8@U1V#%2V'5(-^W2O T],1A^P M1W.>IY:('?/[@E_Z*8 M%&PL'O;F&D3F"2@ V6CJ/(-9-+^(OI)Y CZO5QCQ*F$CN(!7J*3S+<$6Y_%W M21W0DA2>)[<(B<.Y6IYG[6F=BEL0L 6'72;O>(/YC%S(5&T==B-Z?0?$P@_@ M!FO]<_D"L$T@5BQ)Y\T6%&Q=;OL 5O[.?9&DX@00(S\@T?@$7&A&.Q637J&3 M3TX27(W0G[CV"RY5^9SG5�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�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�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

  •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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 119 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 120 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 394 376 1 true 106 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://agexinc.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://agexinc.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://agexinc.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://agexinc.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Operations Comprehensive Loss Sheet http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss Condensed Consolidated Statements of Operations Comprehensive Loss Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit Sheet http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://agexinc.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Organization, Business Overview and Liquidity Sheet http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidity Organization, Business Overview and Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Disposition and Deconsolidation of LifeMap Sciences Sheet http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciences Disposition and Deconsolidation of LifeMap Sciences Notes 10 false false R11.htm 00000011 - Disclosure - Selected Balance Sheet Components Sheet http://agexinc.com/role/SelectedBalanceSheetComponents Selected Balance Sheet Components Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://agexinc.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Warrant Liability Sheet http://agexinc.com/role/WarrantLiability Warrant Liability Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders??? Deficit Sheet http://agexinc.com/role/StockholdersDeficit Stockholders??? Deficit Notes 14 false false R15.htm 00000015 - Disclosure - Stock-Based Awards Sheet http://agexinc.com/role/Stock-basedAwards Stock-Based Awards Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://agexinc.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://agexinc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://agexinc.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Convertible Note Receivable Sheet http://agexinc.com/role/ConvertibleNoteReceivable Convertible Note Receivable Notes 19 false false R20.htm 00000020 - Disclosure - Stockholders??? Equity (Deficit) Sheet http://agexinc.com/role/StockholdersEquityDeficit Stockholders??? Equity (Deficit) Notes 20 false false R21.htm 00000021 - Disclosure - Supplemental Cash Flow Information Sheet http://agexinc.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 21 false false R22.htm 00000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Disposition and Deconsolidation of LifeMap Sciences (Tables) Sheet http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesTables Disposition and Deconsolidation of LifeMap Sciences (Tables) Tables http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciences 24 false false R25.htm 00000025 - Disclosure - Selected Balance Sheet Components (Tables) Sheet http://agexinc.com/role/SelectedBalanceSheetComponentsTables Selected Balance Sheet Components (Tables) Tables http://agexinc.com/role/SelectedBalanceSheetComponents 25 false false R26.htm 00000026 - Disclosure - Related Party Transactions (Tables) Sheet http://agexinc.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://agexinc.com/role/RelatedPartyTransactions 26 false false R27.htm 00000027 - Disclosure - Warrant Liability (Tables) Sheet http://agexinc.com/role/WarrantLiabilityTables Warrant Liability (Tables) Tables http://agexinc.com/role/WarrantLiability 27 false false R28.htm 00000028 - Disclosure - Stock-Based Awards (Tables) Sheet http://agexinc.com/role/Stock-basedAwardsTables Stock-Based Awards (Tables) Tables http://agexinc.com/role/Stock-basedAwards 28 false false R29.htm 00000029 - Disclosure - Income Taxes (Tables) Sheet http://agexinc.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://agexinc.com/role/IncomeTaxes 29 false false R30.htm 00000030 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://agexinc.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://agexinc.com/role/SupplementalCashFlowInformation 30 false false R31.htm 00000031 - Disclosure - Organization, Business Overview and Liquidity (Details Narrative) Sheet http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative Organization, Business Overview and Liquidity (Details Narrative) Details http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidity 31 false false R32.htm 00000032 - Disclosure - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) Details 32 false false R33.htm 00000033 - Disclosure - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://agexinc.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Disaggregated of Revenues (Details) Sheet http://agexinc.com/role/ScheduleOfDisaggregatedOfRevenuesDetails Schedule of Disaggregated of Revenues (Details) Details 34 false false R35.htm 00000035 - Disclosure - Schedule of Disaggregated Geographical Revenue (Details) Sheet http://agexinc.com/role/ScheduleOfDisaggregatedGeographicalRevenueDetails Schedule of Disaggregated Geographical Revenue (Details) Details 35 false false R36.htm 00000036 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) (Parenthetical) Sheet http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) (Parenthetical) Details 37 false false R38.htm 00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) Sheet http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) Details http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 38 false false R39.htm 00000039 - Disclosure - Schedule of Discontinued Operations (Details) Sheet http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails Schedule of Discontinued Operations (Details) Details 39 false false R40.htm 00000040 - Disclosure - Schedule of Discontinued Operations (Details) (Parenthetical) Sheet http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetailsParenthetical Schedule of Discontinued Operations (Details) (Parenthetical) Details 40 false false R41.htm 00000041 - Disclosure - Disposition and Deconsolidation of LifeMap Sciences (Details Narrative) Sheet http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative Disposition and Deconsolidation of LifeMap Sciences (Details Narrative) Details http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesTables 41 false false R42.htm 00000042 - Disclosure - Schedule of Intangible Assets, Net (Details) Sheet http://agexinc.com/role/ScheduleOfIntangibleAssetsNetDetails Schedule of Intangible Assets, Net (Details) Details 42 false false R43.htm 00000043 - Disclosure - Schedule of Amortization Assets (Details) Sheet http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails Schedule of Amortization Assets (Details) Details 43 false false R44.htm 00000044 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details) Sheet http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails Schedule of Accounts Payable and Accrued Liabilities (Details) Details 44 false false R45.htm 00000045 - Disclosure - Selected Balance Sheet Components (Details Narrative) Sheet http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative Selected Balance Sheet Components (Details Narrative) Details http://agexinc.com/role/SelectedBalanceSheetComponentsTables 45 false false R46.htm 00000046 - Disclosure - Schedule of Debt Issuance Costs and Debt Balances (Details) Sheet http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails Schedule of Debt Issuance Costs and Debt Balances (Details) Details 46 false false R47.htm 00000047 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://agexinc.com/role/RelatedPartyTransactionsTables 47 false false R48.htm 00000048 - Disclosure - Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) Sheet http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) Details 48 false false R49.htm 00000049 - Disclosure - Schedule of Warrant Outstanding and Fair Values (Details) Sheet http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails Schedule of Warrant Outstanding and Fair Values (Details) Details 49 false false R50.htm 00000050 - Disclosure - Warrant Liability (Details Narrative) Sheet http://agexinc.com/role/WarrantLiabilityDetailsNarrative Warrant Liability (Details Narrative) Details http://agexinc.com/role/WarrantLiabilityTables 50 false false R51.htm 00000051 - Disclosure - Stockholders??? Deficit (Details Narrative) Sheet http://agexinc.com/role/StockholdersDeficitDetailsNarrative Stockholders??? Deficit (Details Narrative) Details http://agexinc.com/role/StockholdersDeficit 51 false false R52.htm 00000052 - Disclosure - Summary of Stock Option Activity (Details) Sheet http://agexinc.com/role/SummaryOfStockOptionActivityDetails Summary of Stock Option Activity (Details) Details 52 false false R53.htm 00000053 - Disclosure - Schedule of Stock Based Compensation Expense (Details) Sheet http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails Schedule of Stock Based Compensation Expense (Details) Details 53 false false R54.htm 00000054 - Disclosure - Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details) Sheet http://agexinc.com/role/ScheduleOfWeightedAverageAssumptionsToCalculateFairValueOfStockOptionsDetails Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details) Details 54 false false R55.htm 00000055 - Disclosure - Stock-Based Awards (Details Narrative) Sheet http://agexinc.com/role/Stock-basedAwardsDetailsNarrative Stock-Based Awards (Details Narrative) Details http://agexinc.com/role/Stock-basedAwardsTables 55 false false R56.htm 00000056 - Disclosure - Schedule of Components of Deferred Tax Assets and Liabilities (Details) Sheet http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Components of Deferred Tax Assets and Liabilities (Details) Details 56 false false R57.htm 00000057 - Disclosure - Schedule of Income Tax Rate Reconciliation (Details) Sheet http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails Schedule of Income Tax Rate Reconciliation (Details) Details 57 false false R58.htm 00000058 - Disclosure - Schedule of Unrecognized Tax Benefits (Details) Sheet http://agexinc.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails Schedule of Unrecognized Tax Benefits (Details) Details 58 false false R59.htm 00000059 - Disclosure - Income Taxes (Details Narrative) Sheet http://agexinc.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://agexinc.com/role/IncomeTaxesTables 59 false false R60.htm 00000060 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://agexinc.com/role/CommitmentsAndContingencies 60 false false R61.htm 00000061 - Disclosure - Subsequent Events (Details Narrative) Sheet http://agexinc.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://agexinc.com/role/SubsequentEvents 61 false false R62.htm 00000062 - Disclosure - Schedule of Debt Issuance Costs and Debt Balances (Details) (Parenthetical) Sheet http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetailsParenthetical Schedule of Debt Issuance Costs and Debt Balances (Details) (Parenthetical) Details 62 false false R63.htm 00000063 - Disclosure - Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) (Parenthetical) Sheet http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetailsParenthetical Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) (Parenthetical) Details 63 false false R64.htm 00000064 - Disclosure - Schedule of Warrant Outstanding and Fair Values (Details) (Parenthetical) Sheet http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetailsParenthetical Schedule of Warrant Outstanding and Fair Values (Details) (Parenthetical) Details 64 false false R65.htm 00000065 - Disclosure - Convertible Note Receivable (Details Narrative) Sheet http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative Convertible Note Receivable (Details Narrative) Details http://agexinc.com/role/ConvertibleNoteReceivable 65 false false R66.htm 00000066 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative) Sheet http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative Stockholders??? Equity (Deficit) (Details Narrative) Details http://agexinc.com/role/StockholdersEquityDeficit 66 false false R67.htm 00000067 - Disclosure - Schedule of Non-cash Investing and Financing Transactions (Details) Sheet http://agexinc.com/role/ScheduleOfNon-cashInvestingAndFinancingTransactionsDetails Schedule of Non-cash Investing and Financing Transactions (Details) Details 67 false false R68.htm 00000068 - Disclosure - Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) Sheet http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) Details 68 false false R69.htm 00000069 - Disclosure - Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) (Parenthetical) Sheet http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) (Parenthetical) Details 69 false false All Reports Book All Reports age-20230930.xsd age-20230930_cal.xml age-20230930_def.xml age-20230930_lab.xml age-20230930_pre.xml forms-4a.htm annexd_001.jpg annexd_002.jpg annexd_003.jpg annexd_004.jpg annexd_005.jpg annexd_006.jpg annexd_007.jpg annexd_008.jpg annexd_009.jpg audit_001.jpg forms-4_002.jpg forms-4_003.jpg forms-4_004.jpg forms-4_005.jpg forms-4_006.jpg forms-4_007.jpg forms-4_008.jpg forms-4_009.jpg forms-4_01.jpg forms-4_010.jpg forms-4_011.jpg forms-4_012.jpg forms-4_013.jpg forms-4_014.jpg forms-4_015.jpg forms-4_016.jpg forms-4_017.jpg forms-4_018.jpg forms-4_019.jpg forms-4_02.jpg forms-4_020.jpg forms-4_021.jpg forms-4_03.jpg forms-4_04.jpg forms-4_05.jpg forms-4_06.jpg log_001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 122 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "forms-4a.htm": { "nsprefix": "AGE", "nsuri": "http://agexinc.com/20230930", "dts": { "schema": { "local": [ "age-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "age-20230930_cal.xml" ] }, "definitionLink": { "local": [ "age-20230930_def.xml" ] }, "labelLink": { "local": [ "age-20230930_lab.xml" ] }, "presentationLink": { "local": [ "age-20230930_pre.xml" ] }, "inline": { "local": [ "forms-4a.htm" ] } }, "keyStandard": 315, "keyCustom": 61, "axisStandard": 28, "axisCustom": 0, "memberStandard": 35, "memberCustom": 64, "hidden": { "total": 323, "http://fasb.org/us-gaap/2023": 277, "http://agexinc.com/20230930": 42, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 394, "entityCount": 1, "segmentCount": 106, "elementCount": 641, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1758, "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://agexinc.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:AmendmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:AmendmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R2": { "role": "http://agexinc.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R3": { "role": "http://agexinc.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://agexinc.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:CostOfRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R5": { "role": "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss", "longName": "00000005 - Statement - Condensed Consolidated Statements of Operations Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Operations Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2021-01-012021-12-31", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R6": { "role": "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "longName": "00000006 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit", "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R7": { "role": "http://agexinc.com/role/StatementsOfCashFlows", "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "AGE:NetLossAttributable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "AGE:NetLossAttributable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R8": { "role": "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidity", "longName": "00000008 - Disclosure - Organization, Business Overview and Liquidity", "shortName": "Organization, Business Overview and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R9": { "role": "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "longName": "00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R10": { "role": "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciences", "longName": "00000010 - Disclosure - Disposition and Deconsolidation of LifeMap Sciences", "shortName": "Disposition and Deconsolidation of LifeMap Sciences", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ClosedBlockDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ClosedBlockDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R11": { "role": "http://agexinc.com/role/SelectedBalanceSheetComponents", "longName": "00000011 - Disclosure - Selected Balance Sheet Components", "shortName": "Selected Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R12": { "role": "http://agexinc.com/role/RelatedPartyTransactions", "longName": "00000012 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R13": { "role": "http://agexinc.com/role/WarrantLiability", "longName": "00000013 - Disclosure - Warrant Liability", "shortName": "Warrant Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "AGE:WarrantLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "AGE:WarrantLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R14": { "role": "http://agexinc.com/role/StockholdersDeficit", "longName": "00000014 - Disclosure - Stockholders\u2019 Deficit", "shortName": "Stockholders\u2019 Deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R15": { "role": "http://agexinc.com/role/Stock-basedAwards", "longName": "00000015 - Disclosure - Stock-Based Awards", "shortName": "Stock-Based Awards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R16": { "role": "http://agexinc.com/role/IncomeTaxes", "longName": "00000016 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R17": { "role": "http://agexinc.com/role/CommitmentsAndContingencies", "longName": "00000017 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R18": { "role": "http://agexinc.com/role/SubsequentEvents", "longName": "00000018 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R19": { "role": "http://agexinc.com/role/ConvertibleNoteReceivable", "longName": "00000019 - Disclosure - Convertible Note Receivable", "shortName": "Convertible Note Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R20": { "role": "http://agexinc.com/role/StockholdersEquityDeficit", "longName": "00000020 - Disclosure - Stockholders\u2019 Equity (Deficit)", "shortName": "Stockholders\u2019 Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://agexinc.com/role/SupplementalCashFlowInformation", "longName": "00000021 - Disclosure - Supplemental Cash Flow Information", "shortName": "Supplemental Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R22": { "role": "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "AGE:GoingConcernPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "AGE:GoingConcernPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R23": { "role": "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "longName": "00000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R24": { "role": "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesTables", "longName": "00000024 - Disclosure - Disposition and Deconsolidation of LifeMap Sciences (Tables)", "shortName": "Disposition and Deconsolidation of LifeMap Sciences (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ClosedBlockDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ClosedBlockDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R25": { "role": "http://agexinc.com/role/SelectedBalanceSheetComponentsTables", "longName": "00000025 - Disclosure - Selected Balance Sheet Components (Tables)", "shortName": "Selected Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R26": { "role": "http://agexinc.com/role/RelatedPartyTransactionsTables", "longName": "00000026 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "AGE:SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "AGE:SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R27": { "role": "http://agexinc.com/role/WarrantLiabilityTables", "longName": "00000027 - Disclosure - Warrant Liability (Tables)", "shortName": "Warrant Liability (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfRegulatoryLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "AGE:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfRegulatoryLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "AGE:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R28": { "role": "http://agexinc.com/role/Stock-basedAwardsTables", "longName": "00000028 - Disclosure - Stock-Based Awards (Tables)", "shortName": "Stock-Based Awards (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R29": { "role": "http://agexinc.com/role/IncomeTaxesTables", "longName": "00000029 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R30": { "role": "http://agexinc.com/role/SupplementalCashFlowInformationTables", "longName": "00000030 - Disclosure - Supplemental Cash Flow Information (Tables)", "shortName": "Supplemental Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R31": { "role": "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "longName": "00000031 - Disclosure - Organization, Business Overview and Liquidity (Details Narrative)", "shortName": "Organization, Business Overview and Liquidity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2018-08-292018-08-30", "name": "us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2018-08-292018-08-30", "name": "us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R32": { "role": "http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "longName": "00000032 - Disclosure - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "AGE:WarrantLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member", "name": "AGE:WarrantLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R33": { "role": "http://agexinc.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "longName": "00000033 - Disclosure - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:RestrictedCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R34": { "role": "http://agexinc.com/role/ScheduleOfDisaggregatedOfRevenuesDetails", "longName": "00000034 - Disclosure - Schedule of Disaggregated of Revenues (Details)", "shortName": "Schedule of Disaggregated of Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://agexinc.com/role/ScheduleOfDisaggregatedGeographicalRevenueDetails", "longName": "00000035 - Disclosure - Schedule of Disaggregated Geographical Revenue (Details)", "shortName": "Schedule of Disaggregated Geographical Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31_country_US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R36": { "role": "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "00000036 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2022-01-012022-12-31_us-gaap_StockOptionMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31_us-gaap_StockOptionMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R37": { "role": "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical", "longName": "00000037 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) (Parenthetical)", "shortName": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_LoanAgreementsMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R38": { "role": "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:LesseeOperatingLeaseDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:LesseeLeasesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R39": { "role": "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails", "longName": "00000039 - Disclosure - Schedule of Discontinued Operations (Details)", "shortName": "Schedule of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2021-01-012021-12-31", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:ClosedBlockDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2021-01-012021-12-31", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:ClosedBlockDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R40": { "role": "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetailsParenthetical", "longName": "00000040 - Disclosure - Schedule of Discontinued Operations (Details) (Parenthetical)", "shortName": "Schedule of Discontinued Operations (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2021-01-012021-12-31", "name": "us-gaap:DeconsolidationGainOrLossAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:ClosedBlockDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "longName": "00000041 - Disclosure - Disposition and Deconsolidation of LifeMap Sciences (Details Narrative)", "shortName": "Disposition and Deconsolidation of LifeMap Sciences (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2021-01-012021-12-31", "name": "us-gaap:DeconsolidationGainOrLossAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:ClosedBlockDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://agexinc.com/role/ScheduleOfIntangibleAssetsNetDetails", "longName": "00000042 - Disclosure - Schedule of Intangible Assets, Net (Details)", "shortName": "Schedule of Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R43": { "role": "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails", "longName": "00000043 - Disclosure - Schedule of Amortization Assets (Details)", "shortName": "Schedule of Amortization Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R44": { "role": "http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "longName": "00000044 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details)", "shortName": "Schedule of Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R45": { "role": "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative", "longName": "00000045 - Disclosure - Selected Balance Sheet Components (Details Narrative)", "shortName": "Selected Balance Sheet Components (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R46": { "role": "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails", "longName": "00000046 - Disclosure - Schedule of Debt Issuance Costs and Debt Balances (Details)", "shortName": "Schedule of Debt Issuance Costs and Debt Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:LineOfCredit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "AGE:SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "AGE:SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R47": { "role": "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000047 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "AGE:SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockHeldBySubsidiary", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R48": { "role": "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails", "longName": "00000048 - Disclosure - Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details)", "shortName": "Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-02-09_custom_InceptionDateMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRegulatoryLiabilitiesTextBlock", "AGE:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R49": { "role": "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails", "longName": "00000049 - Disclosure - Schedule of Warrant Outstanding and Fair Values (Details)", "shortName": "Schedule of Warrant Outstanding and Fair Values (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "AGE:WarrantsOutstandingAndFairValuesTableTextBlock", "AGE:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "AGE:ChangesInFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "AGE:WarrantsOutstandingAndFairValuesTableTextBlock", "AGE:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R50": { "role": "http://agexinc.com/role/WarrantLiabilityDetailsNarrative", "longName": "00000050 - Disclosure - Warrant Liability (Details Narrative)", "shortName": "Warrant Liability (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2022-07-012022-09-30", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "longName": "00000051 - Disclosure - Stockholders\u2019 Deficit (Details Narrative)", "shortName": "Stockholders\u2019 Deficit (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember_custom_TwoThousandAndTwentyLoanAgreementMember", "name": "us-gaap:ProceedsFromLoans", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R52": { "role": "http://agexinc.com/role/SummaryOfStockOptionActivityDetails", "longName": "00000052 - Disclosure - Summary of Stock Option Activity (Details)", "shortName": "Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2020-12-31_custom_EquityIncentivePlanMember_us-gaap_EmployeeStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R53": { "role": "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails", "longName": "00000053 - Disclosure - Schedule of Stock Based Compensation Expense (Details)", "shortName": "Schedule of Stock Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R54": { "role": "http://agexinc.com/role/ScheduleOfWeightedAverageAssumptionsToCalculateFairValueOfStockOptionsDetails", "longName": "00000054 - Disclosure - Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details)", "shortName": "Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R55": { "role": "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative", "longName": "00000055 - Disclosure - Stock-Based Awards (Details Narrative)", "shortName": "Stock-Based Awards (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R56": { "role": "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails", "longName": "00000056 - Disclosure - Schedule of Components of Deferred Tax Assets and Liabilities (Details)", "shortName": "Schedule of Components of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R57": { "role": "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails", "longName": "00000057 - Disclosure - Schedule of Income Tax Rate Reconciliation (Details)", "shortName": "Schedule of Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R58": { "role": "http://agexinc.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails", "longName": "00000058 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)", "shortName": "Schedule of Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R59": { "role": "http://agexinc.com/role/IncomeTaxesDetailsNarrative", "longName": "00000059 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true, "unique": true } }, "R60": { "role": "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000060 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "AsOf2020-11-03", "name": "us-gaap:NetRentableArea", "unitRef": "Sqft", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:LesseeLeasesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2020-06-012020-06-01", "name": "AGE:LossContingencyDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R61": { "role": "http://agexinc.com/role/SubsequentEventsDetailsNarrative", "longName": "00000061 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-07-24_custom_JuvenescenceLimitedMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R62": { "role": "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetailsParenthetical", "longName": "00000062 - Disclosure - Schedule of Debt Issuance Costs and Debt Balances (Details) (Parenthetical)", "shortName": "Schedule of Debt Issuance Costs and Debt Balances (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:SecuredDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "span", "td", "tr", "table", "AGE:SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetailsParenthetical", "longName": "00000063 - Disclosure - Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) (Parenthetical)", "shortName": "Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LinesOfCreditCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfRegulatoryLiabilitiesTextBlock", "AGE:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R64": { "role": "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetailsParenthetical", "longName": "00000064 - Disclosure - Schedule of Warrant Outstanding and Fair Values (Details) (Parenthetical)", "shortName": "Schedule of Warrant Outstanding and Fair Values (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LinesOfCreditCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfRegulatoryLiabilitiesTextBlock", "AGE:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "longName": "00000065 - Disclosure - Convertible Note Receivable (Details Narrative)", "shortName": "Convertible Note Receivable (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "AsOf2023-03-15", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-03-15_custom_SecuredConvertiblePromissoryNoteMember_custom_SubordinationAgreementMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R66": { "role": "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "longName": "00000066 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-232023-07-24", "name": "us-gaap:ConvertiblePreferredStockTermsOfConversion", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R67": { "role": "http://agexinc.com/role/ScheduleOfNon-cashInvestingAndFinancingTransactionsDetails", "longName": "00000067 - Disclosure - Schedule of Non-cash Investing and Financing Transactions (Details)", "shortName": "Schedule of Non-cash Investing and Financing Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:InterestPaidNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "AGE:IssuanceOfPreferredStockInExchangeForDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R68": { "role": "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "longName": "00000068 - Disclosure - Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details)", "shortName": "Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-14_us-gaap_SubsequentEventMember", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } }, "R69": { "role": "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "longName": "00000069 - Disclosure - Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) (Parenthetical)", "shortName": "Schedule of Condensed Consolidated Pro Forma Balance Sheets (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-4a.htm", "unique": true } } }, "tag": { "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "BASIC", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r234", "r255", "r256", "r258", "r259", "r261", "r266", "r268", "r271", "r272", "r273", "r275", "r537", "r538", "r619", "r637", "r787" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://agexinc.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r247", "r248", "r560", "r561", "r562", "r563", "r690", "r691", "r692", "r693", "r694", "r715", "r717", "r748" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r815" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r832" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r208", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r781" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Value of common stock issued for acquisition", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r18", "r42", "r171" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "Warrants outstanding", "periodStartLabel": "Fair value as of period beginning balance, shares", "periodEndLabel": "Fair value as of period beginning balance, shares", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r138", "r625", "r810" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r831" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee\u2019s taxes", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r18", "r137", "r138", "r171" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r211", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r275", "r342", "r343", "r510", "r535", "r536", "r537", "r538", "r552", "r555", "r556", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r658" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r358", "r359", "r360", "r363", "r893", "r894" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "AGE_FourthAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FourthAmendmentMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fourth Amendment [Member]", "documentation": "Fourth Amendment [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockHeldBySubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockHeldBySubsidiary", "crdr": "debit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock held", "documentation": "Value of entity shares held by subsidiary, which are purchased for the purpose of granting the shares to senior employees as part of an employee stock option plan approved by the Entity's Board of Directors. Presented as a reduction of shareholders' equity at their cost to the subsidiary." } } }, "auth_ref": [ "r40" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "auth_ref": [ "r211", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r275", "r342", "r343", "r510", "r535", "r536", "r537", "r538", "r552", "r555", "r556", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r658" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r830" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "AGE_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears": { "xbrltype": "durationItemType", "nsuri": "http://agexinc.com/20230930", "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortized over Period", "documentation": "Income tax reconciliation nondeductible expense research and development in years." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://agexinc.com/role/Stock-basedAwards" ], "lang": { "en-us": { "role": { "label": "Stock-Based Awards", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r441", "r445", "r476", "r477", "r479", "r805" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "AGE_DerivativesAndHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "DerivativesAndHedgingMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivatives And Hedging [Member]" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortizationDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets for discontinued operations", "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations." } } }, "auth_ref": [ "r212", "r875" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative", "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Research and development credit carryforwards", "verboseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r92", "r93", "r935" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock, shares", "verboseLabel": "Number of common stock shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r18", "r137", "r138", "r171", "r661", "r740", "r759" ] }, "AGE_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "StockOptionsMember", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]", "documentation": "Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r358", "r359", "r360", "r363", "r893", "r894" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpense", "crdr": "debit", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax provisions", "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances." } } }, "auth_ref": [ "r93", "r935" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "AGE_TwoThousandSeventeenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwoThousandSeventeenEquityIncentivePlanMember", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Thousand Seventeen Equity Incentive Plan [Member]", "documentation": "Two Thousand Seventeen Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant to purchase shares of common stock", "verboseLabel": "Warrant purchase", "terseLabel": "Warrant to purchase share of common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r419" ] }, "AGE_TwoThousandAndTwentyTwoSecuredNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwoThousandAndTwentyTwoSecuredNoteMember", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "2022 Secured Note [Member]", "documentation": "2022 Secured Note [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r387", "r432", "r437", "r539", "r573", "r794", "r795", "r801", "r802", "r803" ] }, "AGE_SecuredNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SecuredNoteMember", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Secured Note [Member]", "documentation": "Secured Note [Member]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r489" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://agexinc.com/role/StockholdersDeficit", "http://agexinc.com/role/StockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit", "verboseLabel": "Stockholders\u2019 Equity (Deficit)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r168", "r244", "r402", "r404", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r417", "r420", "r534", "r743", "r745", "r764" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r138", "r697" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r387", "r432", "r437", "r539", "r572", "r801", "r802", "r803" ] }, "us-gaap_DebtConversionDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionDescription", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt conversion description", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "crdr": "debit", "presentation": [ "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subscriptions price", "documentation": "Amount of subscription receivable from investors who have been allocated common stock." } } }, "auth_ref": [ "r138", "r705", "r747" ] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesTable", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r826" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r138" ] }, "AGE_TenThousandMillionSecuredNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TenThousandMillionSecuredNoteMember", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Ten Thousand Million Secured Note [Member]", "documentation": "Ten Thousand Million Secured Note [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "verboseLabel": "Common stock, shares, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r18", "r138", "r697", "r716", "r963", "r964" ] }, "AGE_TotalDebtNetMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TotalDebtNetMember", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Total Debt Net [Member]", "documentation": "Total Debt Net [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r548", "r567" ] }, "us-gaap_TaxCreditCarryforwardDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardDescription", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Description", "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward." } } }, "auth_ref": [ "r91" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r387", "r432", "r433", "r434", "r435", "r436", "r437", "r539", "r574", "r794", "r795", "r801", "r802", "r803" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StatementsOfOperations", "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "NET LOSS", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r213", "r224", "r226", "r237", "r245", "r253", "r263", "r264", "r279", "r291", "r295", "r297", "r340", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r520", "r523", "r524", "r538", "r540", "r620", "r632", "r671", "r718", "r738", "r739", "r789", "r808", "r809", "r822", "r871", "r898" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r18", "r171" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r813", "r814", "r817", "r818", "r819", "r820", "r958", "r963" ] }, "AGE_InceptionDateMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "InceptionDateMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Inception Date [Member]", "documentation": "Inception Date [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r59" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r93", "r935" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseOther", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other, net", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other." } } }, "auth_ref": [ "r93", "r935" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r548", "r567" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r548", "r567" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss": { "parentTag": "AGE_ComprehensiveLossAttributableToCommonStockholders", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "COMPREHENSIVE LOSS", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r45", "r225", "r227", "r233", "r618", "r636" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares issued for acquired, shares", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r137", "r138", "r171" ] }, "AGE_IssuanceDateMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "IssuanceDateMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date [Member]", "documentation": "Issuance Date [Member]" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r837", "r838" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r18", "r137", "r138", "r171", "r455" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "auth_ref": [ "r249", "r521", "r522", "r525", "r526", "r565", "r778", "r897", "r900", "r901" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r18", "r41", "r78", "r171", "r390" ] }, "AGE_PeriodEndingMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "PeriodEndingMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Period Ending [Member]", "documentation": "Period Ending [Member]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disaggregated Geographical Revenue", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r23" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r548", "r567" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r837" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r249", "r521", "r522", "r525", "r526", "r565", "r778", "r897", "r900", "r901" ] }, "AGE_FourAprilTwentyThousandAndTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FourAprilTwentyThousandAndTwentyTwoMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "4/4/2022 [Member]", "documentation": "4/4/2022 [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate of acquisition cost", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r94" ] }, "AGE_InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "Initial measurement date of 2/14/2022 [Member]", "documentation": "Initial measurement date of 2/14/2022 [Member]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "AGE_FourteenFebruaryTwoThousandAndTwentyTwoOneMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FourteenFebruaryTwoThousandAndTwentyTwoOneMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "2/14/2022 [Member]", "documentation": "Fourteen February Two Thousand and Twenty Two One [Member]" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r833" ] }, "us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of accumulated amortization of debt issuance costs classified as noncurrent." } } }, "auth_ref": [ "r106" ] }, "AGE_LossContingencyDescription": { "xbrltype": "stringItemType", "nsuri": "http://agexinc.com/20230930", "localname": "LossContingencyDescription", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notice of delisting", "documentation": "Notice of Delisting." } } }, "auth_ref": [] }, "AGE_FifteenFebruaryTwentyThousandAndTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FifteenFebruaryTwentyThousandAndTwentyTwoMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "2/15/2022 [Member]", "documentation": "Fifteen February Twenty Thousand And Twenty Two [Member]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to noncontrolling interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r102", "r179", "r224", "r226", "r263", "r264", "r633", "r871" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "AGE_SixJuneTwentyThousandAndTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SixJuneTwentyThousandAndTwentyTwoMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "6/6/2022 [Member]", "documentation": "Six June Twenty Thousand And Twenty Two [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedOfRevenuesDetails", "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r298", "r603", "r639", "r640", "r641", "r642", "r643", "r644", "r782", "r799", "r811", "r852", "r895", "r896", "r904", "r957" ] }, "AGE_SixteenAugustTwentyThousandAndTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SixteenAugustTwentyThousandAndTwentyTwoMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "8/16/2022 [Member]", "documentation": "8/16/2022 [Member]" } } }, "auth_ref": [] }, "AGE_TwentyFirstOctoberTwoThousandAndTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwentyFirstOctoberTwoThousandAndTwentyTwoMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "10/21/2022 [Member]", "documentation": "Twenty First October Two Thousand And Twenty Two [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesLineItems", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r806" ] }, "AGE_FourteenDecemberTwoThousandAndTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FourteenDecemberTwoThousandAndTwentyTwoMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "12/14/2022 [Member]", "documentation": "Fourteen December Two Thousand And Twenty Two [Member]" } } }, "auth_ref": [] }, "AGE_TwentyFiveJanuaryTwoThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwentyFiveJanuaryTwoThousandAndTwentyThreeMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "25 January 2023 [Member]", "documentation": "25 January 2023 [Member]" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r837" ] }, "AGE_TwoSeptemberTwoThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwoSeptemberTwoThousandAndTwentyThreeMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "2 September 2023 [Member]", "documentation": "2 September 2023 [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r505" ] }, "AGE_FifteenFebruaryTwentyThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FifteenFebruaryTwentyThousandAndTwentyThreeMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "15 February 2023 [Member]", "documentation": "15 February 2023 [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNoncurrentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNoncurrentGross", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Debt Issuance Costs", "label": "Debt Issuance Costs", "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r106" ] }, "AGE_FourthAprilTwentyThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FourthAprilTwentyThousandAndTwentyThreeMember", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "4 April 2023 [Member]", "documentation": "4 April 2023 [Member]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedOfRevenuesDetails", "http://agexinc.com/role/StatementsOfOperations" ], "auth_ref": [ "r298", "r603", "r639", "r640", "r641", "r642", "r643", "r644", "r782", "r799", "r811", "r852", "r895", "r896", "r904", "r957" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash, Cash Equivalents and Restricted Cash", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r24", "r181", "r955" ] }, "AGE_ChardanCapitalMarketsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ChardanCapitalMarketsLLCMember", "presentation": [ "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chardan Capital Markets LLC [Member]", "documentation": "Chardan Capital Markets LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r51", "r216", "r241" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r140", "r171", "r627", "r650", "r655", "r665", "r698", "r810" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfIntangibleAssetsNetDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r161", "r605" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intrinsic value outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r84" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r439", "r599", "r645", "r687", "r688", "r749", "r751", "r753", "r754", "r756", "r779", "r780", "r791", "r798", "r804", "r812", "r902", "r944", "r945", "r946", "r947", "r948", "r949" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "auth_ref": [ "r355", "r724" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options outstanding, beginning balance", "periodEndLabel": "Number of options outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r450", "r451" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities from continuing operations", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r873" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "BASIC", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r266", "r273" ] }, "us-gaap_NetRentableArea": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetRentableArea", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Office space", "documentation": "Net rentable area for properties owned." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://agexinc.com/role/ScheduleOfWeightedAverageAssumptionsToCalculateFairValueOfStockOptionsDetails", "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, options granted", "label": "Grant Price", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r464" ] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r108", "r953" ] }, "AGE_CommonStockOutstandingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://agexinc.com/20230930", "localname": "CommonStockOutstandingPercentage", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock outstanding percentage", "documentation": "Common stock outstanding percentage." } } }, "auth_ref": [] }, "AGE_DeferredTaxAssetsCapitalizedResearchExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "DeferredTaxAssetsCapitalizedResearchExpenses", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Capitalized Research Expenses", "documentation": "Deferred tax assets capitalized research expenses." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities from continuing operations", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r873" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, outstanding, beginning balance", "periodEndLabel": "Weighted average exercise price, outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r450", "r451" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r161", "r604" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, exercisable, ending balance", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r452" ] }, "AGE_RestrictedStockAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "RestrictedStockAndRestrictedStockUnitsMember", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock And Restricted Stock Units [Member]", "documentation": "Restricted Stock And Restricted Stock Units [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercisable, ending balance", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r452" ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetailsParenthetical", "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetailsParenthetical", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit, Current", "verboseLabel": "Lines of credit current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r134", "r184" ] }, "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary stock, stated value", "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r25", "r74" ] }, "AGE_DebtRefinancedWithNewDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "DebtRefinancedWithNewDebt", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Debt refinanced with new debt (Note 5)", "documentation": "Debt refinanced with new debt." } } }, "auth_ref": [] }, "AGE_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "EquityIncentivePlanMember", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan [Member]", "documentation": "Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r75", "r76", "r77", "r78", "r79", "r80", "r81", "r169", "r170", "r171", "r220", "r221", "r222", "r277", "r403", "r404", "r406", "r408", "r411", "r416", "r418", "r661", "r662", "r663", "r664", "r798", "r844", "r877" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r220", "r221", "r222", "r277", "r403", "r404", "r406", "r408", "r411", "r416", "r418", "r661", "r662", "r663", "r664", "r798", "r844", "r877" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://agexinc.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r807", "r933" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit, current borrowing capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://agexinc.com/role/ScheduleOfWeightedAverageAssumptionsToCalculateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r472" ] }, "AGE_CaliforniaPurposesMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "CaliforniaPurposesMember", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "California Purposes [Member]", "documentation": "California Purposes [Member]" } } }, "auth_ref": [] }, "AGE_DisclosureWarrantLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://agexinc.com/20230930", "localname": "DisclosureWarrantLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Warrant Liability" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails", "http://agexinc.com/role/ScheduleOfWeightedAverageAssumptionsToCalculateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Volatility (annual)", "verboseLabel": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r471" ] }, "AGE_WarrantLiabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://agexinc.com/20230930", "localname": "WarrantLiabilityTextBlock", "presentation": [ "http://agexinc.com/role/WarrantLiability" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant Liability", "documentation": "Warrant Liability [Text Block]", "label": "WarrantLiabilityTextBlock" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails", "http://agexinc.com/role/ScheduleOfWeightedAverageAssumptionsToCalculateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Interest Rate (annual)", "verboseLabel": "Risk-free interest rates", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r473" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan obtained", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r26", "r185", "r954" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedGeographicalRevenueDetails", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StatementsOfOperations", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r250", "r251", "r252", "r276", "r603", "r659", "r683", "r689", "r690", "r691", "r692", "r693", "r694", "r697", "r700", "r701", "r702", "r703", "r704", "r706", "r707", "r708", "r709", "r711", "r712", "r713", "r714", "r715", "r717", "r720", "r721", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r740", "r816" ] }, "AGE_GILTIMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "GILTIMember", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "GILTI [Member]", "documentation": "GILTI [Member]." } } }, "auth_ref": [] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentOperatingActivitiesDomain", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "AGE_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://agexinc.com/20230930", "localname": "GoingConcernPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Going Concern Assessment", "documentation": "Going concern policy [Text Block]" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableGrossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableGrossNoncurrent", "crdr": "debit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Convertible note receivable", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable classified as noncurrent. Excludes net investment in lease." } } }, "auth_ref": [ "r302", "r890" ] }, "AGE_OtherIncomeTaxMattersMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "OtherIncomeTaxMattersMember", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Income Tax Matters [Member]", "documentation": "Other Income Tax Matters [Member]" } } }, "auth_ref": [] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r7", "r114", "r115", "r116" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r446", "r447", "r448", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r470", "r471", "r472", "r473", "r474" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails", "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative", "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r442", "r444", "r446", "r447", "r448", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r470", "r471", "r472", "r473", "r474" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.0001 par value, 5,000 shares authorized", "verboseLabel": "Preferred stock, value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r137", "r624", "r810" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r166", "r356", "r357", "r768", "r892" ] }, "AGE_SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SummaryOfDebtIssuanceCostsAndDebtBalancesTableTextBlock", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt Issuance Costs and Debt Balances", "documentation": "Summary of Debt Issuance Costs and Debt Balances [Table Text Block]" } } }, "auth_ref": [] }, "AGE_GrantRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "GrantRevenuesMember", "presentation": [ "http://agexinc.com/role/ScheduleOfDisaggregatedOfRevenuesDetails", "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Grant Revenues [Member]", "documentation": "Grant Revenues [Member]" } } }, "auth_ref": [] }, "AGE_AccountingForWarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://agexinc.com/20230930", "localname": "AccountingForWarrantsPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting for warrants", "documentation": "Accounting For Warrants [Policy Text Block]" } } }, "auth_ref": [] }, "AGE_PaycheckProtectionProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "PaycheckProtectionProgramMember", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Paycheck Protection Program [Member]", "documentation": "Paycheck Protection Program [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails", "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative", "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r442", "r444", "r446", "r447", "r448", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r470", "r471", "r472", "r473", "r474" ] }, "AGE_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://agexinc.com/20230930", "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Pronouncements Not Yet Adopted", "documentation": "Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Finite lived intangible asset useful life", "verboseLabel": "Estimated useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentContinuingOperationsMember", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Continuing Operations [Member]", "documentation": "Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "AGE_CoronavirusAidReliefAndEconomicSecurityActPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://agexinc.com/20230930", "localname": "CoronavirusAidReliefAndEconomicSecurityActPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "CARES Act", "documentation": "Coronavirus Aid Relief And Economic Security Act [Policy Text Block]" } } }, "auth_ref": [] }, "AGE_WarrantsOutstandingAndFairValuesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://agexinc.com/20230930", "localname": "WarrantsOutstandingAndFairValuesTableTextBlock", "presentation": [ "http://agexinc.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrant Outstanding and Fair Values", "documentation": "Warrants Outstanding And Fair Values [Table Text Block]" } } }, "auth_ref": [] }, "AGE_SegmentContinuingOperationsOneMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SegmentContinuingOperationsOneMember", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Segment Continuing Operations One [Member]", "documentation": "Segment Continuing Operations One [Member]" } } }, "auth_ref": [] }, "AGE_RetainedSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "RetainedSharesOfCommonStock", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Retained shares of common stock", "documentation": "Retained shares of common stock." } } }, "auth_ref": [] }, "AGE_SegmentContinuingOperationsTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SegmentContinuingOperationsTwoMember", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Segment Continuing Operations Two [Member]", "documentation": "Segment Continuing Operations Two [Member]" } } }, "auth_ref": [] }, "AGE_OriginationFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "OriginationFeeMember", "presentation": [ "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Origination Fee [Member]", "documentation": "Origination Fee [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash used in operating activities from discontinued operations (Note 3)", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r129", "r156" ] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary." } } }, "auth_ref": [ "r17", "r103" ] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary stock, par value", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r25", "r74" ] }, "us-gaap_LineOfCreditFacilityDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityDescription", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit facility, description", "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity." } } }, "auth_ref": [ "r30" ] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deconsolidation of cash and cash equivalents from discontinued operations (Note 3)", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r129", "r156" ] }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Partial payment on loan due to AgeX from discontinued operations (Note 3)", "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r156" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Temporary equity balance, value", "documentation": "Value of new stock classified as temporary equity issued during the period." } } }, "auth_ref": [] }, "AGE_PaymentOfMergerConsiderationOnProRataPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "PaymentOfMergerConsiderationOnProRataPortion", "crdr": "credit", "presentation": [ "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment of merger consideration on pro rata portion", "documentation": "Payment of merger consideration on pro rata portion." } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Amortization Assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r68" ] }, "AGE_ConvertibleNotePurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ConvertibleNotePurchaseAgreementMember", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Note Purchase Agreement [Member]", "documentation": "Convertible Note Purchase Agreement [Member]" } } }, "auth_ref": [] }, "AGE_PaidInCashPortionOfIndebtedness": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "PaidInCashPortionOfIndebtedness", "crdr": "credit", "presentation": [ "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Paid in cash portion of indebtedness", "documentation": "Paid in cash portion of Indebtedness." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExaminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationDescription", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax description", "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings." } } }, "auth_ref": [ "r90" ] }, "AGE_SubordinationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SubordinationAgreementMember", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subordination Agreement [Member]", "documentation": "Subordination Agreement [Member]" } } }, "auth_ref": [] }, "AGE_OtherRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "OtherRevenuesMember", "presentation": [ "http://agexinc.com/role/ScheduleOfDisaggregatedOfRevenuesDetails", "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Revenues [Member]", "documentation": "Other Revenues [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://agexinc.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r566", "r568" ] }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase in line of credit", "verboseLabel": "Line of Credit Facility, Increase (Decrease), Net", "documentation": "Amount of increase (decrease) of the credit facility." } } }, "auth_ref": [ "r878" ] }, "AGE_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "documentation": "Finite lived intangible assets amortization expense after year three.", "label": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree" } } }, "auth_ref": [] }, "AGE_IssuanceAndSaleOfWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "IssuanceAndSaleOfWarrantsMember", "presentation": [ "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance And Sale Of Warrants [Member]" } } }, "auth_ref": [] }, "AGE_RoyaltyPercentages": { "xbrltype": "percentItemType", "nsuri": "http://agexinc.com/20230930", "localname": "RoyaltyPercentages", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty percentage", "documentation": "Royalty percentages." } } }, "auth_ref": [] }, "AGE_JuvenescenceLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "JuvenescenceLimitedMember", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Juvenescence Limited [Member]", "documentation": "Juvenescence Limited [Member]" } } }, "auth_ref": [] }, "AGE_WarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "WarrantLiability", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "Warrant liability", "periodStartLabel": "Fair value as of period beginning balance, fair value", "periodEndLabel": "Fair value as of period beginning balance, fair value", "documentation": "Warrant Liability." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://agexinc.com/role/SupplementalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Non-cash Investing and Financing Transactions", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "AGE_LoanFacilityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "LoanFacilityAgreementMember", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan Facility Agreement [Member]", "documentation": "Loan Facility Agreement [Member]" } } }, "auth_ref": [] }, "AGE_DebtExchangedForPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "DebtExchangedForPreferredStock", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Exchanged for Preferred Stock" } } }, "auth_ref": [] }, "AGE_IssuanceOfWarrantsForDebtOne": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "IssuanceOfWarrantsForDebtOne", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants for debt issuance under the Secured Note (Note 6)", "documentation": "Issuance of warrants for debt." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r29" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 11)", "verboseLabel": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r39", "r109", "r623", "r696" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit facility, maximum borrowing capacity", "negatedLabel": "Amount Refinanced", "verboseLabel": "Amount Refinanced", "terseLabel": "Line of credit facility, current borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r30" ] }, "AGE_ComprehensiveLossAttributableToCommonStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ComprehensiveLossAttributableToCommonStockholders", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX COMMON STOCKHOLDERS", "documentation": "Comprehensive loss attributable to common stock holders.", "label": "ComprehensiveLossAttributableToCommonStockholders" } } }, "auth_ref": [] }, "AGE_AgeXMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "AgeXMember", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "AgeX [Member]", "documentation": "AgeX [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "AGE_InsurancePremiumLiabilityAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "InsurancePremiumLiabilityAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Insurance premium liability and other current liabilities", "documentation": "Insurance premium liability and other current liabilities." } } }, "auth_ref": [] }, "AGE_LifeMapSciencesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "LifeMapSciencesIncMember", "presentation": [ "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "LifeMap Sciences Inc [Member]", "documentation": "LifeMap Sciences Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax provisions", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r197", "r205", "r263", "r264", "r283", "r495", "r512", "r638" ] }, "AGE_LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss": { "parentTag": "AGE_ComprehensiveLossAttributableToCommonStockholders", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Less: Comprehensive loss attributable to noncontrolling interest from continuing operations", "documentation": "Less comprehensive loss attributable to non controlling interest from continuing operations." } } }, "auth_ref": [] }, "AGE_WarrantsIssuedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://agexinc.com/20230930", "localname": "WarrantsIssuedPercentage", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants issued percentage", "documentation": "Warrants issued percentage." } } }, "auth_ref": [] }, "AGE_OtherComprehensiveIncomeLossAttributableToNoncontrollingInterestFromDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "OtherComprehensiveIncomeLossAttributableToNoncontrollingInterestFromDiscontinuedOperations", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss": { "parentTag": "AGE_ComprehensiveLossAttributableToCommonStockholders", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Less: Comprehensive loss attributable to noncontrolling interest from discontinued operations", "documentation": "Other comprehensive income loss attributable to non controlling interest from discontinued operations." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "AGE_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Temporary equity balance, shares" } } }, "auth_ref": [] }, "AGE_OriginationFeeDescription": { "xbrltype": "stringItemType", "nsuri": "http://agexinc.com/20230930", "localname": "OriginationFeeDescription", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Origination fee description", "documentation": "Origination fee, description." } } }, "auth_ref": [] }, "AGE_NetLossAttributable": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "NetLossAttributable", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to AgeX" } } }, "auth_ref": [] }, "AGE_AccruedLoanOriginationFees": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "AccruedLoanOriginationFees", "crdr": "credit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued loan origination fees" } } }, "auth_ref": [] }, "AGE_MergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "MergerAgreementMember", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Merger Agreement [Member]", "documentation": "Merger Agreement [Member]" } } }, "auth_ref": [] }, "AGE_Indebtedness": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "Indebtedness", "crdr": "debit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Indebtedness", "documentation": "Indebtedness." } } }, "auth_ref": [] }, "AGE_IssuanceOfWarrantsForDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "IssuanceOfWarrantsForDebt", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants for debt issuance under the 2020 Loan Agreement", "documentation": "Issuance of warrants for debt." } } }, "auth_ref": [] }, "AGE_CashAdvancedOnConvertibleNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "CashAdvancedOnConvertibleNoteReceivable", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash advanced on convertible note receivable", "documentation": "Cash advanced on convertible note receivable.", "label": "CashAdvancedOnConvertibleNoteReceivable" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r88", "r89", "r443" ] }, "AGE_JuvenescenceMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "JuvenescenceMember", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Juvenescence [Member]", "documentation": "Juvenescence [Member]" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtRefinancedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtRefinancedAmount", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfNon-cashInvestingAndFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt refinanced with new debt (Note 5)", "label": "Short-Term Debt, Refinanced, Amount", "documentation": "Amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ClosedBlockDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClosedBlockDisclosureTextBlock", "presentation": [ "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciences" ], "lang": { "en-us": { "role": { "label": "Disposition and Deconsolidation of LifeMap Sciences", "documentation": "The entire disclosure pertaining to the closed block." } } }, "auth_ref": [ "r204", "r207" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_WarrantExercisePriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantExercisePriceDecrease", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercise price, minimum", "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r419" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r31" ] }, "AGE_EffectiveIncomeTaxRateReconciliationReturnToProvisionOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://agexinc.com/20230930", "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionOtherAdjustments", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Return to provision & other adjustments", "documentation": "Effective income tax rate reconciliation return to provision other adjustments." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r553" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableCurrent", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Loans due to Juvenescence, net of debt issuance costs, current portion", "verboseLabel": "Loan due to Juvenescence, net of debt issuance costs, current portion", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r34" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative", "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" ] }, "AGE_ReCyteTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ReCyteTherapeuticsIncMember", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "ReCyte Therapeutics Inc [Member]", "documentation": "ReCyte Therapeutics Inc [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "NET LOSS PER COMMON SHARE:" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/StatementsOfCashFlows", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on extinguishment of debt (Paycheck Protection Program loan)", "label": "Extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r10", "r72", "r73" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r265", "r440", "r845", "r846", "r883" ] }, "AGE_NeuroAirmidMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "NeuroAirmidMember", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "NeuroAirmid [Member]", "documentation": "NeuroAirmid [Member]" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r840" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recognized over weighted average period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r478" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r837" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://agexinc.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r246", "r491", "r497", "r503", "r507", "r511", "r514", "r516", "r517", "r666" ] }, "us-gaap_WarrantExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantExercisePriceIncrease", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercise price, maximum", "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r31" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r153", "r721" ] }, "AGE_ConvertiblePromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ConvertiblePromissoryNoteMember", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note [Member]", "documentation": "Convertible Promissory Note [Member]" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "auth_ref": [ "r265", "r440", "r845", "r883" ] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Related party receivables, net", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "AGE_DeferredTaxAssetsPatentsAndFixedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "DeferredTaxAssetsPatentsAndFixedAssets", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Patents and fixed assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and fixed assets." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive expense, net of tax:" } } }, "auth_ref": [] }, "AGE_SubscriptionAndAdvertisementRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SubscriptionAndAdvertisementRevenuesMember", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subscription and Advertisement Revenues [Member]", "documentation": "Subscription and Advertisement Revenues [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCollectionOfLongtermLoansToRelatedParties", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Partial collection on loan due from LifeMap Sciences", "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates." } } }, "auth_ref": [ "r872", "r940" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r183", "r219", "r245", "r279", "r292", "r296", "r340", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r521", "r525", "r540", "r622", "r710", "r810", "r823", "r898", "r899", "r942" ] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units (Note 8)", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r53", "r54", "r55" ] }, "AGE_NationalInstitutesOfHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "NationalInstitutesOfHealthMember", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "National Institutes of Health [Member]", "documentation": "National Institutes of Health [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r59" ] }, "AGE_LeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "LeaseAgreementMember", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease Agreement [Member]", "documentation": "Lease Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r874" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative", "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r228", "r493", "r494", "r503", "r504", "r506", "r508", "r660" ] }, "AGE_LoanAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "LoanAgreementsMember", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Loan Agreements [Member]", "documentation": "Loan Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "AGE_ForeignMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ForeignMember", "presentation": [ "http://agexinc.com/role/ScheduleOfDisaggregatedGeographicalRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Foreign [Member]", "documentation": "Foreign [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r274" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r446", "r447", "r448", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r470", "r471", "r472", "r473", "r474" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "AGE_AssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "AssetPurchaseAgreementMember", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Asset Purchase Agreement [Member]", "documentation": "Asset Purchase Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedOfRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "AGE_NetOperatingLossesExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://agexinc.com/20230930", "localname": "NetOperatingLossesExpirationDate", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating loss, expiration date", "documentation": "Net operating losses expiration date." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net loss from operations", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r145", "r189", "r279", "r291", "r295", "r297", "r620", "r630", "r789" ] }, "AGE_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and Development [Member]", "documentation": "Research and Development [Member]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical", "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r519" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options outstanding, options forfeited, cancelled or expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r911" ] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebt", "crdr": "credit", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetailsParenthetical", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Secured debt", "verboseLabel": "Secured note", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r26", "r185", "r954" ] }, "AGE_SecuredConvertiblePromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SecuredConvertiblePromissoryNoteMember", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Secured Convertible Promissory Note [Member]", "documentation": "Secured Convertible Promissory Note [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical", "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r519" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r868" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, options forfeited, cancelled or expired", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r911" ] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Extinguishment of Debt, Amount", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "AGE_TwoThousandNineteenLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwoThousandNineteenLoanAgreementMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "2019 Loan Agreement [Member]", "documentation": "2019 Loan Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r148" ] }, "us-gaap_DeconsolidationGainOrLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeconsolidationGainOrLossAmount", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 3.0 }, "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetailsParenthetical", "http://agexinc.com/role/StatementsOfCashFlows", "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain on deconsolidation of LifeMap Sciences (Note 3)", "negatedLabel": "Gain on deconsolidation of LifeMap Sciences (Note 3)", "verboseLabel": "Deconsolidation, gain (loss), amount", "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer." } } }, "auth_ref": [ "r100" ] }, "AGE_TwoThousandAndTwentyLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwoThousandAndTwentyLoanAgreementMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2020 Loan Agreement [Member]", "documentation": "2020 Loan Agreement [Member]" } } }, "auth_ref": [] }, "AGE_TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 Secured Convertible Promissory Note and Security Agreement [Member]", "documentation": "2022 Secured Convertible Promissory Note and Security Agreement [Member]" } } }, "auth_ref": [] }, "AGE_TwoThousandTwentyTwoWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwoThousandTwentyTwoWarrantsMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 Warrants [Member]", "documentation": "2022 Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical", "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r519" ] }, "AGE_SecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SecurityAgreementMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Security Agreement [Member]", "documentation": "Security Agreement [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r439", "r599", "r645", "r687", "r688", "r749", "r751", "r753", "r754", "r756", "r779", "r780", "r791", "r798", "r804", "r812", "r902", "r944", "r945", "r946", "r947", "r948", "r949" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "AGE_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, restricted stock units vested", "documentation": "Weighted Average Exercise Price of Options, Restricted stock units granted." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r18", "r71", "r171" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from convertible debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r48" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical", "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r519" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r149", "r395", "r550", "r875" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r441", "r449", "r468", "r469", "r470", "r471", "r474", "r483", "r484", "r485", "r486" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r431", "r439", "r471", "r472", "r473", "r575", "r599", "r645", "r687", "r688", "r749", "r751", "r753", "r754", "r756", "r779", "r780", "r791", "r798", "r804", "r812", "r815", "r891", "r902", "r945", "r946", "r947", "r948", "r949" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r59" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r337", "r338", "r339" ] }, "AGE_ReverseRatioMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ReverseRatioMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reverse Ratio [Member]", "documentation": "Reverse Ratio [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r59" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r159", "r242" ] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ParentCompanyMember", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Parent Company [Member]" } } }, "auth_ref": [ "r249" ] }, "us-gaap_ScheduleOfRegulatoryLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRegulatoryLiabilitiesTextBlock", "presentation": [ "http://agexinc.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model", "documentation": "Tabular disclosure of regulatory liabilities. Detailed information about liabilities that result from rate actions of a regulator. Rate actions of a regulator can impose a liability on a regulated enterprise resulting in a regulatory liability." } } }, "auth_ref": [ "r193" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r354", "r355", "r724" ] }, "AGE_TwentyTwentyWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwentyTwentyWarrantMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Twenty Twenty Warrant [Member]", "documentation": "Twenty Twenty Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per share attributable to common stockholders", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r59", "r60" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r548", "r567" ] }, "AGE_TwentyTwentyLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "TwentyTwentyLoanAgreementMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Twenty Twenty Loan Agreement [Member]", "documentation": "Twenty Twenty Loan Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit, expiry date", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": [ "r30" ] }, "AGE_RegistrationRightsAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://agexinc.com/20230930", "localname": "RegistrationRightsAgreementsMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Registration Rights Agreements [Member]", "documentation": "Registration Rights Agreements [Member]" } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "auth_ref": [ "r359", "r360", "r361", "r362", "r431", "r439", "r471", "r472", "r473", "r575", "r599", "r645", "r687", "r688", "r749", "r751", "r753", "r754", "r756", "r779", "r780", "r791", "r798", "r804", "r812", "r815", "r891", "r902", "r945", "r946", "r947", "r948", "r949" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://agexinc.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r229", "r230", "r542", "r543", "r544", "r545", "r546", "r547" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consulting fees and services", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r821", "r961", "r962" ] }, "AGE_EffectiveIncomeTaxRateReconciliationPermanentDifferences": { "xbrltype": "percentItemType", "nsuri": "http://agexinc.com/20230930", "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Permanent differences", "documentation": "Effective income tax rate reconciliation permanent differences." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsTables" ], "lang": { "en-us": { "role": { "label": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r19", "r20", "r86" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at January 1", "periodEndLabel": "Balance at December 31", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r492", "r498" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r173" ] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": [ "http://agexinc.com/role/SupplementalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Condensed Consolidated Pro Forma Balance Sheets", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": [ "r56", "r57", "r58" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r829" ] }, "AGE_StockholderOutstandingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://agexinc.com/20230930", "localname": "StockholderOutstandingPercentage", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stockholder outstanding percentage", "documentation": "Stockholder outstanding percentage." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Reductions related to settlements", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r501" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r387", "r432", "r433", "r434", "r435", "r436", "r437", "r572", "r573", "r574", "r794", "r795", "r801", "r802", "r803" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Computed tax benefit at federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r246", "r496", "r513" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently adopted accounting pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of long-lived assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r165" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Reductions for tax positions related to prior years", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r499" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Additions for tax positions related to prior years", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r499" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Reductions related to a lapse of statute", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r502" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Additions for tax positions related to the current year", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r500" ] }, "srt_PlatformOperatorCryptoAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PlatformOperatorCryptoAssetLineItems", "presentation": [ "http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Line Items]" } } }, "auth_ref": [] }, "srt_PlatformOperatorCryptoAssetTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PlatformOperatorCryptoAssetTable", "presentation": [ "http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Table]" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt converted amount", "verboseLabel": "Debt converted to equity", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r53", "r55" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Based Compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r932", "r936" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r836" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r862" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "State tax benefit, net of effect on federal income taxes", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r932", "r936" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "AGE_EffectiveIncomeTaxRateLossAndDeconsolidation": { "xbrltype": "percentItemType", "nsuri": "http://agexinc.com/20230930", "localname": "EffectiveIncomeTaxRateLossAndDeconsolidation", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Loss and deconsolidation of LifeMap Sciences", "documentation": "Effective income tax rate loss and deconsolidation." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "OTHER EXPENSE, NET:" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration of credit risk and other risks and uncertainties", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r110", "r201" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://agexinc.com/role/ScheduleOfIntangibleAssetsNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "totalLabel": "Total intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r64", "r67" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r97", "r151", "r158", "r255", "r256", "r258", "r259", "r270", "r273" ] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r866", "r867", "r903" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r182", "r218", "r621", "r823" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Research and development and other credits", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r932", "r936" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r842" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Based Compensation Expense", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r87" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r154" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r834" ] }, "us-gaap_SupplementalIncomeStatementElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalIncomeStatementElementsAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "AMOUNTS ATTRIBUTABLE TO AGEX:" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Continuing operations", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r144", "r188", "r190", "r234", "r253", "r255", "r256", "r258", "r259", "r268", "r271", "r272", "r538", "r619", "r956" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails", "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "NET LOSS FROM DISCONTINUED OPERATIONS (Note 3)", "totalLabel": "Loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r117", "r118", "r119", "r120", "r121", "r131", "r213", "r515", "r631" ] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock closing price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r405" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": [ "r104", "r180" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://agexinc.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r229", "r230", "r542", "r543", "r544", "r545", "r546", "r547" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Discontinued operations", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r146", "r234", "r269", "r271", "r272", "r952", "r956" ] }, "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod", "crdr": "credit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit facility", "documentation": "Maximum amount borrowed under the credit facility at any time during the period." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r162" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r83" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r162" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r866", "r867", "r903" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Stock Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r162" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r398", "r416", "r533", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r635", "r792", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r885", "r886", "r887", "r888" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r162" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r150", "r245", "r279", "r291", "r295", "r297", "r340", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r540", "r789", "r898" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r162" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative", "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Capital loss carryforwards", "verboseLabel": "Deferred tax assets capital loss carry forwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards." } } }, "auth_ref": [ "r93", "r935" ] }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Transactions with noncontrolling interests \u2013 LifeMap Sciences", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": [ "r98", "r171", "r178" ] }, "us-gaap_TemporaryEquityOtherChanges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityOtherChanges", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Temporary equity balance, value", "label": "Temporary Equity, Other Changes", "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Long-lived intangible assets, net", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r68", "r600", "r601", "r602", "r604", "r786" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAmortizationAssetsDetails" ], "lang": { "en-us": { "role": { "label": "2023", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails", "http://agexinc.com/role/StatementsOfCashFlows", "http://agexinc.com/role/StatementsOfOperations", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of warrants", "label": "Change in fair value of warrants", "verboseLabel": "Fair value as of period beginning balance", "terseLabel": "Loss on change in fair value of warrants", "negatedTerseLabel": "Loss on change in fair value of warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r2", "r10" ] }, "AGE_DebtInstrumentFaceAndInterestOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "DebtInstrumentFaceAndInterestOutstanding", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal and interest outstanding" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r841" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary stock, shares issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r136" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r387", "r432", "r433", "r434", "r435", "r436", "r437", "r539", "r572", "r573", "r574", "r794", "r795", "r801", "r802", "r803" ] }, "us-gaap_TemporaryEquityNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityNetIncome", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Temporary equity balance, value", "label": "Temporary Equity, Net Income", "documentation": "The portion of net income or loss attributable to temporary equity interest." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r33", "r245", "r340", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r522", "r525", "r526", "r540", "r695", "r788", "r823", "r898", "r942", "r943" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r475", "r488" ] }, "us-gaap_InsuranceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InsuranceAbstract", "lang": { "en-us": { "role": { "label": "Insurance [Abstract]" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r826" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r137", "r403" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair market value of common stock", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related party payables, net", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r34", "r810" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedGeographicalRevenueDetails", "http://agexinc.com/role/ScheduleOfDisaggregatedOfRevenuesDetails", "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Total revenues", "verboseLabel": "Revenues, net", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r280", "r281", "r290", "r293", "r294", "r298", "r299", "r301", "r429", "r430", "r603" ] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponents" ], "lang": { "en-us": { "role": { "label": "Selected Balance Sheet Components", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r863" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r826" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Expiration Date", "documentation": "Date the equity-based award expires, in YYYY-MM-DD format." } } }, "auth_ref": [ "r906" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r826" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r137", "r697" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r137", "r697", "r716", "r963", "r964" ] }, "us-gaap_DividendsPayableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableTable", "presentation": [ "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Dividends Payable [Table]", "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid." } } }, "auth_ref": [ "r53" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Temporary stock, shares outstanding", "periodStartLabel": "Temporary equity balance, shares", "periodEndLabel": "Temporary equity balance, shares", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r136" ] }, "us-gaap_PreferredStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockVotingRights", "presentation": [ "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock voting rights", "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r78", "r137" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfNon-cashInvestingAndFinancingTransactionsDetails", "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid during the year for interest", "verboseLabel": "Cash paid during the period for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r236", "r239", "r240" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://agexinc.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Deferred Tax Assets and Liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r175" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r143", "r187", "r629", "r810", "r879", "r889", "r939" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://agexinc.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income Tax Rate Reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r174" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r826" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT", "verboseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense, net", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r106", "r192", "r232", "r282", "r549", "r725", "r821", "r960" ] }, "us-gaap_DividendsPayableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableLineItems", "presentation": [ "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Dividends Payable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts and grants receivable", "label": "Increase (Decrease) in Accounts and Other Receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": [ "r9" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r843" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "verboseLabel": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r137", "r403" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r454" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating losses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r93", "r935" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Calculated fair value per share", "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r84" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r93", "r935" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Discontinued Operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r12", "r22", "r28", "r113", "r122", "r123", "r124", "r125", "r126", "r130", "r132", "r133", "r164" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r934" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantsLiabilitiesAndStockOptionAwardsUsingBlack-scholesOption-pricingModelDetails", "http://agexinc.com/role/ScheduleOfWeightedAverageAssumptionsToCalculateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Time to Maturity (Years)", "verboseLabel": "Expected life (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r470" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r838" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r139", "r810", "r959" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r864", "r955" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://agexinc.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r438", "r560", "r561", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r690", "r691", "r692", "r693", "r694", "r715", "r717", "r748", "r941" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash, cash equivalents, and restricted cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r52", "r181" ] }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://agexinc.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r87" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r837" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r835", "r837", "r838" ] }, "AGE_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesAvailableForGrant", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares available for grant, options granted", "label": "ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesAvailableForGrant" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities from continuing operations", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r156", "r157", "r158" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Line of Credit", "verboseLabel": "Drawdown of Funds", "terseLabel": "Line of credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r26", "r185", "r954" ] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r16", "r44", "r869", "r870", "r871" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r238" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r398", "r416", "r533", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r635", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r885", "r886", "r887", "r888" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "verboseLabel": "Debt interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r36", "r375" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r238" ] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, percentage of ownership after transaction", "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r156", "r157", "r158" ] }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockTermsOfConversion", "presentation": [ "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion percentage, description", "documentation": "Description of conversion terms for preferred stock." } } }, "auth_ref": [ "r27", "r78", "r81", "r137", "r169", "r170" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r932", "r936" ] }, "us-gaap_LesseeOperatingLeaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDescription", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lessee operating lease description", "documentation": "Description of lessee's operating lease." } } }, "auth_ref": [ "r554" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r206", "r793", "r938" ] }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, percentage of ownership before transaction", "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction." } } }, "auth_ref": [] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://agexinc.com/role/SupplementalCashFlowInformation" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r155" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r138" ] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of secured debt", "verboseLabel": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r48" ] }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Net (income) loss attributable to noncontrolling interest", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest." } } }, "auth_ref": [ "r95", "r177" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS FROM CONTINUING OPERATIONS", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r177", "r245", "r253", "r279", "r291", "r295", "r297", "r340", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r538", "r540", "r630", "r789", "r898" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r209", "r220", "r221", "r222", "r245", "r268", "r269", "r271", "r273", "r277", "r278", "r340", "r364", "r366", "r367", "r368", "r371", "r372", "r403", "r404", "r408", "r411", "r418", "r540", "r661", "r662", "r663", "r664", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r697", "r719", "r740", "r758", "r759", "r760", "r761", "r762", "r844", "r877", "r884" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r38", "r249", "r374", "r375", "r376", "r377", "r378", "r380", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r551", "r793", "r794", "r795", "r796", "r797", "r878" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options granted and outstanding exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r21" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r152", "r245", "r340", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r540", "r898" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails", "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss from discontinued operations", "totalLabel": "Loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r117", "r118", "r119", "r120", "r121", "r127", "r131", "r177" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0, "order": 2.0 }, "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails", "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss attributable to noncontrolling interest from discontinued operations", "negatedTerseLabel": "Net loss from discontinued operations attributable to noncontrolling interest", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r95", "r117", "r118", "r119", "r120", "r121", "r127", "r131", "r177" ] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Payments for rent", "label": "Base rent", "verboseLabel": "Lease and rental expense", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r8" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://agexinc.com/role/ScheduleOfIntangibleAssetsNetDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r217", "r353" ] }, "AGE_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageFairValue", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted-average estimated fair value of stock options granted", "documentation": "Weighted-average estimated fair value of stock options granted." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r496" ] }, "us-gaap_ProceedsFromLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLoans", "crdr": "debit", "presentation": [ "http://agexinc.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from loans", "documentation": "Cash received from principal payments made on loans related to operating activities." } } }, "auth_ref": [ "r50" ] }, "us-gaap_LongTermLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermLoansPayable", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Loans due to Juvenescence, net of debt issuance costs, net of current portion", "verboseLabel": "Loan due to Juvenescence, net of debt issuance costs, net of current portion", "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r38" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Total Debt, Net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r26", "r185", "r386", "r401", "r794", "r795", "r954" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of preferred stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r18", "r137", "r138", "r171", "r672", "r740", "r759", "r822" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deductions", "verboseLabel": "Income tax rate deduction", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions." } } }, "auth_ref": [ "r932", "r936" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments to acquire businesses", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r47", "r518" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative", "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "verboseLabel": "Amortization expense of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r10", "r65", "r69" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfNon-cashInvestingAndFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of warrants for debt issuance under the 2020 Loan Agreement", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r827" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r289", "r299", "r790" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH:" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares available for grant, beginning balance", "periodEndLabel": "Shares available for grant, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r84" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r198", "r865", "r876" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest on convertible note receivable", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r61", "r62", "r63", "r199", "r200", "r202", "r203" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Temporary equity preferred stock", "periodStartLabel": "Temporary equity balance, value", "periodEndLabel": "Temporary equity balance, value", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r364", "r366", "r367", "r368", "r371", "r372", "r487", "r626" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of long term debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r48", "r661" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperationsComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustments from discontinued operations", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r163" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options to purchase shares", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r931" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedGeographicalRevenueDetails", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StatementsOfOperations", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r250", "r251", "r252", "r276", "r603", "r659", "r683", "r689", "r690", "r691", "r692", "r693", "r694", "r697", "r700", "r701", "r702", "r703", "r704", "r706", "r707", "r708", "r709", "r711", "r712", "r713", "r714", "r715", "r717", "r720", "r721", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r740", "r816" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit:", "verboseLabel": "Stockholders\u2019 equity (deficit):" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r826" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "DILUTED", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r234", "r255", "r256", "r258", "r259", "r261", "r268", "r271", "r272", "r273", "r275", "r537", "r538", "r619", "r637", "r787" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gains and Losses", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r541" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair value measurements of financial instruments", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "label": "Restricted Cash Equivalents", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r766", "r767", "r876", "r951", "r955" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Related party payables, net", "label": "Increase (Decrease) in Due to Related Parties", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, options granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r454" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/DispositionAndDeconsolidationOfLifemapSciencesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r156" ] }, "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare", "presentation": [ "http://agexinc.com/role/ScheduleOfWeightedAverageAssumptionsToCalculateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Market price", "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time." } } }, "auth_ref": [ "r172" ] }, "us-gaap_AssetsFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueAdjustment", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfNon-cashInvestingAndFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of liability classified warrants at debt inception date (Note 6)", "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Accounts and grants receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r302", "r303" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disaggregated of Revenues", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r904" ] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateAxis", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Fair value of liability classified warrants issued", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/StatementsOfCashFlows", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from the issuance of common stock", "verboseLabel": "Proceeds from sale of common stock", "terseLabel": "Proceeds from issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedOfRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "At beginning of the period", "periodEndLabel": "At end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r51", "r156", "r241" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://agexinc.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r438", "r560", "r561", "r690", "r691", "r692", "r693", "r694", "r715", "r717", "r748" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of RSUs outstanding, options forfeited, cancelled or expired", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r463" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of RSUs outstanding, options granted", "negatedLabel": "Number of RSUs outstanding, options granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r461" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r95", "r420", "r880", "r881", "r882", "r963" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r826" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r828" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of RSUs outstanding, beginning balance", "periodEndLabel": "Number of RSUs outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r458", "r459" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ownership interest", "verboseLabel": "Ownership, percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r337" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total unrecognized compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r478" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of RSUs outstanding, restricted stock units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r462" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 deficit", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r95", "r96", "r101", "r210", "r211", "r230", "r250", "r251", "r252", "r254", "r262", "r341", "r344", "r420", "r480", "r481", "r482", "r509", "r510", "r527", "r528", "r529", "r530", "r531", "r532", "r536", "r542", "r543", "r547", "r556", "r647", "r648", "r670", "r699", "r716", "r741", "r742", "r763", "r822", "r879", "r889", "r939", "r963" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r84" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateDomain", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total AgeX Therapeutics, Inc. stockholders\u2019 deficit", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r138", "r141", "r142", "r160", "r699", "r716", "r741", "r742", "r810", "r823", "r879", "r889", "r939", "r963" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r111", "r490", "r950" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r825" ] }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfEquityMethodInvestments", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from the sale of LifeMap Sciences (Note 3)", "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": [ "r46" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred stock issuance costs", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r838" ] }, "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "crdr": "credit", "presentation": [ "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments for offering", "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r49" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r839" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r99", "r785" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r826" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted options description", "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance." } } }, "auth_ref": [ "r83", "r85" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Drawdown on loan facilities from Juvenescence", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r48", "r878" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r26", "r134", "r135", "r184", "r185", "r249", "r374", "r375", "r376", "r377", "r378", "r380", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r551", "r793", "r794", "r795", "r796", "r797", "r878" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r480", "r481", "r482", "r672", "r880", "r881", "r882", "r937", "r963" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value as of period beginning balance, fair value per share", "periodEndLabel": "Fair value as of period beginning balance, fair value per share", "label": "Warrant excercise price per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r419" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivable" ], "lang": { "en-us": { "role": { "label": "Convertible Note Receivable", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r167", "r243", "r373", "r379", "r380", "r381", "r382", "r383", "r384", "r389", "r396", "r397", "r399" ] }, "AGE_IssuanceOfPreferredStockInExchangeForDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "IssuanceOfPreferredStockInExchangeForDebt", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfNon-cashInvestingAndFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Issuance of preferred stock in exchange for debt" } } }, "auth_ref": [] }, "us-gaap_ReimbursementFromLimitedPartnershipInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReimbursementFromLimitedPartnershipInvestment", "crdr": "debit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reimbursement", "documentation": "A payment from an investee, in which the investment basis has previously been reduced to zero. This amount reduces net cash used in operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11" ] }, "us-gaap_DebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtMember", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Debt [Member]", "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r35", "r215", "r245", "r340", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r522", "r525", "r526", "r540", "r810", "r898", "r942", "r943" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29", "r810" ] }, "AGE_FairValueOfOtherThanOptionIssued": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FairValueOfOtherThanOptionIssued", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "Fair value as of period beginning balance, shares", "documentation": "Fair value of other than option issued." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r813", "r814", "r817", "r818", "r819", "r820" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r32" ] }, "AGE_FairValueIssuedPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://agexinc.com/20230930", "localname": "FairValueIssuedPerShare", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "Fair value as of period beginning balance, fair value per share", "documentation": "Fair value issued per share." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Total Debt", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r26", "r185", "r400" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agexinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS ATTRIBUTABLE TO AGEX", "label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r147", "r158", "r191", "r213", "r224", "r226", "r231", "r245", "r253", "r255", "r256", "r258", "r259", "r263", "r264", "r270", "r279", "r291", "r295", "r297", "r340", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r538", "r540", "r634", "r718", "r738", "r739", "r789", "r821", "r898" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "calculation": { "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Costs, operating and other expenses", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r128" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "calculation": { "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Net revenues", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r128", "r213" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedGeographicalRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r299", "r300", "r684", "r685", "r686", "r750", "r752", "r755", "r757", "r765", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r783", "r800", "r815", "r904", "r957" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r838" ] }, "AGE_WarrantsIssuedFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "WarrantsIssuedFairValue", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "Fair value as of period beginning balance, fair value", "documentation": "Warrants issued fair value." } } }, "auth_ref": [] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedBonusesCurrent", "crdr": "credit", "calculation": { "http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r34" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative" ], "auth_ref": [ "r337", "r338", "r339" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r557", "r558", "r559", "r561", "r564", "r667", "r668", "r669", "r722", "r723", "r724", "r744", "r746" ] }, "AGE_ChangesInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ChangesInFairValue", "crdr": "debit", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value as of period beginning balance, fair value", "documentation": "Changes in fair value.", "label": "Changes in fair value" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedGeographicalRevenueDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r824" ] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income, net", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r235" ] }, "AGE_UnrealizedLossOnChangeInFairValueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "UnrealizedLossOnChangeInFairValueOfWarrants", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "label": "Fair value as of period beginning balance", "documentation": "Unrealized loss on change in fair value of warrants." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value as of period beginning balance", "periodEndLabel": "Fair value as of period beginning balance", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "AGE_UnrealizedLossOnChangeOnOtherThanOptions": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "UnrealizedLossOnChangeOnOtherThanOptions", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value as of period beginning balance, shares", "documentation": "Unrealized loss on change on other than options", "label": "Unrealized loss on change on other than options" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://agexinc.com/role/SelectedBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets, Net", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r66", "r68" ] }, "AGE_UnrealizedLossOnChangeInFairValueOfWarrantsPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://agexinc.com/20230930", "localname": "UnrealizedLossOnChangeInFairValueOfWarrantsPerShare", "presentation": [ "http://agexinc.com/role/ScheduleOfWarrantOutstandingAndFairValuesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value as of period beginning balance, fair value per share", "documentation": "Unrealized loss on change in fair value of warrants per share", "label": "Unrealized loss on change in fair value of warrants per share" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://agexinc.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r279", "r291", "r295", "r297", "r789" ] }, "AGE_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodOptionPool": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodOptionPool", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding increase option pool", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants increase option pool." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityExpirationPeriod", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit, term", "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "AGE_LoanFunds": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "LoanFunds", "crdr": "credit", "presentation": [ "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan funds", "documentation": "Loan funds." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r18", "r42", "r210", "r229", "r230", "r231", "r250", "r251", "r252", "r254", "r262", "r264", "r276", "r341", "r344", "r420", "r480", "r481", "r482", "r509", "r510", "r527", "r528", "r529", "r530", "r531", "r532", "r536", "r542", "r543", "r544", "r545", "r546", "r547", "r556", "r646", "r647", "r648", "r672", "r740" ] }, "AGE_SharesAvailableForGrantIncreaseOptionPool": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SharesAvailableForGrantIncreaseOptionPool", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant increase option pool", "documentation": "Shares available for grant increase option pool." } } }, "auth_ref": [] }, "AGE_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsIncreaseOptionPool": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsIncreaseOptionPool", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options grants increase option pool", "documentation": "Share based compensation arrangement by share based payment award options grants increase option pool." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r210", "r250", "r251", "r252", "r254", "r262", "r264", "r341", "r344", "r480", "r481", "r482", "r509", "r510", "r527", "r529", "r530", "r532", "r536", "r646", "r648", "r672", "r963" ] }, "us-gaap_IncreaseDecreaseInInsuranceLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInsuranceLiabilities", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Insurance premium liability", "documentation": "The increase (decrease) in insurance liability balances during the period." } } }, "auth_ref": [ "r9" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r194", "r195", "r196", "r304", "r305", "r306" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://agexinc.com/role/Stock-basedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of common stock reserved", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r40" ] }, "AGE_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceIncreaseOptionPool": { "xbrltype": "perShareItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceIncreaseOptionPool", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price increase option pool", "documentation": "Share based compensation arrangement by share based payment award options grants In period weighted average exercise price increase option pool." } } }, "auth_ref": [] }, "AGE_EffectiveIncomeTaxRateReconciliationDebtFinanceEquityCosts": { "xbrltype": "percentItemType", "nsuri": "http://agexinc.com/20230930", "localname": "EffectiveIncomeTaxRateReconciliationDebtFinanceEquityCosts", "presentation": [ "http://agexinc.com/role/ScheduleOfIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Debt finance equity costs", "documentation": "Effective income tax rate reconciliation debt finance equity costs." } } }, "auth_ref": [] }, "AGE_SharesAvailableForGrantOptionsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SharesAvailableForGrantOptionsGranted", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant, options granted", "documentation": "Shares Available For Grant Options Granted." } } }, "auth_ref": [] }, "AGE_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://agexinc.com/20230930", "localname": "IssuanceOfCommonStockUponVestingOfRestrictedStockUnits", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ScheduleOfNon-cashInvestingAndFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock upon vesting of restricted stock units (Note 8)", "documentation": "Issuance of common stock upon vesting of restricted stock units.", "label": "IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" } } }, "auth_ref": [] }, "AGE_SharesAvailableForGrantOptionsForfeitedCancelledOrExpired": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SharesAvailableForGrantOptionsForfeitedCancelledOrExpired", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant, options forfeited, cancelled or expired", "documentation": "Shares Available for Grant, Options forfeited, Cancelled or Expired." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://agexinc.com/role/ConvertibleNoteReceivableDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertiable promissoty note", "verboseLabel": "Principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r105", "r107", "r374", "r551", "r794", "r795" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r43", "r186", "r245", "r340", "r364", "r366", "r367", "r368", "r371", "r372", "r540", "r628", "r699" ] }, "AGE_SharesAvailableForGrantRestrictedStockUnitsVested": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "SharesAvailableForGrantRestrictedStockUnitsVested", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant, restricted stock units vested", "documentation": "Shares available for grant, restricted stock units vested." } } }, "auth_ref": [] }, "AGE_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://agexinc.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross", "presentation": [ "http://agexinc.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, restricted stock units vested", "documentation": "Number of Options Outstanding, Restricted stock units granted." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/BalanceSheetsParenthetical", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r209", "r220", "r221", "r222", "r245", "r268", "r269", "r271", "r273", "r277", "r278", "r340", "r364", "r366", "r367", "r368", "r371", "r372", "r403", "r404", "r408", "r411", "r418", "r540", "r661", "r662", "r663", "r664", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r697", "r719", "r740", "r758", "r759", "r760", "r761", "r762", "r844", "r877", "r884" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r813", "r814", "r815", "r817", "r818", "r819", "r820", "r880", "r881", "r937", "r958", "r963" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative", "http://agexinc.com/role/ScheduleOfDisaggregatedGeographicalRevenueDetails" ], "auth_ref": [ "r299", "r300", "r684", "r685", "r686", "r750", "r752", "r755", "r757", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r783", "r800", "r815", "r904", "r957" ] }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDecreaseForgiveness", "crdr": "debit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument, indebtedness", "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument." } } }, "auth_ref": [ "r878" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://agexinc.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://agexinc.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r9" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agexinc.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued vendors and other expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r34" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "REVENUES" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "crdr": "debit", "presentation": [ "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Deconsolidation of LifeMap Sciences", "label": "Noncontrolling Interest, Decrease from Deconsolidation", "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest." } } }, "auth_ref": [ "r15", "r82" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidityDetailsNarrative", "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetailsParenthetical", "http://agexinc.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://agexinc.com/role/StockholdersDeficitDetailsNarrative", "http://agexinc.com/role/StockholdersEquityDeficitDetailsNarrative", "http://agexinc.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r18", "r210", "r229", "r230", "r231", "r250", "r251", "r252", "r254", "r262", "r264", "r276", "r341", "r344", "r420", "r480", "r481", "r482", "r509", "r510", "r527", "r528", "r529", "r530", "r531", "r532", "r536", "r542", "r543", "r544", "r545", "r546", "r547", "r556", "r646", "r647", "r648", "r672", "r740" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://agexinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://agexinc.com/role/ScheduleOfDebtIssuanceCostsAndDebtBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Origination Fee", "verboseLabel": "Origination fee", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r37" ] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAdjustmentMember", "presentation": [ "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": [ "r250", "r251", "r252", "r261", "r262", "r275", "r536", "r537", "r847", "r848", "r849", "r850", "r851", "r853", "r854" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://agexinc.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r51", "r216", "r784" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://agexinc.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r965", "r966", "r967", "r968" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://agexinc.com/role/OrganizationBusinessOverviewAndLiquidity" ], "lang": { "en-us": { "role": { "label": "Organization, Business Overview and Liquidity", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r112", "r176", "r656", "r657" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://agexinc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r52" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://agexinc.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agexinc.com/role/BalanceSheets", "http://agexinc.com/role/ScheduleOfCondensedConsolidatedProFormaBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r214", "r223", "r245", "r340", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r521", "r525", "r540", "r810", "r898", "r899", "r942" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://agexinc.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "DILUTED", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r267", "r273" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(27)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-4" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4M", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4M" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "980", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481854/980-405-25-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "805", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479835/944-805-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "SubTopic": "805", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//944-805/tableOfContent" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r844": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r845": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r846": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 123 0001493152-24-002363-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-002363-xbrl.zip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�].^%?Q"^,6O:;I'P8_:B_P"">/[=_BS0K/\ :Y^& M'AG3);2Y^#WP7\?_ N\,>._$_[1=];2>'+?PY\-OBC\1XO ?P9B^%GB-=< M/IC4/^"8GCV;X5?!;X?V/[1'AI=<_9<^%/@#X#?L]^+-3^$?BR^C?X5?#S]H M[]F3XXZ.?CSH\?QUMKGXK?$(^&?V0O@W\/F\8>%]=^%=E!K^I_&3XDV?AVUM M?B9I7PZ^'_U9^TU^RIXJ^/OC;X(>.?#'Q1TSX1^)/A!?SW\7C?P_X.\0W7Q. M6._^(7P;\9:YX;\/>)].^)7AOPQSTW7-:\#_ _XE_-.\!>!]"'BOQ/<1^)M1^'=OX7O->\0^*-/\)_! M[P7KNN_&GQWX@UC2? %QX*\4?/OA_P#X*!?'[Q[XZMM+\)_"/X*Z7\/_ !%\ M;_AA\ /#7BC4?B=XW\3^)[;Q3\;/V#/"7[7?@WQ;J?A73/AMX?T#4?"?A;Q7 MXMT?P5K]M8>/K34?%?A?4=2\0:7/X7U7PK8:1X^ )O#G_!,_QQHN@_&+P-J_ M[0GA+6_ 7Q_^#NK_ +.WQ(TU/@]XMTCQ)I?P@L?CA\>_BM\.]5^&WB ?'V_L M?"GQJ\-^'?VH?C3X7\2?$F^\/:[H_B'Q?;_!3XD>'_ W@>T^$VO> /BJSQ/_ M ,$T/B7XZ^#.L? +QW^T_I>N^ K/XS_"SQI\//$>@?!_4OAI\<-&^%OP[_;- M\&?MAW?@CQI\<_ GQ=TSQSKOQ(N+KP)HWPU\*_&/X8W'P3?PU'A_''P;^Q!^UM\!;3X%_%?X)Z;\*(_%&CMK'BZ'X MJ:)X^TS49+'0_AHR?%WP']DG]N+XZP?L4_LC>%_C1X(T'QWK%K\#?^#?WQO! M\2(?CU\5;CQQXR\.?M\?M%>&?V<&\7_$K6I?">B:]KOQ1T#QA\,IOBWXLT:Y M\3W_ (0^(UIX^U'X9>,KSQ/HWAC7]=^+ !^I'CW]GWXRZ[^R5X:^%7C;Q]HG MQE^)_P )?B+^S?\ %70O$WA[P%H/PFG^*[?LI?'SX3?'KPGX9UGPW;>(Q\/_ M EXV^)?_"I+7PCXA\1>&AX.^&6E>(/$5QXET#P!X-\)VL'@ZP\I\<_LQ^/? M%=A^T)X8MKC4M3\/_MZ_M.? _P"-OB(OX(@\/WG[.?PW^&OP>_9B^'_Q*T+Q MMJNI_$>ZC\1>)_%?AG]F6P\/_#^Z\)^'K^]T/XK?%/3K_7OA]XI^%O@;QQXJ MM/!H/^"G?[0NFW'AF/QQ\ OA1H]M\4KGXL:+X N? WQ,\?\ Q#OO"T_P+_X* M._L__L#_ !3\7^-O#M_\)_ 6I^*M/TRP_::\*?%SPEX$\%36GB'QE'\+O%G@ MMM>T#4_B/X;U#P1]:6G[6WQ;\-?LN>&OC)\:/A)H/PS^(7B']HKPE^SI:Z'> M:_XA@\'36GC[]K+3_P!ECX=_'J^'B3PKX<\4>&/!WQ(LM7T/XW>$?ASK$4FN MMH/BGPE\.=0\;6_B#5;OQ+IP!+^V3^PS*])^$'C_P M-IFH6'A&T\66#?$^'Q/X"^*?[*OQJUG2Y]>\/?VYKG[('QZ\!V7QC^&OAF]O M/['UC7]7UBQU.6T@O/M"\9\0/^"?.MZ_XE\9>(/!7QV\=?#J^\GP_\$Z?VI_B=^U!:ZYXKU/2_'W@L>*=5^,6H_$EO#&J3:?9 M^N-&'BU&\4W&H_V'I_PG^UM^UG^TMXP\#_ME>!;OQ=X:^&UA\(?V%?V] M-0N&^%4'C_P=X@\6?'K]G?Q/X8M_!7Q:^%7Q\TKX@Z;XHT3PD=&\0>'8-?\ MASIG@[4YO 'Q'T3X[?";Q9XP^->GZ1HFO:3[=XG_ ."G7QU\.?$OXH_LZ/\ M OX87G[1OPI\8?'_ %"?2K'XOZ'I_P &?&/PV^ 7P@_8/_:'U_3!\4/BM?\ MP:U3P'XB?X8?M_>"M)OO&\G@KQ]8Z7JGP>^(GCRX^&G_ B.N6FE>$0#[&_9 MW_8XUWX*^+/@_KOBGXJ:9X^TO]G'X,?&O]G3X(0VG@;4_"_B2+X0?%OXB?!; MQ?I\7Q5\2ZC\0?%\'Q ^(/A;P[^S]\,_"NI>-M+T3P9%XUUNW\6>.]0T'2[G MQ3!X=\/?*OA7_@E]\5_#7Q,3QR?VD_AUJ6BR^-?V=O$&J>&!^S_XJTL'1OV: M_P!J[XR_M'^"-&\)V^F_M#Q_#WX;PWOAKXNCX<:MI'@KX8Z7X5;Q'X<'Q^$'P]U/X(G]O'PC\#H;6Z\6_$Q M;GQ5^QC\9/VFO@Y-XQ^)>FWUM\.+:;2_$.I?!SPSJMIX.\.ZHDR1-K=Q>^*; M?^V++1O#WS_X3_:>^._P>^/7Q3UO69_"GQ8^&7B/X@?L.^!/B)K&N?%+QSX5 M;PCXG^+_ ,'D\*W^L_"#X7ZMI?C[X>?#KPG;^/(?#WB#QUI*?$71-(,4WCC4 MI=-@\4:>=4\6@'VK^S;^Q1%^S_\ &7XE_%"XUSX2>+H_$_B+]H#5O!OB"U_9 MZ\.^%_VAM-T;]I'XY']H?QOX-^)G[0X\5Z[K/Q&\*>&_']S>Z;X"T+PYX2^% MVDQ>#[/PE!\0;#XB^-/"&F>.7^>M?_X)C>*-7\+^"],_X6Q\&/$^H^'/C9^W M_P",_$OA?XW_ ++EC\>#],\<>'O$WPSU/1?BIJVF:#YY\-_^"E/[2?QA MOO!'@+X;_"'X!:A\0/'WQ5TKX;Z;X@\7^/\ XO\ @'PA8VOCC]AG5/VP?"?B MV'PA?_"#5OB#J_A?1M:T+Q=\-[?6=7B\#CXQZ-X-T[XD^#K+PAH/Q'M[?P)] M*6G[+P#X_^./\ P3^^*6M>);?]F$_%/5/$/[/WQV\-?\%1M(T/QGI_P%\2:AXS M^ 6H?MU>%_'7BOQ==?%+XD:=\0)OAEXTTC2?B3\6?%UI\&O#=G\/?@9!I7@7 M2O#'@34]3\5ZQI%WXPUKVW4O^"=7QX\3^(/&WC3Q?^TM\(M0\6?$;]H;QM^T MAXED\,_LW^-O"WAVW\6^*?\ @F5IG_!.&RT'0-(U+]IWQCJ-KH6E6FFQ?%NX MGU#7]2U.^G$_@:WGTQ+P>+K/(M?^"F7Q"U#QGK'A#P]\.?A1X]U/7_@S^T?X M_P#AE:>!?BDD'A?4?&W[-_CS]DCX:R^!/#_QN^+%G\(?@[\;+KXKZ]^U='<> M'[KP[K_PRT7X.O&7B"/X2^)^$_P!NOXP77QY^+'QQ\):- MX8\;?#&/X;_L0>!_B-X*UOX@?'SP8O@;5=;_ ."D?[>_[&OB:\^'GPD^(WPH ML)/!_P :OL_A>TN_C9X?\0:;X3L['QM\'M-^%$7BCXG^&;[2?C7X2 /I;6?^ M"83^*/$O@74/%/Q,^&VOZ!I_[-W[/OP*\9KK?[.FA>(?B/X5\2_LY1>.E\)? M%?\ 9*^)^O>.;^;]FCQ+KDGQ*\42ZV^J>%_C)JVASV7AC6/AOX@\!^+++6O$ MWB#V7]DK]D7XQ_ CXBZ_\2OC!\?/ 7QFUS6OV7OV8/V83_PA'P#OO@DDFE?L ML>-OVD_$OA7QOJ4#_&?XFZ0^N>+M+_:*O;'Q7HOA_1O#7ARVUCPU#JGABQT3 M2-17PUIT7QU_;%\6?##XG?%#P=X8\*>&->L_@%X0_9@^)'Q#\.ZGJ.I#XB_$ MKP;^TK\6OB7\*$L/@YI&G0[4\5^%9OAO?7?@:UU.Q\26?QR^(TS?!*S?X9WT M3_$$'PN_:E^._B+]C_XU_M2>.?A=\(8->\#>'OV@=?\ A]\*_"7QE;1="\02 M? G4_B-X>ATGQI\H:;HEUK%P ?&GBW_@G=KOPI_9S^#WPS@\2Z_P#%+XR?";]GK]FW]C+]E+XF M_"3X.G1K_P"&GBO]G7Q3H7Q8^"7[17Q_AUOXHZGHNK^$O _Q ^#GPR\4>,=* MNM2T7PL^GVWQ$\#:;I/BA?CB/!L'Z-_'S]E^X^)O[.OA/X%_#CQU8_#?4/A] M\2/V4OB-X+\8^,/"FH_%.RBN_P!E7]H?X/?'W1--\5>'[;QO\.M8\31>,[GX M1P>&_$&H0^-]#U-)/$%YXB%S>7MN;2\_.;PS_P %+?BG9>-OC1KOCE?AM;^& M?AAX-_9.\":M\))?"'C+X?>+/ _QT_:$_;4^./[+5_XK^+WBWQQJBZM\-O"7 MA7PIX-\!?&_XI^&+#P3\2?"'@WX:76M>)_A1\:_CU\,K/PK\;OBG[7'^WE\6 MW^+7Q!_9ZN= ^!/A_P")OP+O_B5K?Q!\9?$7Q;XS^'?P@^+7P\^'%U^RWJYU M7X,ZF^A>)M7T.\?P+^U;X7B^)^IZT_CS2O@Y\=/"7_"CELOB5HWCJV^+_A( MX7QE_P $I_&7BG3? L5M\?O 5KK/@7QS^VM\4(9=:^ EYXG\+Z[XR_:N_P"" MD_P9_P""E'AS2/%'A*Y^+]BVL_##P/XU^!_AKX2_$'P:-=L==^+'@?6M%_V;_ ?BOX1?"7Q)X-^-7P3^/GA[Q%X% M_9ZTWPM\&-,\;?!O]L'P+^V)'I%A\ ?!?Q \'M8^#/%/B[P6_AO6+2W^* \7 M7=KKFH^+-?\ &GB7QG"O >H?# M"QU[3KOQJ-+\3_#;Q#\+4/AJ;P+=)7D'[4'[>OQQU7]E7]HWQ1\.H/"WP^?Q M;^R'_P %+O'/PE\6:#/KVM?%'X!>-_V%];U?X?:V/B=I45[HE@GB+7I) VK: MC;7'A/\ X9=^/%EI/P>\2:1\<)M1@\4* >A>%?\ @E?XA\->$)?")^+OP4U* M_P!&^/'[.GQ)\,_%.R_9-\.>%_CIXG^&W[//[;?A']MK0?AS^T+\5=&^)+ZO M\9?$8\2^#E\#>'_'6CV7POT?34\6^/?B7XV^'OQ,\?\ B"VN])D^+/\ P2V\ M:?%:R_:&TV\^/?@K2;3X^?"K_@J#\()9HO@GK%[J'A?0/^"B6E? VUT/64N9 M?C'#'K&M_!B]^"L0UF,P:98?%#2-?33[.+X;SZ(E[J7H?[7?[26H?\$XO@%: MWG@[2-(\?S^#/A%^U3^T5XBT/Q;XJ^,GBS7/&%G\"_!VJ_'3QSX-\''5M4^* M_BWX:>"O%VN:U<>$?#_Q(\>^+]4^#'[*F@ZGX%\$V^A^*+*Y^&7PVU/A_'7[ M>G[4EM\>_'OP<^''P2^!&NV/_#3_ ,0/V.O@[K6I_%[QD^J>*OBW!_P3$A_X M*0_"OQ-XOTR+X<:7H>A> M:TW2-4^%OBV+2O%>JZI9:AXRT;Q-I5U+IWP^O[ M;XD@'U/X0_9*U_PG^V!XU_:?T[XE:5H/A_QUIOB:U\5_"KP5X.U_0=-^(6J: MMX>^#.@>&?%_Q.DUCXC^*/!.J_$CP5!\++_39?BGX!^&WPS\??$3P+>?"WX; M_$+6=:\-? CPPNO_ #-XQ_X)J>/O%GPG\:?">3]H3P>B0_!G]LKX"_!?Q5>_ M!KQ'>>(_!_P]_;#\;^#/$NJGXJSP?'*QF^,&N> M&\)VFDO?V=U\.XOB+X@A MT7QUXE@T[7]+S=>D^#/V^'U7]B;]H#]OC5- L]5^#?PG^ &O_&OP[X8TW3+[ MPMX^U*Z^$OP+;XA_'7P7XMBU#7/%-MX8\8>#?BGIOC/X(:WX0N+%==^&WQ ^ M'7C/PMXM&K:SI4XB\"_:<_:2^*'P[/P'^+/B+QC\'-8UOX,?'/\ :,CUV'X2 M_'CXA>&?@G\2_!^G?\$JOV@?VG/#>A?'S0XK#Q'8_#UEUZV\%ZOIZ:YI_P ; M;K2_!NB>#?CUX,FTN3XG7'PU\.@'W]\:O@1\0OB;XH_9L^('A;XB^#/"'C'X M#>.O$WC+5X?$'PYUWQIX6\;VOC/X->._A7X@T.PT[3?B;X&U/PK="Z\91:[H MNO7NK>+X-.M=.GTJ\\.:M-?Q:II_YV6?_!(;Q/I<7P$O[+X\?#/6/$/[.G[. M/[!7P*\(:=\0OV<;KQU\)?&=_P#L9?"S]M#X->(]=^*OPOD^-6B7GBCPK\5_ M!?[%/'7@/X&^)/!?A7X9?M+>._@KX:^-2_' M7X3^E>!O^"B&O2_ K]K+XO\ Q.^&=AH_BG]E?]G>+]I76_@KX0UF_P#$'C?7 MO ^J^!?BO\2_"MYX7\56&EZQ\)/BC\//B#I'PVO_ M\'/C?\&?B%X^\+_$O M6/#OC63Q5X:^#/Q%\/>+O@5X" /4_B3^QWX[O/"O[*=A\"?BY\/?A%X@_9=\ M/WO@*UT;7OV>=#\9? 3QM\-_$'PGB^%7B'PQ+\"/!OCCX06/@9]*M]/T/6?A MH? GC#1= \"66GZAX$D\-Z_X&\1:GHX\L\:_\$[/&/B:T^(_A*Q^.GAZ/X>^ M)?'^I_&#P'#KGPAGN?B)X&^)>K_LEZY^R]?&]\9^%/B3X+\/ZOX$GEU&T\9K MX1\-> O 2V?A:3Q-\#]/OK3X;:YH]OX3H^)/VU_VB=*^._PX_9M\/> _@-XP M\3_$SXB> -/TCXPV'C'QY!\([;X?_%K]FC]JSX^>$X[&VLO#6NWGB?XE>%M2 M_9(\>Z-XLT.U\3Z5I&I_#CQA\#?BU87NBR?%[4O 7PO[W]IW]MGQ5\!?CCX> M^'&C^&?"/B?1H-5_8MLO%FGRW/BB7Q+)I_[:O[7X_9!T37-2\0:1I%WX4^#> MF_#K6)(?'7AI?&\'BG4OVF9K'QU\/?A_IW@1/A7XZ^(NG 'S];?LC>//&O[2 MGQ5^%OB9[2#X23_L/_\ !+/X5>)O'M[\&/%@\,_$/Q/^RI^T!^V'\3/'NC_" MW6KKQ?;Z3X+\1:98?$+X7W^FW=Y?>-[CPG<^-K+4]!O=<\0?#GQ1:V_2:U_P M3"\7ZUX5_9M\*WO[0.C7<'['\'PD\"_ ?4KGX7>(9-4NO@M\'_VQ_P!CG]JK M0?#OQBN+CXPWD7Q!^)EYH/[#?P7^$][\3]&MO!-G_:6J?$SXI+X&;_A,--^' M7A;S3PI_P4Z_:(O/A1X,^,GQ!^#/P8\&>#KWX$?L9?M>_$*[\+^.O'WCZW\! M?LP?'#XGZIX$_:(\3^(+S7?!'PN&CW_P \!6*_M :AK\-OX@T:#P1H_Q \,7 M6D:K=>$]!\8>._M;QY^TE\:/ /[/_P -?BN_PWT?QGXI^(WCN\DM_"7A*WU7 M_A)=-^$-[8?$#XC>&-4LOA7>ZJWQ'^(_Q/L?A)X5T.X^*'PK^#T/Q"^)/AS4 M+KXA>)OA)\/OCXWPVTWX=?$@ ^7_ (@_\$L_'/CWQ/\ &;73^T;X5T2T^)?P M;_X*,?!WP]IMC\#=8M]/\):?^WO\5O@U\8K/6I/#&B?'#P]\/FU3X8^*/@_: MQ^.M1\&>#/ 7B+]I>Y\0Z[X^^*?B.'XNZOKOQ#UCZ!_9<_8?U[]GSXK^/?B+ MXA^('PB^)"^)O$/QO\8:!KUI^S;H_@[XZZ!K?[37Q1TSXY_&OP?K'QWN?B'X MRU_Q#\&(_BO#?7GPJ^&]IHGAS4/"7@*P^&G@CQ[XR^+-_P#"O1/&&I?(VL?\ M%5/B_JWP\^+OQH^#GP?^#?Q+^%'PA^$&OZKJ'B6]^-$'AK0O%OQ9L/V9?@Q^ MUMX4G^'NJ0:=K_Q*\5?"KXC_ E^*6N:CX9DO_@)X6\1V7ASP[X(^)-[>7GA MSXDZSI_PP[WXH?MO?$?X*?M1:C\!/$GP^\+WOQL^)G@3]D#P;X#\4^%/%^KZ MY\-;CQW\9C_P5"\;>'=$UKP+\4?B)\'?"OA^UMXOV.-5\$Z?KVB>+='\:?$C MQG\3_"&DW\FLQ>'?!'@[3@"+Q%_P3 ^*^J>/]>^(VB?M/>#?#>OVOC?XR?$G MX-/BEH7QVU35?%5YW_C']@#XO^(-7^)7B2T_:&^% MUIJ?Q3\#?LR:=XIMI?V:;K3='M_B%^SC^VA\9OVOAXHT*R\*_'+PY:Z?X-\7 MGXV^(_A[<^%-8M?$7CI)-)TGXB>+OB_X_P#%=[XJ'B/=^"W[O=%^*H^,FAZ_\3+K]ESP]^TC\0OA?X*^*GPVT M'4O 5]\0O"]OXIOY]+^'_P 48?@OXA\<_ ?X;7O[37P4G^./@KQKXOT+]GGD M/BE^W-\5&3Q6?ASHW@O1M U/XK?M>_LEZ+/>C4/$/Q;^$'QQ_9X_9[^-_P ; M_#GQ=^)O@YS9^&H? /CRU^"NHWO@[X9W\^GZOK7PV\=_ 3XQQ^/+_2?C)/X$ M\# %+6?^":7C'7= ^%7AC5OCOX.U*T^ >JOHWP?U"^^#6MSZ[_PJ"7]M#]ES M]K"7P9\4;^;XRS'X@>+I= _94\%_"K5/'MG%X5L_$FKZGJ?Q8U[P?=ZDD/@^ MO7=?_8F\::Q^S=^TU\";7XJ^"[+6/CS\?OB5\8]"\62_"[6[K2/"&A?$;XNZ M/\49_"GB'PK%\4;.[\8ZM8I9:GH$WB:Q\3^$+'4WNK/5&\,6BVEWI>H>1^'O MB7\2/V5/V,?V+_&_QC^,'BN?4]/^$]I:>(/A+^S;IGQ \>:9/XJ^)_[3O@[] MGWXV>+/#_C+X8?$KC/V?_P!O'XT?%@6'A'0?&?[.'CGQU\=?'7[6WB+X ^/C MI?B'P?\ &W^%W[/-_X+'@KP9;ZWI7BWQ?XE^*'C3XO^'?%UKXI\):]9GPO/ M=_#;P?\ 'KXZ6GAC4M+^$]O\'=9 /2OB=_P3(LOBM\0OVJ]>\2?$;P /#/[3 M>@?$Z+3O$9_9X\'ZK^U)\%_%'Q>_9=TS]E;QC!\,_P!I;7?$FI#3?AC%X0T' M2/%6B^!T^%T'BM?$(U+PYKGQ.USX57:?#N#R_P"&_P"S3^U5XM_:!^*OCKQ1 M\4O 7AKXP_"O]K3X;?&;3/B+&;;]F+QB;?P[>?%+XA_#G]K+X?_ !=UG_@G#X)_X*!^!-7\ M)7G@NUTF76M8T;2O'MGX=U[X6V(\/:BGA+P=K_Q4N/&_B/1[_5_@YIGZ,_\ M#8DND?L8?&_]M?4+/0O$_@KP+X/^,/Q/\*>#;?2O%_PO\1^'/#'PKAU^UU7X M??'9O'5IJ6M_#KXI>!O$?A3Q%X<^/%K?>"[!_@[K^B^*-!U3PSJE]X/OWU M^7_V8O\ @EQX^_9WB_9HT[4/VA_!OCG3/V(?^"7/Q$USX>?'?P(W[0G@:WC^-/P)_X*)!9_\+JMTUC3/A3I.OS> ])\.))I-QXVU#3]/\7:CXA\.V:GPDF5^ MT#\8?C+\5_CO^SU^R7XE\1:=X:\+ZY^VQ)\(OB_XK^#VH?$GPMHWQH^"/Q _ MX)K_ +8O[1^@^%](\;>$?B+X2^(?P8^+'@WQ!\,M/U#4+?P9X^U?7-"N;/X# M_'?2?%-CI'C.]^$]I]%?$G]M/Q-\-OVN_A?^S7I'AKP3XA\,>,?&'@KX57VI M:AXE\86^O>'/$GCCX#_M$?&3P]K_ (E\:R^'-6\$:5--J7P-\+_#W2?A+?:C MKGQD\:VOQ2N?B^+30?"'@K2[+XG 'R[^Q3\,?VA-,_:HUWQ?XV^'>HZ1X6\+ M>-?V[K;3M.\;_L_^(?A9??!?P9^UO^TU?_'_ ,26'@'XU6?[6'Q1\%_M#S?& M'XC_ Y^&GC'Q#_8_P *=6L?#FFPRWFE^./@;I2Z?\)/B%R'[3G_ 3^^+7@ M_5[#XX>'OB!9?$B]TS]H>YUS1_AOX(_9Y\^#H8O@OX,_9XUX?%+4OAO\,/!'C7]J34FUCXH?$77-3^/'BC4-:\3 M;7PK_P""I_Q]\5_"3X?_ !I^(WP>^#/@7P%J'P0_X)C?M>?%/7_#?CSQ?XQL MOAM^RS^WYK/QA\#>-?%.NW'B#PW\.=/T"7]GG5OA/'\7OB5X\U74KKP1X.^" M6M>,KW5+34Y/A'-XG^(G[%?!C7O'GBKX8^$?$_Q+TNPT+QAXCT^37K[0K'1= M:\.OH6FZQ>W6I>&M%UG0O$-[J.K:1XLTGPO=:-IWC;3;B^N8K/QC;:[!82G3 MTM%4 _([XD_L-^*?&'[1'Q!^'K7&G0>'/VK_ -EC]O+2?VB_B%9? CQ=_:AUC]D#X8)X5\&13>,XM!T'Q+J_PC_9]U'5-7CUSQ1XI_P"$N\<:3K7Q M$\1:-H%IXW\/^%KSL_C?_P $NO'_ ,9?@/\ $+X&K^T/X1\*6GQ#\2_\%&)= M0\367P7\0S:];^"OV^M5^(?B.UT Z]I'QM\,>-9[KX2^(/'-C+X@T^V\9:=\ M.?CUIGA32;/QS\/-(O+7P]J7A;]CJ* /R=^*/_!.OXJ?$WQY\7/B&?V@? 7A M'Q?\0_$5GXT\(^._"7P5\;Z3\1_A'XRD^ OP'^">N7_@_P 1P?M#KI&N^!]7 MO?@G'XW\2? _XF^&?B#\%OBI;ZAX8\!_&WP3\2=%\"6NIZWPUS_P2V^)LOC/ MQ9XIA_:-\ 16.O>/O@%XXL- B^ OBFRLM)_X9L_X*,VG[>'P[TC2],T_]H&V M\"^%=,OO#=K'\$_&MCX!\ >$[;Q7XH^T_M!ZBK^)=7USP1J7[-T4 (!@ 9)P M ,GDG QDD !SVI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "LG7]!T+Q5H>L^&?%&BZ1XC\->(=+O]$\0>']?TZSUC0].?B9\ M"?C5\-_A?\1;WX/_ !+^('PE^(_@CX=_%K3K274-0^%WCGQ7X.UG0?"7Q%L+ M"&\TZ:]O?!.OW^G^)K6TAU"PEN9],2&.\M7<3H >&?M$_L'?L]?M$?#:7X<7 M_A#PU\-_^)!\/_!EAXL\!?"SX$:OK=C\./AIXRT3QSX:^%$WAWXO_";XJ?#' MQ'\)(M(_!]A.K;7-"UKPWXQU[Q9\$?@%HL_C3P]XCU+0M7USPYJG@SX5 M_"KX;_"/1/"&KZEX6\+ZMJO@GP/\./"?@W6_$FA6_C;7="U3QW?ZUXGU3X8L MOV)OBSJ%EX2?Q/\ L9_LNZ?\+/%.@_'#PI\6OV,_"WQT\3ZC\&K#XB>,?A1^ MS'X(^$O[0_AS4=?^$UIX=\*OX#U3]GOQA\/K9/A;\//"/C?P;\)?C7K?QKT# M2O%'QQO_ !]\,O%7SC\4?V+O#GP+^%OBS7/VA/AG\+/B=\4?BW_P42_X)]:, M?BGXJTWX8Z;X_P#VD? FD:;^QW\)?C+%JLLD\\.BK\>_$OPH^/\ \4O&?P:O M]:A\!^+-*^)OBJY^)=Y;6OCCXKW>F@'[U:?^SM^SWI-_%JNE_ OX-:;J=KXQ MNOB+#J6G_#'P19W]O\0;ZZTV_O?'45Y;Z)'<1>,;R]T;1[VZ\3I(NMW%UI6F MW,U\\MC:O%T/BGX0_";QSJ>JZUXU^%_P[\8:SKOP[\2_"'6]6\4^"O#7B#4] M9^$WC.XM+OQA\+]5O]6TR[NM0^'?BNZT^PN?$O@J[EF\-:[<65I-JFF74EM" MR?C78_\ !/+X\Z=8:I\/ET+X=WO@G5O ]QIW[+_B*3QY=7EW_P $TO&WAW]K MS]H#XQ_#C6_@KH&J^#)6.B^!/@/\7OA3X'\'^%OAMJ/A[PXFJ?LG?"G]G34- M-TW]GC6-.\=_##R#QM_P3)^+T'P)O# M'A;QAIGQ)^*7[4WAWXQ_L@->>)+32O%W@:RT/P!\)8/$7@K_ (67HG@_7OCU M^SYK&C>"?AI^S'XN^''PE\7_ !7UZ] /V[MM+^"/C/P/:_"[P_\ #7P%\0/@ MMJ^K>/OA_K&@:'X9\#Z[\']"U/X=>*-;T7QAX6\5^')2NCQ2Z7\1_#NN>&-1 MT:RT'5Y=/\;Z7?VNKVEA<6D]RFQI/[.O[/N@ZCX#U?0_@5\&]&U;X5ZIX_US MX8:GI/PQ\$Z=J/PXUKXL7TVI_%+6/ =[9Z)#<^#]4^)>I3SZAX_U#P]+IUWX MROIIKOQ%-J5Q(\A_&/4/^">G[3>A>#)_ OPM\#?!WX?>);+X[_\ !6GQ[X5^ M)GA'QW_PC-C=>%/VU/'OQ5^(WP?L_%U]H_P^T[QUX'-[I'C;P#\(?'%[X$TO MQOXA\ Z?X"/BWP;<:A=^$/AY%=:?C3_@F]KWQ$\::OK&M?LR_"_2_@KXGTK] MI/Q)8?LVQ>)?">H^#O 7C+XG_LV_!GP<]E;Z#;V6C^"K8_$;X\> M<\?W_A_ MP]'=_#VP\8Z/X._:3OQHOQU\7>,)/#@!^O\ =_LV_LXWG@7QA\,;SX"?!*Y^ M&OQ%\:7/Q*\>_#ZZ^%G@2?P-XY^(U[XFTWQK=>/_ !?X2FT)M \4>-;KQGI& MC^+;CQ3K5A?:Y<>)]+TW7I;]]5LK6[BY3X8_LI_"_P"&/Q1_:"^+]O;IXL\= M?M&?$"W\>>+M8\5^&OA_+J'AVTMOA%\*_@C:?#_PAJNA>#M"UR#X=+X(^#/@ MIIM"\2ZIXGO+S7X]:U2YU:2'4(=/L/'_ 1X?_:+^*'[(7Q)_9]UW4_'/P$^ M/.B? 9/@5X>_:'O=9D\::K)\4]:_9\T'2Y?CUXW5GK^K:!'>V?B^YU:YUS3_#OPWK7_!.37OB3\>/@'\1/&G[+?P$\)? MD?$KX9^*?CE^R;I\O@'XD_">QUWPW^Q[^W%\ ?BW\2'M=8\&^"] ^)E[\4/& MG[0/[+GAY&U/P3I^N>*_@W^Q_P" _'WC33?"_P 0=-\*_"'00#]?[WX _ 75 M_ '@GX5:C\%/A#JGPM^&=QX4N?AQ\-[WX<>#+WP!\/[KP%"MMX'G\$^#Y]&E M\.^%+CP7;QI;^%)="TZPD\.0HL6D-9HH41ZO^SQ^S_KT/C>#7?@;\'=9M_B9 MK&E^(OB1#J_PS\%:C#\0-?T*XM;S1==\;QWFB3)XKUC1[NQLKK2]3UX7][I] MQ9VL]I/#);PLGP%^U;^RS\=OB=^UA\+_ (Q> ?"?@R_T+P-J?['=UIWBJ?QO M)H_BBQTGX?\ [0WQ3\0_M+:%J4?B;2?%\?A;3-8^#OC;PW;^%K;X%Z3\/_$/ MQZN+GX@>!/VEO'VK_#WP7\&O"!_-_6OV%[W]FSPE\ _$&I>#?@]\+?C+H'@+ MX3WGPI.J>*]#U _&[_@H+\%OV@M4^)?[/WPA2PM(/$7BKQ'/XB^!/_"W/@5_ MPG_AGPIX@USX%_LZ?$[Q]#X M-#\)^"Y+/P\ ?TC^-_AQ\-OB9;Z-I_Q(\!^ M!_B#:^'=8?Q!X?LO&_A?0?%=OH7B"30]9\.2:YHUMKUC?QZ9K#^&O$?B#07U M*R2"];0]>UG2VG-AJE[!/\D?'GPY^PC\(_!?BG_A9GP#^!&O:-X<\)_ :Q\3 M> M,^#'PY\6:W;_#GPY\1](\$? -K[P2=#9O^$"^&OC=HYOAZ+J&/1O!#>'= M8U+PG#9S>';OR&?%#]F#Q#X>_9F^&'P?^"&C^#-<@^&_Q%^&WCCQ_P##B_AT MSX:>$OVAM#L/'@\9?&O1M%_B%\2+:U M\$?$76=(\">-_%_B33_S<\5?\$T?C7I=G\6;/P7\)OA'>:-\5/@G<_"?P=%I MGQ%'ASQC\ ?A[HG[#=23P/IMQ8?#_0O@_P#%[2_#WAOP_P"# MO'FA>$_@Y'\/M5^'_P -HKGPEX=^%JZJ ?MW+\!?@7/\0%^+-Q\&/A+-\58] M3M]='Q,E^'7@^3X@1ZU::#+X7M=87QF^CGQ&NIVWAF:?P[;Z@-2%W#H,LND1 MS+I[O;GHM6^&?PVUWQ?HWQ USX?>!]9\>^';2:P\/>-M6\*:#J/B_0K&>QU[ M3)[+1O$EY83:SIEI-IOBGQ/I\UM8WL$,ECXCUZT=#;ZOJ$=Q^*GA?_@GI\8= M$_:)U62+X1?#.3]DS3/V@H_'7P#^%Z?%34OAE9_LIZMX/^)O@SXQP?&[X2>& M_AOX=UC_ (D_QA\7V_BN_P#''P8\->(/A1'J6K^%O#'A_P 57M[X(^/WQIG\ M"9_QC_9<\/\ [-O_ 1E_P""G6F:G\'?AY\*OB%\0_@9_P %(/'.N'PWIWA' M^U]?;QQK'[1_Q _9TTS4_$'A.WEFUO7? OASQ[X*\&^!-#@GOT\!ZQIUKX/^ M&T*Z-IGAY[D _9CPQ\ ?@1X)OO!&J>#/@I\)/".I?#/P?:?#SX<:CX8^''@[ M0+[X?^ -/BO(+#P-X(N]*T:TN/"G@^RAU'4(;3PSH,EAHMM%?7D<-DB74X?- M@_9I_9QM;F>[MO@!\$K>[NO'/CSXH7-S!\*O D-S<_$KXIV,^F?$_P"(D\T> M@K+-XY^(VFW5SI_CSQ;(S:_XOL;F>T\0ZAJ,$TD;?E7;?\$\-#\7_M)^ /BE MI_P%^$EK^SEJ'QC\;_&32OATEUX$\<^!?A[X@UGX"Z9HD?QLT/P#>077@&U\ M2?&'XXQ:'\4[[PWX!M]:\-:AK'PV\#_M&^*KR'X[^-/%&G>&OF3XL?LG>(OA MC\,OV<[_ /:)^%GPD75+_P")'["W[/WQM\,VWC?0_&%M^VQ\9?"WQP33/%OQ MWUR]\8Z%X9M]3UOQQ\$CXXTC49_B'=1>-_C1I/QO^+'PL_:"^Q?#/X9^&_&W MC8 _>3QQ\&/@=;?"6U\*7G[.OP^\?^ OA1INI^)? 'P9TOX9?#W5=,L-3TCP MWXATVWTSX:^#_$,&E^#-#\2ZIHVN:_X5T=DN?#UFT'B74M+O-5L-*U74Y&X[ MXB? ;]FCPI\-=?U!_!'P>^">G>'ET[QAIGQ0T/X9?!VROOA)XR\%>"5\!_#O MXO\ A(^,_ GB7P39^/\ X5>';31M)^&^J^(O"VOV6D:?I.C^&%T?4?#R?V!< M?C=X@_X).^.[WX9_MS^#9_@U\*O$GBCXE_L$?$7]GW]C#7]5U;P[K]K^SOXT M\;_$S_@I2_@SX>^#M<\26D/B+X:> _@Y^SW^V7\#?V?_ GX@\%:3:IH_P * M_A#XO^'7A30=+\$Z%X!T#Q?ZA^T#_P $\?CI\=_$'[7WBCQE\,?A'\2O$WC[ MPMX[F_9_\$/'W@GPY9?$?XA?$;7/!8!^NGA_]G3X7V?P\\&_ M#SQSH.F?&J#P9XLN/B1;^)?C#X7\#>*?$&J?%W4=9UWQ+KOQ?N;.Q\*:)X-\ M/_$#6?%'BGQ1KWVSP#X2\&Z'XKQ0ZIX'T MNR\BP\):E'%?:!!I]TB2C\/?C7_P3K_:F\?_ !)^(WBR'X/?"%/#WCGPA\;? M!'BCPAX4^)GG:5XFTOQ;\?OV$?C'\#]7D\5^.=(M_'WC?Q!\+_"_[/OQ?^'% MM;^+;WP'X)^!^AZGX$\'?LR^"_#?@2VU&WG^NOA?^RS^S]IO[)_AQ^SZ=/TC0_"S^%[/7 M?%7P'\;V'B*_\*Q:MI'B'X$M^SC^S]XTT+PM;V7QZA\1W(!]!?'']@W]FO\ M: \$:I\$D^$'A_X.Z1H.G>&/^$>^(7P_^#'[-U[:KH>H?% _%[Q#\/\ 0/#W MQ0^&/Q8^'VO>#]=\>>&K;Q'\3_!'CKX57WA?6-;US3?&&F+)XZL[+Q+H'6_L M\?LQ?LU? OX9^,_V0/#&E^ _%VBWVA'Q3\7?A]K'@3X*>';3Q?X>^+T?B'P. MNM>-/@I\(OAQ\,?@KHOACXAV/PU\3>%Y-,\*_";PMX5\93^$/%>H:SIVM>)K MOQ9K6K?(/QY_8E\:_&+]K'7O&&K?!_PAXC^#'B;XN_L8>*O%+ZUK'AA+/Q;H M_P &?A[^TEX3^*VH^(/#R7 U+7(=5T3XL> ?AW>:/K=M=K\0?!6A^(_!GB:S MN/ 4%CIFO?'/A'_@FI^UIX+U2T\6^&_A=\$I=+D^#W[,GPR\8?#CQ/\ $:RM MM>\=?"[]G3]I/]MKQ%=?L[W7B./X<^/=*M/"-]\#?V@?V=;[X/&FE:'H?C'X#_!CQ9HGACP[X MB\'>&]'\2_"[P/KNE>'O"7B^YT6[\6>%M#T_5-#NK32?#OB>\\->';GQ%H=A M#;Z9K5SH&BS:E:W,NE6+04_$WP%_9I9-6\6>,/@Q\"V6P^(.G_'[7/$OB;X= M^ =EG\5?!>CS6FD_&K5M:U31B+;X@^%- %Q:Z?\ $B\N%\1Z#H_G0VVL6MEO M2OR"UC_@F9X]TJ^\<:U\+?@[\'?"WC#P-^RS_P $[?A/\"=3\0>-[_QK]IC_ M &6_C/\ &?Q;^T-\ %^-OC3P]XL^,.E>"_C]^S#X^\)?L9^)_COK7@P>*/B! MX,M/$6H^,_A99^$/#_A'P-JE/7_^"9?Q3UA_ .C>$?AC\-? ?@Q?@K\9OA/J M_@'QS\9M>^.?PL\&^$OB[X0_;0L+[0O#N@^)/AUI/B_X=^--#U#]HWP/X3TZ M3X=>*?%'[.OB[X5:Q\6?AQXD^ 'AVS_9^_9 \4$ _;+X>>#OA/I'@M;/X9^# M? &@>!/&C:GXQ?2_!?AK0M$\,^)9O'I;6]:\276EZ5I]E8:E=^+VU%]4UK4K MNUDN]:FO9+G4I+B:>1F^8K[PG^QY\/\ XA>#O@-X9_95^'>I:O9/\&O&%YI' MPW^ ?P]N?#_P;T;PY:^,/AS^SQ\2/%]I:Z5IK>&]%\./X#\5?#OX8:WX9TW7 M+_X>Z=H]^/(\)>"-/U'5[3S?7?V?_C+>?LT?L7^$8?A7\-(T^"WC'X;ZG^T+ M^RC8>+-&U#X:?%;X6VOPI^(OPN\2?#ZVUO5O .C>"O$&K^ _$_CKPA^TCX6\ M.^(/"6A>#/%OQ6^#?A_P9/XR\(V&JVWQ6T3AOV-/V,OB-^SM^T1J_B[QEX)\ M!:MX>N_V;-!^%O@SQOX?O]#U";X0:5H/[4/[4WQ<\(?LY>#I-2T30O&>J_"3 MX1?!/XX_"WX$>"?%;:=X7;Q'H_P0TJ?5O 7ARUGTRVT\ ^Y_#_[)O[*WA2?3 M[OPK^S1^S]X:N=*L;C3=*N?#_P &OASH\^FZ;>>%+[P)=V&GS:=X;MI+.QN_ M ^J:GX-N+6V:.WG\*:C?>'I8WTB[N+.3JM6^ _P-U[X8Z=\$M=^#/PGUKX,Z M3'X>ATGX1ZM\._"&H_#'38O".J6.N^%(M.\ WFCS>%;./PQK6E:;K/AZ.VTF M-=%U33;'4=-%M=V=O-'^'GC/_@G9^TGXM^+WB76)OAO\/K'P9XU_:,^''Q \ M57&F?$\36UUH7PT_X*O^ _VIK+Q3OUW1M0^*?B?6/%O['4?Q%\,^(KGQK\1= M4?P5\5/&/C'X$?!?P-\/OV9=5TB\MI_A%^QKX3Q(D_[5 M7AOX_P#[/%U:^$/%]OHW_!.+4_VY_B%^UG^P/8II.EV/B?0_"/@KX2EM!_90 M\#_ /6?^$+\"ZEX(^)7QU7X>P^+_ Q^S3X85@#]K+G]G;]GG4O%.N>.KSX% M_!B_\:^)C?GQ+XQN?ACX'NO%/B ZK;^'K34SKGB&71)-6U4ZE:^$/"=M?F_N M[C[9;^%_#T-QYD>B::MMX+<:9^Q%JOCOP=\#H?@E\%/%5Q\7O#?Q*T*T31_A M%X \0^ KG3?V2/B)I,?B?P!XJU*'1I-*MKSX9_%#QY?7&@^$;V"XCT+QM#XS MN+2WTS7-/U21_+?VW?V5OBK\?M=\60^&])\)>-- \:?LV>,?AC\--2\3^)G\ M+:W^R7^TO;:])XG^&?[4?P[N8- UC4D\0Q:I/H&L/\1?"&HZ3\6_@MXQ^!_P MJU7X5:;K*/ GC+]GOX)^*_AM!XT_X*L>/].& MF>*=(DT[XE>)/VP_B&GQ;^ _B#QKX-O?"7@NRM_%'A"34K7P?)-K-SXO@\)^ M,O NC^.-$U6T_L#P+KUD ?N/K?PX^'7B?Q5X4\=^)/ ?@KQ#XW\"PZO;>!O& M6M^%]"U;Q5X.M_$$VDW.OV_A3Q#?V-QJ_AZ'6[CP_H5QJ\6CWEFFI3:'I,MZ MLSZ;9M!4T'X4?"OPMX#NOA5X8^&OP^\.?#&\L==TR]^&^@^#?#FD> [K3?%$ ME[+XET^Z\'Z?IUOX>GL?$4NIZC)KMI+ISV^KR:A>OJ$=PUW.9/P=N/\ @G=^ MT]XI^"?[1V@_&#X:^!OBK\\T#3O#W]M?LJMX;B^'/A;XP>(/'WCSQ'IGA7X6^$_%OP6?POKO MQH^*'A7PO]Q_MF_L::Q\2_@[\$_@E\#_ (1_"*Z_9S\,^(?%_ASXP?LEMKX_ M9Y\$>+OA-\0_A/\ $+X?6UOX5\2_#GP-XML/"E[\./%GC6R\6-X=L?#*Z=>V M#Z]XL\-:G:_$WPG\/S=@'VA=?L__ +-^DZ1>M=_!'X(Z=H=E\/?B+\/KX7'P MV\!6>E6OPK^)>J)XJ^+/@:[,VC0V4'P_^(.N6<7B/XB>&IVC\-^*]5MH]8\3 M6=]=P+!O!GB#X=^./V:_$^K>#/AY_P@]I\0 MOB2/$4?A?4O@(7MIK[0OB +*^O+NXU7P]H>A7PTSQ?\ :-.U74(;GQ#_ &?^ M7.M_\$W/B/J?Q2\=>.;WX8^"M=U'QW^U9XNU'4_$VK^*8M:FO_V9/B-_P2#\ M*?L0?$;P[X@_X2W6/$.OZ]X7^(/[5_AO0_C1\1O ?B&_\3W_ ,1_#G@SPA\3 M/'DOB;XM^$_"GAS3^?\ "W_!/O\ : MC\*M7U+]FW]GFUO\ X8P?\$R]5/@* MZ\?>'Y_ .H>-OV8]*_: \#?%;Q3I'B&T^$][>Z?X@TWP5\9_" M/$4_PWBUG M6;7PAXM\&:1>76DZ;X*U3Q4 ?MCX<^ OP(\(ZSH?B?PK\%OA)X5\2>'+CQI= M>'=>\/\ PY\':'KGA^\^)=[!JOQ%GT;5=.T:UO\ 2KKQ]J-M;:AXVEL9X)?% M5];PW>NM?SQ1R+X7\>Y?V-_ACX<^-%W\4?A+\)O%$/CY/A?/\??"%E\+_!'C M'Q+\0]'^*7C_ $GX/^ _$/Q6\*S:8UQXQ\-W7B6S73(]6\7+J%K%IOA'6'M# M/%X9NH;7XS_8H\$>"_A7I.I?$CX!^%?!'Q]^"%M\=-=^!7['_B_X06.B)%X9 M_91_:!^,UK\+-,\,0>'[[X5_#;XN>-M1^'L&G>'=8N?!OB'X3_L MH_#KQ/IWBS6?B)K^J:5?]!^VI^Q?\4?B_P#&3XS^// /PS^&WB?3?C5^S7^S M3\&K[QC)XS7P-\4_#%Q\#?VI?%GQ5\4Z-::A#X574YM&\:>#/B+#/H^IZ3\0 M]!N=%U/P#J+2VBZI-X3>\ /TG\9? OX(_$3PUH'@SX@?!SX4^._"7A"TDM/" MOA+QC\/O"7B?PWX8M)O#MYX2DM/#^A:UH]]INBVLWA6_O_##P:;:6T"-:D\9^,_$7A+XR?"OX-?A[XY\%'XJ^';;PHG@:Z\0Z]X4\2AK+PY;>&=5 MM]3T73XK ?D;XZ_X)Z_M&Z=XDEL?@K\%_A?X9\ _#_\ :3\2?%3X!:1'\3+/ MPK9?#_PSI_[4/[*?QZ/A#P?HG]@^.?!WP,^&WQ6L/AS\;M:U>?X2?#Y?BQ/\ M3[WX>:1J>K>"_AUJ'C2:X^POAM^QQX_\$_L0?$K]F&S^'?@7X?WU_P#'KXJ: MWX1M/@I\3;+X=65_\-/%O[55[\4/#_C"6<_ [7?!EKKVE_#6^M[:_P#@/XY^ M''Q+^#?Q0T_PW:_ [XN/JOPE\;^++2Q /T4^'G@?0/@]\/-'\(:;J-Q=Z9X6 MTNXGU;Q-XB?1[;6_$VM7,MUKGC'X@^.-0TG3=#T:]\9>.?$E[K/CCQ]XBATG M2X]<\5ZYKFOW-M#-?S8\1\'_ ,_9*\4>$O!G@CPK^S)\#;KX+:#X$E\4?": M;2_A%\*9/@XOA[XZ67BFR\9:7\-=)M--:VTR3Q;X9::\^(4%EX,_&NH?M$M=>(IM%D^$_AVQZ3P3^P%\>K3P'8^"?$GPIT/P%;7/[''_! M.3X/>))/@;\7_ -E+8^._P!CGXG?M,^-/B)=:):>/O@YKWPY^*MQXET?XM^! MKCP]\/OC7\)9?A!\0O$4'C#POX]\0>"M.TCPM\3M0 /T&U6S_9/\#_&'PO\ M!GPA^R3X=\5>-]%\2>#_ (D7MU\+_@/\-9]$^#7B'XD7.I2>$?B9XPUNY7P^ MGA'5-?C_ &==0OV\8Z.E_?V,_P *O!&DZQ?6/BC7?@SHGBWZV\#_ X^'/PW ML]0L?AYX \$?#^TUS45UG5['P5X6T+PK:ZOJT.GV6D1ZKJ-MHFGZ?'?ZA'I& MF:;IJ7UW')=1Z=86-D)%MK2"*/\ $_3/V%/CQI)U34=6_9^^"K^-H? O_!&: MVNO$/PLUO2=/T#7?%/["7Q]\._%/]H30_"-W\1=1O_B9I_A,>"-)T7P?\&=0 M^(/BG7/$GBJX\+II'C?4?#&FZ3H?B?7K7A+_ ()]?M V?PQ\8Z'X_P##>B77 MQ=UCQ%\+M(^)WQZ^&_QPANO$?[3-G\%+OXPZ]X:^.WBC]G_XL?"#7_V!;/Q/X??P;X$:3QSJ7P;\+:3H] MK=Z?KL7@C3+/0M0N/"T>FRRZ?)HWA^]O$@O-.MI.LB^'W[.W[2VA?#;XS^)O M@_\ #/XBOKWA#P3XP\">(OB+\-?"7B'Q3I'A^^O=$^)G@_[+=>(=*U+4=$FT MKQ!;:'XKL[6UND&D^*M,L]7M635+"WNX_@_XJ?LB?'#7O#?[#7B%_A9^SWXR M^*/P _9H^+WP6^(MMX:U_6]$\/>!?%7Q,^ G@CPY?:Q^S[JWQ/\ #OC+QI?^ M#K/QS\.V\/>&](\:^+M"\3WVEZYX4U+QCXJS8^(M5T_Y$G_X)K?'?1_#ND_# M3PM\&/AW>_ '6/!?[)>F_M(_ #4/BV?!?A#]I+Q7I?[,/[1_P'_:4\8ZAJ^D MZ'XV!^(?_"0?$O\ 9R\6ZK\1?%WA>Z\4?&"#]G13JFKVGB7PQ\+/$%?@GXMNM5>\U;3OA;=?#[QMHVHV4.I>!O'/A#5'N[V?UJ_T M;X/?'KPI=:7KV@?#GXP>!K+Q'XL\/7-AKFC>'O'7A6'Q5X(USQ)\-_&>CRV& MJ6>I:5#K?A?7=/\ %G@G7[-XS>:9?6VMZ)>!&%Y ?@7]K/\ 93^.OQ+^&'P# M\.?#�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end GRAPHIC 36 annexd_004.jpg begin 644 annexd_004.jpg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�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�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annexd_005.jpg begin 644 annexd_005.jpg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�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